<?xml version="1.0" encoding="UTF-8"?>
<projectSnippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6775655\results\search\disease\results.xml">
   <result pre="in densely populated tropical regions. For dengue, chikungunya, Zika and" exact="yellow fever" post="viruses, sylvatic (forest) transmission cycles also exist in some"/>
   <result pre="sylvatic cycles involving non-human primates and dengue, chikungunya, Zika and" exact="yellow fever" post="viruses in Africa, dengue viruses in Asia and yellow"/>
   <result pre="yellow fever viruses in Africa, dengue viruses in Asia and" exact="yellow fever" post="virus in the Americas. We also present current putative"/>
   <result pre="[2–5]. This is well documented in the case of the" exact="yellow fever" post="virus (YFV), where amplifications in infected NHPs precede and"/>
   <result pre="the viruses in the population. Some arboviruses, like dengue (DENV)," exact="chikungunya" post="(CHIKV) and Zika (ZIKV), have become fully adapted to"/>
   <result pre="roles in the epidemiology of devastating diseases like dengue, chikungunya," exact="yellow fever" post="and Zika. Below we review the methods used to"/>
   <result pre="Aedes�?; however, humans must be vaccinated against YFV and using" exact="malaria" post="prophylaxis. Further, some would consider this technique unethical. There"/>
   <result pre="in Asia Following the elucidation of the ‘jungle cycle’ of" exact="yellow fever" post="virus in the early 20th century, the possibility of"/>
   <result pre="indicating the presence of cross-reacting antibodies against, for example, Japanese" exact="encephalitis" post="virus (JEV). Attempts to isolate DENV from mosquitoes, animal"/>
   <result pre="for sylvatic DENV circulation in NHPs in the Americas. Natural" exact="chikungunya" post="virus infection in NHPs and mosquitoes Prior to 2004,"/>
   <result pre="chronic arthritis. Rarely, more severe manifestations can include neurological disease," exact="myocarditis" post="and death. The CHIKV is an Alphavirus (Fig. 2),"/>
   <result pre="[22, 30]. Off the coast of Africa, during the 2006" exact="chikungunya" post="epidemic on the French islands of La Réunion, Mayotte"/>
   <result pre="a possibility for sylvatic cycles to develop [9, 82]. Natural" exact="yellow fever" post="virus infections in NHPs and mosquitoes The history and"/>
   <result pre="warning sign of YFV amplification and the heralding of a" exact="yellow fever" post="outbreak in local people [3, 6, 82]. Yellow fever"/>
   <result pre="from lack of surveillance and the similar clinical presentation of" exact="yellow fever" post="and dengue, which is a very common disease in"/>
   <result pre="which might occur in sylvatic cycles with NHPs. Abbreviations CHIKV" exact="chikungunya" post="virus CFT complement fixation test DENV dengue virus ELISA"/>
   <result pre="G IgM immunoglobulin M IFA immunofluorescence antibody test JEV Japanese" exact="encephalitis" post="virus LUMV Lumbo virus MAYV Mayaro virus NHP non-human"/>
   <result pre="future distributions of the sylvatic cycles of dengue virus and" exact="yellow fever" post="virusInfect Genet Evol.20131929231110.1016/j.meegid.2013.03.00823523817 4.VasilakisNCardosaJHanleyKAHolmesECWeaverSCFever from the forest: prospects for"/>
   <result pre="Dis.201610e000505510.1371/journal.pntd.000505527977671 10.AlthouseBMGuerboisMCummingsDATDiopOMFayeOFayeAet al.Role of monkeys in the sylvatic cycle of" exact="chikungunya" post="virus in SenegalNat Commun.20189104610.1038/s41467-018-03332-729535306 11.WeaverSCVasilakisNMolecular evolution of dengue viruses:"/>
   <result pre="synonym of amplifier, or reality?Viruses.2017918510.3390/v9070185 14.HiggsSZieglerSAA nonhuman primate model of" exact="chikungunya" post="diseaseJ Clin Invest.201012065766010.1172/JCI4239220179348 15.KunoGChangGJBiological transmission of arboviruses: reexamination of"/>
   <result pre="Trop Med Hyg.20149167267610.4269/ajtmh.13-049225092823 18.ChenCIClarkDCPesaventoPLercheNWLuciwPAReisenWKet al.Comparative pathogenesis of epidemic and enzootic" exact="chikungunya" post="viruses in a pregnant Rhesus macaque modelAm J Trop"/>
   <result pre="specificityTrans R Soc Trop Med Hyg.19524650952010.1016/0035-9203(52)90042-412995440 22.McIntoshBMPatersonHEMcgillivrayGDesousaJFurther studies on the" exact="chikungunya" post="outbreak in southern Rhodesia in 1962. I. Mosquitoes, wild"/>
   <result pre="ecology in MalaysiaInst Med Res Malays Bull.19862351152 24.WeinbrenMPHaddowAJWilliamsMCThe occurrence of" exact="chikungunya" post="virus in Uganda I. Isolation from mosquitoesTrans R Soc"/>
   <result pre="from mosquitoesTrans R Soc Trop Med Hyg.19585225326210.1016/0035-9203(58)90084-113556869 25.EastwoodGSangRCGuerboisMTarachaELNWeaverSCEnzootic circulation of" exact="chikungunya" post="virus in East Africa: serological evidence in non-human Kenyan"/>
   <result pre="27.SilverJBMosquito ecology: field sampling methods20083LondonSpringer 28.DialloDSallAABuenemannMChenRFayeODiagneCTet al.Landscape ecology of sylvatic" exact="chikungunya" post="virus and mosquito vectors in southeastern SenegalPLoS Negl Trop"/>
   <result pre="1999–2000: entomologic findings and epidemiologic considerationsEmerg Infect Dis.2003936236710.3201/eid0903.02021912643833 30.DialloMThonnonJTraore-LamizanaMFontenilleDVectors of" exact="chikungunya" post="virus in Senegal: current data and transmission cyclesAm J"/>
   <result pre="protection and pathologyEmerg Microbes Infect.20176e3310.1038/emi.2017.4228487557 39.KamYWPokKYEngKETanLKKaurSLeeWWet al.Sero-prevalence and cross-reactivity of" exact="chikungunya" post="virus specific anti-E2EP3 antibodies in arbovirus-infected patientsPLoS Negl Trop"/>
   <result pre="pods in arbovirus detectionRes Virol.199214341742210.1016/S0923-2516(06)80135-41297177 45.MonathTPKempGEImportance of non-human primates in" exact="yellow fever" post="epidemiology in NigeriaTrop Geogr Med.19732528384632785 46.National Centre for the"/>
   <result pre="J Med Sci Biol.196720Suppl.69745301568 53.YuwonoJSuharyonoWKoimanITsuchiyaYTagayaISeroepidemiological survey on dengue and Japanese" exact="encephalitis" post="virus infections in Asian monkeysSoutheast Asian J Trop Med"/>
   <result pre="with dengue hemorrhagic feverPLoS Negl Trop Dis.20093e42310.1371/journal.pntd.000042319399166 55.NakgoiKNitatpattanaNWajjwalkuWPongsopawijitPKaewchotSYoksanSet al.Dengue, Japanese" exact="encephalitis" post="and chikungunya virus antibody prevalence among captive monkey (Macaca"/>
   <result pre="hemorrhagic feverPLoS Negl Trop Dis.20093e42310.1371/journal.pntd.000042319399166 55.NakgoiKNitatpattanaNWajjwalkuWPongsopawijitPKaewchotSYoksanSet al.Dengue, Japanese encephalitis and" exact="chikungunya" post="virus antibody prevalence among captive monkey (Macaca nemestrina) colonies"/>
   <result pre="flaviviruses, West Nile, dengue, Saint Louis encephalitis, Ilheus, Bussuquara, and" exact="yellow fever" post="in free-ranging black howlers (Alouatta caraya) of northeastern ArgentinaPLoS"/>
   <result pre="al.Mosquitoes infected with dengue viruses in BrazilVirol J.2010715210.1186/1743-422X-7-15220624314 69.McIntoshBMAntibody against" exact="chikungunya" post="virus in wild primates in southern AfricaS Afr J"/>
   <result pre="islands after the 2006 CHIKV outbreakVet Res.2014455210.1186/1297-9716-45-5224885529 73.HalsteadSBUdomsakdiSVertebrate hosts of" exact="chikungunya" post="virusBull World Health Organ.1966358920604287 74.MarchetteNJRudnickAGarciaRMacVeanDWAlphaviruses in peninsular Malaysia: I."/>
   <result pre="Trop Med Public Health.1978931732934888 75.ApandiYNazniWANoor AzleenZAVythilinghamINoorazianMYAzahariAHet al.The first isolation of" exact="chikungunya" post="virus from non-human primates in MalaysiaJ Gen Mol Virol200913539"/>
   <result pre="infection of urban and peri-urban nonhuman primates with Zika and" exact="chikungunya" post="viruses in BrazilmSphere20183e00523-1710.1128/mSphere.00523-1729404420 78.HiggsSVanlandinghamDChikungunya virus and its mosquito vectorsVector"/>
   <result pre="and its mosquito vectorsVector Borne Zoonotic Dis.201520151523124010.1089/vbz.2014.1745 79.Lourenço-de-OliveiraRFaillouxABHigh risk for" exact="chikungunya" post="virus to initiate an enzootic sylvatic cycle in the"/>
   <result pre="in the tropical AmericasPLoS Negl Trop Dis.201711e000569 80.TsetsarkinKAChenRWeaverSCInterspecies transmission and" exact="chikungunya" post="virus emergenceCurr Opin Virol.20161614315010.1016/j.coviro.2016.02.00726986235 81.McCraeAWKiryaBGYellow fever and Zika virus"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6776365\results\search\disease\results.xml">
   <result pre="Bunyaviruses: Hantavirus Intrinsic and extrinsic drivers of transmission dynamics of" exact="hemorrhagic fever with renal syndrome" post="caused by Seoul hantavirus Patterns and drivers of Seoul"/>
   <result pre="has recently raised concern by causing geographic range expansion of" exact="hemorrhagic fever with renal syndrome" post="(HFRS). SEOV infections in humans are significantly underestimated worldwide"/>
   <result pre="seroprevalence among the population is found. However, only relatively few" exact="hemorrhagic fever with renal syndrome" post="(HFRS) cases are reported. Comprehensive epidemiological data is necessary"/>
   <result pre="its Supporting Information files. Introduction There are 60,000–100,000 cases of" exact="hemorrhagic fever with renal syndrome" post="(HFRS), a rodent-borne zoonosis, reported annually, globally [1, 2]."/>
   <result pre="of 1998 and 1999. Fig 1 Seasonality and periodicity of" exact="hemorrhagic fever with renal syndrome" post="(HFRS) incidence in Huludao City, 1998 to 2015. (A)"/>
   <result pre="here for additional data file. S4 Fig The relationship between" exact="hemorrhagic fever with renal syndrome" post="(HFRS) incidence, Norway rat population density and environmental variables"/>
   <result pre="Detecting cross-map causality beyond shared seasonality of environmental drivers on" exact="hemorrhagic fever with renal syndrome." post="(A) Time series of hemorrhagic fever with renal syndrome"/>
   <result pre="on hemorrhagic fever with renal syndrome. (A) Time series of" exact="hemorrhagic fever with renal syndrome" post="(HFRS) incidence (orange) and relative humidity (green). (B) The"/>
   <result pre="WalterKS, WesolowskiA, BuckeeCO, ShevliakovaE, TatemAJ, et al.Identifying climate drivers of" exact="infectious disease" post="dynamics: recent advances and challenges ahead. Proc Biol Sci."/>
   <result pre="et al.Changes in rodent abundance and weather conditions potentially drive" exact="hemorrhagic fever with renal syndrome" post="outbreaks in Xi’an, China, 2005–2012. PLoS Negl Trop Dis."/>
   <result pre="van der GroenG, BarriosJM, VerstraetenWW, et al.Beechnuts and outbreaks of" exact="nephropathia epidemica" post="(NE): of mast, mice and men. Nephrol Dial Transplant."/>
   <result pre="Borne Zoonotic Dis. 2014;14(1): 33–40. 10.1089/vbz.2013.137824359425 18SongG. Epidemiological progresses of" exact="hemorrhagic fever with renal syndrome" post="in China. Chin Med J (Engl). 1999;112(5): 472–7.11593522 19JamesonL,"/>
   <result pre="HuangH-G, ZhangL-Q, FengD, ZhaoW-J, et al.Landscape elements and Hantaan virus–related" exact="hemorrhagic fever with renal syndrome," post="People’s Republic of China. Emerg Infect Dis. 2007;13(9): 130110.3201/eid1309.06148118252099"/>
   <result pre="disease. Emerg Infect Dis. 2019;25(2): 38710.3201/eid2502.18164330666956 29LixinChen. Epidemiological survey of" exact="hemorrhagic fever with renal syndrome" post="in Huludao City from 1992 to 2001. Chinese Journal"/>
   <result pre="145–6. 31LeiC, HongboY, PingW. Effect evaluation of intervention measures for" exact="hemorrhagic fever with renal syndrome" post="in Shenyang. Strait Journal of Preventive Medicine. 2014;3: 34–5."/>
   <result pre="LiXJ, TongSL, GaoLD, et al.Atmospheric moisture variability and transmission of" exact="hemorrhagic fever with renal syndrome" post="in Changsha City, Mainland China, 1991–2010. PLoS Negl Trop"/>
   <result pre="effects of climatic variables and reservoir on the incidence of" exact="hemorrhagic fever with renal syndrome" post="in Huludao City, China: a 17-year data analysis based"/>
   <result pre="57LiuX, JiangB, GuW, LiuQ. Temporal trend and climate factors of" exact="hemorrhagic fever with renal syndrome" post="epidemic in Shenyang City, China. BMC Infect Dis. 2011;11(1):"/>
   <result pre="LiYL, SongSX, ZhangWY, et al.Spatiotemporal trends and climatic factors of" exact="hemorrhagic fever with renal syndrome" post="epidemic in Shandong Province, China. PLoS Negl Trop Dis."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6776623\results\search\disease\results.xml">
   <result pre="is still important since the reasons for when a sporadic" exact="viral disease" post="might flare up in a herd, and then &quot;burn"/>
   <result pre="No + aASFV, African swine fever virus; FMDV, foot and" exact="mouth disease" post="virus; CSFV, classical swine fever virus; ADV, Aujeszky's disease"/>
   <result pre="disease virus; PRRSV, porcine reproductive and respiratory syndrome virus; IVA-S," exact="influenza" post="virus A- swine; PCV2, porcine circovirus type 2; PEDV,"/>
   <result pre="A- swine; PCV2, porcine circovirus type 2; PEDV, porcine epidemic" exact="diarrhea" post="virus; SVA, Senecavirus A; JEV, Japanese encephalitis virus; HEV,"/>
   <result pre="PEDV, porcine epidemic diarrhea virus; SVA, Senecavirus A; JEV, Japanese" exact="encephalitis" post="virus; HEV, Hepatitis E virus; EMCV, encephalomyocarditis virus; VSV,"/>
   <result pre="virus; HEV, Hepatitis E virus; EMCV, encephalomyocarditis virus; VSV, Vesicular" exact="stomatitis" post="virus; VESV, Vesicular exanthema of swine virus. bEconomic impact"/>
   <result pre="of transmitting the disease. Following the emergence of the 2009" exact="influenza" post="pandemic, such a ban or threat of a ban"/>
   <result pre="is a major obstacle to improving PRRSV vaccines. Foot and" exact="mouth disease" post="virus (FMDV) is a highly infectious virus that affects"/>
   <result pre="when they occur, and maintain FMDV-free countries. The control of" exact="influenza" post="A viruses in swine (IAV-S) exemplifies the challenges of"/>
   <result pre="then endemic North American H1 subtype, the new virus caused" exact="respiratory disease" post="in fattening hogs and sows (8). In response to"/>
   <result pre="scope of disease and subsequent human-to-human transmission. However, the 2009" exact="influenza" post="pandemic is a stark reminder of the potential for"/>
   <result pre="influenza pandemic is a stark reminder of the potential for" exact="influenza" post="viruses to jump species and become a pandemic. Reverse"/>
   <result pre="can have a higher case fatality rate in people (Japanese" exact="encephalitis" post="virus, Hepatitis E virus). Most zoonotic swine virus crossover"/>
   <result pre="which have been successful to date. In 2013, porcine epidemic" exact="diarrhea" post="virus (PEDV), one of the swine enteric coronaviruses that"/>
   <result pre="(PEDV), one of the swine enteric coronaviruses that causes severe" exact="diarrhea" post="in neonatal pigs, was discovered in the Western Hemisphere"/>
   <result pre="from SVA infection are indistinguishable from FMDV infection. Foot and" exact="mouth disease" post="is the number one disease concern for livestock producers"/>
   <result pre="Academic Press (2019). 4.VincentALLagerKMHarlandMLorussoAZanellaECiacci-ZanellaJRet al.. Absence of 2009 pandemic H1N1" exact="influenza" post="A virus in fresh pork. PLoS ONE. (2009) 4:e8367."/>
   <result pre="future perspective. Front Microbiol. (2017) 8:1635. 10.3389/fmicb.2017.0163528894443 7.MahapatraMParidaS. Foot and" exact="mouth disease" post="vaccine strain selection: current approaches and future perspectives. Expert"/>
   <result pre="10.1080/14760584.2018.149237829950121 8.ZhouNNSenneDALandgrafJSSwensonSLEricksonGRossowKet al.. Genetic reassortment of avian, swine, and human" exact="influenza" post="A viruses in American pigs. J Virol. (1999) 73:8851–6.10482643"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6777354\results\search\disease\results.xml">
   <result pre="(HuNoV) GII.P17-GII.17 (Kawasaki2014 variant) reportedly emerged in 2014 and caused" exact="gastroenteritis" post="outbreaks worldwide. To clarify the evolution of both VP1"/>
   <result pre="norovirus (HuNoV) is a major causative pathogen of acute viral" exact="gastroenteritis" post="(de Graaf et al., 2016). Although HuNoV is most"/>
   <result pre="report suggested that approximately 680 million people annually suffer from" exact="gastroenteritis" post="due to HuNoV infection worldwide (Kirk et al., 2015)."/>
   <result pre="2–3 years in the past decade to cause pandemics of" exact="gastroenteritis" post="in all aged individuals (Bull et al., 2010). Furthermore,"/>
   <result pre="al., 2013). Of these, many genotypes have been associated with" exact="gastroenteritis" post="outbreaks throughout the world (Hoa Tran et al., 2013)."/>
   <result pre="this study. Fecal samples were collected from patients with acute" exact="gastroenteritis" post="associated with HuNoV infection under compliance with the Food"/>
   <result pre="(2016). Emergence of norovirus GII.17 variants among children with acute" exact="gastroenteritis" post="in South Korea. PLoS ONE11:e0154284. 10.1371/journal.pone.015428427148739 DarribaD.TaboadaG. L.DoalloR.PosadaD. (2012)."/>
   <result pre="of a new GII.17 norovirus variant in patients with acute" exact="gastroenteritis" post="in Jiangsu, China, September 2014 to March 2015. Eur."/>
   <result pre="A.NakagomiO. (2013). Molecular epidemiology of noroviruses associated with acute sporadic" exact="gastroenteritis" post="in children: global distribution of genogroups, genotypes and GII.4"/>
   <result pre="characterization of the emergent GII.17_2014 norovirus genotype among children with" exact="gastroenteritis" post="from Northern Brazil. Infect. Genet. Evol. 48, 1–3. 10.1016/j.meegid.2016.11.02727923768"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6778435\results\search\disease\results.xml">
   <result pre="tag-based quantitative proteomic analysis of lycorine treatment in highly pathogenic" exact="avian influenza" post="H5N1 virus infection YangLi12ZhangJia Hao3ZhangXiao Li2LaoGuang Jie3SuGuan Ming3WangLei1LiYao Lan1YeWen"/>
   <result pre="quantitative proteomic analysis of lycorine treatment in highly pathogenic avian" exact="influenza" post="H5N1 virus infection YangLi12ZhangJia Hao3ZhangXiao Li2LaoGuang Jie3SuGuan Ming3WangLei1LiYao Lan1YeWen"/>
   <result pre="of the article must be cited.https://peerj.com/articles/7697 Abstract Highly pathogenic H5N1" exact="influenza" post="viruses (HPAIV) cause rapid systemic illness and death in"/>
   <result pre="this threat, a more effective treatment for H5 strains of" exact="influenza" post="has yet to be developed. Therefore, the development of"/>
   <result pre="be developed. Therefore, the development of therapeutics/drugs that combat H5N1" exact="influenza" post="virus infection is becoming increasingly important. Lycorine, the major"/>
   <result pre="in the nucleus and suggest new potential therapeutic targets for" exact="influenza" post="virus. Highly pathogenic avian influenza virus Multiplex tandem mass"/>
   <result pre="suggest new potential therapeutic targets for influenza virus. Highly pathogenic" exact="avian influenza" post="virus Multiplex tandem mass tag Lycorine Nuclear-cytoplasmic transport Nuclear"/>
   <result pre="new potential therapeutic targets for influenza virus. Highly pathogenic avian" exact="influenza" post="virus Multiplex tandem mass tag Lycorine Nuclear-cytoplasmic transport Nuclear"/>
   <result pre="to publish, or preparation of the manuscript. Introduction Highly pathogenic" exact="influenza" post="A viruses resulting from routine seasonal epidemics and global"/>
   <result pre="(Zhu, Wang &amp;amp; Wang, 2017), which may result in rare" exact="influenza" post="A virus pandemics. Resistance and timeliness to clinical antiviral"/>
   <result pre="substitution (H274Y in N1) (Yusuf et al., 2016). Therefore, novel" exact="influenza" post="inhibitors must be developed. Virus–host interactions involve a complex"/>
   <result pre="Zhang et al., 2018). The mode of RNP exit of" exact="influenza" post="viruses from the nucleus complements active Crm1-dependent export mechanisms"/>
   <result pre="components that deal with different types of diseases, such as" exact="malaria" post="and influenza A virus (Crunkhorn, 2016; Nonaka et al.,"/>
   <result pre="deal with different types of diseases, such as malaria and" exact="influenza" post="A virus (Crunkhorn, 2016; Nonaka et al., 2018). Lycorine"/>
   <result pre="described (Wang et al., 2009). All experiments involving live H5N1" exact="influenza" post="virus were carried out in biosafety level-3 facilities. Figure"/>
   <result pre="effect on viral titers. Therefore, a single replication cycle of" exact="influenza" post="virus (12 h.p.i.) within lycorine treatment at 0.52 µM"/>
   <result pre="control were compared (V/M) to determine the effects of GD178" exact="influenza" post="virus on MDCK cells. The V/M group contained 123"/>
   <result pre="pathways showed that the proteins were involved in pathway in" exact="cancer" post="(path: ko05200), extracellular matrix (ECM)–receptor interaction (path: ko04512), focal"/>
   <result pre="are many changes in the protein profile in response to" exact="influenza" post="virus infection at 12 h.p.i. Figure 2 Differentially expressed"/>
   <result pre="resistance (path: ko01521), Janus kinase-STAT signaling pathway (path: ko04630), and" exact="pancreatic cancer" post="(path: ko05212) (Fig. 3C). These results showed differences between"/>
   <result pre="(path: ko01521), Janus kinase-STAT signaling pathway (path: ko04630), and pancreatic" exact="cancer" post="(path: ko05212) (Fig. 3C). These results showed differences between"/>
   <result pre="the L group, implying that these proteins were downregulated after" exact="influenza" post="virus infection but increased after lycorine treatment. A total"/>
   <result pre="under conditions of lycorine treatment to stop the cycle of" exact="influenza" post="virus, which leads us to search for the proteins"/>
   <result pre="changed as such as the cells treated with lycorine after" exact="influenza" post="virus infection. These results indicate that Nup93 expression was"/>
   <result pre="infection. These results indicate that Nup93 expression was induced after" exact="influenza" post="virus infection but was dramatically decreased after lycorine treatment"/>
   <result pre="modulated and the pathways associated with those proteins, the GD178" exact="influenza" post="virus induced more profound responses to ECM–receptor interaction, focal"/>
   <result pre="of proteins and RNA (Labade, Karmodiya &amp;amp; Sengupta, 2016). The" exact="influenza" post="virus could induce proteins and pathways that it uses"/>
   <result pre="which is correlated with the import and export pathway for" exact="influenza" post="virus infection. In the present study, the expression of"/>
   <result pre="1986). Subsequent studies found that lycorine exhibits antiviral activity toward" exact="herpes simplex" post="virus (Renard-Nozaki et al., 1989), HIV-1 (Lin et al.,"/>
   <result pre="poliovirus (Hwang et al., 2008), West Nile Virus, dengue and" exact="yellow fever" post="viruses (Zou et al., 2009), enterovirus 71 (Liu et"/>
   <result pre="(Zou et al., 2009), enterovirus 71 (Liu et al., 2011)," exact="influenza" post="virus (He et al., 2013), hepatitis C virus (Guo"/>
   <result pre="(Liu et al., 2011), influenza virus (He et al., 2013)," exact="hepatitis" post="C virus (Guo et al., 2016), and adult zika"/>
   <result pre="inactivates the JAK-STAT signaling pathway to inhibit the proliferation of" exact="cancer" post="cells. Furthermore, our present results agree with these specific"/>
   <result pre="group and mock group. Lycorine significantly reduced Nup93 expression after" exact="influenza" post="virus infection, which may have affected nucleocytoplasmic transport instead"/>
   <result pre="time-of-addition effect, lycorine is involved in the early steps of" exact="influenza" post="virus replication aside from virus binding and viral RNP"/>
   <result pre="2013). Nucleocytoplasmic transport is integral to the majority of the" exact="influenza" post="virus explicative cycle and critical for the efficient replication"/>
   <result pre="virus explicative cycle and critical for the efficient replication of" exact="influenza" post="virus. Importantly, shuttling of specific proteins out of the"/>
   <result pre="cell cycle, and apoptosis have become the therapeutic target of" exact="cancer" post="(Gravina et al., 2014; Hill et al., 2014; Rosebeck"/>
   <result pre="of new antiviral drugs. Conclusion Lycorine is an inhibitor of" exact="influenza" post="virus that effectively inhibits AIV infection. Comparative proteomic analysis"/>
   <result pre="al. (2018)AraiYIbrahimMSElgendyEMDaidojiTOnoTSuzukiYNakayaTMatsumotoKWatanabeY2018Genetic compatibility of reassortants between avian H5N1 and H9N2" exact="influenza" post="viruses with higher pathogenicity in mammalsJournal of Virology10.1128/JVI.01969-18 Batth,"/>
   <result pre="grape skin extract induces an unfolded protein response-mediated autophagy in" exact="prostate cancer" post="cells: a TMT-based quantitative proteomic analysisPLOS ONE1110e016411510.1371/journal.pone.016411527755556 Cedron et"/>
   <result pre="skin extract induces an unfolded protein response-mediated autophagy in prostate" exact="cancer" post="cells: a TMT-based quantitative proteomic analysisPLOS ONE1110e016411510.1371/journal.pone.016411527755556 Cedron et"/>
   <result pre="and Rab11-dependent vesiclesNature Communications811396140710.1038/s41467-017-01557-6 Drayman et al. (2017)DraymanNKarinOMayoADanonTShapiraLRafaelDZimmerABrenAKobilerOAlonU2017Dynamic proteomics of" exact="herpes simplex" post="virus infectionMBio86e01612-1710.1128/mBio.01612-17 Flatt &amp;amp; Greber (2015)FlattJWGreberUF2015Misdelivery at the nuclear"/>
   <result pre="factor nucleoporin 93 is involved in the nuclear export of" exact="influenza" post="virus RNAFrontiers in Microbiology91675168310.3389/fmicb.2018.0167530087672 Giordani et al. (2011)GiordaniRBVieiraPde BWeizenmannMRosembergDBSouzaAPBonorinoCDe"/>
   <result pre="conserved inhibitory mechanism of a lycorine derivative against enterovirus and" exact="hepatitis" post="C virusAntimicrobial Agents and Chemotherapy60291392410.1128/AAC.02274-1526596952 He et al. (2013)HeJQiWBWangLTianJJiaoPRLiuGQYeWCLiaoM2013Amaryllidaceae"/>
   <result pre="inhibit nuclear-to-cytoplasmic export of ribonucleoprotein (RNP) complex of highly pathogenic" exact="avian influenza" post="virus H5N1Influenza and Other Respiratory Viruses7692293110.1111/irv.1203523136954 Henry et al."/>
   <result pre="nuclear-to-cytoplasmic export of ribonucleoprotein (RNP) complex of highly pathogenic avian" exact="influenza" post="virus H5N1Influenza and Other Respiratory Viruses7692293110.1111/irv.1203523136954 Henry et al."/>
   <result pre="of novel bicyclic ring systems with activity against drug resistant" exact="cancer" post="cellsEuropean Journal of Medicinal Chemistry12031332810.1016/j.ejmech.2016.05.00427218860 Hill et al. (2014)HillRCautainBDe"/>
   <result pre="Medicinal Chemistry12031332810.1016/j.ejmech.2016.05.00427218860 Hill et al. (2014)HillRCautainBDe PedroNLinkW2014Targeting nucleocytoplasmic transport in" exact="cancer" post="therapyOncotarget51112810.18632/oncotarget.145724429466 Hu et al. (2015)HuMPengSHeYQinMCongXXingYLiuMYiZ2015Lycorine is a novel inhibitor"/>
   <result pre="and expeditious synthesis of organosilanes as potent antivirals targeting multidrug-resistant" exact="influenza" post="A virusesEuropean Journal of Medicinal Chemistry135707610.1016/j.ejmech.2017.04.03828433777 Hui Bin Huang"/>
   <result pre="HuangJH2017Functional proteomic studies of lycorine-treated MDCK cells on highly pathogenic" exact="avian influenza" post="H5N1 virus infectionJournal of Pharmaceutical and Biomedical Sciences07518619710.20936/JPBMS/170511 Hwang"/>
   <result pre="proteomic studies of lycorine-treated MDCK cells on highly pathogenic avian" exact="influenza" post="H5N1 virus infectionJournal of Pharmaceutical and Biomedical Sciences07518619710.20936/JPBMS/170511 Hwang"/>
   <result pre="the main phenanthridine Amaryllidaceae alkaloid, exhibits significant antitumor activity in" exact="cancer" post="cells that display resistance to proapoptotic stimuli: an investigation"/>
   <result pre="et al. (2012)LiuCZhangAGuoJYangJZhouHChenHJinM2012Identification of human host proteins contributing to H5N1" exact="influenza" post="virus propagation by membrane proteomicsJournal of Proteome Research11115396540510.1021/pr300634222985253 Liu"/>
   <result pre="compoundBioorganic &amp;amp; Medicinal Chemistry Letters24235381538410.1016/j.bmcl.2014.10.05125453792 Peschel et al. (2013)PeschelBFrentzelSLaskeTGenzelYReichlU2013Comparison of" exact="influenza" post="virus yields and apoptosis-induction in an adherent and a"/>
   <result pre="Renard-Nozaki et al. (1989)Renard-NozakiJKimTImakuraYKiharaMKobayashiS1989Effect of alkaloids isolated from Amaryllidaceae on" exact="herpes simplex" post="virusResearch in Virology140211512810.1016/S0923-2516(89)80089-52547235 Rosebeck et al. (2016)RosebeckSAlongeMMKandarpaMMayampurathAVolchenboumSLJasielecJDytfeldDMaxwellSPKraftsonSJMcCauleyDShachamSKauffmanMJakubowiakAJ2016Synergistic myeloma cell"/>
   <result pre="of biomolecular interaction networksGenome Research200313112498250410.1101/gr.123930314597658 Shen et al. (2018)ShenJZhangTChengZZhuNWangHLinLWangZYiHHuM2018Lycorine inhibits" exact="glioblastoma multiforme" post="growth through EGFR suppressionJournal of Experimental &amp;amp; Clinical Cancer"/>
   <result pre="Research: CR37115717510.1186/s13046-018-0785-430016965 Sun et al. (2015)SunLZhouPHeSLuoYJiaKFuCSunYHeHTuLNingZYuanZWangHLiSYuanL2015Sparse serological evidence of H5N1" exact="avian influenza" post="virus infections in domestic cats, northeastern ChinaMicrobial Pathogenesis82273010.1016/j.micpath.2015.03.00325752867 Szklarczyk"/>
   <result pre="CR37115717510.1186/s13046-018-0785-430016965 Sun et al. (2015)SunLZhouPHeSLuoYJiaKFuCSunYHeHTuLNingZYuanZWangHLiSYuanL2015Sparse serological evidence of H5N1 avian" exact="influenza" post="virus infections in domestic cats, northeastern ChinaMicrobial Pathogenesis82273010.1016/j.micpath.2015.03.00325752867 Szklarczyk"/>
   <result pre="accumulation of defective viral genomes contributes to severe outcome in" exact="influenza" post="virus infected patientsPLOS Pathogens1310e100665010.1371/journal.ppat.100665029023600 Vrijsen et al. (1986)VrijsenRVanden BergheDAVlietinckAJBoeyeA1986Lycorine:"/>
   <result pre="the drug-resistant S31N mutant of the M2 ion channel of" exact="influenza" post="A virusProceedings of the National Academy of Sciences of"/>
   <result pre="States of America11552E12218–E1222710.1073/pnas.181801211530538201 Zhu, Wang &amp;amp; Wang (2017)ZhuWWangCWangBZ2017From variation of" exact="influenza" post="viral proteins to vaccine developmentInternational Journal of Molecular Sciences187E155410.3390/ijms18071554"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6779206\results\search\disease\results.xml">
   <result pre="primarily by Aedes aegypti and Aedes albopictus, causing an acute" exact="infectious disease" post="named dengue fever (DF),1 which gives rise to public"/>
   <result pre="aegypti and Aedes albopictus, causing an acute infectious disease named" exact="dengue fever" post="(DF),1 which gives rise to public health problems in"/>
   <result pre="Gen Virol78: 2279–2286.9292015 15.JackowiakPKulsKBudzkoLManiaAFiglerowiczMFiglerowiczM, 2014Phylogeny and molecular evolution of the" exact="hepatitis" post="C virus. Infect Genet Evol21: 67–72.24200590 16.XuJZhongHAMadrahimovAHelikarTLuG, 2014Molecular phylogeny"/>
   <result pre="Genet Evol21: 67–72.24200590 16.XuJZhongHAMadrahimovAHelikarTLuG, 2014Molecular phylogeny and evolutionary dynamics of" exact="influenza" post="A nonstructural (NS) gene. Infect Genet Evol22: 192–200.24161299 17.MorenoaltamiranoMMSánchezgarcíaFJMuñozML,"/>
   <result pre="Am J Trop Med Hyg83: 664–671.20810836 21.LiuCLiuQLinHXinBNieJ, 2014Spatial analysis of" exact="dengue fever" post="in Guangdong province, China, 2001–2006. Asia Pac J Public"/>
   <result pre="2001–2006. Asia Pac J Public Health26:58–66.23343642 22.HeJFLuoHMLiangWJZhengKKangMLiuLP, 2007Epidemic situation of" exact="dengue fever" post="in Guangdong province, China, 1990–2005. Dengue Bull31: 1–9. 23.WuWet"/>
   <result pre="2005–2011. PLoS One9: e85596.24465613 25.XiaoJPet al.2016Characterizing a large outbreak of" exact="dengue fever" post="in Guangdong province, China. Infect Dis Poverty5: 44.27142081 26.HuangLet"/>
   <result pre="Appl Toxicol30: 769–774.20669259 32.LuoHHeJZhengKLiLJiangL, 2002Analysis on the epidemiologic features of" exact="dengue fever" post="in Guangdong province, 1990–2000. Chin J Epidemiol23: 427–430. 33.LiangWJet"/>
   <result pre="province, 1990–2000. Chin J Epidemiol23: 427–430. 33.LiangWJet al.2007Epidemiologlcal analysis of" exact="dengue fever" post="in Guangdong province, 2001–2006. South China J Prev Med33:4–7."/>
   <result pre="Infect Genet Evol11: 1183–1187.21473933 50.FanJCLinHLWuHXWangJYangSRLiuQY2013Spatial and temporal distribution characteristics of" exact="dengue fever" post="in Guangdong province, China during 2006–2011. Chin J Vector"/>
   <result pre="389–391. 51.GuoRPengZSongTHeJZhongHLiLLiangW, 2014Current infection status and epidemic risk analysis of" exact="dengue fever" post="and chikungunya in Guangdong province, from 1990 to 2012."/>
   <result pre="infection status and epidemic risk analysis of dengue fever and" exact="chikungunya" post="in Guangdong province, from 1990 to 2012. Zhonghua Liu"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6779578\results\search\disease\results.xml">
   <result pre="of measles-containing vaccine (MCV) has been accepted as confirmation of" exact="measles" post="immunity among healthcare workers (HCWs). However, we encountered measles"/>
   <result pre="of measles immunity among healthcare workers (HCWs). However, we encountered" exact="measles" post="in an HCW who had received two doses of"/>
   <result pre="who had received two doses of MCV. A patient with" exact="measles" post="was admitted to our hospital. Among 62 exposed HCWs,"/>
   <result pre="for anti-measles immunoglobulin G (IgG), and was confirmed to have" exact="measles" post="14 days after exposure. Based on this experience, we"/>
   <result pre="transmission Measles-mumps-rubella vaccine Funding Soonchunhyang Universityhttps://doi.org/10.13039/501100002560 Measles is an airborne" exact="infectious disease" post="that requires rigorous control measures to prevent outbreaks. Measles"/>
   <result pre="particularly important among healthcare workers (HCWs), because large-scale outbreaks of" exact="measles" post="can occur in medical institutions and can result in"/>
   <result pre="confirm that 2 doses of MCV confer immunity. We witnessed" exact="measles" post="in an HCW who had received 2 doses of"/>
   <result pre="days prior to admission, included fever, sore throat, and a" exact="rash" post="on the back of his neck. Before he was"/>
   <result pre="a general multi-bed hospital room. Two days after admission, an" exact="infectious disease" post="doctor made a clinical diagnosis of measles, and recommended"/>
   <result pre="diagnosis of measles, and recommended that the patient have a" exact="measles" post="laboratory test included measles polymerase chain reaction (PCR) and"/>
   <result pre="recommended that the patient have a measles laboratory test included" exact="measles" post="polymerase chain reaction (PCR) and anti-measles IgG test. The"/>
   <result pre="the infection control team screened all exposed HCWs, to prevent" exact="measles" post="transmission. Exposed HCWs were defined as HCWs working in"/>
   <result pre="We interviewed each of the exposed HCWs to check their" exact="measles" post="history and confirmed their MCV history based on infant"/>
   <result pre="she was not immune to measles. Fourteen days after the" exact="measles" post="exposure, the nurse developed fever and a rash that"/>
   <result pre="after the measles exposure, the nurse developed fever and a" exact="rash" post="that began on the back of her neck. She"/>
   <result pre="respiratory symptoms could be classified as atypical measles, her skin" exact="rash" post="resembled that of typical measles. We tested her anti-measles"/>
   <result pre="measles. We tested her anti-measles IgM and tested her for" exact="measles" post="virus using PCR. Both test results were positive. We"/>
   <result pre="results were positive. We isolated her to prevent any further" exact="measles" post="exposure of the HCWs and patients. Although both the"/>
   <result pre="infection control. In our investigation, none of the HCWs with" exact="measles" post="IgG antibodies developed measles, but the one IgG-negative nurse"/>
   <result pre="World Health Organization (WHO) report, 545,000 people worldwide died of" exact="measles" post="in 2000, but the global number of deaths due"/>
   <result pre="in 2000, but the global number of deaths due to" exact="measles" post="declined by 80% between 2000 and 2017 due to"/>
   <result pre="the increase in MMR vaccine coverage and increased awareness of" exact="measles" post="infection control [4]. In the Korea, a massive measles"/>
   <result pre="of measles infection control [4]. In the Korea, a massive" exact="measles" post="outbreak occurred in 2000 – 2001. The epidemic ended"/>
   <result pre="dose of MCV [5]. Subsequently, WHO confirmed the elimination of" exact="measles" post="in Korea. However, in 2014 there was an outbreak"/>
   <result pre="in Korea. However, in 2014 there was an outbreak of" exact="measles" post="among university students. Although the index patient had documentation"/>
   <result pre="failure could not be demonstrated experimentally during the 2 previous" exact="measles" post="outbreaks in Korea because, the measles IgG avidity test"/>
   <result pre="during the 2 previous measles outbreaks in Korea because, the" exact="measles" post="IgG avidity test was unavailable. However, almost all of"/>
   <result pre="main cause of an epidemics in general [9]. In some" exact="measles" post="epidemics, even individuals who were considered immune to measles"/>
   <result pre="some measles epidemics, even individuals who were considered immune to" exact="measles" post="have become infected as a result of massive measles"/>
   <result pre="to measles have become infected as a result of massive" exact="measles" post="virus exposure [10]. This case illustrates that measles can"/>
   <result pre="of massive measles virus exposure [10]. This case illustrates that" exact="measles" post="can be transmitted to IgG-negative individuals, even when they"/>
   <result pre="2 doses of MCV. As there have been no large-scale" exact="measles" post="epidemics in Korea since the 2000-2001 epidemic, the chance"/>
   <result pre="measles, despite having received 2 doses of MCV. Cases of" exact="measles" post="in individuals who have previously received MCV, are generally"/>
   <result pre="hospital in Korea shut down the emergency room during a" exact="measles" post="outbreak as an infection control measure [12]. If we"/>
   <result pre="way to prevent further interruption of medical services, and further" exact="measles" post="transmission. In our hospital and the affiliated medical centers,"/>
   <result pre="was below average. In summary, we report a case of" exact="measles" post="occurred in a nurse who had been considered to"/>
   <result pre="a nurse who had been considered to be immune to" exact="measles" post="based only on documentation of having received 2 doses"/>
   <result pre="among non-immune individuals. We suggest that immunity of HCW to" exact="measles" post="be confirmed by screening them for anti-measles IgG. ACKNOWLEDGEMENTS"/>
   <result pre="Writing - review &amp;amp; editing: SNP, MHJ. References 1ChenSYAndersonSKuttyPKLugoFMcDonaldMRotaPAOrtega-SanchezIRKomatsuKArmstrongGLSunenshineRSewardJFHealth care-associated" exact="measles" post="outbreak in the United States after an importation: challenges"/>
   <result pre="– measlesAccessed 6 May, 2019Available at: https://www.who.int/immunization/diseases 5SoJSGoUYOhHKBaekSJLeeJKAssessment about the" exact="measles" post="elimination from cases and outbreaks, 2002-2007: Assessment about the"/>
   <result pre="measles elimination from cases and outbreaks, 2002-2007: Assessment about the" exact="measles" post="eliminationKorean J Pediatr2009526874 6ChoeYJParkYJKimJWEomHEParkOOhMDLeeJKAn outbreak of measles in a"/>
   <result pre="Assessment about the measles eliminationKorean J Pediatr2009526874 6ChoeYJParkYJKimJWEomHEParkOOhMDLeeJKAn outbreak of" exact="measles" post="in a university in Korea, 2014J Korean Med Sci2017321876187828960044"/>
   <result pre="a university in Korea, 2014J Korean Med Sci2017321876187828960044 7RosenJBRotaJSHickmanCJSowersSBMercaderSRotaPABelliniWJHuangAJDollMKZuckerJRZimmermanCMOutbreak of" exact="measles" post="among persons with prior evidence of immunity, New York"/>
   <result pre="state, federated states of Micronesia, 2014Open Forum Infect Dis20163ofw06427186587 9PaunioMHedmanKDavidkinIValleMHeinonenOPLeinikkiPSalmiAPeltolaHSecondary" exact="measles" post="vaccine failures identified by measurement of IgG avidity: high"/>
   <result pre="at a young ageEpidemiol Infect200012426327110813152 10RotaJSHickmanCJSowersSBRotaPAMercaderSBelliniWJTwo case studies of modified" exact="measles" post="in vaccinated physicians exposed to primary measles cases: high"/>
   <result pre="studies of modified measles in vaccinated physicians exposed to primary" exact="measles" post="cases: high risk of infection but low risk of"/>
   <result pre="low risk of transmissionJ Infect Dis2011204Suppl 1S559S56321666213 11CherryJDZahnMClinical characteristics of" exact="measles" post="in previously vaccinated and unvaccinated patients in californiaClin Infect"/>
   <result pre="Resident nurse 36 (58) Paramedic 13 (21) Past history of" exact="measles" post="Yes 12 (19) No 18 (29) Unknown 32 (52)"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6779579\results\search\disease\results.xml">
   <result pre="properly cited. Abstract Leptospirosis is a widespread worldwide zoonosis. Human" exact="leptospirosis" post="was first identified in the Korea in 1984 as"/>
   <result pre="improving personal hygiene management. Since then, the reported incidence of" exact="leptospirosis" post="has been low. Leptospirosis is currently considered in the"/>
   <result pre="health policies for recognition, identification, and infection control of human" exact="leptospirosis" post="in the Korea. Leptospira Leptospirosis Korea Communicable diseases History"/>
   <result pre="a serious public health challenge in the 1980s. While sporadic" exact="leptospirosis" post="cases have occurred annually in endemic areas, concern about"/>
   <result pre="and experience for recognition, identification, and infection control of human" exact="leptospirosis" post="in the Korea would be able to take advantages"/>
   <result pre="challenges. Herein, the author provides the historical review of human" exact="leptospirosis" post="in the Korea between 1945 and 2015, with a"/>
   <result pre="in Leptospira and leptospirosis. There were many more articles on" exact="leptospirosis" post="than those cited in this review. Some of them"/>
   <result pre="1. Occurrence and epidemics 1) Early history of discovery of" exact="leptospirosis" post="in other countries In beginning the historical review of"/>
   <result pre="leptospirosis in other countries In beginning the historical review of" exact="leptospirosis" post="in the Korea, it is necessary to look back"/>
   <result pre="the early history of the disease in other countries. Since" exact="leptospirosis" post="was first described as Weil's disease, by physician Adolf"/>
   <result pre="by physician Adolf Weil in 1886 in Germany, a characteristic" exact="infectious disease" post="accompanied by splenomegaly, jaundice, and nephritis [1], leptospirosis was"/>
   <result pre="Germany, a characteristic infectious disease accompanied by splenomegaly, jaundice, and" exact="nephritis" post="[1], leptospirosis was recognized as a new disease differentiated"/>
   <result pre="characteristic infectious disease accompanied by splenomegaly, jaundice, and nephritis [1]," exact="leptospirosis" post="was recognized as a new disease differentiated from other"/>
   <result pre="and domestic animals were determined. The important basic knowledge of" exact="leptospirosis" post="and Leptospira species was largely described in the early"/>
   <result pre="the early 1950s [3]. 2) Lack of evidence for human" exact="leptospirosis" post="(1945 – 1969) Historically, the presence of leptospirosis in"/>
   <result pre="for human leptospirosis (1945 – 1969) Historically, the presence of" exact="leptospirosis" post="in Korea had long been a subject of debate"/>
   <result pre="the number of cases of Korean hemorrhagic fever and infectious" exact="hepatitis" post="occurred. Korean and American medical scientists studied extensively on"/>
   <result pre="hepatitis occurred. Korean and American medical scientists studied extensively on" exact="leptospirosis" post="for those with fever, jaundice, and hemorrhagic manifestation, but"/>
   <result pre="isolates were serologically very close to L. icterohaemorrhagica [4]. Therefore," exact="leptospirosis" post="was recognized their existence among animals, but human cases"/>
   <result pre="(n = 137, 91.7%). Based on these findings, primary atypical" exact="pneumonia" post="or viral pneumonia was suggested as a potential cause"/>
   <result pre="137, 91.7%). Based on these findings, primary atypical pneumonia or" exact="viral pneumonia" post="was suggested as a potential cause of the disease"/>
   <result pre="91.7%). Based on these findings, primary atypical pneumonia or viral" exact="pneumonia" post="was suggested as a potential cause of the disease"/>
   <result pre="and cerebral hemorrhage and monocyte infiltrations, especially with hemorrhagic interstitial" exact="pneumonia" post="[14]. In addition, the Korean Armed Forces Capital Hospital"/>
   <result pre="Forces Capital Hospital reported 20 patients with acute febrile hemorrhagic" exact="lung disease" post="of unknown cause who were young and previously healthy"/>
   <result pre="and previously healthy [15]; some cases developed rapid progressive acute" exact="pulmonary edema," post="dyspnea, and death, others recovered completely within short periods"/>
   <result pre="disease, such as pesticide poisoning, pulmonary allergic condition, and idiopathic" exact="viral pneumonia;" post="however, the etiology of the disease remained undetermined. Two"/>
   <result pre="public interest since the epidemic in 1975. 4) Identification of" exact="leptospirosis" post="during the second epidemic (1984) On September 1984, there"/>
   <result pre="fall, serving as carriers. The differential diagnoses included endemic typhus," exact="scrub typhus," post="other rickettsioses, Korean hemorrhagic fever, new viral disease, and"/>
   <result pre="endemic typhus, scrub typhus, other rickettsioses, Korean hemorrhagic fever, new" exact="viral disease," post="and leptospirosis. Leptospirosis was chosen to be the most"/>
   <result pre="a retrospective view, the confirmation of the first epidemic of" exact="leptospirosis" post="occurred in the Korea was delayed by at least"/>
   <result pre="kidney renal failure. 5) Yearly trends in the occurrence of" exact="leptospirosis" post="(1987 – 2015) The exact number of cases of"/>
   <result pre="had been endemic in the Korea. Since serological diagnosis of" exact="leptospirosis" post="was available at the KNIH in 1985, approximately 200"/>
   <result pre="Gyeonggi Province by Choi et al., the attack rate of" exact="leptospirosis" post="from September to December, 1989 was 1.12 - 3.35"/>
   <result pre="nationally [23]. Figure 1 Annual number of reported cases of" exact="leptospirosis" post="and incidence per 100,000 population (1987 – 2015). 6)"/>
   <result pre="incidence per 100,000 population (1987 – 2015). 6) Estimation of" exact="leptospirosis" post="by seroepidemiological studies (1985 – 1990) (1) Serologic tests"/>
   <result pre="for acute febrile illnesses With the confirmation of epidemics of" exact="leptospirosis" post="and scrub typhus in the Korea in 1984 and"/>
   <result pre="febrile illnesses With the confirmation of epidemics of leptospirosis and" exact="scrub typhus" post="in the Korea in 1984 and 1987, respectively, Ho"/>
   <result pre="illnesses With the confirmation of epidemics of leptospirosis and scrub" exact="typhus" post="in the Korea in 1984 and 1987, respectively, Ho"/>
   <result pre="diseases were febrile illnesses that showed early symptoms similar to" exact="hemorrhagic fever with renal syndrome" post="(HFRS), which had been endemic in the Korea; natural"/>
   <result pre="cases (28%) with leptospirosis, and 129 of 1,230 (11%) with" exact="scrub typhus." post="The remaining 41% of patients had undetermined causes. In"/>
   <result pre="and 52% (1,083/2,068) of patients were diagnosed with HFRS, leptospirosis," exact="scrub typhus," post="and undetermined causes, respectively [24]. Since some residents in"/>
   <result pre="8% in Jeonnam, reflecting the decreased number of cases of" exact="leptospirosis" post="in 1986 compared to those reported in 1985. In"/>
   <result pre="microscopic agglutination test (MAT) conducted in 1,141 patients with suspected" exact="leptospirosis" post="in Seoul, Gyeonggi, Gangwon, Chungbuk, Gyeongbuk, Jeonbuk, and Jeonnam"/>
   <result pre="analyzed and reported the yearly, monthly, and regional occurrence of" exact="leptospirosis" post="in local residents as well as the patients with"/>
   <result pre="observed in these patients were similar to those observed in" exact="leptospirosis" post="epidemics in China and that the major serovar responsible"/>
   <result pre="Epidemiological characteristics of epidemics in the Republic of Korea Human" exact="leptospirosis" post="can be classified into water-borne infections or those associated"/>
   <result pre="with seasonal fluctuation of cases [48]. The epidemiological characteristics of" exact="leptospirosis" post="in the Korea were described during the epidemics in"/>
   <result pre="and 13. Figure 2 The epidemic curve of cases with" exact="leptospirosis" post="following a flood in Chunbuk and Chunnam area of"/>
   <result pre="with a total precipitation of 500 mm, an epidemic of" exact="leptospirosis" post="was anticipated; an epidemiologic study was conducted in Yangpyeon-gun,"/>
   <result pre="the floods during September 2000 were associated with occurrence of" exact="leptospirosis" post="in 12 auxiliary police officers who worked in post-flooding"/>
   <result pre="term &quot;serovar-specific syndrome�? is no longer used. Clinical course of" exact="leptospirosis" post="may show a biphasic pattern comprising the leptospiremic and"/>
   <result pre="asphyxiation due to massive hemoptysis from pulmonary hemorrhage and acute" exact="respiratory failure" post="within 4 days. Although many patients recovered without sequelae,"/>
   <result pre="within 5–6 days. The pulmonary findings then improved rapidly like" exact="pulmonary edema," post="which was a clear difference from other types of"/>
   <result pre="edema, which was a clear difference from other types of" exact="pneumonia" post="[55]. The pulmonary hemorrhage finding in leptospirosis had been"/>
   <result pre="other types of pneumonia [55]. The pulmonary hemorrhage finding in" exact="leptospirosis" post="had been already described in China between 1959 and"/>
   <result pre="strain reported in both countries [56]. Since the late 1990s," exact="leptospirosis" post="has regained attention as an emerging infectious disease in"/>
   <result pre="the late 1990s, leptospirosis has regained attention as an emerging" exact="infectious disease" post="in several countries, and severe pulmonary form of leptospirosis"/>
   <result pre="infectious disease in several countries, and severe pulmonary form of" exact="leptospirosis" post="(SPFL) in epidemic or sporadic cases has also been"/>
   <result pre="and cytotoxicity of pore-forming toxin [6566]. Since serological diagnosis of" exact="leptospirosis" post="was provided in the Korea, various clinical manifestations were"/>
   <result pre="organs involved and disease severity: Weil's disease, pulmonary hemorrhage, acute" exact="kidney failure," post="influenza-like illness, and acute hepatitis. Regional differences in clinical"/>
   <result pre="in frequency; hemoptysis (89%), oliguria (37%), jaundice (63%), and skin" exact="rash" post="(18%) [6768]. In terms of regional differences in clinical"/>
   <result pre="infiltration; and 53.8% had abnormal urinary sediments. Jaundice, skin rash," exact="kidney failure," post="central nervous system damage, and thrombocytopenia were relatively rare."/>
   <result pre="Jaundice, skin rash, kidney failure, central nervous system damage, and" exact="thrombocytopenia" post="were relatively rare. More than 90% of patients were"/>
   <result pre="none of the patients experienced hemoptysis, and a few showed" exact="meningitis" post="symptoms and jaundice [70]. In Chuncheon, Gangwon Province, 62.5%"/>
   <result pre="Province, 62.5% and 75% of 18 cases in 1985 showed" exact="pulmonary edema" post="and congestion without hemoptysis and hypoalbuminemia, respectively [71]. Of"/>
   <result pre="involved, and the frequency of blood-tinged sputum, dyspnea, and skin" exact="rash" post="differed regionally. 3. Prevention and infection control As the"/>
   <result pre="regionally. 3. Prevention and infection control As the epidemic of" exact="leptospirosis" post="was confirmed nationwide in the fall of 1984, health"/>
   <result pre="prevention and management strategies; systematic research on clinical microbiology of" exact="leptospirosis" post="in the Korea (determination of the causative serovars, major"/>
   <result pre="[2547]. 1) Detailed investigation of the occurrence Differential diagnosis of" exact="leptospirosis" post="from other febrile illnesses common during fall was difficult"/>
   <result pre="from 1,313 patients with suspected leptospirosis, resulting in diagnoses of" exact="leptospirosis" post="in 264 cases. Clinical and epidemiological characteristics of the"/>
   <result pre="and Welfare for surveillance to assess epidemics). In December 1993," exact="leptospirosis" post="was designated again as a group 2 legal communicable"/>
   <result pre="they can be managed and prevented through vaccination). In 2001," exact="leptospirosis" post="was further designated as a group 3 notifiable communicable"/>
   <result pre="without delay. 3) Prevention and management strategies Preventive measures for" exact="leptospirosis" post="can be divided into management of reservoirs, management of"/>
   <result pre="effects may arise from contamination of media; therefore, the inactivated" exact="leptospirosis" post="vaccine was discontinued. (2) Public health projects on management"/>
   <result pre="below (refer to press release from September 1999): - Since" exact="leptospirosis" post="is common among individuals who work in rice fields"/>
   <result pre="Weil's disease (Spirochaetosis icterohemorrhagica)J Exp Med19162337740219867994 2WeilAOn a strange, acute" exact="infectious disease," post="accompanied by swelling of the spleen, icterus, and nephritis[German]Dtsch"/>
   <result pre="respiratory diseasesJ Korean Med Assoc197619269273 9KimKHHongSJLeeHSKangMWKimHYChungKWChungHYChunCHKimSMLeeCMKimJJClinical pictures of the hemorrhagic" exact="pneumonia" post="like disease which occurred epidemically in the central area"/>
   <result pre="gross and histopathological findingsJ Korean Med Assoc197619307309 15RoYMYukSJYoonHJChoiJSChoHKHahnBSKimKSParkCIHanHSAcute febrile hemorrhagic" exact="lung disease" post="of unknown cause – A report of 20 cases"/>
   <result pre="Med Assoc198023131144 18KimJSLeeCWOhDKInSDLeeYHChoWHLeeWYKimSOAn analytic epidemiological study to test the hypothesis," exact="leptospirosis" post="as the cause of epidemic pulmonary hemorrhagic fever in"/>
   <result pre="pulmonary hemorrhagic fever in KoreaKorean J Epidemiol19846815 19ChoMKPaikSBOhHBSongCBacteriological studies on" exact="leptospirosis" post="in Korea (1984)Korean J Epidemiol198461626 20LeeWYLeeBKKimJDKimJSKimSOLeptospira interrogans &quot;Korea�? isolated"/>
   <result pre="leptospirosisJ Korean Med Assoc19943714081414 23ChoiBYKangSMLeeSJParkHBKimDWOhSJKimJSThe surveillance and management system of" exact="leptospirosis" post="in a rural community of Korea, 1989 and 1990Korean"/>
   <result pre="Korea from 1985 to 1987 (hemorrhagic fever with renal syndrome," exact="leptospirosis" post="and scrub typhus)J Korean Med Assoc198831581593 25collab: National Institute"/>
   <result pre="of Leptospira interrogans isolated in Korea and seroepidemiological study on" exact="leptospirosis" post="(1984-1987)J Korean Med Assoc198831612622 27ChoMKMinCHKimYWYoonCSSerological studies on leptospirosis in"/>
   <result pre="study on leptospirosis (1984-1987)J Korean Med Assoc198831612622 27ChoMKMinCHKimYWYoonCSSerological studies on" exact="leptospirosis" post="in Kangwondo area (1985)J Korean Soc Microbiol198621205210 28ChangWHChoiMSParkKHLeeWKKimSYChoiIHChoeKWWooJHSongYWChoiDHLeeJHKimWYKeeJIParkYSKangSKParkSKYoonSYKimJWChungSSKimSYSeroepidemiological study"/>
   <result pre="in Kangwondo area (1985)J Korean Soc Microbiol198621205210 28ChangWHChoiMSParkKHLeeWKKimSYChoiIHChoeKWWooJHSongYWChoiDHLeeJHKimWYKeeJIParkYSKangSKParkSKYoonSYKimJWChungSSKimSYSeroepidemiological study of" exact="leptospirosis" post="in Korea, 1987Korean J Infect Dis198820179186 29ChangWHChoiMSKeeSHKimISParkCSKimIJChoiSBChoeKWWooJHKangJSChoiDHKimJWKimSHLeeJHKimSYKeeJIKimSYParkKHYoonSYKimMCKangSKLeeYKLeeWKChoiIHKimBCSeroepidemiological survey of"/>
   <result pre="leptospirosis in Korea, 1987Korean J Infect Dis198820179186 29ChangWHChoiMSKeeSHKimISParkCSKimIJChoiSBChoeKWWooJHKangJSChoiDHKimJWKimSHLeeJHKimSYKeeJIKimSYParkKHYoonSYKimMCKangSKLeeYKLeeWKChoiIHKimBCSeroepidemiological survey of" exact="leptospirosis" post="in Korea, 1988 and 1989J Korean Soc Microbiol199025341346 30KimYWChoMKKimHSYoonCSYooKSLeeJHMinCHPatterns"/>
   <result pre="Korean Soc Microbiol199025341346 30KimYWChoMKKimHSYoonCSYooKSLeeJHMinCHPatterns of acute febrile illness (murine typhus," exact="scrub typhus," post="leptospirosis and hemorrhagic fever with renal syndrome) from 1986"/>
   <result pre="Microbiol199025341346 30KimYWChoMKKimHSYoonCSYooKSLeeJHMinCHPatterns of acute febrile illness (murine typhus, scrub typhus," exact="leptospirosis" post="and hemorrhagic fever with renal syndrome) from 1986 to"/>
   <result pre="1990 in KoreaJ Korean Soc Microbiol199126431441 31ChangWHKimISChoiMSKeeSHHahnMJSeongSYUhmKHLeeJHKangJSKimSYParkKHKimIJSeroepidemiological survey of the" exact="leptospirosis" post="in Korea, 1986-1991J Korean Soc Microbiol1993281322 32DikkenHKmetyESerological typing method"/>
   <result pre="with monoclonal antibodiesKorean J Med198732571579 37KimMJParkSCOhHBClinical features of serologically proven" exact="leptospirosis" post="in Korea and changes in leptospiral agglutinin titerKorean J"/>
   <result pre="Leptospirosis Research SocietyTokyoHokusen-sha pub199188103 54ChangWGSongMJChaYHKimKGPaikUHKimYKKimSYKimYJChoMKLeeGJAn epidemiological and clinical study of" exact="leptospirosis" post="acquired by twelves combat policemen in september, 2000Korean J"/>
   <result pre="fever summarized from papers publishedKorean J Epidemiol1984637 56KimMJClinical characteristics of" exact="leptospirosis" post="in KoreaJ Korean Med Assoc198831623627 57SilvaJJDalstonMOCarvalhoJESetúbalSOliveiraJMPereiraMMClinicopathological and immunohistochemical features"/>
   <result pre="an emerging disease in Buenos Aires, ArgentinaEmerg Infect Dis200281004100512194784 59YersinCBovetPMérienFWongTPanowskyJPerolatPHuman" exact="leptospirosis" post="in the Seychelles (Indian Ocean): a population-based studyAm J"/>
   <result pre="pulmonary manifestations in leptospirosisBraz J Infect Dis20071114214817625743 61KangSJLeeKJParkKHJungSIClinical features of" exact="leptospirosis" post="experienced in a university hospital between 2001 and 2007Korean"/>
   <result pre="leptospirosisKorean J Med200977450452 63ChangWKimILeeWParkKLeeJChiJLeeJMicrobiological and pathological features of experimentally induced" exact="leptospirosis" post="in guinea pigsJ Korean Soc Microbiol198621211226 64WooJHAn experimental study"/>
   <result pre="the case identified as leptospirosisKorean J Epidemiol198464751 68LeeJSAhnCOhHYKimSChoiKWLeeMChiJGKimYISulDSParkJMParkYHClinical studies on" exact="leptospirosis" post="in KoreaJ Korean Med Assoc198629537547 69KimSYYoonSJKimJOLeeBHThe leptospirosis associated with"/>
   <result pre="68LeeJSAhnCOhHYKimSChoiKWLeeMChiJGKimYISulDSParkJMParkYHClinical studies on leptospirosis in KoreaJ Korean Med Assoc198629537547 69KimSYYoonSJKimJOLeeBHThe" exact="leptospirosis" post="associated with fever and rashKorean J Infect Dis1986181923 70KimSJKimJMHyunCOHongSYSongBSRhuHKParkSCA"/>
   <result pre="fever and rashKorean J Infect Dis1986181923 70KimSJKimJMHyunCOHongSYSongBSRhuHKParkSCA clinical study of" exact="leptospirosis" post="in Chung Nam areaKorean J Infect Dis1987193337 71KimWYHanSYKimSKSuhJEJooSAKimKMThe 16"/>
   <result pre="Chung Nam areaKorean J Infect Dis1987193337 71KimWYHanSYKimSKSuhJEJooSAKimKMThe 16 cases of" exact="leptospirosis" post="in Chuncheon areaKorean J Med198630745750 72LeeYCLeeSHKwakSTHongKIChoiMKKimYKKimKMKimYWChoMKThe 13 cases of"/>
   <result pre="in Chuncheon areaKorean J Med198630745750 72LeeYCLeeSHKwakSTHongKIChoiMKKimYKKimKMKimYWChoMKThe 13 cases of confirmed" exact="leptospirosis" post="in Chun Cheon area, by the culture and isolation"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6780294\results\search\disease\results.xml">
   <result pre="cited. Abstract Objectives Estimating influenza-associated mortality is important since seasonal" exact="influenza" post="affects persons of all ages, causing severe illness or"/>
   <result pre="influenza-associated mortality, considering both periodic changes and age-specific mortality by" exact="influenza" post="subtypes. Methods Using the Microdata Integrated Service from Statistics"/>
   <result pre="used a negative binomial regression model by age group and" exact="influenza" post="subtype. Results Overall, 1 859 890 deaths were observed"/>
   <result pre="859 890 deaths were observed and the average rate of" exact="influenza" post="virus positivity was 14.7% (standard deviation [SD], 5.8), with"/>
   <result pre="deaths, 2521 (3.05%) respiratory or circulatory deaths, and 1048 (18.23%)" exact="influenza" post="or pneumonia deaths were estimated. Among those 65 years"/>
   <result pre="(3.05%) respiratory or circulatory deaths, and 1048 (18.23%) influenza or" exact="pneumonia" post="deaths were estimated. Among those 65 years of age"/>
   <result pre="16 411 (3.42%) respiratory or circulatory deaths, and 4906 (6.87%)" exact="influenza" post="or pneumonia deaths were estimated. Influenza A(H3N2) virus was"/>
   <result pre="(3.42%) respiratory or circulatory deaths, and 4906 (6.87%) influenza or" exact="pneumonia" post="deaths were estimated. Influenza A(H3N2) virus was the major"/>
   <result pre="and respiratory or circulatory deaths in both age groups. However," exact="influenza" post="A(H1N1) virus–associated influenza or pneumonia deaths were more common"/>
   <result pre="circulatory deaths in both age groups. However, influenza A(H1N1) virus–associated" exact="influenza" post="or pneumonia deaths were more common in those under"/>
   <result pre="in both age groups. However, influenza A(H1N1) virus–associated influenza or" exact="pneumonia" post="deaths were more common in those under 65 years"/>
   <result pre="substantial during this period, especially in the elderly. By subtype," exact="influenza" post="A(H3N2) virus made the largest contribution to influenza-associated mortality."/>
   <result pre="illness Mortality Aged Korea INTRODUCTION Influenza is a common acute" exact="respiratory disease" post="caused by influenza virus. Although influenza is frequently confused"/>
   <result pre="INTRODUCTION Influenza is a common acute respiratory disease caused by" exact="influenza" post="virus. Although influenza is frequently confused with the common"/>
   <result pre="a common acute respiratory disease caused by influenza virus. Although" exact="influenza" post="is frequently confused with the common cold, some individuals"/>
   <result pre="by influenza virus. Although influenza is frequently confused with the" exact="common cold," post="some individuals with influenza can become severely ill, to"/>
   <result pre="is frequently confused with the common cold, some individuals with" exact="influenza" post="can become severely ill, to the point of hospitalization"/>
   <result pre="of adults and 20-30% of children are infected by the" exact="influenza" post="virus every year [1-3]. Therefore, measuring the disease burden"/>
   <result pre="every year [1-3]. Therefore, measuring the disease burden of seasonal" exact="influenza" post="is of major interest among infection epidemiologists [4-6]. A"/>
   <result pre="measure the disease burden is to estimate the mortality of" exact="influenza" post="by comparing the mortality rate to the rate of"/>
   <result pre="influenza by comparing the mortality rate to the rate of" exact="influenza" post="virus positivity. However, because of the seasonality of influenza"/>
   <result pre="of influenza virus positivity. However, because of the seasonality of" exact="influenza" post="virus and the annual variability of subtypes that cause"/>
   <result pre="directly from influenza, we cannot estimate the substantial impact that" exact="influenza" post="virus may exert by inducing severe complications that lead"/>
   <result pre="of influenza. This study aimed to estimate influenza-associated deaths considering" exact="influenza" post="type, patients’ age, and various causes of death, and"/>
   <result pre="and various causes of death, and to explore differences in" exact="influenza" post="severity by age group through these results. We used"/>
   <result pre="or circulatory (diseases of the circulatory system, I00-I99) deaths, and" exact="influenza" post="or pneumonia (influenza and pneumonia, J09-J18) deaths. We also"/>
   <result pre="(diseases of the circulatory system, I00-I99) deaths, and influenza or" exact="pneumonia" post="(influenza and pneumonia, J09-J18) deaths. We also selected other"/>
   <result pre="We also selected other chronic causes of deaths such as" exact="cancer" post="(neoplasms, C00-D48) to compare the results. Age-specific weekly deaths"/>
   <result pre="The Korea Centers for Disease Control and Prevention (KCDC) provided" exact="influenza" post="virus surveillance data through the Korea Influenza and Respiratory"/>
   <result pre="reported tested and positive samples for the following subtypes of" exact="influenza" post="virus: influenza A(H1N1), influenza A(H3N2), and influenza B virus."/>
   <result pre="and positive samples for the following subtypes of influenza virus:" exact="influenza" post="A(H1N1), influenza A(H3N2), and influenza B virus. Since the"/>
   <result pre="samples for the following subtypes of influenza virus: influenza A(H1N1)," exact="influenza" post="A(H3N2), and influenza B virus. Since the KCDC started"/>
   <result pre="following subtypes of influenza virus: influenza A(H1N1), influenza A(H3N2), and" exact="influenza" post="B virus. Since the KCDC started separate monitoring of"/>
   <result pre="B virus. Since the KCDC started separate monitoring of each" exact="influenza" post="virus type in 2009, we used data from 2009"/>
   <result pre="data from 2009 to 2016 in our models. Since the" exact="influenza" post="surveillance system is organized by season globally, we structured"/>
   <result pre="distribution of age-specific deaths and the positivity rate of each" exact="influenza" post="virus in this study needed additional free parameters for"/>
   <result pre="2009-2016, we used a negative binomial regression model [31] considering" exact="influenza" post="subtypes, age, and various causes of death. An additional"/>
   <result pre="475 underlying respiratory or circulatory deaths, and 77 850 underlying" exact="influenza" post="or pneumonia deaths were observed (Table 1). Deaths among"/>
   <result pre="respiratory or circulatory deaths, and 77 850 underlying influenza or" exact="pneumonia" post="deaths were observed (Table 1). Deaths among those at"/>
   <result pre="deaths), 85.3% (respiratory or circulatory deaths), and 92.5% (influenza or" exact="pneumonia" post="deaths) of deaths. In the respiratory virus surveillance data,"/>
   <result pre="data, an average of 14.6% of specimens tested positive for" exact="influenza" post="virus, with the following subtype distribution: influenza A(H1N1) virus,"/>
   <result pre="tested positive for influenza virus, with the following subtype distribution:" exact="influenza" post="A(H1N1) virus, 5.0%; influenza A(H3N2) virus, 4.3%; and influenza"/>
   <result pre="virus, with the following subtype distribution: influenza A(H1N1) virus, 5.0%;" exact="influenza" post="A(H3N2) virus, 4.3%; and influenza B virus, 5.3% (Table"/>
   <result pre="distribution: influenza A(H1N1) virus, 5.0%; influenza A(H3N2) virus, 4.3%; and" exact="influenza" post="B virus, 5.3% (Table 2). Influenza A(H1N1) virus was"/>
   <result pre="cause of epidemics in the 2009-2010 and 2010-2011 seasons, while" exact="influenza" post="A(H3N2) virus was the major cause of epidemics in"/>
   <result pre="epidemic in the 2013-2014 season. In the 2015-2016 season, both" exact="influenza" post="A(H1N1) and influenza B virus were epidemic. The overall"/>
   <result pre="2013-2014 season. In the 2015-2016 season, both influenza A(H1N1) and" exact="influenza" post="B virus were epidemic. The overall estimated influenza-associated all-cause"/>
   <result pre="65 years old were estimated to be influenza-associated deaths. While" exact="influenza" post="A(H3N2) and influenza B virus contributed to deaths in"/>
   <result pre="were estimated to be influenza-associated deaths. While influenza A(H3N2) and" exact="influenza" post="B virus contributed to deaths in the younger population"/>
   <result pre="a similar rate (0.50% and 0.48% of all-cause deaths each)," exact="influenza" post="A(H3N2) virus made the largest contribution of the 3"/>
   <result pre="not significantly different by age group. Similarly to all-cause deaths," exact="influenza" post="A(H3N2) virus made the largest contribution to respiratory or"/>
   <result pre="65 years old (2.27%). Furthermore, 1048 (18.23%) and 4906 (6.87%)" exact="influenza" post="or pneumonia deaths were estimated to have occurred in"/>
   <result pre="old (2.27%). Furthermore, 1048 (18.23%) and 4906 (6.87%) influenza or" exact="pneumonia" post="deaths were estimated to have occurred in the age"/>
   <result pre="and 65 years or older, respectively, and 10.05% of the" exact="influenza" post="or pneumonia deaths in individuals under 65 years old"/>
   <result pre="years or older, respectively, and 10.05% of the influenza or" exact="pneumonia" post="deaths in individuals under 65 years old were due"/>
   <result pre="deaths in individuals under 65 years old were due to" exact="influenza" post="A(H1N1) virus. In addition to season, age group and"/>
   <result pre="cause of death contributed to differences in estimated deaths by" exact="influenza" post="subtype. We only considered 3 causes of death and"/>
   <result pre="subtype. We only considered 3 causes of death and 3" exact="influenza" post="subtypes since no other causes of deaths or respiratory"/>
   <result pre="and model fit. By adding the estimated mortality of each" exact="influenza" post="subtype, we were able to apply the model more"/>
   <result pre="linear models to estimate the excess mortality rate caused by" exact="influenza" post="from 2003 through 2013. However, since it is inappropriate"/>
   <result pre="be monitored, and the laboratory method for detecting positivity. Therefore," exact="influenza" post="positivity rates before and after 2006 are non-comparable. Additionally,"/>
   <result pre="our analysis of estimated influenza-associated deaths by type of influenza," exact="influenza" post="A(H3N2) virus caused the most excess mortality, accounting for"/>
   <result pre="focus on because this study included the 2009-2010 season, when" exact="influenza" post="A(H1N1) virus became pandemic worldwide. Based on this fact,"/>
   <result pre="this fact, it can be inferred that the infectivity of" exact="influenza" post="A(H1N1) virus was high, but the mortality rate was"/>
   <result pre="but the mortality rate was low, or that the later" exact="influenza" post="viruses’ mortality rate was higher than that of influenza"/>
   <result pre="later influenza viruses’ mortality rate was higher than that of" exact="influenza" post="A(H1N1) virus. Regardless of the study period, a higher"/>
   <result pre="Regardless of the study period, a higher mortality rate of" exact="influenza" post="A(H3N2) virus has also been proven in other countries,"/>
   <result pre="the difference in the proportion of deaths attributable to different" exact="influenza" post="subtypes between age groups. According to estimates of influenza-associated"/>
   <result pre="older individuals (65 years or older) were more vulnerable to" exact="influenza" post="A(H3N2) virus. Considering that the deaths of individuals 65"/>
   <result pre="negligible. Since the mortality data were extracted from death certificates," exact="influenza" post="or pneumonia deaths may have been over-estimated, especially in"/>
   <result pre="the mortality data were extracted from death certificates, influenza or" exact="pneumonia" post="deaths may have been over-estimated, especially in the 2009-2010"/>
   <result pre="as supported by previous studies [8,15,35,36], estimated all-cause deaths or" exact="influenza" post="or pneumonia deaths could have been overestimated or underestimated."/>
   <result pre="by previous studies [8,15,35,36], estimated all-cause deaths or influenza or" exact="pneumonia" post="deaths could have been overestimated or underestimated. Therefore, it"/>
   <result pre="lead to underestimation of influenza-associated mortality in young adults because" exact="influenza" post="or pneumonia deaths and respiratory or circulatory deaths occur"/>
   <result pre="underestimation of influenza-associated mortality in young adults because influenza or" exact="pneumonia" post="deaths and respiratory or circulatory deaths occur more frequently"/>
   <result pre="viral or bacterial infections in a particular week. If another" exact="infectious disease" post="were epidemic during these seasons, it could have caused"/>
   <result pre="overall rate of influenza-associated deaths indicates that the burden of" exact="influenza" post="is never light, and as noticed in the USA"/>
   <result pre="in all-cause deaths or respiratory or circulatory deaths, particularly with" exact="influenza" post="A(H3N2) virus. However, the younger (under 65 years) population"/>
   <result pre="(under 65 years) population had a higher mortality due to" exact="influenza" post="A(H1N1) virus, except for all-cause deaths. Additionally, influenza B"/>
   <result pre="due to influenza A(H1N1) virus, except for all-cause deaths. Additionally," exact="influenza" post="B virus should be considered more cautiously in them"/>
   <result pre="elderly. Further studies are needed to explain this variance in" exact="influenza" post="epidemics. CONFLICT OF INTEREST The authors have no conflicts"/>
   <result pre="https://www.who.int/news-room/fact-sheets/detail/influenza-(seasonal) 2NairHBrooksWAKatzMRocaABerkleyJAMadhiSAet al.Global burden of respiratory infections due to seasonal" exact="influenza" post="in young children: a systematic review and meta-analysisLancet201137898071917193022078723 3van"/>
   <result pre="HoekWet al.Mortality attributable to 9 common infections: significant effect of" exact="influenza" post="A, respiratory syncytial virus, influenza B, norovirus, and parainfluenza"/>
   <result pre="common infections: significant effect of influenza A, respiratory syncytial virus," exact="influenza" post="B, norovirus, and parainfluenza in elderly personsJ Infect Dis2012206562863922723641"/>
   <result pre="elderly personsJ Infect Dis2012206562863922723641 4MolinariNAOrtega-SanchezIRMessonnierMLThompsonWWWortleyPMWeintraubEet al.The annual impact of seasonal" exact="influenza" post="in the US: measuring disease burden and costsVaccine200725275086509617544181 5NielsenJVestergaardLSRichterLSchmidDBustosNAsikainenTet"/>
   <result pre="influenza-attributable mortality in the 2017/18 season: should the burden of" exact="influenza" post="B be reconsidered?Clin Microbiol Infect201910.1016/j.cmi.2019.02.011 6PaulesCISullivanSGSubbaraoKFauciASChasing seasonal influenza -"/>
   <result pre="burden of influenza B be reconsidered?Clin Microbiol Infect201910.1016/j.cmi.2019.02.011 6PaulesCISullivanSGSubbaraoKFauciASChasing seasonal" exact="influenza" post="- the need for a universal influenza vaccineN Engl"/>
   <result pre="Infect201910.1016/j.cmi.2019.02.011 6PaulesCISullivanSGSubbaraoKFauciASChasing seasonal influenza - the need for a universal" exact="influenza" post="vaccineN Engl J Med201837817929185857 7ThompsonWWComanorLShayDKEpidemiology of seasonal influenza: use"/>
   <result pre="of diseaseJ Infect Dis2006194 Suppl 2S82S9117163394 8ThompsonWWShayDKWeintraubEBrammerLCoxNAndersonLJet al.Mortality associated with" exact="influenza" post="and respiratory syncytial virus in the United StatesJAMA2003289217918612517228 9WangHFuCLiKLuJChenYLuEet"/>
   <result pre="weekly/annual report[cited 2019 Jun 17]. Available from: http://www.cdc.go.kr/npt/biz/npp/iss/influenzaStatisticsMain.do (Korean) 15NguyenJLYangWItoKMatteTDShamanJKinneyPLSeasonal" exact="influenza" post="infections and cardiovascular disease mortalityJAMA Cardiol20161327428127438105 16ThompsonWWWeintraubEDhankharPChengPYBrammerLMeltzerMIet al.Estimates of"/>
   <result pre="Jun 17]. Available from: http://www.cdc.go.kr/npt/biz/npp/iss/influenzaStatisticsMain.do (Korean) 15NguyenJLYangWItoKMatteTDShamanJKinneyPLSeasonal influenza infections and" exact="cardiovascular disease" post="mortalityJAMA Cardiol20161327428127438105 16ThompsonWWWeintraubEDhankharPChengPYBrammerLMeltzerMIet al.Estimates of US influenza-associated deaths made"/>
   <result pre="adultsVaccine200725584685517074423 19O’BrienMAUyekiTMShayDKThompsonWWKleinmanKMcAdamAet al.Incidence of outpatient visits and hospitalizations related to" exact="influenza" post="in infants and young childrenPediatrics20041133 Pt 158559314993554 20IzurietaHSThompsonWWKramarzPShayDKDavisRLDeStefanoFet al.Influenza"/>
   <result pre="Pt 158559314993554 20IzurietaHSThompsonWWKramarzPShayDKDavisRLDeStefanoFet al.Influenza and the rates of hospitalization for" exact="respiratory disease" post="among infants and young childrenN Engl J Med2000342423223910648764 21EickhoffTCShermanILSerflingREObservations"/>
   <result pre="associated with epidemic influenzaJAMA196117677678213726091 22LukJGrossPThompsonWWObservations on mortality during the 1918" exact="influenza" post="pandemicClin Infect Dis20013381375137811565078 23ParkMWuPGoldsteinEKimWJCowlingBJInfluenza-associated excess mortality in South KoreaAm"/>
   <result pre="2010/11-2016/ 17: the FluMOMO modelInfluenza Other Respir Viruses2018125591604 25YuXWangCChenTZhangWYuHShuYet al.Excess" exact="pneumonia" post="and influenza mortality attributable to seasonal influenza in subtropical"/>
   <result pre="the FluMOMO modelInfluenza Other Respir Viruses2018125591604 25YuXWangCChenTZhangWYuHShuYet al.Excess pneumonia and" exact="influenza" post="mortality attributable to seasonal influenza in subtropical Shanghai, ChinaBMC"/>
   <result pre="Viruses2018125591604 25YuXWangCChenTZhangWYuHShuYet al.Excess pneumonia and influenza mortality attributable to seasonal" exact="influenza" post="in subtropical Shanghai, ChinaBMC Infect Dis201717175629212467 26LytrasTPantavouKMouratidouETsiodrasSMortality attributable to"/>
   <result pre="in subtropical Shanghai, ChinaBMC Infect Dis201717175629212467 26LytrasTPantavouKMouratidouETsiodrasSMortality attributable to seasonal" exact="influenza" post="in Greece, 2013 to 2017: variation by type/subtype and"/>
   <result pre="data in Shaoyang, ChinaEnviron Res201917232633230825682 28NunesBViboudCMachadoARingholzCRebelo-de-AndradeHNogueiraPet al.Excess mortality associated with" exact="influenza" post="epidemics in Portugal, 1980 to 2004PLoS One201166e2066121713040 29HardelidPPebodyRAndrewsNMortality caused"/>
   <result pre="epidemics in Portugal, 1980 to 2004PLoS One201166e2066121713040 29HardelidPPebodyRAndrewsNMortality caused by" exact="influenza" post="and respiratory syncytial virus by age group in England"/>
   <result pre="healthcare delivery organizationsInfluenza Other Respir Viruses201812112213128960732 32ZhouHThompsonWWViboudCGRingholzCMChengPYSteinerCet al.Hospitalizations associated with" exact="influenza" post="and respiratory syncytial virus in the United States, 1993-2008Clin"/>
   <result pre="2S225S23019797736 36WalterNDTaylorTHShayDKThompsonWWBrammerLDowellSFet al.Influenza circulation and the burden of invasive pneumococcal" exact="pneumonia" post="during a non-pandemic period in the United StatesClin Infect"/>
   <result pre="Figure. 1. Estimated influenza-associated deaths per 100 000 people by" exact="influenza" post="virus type and age. A, C and E shows"/>
   <result pre="C and E shows estimated all-cause, respiratory or circulatory, and" exact="influenza" post="or pneumonia deaths by influenza virus in under 65"/>
   <result pre="E shows estimated all-cause, respiratory or circulatory, and influenza or" exact="pneumonia" post="deaths by influenza virus in under 65 years old"/>
   <result pre="all-cause, respiratory or circulatory, and influenza or pneumonia deaths by" exact="influenza" post="virus in under 65 years old group, respectively. B,"/>
   <result pre="D and F shows estimated all-cause, respiratory or circulatory, and" exact="influenza" post="or pneumonia deaths by influenza virus in over 65"/>
   <result pre="F shows estimated all-cause, respiratory or circulatory, and influenza or" exact="pneumonia" post="deaths by influenza virus in over 65 years old"/>
   <result pre="all-cause, respiratory or circulatory, and influenza or pneumonia deaths by" exact="influenza" post="virus in over 65 years old group, respectively. All"/>
   <result pre="269  Total 83 231 483 244 566 475 Influenza or" exact="pneumonia" post="deaths  2009-2010 567 6240 6807  2010-2011 723 7932 8655"/>
   <result pre="generated from Statistics Korea. Table 2. Annual positivity rates of" exact="influenza" post="virus from the 2009-2010 through 2015-2016 seasons1 Season Influenza"/>
   <result pre="2015-2016 seasons1 Season Influenza A virus Influenza B virus All" exact="influenza" post="viruses All respiratory viruses H1N1 H3N2 2009-2010 17.0 0.1"/>
   <result pre="as %. SD, standard deviation. 1The annual positivity rates of" exact="influenza" post="virus were provided by the Korea Influenza and Respiratory"/>
   <result pre="influenza-associated deaths by the cause of death, the type of" exact="influenza" post="virus, and age1 Season Influenza A virus Influenza B"/>
   <result pre="1.49 0.73 0.89 2.27 0.67 0.42 3.05 3.42 Influenza or" exact="pneumonia" post="deaths  2009-2010 121 328 0 7 16 63 137"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6780377\results\search\disease\results.xml">
   <result pre="arthropod-borne viruses 1. Introduction Dengue is an important arthropod-borne viral" exact="infectious disease" post="caused by any one of the four-dengue virus (DENV-1"/>
   <result pre="regions, which has led to its categorization as an emerging" exact="infectious disease" post="[1,2]. The genus includes more than 70 small-enveloped viruses"/>
   <result pre="genus includes more than 70 small-enveloped viruses related to Japanese" exact="encephalitis" post="(JEV), Zika viruses (ZIKV), West Nile (WNV), yellow fever"/>
   <result pre="to Japanese encephalitis (JEV), Zika viruses (ZIKV), West Nile (WNV)," exact="yellow fever" post="virus (YFV), DENV, or tick-borne encephalitis (TBEV), and other"/>
   <result pre="(ZIKV), West Nile (WNV), yellow fever virus (YFV), DENV, or" exact="tick-borne encephalitis" post="(TBEV), and other medically-important arboviruses [3]. Most importantly, DENV"/>
   <result pre="West Nile (WNV), yellow fever virus (YFV), DENV, or tick-borne" exact="encephalitis" post="(TBEV), and other medically-important arboviruses [3]. Most importantly, DENV"/>
   <result pre="symptoms (asymptomatic or only mildly symptomatic). In the case of" exact="dengue fever" post="(DF), patients may experience headache, myalgia, rash, leukopenia, arthralgia,"/>
   <result pre="arthralgia, retro-orbital pain, and hemorrhagic manifestations. Thereafter, patients suffering from" exact="dengue hemorrhagic fever" post="(DHF) may develop petechiae, bruising, thrombocytopenia, and shock. Ultimate"/>
   <result pre="transmission process was akin to the &quot;jungle cycle�? of the" exact="yellow fever" post="virus [14,15,16]. From 1922 to 1945, many outbreaks were"/>
   <result pre="to 1944, a major breakthrough occurred in the treatment of" exact="dengue fever," post="when Dr. R. Kimura (Japan) and Dr. S. Hotta"/>
   <result pre="of needle injuries [25,26,27,28,29], while vertical transmission is responsible for" exact="dengue fever" post="cases in infants born to a DHF-diagnosed mother [30]."/>
   <result pre="complete their life cycles. For example, RNA replication of the" exact="hepatitis" post="C virus (HCV) depends on the human homologue of"/>
   <result pre="4 (CXCR-4)—chemokine receptors as mediators of HIV infections [52,53,54]. The" exact="influenza" post="virus requires post-entry steps for its replication and, for"/>
   <result pre="for biosynthetic processes (Figure 2), such as in the case" exact="cancer" post="cells and human cytomegalovirus (HCMV) cells [3,4,5,6]. As DENV"/>
   <result pre="that using brequinar (a known DHODH inhibitor), an anti-metabolite in" exact="cancer" post="and immune-suppression, can inhibit DENV type 1,2,3 (DENV-1,2,3) serotypes."/>
   <result pre="infected mouse. The efficacy analyses were performed in patients with" exact="dengue fever" post="[115]. The compound celgosivir is generally safe and well-tolerated"/>
   <result pre="from Uncaria tomentosa, Norantea brasiliensis Choisy, Uncaria guianensis [196,197], promyelocytic" exact="leukemia" post="protein intrinsic, Ivermectin [198], extracts from Cissampelos pareira Linn"/>
   <result pre="Walter Reed Army Institute of ResearchWashington, DC, USA1984 45.GermainM.MouchetJ.CordellierR.ChippauxA.CornetM.HerveJ.P.SureauP.FabreJ.RobinY.Epidemiology of" exact="yellow fever" post="in AfricaMed. Infect. Dis.197886977 46.RudnickA.L.B.E.R.T.Ecology of Dengue VirusAsian J."/>
   <result pre="1996Epidemiol. Bull.1996171214 50.TaiA.W.BenitaY.PengL.F.KimS.SakamotoN.XavierR.J.ChungR.T.A functional genomic screen identifies cellular cofactors of" exact="hepatitis" post="C virus replicationCell Host Microbe2009529830710.1016/j.chom.2009.02.00119286138 51.LiuH.M.AizakiH.MachidaK.OuJ.-H.J.LaiM.M.C.Hepatitis C Virus Translation"/>
   <result pre="Hydrolysis of Synthetic Fluorescent SubstratesArch. Biochem. Biophys.200745718719610.1016/j.abb.2006.11.00517184724 103.StadlerK.AllisonS.L.SchalichJ.HeinzF.X.Proteolytic activation of" exact="tick-borne encephalitis" post="virus by furinJ. Virol.199771847584819343204 104.ChambersT.NestorowiczA.AmbergS.RiceC.Mutagenesis of the Yellow Fever"/>
   <result pre="of Synthetic Fluorescent SubstratesArch. Biochem. Biophys.200745718719610.1016/j.abb.2006.11.00517184724 103.StadlerK.AllisonS.L.SchalichJ.HeinzF.X.Proteolytic activation of tick-borne" exact="encephalitis" post="virus by furinJ. Virol.199771847584819343204 104.ChambersT.NestorowiczA.AmbergS.RiceC.Mutagenesis of the Yellow Fever"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6783508\results\search\disease\results.xml">
   <result pre="as the pressures exerted by extant exogenous viruses such as" exact="influenza" post="and human immunodeficiency virus (HIV-1). Our understanding of antiviral"/>
   <result pre="of the human leukocyte antigen (HLA) locus. The co-evolution of" exact="influenza" post="virus and host immunity is discussed in the second"/>
   <result pre="argue that this is an example of antagonistic evolution, with" exact="influenza" post="virus a predator and the human host as prey."/>
   <result pre="compared to the less common motifs, in diseases such as" exact="amyotrophic lateral sclerosis" post="and breast cancer. These results are important not only"/>
   <result pre="common motifs, in diseases such as amyotrophic lateral sclerosis and" exact="breast cancer." post="These results are important not only for understanding the"/>
   <result pre="absence of treatment. The evolutionary gameplay underlying the pathogenesis of" exact="hepatitis" post="B virus's e antigen (HBVeAg) is reviewed and explored"/>
   <result pre="HBV infection as well as the disease outcomes such as" exact="cirrhosis" post="and hepatocellular carcinoma (Lumley et al.). The role of"/>
   <result pre="as well as the disease outcomes such as cirrhosis and" exact="hepatocellular carcinoma" post="(Lumley et al.). The role of interferon-α receptor-1 (IFNAR1)"/>
   <result pre="by Karamitros et al. with respect to the development of" exact="hepatocellular carcinoma." post="The authors show that the variable tandem repeat [VNTR:"/>
   <result pre="transcription profile of IFNAR1 and this may be relevant in" exact="cancer" post="pathophysiology. Finally, Beaver et al., have reviewed evidence of"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6783925\results\search\disease\results.xml">
   <result pre="Abstract The clinical severity and observed case fatality ratio of" exact="influenza" post="A/H1N1pdm09 in India, particularly in 2015 and 2017 far"/>
   <result pre="health phylogenetics India 1. Introduction In early 2009, a novel" exact="influenza" post="A H1N1 (A/H1N1pdm09) virus emerged in Veracruz, Mexico and"/>
   <result pre="Mexico and California, USA and was responsible for the first" exact="influenza" post="pandemic of the 21st century [1]. As a triple-reassortant"/>
   <result pre="influenza pandemic of the 21st century [1]. As a triple-reassortant" exact="influenza" post="virus antigenically distinct from the former seasonal A/H1N1 [2],"/>
   <result pre="since 2009, replacing pre-pandemic A/H1N1 strains [9,10], and co-circulating with" exact="influenza" post="A/H3N2 and influenza B viruses [11,12]. The first case"/>
   <result pre="pre-pandemic A/H1N1 strains [9,10], and co-circulating with influenza A/H3N2 and" exact="influenza" post="B viruses [11,12]. The first case of A/H1N1pdm09 in"/>
   <result pre="health care might be limited have been associated with excess" exact="influenza" post="mortality [6,8,17], however ongoing reports of A/H1N1pdm09 associated mortality"/>
   <result pre="have provided new insights into the evolution and dynamics of" exact="influenza" post="A viruses [21,22,23], however the use of these methods"/>
   <result pre="results have potential implications for predicting the future risk of" exact="influenza" post="A/H1N1pdm09 severity and spread, both within India and around"/>
   <result pre="relative H1 and H3 site numbering was determined using the" exact="influenza" post="research database’s (FluDB) HA Subtype Numbering algorithm [45] and"/>
   <result pre="antigenic drift) is principally responsible for the seasonal emergence of" exact="influenza" post="A epidemics worldwide [54,55], and higher rates of selection"/>
   <result pre="and D222N/G [61,62,63,64]. Outside of typical determinates associated with excess" exact="influenza" post="mortality such as reduced access to health care in"/>
   <result pre="2009 (from A/California/7/2009 to A/Michigan/45/2015) during the 2017–2019 Southern Hemisphere" exact="influenza" post="seasons [70,71]. The 2019–2020 Northern Hemisphere recommendation includes another"/>
   <result pre="includes additional residue changes [72]. Since the uptake of the" exact="influenza" post="vaccine however remains low in India, the increased selection"/>
   <result pre="contributed to the high morbidity and mortality observed there. Increasing" exact="influenza" post="vaccination rates should help to reduce the impact of"/>
   <result pre="the country, as they could also be generalisable for other" exact="influenza" post="A viruses such as A/H3N2 or other potentially pandemic"/>
   <result pre="been shown to be a significant source for globally circulating" exact="influenza" post="A/H3N2 viruses [11]. The emergence of a novel pandemic"/>
   <result pre="influenza A/H3N2 viruses [11]. The emergence of a novel pandemic" exact="influenza" post="A strain in India represents a significant health risk"/>
   <result pre="to the global population. Therefore understanding the transmission patterns of" exact="influenza" post="A within India allows for rapid risk assessment not"/>
   <result pre="with previous biological evidence suggesting cooler temperatures are favourable for" exact="influenza" post="transmission [81,82] and the known seasonality of influenza in"/>
   <result pre="favourable for influenza transmission [81,82] and the known seasonality of" exact="influenza" post="in India where large temperature variations are observed between"/>
   <result pre="(PB2) have been shown to affect viral replication in other" exact="influenza" post="A viruses such as A/H5N1 which are associated with"/>
   <result pre="residue variations within PB2, among the other gene segments of" exact="influenza" post="A. 5. Conclusions Our findings have important implications in"/>
   <result pre="Our findings have important implications in understanding the dynamics of" exact="influenza" post="A/H1N1pdm09 transmission and evolution in India which could inform"/>
   <result pre="for epidemic and pandemic risk prediction around the world. Strengthening" exact="influenza" post="surveillance capacity in the country should remain a priority,"/>
   <result pre="to publish the results. References References 1.GirardM.P.TamJ.S.AssossouO.M.KienyM.P.The 2009 A (H1N1)" exact="influenza" post="virus pandemic: A reviewVaccine2010284895490210.1016/j.vaccine.2010.05.03120553769 2.PeirisJ.S.M.PoonL.L.M.GuanY.Emergence of a novel swine-origin"/>
   <result pre="influenza virus pandemic: A reviewVaccine2010284895490210.1016/j.vaccine.2010.05.03120553769 2.PeirisJ.S.M.PoonL.L.M.GuanY.Emergence of a novel swine-origin" exact="influenza" post="a virus (S-OIV) H1N1 virus in humansJ. Clin. Virol.20094516917310.1016/j.jcv.2009.06.00619540800"/>
   <result pre="New ZealandN. Engl. J. Med.20093611925193419815860 4.MitchellR.OgunremiT.AstrakianakisG.BryceE.GervaisR.GravelD.JohnstonL.LeDucS.RothV.TaylorG.et al.Impact of the 2009" exact="influenza" post="A (H1N1) pandemic on Canadian health care workers: A"/>
   <result pre="personal protective equipmentAm. J. Infect. Control20124061161610.1016/j.ajic.2012.01.01122575285 5.WongJ.Y.KellyH.IpD.K.M.WuJ.T.LeungG.M.CowlingB.J.Case fatality risk of" exact="influenza" post="a (H1N1pdm09): A systematic reviewEpidemiology20132483084110.1097/EDE.0b013e3182a6744824045719 6.DawoodF.S.IulianoA.D.ReedC.MeltzerM.I.ShayD.K.ChengP.-Y.BandaranayakeD.BreimanR.F.BrooksW.A.BuchyP.et al.Estimated global mortality"/>
   <result pre="mortality associated with the first 12 months of 2009 pandemic" exact="influenza" post="A H1N1 virus circulation: a modelling studyLancet Infect. Dis.20121268769510.1016/S1473-3099(12)70121-422738893"/>
   <result pre="Infect. Dis.20121268769510.1016/S1473-3099(12)70121-422738893 7.Van KerkhoveM.D.HirveS.KoukounariA.MountsA.W.Estimating age-specific cumulative incidence for the 2009" exact="influenza" post="pandemic: a meta-analysis of A(H1N1)pdm09 serological studies from 19"/>
   <result pre="around Delhi, IndiaPLOS ONE20127e2912910.1371/journal.pone.002912922235265 11.BedfordT.RileyS.BarrI.G.BroorS.ChadhaM.CoxN.J.DanielsR.S.GunasekaranC.P.HurtA.C.KelsoA.et al.Global circulation patterns of seasonal" exact="influenza" post="viruses vary with antigenic driftNature201552321722010.1038/nature1446026053121 12.RussellC.A.JonesT.C.BarrI.G.CoxN.J.GartenR.J.GregoryV.GustI.D.HampsonA.W.HayA.J.HurtA.C.et al.The Global Circulation"/>
   <result pre="of Seasonal Influenza A (H3N2) VirusesScience200832034034610.1126/science.115413718420927 13.ChoudhryA.SinghS.KhareS.RaiA.RawatD.AggarwalR.ChauhanL.Emergence of pandemic 2009" exact="influenza" post="A H1N1, IndiaIndian J. Med. Res.201213553453722664503 14.GuravY.K.PawarS.D.ChadhaM.S.A PotdarV.DeshpandeA.S.KoratkarS.S.HosmaniA.H.MishraA.C.Pandemic influenza"/>
   <result pre="2009 influenza A H1N1, IndiaIndian J. Med. Res.201213553453722664503 14.GuravY.K.PawarS.D.ChadhaM.S.A PotdarV.DeshpandeA.S.KoratkarS.S.HosmaniA.H.MishraA.C.Pandemic" exact="influenza" post="A(H1N1) 2009 outbreak in a residential school at Panchgani,"/>
   <result pre="http://idsp.nic.in/showfile.php?lid=3908(accessed on 31 December 2017) 17.MurrayC.J.LopezA.D.ChinB.FeehanD.HillK.H.Estimation of potential global pandemic" exact="influenza" post="mortality on the basis of vital registry data from"/>
   <result pre="its implicationsNatl. Med. J. India201910.4103/0970-258X.253355 20.MalhotraB.SinghR.SharmaP.MeenaD.GuptaJ.AtreyaA.MeenaB.R.Epidemiological &amp;amp; clinical profile of" exact="influenza" post="A (H1N1) 2009 virus infections during 2015 epidemic in"/>
   <result pre="RajasthanIndian J. Med. Res.201614491892328474629 21.BaillieG.J.GalianoM.AgapowP.-M.MyersR.ChiamR.GallA.PalserA.L.WatsonS.J.HedgeJ.UnderwoodA.Evolutionary dynamics of local pandemic H1N1/2009" exact="influenza" post="virus lineages revealed by whole-genome analysisJ. Virol.201286111810.1128/JVI.05347-1122013031 22.HedgeJ.LycettS.J.RambautA.Real-time characterization"/>
   <result pre="analysisJ. Virol.201286111810.1128/JVI.05347-1122013031 22.HedgeJ.LycettS.J.RambautA.Real-time characterization of the molecular epidemiology of an" exact="influenza" post="pandemicBoil. Lett.201392013033110.1098/rsbl.2013.0331 23.LemeyP.RambautA.BedfordT.FariaN.R.BielejecF.BaeleG.RussellC.A.SmithD.J.PybusO.G.BrockmannD.et al.Unifying Viral Genetics and Human Transportation"/>
   <result pre="Human Influenza H3N2PLOS Pathog.201410e100393210.1371/journal.ppat.100393224586153 24.ShuY.McCauleyJ.GISAID: Global initiative on sharing all" exact="influenza" post="data—From vision to realityEurosurveillance2017223049410.2807/1560-7917.ES.2017.22.13.3049428382917 25.EdgarR.C.MUSCLE: multiple sequence alignment with"/>
   <result pre="factors that spread and sustained the Ebola epidemicNature201754430910.1038/nature2204028405027 39.ScotchM.MeiC.MakonnenY.J.PintoJ.AliA.VegsoS.KaneM.SarkarI.N.RabinowitzP.Phylogeography of" exact="influenza" post="A H5N1 clade 2.2.1.1 in EgyptBMC Genom.20131487110.1186/1471-2164-14-87124325606 40.Domestic Traffic"/>
   <result pre="online: https://ecdc.europa.eu/sites/portal/files/media/en/publications/Publications/Influenza-2013-14-season-report.pdf(accessed on 23 January 2019) 54.PetrovaV.N.RussellC.A.The evolution of seasonal" exact="influenza" post="virusesNat. Rev. Microbiol.2018164710.1038/nrmicro.2017.11829081496 55.TreanorJ.J.167—influenza (including avian influenza and swine"/>
   <result pre="54.PetrovaV.N.RussellC.A.The evolution of seasonal influenza virusesNat. Rev. Microbiol.2018164710.1038/nrmicro.2017.11829081496 55.TreanorJ.J.167—influenza (including" exact="avian influenza" post="and swine influenza)Mandell, Douglas, and Bennett’s Principles and Practice"/>
   <result pre="evolution of seasonal influenza virusesNat. Rev. Microbiol.2018164710.1038/nrmicro.2017.11829081496 55.TreanorJ.J.167—influenza (including avian" exact="influenza" post="and swine influenza)Mandell, Douglas, and Bennett’s Principles and Practice"/>
   <result pre="of Infectious Diseases8th ed.BennettJ.E.DolinR.BlaserM.J.Elsevier SaundersPhiladelphia, Pennsylvania201520002024 56.HayA.J.GregoryV.DouglasA.R.LinY.P.The evolution of human" exact="influenza" post="virusesPhilos. Trans. R. Soc. B Boil. Sci.20013561861187010.1098/rstb.2001.0999 57.YasuharaA.YamayoshiS.SoniP.TakenagaT.KawakamiC.TakashitaE.Sakai-TagawaY.UrakiR.ItoM.Iwatsuki-HorimotoK.et al.Diversity"/>
   <result pre="Soc. B Boil. Sci.20013561861187010.1098/rstb.2001.0999 57.YasuharaA.YamayoshiS.SoniP.TakenagaT.KawakamiC.TakashitaE.Sakai-TagawaY.UrakiR.ItoM.Iwatsuki-HorimotoK.et al.Diversity of antigenic mutants of" exact="influenza" post="A(H1N1)pdm09 virus escaped from human monoclonal antibodiesSci. Rep.201771773510.1038/s41598-017-17986-829255273 58.HormS.V.MardyS.RithS.LyS.HengS.VongS.KitsutaniP.IengV.TarantolaA.LyS.Epidemiological"/>
   <result pre="from human monoclonal antibodiesSci. Rep.201771773510.1038/s41598-017-17986-829255273 58.HormS.V.MardyS.RithS.LyS.HengS.VongS.KitsutaniP.IengV.TarantolaA.LyS.Epidemiological and virological characteristics of" exact="influenza" post="viruses circulating in Cambodia from 2009 to 2011PloS. ONE20149e11071310.1371/journal.pone.011071325340711"/>
   <result pre="in Cambodia from 2009 to 2011PloS. ONE20149e11071310.1371/journal.pone.011071325340711 59.NguyenH.K.L.NguyenP.T.K.NguyenT.C.HoangP.V.M.LeT.T.VuongC.D.NguyenA.P.TranL.T.T.NguyenB.G.LeM.Q.Virological characterization of" exact="influenza" post="H1N1pdm09 in Vietnam, 2010-2013Influ. Other Respir. Viruses2015921622410.1111/irv.12323 60.PandeyS.SahuM.PotdarV.BardeP.Molecular analysis"/>
   <result pre="H1N1pdm09 in Vietnam, 2010-2013Influ. Other Respir. Viruses2015921622410.1111/irv.12323 60.PandeyS.SahuM.PotdarV.BardeP.Molecular analysis of" exact="influenza" post="A H1N1pdm09 virus circulating in Madhya Pradesh, India in"/>
   <result pre="in the year 2017VirusDisease20182938038410.1007/s13337-018-0474-030159375 61.RamosA.P.HerreraB.A.RamírezO.V.GarcíaA.A.JiménezM.M.ValdésC.S.FernándezA.G.GonzálezG.FernándezS.I.O.BáezG.G.et al.Molecular and phylogenetic analysis of" exact="influenza" post="A H1N1 pandemic viruses in Cuba, May 2009 to"/>
   <result pre="2009 to August 2010Int. J. Infect. Dis.201317e565e56710.1016/j.ijid.2013.01.02823535299 62.HoungH.-S.H.GarnerJ.ZhouY.LyonsA.KuschnerR.DeyeG.ClairK.S.DouceR.W.ChicaizaW.BlairP.J.et al.Emergent 2009" exact="influenza" post="A(H1N1) viruses containing HA D222N mutation associated with severe"/>
   <result pre="in the AmericasJ. Clin. Virol.201253121510.1016/j.jcv.2011.09.00422036040 63.LedesmaJ.PozoF.ReinaG.BlascoM.RodríguezG.MontesM.López-MiragayaI.SalvadorC.ReinaJ.De LejarazuR.O.et al.Genetic diversity of" exact="influenza" post="A(H1N1)2009 virus circulating during the season 2010–2011 in SpainJ."/>
   <result pre="Major Antigenic Change During Influenza Virus EvolutionScience201334297697910.1126/science.124473024264991 66.Arellano-LlamasR.Alfaro-RuizL.CanonC.A.RosshandlerI.I.Cruz-LagunasA.ZúñigaJ.VegaR.R.WongC.W.Maurer-StrohS.CórdobaS.R.Molecular features of" exact="influenza" post="A (H1N1) pdm09 prevalent in Mexico during winter seasons"/>
   <result pre="prevalent in Mexico during winter seasons 2012–2014PloS. ONE201712e018041910.1371/journal.pone.018041928692701 67.ParidaM.DashP.K.KumarJ.S.JoshiG.TandelK.SharmaS.SrivastavaA.AgarwalA.SahaA.SaraswatS.Emergence of" exact="influenza" post="A (H1N1) pdm09 Genogroup 6B and drug resistant virus,"/>
   <result pre="resistant virus, India, January to May 2015Eurosurveillance2016213012410.2807/1560-7917.ES.2016.21.5.3012426876980 68.NakamuraK.ShirakuraM.FujisakiS.KishidaN.BurkeD.F.SmithD.J.KuwaharaT.TakashitaE.TakayamaI.NakauchiM.et al.Characterization of" exact="influenza" post="A(H1N1)pdm09 viruses isolated from Nepalese and Indian outbreak patients"/>
   <result pre="for atypical H1N1 infections among middle-aged adults during the 2013–2014" exact="influenza" post="seasonProc. Natl. Acad. Sci. USA2014111157981580310.1073/pnas.140917111125331901 70.collab: World Health OrganizationRecommended"/>
   <result pre="Natl. Acad. Sci. USA2014111157981580310.1073/pnas.140917111125331901 70.collab: World Health OrganizationRecommended composition of" exact="influenza" post="virus vaccines for use in the 2017 southern hemisphere"/>
   <result pre="RecordWorld Health OrganizationGeneva, Switzerland201691 71.collab: World Health OrganizationRecommended composition of" exact="influenza" post="virus vaccines for use in the 2019 southern hemisphere"/>
   <result pre="RecordWorld Health OrganizationGeneva, Switzerland201893553576 72.collab: World Health OrganizationRecommended composition of" exact="influenza" post="virus vaccines for use in the 2019–2020 northern hemisphere"/>
   <result pre="in MexicoVirol. J.2013104110.1186/1743-422X-10-4123369604 76.GokaE.A.VallelyP.J.MuttonK.J.KlapperP.E.GokaE.Mutations associated with severity of the pandemic" exact="influenza" post="A(H1N1)pdm09 in humans: a systematic review and meta-analysis of"/>
   <result pre="India and Implications for Vaccination TimingPLOS ONE201510012412210.1371/journal.pone.0124122 85.MageeD.SuchardM.A.ScotchM.Bayesian phylogeography of" exact="influenza" post="A/H3N2 for the 2014-15 season in the United States"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6783926\results\search\disease\results.xml">
   <result pre="phenotypic versus target-based screening strategy was established to identify the" exact="influenza" post="A virus inhibitors targeting the virus RNA transcription/replication steps"/>
   <result pre="indicates that the primary screen was robust for identification of" exact="influenza" post="A virus inhibitors targeting RdRp activity. Finally, two hit"/>
   <result pre="inhibitor 1. Introduction Influenza is an acute respiratory and highly" exact="infectious disease" post="that is mainly caused by influenza A viruses (IAVs),"/>
   <result pre="respiratory and highly infectious disease that is mainly caused by" exact="influenza" post="A viruses (IAVs), posing a serious public health problem"/>
   <result pre="health problem globally. According to the World Health Organization (WHO)," exact="influenza" post="epidemics are estimated to result in about three to"/>
   <result pre="deaths annually [1]. Further, the increase of zoonotic transmission with" exact="avian influenza" post="viruses is a growing concern [2,3]. Two classes of"/>
   <result pre="annually [1]. Further, the increase of zoonotic transmission with avian" exact="influenza" post="viruses is a growing concern [2,3]. Two classes of"/>
   <result pre="(RdRp), as well as host components (reviewed in [9,10]). The" exact="influenza" post="virus RdRp is a heterotrimer (comprised of PA, PB2,"/>
   <result pre="transcription and replication. The major role attributed to PA during" exact="influenza" post="virus infection is the endonuclease activity upon &quot;cap-snatching�? for"/>
   <result pre="and recent progress in understanding the structure and functions of" exact="influenza" post="polymerase complex has facilitated the identification of inhibitors targeting"/>
   <result pre="Japan [30,31,32]. Different screening approaches, based on cells expressing the" exact="influenza" post="virus RdRp complex, nucleoprotein (NP) and a viral mini-genomic"/>
   <result pre="mini-genomic RNA, have been recently developed for identifying inhibitors targeting" exact="influenza" post="A viral RNA transcription/replication [33,34]. However, these target-based screen"/>
   <result pre="screen to improve the accuracy and efficacy of screen for" exact="influenza" post="A virus RdRp inhibitors, and we demonstrated that this"/>
   <result pre="and 100 μg/mL of streptomycin (Invitrogen, Carlsbad, CA, USA). The" exact="influenza" post="A reporter PR8-Gluc virus and wild-type PR8 virus were"/>
   <result pre="PB2, PB1, PA, and NP) and a firefly luciferase gene-encoding" exact="influenza" post="viral minigenome using Lipofectamine 2000 (Invitrogen), according to the"/>
   <result pre="expressing PB2, PB1, PA, NP, and the firefly luciferase gene-encoding" exact="influenza" post="viral minigenome. After 4 h of incubation, the cells"/>
   <result pre="MDCK cells grown in 24-well plates were infected with the" exact="influenza" post="A PR8 virus at an MOI of 0.01. After"/>
   <result pre="constructing the mini-genomic plasmid, the open reading frame of the" exact="influenza" post="A/WSN/33 NP protein was replaced by firefly luciferase, and"/>
   <result pre="A phenotypic screening assay was developed using a replication-competent recombinant" exact="influenza" post="A virus expressing the Gaussia luciferase (Gluc), PR8-Gluc [37]."/>
   <result pre="to develop a parallel screening strategy by combining the aforementioned" exact="influenza" post="A virus RdRp-targeted assay and the PR8-Gluc virus-based assay"/>
   <result pre="and the effect of each compound on RdRp activity and" exact="influenza" post="A virus infectivity was directly compared. Three classes of"/>
   <result pre="identified: (1) hits specific to RdRp activity but not to" exact="influenza" post="replication (putative &quot;false positives�?); (2) hits shared by both"/>
   <result pre="screens were potential RdRp inhibitors; and (3) hits that inhibit" exact="influenza" post="A virus infectivity but not RdRp activity (&quot;Secondary hits�?;"/>
   <result pre="potentially target other steps rather than RNA replication/transcription in the" exact="influenza" post="virus replication cycle. Of note, cytotoxic compounds and luciferase"/>
   <result pre="JL-5001 and JL-5002, were identified to possess putative activity against" exact="influenza" post="A virus infection by targeting RdRp (Figure 4f, Table"/>
   <result pre="As a result, JL-5001 showed an inhibitory effect against the" exact="influenza" post="PR8-Gluc virus with an IC50 of 3.8 μM, while"/>
   <result pre="SI of 10.9 (Figure 5a). Moreover, the in vitro cell-based" exact="influenza" post="RdRp assay demonstrated that JL-5001 inhibited IAV RdRp activity"/>
   <result pre="5a). JL-5002 exhibited an IC50 of 1.7 μM against the" exact="influenza" post="PR8-Gluc virus and a CC50 of 10.3 μM against"/>
   <result pre="of lead compounds developed through phenotypic screening [43]. For the" exact="influenza" post="A virus, either phenotypic screens and target-based approaches are"/>
   <result pre="inhibitors is RdRp assay using cells transiently or stably expressing" exact="influenza" post="vRNP components: four viral proteins (PB2, PB1, PA, and"/>
   <result pre="a target (RdRp)-based screen and a phenotypic screen (using reporter" exact="influenza" post="A PR8-Gluc virus). The RdRp-based and PR8-Gluc virus-based screening"/>
   <result pre="screen, likely target steps other than RNA transcription/replication in the" exact="influenza" post="A virus replication cycle—steps such as virus entry, assembly,"/>
   <result pre="a target (RdRp)-based and a phenotypic (by employing a reporter" exact="influenza" post="virus) screen sequentially, to identify influenza inhibitors targeting virus"/>
   <result pre="(by employing a reporter influenza virus) screen sequentially, to identify" exact="influenza" post="inhibitors targeting virus RNA transcription/replication. A pilot screen of"/>
   <result pre="demonstrates that this strategy is a powerful approach to identify" exact="influenza" post="A virus inhibitors targeting RdRp and other steps in"/>
   <result pre="InfectionsFront. Microbiol.2016764710.3389/fmicb.2016.0045027199969 6.LackenbyA.BesselaarT.G.DanielsR.S.FryA.GregoryV.GubarevaL.V.HuangW.HurtA.C.LeangS.-K.LeeR.T.et al.Global update on the susceptibility of human" exact="influenza" post="viruses to neuraminidase inhibitors and status of novel antivirals,"/>
   <result pre="of novel antivirals, 2016–2017Antivir. Res.2018157384610.1016/j.antiviral.2018.07.00129981793 7.HataM.TsuzukiM.GotoY.KumagaiN.HaradaM.HashimotoM.TanakaS.SakaeK.KimuraT.MinagawaH.et al.High frequency of amantadine-resistant" exact="influenza" post="A (H3N2) viruses in the 2005-2006 season and rapid"/>
   <result pre="viruses in the 2005-2006 season and rapid detection of amantadine-resistant" exact="influenza" post="A (H3N2) viruses by MAMA-PCRJpn. J. Infect. Dis.20076020220417642534 8.Van"/>
   <result pre="Mechanisms of Antiviral ResistanceCurr. Med. Chem.2018255115512710.2174/092986732466617092016592628933281 11.DiasA.BouvierD.CrepinT.McCarthyA.A.HartD.J.BaudinF.CusackS.RuigrokR.W.H.The cap-snatching endonuclease of" exact="influenza" post="virus polymerase resides in the PA subunitNature200945891491810.1038/nature0774519194459 12.YuanP.BartlamM.LouZ.ChenS.ZhouJ.HeX.LvZ.GeR.LiX.DengT.et al.Crystal"/>
   <result pre="resides in the PA subunitNature200945891491810.1038/nature0774519194459 12.YuanP.BartlamM.LouZ.ChenS.ZhouJ.HeX.LvZ.GeR.LiX.DengT.et al.Crystal structure of an" exact="avian influenza" post="polymerase PA(N) reveals an endonuclease active siteNature200945890991310.1038/nature0772019194458 13.FechterP.MingayL.SharpsJ.FodorE.BrownleeG.G.ChambersA.Two Aromatic"/>
   <result pre="in the PA subunitNature200945891491810.1038/nature0774519194459 12.YuanP.BartlamM.LouZ.ChenS.ZhouJ.HeX.LvZ.GeR.LiX.DengT.et al.Crystal structure of an avian" exact="influenza" post="polymerase PA(N) reveals an endonuclease active siteNature200945890991310.1038/nature0772019194458 13.FechterP.MingayL.SharpsJ.FodorE.BrownleeG.G.ChambersA.Two Aromatic"/>
   <result pre="BindingJ. Boil. Chem.2003278203812038810.1074/jbc.M300130200 14.MaX.XieL.WartchowC.WarneR.XuY.RivkinA.TullyD.ShiaS.UeharaK.BaldwinD.M.et al.Structural basis for therapeutic inhibition of" exact="influenza" post="A polymerase PB2 subunitSci. Rep.20177938510.1038/s41598-017-09538-x28839261 15.XieL.WartchowC.ShiaS.UeharaK.SteffekM.WarneR.SuttonJ.MuiruG.T.LeonardV.H.BussiereD.E.et al.Molecular Basis of"/>
   <result pre="of a novel, first-in-class, orally bioavailable azaindole inhibitor (VX-787) of" exact="influenza" post="PB2J. Med. Chem.2014576668667810.1021/jm500727525019388 18.FurutaY.GowenB.B.TakahashiK.ShirakiK.SmeeD.F.BarnardD.L.Favipiravir (T-705), a novel viral RNA"/>
   <result pre="of baloxavir acid, a first-in-class cap-dependent endonuclease inhibitor of the" exact="influenza" post="virus polymerase PA subunitAntivir. Res.201816010911710.1016/j.antiviral.2018.10.00830316915 21.YuanS.ChuH.SinghK.ZhaoH.ZhangK.KaoR.Y.T.ChowB.K.C.ZhouJ.ZhengB.-J.A novel small-molecule inhibitor"/>
   <result pre="virus polymerase PA subunitAntivir. Res.201816010911710.1016/j.antiviral.2018.10.00830316915 21.YuanS.ChuH.SinghK.ZhaoH.ZhangK.KaoR.Y.T.ChowB.K.C.ZhouJ.ZhengB.-J.A novel small-molecule inhibitor of" exact="influenza" post="A virus acts by suppressing PA endonuclease activity of"/>
   <result pre="of the viral polymeraseSci. Rep.201662288010.1038/srep2288026956222 22.YuanS.ChuH.ZhangK.YeJ.SinghK.KaoR.Y.T.ChowB.K.C.ZhouJ.ZhengB.-J.A novel small-molecule compound disrupts" exact="influenza" post="A virus PB2 cap-binding and inhibits viral replicationJ. Antimicrob."/>
   <result pre="(PA-PB1) SubunitsJ. Med. Chem.2015583830384210.1021/acs.jmedchem.5b0001225856229 24.YuanS.ChuH.ZhaoH.ZhangK.SinghK.ChowB.K.KaoR.Y.ZhouJ.ZhengB.-J.Identification of a small-molecule inhibitor of" exact="influenza" post="virus via disrupting the subunits interaction of the viral"/>
   <result pre="26.HeX.ZhouJ.BartlamM.ZhangR.MaJ.LouZ.LiX.LiJ.JoachimiakA.ZengZ.et al.Crystal structure of the polymerase PA(C)-PB1(N) complex from an" exact="avian influenza" post="H5N1 virusNature20084541123112610.1038/nature0712018615018 27.ChaseG.WunderlichK.ReutherP.SchwemmleM.Identification of influenza virus inhibitors which disrupt"/>
   <result pre="al.Crystal structure of the polymerase PA(C)-PB1(N) complex from an avian" exact="influenza" post="H5N1 virusNature20084541123112610.1038/nature0712018615018 27.ChaseG.WunderlichK.ReutherP.SchwemmleM.Identification of influenza virus inhibitors which disrupt"/>
   <result pre="PA(C)-PB1(N) complex from an avian influenza H5N1 virusNature20084541123112610.1038/nature0712018615018 27.ChaseG.WunderlichK.ReutherP.SchwemmleM.Identification of" exact="influenza" post="virus inhibitors which disrupt of viral polymerase protein–protein interactionsMethods20115518819110.1016/j.ymeth.2011.08.00721867756"/>
   <result pre="for Next-Generation Anti-influenza TherapeuticsJ. Med. Chem.2016597699771810.1021/acs.jmedchem.5b0147427046062 29.MuratoreG.GoracciL.MercorelliB.FoegleinA.DigardP.CrucianiG.PaluG.LoregianA.Small molecule inhibitors of" exact="influenza" post="A and B viruses that act by disrupting subunit"/>
   <result pre="Transcription and ReplicationPLoS ONE201510e013355810.1371/journal.pone.013355826196128 34.OzawaM.ShimojimaM.GotoH.WatanabeS.HattaY.KisoM.FurutaY.HorimotoT.PetersN.R.HoffmannF.M.et al.A cell-based screening system for" exact="influenza" post="A viral RNA transcription/replication inhibitorsSci. Rep.20133110610.1038/srep0110623346363 35.ZhaoX.WangL.CuiQ.LiP.WangY.ZhangY.YangY.RongL.DuR.A Mechanism Underlying"/>
   <result pre="AntibodiesJ. Virol.2013878272828110.1128/JVI.00969-1323698304 38.GaoQ.WangZ.LiuZ.LiX.ZhangY.ZhangZ.CenS.A cell-based high-throughput approach to identify inhibitors of" exact="influenza" post="A virusActa Pharm. Sin. B2014430130610.1016/j.apsb.2014.06.00526579399 39.ChengH.KoningK.O’HearnA.WangM.Rumschlag-BoomsE.VarhegyiE.RongL.A parallel genome-wide RNAi"/>
   <result pre="host proteins important for entry of Marburg virus and H5N1" exact="influenza" post="virusVirol. J.20151266510.1186/s12985-015-0420-3 40.CuiQ.ChengH.XiongR.ZhangG.DuR.AnantpadmaM.DaveyR.A.RongL.Identification of Diaryl-Quinoline Compounds as Entry Inhibitors"/>
   <result pre="modes of actionIUBMB Life20187092210.1002/iub.169729210173 44.SuC.Y.ChengT.J.LinM.I.WangS.Y.HuangW.I.Lin-ChuS.Y.ChenY.H.WuC.Y.LaiM.M.ChengW.C.et al.High-throughput identification of compounds targeting" exact="influenza" post="RNA-dependent RNA polymerase activityProc. Natl. Acad. Sci. USA2010107191511915610.1073/pnas.101359210720974907 45.WeisshaarM.CoxR.MorehouseZ.KyasaS.K.YanD.OberackerP.MaoS.GoldenJ.E.LowenA.C.NatchusM.G.et"/>
   <result pre="Dual Myxovirus High-Throughput ScreeningJ. Virol.2016907368738710.1128/JVI.00898-1627252534 Figure 1 Optimization of cell-based" exact="influenza" post="RNA-dependent RNA polymerase (RdRp) assay in a high-throughput screen"/>
   <result pre="Establishment of a high-throughput screen system using the replication-competent recombinant" exact="influenza" post="virus carrying Gaussia luciferase, PR8-Gluc. (a) Signal range of"/>
   <result pre="Madin-Darby canine kidney (MDCK) cells were infected with the reporter" exact="influenza" post="virus PR8-Gluc virus at multiplicities of infection (MOIs) of"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6783930\results\search\disease\results.xml">
   <result pre="can also cause fulminant outbreaks (e.g., West Nile virus, Japanese" exact="encephalitis" post="virus and Zika virus). Intense research efforts in the"/>
   <result pre="[1]. In 2016, a sudden raise in incidence rates of" exact="microcephaly" post="in newborns in southern America could be linked to"/>
   <result pre="mild, flu-like symptoms, although recent studies report visual impairment and" exact="infertility" post="[3,4,5]. Following vertical transmission upon maternal infection, ZIKV can"/>
   <result pre="the Flaviviridae family like Dengue (DENV), Yellow fever (YFV), Japanese" exact="encephalitis" post="virus (JEV) and West Nile virus (WNV), ZIKV is"/>
   <result pre="also transmitted by mosquitoes. Furthermore, analogously to JEV, WNV and" exact="tick-borne encephalitis" post="virus (TBEV), Zika virus infections are associated with neurological"/>
   <result pre="transmitted by mosquitoes. Furthermore, analogously to JEV, WNV and tick-borne" exact="encephalitis" post="virus (TBEV), Zika virus infections are associated with neurological"/>
   <result pre="with liquid chromatography and tandem mass spectrometry) approach in SK-N-BE2" exact="neuroblastoma" post="cells [34], we identified in the ZIKV capsid interactome"/>
   <result pre="activity has been mechanistically studied in the context of Japanese" exact="encephalitis" post="virus, whereby ZC3HAV1 has been described to recruit the"/>
   <result pre="associating ZIKV infection or NS4B overexpression to defective neurogenesis via" exact="suppression" post="of the AKT-mTOR signaling pathway [51]. Another conserved target"/>
   <result pre="is ANKLE2, a protein previously shown to cause autosomal recessive" exact="microcephaly" post="in humans [41]. Interestingly, in an ANKLE2-heterozygous mutant drosophila"/>
   <result pre="Western HemisphereJ. Virol.2016904864487510.1128/JVI.00252-1626962217 2.CauchemezS.BesnardM.BompardP.DubT.Guillemette-ArturP.Eyrolle-GuignotD.SaljeH.Van KerkhoveM.D.AbadieV.GarelC.et al.Association between Zika virus and" exact="microcephaly" post="in French Polynesia, 2013–2015: A retrospective studyLancet20163872125213210.1016/S0140-6736(16)00651-626993883 3.VenturaC.V.MaiaM.Bravo-FilhoV.GoisA.L.BelfortR.Jr.Zika virus"/>
   <result pre="Damage and Leads to Male Infertility in MiceCell201716854210.1016/j.cell.2017.01.00928129543 5.KodatiS.PalmoreT.N.SpellmanF.A.CunninghamD.WeistropB.SenH.N.Bilateral posterior" exact="uveitis" post="associated with Zika virus infectionLancet201738912512610.1016/S0140-6736(16)32518-127939402 6.MinerJ.J.CaoB.GoveroJ.SmithA.M.FernandezE.CabreraO.H.GarberC.NollM.KleinR.S.NoguchiK.K.et al.Zika Virus Infection"/>
   <result pre="complex and nonsense-mediated decay in flaviviral infectionNat. Microbiol.2019498599510.1038/s41564-019-0375-z30833725 43.TakataM.A.Goncalves-CarneiroD.ZangT.M.SollS.J.YorkA.Blanco-MeloD.BieniaszP.D.CG dinucleotide" exact="suppression" post="enables antiviral defence targeting non-self RNANature201755012412710.1038/nature2403928953888 44.LiM.M.LauZ.CheungP.AguilarE.G.SchneiderW.M.BozzaccoL.MolinaH.BuehlerE.TakaokaA.RiceC.M.et al.TRIM25 Enhances"/>
   <result pre="Action of Zinc-Finger Antiviral Protein (ZAP)PLoS Pathog.201713e100614510.1371/journal.ppat.100614528060952 45.ChiuH.P.ChiuH.YangC.F.LeeY.L.ChiuF.L.KuoH.C.LinR.J.LinY.L.Inhibition of Japanese" exact="encephalitis" post="virus infection by the host zinc-finger antiviral proteinPLoS Pathog.201814e100716610.1371/journal.ppat.100716630016363"/>
   <result pre="the critical role of JNK1 in neuroinflammation induced by Japanese" exact="encephalitis" post="virusSci. Signal20169ra9810.1126/scisignal.aaf513227703031 75.ZhangH.SunJ.YeJ.AshrafU.ChenZ.ZhuB.HeW.XuQ.WeiY.ChenH.et al.Quantitative Label-Free Phosphoproteomics Reveals Differentially Regulated"/>
   <result pre="tyrosine-protein kinase BAZ1B MRE11A double-strand break repair protein MRE11 BRCA1" exact="breast cancer" post="type 1 susceptibility protein MT-CO2 cytochrome c oxidaes subunit"/>
   <result pre="kinase BAZ1B MRE11A double-strand break repair protein MRE11 BRCA1 breast" exact="cancer" post="type 1 susceptibility protein MT-CO2 cytochrome c oxidaes subunit"/>
   <result pre="ERBB2 Receptor tyrosine-protein kinase erbB-2 TOP2B DNA topoisomerase 2-beta FANCD1" exact="breast cancer" post="type 2 susceptibility protein TWIST twist-related protein 1 HDAC7"/>
   <result pre="Receptor tyrosine-protein kinase erbB-2 TOP2B DNA topoisomerase 2-beta FANCD1 breast" exact="cancer" post="type 2 susceptibility protein TWIST twist-related protein 1 HDAC7"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6784050\results\search\disease\results.xml">
   <result pre="relative to other circulating/reemerging mosquito-borne viruses such as dengue (DENV)," exact="yellow fever" post="(YFV), and chikungunya viruses (CHIKV)) has proven a paradox"/>
   <result pre="mosquito-borne viruses such as dengue (DENV), yellow fever (YFV), and" exact="chikungunya" post="viruses (CHIKV)) has proven a paradox for the field."/>
   <result pre="with reports of human illness. Similar to the related flaviviruses" exact="yellow fever" post="(YFV) and dengue (DENV), ZIKV demonstrates evidence of an"/>
   <result pre="possibly due to it being overshadowed by an outbreak of" exact="chikungunya" post="virus (CHIKV) [19]. During the outbreaks taking place in"/>
   <result pre="Aedes albopictus (Skuse). Prior to the Indian Ocean Lineage (IOL)" exact="chikungunya" post="virus outbreaks taking place beginning in 2005, Ae. albopictus"/>
   <result pre="of Ae. albopictus (including but not limited to La Crosse," exact="eastern equine encephalitis," post="and Japanese encephalitis viruses [39,40]) have largely supported its"/>
   <result pre="not limited to La Crosse, eastern equine encephalitis, and Japanese" exact="encephalitis" post="viruses [39,40]) have largely supported its preconceived role as"/>
   <result pre="contributing to the NY99 genotype’s disappearance [59]. Likewise, Venezuelan equine" exact="encephalitis" post="virus (VEEV) exists as seven different species and multiple"/>
   <result pre="corroborated dramatically in a separate analysis of both St. Louis" exact="encephalitis" post="virus (SLEV) and DENV-2 in Cx. quinquefasciatus and Ae."/>
   <result pre="the Togaviridae family that is a sister clade to the" exact="western equine encephalitis" post="virus (WEEV) serocomplex, was originally isolated from a pool"/>
   <result pre="family that is a sister clade to the western equine" exact="encephalitis" post="virus (WEEV) serocomplex, was originally isolated from a pool"/>
   <result pre="lie within the mosquito-borne arboviruses as close relatives of Japanese" exact="encephalitis" post="virus (JEV), DENV, ZIKV, and WNV, among many others"/>
   <result pre="emergence of arthropod-borne viral diseases: A global prospective on dengue," exact="chikungunya" post="and zika feversActa Trop.201716615516310.1016/j.actatropica.2016.11.02027876643 9.VasilakisN.WeaverS.C.Flavivirus transmission focusing on ZikaCurr."/>
   <result pre="Dengue TransmissionJ. Infect. Dis.20152121177117910.1093/infdis/jiv17425784727 43.CalbaC.Guerbois-GallaM.FrankeF.JeanninC.Auzet-CaillaudM.GrardG.PigaglioL.DecoppetA.WeicherdingJ.SavaillM.C.et al.Preliminary report of an autochthonous" exact="chikungunya" post="outbreak in France, July to September 2017Euro Surveill.20172210.2807/1560-7917.ES.2017.22.39.17-00647 44.RezzaG.Chikungunya"/>
   <result pre="Introduced From the Indian SubcontinentOpen Forum Infect. Dis.20196ofy32110.1093/ofid/ofy32130697571 46.LeroyE.M.NkogheD.OllomoB.Nze-NkogueC.BecquartP.GrardG.PourrutX.CharrelR.MoureauG.Ndjoyi-MbiguinoA.et al.Concurrent" exact="chikungunya" post="and dengue virus infections during simultaneous outbreaks, Gabon, 2007Emerg."/>
   <result pre="Infect. Dis.20091559159310.3201/eid1504.08066419331740 47.Dzul-ManzanillaF.MartinezN.E.Cruz-NolascoM.Gutierrez-CastroC.Lopez-DamianL.Ibarra-LopezJ.Martini-JaimesA.Bibiano-MarinW.Tornez-BenitezC.Vazquez-ProkopecG.M.et al.Evidence of vertical transmission and co-circulation of" exact="chikungunya" post="and dengue viruses in field populations of Aedes aegypti"/>
   <result pre="multiple introductions of Zika virus into the United StatesNature201754640140510.1038/nature2240028538723 49.MillerB.R.MonathT.P.TabachnikW.J.EzikeV.I.Epidemic" exact="yellow fever" post="caused by an incompetent mosquito vectorTrop. Med. Parasitol.1989403963992623418 50.WeaverS.C.Emergence"/>
   <result pre="the e2 envelope glycoprotein are associated with the emergence of" exact="venezuelan equine encephalitis" post="virusJ. Virol.2002761718173010.1128/JVI.76.4.1718-1730.200211799167 63.KramerL.D.SchererW.F.Vector Competence of Mosquitoes as a Marker"/>
   <result pre="envelope glycoprotein are associated with the emergence of venezuelan equine" exact="encephalitis" post="virusJ. Virol.2002761718173010.1128/JVI.76.4.1718-1730.200211799167 63.KramerL.D.SchererW.F.Vector Competence of Mosquitoes as a Marker"/>
   <result pre="of Venezuelan Encephalitis VirusAm. J. Trop. Med. Hyg.19762533634610.4269/ajtmh.1976.25.3361259093 64.BraultA.C.PowersA.M.OrtizD.Estrada-FrancoJ.G.Navarro-LopezR.WeaverS.C.Venezuelan equine" exact="encephalitis" post="emergence: Enhanced vector infection from a single amino acid"/>
   <result pre="Natl. Acad. Sci. USA2004101113441134910.1073/pnas.040290510115277679 65.BraultA.C.PowersA.M.WeaverS.C.Vector infection determinants of Venezuelan equine" exact="encephalitis" post="virus reside within the E2 envelope glycoproteinJ. Virol.2002766387639210.1128/JVI.76.12.6387-6392.200212021373 66.CiotaA.T.BialosukniaS.M.ZinkS.D.BrecherM.EhrbarD.J.MorrissetteM.N.KramerL.D.Effects"/>
   <result pre="and Aedes Mosquito Species on Vector CompetenceEmerg. Infect. Dis.2017231110111710.3201/eid2307.16163328430564 67.MillerB.R.Increased" exact="yellow fever" post="virus infection and dissemination rates in Aedes aegypti mosquitoes"/>
   <result pre="naturally infected mosquitoesPLoS Negl. Trop. Dis.201711e000593310.1371/journal.pntd.000593329145400 84.TsetsarkinK.A.VanlandinghamD.L.McGeeC.E.HiggsS.A single mutation in" exact="chikungunya" post="virus affects vector specificity and epidemic potentialPLoS Pathog.20073e20110.1371/journal.ppat.003020118069894 85.TsetsarkinK.A.ChenR.YunR.RossiS.L.PlanteK.S.GuerboisM.ForresterN.PerngG.C.SreekumarE.LealG.et"/>
   <result pre="specificity and epidemic potentialPLoS Pathog.20073e20110.1371/journal.ppat.003020118069894 85.TsetsarkinK.A.ChenR.YunR.RossiS.L.PlanteK.S.GuerboisM.ForresterN.PerngG.C.SreekumarE.LealG.et al.Multi-peaked adaptive landscape for" exact="chikungunya" post="virus evolution predicts continued fitness optimization in Aedes albopictus"/>
   <result pre="of colonization upon Aedes aegypti susceptibility to oral infection with" exact="yellow fever" post="virusAm. J. Trop. Med. Hyg.19843369069410.4269/ajtmh.1984.33.6906476217 108.JupatanakulN.SimS.DimopoulosG.The insect microbiome modulates"/>
   <result pre="toll pathway controls dengue virus infectionPLoS Pathog.20084e100009810.1371/journal.ppat.100009818604274 114.RamirezJ.L.ShortS.M.BahiaA.C.SaraivaR.G.DongY.KangS.TripathiA.MlamboG.DimopoulosG.Chromobacterium Csp_P reduces" exact="malaria" post="and dengue infection in vector mosquitoes and has entomopathogenic"/>
   <result pre="Studying the Vector Competence of Culex tarsalis for Western Equine" exact="encephalomyelitis" post="virusJ. Am. Mosq. Control Assoc.20042027728215532927 147.WilsonA.J.HarrupL.E.Reproducibility and relevance in"/>
   <result pre="Sci.20182810511210.1016/j.cois.2018.05.00730551760 148.PrudhommeJ.FontaineA.LacourG.GantierJ.C.DiancourtL.VeloE.BinoS.ReiterP.MercierA.The native European Aedes geniculatus mosquito species can transmit" exact="chikungunya" post="virusEmerg. Microbes Infect.2019896297210.1080/22221751.2019.163448931259662 149.KnoxT.B.KayB.H.HallR.A.RyanP.A.Enhanced Vector Competencce of Aedes aegypti"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6784101\results\search\disease\results.xml">
   <result pre="probing experiments, focusing on Sindbis virus (SINV) and Venezuelan equine" exact="encephalitis" post="virus (VEEV), but could not find evidence for broad"/>
   <result pre="were shown to interact with the 3’UTRs of Eastern equine" exact="encephalitis" post="virus (EEEV) [80] and CHIKV [81,82]. The miRNA binding"/>
   <result pre="ElementsVirology199824010010810.1006/viro.1997.89079448694 3.CampbellL.P.LutherC.Moo-LlanesD.RamseyJ.M.Danis-LozanoR.PetersonA.T.Climate change influences on global distributions of dengue and" exact="chikungunya" post="virus vectorsPhilos. Trans. R. Soc. B20153702014013510.1098/rstb.2014.013525688023 4.PowersA.M.BraultA.C.ShirakoY.StraussE.G.KangW.StraussJ.H.WeaverS.C.Evolutionary Relationships and"/>
   <result pre="solutionsInt. J. Infect. Dis.201115e671e67610.1016/j.ijid.2011.06.00221775183 17.SuhrbierA.La LinnM.Clinical and pathologic aspects of" exact="arthritis" post="due to Ross River virus and other alphavirusesCurr. Opin."/>
   <result pre="River virus and other alphavirusesCurr. Opin. Rheumatol.20041637437910.1097/01.bor.0000130537.76808.2615201600 18.WahidB.AliA.RafiqueS.IdreesM.Global expansion of" exact="chikungunya" post="virus: Mapping the 64-year historyInt. J. Infect. Dis.201758697610.1016/j.ijid.2017.03.00628288924 19.DialloM.ThonnonJ.Traore-LamizanaM.FontenilleD.Vectors"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6784384\results\search\disease\results.xml">
   <result pre="Licensure of a vaccine to protect against aerosolized Venezuelan equine" exact="encephalitis" post="virus (VEEV) requires use of the U.S. Food and"/>
   <result pre="15 December 2014 at Fort Detrick, Maryland, USA. Venezuelan equine" exact="encephalitis" post="virus vaccine strain selection Animal Rule cDNA cloned virus"/>
   <result pre="cDNA cloned virus virus stock propagation 1. Introduction Venezuelan equine" exact="encephalitis" post="(VEE) is a mosquito-borne illness, endemic in areas of"/>
   <result pre="and chills, severe headache, malaise, myalgia, and nausea. Unlike equids," exact="encephalitis" post="and mortality in humans from VEEV infection is uncommon"/>
   <result pre="humans were infrequent regardless of the exposure route, and severe" exact="encephalitis" post="(e.g., seizures, paralysis, or coma) was not observed in"/>
   <result pre="with a self-limited febrile illness that uncommonly resulted in severe" exact="encephalitis" post="(e.g., seizures, coma, cranial nerve abnormalities, or paralysis) at"/>
   <result pre="La Guajira state alone during the outbreak. Neurological manifestations of" exact="encephalitis" post="included disorientation, drowsiness, mental depression, and seizures. Thirteen VEEV"/>
   <result pre="during the outbreak. Neurological manifestations of encephalitis included disorientation, drowsiness," exact="mental depression," post="and seizures. Thirteen VEEV human isolates from this epidemic"/>
   <result pre="or parenteral challenge [52,64,79]. While some NHPs exhibited signs of" exact="encephalitis" post="a few days later, nearly all NHPs (similar to"/>
   <result pre="progressed to stupor and coma; and then death due to" exact="encephalitis" post="on day 7 or 8. A VEEV ID ZPC738"/>
   <result pre="characterized [52]. Unlike mice and NHPs, an increased severity of" exact="encephalitis" post="was not observed with aerosol-acquired VEE in humans. Nevertheless,"/>
   <result pre="of interest. References References 1.WeaverS.C.FerroC.BarreraR.BoshellJ.NavarroJ.C.Venezuelan equine encephalitisAnnu. Rev. Entomol.20044914117410.1146/annurev.ento.49.061802.12342214651460 2.RandallR.MillsJ.W.Fatal" exact="encephalitis" post="in man due to the Venezuelan virus of equine"/>
   <result pre="encephalitis in man due to the Venezuelan virus of equine" exact="encephalomyelitis" post="in TrinidadScience19449922525610.1126/science.99.2568.22517844380 3.EhrenkranzN.J.VenturaA.K.Venezuelan equine encephalitis virus infection in manAnnu."/>
   <result pre="the Venezuelan virus of equine encephalomyelitis in TrinidadScience19449922525610.1126/science.99.2568.22517844380 3.EhrenkranzN.J.VenturaA.K.Venezuelan equine" exact="encephalitis" post="virus infection in manAnnu. Rev. Med.19742591410.1146/annurev.me.25.020174.0003014824504 4.AguilarP.V.Estrada-FrancoJ.G.Navarro-LopezR.FerroC.HaddowA.D.WeaverS.C.Endemic Venezuelan equine"/>
   <result pre="encephalitis virus infection in manAnnu. Rev. Med.19742591410.1146/annurev.me.25.020174.0003014824504 4.AguilarP.V.Estrada-FrancoJ.G.Navarro-LopezR.FerroC.HaddowA.D.WeaverS.C.Endemic Venezuelan equine" exact="encephalitis" post="in the Americas: Hidden under the dengue umbrellaFuture Virol.2011672174010.2217/fvl.11.5021765860"/>
   <result pre="the dengue umbrellaFuture Virol.2011672174010.2217/fvl.11.5021765860 5.BowenG.S.FashinellT.R.DeanP.B.GreggM.B.Clinical aspects of human Venezuelan equine" exact="encephalitis" post="in TexasBull. Pan Am. Health Organ.1976104657949558 6.RivasF.DiazL.A.CardenasV.M.DazaD.E.BruzonL.AlcalaA.De la HozO.CaceresF.M.AristizabalG.MartinezJ.W.et"/>
   <result pre="Pan Am. Health Organ.1976104657949558 6.RivasF.DiazL.A.CardenasV.M.DazaD.E.BruzonL.AlcalaA.De la HozO.CaceresF.M.AristizabalG.MartinezJ.W.et al.Epidemic Venezuelan equine" exact="encephalitis" post="in La Guajira, Colombia, 1995J. Infect. Dis.199717582883210.1086/5139789086137 7.collab: U.S."/>
   <result pre="for studying interferon sensitivity and emergence mechanisms of Venezuelan equine" exact="encephalitis" post="virusJ. Virol.2004781810.1128/JVI.78.1.1-8.200414671082 11.AnishchenkoM.BowenR.A.PaesslerS.AustgenL.GreeneI.P.WeaverS.C.Venezuelan encephalitis emergence mediated by a phylogenetically"/>
   <result pre="and emergence mechanisms of Venezuelan equine encephalitis virusJ. Virol.2004781810.1128/JVI.78.1.1-8.200414671082 11.AnishchenkoM.BowenR.A.PaesslerS.AustgenL.GreeneI.P.WeaverS.C.Venezuelan" exact="encephalitis" post="emergence mediated by a phylogenetically predicted viral mutationProc. Natl."/>
   <result pre="mutationProc. Natl. Acad. Sci. USA20061034994499910.1073/pnas.050996110316549790 12.MartinD.H.DietzW.H.AlvaerezO.Jr.JohnsonK.M.Epidemiological significance of Venezuelan equine" exact="encephalomyelitis" post="virus in vitro markersAm. J. Trop. Med. Hyg.19823156156810.4269/ajtmh.1982.31.5617200732 13.WangE.BarreraR.BoshellJ.FerroC.FreierJ.E.NavarroJ.C.SalasR.VasquezC.WeaverS.C.Genetic"/>
   <result pre="changes accompanying the emergence of epizootic subtype IC Venezuelan equine" exact="encephalitis" post="viruses from an enzootic subtype ID progenitorJ. Virol.19997343664371 14.PowersA.M.BraultA.C.KinneyR.M.WeaverS.C.The"/>
   <result pre="subtype ID progenitorJ. Virol.19997343664371 14.PowersA.M.BraultA.C.KinneyR.M.WeaverS.C.The use of chimeric Venezuelan equine" exact="encephalitis" post="viruses as an approach for the molecular identification of"/>
   <result pre="central nervous system of miceJ. Immunol.19618750951713867629 18.JahrlingP.B.DePaoliA.PowandaM.C.Pathogenesis of a Venezuelan" exact="encephalitis" post="virus strain lethal for adult white ratsJ. Med. Virol.1978210911610.1002/jmv.1890020205670947"/>
   <result pre="ratsJ. Med. Virol.1978210911610.1002/jmv.1890020205670947 19.TigerttW.D.DownsW.G.Studies on the virus of Venezuelan equine" exact="encephalomyelitis" post="in Trinidad, W.I. I. The 1943–1944 epizooticAm. J. Trop."/>
   <result pre="J. Trop. Med. Hyg.19621182283410.4269/ajtmh.1962.11.82213985028 20.PowersA.M.ObersteM.S.BraultA.C.Rico-HesseR.SchmuraS.M.SmithJ.F.KangW.SweeneyW.P.WeaverS.C.Repeated emergence of epidemic/epizootic Venezuelan equine" exact="encephalitis" post="from a single genotype of enzootic subtype ID virusJ."/>
   <result pre="and antigenic comparison of the envelope glycoproteins of Venezuelan equine" exact="encephalomyelitis" post="virus strainsJ. Gen. Virol.19794472574010.1099/0022-1317-44-3-725119035 22.KinneyR.M.JohnsonB.J.BrownV.L.TrentD.W.Nucleotide sequence of the 26"/>
   <result pre="mRNA of the virulent Trinidad donkey strain of Venezuelan equine" exact="encephalitis" post="virus and deduced sequence of the encoded structural proteinsVirology198615240041310.1016/0042-6822(86)90142-X3088830"/>
   <result pre="of the encoded structural proteinsVirology198615240041310.1016/0042-6822(86)90142-X3088830 23.WeaverS.C.SalasR.Rico-HesseR.LudwigG.V.ObersteM.S.BoshellJ.TeshR.B.Re-emergence of epidemic Venezuelan equine" exact="encephalomyelitis" post="in South AmericaLancet199634843644010.1016/S0140-6736(96)02275-18709783 24.WangE.BowenR.A.MedinaG.PowersA.M.KangW.ChandlerL.M.ShopeR.E.WeaverS.C.Virulence and viremia characteristics of 1992"/>
   <result pre="and viremia characteristics of 1992 epizootic subtype IC Venezuelan equine" exact="encephalitis" post="viruses and closely related enzootic subtype ID strainsAm. J."/>
   <result pre="J. Trop. Med. Hyg.200165646910.4269/ajtmh.2001.65.6411504410 25.BraultA.C.PowersA.M.WeaverS.C.Vector infection determinants of Venezuelan equine" exact="encephalitis" post="virus reside within the E2 envelope glycoproteinJ. Virol.2002766387639210.1128/JVI.76.12.6387-6392.200212021373 26.BraultA.C.PowersA.M.MedinaG.WangE.KangW.SalasR.A.de"/>
   <result pre="glycoproteinJ. Virol.2002766387639210.1128/JVI.76.12.6387-6392.200212021373 26.BraultA.C.PowersA.M.MedinaG.WangE.KangW.SalasR.A.de SigerJ.WeaverS.G.Potential sources of the 1995 Venezuelan equine" exact="encephalitis" post="subtype IC epidemicJ. Virol.2001755823583210.1128/JVI.75.13.5823-5832.200111390583 27.Rico-HesseR.RoehrigJ.T.TrentD.W.DickermanR.W.Genetic variation of Venezuelan equine"/>
   <result pre="encephalitis subtype IC epidemicJ. Virol.2001755823583210.1128/JVI.75.13.5823-5832.200111390583 27.Rico-HesseR.RoehrigJ.T.TrentD.W.DickermanR.W.Genetic variation of Venezuelan equine" exact="encephalitis" post="virus strains of the ID variety in ColombiaAm. J."/>
   <result pre="Med. Hyg.19883819520410.4269/ajtmh.1988.38.1953341520 28.Rico-HesseR.WeaverS.C.de SigerJ.MedinaG.SalasR.A.Emergence of a new epidemic/epizootic Venezuelan equine" exact="encephalitis" post="virus in South AmericaProc. Natl. Acad. Sci. USA1995925278528110.1073/pnas.92.12.52787777497 29.VilcarromeroS.AguilarP.V.HalseyE.S.Laguna-TorresV.A.RazuriH.PerezJ.ValderramaY.GotuzzoE.SuarezL.CespedesM.et"/>
   <result pre="in South AmericaProc. Natl. Acad. Sci. USA1995925278528110.1073/pnas.92.12.52787777497 29.VilcarromeroS.AguilarP.V.HalseyE.S.Laguna-TorresV.A.RazuriH.PerezJ.ValderramaY.GotuzzoE.SuarezL.CespedesM.et al.Venezuelan equine" exact="encephalitis" post="and 2 human deaths, PeruEmerg. Infect. Dis.20101655355610.3201/eid1603.09097020202445 30.MoncayoA.C.LanzaroG.KangW.OrozcoA.UlloaA.Arredondo-JimenezJ.WeaverS.C.Vector competence"/>
   <result pre="columbiae (Diptera: Culicidae) mosquitoes for enzootic and epizootic Venezuelan equine" exact="encephalitis" post="virusAm. J. Trop. Med. Hyg.20087841342110.4269/ajtmh.2008.78.41318337337 31.WeaverS.C.PfefferM.MarriottK.KangW.KinneyR.M.Genetic evidence of the"/>
   <result pre="Med. Hyg.20087841342110.4269/ajtmh.2008.78.41318337337 31.WeaverS.C.PfefferM.MarriottK.KangW.KinneyR.M.Genetic evidence of the origins of Venezuelan equine" exact="encephalitis" post="virus subtype IAB outbreaksAm. J. Trop. Med. Hyg.19996044144810.4269/ajtmh.1999.60.44110466974 32.DavisN.L.BrownK.W.GreenwaldG.F.ZajacA.J.ZacnyV.L.SmithJ.F.JohnstonR.E.Attenuated"/>
   <result pre="outbreaksAm. J. Trop. Med. Hyg.19996044144810.4269/ajtmh.1999.60.44110466974 32.DavisN.L.BrownK.W.GreenwaldG.F.ZajacA.J.ZacnyV.L.SmithJ.F.JohnstonR.E.Attenuated mutants of Venezuelan equine" exact="encephalitis" post="virus containing lethal mutations in the PE2 cleavage signal"/>
   <result pre="in cell culture coselects for attenuated mutants of Venezuelan equine" exact="encephalitis" post="virusVirology198816243744310.1016/0042-6822(88)90484-93341117 34.BernardK.A.KlimstraW.B.JohnstonR.E.Mutations in the E2 glycoprotein of Venezuelan equine"/>
   <result pre="encephalitis virusVirology198816243744310.1016/0042-6822(88)90484-93341117 34.BernardK.A.KlimstraW.B.JohnstonR.E.Mutations in the E2 glycoprotein of Venezuelan equine" exact="encephalitis" post="virus confer heparin sulfate interaction, low morbidity, and rapid"/>
   <result pre="Acad. Sci. USA20081056970697510.1073/pnas.071213010518458341 36.GilyardR.T.A clinical study of Venezuelan virus equine" exact="encephalomyelitis" post="in Trinidad, B.W.IJAMA1945818267277 37.DupuyL.C.RichardsM.J.EllefsenB.ChauL.LuxembourgA.HannamanD.LivingstonB.D.SchmaljohnC.S.A DNA vaccine for Venezuelan equine"/>
   <result pre="encephalomyelitis in Trinidad, B.W.IJAMA1945818267277 37.DupuyL.C.RichardsM.J.EllefsenB.ChauL.LuxembourgA.HannamanD.LivingstonB.D.SchmaljohnC.S.A DNA vaccine for Venezuelan equine" exact="encephalitis" post="virus delivered by intramuscular electroporation elicits high levels of"/>
   <result pre="to the E3 glycoprotein protects mice against lethal Venezuelan equine" exact="encephalitis" post="virus infectionJ. Virol.201084126831269010.1128/JVI.01345-1020926570 39.ReedD.S.GlassP.F.BakkenR.R.BarthJ.F.LindC.M.da SilvaL.HartM.K.RaynerJ.AltersonK.CusterM.et al.Combined alphavirus replicon particle"/>
   <result pre="particle vaccine induces durable and cross-protective immune responses against equine" exact="encephalitis" post="virusesJ. Virol.201488120771208610.1128/JVI.01406-1425122801 40.HartM.K.Caswell-StephanK.BakkenR.TammarielloR.PrattW.DavisN.JohnstonR.E.SmithJ.SteeleK.Improved mucosal protection against Venezuelan equine encephalitis"/>
   <result pre="equine encephalitis virusesJ. Virol.201488120771208610.1128/JVI.01406-1425122801 40.HartM.K.Caswell-StephanK.BakkenR.TammarielloR.PrattW.DavisN.JohnstonR.E.SmithJ.SteeleK.Improved mucosal protection against Venezuelan equine" exact="encephalitis" post="virus is induced by the molecularly defined, live-attenuated V3526"/>
   <result pre="mice either before or after challenge with virulent Venezuelan equine" exact="encephalomyelitis" post="virusJ. Gen. Virol.2006872467247610.1099/vir.0.81925-016894184 42.O’BrienL.M.GoodchildS.A.PhillpottsR.J.PerkinsS.D.A humanized murine monoclonal antibody protects"/>
   <result pre="42.O’BrienL.M.GoodchildS.A.PhillpottsR.J.PerkinsS.D.A humanized murine monoclonal antibody protects mice from Venezuelan equine" exact="encephalitis" post="virus, Everglades virus and Mucambo virus when administered up"/>
   <result pre="immunisation with defective adenovirus serotype 5 expressing the Venezuelan equine" exact="encephalitis" post="virus E2 glycoprotein protects against airborne challenge with virulent"/>
   <result pre="airborne challenge with virulent virusVaccine2005231615162310.1016/j.vaccine.2004.06.05615694514 44.BennettA.M.LescottT.PhillpottsR.J.Improved protection against Venezuelan equine" exact="encephalitis" post="by genetic engineering of a recombinant vaccinia virusViral Immunol.19981110911710.1089/vim.1998.11.1099918402"/>
   <result pre="airborne challenge following vaccination with a live attenuated Venezuelan equine" exact="encephalitis" post="virus vaccineVaccine20001933734710.1016/S0264-410X(00)00123-710930689 46.MartinS.S.BakkenR.R.LindC.M.GarciaP.JenkinsE.GlassP.J.ParkerM.D.HartM.K.FineD.L.Evaluation of formalin inactivated V3526 virus with"/>
   <result pre="adjuvant as a next generation vaccine candidate for Venezuelan equine" exact="encephalitis" post="virusVaccine2010283143315110.1016/j.vaccine.2010.02.05620193792 47.MartinS.S.BakkenR.R.LindC.M.GarciaP.JenkinsE.GlassP.G.ParkerM.D.HartM.K.FineD.L.Comparison of the immunological responses and efficacy of"/>
   <result pre="vaccine formulations against subcutaneous and aerosol challenge with Venezuelan equine" exact="encephalitis" post="virus subtype IABVaccine2010281031104010.1016/j.vaccine.2009.10.12619914193 48.SteeleK.E.DavisK.J.StephanK.KellW.VogelP.HartM.K.Comparative neurovirulence and tissue tropism of"/>
   <result pre="tissue tropism of wild-type and attenuated strains of Venezuelan equine" exact="encephalitis" post="virus administered by aerosol in C3H/HeN and BALB/c miceVet."/>
   <result pre="an attachment receptorJ. Virol.199872735773669696832 50.PaesslerS.NiH.PetrakovaO.FayzulinR.Z.YunN.AnishchenkoM.WeaverS.C.FrolovI.Replication and clearance of Venezuelan equine" exact="encephalitis" post="virus from the brains of animals vaccinated with chimeric"/>
   <result pre="with chimeric SIN/VEE virusesJ. Virol.2006802784279610.1128/JVI.80.6.2784-2796.200616501087 51.LennetteE.H.KoprowskiH.Human infection with Venezuelan equine" exact="encephalomyelitis" post="virus: A report on eight cases of infection acquired"/>
   <result pre="in the laboratoryJAMA19431231088109510.1001/jama.1943.02840520004002 52.RusnakJ.M.DupuyL.C.NiemuthN.A.GlennA.M.WardL.A.Comparison of aerosol- and percutaneous-acquired Venezuelan equine" exact="encephalitis" post="in humans and nonhuman primates for suitability in predicting"/>
   <result pre="54.McCurdyK.JoyceJ.HamiltonS.NevinsC.SosnaW.PuricelliK.RaynerJ.O.Differential accumulation of genetic and phenotypic changes in Venezuelan equine" exact="encephalitis" post="virus and Japanese encephalitis virus following passage in vitro"/>
   <result pre="and phenotypic changes in Venezuelan equine encephalitis virus and Japanese" exact="encephalitis" post="virus following passage in vitro and in vivoVirology2011415202910.1016/j.virol.2011.03.03021507450 55.PetersC.J.DalrympleJ.M.AlphavirusesFields"/>
   <result pre="and in vivoVirology2011415202910.1016/j.virol.2011.03.03021507450 55.PetersC.J.DalrympleJ.M.AlphavirusesFields Virology3rd ed.FieldsB.N.KnipeD.M.HawleyP.M.Lippincott-RavenPhiladelphia, PA, USA1990713759 56.CasalsJ.CurnenE.C.ThomasL.Venezuelan equine" exact="encephalomyelitis" post="in manJ. Exp. Med.19437752153010.1084/jem.77.6.52119871301 57.KoprowskiH.CoxH.R.Human laboratory infection with Venezuelan"/>
   <result pre="in manJ. Exp. Med.19437752153010.1084/jem.77.6.52119871301 57.KoprowskiH.CoxH.R.Human laboratory infection with Venezuelan equine" exact="encephalomyelitis" post="virus; report of four casesN. Engl. J. Med.194723664765410.1056/NEJM19470501236180120295009 58.SlepushkinA.N.An"/>
   <result pre="of laboratory infections with Venezuelan equine encephalomyelitisVopr. Virusol.19593311314 59.SuttonL.S.BrookeC.C.Venezuelan equine" exact="encephalomyelitis" post="due to vaccination in manJAMA19541551473147610.1001/jama.1954.0369035001500513183767 60.FranckP.T.JohnsonK.M.An outbreak of Venezuelan"/>
   <result pre="encephalomyelitis due to vaccination in manJAMA19541551473147610.1001/jama.1954.0369035001500513183767 60.FranckP.T.JohnsonK.M.An outbreak of Venezuelan" exact="encephalitis" post="in man in the Panama Canal ZoneAm. J. Trop."/>
   <result pre="J. Trop. Med. Hyg.19701986086510.4269/ajtmh.1970.19.8605453912 61.CharlesP.C.WaltersE.MargolisF.JohnstonR.E.Mechanism of neuroinvasion of Venezuelan equine" exact="encephalitis" post="virus in the mouseVirology199520866267110.1006/viro.1995.11977747437 62.RyzhikovA.B.TkachevaN.V.SergeevA.N.RyabchikovaE.I.Venezuelan equine encephalitis virus propagation"/>
   <result pre="of Venezuelan equine encephalitis virus in the mouseVirology199520866267110.1006/viro.1995.11977747437 62.RyzhikovA.B.TkachevaN.V.SergeevA.N.RyabchikovaE.I.Venezuelan equine" exact="encephalitis" post="virus propagation in the olfactory tract of normal and"/>
   <result pre="olfactory tract of normal and immunized miceBiomed. Sci.199126076141841630 63.VogelP.AbplanlpD.KellW.IbrahimM.S.DownsM.B.PrattW.D.DavisK.J.Venezuelan equine" exact="encephalitis" post="in BALB/c mice. Kinetic analysis of central nervous system"/>
   <result pre="route on infection of the respiratory tract with Venezuelan equine" exact="encephalomyelitis" post="virus in normal and operated Macaca rhesus monkeys. I."/>
   <result pre="the olfactory route of the respiratory tract with Venezuelan equine" exact="encephalitis" post="virus in normal and operated Macaca rhesus monkeys. II."/>
   <result pre="virus from the vaccineAm. J. Hyg.19566315016410.1093/oxfordjournals.aje.a11980013302205 69.Guo-YunY.WileyM.R.KugelmanJ.R.LadnerJ.T.BeitzelB.F.EcclestonL.T.MorazzaniE.M.GlassP.J.PalaciosG.F.Complete coding sequences of" exact="eastern equine encephalitis" post="virus and Venezuelan equine encephalitis virus strains isolated from"/>
   <result pre="the vaccineAm. J. Hyg.19566315016410.1093/oxfordjournals.aje.a11980013302205 69.Guo-YunY.WileyM.R.KugelmanJ.R.LadnerJ.T.BeitzelB.F.EcclestonL.T.MorazzaniE.M.GlassP.J.PalaciosG.F.Complete coding sequences of eastern equine" exact="encephalitis" post="virus and Venezuelan equine encephalitis virus strains isolated from"/>
   <result pre="coding sequences of eastern equine encephalitis virus and Venezuelan equine" exact="encephalitis" post="virus strains isolated from human casesGenome Announc.20153e00243-1510.1128/genomeA.00243-1525908124 70.SuzanneM.CastroF.BonillaN.J.de UrdanetaA.G.HutchinsG.M.The"/>
   <result pre="human casesGenome Announc.20153e00243-1510.1128/genomeA.00243-1525908124 70.SuzanneM.CastroF.BonillaN.J.de UrdanetaA.G.HutchinsG.M.The systemic pathology of Venezuelan equine" exact="encephalitis" post="virus infection in humansAm. J. Trop. Med. Hyg.19853419420210.4269/ajtmh.1985.34.1943918474 71.collab:"/>
   <result pre="vaccine-induced protection against parenteral and aerosol infections of Venezuelan equine" exact="encephalitis" post="virus in nonhuman primatesVaccine1998161056106410.1016/S0264-410X(97)00192-89682359 73.AronsonJ.F.GriederF.B.DavisN.L.CharlesP.C.KnottT.BrownK.JohnstonR.E.A single-site mutant and revertants"/>
   <result pre="vivo define early steps in the pathogenesis of Venezuelan equine" exact="encephalitis" post="virusVirology200027011112310.1006/viro.2000.024110772984 74.GriederF.B.DavisN.L.AronsonJ.F.CharlesP.C.SellonD.C.SuzukiK.JohnstonR.E.Specific restrictions in the progression of Venezuelan equine"/>
   <result pre="encephalitis virusVirology200027011112310.1006/viro.2000.024110772984 74.GriederF.B.DavisN.L.AronsonJ.F.CharlesP.C.SellonD.C.SuzukiK.JohnstonR.E.Specific restrictions in the progression of Venezuelan equine" exact="encephalitis" post="virus-induced disease resulting from single amino acid changes in"/>
   <result pre="in the glycoproteinsVirology1995206994100610.1006/viro.1995.10227856110 75.DavisN.L.WillisL.V.SmithJ.F.JohnstonR.E.In vitro synthesis of infectious Venezuelan equine" exact="encephalitis" post="virus from a cDNA clone: Analysis of a viable"/>
   <result pre="76.DavisN.L.PowellN.GreenwaldG.F.WillisL.V.JohnsonB.J.SmithJ.F.JohnstonR.E.Attenuating mutations in the E2 glycoprotein gene of Venezuelan equine" exact="encephalitis" post="virus: Construction of single and multiple mutants in a"/>
   <result pre="77.DavisN.L.GriederF.B.SmithJ.F.GreenwaldG.F.ValenskiM.L.SellonD.C.CharlesP.C.JohnstonR.E.A molecular genetic approach to the study of Venezuelan equine" exact="encephalitis" post="virus pathogenesisArch. Virol. Suppl.199499910910.1007/978-3-7091-9326-68032286 78.RyzhikovA.B.RyabchikovaE.I.SergeevA.N.TkachevaN.V.Spread of Venezuelan equine encephalitis"/>
   <result pre="equine encephalitis virus pathogenesisArch. Virol. Suppl.199499910910.1007/978-3-7091-9326-68032286 78.RyzhikovA.B.RyabchikovaE.I.SergeevA.N.TkachevaN.V.Spread of Venezuelan equine" exact="encephalitis" post="virus in mice olfactory tractArch. Virol.19951402243225410.1007/BF013232438572944 79.RossiS.L.Russell-LodrigueK.E.KilleenS.Z.WangE.LealG.BergrenN.A.Vinet-OliphantH.WeaverS.C.RoyC.J.IRES-containing VEEV vaccine"/>
   <result pre="79.RossiS.L.Russell-LodrigueK.E.KilleenS.Z.WangE.LealG.BergrenN.A.Vinet-OliphantH.WeaverS.C.RoyC.J.IRES-containing VEEV vaccine protects cynomolgus macaques from IE Venezuelan equine" exact="encephalitis" post="virus aerosol challengePLoS Negl. Trop. Dis.20159e000379710.1371/journal.pntd.000379726020513 80.ReedD.S.LindC.M.LackemeyerM.G.SullivanL.J.PrattW.D.ParkerM.D.Genetically engineered, live,"/>
   <result pre="aerosol challenge with a virulent IE strain of Venezuelan equine" exact="encephalitis" post="virusVaccine2005233139314710.1016/j.vaccine.2004.12.02315837213 81.DupuyL.C.RichardsM.J.ReedD.S.SchmaljohnC.S.Immunogenicity and protective efficacy of a DNA vaccine"/>
   <result pre="and protective efficacy of a DNA vaccine against Venezuelan equine" exact="encephalitis" post="virus aerosol challenge in nonhuman primatesVaccine2010287345735010.1016/j.vaccine.2010.09.00520851089 82.PrattW.D.DavisN.L.JohnstonR.E.SmithJ.F.Genetically engineered, live"/>
   <result pre="87.BurkeD.S.RamsburgH.H.EdelmanR.Persistence in humans of antibody to subtypes of Venezuelan equine" exact="encephalomyelitis" post="(VEE) virus after immunization with attenuated (TC-83) VEE virus"/>
   <result pre="vaccineJ. Infect. Dis.197713635435910.1093/infdis/136.3.354903673 88.ForresterN.L.WertheimJ.O.DuganV.G.AugusteA.J.LinD.AdamsP.ChenR.GorchakovR.LealG.Estrada-FrancoJ.G.et al.Evolution and spread of Venezuelan equine" exact="encephalitis" post="complex alphavirus in the AmericasPLoS Negl. Trop. Dis.201711e000569310.1371/journal.pntd.000569328771475 89.RicoA.B.PhillipsA.T.SchountzT.JarvisD.L.TjalkensR.B.PowersA.M.OlsonK.E.Venezuelan"/>
   <result pre="complex alphavirus in the AmericasPLoS Negl. Trop. Dis.201711e000569310.1371/journal.pntd.000569328771475 89.RicoA.B.PhillipsA.T.SchountzT.JarvisD.L.TjalkensR.B.PowersA.M.OlsonK.E.Venezuelan and" exact="western equine encephalitis" post="virus E1 liposome antigen nucleic acid complexes protect mice"/>
   <result pre="in the AmericasPLoS Negl. Trop. Dis.201711e000569310.1371/journal.pntd.000569328771475 89.RicoA.B.PhillipsA.T.SchountzT.JarvisD.L.TjalkensR.B.PowersA.M.OlsonK.E.Venezuelan and western equine" exact="encephalitis" post="virus E1 liposome antigen nucleic acid complexes protect mice"/>
   <result pre="protective immunity to IA/IB and IE strains of Venezuelan equine" exact="encephalitis" post="virus in vaccinated miceVaccine20022061262210.1016/S0264-410X(01)00337-1 91.SchmaljohnA.L.JohnsonE.D.DalrympleJ.M.ColeG.A.Non-neutralizing monoclonal antibodies prevent lethal"/>
   <result pre="9813 strains for challenge material. viruses-11-00807-t001_Table 1Table 1 Venezuelan equine" exact="encephalitis" post="virus (VEEV) strain selection criteria for VEE vaccine animal"/>
   <result pre="Mortality Lethal infection after SC and aerosol exposure due to" exact="encephalitis" post="even at low challenge doses, with death 5–7 days"/>
   <result pre="mortality Lethal infection after SC and aerosol exposure due to" exact="encephalitis" post="even at low challenge doses (100% mortality after 100"/>
   <result pre="brain/spinal cord (n = 17), intracerebral hemorrhage (n = 7)," exact="vasculitis" post="(n = 4), meningitis (n = 13), encephalitis (n"/>
   <result pre="17), intracerebral hemorrhage (n = 7), vasculitis (n = 4)," exact="meningitis" post="(n = 13), encephalitis (n = 7), cerebritis (n"/>
   <result pre="= 7), vasculitis (n = 4), meningitis (n = 13)," exact="encephalitis" post="(n = 7), cerebritis (n = 5). Vasculitis, fibrin"/>
   <result pre="lymphoid depletion/follicular necrosis; hepatocellular degeneration and congestion (11/18 cases); interstitial" exact="pneumonia" post="(19/21 cases) and pulmonary edema (11/21 cases) [70] D"/>
   <result pre="degeneration and congestion (11/18 cases); interstitial pneumonia (19/21 cases) and" exact="pulmonary edema" post="(11/21 cases) [70] D = day; SC = subcutaneous."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6785879\results\search\disease\results.xml">
   <result pre="in calves, lambs and goat kids, characterised by arthrogryposis and" exact="hydranencephaly" post="were reported in continental Europe. Subsequently, SBV RNA was"/>
   <result pre="that are transmitted by mosquito vectors, such as Venezuelan equine" exact="encephalitis" post="virus [43]. This is supported by reports of high"/>
   <result pre="muscle hypoplasia. Image (c) of a second lamb presenting with" exact="scoliosis" post="and bending and twisting of the forelimbs. Images courtesy"/>
   <result pre="range of neurological signs also; hypertonicity, hyperreflexis, depression, blindness, ventrolateral" exact="strabismus" post="and inability to stand [108]. These neurological signs, in"/>
   <result pre="AKAV strain known as the Iriki strain which can cause" exact="encephalomyelitis" post="in naturally infected adult cows [110], there are no"/>
   <result pre="muscle hypoplasia, lymphoid depletion in thymus and lymph node, chronic" exact="hepatitis" post="Skeletal Arthrogryposis, torticollis, lordosis, scoliosis, kyphosis, cranial malformations, brachygnathism"/>
   <result pre="cranial malformations, brachygnathism inferior, prognathia Visceral Ectopia cordis, pulmonary hypoplasia," exact="ventricular septal defect" post="Ovine Head and CNS Non-suppurative meningo-encephalitis, skeletal muscle hypoplasia,"/>
   <result pre="dysplasia, micromyelia Skeletal Arthrogryposis, torticollis, lordosis, scoliosis, kyphosis, Visceral Cardiac" exact="ventricular septal defect," post="unilateral hydronephrosis, colonic atresia Caprine Head and CNS Non-suppurative"/>
   <result pre="hydronephrosis, colonic atresia Caprine Head and CNS Non-suppurative meningo-encephalitis, nonsuppurative" exact="poliomyelitis" post="[4, 113] Hydrocephalus, porencephaly, cerebellar hypoplasia Skeletal Arthrogryposis, vertebral"/>
   <result pre="with Akabane virus and Aino virusAus Vet J197854315115210.1111/j.1751-0813.1978.tb05538.x 58.TsudaTYoshidaKOhashiSYanaseTSueyoshiMKamimuraSet al.Arthrogryposis," exact="hydranencephaly" post="and cerebellar hypoplasia syndrome in neonatal calves resulting from"/>
   <result pre="embryonated chicken egg as a modelInfect Immun19844314134206690412 126.KonnoSKoedaTMadarameHIkedaSSasakiTSatohHet al.Myopathy and" exact="encephalopathy" post="in chick embryos experimentally infected with Akabane virusVet Pathol1988251110.1177/0300985888025001013125658"/>
   <result pre="experimentally infected with Akabane virusVet Pathol1988251110.1177/0300985888025001013125658 127.KitanoYOhzonoHYasudaNShimizuTHydranencephaly, cerebellar hypoplasia, and" exact="myopathy" post="in chick embryos infected with Aino virusVet Pathol199633667268110.1177/0300985896033006068952026 128.KitanoYYasudaNShimizuTOhzonoHIwamotoTTeratogenicity"/>
   <result pre="the foetusVet Micro19816320922410.1016/0378-1135(81)90014-6 133.HartleyWSaramWDella-PortaASnowdonWShepherdNPathology of congenital bovine epizootic arthrogryposis and" exact="hydranencephaly" post="and its relationship to Akabane virusAus Vet J197753731932510.1111/j.1751-0813.1977.tb00240.x 134.KurogiHInabaYTakahashiESatoKSatodaKCongenital"/>
   <result pre="the virusVet Rec19931331434134410.1136/vr.133.14.3418236677 195.NekoueiOStryhnHVanLeeuwenJKeltonDHannaPKeefeGPredicting within-herd prevalence of infection with bovine" exact="leukemia" post="virus using bulk-tank milk antibody levelsPrev Vet Med20151221536010.1016/j.prevetmed.2015.10.00926518725 196.Collins�?GrantJBarrettDDohertyMHallinanAMeeJSchmallenberg"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6787251\results\search\disease\results.xml">
   <result pre="with other medically important flaviviruses such as Wes Nile virus," exact="yellow fever" post="virus, and dengue virus (DENV). The flavivirus envelope (E)"/>
   <result pre="as well as other medically important flaviviruses like dengue and" exact="yellow fever." post="Results Expression of ZIKV rE monomers and homodimers Here,"/>
   <result pre="virionsProc. Natl Acad. Sci. USA20121097439744410.1073/pnas.120056610922499787 8.AllisonSLStadlerKMandlCWKunzCHeinzFXSynthesis and secretion of recombinant" exact="tick-borne encephalitis" post="virus protein E in soluble and particulate formJ. Virol.199569581658207637027"/>
   <result pre="Natl Acad. Sci. USA20121097439744410.1073/pnas.120056610922499787 8.AllisonSLStadlerKMandlCWKunzCHeinzFXSynthesis and secretion of recombinant tick-borne" exact="encephalitis" post="virus protein E in soluble and particulate formJ. Virol.199569581658207637027"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6788403\results\search\disease\results.xml">
   <result pre="is appreciated. During May 19–September 28, 2019,* low levels of" exact="influenza" post="activity were reported in the United States, with cocirculation"/>
   <result pre="activity were reported in the United States, with cocirculation of" exact="influenza" post="A and influenza B viruses. In the Southern Hemisphere"/>
   <result pre="in the United States, with cocirculation of influenza A and" exact="influenza" post="B viruses. In the Southern Hemisphere seasonal influenza viruses"/>
   <result pre="A and influenza B viruses. In the Southern Hemisphere seasonal" exact="influenza" post="viruses circulated widely, with influenza A(H3) predominating in many"/>
   <result pre="In the Southern Hemisphere seasonal influenza viruses circulated widely, with" exact="influenza" post="A(H3) predominating in many regions; however, influenza A(H1N1)pdm09 and"/>
   <result pre="circulated widely, with influenza A(H3) predominating in many regions; however," exact="influenza" post="A(H1N1)pdm09 and influenza B viruses were predominant in some"/>
   <result pre="influenza A(H3) predominating in many regions; however, influenza A(H1N1)pdm09 and" exact="influenza" post="B viruses were predominant in some countries. In late"/>
   <result pre="Health Organization (WHO) recommended components for the 2020 Southern Hemisphere" exact="influenza" post="vaccine and included an update to the A(H3N2) and"/>
   <result pre="included an update to the A(H3N2) and B/Victoria-lineage components. Annual" exact="influenza" post="vaccination is the best means for preventing influenza illness"/>
   <result pre="components. Annual influenza vaccination is the best means for preventing" exact="influenza" post="illness and its complications, and vaccination before influenza activity"/>
   <result pre="for preventing influenza illness and its complications, and vaccination before" exact="influenza" post="activity increases is optimal. Health care providers should recommend"/>
   <result pre="laboratories in the United States tested 7,637 respiratory specimens for" exact="influenza" post="viruses; 1,737 (22.7%) were positive (Figure 1), including 1,213"/>
   <result pre="1,737 (22.7%) were positive (Figure 1), including 1,213 (69.8%) for" exact="influenza" post="A viruses and 524 (30.2%) for influenza B viruses."/>
   <result pre="1,213 (69.8%) for influenza A viruses and 524 (30.2%) for" exact="influenza" post="B viruses. Among the 1,154 seasonal influenza A-positive specimens"/>
   <result pre="524 (30.2%) for influenza B viruses. Among the 1,154 seasonal" exact="influenza" post="A-positive specimens that were subtyped, 324 (28.1%) were influenza"/>
   <result pre="seasonal influenza A-positive specimens that were subtyped, 324 (28.1%) were" exact="influenza" post="A(H1N1)pdm09, and 830 (71.9%) were influenza A(H3N2). Among the"/>
   <result pre="subtyped, 324 (28.1%) were influenza A(H1N1)pdm09, and 830 (71.9%) were" exact="influenza" post="A(H3N2). Among the 440 influenza B viruses for which"/>
   <result pre="A(H1N1)pdm09, and 830 (71.9%) were influenza A(H3N2). Among the 440" exact="influenza" post="B viruses for which lineage was determined, 413 (93.9%)"/>
   <result pre="testing positive for influenza* reported by public health laboratories, by" exact="influenza" post="virus type, subtype/lineage, and surveillance week — United States,"/>
   <result pre="below their region-specific baselines. One human infection with a novel" exact="influenza" post="A virus§ was reported, an influenza A(H1N1) variant virus."/>
   <result pre="infection with a novel influenza A virus§ was reported, an" exact="influenza" post="A(H1N1) variant virus. This virus had hemagglutinin (HA) and"/>
   <result pre="(HA) and neuraminidase gene segments derived from the seasonal human" exact="influenza" post="A(H1N1)pdm09 virus that were likely introduced into swine by"/>
   <result pre="by a recent reverse zoonosis and were closely related to" exact="influenza" post="A(H1N1) viruses now circulating in the U.S. swine population."/>
   <result pre="the U.S. swine population. The percentage of deaths attributed to" exact="pneumonia" post="and influenza from CDC’s National Center for Health Statistics"/>
   <result pre="swine population. The percentage of deaths attributed to pneumonia and" exact="influenza" post="from CDC’s National Center for Health Statistics Mortality Surveillance"/>
   <result pre="during this period were reported to CDC. Additional information on" exact="influenza" post="surveillance methods is available at https://www.cdc.gov/flu/weekly/overview.htm, and a full"/>
   <result pre="is available at https://www.cdc.gov/flu/weekly/overview.htm, and a full description of U.S." exact="influenza" post="activity over the summer months is available in the"/>
   <result pre="influenza activity over the summer months is available in the" exact="influenza" post="surveillance report, FluView (https://www.cdc.gov/flu/weekly/). The timing of influenza activity"/>
   <result pre="in the influenza surveillance report, FluView (https://www.cdc.gov/flu/weekly/). The timing of" exact="influenza" post="activity and the predominant circulating virus in the Southern"/>
   <result pre="region.¶ Influenza A(H3N2) viruses were predominant in most regions; however," exact="influenza" post="A(H1N1)pdm09 and influenza B/Victoria viruses predominated in several countries."/>
   <result pre="viruses were predominant in most regions; however, influenza A(H1N1)pdm09 and" exact="influenza" post="B/Victoria viruses predominated in several countries. Additional information on"/>
   <result pre="B/Victoria viruses predominated in several countries. Additional information on global" exact="influenza" post="virus circulation is available at https://www.who.int/influenza/surveillance_monitoring/updates/en/. Genetic and Antigenic"/>
   <result pre="and Antigenic Characterization of Influenza Viruses CDC genetically characterized 867" exact="influenza" post="viruses submitted by U.S. and international laboratories during May"/>
   <result pre="and international laboratories during May 19–September 28, 2019, including 263" exact="influenza" post="A(H1N1)pdm09 viruses, 427 influenza A(H3N2) viruses, and 177 influenza"/>
   <result pre="May 19–September 28, 2019, including 263 influenza A(H1N1)pdm09 viruses, 427" exact="influenza" post="A(H3N2) viruses, and 177 influenza B viruses. All A(H1N1)pdm09"/>
   <result pre="263 influenza A(H1N1)pdm09 viruses, 427 influenza A(H3N2) viruses, and 177" exact="influenza" post="B viruses. All A(H1N1)pdm09 viruses belonged to genetic subclade"/>
   <result pre="cell-culture propagated 2019–20 Northern Hemisphere vaccine virus component. The 427" exact="influenza" post="A(H3N2) viruses analyzed belonged to either clades 3C.2a (354;"/>
   <result pre="collected during May 19–September 28, 2019 All 21 of the" exact="influenza" post="B/Yamagata lineage viruses analyzed belonged to clade Y3. All"/>
   <result pre="the HA protein belonged to subclade V1A-3Del. Among the 156" exact="influenza" post="B/Victoria lineage viruses analyzed, the HA gene belonged to"/>
   <result pre="V1A-3Del viruses. Antiviral Resistance of Influenza Viruses CDC tested 812" exact="influenza" post="virus specimens collected during May 19–September 28 from the"/>
   <result pre="and zanamivir. All but two of the viruses tested (245" exact="influenza" post="A(H1N1)pdm09 viruses [161 international and 84 U.S. viruses], 406"/>
   <result pre="influenza A(H1N1)pdm09 viruses [161 international and 84 U.S. viruses], 406" exact="influenza" post="A(H3N2) viruses [284 international and 122 U.S.], and 161"/>
   <result pre="influenza A(H3N2) viruses [284 international and 122 U.S.], and 161" exact="influenza" post="B viruses [71 international and 90 U.S.]) were susceptible"/>
   <result pre="viruses [71 international and 90 U.S.]) were susceptible to these" exact="influenza" post="antiviral medications. One (0.1%) influenza A(H1N1)pdm09 virus contained the"/>
   <result pre="U.S.]) were susceptible to these influenza antiviral medications. One (0.1%)" exact="influenza" post="A(H1N1)pdm09 virus contained the H275Y amino acid substitution in"/>
   <result pre="highly reduced inhibition by oseltamivir and peramivir, and one (0.1%)" exact="influenza" post="B virus contained the amino acid substitution I221T and"/>
   <result pre="reduced inhibition by the same two neuraminidase inhibitors. Among 824" exact="influenza" post="virus specimens (253 A(H1N1)pdm09, 406 A(H3N2) and 165 type"/>
   <result pre="of resistance to the adamantanes (amantadine and rimantadine) persisted among" exact="influenza" post="A(H1N1)pdm09 and influenza A(H3N2) viruses, which is consistent with"/>
   <result pre="the adamantanes (amantadine and rimantadine) persisted among influenza A(H1N1)pdm09 and" exact="influenza" post="A(H3N2) viruses, which is consistent with the current recommendation"/>
   <result pre="of the 2020 Southern Hemisphere Influenza Vaccine WHO recommendations for" exact="influenza" post="vaccine composition for the Southern Hemisphere 2020 season were"/>
   <result pre="Switzerland.†† The recommended components for the 2020 Southern Hemisphere egg-based" exact="influenza" post="trivalent vaccines are an A/Brisbane/02/2018 (H1N1)pdm09-like virus, an A/South"/>
   <result pre="a cell-propagated A/Iowa/60/2018-like virus. Discussion From May to September 2019," exact="influenza" post="activity remained low in the United States, as is"/>
   <result pre="A and B viruses cocirculated throughout the summer months with" exact="influenza" post="A(H3N2) viruses predominating overall and influenza B/Victoria, subclade V1A-3Del,"/>
   <result pre="the summer months with influenza A(H3N2) viruses predominating overall and" exact="influenza" post="B/Victoria, subclade V1A-3Del, viruses the most common influenza B"/>
   <result pre="overall and influenza B/Victoria, subclade V1A-3Del, viruses the most common" exact="influenza" post="B virus reported by public health laboratories. Influenza A"/>
   <result pre="however, regardless of what is circulating, the best protection against" exact="influenza" post="is an influenza vaccination. Influenza vaccination has been shown"/>
   <result pre="what is circulating, the best protection against influenza is an" exact="influenza" post="vaccination. Influenza vaccination has been shown to reduce the"/>
   <result pre="Influenza vaccination has been shown to reduce the risk for" exact="influenza" post="illness associated with outpatient health care visits and hospitalizations"/>
   <result pre="care visits and hospitalizations and reduces the risk for serious" exact="influenza" post="outcomes that can result in hospitalization or death. CDC"/>
   <result pre="September, WHO issued its recommendations for the 2020 Southern Hemisphere" exact="influenza" post="vaccine. Compared with the composition of the 2019–20 Northern"/>
   <result pre="vaccine. Compared with the composition of the 2019–20 Northern Hemisphere" exact="influenza" post="vaccine formulation, these recommendations reflect changes to the A(H3N2)"/>
   <result pre="example, activity in Australia during recent seasons has not reflected" exact="influenza" post="virus activity in the subsequent U.S. season. Changes to"/>
   <result pre="might not be a good predictor of the upcoming U.S." exact="influenza" post="season. Although Australia experienced an early start to its"/>
   <result pre="Australia experienced an early start to its 2019 season with" exact="influenza" post="A(H1N1)pdm09 viruses circulating initially and A(H3N2) virus eventually predominating"/>
   <result pre="A(H1N1)pdm09 viruses circulating initially and A(H3N2) virus eventually predominating (2)," exact="influenza" post="is unpredictable, and circumstances can change very quickly. Analysis"/>
   <result pre="of the Northern Hemisphere vaccine viruses used in production of" exact="influenza" post="vaccines for the upcoming U.S. season. Except for one"/>
   <result pre="influenza vaccines for the upcoming U.S. season. Except for one" exact="influenza" post="A(H1N1)pdm09 virus and one influenza B virus, all influenza"/>
   <result pre="U.S. season. Except for one influenza A(H1N1)pdm09 virus and one" exact="influenza" post="B virus, all influenza viruses tested remained susceptible to"/>
   <result pre="one influenza A(H1N1)pdm09 virus and one influenza B virus, all" exact="influenza" post="viruses tested remained susceptible to oseltamivir, peramivir, and zanamivir,"/>
   <result pre="baloxavir. Influenza antiviral medications are a valuable adjunct to annual" exact="influenza" post="vaccination, and early treatment with influenza antiviral medication, especially"/>
   <result pre="valuable adjunct to annual influenza vaccination, and early treatment with" exact="influenza" post="antiviral medication, especially within 48 hours of symptom onset,"/>
   <result pre="symptom onset, is recommended for patients with confirmed or suspected" exact="influenza" post="who 1) have severe, complicated, or progressive illness; 2)"/>
   <result pre="symptom improvement (4–7) and to reduce secondary complications associated with" exact="influenza" post="(8,9). Health care providers should not delay treatment until"/>
   <result pre="effective when given early in the illness. Additional information regarding" exact="influenza" post="viruses, influenza surveillance, influenza vaccines, influenza antiviral medications, and"/>
   <result pre="given early in the illness. Additional information regarding influenza viruses," exact="influenza" post="surveillance, influenza vaccines, influenza antiviral medications, and novel influenza"/>
   <result pre="in the illness. Additional information regarding influenza viruses, influenza surveillance," exact="influenza" post="vaccines, influenza antiviral medications, and novel influenza A virus"/>
   <result pre="illness. Additional information regarding influenza viruses, influenza surveillance, influenza vaccines," exact="influenza" post="antiviral medications, and novel influenza A virus infections in"/>
   <result pre="viruses, influenza surveillance, influenza vaccines, influenza antiviral medications, and novel" exact="influenza" post="A virus infections in humans is available at https://www.cdc.gov/flu."/>
   <result pre="https://www.cdc.gov/flu. Summary What is already known about this topic? Although" exact="influenza" post="activity is typically low in the United States during"/>
   <result pre="summer months, CDC collects, compiles, and analyzes data to monitor" exact="influenza" post="activity throughout the year. What is added by this"/>
   <result pre="What is added by this report? In the United States," exact="influenza" post="activity remained low with cocirculation of influenza A and"/>
   <result pre="the United States, influenza activity remained low with cocirculation of" exact="influenza" post="A and influenza B viruses. Influenza viruses circulated widely"/>
   <result pre="influenza activity remained low with cocirculation of influenza A and" exact="influenza" post="B viruses. Influenza viruses circulated widely in the Southern"/>
   <result pre="Southern Hemisphere, with A(H3) viruses predominating in most regions, although" exact="influenza" post="A(H1N1)pdm09 and influenza B/Victoria viruses predominated in several countries."/>
   <result pre="A(H3) viruses predominating in most regions, although influenza A(H1N1)pdm09 and" exact="influenza" post="B/Victoria viruses predominated in several countries. What are the"/>
   <result pre="are the implications for public health practice? Receiving a seasonal" exact="influenza" post="vaccine each year remains the best way to protect"/>
   <result pre="each year remains the best way to protect against seasonal" exact="influenza" post="and its potentially severe consequences. Acknowledgments State, county, city,"/>
   <result pre="CDC. *Data reported as of October 4, 2019. †The CDC" exact="influenza" post="surveillance system collects five categories of information from eight"/>
   <result pre="the National Respiratory and Enteric Virus Surveillance System, and novel" exact="influenza" post="A virus case reporting); 2) outpatient illness surveillance (U.S."/>
   <result pre="additional states); and 5) summary of the geographic spread of" exact="influenza" post="(state and territorial epidemiologist reports). https://www.cdc.gov/flu/weekly/fluactivitysurv.htm. §Influenza viruses that"/>
   <result pre="https://www.cdc.gov/flu/weekly/fluactivitysurv.htm. §Influenza viruses that circulate in swine are called swine" exact="influenza" post="viruses when isolated from swine but are called variant"/>
   <result pre="influenza viruses when isolated from swine but are called variant" exact="influenza" post="viruses when isolated from humans. Seasonal influenza viruses that"/>
   <result pre="are called variant influenza viruses when isolated from humans. Seasonal" exact="influenza" post="viruses that circulate worldwide in the human population have"/>
   <result pre="the human population have important antigenic and genetic differences form" exact="influenza" post="viruses circulating in swine. https://www.cdc.gov/flu/swineflu/variant/preventspreadfactsheet.htm. ¶In temperate climates, the"/>
   <result pre="swine. https://www.cdc.gov/flu/swineflu/variant/preventspreadfactsheet.htm. ¶In temperate climates, the onset and peak of" exact="influenza" post="activity might vary substantially from one influenza season to"/>
   <result pre="and peak of influenza activity might vary substantially from one" exact="influenza" post="season to the next, but generally begins to increase"/>
   <result pre="fall. In the Northern Hemisphere’s temperate regions, annual epidemics of" exact="influenza" post="typically occur during October–February, but the peak of influenza"/>
   <result pre="of influenza typically occur during October–February, but the peak of" exact="influenza" post="activity can occur as late as April or May."/>
   <result pre="April or May. In temperate regions of the Southern Hemisphere," exact="influenza" post="activity typically peaks during May–August. Although temperate regions of"/>
   <result pre="temperate regions of the world experience a seasonal peak in" exact="influenza" post="activity, influenza viruses can be isolated year-round. The timing"/>
   <result pre="of the world experience a seasonal peak in influenza activity," exact="influenza" post="viruses can be isolated year-round. The timing of seasonal"/>
   <result pre="can be isolated year-round. The timing of seasonal peaks in" exact="influenza" post="activity in tropical and subtropical countries varies by region."/>
   <result pre="the same year have been observed in some areas, and" exact="influenza" post="infection can occur year-round. **A virus is considered similar"/>
   <result pre="≥65 years; 3) persons with chronic pulmonary conditions (including asthma)," exact="cardiovascular disease" post="(except hypertension alone), renal, hepatic, hematologic (including sickle cell)"/>
   <result pre="the brain, spinal cord, peripheral nerves, and muscles, such as" exact="cerebral palsy," post="epilepsy [seizure disorders], stroke, intellectual disability [mental retardation], moderate"/>
   <result pre="spinal cord, peripheral nerves, and muscles, such as cerebral palsy," exact="epilepsy" post="[seizure disorders], stroke, intellectual disability [mental retardation], moderate to"/>
   <result pre="stroke, intellectual disability [mental retardation], moderate to severe developmental delay," exact="muscular dystrophy," post="or spinal cord injury); 4) persons with immunosuppression, including"/>
   <result pre="aspirin therapy; 7) American Indians/Alaska Natives; 8) persons with extreme" exact="obesity" post="(i.e., body mass index ≥40); and 9) residents of"/>
   <result pre="U.S. patent no. 10,272,149 for a live, synthetic, modified bat" exact="influenza" post="virus strain useful for vaccination against a target influenza"/>
   <result pre="bat influenza virus strain useful for vaccination against a target" exact="influenza" post="strain, outside the current work. No other potential conflicts"/>
   <result pre="AlyanakE, BroderKR, WalterEB, FryAM, JerniganDB. Prevention and control of seasonal" exact="influenza" post="with vaccines: recommendations of the Advisory Committee on Immunization"/>
   <result pre="recommendations of the Advisory Committee on Immunization Practices—United States, 2019–20" exact="influenza" post="season.MMWR Recomm Rep2019;68(No. RR-3). 10.15585/mmwr.rr6803a131441906 2. BarrIG, DengYM, GrauML,"/>
   <result pre="Rep2019;68(No. RR-3). 10.15585/mmwr.rr6803a131441906 2. BarrIG, DengYM, GrauML, et al.Intense interseasonal" exact="influenza" post="outbreaks, Australia, 2018/19.Euro Surveill2019;24:1900421. 10.2807/1560-7917.ES.2019.24.33.190042131431210 3. FioreAE, FryA, ShayD,"/>
   <result pre="4. HedrickJA, BarzilaiA, BehreU, et al.Zanamivir for treatment of symptomatic" exact="influenza" post="A and B infection in children five to twelve"/>
   <result pre="10.1097/00006454-200005000-0000510819336 5. HeinonenS, SilvennoinenH, LehtinenP, et al.Early oseltamivir treatment of" exact="influenza" post="in children 1–3 years of age: a randomized controlled"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6789482\results\search\disease\results.xml">
   <result pre="by natural infection in humans [82]. More recently, a modified" exact="vaccinia virus" post="Ankara-vectored vaccine composed of pp65, gB, and PC was"/>
   <result pre="neutralizing antibodiesProc. Natl. Acad. Sci. USA2014111179651797010.1073/pnas.141531011125453106 83.ChiuppesiF.NguyenJ.ParkS.ContrerasH.KhaM.MengZ.KaltchevaT.IniguezA.MartinezJ.La RosaC.et al.Multiantigenic modified" exact="vaccinia virus" post="ankara vaccine vectors to elicit potent humoral and cellular"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6789597\results\search\disease\results.xml">
   <result pre="associated with severe neurological complications such as Guillain–Barré syndrome and" exact="microcephaly" post="in fetuses and newborns. Although enormous efforts were made"/>
   <result pre="such as ZIKV, dengue virus (DENV), West Nile virus (WNV)," exact="yellow fever" post="virus (YFV), and Japanese encephalitis virus (JEV), have become"/>
   <result pre="West Nile virus (WNV), yellow fever virus (YFV), and Japanese" exact="encephalitis" post="virus (JEV), have become an increasing public health concern"/>
   <result pre="with severe neurological complications such as an unexpected rise of" exact="microcephaly" post="cases in fetuses and newborns and a remarkable increase"/>
   <result pre="Although 7-deaza-2-CMA inhibitor failed in human clinical trials for chronic" exact="hepatitis" post="C treatment, probably due to mitochondrial toxicity [48], this"/>
   <result pre="several viruses. In clinical trials of healthy volunteers and in" exact="influenza" post="virus-infected patients, favipiravir has been well tolerated. However, caution"/>
   <result pre="was shown to inhibit ZIKV infection and replication in human" exact="hepatocellular carcinoma" post="(Huh-7) cells, human placental choriocarcinoma (Jar) cells, and SH-Sy5y"/>
   <result pre="and replication in human hepatocellular carcinoma (Huh-7) cells, human placental" exact="choriocarcinoma" post="(Jar) cells, and SH-Sy5y neuroblastoma cells with EC50 values"/>
   <result pre="carcinoma (Huh-7) cells, human placental choriocarcinoma (Jar) cells, and SH-Sy5y" exact="neuroblastoma" post="cells with EC50 values in the range of 0.4–5"/>
   <result pre="antiviral activity against different viruses (influenza virus, DENV, coronaviruses, HIV-1," exact="hepatitis" post="B virus, etc.) [71,72,73], have been tested against NS2B-NS3"/>
   <result pre="addition, mice that survived did not present any signs of" exact="neurological disorder" post="[76]. Similarly, a study done by Yuan et al."/>
   <result pre="infection. Suramin, an anti-parasitic drug used to treat trypanosomal human" exact="sleeping sickness," post="is available for prophylactic and therapeutic use in children."/>
   <result pre="shown to inhibit multiple DNA and RNA viruses including DENV," exact="herpes simplex" post="virus type 1, cytomegaloviruses human hepatitis B, hepatitis D,"/>
   <result pre="viruses including DENV, herpes simplex virus type 1, cytomegaloviruses human" exact="hepatitis" post="B, hepatitis D, hepatitis C, bunyaviruses, enterovirus 71, and"/>
   <result pre="DENV, herpes simplex virus type 1, cytomegaloviruses human hepatitis B," exact="hepatitis" post="D, hepatitis C, bunyaviruses, enterovirus 71, and others [78,79,80,81]."/>
   <result pre="simplex virus type 1, cytomegaloviruses human hepatitis B, hepatitis D," exact="hepatitis" post="C, bunyaviruses, enterovirus 71, and others [78,79,80,81]. Suramin was"/>
   <result pre="enterovirus 71 by neutralizing virus particles prior to attachment and" exact="chikungunya" post="virus in mice [82,83,84]. Albulescu et al. showed that"/>
   <result pre="compound, was shown to abolish ZIKV replication in HeLa (cervical" exact="cancer" post="cells) and JEG3 (human choriocarcinoma cell line) cells; however,"/>
   <result pre="ZIKV replication in HeLa (cervical cancer cells) and JEG3 (human" exact="choriocarcinoma" post="cell line) cells; however, its use in pregnant women"/>
   <result pre="was suggested as a potential option to prevent GBS and" exact="microcephaly" post="[97]. Chloroquine, an anti-inflammatory FDA-approved 4-aminoquinoline, is an old"/>
   <result pre="was very effective at preventing ZIKV-induced neuronal cell death and" exact="neurodegeneration" post="in IFN-α/βR−/−mice [106]. Importantly, memantine is also listed in"/>
   <result pre="2.collab: Centers for Disease Control and Prevention (CDC)Oseltamivir-resistant 2009 pandemic" exact="influenza" post="A (H1N1) virus infection in two summer campers receiving"/>
   <result pre="sequencing of Zika virus from amniotic fluid of fetuses with" exact="microcephaly" post="in Brazil: A case studyLancet Infect. Dis.20161665366010.1016/S1473-3099(16)00095-526897108 22.MussoD.NhanT.RobinE.RocheC.BierlaireD.ZisouK.Shan YanA.Cao-LormeauV.M.BroultJ.Potential"/>
   <result pre="25.ChambersT.J.WeirR.C.GrakouiA.McCourtD.W.BazanJ.F.FletterickR.J.RiceC.M.Evidence that the N-terminal domain of nonstructural protein NS3 from" exact="yellow fever" post="virus is a serine protease responsible for site-specific cleavages"/>
   <result pre="converge within a region of 20 amino acidsJ. Virol.1999733108311610074162 28.TakegamiT.SakamuroD.FurukawaT.Japanese" exact="encephalitis" post="virus nonstructural protein NS3 has RNA binding and ATPase"/>
   <result pre="78.AguilarJ.S.RiceM.WagnerE.K.The polysulfonated compound suramin blocks adsorption and lateral difusion of" exact="herpes simplex" post="virus type-1 in vero cellsVirology199925814115110.1006/viro.1999.972310329576 79.BabaM.KonnoK.ShigetaS.WickramasingheA.MohanP.Selective inhibition of human"/>
   <result pre="Agents Chemother.2014587405741510.1128/AAC.03595-1425267680 81.WangY.QingJ.SunY.RaoZ.Suramin inhibits EV71 infectionAntivir. Res.20141031610.1016/j.antiviral.2013.12.00824374150 82.KuoS.C.WangY.M.HoY.J.ChangT.Y.LaiZ.Z.TsuiP.Y.WuT.Y.LinC.C.Suramin treatment reduces" exact="chikungunya" post="pathogenesis in miceAntivir. Res.2016134899610.1016/j.antiviral.2016.07.02527577529 83.RenP.ZouG.BaillyB.XuS.ZengM.ChenX.ShenL.ZhangY.GuillonP.Arenzana-SeisdedosF.et al.The approved pediatric drug"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6789600\results\search\disease\results.xml">
   <result pre="challenges confronting Zika virus vaccine development. Zika virus flavivirus emerging" exact="infectious disease" post="vaccine sample size 1. Introduction The Zika virus, discovered"/>
   <result pre="soon recognized that Zika virus infection occurring during pregnancy caused" exact="microcephaly" post="and other congenital disorders in the developing fetus, the"/>
   <result pre="[14]. Other less common reported neurologic complications in adults include" exact="meningoencephalitis" post="[15] and an ADEM illness. In contrast, infection during"/>
   <result pre="In contrast, infection during pregnancy has been associated with fetal" exact="microcephaly" post="and a number of other congenital illnesses including visual"/>
   <result pre="began in earnest in late 2015 following the reports of" exact="microcephaly" post="in fetuses and infants in Brazil. Of note, the"/>
   <result pre="attenuated and inactivated whole-viruses; viral-vectored vaccines utilizing adeno-associated virus, vesicular" exact="stomatitis" post="virus, measles virus, and dengue or Yellow Fever chimeric"/>
   <result pre="inactivated whole-viruses; viral-vectored vaccines utilizing adeno-associated virus, vesicular stomatitis virus," exact="measles" post="virus, and dengue or Yellow Fever chimeric vaccines; DNA"/>
   <result pre="vaccine protected against testicular damage, testicular atrophy, spermatozoal damage, and" exact="infertility" post="in mice [28,30]. A Phase I study evaluated GLS-5700"/>
   <result pre="of participants demonstrated the ability to neutralize infection of U87MG" exact="neuroblastoma" post="cells [42]. Vaccine responses were maintained through a year"/>
   <result pre="following vaccination with either the Yellow Fever YF-VAX or Japanese" exact="encephalitis" post="virus (JEV) IXARO vaccines to assess responses in a"/>
   <result pre="virus infections [13], whereas other neurologic complications such as meningoencephalitis," exact="myelitis" post="[15,53,54], and acute disseminated encephalomyelitis [54] are rare. Second,"/>
   <result pre="whereas other neurologic complications such as meningoencephalitis, myelitis [15,53,54], and" exact="acute disseminated encephalomyelitis" post="[54] are rare. Second, and perhaps more important, is"/>
   <result pre="neurologic complications such as meningoencephalitis, myelitis [15,53,54], and acute disseminated" exact="encephalomyelitis" post="[54] are rare. Second, and perhaps more important, is"/>
   <result pre="assessment: Zika virus epidemic in the Americas: Potential association with" exact="microcephaly" post="and Guillain-Barre syndromeProceedings of the ECDCStockholm, Sweden10 December 2015"/>
   <result pre="infection during pregnancyJAMA201717596810.1001/jama.2016.19006 20.LealM.C.MunizL.F.FerreiraT.S.A.SantosC.M.AlmeidaL.C.Van Der LindenV.RamosR.C.F.RodriguesL.C.NetoS.S.C.Hearing loss in infants with" exact="microcephaly" post="and evidence of congenital Zika virus infection—Brazil, November 2015–May"/>
   <result pre="menN. Engl. J. Med.20183781377138510.1056/NEJMoa171103829641964 28.De La VegaM.A.PiretJ.GriffinB.D.RhéaumeC.VenableM.C.CarbonneauJ.CoutureC.das Neves AlmeidaR.TremblayR.R.MagalhãesK.G.et al.Zika-induced" exact="male infertility" post="in mice Is potentially reversible and preventable by deoxyribonucleic"/>
   <result pre="Engl. J. Med.20183781377138510.1056/NEJMoa171103829641964 28.De La VegaM.A.PiretJ.GriffinB.D.RhéaumeC.VenableM.C.CarbonneauJ.CoutureC.das Neves AlmeidaR.TremblayR.R.MagalhãesK.G.et al.Zika-induced male" exact="infertility" post="in mice Is potentially reversible and preventable by deoxyribonucleic"/>
   <result pre="candidates afford protection against lethal challenge in miceSci. Rep.201881650910.1038/s41598-018-34735-730405178 50.NürnbergerC.BodmerB.S.FiedlerA.H.GabrielG.MühlebachM.D.A" exact="measles" post="virus-based vaccine candidate mediates protection against Zika virus in"/>
   <result pre="Dis.2016111894189910.3201/eid2211.160901 54.Brito FerreiraM.L.Antunes de BritoC.A.Moreira�?.J.P.de Morais MachadoM.�?.Henriques-SouzaA.CordeiroM.T.de Azevedo MarquesE.T.Jr.PenaL.J.Guillain-Barré syndrome," exact="acute disseminated encephalomyelitis" post="and encephalitis associated with Zika virus infection in Brazil:"/>
   <result pre="FerreiraM.L.Antunes de BritoC.A.Moreira�?.J.P.de Morais MachadoM.�?.Henriques-SouzaA.CordeiroM.T.de Azevedo MarquesE.T.Jr.PenaL.J.Guillain-Barré syndrome, acute disseminated" exact="encephalomyelitis" post="and encephalitis associated with Zika virus infection in Brazil:"/>
   <result pre="BritoC.A.Moreira�?.J.P.de Morais MachadoM.�?.Henriques-SouzaA.CordeiroM.T.de Azevedo MarquesE.T.Jr.PenaL.J.Guillain-Barré syndrome, acute disseminated encephalomyelitis and" exact="encephalitis" post="associated with Zika virus infection in Brazil: Detection of"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6789677\results\search\disease\results.xml">
   <result pre="Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). Abstract Current seasonal" exact="influenza" post="A virus (IAV) vaccines are strain-specific and require annual"/>
   <result pre="often lead to high morbidity. Hence, development of a universal" exact="influenza" post="A vaccine targeting all IAV strains is urgently needed."/>
   <result pre="these results suggest that NvC-M2ex3 could be a potential universal" exact="influenza" post="A vaccine. universal influenza A vaccine Macrobrachium rosenbergii nodavirus"/>
   <result pre="NvC-M2ex3 could be a potential universal influenza A vaccine. universal" exact="influenza" post="A vaccine Macrobrachium rosenbergii nodavirus extracellular domain of matrix"/>
   <result pre="of highly pathogenic avian IAV to humans raised concerns of" exact="avian influenza" post="pandemics [2,3,4]. IAV is an enveloped virus with a"/>
   <result pre="highly pathogenic avian IAV to humans raised concerns of avian" exact="influenza" post="pandemics [2,3,4]. IAV is an enveloped virus with a"/>
   <result pre="are commonly used as the primary immunogenic components of current" exact="influenza" post="vaccines [5,6]. During a natural infection, HA binds to"/>
   <result pre="and NA reduce the efficacy of these antiviral drugs. Thus," exact="influenza" post="A vaccines have to be reformulated annually to counter"/>
   <result pre="rapidly mutating seasonal IAV [10]. The protective efficacy of current" exact="influenza" post="A vaccines varies between 60% to 90% depending on"/>
   <result pre="event of an unanticipated pandemic caused by genetic reassortments, seasonal" exact="influenza" post="vaccines become less effective, in addition to the considerable"/>
   <result pre="strains is urgently needed for the development of a universal" exact="influenza" post="A vaccine. The matrix 2 (M2) protein of IAV"/>
   <result pre="representing a potential candidate for the development of a universal" exact="influenza" post="A vaccine [14]. Unlike HA and NA, the M2e"/>
   <result pre="infection, or vaccination with the whole inactivated or live attenuated" exact="influenza" post="A vaccine, no notable M2e-specific antibody titer could be"/>
   <result pre="of M2e, various virus-like particles (VLPs) such as those of" exact="hepatitis" post="B virus (HBV), human papilloma virus (HPV), papaya mosaic"/>
   <result pre="RNA-phages Qβ and AP205, were shown to induce carrier-induced epitopic" exact="suppression" post="(CIES) in mice, a condition that is characterized by"/>
   <result pre="(CIES) in mice, a condition that is characterized by the" exact="suppression" post="of humoral immune responses directed against the target antigen"/>
   <result pre="these results demonstrated that NvC-M2ex3 could be a potential universal" exact="influenza" post="A vaccine. 2. Materials and Methods 2.1. Ethics Statement"/>
   <result pre="challenged with H1N1 (Figure 5(Ai)) but demonstrated a very mild" exact="bronchiolitis" post="when they were challenged with H3N2 (Figure 5(Bi)), suggesting"/>
   <result pre="of adjuvants [31]. In an attempt to produce a universal" exact="influenza" post="A vaccine, we previously constructed chimeric VLPs derived from"/>
   <result pre="the anti-M2e antibody was also reported to confer protection against" exact="influenza" post="virus infection via antibody-dependent cytotoxicity and antibody-mediated phagocytosis in"/>
   <result pre="a longer period of time [38]. In general, detection of" exact="influenza" post="viral RNA in the respiratory airway indicates the viral"/>
   <result pre="groups after being challenged with H1N1 or H3N2, suggesting the" exact="suppression" post="of viral shedding. The mice immunized with NvC-M2ex3 demonstrated"/>
   <result pre="the control groups. Positive correlation between IL-12 and IFN-γ in" exact="influenza" post="infection was also reported by Monteiro et al. [40]."/>
   <result pre="the peripheral blood mononuclear cells of patients infected with multidrug-resistant" exact="tuberculosis" post="and cord blood-derived mononuclear cells of neonates stimulated with"/>
   <result pre="of natural heterosubtypic protection, contrary to the current licensed inactivated" exact="influenza" post="vaccine which was reported to hamper the cross-protectivity of"/>
   <result pre="not reflect the risk of virus transmission in mice because" exact="influenza" post="A virus does not spread effectively in mice and"/>
   <result pre="antiviral cytokines could also potentially contribute to early protection against" exact="influenza" post="infections. Recommendations for future studies include investigation of the"/>
   <result pre="serum transfer, long-term protection, and challenges with different strains of" exact="influenza" post="A viruses. 6. Patent A patent entitled &quot;An Influenza"/>
   <result pre="ready?Biosecurity Bioterrorism Biodefense Strategy Pract. Sci.20053707310.1089/bsp.2005.3.70 2.LaiS.QinY.CowlingB.J.RenX.WardropN.A.GilbertM.TsangT.K.WuP.FengL.JiangH.et al.Global epidemiology of" exact="avian influenza" post="A H5N1 virus infection in humans, 1997–2015: A systematic"/>
   <result pre="Bioterrorism Biodefense Strategy Pract. Sci.20053707310.1089/bsp.2005.3.70 2.LaiS.QinY.CowlingB.J.RenX.WardropN.A.GilbertM.TsangT.K.WuP.FengL.JiangH.et al.Global epidemiology of avian" exact="influenza" post="A H5N1 virus infection in humans, 1997–2015: A systematic"/>
   <result pre="A systematic review of individual case dataLancet. Infect. Dis.201616e108e11810.1016/S1473-3099(16)00153-527211899 3.WongS.S.YuenK.Y.Avian" exact="influenza" post="virus infections in humansChest200612915616810.1378/chest.129.1.15616424427 4.YangY.HalloranM.E.SugimotoJ.D.LonginiI.M.Jr.Detecting human-to-human transmission of avian"/>
   <result pre="3.WongS.S.YuenK.Y.Avian influenza virus infections in humansChest200612915616810.1378/chest.129.1.15616424427 4.YangY.HalloranM.E.SugimotoJ.D.LonginiI.M.Jr.Detecting human-to-human transmission of" exact="avian influenza" post="A (H5N1)Emerg. Infect. Dis.2007131348135310.3201/eid1309.07011118252106 5.CoxN.J.SubbaraoK.InfluenzaLancet19993541277128210.1016/S0140-6736(99)01241-610520648 6.HouserK.SubbaraoK.Influenza Vaccines: Challenges and"/>
   <result pre="influenza virus infections in humansChest200612915616810.1378/chest.129.1.15616424427 4.YangY.HalloranM.E.SugimotoJ.D.LonginiI.M.Jr.Detecting human-to-human transmission of avian" exact="influenza" post="A (H5N1)Emerg. Infect. Dis.2007131348135310.3201/eid1309.07011118252106 5.CoxN.J.SubbaraoK.InfluenzaLancet19993541277128210.1016/S0140-6736(99)01241-610520648 6.HouserK.SubbaraoK.Influenza Vaccines: Challenges and"/>
   <result pre="basis of the structure and function of H1 hemagglutinin of" exact="influenza" post="virusProc. Jpn. Acad. Ser. B Phys. Biol. Sci.20128822624910.2183/pjab.88.226 9.BoltzD.A.AldridgeJ.R.WebsterR.G.GovorkovaE.A.Drugs"/>
   <result pre="Biol. Sci.20128822624910.2183/pjab.88.226 9.BoltzD.A.AldridgeJ.R.WebsterR.G.GovorkovaE.A.Drugs in Development for InfluenzaDrugs2010701349136210.2165/11537960-000000000-0000020614944 10.HussainM.GalvinH.D.HawT.Y.NutsfordA.N.HusainM.Drug resistance in" exact="influenza" post="A virus: The epidemiology and managementInfect. Drug Resist.20171012113410.2147/IDR.S10547328458567 11.ZhangX.S.PebodyR.De"/>
   <result pre="ectodomain of matrix protein 2Virol. J.2006310210.1186/1743-422X-3-10217150104 16.De FiletteM.RamneA.BirkettA.LyckeN.LowenadlerB.Min JouW.SaelensX.FiersW.The universal" exact="influenza" post="vaccine M2e-HBc administered intranasally in combination with the adjuvant"/>
   <result pre="particle vaccine with adjuvant protects mice against homologous and heterologous" exact="influenza" post="virusesVaccine2016346464647110.1016/j.vaccine.2016.11.02627866773 18.MaticS.RinaldiR.MasengaV.NorisE.Efficient production of chimeric human papillomavirus 16 L1"/>
   <result pre="of chimeric human papillomavirus 16 L1 protein bearing the M2e" exact="influenza" post="epitope in Nicotiana benthamiana plantsBMC Biotechnol.20111110610.1186/1472-6750-11-10622085463 19.DenisJ.Acosta-RamirezE.ZhaoY.HamelinM.E.KoukavicaI.BazM.AbedY.SavardC.PareC.Lopez MaciasC.et al.Development"/>
   <result pre="Nicotiana benthamiana plantsBMC Biotechnol.20111110610.1186/1472-6750-11-10622085463 19.DenisJ.Acosta-RamirezE.ZhaoY.HamelinM.E.KoukavicaI.BazM.AbedY.SavardC.PareC.Lopez MaciasC.et al.Development of a universal" exact="influenza" post="A vaccine based on the M2e peptide fused to"/>
   <result pre="vaccine platformVaccine2008263395340310.1016/j.vaccine.2008.04.05218511159 20.PetukhovaN.V.GasanovaT.V.StepanovaL.A.RusovaO.A.PotapchukM.V.KorotkovA.V.SkuratE.V.TsybalovaL.M.KiselevO.I.IvanovP.A.et al.Immunogenicity and protective efficacy of candidate universal" exact="influenza" post="A nanovaccines produced in plants by Tobacco mosaic virus-based"/>
   <result pre="Pharm Des.2013195587560010.2174/1381612811319999033723394564 21.HashemiH.PouyanfardS.BandehpourM.NoroozbabaeiZ.KazemiB.SaelensX.Mokhtari-AzadT.Immunization with M2e-displaying T7 bacteriophage nanoparticles protects against" exact="influenza" post="A virus challengePLoS ONE20127e4576510.1371/journal.pone.004576523029232 22.HerzenbergL.A.TokuhisaT.Epitope-specific regulation. I. Carrier-specific induction"/>
   <result pre="A virus challengePLoS ONE20127e4576510.1371/journal.pone.004576523029232 22.HerzenbergL.A.TokuhisaT.Epitope-specific regulation. I. Carrier-specific induction of" exact="suppression" post="for IgG anti-hapten antibody responsesJ. Exp. Med.19821551730174010.1084/jem.155.6.17306176665 23.JegerlehnerA.WieselM.DietmeierK.ZabelF.GattoD.SaudanP.BachmannM.F.Carrier induced"/>
   <result pre="for IgG anti-hapten antibody responsesJ. Exp. Med.19821551730174010.1084/jem.155.6.17306176665 23.JegerlehnerA.WieselM.DietmeierK.ZabelF.GattoD.SaudanP.BachmannM.F.Carrier induced epitopic" exact="suppression" post="of antibody responses induced by virus-like particles is a"/>
   <result pre="is a dynamic phenomenon caused by carrier-specific antibodiesVaccine2010285503551210.1016/j.vaccine.2010.02.10320307591 24.De FiletteM.MartensW.SmetA.SchotsaertM.BirkettA.Londono-ArcilaP.FiersW.SaelensX.Universal" exact="influenza" post="A M2e-HBc vaccine protects against disease even in the"/>
   <result pre="even in the presence of pre-existing anti-HBc antibodiesVaccine2008266503650710.1016/j.vaccine.2008.09.03818835315 25.De FiletteM.JouM.W.BirkettA.LyonsK.SchultzB.TonkyroA.ReschS.FiersW.Universal" exact="influenza" post="A vaccine: Optimization of M2-based constructsVirology200533714916110.1016/j.virol.2005.04.00415914228 26.YongC.Y.YeapS.K.HoK.L.OmarA.R.TanW.S.Potential recombinant vaccine"/>
   <result pre="A vaccine: Optimization of M2-based constructsVirology200533714916110.1016/j.virol.2005.04.00415914228 26.YongC.Y.YeapS.K.HoK.L.OmarA.R.TanW.S.Potential recombinant vaccine against" exact="influenza" post="A virus based on M2e displayed on nodaviral capsid"/>
   <result pre="28.ToapantaF.R.RossT.M.Impaired immune responses in the lungs of aged mice following" exact="influenza" post="infectionRespir. Res.20091011210.1186/1465-9921-10-11219922665 29.HopkinsM.J.MoorcroftJ.F.CorreiaJ.B.HartI.J.Using the full spectral capacity (six channels)"/>
   <result pre="pneumococcal pneumoniaPLoS ONE20138e5819110.1371/journal.pone.005819123483993 31.OngH.K.TanW.S.HoK.L.Virus like particles as a platform for" exact="cancer" post="vaccine developmentPeer J.20175e405310.7717/peerj.405329158984 32.NeirynckS.DerooT.SaelensX.VanlandschootP.JouW.M.FiersW.A universal influenza A vaccine based"/>
   <result pre="as a platform for cancer vaccine developmentPeer J.20175e405310.7717/peerj.405329158984 32.NeirynckS.DerooT.SaelensX.VanlandschootP.JouW.M.FiersW.A universal" exact="influenza" post="A vaccine based on the extracellular domain of the"/>
   <result pre="RooijenN.VerbeekS.FiersW.SaelensX.Universal vaccine based on ectodomain of matrix protein 2 of" exact="influenza" post="A: Fc receptors and alveolar macrophages mediate protectionJ. Immunol.20111861022103110.4049/jimmunol.090214721169548"/>
   <result pre="associated RNA promote T helper 1 type adaptive immunity against" exact="influenza" post="APLoS ONE20138e5908110.1371/journal.pone.005908123527091 35.SchotsaertM.YsenbaertT.NeytK.IbanezL.I.BogaertP.SchepensB.LambrechtB.N.FiersW.SaelensX.Natural and long-lasting cellular immune responses against"/>
   <result pre="influenza APLoS ONE20138e5908110.1371/journal.pone.005908123527091 35.SchotsaertM.YsenbaertT.NeytK.IbanezL.I.BogaertP.SchepensB.LambrechtB.N.FiersW.SaelensX.Natural and long-lasting cellular immune responses against" exact="influenza" post="in the M2e-immune hostMucosal. Immunol.2013627628710.1038/mi.2012.6922806098 36.WangB.Z.GillH.S.KangS.M.WangL.WangY.C.VassilievaE.V.CompansR.W.Enhanced influenza virus-like particle"/>
   <result pre="immune responses against influenza in the M2e-immune hostMucosal. Immunol.2013627628710.1038/mi.2012.6922806098 36.WangB.Z.GillH.S.KangS.M.WangL.WangY.C.VassilievaE.V.CompansR.W.Enhanced" exact="influenza" post="virus-like particle vaccines containing the extracellular domain of matrix"/>
   <result pre="and a Toll-like receptor ligandClin. Vaccine Immunol. CVI2012191119112510.1128/CVI.00153-1222647270 37.KillingleyB.Nguyen-Van-TamJ.Routes of" exact="influenza" post="transmissionInfluenza Other Respir. Viruses20137425110.1111/irv.12080 38.LeekhaS.ZitterkopfN.L.EspyM.J.SmithT.F.ThompsonR.L.SampathkumarP.Duration of influenza A virus"/>
   <result pre="CVI2012191119112510.1128/CVI.00153-1222647270 37.KillingleyB.Nguyen-Van-TamJ.Routes of influenza transmissionInfluenza Other Respir. Viruses20137425110.1111/irv.12080 38.LeekhaS.ZitterkopfN.L.EspyM.J.SmithT.F.ThompsonR.L.SampathkumarP.Duration of" exact="influenza" post="A virus shedding in hospitalized patients and implications for"/>
   <result pre="hospitalized with influenzaJ. Infect. Dis.200920049250010.1086/60038319591575 40.MonteiroJ.M.HarveyC.TrinchieriG.Role of interleukin-12 in primary" exact="influenza" post="virus infectionJ. Virol.199872482548319573248 41.HeX.S.DraghiM.MahmoodK.HolmesT.H.KembleG.W.DekkerC.L.ArvinA.M.ParhamP.GreenbergH.B.T cell-dependent production of IFN-gamma by"/>
   <result pre="cell-dependent production of IFN-gamma by NK cells in response to" exact="influenza" post="A virusJ. Clin. Investig.20041141812181910.1172/JCI2279715599406 42.WeissI.D.WaldO.WaldH.BeiderK.AbrahamM.GalunE.NaglerA.PeledA.IFN-gamma treatment at early stages"/>
   <result pre="A virusJ. Clin. Investig.20041141812181910.1172/JCI2279715599406 42.WeissI.D.WaldO.WaldH.BeiderK.AbrahamM.GalunE.NaglerA.PeledA.IFN-gamma treatment at early stages of" exact="influenza" post="virus infection protects mice from death in a NK"/>
   <result pre="cellsPediatric. Res.19974154755310.1203/00006450-199704000-00015 45.DienzO.RudJ.G.EatonS.M.LanthierP.A.BurgE.DrewA.BunnJ.SurattB.T.HaynesL.RinconM.Essential role of IL-6 in protection against H1N1" exact="influenza" post="virus by promoting neutrophil survival in the lungMucosal Immunol.2012525826610.1038/mi.2012.222294047"/>
   <result pre="47.PaquetteS.G.BannerD.ZhaoZ.FangY.HuangS.S.LeomicronnA.J.NgD.C.AlmansaR.Martin-LoechesI.RamirezP.et al.Interleukin-6 is a potential biomarker for severe pandemic H1N1" exact="influenza" post="A infectionPLoS ONE20127e3821410.1371/journal.pone.003821422679491 48.BodewesR.KreijtzJ.H.BaasC.Geelhoed-MierasM.M.de MutsertG.van AmerongenG.van den BrandJ.M.FouchierR.A.OsterhausA.D.RimmelzwaanG.F.Vaccination against"/>
   <result pre="A infectionPLoS ONE20127e3821410.1371/journal.pone.003821422679491 48.BodewesR.KreijtzJ.H.BaasC.Geelhoed-MierasM.M.de MutsertG.van AmerongenG.van den BrandJ.M.FouchierR.A.OsterhausA.D.RimmelzwaanG.F.Vaccination against human" exact="influenza" post="A/H3N2 virus prevents the induction of heterosubtypic immunity against"/>
   <result pre="prevents the induction of heterosubtypic immunity against lethal infection with" exact="avian influenza" post="A/H5N1 virusPLoS ONE20094e553810.1371/journal.pone.000553819440239 49.McKeeS.J.YoungV.L.ClowF.HaymanC.M.BairdM.A.HermansI.F.YoungS.L.WardV.K.Virus-like particles and alpha-galactosylceramide form a"/>
   <result pre="the induction of heterosubtypic immunity against lethal infection with avian" exact="influenza" post="A/H5N1 virusPLoS ONE20094e553810.1371/journal.pone.000553819440239 49.McKeeS.J.YoungV.L.ClowF.HaymanC.M.BairdM.A.HermansI.F.YoungS.L.WardV.K.Virus-like particles and alpha-galactosylceramide form a"/>
   <result pre="50.EdenboroughK.M.GilbertsonB.P.BrownL.E.A mouse model for the study of contact-dependent transmission of" exact="influenza" post="A virus and the factors that govern transmissibilityJ. Virol.201286125441255110.1128/JVI.00859-1222951824"/>
   <result pre="Figure 2 Mortality and morbidity of BALB/c mice after lethal" exact="influenza" post="A virus infections. Survival rate of mice infected with"/>
   <result pre="= 3) immunized with the chimeric proteins and challenged with" exact="influenza" post="A virus H1N1 or H3N2. (A) The lungs of"/>
   <result pre="as (a), (b), and (c). Dashed and solid arrows indicate" exact="bronchiolitis" post="and interstitial inflammation respectively, and triangles indicate edema, n"/>
   <result pre="inflammatory scores of the mice (n = 3) challenged with" exact="influenza" post="A virus. A lower lung inflammatory score was observed"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6789886\results\search\disease\results.xml">
   <result pre="infection during the first trimester of pregnancy was associated with" exact="microcephaly" post="and other neurological complications in newborns. As a result,"/>
   <result pre="worldwide. Only thereafter, and when ZIKV infection became associated with" exact="microcephaly" post="and cases of Guillain-Barré syndrome [8,9,10,11], did ZIKV call"/>
   <result pre="modified to incorporate a universal Th cell epitope derived from" exact="tetanus" post="toxin (CuMVtt) to enhance antibody responses in individuals previously"/>
   <result pre="(CuMVtt) to enhance antibody responses in individuals previously immunized against" exact="tetanus" post="[31]. Immunogenicity of antigens displayed on VLPs is further"/>
   <result pre="monoclonal antibody and pool of serum from mice infected with" exact="rabies" post="virus were used as controls. The mixture was incubated"/>
   <result pre="warranted as infections of pregnant woman can cause induction of" exact="microcephaly" post="in babies [8,9,10,11]. Current vaccine candidates, which are based"/>
   <result pre="a recent publication has demonstrated that Zika EDIII-domain fused to" exact="hepatitis" post="B core Antigen (HBcAg) induces potent neutralizing antibodies in"/>
   <result pre="microcephaly: Why is this situation a PHEIC?Lancet201638771972110.1016/S0140-6736(16)00320-226876373 9.MéndezN.Oviedo-PastranaM.MattarS.Caicedo-CastroI.ArrietaG.Zika virus disease," exact="microcephaly" post="and Guillain-Barré syndrome in Colombia: Epidemiological situation during 21"/>
   <result pre="virus type 2Sci. Rep.201774550510.1038/srep4550528378782 44.TsuchiyaS.YamabeM.YamaguchiY.KobayashiY.KonnoT.TadaK.Establishment and characterization of a human" exact="acute monocytic leukemia" post="cell line (THP-1)Int. J. Cancer19802617117610.1002/ijc.29102602086970727 45.AbbinkP.LaroccaR.A.De La BarreraR.A.BricaultC.A.MoseleyE.T.BoydM.KirilovaM.LiZ.Ng’ang’aD.NanayakkaraO.et al.Protective"/>
   <result pre="type 2Sci. Rep.201774550510.1038/srep4550528378782 44.TsuchiyaS.YamabeM.YamaguchiY.KobayashiY.KonnoT.TadaK.Establishment and characterization of a human acute" exact="monocytic leukemia" post="cell line (THP-1)Int. J. Cancer19802617117610.1002/ijc.29102602086970727 45.AbbinkP.LaroccaR.A.De La BarreraR.A.BricaultC.A.MoseleyE.T.BoydM.KirilovaM.LiZ.Ng’ang’aD.NanayakkaraO.et al.Protective"/>
   <result pre="2Sci. Rep.201774550510.1038/srep4550528378782 44.TsuchiyaS.YamabeM.YamaguchiY.KobayashiY.KonnoT.TadaK.Establishment and characterization of a human acute monocytic" exact="leukemia" post="cell line (THP-1)Int. J. Cancer19802617117610.1002/ijc.29102602086970727 45.AbbinkP.LaroccaR.A.De La BarreraR.A.BricaultC.A.MoseleyE.T.BoydM.KirilovaM.LiZ.Ng’ang’aD.NanayakkaraO.et al.Protective"/>
   <result pre="merozoite surface protein 1 (MSP1(19)) can enhance protective immunity against" exact="malaria" post="and modulate the immunoglobulin subclass response to MSP1(19)Infect. Immun.2000682102210910.1128/IAI.68.4.2102-2109.200010722607"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6790606\results\search\disease\results.xml">
   <result pre=": Review Article: Reviews Innovative strategies for the elimination of" exact="viral hepatitis" post="at a national level: A country case series SCHRÖEDER"/>
   <result pre="Review Article: Reviews Innovative strategies for the elimination of viral" exact="hepatitis" post="at a national level: A country case series SCHRÖEDER"/>
   <result pre="provided the original work is properly cited.file:LIV-39-1818.pdf Abstract Abstract Viral" exact="hepatitis" post="is a leading cause of morbidity and mortality worldwide,"/>
   <result pre="modelling studies suggest that investing in the global elimination of" exact="viral hepatitis" post="is feasible and cost�?effective. In 2016, all 194 member"/>
   <result pre="studies suggest that investing in the global elimination of viral" exact="hepatitis" post="is feasible and cost�?effective. In 2016, all 194 member"/>
   <result pre="of the World Health Organization endorsed the goal to eliminate" exact="viral hepatitis" post="as a public health threat by 2030, but complex"/>
   <result pre="the World Health Organization endorsed the goal to eliminate viral" exact="hepatitis" post="as a public health threat by 2030, but complex"/>
   <result pre="diverse range of countries that have invested in responses to" exact="viral hepatitis" post="and adopted innovative approaches to tackle their respective epidemics."/>
   <result pre="range of countries that have invested in responses to viral" exact="hepatitis" post="and adopted innovative approaches to tackle their respective epidemics."/>
   <result pre="to build a global investment case for the elimination of" exact="viral hepatitis" post="by 2030, national activities and key enablers are highlighted"/>
   <result pre="build a global investment case for the elimination of viral" exact="hepatitis" post="by 2030, national activities and key enablers are highlighted"/>
   <result pre="are highlighted that showcase the feasibility and impact of concerted" exact="hepatitis" post="responses across a range of settings, with different levels"/>
   <result pre="(a) evidence�?gathering and planning; (b) implementation; and (c) integration of" exact="viral hepatitis" post="services into the Agenda for Sustainable Development. They provide"/>
   <result pre="evidence�?gathering and planning; (b) implementation; and (c) integration of viral" exact="hepatitis" post="services into the Agenda for Sustainable Development. They provide"/>
   <result pre="facing similar challenges and resource constraints. developing countries disease elimination" exact="hepatitis" post="B hepatitis C investment case organizational case studies Funding"/>
   <result pre="challenges and resource constraints. developing countries disease elimination hepatitis B" exact="hepatitis" post="C investment case organizational case studies Funding Qatar Foundation"/>
   <result pre="PedranaA, ScottN, et al. Innovative strategies for the elimination of" exact="viral hepatitis" post="at a national level: A country case series. Liver"/>
   <result pre="ScottN, et al. Innovative strategies for the elimination of viral" exact="hepatitis" post="at a national level: A country case series. Liver"/>
   <result pre="spot GHSSH Global Health Sector Strategy on Viral Hepatitis HBIg" exact="hepatitis" post="B immunoglobulin HBsAg hepatitis B surface antigen HIV human"/>
   <result pre="Sector Strategy on Viral Hepatitis HBIg hepatitis B immunoglobulin HBsAg" exact="hepatitis" post="B surface antigen HIV human immunodeficiency virus MTCT mother�?to�?child"/>
   <result pre="Intellectual Property Rights WHO World Health Organization Key points Viral" exact="hepatitis" post="is the 6th leading cause of death globally, surpassing"/>
   <result pre="death globally, surpassing all other chronic infectious diseases including HIV," exact="tuberculosis" post="and malaria Elimination of viral hepatitis as a public"/>
   <result pre="surpassing all other chronic infectious diseases including HIV, tuberculosis and" exact="malaria" post="Elimination of viral hepatitis as a public health threat"/>
   <result pre="chronic infectious diseases including HIV, tuberculosis and malaria Elimination of" exact="viral hepatitis" post="as a public health threat is achievable; all WHO"/>
   <result pre="infectious diseases including HIV, tuberculosis and malaria Elimination of viral" exact="hepatitis" post="as a public health threat is achievable; all WHO"/>
   <result pre="in 2016 Planning, implementation and integration of national responses to" exact="viral hepatitis" post="is ongoing, and many countries have adopted innovative approaches"/>
   <result pre="2016 Planning, implementation and integration of national responses to viral" exact="hepatitis" post="is ongoing, and many countries have adopted innovative approaches"/>
   <result pre="in their local contexts Existing approaches demonstrate that investing in" exact="viral hepatitis" post="is affordable and cost�?effective, provides multisectoral cost�?benefits, and alleviates"/>
   <result pre="their local contexts Existing approaches demonstrate that investing in viral" exact="hepatitis" post="is affordable and cost�?effective, provides multisectoral cost�?benefits, and alleviates"/>
   <result pre="alleviates the human burden of the epidemic 1 INTRODUCTION Viral" exact="hepatitis" post="contributes substantially to the global burden of disease, with"/>
   <result pre="global burden of disease, with 248 million people infected with" exact="hepatitis" post="B and 71 million infected with hepatitis C worldwide.1"/>
   <result pre="people infected with hepatitis B and 71 million infected with" exact="hepatitis" post="C worldwide.1 If left untreated, chronic viral hepatitis can"/>
   <result pre="million infected with hepatitis C worldwide.1 If left untreated, chronic" exact="viral hepatitis" post="can cause life�?threatening complications, such as cirrhosis and hepatocellular"/>
   <result pre="infected with hepatitis C worldwide.1 If left untreated, chronic viral" exact="hepatitis" post="can cause life�?threatening complications, such as cirrhosis and hepatocellular"/>
   <result pre="untreated, chronic viral hepatitis can cause life�?threatening complications, such as" exact="cirrhosis" post="and hepatocellular carcinoma.2 Despite this, the public health consequences"/>
   <result pre="and hepatocellular carcinoma.2 Despite this, the public health consequences of" exact="viral hepatitis" post="have long been neglected.1 In contrast to the progress"/>
   <result pre="hepatocellular carcinoma.2 Despite this, the public health consequences of viral" exact="hepatitis" post="have long been neglected.1 In contrast to the progress"/>
   <result pre="hepatitis�?related morbidity and mortality continue to rise.1, 3 In 2010" exact="viral hepatitis" post="was the 10th leading cause of death, but by"/>
   <result pre="morbidity and mortality continue to rise.1, 3 In 2010 viral" exact="hepatitis" post="was the 10th leading cause of death, but by"/>
   <result pre="by 2015, with 1.2 million deaths, it had overtaken HIV," exact="malaria" post="and tuberculosis to rise to sixth.4 Most viral hepatitis"/>
   <result pre="with 1.2 million deaths, it had overtaken HIV, malaria and" exact="tuberculosis" post="to rise to sixth.4 Most viral hepatitis deaths are"/>
   <result pre="overtaken HIV, malaria and tuberculosis to rise to sixth.4 Most" exact="viral hepatitis" post="deaths are avertable through increased access to prevention, diagnosis"/>
   <result pre="HIV, malaria and tuberculosis to rise to sixth.4 Most viral" exact="hepatitis" post="deaths are avertable through increased access to prevention, diagnosis"/>
   <result pre="access to prevention, diagnosis and treatment. In areas of high" exact="hepatitis" post="B endemicity (eg Southeast Asia and sub�?Saharan Africa), perinatal"/>
   <result pre="procedures drive transmission elsewhere.5, 6, 7 Risk of developing chronic" exact="hepatitis" post="B infection is inversely related to age at infection:"/>
   <result pre="than 5% of persons infected as adults.8, 9, 10 The" exact="hepatitis" post="C epidemic is similarly geographically diverse and mode of"/>
   <result pre="an estimated 52% of people who inject drugs (PWID) are" exact="hepatitis" post="C antibody positive.15 Lack of access to needle and"/>
   <result pre="and treatment service coverage targets to achieve the elimination of" exact="viral hepatitis" post="as a public health threat by 2030 (defined as"/>
   <result pre="treatment service coverage targets to achieve the elimination of viral" exact="hepatitis" post="as a public health threat by 2030 (defined as"/>
   <result pre="Health Organization (WHO) targets by 2030.21, 22 Table 1 Viral" exact="hepatitis" post="service coverage and impact targets Target area Baseline 2015"/>
   <result pre="(third dose coverage) 82% of infants 90% 90% Prevention of" exact="hepatitis" post="B virus mother�?to�?child transmission: hepatitis B virus birth�?dose coverage"/>
   <result pre="infants 90% 90% Prevention of hepatitis B virus mother�?to�?child transmission:" exact="hepatitis" post="B virus birth�?dose coverage or other approach to prevent"/>
   <result pre="year for people who inject drugs 20 200 300 Viral" exact="hepatitis" post="B and C diagnosis (coverage %) &amp;lt;5% of chronic"/>
   <result pre="hepatitis B and C diagnosis (coverage %) &amp;lt;5% of chronic" exact="hepatitis" post="infections diagnosed 30% 90% Viral hepatitis B and C"/>
   <result pre="%) &amp;lt;5% of chronic hepatitis infections diagnosed 30% 90% Viral" exact="hepatitis" post="B and C treatment (coverage %) &amp;lt;1% receiving treatment"/>
   <result pre="million 80% eligible treated Impact targets Incidence: new cases of" exact="viral hepatitis" post="B and C infections Between 6 and 10 million"/>
   <result pre="80% eligible treated Impact targets Incidence: new cases of viral" exact="hepatitis" post="B and C infections Between 6 and 10 million"/>
   <result pre="reduced to 0.9 million infections by 2030 (95% declined in" exact="hepatitis" post="B virus infections, 80% decline in hepatitis C virus"/>
   <result pre="(95% declined in hepatitis B virus infections, 80% decline in" exact="hepatitis" post="C virus infections) 30% reduction (equivalent to 1% prevalence"/>
   <result pre="reduction (equivalent to 0.1% prevalence of HBsAg among children) Mortality:" exact="viral hepatitis" post="B and C deaths 1.4 million deaths reduced to"/>
   <result pre="(equivalent to 0.1% prevalence of HBsAg among children) Mortality: viral" exact="hepatitis" post="B and C deaths 1.4 million deaths reduced to"/>
   <result pre="to less than 500 000 by 2030 (65% for both" exact="viral hepatitis" post="B and C) 10% reduction 65% reduction Source: Global"/>
   <result pre="less than 500 000 by 2030 (65% for both viral" exact="hepatitis" post="B and C) 10% reduction 65% reduction Source: Global"/>
   <result pre="Hepatitis, 2016�?2021.18(C) John Wiley &amp;amp; Sons, Ltd, 1.1 How can" exact="viral hepatitis" post="be eliminated by 2030? Eliminating viral hepatitis requires substantial"/>
   <result pre="2016�?2021.18(C) John Wiley &amp;amp; Sons, Ltd, 1.1 How can viral" exact="hepatitis" post="be eliminated by 2030? Eliminating viral hepatitis requires substantial"/>
   <result pre="1.1 How can viral hepatitis be eliminated by 2030? Eliminating" exact="viral hepatitis" post="requires substantial investments in health systems strengthening and the"/>
   <result pre="How can viral hepatitis be eliminated by 2030? Eliminating viral" exact="hepatitis" post="requires substantial investments in health systems strengthening and the"/>
   <result pre="investments in health systems strengthening and the full continuum of" exact="hepatitis" post="services.18 Investing in the prevention and treatment of viral"/>
   <result pre="of hepatitis services.18 Investing in the prevention and treatment of" exact="viral hepatitis" post="provides many direct, indirect and cross�?sectoral economic benefits through"/>
   <result pre="hepatitis services.18 Investing in the prevention and treatment of viral" exact="hepatitis" post="provides many direct, indirect and cross�?sectoral economic benefits through"/>
   <result pre="in the delivery of care; and (c) integration of the" exact="viral hepatitis" post="response into SDG 3 by adopting a public health"/>
   <result pre="the delivery of care; and (c) integration of the viral" exact="hepatitis" post="response into SDG 3 by adopting a public health"/>
   <result pre="embedding services into universal health coverage.27 The necessary tools for" exact="viral hepatitis" post="elimination are already available, but worldwide implementation of a"/>
   <result pre="services into universal health coverage.27 The necessary tools for viral" exact="hepatitis" post="elimination are already available, but worldwide implementation of a"/>
   <result pre="elimination are already available, but worldwide implementation of a concerted" exact="viral hepatitis" post="response is slow and faces many challenges. These include"/>
   <result pre="are already available, but worldwide implementation of a concerted viral" exact="hepatitis" post="response is slow and faces many challenges. These include"/>
   <result pre="only 12 countries are currently on track to achieve the" exact="hepatitis" post="C elimination goal that all WHO member states adopted"/>
   <result pre="required to achieve elimination, the cost of the elimination of" exact="viral hepatitis" post="globally, and methods for countries to address existing challenges.31"/>
   <result pre="to achieve elimination, the cost of the elimination of viral" exact="hepatitis" post="globally, and methods for countries to address existing challenges.31"/>
   <result pre="Hepatitis Investment Framework highlights key enablers to support a comprehensive" exact="viral hepatitis" post="response and outlines priority national and international activities to"/>
   <result pre="Investment Framework highlights key enablers to support a comprehensive viral" exact="hepatitis" post="response and outlines priority national and international activities to"/>
   <result pre="(Table 2) that are successfully implementing innovative strategies to eliminate" exact="viral hepatitis" post="(see Table 3). Additional case studies listed in Table"/>
   <result pre="2) that are successfully implementing innovative strategies to eliminate viral" exact="hepatitis" post="(see Table 3). Additional case studies listed in Table"/>
   <result pre="S1 (Figures 2, 3, 4). Figure 1 Investment framework for" exact="viral hepatitis" post="elimination Table 2 Country characteristics Georgia South Africa Scotland"/>
   <result pre="(Figures 2, 3, 4). Figure 1 Investment framework for viral" exact="hepatitis" post="elimination Table 2 Country characteristics Georgia South Africa Scotland"/>
   <result pre="3 National activities and country examples aimed at elimination of" exact="viral hepatitis" post="National activities Country examples presented in this paper Evidence�?gathering"/>
   <result pre="National activities and country examples aimed at elimination of viral" exact="hepatitis" post="National activities Country examples presented in this paper Evidence�?gathering"/>
   <result pre="Country examples presented in this paper Evidence�?gathering and planning National" exact="hepatitis" post="plan (addressing hepatitis B, hepatitis C or both) Georgia,"/>
   <result pre="in this paper Evidence�?gathering and planning National hepatitis plan (addressing" exact="hepatitis" post="B, hepatitis C or both) Georgia, Australia, Brazil, China,"/>
   <result pre="paper Evidence�?gathering and planning National hepatitis plan (addressing hepatitis B," exact="hepatitis" post="C or both) Georgia, Australia, Brazil, China, Egypt, Iceland,"/>
   <result pre="data limit countries' capacity to guide, implement and monitor effective" exact="viral hepatitis" post="responses.32, 33 To advocate for an adequate allocation of"/>
   <result pre="limit countries' capacity to guide, implement and monitor effective viral" exact="hepatitis" post="responses.32, 33 To advocate for an adequate allocation of"/>
   <result pre="achievable targets, informed by a robust local investment case for" exact="viral hepatitis." post="Gathering accurate data to inform a targeted approach can"/>
   <result pre="launch of the GHSSH 2016�?2021, more countries have developed national" exact="hepatitis" post="plans1 and both local and global investment cases for"/>
   <result pre="both local and global investment cases for the elimination of" exact="viral hepatitis" post="have been built.31, 35, 37 Many countries have begun"/>
   <result pre="local and global investment cases for the elimination of viral" exact="hepatitis" post="have been built.31, 35, 37 Many countries have begun"/>
   <result pre="epidemiological data through national seroprevalence surveys or by adding key" exact="hepatitis" post="indicators into existing surveillance systems. Below, we give examples"/>
   <result pre="first country in the WHO European region to set a" exact="hepatitis" post="C elimination goal and develop a national plan for"/>
   <result pre="hepatitis C elimination goal and develop a national plan for" exact="viral hepatitis" post="tailored to the local context. Georgia's significant experience with"/>
   <result pre="C elimination goal and develop a national plan for viral" exact="hepatitis" post="tailored to the local context. Georgia's significant experience with"/>
   <result pre="implement large�?scale health programmes facilitated the implementation of their national" exact="hepatitis" post="C elimination programme.38 An international Technical Advisory Group assisted"/>
   <result pre="An international Technical Advisory Group assisted with describing the local" exact="hepatitis" post="C epidemiology and proposing strategies, objectives and actions to"/>
   <result pre="affordable diagnostics; providing free DAA treatment to persons with severe" exact="liver disease" post="at highest�?risk of hepatitis C�?related mortality; and building capacity"/>
   <result pre="treatment to persons with severe liver disease at highest�?risk of" exact="hepatitis" post="C�?related mortality; and building capacity to achieve programme goals"/>
   <result pre="expanded its scope to treat every person chronically infected with" exact="hepatitis" post="C, as outlined in the &quot;Strategic plan for the"/>
   <result pre="on ability to pay. Georgia is working to integrate its" exact="hepatitis" post="C elimination programme into the overall health system, because"/>
   <result pre="The implementation of the national action plan increased access to" exact="hepatitis" post="C testing and linkage to care while driving improvements"/>
   <result pre="control and prevention.38, 41 The evaluation of harm reduction�?based peer�?supported" exact="hepatitis" post="C treatment demonstrated excellent treatment uptake and retention in"/>
   <result pre="new DAAs, of whom almost 34 800 had already achieved" exact="hepatitis" post="C cure (Figure 5A). Remaining challenges relate to the"/>
   <result pre="of PWID, with stigma and discrimination preventing PWID from accessing" exact="hepatitis" post="C services. Punitive drug laws (such as criminal responsibility"/>
   <result pre="reduction programmes and lead to high rates of incarceration and" exact="hepatitis" post="C transmission in prisons, where access to OST is"/>
   <result pre="is limited. As well, as in other countries aiming for" exact="hepatitis" post="C elimination, treatment numbers declined after the first two"/>
   <result pre="of the programme, with many people being unaware of their" exact="hepatitis" post="C status or not commencing treatment. Figure 5 Timeline"/>
   <result pre="impact modelling, cost�?effectiveness analysis, and fiscal space analysis for scaled�?up" exact="hepatitis" post="B and hepatitis C disease control scenarios.35 The action"/>
   <result pre="analysis, and fiscal space analysis for scaled�?up hepatitis B and" exact="hepatitis" post="C disease control scenarios.35 The action plan was developed"/>
   <result pre="and affordability, health impact and cost�?effectiveness for four priority interventions:" exact="hepatitis" post="B birth dose vaccination, prevention of MTCT and treatment"/>
   <result pre="B birth dose vaccination, prevention of MTCT and treatment for" exact="hepatitis" post="B and C. The model suggests expanded hepatitis B"/>
   <result pre="treatment for hepatitis B and C. The model suggests expanded" exact="hepatitis" post="B prevention and treatment for hepatitis B and C"/>
   <result pre="The model suggests expanded hepatitis B prevention and treatment for" exact="hepatitis" post="B and C (using DAAs for the latter) is"/>
   <result pre="cost�?effective and affordable in the South African context,35 noting that" exact="hepatitis" post="B birth dose vaccination should be prioritised if funds"/>
   <result pre="the initial five�?year investment could avert an estimated 13 000" exact="hepatitis" post="B�?related deaths and 7000 hepatitis C�?related deaths. Moreover, a"/>
   <result pre="avert an estimated 13 000 hepatitis B�?related deaths and 7000" exact="hepatitis" post="C�?related deaths. Moreover, a continued expansion of the treatment"/>
   <result pre="programme beyond 2021 has the potential to avert 672 000" exact="hepatitis" post="B�?infections and 60 000 deaths averted from hepatitis C�?related"/>
   <result pre="672 000 hepatitis B�?infections and 60 000 deaths averted from" exact="hepatitis" post="C�?related liver disease, which would put South Africa firmly"/>
   <result pre="hepatitis B�?infections and 60 000 deaths averted from hepatitis C�?related" exact="liver disease," post="which would put South Africa firmly on the path"/>
   <result pre="develop an investment case for the cost�?effectiveness and affordability of" exact="hepatitis" post="control and elimination for South Africa provides a template"/>
   <result pre="2019, with five priority interventions during the first year: (a)" exact="hepatitis" post="B birth dose vaccination; (b) healthcare worker hepatitis screening,"/>
   <result pre="year: (a) hepatitis B birth dose vaccination; (b) healthcare worker" exact="hepatitis" post="screening, vaccination and training in viral hepatitis (c) increasing"/>
   <result pre="vaccination; (b) healthcare worker hepatitis screening, vaccination and training in" exact="viral hepatitis" post="(c) increasing awareness, diagnosis and management of Hepatitis B"/>
   <result pre="(b) healthcare worker hepatitis screening, vaccination and training in viral" exact="hepatitis" post="(c) increasing awareness, diagnosis and management of Hepatitis B"/>
   <result pre="of DAAs and price negotiations; (e) a comprehensive package of" exact="viral hepatitis" post="services for key populations – men who have sex"/>
   <result pre="DAAs and price negotiations; (e) a comprehensive package of viral" exact="hepatitis" post="services for key populations – men who have sex"/>
   <result pre="a shortage of trained health workers; lack of knowledge about" exact="viral hepatitis" post="in the general public; viral hepatitis�?related stigma; limited access"/>
   <result pre="shortage of trained health workers; lack of knowledge about viral" exact="hepatitis" post="in the general public; viral hepatitis�?related stigma; limited access"/>
   <result pre="and punitive drug laws. There is a need to improve" exact="viral hepatitis" post="services in other key populations, including prisoners, sex workers"/>
   <result pre="punitive drug laws. There is a need to improve viral" exact="hepatitis" post="services in other key populations, including prisoners, sex workers"/>
   <result pre="at the South African Health Products Regulatory Authority, preventing broader" exact="hepatitis" post="C treatment scale�?up. In order to address these obstacles,"/>
   <result pre="Group has established three subcommittees to oversee implementation of the" exact="hepatitis" post="B birth dose vaccine, training of healthcare workers in"/>
   <result pre="in conjunction with training on new HIV treatment regimens, and" exact="hepatitis" post="C micro�?elimination programmes. 1.5 Scotland: accurate data to inform"/>
   <result pre="scientific evidence to raise awareness of the human impact of" exact="hepatitis" post="C and its links to inequalities, which generated political"/>
   <result pre="(DBS) sampling in community drug services made the model of" exact="viral hepatitis" post="care more acceptable to affected communities and helped overcome"/>
   <result pre="sampling in community drug services made the model of viral" exact="hepatitis" post="care more acceptable to affected communities and helped overcome"/>
   <result pre="evidence to inform and generate proposals for the development of" exact="hepatitis" post="C services and identify the additional investment required. Subsequently,"/>
   <result pre="services and deliver evidence�?based actions throughout the country for improved" exact="hepatitis" post="C prevention and control (Figure 5C). Since 2011, the"/>
   <result pre="diagnosis and treatment services led to a significant decline in" exact="hepatitis" post="C incidence, more new diagnoses, more people undergoing hepatitis"/>
   <result pre="in hepatitis C incidence, more new diagnoses, more people undergoing" exact="hepatitis" post="C treatment and achieving cure, reductions in liver�?related morbidity"/>
   <result pre="morbidity and mortality, and a decreased population prevalence of chronic" exact="hepatitis" post="C.47, 50, 51, 52 Scotland's example showcases the utility"/>
   <result pre="51, 52 Scotland's example showcases the utility of evidence�?based national" exact="hepatitis" post="C strategies in reducing the financial and societal burden"/>
   <result pre="Scotland during the era of interferon�?based treatment, the prevalence of" exact="hepatitis" post="C infection had remained stubbornly high. The recent scale�?up"/>
   <result pre="1.6 Implementation Globally, nine of the 10 people living with" exact="viral hepatitis" post="are unaware of their infection,33 and lack of public"/>
   <result pre="Implementation Globally, nine of the 10 people living with viral" exact="hepatitis" post="are unaware of their infection,33 and lack of public"/>
   <result pre="compounded by viral hepatitis�?related stigma and discrimination. Implementation of a" exact="viral hepatitis" post="strategy should therefore include awareness�?raising activities to generate demand"/>
   <result pre="by viral hepatitis�?related stigma and discrimination. Implementation of a viral" exact="hepatitis" post="strategy should therefore include awareness�?raising activities to generate demand"/>
   <result pre="strategy should therefore include awareness�?raising activities to generate demand for" exact="viral hepatitis" post="care (eg through social media campaigns, such as in"/>
   <result pre="should therefore include awareness�?raising activities to generate demand for viral" exact="hepatitis" post="care (eg through social media campaigns, such as in"/>
   <result pre="activities should be implemented and scaled up to effectively eliminate" exact="viral hepatitis" post="transmission. A highly effective hepatitis B vaccine has been"/>
   <result pre="should be implemented and scaled up to effectively eliminate viral" exact="hepatitis" post="transmission. A highly effective hepatitis B vaccine has been"/>
   <result pre="up to effectively eliminate viral hepatitis transmission. A highly effective" exact="hepatitis" post="B vaccine has been available since the 1980s, and"/>
   <result pre="since the 1980s, and early immunisation plus the distribution of" exact="hepatitis" post="B immunoglobulin (HBIg) to at�?risk infants prevents perinatal transmission,"/>
   <result pre="contributing to health systems strengthening.4, 64 Finally, implementation of a" exact="viral hepatitis" post="response must aim to optimise the viral hepatitis care"/>
   <result pre="to health systems strengthening.4, 64 Finally, implementation of a viral" exact="hepatitis" post="response must aim to optimise the viral hepatitis care"/>
   <result pre="of a viral hepatitis response must aim to optimise the" exact="viral hepatitis" post="care cascade by substantially improving testing rates, linkage to"/>
   <result pre="a viral hepatitis response must aim to optimise the viral" exact="hepatitis" post="care cascade by substantially improving testing rates, linkage to"/>
   <result pre="and civil society engagement.67 It has championed the cause of" exact="viral hepatitis" post="and advocated for an intensified global response for many"/>
   <result pre="civil society engagement.67 It has championed the cause of viral" exact="hepatitis" post="and advocated for an intensified global response for many"/>
   <result pre="the trend of the HIV epidemic, Brazil established a national" exact="hepatitis" post="programme informed by up�?to�?date estimates of disease prevalence, international"/>
   <result pre="in the Brazilian Unified Health System.57 Brazil invested in universal" exact="hepatitis" post="B vaccination, increased capacity for hepatitis C testing in"/>
   <result pre="Brazil invested in universal hepatitis B vaccination, increased capacity for" exact="hepatitis" post="C testing in HIV services, expanded its laboratory network"/>
   <result pre="its laboratory network and set up a referral system for" exact="hepatitis" post="patients. To reach the target population, the Ministry of"/>
   <result pre="these goals by 2030.57 Brazil has pledged to provide free" exact="hepatitis" post="C treatment to everyone infected and is one of"/>
   <result pre="and is one of 12 countries on track to achieve" exact="hepatitis" post="C elimination by 2030 (Figure 6A).30 Figure 6 Timeline"/>
   <result pre="home to nearly one third of all people living with" exact="hepatitis" post="B infection globally. HBsAg prevalence is estimated at 5.5%2"/>
   <result pre="B infection globally. HBsAg prevalence is estimated at 5.5%2 and" exact="hepatitis" post="B causes over 300 000 deaths annually due to"/>
   <result pre="annually due to liver diseases.69 The implementation of a universal" exact="hepatitis" post="B vaccination programme for infants has reduced chronic hepatitis"/>
   <result pre="universal hepatitis B vaccination programme for infants has reduced chronic" exact="hepatitis" post="B incidence dramatically during the past two decades. The"/>
   <result pre="supply of HBIg for at�?risk newborns. Domestic procurement of the" exact="hepatitis" post="B vaccine and auto�?disable syringes ensures sustainable supply chains"/>
   <result pre="including an investment of ~ USD76 million to subsidise the" exact="hepatitis" post="B catch�?up vaccination programme for 15 million children through"/>
   <result pre="(Figure 6B). As a result, &amp;gt;95% of infants receive the" exact="hepatitis" post="B vaccine within 24 hours of birth.72, 73, 74,"/>
   <result pre="2013, China's efforts have prevented 90 million cases of chronic" exact="hepatitis" post="B infection and 24 million fewer people are carriers"/>
   <result pre="of viral hepatitis.70 Although China has made considerable progress with" exact="hepatitis" post="B, systemic obstacles to the elimination of MTCT remain."/>
   <result pre="physicians trained to provide treatment (ie obstetricians, gynaecologists, gastroenterologists and" exact="infectious disease" post="specialists working in central hospitals) are often reluctant to"/>
   <result pre="is yet to implement a comprehensive national strategy addressing its" exact="hepatitis" post="C epidemic. Few DAAs have been approved and their"/>
   <result pre="care and treatment Egypt has a very high burden of" exact="hepatitis" post="C infection and disease, with approximately 7% of Egyptians"/>
   <result pre="with approximately 7% of Egyptians aged 18�?59 living with chronic" exact="hepatitis" post="C infection in 2015.76 This large reservoir of active"/>
   <result pre="were newly infected.77 Egypt is committed to ending its generalised" exact="hepatitis" post="C epidemic. It has developed one of the largest"/>
   <result pre="It has developed one of the largest national programmes for" exact="hepatitis" post="C treatment.78 Egypt provides free and universal access to"/>
   <result pre="a national action plan for the prevention and control of" exact="viral hepatitis." post="To maximise efficiencies, the country has rolled out mass"/>
   <result pre="out mass screening since October 2018, providing direct linkage to" exact="hepatitis" post="C care. Over six months, more than 49 million"/>
   <result pre="were reached, of whom over 2 million were diagnosed as" exact="hepatitis" post="C�?antibody positive (in addition, &amp;gt;2.5 million possible cases of"/>
   <result pre="were identified and referred for further assessment and management). Of" exact="hepatitis" post="C patients linked to care and confirmed as ribonucleic"/>
   <result pre="to achieve WHO elimination targets in spite of its high" exact="hepatitis" post="C prevalence (Figure 6C).78, 79 Egypt's response was facilitated"/>
   <result pre="Finally, plans and strategies for surveillance to reliably capture whether" exact="hepatitis" post="C elimination targets have been met are not fully"/>
   <result pre="are not fully developed. 1.10 Integration The cost burden of" exact="viral hepatitis" post="diagnostic tests and treatment – in particular the new"/>
   <result pre="not fully developed. 1.10 Integration The cost burden of viral" exact="hepatitis" post="diagnostic tests and treatment – in particular the new"/>
   <result pre="and treatment – in particular the new DAA treatment for" exact="hepatitis" post="C – challenges the feasibility and sustainability of effective"/>
   <result pre="hepatitis C – challenges the feasibility and sustainability of effective" exact="viral hepatitis" post="elimination activities. Unlike for other major communicable diseases such"/>
   <result pre="C – challenges the feasibility and sustainability of effective viral" exact="hepatitis" post="elimination activities. Unlike for other major communicable diseases such"/>
   <result pre="activities. Unlike for other major communicable diseases such as HIV," exact="tuberculosis" post="and malaria, there is little funding available for viral"/>
   <result pre="HIV, tuberculosis and malaria, there is little funding available for" exact="viral hepatitis" post="at an international level and most countries lack dedicated"/>
   <result pre="tuberculosis and malaria, there is little funding available for viral" exact="hepatitis" post="at an international level and most countries lack dedicated"/>
   <result pre="hepatitis at an international level and most countries lack dedicated" exact="hepatitis" post="budgets or programmes.18 Although the private sector (such as"/>
   <result pre="mobilised from public, domestic sources to ensure the sustainability of" exact="viral hepatitis" post="services as part of a broader effort to increase"/>
   <result pre="from public, domestic sources to ensure the sustainability of viral" exact="hepatitis" post="services as part of a broader effort to increase"/>
   <result pre="health systems strengthening) is not only a key enabler for" exact="viral hepatitis" post="elimination but a requirement to reach the overarching SDG"/>
   <result pre="systems strengthening) is not only a key enabler for viral" exact="hepatitis" post="elimination but a requirement to reach the overarching SDG"/>
   <result pre="health and its target of universal health coverage.19 Ensuring that" exact="hepatitis" post="services are integrated within these systems can reduce costs,"/>
   <result pre="access to services for key risk populations.83 For example conducting" exact="viral hepatitis" post="testing at HIV services is likely to yield high"/>
   <result pre="to services for key risk populations.83 For example conducting viral" exact="hepatitis" post="testing at HIV services is likely to yield high"/>
   <result pre="because people living with HIV have a higher risk of" exact="hepatitis" post="B or hepatitis C co�?infection, and may improve their"/>
   <result pre="with HIV have a higher risk of hepatitis B or" exact="hepatitis" post="C co�?infection, and may improve their engagement in care.84"/>
   <result pre="into HIV programmes, because further opportunities exist to broaden the" exact="viral hepatitis" post="response by integrating it within tuberculosis, maternal and child"/>
   <result pre="HIV programmes, because further opportunities exist to broaden the viral" exact="hepatitis" post="response by integrating it within tuberculosis, maternal and child"/>
   <result pre="activity. For example, additional time is needed to administer a" exact="hepatitis" post="B vaccine or to provide post�?test counselling for positive"/>
   <result pre="to concerns about extra costs and workload, efforts to integrate" exact="viral hepatitis" post="responses into existing systems and platforms may receive substantial"/>
   <result pre="concerns about extra costs and workload, efforts to integrate viral" exact="hepatitis" post="responses into existing systems and platforms may receive substantial"/>
   <result pre="there is no evidence to support the notion that introducing" exact="viral hepatitis" post="care into these systems causes existing structures to collapse.85"/>
   <result pre="is no evidence to support the notion that introducing viral" exact="hepatitis" post="care into these systems causes existing structures to collapse.85"/>
   <result pre="Table 4 Hepatitis B vaccination coverage and procurement status of" exact="hepatitis" post="C medicines Country Hepatitis B vaccination coverage (2019)75 Hepatitis"/>
   <result pre="South Africa 74%2 n/a Yes VL No No aEstimates of" exact="hepatitis" post="B vaccination coverage were produced only for countries with"/>
   <result pre="low�?income country that is using a public health framework for" exact="hepatitis" post="control and care to progress on its aim to"/>
   <result pre="has made tremendous gains in maternal and child health, malaria," exact="tuberculosis" post="and HIV outcomes. The Rwandan Government now invests major"/>
   <result pre="HIV outcomes. The Rwandan Government now invests major resources in" exact="viral hepatitis," post="using programmatic steps that form a blueprint for other"/>
   <result pre="countries in the region.88 Key elements of Rwanda's programme for" exact="viral hepatitis" post="prevention and treatment include: Simplified treatment algorithms not requiring"/>
   <result pre="in the region.88 Key elements of Rwanda's programme for viral" exact="hepatitis" post="prevention and treatment include: Simplified treatment algorithms not requiring"/>
   <result pre="hepatitis prevention and treatment include: Simplified treatment algorithms not requiring" exact="hepatitis" post="C genotype or hepatitis B viral load and largely"/>
   <result pre="include: Simplified treatment algorithms not requiring hepatitis C genotype or" exact="hepatitis" post="B viral load and largely able to be delivered"/>
   <result pre="staff Development, funding and implementation of birth dose vaccination for" exact="hepatitis" post="B. To ascertain feasibility and ensure financing for sustainability,"/>
   <result pre="levels of coverage of screening, diagnosis, and treatment of both" exact="hepatitis" post="B and C.88 Several initiatives were used to secure"/>
   <result pre="560 in 2017).66, 88 Rwanda's Essential Medicines List includes generic" exact="hepatitis" post="B medicines treatment; this is subsidised by government for"/>
   <result pre="the cost. Ultimately, the aim is to provide reimbursement for" exact="hepatitis" post="C diagnostics and treatment by the community�?based health insurance"/>
   <result pre="Rwanda (A) and Australia (B) Major ongoing barriers to addressing" exact="viral hepatitis" post="in Rwanda include the lower awareness of, and priority"/>
   <result pre="(A) and Australia (B) Major ongoing barriers to addressing viral" exact="hepatitis" post="in Rwanda include the lower awareness of, and priority"/>
   <result pre="Rwanda include the lower awareness of, and priority given to," exact="viral hepatitis" post="compared to other infectious diseases (eg malaria and HIV)"/>
   <result pre="include the lower awareness of, and priority given to, viral" exact="hepatitis" post="compared to other infectious diseases (eg malaria and HIV)"/>
   <result pre="given to, viral hepatitis compared to other infectious diseases (eg" exact="malaria" post="and HIV) and the competing priorities for limited public�?sector"/>
   <result pre="failed and has since been abandoned was to develop local" exact="viral hepatitis" post="treatment guidelines based upon international consensus guidelines, without sufficient"/>
   <result pre="and has since been abandoned was to develop local viral" exact="hepatitis" post="treatment guidelines based upon international consensus guidelines, without sufficient"/>
   <result pre="the first countries to implement and subsequently refine their national" exact="hepatitis" post="C strategies and has since then become a best"/>
   <result pre="and has since then become a best practice model for" exact="hepatitis" post="C elimination. Key to Australia's response, including achieving universal"/>
   <result pre="for treatment, such as PWID and prisoners, necessary to achieve" exact="hepatitis" post="C elimination. In addition, all registered medical practitioners are"/>
   <result pre="patient�?centred care. In Australia, close collaboration between people living with" exact="hepatitis" post="C, community organisations, clinicians and policymakers facilitated improved access"/>
   <result pre="Australia aims to treat around 15 000 to 20 000" exact="hepatitis" post="C patients per year, to reach the WHO target"/>
   <result pre="patients per year, to reach the WHO target to eliminate" exact="viral hepatitis" post="as a major public health threat by 2030. This"/>
   <result pre="per year, to reach the WHO target to eliminate viral" exact="hepatitis" post="as a major public health threat by 2030. This"/>
   <result pre="39% in June 2017.93 With the successful implementation of its" exact="hepatitis" post="C strategy – a global benchmark for best practice94"/>
   <result pre="DISCUSSION The broader benefits of investing in the elimination of" exact="viral hepatitis" post="– including progressing on the SDGs �? are increasingly"/>
   <result pre="The broader benefits of investing in the elimination of viral" exact="hepatitis" post="– including progressing on the SDGs �? are increasingly"/>
   <result pre="environments are effectively responding to their respective epidemics. Attaining the" exact="viral hepatitis" post="elimination targets set by the global community in 2016"/>
   <result pre="are effectively responding to their respective epidemics. Attaining the viral" exact="hepatitis" post="elimination targets set by the global community in 2016"/>
   <result pre="and maintain national elimination efforts. Gathering sufficient funds to finance" exact="viral hepatitis" post="programmes continues to be difficult among competing health priorities"/>
   <result pre="maintain national elimination efforts. Gathering sufficient funds to finance viral" exact="hepatitis" post="programmes continues to be difficult among competing health priorities"/>
   <result pre="example, in Egypt expenditure on diagnostics now exceeds that on" exact="hepatitis" post="C treatment.68 There are few WHO prequalified point�?of�?care viral"/>
   <result pre="on hepatitis C treatment.68 There are few WHO prequalified point�?of�?care" exact="viral hepatitis" post="tests and little production of low�?cost high�?quality generic tests."/>
   <result pre="hepatitis C treatment.68 There are few WHO prequalified point�?of�?care viral" exact="hepatitis" post="tests and little production of low�?cost high�?quality generic tests."/>
   <result pre="procurement systems for essential medicines is an ongoing challenge. For" exact="hepatitis" post="B, cold chain barriers to vaccination including birth dose"/>
   <result pre="a challenge globally; meanwhile, in countries where scale�?up of a" exact="viral hepatitis" post="response is pending, demand for viral hepatitis testing and"/>
   <result pre="challenge globally; meanwhile, in countries where scale�?up of a viral" exact="hepatitis" post="response is pending, demand for viral hepatitis testing and"/>
   <result pre="scale�?up of a viral hepatitis response is pending, demand for" exact="viral hepatitis" post="testing and treatment can outstrip available testing and treatment"/>
   <result pre="of a viral hepatitis response is pending, demand for viral" exact="hepatitis" post="testing and treatment can outstrip available testing and treatment"/>
   <result pre="impediments imposed on key populations at risk or infected with" exact="viral hepatitis" post="(eg PWID, prisoners, men who have sex with men,"/>
   <result pre="imposed on key populations at risk or infected with viral" exact="hepatitis" post="(eg PWID, prisoners, men who have sex with men,"/>
   <result pre="screening efforts in Egypt and using innovative approaches to increase" exact="hepatitis" post="C testing in Scotland, to building local investment cases"/>
   <result pre="to building local investment cases in South Africa, to integrating" exact="viral hepatitis" post="services into existing health infrastructure in Brazil and Rwanda,"/>
   <result pre="building local investment cases in South Africa, to integrating viral" exact="hepatitis" post="services into existing health infrastructure in Brazil and Rwanda,"/>
   <result pre="99) can help persuade policymakers in other countries to support" exact="viral hepatitis" post="prevention and control plans. In�?country and global advocacy must"/>
   <result pre="can help persuade policymakers in other countries to support viral" exact="hepatitis" post="prevention and control plans. In�?country and global advocacy must"/>
   <result pre="plans. In�?country and global advocacy must be maintained to keep" exact="viral hepatitis" post="high on the political agenda.82 3 CONCLUSION At the"/>
   <result pre="In�?country and global advocacy must be maintained to keep viral" exact="hepatitis" post="high on the political agenda.82 3 CONCLUSION At the"/>
   <result pre="the global community uniformly endorsed the unique opportunity to eliminate" exact="viral hepatitis" post="as a public health threat. Although an ambitious goal,"/>
   <result pre="global community uniformly endorsed the unique opportunity to eliminate viral" exact="hepatitis" post="as a public health threat. Although an ambitious goal,"/>
   <result pre="and increasing recognition of the public health threat posed by" exact="viral hepatitis" post="provides the grounds for substantial political and societal support."/>
   <result pre="increasing recognition of the public health threat posed by viral" exact="hepatitis" post="provides the grounds for substantial political and societal support."/>
   <result pre="support. The broader benefits of investing in the elimination of" exact="viral hepatitis" post="– including progress on the Agenda for Sustainable Development"/>
   <result pre="The broader benefits of investing in the elimination of viral" exact="hepatitis" post="– including progress on the Agenda for Sustainable Development"/>
   <result pre="countries will need to take action if global elimination of" exact="viral hepatitis" post="is to be achieved. Looking to existing approaches that"/>
   <result pre="will need to take action if global elimination of viral" exact="hepatitis" post="is to be achieved. Looking to existing approaches that"/>
   <result pre="is to be achieved. Looking to existing approaches that address" exact="viral hepatitis" post="can facilitate political support, because they demonstrate that investing"/>
   <result pre="to be achieved. Looking to existing approaches that address viral" exact="hepatitis" post="can facilitate political support, because they demonstrate that investing"/>
   <result pre="can facilitate political support, because they demonstrate that investing in" exact="viral hepatitis" post="is cost�?effective and can be made affordable, provide multiple"/>
   <result pre="facilitate political support, because they demonstrate that investing in viral" exact="hepatitis" post="is cost�?effective and can be made affordable, provide multiple"/>
   <result pre="by low�?, middle�? and high�?income countries with diverse epidemics of" exact="hepatitis" post="B and C to achieve the WHO 2030 viral"/>
   <result pre="of hepatitis B and C to achieve the WHO 2030" exact="viral hepatitis" post="elimination targets. CONFLICT OF INTEREST AHS reports grants and"/>
   <result pre="hepatitis B and C to achieve the WHO 2030 viral" exact="hepatitis" post="elimination targets. CONFLICT OF INTEREST AHS reports grants and"/>
   <result pre="HornJ, MikolajczykRT, KrauseG, OttJJ. Estimations of worldwide prevalence of chronic" exact="hepatitis" post="B virus infection: a systematic review of data published"/>
   <result pre="from: http://apps.who.int/iris/bitstream/handle/10665/255016/9789241565455-eng.pdf;jsessionxml:id=9DECA1FF83BC4A8C41B74E3BE2649662?sequence=1. 5EdmundsWJ, MedleyGF, NokesDJ, et al. Epidemiological patterns of" exact="hepatitis" post="B virus (HBV) in highly endemic areas. Epidemiol Infect."/>
   <result pre="areas. Epidemiol Infect. 1996;117:313�?325.8870629 6KiireCF. The epidemiology and prophylaxis of" exact="hepatitis" post="B in sub�?Saharan Africa: a view from tropical and"/>
   <result pre="2):S5�?S12.8786055 7CornbergM, RazaviHA, AlbertiA, et al. A systematic review of" exact="hepatitis" post="C virus epidemiology in Europe, Canada and Israel. Liver"/>
   <result pre="Available from: https://www.who.int/news-room/fact-sheets/detail/hepatitis-b. 9OttJJ, StevensGA, GroegerJ, WiersmaST. Global epidemiology of" exact="hepatitis" post="B virus infection: new estimates of age�?specific HBsAg seroprevalence"/>
   <result pre="and endemicity. Vaccine. 2012;30:2212�?2219.22273662 10HyamsKC. Risks of chronicity following acute" exact="hepatitis" post="B virus infection: a review. Clin Infect Dis. 1995;20:992�?1000.7795104"/>
   <result pre="Dis. 1995;20:992�?1000.7795104 11BruggmannP, BergT, OvrehusAL, et al. Historical epidemiology of" exact="hepatitis" post="C virus (HCV) in selected countries. J Viral Hepat."/>
   <result pre="2014;21(Suppl 1):5�?33.24713004 12LiakinaV, HamidS, TanakaJ, et al. Historical epidemiology of" exact="hepatitis" post="C virus (HCV) in select countries �? volume 3."/>
   <result pre="2015;22(Suppl 4):4�?20.26513445 13MaaroufiA, VinceA, HimattSM, et al. Historical epidemiology of" exact="hepatitis" post="C virus in select countries�?volume 4. J Viral Hepat."/>
   <result pre="2):8�?24.29105285 14SaraswatV, NorrisS, de KnegtRJ, et al. Historical epidemiology of" exact="hepatitis" post="C virus (HCV) in select countries �? volume 2."/>
   <result pre="to injecting drug use as a risk factor for HIV," exact="hepatitis" post="C, and hepatitis B: findings from the Global Burden"/>
   <result pre="use as a risk factor for HIV, hepatitis C, and" exact="hepatitis" post="B: findings from the Global Burden of Disease Study"/>
   <result pre="26, 2017. 20HutinYJ�?F, BulterysM, HirnschallGO. How far are we from" exact="viral hepatitis" post="elimination service coverage targets?J Int AIDS Soc. 2018;21:e25050.29633520 21HeffernanA,"/>
   <result pre="2017. 20HutinYJ�?F, BulterysM, HirnschallGO. How far are we from viral" exact="hepatitis" post="elimination service coverage targets?J Int AIDS Soc. 2018;21:e25050.29633520 21HeffernanA,"/>
   <result pre="HallettTB. Scaling up prevention and treatment towards the elimination of" exact="hepatitis" post="C: a global mathematical model. Lancet. 2019;393(10178):1319�?1329.30704789 22NayagamS, ThurszM,"/>
   <result pre="22NayagamS, ThurszM, SicuriE, et al. Requirements for global elimination of" exact="hepatitis" post="B: a modelling study. Lancet Infect Dis. 2016;16:1399�?1408.27638356 23ScottN,"/>
   <result pre="Hepatol. 2018;16:1641�?1649.e629505905 25YounossiZ, BrownA, ButiM, et al. Impact of eradicating" exact="hepatitis" post="C virus on the work productivity of chronic hepatitis"/>
   <result pre="eradicating hepatitis C virus on the work productivity of chronic" exact="hepatitis" post="C (CH�?C) patients: an economic model from five European"/>
   <result pre="26DiBonaventuraMD, WagnerJ�?S, YuanY, L'ItalienG, LangleyP, Ray KimW. The impact of" exact="hepatitis" post="C on labor force participation, absenteeism, presenteeism and non�?work"/>
   <result pre="World Bank; 2017. Licence: CC BY-NC-SA 3.0 IGO. 28FitzsimonsD. A" exact="viral hepatitis" post="free future: how to make it feasible and affordable"/>
   <result pre="Bank; 2017. Licence: CC BY-NC-SA 3.0 IGO. 28FitzsimonsD. A viral" exact="hepatitis" post="free future: how to make it feasible and affordable"/>
   <result pre="5–6. 29collab: Viral Hepatitis Prevention Board . Innovative financing into" exact="hepatitis" post="B and C prevention and treatment in low and"/>
   <result pre="Foundation . Just 12 countries worldwide on track to eliminate" exact="hepatitis" post="C infection by 2030, with United Kingdom, Italy and"/>
   <result pre="32collab: World Health Organization . Global health sector strategy on" exact="viral hepatitis" post="2016–2021 In: collab: HIV/AIDS Do , ed. Towards ending"/>
   <result pre="World Health Organization . Global health sector strategy on viral" exact="hepatitis" post="2016–2021 In: collab: HIV/AIDS Do , ed. Towards ending"/>
   <result pre="hepatitis 2016–2021 In: collab: HIV/AIDS Do , ed. Towards ending" exact="viral hepatitis." post="Geneva, Switzerland: WHO Document Production Services; 2016. 33collab: World"/>
   <result pre="Accessed January 16, 2019. 34ScottN, StoovéM, WilsonDP, et al. Eliminating" exact="hepatitis" post="C virus as a public health threat among HIV�?positive"/>
   <result pre="2018;21:e25059. 35HechtR, HiebertL, SpearmanWC, et al. The investment case for" exact="hepatitis" post="B and C in South Africa: adaptation and innovation"/>
   <result pre="36LazarusJ, Safreed�?HarmonK, ThurszM, et al. The micro�?elimination approach to eliminating" exact="hepatitis" post="C: strategic and operational considerations. Semin Liver Dis. 2018;38:181�?192.29986353"/>
   <result pre="Hepatol. 2016;64:S469. 38GvinjiliaL, NasrullahM, SergeenkoD, et al. National progress toward" exact="hepatitis" post="c elimination �? Georgia, 2015–2016. MMWR Morb Mortal Wkly"/>
   <result pre="PLoS ONE. 2019;14:e0216123.31034530 41collab: World Health Organization Europe . Georgia's" exact="hepatitis" post="C elimination programme setting an example in Europe. Health"/>
   <result pre="http://www.euro.who.int/en/health-topics/communicable-diseases/pages/news/news/2017/08/georgias-hepatitis-c-elimination-programme-setting-an-example-in-europe. 42KikvidzeT, LuhmannN, AvrilE, et al. Harm reduction�?based and peer�?supported" exact="hepatitis" post="C treatment for people who inject drugs in Georgia."/>
   <result pre="52HutchinsonS, ValerioH, DillonJ, et al. Reduction in the incidence of" exact="hepatitis" post="C�?related decompensated cirrhosis associated with national scale�?up of direct�?acting"/>
   <result pre="et al. Reduction in the incidence of hepatitis C�?related decompensated" exact="cirrhosis" post="associated with national scale�?up of direct�?acting antiviral therapies targeting"/>
   <result pre="CullenBL, HutchinsonSJ, et al. Limited impact of awareness�?raising campaigns on" exact="hepatitis" post="C testing practices among general practitioners. J Viral Hepat."/>
   <result pre="57MesquitaF, SantosME, BenzakenA, et al. The Brazilian comprehensive response to" exact="hepatitis" post="C: from strategic thinking to access to interferon�?free therapy."/>
   <result pre="syringe provision and opiate substitution therapy on the incidence of" exact="hepatitis" post="C virus in injecting drug users: pooling of UK"/>
   <result pre="effects of needle�?sharing and opioid substitution therapy on incidence of" exact="hepatitis" post="C virus infection and reinfection in people who inject"/>
   <result pre="65El�?AkelW, El�?SayedMH, El KassasM, et al. National treatment programme of" exact="hepatitis" post="C in Egypt: Hepatitis C virus model of care."/>
   <result pre="J Viral Hepatitis. 2017;24:262�?267. 66AyoubHH, Abu�?RaddadLJ. Impact of treatment on" exact="hepatitis" post="C virus transmission and incidence in Egypt: A case"/>
   <result pre="Hepatol. 2019;4:135�?184.30647010 69LieuJ, LiangW, JingW, LiuM. Countdown to 2030: eliminating" exact="hepatitis" post="B disease, China. Bull World Health Organ. 2019;2019:230�?238. 70LiangX,"/>
   <result pre="71collab: Centers for Disease Control and Prevention . Progress in" exact="hepatitis" post="B prevention through universal infant vaccination–China, 1997–2006. MMWR Morb"/>
   <result pre="Morb Mortal Wkly Rep. 2007;56:441�?445.17495790 72ZhouYH, WuC, ZhuangH. Vaccination against" exact="hepatitis" post="B: the Chinese experience. Chin Med J (Engl). 2009;122:98�?102.19187625"/>
   <result pre="Immunization. Vaccine. 2013;31(Suppl 9):J15�?20.24331015 74HutinY, HennesseyK, CairnsL, et al. Improving" exact="hepatitis" post="B vaccine timely birth dose coverage: lessons from five"/>
   <result pre="https://data.unicef.org/wp-content/uploads/country_profiles/China/immunization_country_profiles/immunization_chn.pdf. 76KandeelA, GenedyM, El�?RefaiS, FunkAL, FontanetA, TalaatM. The prevalence of" exact="hepatitis" post="C virus infection in Egypt 2015: implications for future"/>
   <result pre="current trends and policy recommendations - policy brief (English). Egypt's" exact="viral hepatitis" post="program. Washington, DC: World Bank Group; 2018http://documents.worldbank.org/curated/en/164381517333701631/Eliminating-Hepatitis-Cfrom-Egypt-2017-update-on-current-trends-and-policyrecommendations-policy-brief 78ElsharkawyA, El�?RazikyM,"/>
   <result pre="trends and policy recommendations - policy brief (English). Egypt's viral" exact="hepatitis" post="program. Washington, DC: World Bank Group; 2018http://documents.worldbank.org/curated/en/164381517333701631/Eliminating-Hepatitis-Cfrom-Egypt-2017-update-on-current-trends-and-policyrecommendations-policy-brief 78ElsharkawyA, El�?RazikyM,"/>
   <result pre="Hepatitis Alliance . Nine countries now on track to eliminate" exact="hepatitis" post="C Sao Paolo: World Hepatitis Alliance; 2017 [updated 1"/>
   <result pre="from: http://www.worldhepatitisalliance.org/news/nov-2017/nine-countries-now-track-eliminate-hepatitis-c. 80AssefaY, HillPS, UlikpanA, WilliamsOD. Access to medicines and" exact="hepatitis" post="C in Africa: can tiered pricing and voluntary licencing"/>
   <result pre="81RosenthalES, GrahamCS. Price and affordability of direct�?acting antiviral regimens for" exact="hepatitis" post="C virus in the United States. Infect Agent Cancer."/>
   <result pre="82FitzSimonsD, HendrickxG, HallauerJ, et al. Innovative sources for funding of" exact="viral hepatitis" post="prevention and treatment in low�? and middle�?income countries: a"/>
   <result pre="HendrickxG, HallauerJ, et al. Innovative sources for funding of viral" exact="hepatitis" post="prevention and treatment in low�? and middle�?income countries: a"/>
   <result pre="Med Policy. 2016;1:1630288319 83SutharAB, HarriesAD. A public health approach to" exact="hepatitis" post="c control in low�? and middle�?income countries. PLoS Medicine."/>
   <result pre="countries. PLoS Medicine. 2015;12:e1001795.25757228 84EasterbrookP, JohnsonC, FigueroaC, BaggaleyR. HIV and" exact="hepatitis" post="testing: global progress, challenges, and future directions. AIDS Rev."/>
   <result pre="Virus Erad. 2019;5:60�?66.30800429 86collab: Medicines Patent Pool . Our work:" exact="hepatitis" post="C. 2019 [cited 2019 05 March 2019]; Available from:"/>
   <result pre="et al. Pathways to ensure universal and affordable access to" exact="hepatitis" post="C treatment. BMC Med. 2018;16:175.30296935 88MbituyumuremyiA, Van NuilJI, UmuhireJ,"/>
   <result pre="BMC Med. 2018;16:175.30296935 88MbituyumuremyiA, Van NuilJI, UmuhireJ, et al. Controlling" exact="hepatitis" post="C in Rwanda: a framework for a national response."/>
   <result pre="ThompsonAJ, HellardME. Treatment access is only the first step to" exact="hepatitis" post="C elimination: experience of universal anti�?viral treatment access in"/>
   <result pre="2030. J Hepatol. 2017;67:419�?420.28411042 93collab: The Kirby Institute . Monitoring" exact="hepatitis" post="C treatment uptake in Australia (Issue 8). Sydney, Australia:"/>
   <result pre="Group . Road to elimination: Barriers and best practices in" exact="hepatitis" post="C management. The Boston Consulting Group; 2017 95collab: The"/>
   <result pre="Boston Consulting Group; 2017 95collab: The Kirby Institute . Monitoring" exact="hepatitis" post="C treatment uptake in Australia. Sydney, Australia: UNSW; 2017"/>
   <result pre="et al. Cost�?effectiveness of the controlled temperature chain for the" exact="hepatitis" post="B virus birth dose vaccine in various global settings:"/>
   <result pre="get there?J Int AIDS Soc. 2017;20:1�?11. 98RichmondJA, WallaceJ. Implementation of" exact="hepatitis" post="C cure in Australia: one year on. J Virus"/>
   <result pre="ThurszM. Micro�?elimination &amp;amp; #x2013; A path to global elimination of" exact="hepatitis" post="C. J Hepatol. 2017;67:665�?666.28760329 100SchnierC, WallaceL, TempeltonK, et al."/>
   <result pre="data to estimate the number of people chronically infected with" exact="hepatitis" post="B living in Scotland. Epidemiol Infect. 2014;142:2121�?2130.24480044 101collab: Georgia"/>
   <result pre="Observatory HCV Collaborators . Global prevalence and genotype distribution of" exact="hepatitis" post="C virus infection in 2015: a modelling study. Lancet"/>
   <result pre="ZeuzemS, MannsM, et al. Global prevalence and genotype distribution of" exact="hepatitis" post="C virus infection in 2015: a modelling study. Lancet"/>
   <result pre=". Global policy report on the prevention and control of" exact="viral hepatitis" post="in WHO member states. Geneva, Switzerland: WHO Press, World"/>
   <result pre="Global policy report on the prevention and control of viral" exact="hepatitis" post="in WHO member states. Geneva, Switzerland: WHO Press, World"/>
   <result pre="107collab: World Health Organization . Progress report on access to" exact="hepatitis" post="C treatment: focus on overcoming barriers in low- and"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6790760\results\search\disease\results.xml">
   <result pre="Article Phylodynamics reveals extinction–recolonization dynamics underpin apparently endemic vampire bat" exact="rabies" post="in Costa Rica Serial fadeouts of bat rabies epidemics"/>
   <result pre="vampire bat rabies in Costa Rica Serial fadeouts of bat" exact="rabies" post="epidemics http://orcid.org/0000-0001-7475-2705StreickerDaniel G.12Fallas GonzálezSilvia Lucia3LuconiGiovanna4BarrientosRocío González56LeonBernal5[1], MRC—University of Glasgow"/>
   <result pre="field studies. Here, we analysed longitudinal sequence data collected from" exact="rabies" post="virus outbreaks over 14 years in Costa Rica, a"/>
   <result pre="a Central American country that has recorded continuous vampire bat-transmitted" exact="rabies" post="outbreaks in humans and livestock since 1985. We identified"/>
   <result pre="importance of international viral dispersal for shaping the burden of" exact="rabies" post="in Costa Rica, suggest a Central American corridor of"/>
   <result pre="rabies in Costa Rica, suggest a Central American corridor of" exact="rabies" post="virus invasions between continents, and show that apparent disease"/>
   <result pre="and domestic animal pathogens (e.g. dengue virus and foot and" exact="mouth disease" post="virus), where cycles of extinction and replacement of antigenic"/>
   <result pre="on these models will less effective. Vampire bat (Desmodus rotundus)" exact="rabies" post="virus (VBRV) exemplifies a zoonosis for which limited understanding"/>
   <result pre="remains the primary cause of uniformly lethal human and animal" exact="rabies" post="outbreaks throughout most of the Latin American tropics and"/>
   <result pre="levels of population reduction appear to have negligible effects on" exact="rabies" post="risk, in part due to the weak relationship between"/>
   <result pre="due to the weak relationship between bat colony size and" exact="rabies" post="incidence [16]. Better understanding of VBRV spatio-temporal dynamics could"/>
   <result pre="Brazil, Peru) that sustain high incidence of human and/or livestock" exact="rabies" post="[17–19]. These studies have revealed that single bat colonies"/>
   <result pre="identified [22–24]. A key remaining knowledge gap for VBRV, and" exact="rabies" post="virus more generally, is the spatial scale required to"/>
   <result pre="ecology of VBRV circulation in Central America, although rising human" exact="rabies" post="incidence has been noted [12,25,26]. Here, we present the"/>
   <result pre="Rica, where the virus was first reported in 1968, and" exact="rabies" post="outbreaks in humans and livestock have been documented annually"/>
   <result pre="virus sequence data obtained from domestic animals that succumbed to" exact="rabies" post="over a 14-year period, we (i) identified the time"/>
   <result pre="sequencing Over the time period of this study (2004–2017), 60" exact="rabies" post="outbreaks were reported in domestic animals from Costa Rica,"/>
   <result pre="reported by their owners to have clinical signs consistent with" exact="rabies" post="encephalitis, and brain samples were confirmed rabies positive by"/>
   <result pre="signs consistent with rabies encephalitis, and brain samples were confirmed" exact="rabies" post="positive by direct immunofluorescence by the National Veterinary Service"/>
   <result pre="dog from 38 outbreaks. Importantly, as cattle do not transmit" exact="rabies" post="intra-specifically or back to bats, each record represents an"/>
   <result pre="represents an independent spillover from the bat reservoir. The single" exact="rabies" post="virus from a domestic dog (GenBank accession no. KU550098)"/>
   <result pre="The nucleoprotein is an informative gene for phylogeographic analyses of" exact="rabies" post="and is the most widely sequenced VBRV gene in"/>
   <result pre="modelled the identity of the viral lineage associated with each" exact="rabies" post="outbreak as a nominal dependent variable with five levels"/>
   <result pre="12.62–2522.36). Figure 2. Reconstructed geographical origins of two vampire bat" exact="rabies" post="viruses encountered in Costa Rica. Map shows kernel density"/>
   <result pre="(range: 4.7–18.65 years). Figure 3. Spatio-temporal dynamics of vampire bat" exact="rabies" post="within Costa Rica. (a) The location of all samples"/>
   <result pre="Costa Rica, a small Central American country that has detected" exact="rabies" post="nearly every year for decades, we observed invasions of"/>
   <result pre="supplementary material, figure S1). Given the characteristic clinical signs of" exact="rabies" post="in cattle (hind limb paralysis, rapidly followed by death),"/>
   <result pre="landscape and vaccine barriers to block the spread of raccoon" exact="rabies" post="in North America [46]. As less than 3% of"/>
   <result pre="relatively small widths [42]. Other migratory bat species might spread" exact="rabies" post="over larger distances, but maintain epidemiologically independent viruses that"/>
   <result pre="sparse sampling of viruses and the relatively slow progression of" exact="rabies" post="expansions in vampire bats observed here (11.6 km yr−1)"/>
   <result pre="observed provides new insights into the epidemiological mechanisms that underlie" exact="rabies" post="endemicity. The ability of successive viral introductions to invade"/>
   <result pre="antigenic differences that allow viruses to evade host immunity as" exact="rabies" post="antibodies are broadly protective within and among divergent lyssavirus"/>
   <result pre="more likely to be explained by a low R0 of" exact="rabies" post="in bats, which creates frequent stochastic extinctions that leave"/>
   <result pre="fine spatial scales in carnivore rabies. For example, endemicity of" exact="rabies" post="in domestic dogs in Bangui, a city in Central"/>
   <result pre="that trigger short-lived chains of transmission [50]. However, in other" exact="rabies" post="systems, including dog rabies in Tanzania and raccoon rabies"/>
   <result pre="of transmission [50]. However, in other rabies systems, including dog" exact="rabies" post="in Tanzania and raccoon rabies in North America, viral"/>
   <result pre="other rabies systems, including dog rabies in Tanzania and raccoon" exact="rabies" post="in North America, viral lineages appear pervasively endemic and"/>
   <result pre="These differences are likely to reflect both spatial heterogeneity in" exact="rabies" post="persistence (e.g. source–sink dynamics) and observational artefacts, with all"/>
   <result pre="rabies persistence (e.g. source–sink dynamics) and observational artefacts, with all" exact="rabies" post="viruses experiencing extinctions at some spatial scale. How host"/>
   <result pre="the scale of viral maintenance remains an outstanding question across" exact="rabies" post="systems. In conclusion, this study shows that combining phylogenetic"/>
   <result pre="Salud Publica25, 260–269. (10.1590/S1020-49892009000300010)19454154 13BelottoA, LeanesL, SchneiderM, TamaypH, CorreaE2005Overview of" exact="rabies" post="in the Americas. Virus Res.111, 5–12. (10.1016/j.virusres.2005.03.006)15896398 14BenavidesJA, Rojas"/>
   <result pre="Rojas PaniaguaE, HampsonK, ValderramaW, StreickerDG2017Quantifying the burden of vampire bat" exact="rabies" post="in Peruvian livestock. PLoS Negl. Trop. Dis.11, e0006105 (10.1371/journal.pntd.0006105)29267276"/>
   <result pre="RamírezAJ, ShwiffS, KohlerD, LecuonaL2014Economic evaluation of vampire bat (Desmodus rotundus)" exact="rabies" post="prevention in Mexico. Transbound. Emerg. Dis.61, 140–146. (10.1111/tbed.12007)22984914 16StreickerDG,"/>
   <result pre="Dis.61, 140–146. (10.1111/tbed.12007)22984914 16StreickerDG, FrankaR, JacksonFR, RupprechtCE2013Anthropogenic roost switching and" exact="rabies" post="virus dynamics in house-roosting big brown bats. Vector Borne"/>
   <result pre="Borne Zoonotic Dis.13, 498–504. (10.1089/vbz.2012.1113)23590325 17TorresCet al.2014Phylodynamics of vampire bat-transmitted" exact="rabies" post="in Argentina. Mol. Ecol.23, 2340–2352. (10.1111/mec.12728)24661865 18StreickerDGet al.2016Host–pathogen evolutionary"/>
   <result pre="Sci. USA113, 10 926–10 931. (10.1073/pnas.1606587113)26699498 19Velasco-VillaAet al.2006Molecular diversity of" exact="rabies" post="viruses associated with bats in Mexico and other countries"/>
   <result pre="AltizerS, RohaniP2013Resolving the roles of immunity, pathogenesis, and immigration for" exact="rabies" post="persistence in vampire bats. Proc. Natl Acad. Sci. USA110,"/>
   <result pre="20 837–20 842. (10.1073/pnas.1308817110) 21StreickerDGet al.2012Ecological and anthropogenic drivers of" exact="rabies" post="exposure in vampire bats: implications for transmission and control."/>
   <result pre="Organ.9, 189–195.1212534 23Oviedo-PastranaME, OliveiraCSF, CapanemaRO, NicolinoRR, Oviedo-SocarrasTJ, HaddadJPA2015Trends in animal" exact="rabies" post="surveillance in the endemic state of Minas Gerais, Brazil."/>
   <result pre="e0003591 (10.1371/journal.pntd.0003591)25774775 24BenavidesJA, ValderramaW, StreickerDG2016Spatial expansions and travelling waves of" exact="rabies" post="in vampire bats. Proc. R. Soc. B283, 20160328 (10.1098/rspb.2016.0328)"/>
   <result pre="vampire bats. Proc. R. Soc. B283, 20160328 (10.1098/rspb.2016.0328) 25EllisonJAet al.2014Bat" exact="rabies" post="in Guatemala. PLoS Negl. Trop. Dis.8, e3070 (10.1371/journal.pntd.0003070)25080103 26BadillaXet"/>
   <result pre="weather and the El Niño Southern Oscillation impacts on cattle" exact="rabies" post="outbreaks and mortality in Costa Rica (1985–2016). BMC Vet."/>
   <result pre="BegotAL, RamosOdS, FernandesMEB2016Geographical analysis for detecting high-risk areas for bovine/human" exact="rabies" post="transmitted by the common hematophagous bat in the Amazon"/>
   <result pre="(10.7589/0090-3558-28.2.292)1602584 44FornesA, LordR, KunsM, LarghiO, FuenzalidaE, LazaraLet al.1974Control of bovine" exact="rabies" post="through vampire bat control. J. Wildl. Dis.10, 310 (10.7589/0090-3558-10.4.310)4436917"/>
   <result pre="EllisonJA, CarsonWC, SatheshkumarPS, RockeTE, OsorioJE2017Protection of bats (Eptesicus fuscus) against" exact="rabies" post="following topical or oronasal exposure to a recombinant raccoon"/>
   <result pre="1–19. (10.1371/journal.pntd.0005958) 46SlateD, AlgeoTP, NelsonKM, ChipmanRB, DonovanD, BlantonJD, NiezgodaM, RupprechtCE2009Oral" exact="rabies" post="vaccination in North America: opportunities, complexities, and challenges. PLoS"/>
   <result pre="Trop. Dis.3, e549 (10.1371/journal.pntd.0000549)20027214 47SeetahalJFRet al.2013Evolutionary history and phylogeography of" exact="rabies" post="viruses associated with outbreaks in Trinidad. PLoS Negl. Trop."/>
   <result pre="Trop. Dis.7, e2365 (10.1371/journal.pntd.0002365)23991230 48BrunkerKet al.2015Elucidating the phylodynamics of endemic" exact="rabies" post="virus in eastern Africa using whole-genome sequencing. Virus Evol.1,"/>
   <result pre="Evol.1, 1–11. (10.1093/ve/vev011)27774275 49FisherCR, StreickerDG, SchnellMJ2018The spread and evolution of" exact="rabies" post="virus: conquering new frontiers. Nat. Rev. Microbiol.16, 241–255. (10.1038/nrmicro.2018.11)29479072"/>
   <result pre="setting. PLoS Pathog.12, e1005525 (10.1371/journal.ppat.1005525)27058957 51TrewbyH, Nadin-DavisSA, RealLA, BiekR2017Processes underlying" exact="rabies" post="virus incursions across US–Canada border as revealed by whole-genome"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6792355\results\search\disease\results.xml">
   <result pre="symptoms that range from fever, headache, myalgia, articular edema and" exact="rash" post="to intense polyarthralgia and severe joint pain3-6. Furthermore, a"/>
   <result pre="of the following symptoms: fever (&amp;gt;38.5 °C), headache, arthralgia, myalgia," exact="rash" post="and/or hemorrhagic manifestations. Informed consent was obtained from all"/>
   <result pre="(3.03%) patient of 11 years old presented clinical signs of" exact="encephalitis" post="as well as fever, vomiting, headache, myalgia and eye"/>
   <result pre="diseaseN Engl J Med20153721231123925806915 3NakkharaPChongsuvivatwongVThammapaloSRisk factors for symptomatic and asymptomatic" exact="chikungunya" post="infectionTrans R Soc Trop Med Hyg201310778979624052594 4QueyriauxBSimonFGrandadamMMichelRTolouHBoutinJPClinical burden of"/>
   <result pre="chikungunya infectionTrans R Soc Trop Med Hyg201310778979624052594 4QueyriauxBSimonFGrandadamMMichelRTolouHBoutinJPClinical burden of" exact="chikungunya" post="virus infectionLancet Infect Dis200882318156079 5AyuSMLaiLRChanYFHatimAHairiNNAyobAet al.Seroprevalence survey of Chikungunya"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6794271\results\search\disease\results.xml">
   <result pre="emergencies in recent years, including SARS and MERS coronaviruses, H5N1" exact="influenza" post="A and ebolavirus1. However, detailed information on the epidemiology"/>
   <result pre="on viruses in Vietnam: Complete genome characterization of two wild-type" exact="measles" post="viruses from Vietnamese infants4; Genome sequences of a novel"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6794280\results\search\disease\results.xml">
   <result pre="occurrence dataPloS one201712e018760229190296 43.DalrympleUet al.Quantifying the contribution of Plasmodium falciparum" exact="malaria" post="to febrile illness amongst African childrenElife20176e2919829034876 44.WellsCRet al.Ebola vaccination"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6795694\results\search\disease\results.xml">
   <result pre="There is an unmet public health need for a universal" exact="influenza" post="vaccine (UIV) to provide broad and durable protection from"/>
   <result pre="influenza vaccine (UIV) to provide broad and durable protection from" exact="influenza" post="virus infections. The identification of broadly protective antibodies and"/>
   <result pre="of broadly protective antibodies and cross-reactive T cells directed to" exact="influenza" post="viral targets present a promising prospect for the development"/>
   <result pre="trials. Mucosal immune responses and cross-reactive T cell immunity across" exact="influenza" post="A and B viruses intrinsic to live attenuated influenza"/>
   <result pre="across influenza A and B viruses intrinsic to live attenuated" exact="influenza" post="vaccine (LAIV) have emerged as essential features to be"/>
   <result pre="protection. Preexisting immunity in humans established by prior exposure to" exact="influenza" post="viruses may affect the hierarchy and magnitude of immune"/>
   <result pre="the hierarchy and magnitude of immune responses elicited by an" exact="influenza" post="vaccine, limiting the interpretation of preclinical data based on"/>
   <result pre="a wide spectrum of protection, and safety relevant to UIVs." exact="influenza" post="virus universal influenza vaccine cross-protection HA stalk M2e T"/>
   <result pre="of protection, and safety relevant to UIVs. influenza virus universal" exact="influenza" post="vaccine cross-protection HA stalk M2e T cell live attenuated"/>
   <result pre="influenza vaccine cross-protection HA stalk M2e T cell live attenuated" exact="influenza" post="vaccine Funding National Research Foundation of Korea10.13039/5011000037252018M3A9H40793582018R1D1A1B07048881 Korea Food"/>
   <result pre="season and, thus, c represents the primary targets of seasonal" exact="influenza" post="vaccines (Sridhar et al., 2015). In addition to seasonal"/>
   <result pre="vaccines (Sridhar et al., 2015). In addition to seasonal epidemics," exact="influenza" post="viruses have caused pandemics at the intervals of ~10–40"/>
   <result pre="2016). While vaccination remains the most cost-effective measure to prevent" exact="influenza" post="virus infections, antigenic drift in the surface antigens allows"/>
   <result pre="is unpredictable, posing a serious challenge to the management of" exact="influenza" post="outbreak. Based on the amino acid sequences of HAs,"/>
   <result pre="influenza outbreak. Based on the amino acid sequences of HAs," exact="influenza" post="A viruses (IAVs) are divided into two phylogenetic groups."/>
   <result pre="Victoria-like lineages. Influenza C viruses (ICVs) generally cause a mild" exact="respiratory disease" post="in humans and do not cause epidemics (Dykes et"/>
   <result pre="and do not cause epidemics (Dykes et al., 1980). Contemporary" exact="influenza" post="epidemics are caused by the H1N1 and H3N2 of"/>
   <result pre="two lineages of the IBVs, dictating trivalent (TIV) or quadrivalent" exact="influenza" post="vaccine (QIV) containing two IAV antigens and one or"/>
   <result pre="Figure 1 Phylogenetic trees representing HA and NA diversity among" exact="influenza" post="viruses. The 18 subtypes of HAs of IAV are"/>
   <result pre="trees were constructed based on amino acid sequence comparisons among" exact="influenza" post="viruses. Multiple alignments were carried out using the representative"/>
   <result pre="have been undertaken on the pursuit of developing a universal" exact="influenza" post="vaccine (UIV) (Paules et al., 2017). The induction of"/>
   <result pre="While these vaccines showed broader cross-protection than the classical inactivated" exact="influenza" post="vaccines (IIVs), their protection potency was weak. They provided"/>
   <result pre="(B) Cytotoxic T lymphocyte (CTL) recognizing the conserved epitopes of" exact="influenza" post="internal proteins such as NP, M1, or PB1 has"/>
   <result pre="HA stalk in animals and humans with prior exposure to" exact="influenza" post="viruses. Some of these antibodies show extremely broad specificity,"/>
   <result pre="immunity have emerged as potential correlates of broad protection against" exact="influenza" post="infections (Krammer and Palese, 2015), the exact molecular mechanisms"/>
   <result pre="imprinting or antigenic sin-like phenomenon) shaped by prior exposure to" exact="influenza" post="viruses affects the magnitude, hierarchy, and sustainability of antibody"/>
   <result pre="that provides durable and broad protection against multiple strains of" exact="influenza" post="virus, the definition of the &quot;universality�? of UIV is"/>
   <result pre="reasonable UIV should be at least 75% effective against symptomatic" exact="influenza" post="virus infection caused by group 1 and group 2"/>
   <result pre="criteria for a UIV. NIAID WHO BMGF Consensus Breadth All" exact="influenza" post="A viruses (influenza B protection would be the second"/>
   <result pre="viruses (influenza B protection would be the second target) All" exact="influenza" post="A viruses All influenza A and B viruses All"/>
   <result pre="would be the second target) All influenza A viruses All" exact="influenza" post="A and B viruses All influenza A viruses Efficacy"/>
   <result pre="influenza A viruses All influenza A and B viruses All" exact="influenza" post="A viruses Efficacy At least 75% effective against symptomatic"/>
   <result pre="influenza A viruses Efficacy At least 75% effective against symptomatic" exact="influenza" post="infection Better than that of current seasonal influenza vaccine"/>
   <result pre="against symptomatic influenza infection Better than that of current seasonal" exact="influenza" post="vaccine At least 70% effective against symptomatic influenza infection"/>
   <result pre="current seasonal influenza vaccine At least 70% effective against symptomatic" exact="influenza" post="infection At least 70% effective Target population All age"/>
   <result pre="World Health Organization (https://apps.who.int/iris/bitstream/handle/10665/258767/9789241512466-eng.pdf; https://jsessionid=37D9E056C3EA58A90EE237432AA7D65F?sequence=1). Figure 3 Protection breadth of" exact="influenza" post="vaccines ranging from strain-specific protection to pan-influenza universal protection."/>
   <result pre="from strain-specific protection to pan-influenza universal protection. Currently licensed seasonal" exact="influenza" post="vaccine provides only strain-specific protection against well-matched strains. Recently,"/>
   <result pre="the knowledge gaps in developing a UIV; (1) understanding of" exact="influenza" post="transmission, natural history, and viral pathogenesis, (2) characterization of"/>
   <result pre="quality, depending on the vaccine type used and the target" exact="influenza" post="virus tested. For instance, while the protection potency of"/>
   <result pre="assay or microneutralization assay is the gold standard for seasonal" exact="influenza" post="vaccines (Ohmit et al., 2011). However, the assay cannot"/>
   <result pre="simply to reflect the cross-protection by a UIV against heterologous/heterosubtypic" exact="influenza" post="viruses. Therefore, it is essential to develop mechanistically distinct"/>
   <result pre="determination of the precise protection mechanisms of immune response against" exact="influenza" post="viruses. Influenza HA recognizes sialic acid on the cellular"/>
   <result pre="the conserved regions have shown an exceptional breadth, inhibiting divergent" exact="influenza" post="viruses (Chen et al., 2018). In addition to the"/>
   <result pre="M2e on their surface. It has been shown that the" exact="hepatitis" post="B virus core (HBc) protein fused with M2e self-assembled"/>
   <result pre="enveloped VLPs displayed M2e in a membrane-anchored manner by combining" exact="influenza" post="matrix protein and transmembrane (TM) domain of HA fused"/>
   <result pre="M2e. The Sf9 insect cells infected with baculoviral vectors expressing" exact="influenza" post="M1 and M2e-TM of influenza HA produced influenza VLPs"/>
   <result pre="infected with baculoviral vectors expressing influenza M1 and M2e-TM of" exact="influenza" post="HA produced influenza VLPs displaying much higher levels of"/>
   <result pre="vectors expressing influenza M1 and M2e-TM of influenza HA produced" exact="influenza" post="VLPs displaying much higher levels of M2e than the"/>
   <result pre="vaccine antigen and the low abundance of M2 proteins on" exact="influenza" post="virions and infected cells. From the clinical and practical"/>
   <result pre="a stand-alone UIV. Consequently, M2e antigen was combined with other" exact="influenza" post="viral antigens (mostly HA) or supplemented with strain-specific vaccines,"/>
   <result pre="and broader cross-protection. For instance, several studies combined M2e with" exact="influenza" post="HA head or stalk domain to elicit broadly protective"/>
   <result pre="or stalk domain to elicit broadly protective immunity against heterologous" exact="influenza" post="infections with various vaccine platforms including nanoparticles, recombinant proteins,"/>
   <result pre="with various vaccine platforms including nanoparticles, recombinant proteins, and recombinant" exact="influenza" post="viruses (Guo et al., 2017; Bernasconi et al., 2018;"/>
   <result pre="activity of the stalk antibodies may lead to neutralization of" exact="influenza" post="viruses, although the neutralizing potency is weaker than head"/>
   <result pre="paved the way to increase the breadth of protection against" exact="influenza" post="viruses. Figure 5 HA stalk-based approaches. Influenza HA comprises"/>
   <result pre="function of stalk-reactive antibodies is membrane fusion inhibition. Following the" exact="influenza" post="virus entry into the cells via endocytosis, a pH-dependent"/>
   <result pre="ADCP, by which macrophages or neutrophils recognize and engulf antibody-bound" exact="influenza" post="viral particles or infected cells (Ana-Sosa-Batiz et al., 2016)."/>
   <result pre="infection. Overall, the stalk antibodies confer a broad protection from" exact="influenza" post="virus infection through multiple mechanisms affecting both HA and"/>
   <result pre="affecting both HA and NA throughout the infection cycle of" exact="influenza" post="virus. HA Stalk-Based Vaccine Constructs The first reported HA"/>
   <result pre="genetically engineered viruses of the wild type or live attenuated" exact="influenza" post="viruses (Krammer et al., 2013; Isakova-Sivak et al., 2018)."/>
   <result pre="and rather than the stalk antibodies (see section Live attenuated" exact="influenza" post="vaccine as an alternative strategy below). This observation in"/>
   <result pre="2013). Similarly, the HA subunit vaccine resulted in vaccine-associated enhanced" exact="respiratory disease" post="(VAERD) in pigs after heterologous challenge (Gauger et al.,"/>
   <result pre="the stalk flexibility and membrane fusion kinetics, resulting in enhanced" exact="respiratory disease" post="in a mouse model (Winarski et al., 2019). These"/>
   <result pre="(Ng et al., 2019). Stalk Variability Although conserved among the" exact="influenza" post="viruses, the HA stalk is not antigenically identical, showing"/>
   <result pre="responses (Kirkpatrick et al., 2018). Several studies have isolated mutant" exact="influenza" post="viruses showing resistance to stalk antibodies (Ekiert et al.,"/>
   <result pre="importantly, most humans have a diverse history of exposure to" exact="influenza" post="antigens, by natural infection, or vaccination. The established immune"/>
   <result pre="bind to the RBS in HA and neutralize multiple H1N1" exact="influenza" post="strains (Whittle et al., 2011). A caveat is that"/>
   <result pre="to recognize conserved region in the RBS and neutralize multiple" exact="influenza" post="viruses (Krause et al., 2011, 2012; Ekiert et al.,"/>
   <result pre="conserved regions located in HA head domain and neutralized multiple" exact="influenza" post="viruses without detectable HI activity (Iba et al., 2014;"/>
   <result pre="induced stronger immune response and provided better protection against heterologous" exact="influenza" post="viruses, as compared to natural wild type HA antigen."/>
   <result pre="The COBRA strategy was tested against H1N1, H3N2, and H5N1" exact="influenza" post="viruses, and demonstrated broad protection within a subtype (Giles"/>
   <result pre="II transmembrane glycoprotein and the second major surface protein of" exact="influenza" post="viruses. The role of NA in influenza infection cycle"/>
   <result pre="surface protein of influenza viruses. The role of NA in" exact="influenza" post="infection cycle is classically known as an expedited release"/>
   <result pre="stage of infection. At the entry site in the mucus," exact="influenza" post="virus meets mucosal defense proteins such as mucins that"/>
   <result pre="cooperates with HA to enable crawling and gliding motions of" exact="influenza" post="virus on cell surface to enhance viral entry into"/>
   <result pre="NA antibodies may represent an important means of protection against" exact="influenza" post="viruses. NA Antibodies as Important Correlate of Protection The"/>
   <result pre="shift in HA, but NA remained close to the previous" exact="influenza" post="A/H2N2 viruses (Schulman and Kilbourne, 1969). Notably, it has"/>
   <result pre="However, NA has been largely ignored in the formulation of" exact="influenza" post="vaccines due to the general beliefs that NA antibodies"/>
   <result pre="functional NA antibodies has rendered the NA forgotten antigens in" exact="influenza" post="vaccines for decades (Eichelberger and Monto, 2019). Most of"/>
   <result pre="on the induction of HA antibodies, both in trivalent/quadrivalent seasonal" exact="influenza" post="vaccines and in the recent UIV candidates. However, it"/>
   <result pre="vaccination-induced or preexisting NAI antibody levels and decreased frequency of" exact="influenza" post="infection and illness (Couch et al., 2013; Monto et"/>
   <result pre="identified NAI monoclonal antibodies that show protective effects against heterologous" exact="influenza" post="infection. The breadth of NAI antibodies varied from subtype-specific"/>
   <result pre="2013a,b; Wan et al., 2013). Recently, it was reported that" exact="influenza" post="infection in humans induces a variety of broadly reactive"/>
   <result pre="the importance of NA-immunity in protection against homologous and heterologous" exact="influenza" post="infections is clearly established, only a few literatures have"/>
   <result pre="However, co-administration of H7 HA and N3 NA in modified" exact="vaccinia virus" post="Ankara (MVA) vectors did not demonstrate enhanced protection efficacy"/>
   <result pre="in favor of HA over NA, when presented in an" exact="influenza" post="virion, is already well-documented (Johansson et al., 1987), and"/>
   <result pre="of NA-based vaccines in animal models. Considering the repertoire of" exact="influenza" post="viruses infecting humans and animals (including N1, N2, N3,"/>
   <result pre="Against Influenza B Viruses Besides IAVs, ~25% of all human" exact="influenza" post="virus infections in each epidemic season is caused by"/>
   <result pre="and Yamagata-like lineages (Ambrose and Levin, 2012). The current seasonal" exact="influenza" post="vaccine is prepared in a trivalent or quadrivalent formulation,"/>
   <result pre="broadly protective antibodies binding to head or stalk domain of" exact="influenza" post="B HA have been isolated in humans. Overall, these"/>
   <result pre="acknowledged as a potential immune correlate of broad protection against" exact="influenza" post="infections (Sridhar, 2016; Clemens et al., 2018). T cell"/>
   <result pre="cell immunity may not provide sterilizing or neutralizing immunity against" exact="influenza" post="viruses but improves the standard of care by reducing"/>
   <result pre="critical to provide a truly universal protection against highly variable" exact="influenza" post="viruses. The influenza-specific T cell immunity is known to"/>
   <result pre="that inducing T cell immunity directed to internal proteins of" exact="influenza" post="virus may provide a basis of developing T cell-based"/>
   <result pre="epitopes but also T cell epitopes encompassing both types of" exact="influenza" post="viruses. The fusion peptide in HA stalk contains a"/>
   <result pre="cells in humans that could be induced by exposure to" exact="influenza" post="viruses, but also presents the prospect of designing a"/>
   <result pre="cells were not induced in HHD-A2 mouse model despite multiple" exact="influenza" post="infections or vaccinations and the protective role of the"/>
   <result pre="al., 2014; Folegatti et al., 2019). The baculovirus VLPs carrying" exact="influenza" post="HA/NA and M1 offered cross-protection where T cells played"/>
   <result pre="fact, the first report on DNA vaccines was targeted to" exact="influenza" post="virus (Cohen, 1993; Ulmer et al., 1993), but initial"/>
   <result pre="been made to improve the efficacy of DNA vaccine against" exact="influenza" post="virus, encompassing rational design of antigens and expression vectors"/>
   <result pre="in humans since 2003 and is proven effective in preventing" exact="influenza" post="infections (Mohn et al., 2018). The protection of LAIV"/>
   <result pre="LAIV are critical for broad protection against heterologous and heterosubtypic" exact="influenza" post="infections in animal models (Cheng et al., 2013; Jang"/>
   <result pre="investigate if the cross-protection could be extended to group 2" exact="influenza" post="viruses such as H3 or H7 strains. Besides the"/>
   <result pre="the LAIV presents a remarkable prospect for a broadly protective" exact="influenza" post="vaccine, several important issues need to be addressed for"/>
   <result pre="mutations among various internal genes and proven safe as seasonal" exact="influenza" post="vaccines (especially for A/Ann Arbor strain as the master"/>
   <result pre="strains. During the past century, H1N1 and H3N2 subtypes of" exact="influenza" post="A viruses were the most prevalent strains in humans,"/>
   <result pre="of H2N2 during 1957–1968 (Kilbourne, 2006) (Figure 6). Accordingly, seasonal" exact="influenza" post="vaccines are recommended to include H1N1 and H3N2 vaccine"/>
   <result pre="nature of strain itself does not really matter for seasonal" exact="influenza" post="vaccine, for which strain-specific immunity is focused on the"/>
   <result pre="T cell immunity as an essential factor for truly universal" exact="influenza" post="protection for internal proteins). It is likely that human"/>
   <result pre="protection by a UIV; Figure 3). Figure 6 Co-evolution of" exact="influenza" post="viruses and influenza vaccines. Within the past century, there"/>
   <result pre="UIV; Figure 3). Figure 6 Co-evolution of influenza viruses and" exact="influenza" post="vaccines. Within the past century, there were four influenza"/>
   <result pre="and influenza vaccines. Within the past century, there were four" exact="influenza" post="pandemics; 1918 Spanish flu (H1N1), 1957 Asian flu (H2N2),"/>
   <result pre="Krewski, 2016). The 1918 Spanish flu (H1N1) evolved into seasonal" exact="influenza" post="strain and had circulated for ~40 years until the"/>
   <result pre="Hong Kong flu (H3N2) has circulated until now as seasonal" exact="influenza" post="strains. In 1977, H1N1 strain reemerged and was replaced"/>
   <result pre="by the 2009 swine flu (H1N1), which evolved into seasonal" exact="influenza" post="strains circulating until now. Thus, H1N1 and H3N2 strains"/>
   <result pre="necessitates the incorporation of Victoria-like and Yamagata-like lineages in seasonal" exact="influenza" post="vaccines. This leads us to raise a possibility of"/>
   <result pre="leads us to raise a possibility of using an ancestral" exact="influenza" post="B strain (such as B/Lee/40) before divergence into two"/>
   <result pre="internal proteins. Alternatively, vaccination with LAIV carrying HA from non-human" exact="influenza" post="viruses such as H5 or H9 may be effective"/>
   <result pre="use infection-competent but replication-defective viruses. For instance, the M2 knock-out" exact="influenza" post="virus (M2SR) rescued from M2-producing cells is able to"/>
   <result pre="and to provide broad protection against both homologous and heterologous" exact="influenza" post="virus challenge in mice and ferrets (Sarawar et al.,"/>
   <result pre="al., 2017, 2018). A conceptually similar to M2SR, PB2 knock-out" exact="influenza" post="virus could be produced in PB2-expressing cells as a"/>
   <result pre="The protection efficacy of PB2-KO vaccine was tested against diverse" exact="influenza" post="strains in mice (Victor et al., 2012; Uraki et"/>
   <result pre="2012; Uraki et al., 2013; Ui et al., 2017). Pseudotyped" exact="influenza" post="A virus also presents a similar replication-incompetent virus approach."/>
   <result pre="virus also presents a similar replication-incompetent virus approach. The pseudotyped" exact="influenza" post="virus lacking HA produced in HA-expressing cells can infect"/>
   <result pre="that the vaccination of mice and ferrets with the pseudotyped" exact="influenza" post="virus generated a vigorous T cell response and reduced"/>
   <result pre="loads and weight loss after challenge with homologous and heterologous" exact="influenza" post="viruses (Powell et al., 2012; Baz et al., 2015)."/>
   <result pre="to conventional vaccine platforms against various infectious diseases including the" exact="influenza" post="virus (Pardi et al., 2018a). Initially, the mRNA vaccines"/>
   <result pre="antibody responses were associated with protection against homologous and heterologous" exact="influenza" post="virus infection in mice (Pardi et al., 2018b), depicting"/>
   <result pre="Preexisting immunity or immunologic imprinting, established by prior exposure to" exact="influenza" post="by infection or vaccination, may influence or thwart the"/>
   <result pre="evasion and provide a truly universal protection against the ever-changing" exact="influenza" post="viruses. Author Contributions BS designed and conceived the review."/>
   <result pre="Korea (19172MFDS255). References References AdarY.SingerY.LeviR.TzehovalE.PerkS.Banet-NoachC.et al.. (2009). A universal epitope-based" exact="influenza" post="vaccine and its efficacy against H5N1. Vaccine27, 2099–2107. 10.1016/j.vaccine.2009.02.01119356612"/>
   <result pre="2099–2107. 10.1016/j.vaccine.2009.02.01119356612 AmbroseC. S.LevinM. J. (2012). The rationale for quadrivalent" exact="influenza" post="vaccines. Hum. Vaccin Immunother.8, 81–88. 10.4161/hv.8.1.1762322252006 Ana-Sosa-BatizF.VandervenH.JegaskandaS.JohnstonA.RockmanS.LaurieK.et al.. (2016)."/>
   <result pre="al.. (2017). Natural and directed antigenic drift of the H1" exact="influenza" post="virus hemagglutinin stalk domain. Sci. Rep.7:14614. 10.1038/s41598-017-14931-729097696 AntrobusR. D.LillieP."/>
   <result pre="D.LillieP. J.BerthoudT. K.SpencerA. J.McLarenJ. E.LadellK.et al.. (2012). A T cell-inducing" exact="influenza" post="vaccine for the elderly: safety and immunogenicity of MVA-NP+M1"/>
   <result pre="ONE7:e48322. 10.1371/journal.pone.004832223118984 ArevaloM. T.LiJ.Diaz-ArevaloD.ChenY.NavarroA.WuL.et al.. (2017). A dual purpose universal" exact="influenza" post="vaccine candidate confers protective immunity against anthrax. Immunology150, 276–289."/>
   <result pre="(2008). Immunomic analysis of the repertoire of T-cell specificities for" exact="influenza" post="A virus in humans. J. Virol.82, 12241–12251. 10.1128/JVI.01563-0818842709 Asthagiri"/>
   <result pre="Asthagiri ArunkumarG.IoannouA.WohlboldT. J.MeadeP.AslamS.AmanatF.et al.. (2019). Broadly cross-reactive, nonneutralizing antibodies against" exact="influenza" post="B virus hemagglutinin demonstrate effector function-dependent protection against lethal"/>
   <result pre="A.YinL.TerajimaM. (2012). A human CD4+ T cell epitope in the" exact="influenza" post="hemagglutinin is cross-reactive to influenza A virus subtypes and"/>
   <result pre="T cell epitope in the influenza hemagglutinin is cross-reactive to" exact="influenza" post="A virus subtypes and to influenza B virus. J."/>
   <result pre="hemagglutinin is cross-reactive to influenza A virus subtypes and to" exact="influenza" post="B virus. J. Virol.86, 9233–9243. 10.1128/JVI.06325-1122718815 BajicG.MaronM. J.AdachiY.OnoderaT.McCarthyK. R.McGeeC."/>
   <result pre="der PoelC. E.KuraokaM.SchmidtA. G.CarrollM. C.KelsoeG.et al.. (2019b). Autoreactivity profiles of" exact="influenza" post="hemagglutinin broadly neutralizing antibodies. Sci. Rep.9:3492. 10.1038/s41598-019-40175-830837606 BangaruS.ZhangH.GilchukI. M.VossT."/>
   <result pre="monoclonal neutralizing antibody that targets a unique conserved epitope on" exact="influenza" post="HA. Nat. Commun.9:2669. 10.1038/s41467-018-04704-929991715 BazM.BoonnakK.PaskelM.SantosC.PowellT.TownsendA.et al.. (2015). Nonreplicating influenza"/>
   <result pre="on influenza HA. Nat. Commun.9:2669. 10.1038/s41467-018-04704-929991715 BazM.BoonnakK.PaskelM.SantosC.PowellT.TownsendA.et al.. (2015). Nonreplicating" exact="influenza" post="A virus vaccines confer broad protection against lethal challenge."/>
   <result pre="(2000). Efficacy of vaccination with live attenuated, cold-adapted, trivalent, intranasal" exact="influenza" post="virus vaccine against a variant (A/Sydney) not contained in"/>
   <result pre="monoclonal antibody directed against a novel conserved epitope on the" exact="influenza" post="virus H3 hemagglutinin globular head. J. Virol.88, 6743–6750. 10.1128/JVI.03562-1324696468"/>
   <result pre="and recombinant hemagglutinin provide strong and broadly protective immunity against" exact="influenza" post="virus infections. Front. Immunol.9:2060. 10.3389/fimmu.2018.0206030271406 BessaJ.SchmitzN.HintonH. J.SchwarzK.JegerlehnerA.BachmannM. F. (2008)."/>
   <result pre="M.van AmerongenG.VerburghR. J.van TrierumS. E.et al.. (2011). Vaccination against seasonal" exact="influenza" post="A/H3N2 virus reduces the induction of heterosubtypic immunity against"/>
   <result pre="influenza A/H3N2 virus reduces the induction of heterosubtypic immunity against" exact="influenza" post="A/H5N1 virus infection in ferrets. J. Virol.85, 2695–2702. 10.1128/JVI.02371-1021228239"/>
   <result pre="ferrets. J. Virol.85, 2695–2702. 10.1128/JVI.02371-1021228239 BragstadK.VinnerL.HansenM. S.NielsenJ.FomsgaardA. (2013). A polyvalent" exact="influenza" post="A DNA vaccine induces heterologous immunity and protects pigs"/>
   <result pre="2281–2288. 10.1016/j.vaccine.2013.02.06123499598 BrandenburgB.KoudstaalW.GoudsmitJ.KlarenV.TangC.BujnyM. V.et al.. (2013). Mechanisms of hemagglutinin targeted" exact="influenza" post="virus neutralization. PLoS ONE8:e80034. 10.1371/journal.pone.008003424348996 BrazzoliM.MaginiD.BonciA.BuccatoS.GiovaniC.KratzerR.et al.. (2016). Induction"/>
   <result pre="broad-based immunity and protective efficacy by self-amplifying mRNA vaccines encoding" exact="influenza" post="virus hemagglutinin. J. Virol.90, 332–344. 10.1128/JVI.01786-1526468547 CarterD. M.DarbyC. A.LefoleyB."/>
   <result pre="ChaiN.SwemL. R.ParkS.NakamuraG.ChiangN.EstevezA.et al. (2017). A broadly protective therapeutic antibody against" exact="influenza" post="B virus with two mechanisms of action. Nat. Commun.8:1423410.1038/ncomms1423428102191"/>
   <result pre="Nat. Commun.8:1423410.1038/ncomms1423428102191 ChaiN.SwemL. R.ReicheltM.Chen-HarrisH.LuisE.ParkS.et al.. (2016). Two escape mechanisms of" exact="influenza" post="A virus to a broadly neutralizing stalk-binding antibody. PLoS"/>
   <result pre="ChenY. Q.LanL. Y.HuangM.HenryC.WilsonP. C. (2019). Hemagglutinin stalk-reactive antibodies interfere with" exact="influenza" post="virus neuraminidase activity by steric hindrance. J. Virol.93:e01526–18. 10.1128/JVI.01526-1830518651"/>
   <result pre="cellular immune responses elicited by the live attenuated and inactivated" exact="influenza" post="vaccines and their roles in heterologous protection in ferrets."/>
   <result pre="power of T cells: the promising hope for a universal" exact="influenza" post="vaccine. Vaccines6:18. 10.3390/vaccines602001829587436 CohenJ. (1993). Naked DNA points way"/>
   <result pre="S.MoinS. M.YassineH. M.CagigiA.KanekiyoM.Boyoglu-BarnumS.et al.. (2019). Design of nanoparticulate group 2" exact="influenza" post="virus hemagglutinin stem antigens that activate unmutated ancestor B"/>
   <result pre="plasma cells that binds to group 1 and group 2" exact="influenza" post="A hemagglutinins. Science333, 850–856. 10.1126/science.120566921798894 CouchR. B.AtmarR. L.FrancoL. M.QuarlesJ."/>
   <result pre="(2013). Antibody correlates and predictors of immunity to naturally occurring" exact="influenza" post="in humans and the importance of antibody to the"/>
   <result pre="CroweJ. E.Jr. (2018). Is it possible to develop a &quot;universal�?" exact="influenza" post="virus vaccine? potential for a universal influenza vaccine. Cold"/>
   <result pre="develop a &quot;universal�? influenza virus vaccine? potential for a universal" exact="influenza" post="vaccine. Cold Spring Harb. Perspect. Biol.10:a029496. 10.1101/cshperspect.a02949628663208 De FiletteM.FiersW.MartensW.BirkettA.RamneA.LowenadlerB.et"/>
   <result pre="(2006). Improved design and intranasal delivery of an M2e-based human" exact="influenza" post="A vaccine. Vaccine24, 6597–6601. 10.1016/j.vaccine.2006.05.08216814430 DengL.ChoK. J.FiersW.SaelensX. (2015a). M2e-based"/>
   <result pre="A vaccine. Vaccine24, 6597–6601. 10.1016/j.vaccine.2006.05.08216814430 DengL.ChoK. J.FiersW.SaelensX. (2015a). M2e-based universal" exact="influenza" post="a vaccines. Vaccines3, 105–136. 10.3390/vaccines301010526344949 DengL.IbanezL. I.Van den BosscheV.RooseK.YoussefS."/>
   <result pre="DengL.IbanezL. I.Van den BosscheV.RooseK.YoussefS. A.de BruinA.et al.. (2015b). Protection against" exact="influenza" post="A virus challenge with M2e-displaying filamentous Escherichia coli phages."/>
   <result pre="al.. (2018). Double-layered protein nanoparticles induce broad protection against divergent" exact="influenza" post="A viruses. Nat. Commun.9:359. 10.1038/s41467-017-02725-429367723 DenisJ.Acosta-RamirezE.ZhaoY.HamelinM. E.KoukavicaI.BazM.et al.. (2008)."/>
   <result pre="Commun.9:359. 10.1038/s41467-017-02725-429367723 DenisJ.Acosta-RamirezE.ZhaoY.HamelinM. E.KoukavicaI.BazM.et al.. (2008). Development of a universal" exact="influenza" post="A vaccine based on the M2e peptide fused to"/>
   <result pre="10.1016/j.vaccine.2008.04.05218511159 DeZureA. D.CoatesE. E.HuZ.YamshchikovG. V.ZephirK. L.EnamaM. E.et al.. (2017). An" exact="avian influenza" post="H7 DNA priming vaccine is safe and immunogenic in"/>
   <result pre="DeZureA. D.CoatesE. E.HuZ.YamshchikovG. V.ZephirK. L.EnamaM. E.et al.. (2017). An avian" exact="influenza" post="H7 DNA priming vaccine is safe and immunogenic in"/>
   <result pre="neutralizing hemagglutinin stalk-specific antibodies require FcγR interactions for protection against" exact="influenza" post="virus in vivo. Nat. Med.20, 143–151. 10.1038/nm.344324412922 DoyleT. M.HashemA."/>
   <result pre="M.HashemA. M.LiC.Van DomselaarG.LarocqueL.WangJ.et al.. (2013a). Universal anti-neuraminidase antibody inhibiting all" exact="influenza" post="A subtypes. Antiviral Res.100, 567–574. 10.1016/j.antiviral.2013.09.01824091204 DoyleT. M.LiC.BucherD. J.HashemA."/>
   <result pre="(2013b). A monoclonal antibody targeting a highly conserved epitope in" exact="influenza" post="B neuraminidase provides protection against drug resistant strains. Biochem."/>
   <result pre="DreyfusC.LaursenN. S.KwaksT.ZuijdgeestD.KhayatR.EkiertD. C.et al.. (2012). Highly conserved protective epitopes on" exact="influenza" post="B viruses. Science337, 1343–1348. 10.1126/science.122290822878502 DuanS.ThomasP. G. (2016). Balancing"/>
   <result pre="immune protection and immune pathology by CD8(+) T-cell responses to" exact="influenza" post="infection. Front. Immunol.7:25. 10.3389/fimmu.2016.0002526904022 DucatezM. F.BahlJ.GriffinY.Stigger-RosserE.FranksJ.BarmanS.et al.. (2011). Feasibility"/>
   <result pre="10.3389/fimmu.2016.0002526904022 DucatezM. F.BahlJ.GriffinY.Stigger-RosserE.FranksJ.BarmanS.et al.. (2011). Feasibility of reconstructed ancestral H5N1" exact="influenza" post="viruses for cross-clade protective vaccine development. Proc. Natl. Acad."/>
   <result pre="F.WebbA.CrumptonJ. C.WebbyR. J. (2013). Long-term vaccine-induced heterologous protection against H5N1" exact="influenza" post="viruses in the ferret model. Influenza Other Respir. Viruses7,"/>
   <result pre="E. (1980). A clinical, epidemiologic, serologic, and virologic study of" exact="influenza" post="C virus infection. Arch. Intern. Med.140, 1295–1298. 10.1001/archinte.1980.003302100430217425764 EasterbrookJ."/>
   <result pre="M.GaoJ.KashJ. C.MorensD. M.CouzensL.et al.. (2012). Protection against a lethal H5N1" exact="influenza" post="challenge by intranasal immunization with virus-like particles containing 2009"/>
   <result pre="39–44. 10.1016/j.virol.2012.06.00322727831 EgginkD.GoffP. H.PaleseP. (2014). Guiding the immune response against" exact="influenza" post="virus hemagglutinin toward the conserved stalk domain by hyperglycosylation"/>
   <result pre="S. (2019). Neuraminidase, the forgotten surface antigen, emerges as an" exact="influenza" post="vaccine target for broadened protection. J. Infect. Dis.219(Suppl 1),"/>
   <result pre="A.FriesenR. H.JongeneelenM.ThrosbyM.et al.. (2009). Antibody recognition of a highly conserved" exact="influenza" post="virus epitope. Science324, 246–251. 10.1126/science.117149119251591 EkiertD. C.FriesenR. H.BhabhaG.KwaksT.JongeneelenM.YuW.et al.."/>
   <result pre="al.. (2011). A highly conserved neutralizing epitope on group 2" exact="influenza" post="A viruses. Science333, 843–850. 10.1126/science.120483921737702 EkiertD. C.KashyapA. K.SteelJ.RubrumA.BhabhaG.KhayatR.et al.."/>
   <result pre="Science333, 843–850. 10.1126/science.120483921737702 EkiertD. C.KashyapA. K.SteelJ.RubrumA.BhabhaG.KhayatR.et al.. (2012). Cross-neutralization of" exact="influenza" post="A viruses mediated by a single antibody loop. Nature489,"/>
   <result pre="G.El BakkouriK.SchonK.RamneA.FestjensE.LowenadlerB.et al.. (2008). CTA1-M2e-DD: a novel mucosal adjuvant targeted" exact="influenza" post="vaccine. Vaccine26, 1243–1252. 10.1016/j.vaccine.2007.12.02718243429 EliassonD. G.OmokanyeA.SchonK.WenzelU. A.BernasconiV.BemarkM.et al.. (2018)."/>
   <result pre="(2018). M2e-tetramer-specific memory CD4 T cells are broadly protective against" exact="influenza" post="infection. Mucosal Immunol.11, 273–289. 10.1038/mi.2017.1428295019 ErbeldingE. J.PostD. J.StemmyE. J.RobertsP."/>
   <result pre="ErbeldingE. J.PostD. J.StemmyE. J.RobertsP. C.AugustineA. D.FergusonS.et al.. (2018). A universal" exact="influenza" post="vaccine: the strategic plan for the National Institute of"/>
   <result pre="E.KirkpatrickE.SunW.HaiR.AmanatF.ChromikovaV.et al.. (2017). Chimeric hemagglutinin constructs induce broad protection against" exact="influenza" post="B virus challenge in the mouse model. J. Virol.91:e00286–17."/>
   <result pre="J. Virol.91:e00286–17. 10.1128/JVI.00286-1728356526 EstradaL. D.Schultz-CherryS. (2019). Development of a universal" exact="influenza" post="vaccine. J. Immunol. 202, 392–398. 10.4049/jimmunol.180105430617121 FolegattiP. M.BellamyD.FlaxmanA.MairC.EllisC.RamonR. L.et"/>
   <result pre="M.BellamyD.FlaxmanA.MairC.EllisC.RamonR. L.et al.. (2019). Safety and immunogenicity of the heterosubtypic" exact="influenza" post="A vaccine MVA-NP+M1 mnufactured on the AGE1.CR.pIX avian cell"/>
   <result pre="(2008). Correlation of cellular immune responses with protection against culture-confirmed" exact="influenza" post="virus in young children. Clin. Vaccine Immunol.15, 1042–1053. 10.1128/CVI.00397-0718448618"/>
   <result pre="M.EkiertD. C.BhabhaG.et al.. (2014). A common solution to group 2" exact="influenza" post="virus neutralization. Proc. Natl. Acad. Sci. U.S.A.111, 445–450. 10.1073/pnas.131905811024335589"/>
   <result pre="Natl. Acad. Sci. U.S.A.111, 445–450. 10.1073/pnas.131905811024335589 GaoX.WangW.LiY.ZhangS.DuanY.XingL.et al.. (2013). Enhanced" exact="influenza" post="VLP vaccines comprising matrix-2 ectodomain and nucleoprotein epitopes protects"/>
   <result pre="GaugerP. C.VincentA. L.LovingC. L.LagerK. M.JankeB. H.KehrliM. E.Jr.et al.. (2011). Enhanced" exact="pneumonia" post="and disease in pigs vaccinated with an inactivated human-like"/>
   <result pre="human-like (delta-cluster) H1N2 vaccine and challenged with pandemic 2009 H1N1" exact="influenza" post="virus. Vaccine29, 2712–2719. 10.1016/j.vaccine.2011.01.08221310191 GianfraniC.OseroffC.SidneyJ.ChesnutR. W.SetteA. (2000). Human memory"/>
   <result pre="10.1016/j.vaccine.2011.01.08221310191 GianfraniC.OseroffC.SidneyJ.ChesnutR. W.SetteA. (2000). Human memory CTL response specific for" exact="influenza" post="A virus is broad and multispecific. Hum. Immunol.61, 438–452."/>
   <result pre="GosticK. M.AmbroseM.WorobeyM.Lloyd-SmithJ. O. (2016). Potent protection against H5N1 and H7N9" exact="influenza" post="via childhood hemagglutinin imprinting. Science354, 722–726. 10.1126/science.aag132227846599 GrasS.KedzierskiL.ValkenburgS. A.LaurieK.LiuY."/>
   <result pre="Cross-reactive CD8 T-cell immunity between the pandemic H1N1–2009 and H1N1–1918" exact="influenza" post="A viruses. Proc. Natl. Acad. Sci. U.S.A.107, 12599–12604. 10.1073/pnas.100727010720616031"/>
   <result pre="U.S.A.107, 12599–12604. 10.1073/pnas.100727010720616031 GravesP. N.SchulmanJ. L.YoungJ. F.PaleseP. (1983). Preparation of" exact="influenza" post="virus subviral particles lacking the HA1 subunit of hemagglutinin:"/>
   <result pre="conserved M2e and hemagglutinin epitope-based recombinant proteins induce protection against" exact="influenza" post="virus infection. Microbes Infect.19, 641–647. 10.1016/j.micinf.2017.08.01028903071 HaY.StevensD. J.SkehelJ. J.WileyD."/>
   <result pre="HaY.StevensD. J.SkehelJ. J.WileyD. C. (2002). H5 avian and H9 swine" exact="influenza" post="virus haemagglutinin structures: possible origin of influenza subtypes. EMBO"/>
   <result pre="and H9 swine influenza virus haemagglutinin structures: possible origin of" exact="influenza" post="subtypes. EMBO J.21, 865–875. 10.1093/emboj/21.5.86511867515 HaiR.KrammerF.TanG. S.PicaN.EgginkD.MaamaryJ.et al.. (2012)."/>
   <result pre="J. Virol.86, 5774–5781. 10.1128/JVI.00137-1222398287 HannounC. (2013). The evolving history of" exact="influenza" post="viruses and influenza vaccines. Exp. Rev. Vaccines12, 1085–1094. 10.1586/14760584.2013.82470924024871"/>
   <result pre="10.1128/JVI.00137-1222398287 HannounC. (2013). The evolving history of influenza viruses and" exact="influenza" post="vaccines. Exp. Rev. Vaccines12, 1085–1094. 10.1586/14760584.2013.82470924024871 HashemiH.PouyanfardS.BandehpourM.NoroozbabaeiZ.KazemiB.SaelensX.et al.. (2012)."/>
   <result pre="al.. (2012). Immunization with M2e-displaying T7 bacteriophage nanoparticles protects against" exact="influenza" post="A virus challenge. PLoS ONE7:e45765. 10.1371/journal.pone.004576523029232 HashimotoY.MokiT.TakizawaT.ShiratsuchiA.NakanishiY. (2007). Evidence"/>
   <result pre="challenge. PLoS ONE7:e45765. 10.1371/journal.pone.004576523029232 HashimotoY.MokiT.TakizawaT.ShiratsuchiA.NakanishiY. (2007). Evidence for phagocytosis of" exact="influenza" post="virus-infected, apoptotic cells by neutrophils and macrophages in mice."/>
   <result pre="J. Immunol.178, 2448–2457. 10.4049/jimmunol.178.4.244817277152 HattaY.BoltzD.SarawarS.KawaokaY.NeumannG.BilselP. (2017). M2SR, a novel live" exact="influenza" post="vaccine, protects mice and ferrets against highly pathogenic avian"/>
   <result pre="live influenza vaccine, protects mice and ferrets against highly pathogenic" exact="avian influenza." post="Vaccine35, 4177–4183. 10.1016/j.vaccine.2017.06.03928668565 HattaY.BoltzD.SarawarS.KawaokaY.NeumannG.BilselP. (2018). Novel influenza vaccine M2SR"/>
   <result pre="highly pathogenic avian influenza. Vaccine35, 4177–4183. 10.1016/j.vaccine.2017.06.03928668565 HattaY.BoltzD.SarawarS.KawaokaY.NeumannG.BilselP. (2018). Novel" exact="influenza" post="vaccine M2SR protects against drifted H1N1 and H3N2 influenza"/>
   <result pre="Novel influenza vaccine M2SR protects against drifted H1N1 and H3N2" exact="influenza" post="virus challenge in ferrets with pre-existing immunity. Vaccine36, 5097–5103."/>
   <result pre="responses in children and adults receiving inactivated or live attenuated" exact="influenza" post="vaccines. J. Virol.80, 11756–11766. 10.1128/JVI.01460-0616971435 HemannE. A.KangS. M.LeggeK. L."/>
   <result pre="A.KangS. M.LeggeK. L. (2013). Protective CD8 T cell-mediated immunity against" exact="influenza" post="A virus infection following influenza virus-like particle vaccination. J."/>
   <result pre="CD8 T cell-mediated immunity against influenza A virus infection following" exact="influenza" post="virus-like particle vaccination. J. Immunol.191, 2486–2494. 10.4049/jimmunol.130095423885108 Henry DunandC."/>
   <result pre="Y.AndrewsS.et al.. (2015). Preexisting human antibodies neutralize recently emerged H7N9" exact="influenza" post="strains. J. Clin. Invest.125, 1255–1268. 10.1172/JCI7437425689254 HenryC.PalmA. E.KrammerF.WilsonP. C."/>
   <result pre="E.KrammerF.WilsonP. C. (2018). From original antigenic sin to the universal" exact="influenza" post="virus vaccine. Trends Immunol.39, 70–79. 10.1016/j.it.2017.08.00328867526 HesselA.Savidis-DachoH.CoulibalyS.PortsmouthD.KreilT. R.CroweB. A.et"/>
   <result pre="10.1016/j.it.2017.08.00328867526 HesselA.Savidis-DachoH.CoulibalyS.PortsmouthD.KreilT. R.CroweB. A.et al.. (2014). MVA vectors expressing conserved" exact="influenza" post="proteins protect mice against lethal challenge with H5N1, H9N2"/>
   <result pre="TrierumS. E.KreijtzJ. H.BodewesR.Geelhoed-MierasM. M.NieuwkoopN. J.et al.. (2011). Cross-protective immunity against" exact="influenza" post="pH1N1 2009 viruses induced by seasonal influenza A (H3N2)"/>
   <result pre="Cross-protective immunity against influenza pH1N1 2009 viruses induced by seasonal" exact="influenza" post="A (H3N2) virus is mediated by virus-specific T-cells. J."/>
   <result pre="HiranoD.OhshimaN.Kubota-KoketsuR.YamasakiA.KurosawaG.OkunoY.et al.. (2018). Three types of broadly reacting antibodies against" exact="influenza" post="B viruses induced by vaccination with seasonal influenza viruses."/>
   <result pre="antibodies against influenza B viruses induced by vaccination with seasonal" exact="influenza" post="viruses. J. Immunol. Res.2018:7251793. 10.1155/2018/725179329854845 HoftD. F.BabusisE.WorkuS.SpencerC. T.LottenbachK.TruscottS. M.et"/>
   <result pre="10.1155/2018/725179329854845 HoftD. F.BabusisE.WorkuS.SpencerC. T.LottenbachK.TruscottS. M.et al.. (2011). Live and inactivated" exact="influenza" post="vaccines induce similar humoral responses, but only live vaccines"/>
   <result pre="Fc receptor-mediated phagocytosis makes a significant contribution to clearance of" exact="influenza" post="virus infections. J. Immunol.166, 7381–7388. 10.4049/jimmunol.166.12.738111390489 IbaY.FujiiY.OhshimaN.SumidaT.Kubota-KoketsuR.IkedaM.et al.. (2014)."/>
   <result pre="Conserved neutralizing epitope at globular head of hemagglutinin in H3N2" exact="influenza" post="viruses. J. Virol. 88, 7130–7144. 10.1128/JVI.00420-1424719430 IbanezL. I.RooseK.De FiletteM.SchotsaertM.De"/>
   <result pre="associated RNA promote T helper 1 type adaptive immunity against" exact="influenza" post="A. PLoS ONE8:e59081. 10.1371/journal.pone.005908123527091 ImpagliazzoA.MilderF.KuipersH.WagnerM. V.ZhuX.HoffmanR. M.et al.. (2015)."/>
   <result pre="ONE8:e59081. 10.1371/journal.pone.005908123527091 ImpagliazzoA.MilderF.KuipersH.WagnerM. V.ZhuX.HoffmanR. M.et al.. (2015). A stable trimeric" exact="influenza" post="hemagglutinin stem as a broadly protective immunogen. Science349, 1301–1306."/>
   <result pre="(2018). Broadly protective anti-hemagglutinin stalk antibodies induced by live attenuated" exact="influenza" post="vaccine expressing chimeric hemagglutinin. Virology518, 313–323. 10.1016/j.virol.2018.03.01329574336 JamesonJ.CruzJ.EnnisF. A."/>
   <result pre="313–323. 10.1016/j.virol.2018.03.01329574336 JamesonJ.CruzJ.EnnisF. A. (1998). Human cytotoxic T-lymphocyte repertoire to" exact="influenza" post="A viruses. J. Virol.72, 8682–8689. 9765409 JangY. H.ByunY. H.LeeD."/>
   <result pre="H.et al.. (2013a). Cold-adapted X-31 live attenuated 2009 pandemic H1N1" exact="influenza" post="vaccine elicits protective immune responses in mice and ferrets."/>
   <result pre="H.LeeY. J.LeeY. H.LeeK. H.SeongB. L. (2012). Cold-adapted pandemic 2009 H1N1" exact="influenza" post="virus live vaccine elicits cross-reactive immune responses against seasonal"/>
   <result pre="live vaccine elicits cross-reactive immune responses against seasonal and H5" exact="influenza" post="A viruses. J. Virol.86, 5953–5958. 10.1128/JVI.07149-1122438541 JangY. H.JungE. J.ByunY."/>
   <result pre="and protective efficacy of cold-adapted X-31 live attenuated pre-pandemic H5N1" exact="influenza" post="vaccines. Vaccine31, 3339–3346. 10.1016/j.vaccine.2013.05.08023742997 JangY. H.JungE. J.LeeK. H.ByunY. H.YangS."/>
   <result pre="L. (2016). Genetic analysis of attenuation markers of cold-adapted X-31" exact="influenza" post="live vaccine donor strain. Vaccine34, 1343–1349. 10.1016/j.vaccine.2016.01.05326851733 JangY. H.KimJ."/>
   <result pre="(2018). Pan-influenza A protection by prime-boost vaccination with cold-adapted live-attenuated" exact="influenza" post="vaccine in a mouse model. Front. Immunol.9:116. 10.3389/fimmu.2018.0011629449842 JangY."/>
   <result pre="Protective efficacy in mice of monovalent and trivalent live attenuated" exact="influenza" post="vaccines in the background of cold-adapted A/X-31 and B/Lee/40"/>
   <result pre="H.SeongB. L. (2013a). Cross-protective immune responses elicited by live attenuated" exact="influenza" post="vaccines. Yonsei Med. J. 54, 271–282. 10.3349/ymj.2013.54.2.27123364956 JangY. H.SeongB."/>
   <result pre="54, 271–282. 10.3349/ymj.2013.54.2.27123364956 JangY. H.SeongB. L. (2013b). Toward a universal" exact="influenza" post="vaccine: from the perspective of protective efficacy. Clin. Exp."/>
   <result pre="H.SeongB. L. (2014). Options and obstacles for designing a universal" exact="influenza" post="vaccine. Viruses6, 3159–3180. 10.3390/v608315925196381 JanjuaN. Z.SkowronskiD. M.HottesT. S.OseiW.AdamsE.PetricM.et al.."/>
   <result pre="Viruses6, 3159–3180. 10.3390/v608315925196381 JanjuaN. Z.SkowronskiD. M.HottesT. S.OseiW.AdamsE.PetricM.et al.. (2010). Seasonal" exact="influenza" post="vaccine and increased risk of pandemic A/H1N1-related illness: first"/>
   <result pre="1017–1027. 10.1086/65658620887210 JeffersonT.Di PietrantonjC.RivettiA.BawazeerG. A.Al-AnsaryL. A.FerroniE. (2010). Vaccines for preventing" exact="influenza" post="in healthy adults. Cochrane Database Syst. Rev.7:Cd00126910.1002/14651858.CD001269.pub4 JeffersonT.RivettiA.HarndenA.Di PietrantonjC.DemicheliV."/>
   <result pre="Cochrane Database Syst. Rev.7:Cd00126910.1002/14651858.CD001269.pub4 JeffersonT.RivettiA.HarndenA.Di PietrantonjC.DemicheliV. (2008). Vaccines for preventing" exact="influenza" post="in healthy children. Cochrane Database Syst. Rev.16:Cd00487910.1002/14651858.CD004879.pub3 JegaskandaS.CoM. D."/>
   <result pre="Induction of H7N9-cross-reactive antibody-dependent cellular cytotoxicity antibodies by human seasonal" exact="influenza" post="A viruses that are directed toward the nucleoprotein. J."/>
   <result pre="cytotoxicity in intravenous immunoglobulin as a potential therapeutic against emerging" exact="influenza" post="viruses. J. Infect. Dis.210, 1811–1822. 10.1093/infdis/jiu33424916185 JegaskandaS.VandervenH. A.WheatleyA. K.KentS."/>
   <result pre="is the question: antibody Fc-receptor interactions are key to universal" exact="influenza" post="vaccine design. Hum. Vaccin Immunother.13, 1–9. 10.1080/21645515.2017.129001828332900 JegerlehnerA.SchmitzN.StorniT.BachmannM. F."/>
   <result pre="5598–5605. 10.4049/jimmunol.172.9.559815100303 JobE. R.YsenbaertT.SmetA.ChristopoulouI.StrugnellT.OlooE. O.et al.. (2018). Broadened immunity against" exact="influenza" post="by vaccination with computationally designed influenza virus N1 neuraminidase"/>
   <result pre="(2018). Broadened immunity against influenza by vaccination with computationally designed" exact="influenza" post="virus N1 neuraminidase constructs. NPJ Vaccines3:55. 10.1038/s41541-018-0093-130510776 JohanssonB. E.KilbourneE."/>
   <result pre="constructs. NPJ Vaccines3:55. 10.1038/s41541-018-0093-130510776 JohanssonB. E.KilbourneE. D. (1993). Dissociation of" exact="influenza" post="virus hemagglutinin and neuraminidase eliminates their intravirionic antigenic competition."/>
   <result pre="D. (1996). Immunization with dissociated neuraminidase, matrix, and nucleoproteins from" exact="influenza" post="A virus eliminates cognate help and antigenic competition. Virology225,"/>
   <result pre="and helper T cells cooperatively mediate intravirionic antigenic competition between" exact="influenza" post="A virus surface glycoproteins. Proc. Natl. Acad. Sci. U.S.A.84,"/>
   <result pre="(2019). Induction of protective immune response to intranasal administration of" exact="influenza" post="virus-like particles in a mouse model. J. Cell Physiol."/>
   <result pre="226, 1110–1117. 10.1002/jcp.28339 KhuranaS. (2018). Development and regulation of novel" exact="influenza" post="virus vaccines: a United States young scientist perspective. Vaccines6:24."/>
   <result pre="al.. (2013). Vaccine-induced anti-HA2 antibodies promote virus fusion and enhance" exact="influenza" post="virus respiratory disease. Sci. Transl. Med.5:200ra114. 10.1126/scitranslmed.300636623986398 KilbourneE. D."/>
   <result pre="Vaccine-induced anti-HA2 antibodies promote virus fusion and enhance influenza virus" exact="respiratory disease." post="Sci. Transl. Med.5:200ra114. 10.1126/scitranslmed.300636623986398 KilbourneE. D. (2006). Influenza pandemics"/>
   <result pre="Neuraminidase expressing virus-like particle vaccine provides effective cross protection against" exact="influenza" post="virus. Virology535, 179–188. 10.1016/j.virol.2019.07.00831310875 KimM. C.LeeJ. W.ChoiH. J.LeeY. N.HwangH."/>
   <result pre="skin of virus-like particles containing heterologous M2e extracellular domains of" exact="influenza" post="virus induces broad heterosubtypic cross-protection. J. Control Release210, 208–216."/>
   <result pre="key role in inducing humoral and cellular immune responses to" exact="influenza" post="virus strain-specific hemagglutinin-based or cross-protective M2 extracellular domain-based vaccination."/>
   <result pre="T.KimM. C.LeeY. N.KimK. H.KoE. J.et al.. (2017). Cross-protective efficacy of" exact="influenza" post="virus M2e containing virus-like particles is superior to hemagglutinin"/>
   <result pre="backgrounds of mice. Front. Immunol.8:1730. 10.3389/fimmu.2017.0173029276514 KirkpatrickE.QiuX.WilsonP. C.BahlJ.KrammerF. (2018). The" exact="influenza" post="virus hemagglutinin head evolves faster than the stalk domain."/>
   <result pre="DNA vaccine induces protective cross-reactive T cell responses against heterologous" exact="influenza" post="virus in nonhuman primates. PLoS ONE12:e0189780. 10.1371/journal.pone.018978029267331 KosikI.AngelettiD.GibbsJ. S.AngelM.TakedaK.KosikovaM.et"/>
   <result pre="ONE12:e0189780. 10.1371/journal.pone.018978029267331 KosikI.AngelettiD.GibbsJ. S.AngelM.TakedaK.KosikovaM.et al.. (2019). Neuraminidase inhibition contributes to" exact="influenza" post="A virus neutralization by anti-hemagglutinin stem antibodies. J. Exp."/>
   <result pre="A.CrawfordJ. C.RizzettoS.et al.. (2019). Human CD8(+) T cell cross-reactivity across" exact="influenza" post="A, B and C viruses. Nat. Immunol.20, 613–625. 10.1038/s41590-019-0320-630778243"/>
   <result pre="Immunol.20, 613–625. 10.1038/s41590-019-0320-630778243 KrammerF. (2019). The human antibody response to" exact="influenza" post="A virus infection and vaccination. Nat. Rev. Immunol.19, 383–397."/>
   <result pre="al.. (2018a). NAction! How can neuraminidase-based immunity contribute to better" exact="influenza" post="virus vaccines?MBio9:e02332–e02317. 10.1128/mBio.02332-1729615508 KrammerF.Garcia-SastreA.PaleseP. (2018b). Is it possible to"/>
   <result pre="10.1128/mBio.02332-1729615508 KrammerF.Garcia-SastreA.PaleseP. (2018b). Is it possible to develop a &quot;universal�?" exact="influenza" post="virus vaccine? Potential target antigens and critical aspects for"/>
   <result pre="vaccine? Potential target antigens and critical aspects for a universal" exact="influenza" post="vaccine. Cold Spring Harb Perspect. Biol.10:a028845. 10.1101/cshperspect.a02884528663209 KrammerF.HaiR.YondolaM.TanG. S.Leyva-GradoV."/>
   <result pre="Biol.10:a028845. 10.1101/cshperspect.a02884528663209 KrammerF.HaiR.YondolaM.TanG. S.Leyva-GradoV. H.RyderA. B.et al.. (2014). Assessment of" exact="influenza" post="virus hemagglutinin stalk-based immunity in ferrets. J. Virol.88, 3432–3442."/>
   <result pre="Virol.3, 521–530. 10.1016/j.coviro.2013.07.00723978327 KrammerF.PaleseP. (2015). Advances in the development of" exact="influenza" post="virus vaccines. Nat. Rev. Drug Discov.14, 167–182. 10.1038/nrd452925722244 KrammerF.PicaN.HaiR.MargineI.PaleseP."/>
   <result pre="Nat. Rev. Drug Discov.14, 167–182. 10.1038/nrd452925722244 KrammerF.PicaN.HaiR.MargineI.PaleseP. (2013). Chimeric hemagglutinin" exact="influenza" post="virus vaccine constructs elicit broadly protective stalk-specific antibodies. J."/>
   <result pre="monoclonal antibodies to pandemic 1957 H2N2 and pandemic 1968 H3N2" exact="influenza" post="viruses. J. Virol.86, 6334–6340. 10.1128/JVI.07158-1122457520 KrauseJ. C.TsibaneT.TumpeyT. M.HuffmanC. J.BaslerC."/>
   <result pre="a conserved, novel epitope on the globular head of the" exact="influenza" post="H1N1 virus hemagglutinin. J. Virol.85, 10905–10908. 10.1128/JVI.00700-1121849447 KreijtzJ. H.BodewesR.van"/>
   <result pre="10905–10908. 10.1128/JVI.00700-1121849447 KreijtzJ. H.BodewesR.van AmerongenG.KuikenT.FouchierR. A.OsterhausA. D.et al.. (2007). Primary" exact="influenza" post="A virus infection induces cross-protective immunity against a lethal"/>
   <result pre="MutsertG.BaasC.van AmerongenG.et al.. (2009). Infection of mice with a human" exact="influenza" post="A/H3N2 virus induces protective immunity against lethal infection with"/>
   <result pre="influenza A/H3N2 virus induces protective immunity against lethal infection with" exact="influenza" post="A/H5N1 virus. Vaccine27, 4983–4989. 10.1016/j.vaccine.2009.05.07919538996 KreijtzJ. H.de MutsertG.van BaalenC."/>
   <result pre="BaalenC. A.FouchierR. A.OsterhausA. D.RimmelzwaanG. F. (2008). Cross-recognition of avian H5N1" exact="influenza" post="virus by human cytotoxic T-lymphocyte populations directed to human"/>
   <result pre="influenza virus by human cytotoxic T-lymphocyte populations directed to human" exact="influenza" post="A virus. J. Virol.82, 5161–5166. 10.1128/JVI.02694-0718353950 LeclercD.RivestM.BabinC.Lopez-MaciasC.SavardP. (2013). A"/>
   <result pre="identify the minimum interval necessary to observe the H5 DNA" exact="influenza" post="vaccine priming effect. J. Infect. Dis.208, 418–422. 10.1093/infdis/jit18023633407 LeeJ.BoutzD."/>
   <result pre="serum antibody repertoire in young adults before and after seasonal" exact="influenza" post="vaccination. Nat. Med.22, 1456–1464. 10.1038/nm.422427820605 LeeK. H.SeongB. L. (1998)."/>
   <result pre="The position 4 nucleotide at the 3' end of the" exact="influenza" post="virus neuraminidase vRNA is involved in temporal regulation of"/>
   <result pre="and replication of neuraminidase RNAs and affects the repertoire of" exact="influenza" post="virus surface antigens. J. Gen Virol.79 (Pt 8), 1923–1934."/>
   <result pre="V.SchumacherR.et al.. (2008). Memory T cells established by seasonal human" exact="influenza" post="A infection cross-react with avian influenza A (H5N1) in"/>
   <result pre="cells established by seasonal human influenza A infection cross-react with" exact="avian influenza" post="A (H5N1) in healthy individuals. J. Clin. Invest.118, 3478–3490."/>
   <result pre="established by seasonal human influenza A infection cross-react with avian" exact="influenza" post="A (H5N1) in healthy individuals. J. Clin. Invest.118, 3478–3490."/>
   <result pre="N.KimM. C.LeeY. T.KimY. J.KangS. M. (2015). Mechanisms of cross-protection by" exact="influenza" post="virus M2-based vaccines. Immune Netw.15, 213–221. 10.4110/in.2015.15.5.21326557805 LeeY. N.LeeY."/>
   <result pre="antibodies but plays a critical role in conferring protection after" exact="influenza" post="M2 vaccination. Immunology143, 300–309. 10.1111/imm.1231024773389 LinS. C.LinY. F.ChongP.WuS. C."/>
   <result pre="and recombinant protein immunizations elicits broadly neutralizing antibodies against H5N1" exact="avian influenza" post="viruses. PLoS ONE9:e92822. 10.1371/journal.pone.009282224671139 LinY. P.GregoryV.CollinsP.KloessJ.WhartonS.CattleN.et al.. (2010). Neuraminidase"/>
   <result pre="recombinant protein immunizations elicits broadly neutralizing antibodies against H5N1 avian" exact="influenza" post="viruses. PLoS ONE9:e92822. 10.1371/journal.pone.009282224671139 LinY. P.GregoryV.CollinsP.KloessJ.WhartonS.CattleN.et al.. (2010). Neuraminidase"/>
   <result pre="LinY. P.GregoryV.CollinsP.KloessJ.WhartonS.CattleN.et al.. (2010). Neuraminidase receptor binding variants of human" exact="influenza" post="A(H3N2) viruses resulting from substitution of aspartic acid 151"/>
   <result pre="immunization with live-attenuated chimeric hemagglutinin-based vaccines confers heterosubtypic immunity against" exact="influenza" post="A viruses in a preclinical ferret model. Front. Immunol.10:756."/>
   <result pre="immunization with recombinant neuraminidase proteins of H5N1 and pandemic H1N1" exact="influenza" post="A viruses. J. Virol.89, 7224–7234. 10.1128/JVI.00585-1525948745 LiuY.TanH. X.KoutsakosM.JegaskandaS.EsterbauerR.TilmanisD.et al.."/>
   <result pre="X.KoutsakosM.JegaskandaS.EsterbauerR.TilmanisD.et al.. (2019b). Cross-lineage protection by human antibodies binding the" exact="influenza" post="B hemagglutinin. Nat. Commun.10:324. 10.1038/s41467-018-08165-y30659197 LowenA. C. (2017). Constraints,"/>
   <result pre="Commun.10:324. 10.1038/s41467-018-08165-y30659197 LowenA. C. (2017). Constraints, drivers, and implications of" exact="influenza" post="A virus reassortment. Annu. Rev. Virol.4, 105–121. 10.1146/annurev-virology-101416-04172628548881 LuY.WelshJ."/>
   <result pre="LuY.WelshJ. P.SwartzJ. R. (2014). Production and stabilization of the trimeric" exact="influenza" post="hemagglutinin stem domain for potentially broadly protective influenza vaccines."/>
   <result pre="the trimeric influenza hemagglutinin stem domain for potentially broadly protective" exact="influenza" post="vaccines. Proc. Natl. Acad. Sci. U.S.A.111, 125–130. 10.1073/pnas.130870111024344259 MallajosyulaV."/>
   <result pre="(2013). Hemagglutinin stalk-based universal vaccine constructs protect against group 2" exact="influenza" post="A viruses. J. Virol.87, 10435–10446. 10.1128/JVI.01715-1323903831 McMahonM.KirkpatrickE.StadlbauerD.StrohmeierS.BouvierN. M.KrammerF. (2019)."/>
   <result pre="10435–10446. 10.1128/JVI.01715-1323903831 McMahonM.KirkpatrickE.StadlbauerD.StrohmeierS.BouvierN. M.KrammerF. (2019). Mucosal immunity against neuraminidase prevents" exact="influenza" post="B virus transmission in Guinea Pigs. MBio10:e00560–19. 10.1128/mBio.00560-1931113896 MemoliM."/>
   <result pre="antihemagglutinin and antineuraminidase antibodies as correlates of protection in an" exact="influenza" post="A/H1N1 virus healthy human challenge model. MBio7:e00417–e00416. 10.1128/mBio.00417-1627094330 MesedaC."/>
   <result pre="10.1128/mBio.00417-1627094330 MesedaC. A.AtukoraleV.SotoJ.EichelbergerM. C.GaoJ.WangW.et al. (2018). Immunogenicity and protection against" exact="influenza" post="H7N3 in mice by modified vaccinia virus Ankara vectors"/>
   <result pre="Immunogenicity and protection against influenza H7N3 in mice by modified" exact="vaccinia virus" post="Ankara vectors expressing influenza virus hemagglutinin or neuraminidase. Sci."/>
   <result pre="H7N3 in mice by modified vaccinia virus Ankara vectors expressing" exact="influenza" post="virus hemagglutinin or neuraminidase. Sci. Rep.8:536410.1038/s41598-018-23712-929599502 MoglingR.RichardM. J.VlietS. V.BeekR."/>
   <result pre="J. A.SpronkenM. I.et al.. (2017). Neuraminidase-mediated haemagglutination of recent human" exact="influenza" post="A(H3N2) viruses is determined by arginine 150 flanking the"/>
   <result pre="(2015). Longevity of B-cell and T-cell responses after live attenuated" exact="influenza" post="vaccination in children. J. Infect. Dis.211, 1541–1549. 10.1093/infdis/jiu65425425696 MohnK."/>
   <result pre="10.1093/infdis/jiu65425425696 MohnK. G.SmithI.SjursenH.CoxR. J. (2018). Immune responses after live attenuated" exact="influenza" post="vaccination. Hum. Vaccin Immunother.14, 571–578. 10.1080/21645515.2017.137737628933664 MohnK. G. I.ZhouF.BrokstadK."/>
   <result pre="cross-reactive and protection-associated T cells in children after live attenuated" exact="influenza" post="vaccination. J. Infect. Dis.215, 1527–1535. 10.1093/infdis/jix16528368530 MonsalvoA. C.BatalleJ. P.LopezM."/>
   <result pre="P.LopezM. F.KrauseJ. C.KlemencJ.HernandezJ. Z.et al.. (2011). Severe pandemic 2009 H1N1" exact="influenza" post="disease due to pathogenic immune complexes. Nat. Med. 17,"/>
   <result pre="623–625. 10.1016/S0140-6736(73)92196-X4121842 MontoA. S.PetrieJ. G.CrossR. T.JohnsonE.LiuM.ZhongW.et al.. (2015). Antibody to" exact="influenza" post="virus neuraminidase: an independent correlate of protection. J. Infect."/>
   <result pre="J. Infect. Dis.212, 1191–1199. 10.1093/infdis/jiv19525858957 MozdzanowskaK.FengJ.EidM.KragolG.CudicM.OtvosL.Jr.et al.. (2003). Induction of" exact="influenza" post="type A virus-specific resistance by immunization of mice with"/>
   <result pre="M. (1972). Association of serum anti-neuraminidase antibody with resistance to" exact="influenza" post="in man. N. Engl. J. Med.286, 1329–1332. 10.1056/NEJM1972062228625025027388 MusicN.ReberA."/>
   <result pre="live-attenuated prime, inactivated boost vaccination strategy with chimeric hemagglutinin-based universal" exact="influenza" post="virus vaccines provides protection in ferrets: a confirmatory study."/>
   <result pre="study. Vaccines6:47. 10.3390/vaccines603004730044403 NachbagauerR.LiuW. C.ChoiA.WohlboldT. J.AtlasT.RajendranM.et al.. (2017). A universal" exact="influenza" post="virus vaccine candidate confers protection against pandemic H1N1 infection"/>
   <result pre="ferret studies. NPJ Vaccines2:26. 10.1038/s41541-017-0026-429263881 NeirynckS.DerooT.SaelensX.VanlandschootP.JouW. M.FiersW. (1999). A universal" exact="influenza" post="A vaccine based on the extracellular domain of the"/>
   <result pre="NgS.NachbagauerR.BalmasedaA.StadlbauerD.OjedaS.PatelM.et al.. (2019). Novel correlates of protection against pandemic H1N1" exact="influenza" post="A virus infection. Nat. Med.25, 962–967. 10.1038/s41591-019-0463-x31160818 OhH. L.AkerstromS.ShenS.BereczkyS.KarlbergH.KlingstromJ.et"/>
   <result pre="conserved epitope in the hemagglutinin 1 subunit neutralizes numerous H5N1" exact="influenza" post="viruses. J. Virol.84, 8275–8286. 10.1128/JVI.02593-0920519402 OhmitS. E.PetrieJ. G.CrossR. T.JohnsonE.MontoA."/>
   <result pre="10.1038/nrd.2017.24329326426 PardiN.ParkhouseK.KirkpatrickE.McMahonM.ZostS. J.MuiB. L.et al.. (2018b). Nucleoside-modified mRNA immunization elicits" exact="influenza" post="virus hemagglutinin stalk-specific antibodies. Nat. Commun.9:3361. 10.1038/s41467-018-05482-030135514 ParkJ. K.HanA.CzajkowskiL.ReedS.AthotaR.BristolT.et"/>
   <result pre="a correlate of protection in a healthy volunteer challenge with" exact="influenza" post="A/H1N1pdm Virus. MBio9:e02284–17. 10.1128/mBio.02284-1729362240 PaulS. S.MokC. K.MakT. M.NgO. W.AboagyeJ."/>
   <result pre="K.MakT. M.NgO. W.AboagyeJ. O.WohlboldT. J.et al.. (2017). A cross-clade H5N1" exact="influenza" post="A virus neutralizing monoclonal antibody binds to a novel"/>
   <result pre="I.MarstonH. D.EisingerR. W.BaltimoreD.FauciA. S. (2017). The pathway to a universal" exact="influenza" post="vaccine. Immunity47, 599–603. 10.1016/j.immuni.2017.09.00729045889 PeirisJ. S.HuiK. P.YenH. L. (2010)."/>
   <result pre="599–603. 10.1016/j.immuni.2017.09.00729045889 PeirisJ. S.HuiK. P.YenH. L. (2010). Host response to" exact="influenza" post="virus: protection versus immunopathology. Curr. Opin. Immunol.22, 475–481. 10.1016/j.coi.2010.06.00320594815"/>
   <result pre="conserved part of the viral M2 ectodomain cure and prevent" exact="influenza" post="A virus infection. Antiviral Res.141, 155–164. 10.1016/j.antiviral.2017.02.01628257797 PerezJ. T.PhamA."/>
   <result pre="T.PhamA. M.LoriniM. H.ChuaM. A.SteelJ.tenOeverB. R. (2009). MicroRNA-mediated species-specific attenuation of" exact="influenza" post="A virus. Nat. Biotechnol.27, 572–576. 10.1038/nbt.154219483680 PetschB.SchneeM.VogelA. B.LangeE.HoffmannB.VossD.et al.."/>
   <result pre="Protective efficacy of in vitro synthesized, specific mRNA vaccines against" exact="influenza" post="A virus infection. Nat. Biotechnol.30, 1210–1216. 10.1038/nbt.243623159882 PetukhovaN. V.GasanovaT."/>
   <result pre="V.et al.. (2013). Immunogenicity and protective efficacy of candidate universal" exact="influenza" post="A nanovaccines produced in plants by Tobacco mosaic virus-based"/>
   <result pre="PiepenbrinkM. S.NogalesA.BasuM.FucileC. F.LiesveldJ. L.KeeferM. C.et al.. (2019). Broad and protective" exact="influenza" post="B virus neuraminidase antibodies in humans after vaccination and"/>
   <result pre="PowellT. J.PengY.BerthoudT. K.BlaisM. E.LillieP. J.HillA. V.et al.. (2013). Examination of" exact="influenza" post="specific T cell responses after influenza virus challenge in"/>
   <result pre="al.. (2013). Examination of influenza specific T cell responses after" exact="influenza" post="virus challenge in individuals vaccinated with MVA-NP+M1 vaccine. PLoS"/>
   <result pre="vaccine. PLoS ONE8:e62778. 10.1371/journal.pone.006277823658773 PowellT. J.SilkJ. D.SharpsJ.FodorE.TownsendA. R. (2012). Pseudotyped" exact="influenza" post="A virus as a vaccine for the induction of"/>
   <result pre="antigens protects mice and ferrets against virulent H1N1 and H5N1" exact="influenza" post="A viruses. Vaccine27, 6512–6521. 10.1016/j.vaccine.2009.08.05319729082 RajaoD. S.ChenH.PerezD. R.SandbulteM. R.GaugerP."/>
   <result pre="RajaoD. S.ChenH.PerezD. R.SandbulteM. R.GaugerP. C.LovingC. L.et al.. (2016). Vaccine-associated enhanced" exact="respiratory disease" post="is influenced by haemagglutinin and neuraminidase in whole inactivated"/>
   <result pre="disease is influenced by haemagglutinin and neuraminidase in whole inactivated" exact="influenza" post="virus vaccines. J. Gen. Virol.97, 1489–1499. 10.1099/jgv.0.00046827031847 RajaoD. S.LovingC."/>
   <result pre="Influenza A virus hemagglutinin protein subunit vaccine elicits vaccine-associated enhanced" exact="respiratory disease" post="in pigs. Vaccine32, 5170–5176. 10.1016/j.vaccine.2014.07.05925077416 RavinN. V.BlokhinaE. A.KuprianovV. V.StepanovaL."/>
   <result pre="V.StepanovaL. A.ShaldjanA. A.KovalevaA. A.et al.. (2015). Development of a candidate" exact="influenza" post="vaccine based on virus-like particles displaying influenza M2e peptide"/>
   <result pre="of a candidate influenza vaccine based on virus-like particles displaying" exact="influenza" post="M2e peptide into the immunodominant loop region of hepatitis"/>
   <result pre="displaying influenza M2e peptide into the immunodominant loop region of" exact="hepatitis" post="B core antigen: Insertion of multiple copies of M2e"/>
   <result pre="cross protection in mice afforded by pandemic H1N1 live attenuated" exact="influenza" post="vaccine containing wild-type nucleoprotein. Biomed. Res. Int.2017:9359276. 10.1155/2017/935927628210631 Rosendahl"/>
   <result pre="K.CampsM. G.JacobiR. H.MouthaanJ.van DijkenH.van BeekJ.et al.. (2015). Synthetic long peptide" exact="influenza" post="vaccine containing conserved T and B cell epitopes reduces"/>
   <result pre="SagawaH.OhshimaA.KatoI.OkunoY.IsegawaY. (1996). The immunological activity of a deletion mutant of" exact="influenza" post="virus haemagglutinin lacking the globular region. J. Gen Virol.77"/>
   <result pre="10.1038/srep4504328344335 SarawarS.HattaY.WatanabeS.DiasP.NeumannG.KawaokaY.et al.. (2016). M2SR, a novel live single replication" exact="influenza" post="virus vaccine, provides effective heterosubtypic protection in mice. Vaccine34,"/>
   <result pre="L. (1969). The role of antineuraminidase antibody in immunity to" exact="influenza" post="virus infection. Bull World Health Organ.41, 647–650. 5309490 SchulmanJ."/>
   <result pre="Independent variation in nature of hemagglutinin and neuraminidase antigens of" exact="influenza" post="virus: distinctiveness of hemagglutinin antigen of Hong Kong-68 virus."/>
   <result pre="multimechanistic antibody targeting the receptor binding site potently cross-protects against" exact="influenza" post="B viruses. Sci. Transl. Med.9:eaam5752. 10.1126/scitranslmed.aam575229046433 SkowronskiD. M.De SerresG.CrowcroftN."/>
   <result pre="S.JanjuaN. Z.BoulianneN.HottesT. S.et al.. (2010). Association between the 2008–09 seasonal" exact="influenza" post="vaccine and pandemic H1N1 illness during Spring-Summer 2009: four"/>
   <result pre="chickens. Vaccine34, 678–686. 10.1016/j.vaccine.2015.11.07426691568 SridharS. (2016). Heterosubtypic T-cell immunity to" exact="influenza" post="in humans: challenges for universal T-cell influenza vaccines. Front."/>
   <result pre="T-cell immunity to influenza in humans: challenges for universal T-cell" exact="influenza" post="vaccines. Front. Immunol.7:195. 10.3389/fimmu.2016.0019527242800 SridharS.BrokstadK. A.CoxR. J. (2015). Influenza"/>
   <result pre="J. (2015). Influenza vaccination strategies: comparing inactivated and live attenuated" exact="influenza" post="vaccines. Vaccines3, 373–389. 10.3390/vaccines302037326343192 StechJ.GarnH.WegmannM.WagnerR.KlenkH. D. (2005). A new"/>
   <result pre="373–389. 10.3390/vaccines302037326343192 StechJ.GarnH.WegmannM.WagnerR.KlenkH. D. (2005). A new approach to an" exact="influenza" post="live vaccine: modification of the cleavage site of hemagglutinin."/>
   <result pre="MBio1:e00018–10. 10.1128/mBio.00018-1020689752 SuB.WurtzerS.Rameix-WeltiM.-A.DwyerD.van der WerfS.NaffakhN.et al.. (2010). Enhancement of the" exact="influenza" post="A hemagglutinin (HA)-mediated cell-cell fusion and virus entry by"/>
   <result pre="SubbramanianR. A.BashaS.ShataM. T.BradyR. C.BernsteinD. I. (2010). Pandemic and seasonal H1N1" exact="influenza" post="hemagglutinin-specific T cell responses elicited by seasonal influenza vaccination."/>
   <result pre="seasonal H1N1 influenza hemagglutinin-specific T cell responses elicited by seasonal" exact="influenza" post="vaccination. Vaccine28, 8258–8267. 10.1016/j.vaccine.2010.10.07721050903 SuiJ.HwangW. C.PerezS.WeiG.AirdD.ChenL. M.et al.. (2009)."/>
   <result pre="and functional bases for broad-spectrum neutralization of avian and human" exact="influenza" post="A viruses. Nat. Struct. Mol. Biol.16, 265–273. 10.1038/nsmb.156619234466 SunW.KirkpatrickE.ErmlerM.NachbagauerR.BroeckerF.KrammerF.et"/>
   <result pre="Struct. Mol. Biol.16, 265–273. 10.1038/nsmb.156619234466 SunW.KirkpatrickE.ErmlerM.NachbagauerR.BroeckerF.KrammerF.et al.. (2019). Development of" exact="influenza" post="B universal vaccine candidates using the &quot;mosaic�? hemagglutinin approach."/>
   <result pre="(2015). High copy numbers and N terminal insertion position of" exact="influenza" post="A M2E fused with hepatitis B core antigen enhanced"/>
   <result pre="N terminal insertion position of influenza A M2E fused with" exact="hepatitis" post="B core antigen enhanced immunogenicity. Biosci. Trends9, 221–227. 10.5582/bst.2015.0106026355223"/>
   <result pre="monoclonal antibody that targets the fusion domain of group 2" exact="influenza" post="A virus hemagglutinin. J. Virol.88, 13580–13592. 10.1128/JVI.02289-1425210195 TanG. S.LeonP."/>
   <result pre="(2016). Broadly-reactive neutralizing and non-neutralizing antibodies directed against the H7" exact="influenza" post="virus hemagglutinin reveal divergent mechanisms of protection. PLoS Pathog.12:e1005578."/>
   <result pre="mechanisms of protection. PLoS Pathog.12:e1005578. 10.1371/journal.ppat.100557827081859 TanJ.Asthagiri ArunkumarG.KrammerF. (2018). Universal" exact="influenza" post="virus vaccines and therapeutics: where do we stand with"/>
   <result pre="influenza virus vaccines and therapeutics: where do we stand with" exact="influenza" post="B virus?Curr. Opin. Immunol.53, 45–50. 10.1016/j.coi.2018.04.00229677684 TerajimaM.BabonJ. A.CoM. D.EnnisF."/>
   <result pre="(2013). Cross-reactive human B cell and T cell epitopes between" exact="influenza" post="A and B viruses. Virol. J.10:244. 10.1186/1743-422X-10-24423886073 TerajimaM.CruzJ.CoM. D.LeeJ."/>
   <result pre="J.10:244. 10.1186/1743-422X-10-24423886073 TerajimaM.CruzJ.CoM. D.LeeJ. H.KaurK.WrammertJ.et al.. (2011). Complement-dependent lysis of" exact="influenza" post="a virus-infected cells by broadly cross-reactive human monoclonal antibodies."/>
   <result pre="A.LiuT.YeZ.et al.. (2007). Matrix protein 2 vaccination and protection against" exact="influenza" post="viruses, including subtype H5N1. Emerg. Infect. Dis.13, 426–435. 10.3201/eid1303.06112517552096"/>
   <result pre="V.BlokhinaE. A.PotapchukM. V.KorotkovA. V.et al.. (2015). Development of a candidate" exact="influenza" post="vaccine based on virus-like particles displaying influenza M2e peptide"/>
   <result pre="of a candidate influenza vaccine based on virus-like particles displaying" exact="influenza" post="M2e peptide into the immunodominant region of hepatitis B"/>
   <result pre="particles displaying influenza M2e peptide into the immunodominant region of" exact="hepatitis" post="B core antigen: broad protective efficacy of particles carrying"/>
   <result pre="(2018). Combination of M2e peptide with stalk HA epitopes of" exact="influenza" post="A virus enhances protective properties of recombinant vaccine. PLoS"/>
   <result pre="vaccine. PLoS ONE13:e0201429. 10.1371/journal.pone.020142930138320 UiH.YamayoshiS.UrakiR.KisoM.OishiK.MurakamiS.et al.. (2017). Evaluation of seasonal" exact="influenza" post="vaccines for H1N1pdm09 and type B viruses based on"/>
   <result pre="J.ParkerS. E.RhodesG. H.FelgnerP. L.DwarkiV. J.et al.. (1993). Heterologous protection against" exact="influenza" post="by injection of DNA encoding a viral protein. Science259,"/>
   <result pre="al.. (2013). A novel bivalent vaccine based on a PB2-knockout" exact="influenza" post="virus protects mice from pandemic H1N1 and highly pathogenic"/>
   <result pre="virus-specific CD8+ T-lymphocytes strongly cross-react with viruses of the opposing" exact="influenza" post="B lineage. J. Gen Virol.96, 2061–2073. 10.1099/vir.0.00015625900135 van de"/>
   <result pre="E.et al.. (2014). Human cytotoxic T lymphocytes directed to seasonal" exact="influenza" post="A viruses cross-react with the newly emerging H7N9 virus."/>
   <result pre="J. Virol.88, 1684–1693. 10.1128/JVI.02843-1324257602 VictorS. T.WatanabeS.KatsuraH.OzawaM.KawaokaY. (2012). A replication-incompetent PB2-knockout" exact="influenza" post="A virus vaccine vector. J. Virol.86, 4123–4128. 10.1128/JVI.06232-1122301144 VigilA.EstellesA.KauvarL."/>
   <result pre="(2018). Native human monoclonal antibodies with potent cross-lineage neutralization of" exact="influenza" post="B viruses. Antimicrob. Agents Chemother.62:e02269–e02217. 10.1128/AAC.02269-1729507069 WalzL.KaysS. K.ZimmerG.von MesslingV."/>
   <result pre="MesslingV. (2018). Neuraminidase-inhibiting antibody titers correlate with protection from heterologous" exact="influenza" post="virus strains of the same neuraminidase subtype. J. Virol.92:e01006–e01018."/>
   <result pre="epitopes in seasonal and pandemic H1N1 as well as H5N1" exact="influenza" post="viruses. J. Virol.87, 9290–9300. 10.1128/JVI.01203-1323785204 WangR.SongA.LevinJ.DennisD.ZhangN. J.YoshidaH.et al.. (2008)."/>
   <result pre="(2008). Therapeutic potential of a fully human monoclonal antibody against" exact="influenza" post="A virus M2 protein. Antiviral Res.80, 168–177. 10.1016/j.antiviral.2008.06.00218598723 WangS.RenH.JiangW.ChenH.HuH.ChenZ.et"/>
   <result pre="requirement of Fc-Fcγ receptor interactions for in vivo protection against" exact="influenza" post="viruses by two pan-H5 hemagglutinin antibodies. J. Virol.91, e02065–e02016."/>
   <result pre="M1 proteins as immunogens in DNA- and vaccinia virus-based universal" exact="influenza" post="A virus vaccines in mice. Clin. Vaccine Immunol.22, 618–630."/>
   <result pre="Clin. Vaccine Immunol.22, 618–630. 10.1128/CVI.00091-1525834017 WangY.DengL.KangS. M.WangB. Z. (2018a). Universal" exact="influenza" post="vaccines: from viruses to nanoparticles. Exp. Rev. Vaccines17, 967–976."/>
   <result pre="10.1038/s41467-018-03243-729483513 WeaverE. A.RubrumA. M.WebbyR. J.BarryM. A. (2011). Protection against divergent" exact="influenza" post="H1N1 virus by a centralized influenza hemagglutinin. PLoS ONE6:e18314."/>
   <result pre="(2011). Protection against divergent influenza H1N1 virus by a centralized" exact="influenza" post="hemagglutinin. PLoS ONE6:e18314. 10.1371/journal.pone.001831421464940 WhittleJ. R.ZhangR.KhuranaS.KingL. R.ManischewitzJ.GoldingH.et al.. (2011)."/>
   <result pre="Broadly neutralizing human antibody that recognizes the receptor-binding pocket of" exact="influenza" post="virus hemagglutinin. Proc. Natl. Acad. Sci. U.S.A.108, 14216–14221. 10.1073/pnas.111149710821825125"/>
   <result pre="14216–14221. 10.1073/pnas.111149710821825125 WinarskiK. L.TangJ.KlenowL.LeeJ.CoyleE. M.ManischewitzJ.et al.. (2019). Antibody-dependent enhancement of" exact="influenza" post="disease promoted by increase in hemagglutinin stem flexibility and"/>
   <result pre="Hemagglutinin stalk- and neuraminidase-specific monoclonal antibodies protect against lethal H10N8" exact="influenza" post="virus infection in mice. J. Virol.90, 851–861. 10.1128/JVI.02275-1526512088 WohlboldT."/>
   <result pre="(2014). In the shadow of hemagglutinin: a growing interest in" exact="influenza" post="viral neuraminidase and its role as a vaccine antigen."/>
   <result pre="recombinant neuraminidase induces broad heterologous, but not heterosubtypic, cross-protection against" exact="influenza" post="virus infection in mice. MBio6:e0255610.1128/mBio.02556-1425759506 WohlboldT. J.PodolskyK. A.ChromikovaV.KirkpatrickE.FalconieriV.MeadeP.et al.."/>
   <result pre="J.PodolskyK. A.ChromikovaV.KirkpatrickE.FalconieriV.MeadeP.et al.. (2017). Broadly protective murine monoclonal antibodies against" exact="influenza" post="B virus target highly conserved neuraminidase epitopes. Nat. Microbiol.2,"/>
   <result pre="YangC.SkienaS.FutcherB.MuellerS.WimmerE. (2013). Deliberate reduction of hemagglutinin and neuraminidase expression of" exact="influenza" post="virus leads to an ultraprotective live vaccine in mice."/>
   <result pre="YangX.SteukersL.ForierK.XiongR.BraeckmansK.Van ReethK.et al.. (2014). A beneficiary role for neuraminidase in" exact="influenza" post="virus penetration through the respiratory mucus. PLoS ONE9:e110026. 10.1371/journal.pone.011002625333824"/>
   <result pre="C.McTamneyP. M.WeiC. J.KanekiyoM.KongW. P.et al.. (2015). Hemagglutinin-stem nanoparticles generate heterosubtypic" exact="influenza" post="protection. Nat. Med. 21, 1065–1070. 10.1038/nm.392726301691 ZhangG. G.LiD. X.ZhangH."/>
   <result pre="adjuvant LTB induces T cell dependent, cross-clade protection against H5N1" exact="influenza" post="virus in mice. Vaccine34, 622–629. 10.1016/j.vaccine.2015.12.03926724200 ZhengZ.PaulS. S.MoX.YuanY. A.TanY."/>
   <result pre="J. (2018). The vestigial esterase domain of haemagglutinin of H5N1" exact="avian influenza" post="A virus: antigenicity and contribution to viral pathogenesis. Vaccines6:53."/>
   <result pre="(2018). The vestigial esterase domain of haemagglutinin of H5N1 avian" exact="influenza" post="A virus: antigenicity and contribution to viral pathogenesis. Vaccines6:53."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6797215\results\search\disease\results.xml">
   <result pre="Control A peridomestic Aedes malayensis population in Singapore can transmit" exact="yellow fever" post="virus Aedes malayensis is a competent YFV vector MiotElliott"/>
   <result pre="author and source are credited.pntd.0007783.pdf Abstract The case-fatality rate of" exact="yellow fever" post="virus (YFV) is one of the highest among arthropod-borne"/>
   <result pre="aegypti in Singapore has failed to prevent re-emergence of dengue," exact="chikungunya" post="and Zika viruses in the last two decades, raising"/>
   <result pre="South America. Historically, the Asia-Pacific region has remained free of" exact="yellow fever" post="but the ever increasing influx of travelers puts places"/>
   <result pre="travelers puts places such as Singapore at unprecedented risk of" exact="yellow fever" post="virus introduction. The present study characterized the potential contribution"/>
   <result pre="potential contribution of a mosquito species called Aedes malayensis to" exact="yellow fever" post="virus transmission in Singapore. Aedes malayensis breeds in urban"/>
   <result pre="only was Ae. malayensis able to experimentally acquire and transmit" exact="yellow fever" post="virus, but it was also found to engage in"/>
   <result pre="evidence indicates that Ae. malayensis is a competent vector of" exact="yellow fever" post="virus and should be targeted by mosquito control programs."/>
   <result pre="and its Supporting Information files. Introduction The case-fatality rate of" exact="yellow fever" post="virus (YFV) ranges from 15% to 50% [1] and"/>
   <result pre="arbovirus vector Aedes aegypti [9]. Re-emergence of dengue virus (DENV)," exact="chikungunya" post="virus (CHIKV) and Zika virus in Singapore in the"/>
   <result pre="conferred by other widespread flaviviruses such as DENV and Japanese" exact="encephalitis" post="virus, but it could also reflect relatively fewer opportunities"/>
   <result pre="ColemanPG. Reconstructing historical changes in the force of infection of" exact="dengue fever" post="in Singapore: implications for surveillance and control. Bull World"/>
   <result pre="10HapuarachchiHC, KooC, RajarethinamJ, ChongC-S, LinC, YapG, et al.Epidemic resurgence of" exact="dengue fever" post="in Singapore in 2013–2014: A virological and entomological perspective."/>
   <result pre="Dis. 2017;11: e000566710.1371/journal.pntd.000566728650959 15RodhainF, HannounC, JoussetFX, RavisseP. Isolation of the" exact="yellow fever" post="virus in Paris from 2 imported human cases. Bull"/>
   <result pre="USA. 2013;110: 9072–9077. 10.1073/pnas.130339511023674683 37BarrettAD, MonathTP. Epidemiology and ecology of" exact="yellow fever" post="virus. Adv Virus Res. 2003;61: 291–315. 14714435 38AitkenTH, DownsWG,"/>
   <result pre="291–315. 14714435 38AitkenTH, DownsWG, ShopeRE. Aedes aegypti strain fitness for" exact="yellow fever" post="virus transmission. Am J Trop Med Hyg. 1977;26: 985–989."/>
   <result pre="MillerBR, AmatoGD, LorenzL, et al.Oral infection of Aedes aegypti with" exact="yellow fever" post="virus: geographic variation and genetic considerations. Am J Trop"/>
   <result pre="future distributions of the sylvatic cycles of dengue virus and" exact="yellow fever" post="virus. Infect Genet Evol. 2013;19: 292–311. 10.1016/j.meegid.2013.03.00823523817"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6797548\results\search\disease\results.xml">
   <result pre="does not comply with these terms. Abstract Epidemics of seasonal" exact="influenza" post="caused by H1N1pdm09, H3N2, and type B viruses occur"/>
   <result pre="virus infections are also reported in particular regions. To treat" exact="influenza" post="patients effectively with antivirals, sensitive and broad-reactive influenza rapid"/>
   <result pre="To treat influenza patients effectively with antivirals, sensitive and broad-reactive" exact="influenza" post="rapid diagnostic tests (IRDTs) are required. Here, we tested"/>
   <result pre="we tested the sensitivity of 23 IRDTs during the 2018–2019" exact="influenza" post="season for their ability to detect H1N1pdm09, H3N2, H5N1,"/>
   <result pre="Victoria- and Yamagata-lineage type B viruses. All IRDTs detected all" exact="influenza" post="A and B viruses tested but with different sensitivities."/>
   <result pre="useful for diagnosing patients infected with H5 and H7 viruses." exact="influenza" post="rapid diagnosis test point-of-care testing sensitivity specificity Funding Japan"/>
   <result pre="infection is one of the most prevalent infectious diseases. Seasonal" exact="influenza" post="viruses, including H1N1pdm09, H3N2, and type B viruses, cause"/>
   <result pre="viruses, cause annual epidemics, despite the use of vaccines against" exact="influenza" post="virus. Other subtypes of influenza A virus from other"/>
   <result pre="the use of vaccines against influenza virus. Other subtypes of" exact="influenza" post="A virus from other animal species such as chickens"/>
   <result pre="pigs have caused sporadic human cases. For example, highly pathogenic" exact="influenza" post="virus subtype H5N1 is circulating among poultry in Asian"/>
   <result pre="Kaplan et al., 2016). Since 2013, human infections with the" exact="avian influenza" post="H7N9 virus have been reported (Gao et al., 2013)."/>
   <result pre="et al., 2016). Since 2013, human infections with the avian" exact="influenza" post="H7N9 virus have been reported (Gao et al., 2013)."/>
   <result pre="NA inhibitors and an endonuclease inhibitor. For antiviral drugs against" exact="influenza" post="to be effective, it is important to identify patients"/>
   <result pre="be effective, it is important to identify patients infected with" exact="influenza" post="virus as soon as possible. In particular, NA inhibitors"/>
   <result pre="that are read by the human eye fail to detect" exact="influenza" post="viruses at early timepoints after onset (Watanabe et al.,"/>
   <result pre="are available in 2018–2019 to detect various isolates of seasonal" exact="influenza" post="A and B viruses as well as human and"/>
   <result pre="results is based on the individual manufacturer’s instructions. Viruses The" exact="influenza" post="viruses listed in Table 2 were propagated in MDCK"/>
   <result pre="the sensitivity of 23 IRDTs commercially available in the 2018–2019" exact="influenza" post="season (Table 1). All of the IRDTs tested employed"/>
   <result pre="the IRDTs tested employed an immunochromatographic method to detect seasonal" exact="influenza" post="A and B viruses. Therefore, the sensitivity of the"/>
   <result pre="uses a rat monoclonal antibody against the nucleoprotein (NP) of" exact="influenza" post="A virus, whereas the others use mouse monoclonal antibodies"/>
   <result pre="the others use mouse monoclonal antibodies against the NPs of" exact="influenza" post="A and B viruses. Because the epitopes of these"/>
   <result pre="the epitopes of these monoclonal antibodies on the NP of" exact="influenza" post="A virus are conserved among influenza A viruses, 19"/>
   <result pre="on the NP of influenza A virus are conserved among" exact="influenza" post="A viruses, 19 of the 23 IRDTs (the exceptions"/>
   <result pre="QuickNavi Flu2) claim to be able to detect several animal" exact="influenza" post="A viruses, including subtypes H1 through H16, in their"/>
   <result pre="than those in HA, NP mutations do occur in seasonal" exact="influenza" post="viruses and may affect the sensitivity of IRDTs. The"/>
   <result pre="B/Victoria- and B/Yamagata-lineages but lower or similar sensitivity for seasonal" exact="influenza" post="B viruses compared with that for seasonal influenza A"/>
   <result pre="for seasonal influenza B viruses compared with that for seasonal" exact="influenza" post="A viruses (Table 3). The most sensitive IRDT for"/>
   <result pre="A viruses (Table 3). The most sensitive IRDT for seasonal" exact="influenza" post="A and B viruses was Sofia Influenza A +"/>
   <result pre="+ B FIA. TABLE 3 Sensitivity of IRDTs for seasonal" exact="influenza" post="A and B virusesa. IRDT Minimum virus titer (log10"/>
   <result pre="IRDTs tested in this study showed similar sensitivity for seasonal" exact="influenza" post="A and B viruses as the IRDTs we tested"/>
   <result pre="B FIA showed the best sensitivity to all of the" exact="influenza" post="A and B viruses tested. Of note, the sensitivity"/>
   <result pre="note, the sensitivity of several of the IRDTs for seasonal" exact="influenza" post="viruses differed by 10 times compared with our previous"/>
   <result pre="of the IRDTs to improve their sensitivity to recent seasonal" exact="influenza" post="viruses. Therefore, we need to continue to periodically monitor"/>
   <result pre="of the IRDTs tested here would, in theory, detect these" exact="influenza" post="viruses in patients during this period. However, to detect"/>
   <result pre="influenza viruses in patients during this period. However, to detect" exact="influenza" post="viruses within 24 h of onset, more sensitive IRDTs"/>
   <result pre="viruses at a high sensitivity, identical to that for seasonal" exact="influenza" post="A and B viruses; the detection limit was 101–104"/>
   <result pre="TCID50 per 100 μl, suggesting that this IRDT can diagnose" exact="influenza" post="caused by such viruses. Data Availability Statement The raw"/>
   <result pre="References GaoR.CaoB.HuY.FengZ.WangD.HuW.et al. (2013). Human infection with a novel avian-origin" exact="influenza" post="A (H7N9) virus.N. Engl. J. Med.3681888–1897. 10.1056/NEJMoa130445923577628 HarfootR.WebbyR. J."/>
   <result pre="alpha2,6-linked sialic acid on MDCK cells improves isolation of human" exact="influenza" post="viruses and evaluation of their sensitivity to a neuraminidase"/>
   <result pre="Microbiol.434139–4146. 10.1128/JCM.43.8.4139-4146.200516081961 ImaiM.WatanabeT.KisoM.NakajimaN.YamayoshiS.Iwatsuki-HorimotoK.et al. (2017). A highly pathogenic avian H7N9" exact="influenza" post="virus isolated from a human is lethal in some"/>
   <result pre="J.et al. (2016). Novel highly pathogenic avian A(H5N2) and A(H5N8)" exact="influenza" post="viruses of clade 2.3.4.4 from north america have limited"/>
   <result pre="Pharmacother.3557–70. 10.1345/aph.1011811197587 NunezI. A.RossT. M. (2019). A review of H5Nx" exact="avian influenza" post="viruses.Ther. Adv. Vaccines Immunother.7:2515135518821625. 10.1177/251513551882162530834359 Pulit-PenalozaJ. A.SunX.CreagerH. M.ZengH.BelserJ. A.MainesT."/>
   <result pre="10.1345/aph.1011811197587 NunezI. A.RossT. M. (2019). A review of H5Nx avian" exact="influenza" post="viruses.Ther. Adv. Vaccines Immunother.7:2515135518821625. 10.1177/251513551882162530834359 Pulit-PenalozaJ. A.SunX.CreagerH. M.ZengH.BelserJ. A.MainesT."/>
   <result pre="R.et al. (2015). Pathogenesis and transmission of novel highly pathogenic" exact="avian influenza" post="H5N2 and H5N8 Viruses in Ferrets and Mice.J. Virol.8910286–10293."/>
   <result pre="al. (2015). Pathogenesis and transmission of novel highly pathogenic avian" exact="influenza" post="H5N2 and H5N8 Viruses in Ferrets and Mice.J. Virol.8910286–10293."/>
   <result pre="potential.FEMS Microbiol. Rev.4068–85. 10.1093/femsre/fuv03926385895 Sakai-TagawaY.OzawaM.YamadaS.UchidaY.SaitoT.TakahashiK.et al. (2014). Detection sensitivity of" exact="influenza" post="rapid diagnostic tests.Microbiol. Immunol.58600–606. 10.1111/1348-0421.1218525079880 Sakai-TagawaY.YamayoshiS.KawakamiC.LeM. Q.UchidaY.SaitoT.et al. (2017)."/>
   <result pre="Sakai-TagawaY.YamayoshiS.KawakamiC.LeM. Q.UchidaY.SaitoT.et al. (2017). Reactivity and sensitivity of commercially available" exact="influenza" post="rapid diagnostic tests in Japan.Sci. Rep.7:14483. 10.1038/s41598-017-14536-1453029101372 ShibataA.HionoT.FukuharaH.SumiyoshiR.OhkawaraA.MatsunoK.et al."/>
   <result pre="Japan.Sci. Rep.7:14483. 10.1038/s41598-017-14536-1453029101372 ShibataA.HionoT.FukuharaH.SumiyoshiR.OhkawaraA.MatsunoK.et al. (2018a). Isolation and characterization of" exact="avian influenza" post="viruses from raw poultry products illegally imported to Japan"/>
   <result pre="Rep.7:14483. 10.1038/s41598-017-14536-1453029101372 ShibataA.HionoT.FukuharaH.SumiyoshiR.OhkawaraA.MatsunoK.et al. (2018a). Isolation and characterization of avian" exact="influenza" post="viruses from raw poultry products illegally imported to Japan"/>
   <result pre="Dis.65465–475. 10.1111/tbed.1272629034617 ShibataA.OkamatsuM.SumiyoshiR.MatsunoK.WangZ. J.KidaH.et al. (2018b). Repeated detection of H7N9" exact="avian influenza" post="viruses in raw poultry meat illegally brought to Japan"/>
   <result pre="10.1111/tbed.1272629034617 ShibataA.OkamatsuM.SumiyoshiR.MatsunoK.WangZ. J.KidaH.et al. (2018b). Repeated detection of H7N9 avian" exact="influenza" post="viruses in raw poultry meat illegally brought to Japan"/>
   <result pre="10.1016/j.virol.2018.08.00130138834 UchidaY.MineJ.TakemaeN.TanikawaT.TsunekuniR.SaitoT. (2019). Comparative pathogenicity of H5N6 subtype highly pathogenic" exact="avian influenza" post="viruses in chicken, Pekin duck and Muscovy duck.Transbound Emerg."/>
   <result pre="UchidaY.MineJ.TakemaeN.TanikawaT.TsunekuniR.SaitoT. (2019). Comparative pathogenicity of H5N6 subtype highly pathogenic avian" exact="influenza" post="viruses in chicken, Pekin duck and Muscovy duck.Transbound Emerg."/>
   <result pre="Emerg. Dis.661227–1251. 10.1111/tbed.1314130720248 WatanabeM.NakagawaN.ItoM.IharaT. (2009). Sensitivity of rapid immunoassay for" exact="influenza" post="A and B in the early phase of the"/>
   <result pre="ZhangF.BiY.WangJ.WongG.ShiW.HuF.et al. (2017). Human infections with recently-emerging highly pathogenic H7N9" exact="avian influenza" post="virus in China.J. Infect.7571–75. 10.1016/j.jinf.2017.04.00128390707 ZhuW.ZhouJ.LiZ.YangL.LiX.HuangW.et al. (2017). Biological"/>
   <result pre="al. (2017). Human infections with recently-emerging highly pathogenic H7N9 avian" exact="influenza" post="virus in China.J. Infect.7571–75. 10.1016/j.jinf.2017.04.00128390707 ZhuW.ZhouJ.LiZ.YangL.LiX.HuangW.et al. (2017). Biological"/>
   <result pre="ZhuW.ZhouJ.LiZ.YangL.LiX.HuangW.et al. (2017). Biological characterisation of the emerged highly pathogenic" exact="avian influenza" post="(HPAI) A(H7N9) viruses in humans, in mainland China, 2016"/>
   <result pre="al. (2017). Biological characterisation of the emerged highly pathogenic avian" exact="influenza" post="(HPAI) A(H7N9) viruses in humans, in mainland China, 2016"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6798124\results\search\disease\results.xml">
   <result pre="SC, García-Sastre A, Fernandez-Sesma A. 2019. Innate immune response to" exact="influenza" post="virus at single-cell resolution in human epithelial cells revealed"/>
   <result pre="the virus counteracts this system. Abstract ABSTRACT Early interactions of" exact="influenza" post="A virus (IAV) with respiratory epithelium might determine the"/>
   <result pre="and how the virus counteracts this system. KEYWORDS epithelial cells" exact="influenza" post="innate immunity interferons single cell Funding HHS | National"/>
   <result pre="cells. For infections of A549 cells, infectivity was measured by" exact="influenza" post="virus hemagglutinin (HA) staining and automated imaging using a"/>
   <result pre="DurhamN, Belicha-VillanuevaA, LowenAC, SteelJ, Fernandez-SesmaA2011Effects of receptor binding specificity of" exact="avian influenza" post="virus on the human innate immune response. J Virol85:4421–4431."/>
   <result pre="Belicha-VillanuevaA, LowenAC, SteelJ, Fernandez-SesmaA2011Effects of receptor binding specificity of avian" exact="influenza" post="virus on the human innate immune response. J Virol85:4421–4431."/>
   <result pre="DoyleSE, KotenkoSV, ThanopoulouK, AndreakosE2017Interferon-lambda mediates non-redundant front-line antiviral protection against" exact="influenza" post="virus infection without compromising host fitness. Immunity46:875–890.e6. doi:10.1016/j.immuni.2017.04.025.28514692 16.FoxJM,"/>
   <result pre="TrippRA2015Interferon lambda upregulates IDO1 expression in respiratory epithelial cells after" exact="influenza" post="virus infection. J Interferon Cytokine Res35:554–562. doi:10.1089/jir.2014.0052.25756191 17.KlinkhammerJ, SchnepfD,"/>
   <result pre="17.KlinkhammerJ, SchnepfD, YeL, SchwaderlappM, GadHH, HartmannR, GarcinD, MahlakoivT, StaeheliP2018IFN-lambda prevents" exact="influenza" post="virus spread from the upper airways to the lungs"/>
   <result pre="I-mediated induction of beta interferon by the NS1 protein of" exact="influenza" post="A virus. J Virol81:514–524. doi:10.1128/JVI.01265-06.17079289 19.GackMU, AlbrechtRA, UranoT, InnKS,"/>
   <result pre="GackMU2012Species-specific inhibition of RIG-I ubiquitination and IFN induction by the" exact="influenza" post="A virus NS1 protein. PLoS Pathog8:e1003059. doi:10.1371/journal.ppat.1003059.23209422 21.MinJY, KrugRM2006The"/>
   <result pre="doi:10.1371/journal.ppat.1003059.23209422 21.MinJY, KrugRM2006The primary function of RNA binding by the" exact="influenza" post="A virus NS1 protein in infected cells: inhibiting the"/>
   <result pre="PKR-mediated inhibition of replication. J Virol74:6203–6206. doi:10.1128/jvi.74.13.6203-6206.2000.10846107 23.HatadaE, SaitoS, FukudaR1999Mutant" exact="influenza" post="viruses with a defective NS1 protein cannot block the"/>
   <result pre="infected cells. J Virol73:2425–2433.9971827 24.LuY, WambachM, KatzeMG, KrugRM1995Binding of the" exact="influenza" post="virus NS1 protein to double-stranded RNA inhibits the activation"/>
   <result pre="pre-mRNAs. Mol Cell1:991–1000. doi:10.1016/S1097-2765(00)80099-4.9651582 26.NoahDL, TwuKY, KrugRM2003Cellular antiviral responses against" exact="influenza" post="A virus are countered at the posttranscriptional level by"/>
   <result pre="a cellular target for NS1 protein, a translational activator of" exact="influenza" post="virus. Mol Cell Biol20:6259–6268. doi:10.1128/mcb.20.17.6259-6268.2000.10938102 30.BurguiI, AragonT, OrtinJ, NietoA2003PABP1"/>
   <result pre="Biol20:6259–6268. doi:10.1128/mcb.20.17.6259-6268.2000.10938102 30.BurguiI, AragonT, OrtinJ, NietoA2003PABP1 and eIF4GI associate with" exact="influenza" post="virus NS1 protein in viral mRNA translation initiation complexes."/>
   <result pre="KillipMJ, RandallRE, RussellRJ2010Structural insights into phosphoinositide 3-kinase activation by the" exact="influenza" post="A virus NS1 protein. Proc Natl Acad Sci U"/>
   <result pre="LeeK, Garcia-SastreA, RoederRG, TarakhovskyA2012Suppression of the antiviral response by an" exact="influenza" post="histone mimic. Nature483:428–433. doi:10.1038/nature10892.22419161 36.HartmannBM, AlbrechtRA, ZaslavskyE, NudelmanG, PincasH,"/>
   <result pre="SchotsaertM, Martínez-RomeroC, FenutriaR, IngramJP, RamosI, Fernandez-SesmaA, BalachandranS, García-SastreA, SealfonSC2017Pandemic H1N1" exact="influenza" post="A viruses suppress immunogenic RIPK3-driven dendritic cell death. Nat"/>
   <result pre="Nat Commun8:1931. doi:10.1038/s41467-017-02035-9.29203926 37.VargaZT, RamosI, HaiR, SchmolkeM, Garcia-SastreA, Fernandez-SesmaA, PaleseP2011The" exact="influenza" post="virus protein PB1-F2 inhibits the induction of type I"/>
   <result pre="39.HeatonNS, Leyva-GradoVH, TanGS, EgginkD, HaiR, PaleseP2013In vivo bioluminescent imaging of" exact="influenza" post="A virus infection and characterization of novel cross-protective monoclonal"/>
   <result pre="ManicassamyS, Belicha-VillanuevaA, PisanelliG, PulendranB, García-SastreA2010Analysis of in vivo dynamics of" exact="influenza" post="virus infection in mice using a GFP reporter virus."/>
   <result pre="U S A107:11531–11536. doi:10.1073/pnas.0914994107.20534532 41.AbdoliA, SoleimanjahiH, Tavassoti KheiriM, JamaliA, JamaatiA2013Determining" exact="influenza" post="virus shedding at different time points in Madin-Darby canine"/>
   <result pre="Knowledgebase. Nucleic Acids Res46:D649–D655. doi:10.1093/nar/gkx1132.29145629 43.RussellAB, TrapnellC, BloomJD2018Extreme heterogeneity of" exact="influenza" post="virus infection in single cells. Elife7:e32303. doi:10.7554/eLife.32303.29451492 44.SjaastadLE, FayEJ,"/>
   <result pre="LangloisRA2018Distinct antiviral signatures revealed by the magnitude and round of" exact="influenza" post="virus replication in vivo. Proc Natl Acad Sci U"/>
   <result pre="Peshes-YalozN, ValadarskyL, CohnO, DavidE, FrishbergA, MayoL, BacharachE, AmitI, Gat-ViksI2018Dissection of" exact="influenza" post="infection in vivo by single-cell RNA sequencing. Cell Syst6:679–691.e4."/>
   <result pre="LoA, EfstathiouS, AtkinsJF, FirthAE, TaubenbergerJK, DigardP2012An overlapping protein-coding region in" exact="influenza" post="A virus segment 3 modulates the host response. Science337:199–204."/>
   <result pre="modulates the host response. Science337:199–204. doi:10.1126/science.1222213.22745253 47.LeveneRE, GagliaMM2018Host shutoff in" exact="influenza" post="A virus: many means to an end. Viruses10:475. doi:10.3390/v10090475."/>
   <result pre="ZhuN2011Interleukin-6 expression was regulated by epigenetic mechanisms in response to" exact="influenza" post="virus infection or dsRNA treatment. Mol Immunol48:1001–1008. doi:10.1016/j.molimm.2011.01.003.21353307 50.BrownellJ,"/>
   <result pre="CXCL10 promoter by NF-kappaB and interferon regulatory factor 3 during" exact="hepatitis" post="C virus infection. J Virol88:1582–1590. doi:10.1128/JVI.02007-13.24257594 51.SungPS, HongSH, LeeJ,"/>
   <result pre="51.SungPS, HongSH, LeeJ, ParkSH, YoonSK, ChungWJ, ShinEC2017CXCL10 is produced in" exact="hepatitis" post="A virus-infected cells in an IRF3-dependent but IFN-independent manner."/>
   <result pre="recipient host. Cell Host Microbe16:691–700. doi:10.1016/j.chom.2014.09.020.25456074 54.AlfordRH, KaselJA, GeronePJ, KnightV1966Human" exact="influenza" post="resulting from aerosol inhalation. Proc Soc Exp Biol Med122:800–804."/>
   <result pre="Exp Biol Med122:800–804. doi:10.3181/00379727-122-31255.5918954 55.BaccamP, BeaucheminC, MackenCA, HaydenFG, PerelsonAS2006Kinetics of" exact="influenza" post="A virus infection in humans. J Virol80:7590–7599. doi:10.1128/JVI.01623-05.16840338 56.Sobel"/>
   <result pre="RansierA, StockwellTB, DasSR, GilbertAS, Lambkin-WilliamsR, GinsburgGS, WoodsCW, KoelleK2016Deep sequencing of" exact="influenza" post="A virus from a human challenge study reveals a"/>
   <result pre="Garcia-SastreA2000Activation of interferon regulatory factor 3 is inhibited by the" exact="influenza" post="A virus NS1 protein. J Virol74:7989–7996. doi:10.1128/JVI.74.17.7989-7996.2000.10933707 59.WangX, LiM,"/>
   <result pre="ChantierT, TafforeauL, MangeotP-E, CianciaC, Perrin-CoconL, BartenschlagerR, AndréP, LotteauV2013The interactomes of" exact="influenza" post="virus NS1 and NS2 proteins identify new host factors"/>
   <result pre="LiuHP, ShihSR, WuCC2016Interactome analysis of the NS1 protein encoded by" exact="influenza" post="A H1N1 virus reveals a positive regulatory role of"/>
   <result pre="SealfonSC, KleinsteinSH2015Comparative analysis of anti-viral transcriptomics reveals novel effects of" exact="influenza" post="immune antagonism. BMC Immunol16:46. doi:10.1186/s12865-015-0107-y.26272204 66.KhaperskyyDA, SchmalingS, Larkins-FordJ, McCormickC,"/>
   <result pre="McCormickC, GagliaMM2016Selective degradation of host RNA polymerase II transcripts by" exact="influenza" post="A virus PA-X host shutoff protein. PLoS Pathog12:e1005427. doi:10.1371/journal.ppat.1005427.26849127"/>
   <result pre="MDA5 as a significant contributor to the cellular defense against" exact="influenza" post="A virus. Cell Rep11:1714–1726. doi:10.1016/j.celrep.2015.05.032.26074083 72.PaludanSR2016Innate antiviral defenses independent"/>
   <result pre="doi:10.1126/scisignal.2005728.25670204 80.RussellAB, ElshinaE, KowalskyJR, Te VelthuisAJW, BloomJD2019Single-cell virus sequencing of" exact="influenza" post="infections that trigger innate immunity. J Virol93:e00500-19. doi:10.1128/JVI.00500-19.31068418 81.BaumA,"/>
   <result pre="new interferon gene IFNL4 is associated with impaired clearance of" exact="hepatitis" post="C virus. Nat Genet45:164–171. doi:10.1038/ng.2521.23291588 89.ThomsonSJ, GohFG, BanksH, KrausgruberT,"/>
   <result pre="stem cells. Cell Stem Cell5:515–526. doi:10.1016/j.stem.2009.08.017.19896442 91.Martinez-SobridoL, Garcia-SastreA2010Generation of recombinant" exact="influenza" post="virus from plasmid DNA. J Vis Exp2010:2057. doi:10.3791/2057. 92.TanGS,"/>
   <result pre="monoclonal antibody that targets the fusion domain of group 2" exact="influenza" post="A virus hemagglutinin. J Virol88:13580–13592. doi:10.1128/JVI.02289-14.25210195 93.HartmannBM, MarjanovicN, NudelmanG,"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6798183\results\search\disease\results.xml">
   <result pre="roles of IL-17A in modulating virus infection. transcriptome analysis H1N1" exact="influenza" post="virus human cells IL-17A differential replication fig-count: table-count: equation-count:"/>
   <result pre="is thought to be important for the prevention of severe" exact="influenza" post="symptoms (Yoneyama and Fujita, 2010; Iwasaki and Pillai, 2014;"/>
   <result pre="infections and diseases, although previous studies have primarily focused on" exact="influenza" post="virus infection of mouse models (Xiao et al., 2013;"/>
   <result pre="dendritic cells and natural killer cells 2.72e-05 6/106 Type I" exact="diabetes mellitus" post="signaling 7.59e-05 6/121 293T Differential regulation of cytokine production"/>
   <result pre="cells by IL-17A and IL-17F 2.22e-04 3/23 Airway inflammation in" exact="asthma" post="2.63e-04 2/5 Hepatic cholestasis 3.21e-04 6/177 Agranulocyte adhesion and"/>
   <result pre="IL-17F 2.22e-04 3/23 Airway inflammation in asthma 2.63e-04 2/5 Hepatic" exact="cholestasis" post="3.21e-04 6/177 Agranulocyte adhesion and diapedesis 4.68e-04 6/190 Granulocyte"/>
   <result pre="cells, indicating the boosted cellular response in A549 cells upon" exact="influenza" post="virus infection. FIGURE 3 Verification of DEGs by qRT-PCR."/>
   <result pre="were treated with IL-17A protein and then infected with PR8" exact="influenza" post="virus. With increasing amounts of IL-17A protein, the viral"/>
   <result pre="was employed to further determine the function of IL-17A during" exact="influenza" post="virus infection, and we utilized an IL-17A knock-out mouse"/>
   <result pre="wild-type (WT) mice were infected with 106 TCID50 of PR8" exact="influenza" post="virus and then followed-up for 14 days to evaluate"/>
   <result pre="(Supplementary Figure S2). Furthermore, necropsy examinations also indicated significantly alleviated" exact="pneumonia" post="lesions at 5 and 7 dpi in IL-17A knock-out"/>
   <result pre="WT mice displayed slight pulmonary damage after infection with PR8" exact="influenza" post="virus at 7 dpi, presenting with moderate thickening of"/>
   <result pre="IL-17A knock-out mice displayed decreased virulence after infection with PR8" exact="influenza" post="virus. (A) IL-17A knock-out or WT mice were infected"/>
   <result pre="(A) IL-17A knock-out or WT mice were infected with PR8" exact="influenza" post="virus. Body weights were determined daily for 14 days"/>
   <result pre="&amp;lt; 0.05). Discussion Host defense barriers that prevent transmission of" exact="influenza" post="viruses from one species of animal to another do"/>
   <result pre="The receptor specificity of the hemagglutinin and internal genes of" exact="influenza" post="viruses play roles in host range restriction (Kuiken et"/>
   <result pre="2009). Although numerous studies have documented the roles of various" exact="influenza" post="virus proteins in immune evasion, factors that maintain the"/>
   <result pre="hiding behind the robust interferon response and antiviral response upon" exact="influenza" post="virus infection. In addition, H1N1 IAV-infected 293T cells apparently"/>
   <result pre="to impaired antiviral immune responses, resulting in a more severe" exact="influenza" post="virus infection (Chang et al., 2011). We speculate that"/>
   <result pre="cellular components on lung pathology and the inflammatory response during" exact="influenza" post="virus infection in IL-17A knock-out mice. Materials and Methods"/>
   <result pre="cells (293T), Madin-Darby canine kidney (MDCK) epithelial cells, and human" exact="lung carcinoma" post="(A549) epithelial cells were grown in Dulbecco’s modified Eagle’s"/>
   <result pre="(A) IL-17A knock-out or WT mice were infected with CA04" exact="influenza" post="virus. Body weights were determined daily for 14 days"/>
   <result pre="variation affects resistance to infection with a highly pathogenic H5N1" exact="influenza" post="A virus in mice.J. Virol.8310417–10426. 10.1128/JVI.00514-0919706712 BrandesM.KlauschenF.KuchenS.GermainR. N. (2013)."/>
   <result pre="systems analysis identifies a feedforward inflammatory circuit leading to lethal" exact="influenza" post="infection.Cell154197–212. 10.1016/j.cell.2013.06.01323827683 BrassA. L.HuangI. C.BenitaY.JohnS. P.KrishnanM. N.FeeleyE. M.et al."/>
   <result pre="M.et al. (2009). The IFITM proteins mediate cellular resistance to" exact="influenza" post="A H1N1 virus, West Nile virus, and dengue virus.Cell1391243–1254."/>
   <result pre="10.1016/j.cell.2009.12.01720064371 CalifanoD.FuruyaY.RobertsS.AvramD.McKenzieA. N. J.MetzgerD. W. (2018). IFN-gamma increases susceptibility to" exact="influenza" post="A infection through suppression of group II innate lymphoid"/>
   <result pre="W. (2018). IFN-gamma increases susceptibility to influenza A infection through" exact="suppression" post="of group II innate lymphoid cells.Mucosal. Immunol.11209–219. 10.1038/mi.2017.4128513592 CameronC."/>
   <result pre="Virol.8211308–11317. 10.1128/JVI.00691-0818684821 CaoY.ZhangK.LiuL.LiW.ZhuB.ZhangS.et al. (2019). Global transcriptome analysis of H5N1" exact="influenza" post="virus-infected human cells.Hereditas156:10. 10.1186/s41065-019-0085-930774581 ChakrabartiA. K.VipatV. C.MukherjeeS.SinghR.PawarS. D.MishraA. C."/>
   <result pre="K.VipatV. C.MukherjeeS.SinghR.PawarS. D.MishraA. C. (2010). Host gene expression profiling in" exact="influenza" post="A virus-infected lung epithelial (A549) cells: a comparative analysis"/>
   <result pre="CillonizC.Pantin-JackwoodM. J.NiC.GoodmanA. G.PengX.ProllS. C.et al. (2010). Lethal dissemination of H5N1" exact="influenza" post="virus is associated with dysregulation of inflammation and lipoxin"/>
   <result pre="Strand-specific dual RNA sequencing of bronchial epithelial cells infected with" exact="influenza" post="A/H3N2 viruses reveals splicing of gene segment 6 and"/>
   <result pre="in HA and PB2 critical for the transmission of H5N1" exact="avian influenza" post="viruses in a mammalian host.PLoS Pathog.5:e1000709. 10.1371/journal.ppat.100070920041223 GeissG. K.SalvatoreM.TumpeyT."/>
   <result pre="HA and PB2 critical for the transmission of H5N1 avian" exact="influenza" post="viruses in a mammalian host.PLoS Pathog.5:e1000709. 10.1371/journal.ppat.100070920041223 GeissG. K.SalvatoreM.TumpeyT."/>
   <result pre="K.SalvatoreM.TumpeyT. M.CarterV. S.WangX.BaslerC. F.et al. (2002). Cellular transcriptional profiling in" exact="influenza" post="A virus-infected lung epithelial cells: the role of the"/>
   <result pre="GoJ. T.BelisleS. E.TchitchekN.TumpeyT. M.MaW.RichtJ. A.et al. (2012). 2009 pandemic H1N1" exact="influenza" post="virus elicits similar clinical course but differential host transcriptional"/>
   <result pre="infection models.BMC Genomics13:627. 10.1186/1471-2164-13-62723153050 HartshornK. L. (2013). Why does pandemic" exact="influenza" post="virus kill?Am. J. Pathol.1831125–1127. 10.1016/j.ajpath.2013.06.02023916382 HuangY.LiY.BurtD. W.ChenH.ZhangY.QianW.et al. (2013)."/>
   <result pre="(2013). The duck genome and transcriptome provide insight into an" exact="avian influenza" post="virus reservoir species.Nat. Genet.45776–783. 10.1038/ng.265723749191 IwasakiA.PillaiP. S. (2014). Innate"/>
   <result pre="The duck genome and transcriptome provide insight into an avian" exact="influenza" post="virus reservoir species.Nat. Genet.45776–783. 10.1038/ng.265723749191 IwasakiA.PillaiP. S. (2014). Innate"/>
   <result pre="reservoir species.Nat. Genet.45776–783. 10.1038/ng.265723749191 IwasakiA.PillaiP. S. (2014). Innate immunity to" exact="influenza" post="virus infection.Nat. Rev. Immunol.14315–328. 10.1038/nri366524762827 JinS.LiY.PanR.ZouX. (2014). Characterizing and"/>
   <result pre="10.1038/nri366524762827 JinS.LiY.PanR.ZouX. (2014). Characterizing and controlling the inflammatory network during" exact="influenza" post="A virus infection.Sci. Rep.4:3799. 10.1038/srep0379924445954 JonesM.DryI. R.FramptonD.SinghM.KandaR. K.YeeM. B.et"/>
   <result pre="KuikenT.HolmesE. C.McCauleyJ.RimmelzwaanG. F.WilliamsC. S.GrenfellB. T. (2006). Host species barriers to" exact="influenza" post="virus infections.Science312394–397. 10.1126/science.112281816627737 LeymarieO.JouvionG.HerveP. L.ChevalierC.LorinV.LecardonnelJ.et al. (2013). Kinetic characterization"/>
   <result pre="Kinetic characterization of PB1-F2-mediated immunopathology during highly pathogenic avian H5N1" exact="influenza" post="virus infection.PLoS One8:e57894. 10.1371/journal.pone.005789423469251 LiC.YangP.SunY.LiT.WangC.WangZ.et al. (2012). IL-17 response"/>
   <result pre="response mediates acute lung injury induced by the 2009 pandemic" exact="influenza" post="A (H1N1) virus.Cell Res.22528–538. 10.1038/cr.2011.16522025253 NeteaM. G.LatzE.MillsK. H.O’NeillL. A."/>
   <result pre="D. (2014). The immune response and within-host emergence of pandemic" exact="influenza" post="virus.Lancet3842077–2081. 10.1016/S0140-6736(13)62425-324767965 RussellA. B.TrapnellC.BloomJ. D. (2018). Extreme heterogeneity of"/>
   <result pre="influenza virus.Lancet3842077–2081. 10.1016/S0140-6736(13)62425-324767965 RussellA. B.TrapnellC.BloomJ. D. (2018). Extreme heterogeneity of" exact="influenza" post="virus infection in single cells.eLife7:e32303. 10.7554/eLife.3230329451492 ShinyaK.GaoY.CillonizC.SuzukiY.FujieM.DengG.et al. (2012)."/>
   <result pre="(2012). Integrated clinical, pathologic, virologic, and transcriptomic analysis of H5N1" exact="influenza" post="virus-induced viral pneumonia in the rhesus macaque.J. Virol.866055–6066. 10.1128/JVI.00365-1222491448"/>
   <result pre="clinical, pathologic, virologic, and transcriptomic analysis of H5N1 influenza virus-induced" exact="viral pneumonia" post="in the rhesus macaque.J. Virol.866055–6066. 10.1128/JVI.00365-1222491448 TaubenbergerJ. K.MorensD. M."/>
   <result pre="pathologic, virologic, and transcriptomic analysis of H5N1 influenza virus-induced viral" exact="pneumonia" post="in the rhesus macaque.J. Virol.866055–6066. 10.1128/JVI.00365-1222491448 TaubenbergerJ. K.MorensD. M."/>
   <result pre="Mapping the innate signaling cascade essential for cytokine storm during" exact="influenza" post="virus infection.Proc. Natl. Acad. Sci. U.S.A.1113799–3804. 10.1073/pnas.140059311124572573 TempertonN. J.HoschlerK.MajorD.NicolsonC.ManvellR.HienV."/>
   <result pre="J.HoschlerK.MajorD.NicolsonC.ManvellR.HienV. M.et al. (2007). A sensitive retroviral pseudotype assay for" exact="influenza" post="H5N1-neutralizing antibodies.Influenza Other Respir. Viruses1105–112. 10.1111/j.1750-2659.2007.00016.x19453415 TisoncikJ. R.KorthM. J.SimmonsC."/>
   <result pre="role of IL-17 in modulating the B-cell response during H5N1" exact="influenza" post="virus infection.Cell. Mol. Immunol.8462–468. 10.1038/cmi.2011.3821946434 WangX.MaK.ChenM.KoK. H.ZhengB. J.LuL. (2016)."/>
   <result pre="pulmonary B-1a cell differentiation via induction of Blimp-1 expression during" exact="influenza" post="virus infection.PLoS Pathog.12:e1005367. 10.1371/journal.ppat.100536726735852 WangY.LupianiB.ReddyS. M.LamontS. J.ZhouH. (2014). RNA-seq"/>
   <result pre="novel genes and signaling pathway associated with disease resistance to" exact="avian influenza" post="virus infection in chickens.Poult. Sci.93485–493. 10.3382/ps.2013-0355724570473 WilkinsC.GaleM.Jr. (2010). Recognition"/>
   <result pre="genes and signaling pathway associated with disease resistance to avian" exact="influenza" post="virus infection in chickens.Poult. Sci.93485–493. 10.3382/ps.2013-0355724570473 WilkinsC.GaleM.Jr. (2010). Recognition"/>
   <result pre="immunity.J. Immunol.1812303–2310. 10.4049/jimmunol.181.4.230318684919 WuS.MetcalfJ. P.WuW. (2011). Innate immune response to" exact="influenza" post="virus.Curr. Opin. Infect. Dis.24235–240. 10.1097/QCO.0b013e328344c0e321330918 XiaoY. L.KashJ. C.BeresS. B.ShengZ."/>
   <result pre="a formalin-fixed, paraffin-embedded autopsy lung tissue sample from the 1918" exact="influenza" post="pandemic.J. Pathol.229535–545. 10.1002/path.414523180419 XueC.WenM.BaoL.LiH.LiF.LiuM.et al. (2017). Vgamma4(+)gammadeltaT cells aggravate"/>
   <result pre="Pathol.229535–545. 10.1002/path.414523180419 XueC.WenM.BaoL.LiH.LiF.LiuM.et al. (2017). Vgamma4(+)gammadeltaT cells aggravate severe H1N1" exact="influenza" post="virus infection-induced acute pulmonary immunopathological injury via secreting interleukin-17A.Front."/>
   <result pre="PB2 contribute to efficient transmission of the 2009 H1N1 pandemic" exact="influenza" post="virus.J. Virol.869666–9674. 10.1128/JVI.00958-1222740390 ZhouB.LiJ.LiangX.YangZ.JiangZ. (2017). Transcriptome profiling of influenza"/>
   <result pre="pandemic influenza virus.J. Virol.869666–9674. 10.1128/JVI.00958-1222740390 ZhouB.LiJ.LiangX.YangZ.JiangZ. (2017). Transcriptome profiling of" exact="influenza" post="A virus-infected lung epithelial (A549) cells with lariciresinol-4-beta-D-glucopyranoside treatment.PLoS"/>
   <result pre="Insights into the increasing virulence of the swine-origin pandemic H1N1/2009" exact="influenza" post="virus.Sci. Rep.3:1601. 10.1038/srep0160123549303"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6798416\results\search\disease\results.xml">
   <result pre="one of the common causative pathogens for hand foot and" exact="mouth disease" post="(HFMD) affecting young children. HFMD outbreak can result in"/>
   <result pre="has been recognized as the most common pathogen of the" exact="hand, foot, and mouth disease" post="(HFMD), which is highly contagious and frequently affects young"/>
   <result pre="as the most common pathogen of the hand, foot, and" exact="mouth disease" post="(HFMD), which is highly contagious and frequently affects young"/>
   <result pre="can also occasionally cause serious neuropathology and cardiopulmonary complications, including" exact="aseptic meningitis," post="acute flaccid paralysis, brainstem encephalitis, and fatal myocarditis and"/>
   <result pre="including aseptic meningitis, acute flaccid paralysis, brainstem encephalitis, and fatal" exact="myocarditis" post="and pulmonary edema [1, 2]. EV-A71 is a member"/>
   <result pre="meningitis, acute flaccid paralysis, brainstem encephalitis, and fatal myocarditis and" exact="pulmonary edema" post="[1, 2]. EV-A71 is a member of the genus"/>
   <result pre="factor that interacts with EV-A71 during viral entry into human" exact="rhabdomyosarcoma" post="(RD) cells [10]. The fifth attachment receptor is heparan"/>
   <result pre="EV-A71 was first isolated from the feces of a female" exact="encephalitis" post="patient in 1969 in California [14]. A retrospective analysis"/>
   <result pre="the first half of 2012, including 56 deaths with severe" exact="encephalitis" post="(Fig. 1). A high case-fatality rate of EV-A71 infection"/>
   <result pre="there were 2628 HFMD cases, including 29 deaths due to" exact="encephalitis" post="and cardiac failure (Fig. 1) [59]. During this period,"/>
   <result pre="and cardiac failure (Fig. 1) [59]. During this period, such" exact="encephalomyelitis" post="associated with neurogenic pulmonary edema caused by EV-A71 infection"/>
   <result pre="1) [59]. During this period, such encephalomyelitis associated with neurogenic" exact="pulmonary edema" post="caused by EV-A71 infection in Kuala Lumpur were implicated"/>
   <result pre="and in 1981 [70]. Since then, occurrence of HFMD and" exact="aseptic meningitis" post="associated with EV-A71 was reported in 1987 [16]. The"/>
   <result pre="in 1981 [70]. Since then, occurrence of HFMD and aseptic" exact="meningitis" post="associated with EV-A71 was reported in 1987 [16]. The"/>
   <result pre="For example, two children diagnosed with HFMD presented with brainstem" exact="encephalitis" post="and cardiopulmonary failure [83, 84]. In addition, three HFMD"/>
   <result pre="cardiopulmonary failure [83, 84]. In addition, three HFMD patients had" exact="encephalomyelitis" post="[85]. In 2012, HFMD outbreak again reemerged in Taiwan"/>
   <result pre="India, respectively [104–106]. Genotype A was last isolated from an" exact="encephalitis" post="case 50 years ago [14], no representative virus had been"/>
   <result pre="EV-A Enterovirus A EV-A71 Enterovirus A71 HFMD Hand foot and" exact="mouth disease" post="ORF Open reading frame PSGL-1 Human P-selectin glycoprotein ligand-1"/>
   <result pre="Biol Med1975148120320710.3181/00379727-148-38506165523 19.BlombergJLyckeEAhlforsKJohnssonTWolontisSvon ZeipelGNew enterovirus type associated with epidemic of" exact="aseptic meningitis" post="and/or hand, foot, and mouth diseaseLancet.1974211210.1016/S0140-6736(74)91684-54136956 20.ChumakovMVoroshilovaMShindarovLLavrovaIGrachevaLKorolevaGet al.Enterovirus 71"/>
   <result pre="Med1975148120320710.3181/00379727-148-38506165523 19.BlombergJLyckeEAhlforsKJohnssonTWolontisSvon ZeipelGNew enterovirus type associated with epidemic of aseptic" exact="meningitis" post="and/or hand, foot, and mouth diseaseLancet.1974211210.1016/S0140-6736(74)91684-54136956 20.ChumakovMVoroshilovaMShindarovLLavrovaIGrachevaLKorolevaGet al.Enterovirus 71"/>
   <result pre="OrganizationA guide to clinical management and public health response for" exact="hand, foot and mouth disease" post="(HFMD)2011 29.ShekharKLyeMSNorlijahOOngFLooiLMKhuzaiahRet al.Deaths in children during an outbreak of"/>
   <result pre="clinical management and public health response for hand, foot and" exact="mouth disease" post="(HFMD)2011 29.ShekharKLyeMSNorlijahOOngFLooiLMKhuzaiahRet al.Deaths in children during an outbreak of"/>
   <result pre="disease (HFMD)2011 29.ShekharKLyeMSNorlijahOOngFLooiLMKhuzaiahRet al.Deaths in children during an outbreak of" exact="hand, foot and mouth disease" post="in Peninsular Malaysia--clinical and pathological characteristicsMed J Malaysia200560329730416379183 30.HoMChenERHsuKHTwuSJChenKTTsaiSFet"/>
   <result pre="al.Deaths in children during an outbreak of hand, foot and" exact="mouth disease" post="in Peninsular Malaysia--clinical and pathological characteristicsMed J Malaysia200560329730416379183 30.HoMChenERHsuKHTwuSJChenKTTsaiSFet"/>
   <result pre="Epidemic Working GroupN Engl J Med19993411392993510.1056/NEJM19990923341130110498487 31.ChangLYLeeCYKaoCLFangTYLuCYLeePIet al.Hand, foot and" exact="mouth disease" post="complicated with central nervous system involvement in Taiwan in"/>
   <result pre="system involvement in Taiwan in 1980-1981J Formos Med Assoc2007106217317610.1016/S0929-6646(09)60236-917339164 32.ChanKPGohKTChongCYTeoESLauGLingAEEpidemic" exact="hand, foot and mouth disease" post="caused by human enterovirus 71, SingaporeEmerg Infect Dis.200391788510.3201/eid1301.02011212533285 33.LinTYChangLYHsiaSHHuangYCChiuCHHsuehCet"/>
   <result pre="Taiwan in 1980-1981J Formos Med Assoc2007106217317610.1016/S0929-6646(09)60236-917339164 32.ChanKPGohKTChongCYTeoESLauGLingAEEpidemic hand, foot and" exact="mouth disease" post="caused by human enterovirus 71, SingaporeEmerg Infect Dis.200391788510.3201/eid1301.02011212533285 33.LinTYChangLYHsiaSHHuangYCChiuCHHsuehCet"/>
   <result pre="71 responsible for the 2008 outbreak of hand foot and" exact="mouth disease" post="in Fuyang city of ChinaVirol J201079410.1186/1743-422X-7-9420459851 37.KennettMLBirchCJLewisFAYungAPLocarniniSAGustIDEnterovirus type 71"/>
   <result pre="decades in an Australian urban communityArch Virol200615151003101310.1007/s00705-005-0684-916369861 40.NolanMACraigMELahraMMRawlinsonWDPragerPCWilliamsGDet al.Survival after" exact="pulmonary edema" post="due to enterovirus 71 encephalitisNeurology.200360101651165610.1212/01.WNL.0000066810.62490.FF12771257 41.ZanderABrittonPNNavinTHorsleyETobinSMcAnultyJMAn outbreak of enterovirus"/>
   <result pre="enterovirus 71 at the origin of an epidemic of fatal" exact="hand, foot and mouth disease" post="cases in CambodiaEmerg Microbes Infect201659e10427651091 45.LeeMSTsengFCWangJRChiCYChongPSuIJChallenges to licensure of"/>
   <result pre="the origin of an epidemic of fatal hand, foot and" exact="mouth disease" post="cases in CambodiaEmerg Microbes Infect201659e10427651091 45.LeeMSTsengFCWangJRChiCYChongPSuIJChallenges to licensure of"/>
   <result pre="enterovirus 71 vaccinesPLoS Negl Trop Dis201268e173710.1371/journal.pntd.000173722953003 46.XingWLiaoQViboudCZhangJSunJWuJTet al.Hand, foot, and" exact="mouth disease" post="in China, 2008-12: an epidemiological studyLancet Infect Dis201414430831810.1016/S1473-3099(13)70342-624485991 47.Huang"/>
   <result pre="Wu P, Chang Z, Huang J, et al. Epidemiology of" exact="hand, foot and mouth disease" post="in China, 2008 to 2015 prior to the introduction"/>
   <result pre="Z, Huang J, et al. Epidemiology of hand, foot and" exact="mouth disease" post="in China, 2008 to 2015 prior to the introduction"/>
   <result pre="the introduction of EV-A71 vaccine. Euro Surveill. 2017;22(50):1-10. 49.IshimaruYNakanoSYamaokaKTakamiSOutbreaks of" exact="hand, foot, and mouth disease" post="by enterovirus 71. High incidence of complication disorders of"/>
   <result pre="EV-A71 vaccine. Euro Surveill. 2017;22(50):1-10. 49.IshimaruYNakanoSYamaokaKTakamiSOutbreaks of hand, foot, and" exact="mouth disease" post="by enterovirus 71. High incidence of complication disorders of"/>
   <result pre="1973 in the city of MatsueMicrobiol Immunol19772120721710.1111/j.1348-0421.1977.tb00282.x875762 51.TaniguchiKHashimotoSKawadoMMurakamiYIzumidaMOhtaAet al.Overview of" exact="infectious disease" post="surveillance system in Japan, 1999-2005J Epidemiol200717SupplS31310.2188/jea.17.S318239339 52.Infectious Agent Surveillance"/>
   <result pre="Japan, 1999-2005J Epidemiol200717SupplS31310.2188/jea.17.S318239339 52.Infectious Agent Surveillance Report. Hand, foot and" exact="mouth disease" post="in Japan, 2002-2011. https://www.niid.go.jp/niid/en/component/content/article/865-iasr/1735-tpc385.html. Accessed 12 May 2019. 53.Infectious"/>
   <result pre="12 May 2019. 53.Infectious Agent Surveillance Report. Hand, foot, and" exact="mouth disease" post="and herpangina, 2007 to September 2017 (week 38), Japan."/>
   <result pre="https:// www.niid.go.jp/niid/en/iasr-vol38-e/865-iasr/7617-452te.html. Accessed 12 May 2019. 54.FujimotoTIizukaSEnomotoMAbeKYamashitaKHanaokaNet al.Hand, foot, and" exact="mouth disease" post="caused by coxsackievirus A6, Japan, 2011Emerg Infect Dis201218233733910.3201/eid1802.11114722304983 55.Infectious"/>
   <result pre="2011Emerg Infect Dis201218233733910.3201/eid1802.11114722304983 55.Infectious Agent Surveillance Report. Hand, foot, and" exact="mouth disease" post="and herpangina, 2009 to October 2018 (week 41), Japan."/>
   <result pre="https://www.who.int/westernpacific/emergencies/surveillance/archives/hand-foot-and-mouth-disease. Accessed 13 May 2019. 57.collab: World Health OrganizationOutbreak of" exact="hand, foot and mouth disease" post="in Sarawak. Cluster of deaths among infants and young"/>
   <result pre="May 2019. 57.collab: World Health OrganizationOutbreak of hand, foot and" exact="mouth disease" post="in Sarawak. Cluster of deaths among infants and young"/>
   <result pre="J Malaysia2002571889114569723 59.ChanLGParasharUDLyeMSOngFGZakiSRAlexanderJPet al.Deaths of children during an outbreak of" exact="hand, foot, and mouth disease" post="in sarawak, malaysia: clinical and pathological characteristics of the"/>
   <result pre="al.Deaths of children during an outbreak of hand, foot, and" exact="mouth disease" post="in sarawak, malaysia: clinical and pathological characteristics of the"/>
   <result pre="subgenus B adenovirus during a fatal outbreak of enterovirus 71-associated" exact="hand, foot, and mouth disease" post="in Sibu, SarawakLancet1999354918398799110.1016/S0140-6736(98)11032-210501361 63.PodinYGiasELOngFLeongYWYeeSFYusofMAet al.Sentinel surveillance for human enterovirus"/>
   <result pre="during a fatal outbreak of enterovirus 71-associated hand, foot, and" exact="mouth disease" post="in Sibu, SarawakLancet1999354918398799110.1016/S0140-6736(98)11032-210501361 63.PodinYGiasELOngFLeongYWYeeSFYusofMAet al.Sentinel surveillance for human enterovirus"/>
   <result pre="64.ChuaKBChuaBHLeeCSChemYKIsmailNKiyuAet al.Genetic diversity of enterovirus 71 isolated from cases of" exact="hand, foot and mouth disease" post="in the 1997, 2000 and 2005 outbreaks, Peninsular MalaysiaMalays"/>
   <result pre="of enterovirus 71 isolated from cases of hand, foot and" exact="mouth disease" post="in the 1997, 2000 and 2005 outbreaks, Peninsular MalaysiaMalays"/>
   <result pre="predictors for the risk of neurological involvement in children with" exact="hand, foot, and mouth disease" post="in SarawakBMC Infect Dis20099310.1186/1471-2334-9-319152683 66.International Society for Infectious Diseases."/>
   <result pre="risk of neurological involvement in children with hand, foot, and" exact="mouth disease" post="in SarawakBMC Infect Dis20099310.1186/1471-2334-9-319152683 66.International Society for Infectious Diseases."/>
   <result pre="Enterovirus A71 in MalaysiaPLoS Negl Trop Dis2016103e000456210.1371/journal.pntd.000456227010319 68.ChuaKBKasriARHand foot and" exact="mouth disease" post="due to enterovirus 71 in MalaysiaVirol Sin201126422122810.1007/s12250-011-3195-821847753 69.TayCHGawCYNLowTOngCChiaKWYeoHet al.Outbreak"/>
   <result pre="due to enterovirus 71 in MalaysiaVirol Sin201126422122810.1007/s12250-011-3195-821847753 69.TayCHGawCYNLowTOngCChiaKWYeoHet al.Outbreak of" exact="hand, foot and mouth disease" post="in SingaporeSingap Med J197415174183 70.GohKTDoraisinghamSTanJLLimGNChewSEAn outbreak of hand, foot,"/>
   <result pre="71 in MalaysiaVirol Sin201126422122810.1007/s12250-011-3195-821847753 69.TayCHGawCYNLowTOngCChiaKWYeoHet al.Outbreak of hand, foot and" exact="mouth disease" post="in SingaporeSingap Med J197415174183 70.GohKTDoraisinghamSTanJLLimGNChewSEAn outbreak of hand, foot,"/>
   <result pre="and mouth disease in SingaporeSingap Med J197415174183 70.GohKTDoraisinghamSTanJLLimGNChewSEAn outbreak of" exact="hand, foot, and mouth disease" post="in SingaporeBull World Health Organ19826069659696297819 71.AngLWKohBKChanKPChuaLTJamesLGohKTEpidemiology and control of"/>
   <result pre="in SingaporeSingap Med J197415174183 70.GohKTDoraisinghamSTanJLLimGNChewSEAn outbreak of hand, foot, and" exact="mouth disease" post="in SingaporeBull World Health Organ19826069659696297819 71.AngLWKohBKChanKPChuaLTJamesLGohKTEpidemiology and control of"/>
   <result pre="disease in SingaporeBull World Health Organ19826069659696297819 71.AngLWKohBKChanKPChuaLTJamesLGohKTEpidemiology and control of" exact="hand, foot and mouth disease" post="in Singapore, 2001-2007Ann Acad Med Singap200938210611219271036 72.WuYYeoAPhoonMCTanELPohCLQuakSHet al.The largest"/>
   <result pre="World Health Organ19826069659696297819 71.AngLWKohBKChanKPChuaLTJamesLGohKTEpidemiology and control of hand, foot and" exact="mouth disease" post="in Singapore, 2001-2007Ann Acad Med Singap200938210611219271036 72.WuYYeoAPhoonMCTanELPohCLQuakSHet al.The largest"/>
   <result pre="Med Singap200938210611219271036 72.WuYYeoAPhoonMCTanELPohCLQuakSHet al.The largest outbreak of hand; foot and" exact="mouth disease" post="in Singapore in 2008: the role of enterovirus 71"/>
   <result pre="71, Taiwan, 2008Virol J2010727710.1186/1743-422X-7-27720959020 89.ChenKTChangHLWangSTChengYTYangJYEpidemiologic features of hand-foot-mouth disease and" exact="herpangina" post="caused by enterovirus 71 in Taiwan, 1998-2005Pediatrics.20071202e244e25210.1542/peds.2006-333117671037 90.ChangHLChioCPSuHJLiaoCMLinCYShauWYet al.The"/>
   <result pre="Thai). http://www.boe.moph.go.th/boedb/surdata/disease.php?dcontent=old&amp;amp;ds=71. Accessed 18 March 2019. 92.PuenpaJChieochansinTLinsuwanonPKorkongSThongkomplewSVichaiwattanaPet al.Hand, foot, and" exact="mouth disease" post="caused by coxsackievirus A6, Thailand, 2012Emerg Infect Dis201319464164310.3201/eid1904.12166623631943 93.PuenpaJMauleekoonphairojJLinsuwanonPSuwannakarnKChieochansinTKorkongSet"/>
   <result pre="characterization of enterovirus infections among pediatric patients with hand foot" exact="mouth disease," post="herpangina and influenza like illness in Thailand, 2012PLoS One201496e9888810.1371/journal.pone.009888824887237"/>
   <result pre="enterovirus infections among pediatric patients with hand foot mouth disease," exact="herpangina" post="and influenza like illness in Thailand, 2012PLoS One201496e9888810.1371/journal.pone.009888824887237 94.PuenpaJAuphimaiCKorkongSVongpunsawadSPoovorawanYEnterovirus"/>
   <result pre="among pediatric patients with hand foot mouth disease, herpangina and" exact="influenza" post="like illness in Thailand, 2012PLoS One201496e9888810.1371/journal.pone.009888824887237 94.PuenpaJAuphimaiCKorkongSVongpunsawadSPoovorawanYEnterovirus A71 Infection,"/>
   <result pre="of human enterovirus 71 and coxsackievirus A16 from children with" exact="hand, foot and mouth disease" post="in Thailand during 2008-2011Arch Virol2011156112007201310.1007/s00705-011-1098-521898187 96.LinsuwanonPPuenpaJHuangSWWangYFMauleekoonphairojJWangJRet al.Epidemiology and seroepidemiology"/>
   <result pre="71 and coxsackievirus A16 from children with hand, foot and" exact="mouth disease" post="in Thailand during 2008-2011Arch Virol2011156112007201310.1007/s00705-011-1098-521898187 96.LinsuwanonPPuenpaJHuangSWWangYFMauleekoonphairojJWangJRet al.Epidemiology and seroepidemiology"/>
   <result pre="Thai populationsJ Biomed Sci2014211610.1186/1423-0127-21-1624548776 97.UpalaPApidechkulTSuttanaWKullawongNTamornparkRIntaCMolecular epidemiology and clinical features of" exact="hand, foot and mouth disease" post="in northern Thailand in 2016: a prospective cohort studyBMC"/>
   <result pre="Sci2014211610.1186/1423-0127-21-1624548776 97.UpalaPApidechkulTSuttanaWKullawongNTamornparkRIntaCMolecular epidemiology and clinical features of hand, foot and" exact="mouth disease" post="in northern Thailand in 2016: a prospective cohort studyBMC"/>
   <result pre="studyBMC Infect Dis201818163010.1186/s12879-018-3560-430522440 98.Van TuPThaoNTTPereraDTruongKHTienNTKThuongTCet al.Epidemiologic and virologic investigation of" exact="hand, foot, and mouth disease," post="southern Vietnam, 2005Emerg Infect Dis200713111733174110.3201/eid1311.07063218217559 99.KhanhTHSabanathanSThanhTTle PKTThuongTCHangVet al.Enterovirus 71-associated"/>
   <result pre="98.Van TuPThaoNTTPereraDTruongKHTienNTKThuongTCet al.Epidemiologic and virologic investigation of hand, foot, and" exact="mouth disease," post="southern Vietnam, 2005Emerg Infect Dis200713111733174110.3201/eid1311.07063218217559 99.KhanhTHSabanathanSThanhTTle PKTThuongTCHangVet al.Enterovirus 71-associated"/>
   <result pre="disease, southern Vietnam, 2005Emerg Infect Dis200713111733174110.3201/eid1311.07063218217559 99.KhanhTHSabanathanSThanhTTle PKTThuongTCHangVet al.Enterovirus 71-associated" exact="hand, foot, and mouth disease," post="Southern Vietnam, 2011Emerg Infect Dis201218122002200510.3201/eid1812.12092923194699 100.HoangMTVNguyenTATranTTVuTTHLeNTNNguyenTHNet al.Clinical and aetiological"/>
   <result pre="2005Emerg Infect Dis200713111733174110.3201/eid1311.07063218217559 99.KhanhTHSabanathanSThanhTTle PKTThuongTCHangVet al.Enterovirus 71-associated hand, foot, and" exact="mouth disease," post="Southern Vietnam, 2011Emerg Infect Dis201218122002200510.3201/eid1812.12092923194699 100.HoangMTVNguyenTATranTTVuTTHLeNTNNguyenTHNet al.Clinical and aetiological"/>
   <result pre="Vietnam, 2011Emerg Infect Dis201218122002200510.3201/eid1812.12092923194699 100.HoangMTVNguyenTATranTTVuTTHLeNTNNguyenTHNet al.Clinical and aetiological study of" exact="hand, foot and mouth disease" post="in southern Vietnam, 2013-2015: Inpatients and outpatientsInt J Infect"/>
   <result pre="Dis201218122002200510.3201/eid1812.12092923194699 100.HoangMTVNguyenTATranTTVuTTHLeNTNNguyenTHNet al.Clinical and aetiological study of hand, foot and" exact="mouth disease" post="in southern Vietnam, 2013-2015: Inpatients and outpatientsInt J Infect"/>
   <result pre="Ny NTH, Thanh TT, et al. Severe enterovirus A71 associated" exact="hand, foot and mouth disease," post="Vietnam, 2018: preliminary report of an impending outbreak. Euro"/>
   <result pre="TT, et al. Severe enterovirus A71 associated hand, foot and" exact="mouth disease," post="Vietnam, 2018: preliminary report of an impending outbreak. Euro"/>
   <result pre="of China in 2008J Clin Microbiol20094772351235210.1128/JCM.00563-0919439545 111.ZhangYTanXJWangHYYanDMZhuSLWangDYet al.An outbreak of" exact="hand, foot, and mouth disease" post="associated with subgenotype C4 of human enterovirus 71 in"/>
   <result pre="2008J Clin Microbiol20094772351235210.1128/JCM.00563-0919439545 111.ZhangYTanXJWangHYYanDMZhuSLWangDYet al.An outbreak of hand, foot, and" exact="mouth disease" post="associated with subgenotype C4 of human enterovirus 71 in"/>
   <result pre="study on enterovirus A71 and coxsackievirus A16 genotype/subgenotype replacements in" exact="hand, foot and mouth disease" post="patients in Thailand, 2000-2017Int J Infect Dis201980849110.1016/j.ijid.2018.12.02030639624 116.ChatproedpraiSTheanboonlersAKorkongSThongmeeCWananukulSPoovorawanYClinical and"/>
   <result pre="A71 and coxsackievirus A16 genotype/subgenotype replacements in hand, foot and" exact="mouth disease" post="patients in Thailand, 2000-2017Int J Infect Dis201980849110.1016/j.ijid.2018.12.02030639624 116.ChatproedpraiSTheanboonlersAKorkongSThongmeeCWananukulSPoovorawanYClinical and"/>
   <result pre="118.WiyatnoAHartoyoEJayaUAMa'roefCNMyintKSGillisAet al.Detection and genetic characterization of human enteroviurs A71 from" exact="hand, foot and mouth disease" post="cases in Banjarmasin, IndonesiaSoutheast Asian J Trop Med Public"/>
   <result pre="genetic characterization of human enteroviurs A71 from hand, foot and" exact="mouth disease" post="cases in Banjarmasin, IndonesiaSoutheast Asian J Trop Med Public"/>
   <result pre="of enterovirus A71 and coxsackievirus A16 from hand foot and" exact="mouth disease" post="patients in the Lao PDRNew Microbes New Infect20142617017210.1002/nmi2.6325566395 120.ZhangYNanLJWuGSTanXJXuDDGuSYet"/>
   <result pre="120.ZhangYNanLJWuGSTanXJXuDDGuSYet al.The epidemiologic and virological analysis of an outbreak of" exact="hand, foot, and mouth disease" post="in Inner Mongolia in 2007Bing Du Xue Bao200925315916519634756 121.TianXLZhangYYanSHMaXEWangWRThe"/>
   <result pre="and virological analysis of an outbreak of hand, foot, and" exact="mouth disease" post="in Inner Mongolia in 2007Bing Du Xue Bao200925315916519634756 121.TianXLZhangYYanSHMaXEWangWRThe"/>
   <result pre="Mongolia in 2007Bing Du Xue Bao200925315916519634756 121.TianXLZhangYYanSHMaXEWangWRThe pathogenic spectrum of" exact="hand, foot and mouth disease" post="and molecular characterizations of human enterovirus 71 in Inner"/>
   <result pre="Du Xue Bao200925315916519634756 121.TianXLZhangYYanSHMaXEWangWRThe pathogenic spectrum of hand, foot and" exact="mouth disease" post="and molecular characterizations of human enterovirus 71 in Inner"/>
   <result pre="genome sequence analysis of enterovirus 71 isolated from children with" exact="hand, foot, and mouth disease" post="in Thailand, 2012-2014Virus Genes201551229029310.1007/s11262-015-1239-026303899 124.NoisumdaengPSangsiriwutKPrasertsoponJKlinmalaiCPayungpornSMungaomklangAet al.Complete genome analysis demonstrates"/>
   <result pre="of enterovirus 71 isolated from children with hand, foot, and" exact="mouth disease" post="in Thailand, 2012-2014Virus Genes201551229029310.1007/s11262-015-1239-026303899 124.NoisumdaengPSangsiriwutKPrasertsoponJKlinmalaiCPayungpornSMungaomklangAet al.Complete genome analysis demonstrates"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6800501\results\search\disease\results.xml">
   <result pre="Science1021-77701423-0127BioMed CentralLondon pmcid: 6800501572 doi: 10.1186/s12929-019-0572-3 : Review M2e-based universal" exact="influenza" post="vaccines: a historical overview and new approaches to development"/>
   <result pre="made available in this article, unless otherwise stated. Abstract The" exact="influenza" post="A virus was isolated for the first time in"/>
   <result pre="virus began soon afterwards. In addition to causing seasonal epidemics," exact="influenza" post="viruses can cause pandemics at random intervals, which are"/>
   <result pre="is the most effective way of preventing the spread of" exact="influenza" post="infection. However, seasonal vaccination is ineffective against pandemic influenza"/>
   <result pre="of influenza infection. However, seasonal vaccination is ineffective against pandemic" exact="influenza" post="viruses because of antigenic differences, and it takes approximately"/>
   <result pre="action. The extracellular domain of the M2 protein (M2e) of" exact="influenza" post="A virus is a conservative region, and an attractive"/>
   <result pre="a conservative region, and an attractive target for a universal" exact="influenza" post="vaccine. This review gives a historical overview of the"/>
   <result pre="summarizes the latest developments in the preparation of M2e-based universal" exact="influenza" post="vaccines. Keywords Influenza a virus Influenza M2 ectodomain Conserved"/>
   <result pre="Influenza a virus Influenza M2 ectodomain Conserved protein Cross-protection Universal" exact="influenza" post="vaccine Funding http://dx.doi.org/10.13039/501100006769Russian Science Foundation 19-15-00015RudenkoLarisa Introduction The extremely"/>
   <result pre="Introduction The extremely high variability in the antigenic properties of" exact="influenza" post="virus is related to the structure of its genome"/>
   <result pre="drift variants. In addition, completely new antigenic variants of the" exact="influenza" post="virus are occasionally introduced into the human population; since"/>
   <result pre="viruses spread easily and can cause pandemics. These features of" exact="influenza" post="infection explain why there is interest around the world"/>
   <result pre="there is interest around the world in developing a universal" exact="influenza" post="vaccine, which could induce a cross-reactive immune response to"/>
   <result pre="to the most conservative parts of the viral proteins. Classic" exact="influenza" post="vaccines commonly induce antibodies to the viral surface antigens,"/>
   <result pre="need for annual updating of vaccine strains in the seasonal" exact="influenza" post="vaccines [95, 129]. The performance of seasonal influenza vaccines"/>
   <result pre="the seasonal influenza vaccines [95, 129]. The performance of seasonal" exact="influenza" post="vaccines can be improved by increasing the speed of"/>
   <result pre="will not be able to protect against newly emerging pandemic" exact="influenza" post="viruses because of significant antigenic differences. Potentially pandemic viruses"/>
   <result pre="would provide long-term protection not only against drifted variants of" exact="influenza" post="A viruses of one subtype but also against viruses"/>
   <result pre="approach to expanding the spectrum of the protective action of" exact="influenza" post="vaccines is to enhance the induction of cross-reacting immune"/>
   <result pre="cross-reacting immune response factors that target highly conserved antigens in" exact="influenza" post="viruses of various subtypes [61, 62]. The influenza virion"/>
   <result pre="antigens in influenza viruses of various subtypes [61, 62]. The" exact="influenza" post="virion contains multiple conservative domains that, because of their"/>
   <result pre="the hemagglutinin which is important for the penetration of the" exact="influenza" post="virus into the cell [63]; broadly immunogenic epitopes located"/>
   <result pre="cells specific to conserved viral epitopes with cross-protection against symptomatic" exact="influenza" post="in the absence of cross-reactive neutralizing antibodies [111]. Historical"/>
   <result pre="of studying M2 protein Most attempts to create a universal" exact="influenza" post="vaccine have been based on the M2e epitopes. The"/>
   <result pre="in 1981 [65]. Several groups had already shown that the" exact="influenza" post="A virus has a segmented genome consisting of 8"/>
   <result pre="new protein with greater electrophoretic mobility than the already known" exact="influenza" post="A protein. Isolation of different mRNA segments followed by"/>
   <result pre="concluded that the 7th segment of the mRNA of the" exact="influenza" post="A genome and the new M2 protein were genetically"/>
   <result pre="detected only in infected cells [65], and not in the" exact="influenza" post="virions themselves, which made it possible to put forward"/>
   <result pre="is not able to inhibit the adsorption and penetration of" exact="influenza" post="virus into cells, but is able to limit the"/>
   <result pre="into cells, but is able to limit the growth of" exact="influenza" post="A virus in vitro, though this restriction is highly"/>
   <result pre="monoclonal antibody (3F12), which not only had cross-reactivity to different" exact="influenza" post="A strains, but could also bind to the T-cell"/>
   <result pre="a bispecific antibody is able to limit the growth of" exact="influenza" post="A virus in vitro (with less efficiency than 14C2)"/>
   <result pre="N-terminus of M2 (a.a 2–12) have virus-neutralizing activity against both" exact="influenza" post="A and B in vitro [77]. The authors suggested"/>
   <result pre="additional evidence that could confirm that anti-M2e immunity can suppress" exact="influenza" post="B virus replication. Later, the same group of scientists"/>
   <result pre="the M2e2–6 epitope [37] and may provide immediate immunity against" exact="influenza" post="A infection [99]. Another potential therapeutic antibody is anti-M2e"/>
   <result pre="which play an important role in the life cycle of" exact="influenza" post="virus [115]. Highly conserved and oxidized cysteine residues at"/>
   <result pre="acid residues and is a highly conserved region in all" exact="influenza" post="A viruses. One of the reasons for the low"/>
   <result pre="27,253 human, 15,367 avian and 5379 swine individual sequences of" exact="influenza" post="A virus M gene (obtained from the Influenza Research"/>
   <result pre="[76]. As shown on Fig. 1a, the M2e sequences of" exact="influenza" post="A viruses have evolutionary diverged into several lineages mainly"/>
   <result pre="exception is the residue at 19th position in the swine" exact="influenza" post="viruses that fall into lineage 2, in which Tyr"/>
   <result pre="not protect the animals from the lethal swine subtype of" exact="influenza" post="A virus [41]. It has also been shown that"/>
   <result pre="substitution at the 11th position in avian M2e may allow" exact="avian influenza" post="A virus to escape the immune response in humans"/>
   <result pre="at the 11th position in avian M2e may allow avian" exact="influenza" post="A virus to escape the immune response in humans"/>
   <result pre="available M2e sequences, in order to develop a M2e-based universal" exact="influenza" post="vaccine we propose using four different consensus M2e protein"/>
   <result pre="protein sequences that will cover most human, avian and swine" exact="influenza" post="A viruses (Fig. 1c). In contrast to previously published"/>
   <result pre="studies, we suggest using two different M2e sequences for human" exact="influenza" post="viruses due to the significant variations between the human"/>
   <result pre="Fig. 1 Analysis of M2e sequences of human, swine and" exact="avian influenza" post="viruses. a Phylogenetic tree was generated from 27,253 human,"/>
   <result pre="1 Analysis of M2e sequences of human, swine and avian" exact="influenza" post="viruses. a Phylogenetic tree was generated from 27,253 human,"/>
   <result pre="27,253 human, 15,367 avian and 5379 swine individual sequences of" exact="influenza" post="A virus M gene (obtained from the Influenza Research"/>
   <result pre="Proposed consensus M2e sequences for the development of a universal" exact="influenza" post="vaccine The structure of free M2e is currently unknown."/>
   <result pre="aliphatic helix (a.a. 51–59) [104]. The 7th segment of the" exact="influenza" post="A virus genome can be subjected to alternative splicing"/>
   <result pre="some strains [100]. This process can proceed independently of other" exact="influenza" post="A virus proteins [68] using only the host cell"/>
   <result pre="have reported the control of M1 mRNA splicing using other" exact="influenza" post="A virus proteins [10, 100, 106, 107]. Currently, it"/>
   <result pre="four fragments of H37xxxW41 [4, 118, 125]. Shortly after the" exact="influenza" post="virus enters a cell as part of the endosome"/>
   <result pre="M2 is participation in the formation and budding of new" exact="influenza" post="A virions. The study of this feature began with"/>
   <result pre="despite the small amount of M2 on the surface of" exact="influenza" post="A virus [83]. Using reverse genetics and mutational analysis,"/>
   <result pre="the cell membrane (reviewed in [81]). Furthermore, the M2 of" exact="influenza" post="A virus is a mediator of macroautophagy inhibition at"/>
   <result pre="a subsequent increase in cell death as a result of" exact="influenza" post="infection and an increase in viral antigen yield [7,"/>
   <result pre="in viral antigen yield [7, 34]. The functional ortholog of" exact="influenza" post="A virus M2 is M2 from influenza B virus"/>
   <result pre="functional ortholog of influenza A virus M2 is M2 from" exact="influenza" post="B virus (BM2), which also carries electrons through the"/>
   <result pre="also carries electrons through the membrane [86], interacts with the" exact="influenza" post="B matrix 1 protein [127], crucial for virus assembly"/>
   <result pre="which is obtained by splicing the 7th segment of the" exact="influenza" post="A virus genome in some influenza strains [136]. Despite"/>
   <result pre="7th segment of the influenza A virus genome in some" exact="influenza" post="strains [136]. Despite the importance of the M2 functions,"/>
   <result pre="the M2 functions, it is not an essential protein for" exact="influenza" post="A virus. In laboratory practice, so-called &quot;M2 null�? viruses"/>
   <result pre="been generated and evaluated as a possible candidate for live" exact="influenza" post="vaccine. The M2SR vaccine was able to infect cells"/>
   <result pre="proved efficient in protecting animals (mice and ferrets) against heterologous/heterosubtypic" exact="influenza" post="virus infections [39, 40], and is now undergoing phase"/>
   <result pre="[19, 22, 59]. Importantly, several groups have noted that M2e-based" exact="influenza" post="vaccines induced a long-lasting M2e-specific antibody response [56, 105,"/>
   <result pre="of new viral particles. However, it has been shown that" exact="influenza" post="viruses that have mutations in the C-terminal region of"/>
   <result pre="Van den Hoecke et al. [124] showed that protection against" exact="influenza" post="virus with different IgG antibody subclasses requires different FcR"/>
   <result pre="also raises questions [71]. The complement system can bind to" exact="influenza" post="virions in the presence of virus-specific antibodies [8, 43]."/>
   <result pre="by mucosal CTA1-3M2e-DD vaccine in protecting mice against a lethal" exact="influenza" post="virus infection. Importantly, these CD4 T-cell responses were long-lasting,"/>
   <result pre="of M2e Most studies aimed at preparing a universal M2e-based" exact="influenza" post="vaccine have used the whole M2 ectodomain (a.a. 2–24)."/>
   <result pre="these antibodies have different protective characteristics, and an optimum universal" exact="influenza" post="vaccine may use only some of the M2e sites"/>
   <result pre="the M2e 7–13 site) did not protect mice against lethal" exact="influenza" post="A virus challenge. Data from other groups indicate that"/>
   <result pre="Development of M2e-based vaccines The inhibition of replication of some" exact="influenza" post="A strains by 14C2 antibody [140] merited further study"/>
   <result pre="BALB/c mice showed that it significantly reduced the replication of" exact="influenza" post="A (but not influenza B) virus in lung tissue."/>
   <result pre="it significantly reduced the replication of influenza A (but not" exact="influenza" post="B) virus in lung tissue. This prompted the suggestion"/>
   <result pre="that the higher immunity of adults who have previously had" exact="influenza" post="A infection compared with children is provided by the"/>
   <result pre="immunogen and that only about half the people infected with" exact="influenza" post="A virus are able to produce anti-M2e antibodies [143]."/>
   <result pre="been suggested that the introduction of M2e epitopes into the" exact="influenza" post="vaccine will have a priming effect on the production"/>
   <result pre="a priming effect on the production of antibodies before subsequent" exact="influenza" post="A virus infection [143]. Despite numerous reports of the"/>
   <result pre="and the possible shielding effect of larger surface proteins of" exact="influenza" post="A virus [29, 47, 140], it has been shown"/>
   <result pre="high titers of anti-M2e antibodies that protect mice from lethal" exact="influenza" post="challenge [138]. However, most attempts to create a universal"/>
   <result pre="challenge [138]. However, most attempts to create a universal M2e-based" exact="influenza" post="vaccine have used different carriers. One of the first"/>
   <result pre="the first studies used a recombinant baculovirus containing M2 from" exact="influenza" post="virus A/Ann Arbor/6/60 (Bac-AM2), to infect the Spodoptera frugipedra"/>
   <result pre="the antibody response to M2 in people previously infected with" exact="influenza" post="A virus [11]. One of the first prototypes of"/>
   <result pre="virus [11]. One of the first prototypes of a universal" exact="influenza" post="vaccine used hepatitis B core protein combined with the"/>
   <result pre="of the first prototypes of a universal influenza vaccine used" exact="hepatitis" post="B core protein combined with the M2e peptide (M2HBc)"/>
   <result pre="a high level of protection against the lethal dose of" exact="influenza" post="A virus, and led to the formation of anti-M2e"/>
   <result pre="which protected vaccinated mice from a lethal dose of mouse-adapted" exact="influenza" post="virus [17]. The most effective and cost-effective method is"/>
   <result pre="repeats (M2e5x). The intramuscular administration of M2e5x protected mice from" exact="influenza" post="A viruses of different serotypes [56, 58, 74]. There"/>
   <result pre="are also being sought, such as priming with live attenuated" exact="influenza" post="virus, and boosting with M2e VLP [73]. Table 2"/>
   <result pre="n/m, not mentioned; +, with adjuvant Clinical studies of M2e-based" exact="influenza" post="vaccines M2e-based vaccines are not available commercially, but some"/>
   <result pre="time [clinicaltrials.gov NCT00819013]. A similar recombinant protein HBc-based prototype universal" exact="influenza" post="vaccine, &quot;Uniflu�?, is currently being evaluated in a single-site,"/>
   <result pre="VA Pharma LLC (Russian Federation) I 2018 NCT03789539 No Another" exact="influenza" post="vaccine based on the use of flagellin to increase"/>
   <result pre="as parenteral administration provided immediate immunity and therapeutic benefit in" exact="influenza" post="A infection [99]. Overall, many prototype universal influenza vaccines"/>
   <result pre="benefit in influenza A infection [99]. Overall, many prototype universal" exact="influenza" post="vaccines contain an increased number of M2e epitopes. The"/>
   <result pre="spread of influenza. However, seasonal vaccination is ineffective against pandemic" exact="influenza" post="viruses, as it is often antigenically different from the"/>
   <result pre="new vaccine candidate for deployment. The development of a universal" exact="influenza" post="vaccine, which would have a long and broad spectrum"/>
   <result pre="an urgent issue of practical public health. Currently, new universal" exact="influenza" post="vaccines are being developed using various strategies, but none"/>
   <result pre="been licensed so far. The development of a new universal" exact="influenza" post="vaccine will both avoid the need for annual updates"/>
   <result pre="long-lasting protection. It is also unknown how the effects of" exact="influenza" post="viruses and previous vaccinations will affect the performance of"/>
   <result pre="affect the performance of new vaccines [91]. Ideally, a universal" exact="influenza" post="vaccine should induce both a humoral (antibodies) and a"/>
   <result pre="and a T-cell immune response to conservative epitopes of the" exact="influenza" post="virus. M2e and HA stalk domain are the most"/>
   <result pre="are the most widely used viral targets for a universal" exact="influenza" post="vaccine design due to their conserved nature and the"/>
   <result pre="between the two HA groups, suggesting that a cHA-based universal" exact="influenza" post="vaccine has to include three components: a group 1"/>
   <result pre="a group 1 HA, a group 2 HA, and an" exact="influenza" post="B stalk-based antigen [64, 82]. In contrast, a properly"/>
   <result pre="In contrast, a properly designed M2e-based vaccine should cover all" exact="influenza" post="A virus subtypes circulating in both human and animal"/>
   <result pre="to maximize cross-reactivity of the M2e-targeted antibody against all circulating" exact="influenza" post="A viruses (Fig. 1). Licensing of a new M2e-based"/>
   <result pre="neutralizing immunity, therefore the problem of proving non-inferiority over existing" exact="influenza" post="vaccines remains to be solved. Nevertheless, the conserved M2"/>
   <result pre="strain specificity and improve long-term cross-protection of currently licensed seasonal" exact="influenza" post="vaccines [57, 87]. It is worth mentioning that it"/>
   <result pre="affecting the conserved M2e region also require changes in other" exact="influenza" post="A viral proteins because of the various functions of"/>
   <result pre="acid ADCC Antibody-dependent cellular cytotoxicity Bac-AM2 Baculovirus containing M2 from" exact="influenza" post="virus A/Ann Arbor/6/60 BLS Brucella abortus lumazine synthase protein"/>
   <result pre="in VesiVax((R)) liposomes stimulates protection against type a strains of" exact="influenza" post="comparable to liposomes with multimeric forms of M2eJ Liposome"/>
   <result pre="Res201727321022010.1080/08982104.2017.138170828922045 2.AlvarezPZylbermanVGhersiGBoadoLPalaciosCGoldbaumFMattionNTandem repeats of the extracellular domain of matrix 2" exact="influenza" post="protein exposed in Brucella lumazine synthase decameric carrier molecule"/>
   <result pre="induce protection in miceVaccine201331580681210.1016/j.vaccine.2012.11.07223246552 3.AnderssonAMHakanssonKOJensenBAChristensenDAndersenPThomsenARChristensenJPIncreased immunogenicity and protective efficacy of" exact="influenza" post="M2e fused to a tetramerizing proteinPLoS One2012710111 4.BalannikVCarnevaleVFiorinGLevineBGLambRAKleinMLDegradoWFPintoLHFunctional studies"/>
   <result pre="4.BalannikVCarnevaleVFiorinGLevineBGLambRAKleinMLDegradoWFPintoLHFunctional studies and modeling of pore-lining residue mutants of the" exact="influenza" post="a virus M2 ion channelBiochemistry201049469670810.1021/bi901799k20028125 5.BangaruSLangSSchotsaertMVandervenHAZhuXKoseNBombardiRFinnJAKentSJGilchukPGilchukITurnerHLGarcia-SastreALiSWardABWilsonIACroweJEJrA Site of Vulnerability"/>
   <result pre="response in lung tissueJ Virol1996707441144188676464 7.BealeRWiseHStuartARavenhillBJDigardPRandowFA LC3-interacting motif in the" exact="influenza" post="a virus M2 protein is required to subvert autophagy"/>
   <result pre="Normal human sera: mechanisms involving antibody and complementJ Immunol19831303131713226822737 9.BerlandaSFTsvetnitskyVDonnellyJJUniversal" exact="influenza" post="vaccines: shifting to better vaccinesVaccine201634262926293310.1016/j.vaccine.2016.03.08527038130 10.BierKYorkAFodorECellular cap-binding proteins associate"/>
   <result pre="vaccines: shifting to better vaccinesVaccine201634262926293310.1016/j.vaccine.2016.03.08527038130 10.BierKYorkAFodorECellular cap-binding proteins associate with" exact="influenza" post="virus mRNAsJ Gen Virol201192Pt 71627163410.1099/vir.0.029231-021402597 11.BlackRARotaPAGorodkovaNKlenkHDKendalAPAntibody response to the"/>
   <result pre="Gen Virol201192Pt 71627163410.1099/vir.0.029231-021402597 11.BlackRARotaPAGorodkovaNKlenkHDKendalAPAntibody response to the M2 protein of" exact="influenza" post="a virus expressed in insect cellsJ Gen Virol19937414314610.1099/0022-1317-74-1-1438423445 12.ChenBJLeserGPJacksonDLambRAThe"/>
   <result pre="influenza a virus expressed in insect cellsJ Gen Virol19937414314610.1099/0022-1317-74-1-1438423445 12.ChenBJLeserGPJacksonDLambRAThe" exact="influenza" post="virus M2 protein cytoplasmic tail interacts with the M1"/>
   <result pre="at the site of virus buddingJ Virol20088220100591007010.1128/JVI.01184-0818701586 13.CheungTKGuanYNgSSChenHWongCHPeirisJSPoonLLGeneration of recombinant" exact="influenza" post="a virus without M2 ion-channel protein by introduction of"/>
   <result pre="Virol200586Pt 51447145410.1099/vir.0.80727-015831957 14.ChizhmakovIVGeraghtyFMOgdenDCHayhurstAAntoniouMHayAJSelective proton permeability and pH regulation of the" exact="influenza" post="virus M2 channel expressed in mouse erythroleukaemia cellsJ Physiol1996494232933610.1113/jphysiol.1996.sp0214958841994"/>
   <result pre="HammeESchymkowitzJRousseauFFiersWSaelensXKimKHStructure of the extracellular domain of matrix protein 2 of" exact="influenza" post="a virus in complex with a protective monoclonal antibodyJ"/>
   <result pre="FiletteMYsenbaertTRooseKSchotsaertMRoelsSGoossensESchepensBFiersWSaelensXAntiserum against the conserved nine amino acid N-terminal peptide of" exact="influenza" post="a virus matrix protein 2 is not immunoprotectiveJ Gen"/>
   <result pre="RooijenNVerbeekSFiersWSaelensXUniversal vaccine based on ectodomain of matrix protein 2 of" exact="influenza" post="a: fc receptors and alveolar macrophages mediate protectionJ Immunol201118621022103110.4049/jimmunol.090214721169548"/>
   <result pre="mediate protectionJ Immunol201118621022103110.4049/jimmunol.090214721169548 25.EliassonDGEl BakkouriKSchonKRamneAFestjensELowenadlerBFiersWSaelensXLyckeNCTA1-M2e-DD: a novel mucosal adjuvant targeted" exact="influenza" post="vaccineVaccine20082691243125210.1016/j.vaccine.2007.12.02718243429 26.EliassonDGOmokanyeASchonKWenzelUABernasconiVBemarkMKolpeAEl BakkouriKYsenbaertTDengLFiersWSaelensXLyckeNM2e-tetramer-specific memory CD4 T cells are broadly"/>
   <result pre="26.EliassonDGOmokanyeASchonKWenzelUABernasconiVBemarkMKolpeAEl BakkouriKYsenbaertTDengLFiersWSaelensXLyckeNM2e-tetramer-specific memory CD4 T cells are broadly protective against" exact="influenza" post="infectionMucosal Immunol201811127328910.1038/mi.2017.1428295019 27.EpsteinSLUniversal Influenza vaccines: Progress in achieving broad"/>
   <result pre="achieving broad cross-protection in vivoAm J Epidemiol2018187122603261430084906 28.FanJLiangXHortonMSPerryHCCitronMPHeideckerGJFuTMJoyceJPrzysieckiCTKellerPMGarskyVMIonescuRRippeonYShiLChastainMACondraJHDaviesMELiaoJEminiEAShiverJWPreclinical study of" exact="influenza" post="virus a M2 peptide conjugate vaccines in mice, ferrets,"/>
   <result pre="inhibit virus replication in vitroJ Virol1996707480048048676511 31.FiersWDe FiletteMEl BakkouriKSchepensBRooseKSchotsaertMBirkettASaelensXM2e-based universal" exact="influenza" post="a vaccineVaccine200927456280628310.1016/j.vaccine.2009.07.00719840661 32.FuT-MFreedDCHortonMSFanJCitronMPJoyceJGGarskyVMCasimiroDRZhaoQShiverJWLiangXCharacterizations of four monoclonal antibodies against M2"/>
   <result pre="32.FuT-MFreedDCHortonMSFanJCitronMPJoyceJGGarskyVMCasimiroDRZhaoQShiverJWLiangXCharacterizations of four monoclonal antibodies against M2 protein ectodomain of" exact="influenza" post="a virusVirology2009385121822610.1016/j.virol.2008.11.03519070878 33.FuruseYSuzukiAKamigakiTOshitaniHEvolution of the M gene of the"/>
   <result pre="influenza a virusVirology2009385121822610.1016/j.virol.2008.11.03519070878 33.FuruseYSuzukiAKamigakiTOshitaniHEvolution of the M gene of the" exact="influenza" post="a virus in different host species: large-scale sequence analysisVirol"/>
   <result pre="host species: large-scale sequence analysisVirol J200966710.1186/1743-422X-6-6719476650 34.GannageMDormannDAlbrechtRDengjelJTorossiTRamerPCLeeMStrowigTArreyFConenelloGPypaertMAndersenJGarcia-SastreAMunzCMatrix protein 2 of" exact="influenza" post="a virus blocks autophagosome fusion with lysosomesCell Host Microbe20096436738010.1016/j.chom.2009.09.00519837376"/>
   <result pre="virus blocks autophagosome fusion with lysosomesCell Host Microbe20096436738010.1016/j.chom.2009.09.00519837376 35.GeorgievaERBorbatPPNormanHDFreedJHMechanism of" exact="influenza" post="a M2 transmembrane domain assembly in lipid membranesSci Rep201551175710.1038/srep1175726190831"/>
   <result pre="protective epitope that is highly conserved among human and nonhuman" exact="influenza" post="A virusesProc Natl Acad Sci U S A20101072812665811266310.1073/pnas.0911806107 38.HashemiHPouyanfardSBandehpourMNoroozbabaeiZKazemiBSaelensXMokhtari-AzadTImmunization"/>
   <result pre="S A20101072812665811266310.1073/pnas.0911806107 38.HashemiHPouyanfardSBandehpourMNoroozbabaeiZKazemiBSaelensXMokhtari-AzadTImmunization with M2e-displaying T7 bacteriophage nanoparticles protects against" exact="influenza" post="a virus challengePLoS One201279e4576510.1371/journal.pone.004576523029232 39.HattaYBoltzDSarawarSKawaokaYNeumannGBilselPM2SR, a novel live influenza"/>
   <result pre="against influenza a virus challengePLoS One201279e4576510.1371/journal.pone.004576523029232 39.HattaYBoltzDSarawarSKawaokaYNeumannGBilselPM2SR, a novel live" exact="influenza" post="vaccine, protects mice and ferrets against highly pathogenic avian"/>
   <result pre="protects mice and ferrets against highly pathogenic avian influenzaVaccine201735334177418310.1016/j.vaccine.2017.06.03928668565 40.HattaYBoltzDSarawarSKawaokaYNeumannGBilselPNovel" exact="influenza" post="vaccine M2SR protects against drifted H1N1 and H3N2 influenza"/>
   <result pre="40.HattaYBoltzDSarawarSKawaokaYNeumannGBilselPNovel influenza vaccine M2SR protects against drifted H1N1 and H3N2" exact="influenza" post="virus challenge in ferrets with pre-existing immunityVaccine201836335097510310.1016/j.vaccine.2018.06.05330007825 41.HeinenPPRijsewijkFAde Boer-LuijtzevEABianchiATVaccination"/>
   <result pre="41.HeinenPPRijsewijkFAde Boer-LuijtzevEABianchiATVaccination of pigs with a DNA construct expressing an" exact="influenza" post="virus M2–nucleoprotein fusion protein exacerbates disease after challenge with"/>
   <result pre="influenza virus M2–nucleoprotein fusion protein exacerbates disease after challenge with" exact="influenza" post="a virusJ Gen Virol2002831851185910.1099/0022-1317-83-8-185112124449 42.HeleniusAUnpacking the incoming Influenza virusCell19926957757810.1016/0092-8674(92)90219-31375129"/>
   <result pre="by formation of disulfide bondsVirology19911831324310.1016/0042-6822(91)90115-R2053285 45.HugheyPGRobertsPCHolsingerLJZebedeeSLLambRACompansRWEffects of antibody to the" exact="influenza" post="a virus M2 protein on M2 surface expression and"/>
   <result pre="and virus assemblyVirology1995212241142110.1006/viro.1995.14987571410 46.HuleattJWNakaarVDesaiPHuangYHewittDJacobsATangJMcDonaldWSongLEvansRKUmlaufSTusseyLPowellTJPotent immunogenicity and efficacy of a universal" exact="influenza" post="vaccine candidate comprising a recombinant fusion protein linking influenza"/>
   <result pre="universal influenza vaccine candidate comprising a recombinant fusion protein linking" exact="influenza" post="M2e to the TLR5 ligand flagellinVaccine200826220121410.1016/j.vaccine.2007.10.06218063235 47.HutchinsonECCharlesPDHesterSSThomasBTrudgianDMartinez-AlonsoMFodorEConserved and host-specific"/>
   <result pre="to the TLR5 ligand flagellinVaccine200826220121410.1016/j.vaccine.2007.10.06218063235 47.HutchinsonECCharlesPDHesterSSThomasBTrudgianDMartinez-AlonsoMFodorEConserved and host-specific features of" exact="influenza" post="virion architectureNat Commun20145481610.1038/ncomms581625226414 48.HutchinsonECCurranMDReadEKGogJRDigardPMutational analysis of cis-acting RNA signals"/>
   <result pre="48.HutchinsonECCurranMDReadEKGogJRDigardPMutational analysis of cis-acting RNA signals in segment 7 of" exact="influenza" post="a virusJ Virol20088223118691187910.1128/JVI.01634-0818815307 49.IchinoheTPangIKIwasakiAInfluenza virus activates inflammasomes via its"/>
   <result pre="into virions during virus assemblyJ Virol20047820110071101510.1128/JVI.78.20.11007-11015.200415452221 51.ItoTGormanOTKawaokaYBeanWJWebsterRJEvolutionary analysis of the" exact="influenza" post="a virus M gene with comparison of the M1"/>
   <result pre="virus-like particles confer broader and stronger M2 immunity than live" exact="influenza" post="A virus infectionAntiviral Res201399332833510.1016/j.antiviral.2013.06.01023811283 57.KimMCLeeYNKoEJLeeJSKwonYMHwangHSSongJMSongBMLeeYJChoiJGKangHMQuanFSCompansRWKangSMSupplementation of influenza split vaccines"/>
   <result pre="immunity than live influenza A virus infectionAntiviral Res201399332833510.1016/j.antiviral.2013.06.01023811283 57.KimMCLeeYNKoEJLeeJSKwonYMHwangHSSongJMSongBMLeeYJChoiJGKangHMQuanFSCompansRWKangSMSupplementation of" exact="influenza" post="split vaccines with conserved M2 ectodomains overcomes strain specificity"/>
   <result pre="M2 extracellular domains confer improved cross-protection against various subtypes of" exact="influenza" post="virusMol Ther201321248549210.1038/mt.2012.24623247101 59.KolpeASchepensBFiersWSaelensXM2-based influenza vaccines: recent advances and clinical"/>
   <result pre="improved cross-protection against various subtypes of influenza virusMol Ther201321248549210.1038/mt.2012.24623247101 59.KolpeASchepensBFiersWSaelensXM2-based" exact="influenza" post="vaccines: recent advances and clinical potentialExpert Rev Vaccines201716212313610.1080/14760584.2017.124004127653543 60.KolpeASchepensBYeLStaeheliPSaelensXPassively"/>
   <result pre="clinical potentialExpert Rev Vaccines201716212313610.1080/14760584.2017.124004127653543 60.KolpeASchepensBYeLStaeheliPSaelensXPassively transferred M2e-specific monoclonal antibody reduces" exact="influenza" post="a virus transmission in miceAntivir Res201815824425410.1016/j.antiviral.2018.08.01730179634 61.KrammerFEmerging influenza viruses"/>
   <result pre="antibody reduces influenza a virus transmission in miceAntivir Res201815824425410.1016/j.antiviral.2018.08.01730179634 61.KrammerFEmerging" exact="influenza" post="viruses and the prospect of a universal influenza virus"/>
   <result pre="Res201815824425410.1016/j.antiviral.2018.08.01730179634 61.KrammerFEmerging influenza viruses and the prospect of a universal" exact="influenza" post="virus vaccineBiotechnol J201510569070110.1002/biot.20140039325728134 62.KrammerFPalesePAdvances in the development of influenza"/>
   <result pre="universal influenza virus vaccineBiotechnol J201510569070110.1002/biot.20140039325728134 62.KrammerFPalesePAdvances in the development of" exact="influenza" post="virus vaccinesNat Rev Drug Discov201514316718210.1038/nrd452925722244 63.KrammerFPalesePInfluenza virus hemagglutinin stalk-based"/>
   <result pre="virus hemagglutinin stalk-based antibodies and vaccinesCurr Opin Virol20133552153010.1016/j.coviro.2013.07.00723978327 64.KrammerFPicaNHaiRMargineIPalesePChimeric hemagglutinin" exact="influenza" post="virus vaccine constructs elicit broadly protective stalk-specific antibodiesJ Virol201387126542655010.1128/JVI.00641-1323576508"/>
   <result pre="RNA segment 7 of Influenza virusVirology198111272973710.1016/0042-6822(81)90317-27257188 66.LambRAChoppinPWSegment 8 of the" exact="influenza" post="virus genome is unique in coding for two polypeptidesBiochemistry1979761049084912"/>
   <result pre="antibodies but plays a critical role in conferring protection after" exact="influenza" post="M2 vaccinationImmunology2014143230030910.1111/imm.1231024773389 73.LeeYTKimKHKoEJKimMCLeeYNHwangHSLeeYJungYJKimYJSantosJPerezDRKangSMEnhancing the cross protective efficacy of live"/>
   <result pre="M2 vaccinationImmunology2014143230030910.1111/imm.1231024773389 73.LeeYTKimKHKoEJKimMCLeeYNHwangHSLeeYJungYJKimYJSantosJPerezDRKangSMEnhancing the cross protective efficacy of live attenuated" exact="influenza" post="virus vaccine by supplemented vaccination with M2 ectodomain virus-like"/>
   <result pre="induces humoral and cellular immune responses conferring cross-protection against heterosubtypic" exact="influenza" post="virusesPLoS One2018131e019086810.1371/journal.pone.019086829324805 75.LeidingTWangJMartinssonJDeGradoWFArskoldSPProton and cation transport activity of the"/>
   <result pre="and cation transport activity of the M2 proton channel from" exact="influenza" post="a virusProc Natl Acad Sci U S A201010735154091541410.1073/pnas.100999710720713739 76.LetunicIBorkPInteractive"/>
   <result pre="of M2 protein could induce antibodies with inhibitory activity against" exact="influenza" post="virus replicationFEMS Immunol Med Microbiol200335214114610.1016/S0928-8244(03)00009-912628550 78.LiuWZouPChenYHMonoclonal antibodies recognizing EVETPIRN"/>
   <result pre="replicationFEMS Immunol Med Microbiol200335214114610.1016/S0928-8244(03)00009-912628550 78.LiuWZouPChenYHMonoclonal antibodies recognizing EVETPIRN epitope of" exact="influenza" post="a virus M2 protein could protect mice from lethal"/>
   <result pre="influenza a virus M2 protein could protect mice from lethal" exact="influenza" post="a virus challengeImmunol Lett2004932–313113610.1016/j.imlet.2004.03.00315158608 79.LiuWZouPDingJLuYChenYHSequence comparison between the extracellular"/>
   <result pre="comparison between the extracellular domain of M2 protein human and" exact="avian influenza" post="a virus provides new information for bivalent influenza vaccine"/>
   <result pre="between the extracellular domain of M2 protein human and avian" exact="influenza" post="a virus provides new information for bivalent influenza vaccine"/>
   <result pre="and avian influenza a virus provides new information for bivalent" exact="influenza" post="vaccine designMicrobes Infect20057217117710.1016/j.micinf.2004.10.00615777646 80.LotfiZGolchinMKhalili-YazdiAKhaliliMImmunological properties of the SLLTEVET epitope"/>
   <result pre="Sciences20171812264910.3390/ijms18122649 82.MargineIKrammerFHaiRHeatonNSTanGSAndrewsSARunstadlerJAWilsonPCAlbrechtRAGarcia-SastreAPalesePHemagglutinin stalk-based universal vaccine constructs protect against group 2" exact="influenza" post="a virusesJ Virol20138719104351044610.1128/JVI.01715-1323903831 83.McCownMFPekoszAThe influenza a virus M2 cytoplasmic"/>
   <result pre="constructs protect against group 2 influenza a virusesJ Virol20138719104351044610.1128/JVI.01715-1323903831 83.McCownMFPekoszAThe" exact="influenza" post="a virus M2 cytoplasmic tail is required for infectious"/>
   <result pre="M2e5x virus-like particles confers improved cross-protection in ferretsVaccine201634446647310.1016/j.vaccine.2015.12.02326709639 88.NeirynckSDerooTSaelensXVanlandschootPJouWMFiersWA universal" exact="influenza" post="a vaccine based on the extracellular domain of the"/>
   <result pre="extracellular domain of the M2 proteinNat Med19995101157116310.1038/1348410502819 89.OkudaKIhataAWatabeSOkadaEYamakawaTHamajimaKYangJIshiiNNakazawaMOkudaKOhnariKNakajimaKXinKQProtective immunity against" exact="influenza" post="a virus induced by immunization with DNA plasmid containing"/>
   <result pre="influenza a virus induced by immunization with DNA plasmid containing" exact="influenza" post="M geneVaccine2001193681369110.1016/S0264-410X(01)00078-011395202 90.PalesePSchulmanJLDifferences in RNA patterns of Influenza a"/>
   <result pre="the possible dream?ACS Infect Dis2016215710.1021/acsinfecdis.5b0014626977452 92.ParkKSSeoYBLeeJYImSJSeoSHSongMSChoiYKSungYCComplete protection against a H5N2" exact="avian influenza" post="virus by a DNA vaccine expressing a fusion protein"/>
   <result pre="possible dream?ACS Infect Dis2016215710.1021/acsinfecdis.5b0014626977452 92.ParkKSSeoYBLeeJYImSJSeoSHSongMSChoiYKSungYCComplete protection against a H5N2 avian" exact="influenza" post="virus by a DNA vaccine expressing a fusion protein"/>
   <result pre="94.PejoskiDZengWRockmanSBrownLEJacksonDCA lipopeptide based on the M2 and HA proteins of" exact="influenza" post="a viruses induces protective antibodyImmunol Cell Biol201088560561110.1038/icb.2010.1520177411 95.PetrieJGMaloshREChengCKOhmitSEMartinETJohnsonETrusconREichelbergerMCGubarevaLVFryAMMontoASThe household"/>
   <result pre="virus M2 protein has ion channel activityCell19926951752810.1016/0092-8674(92)90452-I1374685 98.PonsMWA reexamination of" exact="influenza" post="single- and double-stranded RNAs by gel electrophoresisVirology19766978979210.1016/0042-6822(76)90508-01258370 99.RamosELMitchamJLKollerTDBonaviaAUsnerDWBalaratnamGFredlundPSwiderekKMEfficacy and"/>
   <result pre="antibody in experimental human influenzaJ Infect Dis201521171038104410.1093/infdis/jiu53925281755 100.RobbNCFodorEThe accumulation of" exact="influenza" post="a virus segment 7 spliced mRNAs is regulated by"/>
   <result pre="Journal of Infectious Diseases2019219Supplement_1S68S7410.1093/infdis/jiz00330715367 103.SarawarSHattaYWatanabeSDiasPNeumannGKawaokaYBilselPM2SR, a novel live single replication" exact="influenza" post="virus vaccine, provides effective heterosubtypic protection in miceVaccine201634425090509810.1016/j.vaccine.2016.08.06127595896 104.SchnellJRChouJJStructure"/>
   <result pre="miceVaccine201634425090509810.1016/j.vaccine.2016.08.06127595896 104.SchnellJRChouJJStructure and mechanism of the M2 proton channel of" exact="influenza" post="a virusNature2008451717859159510.1038/nature0653118235503 105.SchotsaertMYsenbaertTSmetASchepensBVanderschaegheDStegalkinaSVogelTUCallewaertNFiersWSaelensXLong-lasting cross-protection against Influenza a by neuraminidase"/>
   <result pre="polymerase proteinsVirology199622643043510.1006/viro.1996.06738955065 107.ShihSRNemeroffMEKrugRMThe choice of alternative 5′ splice sites in" exact="influenza" post="virus M1 mRNA is regulated by the viral polymerase"/>
   <result pre="One2015104e012467710.1371/journal.pone.012467725915748 109.SmithGJVijaykrishnaDBahlJLycettSJWorobeyMPybusOGMaSKCheungCLRaghwaniJBhattSPeirisJSGuanYRambautAOrigins and evolutionary genomics of the 2009 swine-origin H1N1" exact="influenza" post="a epidemicNature200945972501122112510.1038/nature0818219516283 110.SongJMWangBZParkKMRooijenNVQuanFSKimMCJinHTPekoszACompansRWKangSMInfluenza virus-like particles containing M2 induce broadly"/>
   <result pre="a high K+ concentration is required for efficient uncoating of" exact="influenza" post="a virus cores after penetrationJ Virol20148822130291304610.1128/JVI.01430-1425165113 113.StepanovaLAMardanovaESShuklinaMABlokhinaEAKotlyarovRYPotapchukMVKovalevaAAVidyaevaIGKorotkovAVEletskayaEIRavinNVTsybalovaLMFlagellin-fused protein targeting"/>
   <result pre="potent humoral and T-cell responses and protects mice against various" exact="influenza" post="viruses a subtypesJ Biomed Sci20182513310.1186/s12929-018-0433-529631629 114.StoloffGACaparros-WanderleyWSynthetic multi-epitope peptides identified"/>
   <result pre="multi-epitope peptides identified in silico induce protective immunity against multiple" exact="influenza" post="serotypesEur J Immunol20073792441244910.1002/eji.20073725417668898 115.StoufferALAcharyaRSalomDLevineASDi CostanzoLSotoCSTereshkoVNandaVStayrookSDeGradoWFStructural basis for the function"/>
   <result pre="115.StoufferALAcharyaRSalomDLevineASDi CostanzoLSotoCSTereshkoVNandaVStayrookSDeGradoWFStructural basis for the function and inhibition of an" exact="influenza" post="virus proton channelNature2008451717859659910.1038/nature0652818235504 116.TakedaMPekoszAShuckKPintoLHLambRAInfluenza a virus M2 Ion Channel"/>
   <result pre="for efficient replication in tissue cultureJ Virol20027631391139910.1128/JVI.76.3.1391-1399.200211773413 117.TalbotHKRockMTJohnsonCTusseyLKavitaUShankerAShawARTaylorDNImmunopotentiation of trivalent" exact="influenza" post="vaccine when given with VAX102, a recombinant influenza M2e"/>
   <result pre="of trivalent influenza vaccine when given with VAX102, a recombinant" exact="influenza" post="M2e vaccine fused to the TLR5 ligand flagellinPLoS One2010512e1444210.1371/journal.pone.001444221203437"/>
   <result pre="to the TLR5 ligand flagellinPLoS One2010512e1444210.1371/journal.pone.001444221203437 118.TangYZaitsevaFLambRAPintoLHThe gate of the" exact="influenza" post="virus M2 proton channel is formed by a single"/>
   <result pre="residueJ Biol Chem200227742398803988610.1074/jbc.M20658220012183461 119.TompkinsSMZhaoZSLoCYMisplonJALiuTYeZHoganRJWuZBentonKATumpeyTMEpsteinSLMatrix protein 2 vaccination and protection against" exact="influenza" post="viruses, including subtype H5N1Emerg Infect Dis200713342643510.3201/eid1303.06112517552096 120.TophamDITrippRADohertyPCCD8+ T cells"/>
   <result pre="a virus replication in miceJ Virol1990643137513772304147 122.TsybalovaLMStepanovaLAKuprianovVVBlokhinaEAPotapchukMVKorotkovAVGorshkovANKasyanenkoMARavinNVKiselevOIDevelopment of a candidate" exact="influenza" post="vaccine based on virus-like particles displaying influenza M2e peptide"/>
   <result pre="of a candidate influenza vaccine based on virus-like particles displaying" exact="influenza" post="M2e peptide into the immunodominant region of hepatitis B"/>
   <result pre="particles displaying influenza M2e peptide into the immunodominant region of" exact="hepatitis" post="B core antigen: broad protective efficacy of particles carrying"/>
   <result pre="copies of M2eVaccine201533293398340610.1016/j.vaccine.2015.04.07325976545 123.TurleyCBRuppREJohnsonCTaylorDNWolfsonJTusseyLKavitaUStanberryLShawASafety and immunogenicity of a recombinant M2e-flagellin" exact="influenza" post="vaccine (STF2.4xM2e) in healthy adultsVaccine201129325145515210.1016/j.vaccine.2011.05.04121624416 124.Van den Hoecke S,"/>
   <result pre="histidine selectivity filter mutants of the M2 ion channel of" exact="influenza" post="a virusJ Biol Chem200528022214632147210.1074/jbc.M41240620015784624 126.Von HolleTAMoodyMAInfluenza and antibody-dependent cellular"/>
   <result pre="cellular cytotoxicityFront Immunol201910145710.3389/fimmu.2019.0145731316510 127.WangJPielakRMMcClintockMAChouJJSolution structure and functional analysis of the" exact="influenza" post="B proton channelNat Struct Mol Biol200916121267127110.1038/nsmb.170719898475 128.WangRSongALevinJDennisDZhangNJYoshidaHKoriazovaLMaduraLShapiroLMatsumotoAYoshidaHMikayamaTKuboRTSarawarSCheroutreHKatoSTherapeutic potential of"/>
   <result pre="Biol200916121267127110.1038/nsmb.170719898475 128.WangRSongALevinJDennisDZhangNJYoshidaHKoriazovaLMaduraLShapiroLMatsumotoAYoshidaHMikayamaTKuboRTSarawarSCheroutreHKatoSTherapeutic potential of a fully human monoclonal antibody against" exact="influenza" post="a virus M2 proteinAntivir Res200880216817710.1016/j.antiviral.2008.06.00218598723 129.WangYChenLChengYZhouSPangYZhangJGreeneCMSongYZhangTZhaoGPotential impact of B"/>
   <result pre="proteinAntivir Res200880216817710.1016/j.antiviral.2008.06.00218598723 129.WangYChenLChengYZhouSPangYZhangJGreeneCMSongYZhangTZhaoGPotential impact of B lineage mismatch on trivalent" exact="influenza" post="vaccine effectiveness during the 2015-2016 influenza season among nursery"/>
   <result pre="lineage mismatch on trivalent influenza vaccine effectiveness during the 2015-2016" exact="influenza" post="season among nursery school children in SuzhouChina Hum Vaccin"/>
   <result pre="ion channel activityJ Virol200175125656566210.1128/JVI.75.12.5656-5662.200111356973 132.WhartonSABelsheRBSkehelJJHayAJRole of virion M2 protein in" exact="influenza" post="virus uncoating: specific reduction in the rate of membrane"/>
   <result pre="Gen Virol199475Pt 494594810.1099/0022-1317-75-4-9458151308 133.WHO. Antigenic and genetic characteristics of zoonotic" exact="influenza" post="viruses and candidate vaccine viruses developed for potential use"/>
   <result pre="Available at: http://www.who.int/entity/influenza/vaccines/virus/201802_zoonotic_vaccinevirusupdate.pdf?ua=1. 2018. 134.WHO. Tables on clinical evaluation of" exact="influenza" post="vaccines. Pandemic and potentially pandemic influenza vaccines. Available at:"/>
   <result pre="on clinical evaluation of influenza vaccines. Pandemic and potentially pandemic" exact="influenza" post="vaccines. Available at: http://www.who.int/entity/immunization/diseases/influenza/Table_clinical_evaluation_influenza_pandemic.xlsx?ua=1. 2018. 135.WinterGFieldsSCloning of influenza cDNA"/>
   <result pre="potentially pandemic influenza vaccines. Available at: http://www.who.int/entity/immunization/diseases/influenza/Table_clinical_evaluation_influenza_pandemic.xlsx?ua=1. 2018. 135.WinterGFieldsSCloning of" exact="influenza" post="cDNA into M13: the sequence of the RNA segment"/>
   <result pre="Res1980891965197410.1093/nar/8.9.19656927841 136.WiseHMHutchinsonECJaggerBWStuartADKangZHRobbNSchwartzmanLMKashJCFodorEFirthAEGogJRTaubenbergerJKDigardPIdentification of a novel splice variant form of the" exact="influenza" post="a virus M2 ion channel with an antigenically distinct"/>
   <result pre="Virol. 2018;92(22). 10.1128/JVI.01425-18. 138.WuFHuangJHYuanXYHuangWSChenYHCharacterization of immunity induced by M2e of" exact="influenza" post="virusVaccine200725528868887310.1016/j.vaccine.2007.09.05618061317 139.ZebedeeSLLambRAGrowth restriction of influenza a virus by M2"/>
   <result pre="immunity induced by M2e of influenza virusVaccine200725528868887310.1016/j.vaccine.2007.09.05618061317 139.ZebedeeSLLambRAGrowth restriction of" exact="influenza" post="a virus by M2 protein antibody is genetically linked"/>
   <result pre="to matrix protein 2 following natural infection with 2009 pandemic" exact="influenza" post="A(H1N1) virus in humansJ Infect Dis2014209798699410.1093/infdis/jit81124325965"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6800565\results\search\disease\results.xml">
   <result pre="doi: 10.2147/OPTO.S217722 : Original Research Epidemiology and molecular diagnosis of" exact="acute conjunctivitis" post="in patients attending Hamadan, west Iran ophthalmology clinics 2016–2017"/>
   <result pre="10.2147/OPTO.S217722 : Original Research Epidemiology and molecular diagnosis of acute" exact="conjunctivitis" post="in patients attending Hamadan, west Iran ophthalmology clinics 2016–2017"/>
   <result pre="conjunctivitis. This study was conducted to investigate epidemiological patterns of" exact="conjunctivitis" post="in Hamadan, west Iran. In addition, the frequency of"/>
   <result pre="addition, the frequency of the most important cause of infectious" exact="conjunctivitis" post="diagnosed by PCR and its seasonal variations and association"/>
   <result pre="Methods In this cross-sectional study, 125 patients with suspected viral" exact="conjunctivitis" post="or keratoconjunctivitis in Hamadan, west Iran from July 2016"/>
   <result pre="this cross-sectional study, 125 patients with suspected viral conjunctivitis or" exact="keratoconjunctivitis" post="in Hamadan, west Iran from July 2016 to June"/>
   <result pre="2016 to June 2017 were examined for the presence of" exact="herpes simplex" post="virus 1 (HSV1), HSV2, varicella-zoster virus (VZV), adenovirus. and"/>
   <result pre="in any patients. There was no difference in acquisition of" exact="conjunctivitis" post="between men and women. A total of 55 (44%)"/>
   <result pre="that adenoviruses were a much more common viral cause of" exact="conjunctivitis" post="in the studied region compared to findings in other"/>
   <result pre="not significantly associated with acquisition of viral infection. Keywords epidemiology" exact="conjunctivitis" post="virus polymerase chain reaction fig-count: table-count: ref-count: page-count: Introduction"/>
   <result pre="virus polymerase chain reaction fig-count: table-count: ref-count: page-count: Introduction Worldwide," exact="conjunctivitis" post="is a common eye disease and caused by infection"/>
   <result pre="fig-count: table-count: ref-count: page-count: Introduction Worldwide, conjunctivitis is a common" exact="eye disease" post="and caused by infection with viruses, bacteria, or in"/>
   <result pre="the most common cause of infectious conjunctivitis.1,2 Symptoms of viral" exact="conjunctivitis" post="include redness, swelling, tearing, and irritation, which often last"/>
   <result pre="great pain until complete healing of the disease.5 Although viral" exact="conjunctivitis" post="is a self-limiting disease, it is associated with high"/>
   <result pre="to the likelihood of contagion and its symptoms.6 Adenovirus and" exact="herpes simplex" post="virus (HSV) are common viral causes of keratoconjunctivitis for"/>
   <result pre="and herpes simplex virus (HSV) are common viral causes of" exact="keratoconjunctivitis" post="for which a rapid laboratory diagnosis is often very"/>
   <result pre="blindness in developed countries.8 Also, chlamydia is a cause of" exact="conjunctivitis" post="that can result in focal corneal scarring, chronic inclusion"/>
   <result pre="of conjunctivitis that can result in focal corneal scarring, chronic" exact="inclusion conjunctivitis," post="and neovascularization, probably leading to pneumonitis and otitis media"/>
   <result pre="chronic inclusion conjunctivitis, and neovascularization, probably leading to pneumonitis and" exact="otitis media" post="in neonates.9 Severity of conjunctivitis can be mild to"/>
   <result pre="leading to pneumonitis and otitis media in neonates.9 Severity of" exact="conjunctivitis" post="can be mild to severely disabling. Ocular adenovirus infections"/>
   <result pre="cause of 15%–70% of eye infections.10 A diagnosis of adenoviral" exact="conjunctivitis" post="is usually based on history, symptoms, and clinical evidence."/>
   <result pre="than cell culture. In a study at Johns Hopkins Hospital," exact="conjunctivitis" post="specimens of 307 staff were taken and examined by"/>
   <result pre="Sambursky et al reported that among 50 patients with suspected" exact="acute conjunctivitis," post="31 were found to be positive for adenovirus by"/>
   <result pre="on the basis of clinical appearance.14 Because different types of" exact="conjunctivitis" post="cannot be diagnosed or especially differentiated by clinical approaches15"/>
   <result pre="especially differentiated by clinical approaches15 and no specific treatment for" exact="conjunctivitis" post="has yet been offered, early diagnosis can greatly contribute"/>
   <result pre="process of recovery. Considering that identifying the causative agents of" exact="conjunctivitis" post="in a specific geographic region can help select appropriate"/>
   <result pre="Iran, this study was conducted to investigate epidemiological patterns of" exact="conjunctivitis" post="in this region. In addition, the frequency of viral"/>
   <result pre="conjunctivitis in this region. In addition, the frequency of viral" exact="conjunctivitis" post="(due to adenoviruses, HSV1, HSV2, varicella zoster virus [VZV],"/>
   <result pre="In this cross-sectional nonrandomized study, 125 patients with suspected viral" exact="conjunctivitis" post="or keratoconjunctivitis attending ophthalmology clinics in Hamedan from July"/>
   <result pre="cross-sectional nonrandomized study, 125 patients with suspected viral conjunctivitis or" exact="keratoconjunctivitis" post="attending ophthalmology clinics in Hamedan from July 2016 to"/>
   <result pre="with the Declaration of Helsinki. The initial diagnosis of viral" exact="conjunctivitis" post="was made by clinical examinations conducted by an ophthalmologist,"/>
   <result pre="The patients’ age range was 3–77 years. Most patients with" exact="conjunctivitis" post="were 30–40 years old, and only two were aged"/>
   <result pre="(99.2%) 117 History of eye diseases (retinoblastoma or any chronic" exact="eye disease," post="such as retinal detachment) Yes 20 (16%) 20 0.693"/>
   <result pre="prevalence (P=0.809, 0.871, and 0.652, respectively) Figure 1 Frequency of" exact="conjunctivitis" post="cases in different seasons. Discussion Real-time PCR was used"/>
   <result pre="Real-time PCR was used to study the prevalence of viral" exact="conjunctivitis" post="in 125 patients attending ophthalmology clinics in Hamedan. Previous"/>
   <result pre="lower conjunctival discharge. This study was first to investigate viral" exact="conjunctivitis" post="and associated demographic characteristics in a city in west"/>
   <result pre="these was conducted on 100 patients with eye redness and" exact="conjunctivitis" post="symptoms attending a university-affiliated hospital in Tehran, 16 of"/>
   <result pre="pathogens has a significant effect in reducing the spread of" exact="conjunctivitis" post="and promoting eye health. On the other hand, adenoviruses"/>
   <result pre="A 5-year study in Turkey investigated 488 patients with suspected" exact="conjunctivitis" post="and found adenovirus DNA in 43.6% of these patients"/>
   <result pre="ophthalmology center in Karachi, Pakistan found that 75% of 388" exact="conjunctivitis" post="specimens had adenovirus, 2% had HSV, and 5% had"/>
   <result pre="epidemiological study in Saudi Arabia investigated 65 patients with adenoviral" exact="keratoconjunctivitis" post="with clinical complications of sudden redness, irritation, tearing, and"/>
   <result pre="of conjunctivitis, while a study on 18 patients with suspected" exact="conjunctivitis" post="in Egypt using real-time PCR indicated that none of"/>
   <result pre="adenovirus and 17 carried enterovirus.22 Although the prevalence of adenoviral" exact="conjunctivitis" post="was 94.4% in the present study, we cannot consider"/>
   <result pre="the patients. A study estimated the incidence rates of HSV" exact="eye disease" post="ranged from approximately four to 13 new cases per"/>
   <result pre="population.24 Chlamydia is the most frequent identifiable cause of neonatal" exact="conjunctivitis" post="in many countries, and its incidence is still on"/>
   <result pre="is a main pediatric infection that presents with a vesicular" exact="rash" post="referred to as chickenpox.25 Despite the fact that no"/>
   <result pre="reasons for referral to the doctor) and the acquisition of" exact="conjunctivitis" post="(P&amp;gt;0.05). However, the highest prevalence of disease was seen"/>
   <result pre="seasonal variations were not significantly associated.14 The increased prevalence of" exact="conjunctivitis" post="in summer and autumn is likely to be related"/>
   <result pre="increased prevalence of the disease.26 Considering that most patients with" exact="conjunctivitis" post="are diagnosed and treated with clinical symptoms, the prevalence"/>
   <result pre="Adenoviruses were found to be the most common cause of" exact="conjunctivitis" post="in the studied region, as with other regions of"/>
   <result pre="that adenoviruses were a much more common viral cause of" exact="conjunctivitis" post="in the studied region than found in other regions."/>
   <result pre="significantly associated with acquisition of viral conjunctivitis. Most cases of" exact="conjunctivitis" post="were reported to occur in summer and autumn. On"/>
   <result pre="by clinicians. In light of the high prevalence of adenoviral" exact="conjunctivitis" post="in the studied region, additional studies should investigate common"/>
   <result pre="work. References References 1.LiJ, YangY, LinC, et al. Etiology of" exact="acute conjunctivitis" post="due to coxsackievirus A24 variant, human adenovirus, herpes simplex"/>
   <result pre="References References 1.LiJ, YangY, LinC, et al. Etiology of acute" exact="conjunctivitis" post="due to coxsackievirus A24 variant, human adenovirus, herpes simplex"/>
   <result pre="of acute conjunctivitis due to coxsackievirus A24 variant, human adenovirus," exact="herpes simplex" post="virus, and Chlamydia in Beijing, China. Jpn J Infect"/>
   <result pre="Infect Dis. 2014;67(5):349–355.25241684 2.SamburskyRP, FramN, CohenEJ. The prevalence of adenoviral" exact="conjunctivitis" post="at the wills eye hospital emergency room. Optometry. 2007;78(5):236–239."/>
   <result pre="Oftalmol. 2014;77(2):99–102.25076474 7.El-AalAMA, El SayedM, FoadMF, et al. Adeno and" exact="herpes simplex" post="viral infection in keratoconjunctivitis a comparison between two diagnostic"/>
   <result pre="FoadMF, et al. Adeno and herpes simplex viral infection in" exact="keratoconjunctivitis" post="a comparison between two diagnostic laboratory methods. Int J"/>
   <result pre="App Sci. 2015;4(12):807–814. 8.LiesegangTJ, MeltonLJ3rd, DalyPJ, IlstrupDM. Epidemiology of ocular" exact="herpes simplex." post="Incidence in Rochester, Minn, 1950 through 1982. Arch Ophthalmol."/>
   <result pre="OttA, et al. Chlamydia trachomatis as a cause of neonatal" exact="conjunctivitis" post="in Dutch infants. Pediatrics. 2008;121(2):321–326. doi:10.1542/peds.2007-0153 10.JhanjiV, ChanTC, LiEY,"/>
   <result pre="keratoconjunctivitis. Surv Ophthalmol. 2015;60(5):435–443. doi:10.1016/j.survophthal.2015.04.00126077630 11.TrinavaratA, AtchaneeyasakulLO. Treatment of epidemic" exact="keratoconjunctivitis" post="with 2% povidone-iodine: a pilot study. J Ocul Pharmacol"/>
   <result pre="chain reaction-based algorithm to detect and prevent transmission of adenoviral" exact="conjunctivitis" post="in hospital employees. Am J Ophthalmol. 2016;163:38–44. doi:10.1016/j.ajo.2015.12.00726694258 14.SohrabiM,"/>
   <result pre="2016;163:38–44. doi:10.1016/j.ajo.2015.12.00726694258 14.SohrabiM, GoodarziZ, SaberfarE, LashiniH. The prevalence of viral" exact="conjunctivitis" post="in patients who referred to eye specialist hospitals in"/>
   <result pre="1993;36(2):79–83. doi:10.1159/0001503258294185 16.Shamsi-ShahrabadiM, MousaviE, MonavariSHR, Ataei-PirkoohA, BakhtiariP. Incidence of adenoviral" exact="conjunctivitis" post="in patients referred to the Iran university affiliated hospital."/>
   <result pre="doi:10.21859/isv.3.2.7 17.PintoRD, LiraRP, ArietaCE, CastroRS, BononSH. The prevalence of adenoviral" exact="conjunctivitis" post="at the clinical hospital of the State University of"/>
   <result pre="PasSD, DurakI, SchuttenM, SayınerAA. A 5-year study of adenoviruses causing" exact="conjunctivitis" post="in Izmir, Turkey. J Med Virol. 2015;87(3):472–477. doi:10.1002/jmv.2407125196311 19.MatsuiK,"/>
   <result pre="Virol. 2008;80(6):997–1003. doi:10.1002/jmv.2117518428122 20.WoodlandRM, DarougarS, ThakerU, et al. Causes of" exact="conjunctivitis" post="and keratoconjunctivitis in Karachi, Pakistan. Trans R Soc Trop"/>
   <result pre="doi:10.1002/jmv.2117518428122 20.WoodlandRM, DarougarS, ThakerU, et al. Causes of conjunctivitis and" exact="keratoconjunctivitis" post="in Karachi, Pakistan. Trans R Soc Trop Med Hyg."/>
   <result pre="doi:10.1016/0035-9203(92)90328-a1412664 21.TabbaraKF, OmarM, HammoudaE, et al. Molecular epidemiology of adenoviral" exact="keratoconjunctivitis" post="in Saudi Arabia. Mol Vis. 2010;16:2132–2136.21139691 22.AyoubEA, ShafikCF, GaynorAM,"/>
   <result pre="A molecular investigative approach to an outbreak of acute hemorrhagic" exact="conjunctivitis" post="in Egypt, October 2010. Virol J. 2013;10:96. doi:10.1186/1743-422X-10-9623531270 23.GordonYJ."/>
   <result pre="1993;33(1):153–161. 24.YoungRC, HodgeDO, LiesegangTJ, BaratzKH. Incidence, recurrence, and outcomes of" exact="herpes simplex" post="virus eye disease in Olmsted County, Minnesota, 1976–2007: the"/>
   <result pre="LiesegangTJ, BaratzKH. Incidence, recurrence, and outcomes of herpes simplex virus" exact="eye disease" post="in Olmsted County, Minnesota, 1976–2007: the effect of oral"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6802317\results\search\disease\results.xml">
   <result pre="ranging from hand-foot-and-mouth disease (HFMD), herpangina, rashes, and diarrhea, to" exact="aseptic meningitis," post="pulmonary edema, acute flaccid paralysis (AFP), brainstem encephalitis and"/>
   <result pre="hand-foot-and-mouth disease (HFMD), herpangina, rashes, and diarrhea, to aseptic meningitis," exact="pulmonary edema," post="acute flaccid paralysis (AFP), brainstem encephalitis and Guillain–Barré syndrome"/>
   <result pre="to aseptic meningitis, pulmonary edema, acute flaccid paralysis (AFP), brainstem" exact="encephalitis" post="and Guillain–Barré syndrome [1, 2]. Although EV-A71 infections are"/>
   <result pre="the Asia-Pacific region (Table 1). The first large HFMD and" exact="herpangina" post="outbreak occurred in 1997 and further outbreaks appeared in"/>
   <result pre="also found that VP1Q145E enhances binding of EV-A71 to mouse" exact="neuroblastoma" post="(Table 2) [86]. In a non-human primate model, VP1145E"/>
   <result pre="of EV-A71 [82] VP1 31G • Enhances EV-A71 entry into" exact="neuroblastoma" post="• Increases viral growth and fitness in human neuronal"/>
   <result pre="selection [45] Q145E • Enhances binding of EV-A71 to mouse" exact="neuroblastoma" post="• Increases viral binding and RNA accumulation of EV-A71"/>
   <result pre="features, diagnosis, and management of enterovirus 71Lancet Neurol20109111097110510.1016/S1474-4422(10)70209-X20965438 3.HagiwaraATagayaIYoneyamaTEpidemic of" exact="hand, foot and mouth disease" post="associated with enterovirus 71 infectionIntervirology.197891606310.1159/000148922202573 4.SamudaGMChangWKYeungCYTangPSMonoplegia caused by enterovirus"/>
   <result pre="management of enterovirus 71Lancet Neurol20109111097110510.1016/S1474-4422(10)70209-X20965438 3.HagiwaraATagayaIYoneyamaTEpidemic of hand, foot and" exact="mouth disease" post="associated with enterovirus 71 infectionIntervirology.197891606310.1159/000148922202573 4.SamudaGMChangWKYeungCYTangPSMonoplegia caused by enterovirus"/>
   <result pre="5.AbuBakarSCheeHYAl-KobaisiMFXiaoshanJBing ChuaKKitLSIdentification of enterovirus 71 isolates from an outbreak of" exact="hand, foot and mouth disease" post="(HFMD) with fatal cases of encephalomyelitis in MalaysiaVirus Res19996111910.1016/S0168-1702(99)00019-210426204"/>
   <result pre="enterovirus 71 isolates from an outbreak of hand, foot and" exact="mouth disease" post="(HFMD) with fatal cases of encephalomyelitis in MalaysiaVirus Res19996111910.1016/S0168-1702(99)00019-210426204"/>
   <result pre="hand, foot and mouth disease (HFMD) with fatal cases of" exact="encephalomyelitis" post="in MalaysiaVirus Res19996111910.1016/S0168-1702(99)00019-210426204 6.ChuaKBChuaBHLeeCSChemYKNorizahIKiyuAet al.Genetic diversity of enterovirus 71"/>
   <result pre="6.ChuaKBChuaBHLeeCSChemYKNorizahIKiyuAet al.Genetic diversity of enterovirus 71 isolated from cases of" exact="hand, foot and mouth disease" post="in the 1997, 2000 and 2005 outbreaks, Peninsular MalaysiaMalaysian"/>
   <result pre="of enterovirus 71 isolated from cases of hand, foot and" exact="mouth disease" post="in the 1997, 2000 and 2005 outbreaks, Peninsular MalaysiaMalaysian"/>
   <result pre="Pathol20082926978 7.ShimizuHUtamaAYoshiiKYoshidaHYoneyamaTSinniahMet al.Enterovirus 71 from fatal and nonfatal cases of" exact="hand, foot and mouth disease" post="epidemics in Malaysia, Japan and Taiwan in 1997-1998Jpn J"/>
   <result pre="71 from fatal and nonfatal cases of hand, foot and" exact="mouth disease" post="epidemics in Malaysia, Japan and Taiwan in 1997-1998Jpn J"/>
   <result pre="71 responsible for the 2008 outbreak of hand foot and" exact="mouth disease" post="in Fuyang City of ChinaVirol J201079410.1186/1743-422X-7-9420459851 13.SunLMZhengHYZhengHZGuoXHeJFGuanDWet al.An enterovirus"/>
   <result pre="of enterovirus type 71. Brief Report1979 35.TagayaITakayamaRHagiwaraAA large-scale epidemic of" exact="hand, foot and mouth disease" post="associated with enterovirus 71 infection in Japan in 1978Jpn"/>
   <result pre="71. Brief Report1979 35.TagayaITakayamaRHagiwaraAA large-scale epidemic of hand, foot and" exact="mouth disease" post="associated with enterovirus 71 infection in Japan in 1978Jpn"/>
   <result pre="Infect Dis20039329129310.3201/eid0903.02028512643822 48.HosoyaMKawasakiYSatoMHonzumiKKatoAHiroshimaTet al.Genetic diversity of enterovirus 71 associated with" exact="hand, foot and mouth disease" post="epidemics in Japan from 1983 to 2003Pediatr Infect Dis"/>
   <result pre="al.Genetic diversity of enterovirus 71 associated with hand, foot and" exact="mouth disease" post="epidemics in Japan from 1983 to 2003Pediatr Infect Dis"/>
   <result pre="Dis J200625869169410.1097/01.inf.0000227959.89339.c316874167 49.WuYYeoAPhoonMCTanELPohCLQuakSHet al.The largest outbreak of hand; foot and" exact="mouth disease" post="in Singapore in 2008: the role of enterovirus 71"/>
   <result pre="coxsackievirus A strainsInt J Infect Dis20101412e1076e1e8110.1016/j.ijid.2010.07.00620952237 50.ChongCYChanKPShahVNgWLauGTeoTSet al.Hand, foot and" exact="mouth disease" post="in Singapore: a comparison of fatal and non-fatal casesActa"/>
   <result pre="non-fatal casesActa Paediatr200392101163116910.1111/j.1651-2227.2003.tb02478.x14632332 51.WangYZouGXiaAWangXCaiJGaoQet al.Enterovirus 71 infection in children with" exact="hand, foot, and mouth disease" post="in Shanghai, China: epidemiology, clinical feature and diagnosisVirol J2015128310.1186/s12985-015-0308-226036928"/>
   <result pre="51.WangYZouGXiaAWangXCaiJGaoQet al.Enterovirus 71 infection in children with hand, foot, and" exact="mouth disease" post="in Shanghai, China: epidemiology, clinical feature and diagnosisVirol J2015128310.1186/s12985-015-0308-226036928"/>
   <result pre="of enterovirus 71 infection in children during an outbreak of" exact="hand, foot, and mouth disease" post="in Western AustraliaClin Infect Dis200132223624210.1086/31845411170913 54.Van TuPThaoNTTPereraDTruongKHTienNTKThuongTCet al.Epidemiologic and"/>
   <result pre="infection in children during an outbreak of hand, foot, and" exact="mouth disease" post="in Western AustraliaClin Infect Dis200132223624210.1086/31845411170913 54.Van TuPThaoNTTPereraDTruongKHTienNTKThuongTCet al.Epidemiologic and"/>
   <result pre="AustraliaClin Infect Dis200132223624210.1086/31845411170913 54.Van TuPThaoNTTPereraDTruongKHTienNTKThuongTCet al.Epidemiologic and virologic investigation of" exact="hand, foot, and mouth disease," post="southern Vietnam, 2005Emerg Infect Dis200713111733174110.3201/eid1311.07063218217559 55.LeTVNguyen VanTTNguyen QuanHPhamDTMolecular epidemiology"/>
   <result pre="54.Van TuPThaoNTTPereraDTruongKHTienNTKThuongTCet al.Epidemiologic and virologic investigation of hand, foot, and" exact="mouth disease," post="southern Vietnam, 2005Emerg Infect Dis200713111733174110.3201/eid1311.07063218217559 55.LeTVNguyen VanTTNguyen QuanHPhamDTMolecular epidemiology"/>
   <result pre="of human enterovirus 71 and coxsackievirus A16 from children with" exact="hand, foot and mouth disease" post="in Thailand during 2008-2011Arch Virol20111562007201310.1007/s00705-011-1098-521898187 58.SanjuánRNebotMRChiricoNManskyLMBelshawRViral mutation ratesJ Virol201084199733974810.1128/JVI.00694-1020660197"/>
   <result pre="71 and coxsackievirus A16 from children with hand, foot and" exact="mouth disease" post="in Thailand during 2008-2011Arch Virol20111562007201310.1007/s00705-011-1098-521898187 58.SanjuánRNebotMRChiricoNManskyLMBelshawRViral mutation ratesJ Virol201084199733974810.1128/JVI.00694-1020660197"/>
   <result pre="Taiwan between 1998 and 2000J Clin Microbiol2002401101510.1128/JCM.40.1.10-15.200211773085 63.FujimotoTChikahiraMYoshidaSEbiraHHasegawaATotsukaAet al.Outbreak of" exact="central nervous system disease" post="associated with hand, foot, and mouth disease in Japan"/>
   <result pre="between 1998 and 2000J Clin Microbiol2002401101510.1128/JCM.40.1.10-15.200211773085 63.FujimotoTChikahiraMYoshidaSEbiraHHasegawaATotsukaAet al.Outbreak of central" exact="nervous system disease" post="associated with hand, foot, and mouth disease in Japan"/>
   <result pre="Microbiol2002401101510.1128/JCM.40.1.10-15.200211773085 63.FujimotoTChikahiraMYoshidaSEbiraHHasegawaATotsukaAet al.Outbreak of central nervous system disease associated with" exact="hand, foot, and mouth disease" post="in Japan during the summer of 2000: detection and"/>
   <result pre="of central nervous system disease associated with hand, foot, and" exact="mouth disease" post="in Japan during the summer of 2000: detection and"/>
   <result pre="human enterovirus 71 subgenotypesBMC Microbiol200667410.1186/1471-2180-6-7416939656 72.ChanYFAbuBakerSRecombinant human enterovirus 71 in" exact="hand, foot and mouth disease" post="patientsEmerg Infect Dis20041081468147010.3201/eid1008.03051815496251 73.HuangSCHsuYWWangHCHuangSWKiangDTsaiHPet al.Appearance of intratypic recombination of"/>
   <result pre="subgenotypesBMC Microbiol200667410.1186/1471-2180-6-7416939656 72.ChanYFAbuBakerSRecombinant human enterovirus 71 in hand, foot and" exact="mouth disease" post="patientsEmerg Infect Dis20041081468147010.3201/eid1008.03051815496251 73.HuangSCHsuYWWangHCHuangSWKiangDTsaiHPet al.Appearance of intratypic recombination of"/>
   <result pre="coxsackievirus A16 and enterovirus 71 during a large outbreak of" exact="hand, foot, and mouth disease" post="in Central ChinaPloS One201494e96051-e10.1371/journal.pone.009605124776922 78.WangYFChouCTLeiHYLiuCCWangSMYanJJet al.A mouse-adapted enterovirus 71"/>
   <result pre="enterovirus 71 during a large outbreak of hand, foot, and" exact="mouth disease" post="in Central ChinaPloS One201494e96051-e10.1371/journal.pone.009605124776922 78.WangYFChouCTLeiHYLiuCCWangSMYanJJet al.A mouse-adapted enterovirus 71"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6804639\results\search\disease\results.xml">
   <result pre="along with the article's URL.file:JIA2-22-e25361.pdf sexually transmitted infections surveillance gonorrhoea" exact="syphilis" post="chlamydia trichomoniasis Funding World Health Organization Department of Reproductive"/>
   <result pre="the article's URL.file:JIA2-22-e25361.pdf sexually transmitted infections surveillance gonorrhoea syphilis chlamydia" exact="trichomoniasis" post="Funding World Health Organization Department of Reproductive Health and"/>
   <result pre="occurred in 2016, including chlamydia (127 million), gonorrhoea (87 million)," exact="syphilis" post="(6.3 million) and trichomoniasis (156 million) 1. More than"/>
   <result pre="chlamydia (127 million), gonorrhoea (87 million), syphilis (6.3 million) and" exact="trichomoniasis" post="(156 million) 1. More than 500 million people were"/>
   <result pre="500 million people were estimated to have genital infections with" exact="herpes simplex" post="virus (HSV�?1 or HSV�?2) in 2012 2. Approximately 290"/>
   <result pre="women infected and their new�?born infants. More than 500,000 incident" exact="cervical cancer" post="cases, caused by HPV occurred in 2018, with a"/>
   <result pre="infected and their new�?born infants. More than 500,000 incident cervical" exact="cancer" post="cases, caused by HPV occurred in 2018, with a"/>
   <result pre="For 2016, WHO estimated 988,000 pregnant women were infected with" exact="syphilis" post="resulting in 660,000 congenital syphilis cases of which 350,000"/>
   <result pre="988,000 pregnant women were infected with syphilis resulting in 660,000" exact="congenital syphilis" post="cases of which 350,000 were adverse birth outcomes including"/>
   <result pre="pregnant women were infected with syphilis resulting in 660,000 congenital" exact="syphilis" post="cases of which 350,000 were adverse birth outcomes including"/>
   <result pre="including stillbirth and neonatal death 5. Additional STIs such as" exact="viral hepatitis," post="Mycoplasma genitalium infection, and lymphogranuloma venereum add further weight"/>
   <result pre="Additional STIs such as viral hepatitis, Mycoplasma genitalium infection, and" exact="lymphogranuloma venereum" post="add further weight to these estimates 6, 7. Newly"/>
   <result pre="Estimated new cases of curable sexually transmitted infections (gonorrhoea, chlamydia," exact="syphilis" post="and trichomoniasis) by WHO region, 2016 1. In 2016,"/>
   <result pre="2016 1. In 2016, three linked WHO strategies for HIV," exact="hepatitis" post="and STIs were endorsed by the World Health Assembly"/>
   <result pre="globally (based on the 2018 global baseline). ≤50 cases of" exact="congenital syphilis" post="per 100,000 live births in 80% of countries Sustain"/>
   <result pre="(based on the 2018 global baseline). ≤50 cases of congenital" exact="syphilis" post="per 100,000 live births in 80% of countries Sustain"/>
   <result pre="to align national�?level reporting of key STI indicators related to" exact="syphilis" post="and gonorrhoea alongside those of HIV, but reported data"/>
   <result pre="modelling tools such as Spectrum STI 20 and the WHO" exact="congenital syphilis" post="estimation tool 21 to allow the use of country�?reported"/>
   <result pre="tools such as Spectrum STI 20 and the WHO congenital" exact="syphilis" post="estimation tool 21 to allow the use of country�?reported"/>
   <result pre="and control. Alignment of STI control programmes alongside HIV and" exact="hepatitis" post="prevention through linked WHO strategies has offered frameworks for"/>
   <result pre="on the importance of STIs as indicators of HIV and" exact="hepatitis" post="risk and as opportunities for prevention and control of"/>
   <result pre="TurnerKM, VickermanP, GottliebSL, NewmanLM. Global estimates of prevalent and incident" exact="herpes simplex" post="virus type 2 infections in 2012. PLoS ONE. 2015;10(1):e114989."/>
   <result pre="RowleyJ, AlonsoM, MelloMB, WijesooriyaNS, MahianéSG. Global burden of maternal and" exact="congenital syphilis" post="and associated adverse birth outcomes—Estimates for 2016 and progress"/>
   <result pre="AlonsoM, MelloMB, WijesooriyaNS, MahianéSG. Global burden of maternal and congenital" exact="syphilis" post="and associated adverse birth outcomes—Estimates for 2016 and progress"/>
   <result pre="6collab: World Health Organization . Global Health Sector Strategy on" exact="viral hepatitis," post="2016–2021. [cited 2019 June 20]. Available at: https://www.who.int/hepatitis/strategy2016-2021/ghss-hep/en/ 7collab:"/>
   <result pre="European Centre for Disease Prevention and Control . Syphilis and" exact="congenital syphilis" post="in Europe – A review of epidemiological trends (2007�?2018)"/>
   <result pre="Centre for Disease Prevention and Control . Syphilis and congenital" exact="syphilis" post="in Europe – A review of epidemiological trends (2007�?2018)"/>
   <result pre="2019https://ecdc.europa.eu/sites/portal/files/documents/Syphilis-and-congenital-syphilis-in-Europe.pdf. Accessed on July 16, 2019 27Progress report on HIV," exact="viral hepatitis" post="and sexually transmitted infections 2019. Accountability for the global"/>
   <result pre="Accessed on July 16, 2019 27Progress report on HIV, viral" exact="hepatitis" post="and sexually transmitted infections 2019. Accountability for the global"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6805736\results\search\disease\results.xml">
   <result pre=": Original Paper Assessment of population susceptibility to upcoming seasonal" exact="influenza" post="epidemic strain using interepidemic emerging influenza virus strains Lin-Lei"/>
   <result pre="susceptibility to upcoming seasonal influenza epidemic strain using interepidemic emerging" exact="influenza" post="virus strains Lin-Lei Chen et al. Epidemiology and Infection"/>
   <result pre="any medium, provided the original work is properly cited.S0950268819001717a.pdf Seasonal" exact="influenza" post="virus epidemics have a major impact on healthcare systems."/>
   <result pre="impact on healthcare systems. Data on population susceptibility to emerging" exact="influenza" post="virus strains during the interepidemic period can guide planning"/>
   <result pre="period can guide planning for resource allocation of an upcoming" exact="influenza" post="season. This study sought to assess the population susceptibility"/>
   <result pre="study sought to assess the population susceptibility to representative emerging" exact="influenza" post="virus strains collected during the interepidemic period. The microneutralisation"/>
   <result pre="(MN titers) of a human serum panel against representative emerging" exact="influenza" post="strains collected during the interepidemic period before the 2018/2019"/>
   <result pre="strains collected during the interepidemic period before the 2018/2019 winter" exact="influenza" post="season (H1N1-inter and H3N2-inter) were compared with those against"/>
   <result pre="influenza season (H1N1-inter and H3N2-inter) were compared with those against" exact="influenza" post="strains representative of previous epidemics (H1N1-pre and H3N2-pre). A"/>
   <result pre="genetic and antigenic data, was used in selecting these representative" exact="influenza" post="virus strains for the MN assay. A significantly higher"/>
   <result pre="between H3N2-inter and H3N2-pre. Since A(H1N1) predominated the 2018–2019 winter" exact="influenza" post="epidemic, our results corroborated the epidemic subtype. Key words"/>
   <result pre="infections serology population susceptibility fig-count: table-count: ref-count: page-count: Introduction Seasonal" exact="influenza" post="virus infection has been associated with an estimated 9.4"/>
   <result pre="to 0.6 million deaths per year globally [1, 2]. During" exact="influenza" post="epidemics, the sudden surge in the number of patients"/>
   <result pre="$11.2 billion per year in the United States [5]. Seasonal" exact="influenza" post="epidemics are caused by influenza A(H1N1), A(H3N2) and influenza"/>
   <result pre="the United States [5]. Seasonal influenza epidemics are caused by" exact="influenza" post="A(H1N1), A(H3N2) and influenza B virus. There are important"/>
   <result pre="Seasonal influenza epidemics are caused by influenza A(H1N1), A(H3N2) and" exact="influenza" post="B virus. There are important epidemiological differences between these"/>
   <result pre="influenza B virus. There are important epidemiological differences between these" exact="influenza" post="viruses [6]. Studies have shown that the median ages"/>
   <result pre="Studies have shown that the median ages of patients with" exact="influenza" post="A(H1N1) (20 years) and influenza B (16 years) virus"/>
   <result pre="median ages of patients with influenza A(H1N1) (20 years) and" exact="influenza" post="B (16 years) virus infection are younger than those"/>
   <result pre="B (16 years) virus infection are younger than those with" exact="influenza" post="A(H3N2) (30 years) virus infection [7]. For influenza B"/>
   <result pre="those with influenza A(H3N2) (30 years) virus infection [7]. For" exact="influenza" post="B virus, patients infected by the Victoria lineage are"/>
   <result pre="born after 1947 [9]. Vaccine effectiveness is much lower for" exact="influenza" post="A(H3N2) virus than influenza A(H1N1) or influenza B virus"/>
   <result pre="Vaccine effectiveness is much lower for influenza A(H3N2) virus than" exact="influenza" post="A(H1N1) or influenza B virus [10]. These differences in"/>
   <result pre="much lower for influenza A(H3N2) virus than influenza A(H1N1) or" exact="influenza" post="B virus [10]. These differences in epidemiological characteristics and"/>
   <result pre="significant implication in healthcare resource and workforce planning for an" exact="influenza" post="season. An antibody titer against an influenza virus strain"/>
   <result pre="planning for an influenza season. An antibody titer against an" exact="influenza" post="virus strain correlates with protection against antigenically similar strains"/>
   <result pre="strain correlates with protection against antigenically similar strains [11]. As" exact="influenza" post="virus strains evolve, the population antibody titer against the"/>
   <result pre="will emerge as the predominant strain [12]. For example, the" exact="influenza" post="virus A(H1N1)pdm09 has quickly spread around the world because"/>
   <result pre="of this study is to determine the population susceptibility to" exact="influenza" post="viruses that are newly emerging in the interepidemic period."/>
   <result pre="as we described previously [12, 16]. We hypothesise that the" exact="influenza" post="subtype with a greater reduction in the antibody titer"/>
   <result pre="April to June 2018, which is after the 2017/2018 winter" exact="influenza" post="season. This study was approved by the HKU/HA HKW"/>
   <result pre="by the HKU/HA HKW Institutional Review Board (UW 18–141). Choosing" exact="influenza" post="A virus strains for microneutralisation assay Influenza A strains"/>
   <result pre="previous epidemics (H1N1-pre and H3N2-pre) and those representative of emerging" exact="influenza" post="strains collected during the interepidemic period before the 2018/2019"/>
   <result pre="strains collected during the interepidemic period before the 2018/2019 winter" exact="influenza" post="season (H1N1-inter and H3N2-inter) were chosen based on genetic"/>
   <result pre="(CI) as we described previously [23, 24]. Results Selection of" exact="influenza" post="A(H1N1) strains Before the 2018/2019 winter influenza season, the"/>
   <result pre="Results Selection of influenza A(H1N1) strains Before the 2018/2019 winter" exact="influenza" post="season, the last A(H1N1) epidemic occurred in the 2015/2016"/>
   <result pre="season, the last A(H1N1) epidemic occurred in the 2015/2016 winter" exact="influenza" post="season. S183P substitution in the HA, which was absent"/>
   <result pre="Influenza A strains emerging in Hong Kong. (a) Emergence of" exact="influenza" post="A(H1N1) strains with HA S183P substitution. (b) Emergence of"/>
   <result pre="influenza A(H1N1) strains with HA S183P substitution. (b) Emergence of" exact="influenza" post="A(H3N2) strains belonging to lineage 3C.2a1b. Amino acid sequences"/>
   <result pre="2018 and are indicated by the black arrows. Selection of" exact="influenza" post="A(H3N2) strains Phylogenetic analysis showed that A(H3N2) clade 3C.2a2"/>
   <result pre="2. Phylogenetic tree of HA showing the genetic relationship of" exact="influenza" post="A(H3N2) in Hong Kong. Nucleotide sequences were downloaded from"/>
   <result pre="Nucleotide sequences were downloaded from GISAID (Supplementary Table S2). All" exact="influenza" post="A(H3N2) strains from Hong Kong available at GISAID as"/>
   <result pre="for H3N2. Table 1. Comparison of microneutralisation antibody titer between" exact="influenza" post="A virus strains representative of previous epidemics and those"/>
   <result pre="than H3N2-pre. Table 2. Geometric mean microneutralisation antibody titer against" exact="influenza" post="A virus of each age group Geometric mean microneutralisation"/>
   <result pre="3). Table 3. Microneutralisation antibody titer of pooled serum against" exact="influenza" post="A H1N1 virus of each age group Microneutralisation antibody"/>
   <result pre="healthcare system. Assessing the population susceptibility to the upcoming epidemic" exact="influenza" post="strain is one of the important components in preparing"/>
   <result pre="strain is one of the important components in preparing for" exact="influenza" post="epidemics. In this study, we determined the population susceptibility"/>
   <result pre="the population susceptibility by comparing the antibody titers against representative" exact="influenza" post="virus strains that emerge during the interepidemic period with"/>
   <result pre="influenza virus strains that emerge during the interepidemic period with" exact="influenza" post="virus strains representative of those in the previous epidemic."/>
   <result pre="lower MN titers against H3N2-inter compared with H3N2-pre. For the" exact="influenza" post="season 2018/19 winter influenza season in Hong Kong, A(H1N1)"/>
   <result pre="H3N2-inter compared with H3N2-pre. For the influenza season 2018/19 winter" exact="influenza" post="season in Hong Kong, A(H1N1) was the predominant subtype"/>
   <result pre="[25]. Similarly, A(H1N1) subtype affects most hospitalised patients with laboratory-confirmed" exact="influenza" post="virus infection in the 2018/2019 season in Europe [26]."/>
   <result pre="season in Europe [26]. A(H1N1) is also the most predominant" exact="influenza" post="virus subtype affecting the United States [27]. Therefore, the"/>
   <result pre="States [27]. Therefore, the findings from our serosurveillance of interepidemic" exact="influenza" post="virus strains, which were collected before the 2018/2019 winter"/>
   <result pre="collected before the 2018/2019 winter epidemic, corroborated with the predominant" exact="influenza" post="virus subtype in the 2018/2019 winter epidemic. Although the"/>
   <result pre="virus subtype in the 2018/2019 winter epidemic. Although the predominant" exact="influenza" post="virus strains of a particular influenza subtype during an"/>
   <result pre="epidemic. Although the predominant influenza virus strains of a particular" exact="influenza" post="subtype during an influenza season can only be ascertained"/>
   <result pre="influenza virus strains of a particular influenza subtype during an" exact="influenza" post="season can only be ascertained after the influenza season"/>
   <result pre="during an influenza season can only be ascertained after the" exact="influenza" post="season has begun, these can be predicted by analysing"/>
   <result pre="season has begun, these can be predicted by analysing the" exact="influenza" post="virus strains collected during the interepidemic period. As seen"/>
   <result pre="found in most A(H1N1) strains collected in the 2018/19 winter" exact="influenza" post="season, showed a clear trend of increase since the"/>
   <result pre="season in 2015/16 winter. Our approach, which used representative emerging" exact="influenza" post="strains collected during the interepidemic period, provides population susceptibility"/>
   <result pre="a low-vaccine uptake rate. In Hong Kong, the overall seasonal" exact="influenza" post="uptake rate was only 14.8% as of 3 March"/>
   <result pre="assay instead of HA inhibition assay. Traditionally, antigenic characteristics of" exact="influenza" post="viruses are determined by haemagglutination inhibition assay (HAI) using"/>
   <result pre="30]. Other groups have developed models to predict the predominant" exact="influenza" post="virus subtype in the upcoming influenza season. These models"/>
   <result pre="to predict the predominant influenza virus subtype in the upcoming" exact="influenza" post="season. These models are based on the evolution rate,"/>
   <result pre="Europe, A(H3N2) was the predominant subtype in the 2018/2019 winter" exact="influenza" post="season. Second, we have used a limited number of"/>
   <result pre="influenza season. Second, we have used a limited number of" exact="influenza" post="virus strains. Third, one mutation arose during the virus"/>
   <result pre="virus, which was the virus subtype that predominated the 2018/2019" exact="influenza" post="season in Hong Kong. Our results support the use"/>
   <result pre="Public Health Laboratory Services of Hong Kong in providing the" exact="influenza" post="strain A/Hong Kong/656/2018; the division of Clinical Chemistry, Department"/>
   <result pre="2.collab: Collaborators GBDI (2019) Mortality, morbidity, and hospitalisations due to" exact="influenza" post="lower respiratory tract infections, 2017: an analysis for the"/>
   <result pre="Respiratory medicine7, 69–89.30553848 3.BeysardNet al. (2018) Impact of the 2014–2015" exact="influenza" post="season on the activity of an academic emergency department."/>
   <result pre="Kong. QJM112, 11–16.30295857 5.PutriWet al. (2018) Economic burden of seasonal" exact="influenza" post="in the United States. Vaccine36, 3960–3966.29801998 6.CainiSet al. (2018)"/>
   <result pre="Vaccine36, 3960–3966.29801998 6.CainiSet al. (2018) Clinical characteristics and severity of" exact="influenza" post="infections by virus type, subtype, and lineage: a systematic"/>
   <result pre="Viruses12, 780–792.29858537 7.BedfordTet al. (2015) Global circulation patterns of seasonal" exact="influenza" post="viruses vary with antigenic drift. Nature523, 217–220.26053121 8.SkowronskiDMet al."/>
   <result pre="antigenic drift. Nature523, 217–220.26053121 8.SkowronskiDMet al. (2017) Age-related differences in" exact="influenza" post="B infection by lineage in a community-based sentinel system,"/>
   <result pre="Infectious Diseases216, 697–702.28934439 9.BuddAPet al. (2019) Birth cohort effects in" exact="influenza" post="surveillance data: evidence that first influenza infection affects later"/>
   <result pre="Birth cohort effects in influenza surveillance data: evidence that first" exact="influenza" post="infection affects later influenza-associated illness. Journal of Infectious Diseases220,"/>
   <result pre="illness. Journal of Infectious Diseases220, 820–829.31053844 10.BelongiaEAet al. (2016) Variable" exact="influenza" post="vaccine effectiveness by subtype: a systematic review and meta-analysis"/>
   <result pre="studies. Lancet Infectious Diseases16, 942–951.27061888 11.MontoASet al. (2015) Antibody to" exact="influenza" post="virus neuraminidase: an independent correlate of protection. Journal of"/>
   <result pre="(2018) Low population serum microneutralization antibody titer against the predominating" exact="influenza" post="A(H3N2) N121K virus during the severe influenza summer peak"/>
   <result pre="against the predominating influenza A(H3N2) N121K virus during the severe" exact="influenza" post="summer peak of Hong Kong in 2017. Emerging Microbes"/>
   <result pre="presentation and outcome between adult patients suffering from the pandemic" exact="influenza" post="A (H1N1) 2009 virus and the seasonal influenza A"/>
   <result pre="the pandemic influenza A (H1N1) 2009 virus and the seasonal" exact="influenza" post="A virus infection. Postgraduate Medical Journal86, 515–521.20693151 14.ZhangAJet al."/>
   <result pre="Medical Journal86, 515–521.20693151 14.ZhangAJet al. (2011) High incidence of severe" exact="influenza" post="among individuals over 50 years of age. Clinical and"/>
   <result pre="Vaccine Immunology18, 1918–1924.21900532 15.ChengVCet al. (2012) Two years after pandemic" exact="influenza" post="A/2009/H1N1: what have we learned?Clinical Microbiology Reviews25, 223–263.22491771 16.ChanKHet"/>
   <result pre="Immunology18, 867–873.21411604 17.collab: World Health Organization (2018) Recommended composition of" exact="influenza" post="virus vaccines for use in the 2019 southern hemisphere"/>
   <result pre="influenza virus vaccines for use in the 2019 southern hemisphere" exact="influenza" post="season. Available athttps://www.who.int/influenza/vaccines/virus/recommendations/201809_recommendation.pdf (Accessed 20 December 2018). 18.ShuY and"/>
   <result pre="18.ShuY and McCauleyJ (2017) GISAID: Global initiative on sharing all" exact="influenza" post="data – from vision to reality. Eurosurveillance22, pii: 30494."/>
   <result pre="Influenza Surveillance Network. 21.LaurieKLet al. (2015) International laboratory comparison of" exact="influenza" post="microneutralization assays for A(H1N1)pdm09, A(H3N2), and A(H5N1) influenza viruses"/>
   <result pre="comparison of influenza microneutralization assays for A(H1N1)pdm09, A(H3N2), and A(H5N1)" exact="influenza" post="viruses by CONSISE. Clinical and Vaccine Immunology22, 957–964.26108286 22.WangYDet"/>
   <result pre="Journal30, 703–705. 23.HungIFet al. (2016) Topical imiquimod before intradermal trivalent" exact="influenza" post="vaccine for protection against heterologous non-vaccine and antigenically drifted"/>
   <result pre="al. (2012) High titer and avidity of nonneutralizing antibodies against" exact="influenza" post="vaccine antigen are associated with severe influenza. Clinical and"/>
   <result pre="1012–1018.22573737 25.collab: Centre for Health Protection (2019) Local situation of" exact="influenza" post="activity (as of Jan 9, 2019). Flu Express16, 1–9."/>
   <result pre="17 January 2019). 28.XieHet al. (2017) Differential effects of prior" exact="influenza" post="exposures on H3N2 cross-reactivity of human postvaccination sera. Clinical"/>
   <result pre="of the Hong Kong Special Administration Region (2019) LCQ11: Seasonal" exact="influenza" post="vaccination. Available athttps://www.info.gov.hk/gia/general/201903/20/P2019032000606.htm (Accessed 11 May 2019). 30.collab: European"/>
   <result pre="January 2019). 32.PetrovaVN and RussellCA (2018) The evolution of seasonal" exact="influenza" post="viruses. Nature Reviews Microbiology16, 60. 33.SkowronskiDMet al. (2016) A"/>
   <result pre="storm: impact of genomic variation and serial vaccination on low" exact="influenza" post="vaccine effectiveness during the 2014–2015 season. Clinical Infectious Diseases63,"/>
   <result pre="34.SmithDJet al. (2004) Mapping the antigenic and genetic evolution of" exact="influenza" post="virus. Science305, 371–376.15218094 35.DuXet al. (2017) Evolution-informed forecasting of"/>
   <result pre="virus. Science305, 371–376.15218094 35.DuXet al. (2017) Evolution-informed forecasting of seasonal" exact="influenza" post="A (H3N2). Science Translational Medicine9, pii: eaan5325.29070700 36.NeherRAet al."/>
   <result pre="(2016) Prediction, dynamics, and visualization of antigenic phenotypes of seasonal" exact="influenza" post="viruses. Proceedings of the National Academy of Sciences113, E1701–E1709."/>
   <result pre="Sciences113, E1701–E1709. 37.collab: World Health Organization (2019) Recommended composition of" exact="influenza" post="virus vaccines for use in the 2019–2020 northern hemisphere"/>
   <result pre="influenza virus vaccines for use in the 2019–2020 northern hemisphere" exact="influenza" post="season. Available athttps://www.who.int/influenza/vaccines/virus/recommendations/2019_20_north/en/ (Accessed 20 May 2019). 38.ZostSJet al."/>
   <result pre="athttps://www.who.int/influenza/vaccines/virus/recommendations/2019_20_north/en/ (Accessed 20 May 2019). 38.ZostSJet al. (2017) Contemporary H3N2" exact="influenza" post="viruses have a glycosylation site that alters binding of"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6805747\results\search\disease\results.xml">
   <result pre="chronic infection. Approximately 399 thousands of people died because of" exact="hepatitis" post="C or diseases caused by HCV infection (cirrhosis and"/>
   <result pre="hepatitis C or diseases caused by HCV infection (cirrhosis and" exact="hepatocellular carcinoma" post="(HCC)) each year [1]. HCV infection in the HIV-infected"/>
   <result pre="that the serum iron level was a risk factor for" exact="hepatitis" post="B virus (HBV)-related HCC, and it was also positively"/>
   <result pre="addicts. Molecular Neurobiology53, 3873–3881.26162319 7.ChenWet al. (2016) Changing epidemiology of" exact="hepatitis" post="C virus genotype among patients with human immunodeficiency virus/hepatitis"/>
   <result pre="China. PLoS One11, e0161844.27603929 8.WuZet al. (2016) Molecular epidemiology of" exact="hepatitis" post="C infections in Ningxia, China: genotype, phylogeny and mutation"/>
   <result pre="of STD &amp;amp; AIDS20, 399–405.19451325 10.XiaXet al. (2008) Epidemiology of" exact="hepatitis" post="C virus infection among injection drug users in China:"/>
   <result pre="analyses. PLoS One7, e28006.22253686 15.PengJSet al. (2008) Genetic variation of" exact="hepatitis" post="C virus in a cohort of injection heroin users"/>
   <result pre="191–196.18353479 16.ZhaoRet al. (2013) Epidemiological distribution and genotype characterization of" exact="hepatitis" post="C virus and HIV co-infection in Wuhan, China, where"/>
   <result pre="China. PLoS One3, e3608.18974888 18.QiYet al. (2016) Subtype distribution of" exact="hepatitis" post="C virus in Jiangsu, China. Journal of Medical Virology88,"/>
   <result pre="ZhaoW (2018) Serum iron levels decreased in patients with HBV-related" exact="hepatocellular carcinoma," post="as a risk factor for the prognosis of HBV-related"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6805938\results\search\disease\results.xml">
   <result pre="the spread of harmful contagions, including human viruses such as" exact="influenza" post="or dengue fever1–3, chytrid fungus in frogs4, and bacterial"/>
   <result pre="effects that increase its spread, and the interplay between an" exact="infectious disease" post="and changes in the underlying network structure has been"/>
   <result pre="interests. References References 1.SalathéMet al.A high-resolution human contact network for" exact="infectious disease" post="transmissionProc. Natl. Acad. Sci. USA2010107220202202510.1073/pnas.100909410821149721 2.YangWCowlingBJLauEHShamanJForecasting influenza epidemics in"/>
   <result pre="network for infectious disease transmissionProc. Natl. Acad. Sci. USA2010107220202202510.1073/pnas.100909410821149721 2.YangWCowlingBJLauEHShamanJForecasting" exact="influenza" post="epidemics in Hong KongPLoS Comput. Biol.201511117 3.BarmakDHDorsoCOteroMModelling dengue epidemic"/>
   <result pre="Rev. E20108211010.1103/PhysRevE.82.036116 39.VolzEMMillerJCGalvaniAMeyersLAEffects of heterogeneous and clustered contact patterns on" exact="infectious disease" post="dynamicsPLoS Comput. Biol.2011711310.1371/annotation/85b99614-44b4-4052-9195-a77d52dbdc05 40.AlthouseBMHébert-DufresneLEpidemic cycles driven by host behaviourJ."/>
   <result pre="Acad. Sci. USA20111086306631110.1073/pnas.101125010821444809 44.Del ValleSHethcoteHHymanJMCastillo-ChavezCEffects of behavioral changes in a" exact="smallpox" post="attack modelMath. Biosci.200519522825110.1016/j.mbs.2005.03.00615913667 45.Olson, M. The logic of collective"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6805996\results\search\disease\results.xml">
   <result pre="which the virus infection causes disease. Abstract ABSTRACT Acute flaccid" exact="myelitis" post="(AFM) is a rare but serious illness of the"/>
   <result pre="6 years. Enterovirus D68 (EV-D68) was first isolated from children with" exact="pneumonia" post="in 1962, but an association with AFM was not"/>
   <result pre="and death in adult ifnar knockout mice. In contrast, no" exact="viral disease" post="was observed after intracranial inoculation of wild-type mice. Six"/>
   <result pre="response is critical for restricting EV-D68 disease. KEYWORDS acute flaccid" exact="myelitis" post="astrocyte enterovirus neuron neurotropism picornavirus Funding HHS | NIH"/>
   <result pre="(1–12). While the virus was originally isolated from children with" exact="pneumonia" post="in 1962 (13), few cases of EV-D68 infection were"/>
   <result pre="distress induced by EV-D68 infection also developed an acute flaccid" exact="myelitis" post="(AFM) similar to that caused by poliovirus, a related"/>
   <result pre="phenotype (6, 31–34). This conclusion has been made by using" exact="neuroblastoma" post="cells, which are not primary cells of the nervous"/>
   <result pre="of the nervous system. Two murine models of EV-D68-induced paralytic" exact="myelitis" post="have been established. These two models address the question"/>
   <result pre="of this sugar in neurotropism. RESULTS EV-D68 infection of mouse" exact="neuroblastoma" post="and embryonic fibroblasts. To determine if mouse cells are"/>
   <result pre="a mouse embryonic fibroblast cell line (MEF) and a mouse" exact="neuroblastoma" post="cell line (N2A) were infected with multiple isolates of"/>
   <result pre="1 Replication of EV-D68 isolates in mouse embryonic fibroblasts and" exact="neuroblastoma" post="cells. Time course of replication of multiple isolates of"/>
   <result pre="a mouse embryonic fibroblast (MEF) cell line and a mouse" exact="neuroblastoma" post="cell line (N2A). Cells were infected with virus at"/>
   <result pre="acid for infection with EV-D68, cultures of various cells, including" exact="rhabdomyosarcoma" post="(RD) cells, the cells used for propagation and titration"/>
   <result pre="receptor than other isolates, and the presence of sialic acid" exact="aids" post="could increase the affinity/avidity of the interaction between virion"/>
   <result pre="neuraminidase-containing medium for 30 min prior to the addition of" exact="influenza" post="A virus. Production of infectious virus after infection of"/>
   <result pre="neuraminidase was severely attenuated (Fig. 2). Additionally, no hemagglutination by" exact="influenza" post="A virus was observed when human RBCs were pretreated"/>
   <result pre="attachment to the cell surface, as described for Theiler’s murine" exact="encephalomyelitis" post="virus, enterovirus 70, and coxsackievirus A24 (45–49). FIG 2"/>
   <result pre="independent experiments. Bottom, effect of neuraminidase treatment on yield of" exact="influenza" post="virus. MDCK cells were pretreated with neuraminidase as described"/>
   <result pre="cells were pretreated with neuraminidase as described above, infected with" exact="influenza" post="virus at a multiplicity of infection of 3, and"/>
   <result pre="onset of paralysis, as observed in the murine model of" exact="poliomyelitis" post="(62). Despite the absence of evidence that EV-D68 replicates"/>
   <result pre="described. These models have been predominantly used to investigate the" exact="respiratory disease" post="associated with virus infection. In the cotton rat model,"/>
   <result pre="They have also been used to study Zika virus and" exact="measles" post="virus infections (53, 70, 71). Findings from organotypic brain"/>
   <result pre="initially isolated from the bone marrow of a patient with" exact="neuroblastoma" post="and are known to lose their neuronal characteristics upon"/>
   <result pre="AFM in 2014, for the ability to infect the mouse" exact="neuroblastoma" post="cell line N2A; organotypic brain slice cultures from day"/>
   <result pre="develop paralytic disease 8 to 10 days after diagnosis of the" exact="respiratory disease." post="We find that all EV-D68 isolates replicate in human"/>
   <result pre="flaviviruses West Nile virus and Zika virus and the alphavirus" exact="chikungunya" post="virus (75, 77–79). The ability of West Nile virus"/>
   <result pre="81). A role for astrocytosis in motor neuron destruction during" exact="amyotrophic lateral sclerosis" post="has also been proposed (82). The identity of the"/>
   <result pre="for 2 h. Activity of neuraminidase was verified by lack of" exact="influenza" post="virus hemagglutination on treated guinea pig red blood cells"/>
   <result pre="for Disease Control and Prevention. 2014Acute flaccid paralysis with anterior" exact="myelitis" post="- California, June 2012-June 2014. MMWR Morb Mortal Wkly"/>
   <result pre="D68 detected in the United States during the 2014 severe" exact="respiratory disease" post="outbreak. Genome Announc2:e01201-14. doi:10.1128/genomeA.01201-14.25414503 5.DuJ, ZhengB, ZhengW, LiP, KangJ,"/>
   <result pre="ChiuCY2015A novel outbreak enterovirus D68 strain associated with acute flaccid" exact="myelitis" post="cases in the USA (2012-14): a retrospective cohort study."/>
   <result pre="Holberg-PetersenM, VainioK, DudmanSG, KranAM, RojahnAE2015Two cases of acute severe flaccid" exact="myelitis" post="associated with enterovirus D68 infection in children, Norway, autumn"/>
   <result pre="18.EspositoS, ChidiniG, CinnanteC, NapolitanoL, GianniniA, TerranovaL, NiestersH, PrincipiN, CalderiniE2017Acute flaccid" exact="myelitis" post="associated with enterovirus-D68 infection in an otherwise healthy child."/>
   <result pre="YuG, LeserJS, YagiS, ClarkeP, ChiuCY, TylerKL2017A mouse model of paralytic" exact="myelitis" post="caused by enterovirus D68. PLoS Pathog13:e1006199. doi:10.1371/journal.ppat.1006199.28231269 36.CroneM, TellierR,"/>
   <result pre="SiddharthanV, Van WettereAJ, SinexDG, TarbetEB2018Causation of acute flaccid paralysis by" exact="myelitis" post="and myositis in enterovirus-D68 infected mice deficient in interferon"/>
   <result pre="WettereAJ, SinexDG, TarbetEB2018Causation of acute flaccid paralysis by myelitis and" exact="myositis" post="in enterovirus-D68 infected mice deficient in interferon alphabeta/gamma receptor"/>
   <result pre="usage of carbohydrate co-receptors influences cellular tropism of Theiler’s murine" exact="encephalomyelitis" post="virus infection of the central nervous system. Glycoconj J23:39–49."/>
   <result pre="macrophages versus oligodendrocytes. Virus Res111:214–223. doi:10.1016/j.virusres.2005.04.010.15893838 47.TsunodaI, LibbeyJE, FujinamiRS2009Theiler’s murine" exact="encephalomyelitis" post="virus attachment to the gastrointestinal tract is associated with"/>
   <result pre="receptor engagement in the evolution of a pandemic acute hemorrhagic" exact="conjunctivitis" post="virus. Proc Natl Acad Sci U S A115:397–402. doi:10.1073/pnas.1713284115.29284752"/>
   <result pre="Sci U S A115:397–402. doi:10.1073/pnas.1713284115.29284752 50.DoobinDJ, KemalS, DantasTJ, ValleeRB2016Severe NDE1-mediated" exact="microcephaly" post="results from neural progenitor cell cycle arrests at multiple"/>
   <result pre="receptor signaling drives selective permissiveness of astrocytes and microglia to" exact="measles" post="virus during brain infection. J Virol93:e00618-19. doi:10.1128/JVI.00618-19.31019048 72.QianX, NguyenHN,"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6812237\results\search\disease\results.xml">
   <result pre="highly contagious and it spreads through air. In 2009 H1N1" exact="influenza" post="virus emerged after reassortment of North American TRIG and"/>
   <result pre="with cough (89.6%) was the most common symptom followed by" exact="shortness" post="of breath (72.7%). Post monsoon was the peak season"/>
   <result pre="and that exposes human population with a new strain of" exact="influenza" post="leading to higher or lower morbidity or mortality. The"/>
   <result pre="to higher or lower morbidity or mortality. The first human" exact="influenza" post="epidemic of 21st century was an Influenza A(H1N1)pdm09 subtype"/>
   <result pre="reported during this pandemic. In next two-three years only sporadic" exact="influenza" post="activity was reported i.e. 2 confirmed cases of Influenza"/>
   <result pre="study was carried out at Virology Laboratory specially designated for" exact="influenza" post="testing at Regional Medical Research Centre (ICMR), Bhubaneswar, Odisha,"/>
   <result pre="22.77%. Table 2 Proportion of suspected and confirmed cases of" exact="influenza" post="by age group and gender. [alt-text] Table 2 Age"/>
   <result pre="and cough were the most common (89.6%) symptom followed by" exact="shortness" post="of breath (72.7%) where as sore throat and nasal"/>
   <result pre="in the community where there are one or more confirmed" exact="influenza" post="cases 444 15.4 110 18.15 334 14.74 Similarly, among"/>
   <result pre="Similarly, among the cases of pandemic Influenza A(H1N1)pdm09 negative but" exact="influenza" post="A positives; fever (91.4%) and cough (87.67%) were most"/>
   <result pre="(91.4%) and cough (87.67%) were most common symptoms followed by" exact="shortness" post="of breath (77.6%). No follow up data was available"/>
   <result pre="doctor's consultation before attending referral hospitals. Year wise analysis of" exact="influenza" post="activity revealed no case of Influenza A(H1N1)pdm09 in 2011"/>
   <result pre="month of March in 2015. Fig. 2 Month-wise analysis of" exact="influenza" post="H1N1 positive cases. 4 Discussion India reported its first"/>
   <result pre="with flu like symptoms were hospitalized and tested for pandemic" exact="influenza" post="Influenza A(H1N1)pdm09 infection, of which 606 (21.1%) were found"/>
   <result pre="found to be positive. The characteristic feature of this pandemic" exact="influenza" post="infection was that, case distribution was disproportionate among all"/>
   <result pre="common symptoms observed were fever with cough (89.6%) followed by" exact="shortness" post="of breath (72.7%). Similar symptoms of positive cases were"/>
   <result pre="used for preliminary diagnosis of Influenza A infection during the" exact="influenza" post="season prior to lab diagnosis report. Month-wise analysis of"/>
   <result pre="influenza season prior to lab diagnosis report. Month-wise analysis of" exact="influenza" post="activity in the present study showed that in our"/>
   <result pre="post monsoon season i.e. August–September where second was dominant. Increased" exact="influenza" post="activity in monsoon and post monsoon seasons also observed"/>
   <result pre="cases during April–June; dry and sunny season which indicated increased" exact="influenza" post="activity in cold temperature and in low solar radiation"/>
   <result pre="low solar radiation [15, 16, 17]. Exact reason for increased" exact="influenza" post="activity in winter is not known but when temperature"/>
   <result pre="to 90% patients having any one underlying conditions like pregnancy," exact="obesity" post="etc. [26]. Neurological complication has been reported in 15.4%"/>
   <result pre="infection in some cases might have accentuated an underlying chronic" exact="neurological disorder" post="[28]. Pregnancy is a well documented risk factor for"/>
   <result pre="of other syndromes like Down syndrome with immune compromised state," exact="cerebral malaria" post="and hypothyroidism. There is considerable variation depending on country"/>
   <result pre="other syndromes like Down syndrome with immune compromised state, cerebral" exact="malaria" post="and hypothyroidism. There is considerable variation depending on country"/>
   <result pre="limited by certain amount of missing clinical data like pre-existing" exact="respiratory disease," post="small numbers, incomplete records on epidemic dynamics within the"/>
   <result pre="should be taken into account and health providers can recommend" exact="influenza" post="vaccination on priority to patients with discussed medical conditions."/>
   <result pre="is available for this paper. References References 1TrevennecK.LegerL.LyazrhiF.Transmission of pandemic" exact="influenza" post="H1N1 (2009) in Vietnamese swine in 2009-2010Influenza Other Respir."/>
   <result pre="Viruses65201234835722212737 2KulkarniP.S.RautS.K.DhereR.M.A post-marketing surveillance study of a human live-virus pandemic" exact="influenza" post="A (H1N1) vaccine (Nasovac (®)) in IndiaHum. Vaccines Immunother.912013122124"/>
   <result pre="vaccine (Nasovac (®)) in IndiaHum. Vaccines Immunother.912013122124 3AdhikariB.R.ShakyaG.UpadhyayB.P.Outbreak of pandemic" exact="influenza" post="A/H1N1 2009 in NepalVirol. J.82011133Mar 2321426589 4Interim WHO Guidance"/>
   <result pre="MaharashtraIndian J. Public Health563201224224423229220 7LvJ.RenZ.Y.ZhangY.Y.Study on age-dependent pre-existing 2009 pandemic" exact="influenza" post="virus T and B cell responses from Chinese populationBMC"/>
   <result pre="Chinese populationBMC Infect. Dis.1712017136Published 2017 Feb 1028187750 8ChoiW.RhoB.H.LeeM.Y.Male predominance of" exact="pneumonia" post="and hospitalization in pandemic influenza A (H1N1) 2009 infectionBMC"/>
   <result pre="Feb 1028187750 8ChoiW.RhoB.H.LeeM.Y.Male predominance of pneumonia and hospitalization in pandemic" exact="influenza" post="A (H1N1) 2009 infectionBMC Res. Notes42011351http://www.biomedcentral.com/1756-0500/4/35121906395 9RevdiwalaS.MullaS.PanwalaT.Clinical characterisation of"/>
   <result pre="A (H1N1) 2009 infectionBMC Res. Notes42011351http://www.biomedcentral.com/1756-0500/4/35121906395 9RevdiwalaS.MullaS.PanwalaT.Clinical characterisation of H1N1" exact="influenza" post="Taqman real time PCR positive casesNatl. J. Med. Res.2120121214"/>
   <result pre="experience in local population of LahoreBiomedia261920105053 11ChoudhryA.SinghS.KhareS.Emergence of pandemic 2009" exact="influenza" post="A H1N1, IndiaIndian J. Med. Res.1354201253453722664503 12RasmussenS.A.JamiesonD.J.MacfarlaneK.Pandemic influenza and"/>
   <result pre="pandemic 2009 influenza A H1N1, IndiaIndian J. Med. Res.1354201253453722664503 12RasmussenS.A.JamiesonD.J.MacfarlaneK.Pandemic" exact="influenza" post="and pregnant women: summary of a meeting of expertsAm."/>
   <result pre="18[Epub ahead of print] 13BalaganesakumarS.R.MurhekarM.V.SwamyK.K.Risk factors associated with death among" exact="influenza" post="A (H1N1) patients, Tamil Nadu, India, 2010J. Postgrad. Med.5912013"/>
   <result pre="hospital with pandemic (H1N1) influenzaCMAJ1824201034935520159893 15JainS.KamimotoL.BramleyA.M.Hospitalized patients with 2009 H1N1" exact="influenza" post="in the United States, april–june 2009N. Engl. J. Med.36120091935194419815859"/>
   <result pre="hospitalizations and mortality from seasonal and pandemic 2009 a (H1N1)" exact="influenza" post="in Saurashtra, India: 2009-2011Ann. Med. Health Sci. Res.33201333434024116309 18CunhaB.A.SyedU.MickailN.StrolloS.Rapid"/>
   <result pre="Med. Health Sci. Res.33201333434024116309 18CunhaB.A.SyedU.MickailN.StrolloS.Rapid clinical diagnosis in fatal swine" exact="influenza" post="(H1N1) pneumonia in an adult with negative rapid influenza"/>
   <result pre="Sci. Res.33201333434024116309 18CunhaB.A.SyedU.MickailN.StrolloS.Rapid clinical diagnosis in fatal swine influenza (H1N1)" exact="pneumonia" post="in an adult with negative rapid influenza diagnostic tests"/>
   <result pre="swine influenza (H1N1) pneumonia in an adult with negative rapid" exact="influenza" post="diagnostic tests (RIDTs): diagnostic swine influenza triadHeart Lung3912010 Jan-Feb788620109989"/>
   <result pre="adult with negative rapid influenza diagnostic tests (RIDTs): diagnostic swine" exact="influenza" post="triadHeart Lung3912010 Jan-Feb788620109989 19LouieJ.K.AcostaM.WinterK.Factors associated with death or hospitalization"/>
   <result pre="19LouieJ.K.AcostaM.WinterK.Factors associated with death or hospitalization due to pandemic 2009" exact="influenza" post="A(H1N1) infection in CaliforniaJ. Am. Med. Assoc.30217200918961902 20Echevarría-ZunoS.Mejía-AranguréJ.M.Mar-ObesoA.J.Infection and"/>
   <result pre="infection in CaliforniaJ. Am. Med. Assoc.30217200918961902 20Echevarría-ZunoS.Mejía-AranguréJ.M.Mar-ObesoA.J.Infection and death from" exact="influenza" post="A H1N1 virus in Mexico: a retrospective analysisLancet374970720092072207919; Epub"/>
   <result pre="a retrospective analysisLancet374970720092072207919; Epub 2009 Nov 1119913290 21LouieJ.K.AcostaM.JamiesonD.J.Severe, 2009 H1N1" exact="influenza" post="in pregnant and postpartum women in CaliforniaN. Engl. J."/>
   <result pre="Maternity Outcomes Surveillance System: critical illness due to 2009 A/H1N1" exact="influenza" post="in pregnant and postpartum women: population based cohort studyBMJ2010340"/>
   <result pre="studyBMJ2010340 23ZarychanskiR.StuartT.L.KumarA.Correlates of severe disease in patients with 2009 pandemic" exact="influenza" post="(H1N1) virus infectionCMAJ1823201025726420093297 24PalaciosG.HornigM.CisternaD.Streptococcus pneumoniae coinfection is correlated with"/>
   <result pre="H1N1 pandemic influenzaPLoS One4122009e8540Published 2009 Dec 31 25World Health OrganizationNew" exact="influenza" post="A (H1N1) virus: global epidemiological situation, June 2009Wkly. Epidemiol."/>
   <result pre="Neurol.92201014214320129164 29ReedC.KatzJ.M.HancockK.BalishA.FryA.M.collab: H1N1 Serosurvey Working GroupPrevalence of seropositivity to pandemic" exact="influenza" post="A/H1N1 virus in the United States following the 2009"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6812269\results\search\disease\results.xml">
   <result pre="tick-borne diseases such as Lyme borreliosis (Borrelia burgdorferi sensu lato)," exact="tick-borne encephalitis" post="(due to several flaviviruses such as tick-borne encephalitis virus"/>
   <result pre="diseases such as Lyme borreliosis (Borrelia burgdorferi sensu lato), tick-borne" exact="encephalitis" post="(due to several flaviviruses such as tick-borne encephalitis virus"/>
   <result pre="sensu lato), tick-borne encephalitis (due to several flaviviruses such as" exact="tick-borne encephalitis" post="virus or Powassan virus), and spotted fever (several Rickettsia)"/>
   <result pre="lato), tick-borne encephalitis (due to several flaviviruses such as tick-borne" exact="encephalitis" post="virus or Powassan virus), and spotted fever (several Rickettsia)"/>
   <result pre="flaviviruses such as tick-borne encephalitis virus or Powassan virus), and" exact="spotted fever" post="(several Rickettsia) (Moyer, 2015; Nelder et al., 2016). However,"/>
   <result pre="to contain tick-borne pathogens such as the severe fever with" exact="thrombocytopenia" post="syndrome phlebovirus (SFTS virus) (Silvas and Aguilar, 2017), recent"/>
   <result pre="humans, pigs, and bats), Pestivirus (animal viruses such as bovine" exact="diarrhea" post="virus or classical swine fever virus), and Hepacivirus (human"/>
   <result pre="(GP), the nucleoprotein (NP) and the matrix protein (M). Although" exact="influenza" post="viruses present a surface GP constituted of hemagglutin and"/>
   <result pre="including humans, causing for the latter from febrile illness to" exact="encephalitis" post="(McCauley et al., 2012). Apart from ticks, many arthropods"/>
   <result pre="(2016). Ecology of the tick-borne phlebovirus causing severe fever with" exact="thrombocytopenia" post="syndrome in an endemic area of China. PLoS Negl."/>
   <result pre="SilvasJ. A.AguilarP. V. (2017). The emergence of severe fever with" exact="thrombocytopenia" post="syndrome virus. Am. J. Trop. Med. Hyg. 97, 992–996."/>
   <result pre="YuX. J.LiangM. F.ZhangS. Y.LiuY.LiJ. D.SunY. L.et al.. (2011). Fever with" exact="thrombocytopenia" post="associated with a novel bunyavirus in China. N. Engl."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6814656\results\search\disease\results.xml">
   <result pre="epub: 2019-5-5collection: 2019-10345592595received: 2018-12-19accepted: 2019-4-15(C) , Dear Editor, Porcine epidemic" exact="diarrhea" post="virus (PEDV) is the etiologic agent of porcine epidemic"/>
   <result pre="diarrhea virus (PEDV) is the etiologic agent of porcine epidemic" exact="diarrhea" post="(PED), which is an acute, highly contagious, and devastating"/>
   <result pre="(PED), which is an acute, highly contagious, and devastating enteric" exact="viral disease" post="in pigs (Lee 2015). PEDV is a coronavirus that"/>
   <result pre="and viremia detection. Following infection, only a short period of" exact="diarrhea" post="(2–3 days) was observed from portions of both WT"/>
   <result pre="pigs (Supplementary Table S4). Two APN KO pigs manifested consistent" exact="diarrhea" post="and evident body weight loss, and died at PIDs"/>
   <result pre="pigs remained active and maintained good bodily condition after the" exact="diarrhea" post="resolved. To analyze PEDV RNA titers in fecal samples,"/>
   <result pre="et al. 2019). These pigs showed resistance to porcine transmissible" exact="gastroenteritis" post="virus (TGEV) infection. However, only one APN null pig"/>
   <result pre="China Agricultural University. References References JiCMWangBZhouJHuangYWAminopeptidase-N-independent entry of porcine epidemic" exact="diarrhea" post="virus into Vero or porcine small intestine epithelial cellsVirology2018517162310.1016/j.virol.2018.02.01929502803"/>
   <result pre="into Vero or porcine small intestine epithelial cellsVirology2018517162310.1016/j.virol.2018.02.01929502803 LeeCPorcine epidemic" exact="diarrhea" post="virus: an emerging and re-emerging epizootic swine virusVirol J20151219310.1186/s12985-015-0421-226689811"/>
   <result pre="receptor for the PEDV coronavirusVirology200736516617210.1016/j.virol.2007.03.03117467767 LiWLiHLiuYPanYDengFSongYTangXHeQNew variants of porcine epidemic" exact="diarrhea" post="virus, China, 2011Emerg Infect Dis201218135010.3201/eid1803.12000222840964 LiWvan KuppeveldFJMHeQRottierPJMBoschBJCellular entry of"/>
   <result pre="2011Emerg Infect Dis201218135010.3201/eid1803.12000222840964 LiWvan KuppeveldFJMHeQRottierPJMBoschBJCellular entry of the porcine epidemic" exact="diarrhea" post="virusVirus Res201622611712710.1016/j.virusres.2016.05.03127317167 LiWLuoRHeQvan KuppeveldFJMRottierPJMBoschBJAminopeptidase N is not required for"/>
   <result pre="Res201622611712710.1016/j.virusres.2016.05.03127317167 LiWLuoRHeQvan KuppeveldFJMRottierPJMBoschBJAminopeptidase N is not required for porcine epidemic" exact="diarrhea" post="virus cell entryVirus Res201723561310.1016/j.virusres.2017.03.01828363778 LiWHulswitRJGKenneySPWidjajaIJungKAlhamoMAvan DierenBvan KuppeveldFJMSaifLJBoschBJBroad receptor engagement"/>
   <result pre="of two real-time polymerase chain reaction assays for Porcine epidemic" exact="diarrhea" post="virus (PEDV) to assess PEDV transmission in growing pigsJ"/>
   <result pre="virus carriage, antibody response, and aerosol transmission of Porcine epidemic" exact="diarrhea" post="virus following inoculation of 4-week-old feeder pigsJ Vet Diagn"/>
   <result pre="aminopeptidase N is not a cellular receptor of porcine epidemic" exact="diarrhea" post="virus, but promotes its infectivity via aminopeptidase activityJ Gen"/>
   <result pre="infectivity via aminopeptidase activityJ Gen Virol2016972528253910.1099/jgv.0.00056327449937 StevensonGWHoangHSchwartzKJBurroughERSunDMadsonDCooperVLPillatzkiAGaugerPSchmittBJKosterLGEmergence of porcine epidemic" exact="diarrhea" post="virus in the United States: clinical signs, lesions, and"/>
   <result pre="insights into the phylogeographical and spatiotemporal spread of porcine epidemic" exact="diarrhea" post="virus in AsiaJ Clin Microbiol2015531484149210.1128/JCM.02898-1425694517 WhitworthKMLeeKBenneJABeatonBPSpateLDMurphySLSamuelMSMaoJO’GormanCWaltersEMMurphyCNDriverJMilehamAMcLarenDWellsKDPratherRSUse of the CRISPR/Cas9"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6814692\results\search\disease\results.xml">
   <result pre="and Prevention, epub: 2019-6-6collection: 2019-10345583591received: 2019-2-1accepted: 2019-4-29(C) , Abstract Conventional" exact="influenza" post="vaccines need to be designed and manufactured yearly. However,"/>
   <result pre="there is an urgent need to develop universal vaccines against" exact="influenza" post="virus. Using nucleoprotein (NP) and extracellular domain of matrix"/>
   <result pre="extracellular domain of matrix protein 2 (M2e) genes from the" exact="influenza" post="A virus A/Beijing/30/95 (H3N2), we constructed four recombinant vaccinia"/>
   <result pre="A virus A/Beijing/30/95 (H3N2), we constructed four recombinant vaccinia virus-based" exact="influenza" post="vaccines carrying NP fused with one or four copies"/>
   <result pre="measured, and then the immunized mice were challenged with the" exact="influenza" post="A virus A/Puerto Rico/8/34 (PR8). NP-specific humoral response was"/>
   <result pre="4M2eNP fusion antigen may be employed to develop a universal" exact="influenza" post="vaccine. Electronic supplementary material The online version of this"/>
   <result pre="to authorized users. Keywords Influenza A virus (IAV) Cross-protection Recombinant" exact="vaccinia virus" post="Conserved antigen Introduction Seasonal influenza is an acute respiratory"/>
   <result pre="virus (IAV) Cross-protection Recombinant vaccinia virus Conserved antigen Introduction Seasonal" exact="influenza" post="is an acute respiratory infectious disease that can cause"/>
   <result pre="virus Conserved antigen Introduction Seasonal influenza is an acute respiratory" exact="infectious disease" post="that can cause serious health problems. Seasonal influenza epidemics"/>
   <result pre="respiratory infectious disease that can cause serious health problems. Seasonal" exact="influenza" post="epidemics caused by influenza A and B viruses result"/>
   <result pre="can cause serious health problems. Seasonal influenza epidemics caused by" exact="influenza" post="A and B viruses result in 3–5 million severe"/>
   <result pre="suffer from flu annually (World Health Organization, WHO 2019). Seasonal" exact="influenza" post="viruses undergo antigenic drift, which makes the conventional seasonal"/>
   <result pre="the vaccine strains mismatch with the epidemic strains. Therefore, seasonal" exact="influenza" post="vaccines must be updated regularly for effective prevention of"/>
   <result pre="for effective prevention of influenza. The production time for conventional" exact="influenza" post="vaccines can be lengthy. It takes 1–2 months to"/>
   <result pre="technology, followed by several more months for large-scale expansion of" exact="influenza" post="vaccine using an ample supply of specific pathogen-free (SPF)"/>
   <result pre="an ample supply of specific pathogen-free (SPF) chicken embryos. Generally," exact="influenza" post="vaccine production takes 3–6 months from the prediction of"/>
   <result pre="long-lasting immune responses (Erbelding et al.2018). Recently, great strides in" exact="influenza" post="vaccine research have been made using conserved antigens of"/>
   <result pre="influenza vaccine research have been made using conserved antigens of" exact="influenza" post="virus. The highly conserved internal protein nucleoprotein (NP) and"/>
   <result pre="domain of matrix protein 2 (M2e) can induce cross-protection against" exact="influenza" post="A virus, showing promise as candidate antigens for the"/>
   <result pre="promise as candidate antigens for the development of a broad-spectrum" exact="influenza" post="vaccine (Erbelding et al. 2018; Zhang et al.2015; Kui"/>
   <result pre="hydroxide gel protected mice from a lethal challenge with heterologous" exact="influenza" post="virus (Wang et al.2012). Therefore, vaccination with recombinant NM2e"/>
   <result pre="is a promising strategy for the development of a universal" exact="influenza" post="vaccine. However, a new expression system is required to"/>
   <result pre="required to further optimize the NP- and M2e-based vaccine. The" exact="vaccinia virus" post="(Tiantan strain) was developed in China as a vaccination"/>
   <result pre="~50 years, playing a key role in the eradication of" exact="smallpox" post="in China (Ruan 2013). The Tiantan strain has favorable"/>
   <result pre="Using the TK gene system of the Tiantan strain, this" exact="vaccinia virus" post="has been developed successfully as a viral vector for"/>
   <result pre="a viral vector for various vaccine applications (Ruan 2013) including" exact="hepatitis" post="B virus (Chuai et al.2018), hepatitis C virus (Wen"/>
   <result pre="applications (Ruan 2013) including hepatitis B virus (Chuai et al.2018)," exact="hepatitis" post="C virus (Wen et al.2013), and severe acute respiratory"/>
   <result pre="(Chuai et al.2018), hepatitis C virus (Wen et al.2013), and" exact="severe acute respiratory syndrome" post="coronavirus vaccines (Yan et al. 2009). We have developed"/>
   <result pre="vaccinia viruses based on NP, M1, M2, and PB1 of" exact="influenza" post="A virus (Huang et al. 2012; Wang et al.2007,"/>
   <result pre="well as protective effect against lethal challenge with a heterologous" exact="influenza" post="virus. Materials and Methods Materials β-Gal (40-1a) monoclonal antibody"/>
   <result pre="Ltd. Co. (Beijing, China). Viruses Vaccinia virus (Tiantan strain) and" exact="influenza" post="A virus A/Puerto Rico/8/34 (PR8) (H1N1) (Wang et al."/>
   <result pre="and titrated in primary chicken embryo fibroblasts (CEFs). The PR8" exact="influenza" post="virus was propagated in 9-day-old chicken embryos at 34"/>
   <result pre="until use. Mouse 50% lethal dose (MLD50) titer of the" exact="influenza" post="virus PR8 was assessed in BALB/c mice before conducting"/>
   <result pre="pJSC1175 contains two DNA fragments (TKL and TKR) derived from" exact="vaccinia virus" post="Tiantan strain to facilitate homologous recombination with vaccinia virus"/>
   <result pre="from vaccinia virus Tiantan strain to facilitate homologous recombination with" exact="vaccinia virus" post="in host cells. Between the two homology arms, there"/>
   <result pre="the two homology arms, there are p11 late promoter of" exact="vaccinia virus" post="to regulate the lacZ gene and p7.5 early/late promoter"/>
   <result pre="to regulate the lacZ gene and p7.5 early/late promoter of" exact="vaccinia virus" post="to regulate the target genes. The pJSC1175 was linearized"/>
   <result pre="amino acids) and the succeeding M2e (23 amino acids) from" exact="influenza" post="A virus, A/Beijing/30/95 (H3N2) (BJ95) (Wang et al. 2012)."/>
   <result pre="by Wang et al. (2015). Briefly, CEFs were infected with" exact="vaccinia virus" post="Tiantan strain at a multiplicity of infection of 0.01–0.1,"/>
   <result pre="by blue-white selection. Viral DNA was isolated from each recombinant" exact="vaccinia virus" post="to confirm the presence of fusion genes (NPM2e, M2eNP,"/>
   <result pre="produced on a large scale in CEFs. The control recombinant" exact="vaccinia virus" post="RVJ1175 was generated using the same method with the"/>
   <result pre="mouse monoclonal antibody (MAb) against β-Gal (40-1a), mouse MAb against" exact="influenza" post="A virus M2 (14C2), and mouse MAb against influenza"/>
   <result pre="against influenza A virus M2 (14C2), and mouse MAb against" exact="influenza" post="A virus NP (5D8). The signals were then visualized"/>
   <result pre="length of NPs. The NP and M2e gene fragments of" exact="influenza" post="A virus A/Beijing/30/95 (H3N2) were joined to create NPM2e,"/>
   <result pre="shown). Each confirmed plasmid was transfected into CEFs infected by" exact="vaccinia virus" post="Tiantan strain to facilitate homologous DNA recombination between plasmid"/>
   <result pre="RVJ-M2eNP, RVJ-4M2eNP, and RVJ-4M2eNPs were screened by blue-white selection. The" exact="vaccinia virus" post="DNA was extracted to amplify the target gene fragments"/>
   <result pre="vaccinia viruses. Except the control virus RVJ1175, all other recombinant" exact="vaccinia virus" post="expressed M2e and NP in the infected cells. It"/>
   <result pre="by mouse monoclonal antibodies to detect β-galactosidase (β-Gal) (upper panel)," exact="influenza" post="NP (middle panel), and M2e (lower panel), followed by"/>
   <result pre="of BALB/c mice were immunized with 107 PFU of recombinant" exact="vaccinia virus" post="at week 0 and 4. Ten days after the"/>
   <result pre="measure the cellular immune response. Mice immunized with the recombinant" exact="vaccinia virus" post="RVJ-NPM2e and RVJ-M2eNP showed strong antibody responses against NP,"/>
   <result pre="compared with RVJ-M2eNP. Except the control virus, all other recombinant" exact="vaccinia virus" post="seemed to induce M2e-specific cellular immune responses (Fig. 3B)."/>
   <result pre="second immunization, BALB/c mice were challenged with 20 MLD50 of" exact="influenza" post="A virus PR8, and then weight loss and survival"/>
   <result pre="three groups (Fig. 4B). Fig. 4 Protective efficacy of recombinant" exact="vaccinia virus" post="containing NP and M2e genes against 20 MLD50 of"/>
   <result pre="with recombinant vaccinia viruses and challenged with 20 MLD50 of" exact="influenza" post="virus strain PR8. Among them, mice immunized with recombinant"/>
   <result pre="influenza virus strain PR8. Among them, mice immunized with recombinant" exact="vaccinia virus" post="RVJ1175 served as vector control. Mice were monitored daily"/>
   <result pre="Discussion The extracellular domain of M2e is highly conserved among" exact="influenza" post="A virus subtypes (Muñoz-Medina et al.2015; Zebedee and Lamb"/>
   <result pre="as a target antigen in the development of a universal" exact="influenza" post="vaccine. In the present study, a single M2e induced"/>
   <result pre="stronger cross-protection than that of other groups against heterosubtypic H1N1" exact="influenza" post="virus challenge (Fig. 4B, RVJ-4M2eNP, RVJ-4M2eNPs). It had been"/>
   <result pre="by antibody-dependent cell-mediated cytotoxicity (ADCC), although it could not neutralize" exact="influenza" post="virus (Kim et al. 2017; Lee et al.2015). Besides,"/>
   <result pre="also been used as a target antigen to develop universal" exact="influenza" post="vaccines (Huang et al.2012; Li et al.2013; Wang et"/>
   <result pre="in BALB/c mouse. Previous research proved that human MAb against" exact="influenza" post="NP played an important role in fighting low-dose infection"/>
   <result pre="NP played an important role in fighting low-dose infection of" exact="influenza" post="virus (Fujimoto et al.2016), and NP might exert a"/>
   <result pre="played important roles in protection. NP-specific antibody could not neutralize" exact="influenza" post="virus just as M2e. However, it may protect animals"/>
   <result pre="peptides (Fig. 3C, RVJ-M2eNP). Significant progress is made to develop" exact="influenza" post="vaccine using viral vectors (Kim et al.2013; Li et"/>
   <result pre="Several recombinant viral vaccines have been constructed based on modified" exact="vaccinia virus" post="Ankara expressing HA, NP, M1, and PB1 antigens (Coughlan"/>
   <result pre="studies to develop recombinant viral vaccines. In this study, the" exact="vaccinia virus" post="Tiantan strain was used to construct recombinant vaccinia viruses"/>
   <result pre="vaccinia viruses expressing fusion antigens with different configurations. The recombinant" exact="vaccinia virus" post="expressing 4M2e and full-length NP fusion antigen induced strong"/>
   <result pre="successfully sometimes. Compared with an E. coli system, the recombinant" exact="vaccinia virus" post="system has characteristics such as high multiplication capacity, no"/>
   <result pre="al.2017). Future studies should focus on the development of universal" exact="influenza" post="vaccines containing multiple antigens to induce broad neutralizing responses,"/>
   <result pre="of the murine Th2 response to immunization with liposomal M2e" exact="influenza" post="vaccineVaccine2011294460446810.1016/j.vaccine.2011.04.04021545821 AltenburgAFMagnussonSEBosmanFStertmanLDe VriesRRimmelzwaanGFProtein- and modified vaccinia virus Ankara-based influenza"/>
   <result pre="immunization with liposomal M2e influenza vaccineVaccine2011294460446810.1016/j.vaccine.2011.04.04021545821 AltenburgAFMagnussonSEBosmanFStertmanLDe VriesRRimmelzwaanGFProtein- and modified" exact="vaccinia virus" post="Ankara-based influenza virus nucleoprotein vaccines are differentially immunogenic in"/>
   <result pre="M2e influenza vaccineVaccine2011294460446810.1016/j.vaccine.2011.04.04021545821 AltenburgAFMagnussonSEBosmanFStertmanLDe VriesRRimmelzwaanGFProtein- and modified vaccinia virus Ankara-based" exact="influenza" post="virus nucleoprotein vaccines are differentially immunogenic in BALB/c miceClin"/>
   <result pre="Immunol2017190192810.1111/cei.1300428665497 AlvarezPZylbermanVGhersiGBoadoLPalaciosCGoldbaumFMattionNTandem repeats of the extracellular domain of matrix 2" exact="influenza" post="protein exposed in Brucella lumazine synthase decameric carrier molecule"/>
   <result pre="ChuaiXXieBChenHTanXWangWHuangBDengYLiWTanWThe immune response of rhesus macaques to novel vaccines comprising" exact="hepatitis" post="B virus S, PreS1, and Core antigensVaccine2018363740374610.1016/j.vaccine.2018.05.06129778513 CoughlanLSridharSPayneREdmansMMilicicAVenkatramanNLugonjaBCliftonLQiCFolegattiPMLawrieAMRobertsRde GraafHSukhtankarPFaustSNLewisDJMLambeTHillAVSGilbertSCHeterologous"/>
   <result pre="simian adenovirus and poxvirus vectors elicits long-lasting cellular immunity to" exact="influenza" post="virus A in healthy adultsEBioMedicine20182914615410.1016/j.ebiom.2018.02.01129519670 DhanwaniRZhouYHuangQVermaVDileepanMLyHLiangYA novel live Pichinde"/>
   <result pre="immunity after a booster doseJ Virol2016902551256010.1128/JVI.02705-154810697 Di MarioGSciaraffiaEFacchiniMGubinelliFSopranaEPanigadaMBernasconiVGarulliBSiccardiADonatelliICastrucciMRProtective immunity against" exact="influenza" post="in HLA-A2 transgenic mice by modified vaccinia virus Ankara"/>
   <result pre="MarioGSciaraffiaEFacchiniMGubinelliFSopranaEPanigadaMBernasconiVGarulliBSiccardiADonatelliICastrucciMRProtective immunity against influenza in HLA-A2 transgenic mice by modified" exact="vaccinia virus" post="Ankara vectored vaccines containing internal influenza proteinsPathog Glob Health2017111768210.1080/20477724.2016.127546528079473"/>
   <result pre="mice by modified vaccinia virus Ankara vectored vaccines containing internal" exact="influenza" post="proteinsPathog Glob Health2017111768210.1080/20477724.2016.127546528079473 EbrahimiSMDabaghianMTebianianMZabeh JaziMHIn contrast to conventional inactivated"/>
   <result pre="influenza proteinsPathog Glob Health2017111768210.1080/20477724.2016.127546528079473 EbrahimiSMDabaghianMTebianianMZabeh JaziMHIn contrast to conventional inactivated" exact="influenza" post="vaccines, 4 × M2e.HSP70c fusion protein fully protected mice against lethal"/>
   <result pre="protected mice against lethal dose of H1, H3 and H9" exact="influenza" post="A isolates circulating in IranVirology2012430637210.1016/j.virol.2012.04.01522595444 EmanuelEJWertheimerAWho should get influenza"/>
   <result pre="H9 influenza A isolates circulating in IranVirology2012430637210.1016/j.virol.2012.04.01522595444 EmanuelEJWertheimerAWho should get" exact="influenza" post="vaccine when not all canScience200631285485510.1126/science.112534716690847 ErbeldingEJPostDJStemmyEJRobertsPCAugustineADFergusonSPaulesCIGrahamBSFauciASA universal influenza vaccine:"/>
   <result pre="should get influenza vaccine when not all canScience200631285485510.1126/science.112534716690847 ErbeldingEJPostDJStemmyEJRobertsPCAugustineADFergusonSPaulesCIGrahamBSFauciASA universal" exact="influenza" post="vaccine: the strategic plan for the national institute of"/>
   <result pre="influenza vaccine: the strategic plan for the national institute of" exact="allergy" post="and infectious diseasesJ Infect Dis201821834735410.1093/infdis/jiy10329506129 FennerFHendersonDAAritaIJezekZLadnyiIDSmallpox and its eradication1988GenevaWorld"/>
   <result pre="Organization FujimotoYTomiokaYTakakuwaHUechiGIYabutaTOzakiKSuyamaHYamamotoSMorimatsuMMaiLQCross-protective potential of anti-nucleoprotein human monoclonal antibodies against lethal" exact="influenza" post="A virus infectionJ Gen Virol2016972104211610.1099/jgv.0.00051827260213 GuoLZhengMDingYLiDYangZWangHChenQSuiZFangFChenZProtection against multiple influenza"/>
   <result pre="lethal influenza A virus infectionJ Gen Virol2016972104211610.1099/jgv.0.00051827260213 GuoLZhengMDingYLiDYangZWangHChenQSuiZFangFChenZProtection against multiple" exact="influenza" post="A virus subtypes by intranasal administration of recombinant nucleoproteinArch"/>
   <result pre="JegaskandaSCoMDTCruzJSubbaraoKEnnisFATerajimaMInduction of H7N9-cross-reactive antibody-dependent cellular cytotoxicity antibodies by human seasonal" exact="influenza" post="a viruses that are directed toward the nucleoproteinJ Infect"/>
   <result pre="vaccination with recombinant adenovirus encoding nucleoprotein provides potent protection against" exact="influenza" post="virus infectionPLoS ONE2013811110.1371/annotation/c8b2e360-b78a-4c2f-a1a3-c53325f18211 KimYJKoEJKimMCLeeYNKimKHJungYJKangSMRoles of antibodies to influenza A"/>
   <result pre="protection against influenza virus infectionPLoS ONE2013811110.1371/annotation/c8b2e360-b78a-4c2f-a1a3-c53325f18211 KimYJKoEJKimMCLeeYNKimKHJungYJKangSMRoles of antibodies to" exact="influenza" post="A virus hemagglutinin, neuraminidase, and M2e in conferring cross"/>
   <result pre="DNA vaccine induces protective cross-reactive T cell responses against heterologous" exact="influenza" post="virus in nonhuman primatesPLoS One201712e018978010.1371/journal.pone.018978029267331 KuiXGuanYZhouYYanSSZhangLLiHJSunMSProgress on adenovirus-vectored universal"/>
   <result pre="influenza virus in nonhuman primatesPLoS One201712e018978010.1371/journal.pone.018978029267331 KuiXGuanYZhouYYanSSZhangLLiHJSunMSProgress on adenovirus-vectored universal" exact="influenza" post="vaccinesHum Vaccines Immunother2015111209122210.1080/21645515.2015.1016674 LamereMWLamHMoquinAHaynesLLundFERandallTDKaminskiDAContributions of antinucleoprotein IgG to heterosubtypic"/>
   <result pre="Vaccines Immunother2015111209122210.1080/21645515.2015.1016674 LamereMWLamHMoquinAHaynesLLundFERandallTDKaminskiDAContributions of antinucleoprotein IgG to heterosubtypic immunity against" exact="influenza" post="virusJ Immunol20111864331433910.4049/jimmunol.100305721357542 LeeYNKimMCLeeYTKimYJKangSMMechanisms of cross-protection by influenza virus M2-based"/>
   <result pre="heterosubtypic immunity against influenza virusJ Immunol20111864331433910.4049/jimmunol.100305721357542 LeeYNKimMCLeeYTKimYJKangSMMechanisms of cross-protection by" exact="influenza" post="virus M2-based vaccinesImmune Netw20151521322110.4110/in.2015.15.5.21326557805 LeiHPengXJiaoHZhaoDOuyangJBroadly protective immunity against divergent"/>
   <result pre="influenza virus M2-based vaccinesImmune Netw20151521322110.4110/in.2015.15.5.21326557805 LeiHPengXJiaoHZhaoDOuyangJBroadly protective immunity against divergent" exact="influenza" post="viruses by oral co-administration of Lactococcus lactis expressing nucleoprotein"/>
   <result pre="5 expressing NP from H5N1 virus provides broad immunity against" exact="influenza" post="A virusesJ Virol2013875985599310.1128/JVI.00120-1323514880 MaJYangFYuHZhouYLiGHuangMWenFTongGAn M2e-based synthetic peptide vaccine for"/>
   <result pre="influenza A virusesJ Virol2013875985599310.1128/JVI.00120-1323514880 MaJYangFYuHZhouYLiGHuangMWenFTongGAn M2e-based synthetic peptide vaccine for" exact="influenza" post="A virus confers heterosubtypic protection from lethal virus challengeVirol"/>
   <result pre="MacLeodMKDavidAJinNNogesLWangJKapplerJWMarrackPInfluenza nucleoprotein delivered with aluminium salts protects mice from an" exact="influenza" post="A virus that expresses an altered nucleoprotein sequencePLoS One20138e6177510.1371/journal.pone.006177523613928"/>
   <result pre="human nasopharynx-associated lymphoid tissue in vitro by modified vaccinia Ankara-vectored" exact="influenza" post="vaccinesVaccine2016341688169510.1016/j.vaccine.2016.02.02826902548 Muñoz-MedinaJESánchez-VallejoCJMéndez-TenorioAMonroy-MuñozIEAngeles-MartínezJSantos Coy-ArechavaletaASantacruz-TinocoCEGonzález-IbarraJAnguiano-HernándezYMGonzález-BonillaCRRamón-GallegosEDíaz-QuiñonezJAIn silico identification of highly conserved epitopes"/>
   <result pre="vaccinesVaccine2016341688169510.1016/j.vaccine.2016.02.02826902548 Muñoz-MedinaJESánchez-VallejoCJMéndez-TenorioAMonroy-MuñozIEAngeles-MartínezJSantos Coy-ArechavaletaASantacruz-TinocoCEGonzález-IbarraJAnguiano-HernándezYMGonzález-BonillaCRRamón-GallegosEDíaz-QuiñonezJAIn silico identification of highly conserved epitopes of" exact="influenza" post="A H1N1, H2N2, H3N2, and H5N1 with diagnostic and"/>
   <result pre="RotiMYangJBergerDHustonLJamesEAKwokWWHealthy human subjects have CD4+ T cells directed against H5N1" exact="influenza" post="virusJ Immunol20081801758176810.4049/jimmunol.180.3.175818209073 RuanLResearch and application of vaccinia virus Tiantan"/>
   <result pre="directed against H5N1 influenza virusJ Immunol20081801758176810.4049/jimmunol.180.3.175818209073 RuanLResearch and application of" exact="vaccinia virus" post="Tiantan strain vectorJ Microbes Infect2013828 SchotsaertMDe FiletteMFiersWSaelensXUniversal M2 ectodomain-based"/>
   <result pre="virus Tiantan strain vectorJ Microbes Infect2013828 SchotsaertMDe FiletteMFiersWSaelensXUniversal M2 ectodomain-based" exact="influenza" post="A vaccines: preclinical and clinical developmentsExpert Rev Vaccines2009849950810.1586/erv.09.619348565 TutykhinaIEsmagambetovIBagaevAPichuginALysenkoAShcherbininDSedovaELogunovDShmarovMAtaullakhanovRNaroditskyBGintsburgAVaccination"/>
   <result pre="potential of B and T epitope-enriched NP and M2 against" exact="influenza" post="A viruses from different clades and hostsPLoS One201813e019157410.1371/journal.pone.019157429377916 WangWHuangBDengYWangXTanWRuanLExpression"/>
   <result pre="A viruses from different clades and hostsPLoS One201813e019157410.1371/journal.pone.019157429377916 WangWHuangBDengYWangXTanWRuanLExpression of" exact="influenza" post="A3 virus (H3N2) M2 gene in vaccinia virus Tiantan"/>
   <result pre="One201813e019157410.1371/journal.pone.019157429377916 WangWHuangBDengYWangXTanWRuanLExpression of influenza A3 virus (H3N2) M2 gene in" exact="vaccinia virus" post="Tiantan strainChin J Virol200723377 WangWHuangBJiangTWangXQiXGaoYTanWRuanLRobust immunity and heterologous protection"/>
   <result pre="Tiantan strainChin J Virol200723377 WangWHuangBJiangTWangXQiXGaoYTanWRuanLRobust immunity and heterologous protection against" exact="influenza" post="in mice elicited by a novel recombinant NP-M2e fusion"/>
   <result pre="E. coliPLoS One20127e5248810.1371/journal.pone.005248823285063 WangWHuangBJiangTWangXQiXTanWRuanLMaximal immune response and cross protection by" exact="influenza" post="virus nucleoprotein derived from E. coli using an optimized"/>
   <result pre="M1 proteins as immunogens in DNA- and vaccinia virus-based universal" exact="influenza" post="A virus vaccines in miceClin Vaccine Immunol20152261863010.1128/CVI.00091-1525834017 WenBDengYChenHGuanJChuaiXRuanLKongWTanWthe novel"/>
   <result pre="A virus vaccines in miceClin Vaccine Immunol20152261863010.1128/CVI.00091-1525834017 WenBDengYChenHGuanJChuaiXRuanLKongWTanWthe novel replication-defective" exact="vaccinia virus" post="(Tiantan strain)-based hepatitis C virus vaccine induces robust immunity"/>
   <result pre="miceClin Vaccine Immunol20152261863010.1128/CVI.00091-1525834017 WenBDengYChenHGuanJChuaiXRuanLKongWTanWthe novel replication-defective vaccinia virus (Tiantan strain)-based" exact="hepatitis" post="C virus vaccine induces robust immunity in macaquesMol Ther2013211787179510.1038/mt.2013.12223774793"/>
   <result pre="Accessed 1 Feb 2019 YanKTanWWangHWangYZhangXLiYRuanLSARS-CoV spike proteins expressed by the" exact="vaccinia virus" post="Tiantan strain: secreted SQ protein induces robust neutralization antibody"/>
   <result pre="with different M2e epitope densities confers partial protection against H5N1" exact="influenza" post="A virus challenge in chickensIntervirology20115429029910.1159/00031944021228535 ZhangNZhengB-JLuLZhouYJiangSDuLAdvancements in the development"/>
   <result pre="virus challenge in chickensIntervirology20115429029910.1159/00031944021228535 ZhangNZhengB-JLuLZhouYJiangSDuLAdvancements in the development of subunit" exact="influenza" post="vaccinesMicrobes Infect20151712313410.1016/j.micinf.2014.12.00625529753 ZhaoGDuLXiaoWSunSLinYChenMKouZHeYLustigmanSJiangSZhengB-JZhouYInduction of protection against divergent H5N1 influenza"/>
   <result pre="subunit influenza vaccinesMicrobes Infect20151712313410.1016/j.micinf.2014.12.00625529753 ZhaoGDuLXiaoWSunSLinYChenMKouZHeYLustigmanSJiangSZhengB-JZhouYInduction of protection against divergent H5N1" exact="influenza" post="viruses using a recombinant fusion protein linking influenza M2e"/>
   <result pre="divergent H5N1 influenza viruses using a recombinant fusion protein linking" exact="influenza" post="M2e to Onchocerca volvulus activation associated protein-1 (ASP-1) adjuvantVaccine2010287233724010.1016/j.vaccine.2010.08.04920732469"/>
   <result pre="using a recombinant fusion protein linking influenza M2e to Onchocerca" exact="volvulus" post="activation associated protein-1 (ASP-1) adjuvantVaccine2010287233724010.1016/j.vaccine.2010.08.04920732469 ZhaoGSunSDuLXiaoWRuZKouZGuoYYuHJiangSLoneYAn H5N1 M2e-based multiple"/>
   <result pre="lethal infection with pandemic 2009 H1N1 virusVirol J2010715110.1186/1743-422X-7-15120624292 ZhengMLiuFShenYWangSXuWFangFSunBXieZChenZCross-protection against" exact="influenza" post="virus infection by intranasal administration of nucleoprotein-based vaccine with"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6815955\results\search\disease\results.xml">
   <result pre="pmcid: 6815955 doi: 10.7150/thno.35826thnov09p6920 : Research Paper Catalytic inactivation of" exact="influenza" post="virus by iron oxide nanozyme QinTao135*MaRuonan1*YinYinyan23MiaoXinyu1ChenSujuan135FanKelong4XiJuqun2LiuQi2GuYunhao2YinYuncong1HuJiao135LiuXiufan135PengDaxin1356✉GaoLizeng234✉[1], [2], [3], [4],"/>
   <result pre="oxide nanozymes (IONzymes) to target the lipid envelope of the" exact="influenza" post="virus. Methods: We evaluated the antiviral activities of our"/>
   <result pre="hemagglutinin, neuraminidase, and matrix protein 1, causing the inactivation of" exact="influenza" post="A viruses (IAVs). Furthermore, we show that our IONzymes"/>
   <result pre="transmission and infection. Iron oxide nanozyme lipid peroxidation lipoxidase-like activity" exact="influenza" post="virus antivirus Introduction Influenza A viruses (IAVs) are characterized"/>
   <result pre="rapidly renders those drugs ineffective3. Moreover, the presence of multiple" exact="influenza" post="subtypes renders developing a universal anti-IAVs strategy difficult. In"/>
   <result pre="treatments4. Specifically, many inorganic nanoparticles have shown antiviral effects on" exact="influenza" post="viruses, such as silver nanoparticles5 or gold nanoparticles6. However,"/>
   <result pre="whether IONzymes induce lipid peroxidation on the viral envelope of" exact="influenza" post="A virus that possesses a liposome-like structure (named henceforth"/>
   <result pre="tissues of mice infected with intact H5N1 virus exhibited severe" exact="pneumonia" post="with inflammatory cellular infiltration, alveolar wall edema and thickening,"/>
   <result pre="When treated with 2 mg/mL IONzymes, H7N9, a subtype of" exact="avian influenza" post="which was first found in 2013 in China and"/>
   <result pre="treated with 2 mg/mL IONzymes, H7N9, a subtype of avian" exact="influenza" post="which was first found in 2013 in China and"/>
   <result pre="effect on various subtypes of IAVs. IONzyme-loaded facemask protects against" exact="influenza" post="Given the fact that IONzymes effectively abolish virus activity,"/>
   <result pre="represent a suitable candidate to prevent the spread of active" exact="influenza" post="virus, especially for representative IAVs that have a serious"/>
   <result pre="are highly vulnerable to lipid peroxidation attack38. Lipid envelope of" exact="influenza" post="virus enriched with PUFA-phospholipids39 might be more sensitive to"/>
   <result pre="we found that peroxidation cannot impact nucleoprotein (NP), an internal" exact="influenza" post="virus protein, encapsulating the virus genome to form a"/>
   <result pre="destroy neighboring proteins. Importantly, IONzymes inactivate a broad spectrum of" exact="influenza" post="A viruses. IAVs can be classified into various subtypes"/>
   <result pre="NA are highly conserved in sequence in all subtypes of" exact="influenza" post="virus46, 47. IONzymes treatment remarkably disintegrate envelope and destruct"/>
   <result pre="known that facemasks are very important to protect people from" exact="influenza" post="infection in crowded spaces. For instance, live-poultry markets (LPMs)"/>
   <result pre="frequency of human-poultry contact and results in a five H7N9" exact="influenza" post="epidemic waves in China 33. Therefore, such protective equipment"/>
   <result pre="to human. However, most facemasks only provide isolation protection for" exact="influenza" post="virus but cannot inactivate the adsorbed virus. This may"/>
   <result pre="broad applications of IONzymes in bioprotective PPEs against the emerging" exact="influenza" post="threats, especially in high-risk places, such as hospitals and"/>
   <result pre="we propose that IONzymes represent a general antiviral agent against" exact="influenza" post="viruses and other enveloped viruses, such as HIV, Ebola"/>
   <result pre="gradient according to our previously described method51. Fluorescent labeling of" exact="influenza" post="virus was performed using our established method described previously51."/>
   <result pre="then negatively stained with 2% uranyl acetate. The images of" exact="influenza" post="virus were captured using a Tecnai 12 transmission electron"/>
   <result pre="and incubated at 37 °C for 72 h. To identify" exact="influenza" post="virus positive wells, the HA assay was performed57. The"/>
   <result pre="S.C., YC.Y., J.H., and X.L. contributed to the preparation of" exact="influenza" post="virus. T.Q. wrote the paper; all authors have contributed"/>
   <result pre="next pandemicEvol Med Public Health20182018260930455951 2HuJLiuXEndemicity of H9N2 and H5N1" exact="avian influenza" post="viruses in poultry in China poses a serious threat"/>
   <result pre="pandemicEvol Med Public Health20182018260930455951 2HuJLiuXEndemicity of H9N2 and H5N1 avian" exact="influenza" post="viruses in poultry in China poses a serious threat"/>
   <result pre="Agr Sci Eng201631124 3de JongMDTranTTTruongHKVoMHSmithGJNguyenVCet al.Oseltamivir resistance during treatment of" exact="influenza" post="A (H5N1) infectionN Engl J Med200535326677216371632 4SinghLKrugerHGMaguireGEMGovenderTParboosingRThe role of"/>
   <result pre="mutans biofilm matrix degradation and enhance bacterial killing to suppress" exact="dental caries" post="in vivoBiomaterials20161012728427294544 19XuZQiuZLiuQHuangYLiDShenXet al.Converting organosulfur compounds to inorganic polysulfides"/>
   <result pre="al.Cardioprotective activity of iron oxide nanoparticlesSci Rep20155857925716309 24KillianMLHemagglutination assay for" exact="influenza" post="virusMethods Mol Biol201411613924899415 25QinTZhuJMaRYinYChenSPengDet al.Compatibility between haemagglutinin and neuraminidase"/>
   <result pre="neuraminidase drives the recent emergence of novel clade 2.3.4.4 H5Nx" exact="avian influenza" post="viruses in ChinaTransbound Emerg Dis20186517576929999588 26World Health Organization/World Organisation"/>
   <result pre="drives the recent emergence of novel clade 2.3.4.4 H5Nx avian" exact="influenza" post="viruses in ChinaTransbound Emerg Dis20186517576929999588 26World Health Organization/World Organisation"/>
   <result pre="Organisation for AnimalHFAgriculture OrganizationHNEWGRevised and updated nomenclature for highly pathogenic" exact="avian influenza" post="A (H5N1) virusesInfluenza Other Respir Viruses20148384824483237 27ReedLJMuenchHA simple method"/>
   <result pre="for AnimalHFAgriculture OrganizationHNEWGRevised and updated nomenclature for highly pathogenic avian" exact="influenza" post="A (H5N1) virusesInfluenza Other Respir Viruses20148384824483237 27ReedLJMuenchHA simple method"/>
   <result pre="innate immune response contribute to the high virulence of H5N1" exact="avian influenza" post="virus in miceJ Virol20138726607223255810 29EdingerTOPohlMOStertzSEntry of influenza A virus:"/>
   <result pre="immune response contribute to the high virulence of H5N1 avian" exact="influenza" post="virus in miceJ Virol20138726607223255810 29EdingerTOPohlMOStertzSEntry of influenza A virus:"/>
   <result pre="of H5N1 avian influenza virus in miceJ Virol20138726607223255810 29EdingerTOPohlMOStertzSEntry of" exact="influenza" post="A virus: host factors and antiviral targetsJ Gen Virol2014952637724225499"/>
   <result pre="Virol2014952637724225499 30HuJMoYWangXGuMHuZZhongLet al.PA-X decreases the pathogenicity of highly pathogenic H5N1" exact="influenza" post="A virus in avian species by inhibiting virus replication"/>
   <result pre="al.Hemagglutinin glycosylation modulates the pathogenicity and antigenicity of the H5N1" exact="avian influenza" post="virusVet Microbiol20151752445625544041 32WuASuCWangDPengYLiuMHuaSet al.Sequential reassortments underlie diverse influenza H7N9"/>
   <result pre="glycosylation modulates the pathogenicity and antigenicity of the H5N1 avian" exact="influenza" post="virusVet Microbiol20151752445625544041 32WuASuCWangDPengYLiuMHuaSet al.Sequential reassortments underlie diverse influenza H7N9"/>
   <result pre="H5N1 avian influenza virusVet Microbiol20151752445625544041 32WuASuCWangDPengYLiuMHuaSet al.Sequential reassortments underlie diverse" exact="influenza" post="H7N9 genotypes in ChinaCell Host Microbe2013144465224055604 33SuSGuMLiuDCuiJGaoGFZhouJet al.Epidemiology, Evolution,"/>
   <result pre="ChinaTrends Microbiol2017257132828734617 34ZhaoGFanQZhongLLiYLiuWLiuXet al.Isolation and phylogenetic analysis of pandemic H1N1/09" exact="influenza" post="virus from swine in Jiangsu province of ChinaRes Vet"/>
   <result pre="Appl20144259560025063158 37KumarRNayakMSahooGCPandeyKSarkarMCAnsariYet al.Iron oxide nanoparticles based antiviral activity of H1N1" exact="influenza" post="A virusJ Infect Chemother201925325930770182 38CatalaALipid peroxidation modifies the picture"/>
   <result pre="Model&quot;Biochimie201294101921983178 39IvanovaPTMyersDSMilneSBMcClarenJLThomasPGBrownHALipid composition of viral envelope of three strains of" exact="influenza" post="virus - not all viruses are created equalACS Infect"/>
   <result pre="to neuraminidase on the maturation and hemagglutinating activity of an" exact="influenza" post="A2 virusJ Virol19694528345823234 42RossmanJSLambRAInfluenza virus assembly and buddingVirology20114112293621237476 43PortelaADigardPThe"/>
   <result pre="influenza A2 virusJ Virol19694528345823234 42RossmanJSLambRAInfluenza virus assembly and buddingVirology20114112293621237476 43PortelaADigardPThe" exact="influenza" post="virus nucleoprotein: a multifunctional RNA-binding protein pivotal to virus"/>
   <result pre="stressed plantsEnviron Sci Pollut Res Int201522409912125471723 45YoonSWWebbyRJWebsterRGEvolution and ecology of" exact="influenza" post="A virusesCurr Top Microbiol Immunol20143853597524990620 46JinHLeserGPZhangJLambRAInfluenza virus hemagglutinin and"/>
   <result pre="cytoplasmic tails control particle shapeEMBO J1997161236479135140 47MitnaulLJCastrucciMRMurtiKGKawaokaYThe cytoplasmic tail of" exact="influenza" post="A virus neuraminidase (NA) affects NA incorporation into virions,"/>
   <result pre="single-atom strategySci China Life Sci201962710230941648 50TangYWuPPengDWangXWanHZhangPet al.Characterization of duck H5N1" exact="influenza" post="viruses with differing pathogenicity in mallard (Anas platyrhynchos) ducksAvian"/>
   <result pre="glycans attached to haemagglutinin in the biological characteristics of H5N1" exact="avian influenza" post="virusJ Gen Virol20159612485725667326 56WuYZhangZNiXMengFQinTChenSet al.Prokaryotic expression of the NA"/>
   <result pre="attached to haemagglutinin in the biological characteristics of H5N1 avian" exact="influenza" post="virusJ Gen Virol20159612485725667326 56WuYZhangZNiXMengFQinTChenSet al.Prokaryotic expression of the NA"/>
   <result pre="of the NA and NS1 genes of H5N1 subtype aivian" exact="influenza" post="virus and preparation of their polyclonal antibodiesHeilongjiang Animal Science"/>
   <result pre="PCV2b strain 0233Arch Virol20171622354627722993 59WangXMengFWangDLiuXChenSQinTet al.Characteristics of two highly pathogenic" exact="avian influenza" post="H5N8 viruses with different pathogenicity in miceArch Virol201616133657427589977 60HuJMoYGaoZWangXGuMLiangYet"/>
   <result pre="strain 0233Arch Virol20171622354627722993 59WangXMengFWangDLiuXChenSQinTet al.Characteristics of two highly pathogenic avian" exact="influenza" post="H5N8 viruses with different pathogenicity in miceArch Virol201616133657427589977 60HuJMoYGaoZWangXGuMLiangYet"/>
   <result pre="injury contributes to the attenuation of a highly pathogenic H5N1" exact="avian influenza" post="virus in miceMed Microbiol Immunol20162053819527289459 Scheme 1 Schematic of"/>
   <result pre="contributes to the attenuation of a highly pathogenic H5N1 avian" exact="influenza" post="virus in miceMed Microbiol Immunol20162053819527289459 Scheme 1 Schematic of"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6816385\results\search\disease\results.xml">
   <result pre="the article must be cited.https://peerj.com/articles/7754 Abstract Background The classification of" exact="hepatitis" post="viruses still predominantly relies on ad hoc criteria, i.e.,"/>
   <result pre="becomes cumbersome and impossible to generalize. Methods Using two well-studied" exact="hepatitis" post="virus datasets, HBV and HCV, we assess if computational"/>
   <result pre="to barcoding biodiversity studies can also be successfully deployed for" exact="hepatitis" post="virus classification. For comparison, we also used ABGD, a"/>
   <result pre="practice, since response rates to immunomodulatory treatment for the chronic" exact="hepatitis" post="C differs across genotypes. Nevertheless, new, unassigned lineages are"/>
   <result pre="palynologyForensic Science International: Genetics2111011610.1016/j.fsigen.2015.12.01026751251 Biswas et al. (2013)BiswasAPanigrahiRPalMChakrabortySBhattacharyaPChakrabartiSChakravartyR2013Shift in the" exact="hepatitis" post="B virus genotype distribution in the last decade among"/>
   <result pre="Studies in Oceanography571–2404810.1016/j.dsr2.2009.08.005 Combet et al. (2007)CombetCGarnierNCharavayCGrandoDCrisanDLopezJDehne-GarciaAGeourjonCBettlerEHuloCLe MercierPBartenschlagerRDiepolderHMoradpourDPawlotskyJ-MRiceCMTrépoCPeninFDeléageG2007euHCVdb: the European" exact="hepatitis" post="C virus databaseNucleic Acids Research35D363D36610.1093/nar/gkl97017142229 Galimberti et al. (2013)GalimbertiADe"/>
   <result pre="Research International501556310.1016/j.foodres.2012.09.036 Ge et al. (2009)GeDFellayJThompsonAJSimonJSShiannaKVUrbanTJHeinzenELQiuPBertelsenAHMuirAJSulkowskiM2009Genetic variation in IL28B predicts" exact="hepatitis" post="C treatment-induced viral clearanceNature461726239940110.1038/nature0830919684573 Gibson et al. (2014)GibsonJShokrallaSPorterTMKingIVan KonynenburgSJanzenDHHallwachsWHajibabaeiM2014Simultaneous"/>
   <result pre="print May 9 201910.1093/bioinformatics/btz305 Kramvis (2014)KramvisA2014Genotypes and genetic variability of" exact="hepatitis" post="B virusIntervirology573–414115010.1159/00036094725034481 Kramvis &amp;amp; Kew (2007)KramvisAKewMC2007Epidemiology of hepatitis B"/>
   <result pre="variability of hepatitis B virusIntervirology573–414115010.1159/00036094725034481 Kramvis &amp;amp; Kew (2007)KramvisAKewMC2007Epidemiology of" exact="hepatitis" post="B virus in Africa, its genotypes and clinical associations"/>
   <result pre="genomeBiological Reviews90115716610.1111/brv.1210424666563 Lu et al. (2013)LuLLiCYuanJLuTOkamotoHMurphyDG2013Full-length genome sequences of five" exact="hepatitis" post="C virus isolates representing subtypes 3g, 3 h, 3i"/>
   <result pre="diseasesScientific Reports16210.1038/srep0006222355581 Messina et al. (2015)MessinaJPHumphreysIFlaxmanABrownACookeGSPybusOGBarnesE2015Global distribution and prevalence of" exact="hepatitis" post="C virus genotypesHepatology611778710.1002/hep.2725925069599 Mishra et al. (2016)MishraPKumarANagireddyAManiDNShuklaAKTiwariRSundaresanV2016DNA barcoding: an"/>
   <result pre="Moura et al. (2013)MouraIFLopesEPAlvarado-MoraMVPinhoJRCarrilhoFJ2013Phylogenetic analysis and subgenotypic distribution of the" exact="hepatitis" post="B virus in Recife, BrazilInfection, Genetics and Evolution1419519910.1016/j.meegid.2012.11.022 Nakano"/>
   <result pre="Genetics and Evolution1419519910.1016/j.meegid.2012.11.022 Nakano et al. (2012)NakanoTLauGMLauGMSugiyamaMMizokamiM2012An updated analysis of" exact="hepatitis" post="C virus genotypes and subtypes based on the complete"/>
   <result pre="complete coding regionLiver International32233934510.1111/j.1478-3231.2011.02684.x22142261 Norder et al. (2004)NorderHCouroucéAMCoursagetPEchevarriaJMShou-DongLMushahwarIKMagniusLO2004Genetic diversity of" exact="hepatitis" post="B virus strains derived worldwide: genotypes, subgenotypes, and HBsAg"/>
   <result pre="viromeNature536761742543010.1038/nature1909427533034 Paraskevis et al. (2013)ParaskevisDMagiorkinisGMagiorkinisEHoSYBelshawRAllainJPHatzakisA2013Dating the origin and dispersal of" exact="hepatitis" post="B virus infection in humans and primatesHepatology57390891610.1002/hep.2607922987324 Puillandre et"/>
   <result pre="Biological Sciences28218212014287810.1098/rspb.2014.2878 Radziwill, Tucker &amp;amp; Schaller (1990)RadziwillGTuckerWSchallerH1990Mutational analysis of the" exact="hepatitis" post="B virus P gene product: domain structure and RNase"/>
   <result pre="al. (2005)SimmondsPBukhJCombetCDeléageGEnomotoNFeinstoneSHalfonPInchauspeGKuikenCMaertensGMiyokamiMMurphyDGOkamotoHPawlotskyJMPeninFSablonEShinITStuyverLJThielHJViayovSWeinerAJWidellA2005Consensus proposals for a unified system of nomenclature of" exact="hepatitis" post="C virus genotypesHepatology42496297310.1002/hep.2081916149085 Smith et al. (2014)SmithDBBukhJKuikenCMuerhoffASRiceCMStapletonJTSimmondsP2014Expanded classification of"/>
   <result pre="hepatitis C virus genotypesHepatology42496297310.1002/hep.2081916149085 Smith et al. (2014)SmithDBBukhJKuikenCMuerhoffASRiceCMStapletonJTSimmondsP2014Expanded classification of" exact="hepatitis" post="C virus into 7 genotypes and 67 subtypes: updated"/>
   <result pre="phylogeniesBioinformatics3091312131310.1093/bioinformatics/btu03324451623 Stanaway et al. (2016)StanawayJDFlaxmanADNaghaviMFitzmauriceCVosTAbubakarIAbu-RaddadLAssadiRBhalaNCowieBForouzanfourMHGroegerJHanafiahMJacobsenKHJamesSLMacLachlanJMalekyadehRMartinNKMokhadAAMokdadAHMurrayCJLPlassDRanaSReinDBRichardusJHSanabriaJSazyanMShahrazSSoSVlassovVVWeiderpassEWiersmaSTYounisMYuCEl Sayed ZakiMCookeGS2016The global burden of" exact="viral hepatitis" post="from 1990 to 2013: findings from the Global Burden"/>
   <result pre="Stanaway et al. (2016)StanawayJDFlaxmanADNaghaviMFitzmauriceCVosTAbubakarIAbu-RaddadLAssadiRBhalaNCowieBForouzanfourMHGroegerJHanafiahMJacobsenKHJamesSLMacLachlanJMalekyadehRMartinNKMokhadAAMokdadAHMurrayCJLPlassDRanaSReinDBRichardusJHSanabriaJSazyanMShahrazSSoSVlassovVVWeiderpassEWiersmaSTYounisMYuCEl Sayed ZakiMCookeGS2016The global burden of viral" exact="hepatitis" post="from 1990 to 2013: findings from the Global Burden"/>
   <result pre="2013The Lancet388100491081108810.1016/S0140-6736(16)30579-7 Strader et al. (2004)StraderDBWrightTThomasDLSeeffLB2004Diagnosis, management, and treatment of" exact="hepatitis" post="CHepatology3941147117110.1002/hep.2011915057920 Sulbaran et al. (2010)SulbaranMZDi LelloFASulbaranYCossonCLoureiroCLRangelHRCantaloubeJFCamposRHMoratorioGCristinaHPujolFH2010Genetic history of hepatitis"/>
   <result pre="of hepatitis CHepatology3941147117110.1002/hep.2011915057920 Sulbaran et al. (2010)SulbaranMZDi LelloFASulbaranYCossonCLoureiroCLRangelHRCantaloubeJFCamposRHMoratorioGCristinaHPujolFH2010Genetic history of" exact="hepatitis" post="C virus in Venezuela: high diversity and long time"/>
   <result pre="using DNA metabarcodingMolecular Ecology2182045205010.1111/j.1365-294X.2012.05470.x22486824 Tang &amp;amp; McLachlan (2001)TangHMcLachlanA2001Transcriptional regulation of" exact="hepatitis" post="B virus by nuclear hormone receptors is a critical"/>
   <result pre="and present biodiversityBiological Conservation18341810.1016/j.biocon.2014.11.019 Tong et al. (2015)TongYQLiuBLiuHZhengHYGuJSongEJSongCLiY2015Accurate genotyping of" exact="hepatitis" post="C virus through nucleotide sequencing and identification of new"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6816401\results\search\disease\results.xml">
   <result pre="important human arthropod-borne pathogens, such as dengue (DENV), Zika (ZIKV)," exact="tick-borne encephalitis" post="(TBEV), Yellow fever (YFV) or Japanese encephalitis (JEV) viruses.1"/>
   <result pre="human arthropod-borne pathogens, such as dengue (DENV), Zika (ZIKV), tick-borne" exact="encephalitis" post="(TBEV), Yellow fever (YFV) or Japanese encephalitis (JEV) viruses.1"/>
   <result pre="Zika (ZIKV), tick-borne encephalitis (TBEV), Yellow fever (YFV) or Japanese" exact="encephalitis" post="(JEV) viruses.1 WNV circulates in birds and is transmitted"/>
   <result pre="infections.2 Symptoms include high fever, but also neurological complications like" exact="encephalitis" post="or meningitis. Fatality rates reach 10% among the severe"/>
   <result pre="been performed with a DNA vaccine, chimeric flaviviruses using the" exact="yellow fever" post="vaccine strain or an attenuated DENV as backbones and"/>
   <result pre="formaldehyde Neutralizing antibodies after three doses. I/II 21 ChimeriVax-WN02 Recombinant" exact="yellow fever" post="vaccine strain expressing the prM/E-fragment of WNV Neutralizing antibodies"/>
   <result pre="still be markedly lower as compared, for example, to the" exact="herpes zoster" post="vaccine, which also targets aged individuals.40 Obviously, an increase"/>
   <result pre="between different members of the JEV-serocomplex (WNV, JEV, Murray Valley" exact="encephalitis" post="virus and Saint Louis encephalitis virus) is not very"/>
   <result pre="JEV-serocomplex (WNV, JEV, Murray Valley encephalitis virus and Saint Louis" exact="encephalitis" post="virus) is not very probable in light of existing"/>
   <result pre="virus growth in human monocytes as a risk factor for" exact="dengue hemorrhagic fever." post="Am J Trop Med Hyg. 1989;40:444–51. doi:10.4269/ajtmh.1989.40.444.2712199 44.RothmanALImmunity to"/>
   <result pre="FosterGA, KrysztofD, StramerSL, Bermúdez GonzálezMC, MenichettiE, GeretschlägerR, GabrielC, et alTick-borne" exact="encephalitis" post="virus vaccine-induced human antibodies mediate negligible enhancement of zika"/>
   <result pre="54.LobigsM, DiamondMSFeasibility of cross-protective vaccination against flaviviruses of the Japanese" exact="encephalitis" post="serocomplex. Expert Rev Vaccines. 2012;11:177–87. doi:10.1586/erv.11.180.22309667 55.CrillWD, TrainorNB, ChangGJA"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6816430\results\search\disease\results.xml">
   <result pre="doi: 10.1080/21645515.2019.1638205 : Commentary A review of epidemic preparedness for" exact="influenza" post="through local vaccine production: national security for Thailand P."/>
   <result pre="way.khvi-15-10-1638205.pdf Abstract ABSTRACT Being vigilant of the potential for an" exact="influenza" post="pandemic, the Global Action Plan for Influenza Vaccines (GAP)"/>
   <result pre="the Thai government has developed its national strategic plan for" exact="influenza" post="pandemic preparedness including the plan for manufacturing influenza vaccine"/>
   <result pre="plan for influenza pandemic preparedness including the plan for manufacturing" exact="influenza" post="vaccine in Thailand. With the support of WHO, the"/>
   <result pre="Pharmaceutical Organization (GPO) as the developed local production capacity of" exact="influenza" post="vaccines. The H1N1 live attenuated influenza vaccine (LAIV) and"/>
   <result pre="local production capacity of influenza vaccines. The H1N1 live attenuated" exact="influenza" post="vaccine (LAIV) and H5N2 LAIV produced by GPO have"/>
   <result pre="its capacity to Inactivated Influenza Vaccine (IIV), aiming for sustainable" exact="influenza" post="vaccine production for national coverage. KEYWORDS Influenza vaccine live"/>
   <result pre="attenuated national security fig-count: table-count: ref-count: page-count: Current situation of" exact="influenza" post="pandemic risk and the 2009 H1N1 pandemic Since the"/>
   <result pre="pandemic Since the first human infection of highly pathogenic H5N1" exact="avian influenza" post="in Hong Kong in 1997, sporadic cases have been"/>
   <result pre="Since the first human infection of highly pathogenic H5N1 avian" exact="influenza" post="in Hong Kong in 1997, sporadic cases have been"/>
   <result pre="have been 861 confirmed human infections including 455 deaths from" exact="avian influenza" post="A(H5N1) reported from 17 countries.1 Moreover, since March 2013"/>
   <result pre="been 861 confirmed human infections including 455 deaths from avian" exact="influenza" post="A(H5N1) reported from 17 countries.1 Moreover, since March 2013"/>
   <result pre="reported from 17 countries.1 Moreover, since March 2013 when the" exact="avian influenza" post="A(H7N9) infection was first detected in humans, a total"/>
   <result pre="from 17 countries.1 Moreover, since March 2013 when the avian" exact="influenza" post="A(H7N9) infection was first detected in humans, a total"/>
   <result pre="World Health Organization (WHO). In 2006, with growing concern that" exact="avian influenza" post="viruses could mutate to become transmissible between humans and"/>
   <result pre="Health Organization (WHO). In 2006, with growing concern that avian" exact="influenza" post="viruses could mutate to become transmissible between humans and"/>
   <result pre="inactivated trivalent vaccine and 2,340 million doses of monovalent pandemic" exact="influenza" post="vaccine.2 Therefore, one of the major approaches to increasing"/>
   <result pre="one of the major approaches to increasing supplies of pandemic" exact="influenza" post="vaccine was capacity building and infrastructure strengthening or new"/>
   <result pre="agreement with WHO in 2007. At the time of the" exact="influenza" post="A(H1N1) pandemic in 2009, the first imported case of"/>
   <result pre="By the second week of June 2009, there were two" exact="influenza" post="outbreak notifications in the central region of Thailand, and"/>
   <result pre="of Thailand, and then only a few weeks later the" exact="influenza" post="virus spread throughout the country.3 At that time, there"/>
   <result pre="At that time, there was no commitment to supplying inactivated" exact="influenza" post="vaccines to Thailand during potential pandemics and there was"/>
   <result pre="potential pandemics and there was no domestic production of bulk" exact="influenza" post="vaccines. In fact, prior to 2007, there was no"/>
   <result pre="By 2010, Thailand was importing 2.1 million doses of seasonal" exact="influenza" post="vaccine: GPO-MBP, a joint venture between the Government Pharmaceutical"/>
   <result pre="(GPO) and Sanofi Pasteur, supplied approximately 800,000 doses of seasonal" exact="influenza" post="vaccine by formulating and filling imported bulk, and the"/>
   <result pre="In 2005, the Thai government issued the first national pandemic" exact="influenza" post="preparedness plans in response to the highly pathogenic avian"/>
   <result pre="pandemic influenza preparedness plans in response to the highly pathogenic" exact="avian influenza" post="outbreak in 2004. The second national strategic plan was"/>
   <result pre="influenza preparedness plans in response to the highly pathogenic avian" exact="influenza" post="outbreak in 2004. The second national strategic plan was"/>
   <result pre="for the year 2008–2010. The first national strategic plan for" exact="influenza" post="pandemic preparedness (2005–2007) focused on supporting research and development"/>
   <result pre="set up a local industrial-scale manufacture plant for egg-based pandemic" exact="influenza" post="vaccines and train personnel for industrial-scale vaccine research and"/>
   <result pre="(BARDA), the GPO has been able to develop live attenuated" exact="influenza" post="vaccine (LAIV) for potential pandemic vaccines (H1N1 and H5N2"/>
   <result pre="for potential pandemic vaccines (H1N1 and H5N2 LAIV) and inactivated" exact="influenza" post="vaccine for seasonal use. In 2009, the Thai Government"/>
   <result pre="of Experimental Medicine (IEM), Saint Petersburg, Russia. After receiving the" exact="influenza" post="A H1N1 (2009) pre-master seed from Russia through the"/>
   <result pre="the criteria for licensure for emergency use.8 GPO-manufactured live attenuated" exact="influenza" post="H5 candidate vaccine GPO had received master donor seed"/>
   <result pre="was culture-positive on day 1 after the 2nd immunization. No" exact="influenza" post="virus was isolated from Madin-Darby Canine Kidney epithelial (MDCK)"/>
   <result pre="to evaluate the immune response and safety of live attenuated" exact="influenza" post="H5 vaccine candidate strain A/17/turkey/Turkey/05/133 (H5N2) manufactured by GPO"/>
   <result pre="environment with the vaccine strain. Two doses of live attenuated" exact="influenza" post="H5 vaccine candidate strain A/17/turkey/Turkey/05/133 (H5N2) were given by"/>
   <result pre="study conducted in the US by K. Subbarao showed that" exact="influenza" post="A(H5N1) pLAIV recipients with poor primary immune responses were"/>
   <result pre="having a long-lasting immunity and could be boosted with inactivated" exact="influenza" post="H5N1 vaccine at 52, 54 or 56 months after"/>
   <result pre="study The booster vaccine used was subunit aluminum hydroxide adsorbed" exact="influenza" post="vaccine containing HA and NA proteins from the influenza"/>
   <result pre="adsorbed influenza vaccine containing HA and NA proteins from the" exact="influenza" post="virus A/turkey/Turkey/1/05 (H5N1). Sixty participants (40 vaccinees, 20 placebos"/>
   <result pre="been enrolled and received one dose of the H5 inactivated" exact="influenza" post="vaccine (IIV) 1 year after the H5N2 vaccination. The"/>
   <result pre="are described in our previous report.10 Efforts in manufacturing inactivated" exact="influenza" post="vaccines (IIVs) Following experience with the successful clinical trials"/>
   <result pre="experience with the successful clinical trials of the H5N2 live-attenuated" exact="influenza" post="vaccine and obtaining the licensure for its pandemic use"/>
   <result pre="seroconversion rate of participants who had received the GPO trivalent-inactivated" exact="influenza" post="vaccine 21 days later were 85%, 45%, and 95%"/>
   <result pre="manufacturer (the GPO) to be able to manufacture its own" exact="influenza" post="vaccines as a part of the strategy of self-reliance"/>
   <result pre="have the capacity to produce 2 million doses of seasonal" exact="influenza" post="vaccines, then to increase to 10 million doses in"/>
   <result pre="of the study; Microgen (Moscow, Russia) for providing the inactivated" exact="influenza" post="vaccine used in part 2; the clinical and nursing"/>
   <result pre="References References 1.collab: WHOCumulative number of confirmed human cases for" exact="avian influenza" post="A(H5N1) reported to WHO, 2003–2018. Geneva, Switzerland: WHO/GIP; 2018."/>
   <result pre="References 1.collab: WHOCumulative number of confirmed human cases for avian" exact="influenza" post="A(H5N1) reported to WHO, 2003–2018. Geneva, Switzerland: WHO/GIP; 2018."/>
   <result pre="to WHO, 2003–2018. Geneva, Switzerland: WHO/GIP; 2018. 2.collab: WHOGlobal pandemic" exact="influenza" post="action plan to increase vaccine supply. Geneva, Switzerland: WHO;"/>
   <result pre="AkarasewiP, YingyongT, SuthachanaS, PittayawonganonC, UngchusakK.Three waves of the 2009 H1N1" exact="influenza" post="pandemic in Thailand. Siriraj Med J. 2011;63:64–67. 4.The National"/>
   <result pre="PandemicThe second national strategic plan for prevention and control of" exact="avian influenza" post="and preparedness for influenza pandemic. Bangkok, Thailand: The Ministry"/>
   <result pre="second national strategic plan for prevention and control of avian" exact="influenza" post="and preparedness for influenza pandemic. Bangkok, Thailand: The Ministry"/>
   <result pre="for prevention and control of avian influenza and preparedness for" exact="influenza" post="pandemic. Bangkok, Thailand: The Ministry of Public Health; 2008."/>
   <result pre="HeXS, GreenbergHB.Distinct cross-reactive B-cell responses to live attenuated and inactivated" exact="influenza" post="vaccines. J Infect Dis. 2014;210:865–74. doi:10.1093/infdis/jiu190.24676204 7.ClementsML, MurphyBRDevelopment and"/>
   <result pre="systemic antibody responses in adults given live attenuated or inactivated" exact="influenza" post="A virus vaccine. J Clin Microbiol. 1986;23:66–72.3700610 8.PhonratB, PitisuttithumP,"/>
   <result pre="WibulpolprasertSSafety and immune responses following administration of H1N1 live attenuated" exact="influenza" post="vaccine in Thais. Vaccine. 2013;31:1503–09. doi:10.1016/j.vaccine.2012.12.082.23318149 9.SurichanS, WirachwongP, SupachaturasW,"/>
   <result pre="UtidK, TheerasurakarnS, LangsanamP, LakornrachP, NitisapornL, ChansikkakornC, VangkanontaW, et alDevelopment of" exact="influenza" post="vaccine production capacity by the government pharmaceutical organization of"/>
   <result pre="government pharmaceutical organization of Thailand: addressing the threat of an" exact="influenza" post="pandemic. Vaccine. 2011;29(Suppl 1):A29–A33. doi:10.1016/j.vaccine.2011.04.120.21684425 10.PitisuttithumP, BoonnakK, ChamnanchanuntS, PuthavathanaP,"/>
   <result pre="ThanachartwetV, SilachamroonU, et alSafety and immunogenicity of a live attenuated" exact="influenza" post="H5 candidate vaccine strain A/17/turkey/Turkey/05/133 H5N2 and its priming"/>
   <result pre="LRK, BAM, RAK, KDL, QinJ, DAF, et alA live attenuated" exact="influenza" post="A(H5N1) vaccine induces long-term immunity in the absence of"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6818521\results\search\disease\results.xml">
   <result pre="and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.bjsports-2018-100487.pdf Abstract Objectives The" exact="common cold" post="is the main cause of medical time loss in"/>
   <result pre="(POCT). Methods We performed a prospective observational study of the" exact="common cold" post="in Team Finland during the 2018 Winter Olympic Games."/>
   <result pre="staff members. The chief physician recorded the symptoms of the" exact="common cold" post="daily on a standardised form. Two nasal swabs were"/>
   <result pre="45 min using a molecular POCT for respiratory syncytial virus and" exact="influenza" post="A and B viruses. After the Games, the other"/>
   <result pre="out of 68 (32%) staff members experienced symptoms of the" exact="common cold" post="during a median stay of 21 days. Eleven (26%)"/>
   <result pre="Eleven (26%) samples tested virus-positive using POCT. All subjects with" exact="influenza" post="(n=6) and 32 close contacts were treated with oseltamivir."/>
   <result pre="close contacts were treated with oseltamivir. The aetiology of the" exact="common cold" post="was finally detected in 75% of the athletes and"/>
   <result pre="identified. They were caused by coronaviruses 229E, NL63 and OC43," exact="influenza" post="B virus, respiratory syncytial virus A, rhinovirus and human"/>
   <result pre="be clinically valuable, especially for influenza. The aetiology of the" exact="common cold" post="was identified in most cases. athlete infection respiratory olympics"/>
   <result pre="Ane Gyllenbergin Säätiö Introduction Elite athletes are predisposed to the" exact="common cold" post="due to heavy physical and mental stress which may"/>
   <result pre="its timing coincides with epidemics of many respiratory viruses. The" exact="common cold" post="has been said to be ‘the most dreaded opponent’"/>
   <result pre="and may ruin the athlete’s long-term goal of success.7 The" exact="common cold" post="is a prevalent, complex and heterogeneous illness.8 More than"/>
   <result pre="study was to investigate the occurrence and aetiology of the" exact="common cold" post="in Team Finland during the 2018 Winter Olympic Games."/>
   <result pre="Olympic Games. We used recently developed molecular multiplexed POCT for" exact="influenza" post="A and B viruses and respiratory syncytial virus at"/>
   <result pre="+8°C and between 12% and 77%, respectively. Monitoring of the" exact="common cold" post="was provided to Team Finland members who stayed in"/>
   <result pre="also taken from subjects exposed to a patient with the" exact="common cold." post="Specimens for POCT were collected as part of the"/>
   <result pre="provisions of the Declaration of Helsinki. Assessment of illness The" exact="common cold" post="was defined as the acute onset of any of"/>
   <result pre="instructions to detect respiratory syncytial virus A and B, adenovirus," exact="influenza" post="A and B viruses, rhinovirus, parainfluenza type 1–4 viruses,"/>
   <result pre="pneumoniae and Mycoplasma pneumoniae. A laboratory-designed triplex RT-PCR assay for" exact="influenza" post="A, A/H1pdm09 and B viruses was performed as described"/>
   <result pre="and 95% CIs were calculated accordingly. Results Occurrence of the" exact="common cold" post="Forty-two out of 112 team members reported symptoms of"/>
   <result pre="A and B. Figure 2 Occurrence and aetiology of the" exact="common cold." post="The figure shows the departure day (D) from Helsinki"/>
   <result pre="day (A) to Helsinki of each subject who got the" exact="common cold" post="during the Games. The coloured bars represent different viruses"/>
   <result pre="virus A; RSV B, respiratory syncytial virus B; Inf B," exact="influenza" post="B virus; Inf A, influenza A virus; MPV, human"/>
   <result pre="syncytial virus B; Inf B, influenza B virus; Inf A," exact="influenza" post="A virus; MPV, human metapneumovirus; RV, rhinovirus; 229E, human"/>
   <result pre="human coronavirus OC43; NL63, human coronavirus NL63. Aetiology of the" exact="common cold" post="detected by molecular POCT Onsite, the aetiology of respiratory"/>
   <result pre="42 (26%) symptomatic cases. Before the Games, two cases of" exact="influenza" post="B were detected by local healthcare services using antigen"/>
   <result pre="POCT in the team’s medical room detected one case of" exact="influenza" post="A virus, three cases of influenza B virus and"/>
   <result pre="detected one case of influenza A virus, three cases of" exact="influenza" post="B virus and five cases of respiratory syncytial virus"/>
   <result pre="cases of respiratory syncytial virus A. The aetiology of the" exact="common cold" post="was identified in six athletes and in five staff"/>
   <result pre="and in five staff members. All six patients with an" exact="influenza" post="virus infection were treated with oseltamivir. Oseltamivir prophylaxis was"/>
   <result pre="None of them developed a symptomatic infection. Aetiology of the" exact="common cold" post="detected by multiplex-PCR-testing in the laboratory The aetiology of"/>
   <result pre="detected by multiplex-PCR-testing in the laboratory The aetiology of the" exact="common cold" post="was finally detected in 30 of 42 patients, in"/>
   <result pre="the laboratory. Four athletes competed with mild symptoms of the" exact="common cold." post="One athlete competed 5 days after the onset of"/>
   <result pre="One athlete competed 5 days after the onset of an" exact="influenza" post="B infection, another competed 5 days after the onset"/>
   <result pre="after the onset of a metapneumovirus infection. Transmission of the" exact="common cold" post="within the team One subject reported nasal congestion when"/>
   <result pre="respiratory syncytial virus A detection. One subject developed a febrile" exact="influenza" post="B infection during the 9-hour outbound flight. Another subject"/>
   <result pre="on the same flight (seated one row behind) developed an" exact="influenza" post="B infection 1.5 days later. Three more subjects were"/>
   <result pre="1.5 days later. Three more subjects were infected with the" exact="influenza" post="B virus. These cases were separate and were not"/>
   <result pre="one asymptomatic subject staying outside the village was predisposed to" exact="influenza" post="B infection. In both cases, rhinovirus infection was later"/>
   <result pre="Rhinovirus 1 – –  Ski jumping 6 3 Metapneumovirus 2," exact="influenza" post="A 1 – – Staff members  Coaches 18 6"/>
   <result pre="1 Rhinovirus 1  Physiotherapists 5 3 Coronavirus 229E+coronavirus NL63 1," exact="influenza" post="B 1 1 –  Masseuses 4 1 Negative 2"/>
   <result pre="of the staff members suffered from the symptoms of the" exact="common cold" post="during the median stay of 3 weeks at the"/>
   <result pre="Winter Olympic Games. Second, POCT multiplex PCR diagnostics rapidly detected" exact="influenza" post="A and B virus, and respiratory syncytial virus infections."/>
   <result pre="respiratory syncytial virus infections. Third, the probable aetiology of the" exact="common cold" post="could be detected in 75% of the athletes and"/>
   <result pre="respiratory viruses were found within the team. Occurrence of the" exact="common cold" post="during the winter games Two previous studies by the"/>
   <result pre="physician informed all team members about the monitoring of the" exact="common cold." post="She stayed in the same building as the team"/>
   <result pre="days immediately after the Tour de Ski.23 Aetiology of the" exact="common cold" post="in elite athletes Our study is the first to"/>
   <result pre="Diagnostics had clinical implications in the treatment and prevention of" exact="influenza" post="A and B infections. In addition to early treatment"/>
   <result pre="causative virus in 75% of the elite athletes with the" exact="common cold." post="Causality is supported by a 4%–6% occurrence of respiratory"/>
   <result pre="the staff (table 1). Before and during the Winter Games," exact="influenza" post="and respiratory syncytial virus epidemics were occurring in Finland"/>
   <result pre="and respiratory syncytial virus epidemics were occurring in Finland and" exact="influenza" post="and coronavirus epidemics were under way in South Korea."/>
   <result pre="contributed to the transmission of the infections. Transmission of the" exact="common cold" post="In three subjects, the symptoms of the common cold—one"/>
   <result pre="three subjects, the symptoms of the common cold—one caused by" exact="influenza" post="B virus and the others by respiratory syncytial virus"/>
   <result pre="factor for the transmission of contagious diseases. One person with" exact="influenza" post="can transmit the infection to 5–10 people during an"/>
   <result pre="and clinical significance of asymptomatic infections (eg, most coronavirus and" exact="influenza" post="infections are asymptomatic) and prolonged virus shedding (ie, infectiousness)"/>
   <result pre="The POCT diagnostics detected only three respiratory viruses.16 The 2018" exact="influenza" post="and respiratory syncytial virus epidemics were prominent, which may"/>
   <result pre="Molecular POCT diagnostics proved clinically valuable. The aetiology of the" exact="common cold" post="was identified in the majority of cases. The viruses"/>
   <result pre="athletes and 32% of the support staff suffered from the" exact="common cold" post="during a median observation period of 21 days. We"/>
   <result pre="used a fast and automated molecular point-of-care test (POCT) for" exact="influenza" post="A and B viruses and respiratory syncytial virus on"/>
   <result pre="in 11 of 42 (26%) symptomatic cases. All subjects with" exact="influenza" post="and close contact with individuals with influenza were treated"/>
   <result pre="All subjects with influenza and close contact with individuals with" exact="influenza" post="were treated with oseltamivir. In the laboratory the aetiology"/>
   <result pre="treated with oseltamivir. In the laboratory the aetiology of the" exact="common cold" post="was detected in 75% of the elite athletes. These"/>
   <result pre="enhance timely isolation to decrease viral transmission. The incidence of" exact="influenza" post="virus infection reinforces the need for influenza vaccination in"/>
   <result pre="The incidence of influenza virus infection reinforces the need for" exact="influenza" post="vaccination in sport teams. At major sport events, healthcare"/>
   <result pre="New York TimesThe most dreaded opponent at the Olympics: the" exact="common cold," post="2018 Available: https://www.nytimes.com/2018/02/11/sports/olympics/common-cold-athletes.html 8HeikkinenT, JärvinenAThe common cold. Lancet2003;361:51–9. 10.1016/S0140-6736(03)12162-912517470"/>
   <result pre="the Olympics: the common cold, 2018 Available: https://www.nytimes.com/2018/02/11/sports/olympics/common-cold-athletes.html 8HeikkinenT, JärvinenAThe" exact="common cold." post="Lancet2003;361:51–9. 10.1016/S0140-6736(03)12162-912517470 9MäkeläMJ, PuhakkaT, RuuskanenO, et al.Viruses and bacteria"/>
   <result pre="RuuskanenO, et al.Viruses and bacteria in the etiology of the" exact="common cold." post="J Clin Microbiol1998;36:539–42.9466772 10van BeekJ, VeenhovenRH, BruinJP, et al.Influenza-like"/>
   <result pre="VeenhovenRH, BruinJP, et al.Influenza-like illness incidence is not reduced by" exact="influenza" post="vaccination in a cohort of older adults, despite effectively"/>
   <result pre="in a cohort of older adults, despite effectively reducing laboratory-confirmed" exact="influenza" post="virus infections. J Infect Dis2017;216:415–24. 10.1093/infdis/jix26828931240 11ByingtonCL, AmpofoK, StockmannC,"/>
   <result pre="literature review. Rev Med Virol2018;28:e199710.1002/rmv.199730043515 13LauMSY, CowlingBJ, CookAR, et al.Inferring" exact="influenza" post="dynamics and control in households. Proc Natl Acad Sci"/>
   <result pre="Med2017;5:401–11. 10.1016/S2213-2600(17)30120-028392237 16CohenDM, KlineJ, MayLS, et al.Accurate PCR detection of" exact="influenza" post="A/B and respiratory syncytial viruses by use of Cepheid"/>
   <result pre="10.1016/S0091-6749(98)70301-X9648698 18JokelaP, VuorinenT, WarisM, et al.Performance of the Alere i" exact="influenza" post="A&amp;amp;B assay and mariPOC test for the rapid detection"/>
   <result pre="A&amp;amp;B assay and mariPOC test for the rapid detection of" exact="influenza" post="A and B viruses. J Clin Virol2015;70:72–6. 10.1016/j.jcv.2015.07.29426305824 19OsterbackR,"/>
   <result pre="et al.Viral shedding and transmission potential of asymptomatic and paucisymptomatic" exact="influenza" post="virus infections in the community. Clin Infect Dis2017;64:736–42. 10.1093/cid/ciw84128011603"/>
   <result pre="intervention study on higher-dose oseltamivir treatment in adults hospitalized with" exact="influenza" post="A and B infections. Clin Infect Dis2013;57:1511–9. 10.1093/cid/cit59724046309 25LeeN,"/>
   <result pre="Dis2013;57:1511–9. 10.1093/cid/cit59724046309 25LeeN, ChanMCW, LuiGCY, et al.High viral load and" exact="respiratory failure" post="in adults hospitalized for respiratory syncytial virus infections. J"/>
   <result pre="al.Serology enhances molecular diagnosis of respiratory virus infections other than" exact="influenza" post="in children and adults hospitalized with community-acquired pneumonia. J"/>
   <result pre="with community-acquired pneumonia. J Clin Microbiol2017;55:79–89. 10.1128/JCM.01701-1627795341 33LeitmeyerK, AdlhochCReview article:" exact="influenza" post="transmission on aircraft: a systematic literature review. Epidemiology2016;27:743–51. 10.1097/EDE.000000000000043827253070"/>
   <result pre="PantelicJ, et al.Infectious virus in exhaled breath of symptomatic seasonal" exact="influenza" post="cases from a College Community. Proc Natl Acad Sci"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6819614\results\search\disease\results.xml">
   <result pre="because of their well-known impact on human health, including the" exact="influenza" post="virus that causes seasonal flu epidemics and the viruses"/>
   <result pre="incorporating the genes that code for the toxin that induces" exact="diarrhea" post="[9]. Phages may thus serve as important reservoirs and"/>
   <result pre="Spounaviridae subfamily of phages could serve as informative markers for" exact="colitis" post="[60]. Table 1 Selection of studies on gut virome"/>
   <result pre="2018 [51] Inflammatory bowel disease (IBD) Crohn’s disease (n = 16) and" exact="ulcerative colitis" post="(n = 36) and household controls (n = 21) Enteric virome richness was"/>
   <result pre="[51] Inflammatory bowel disease (IBD) Crohn’s disease (n = 16) and ulcerative" exact="colitis" post="(n = 36) and household controls (n = 21) Enteric virome richness was"/>
   <result pre="(n = 21) Enteric virome richness was increased in Crohn’s disease and" exact="ulcerative colitis," post="and both forms of IBD were associated with a"/>
   <result pre="expansion of Caudovirales bacteriophages Norman et al. 2015 [52] Colorectal" exact="cancer" post="(CRC) CRC cases (n = 74) and controls without CRC (n = 92)"/>
   <result pre="cocktail protects against cholera by reducing both colonization and cholera-like" exact="diarrhea" post="in infant murine and rabbit models [72]. In contrast,"/>
   <result pre="acute bacterial diarrhea, failed to achieve intestinal amplification and improve" exact="diarrhea" post="outcome [73]. This was possibly due to insufficient phage"/>
   <result pre="bowel diseaseCell.201516044746010.1016/j.cell.2015.01.00225619688 53.NakatsuGZhouHWuWKKWongSHCokerOODaiZet al.Alterations in enteric virome are associated with" exact="colorectal cancer" post="and survival outcomesGastroenterology201815552941.e510.1053/j.gastro.2018.04.01829689266 54.MonacoCLGootenbergDBZhaoGHandleySAGhebremichaelMSLimESet al.Altered virome and bacterial microbiome"/>
   <result pre="diseaseCell.201516044746010.1016/j.cell.2015.01.00225619688 53.NakatsuGZhouHWuWKKWongSHCokerOODaiZet al.Alterations in enteric virome are associated with colorectal" exact="cancer" post="and survival outcomesGastroenterology201815552941.e510.1053/j.gastro.2018.04.01829689266 54.MonacoCLGootenbergDBZhaoGHandleySAGhebremichaelMSLimESet al.Altered virome and bacterial microbiome"/>
   <result pre="viral genera that help to decipher intestinal viromesMicrobiome.201866510.1186/s40168-018-0452-129615108 60.DuerkopBAKleinerMPaez-EspinoDZhuWBushnellBHassellBet al.Murine" exact="colitis" post="reveals a disease-associated bacteriophage communityNat Microbiol201831023103110.1038/s41564-018-0210-y30038310 61.MokiliJLRohwerFDutilhBEMetagenomics and future"/>
   <result pre="al.Microbiota transfer therapy alters gut ecosystem and improves gastrointestinal and" exact="autism" post="symptoms: an open-label studyMicrobiome.201751010.1186/s40168-016-0225-728122648 63.KauALPlanerJDLiuJRaoSYatsunenkoTTrehanIet al.Functional characterization of IgA-targeted"/>
   <result pre="a highly stable DNA vaccine delivery vehicleVaccine.2004222413241910.1016/j.vaccine.2003.11.06515193403 69.MarchJBClarkJRJepsonCDGenetic immunisation against" exact="hepatitis" post="B using whole bacteriophage λ particlesVaccine.2004221666167110.1016/j.vaccine.2003.10.04715068849 70.TeminHMMizutaniSRNA-dependent DNA polymerase"/>
   <result pre="bacteriophage λ particlesVaccine.2004221666167110.1016/j.vaccine.2003.10.04715068849 70.TeminHMMizutaniSRNA-dependent DNA polymerase in virions of Rous" exact="sarcoma" post="virusNature.19702261211121310.1038/2261211a04316301 71.SmithGFilamentous fusion phage: novel expression vectors that display"/>
   <result pre="animal modelsNat Commun201781418710.1038/ncomms1418728146150 73.SarkerSASultanaSReutelerGMoineDDescombesPChartonFet al.Oral phage therapy of acute bacterial" exact="diarrhea" post="with two coliphage preparations: a randomized trial in children"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6821451\results\search\disease\results.xml">
   <result pre="this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/. Abstract Non-structural protein 1 (NS1) of" exact="influenza" post="virus has been shown to inhibit the innate immune"/>
   <result pre="interaction of NS1 with tripartite motif-containing protein 25 (TRIM25), and" exact="suppression" post="of NS1 enabled retinoic acid inducible gene I (RIG-I)"/>
   <result pre="reporter assay and quantitative real-time PCR (RT-PCR) experiments demonstrated that" exact="suppression" post="of NS1 by the selected aptamers induced IFN production."/>
   <result pre="aptamers are strongly expected to be new therapeutic agents against" exact="influenza" post="infection. aptamer influenza virus non-structural 1 systematic evolution of"/>
   <result pre="expected to be new therapeutic agents against influenza infection. aptamer" exact="influenza" post="virus non-structural 1 systematic evolution of ligands by exponential"/>
   <result pre="threat causing occasional pandemics and seasonal epidemics. The causative agents," exact="influenza" post="viruses, belong to the family of Orthomyxoviridae and have"/>
   <result pre="have single-stranded negative-sense RNA genome of 8 segments. Thus far," exact="influenza" post="is classified on the subtypes of 18 hemagglutinins and"/>
   <result pre="antiviral cytokine interferons (IFNs). To evade host’s innate immune response," exact="influenza" post="has evolved a few strategies for viral replication. Influenza"/>
   <result pre="the host. NS1 is encoded by segment 8 of the" exact="influenza" post="and range in size 217–237 amino acids. NS1 is"/>
   <result pre="In the present study, we isolated RNA aptamers specific to" exact="influenza" post="NS1 protein. Because nucleic acid aptamers have comparable binding"/>
   <result pre="cells and incubated for 6 h prior to infection of" exact="influenza" post="virus containing PR8–green fluorescent protein (GFP) as described previously"/>
   <result pre="of RIG-I ubiquitination by TRIM25 induces IFN production. Inhibition of" exact="influenza" post="virus replication by the RNA aptamers To determine whether"/>
   <result pre="by inhibiting the TRIM25-mediated RIG-I CARD ubiquitination, which leads to" exact="suppression" post="of IFN induction (Gack et al., 2009). Our results"/>
   <result pre="interface of the effector domain of non-structural protein 1 from" exact="influenza" post="A virus: an interface with multiple functionsJ Biol Chem286260502606010.1074/jbc.M111.24876521622573"/>
   <result pre="A virus: an interface with multiple functionsJ Biol Chem286260502606010.1074/jbc.M111.24876521622573 BasuD.WalkiewiczM.P.FriemanM.BaricR.S.AubleD.T.EngelD.A.2009Novel" exact="influenza" post="virus NS1 antagonists block replication and restore innate immune"/>
   <result pre="replication and restore innate immune functionJ Virol831881189110.1128/JVI.01805-0819052087 BornholdtZ.A.PrasadB.V.2006X-ray structure of" exact="influenza" post="virus NS1 effector domainNat Struct Mol Biol1355956010.1038/nsmb109916715094 BrodyE.N.GoldL.2000Aptamers as"/>
   <result pre="as therapeutic and diagnostic agentsJ Biotechnol7451310943568 ChengC.DongJ.YaoL.ChenA.JiaR.HuanL.GuoJ.ShuY.ZhangZ.2008Potent inhibition of human" exact="influenza" post="H5N1 virus by oligonucleotides derived by SELEXBiochem Biophys Res"/>
   <result pre="RNA and the N-terminal domain of the NS1 protein from" exact="influenza" post="A virus: evidence for a novel RNA-binding modeBiochemistry431950196210.1021/bi030176o14967035 CuiS.EisenacherK.KirchhoferA.BrzozkaK.LammensA.LammensK.FujitaT.ConzelmannK.K.KrugA.HopfnerK.P.2008The"/>
   <result pre="domain is the RNA 5′-triphosphate sensor of RIG-IMol Cell2916917910.1016/j.molcel.2007.10.03218243112 EngelD.A.2013The" exact="influenza" post="virus NS1 protein as a therapeutic targetAntiviral Res9940941610.1016/j.antiviral.2013.06.00523796981 GackM.U.AlbrechtR.A.UranoT.InnK.S.HuangI.C.CarneroE.FarzanM.InoueS.JungJ.U.Garcia-SastreA.2009Influenza"/>
   <result pre="the NS1 gene replicates in interferon-deficient systemsVirology25232433010.1006/viro.1998.95089878611 HaleB.G.BarclayW.S.RandallR.E.RussellR.J.2008Structure of an" exact="avian influenza" post="A virus NS1 protein effector domainVirology3781510.1016/j.virol.2008.05.02618585749 JangK.J.LeeN.R.YeoW.S.JeongY.J.KimD.E.2008Isolation of inhibitory"/>
   <result pre="NS1 gene replicates in interferon-deficient systemsVirology25232433010.1006/viro.1998.95089878611 HaleB.G.BarclayW.S.RandallR.E.RussellR.J.2008Structure of an avian" exact="influenza" post="A virus NS1 protein effector domainVirology3781510.1016/j.virol.2008.05.02618585749 JangK.J.LeeN.R.YeoW.S.JeongY.J.KimD.E.2008Isolation of inhibitory"/>
   <result pre="NS1 protein effector domainVirology3781510.1016/j.virol.2008.05.02618585749 JangK.J.LeeN.R.YeoW.S.JeongY.J.KimD.E.2008Isolation of inhibitory RNA aptamers against" exact="severe acute respiratory syndrome" post="(SARS) coronavirus NTPase/HelicaseBiochem Biophys Res Commun36673874410.1016/j.bbrc.2007.12.02018082623 JurekaA.S.KleinpeterA.B.CornilescuG.CornilescuC.C.PetitC.M.2015Structural Basis for"/>
   <result pre="signalingJ Allergy Clin Immunol117979987quiz 98810.1016/j.jaci.2006.02.02316675322 KochsG.Garcia-SastreA.Martinez-SobridoL.2007Multiple anti-interferon actions of the" exact="influenza" post="A virus NS1 proteinJ Virol817011702110.1128/JVI.02581-0617442719 LiuJ.LynchP.A.ChienC.Y.MontelioneG.T.KrugR.M.BermanH.M.1997Crystal structure of the"/>
   <result pre="Virol817011702110.1128/JVI.02581-0617442719 LiuJ.LynchP.A.ChienC.Y.MontelioneG.T.KrugR.M.BermanH.M.1997Crystal structure of the unique RNA-binding domain of the" exact="influenza" post="virus NS1 proteinNat Struct Biol489689910.1038/nsb1197-8969360602 LivakK.J.SchmittgenT.D.2001Analysis of relative gene"/>
   <result pre="single-stranded RNA bearing 5′-phosphatesScience314997100110.1126/science.113299817038589 TongS.ZhuX.LiY.ShiM.ZhangJ.BourgeoisM.YangH.ChenX.RecuencoS.GomezJ.et al.2013New world bats harbor diverse" exact="influenza" post="A virusesPLoS Pathog9e100365710.1371/journal.ppat.100365724130481 WooH.M.KimK.S.LeeJ.M.ShimH.S.ChoS.J.LeeW.K.KoH.W.KeumY.S.KimS.Y.PathinayakeP.et al.2013Single-stranded DNA aptamer that specifically"/>
   <result pre="Pathog9e100365710.1371/journal.ppat.100365724130481 WooH.M.KimK.S.LeeJ.M.ShimH.S.ChoS.J.LeeW.K.KoH.W.KeumY.S.KimS.Y.PathinayakeP.et al.2013Single-stranded DNA aptamer that specifically binds to the" exact="influenza" post="virus NS1 protein suppresses interferon antagonismAntiviral Res10033734510.1016/j.antiviral.2013.09.00424055449 WuN.C.YoungA.P.Al-MawsawiL.Q.OlsonC.A.FengJ.QiH.LuanH.H.LiX.WuT.T.SunR.2014High-throughput identification"/>
   <result pre="WuN.C.YoungA.P.Al-MawsawiL.Q.OlsonC.A.FengJ.QiH.LuanH.H.LiX.WuT.T.SunR.2014High-throughput identification of loss-of-function mutations for anti-interferon activity in the" exact="influenza" post="A virus NS segmentJ Virol88101571016410.1128/JVI.01494-1424965464 YoneyamaM.FujitaT.2004RIG-I: critical regulator for"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6822366\results\search\disease\results.xml">
   <result pre="doi: 10.1186/s13567-019-0707-2 : Research Article Host-range shift of H3N8 canine" exact="influenza" post="virus: a phylodynamic analysis of its origin and adaptation"/>
   <result pre="otherwise stated. Abstract Prior to the emergence of H3N8 canine" exact="influenza" post="virus (CIV) and the latest avian-origin H3N2 CIV, there"/>
   <result pre="H3N2 CIV, there was no evidence of a circulating canine-specific" exact="influenza" post="virus. Molecular and epidemiological evidence suggest that H3N8 CIV"/>
   <result pre="epidemiological evidence suggest that H3N8 CIV emerged from H3N8 equine" exact="influenza" post="virus (EIV). This host-range shift of EIV from equine"/>
   <result pre="framework to understand the molecular basis of host-range shifts of" exact="influenza" post="viruses and that dogs are potential &quot;mixing vessels�? for"/>
   <result pre="dogs are potential &quot;mixing vessels�? for the establishment of novel" exact="influenza" post="viruses. Funding China2017YFD0500101SuShuo Introduction Influenza A virus (IAV) is"/>
   <result pre="pigs and H3N8 among horses. The establishment of these mammalian" exact="influenza" post="viruses, including human influenza A virus (hIAV), was the"/>
   <result pre="horses. The establishment of these mammalian influenza viruses, including human" exact="influenza" post="A virus (hIAV), was the result of interspecies transmission"/>
   <result pre="virus (hIAV), was the result of interspecies transmission of an" exact="avian influenza" post="virus (AIV) in the past, either directly or through"/>
   <result pre="(hIAV), was the result of interspecies transmission of an avian" exact="influenza" post="virus (AIV) in the past, either directly or through"/>
   <result pre="circulating contemporary virus. Current evidence supports that interspecies transmission of" exact="influenza" post="viruses occurs frequently; however, these occurrences usually result in"/>
   <result pre="experimentally inoculated mouse models. Of the two subtypes of equine" exact="influenza" post="virus (EIV), only H3N8 EIV (formerly equine-2 influenza virus)"/>
   <result pre="of equine influenza virus (EIV), only H3N8 EIV (formerly equine-2" exact="influenza" post="virus) remains circulating in horses, causing sporadic epizootics and"/>
   <result pre="2003, there was no evidence of circulation of a canine-specific" exact="influenza" post="virus despite close contact with humans and with other"/>
   <result pre="with other mammalian species, such as swine and equines. Most" exact="influenza" post="viruses can be cultivated in Madin-Darby Canine Kidney (MDCK)"/>
   <result pre="Kidney (MDCK) cells, indicating the potential susceptibility of dogs to" exact="influenza" post="virus infection, at least at the cellular level. In"/>
   <result pre="In fact, there were reports of isolation of H3N2 human" exact="influenza" post="A virus (hIAV) from dogs during influenza epidemics [26],"/>
   <result pre="of H3N2 human influenza A virus (hIAV) from dogs during" exact="influenza" post="epidemics [26], as well as serological evidence of hIAV"/>
   <result pre="in dogs [27]. Natural and experimental transmission of pandemic H1N1/2009" exact="influenza" post="virus to dogs has been reported [28]. Notably, there"/>
   <result pre="These reports suggest that dogs can be a host for" exact="influenza" post="A virus. However, these influenza infections were &quot;dead-end�? infections,"/>
   <result pre="can be a host for influenza A virus. However, these" exact="influenza" post="infections were &quot;dead-end�? infections, as there was no further"/>
   <result pre="although pigs have been implicated as a &quot;mixing vessel�? for" exact="influenza" post="viruses [1, 35, 36]. Furthermore, there were no phenotypic"/>
   <result pre="content of the HA and NA gene segments from multiple" exact="influenza" post="A viruses was calculated using BioEdit [46]. Regression and"/>
   <result pre="gene segment to have emerged 1997–2005. The NS1 gene of" exact="influenza" post="viruses, including H3N8 EIV, has been shown to counteract"/>
   <result pre="occur in other sublineages. Phenotypic heterogeneity is common in equine" exact="influenza" post="virus. For example, there is heterogeneity in virulence among"/>
   <result pre="remains to be determined. Reassortment among multiple lineages of co-circulating" exact="influenza" post="viruses is not uncommon [66–68]. Likewise, for the diverged"/>
   <result pre="of the susceptibility of dogs to a wide spectrum of" exact="influenza" post="viruses, the high frequency of reassortment among these influenza"/>
   <result pre="of influenza viruses, the high frequency of reassortment among these" exact="influenza" post="viruses [70] and that stray dogs have a high"/>
   <result pre="risk of dogs as a &quot;mixing vessel�? generating a pandemic" exact="influenza" post="virus should not be overlooked. In conclusion, by conducting"/>
   <result pre="virus involving an &quot;ancestral NS1 gene segment�?. Interspecies transmission of" exact="influenza" post="viruses might occur more frequently than previously thought, but"/>
   <result pre="virus evolves within geographic or facility boundaries. Similar to other" exact="influenza" post="viruses, frequent reassortment within and among these clades was"/>
   <result pre="understand the mechanism of interspecies transmission and host-range shifts of" exact="influenza" post="viruses. Finally, although we utilized a computation-intensive genomics approach"/>
   <result pre="information LINK Additional file 1.List of genetic sequences from multiple" exact="influenza" post="A viruses used in this study. LINK Additional file"/>
   <result pre="that differentiate H3N8 CIV into six clades. Abbreviations EIV equine" exact="influenza" post="virus CIV canine influenza virus AIV avian influenza virus"/>
   <result pre="into six clades. Abbreviations EIV equine influenza virus CIV canine" exact="influenza" post="virus AIV avian influenza virus hIAV human influenza A"/>
   <result pre="Abbreviations EIV equine influenza virus CIV canine influenza virus AIV" exact="avian influenza" post="virus hIAV human influenza A virus HA haemagglutinin NA"/>
   <result pre="EIV equine influenza virus CIV canine influenza virus AIV avian" exact="influenza" post="virus hIAV human influenza A virus HA haemagglutinin NA"/>
   <result pre="CIV canine influenza virus AIV avian influenza virus hIAV human" exact="influenza" post="A virus HA haemagglutinin NA neuraminidase NP nucleoprotein NS"/>
   <result pre="have no competing interests. References References 1.WebsterRGBeanWJGormanOTChambersTMKawaokaYEvolution and ecology of" exact="influenza" post="A virusesMicrobiol Rev1992561521791579108 2.GormanOTBeanWJKawaokaYDonatelliIGuoYJWebsterRGEvolution of influenza A virus nucleoprotein"/>
   <result pre="1.WebsterRGBeanWJGormanOTChambersTMKawaokaYEvolution and ecology of influenza A virusesMicrobiol Rev1992561521791579108 2.GormanOTBeanWJKawaokaYDonatelliIGuoYJWebsterRGEvolution of" exact="influenza" post="A virus nucleoprotein genes: implications for the origins of"/>
   <result pre="of H1N1 human and classical swine virusesJ Virol199165370437142041090 3.GormanOTDonisROKawaokaYWebsterRGEvolution of" exact="influenza" post="A virus PB2 genes: implications for evolution of the"/>
   <result pre="for evolution of the ribonucleoprotein complex and origin of human" exact="influenza" post="A virusJ Virol199064489349022398532 4.KawaokaYGormanOTItoTWellsKDonisROCastrucciMRDonatelliIWebsterRGInfluence of host species on the"/>
   <result pre="species on the evolution of the nonstructural (NS) gene of" exact="influenza" post="A virusesVirus Res19985514315610.1016/S0168-1702(98)00038-09725667 5.BeanWJSchellMKatzJKawaokaYNaeveCGormanOWebsterRGEvolution of the H3 influenza virus"/>
   <result pre="gene of influenza A virusesVirus Res19985514315610.1016/S0168-1702(98)00038-09725667 5.BeanWJSchellMKatzJKawaokaYNaeveCGormanOWebsterRGEvolution of the H3" exact="influenza" post="virus hemagglutinin from human and nonhuman hostsJ Virol199266112911381731092 6.DanzySStuddardLRManicassamyBSolorzanoAMarshallNGarcia-SastreASteelJLowenACMutations"/>
   <result pre="hostsJ Virol199266112911381731092 6.DanzySStuddardLRManicassamyBSolorzanoAMarshallNGarcia-SastreASteelJLowenACMutations to PB2 and NP proteins of an" exact="avian influenza" post="virus combine to confer efficient growth in primary human"/>
   <result pre="Virol199266112911381731092 6.DanzySStuddardLRManicassamyBSolorzanoAMarshallNGarcia-SastreASteelJLowenACMutations to PB2 and NP proteins of an avian" exact="influenza" post="virus combine to confer efficient growth in primary human"/>
   <result pre="2 gene contribute to the pathogenicity of the novel A/H7N9" exact="influenza" post="virus in mammalian hostsJ Virol2014883568357610.1128/JVI.02740-1324403592 8.SongWWangPMokBWLauSYHuangXWuWLZhengMWenXYangSChenYLiLYuenKYChenHThe K526R substitution in"/>
   <result pre="in viral protein PB2 enhances the effects of E627K on" exact="influenza" post="virus replicationNat Commun20145550910.1038/ncomms650925409547 9.KimJHHattaMWatanabeSNeumannGWatanabeTKawaokaYRole of host-specific amino acids in"/>
   <result pre="of host-specific amino acids in the pathogenicity of avian H5N1" exact="influenza" post="viruses in miceJ Gen Virol2010911284128910.1099/vir.0.018143-020016035 10.DalyJMMacRaeSNewtonJRWattrangEEltonDMEquine influenza: a review"/>
   <result pre="an unpredictable virusVet J201118971410.1016/j.tvjl.2010.06.02620685140 11.LaiACLinYPPowellDGShortridgeKFWebsterRGDalyJChambersTMGenetic and antigenic analysis of the" exact="influenza" post="virus responsible for the 1992 Hong Kong equine influenza"/>
   <result pre="the influenza virus responsible for the 1992 Hong Kong equine" exact="influenza" post="epizooticVirology199420467367910.1006/viro.1994.15837941336 12.LandoltGAEquine influenza virusVet Clin North Am Equine Pract20143050752210.1016/j.cveq.2014.08.00325282321"/>
   <result pre="responsible for the 1992 Hong Kong equine influenza epizooticVirology199420467367910.1006/viro.1994.15837941336 12.LandoltGAEquine" exact="influenza" post="virusVet Clin North Am Equine Pract20143050752210.1016/j.cveq.2014.08.00325282321 13.WaddellGHTeiglandMBSigelMMA new influenza"/>
   <result pre="12.LandoltGAEquine influenza virusVet Clin North Am Equine Pract20143050752210.1016/j.cveq.2014.08.00325282321 13.WaddellGHTeiglandMBSigelMMA new" exact="influenza" post="virus associated with equine respiratory diseaseJ Am Vet Med"/>
   <result pre="respiratory diseaseJ Am Vet Med Assoc196314358759014077956 14.PowellDGThomsonGRSpoonerPPlowrightWBurrowsRSchildGCThe outbreak of equine" exact="influenza" post="in England April–May 1973Vet Rec19749428228710.1136/vr.94.13.2824826197 15.WilsonWDEquine influenzaVet Clin North"/>
   <result pre="influenzaVet Clin North Am Equine Pract1993925728210.1016/S0749-0739(17)30395-48358645 16.OxburghLBergMKlingebornBEmmothELinneTEvolution of H3N8 equine" exact="influenza" post="virus from 1963 to 1991Virus Res19943415316510.1016/0168-1702(94)90097-37545975 17.Olguin PerglioneCGolembaMDTorresCBarrandeguyMMolecular epidemiology"/>
   <result pre="17.Olguin PerglioneCGolembaMDTorresCBarrandeguyMMolecular epidemiology and spatio-temporal dynamics of the H3N8 equine" exact="influenza" post="virus in South AmericaPathogens20165E6110.3390/pathogens504006127754468 18.Alves BeuttemmullerEWoodwardARashADos Santos FerrazLEFernandes AlfieriAAlfieriAAEltonDCharacterisation"/>
   <result pre="Santos FerrazLEFernandes AlfieriAAlfieriAAEltonDCharacterisation of the epidemic strain of H3N8 equine" exact="influenza" post="virus responsible for outbreaks in South America in 2012Virology2016134510.1186/s12985-016-0503-9"/>
   <result pre="virus responsible for outbreaks in South America in 2012Virology2016134510.1186/s12985-016-0503-9 19.Reeve-JohnsonLEquine" exact="influenza" post="in AustraliaVet Rec200716163510.1136/vr.161.18.63517982150 20.Alder M (ed) (2008) Summary of"/>
   <result pre="Rec200716163510.1136/vr.161.18.63517982150 20.Alder M (ed) (2008) Summary of the Australian equine" exact="influenza" post="outbreak. Vet Rec 163:378 21.Scott-OrrHProof of freedom from equine"/>
   <result pre="influenza outbreak. Vet Rec 163:378 21.Scott-OrrHProof of freedom from equine" exact="influenza" post="infection in Australia in 2007–08Aust Vet J201189Suppl 116316410.1111/j.1751-0813.2011.00778.x21711321 22.WatsonJDanielsPKirklandPCarrollAJeggoMThe"/>
   <result pre="in 2007–08Aust Vet J201189Suppl 116316410.1111/j.1751-0813.2011.00778.x21711321 22.WatsonJDanielsPKirklandPCarrollAJeggoMThe 2007 outbreak of equine" exact="influenza" post="in Australia: lessons learned for international trade in horsesRev"/>
   <result pre="horsesRev Sci Tech201130879310.20506/rst.30.1.202121809755 23.DalyJMLaiACBinnsMMChambersTMBarrandeguyMMumfordJAAntigenic and genetic evolution of equine H3N8" exact="influenza" post="A virusesJ Gen Virol19967766167110.1099/0022-1317-77-4-6618627254 24.LaiACRogersKMGlaserATudorLChambersTAlternate circulation of recent equine-2"/>
   <result pre="influenza A virusesJ Gen Virol19967766167110.1099/0022-1317-77-4-6618627254 24.LaiACRogersKMGlaserATudorLChambersTAlternate circulation of recent equine-2" exact="influenza" post="viruses (H3N8) from two distinct lineages in the United"/>
   <result pre="in the United StatesVirus Res200410015916410.1016/j.virusres.2003.11.01915019234 25.LaiACChambersTMHollandREJrMorleyPSHainesDMTownsendHGBarrandeguyMDiverged evolution of recent equine-2" exact="influenza" post="(H3N8) viruses in the Western HemisphereArch Virol20011461063107410.1007/s00705017010611504416 26.ChangCPNewAETaylorJFChiangHSInfluenza virus"/>
   <result pre="of antibodies to both hemagglutinin and neuraminidase antigens of H3N2" exact="influenza" post="A virus in domestic dogsIntervirology1975631531810.1159/0001494851235862 28.LinDSunSDuLMaJFanLPuJSunYZhaoJSunHLiuJNatural and experimental infection"/>
   <result pre="dogsIntervirology1975631531810.1159/0001494851235862 28.LinDSunSDuLMaJFanLPuJSunYZhaoJSunHLiuJNatural and experimental infection of dogs with pandemic H1N1/2009" exact="influenza" post="virusJ Gen Virol20129311912310.1099/vir.0.037358-021976611 29.DalyJMBlundenASMacraeSMillerJBowmanSJKolodziejekJNowotnyNSmithKCTransmission of equine influenza virus to"/>
   <result pre="with pandemic H1N1/2009 influenza virusJ Gen Virol20129311912310.1099/vir.0.037358-021976611 29.DalyJMBlundenASMacraeSMillerJBowmanSJKolodziejekJNowotnyNSmithKCTransmission of equine" exact="influenza" post="virus to English foxhoundsEmerg Infect Dis20081446146410.3201/eid1403.07064318325262 30.AndersonTCBromfieldCRCrawfordPCDoddsWJGibbsEPHernandezJASerological evidence of"/>
   <result pre="in USA dogs prior to 2004Vet J201219131231610.1016/j.tvjl.2011.11.01022178358 31.CrawfordPCDuboviEJCastlemanWLStephensonIGibbsEPChenLSmithCHillRCFerroPPompeyJBrightRAMedinaMJJohnsonCMOlsenCWCoxNJKlimovAIKatzJMDonisROTransmission of equine" exact="influenza" post="virus to dogsScience200531048248510.1126/science.111795016186182 32.PayungpornSCrawfordPCKouoTSChenLMPompeyJCastlemanWLDuboviEJKatzJMDonisROInfluenza A virus (H3N8) in dogs"/>
   <result pre="virus to dogsScience200531048248510.1126/science.111795016186182 32.PayungpornSCrawfordPCKouoTSChenLMPompeyJCastlemanWLDuboviEJKatzJMDonisROInfluenza A virus (H3N8) in dogs with" exact="respiratory disease," post="FloridaEmerg Infect Dis20081490290810.3201/eid1406.07127018507900 33.TuJZhouHJiangTLiCZhangAGuoXZouWChenHJinMIsolation and molecular characterization of equine"/>
   <result pre="FloridaEmerg Infect Dis20081490290810.3201/eid1406.07127018507900 33.TuJZhouHJiangTLiCZhangAGuoXZouWChenHJinMIsolation and molecular characterization of equine H3N8" exact="influenza" post="viruses from pigs in ChinaArch Virol200915488789010.1007/s00705-009-0381-119396578 34.SolorzanoAFoniECordobaLBaratelliMRazzuoliEBilatoDMartin del BurgoMAPerlinDSMartinezJMartinez-OrellanaPFraileLChiapponiCAmadoriMdel"/>
   <result pre="in ChinaArch Virol200915488789010.1007/s00705-009-0381-119396578 34.SolorzanoAFoniECordobaLBaratelliMRazzuoliEBilatoDMartin del BurgoMAPerlinDSMartinezJMartinez-OrellanaPFraileLChiapponiCAmadoriMdel RealGMontoyaMCross-species infectivity of H3N8" exact="influenza" post="virus in an experimental infection in swineJ Virol201589111901120210.1128/JVI.01509-1526311894 35.WebsterRGHinshawVSBeanWJJrTurnerBShortridgeKFInfluenza"/>
   <result pre="of human pandemic strainsDev Biol Stand197739461468604130 36.ShortridgeKFWebsterRGButterfieldWKCampbellCHPersistence of Hong Kong" exact="influenza" post="virus variants in pigsScience19771961454145510.1126/science.867041867041 37.FengKHGonzalezGDengLYuHTseVLHuangLHuangKWasikBRZhouBWentworthDEHolmesECChenXVarkiAMurciaPRParrishCREquine and canine influenza H3N8"/>
   <result pre="Hong Kong influenza virus variants in pigsScience19771961454145510.1126/science.867041867041 37.FengKHGonzalezGDengLYuHTseVLHuangLHuangKWasikBRZhouBWentworthDEHolmesECChenXVarkiAMurciaPRParrishCREquine and canine" exact="influenza" post="H3N8 viruses show minimal biological differences despite phylogenetic divergenceJ"/>
   <result pre="for efficient detection of episodic diversifying selectionMol Biol Evol2015321342135310.1093/molbev/msv02225697341 51.BarbaMDalyJMThe" exact="influenza" post="NS1 protein: what do we know in equine influenza"/>
   <result pre="51.BarbaMDalyJMThe influenza NS1 protein: what do we know in equine" exact="influenza" post="virus pathogenesis?Pathogens20165E5710.3390/pathogens503005727589809 52.MurciaPRBaillieGJDalyJEltonDJervisCMumfordJANewtonRParrishCRHoelzerKDouganGParkhillJLennardNOrmondDMouleSWhitwhamAMcCauleyJWMcKinleyTJHolmesECGrenfellBTWoodJLIntra- and interhost evolutionary dynamics of equine"/>
   <result pre="influenza virus pathogenesis?Pathogens20165E5710.3390/pathogens503005727589809 52.MurciaPRBaillieGJDalyJEltonDJervisCMumfordJANewtonRParrishCRHoelzerKDouganGParkhillJLennardNOrmondDMouleSWhitwhamAMcCauleyJWMcKinleyTJHolmesECGrenfellBTWoodJLIntra- and interhost evolutionary dynamics of equine" exact="influenza" post="virusJ Virol2010846943695410.1128/JVI.00112-1020444896 53.WestgeestKBRussellCALinXSpronkenMIBestebroerTMBahlJvan BeekRSkepnerEHalpinRAde JongJCRimmelzwaanGFOsterhausADSmithDJWentworthDEFouchierRAde GraafMGenomewide analysis of reassortment"/>
   <result pre="BeekRSkepnerEHalpinRAde JongJCRimmelzwaanGFOsterhausADSmithDJWentworthDEFouchierRAde GraafMGenomewide analysis of reassortment and evolution of human" exact="influenza" post="A(H3N2) viruses circulating between 1968 and 2011J Virol2014882844285710.1128/JVI.02163-1324371052 54.WenFBlackmonSOlivierAKLiLGuanMSunHWangPGWanXFMutation"/>
   <result pre="binding site of hemagglutinin could facilitate viral adaption from equine" exact="influenza" post="A(H3N8) virus to dogsJ Virol201892e01115-1810.1128/JVI.01115-1829997206 55.RabadanRLevineAJRobinsHComparison of avian and"/>
   <result pre="A(H3N8) virus to dogsJ Virol201892e01115-1810.1128/JVI.01115-1829997206 55.RabadanRLevineAJRobinsHComparison of avian and human" exact="influenza" post="A viruses reveals a mutational bias on the viral"/>
   <result pre="56.WorobeyMHanGZRambautAA synchronized global sweep of the internal genes of modern" exact="avian influenza" post="virusNature201450825425710.1038/nature1301624531761 57.NewtonJRDalyJMSpencerLMumfordJADescription of the outbreak of equine influenza (H3N8)"/>
   <result pre="synchronized global sweep of the internal genes of modern avian" exact="influenza" post="virusNature201450825425710.1038/nature1301624531761 57.NewtonJRDalyJMSpencerLMumfordJADescription of the outbreak of equine influenza (H3N8)"/>
   <result pre="modern avian influenza virusNature201450825425710.1038/nature1301624531761 57.NewtonJRDalyJMSpencerLMumfordJADescription of the outbreak of equine" exact="influenza" post="(H3N8) in the United Kingdom in 2003, during which"/>
   <result pre="NS1 gene replicates in interferon-deficient systemsVirology199825232433010.1006/viro.1998.95089878611 59.GeissGKSalvatoreMTumpeyTMCarterVSWangXBaslerCFTaubenbergerJKBumgarnerREPalesePKatzeMGGarcía-SastreACellular transcriptional profiling in" exact="influenza" post="A virus-infected lung epithelial cells: the role of the"/>
   <result pre="Sci U S A200299107361074110.1073/pnas.11233809912149435 60.KwasnikMGoraIMRolaJZmudzinskiJFRozekWNS-gene based phylogenetic analysis of equine" exact="influenza" post="viruses isolated in PolandVet Microbiol20161829510110.1016/j.vetmic.2015.10.02826711034 61.FulviniAARamanunninairMLeJPokornyBAArroyoJMSilvermanJDevisRBucherDGene constellation of influenza"/>
   <result pre="equine influenza viruses isolated in PolandVet Microbiol20161829510110.1016/j.vetmic.2015.10.02826711034 61.FulviniAARamanunninairMLeJPokornyBAArroyoJMSilvermanJDevisRBucherDGene constellation of" exact="influenza" post="A virus reassortants with high growth phenotype prepared as"/>
   <result pre="from horses to dogs, AustraliaEmerg Infect Dis20101669970210.3201/eid1604.09148920350392 63.HaywardJJDuboviEJScarlettJMJaneczkoSHolmesECParrishCRMicroevolution of canine" exact="influenza" post="virus in shelters and its molecular epidemiology in the"/>
   <result pre="in the United StatesJ Virol201084126361264510.1128/JVI.01350-1020943966 64.RahnamaLAris-BrosouSPhylodynamics of the emergence of" exact="influenza" post="viruses after cross-species transmissionPLoS One20138e8248610.1371/journal.pone.008248624358190 65.FengWSunXShiNZhangMGuanZDuanMInfluenza a virus NS1"/>
   <result pre="antiviral responseBiochem Biophysics Res Commun20174821107111310.1016/j.bbrc.2016.11.166 66.HolmesECGhedinEMillerNTaylorJBaoYSt GeorgeKGrenfellBTSalzbergSLFraserCMLipmanDJTaubenbergerJKWhole-genome analysis of human" exact="influenza" post="A virus reveals multiple persistent lineages and reassortment among"/>
   <result pre="virusesPLoS Biol20053e30010.1371/journal.pbio.003030016026181 67.JianJWLaiCTKuoCYKuoSHHsuLCChenPJWuHSLiuMTGenetic analysis and evaluation of the reassortment of" exact="influenza" post="B viruses isolated in Taiwan during the 2004–2005 and"/>
   <result pre="Res200813124324910.1016/j.virusres.2007.09.01417996973 68.JosephUVijaykrishnaDSmithGJDSuYCFAdaptive evolution during the establishment of European avian-like H1N1" exact="influenza" post="A virus in swineEvol Appl20181153454610.1111/eva.1253629636804 69.ZhuHHughesJMurciaPROrigins and evolutionary dynamics"/>
   <result pre="in swineEvol Appl20181153454610.1111/eva.1253629636804 69.ZhuHHughesJMurciaPROrigins and evolutionary dynamics of H3N2 canine" exact="influenza" post="virusJ Virol2015895406541810.1128/JVI.03395-1425740996 70.ChenYTrovaoNSWangGZhaoWHePZhouHMoYWeiZOuyangKHuangWGarcía-SastreANelsonMEmergence and evolution of novel reassortant influenza"/>
   <result pre="canine influenza virusJ Virol2015895406541810.1128/JVI.03395-1425740996 70.ChenYTrovaoNSWangGZhaoWHePZhouHMoYWeiZOuyangKHuangWGarcía-SastreANelsonMEmergence and evolution of novel reassortant" exact="influenza" post="A viruses in canines in Southern ChinamBio20189e00909-1810.1128/mBio.00909-1829871917"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6822705\results\search\disease\results.xml">
   <result pre="mosquito-borne virus infection and the most common cause of viral" exact="encephalitis" post="in the country. To bring new attention to one"/>
   <result pre="in the Americas [16–18] and revealed the sources causing the" exact="yellow fever" post="outbreaks in Brazil [19,20]. For WNV, virus genomics played"/>
   <result pre="concept was born from a large collaborative project to track" exact="influenza" post="virus evolution using rapid virus sequencing and data sharing"/>
   <result pre="virus sequencing and data sharing [31]. This aided the seasonal" exact="influenza" post="vaccine selection process by identifying emerging virus strains that"/>
   <result pre="professionals in Queens observed an unusual peak of unexplained human" exact="encephalitis" post="cases, but the connection was not initially made with"/>
   <result pre="bird mortality [37]. Early serological investigations pointed to Saint Louis" exact="encephalitis" post="virus (SLEV), a mosquito-borne flavivirus endemic to the Americas,"/>
   <result pre="to the Americas, as the causative agent of the human" exact="encephalitis" post="cases [38]. Electron microscopy investigation of viruses isolated from"/>
   <result pre="further investigation of a possible link between the virus causing" exact="encephalitis" post="in birds and humans [36]. Sequencing of viruses from"/>
   <result pre="de JesusJ, AguiarRS, IaniFCM, et al.Genomic and epidemiological monitoring of" exact="yellow fever" post="virus transmission potential. Science. 2018; 10.1126/science.aat711530139911 20Moreira-SotoA, TorresMC, Lima"/>
   <result pre="et al.Evidence for multiple sylvatic transmission cycles during the 2016–2017" exact="yellow fever" post="virus outbreak, Brazil. Clin Microbiol Infect. 2018;24: 1019.e1–1019.e4. 21LanciottiRS,"/>
   <result pre="of the West Nile virus responsible for an outbreak of" exact="encephalitis" post="in the northeastern United States. Science. 1999;286: 2333–2337. 10.1126/science.286.5448.233310600742"/>
   <result pre="2018;24: 2184–2194. 10.3201/eid2412.18038230457531 28LadnerJT, GrubaughND, PybusOG, AndersenKG. Precision epidemiology for" exact="infectious disease" post="control. Nat Med. 2019;25: 206–211. 10.1038/s41591-019-0345-230728537 29DellicourS, BaeleG, DudasG,"/>
   <result pre="2019 May 18]. 32NeherRA, BedfordT. Nextflu: Real-time tracking of seasonal" exact="influenza" post="virus evolution in humans. Bioinformatics. 2015;31: 3546–3548. 10.1093/bioinformatics/btv38126115986 33NeherRA,"/>
   <result pre="ShraimanBI. Prediction, dynamics, and visualization of antigenic phenotypes of seasonal" exact="influenza" post="viruses. Proc Natl Acad Sci U S A. 2016;113:"/>
   <result pre="MackenzieJS, et al.Genetic analysis of West Nile New York 1999" exact="encephalitis" post="virus. Lancet. 1999;354: 1971–1972. 10.1016/s0140-6736(99)05384-210622305 40SmithburnKC, HughesTP, BurkeAW, PaulJH."/>
   <result pre="Birds, migration and emerging zoonoses: West Nile virus, Lyme disease," exact="influenza" post="A and enteropathogens. Clin Med Res. 2003;1: 5–12. 15931279"/>
   <result pre="HarperJM, MillerRA, et al.Provenance and geographic spread of St. Louis" exact="encephalitis" post="virus. MBio. 2013;4: e00322–13. 10.1128/mBio.00322-1323760463 124DiazA, CoffeyLL, Burkett-CadenaN, DayJF."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6823455\results\search\disease\results.xml">
   <result pre="of viruses including e.g. Dengue, West Nile, Japanese encephalitis, Tick-borne" exact="encephalitis" post="and many other important human pathogenic viruses. In most"/>
   <result pre="corresponding to the phosphorylated form of IRF3 (P-IRF3), while in" exact="influenza" post="A virus-infected cells (a positive control) P-IRF3 was readily"/>
   <result pre="immunoblotting. Uninfected mock samples were used as negative control and" exact="influenza" post="A virus-infected cells (MOI 1, 24 h infection) as positive"/>
   <result pre="by qRT-PCR. As a positive control cells were infected with" exact="influenza" post="A/Beijing/353/89 virus at MOI of 1 for 24 h. The"/>
   <result pre="10 to 100-fold lower levels compared with those induced by" exact="influenza" post="A virus (Fig. 6B). It has to be pointed"/>
   <result pre="6B). It has to be pointed out that in general," exact="influenza" post="A virus is an excellent inducer of cytokine gene"/>
   <result pre="in the Americas and its association with congenital defects like" exact="microcephaly" post="raised a global infection alert. The characterization of ZIKV"/>
   <result pre="African strain MR766 in some cell lines, such as in" exact="glioma" post="cells or in microvascular endothelial cells of the newborn30."/>
   <result pre="much lower level as compared to our positive control virus," exact="influenza" post="A virus, but yet the expression of antiviral MxA"/>
   <result pre="cell barrier against several human viral pathogens, including Dengue virus37," exact="influenza" post="A virus38, as well as other viruses infecting the"/>
   <result pre="signal transduction by non-structural proteins. For instance, Dengue and Tick-borne" exact="encephalitis" post="viruses have been shown to use specific membrane vesicle"/>
   <result pre="(the second GWUH stock), 5.0 × 106 and 2.4 × 108, respectively. A human" exact="influenza" post="A virus strain A/Beijing/353/1989 (H3N2) was propagated in 11-days-old"/>
   <result pre="MicronesiaN. Engl. J. Med.20093602536254310.1056/NEJMoa080571519516034 2.CauchemezSet al.Association between Zika virus and" exact="microcephaly" post="in French Polynesia, 2013–15: a retrospective studyThe Lancet20163872125213210.1016/S0140-6736(16)00651-6 3.BrasilPet"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6826150\results\search\disease\results.xml">
   <result pre="specific inflammation in mice that had been infected by two" exact="influenza" post="virus strains, A/chicken/Kurgan/5/2005 (H5N1) and A/Hamburg/2009 MA (H1N1), was"/>
   <result pre="was shown to induce interferon-β synthesis, both in healthy and" exact="influenza" post="A virus-infected mice, and to promote production of antiviral"/>
   <result pre="of antiviral antibodies in the blood of the influenza-infected animals." exact="influenza" post="virus H5N1 H1N1 Rhodobacter capsulatus PG lipopolysaccharide mice antiviral"/>
   <result pre="stimulating the response of innate immune cells to pathogens, including" exact="influenza" post="viruses [4]. TLR4 can be activated by damage-associated molecular"/>
   <result pre="which are molecular structures released by virus-infected cells [5]. Different" exact="influenza" post="strains activate cells through various mechanisms, which lead to"/>
   <result pre="to protect mice from death caused by the mouse-adapted H1N1" exact="influenza" post="virus [8]. The nuclear non-histone high mobility group box"/>
   <result pre="is involved in the development of both gram-negative sepsis and" exact="influenza" post="complications, interacting with MD-2 and activating TLR4 [5, 9,"/>
   <result pre="of TLR4 by Eritoran can significantly reduce mouse mortality from" exact="avian influenza" post="[8]. A lipopolysaccharide (LPS) from a phototrophic bacterium R."/>
   <result pre="TLR4 by Eritoran can significantly reduce mouse mortality from avian" exact="influenza" post="[8]. A lipopolysaccharide (LPS) from a phototrophic bacterium R."/>
   <result pre="anti-inflammatory cytokines and survival rates of mice infected with various" exact="influenza" post="A strains. The study aim was to investigate the"/>
   <result pre="features of the inflammatory processes caused by H1N1 and H5N1" exact="influenza" post="viruses. EXPERIMENTAL The following ELISA kits were used: mouse"/>
   <result pre="the procedure described previously [16]. Viruses We used the following" exact="influenza" post="A virus strains: chicken/Kurgan/5/2005 (H5N1) and mouse-adapted Hamburg/2009 MA"/>
   <result pre="compliance with biological ethics in experiments on laboratory animals. Experimental" exact="influenza" post="infection in mice infected with the influenza virus strain"/>
   <result pre="laboratory animals. Experimental influenza infection in mice infected with the" exact="influenza" post="virus strain H5N1 Mice were divided into six groups"/>
   <result pre="ether anesthesia, intranasally (50 μL each) with the highly pathogenic" exact="avian influenza" post="virus H5N1 at doses of 10 to 105 TCID50"/>
   <result pre="anesthesia, intranasally (50 μL each) with the highly pathogenic avian" exact="influenza" post="virus H5N1 at doses of 10 to 105 TCID50"/>
   <result pre="the resulting serum was frozen at –20°C until the H5N1" exact="influenza" post="virus antibody titer in the serum was determined by"/>
   <result pre="experiment on the infection of mice with the A/chicken/Kurgan/5/2005 (H5N1)" exact="influenza" post="virus strain Experimental influenza infection in mice infected with"/>
   <result pre="of mice with the A/chicken/Kurgan/5/2005 (H5N1) influenza virus strain Experimental" exact="influenza" post="infection in mice infected with the mouse adapted influenza"/>
   <result pre="Experimental influenza infection in mice infected with the mouse adapted" exact="influenza" post="virus strain H1N1 The mice-adapted pandemic virus H1N1 used"/>
   <result pre="the HA, NP, PA, and PB1 proteins (Table). The H1N1" exact="influenza" post="virus is 105–fold more pathogenic for mice compared to"/>
   <result pre="ether anesthesia, intranasally (50 μL each) with the mouse-adapted H1N1" exact="influenza" post="virus at doses of 10 and 300 TCID50 per"/>
   <result pre="at –20 °C until the serum levels of the H1N1" exact="influenza" post="virus IgG1 and IgG2a antibodies were determined by ELISA."/>
   <result pre="on the infection of mice with the A/Hamburg/2009 MA (H1N1)" exact="influenza" post="virus strain Determining Cytokine Levels Levels of TNF-α, IL-6,"/>
   <result pre="in the blood serum of mice infected with the H1N1" exact="influenza" post="virus were determined using ELISA kits according to the"/>
   <result pre="analyzer (Awareness, USA) at a wavelength of 450 nm. Determining" exact="influenza" post="virus antibody levels EXPERIMENTAL PROCEDURES To determine the levels"/>
   <result pre="of antibodies to hemagglutinin (HA) of the H5N1 and H1N1" exact="influenza" post="viruses in the serum of the mice, allantoic fluid"/>
   <result pre="to the administration of the Rb. LPS, A/chicken/Kurgan/ 5/2005 (H5N1)" exact="influenza" post="virus, and both factors simultaneously The condition of the"/>
   <result pre="that had received 103, 104, and 105 TCID50 of the" exact="influenza" post="virus died by day 10 after the infection, regardless"/>
   <result pre="administration of the Rb. LPS to mice infected with the" exact="influenza" post="virus at a dose of 102 TCID50 increased their"/>
   <result pre="to the administration of the Rb. LPS, A/chicken/ Kurgan/5/2005 (H5N1)" exact="influenza" post="virus, and both factors simultaneously The administration of the"/>
   <result pre="infection with a dose of 10 TCID50 of the H1N1" exact="influenza" post="virus, followed by the administration of the Rb. LPS,"/>
   <result pre="(day 12). In the group of mice infected with the" exact="influenza" post="virus at a dose of 300 TCID50, 14% of"/>
   <result pre="the administration of the Rb. LPS, A/Hamburg/ 2009 MA (H1N1)" exact="influenza" post="virus, and both factors simultaneously Survival and weight changes"/>
   <result pre="changes in the animals infected with the H5N1 or H1N1" exact="influenza" post="virus revealed the absence of a protective effect on"/>
   <result pre="infection was shown to protect mice from the A/PR/8/34 (H1N1)" exact="influenza" post="virus. Protection from DAMPs released from influenza infected and"/>
   <result pre="the A/PR/8/34 (H1N1) influenza virus. Protection from DAMPs released from" exact="influenza" post="infected and destroyed cells that occurred through the TLR4-"/>
   <result pre="the administration of the Rb. LPS, A/ Hamburg/2009 MA (H1N1)" exact="influenza" post="virus, and both factors simultaneously Signs of viral infection"/>
   <result pre="to the administration of the Rb. LPS, A/Hamburg/2009 MA (H1N1)" exact="influenza" post="virus, and both factors simultaneously. A – TNF-α, B"/>
   <result pre="that exceeded the baseline level 3-fold by day 5. The" exact="influenza" post="virus, regardless of the dose, had no effect on"/>
   <result pre="to the administration of the Rb. LPS to mice. The" exact="influenza" post="virus increases the blood IFN-γ level in mice in"/>
   <result pre="of the Rb. LPS to mice infected with the H1N1" exact="influenza" post="virus reduced IFN-γ production in their blood (Fig. 7D)."/>
   <result pre="level increased 3-fold by day 5 of the experiment. The" exact="influenza" post="virus at a dose of 300 TCID50 significantly increased"/>
   <result pre="mice infected with 10 TCID50 and 300 TCID50 of the" exact="influenza" post="virus enhanced or decreased, respectively, the cytokine level, compared"/>
   <result pre="cytokine level, compared to that in mice infected with the" exact="influenza" post="virus alone (Fig. 7E). These results demonstrated that the"/>
   <result pre="the virus strains under study. IFN-β, a component of the" exact="influenza" post="vaccine, acts as a powerful adjuvant and helps induce"/>
   <result pre="a viral infection, has a protective and neutralizing effect against" exact="influenza" post="viruses. Expression of type I IFN and generation of"/>
   <result pre="LPS on the levels of antibodies to the A/chicken/Kurgan/5/2005 (H5N1)" exact="influenza" post="virus in the serum of mice survived by day"/>
   <result pre="***p &amp;lt; 0.001 The action of existing vaccines against an" exact="influenza" post="virus infection is based mainly on the induction of"/>
   <result pre="and B – IgG2a antibodies to the A/Hamburg/2009 MA (H1N1)" exact="influenza" post="virus (virus dose of 10 TCID50) in the serum"/>
   <result pre="IFN-β level in mice infected with various doses of the" exact="influenza" post="virus. IFN-β promotes antibody production by acquired immunity cells"/>
   <result pre="of antibodies in the blood of animals infected with the" exact="influenza" post="A virus (Fig. 8, Fig. 9). CONCLUSION Our study"/>
   <result pre="IFN-β both in healthy mice and in animals infected with" exact="influenza" post="A/chicken/Kurgan/ 5/2005 (H5N1) and A/Hamburg/2009 MA (H1N1) strains and"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6827050\results\search\disease\results.xml">
   <result pre="occurs in a subacute or chronic form, with severe productive" exact="rhinitis" post="and dyspnea [5,6]. Affected rabbits can have a rapid"/>
   <result pre="is of particular note. RHD is characterized by disseminated necrotic" exact="hepatitis" post="[9]; it evolves peracutely or acutely with high mortality."/>
   <result pre="of myxomatosis including prostration or dyspnea, and lesions such as" exact="blepharitis" post="and conjunctivitis, ear edema or myxomas. When we detected"/>
   <result pre="2-week-old rabbits, (2) in cases of concurrent diseases such as" exact="dermatophytosis" post="or rhinitis, (3) in peracute forms resulting in death,"/>
   <result pre="some of which were confirmed to be bacterial septicemia, or" exact="bacterial pneumonia" post="and RHD, simultaneously. From 2011 onwards we decided to"/>
   <result pre="of which were confirmed to be bacterial septicemia, or bacterial" exact="pneumonia" post="and RHD, simultaneously. From 2011 onwards we decided to"/>
   <result pre="presence of blood on the nose in cases of myxomatosis," exact="rhinitis" post="and pneumonia, acute mastitis, in rabbits affected by mucoid"/>
   <result pre="rhinitis and pneumonia, acute mastitis, in rabbits affected by mucoid" exact="enteropathy" post="(similar to epizootic rabbit enteropathy) [52]; this could also"/>
   <result pre="https://www.cunivetservice.com/wp-content/uploads/2019/04/Rabbit.Myxomatosis.Rosell.April_.25.2019.pdf(accessed on 5 May 2019) 38.BadiolaJ.I.RosellJ.M.BadiolaJ.J.PujolsJ.Pérez de RozasA.García de JalónJ.A.VargasM.A.Haemorrhagic" exact="viral disease" post="of the rabbit. II. Laboratory studies of the virusProceedings"/>
   <result pre="and prevention of rabbit viral haemorrhagic disease 2Practice201840111610.1136/inp.k54 51.LiuS.J.XueH.P.PuB.Q.QianN.H.A new" exact="viral disease" post="in rabbits. Summary in English in CAB directAnim. Husb."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6827708\results\search\disease\results.xml">
   <result pre="symptoms of encephalitis, diagnosed with WNV infection. west nile virus" exact="encephalitis" post="viral fever west nile virus The content published in"/>
   <result pre="management of its sequelae. While central nervous involvement presenting with" exact="meningitis" post="and encephalitis is often found with these diseases [2],"/>
   <result pre="its sequelae. While central nervous involvement presenting with meningitis and" exact="encephalitis" post="is often found with these diseases [2], it is"/>
   <result pre="unclear and observation of complications that may arise, such as" exact="respiratory failure," post="is pertinent in the care of these patients. Prognostically,"/>
   <result pre="no complaints of neck rigidity nor any confusion suggestive of" exact="meningitis" post="or encephalitis. His blood work and imaging including CBC,"/>
   <result pre="or encephalitis. His blood work and imaging including CBC, CMP," exact="hepatitis" post="panel, and blood parasite smear were unremarkable. He had"/>
   <result pre="and blood parasite smear were unremarkable. He had a mild" exact="lactic acidosis" post="of 2.3 mmol/L. A chest X-ray was also unremarkable"/>
   <result pre="(figure 1). The noted differentials at the time included transverse" exact="myelitis" post="or a demyelinating process such as Guillain Barre syndrome"/>
   <result pre="glucose level was 56 mg/dL. The data were consistent with" exact="viral meningitis" post="with pending viral serology. On the third day of"/>
   <result pre="level was 56 mg/dL. The data were consistent with viral" exact="meningitis" post="with pending viral serology. On the third day of"/>
   <result pre="IgG negativity. The patient was subsequently diagnosed with West Nile" exact="myelitis" post="based on clinical presentation, CSF, and serology. The patient’s"/>
   <result pre="within the enterovirus genus. This virus was responsible for the" exact="poliomyelitis" post="epidemic in the 1800s and 1900s. It is a"/>
   <result pre="the discovery and implementation of vaccination against poliovirus, infections and" exact="poliomyelitis" post="due to poliovirus have been thought to be eradicated"/>
   <result pre="no new cases reported in the country since 1979. While" exact="poliomyelitis" post="is the condition most commonly associated with the complications"/>
   <result pre="in the enterovirus genus, such as West Nile virus (WNV)," exact="herpes zoster" post="virus, or rabies virus [3-6]. Poliovirus, a virus that"/>
   <result pre="such as West Nile virus (WNV), herpes zoster virus, or" exact="rabies" post="virus [3-6]. Poliovirus, a virus that has mostly been"/>
   <result pre="traveled to these areas [3]. Enteroviruses are usually associated with" exact="aseptic meningitis" post="and encephalitis, but coxsackieviruses and echoviruses have also been"/>
   <result pre="to these areas [3]. Enteroviruses are usually associated with aseptic" exact="meningitis" post="and encephalitis, but coxsackieviruses and echoviruses have also been"/>
   <result pre="can involve widespread myotomes compared to the dermatome-affected [6]. Finally," exact="rabies" post="virus can sometimes present as ascending paralysis from demyelination"/>
   <result pre="which is accompanied by fever, fatigue, body aches, nausea, vomiting," exact="rash" post="on the trunk, and lymphadenopathy. An even rarer presentation"/>
   <result pre="This devastating complication can include encephalitis, meningitis, and/or West Nile" exact="myelitis" post="with symptoms consisting of high fever, headache, neck stiffness,"/>
   <result pre="in CSF [11]. Up to 75% of cases of WNV" exact="myelitis" post="present with encephalitis, which was not present in our"/>
   <result pre="our patient [12]. Pathogenically, it presents similarly to poliomyelitis. WNV" exact="myelitis" post="uniquely presents with asymmetric areflexic or hyporeflexic weakness with"/>
   <result pre="identification of disease allows for monitoring for complications such as" exact="respiratory failure" post="[14], which, fortunately, our patient did not develop. Differentiation"/>
   <result pre="with GBS, occurring weeks after an acute infection. West Nile" exact="myelitis" post="occurs more frequently during the acute infection. Fever and"/>
   <result pre="GBS it is usually not. As previously stated, West Nile" exact="myelitis" post="often causes encephalopathy, which is not seen in GBS."/>
   <result pre="is not seen in GBS. Electrodiagnostic studies in West Nile" exact="myelitis" post="show significantly decreased or absent motor function from likely"/>
   <result pre="can show both conditions having elevated protein, but West Nile" exact="myelitis" post="can have a pleocytosis while GBS does not [10]."/>
   <result pre="meningitis, or myelitis. It has been shown that patients with" exact="encephalitis" post="and meningoencephalitis demonstrate at least a 95% recovery within"/>
   <result pre="myelitis. It has been shown that patients with encephalitis and" exact="meningoencephalitis" post="demonstrate at least a 95% recovery within a year"/>
   <result pre="discharge from the hospital, only one-third of patients suffering from" exact="encephalitis" post="alone is reported to be fully functional. Notably, patients"/>
   <result pre="alone is reported to be fully functional. Notably, patients with" exact="meningitis" post="alone have been shown to have a more favorable"/>
   <result pre="have a more favorable short-term prognosis [17]. In contrast, WNV-associated" exact="myelitis" post="has been repeatedly demonstrated to have a poor functional"/>
   <result pre="function, if impaired, is usually fully restored in patients with" exact="myelitis" post="[18]. The degree of motor-neuron loss, absent motor responses,"/>
   <result pre="thought to have been eradicated in the US, mimicry of" exact="poliomyelitis" post="symptoms can still rarely occur from other viral illnesses."/>
   <result pre="other viral illnesses. We presented a case of West Nile" exact="myelitis" post="presenting with symptoms similar to poliomyelitis. This case highlights"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6832137\results\search\disease\results.xml">
   <result pre="human diseases are caused by enveloped RNA viruses: Influenza, AIDS," exact="hepatitis" post="C, dengue hemorrhagic fever, microcephaly, and Guillain–Barré Syndrome. Being"/>
   <result pre="are caused by enveloped RNA viruses: Influenza, AIDS, hepatitis C," exact="dengue hemorrhagic fever," post="microcephaly, and Guillain–Barré Syndrome. Being enveloped, the life cycle"/>
   <result pre="feature a few medically important enveloped RNA viruses, such as" exact="hepatitis" post="C virus (HCV), dengue virus (DENV), Zika virus (ZIKV),"/>
   <result pre="virus (DENV), Zika virus (ZIKV), human immunodeficiency virus (HIV), and" exact="influenza" post="virus (IAV), and highlight the role of sphingolipids in"/>
   <result pre="membrane trafficking, cell signaling, and play a crucial role in" exact="influenza" post="virus particles’ release or cell surface binding of HIV-1"/>
   <result pre="and Sphingolipids Hepatitis C virus (HCV) is responsible for chronic" exact="liver disease" post="in 60–90 million people worldwide [31] and is a"/>
   <result pre="mild complications resembling flu-like symptoms and major complications, including deadly" exact="dengue hemorrhagic fever." post="WNV causes flu-like symptoms, neuroinvasive disease, and death in"/>
   <result pre="since 2016, due its association with neurological disorders, such as" exact="microcephaly" post="in newborns and Guillain–Barré syndrome in adults [27,43]. Like"/>
   <result pre="microcephaly in newborns and Guillain–Barré syndrome in adults [27,43]. Like" exact="hepatitis" post="C virus (HCV), DENV, WNV, and ZIKV are enveloped"/>
   <result pre="to T cells. 5. Influenza Virus Propagation and Sphingolipids Seasonal" exact="influenza" post="epidemics are responsible for over 200,000 hospitalizations in the"/>
   <result pre="of the flu NA protein. As such, novel antivirals against" exact="influenza" post="are critically needed. 5.1. Sphingolipids and IAV Entry The"/>
   <result pre="influenza are critically needed. 5.1. Sphingolipids and IAV Entry The" exact="influenza" post="virus’s envelope, derived from the host cell’s plasma membrane,"/>
   <result pre="Sphingolipids and IAV Replication Following binding to host target cells," exact="influenza" post="virus enters the cytoplasm via receptor-mediated endocytosis. The viral"/>
   <result pre="travel to the nucleus for transcription and replication of the" exact="influenza" post="virus genome. Research suggests that products derived from sphingolipids"/>
   <result pre="Research suggests that products derived from sphingolipids are involved in" exact="influenza" post="virus’s genome replication. Seo et al. [78] found that"/>
   <result pre="replication. Seo et al. [78] found that cells infected with" exact="influenza" post="virus possessed increased levels of the enzyme sphingosine kinase"/>
   <result pre="5.3. Sphingolipids and IAV Egress Like several other enveloped viruses," exact="influenza" post="uses &quot;raft-like�? microdomains on the cell surface as platforms"/>
   <result pre="perturbation of host sphingomyelin biosynthesis adversely impacted the trafficking of" exact="influenza" post="virus HA and NA to the cell surface, which"/>
   <result pre="Dengue virus entryCell Host Microbe20121254455710.1016/j.chom.2012.08.00923084921 4.AligoJ.JiaS.MannaD.KonanK.V Formation and function of" exact="hepatitis" post="C virus replication complexes require residues in the carboxy-terminal"/>
   <result pre="structuresJ. Virol.199771665066619261387 8.MiyanariY.AtsuzawaK.UsudaN.WatashiK.HishikiT.ZayasM.BartenschlagerR.WakitaT.HijikataM.ShimotohnoK.The lipid droplet is an important organelle for" exact="hepatitis" post="C virus productionNat. Cell Biol.200791089109710.1038/ncb163117721513 9.JacksonD.A.CatonA.J.McCreadyS.J.CookP.R.Influenza virus RNA is"/>
   <result pre="12.TafesseF.G.SanyalS.AshourJ.GuimaraesC.P.HermanssonM.SomerharjuP.PloeghH.L.Intact sphingomyelin biosynthetic pathway is essential for intracellular transport of" exact="influenza" post="virus glycoproteinsProc. Natl. Acad. Sci. USA20131106406641110.1073/pnas.121990911023576732 13.AizakiH.LeeK.-J.SungV.M.-H.IshikoH.LaiM.M.Characterization of the"/>
   <result pre="influenza virus glycoproteinsProc. Natl. Acad. Sci. USA20131106406641110.1073/pnas.121990911023576732 13.AizakiH.LeeK.-J.SungV.M.-H.IshikoH.LaiM.M.Characterization of the" exact="hepatitis" post="C virus RNA replication complex associated with lipid raftsVirology200432445046110.1016/j.virol.2004.03.03415207630"/>
   <result pre="replication by promotion of specific sphingolipid biosynthesisPLoS Pathog.20128e100286010.1371/journal.ppat.100286022916015 15.BejaouiK.UchidaY.YasudaS.HoM.NishijimaM.BrownR.H.HolleranW.M.HanadaK.Hereditary sensory" exact="neuropathy" post="type 1 mutations confer dominant negative effects on serine"/>
   <result pre="SPTLC2 subunit of serine palmitoyltransferase cause hereditary sensory and autonomic" exact="neuropathy" post="type IAm. J. Hum. Genet.20108751352210.1016/j.ajhg.2010.09.01020920666 18.YasudaS.NishijimaM.HanadaK.Localization, topology, and function"/>
   <result pre="of ceramideBiochim. Biophys. Acta Mol. Cell Biol. Lipids2009179168469110.1016/j.bbalip.2009.01.006 20.KhanI.KatikaneniD.S.HanQ.Sanchez-FelipeL.HanadaK.AmbroseR.L.MackenzieJ.M.KonanK.V.Modulation of" exact="hepatitis" post="C virus genome replication by glycosphingolipids and four-phosphate adaptor"/>
   <result pre="Pathog.20128e100258410.1371/journal.ppat.100258422457619 31.MannsM.P.ButiM.GaneE.PawlotskyJ.-M.RazaviH.TerraultN.YounossiZ.Hepatitis C virus infectionNat. Rev. Dis. Primer201731700610.1038/nrdp.2017.628252637 32.MoradpourD.PeninF.RiceC.M.Replication of" exact="hepatitis" post="C virusNat. Rev. Microbiol.2007545346310.1038/nrmicro164517487147 33.PaulD.MadanV.BartenschlagerR.Hepatitis C virus RNA replication"/>
   <result pre="Drug Resistance of Hepatitis C VirusMethods Mol. Biol.2019191133230593615 35.AsselahT.MarcellinP.SchinaziR.F.Treatment of" exact="hepatitis" post="C virus infection with direct-acting antiviral agents: 100% cure?Liver"/>
   <result pre="and sphingolipid in Hepatitis C virus infectionJ. Virol.2008825715572410.1128/JVI.02530-0718367533 41.EggerD.WölkB.GosertR.BianchiL.BlumH.E.MoradpourD.BienzK.Expression of" exact="hepatitis" post="C virus proteins induces distinct membrane alterations including a"/>
   <result pre="candidate viral replication complexJ. Virol.2002765974598410.1128/JVI.76.12.5974-5984.200212021330 42.KonanK.V.GiddingsT.H.IkedaM.LiK.LemonS.M.KirkegaardK.Nonstructural protein precursor NS4A/B from" exact="hepatitis" post="C virus alters function and ultrastructure of host secretory"/>
   <result pre="70.AhlquistP.RNA-Dependent RNA Polymerases, Viruses, and RNA SilencingScience20022961270127310.1126/science.106913212016304 71.BouvierN.M.PaleseP.The biology of" exact="influenza" post="virusesVaccine200826Suppl. 4D49D5310.1016/j.vaccine.2008.07.03919230160 72.GerlM.J.SampaioJ.L.UrbanS.KalvodovaL.VerbavatzJ.-M.BinningtonB.LindemannD.LingwoodC.A.ShevchenkoA.SchroederC.et al.Quantitative analysis of the lipidomes of"/>
   <result pre="virusesVaccine200826Suppl. 4D49D5310.1016/j.vaccine.2008.07.03919230160 72.GerlM.J.SampaioJ.L.UrbanS.KalvodovaL.VerbavatzJ.-M.BinningtonB.LindemannD.LingwoodC.A.ShevchenkoA.SchroederC.et al.Quantitative analysis of the lipidomes of the" exact="influenza" post="virus envelope and MDCK cell apical membraneJ. Cell Biol.201219621322110.1083/jcb.20110817522249292"/>
   <result pre="Cell Biol.201219621322110.1083/jcb.20110817522249292 73.TannerL.B.ChngC.GuanX.L.LeiZ.RozenS.G.WenkM.R.Lipidomics identifies a requirement for peroxisomal function during" exact="influenza" post="virus replicationJ. Lipid Res.2014551357136510.1194/jlr.M04914824868094 74.SkibbensJ.E.RothM.G.MatlinK.S.Differential extractability of influenza virus"/>
   <result pre="function during influenza virus replicationJ. Lipid Res.2014551357136510.1194/jlr.M04914824868094 74.SkibbensJ.E.RothM.G.MatlinK.S.Differential extractability of" exact="influenza" post="virus hemagglutinin during intracellular transport in polarized epithelial cells"/>
   <result pre="for efficient viral fusionProc. Natl. Acad. Sci. USA2003100146101461710.1073/pnas.223562010014561897 76.ScheiffeleP.RothM.G.SimonsK.Interaction of" exact="influenza" post="virus haemagglutinin with sphingolipid-cholesterol membrane domains via its transmembrane"/>
   <result pre="sphingolipid-cholesterol membrane domains via its transmembrane domainEMBO J.1997165501550810.1093/emboj/16.18.55019312009 77.SunX.WhittakerG.R.Role for" exact="influenza" post="virus envelope cholesterol in virus entry and infectionJ. Virol.200377125431255110.1128/JVI.77.23.12543-12551.200314610177"/>
   <result pre="complex upon Influenza virus infectionPLoS ONE20138e7500510.1371/journal.pone.007500524137500 79.ShimizuT.TakizawaN.WatanabeK.NagataK.KobayashiN.Crucial role of the" exact="influenza" post="virus NS2 (NEP) C-terminal domain in M1 binding and"/>
   <result pre="signals and hemagglutinin residues improves the growth of A/Anhui/1/2013 (H7N9)" exact="influenza" post="vaccine virus yield in eggsVaccine2017351424143010.1016/j.vaccine.2017.01.06128162820 82.NayakD.P.BalogunR.A.YamadaH.ZhouZ.H.BarmanS.Influenza virus morphogenesis and"/>
   <result pre="protein 2; GlcCer: glucosylceramide; LacCer: lactosylceramide. Figure 2 Diagram of" exact="hepatitis" post="C virus genome. The HCV genome consists of a"/>
   <result pre="Figure 5 Organization of the Influenza A virus’s genome. The" exact="influenza" post="A virus’s (IAV’s) genome consists of eight segments of"/>
   <result pre="the replication of HCV and flaviviruses (red), HIV (green), and" exact="influenza" post="virus (yellow). Reported roles for lipids (sphingomyelin [SM], glycosphingolipids"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6832241\results\search\disease\results.xml">
   <result pre="most effective strategy to prevent such infections and/or to reduce" exact="viral disease." post="Two major types of influenza vaccines are approved for"/>
   <result pre="infections and/or to reduce viral disease. Two major types of" exact="influenza" post="vaccines are approved for human use: inactivated influenza vaccines"/>
   <result pre="types of influenza vaccines are approved for human use: inactivated" exact="influenza" post="vaccines (IIVs) and live attenuated influenza vaccines (LAIVs). Two"/>
   <result pre="for human use: inactivated influenza vaccines (IIVs) and live attenuated" exact="influenza" post="vaccines (LAIVs). Two Master Donor Virus (MDV) backbones have"/>
   <result pre="Virus (MDV) backbones have been used to create LAIVs against" exact="influenza" post="A virus (IAV): the United States (US) A/Ann Arbor/6/60"/>
   <result pre="compared the In vitro and in vivo phenotype of recombinant" exact="influenza" post="A/Puerto Rico/8/34 H1N1 (PR8) viruses containing the ts, ca"/>
   <result pre="development of improved LAIVs for the prevention of IAV infections." exact="influenza" post="vaccine live-attenuated vaccine 1. Introduction In the United States"/>
   <result pre="Centers for Disease Control and Prevention (CDC) has estimated that" exact="influenza" post="has caused between 9.3 and 49.0 million illnesses each"/>
   <result pre="between 12,000 and 79,000 deaths annually [1]. Two types of" exact="influenza" post="cause seasonal, global epidemics in human populations each year:"/>
   <result pre="influenza cause seasonal, global epidemics in human populations each year:" exact="influenza" post="A virus (IAV) and influenza B virus (IBV) [2,3]."/>
   <result pre="in human populations each year: influenza A virus (IAV) and" exact="influenza" post="B virus (IBV) [2,3]. IAVs can also cause sporadic"/>
   <result pre="humans [4]. Vaccination is the most cost-effective approach to prevent" exact="influenza" post="infections [5]. Currently, three major influenza vaccines are approved"/>
   <result pre="cost-effective approach to prevent influenza infections [5]. Currently, three major" exact="influenza" post="vaccines are approved for human use in the US:"/>
   <result pre="use in the US: recombinant (r) hemagglutinin (HA) protein, inactivated" exact="influenza" post="vaccines (IIVs) and live attenuated influenza vaccines (LAIVs) [1]."/>
   <result pre="hemagglutinin (HA) protein, inactivated influenza vaccines (IIVs) and live attenuated" exact="influenza" post="vaccines (LAIVs) [1]. IIVs are delivered by the intramuscular"/>
   <result pre="HA protein [6,7,8], one of the major antigenic determinants of" exact="influenza" post="viruses which is responsible for viral entry [9]. On"/>
   <result pre="the introduction of the quadrivalent vaccine formulation during the 2013–2014" exact="influenza" post="season, different studies revealed less than expected effectiveness of"/>
   <result pre="over LAIV over IIVs. LAIVs have been generated by passaging" exact="influenza" post="viruses at gradually reduced temperatures in eggs or cultured"/>
   <result pre="of these viral variants was based on the ability of" exact="influenza" post="viruses to replicate in the upper (25–33 °C) and"/>
   <result pre="AA and the Russian Len MDVs using the backbone of" exact="influenza" post="PR8 In vitro and in vivo. Our results show"/>
   <result pre="recombinant virus containing the HA and NA viral segments of" exact="influenza" post="A/Hong Kong/1/1968 H3N2 in the background of PR8 virus"/>
   <result pre="cells at 33 °C using a monoclonal antibody (mAb) against" exact="influenza" post="virus nucleoprotein, NP (ATCC HB-65, HL16-L10-4R5); as described [46]."/>
   <result pre="collected by submandibular bleeding to evaluate the presence of total" exact="influenza" post="antibodies (Abs) by enzyme-linked immunosorbent assay (ELISA) and hemagglutination"/>
   <result pre="of the Russian Len MDV (Figure 9). Using a bat" exact="influenza" post="A virus polymerase structure solved by X-ray crystallography as"/>
   <result pre="US AA MDV can attenuate a broad range of other" exact="influenza" post="viral strains, including human [35], canine [11,12,21] and equine"/>
   <result pre="remains to be determined whether this also applies to different" exact="influenza" post="virus strains and/or subtypes. Nevertheless, our results have important"/>
   <result pre="and improved LAIVs for the treatment of human and/or animal" exact="influenza" post="infections. Specifically, our findings with PR8 suggest that it"/>
   <result pre="Care Med.20072814415810.1055/s-2007-97648717458769 3.BarrI.G.McCauleyJ.CoxN.DanielsR.EngelhardtO.G.FukudaK.GrohmannG.HayA.KelsoA.KlimovA.et al.Epidemiological, antigenic and genetic characteristics of seasonal" exact="influenza" post="A(H1N1), A(H3N2) and B influenza viruses: Basis for the"/>
   <result pre="and genetic characteristics of seasonal influenza A(H1N1), A(H3N2) and B" exact="influenza" post="viruses: Basis for the WHO recommendation on the composition"/>
   <result pre="viruses: Basis for the WHO recommendation on the composition of" exact="influenza" post="vaccines for use in the 2009–2010 Northern Hemisphere seasonVaccine2010281156116710.1016/j.vaccine.2009.11.04320004635"/>
   <result pre="4.SmithG.J.VijaykrishnaD.BahlJ.LycettS.J.WorobeyM.PybusO.G.MaS.K.CheungC.L.RaghwaniJ.BhattS.et al.Origins and evolutionary genomics of the 2009 swine-origin H1N1" exact="influenza" post="A epidemicNature20094591122112510.1038/nature0818219516283 5.PicaN.PaleseP.Toward a universal influenza virus vaccine: Prospects"/>
   <result pre="the 2009 swine-origin H1N1 influenza A epidemicNature20094591122112510.1038/nature0818219516283 5.PicaN.PaleseP.Toward a universal" exact="influenza" post="virus vaccine: Prospects and challengesAnnu. Rev. Med.20136418920210.1146/annurev-med-120611-14511523327522 6.BelongiaE.A.KiekeB.A.DonahueJ.G.GreenleeR.T.BalishA.FoustA.LindstromS.ShayD.K.Effectiveness of"/>
   <result pre="virus vaccine: Prospects and challengesAnnu. Rev. Med.20136418920210.1146/annurev-med-120611-14511523327522 6.BelongiaE.A.KiekeB.A.DonahueJ.G.GreenleeR.T.BalishA.FoustA.LindstromS.ShayD.K.Effectiveness of inactivated" exact="influenza" post="vaccines varied substantially with antigenic match from the 2004–2005"/>
   <result pre="to the 2006–2007 seasonJ. Infect. Dis.200919915916710.1086/59586119086915 7.OsterholmM.T.KelleyN.S.SommerA.BelongiaE.A.Efficacy and effectiveness of" exact="influenza" post="vaccines: A systematic review and meta-analysisLancet Infect. Dis.201212364410.1016/S1473-3099(11)70295-X22032844 8.CoxM.M.PatriarcaP.A.TreanorJ.FluBlok,"/>
   <result pre="systematic review and meta-analysisLancet Infect. Dis.201212364410.1016/S1473-3099(11)70295-X22032844 8.CoxM.M.PatriarcaP.A.TreanorJ.FluBlok, a recombinant hemagglutinin" exact="influenza" post="vaccineInfluenza Other Respir Viruses2008221121910.1111/j.1750-2659.2008.00053.x19453397 9.PaleseP.S.MeganL.Fields Virology5th ed.Lippincott Williams &amp;amp;"/>
   <result pre="Williams &amp;amp; WilkinsPhiladelphia, PA, USA2007Volume 2 10.HoftD.F.BabusisE.WorkuS.SpencerC.T.LottenbachK.TruscottS.M.AbateG.SakalaI.G.EdwardsK.M.CreechC.B.et al.Live and inactivated" exact="influenza" post="vaccines induce similar humoral responses, but only live vaccines"/>
   <result pre="in young childrenJ. Infect. Dis.201120484585310.1093/infdis/jir43621846636 11.NogalesA.RodriguezL.ChaucheC.HuangK.ReillyE.C.TophamD.J.MurciaP.R.ParrishC.R.Martinez-SobridoL.A temperature sensitive live-attenuated canine" exact="influenza" post="virus H3N8 vaccineJ. Virol.20169110.1128/JVI.02211-16 12.RodriguezL.NogalesA.ReillyE.C.TophamD.J.MurciaP.R.ParrishC.R.Martinez SobridoL.A live-attenuated influenza vaccine"/>
   <result pre="live-attenuated canine influenza virus H3N8 vaccineJ. Virol.20169110.1128/JVI.02211-16 12.RodriguezL.NogalesA.ReillyE.C.TophamD.J.MurciaP.R.ParrishC.R.Martinez SobridoL.A live-attenuated" exact="influenza" post="vaccine for H3N2 canine influenza virusVirology20175049610610.1016/j.virol.2017.01.02028167384 13.RodriguezL.ReedyS.NogalesA.MurciaP.R.ChambersT.M.Martinez-SobridoL.Development of a"/>
   <result pre="vaccineJ. Virol.20169110.1128/JVI.02211-16 12.RodriguezL.NogalesA.ReillyE.C.TophamD.J.MurciaP.R.ParrishC.R.Martinez SobridoL.A live-attenuated influenza vaccine for H3N2 canine" exact="influenza" post="virusVirology20175049610610.1016/j.virol.2017.01.02028167384 13.RodriguezL.ReedyS.NogalesA.MurciaP.R.ChambersT.M.Martinez-SobridoL.Development of a novel equine influenza virus live-attenuated"/>
   <result pre="for H3N2 canine influenza virusVirology20175049610610.1016/j.virol.2017.01.02028167384 13.RodriguezL.ReedyS.NogalesA.MurciaP.R.ChambersT.M.Martinez-SobridoL.Development of a novel equine" exact="influenza" post="virus live-attenuated vaccineVirology2018516768510.1016/j.virol.2018.01.00529331866 14.MaassabH.F.Adaptation and growth characteristics of influenza"/>
   <result pre="equine influenza virus live-attenuated vaccineVirology2018516768510.1016/j.virol.2018.01.00529331866 14.MaassabH.F.Adaptation and growth characteristics of" exact="influenza" post="virus at 25 degrees cNature196721361261410.1038/213612a06040602 15.AleksandrovaG.I.MikutskaiaB.A.PleshanovaR.A.PanovaN.G.SmorodintsevA.A.The reactive and immunogenic"/>
   <result pre="reactive and immunogenic properties and epidemiological effectiveness of further attenuated" exact="influenza" post="virus vaccinal strains (observed in preschool children)Vopr. Virusol.19651067735865829 16.WilsonW.D.RobinsonD.Field"/>
   <result pre="children)Vopr. Virusol.19651067735865829 16.WilsonW.D.RobinsonD.Field safety of a modified-live, cold-adapted intranasal equine" exact="influenza" post="vaccine (HESKAFlu Avert IN vaccine) in horsesJ. Equine Vet."/>
   <result pre="Vet. Sci.20002081010.1016/S0737-0806(00)80310-X 17.YoungnerJ.S.Whitaker-DowlingP.ChambersT.M.RushlowK.E.SebringR.Derivation and characterization of a live attenuated equine" exact="influenza" post="vaccine virusAm. J. Vet. Res.2001621290129410.2460/ajvr.2001.62.129011497453 18.ChanW.ZhouH.KembleG.JinH.The cold adapted and"/>
   <result pre="virusAm. J. Vet. Res.2001621290129410.2460/ajvr.2001.62.129011497453 18.ChanW.ZhouH.KembleG.JinH.The cold adapted and temperature sensitive" exact="influenza" post="A/Ann Arbor/6/60 virus, the master donor virus for live"/>
   <result pre="A/Ann Arbor/6/60 virus, the master donor virus for live attenuated" exact="influenza" post="vaccines, has multiple defects in replication at the restrictive"/>
   <result pre="19.MurphyB.R.CoelinghK.Principles underlying the development and use of live attenuated cold-adapted" exact="influenza" post="A and B virus vaccinesViral Immunol.20021529532310.1089/0882824026006624212081014 20.KohlmeierJ.E.WoodlandD.L.Immunity to respiratory"/>
   <result pre="Immunol.20021529532310.1089/0882824026006624212081014 20.KohlmeierJ.E.WoodlandD.L.Immunity to respiratory virusesAnnu. Rev. Immunol.200927618210.1146/annurev.immunol.021908.13262518954284 21.RodriguezL.NogalesA.MurciaP.R.ParrishC.R.Martinez-SobridoL.A bivalent live-attenuated" exact="influenza" post="vaccine for the control and prevention of H3N8 and"/>
   <result pre="for the control and prevention of H3N8 and H3N2 canine" exact="influenza" post="virusesVaccine2017354374438110.1016/j.vaccine.2017.06.06028709557 22.ChengX.ZengelJ.R.SuguitanA.L.Jr.XuQ.WangW.LinJ.JinH.Evaluation of the humoral and cellular immune responses"/>
   <result pre="cellular immune responses elicited by the live attenuated and inactivated" exact="influenza" post="vaccines and their roles in heterologous protection in ferretsJ."/>
   <result pre="in heterologous protection in ferretsJ. Infect. Dis.201320859460210.1093/infdis/jit20723656978 23.VictorS.T.WatanabeS.KatsuraH.OzawaM.KawaokaY.A replication-incompetent PB2-knockout" exact="influenza" post="A virus vaccine vectorJ. Virol.201210.1128/JVI.06232-11 24.De VilliersP.J.SteeleA.D.HiemstraL.A.RappaportR.DunningA.J.GruberW.C.ForrestB.D.Efficacy and safety"/>
   <result pre="vectorJ. Virol.201210.1128/JVI.06232-11 24.De VilliersP.J.SteeleA.D.HiemstraL.A.RappaportR.DunningA.J.GruberW.C.ForrestB.D.Efficacy and safety of a live attenuated" exact="influenza" post="vaccine in adults 60 years of age and olderVaccine20092822823410.1016/j.vaccine.2009.09.09219796721"/>
   <result pre="25.BakerS.F.GuoH.AlbrechtR.A.Garcia-SastreA.TophamD.J.Martinez-SobridoL.Protection against Lethal Influenza with a Viral MimicJ. Virol.2013878591860510.1128/JVI.01081-1323720727 26.PowellT.J.SilkJ.D.SharpsJ.FodorE.TownsendA.R.Pseudotyped" exact="influenza" post="A virus as a vaccine for the induction of"/>
   <result pre="immunityJ. Virol.201286133971340610.1128/JVI.01820-1223015719 27.UrakiR.KisoM.Iwatsuki-HorimotoK.FukuyamaS.TakashitaE.OzawaM.KawaokaY.A novel bivalent vaccine based on a PB2-knockout" exact="influenza" post="virus protects mice from pandemic H1N1 and highly pathogenic"/>
   <result pre="Virol.2013877874788110.1128/JVI.00076-1323658445 28.KatsuraH.Iwatsuki-HorimotoK.FukuyamaS.WatanabeS.SakabeS.HattaY.MurakamiS.ShimojimaM.HorimotoT.KawaokaY.A replication-incompetent virus possessing an uncleavable hemagglutinin as an" exact="influenza" post="vaccineVaccine2012306027603310.1016/j.vaccine.2012.07.05922867723 29.collab: World Health Organization (WHO)Recommendations to assure the"/>
   <result pre="Organization (WHO)Recommendations to assure the quality, safety and efficacy of" exact="influenza" post="vaccines (human, live attenuated) for intranasal administrationWHO Tech. Rep."/>
   <result pre="Influenza Vaccine EffectivenessWHOGeneva, Switzerland2016 31.RudenkoL.YeolekarL.KiselevaI.Isakova-SivakI.Development and approval of live attenuated" exact="influenza" post="vaccines based on Russian master donor viruses: Process challenges"/>
   <result pre="storiesVaccine2016345436544110.1016/j.vaccine.2016.08.01827593158 32.CoxN.J.KitameF.KendalA.P.MaassabH.F.NaeveC.Identification of sequence changes in the cold-adapted, live attenuated" exact="influenza" post="vaccine strain, A/Ann Arbor/6/60 (H2N2)Virology198816755456710.1016/0042-6822(88)90118-32974219 33.SnyderM.H.BettsR.F.DeBordeD.TierneyE.L.ClementsM.L.HerringtonD.SearsS.D.DolinR.MaassabH.F.MurphyB.R.Four viral genes independently"/>
   <result pre="(H2N2)Virology198816755456710.1016/0042-6822(88)90118-32974219 33.SnyderM.H.BettsR.F.DeBordeD.TierneyE.L.ClementsM.L.HerringtonD.SearsS.D.DolinR.MaassabH.F.MurphyB.R.Four viral genes independently contribute to attenuation of live" exact="influenza" post="A/Ann Arbor/6/60 (H2N2) cold-adapted reassortant virus vaccinesJ. Virol.1988624884953336068 34.Isakova-SivakI.ChenL.M.MatsuokaY.VoetenJ.T.KiselevaI.HeldensJ.G.den"/>
   <result pre="phenotype of a master donor virus used in live attenuated" exact="influenza" post="vaccines: A/Leningrad/134/17/57 (H2N2)Virology201141229730510.1016/j.virol.2011.01.00421315402 35.CoxA.BakerS.F.NogalesA.Martinez-SobridoL.DewhurstS.Development of a mouse-adapted live attenuated"/>
   <result pre="influenza vaccines: A/Leningrad/134/17/57 (H2N2)Virology201141229730510.1016/j.virol.2011.01.00421315402 35.CoxA.BakerS.F.NogalesA.Martinez-SobridoL.DewhurstS.Development of a mouse-adapted live attenuated" exact="influenza" post="virus that permits in vivo analysis of enhancements to"/>
   <result pre="vivo analysis of enhancements to the safety of live attenuated" exact="influenza" post="virus vaccineJ. Virol.2015893421342610.1128/JVI.02636-1425552727 36.JinH.ZhouH.LuB.KembleG.Imparting temperature sensitivity and attenuation in"/>
   <result pre="36.JinH.ZhouH.LuB.KembleG.Imparting temperature sensitivity and attenuation in ferrets to A/Puerto Rico/8/34" exact="influenza" post="virus by transferring the genetic signature for temperature sensitivity"/>
   <result pre="from cold-adapted A/Ann Arbor/6/60J. Virol.20047899599810.1128/JVI.78.2.995-998.200414694130 37.ZhouB.LiY.SpeerS.D.SubbaA.LinX.WentworthD.E.Engineering temperature sensitive live attenuated" exact="influenza" post="vaccines from emerging virusesVaccine2012303691370210.1016/j.vaccine.2012.03.02522449422 38.NogalesA.RodriguezL.DeDiegoM.L.TophamD.J.Martinez-SobridoL.Interplay of PA-X and NS1"/>
   <result pre="39.BroadbentA.J.SantosC.P.GodboutR.A.SubbaraoK.The temperature-sensitive and attenuation phenotypes conferred by mutations in the" exact="influenza" post="virus PB2, PB1, and NP genes are influenced by"/>
   <result pre="origin of the PB2 gene in reassortant viruses derived from" exact="influenza" post="A/California/07/2009 and A/WSN/33 virusesJ. Virol.201488123391234710.1128/JVI.02142-1425122786 40.CzakoR.VogelL.SuttonT.MatsuokaY.KrammerF.ChenZ.JinH.SubbaraoK.H5N2 vaccine viruses on"/>
   <result pre="Virol.201488123391234710.1128/JVI.02142-1425122786 40.CzakoR.VogelL.SuttonT.MatsuokaY.KrammerF.ChenZ.JinH.SubbaraoK.H5N2 vaccine viruses on Russian and US live attenuated" exact="influenza" post="virus backbones demonstrate similar infectivity, immunogenicity and protection in"/>
   <result pre="protection in ferretsVaccine2018361871187910.1016/j.vaccine.2018.02.06129503113 41.ChenZ.BazM.LuJ.PaskelM.SantosC.SubbaraoK.JinH.MatsuokaY.Development of a high-yield live attenuated H7N9" exact="influenza" post="virus vaccine that provides protection against homologous and heterologous"/>
   <result pre="Pandemic Live Attenuated Influenza Virus VaccinationFront. Immunol.2015628710.3389/fimmu.2015.0028726082783 43.Martinez-SobridoL.Garcia-SastreA.Generation of recombinant" exact="influenza" post="virus from plasmid DNAJ. Vis. Exp.201010.3791/2057 44.GrimmD.StaeheliP.HufbauerM.KoernerI.Martinez-SobridoL.SolorzanoA.Garcia-SastreA.HallerO.KochsG.Replication fitness determines"/>
   <result pre="plasmid DNAJ. Vis. Exp.201010.3791/2057 44.GrimmD.StaeheliP.HufbauerM.KoernerI.Martinez-SobridoL.SolorzanoA.Garcia-SastreA.HallerO.KochsG.Replication fitness determines high virulence of" exact="influenza" post="A virus in mice carrying functional Mx1 resistance geneProc."/>
   <result pre="carrying functional Mx1 resistance geneProc. Natl. Acad. Sci. USA20071046806681110.1073/pnas.070184910417426143 45.KilbourneE.D.Future" exact="influenza" post="vaccines and the use of genetic recombinantsBull. World Health"/>
   <result pre="the NS Gene for Vaccine DevelopmentJ. Virol.201488105251054010.1128/JVI.01565-1424965472 47.SchickliJ.H.FlandorferA.NakayaT.Martinez-SobridoL.Garcia-SastreA.PaleseP.Plasmid-only rescue of" exact="influenza" post="A virus vaccine candidatesPhilos. Trans. R. Soc. Lond. B"/>
   <result pre="ImmunityPLoS ONE201611e016427410.1371/journal.pone.016424727727324 53.BelsheR.LeeM.S.WalkerR.E.StoddardJ.MendelmanP.M.Safety, immunogenicity and efficacy of intranasal, live attenuated" exact="influenza" post="vaccineExpert Rev. Vaccines2004364365410.1586/14760584.3.6.64315606348 54.BelsheR.B.EdwardsK.M.VesikariT.BlackS.V.WalkerR.E.HultquistM.KembleG.ConnorE.M.GroupC.T.C.E.S.Live attenuated versus inactivated influenza vaccine"/>
   <result pre="live attenuated influenza vaccineExpert Rev. Vaccines2004364365410.1586/14760584.3.6.64315606348 54.BelsheR.B.EdwardsK.M.VesikariT.BlackS.V.WalkerR.E.HultquistM.KembleG.ConnorE.M.GroupC.T.C.E.S.Live attenuated versus inactivated" exact="influenza" post="vaccine in infants and young childrenN. Engl. J. Med.200735668569610.1056/NEJMoa06536817301299"/>
   <result pre="Engl. J. Med.200735668569610.1056/NEJMoa06536817301299 55.GorseG.J.BelsheR.B.MunnN.J.Superiority of live attenuated compared with inactivated" exact="influenza" post="A virus vaccines in older, chronically ill adultsChest199110097798410.1378/chest.100.4.9771914615 56.RudenkoL.G.SlepushkinA.N.MontoA.S.KendalA.P.GrigorievaE.P.BurtsevaE.P.RekstinA.R.BeljaevA.L.BraginaV.E.CoxN.et"/>
   <result pre="chronically ill adultsChest199110097798410.1378/chest.100.4.9771914615 56.RudenkoL.G.SlepushkinA.N.MontoA.S.KendalA.P.GrigorievaE.P.BurtsevaE.P.RekstinA.R.BeljaevA.L.BraginaV.E.CoxN.et al.Efficacy of live attenuated and inactivated" exact="influenza" post="vaccines in schoolchildren and their unvaccinated contacts in Novgorod,"/>
   <result pre="RussiaJ. Infect. Dis.199316888188710.1093/infdis/168.4.8818376833 57.SlepushkinA.N.Obrosova-SerovaN.P.BurtsevaE.I.RudenkoL.G.GovorkovaE.A.VartanyanR.V.VerestsinskyA.I.LonskayaN.I.HarmonM.W.TorokT.et al.Comparison of live attenuated and inactivated" exact="influenza" post="vaccines in schoolchildren in Russia: I. Safety and efficacy"/>
   <result pre="Moscow schools, 1987/88Vaccine19931132332810.1016/0264-410X(93)90194-38447161 58.LukarskaM.FournierG.PflugA.Resa-InfanteP.ReichS.NaffakhN.CusackS.Structural basis of an essential interaction between" exact="influenza" post="polymerase and Pol II CTDNature201754111712110.1038/nature2059428002402 59.DeLanoW.L.The PyMOL Molecular Graphics"/>
   <result pre="antibodies (B) and by ELISA for IgG Abs against total" exact="influenza" post="viral proteins using cell extracts of MDCK cells infected"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6832525\results\search\disease\results.xml">
   <result pre="against this re-emerging pathogen which continues to cause devastating disease." exact="yellow fever" post="virus flavivirus entry factor global diversity yellow fever virus"/>
   <result pre="devastating disease. yellow fever virus flavivirus entry factor global diversity" exact="yellow fever" post="virus tropism animal models transmission and vector control vaccine"/>
   <result pre="described viral hemorrhagic fever (VHF) and its causative agent, the" exact="yellow fever" post="virus (YFV), is the prototypic member of the family"/>
   <result pre="infections, including dengue virus (DENV), West Nile virus (WNV), Japanese" exact="encephalitis" post="virus (JEV) and Zika virus (ZIKV) (Figure 1). Transmission"/>
   <result pre="cause a range of clinical outcomes, ranging from asymptomatic to" exact="encephalitis" post="(WNV, JEV and ZIKV) or fatal hemorrhagic fever (YFV"/>
   <result pre="abnormalities during this &quot;period of infection�? include elevated liver enzymes," exact="leukopenia" post="and proteinuria. A phase of improvement, lasting up to"/>
   <result pre="targeted at other members of the family Flaviviridae, most prominently" exact="hepatitis" post="C virus (HCV) and DENV. Ribavirin, a nucleoside analog,"/>
   <result pre="infection rates for WNV and YFV-17D to differing degrees, while" exact="herpes simplex" post="virus-1 (HSV-1) infection rates were unaffected [67]. Therefore, these"/>
   <result pre="also facilitates attachment for the related flaviviruses DENV [68] and" exact="tick-borne encephalitis" post="virus (TBEV) [69], as well as unrelated viruses, including"/>
   <result pre="facilitates attachment for the related flaviviruses DENV [68] and tick-borne" exact="encephalitis" post="virus (TBEV) [69], as well as unrelated viruses, including"/>
   <result pre="YFV was isolated from a Ghanaian patient suffering from mild" exact="yellow fever" post="and inoculated into rhesus macaques by direct blood/serum transfer"/>
   <result pre="mouse brain increased FNV’s neurotropism, leading to high levels of" exact="post-vaccinal encephalitis" post="in children. Consequently, the use of FNV was discontinued"/>
   <result pre="brain increased FNV’s neurotropism, leading to high levels of post-vaccinal" exact="encephalitis" post="in children. Consequently, the use of FNV was discontinued"/>
   <result pre="delivery platform for other experimental vaccines including HIV-1, Lassa fever," exact="malaria" post="and DENV [175,176,177,178,179,180]. After early successes in outbreak prevention"/>
   <result pre="to symptomatic HIV or the presence of thymus disorder, and" exact="hypersensitivity" post="to chicken eggs [161,187]. In addition, there are common"/>
   <result pre="[191]. The use of a live attenuated vaccine can prevent" exact="yellow fever," post="but vaccine-associated neurologic disease has been reported and is"/>
   <result pre="memory loss, problems with breathing, behavioral changes, seizures, viscerotropic disease," exact="encephalitis" post="and death can occur. In addition, the vaccine is"/>
   <result pre="epidemic in Asia remains daunting and YFV is the only" exact="infectious disease" post="where an international vaccination certificate is required [160]. However,"/>
   <result pre="certificates [198]. 6.5. Future Directions Yellow fever is a re-emerging" exact="infectious disease," post="as vector control and routine immunization strategies have dwindled"/>
   <result pre="this, the WHO has initiated a global strategy to eliminate" exact="yellow fever" post="epidemics (EYE) by 2026, focusing on management of global"/>
   <result pre="This approach has been applied to other RNA viruses, including" exact="chikungunya" post="(CHIKV) and TBEV [217,218]. In summary, in addition to"/>
   <result pre="[199]. Hence, novel manufacturing techniques to produce large quantities of" exact="yellow fever" post="vaccine at short notice are required which also eliminate"/>
   <result pre="from infected patients’ material, and these metagenomic approaches have revolutionized" exact="infectious disease" post="outbreak diagnostics and surveillance in recent years [225]. In"/>
   <result pre="likelihood of future arbovirus outbreaks, including YFV [243]. Mosquito population" exact="suppression" post="strategies which harness the power of genetic modification include"/>
   <result pre="carrying a dominant lethal transgene were released, resulting in the" exact="suppression" post="of wild mosquito numbers [244]. In a complementary approach"/>
   <result pre="Ae. albopictus from two test-release sites in China, combining population" exact="suppression" post="and population replacement strategies [245]. Male mosquitoes artificially infected"/>
   <result pre="with intrinsically expressed Loquacious and r2d2 to restore efficient siRNA" exact="suppression" post="of viral replication in the mosquito midgut [247]. Furthermore,"/>
   <result pre="future of eliminating YFV from endemic regions may involve the" exact="suppression" post="or replacement of wild-type mosquitos with modified insects which"/>
   <result pre="Yellow Fever in Angola, 2015–2016Emerg. Infect. Dis.2016221854185510.3201/eid2210.16081827536787 13.KraemerM.U.G.FariaN.R.ReinerR.C.GoldingN.NikolayB.StasseS.JohanssonM.A.SaljeH.FayeO.WintG.R.W.et al.Spread of" exact="yellow fever" post="virus outbreak in Angola and the Democratic Republic of"/>
   <result pre="feverScience201836184784810.1126/science.aau822530139914 16.FariaN.R.KraemerM.U.G.HillS.C.Goes de JesusJ.AguiarR.S.IaniF.C.M.XavierJ.QuickJ.Du PlessisL.DellicourS.et al.Genomic and epidemiological monitoring of" exact="yellow fever" post="virus transmission potentialScience201836189489910.1126/science.aat711530139911 17.DorigattiI.HamletA.AguasR.CattarinoL.CoriA.DonnellyC.A.GarskeT.ImaiN.FergusonN.M.International risk of yellow fever spread"/>
   <result pre="monitoring of yellow fever virus transmission potentialScience201836189489910.1126/science.aat711530139911 17.DorigattiI.HamletA.AguasR.CattarinoL.CoriA.DonnellyC.A.GarskeT.ImaiN.FergusonN.M.International risk of" exact="yellow fever" post="spread from the ongoing outbreak in Brazil, December 2016"/>
   <result pre="Surveill.20172210.2807/1560-7917.ES.2017.22.28.30572 18.MonathT.P.Yellow fever: An updateLancet Infect. Dis.20011112010.1016/S1473-3099(01)00016-011871403 19.RiceC.M.GrakouiA.GallerR.ChambersT.J.Transcription of infectious" exact="yellow fever" post="RNA from full-length cDNA templates produced by in vitro"/>
   <result pre="vitro ligationNew Biol.198912852962487295 20.HahnC.S.DalrympleJ.M.StraussJ.H.RiceC.M.Comparison of the virulent Asibi strain of" exact="yellow fever" post="virus with the 17D vaccine strain derived from itProc."/>
   <result pre="derived from itProc. Natl. Acad. Sci. USA1987842019202310.1073/pnas.84.7.20193470774 21.BredenbeekP.J.KooiE.A.LindenbachB.HuijkmanN.RiceC.M.SpaanW.J.M.A stable full-length" exact="yellow fever" post="virus cDNA clone and the role of conserved RNA"/>
   <result pre="RNA elements in flavivirus replicationJ. Gen. Virol.2003841261126810.1099/vir.0.18860-012692292 22.RiceC.M.LenchesE.M.EddyS.R.ShinS.J.SheetsR.L.StraussJ.H.Nucleotide sequence of" exact="yellow fever" post="virus: Implications for flavivirus gene expression and evolutionScience198522972673310.1126/science.40237074023707 23.McElroyK.L.TsetsarkinK.A.VanlandinghamD.L.HiggsS.Characterization"/>
   <result pre="and evolutionScience198522972673310.1126/science.40237074023707 23.McElroyK.L.TsetsarkinK.A.VanlandinghamD.L.HiggsS.Characterization of an infectious clone of the wild-type" exact="yellow fever" post="virus Asibi strain that is able to infect and"/>
   <result pre="applications: A historical perspectiveAntivir. Res.2015114678510.1016/j.antiviral.2014.12.00725512228 25.FuruseY.Analysis of research intensity on" exact="infectious disease" post="by disease burden reveals which infectious diseases are neglected"/>
   <result pre="12 August 2019) 29.QuaresmaJ.A.BarrosV.L.PagliariC.FernandesE.R.AndradeH.F.Jr.VasconcelosP.F.DuarteM.I.Hepatocyte lesions and cellular immune response in" exact="yellow fever" post="infectionTrans. R. Soc. Trop. Med. Hyg.200710116116810.1016/j.trstmh.2006.02.01916872652 30.BlakeL.E.Garcia-BlancoM.A.Human genetic variation"/>
   <result pre="infectionTrans. R. Soc. Trop. Med. Hyg.200710116116810.1016/j.trstmh.2006.02.01916872652 30.BlakeL.E.Garcia-BlancoM.A.Human genetic variation and" exact="yellow fever" post="mortality during 19th century U.S. epidemicsMBio20145e01253-1410.1128/mBio.01253-1424895309 31.TuboiS.H.CostaZ.G.da Costa VasconcelosP.F.HatchD.Clinical"/>
   <result pre="century U.S. epidemicsMBio20145e01253-1410.1128/mBio.01253-1424895309 31.TuboiS.H.CostaZ.G.da Costa VasconcelosP.F.HatchD.Clinical and epidemiological characteristics of" exact="yellow fever" post="in Brazil: Analysis of reported cases 1998-2002Trans. R. Soc."/>
   <result pre="targets the capsid proteinAntimicrob. Agents Chemother.201357152510.1128/AAC.01429-1223070172 40.PatkarC.G.LarsenM.OwstonM.SmithJ.L.KuhnR.J.Identification of inhibitors of" exact="yellow fever" post="virus replication using a replicon-based high-throughput assayAntimicrob. Agents Chemother.2009534103411410.1128/AAC.00074-0919651907"/>
   <result pre="by Specifically Targeting NS4B ProteinJ. Virol.201690107741078810.1128/JVI.01253-1627654301 42.PaccaC.C.SeverinoA.A.MondiniA.RahalP.D’Avila SG.CordeiroJ.A.NogueiraM.C.BronzoniR.V.NogueiraM.L.RNA interference inhibits" exact="yellow fever" post="virus replication in vitro and in vivoVirus Genes20093822423110.1007/s11262-009-0328-319169857 43.JulanderJ.G.Experimental"/>
   <result pre="46.PiersonT.C.KielianM.Flaviviruses: Braking the enteringCurr. Opin. Virol.2013331210.1016/j.coviro.2012.12.00123352692 47.PatkarC.G.JonesC.T.ChangY.-H.WarrierR.KuhnR.J.Functional requirements of the" exact="yellow fever" post="virus capsid proteinJ. Virol.2007816471648110.1128/JVI.02120-0617526891 48.Op de BeeckA.RouilléY.CaronM.DuvetS.DubuissonJ.The transmembrane domains"/>
   <result pre="BeeckA.RouilléY.CaronM.DuvetS.DubuissonJ.The transmembrane domains of the prM and E proteins of" exact="yellow fever" post="virus are endoplasmic reticulum localization signalsJ. Virol.200478125911260210.1128/JVI.78.22.12591-12602.200415507646 49.KielianM.Class II"/>
   <result pre="diversity in the flavivirus fusion peptideVirol. J.200852710.1186/1743-422X-5-2718275613 51.VolkD.E.MayF.J.GandhamS.H.A.AndersonA.von LindernJ.J.BeasleyD.W.C.BarrettA.D.T.GorensteinD.G.Structure of" exact="yellow fever" post="virus envelope protein domain IIIVirology2009394121810.1016/j.virol.2009.09.00119818466 52.RymanK.D.LedgerT.N.CampbellG.A.WatowichS.J.BarrettA.D.Mutation in a 17D-204"/>
   <result pre="17D-204 vaccine substrain-specific envelope protein epitope alters the pathogenesis of" exact="yellow fever" post="virus in miceVirology1998244596510.1006/viro.1998.90579581778 53.DaffisS.KontermannR.E.KorimbocusJ.ZellerH.KlenkH.-D.Ter MeulenJ.Antibody responses against wild-type yellow"/>
   <result pre="yellow fever virus in miceVirology1998244596510.1006/viro.1998.90579581778 53.DaffisS.KontermannR.E.KorimbocusJ.ZellerH.KlenkH.-D.Ter MeulenJ.Antibody responses against wild-type" exact="yellow fever" post="virus and the 17D vaccine strain: Characterization with human"/>
   <result pre="for exploratory research and analysisJ. Comput. Chem.2004251605161210.1002/jcc.2008415264254 56.ChenZ.LiuL.LvY.ZhangW.LiJ.ZhangY.DiT.ZhangS.LiuJ.LiJ.et al.A fatal" exact="yellow fever" post="virus infection in China: Description and lessonsEmerg. Microbes Infect.20165e6910.1038/emi.2016.8927406389"/>
   <result pre="68.GermiR.CranceJ.-M.GarinD.GuimetJ.Lortat-JacobH.RuigrokR.W.H.ZarskiJ.-P.DrouetE.Heparan sulfate-mediated binding of infectious dengue virus type 2 and" exact="yellow fever" post="virusVirology200229216216810.1006/viro.2001.123211878919 69.KroschewskiH.AllisonS.L.HeinzF.X.MandlC.W.Role of heparan sulfate for attachment and entry"/>
   <result pre="virusVirology200229216216810.1006/viro.2001.123211878919 69.KroschewskiH.AllisonS.L.HeinzF.X.MandlC.W.Role of heparan sulfate for attachment and entry of" exact="tick-borne encephalitis" post="virusVirology20033089210010.1016/S0042-6822(02)00097-112706093 70.ShuklaD.LiuJ.BlaiklockP.ShworakN.W.BaiX.EskoJ.D.CohenG.H.EisenbergR.J.RosenbergR.D.SpearP.G.A novel role for 3-O-sulfated heparan sulfate in"/>
   <result pre="69.KroschewskiH.AllisonS.L.HeinzF.X.MandlC.W.Role of heparan sulfate for attachment and entry of tick-borne" exact="encephalitis" post="virusVirology20033089210010.1016/S0042-6822(02)00097-112706093 70.ShuklaD.LiuJ.BlaiklockP.ShworakN.W.BaiX.EskoJ.D.CohenG.H.EisenbergR.J.RosenbergR.D.SpearP.G.A novel role for 3-O-sulfated heparan sulfate in"/>
   <result pre="encephalitis virusVirology20033089210010.1016/S0042-6822(02)00097-112706093 70.ShuklaD.LiuJ.BlaiklockP.ShworakN.W.BaiX.EskoJ.D.CohenG.H.EisenbergR.J.RosenbergR.D.SpearP.G.A novel role for 3-O-sulfated heparan sulfate in" exact="herpes simplex" post="virus 1 entryCell199999132210.1016/S0092-8674(00)80058-610520990 71.PatelM.YanagishitaM.RoderiquezG.Bou-HabibD.C.OraveczT.HascallV.C.NorcrossM.A.Cell-surface heparan sulfate proteoglycan mediates HIV-1"/>
   <result pre="and Its Infectious Molecular CloneJ. Virol.2001751091210.1128/JVI.75.22.10912-10922.200111602731 81.MaillyL.XiaoF.LupbergerJ.WilsonG.K.AubertP.DuongF.H.T.CalabreseD.LeboeufC.FofanaI.ThumannC.et al.Clearance of persistent" exact="hepatitis" post="C virus infection in humanized mice using a claudin-1-targeting"/>
   <result pre="That Promote Early Viral Protein AccumulationJ. Virol.20179110.1128/JVI.01706-1627974556 83.ChambersT.J.GrakouiA.RiceC.M.Processing of the" exact="yellow fever" post="virus nonstructural polyprotein: A catalytically active NS3 proteinase domain"/>
   <result pre="94.ChambersT.J.WeirR.C.GrakouiA.McCourtD.W.BazanJ.F.FletterickR.J.RiceC.M.Evidence that the N-terminal domain of nonstructural protein NS3 from" exact="yellow fever" post="virus is a serine protease responsible for site-specific cleavages"/>
   <result pre="linked to differential phosphorylation of NS5J. Biol. Chem.1995270191001910610.1074/jbc.270.32.191007642575 99.BhattacharyaD.HooverS.FalkS.P.WeisblumB.VestlingM.StrikerR.Phosphorylation of" exact="yellow fever" post="virus NS5 alters methyltransferase activityVirology200838027628410.1016/j.virol.2008.07.01318757072 100.KümmererB.M.RiceC.M.Mutations in the yellow"/>
   <result pre="yellow fever virus NS5 alters methyltransferase activityVirology200838027628410.1016/j.virol.2008.07.01318757072 100.KümmererB.M.RiceC.M.Mutations in the" exact="yellow fever" post="virus nonstructural protein NS2A selectively block production of infectious"/>
   <result pre="by West Nile virus non-structural protein 4BPLoS ONE20149e8404010.1371/journal.pone.008404024465392 106.DesprèsP.GirardM.BouloyM.Characterization of" exact="yellow fever" post="virus proteins E and NS1 expressed in Vero and"/>
   <result pre="protein prM is necessary for infection of BHK-21 cells by" exact="tick-borne encephalitis" post="virusJ. Gen. Virol.20038418319110.1099/vir.0.18723-012533715 112.StadlerK.AllisonS.L.SchalichJ.HeinzF.X.Proteolytic activation of tick-borne encephalitis virus"/>
   <result pre="prM is necessary for infection of BHK-21 cells by tick-borne" exact="encephalitis" post="virusJ. Gen. Virol.20038418319110.1099/vir.0.18723-012533715 112.StadlerK.AllisonS.L.SchalichJ.HeinzF.X.Proteolytic activation of tick-borne encephalitis virus"/>
   <result pre="cells by tick-borne encephalitis virusJ. Gen. Virol.20038418319110.1099/vir.0.18723-012533715 112.StadlerK.AllisonS.L.SchalichJ.HeinzF.X.Proteolytic activation of" exact="tick-borne encephalitis" post="virus by furinJ. Virol.199771847584819343204 113.QuaresmaJ.A.S.BarrosV.L.R.S.PagliariC.FernandesE.R.GuedesF.TakakuraC.F.H.AndradeH.F.VasconcelosP.F.C.DuarteM.I.S.Revisiting the liver in human"/>
   <result pre="by tick-borne encephalitis virusJ. Gen. Virol.20038418319110.1099/vir.0.18723-012533715 112.StadlerK.AllisonS.L.SchalichJ.HeinzF.X.Proteolytic activation of tick-borne" exact="encephalitis" post="virus by furinJ. Virol.199771847584819343204 113.QuaresmaJ.A.S.BarrosV.L.R.S.PagliariC.FernandesE.R.GuedesF.TakakuraC.F.H.AndradeH.F.VasconcelosP.F.C.DuarteM.I.S.Revisiting the liver in human"/>
   <result pre="synthesis of tumor necrosis factor-alpha in healthy humans after live" exact="yellow fever" post="vaccinationJ. Infect. Dis.1998377477810.1086/5178069498462 116.QuerecT.BennounaS.AlkanS.LaouarY.GordenK.FlavellR.AkiraS.AhmedR.PulendranB.Yellow fever vaccine YF-17D activates multiple"/>
   <result pre="secrete interferonsSci. Rep.201881088910.1038/s41598-018-29235-730022130 118.Laurent-RolleM.MorrisonJ.RajsbaumR.MacleodJ.M.L.PisanelliG.PhamA.AyllonJ.MiorinL.MartinezC.tenOeverB.R.et al.The interferon signaling antagonist function of" exact="yellow fever" post="virus NS5 protein is activated by type I interferonCell"/>
   <result pre="exerts a critical early restriction on replication and dissemination of" exact="yellow fever" post="virus vaccine strain 17D-204NPJ Vaccines20183510.1038/s41541-017-0039-z29387474 122.DouamF.HrebikovaG.AlbrechtY.E.S.SellauJ.SharonY.DingQ.PlossA.Single-cell tracking of flavivirus"/>
   <result pre="in Resisting FlavivirusJ. Immunol. Res.20182018610658210.1155/2018/610658229888293 128.OlagnierD.ScholteF.E.M.ChiangC.AlbulescuI.C.NicholsC.HeZ.LinR.SnijderE.J.van HemertM.J.HiscottJ.Inhibition of dengue and" exact="chikungunya" post="virus infections by RIG-I-mediated type I interferon-independent stimulation of"/>
   <result pre="IPS-1J. Virol.20088260961610.1128/JVI.01305-0717977974 130.NazmiA.MukhopadhyayR.DuttaK.BasuA.STING mediates neuronal innate immune response following Japanese" exact="encephalitis" post="virus infectionSci. Rep.2012234710.1038/srep0034722470840 131.IshikawaH.BarberG.N.STING is an endoplasmic reticulum adaptor"/>
   <result pre="reservoirs for flaviviruses (yellow fever, dengue 2 and St Louis" exact="encephalitis" post="viruses) in French GuianaTrans. R. Soc. Trop. Med. Hyg.20049840941210.1016/j.trstmh.2003.12.00315138077"/>
   <result pre="French GuianaTrans. R. Soc. Trop. Med. Hyg.20049840941210.1016/j.trstmh.2003.12.00315138077 144.JulanderJ.G.Animal models of" exact="yellow fever" post="and their application in clinical researchCurr. Opin. Virol.201618646910.1016/j.coviro.2016.03.01027093699 145.WilsonE.M.BialJ.TarlowB.BialG.JensenB.GreinerD.L.BrehmM.A.GrompeM.Extensive"/>
   <result pre="human hepatocytesPLoS ONE201510e011982010.1371/journal.pone.011982025782010 147.BarrettA.D.GouldE.A.Comparison of neurovirulence of different strains of" exact="yellow fever" post="virus in miceJ. Gen. Virol.19866763163710.1099/0022-1317-67-4-6313958694 148.AlmeidaM.A.B.CardosoJ.d.C.Dos SantosE.da FonsecaD.F.CruzL.L.FaracoF.J.C.BerciniM.A.VettorelloK.C.PortoM.A.MohrdieckR.et al.Surveillance"/>
   <result pre="MosquitoesViruses201573741376710.3390/v707279526184281 151.DanetL.BeauclairG.BerthetM.MoratorioG.GraciasS.TangyF.ChoumetV.JouvenetN.Midgut barriers prevent the replication and dissemination of the" exact="yellow fever" post="vaccine in Aedes aegyptiPLoS Negl. Trop. Dis.201957721310.1371/journal.pntd.0007299 152.EricksonA.K.PfeifferJ.K.Dynamic viral"/>
   <result pre="Negl. Trop. Dis.201957721310.1371/journal.pntd.0007299 152.EricksonA.K.PfeifferJ.K.Dynamic viral dissemination in mice infected with" exact="yellow fever" post="virus strain 17DJ. Virol.201387123921239710.1128/JVI.02149-1324027319 153.DouamF.Soto AlbrechtY.E.HrebikovaG.SadiminE.DavidsonC.KotenkoS.V.PlossA.Type III Interferon-Mediated Signaling"/>
   <result pre="VivoMBio20178e00819-1710.1128/mBio.00819-1728811340 154.MeierK.C.GardnerC.L.KhoretonenkoM.V.KlimstraW.B.RymanK.D.A mouse model for studying viscerotropic disease caused by" exact="yellow fever" post="virus infectionPLoS Pathog.20095e100061410.1371/journal.ppat.100061419816561 155.MiorinL.Laurent-RolleM.PisanelliG.CoP.H.AlbrechtR.A.Garcia-SastreA.MorrisonJ.Host-Specific NS5 Ubiquitination Determines Yellow Fever"/>
   <result pre="TropismJ. Virol.20199310.1128/JVI.00151-1931043530 156.MinorP.The polio endgameHum. Vaccin. Immunother.2014102106210810.4161/21645515.2014.98111525608050 157.StokesA.BauerJ.H.HudsonN.P.The transmission of" exact="yellow fever" post="to Macacus rhesusRev. Med. Virol.20011114114810.1002/rmv.31111376477 158.RoukensA.H.VisserL.G.Yellow fever vaccine: Past,"/>
   <result pre="Opin. Biol. Ther.200881787179510.1517/14712598.8.11.178718847312 159.FerreiraC.C.Campi-AzevedoA.C.Peruhype-MagalhaesV.Costa-PereiraC.AlbuquerqueC.P.MunizL.F.Yokoy de SouzaT.OliveiraA.C.V.Martins-FilhoO.A.da MotaL.M.H.The 17D-204 and 17DD" exact="yellow fever" post="vaccines: An overview of major similarities and subtle differencesExpert"/>
   <result pre="for Studies on Yellow Fever VaccinesDuration of post-vaccination immunity against" exact="yellow fever" post="in adultsVaccine2014324977498410.1016/j.vaccine.2014.07.02125090646 164.GotuzzoE.YactayoS.CórdovaE.Efficacy and duration of immunity after yellow"/>
   <result pre="yellow fever in adultsVaccine2014324977498410.1016/j.vaccine.2014.07.02125090646 164.GotuzzoE.YactayoS.CórdovaE.Efficacy and duration of immunity after" exact="yellow fever" post="vaccination: Systematic review on the need for a booster"/>
   <result pre="humoral and cellular parameters of immune activation after vaccination with" exact="yellow fever" post="virus strain 17D: A model of human flavivirus infectionJ."/>
   <result pre="T-Cell Responses after VaccinationPLoS ONE201611e014987110.1371/journal.pone.014987126977808 167.NiedrigM.LademannM.EmmerichP.LafrenzM.Assessment of IgG antibodies against" exact="yellow fever" post="virus after vaccination with 17D by different assays: Neutralization"/>
   <result pre="Med. Biol.2007590435310.1007/978-0-387-34814-8_317191376 170.QuerecT.D.AkondyR.S.LeeE.K.CaoW.NakayaH.I.TeuwenD.PiraniA.GernertK.DengJ.MarzolfB.et al.Systems biology approach predicts immunogenicity of the" exact="yellow fever" post="vaccine in humansNat. Immunol.20091011612510.1038/ni.168819029902 171.KasturiS.P.SkountzouI.AlbrechtR.A.KoutsonanosD.HuaT.NakayaH.I.RavindranR.StewartS.AlamM.KwissaM.et al.Programming the magnitude and"/>
   <result pre="172.Da Costa NevesP.C.MatosD.C.d.S.MarcovistzR.GallerR.TLR expression and NK cell activation after human" exact="yellow fever" post="vaccinationVaccine2009275543554910.1016/j.vaccine.2009.07.02819647065 173.GaucherD.TherrienR.KettafN.AngermannB.R.BoucherG.Filali-MouhimA.MoserJ.M.MehtaR.S.DrakeD.R.CastroE.et al.Yellow fever vaccine induces integrated multilineage and"/>
   <result pre="vaccine vector for microbial CTL epitopes: Protection in a rodent" exact="malaria" post="modelJ. Exp. Med.200520120120910.1084/jem.2004152615657290 176.BredenbeekP.J.MolenkampR.SpaanW.J.DeubelV.MarianneauP.SalvatoM.S.MoshkoffD.ZapataJ.TikhonovI.PattersonJ.et al.A recombinant Yellow Fever 17D"/>
   <result pre="Yellow Fever 17D vaccine expressing Lassa virus glycoproteinsVirology200634529930410.1016/j.virol.2005.12.00116412488 177.FrancoD.LiW.QingF.StoyanovC.T.MoranT.RiceC.M.HoD.D.Evaluation of" exact="yellow fever" post="virus 17D strain as a new vector for HIV-1"/>
   <result pre="YFV 17D-based chimeric vaccines against dengue, West Nile and Japanese" exact="encephalitis" post="virusesVaccine20102863264910.1016/j.vaccine.2009.09.09819808029 179.StoyanovC.T.BoscardinS.B.DeroubaixS.Barba-SpaethG.FrancoD.NussenzweigR.S.NussenzweigM.RiceC.M.Immunogenicity and protective efficacy of a recombinant yellow"/>
   <result pre="Japanese encephalitis virusesVaccine20102863264910.1016/j.vaccine.2009.09.09819808029 179.StoyanovC.T.BoscardinS.B.DeroubaixS.Barba-SpaethG.FrancoD.NussenzweigR.S.NussenzweigM.RiceC.M.Immunogenicity and protective efficacy of a recombinant" exact="yellow fever" post="vaccine against the murine malarial parasite Plasmodium yoeliiVaccine2010284644465210.1016/j.vaccine.2010.04.07120451637 180.BonaldoM.C.SequeiraP.C.GallerR.The"/>
   <result pre="fever vaccine against the murine malarial parasite Plasmodium yoeliiVaccine2010284644465210.1016/j.vaccine.2010.04.07120451637 180.BonaldoM.C.SequeiraP.C.GallerR.The" exact="yellow fever" post="17D virus as a platform for new live attenuated"/>
   <result pre="attenuated vaccinesHum. Vaccin. Immunother.2014101256126510.4161/hv.2811724553128 181.BeckA.S.BarrettA.D.T.Current status and future prospects of" exact="yellow fever" post="vaccinesExpert Rev. Vaccines2015141479149210.1586/14760584.2015.108343026366673 182.OtshudiemaJ.O.NdakalaN.G.MawandaE.-T.K.TshapendaG.P.KimfutaJ.M.NsibuL.-R.N.GueyeA.S.DeeJ.PhilenR.M.GieseC.et al.Yellow Fever Outbreak - Kongo"/>
   <result pre="challenges for immunisationMem. Inst. Oswaldo Cruz2018113e18027810.1590/0074-0276018027830427974 187.JonkerE.F.VisserL.G.RoukensA.H.Advances and controversies in" exact="yellow fever" post="vaccinationTher. Adv. Vaccines2013114415210.1177/205101361349895424757521 188.KartogluU.MilstienJ.Tools and approaches to ensure quality"/>
   <result pre="al.Metabolic perturbations and cellular stress underpin susceptibility to symptomatic live-attenuated" exact="yellow fever" post="infectionNat. Med.2019251218122410.1038/s41591-019-0510-731308506 192.McMahonA.W.EidexR.B.MarfinA.A.RussellM.SejvarJ.J.MarkoffL.HayesE.B.ChenR.T.BallR.BraunM.M.et al.Neurologic disease associated with 17D-204 yellow"/>
   <result pre="yellow fever infectionNat. Med.2019251218122410.1038/s41591-019-0510-731308506 192.McMahonA.W.EidexR.B.MarfinA.A.RussellM.SejvarJ.J.MarkoffL.HayesE.B.ChenR.T.BallR.BraunM.M.et al.Neurologic disease associated with 17D-204" exact="yellow fever" post="vaccination: A report of 15 casesVaccine2007251727173410.1016/j.vaccine.2006.11.02717240001 193.ThomasR.E.LorenzettiD.L.SpraginsW.JacksonD.WilliamsonT.Active and passive"/>
   <result pre="A report of 15 casesVaccine2007251727173410.1016/j.vaccine.2006.11.02717240001 193.ThomasR.E.LorenzettiD.L.SpraginsW.JacksonD.WilliamsonT.Active and passive surveillance of" exact="yellow fever" post="vaccine 17D or 17DD-associated serious adverse events: Systematic reviewVaccine2011294544455510.1016/j.vaccine.2011.04.05521549787"/>
   <result pre="reviewRev. Panam Salud Publica201842e7510.26633/RPSP.2018.7531093103 195.BelsherJ.L.GayP.BrintonM.DellaVallaJ.RidenourR.LanciottiR.PerelyginA.ZakiS.PaddockC.QuerecT.et al.Fatal multiorgan failure due to" exact="yellow fever" post="vaccine-associated viscerotropic diseaseVaccine2007258480848510.1016/j.vaccine.2007.08.06118023511 196.Conesa-BotellaA.ColebundersR.Response to &quot;Case of yellow fever"/>
   <result pre="to yellow fever vaccine-associated viscerotropic diseaseVaccine2007258480848510.1016/j.vaccine.2007.08.06118023511 196.Conesa-BotellaA.ColebundersR.Response to &quot;Case of" exact="yellow fever" post="vaccine-associated viscerotropic disease with prolonged viremia, robust adaptive immune"/>
   <result pre="IFNAR1 deficiency in otherwise healthy patients with adverse reaction to" exact="measles" post="and yellow fever live vaccinesJ. Exp. Med.201910.1084/jem.20182295 198.CalisherC.H.WoodallJ.P.Yellow Fever-More"/>
   <result pre="in otherwise healthy patients with adverse reaction to measles and" exact="yellow fever" post="live vaccinesJ. Exp. Med.201910.1084/jem.20182295 198.CalisherC.H.WoodallJ.P.Yellow Fever-More a Policy and"/>
   <result pre="Yellow Fever VaccinationAm. J. Trop. Med. Hyg.2016951435143910.4269/ajtmh.16-040127928091 201.ZhaoS.StoneL.GaoD.HeD.Modelling the large-scale" exact="yellow fever" post="outbreak in Luanda, Angola, and the impact of vaccinationPLoS"/>
   <result pre="Trop. Dis.201812e000615810.1371/journal.pntd.000615829338001 202.HamletA.JeanK.YactayoS.BenzlerJ.CibrelusL.FergusonN.GarskeT.POLICI: A web application for visualising and extracting" exact="yellow fever" post="vaccination coverage in AfricaVaccine2019371384138810.1016/j.vaccine.2019.01.07430770224 203.SchaferB.HolzerG.W.JoachimsthalerA.CoulibalyS.SchwendingerM.CroweB.A.KreilT.R.BarrettP.N.FalknerF.G.Pre-clinical efficacy and safety of"/>
   <result pre="204.MacielM.Jr.Cruz FdaS.CordeiroM.T.da MottaM.A.CassemiroK.M.Maia RdeC.de FigueiredoR.C.GallerR.Freire MdaS.AugustJ.T.et al.A DNA vaccine against" exact="yellow fever" post="virus: Development and evaluationPLoS Negl. Trop. Dis.20159e000369310.1371/journal.pntd.000369325875109 205.TotteyS.ShojiY.JonesR.M.ChichesterJ.A.GreenB.J.MusiychukK.SiH.MancevaS.D.RheeA.ShamloulM.et al.Plant-Produced"/>
   <result pre="Protection Conferred by the VSV-Vectored Ebola Virus VaccineMBio20191010.1128/mBio.01597-19 209.MonathT.P.LeeC.K.JulanderJ.G.BrownA.BeasleyD.W.WattsD.M.HaymanE.GuertinP.MakowieckiJ.CrowellJ.et al.Inactivated" exact="yellow fever" post="17D vaccine: Development and nonclinical safety, immunogenicity and protective"/>
   <result pre="vaccination: Past, present and futureFuture Microbiol.20151079180810.2217/fmb.15.1925824845 215.KlittingR.RizikiT.MoureauG.PiorkowskiG.GouldE.A.de LamballerieX.Exploratory re-encoding of" exact="yellow fever" post="virus genome: New insights for the design of live-attenuated"/>
   <result pre="in primate and mosquito cellsPLoS Pathog.20139e100317210.1371/journal.ppat.100317223436995 218.de FabritusL.NougairedeA.AubryF.GouldE.A.de LamballerieX.Attenuation of" exact="tick-borne encephalitis" post="virus using large-scale random codon re-encodingPLoS Pathog.201511e100473810.1371/journal.ppat.100473825734338 219.CarringtonC.V.F.AugusteA.J.Evolutionary and"/>
   <result pre="primate and mosquito cellsPLoS Pathog.20139e100317210.1371/journal.ppat.100317223436995 218.de FabritusL.NougairedeA.AubryF.GouldE.A.de LamballerieX.Attenuation of tick-borne" exact="encephalitis" post="virus using large-scale random codon re-encodingPLoS Pathog.201511e100473810.1371/journal.ppat.100473825734338 219.CarringtonC.V.F.AugusteA.J.Evolutionary and"/>
   <result pre="219.CarringtonC.V.F.AugusteA.J.Evolutionary and ecological factors underlying the tempo and distribution of" exact="yellow fever" post="virus activityInfect. Genet. Evol.20131319821010.1016/j.meegid.2012.08.01522981999 220.LemoineF.CorreiaD.LefortV.Doppelt-AzeroualO.MareuilF.Cohen-BoulakiaS.GascuelO.NGPhylogeny.fr: New generation phylogenetic services"/>
   <result pre="frontier of genome engineering with CRISPR-Cas9Science2014346125809610.1126/science.125809625430774 223.PugachevK.V.GuirakhooF.OcranS.W.MitchellF.ParsonsM.PenalC.GirakhooS.PougatchevaS.O.ArroyoJ.TrentD.W.et al.High fidelity of" exact="yellow fever" post="virus RNA polymeraseJ. Virol.2004781032103810.1128/JVI.78.2.1032-1038.200414694136 224.VlachakisD.KoumandouV.L.KossidaS.A holistic evolutionary and structural"/>
   <result pre="Negl. Trop. Dis.201711e000607510.1371/journal.pntd.000607529155823 227.McMullanL.K.FraceM.SammonsS.A.ShoemakerT.BalinandiS.WamalaJ.F.LutwamaJ.J.DowningR.G.StroeherU.MacNeilA.et al.Using next generation sequencing to identify" exact="yellow fever" post="virus in UgandaVirology20124221510.1016/j.virol.2011.08.02421962764 228.QuickJ.LomanN.J.DuraffourS.SimpsonJ.T.SeveriE.CowleyL.BoreJ.A.KoundounoR.DudasG.MikhailA.et al.Real-time, portable genome sequencing for"/>
   <result pre="epidemicInt. J. Infect. Dis.2016489810310.1016/j.ijid.2016.04.02527156836 233.ChenC.JiangD.NiM.LiJ.ChenZ.LiuJ.YeH.WongG.LiW.ZhangY.et al.Phylogenomic analysis unravels evolution of" exact="yellow fever" post="virus within hostsPLoS Negl. Trop. Dis.201812e000673810.1371/journal.pntd.000673830188905 234.SallA.A.FayeO.DialloM.FirthC.KitchenA.HolmesE.C.Yellow fever virus"/>
   <result pre="Arbovirus Vertical Transmission in MosquitoesPLoS Pathog.201612e100554810.1371/journal.ppat.100554827171170 237.DialloM.ThonnonJ.FontenilleD.Vertical transmission of the" exact="yellow fever" post="virus by Aedes aegypti (Diptera, Culicidae): Dynamics of infection"/>
   <result pre="Trop. Med. Hyg.20006215115610.4269/ajtmh.2000.62.15110761742 238.AmraouiF.VazeilleM.FaillouxA.B.French Aedes albopictus are able to transmit" exact="yellow fever" post="virusEuro Surveill.20162110.2807/1560-7917.ES.2016.21.39.30361 239.KraemerM.U.G.ReinerR.C.Jr.BradyO.J.MessinaJ.P.GilbertM.PigottD.M.YiD.JohnsonK.EarlL.MarczakL.B.et al.Past and future spread of the"/>
   <result pre="albopictusNat. Microbiol.2019485486310.1038/s41564-019-0376-y30833735 240.HamrickP.N.AldighieriS.MachadoG.LeonelD.G.VilcaL.M.UrionaS.SchneiderM.C.Geographic patterns and environmental factors associated with human" exact="yellow fever" post="presence in the AmericasPLoS Negl. Trop. Dis.201711e000589710.1371/journal.pntd.000589728886023 241.KupferschmidtK.After 40"/>
   <result pre="vector-borne diseases by releasing modified mosquitoesNat. Rev. Microbiol.20181650851810.1038/s41579-018-0025-029777177 244.HarrisA.F.McKemeyA.R.NimmoD.CurtisZ.BlackI.MorganS.A.OviedoM.N.LacroixR.NaishN.MorrisonN.I.et al.Successful" exact="suppression" post="of a field mosquito population by sustained release of"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6832697\results\search\disease\results.xml">
   <result pre="and potentially debilitating symptoms. Zika virus pathogenesis Guillain-Barré syndrome fetal" exact="microcephaly" post="congenital Zika syndrome 1. Introduction Zika virus (ZIKV) was"/>
   <result pre="associated with ZIKV infection is Guillain-Barré syndrome (GBS), an acute" exact="peripheral neuropathy" post="that causes ascending paralysis. The link between ZIKV infection"/>
   <result pre="with ZIKV infection is Guillain-Barré syndrome (GBS), an acute peripheral" exact="neuropathy" post="that causes ascending paralysis. The link between ZIKV infection"/>
   <result pre="of GBS: acute inflammatory demyelinating polyradiculoneuropathy (AIDP), acute motor axonal" exact="neuropathy" post="(AMAN), and acute motor and sensory axonal neuropathy (AMSAN)."/>
   <result pre="motor axonal neuropathy (AMAN), and acute motor and sensory axonal" exact="neuropathy" post="(AMSAN). AIDP features mononuclear cell (macrophage or T cell)"/>
   <result pre="for an association between ZIKV infection during pregnancy and fetal" exact="microcephaly" post="[17]. Fetal microcephaly represents one of several symptoms that"/>
   <result pre="between ZIKV infection during pregnancy and fetal microcephaly [17]. Fetal" exact="microcephaly" post="represents one of several symptoms that are collectively referred"/>
   <result pre="a frontal headache, muscle pain, fever, and a diffuse maculopapular" exact="rash" post="on his face, neck, trunk, and limbs. On the"/>
   <result pre="evening of the second day, his fever broke, and the" exact="rash" post="faded over the following three days [3]. Similar to"/>
   <result pre="joint pain on the first day, although he reported no" exact="rash" post="throughout his illness [19]. Symptoms were maintained for two"/>
   <result pre="care unit (ICU), only three deaths were reported (due to" exact="respiratory failure" post="and sepsis) among all GBS cases [21,22,24]. When follow-up"/>
   <result pre="included other neurological symptoms such as encephalitis, transverse myelitis, and" exact="chronic inflammatory demyelinating polyneuropathy," post="which is considered to be a chronic version of"/>
   <result pre="chronic version of GBS [21]. Other case studies have identified:" exact="meningoencephalitis" post="and meningitis, with ZIKV RNA in the cerebrospinal fluid"/>
   <result pre="American outbreak, when a cluster of 58 cases of fetal" exact="microcephaly" post="were reported in a single month in Northeastern Brazil,"/>
   <result pre="years [48]. Since then, improving our understanding of ZIKV-induced fetal" exact="microcephaly" post="and CZS has been a primary focus of ZIKV"/>
   <result pre="infection of the developing fetus may be required for fetal" exact="microcephaly" post="to develop, not just infection of the mother [49]."/>
   <result pre="to develop, not just infection of the mother [49]. Fetal" exact="microcephaly" post="and other negative fetal outcomes are most closely linked"/>
   <result pre="women [54]. Other birth defects linked to ZIKV infection include" exact="patent foramen ovale" post="(failure of a natural hole between the left and"/>
   <result pre="right atria of the heart to close before birth), clubfoot," exact="cryptorchidism" post="(failure of the testes to descend into the scrotum),"/>
   <result pre="study of 216 infants born to mothers who had a" exact="rash" post="and positive ZIKV RT-PCR in either serum or urine"/>
   <result pre="(Vianna et al.) and two infants (Nielsen-Saines et al.) developed" exact="microcephaly" post="after birth, despite being born without indications of CZS"/>
   <result pre="to what is typically described in adult ZIKV infection, maculopapular" exact="rash" post="and fever were present in the majority of patients"/>
   <result pre="InfantsClin Infect. Dis.2019ciz70410.1093/cid/ciz70431346616 17.CauchemezS.BesnardM.BompardP.DubT.Guillemette-ArturP.Eyrolle-GuignotD.SaljeH.Van KerkhoveM.D.AbadieV.GarelC.et al.Association between Zika virus and" exact="microcephaly" post="in French Polynesia, 2013–2015: A retrospective studyLancet20163872125213210.1016/S0140-6736(16)00651-626993883 18.MooreC.A.StaplesJ.E.DobynsW.B.PessoaA.VenturaC.V.FonsecaE.B.RibeiroE.M.VenturaL.O.NetoN.N.ArenaJ.F.et al.Characterizing"/>
   <result pre="Zika virus in the cerebrospinal fluid of 30 neonates with" exact="microcephaly" post="in BrazilLancet20163871811181210.1016/S0140-6736(16)30253-7 50.LimaG.P.RozenbaumD.PimentelC.FrotaA.C.C.VivacquaD.MachadoE.S.SztajnbokF.AbreuT.SoaresR.A.HoferC.B.Factors associated with the development of Congenital"/>
   <result pre="de JaneiroN. Engl. J. Med.20163752321233410.1056/NEJMoa160241226943629 54.RobbianiD.F.OlsenP.C.CostaF.WangQ.OliveiraT.Y.NeryN.Jr.AromolaranA.do RosarioM.S.SacramentoG.A.CruzJ.S.et al.Risk of Zika" exact="microcephaly" post="correlates with features of maternal antibodiesJ. Exp. Med.201910.1084/jem.2019106131413072 55.MarinhoP.E.S.AlvarengaP.P.M.LimaM.T.de"/>
   <result pre="involvement in Zika virus infection in a childJ. Neurovirol.201910.1007/s13365-019-00770-x31222674 56.MecharlesS.HerrmannC.PoullainP.TranT.H.DeschampsN.MathonG.LandaisA.BreurecS.LannuzelA.Acute" exact="myelitis" post="due to Zika virus infectionLancet2016387148110.1016/S0140-6736(16)00644-926946926 57.LindseyN.P.PorseC.C.PottsE.HyunJ.SandhuK.SchiffmanE.CervantesK.B.WhiteJ.L.MasonK.OwensK.et al.Postnatally acquired Zika"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6832754\results\search\disease\results.xml">
   <result pre="month or less presented to University Hospital Geelong with fever," exact="rash" post="and irritability and both were admitted for treatment. Both"/>
   <result pre="late June 2019 with a 24 h history of irritability," exact="rash" post="and fever. There was no significant past history, having"/>
   <result pre="had impaired perfusion with delayed capillary refill. An erythematous macular" exact="rash" post="was apparent across the torso. The fontanelle was full"/>
   <result pre="CSF was positive for parechovirus by PCR and negative for" exact="herpes simplex" post="virus and enterovirus. A nasopharyngeal (NPA) swab tested negative"/>
   <result pre="virus and enterovirus. A nasopharyngeal (NPA) swab tested negative for" exact="influenza" post="A/B virus by rapid test and a second NPA"/>
   <result pre="of oxygen saturation to 80%. There was a blanching macular" exact="rash" post="on the torso. The fontanelle was soft. Haemoglobin was"/>
   <result pre="rhinovirus by PCR (Ct value of 37.8) and negative for" exact="influenza" post="A/B virus. PCR on CSF was positive for parechovirus"/>
   <result pre="CSF was positive for parechovirus and negative for enterovirus and" exact="herpes simplex" post="virus. The chest X-ray was normal. The infant was"/>
   <result pre="four HPeV5 infections, the infant had been treated for suspected" exact="meningitis" post="or sepsis, and in 6 out of the 7"/>
   <result pre="with the more severe manifestations of parechovirus infections, such as" exact="meningitis" post="and sepsis-like symptoms in children, the recombinant HPeV5 described"/>
   <result pre="only likely to be detected in patients screened for both" exact="respiratory disease" post="and viral meningitis, or those in which metagenomics are"/>
   <result pre="be detected in patients screened for both respiratory disease and" exact="viral meningitis," post="or those in which metagenomics are performed. Nevertheless, although"/>
   <result pre="abdomen 615 G001-19/Vic/Jun/19 HPeV-5 CSF, Plasma, Nasal swab Meningitis/sepsis-like, fever," exact="rash" post="and irritability 17 G002-19/Vic/Jul/19 HPeV-5 CSF, Nasal Swab Meningitis/sepsis-like,"/>
   <result pre="and irritability 17 G002-19/Vic/Jul/19 HPeV-5 CSF, Nasal Swab Meningitis/sepsis-like, fever," exact="rash" post="and irritability 32"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6832874\results\search\disease\results.xml">
   <result pre="identification of several novel viruses that have been associated with" exact="gastroenteritis" post="in cats. In the last few years, noroviruses, kobuviruses,"/>
   <result pre="viruses cats etiology epidemiology pathogenesis diagnosis 1. Introduction Feline viral" exact="gastroenteritis" post="is considered a common worldwide disease, especially in cats"/>
   <result pre="virus (FPV) [1,2,3], feline enteric coronavirus (FeCoV) [4,5], and feline" exact="leukemia" post="virus (FeLV) [6] are the most important known viral"/>
   <result pre="[6] are the most important known viral causes of feline" exact="gastrointestinal disease," post="although various viral agents including astrovirus, adenovirus, rotavirus, and"/>
   <result pre="decade, there has been a resurgence of interest for viral" exact="gastroenteritis" post="that was sparked by the identification of novel viruses"/>
   <result pre="was sparked by the identification of novel viruses associated with" exact="diarrhea" post="either alone or in mixed infections, occasionally resulting in"/>
   <result pre="Feline Noroviruses Noroviruses (NoVs) are a major cause of epidemic" exact="gastroenteritis" post="in children and adults. They cause nearly half of"/>
   <result pre="in children and adults. They cause nearly half of all" exact="gastroenteritis" post="cases and &amp;gt; 90% of nonbacterial gastroenteritis epidemics worldwide"/>
   <result pre="half of all gastroenteritis cases and &amp;gt; 90% of nonbacterial" exact="gastroenteritis" post="epidemics worldwide [20]. NoVs have also been identified in"/>
   <result pre="a stool sample collected from a 60-day-old mixed-breed pup with" exact="diarrhea" post="and vomiting, hospitalized at the Faculty of Veterinary Medicine"/>
   <result pre="(75.5%–74.0% nt). Since then, by implementing the diagnostic algorithms of" exact="gastroenteritis" post="cases with NoV-specific molecular assays, canine NoVs have been"/>
   <result pre="with the feline GVI.1 strain JPN/2012/M49 could induce enteritis signs," exact="diarrhea" post="and vomiting [43,53]. Taken together, these findings seem to"/>
   <result pre="first discovered in 1989 as the cause of oyster-associated nonbacterial" exact="gastroenteritis" post="in humans in Aichi Prefecture, Japan [68]. Since then,"/>
   <result pre="AiVs are involved in 0.9–4.1% of sporadic cases of pediatric" exact="gastroenteritis" post="[69,70,71,72]. Recently, novel kobuviruses genetically closely related to human"/>
   <result pre="assessing a collection of stool samples from cats molecularly with" exact="diarrhea" post="that revealed the presence of FeKoV RNA in six"/>
   <result pre="from 13.5% to 28.8%. Although, the relationship between infections and" exact="gastroenteritis" post="in cats is far from elucidated and still requires"/>
   <result pre="protoparvovirus 1 (Protoparvovirus genus), causes feline panleukopenia, the oldest known" exact="viral disease" post="of cats [1], characterized by severe panleukopenia and enteritis"/>
   <result pre="characterized by severe panleukopenia and enteritis in cats [2,3] and" exact="cerebellar ataxia" post="in kittens [95]. Infection is highly contagious, often associated"/>
   <result pre="it has been confirmed that the infection is linked to" exact="gastroenteritis" post="[124]. Furthermore, the detection in extra-intestinal sites such as"/>
   <result pre="in Europe and North America, mainly associated with serious hemorrhagic" exact="gastroenteritis" post="and myocarditis in puppies [135] and likely arisen from"/>
   <result pre="and North America, mainly associated with serious hemorrhagic gastroenteritis and" exact="myocarditis" post="in puppies [135] and likely arisen from FPV after"/>
   <result pre="of five-month-old puppies during an Italian outbreak of canine infectious" exact="respiratory disease" post="(CIRD). In the NS1 protein, CBuV displayed low aa"/>
   <result pre="the most common viruses associated with either mild or severe" exact="gastroenteritis" post="in humans, mainly in young children and immunodeficient patients"/>
   <result pre="by EM from the stool of a domestic kitten with" exact="diarrhea" post="in the USA [7]. Subsequent EM-based investigations revealed the"/>
   <result pre="Furthermore, natural infection has been described in domestic cats with" exact="diarrhea" post="either alone or in mixed infections mainly with FPV"/>
   <result pre="have been recognized as a major cause of human acute" exact="gastroenteritis" post="since 1973 [161]. They primarily affect young children, accounting"/>
   <result pre="young children, accounting for almost 40% of hospital admissions for" exact="diarrhea" post="and 200000 deaths worldwide [162]. RVs (genus Rotavirus, family"/>
   <result pre="with an overall prevalence of 3.0% (57/1727); statistical associations with" exact="diarrhea" post="or age have not been found [174]. Sequence analysis"/>
   <result pre="disease characterized by hemorrhagic gastroenteritis, severe necrotizing vasculitis, and granulomatous" exact="lymphadenitis" post="[179,180]. By converse, information on the epidemiology of circoviruses"/>
   <result pre="have been recently found in cat fecal samples during a" exact="diarrhea" post="outbreak in Canada by using a metagenomic approach [19]."/>
   <result pre="IARC PyVs (LIPyVs). The etiologic role of LIPyV in feline" exact="diarrhea" post="should be investigated as well as its zoonotic potential."/>
   <result pre="role as primary causative pathogens or synergistic agents in feline" exact="gastrointestinal disease." post="In order to obtain a complete picture, each novel"/>
   <result pre="Am. Small Anim. Pract.2011411133116910.1016/j.cvsm.2011.08.004 6.KiparA.KremendahlJ.JacksonM.L.ReinacherM.Comparative examination of cats with feline" exact="leukemia" post="virus-associated enteritis and other relevant forms of feline enteritisVet."/>
   <result pre="Diagn. Investig.1993527327610.1177/1040638793005002248389604 11.PintoP.WangQ.ChenN.DuboviE.J.DanielsJ.B.MillwardL.M.BuonavogliaC.MartellaV.SaifL.J.Discovery and genomic characterization of noroviruses from a" exact="gastroenteritis" post="outbreak in domestic cats in the USPLoS ONE20127e3273910.1371/journal.pone.003273922389721 12.LauS.K.P.WooP.C.Y.YeungH.C.TengJ.L.L.WuY.BaiR.FanR.Y.Y.ChanK.H.YuenK.Y.Identification"/>
   <result pre="22.GüntherH.OttoP.Diarrhea in young calves. ‘‘Zackenvirus�? (Jena agent 117/80) a new" exact="diarrhea" post="pathogen in calvesArch. Exp. Vet.198741934938 23.SugiedaM.NagaokaH.KakishimaY.OhshitaT.NakamuraS.NakajimaS.Detection of Norwalk-like virus"/>
   <result pre="of caliciviruses (vesivirus and norovirus) in an outbreak of acute" exact="diarrhea" post="in kittens from BrazilVet. J.201520611511710.1016/j.tvjl.2015.06.01426189893 53.TakanoT.HiramatsuK.MatsuyamaM.MutohK.MatsumotoY.FukushimaT.DokiT.KusuharaH.HohdatsuT.Viral shedding and clinical"/>
   <result pre="in HungaryArch. Virol.20091541529153210.1007/s00705-009-0473-y19669615 71.KaikkonenS.RäsänenS.RämetM.VesikariT.Aichi virus infection in children with acute" exact="gastroenteritis" post="in FinlandEpidemiol. Infect.20101381166117110.1017/S095026880999130019961643 72.JonssonN.WahlströmK.SvenssonL.SerranderL.LindbergA.M.Aichi virus infection in elderly people"/>
   <result pre="children, FinlandEmerg. Infect. Dis.2009151423143010.3201/eid1509.09020419788810 120.ArthurJ.L.HigginsG.D.DavidsonG.P.GivneyR.C.RatcliffR.M.A novel bocavirus associated with acute" exact="gastroenteritis" post="in Australian childrenPLoS Pathog.20095e100039110.1371/journal.ppat.100039119381259 121.KapoorA.SlikasE.SimmondsP.ChieochansinT.NaeemA.ShaukatS.AlamM.M.SharifS.AngezM.ZaidiS.et al.A newly identified bocavirus"/>
   <result pre="Parvovirus Related to Primate Bufaviruses in DogsEmerg. Infect. Dis.2018241061106810.3201/eid2406.17196529774829 142.PhanT.G.VoN.P.BonkoungouI.J.KapoorA.BarroN.O’RyanM.KapusinszkyB.WangC.DelwartE.Acute" exact="diarrhea" post="in West African children: Diverse enteric viruses and a"/>
   <result pre="astrovirus and Feline panleukopenia virus in a domestic cat with" exact="gastroenteritis" post="and panleukopeniaJ. Vet. Diagn. Investig.20112358158410.1177/104063871140414921908295 158.LauS.K.WooP.C.YipC.C.BaiR.WuY.TseH.YuenK.Y.Complete genome sequence of"/>
   <result pre="opportunistic agent?Virology2016490697410.1016/j.virol.2016.01.00726848830 179.LiL.McGrawS.ZhuK.LeuteneggerC.M.MarksS.L.KubiskiS.GaffneyP.Dela CruzF.N.WangC.DelwartE.et al.Circovirus in tissues of dogs with" exact="vasculitis" post="and hemorrhageEmerg. Infect. Dis.20131953454110.3201/eid1904.12139023628223 180.DecaroN.MartellaV.DesarioC.LanaveG.CircellaE.CavalliA.EliaG.CameroM.BuonavogliaC.Genomic characterization of a circovirus"/>
   <result pre="rotaviruses with a Kun-like NSP4 gene detected in children with" exact="diarrhea" post="in ItalyJ. Clin. Microbiol.20084635736010.1128/JCM.01593-0718063802 186.PietschP.LiebertU.G.Evidence for presumable feline origin"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6833027\results\search\disease\results.xml">
   <result pre="the order Mononegavirales. Other members of the genus include the" exact="measles" post="virus, the now eradicated virus of cattle, rinderpest, peste"/>
   <result pre="cells from different species [13]. CDV and PDV, like the" exact="measles" post="virus and the other veterinary morbilliviruses, use both the"/>
   <result pre="dog populations did not occur at this time. Widespread epidemic" exact="measles" post="in the Americas closely preceded the first descriptions of"/>
   <result pre="been reported in the last 30 years. A case of" exact="encephalitis" post="in a Japanese macaque (snow monkey) (Macaca fuscata) was"/>
   <result pre="monkeys imported from China. Forty six monkeys died from severe" exact="pneumonia" post="during a quarantine period. Phylogenic analysis also showed that"/>
   <result pre="the vaccine continued to be used.. In 1982–83, cases of" exact="post-vaccinal encephalitis" post="were recorded in dogs in various parts of Britain"/>
   <result pre="vaccine continued to be used.. In 1982–83, cases of post-vaccinal" exact="encephalitis" post="were recorded in dogs in various parts of Britain"/>
   <result pre="binding region for the basal epithelial receptor nectin-4 for the" exact="measles" post="virus [13,89] and CDV and PDV [14,90] were conserved"/>
   <result pre="also indicate that CDV previously infected humans [24]. At present," exact="measles" post="vaccination of humans provides at least partial protection against"/>
   <result pre="humans a more CDV-specific vaccine may be required, as this" exact="measles" post="vaccine has been shown to give only partial protection"/>
   <result pre="from related veterinary viruses and need for continued vaccination post" exact="measles" post="eradicationHum. Vaccines Immunother.20181422923310.1080/21645515.2017.140367729173050 4.BarrettT.Morbillivirus infections, with special emphasis on"/>
   <result pre="BaikalVet. Microbiol.20018220321010.1016/S0378-1135(01)00371-611470542 7.LonghiS.Nucleocapsid Structure and FunctionCurr. Top. Microbiol. Immunol.200932910312819198564 8.RimaB.K.DuprexW.P.The" exact="measles" post="virus replication cycleCurr. Top. Microbiol. Immunol.20093297710219198563 9.LiljeroosL.HuiskonenJ.T.OraA.SusiP.ButcherS.J.Electron cryotomography of"/>
   <result pre="measles virus replication cycleCurr. Top. Microbiol. Immunol.20093297710219198563 9.LiljeroosL.HuiskonenJ.T.OraA.SusiP.ButcherS.J.Electron cryotomography of" exact="measles" post="virus reveals how matrix protein coats the ribonucleocapsid within"/>
   <result pre="ribonucleocapsid within intact virionsProc. Natl. Acad. Sci. USA2011108180851809010.1073/pnas.110577010822025713 10.CathomenT.MrkicB.SpehnerD.DrillienR.NaefR.PavlovicJ.AguzziA.BilleterM.A.CattaneoR.A matrix-less" exact="measles" post="virus is infectious and elicits extensive cell fusion: Consequences"/>
   <result pre="properties of matrix proteins expressed by M genes cloned from" exact="measles" post="viruses and diseased human brain tissueJ. Virol.199468153215438107216 12.HallW.W.MartinS.J.Structure and"/>
   <result pre="tissueJ. Virol.199468153215438107216 12.HallW.W.MartinS.J.Structure and function relationships of the envelope of" exact="measles" post="virusMed. Microbiol. Immunol.197416014315410.1007/BF021217214444684 13.LinL.T.RichardsonC.D.The Host Cell Receptors for Measles"/>
   <result pre="marker PVRL4 (nectin 4) is an epithelial cell receptor for" exact="measles" post="virusPLoS Pathog.20017e100224010.1371/journal.ppat.1002240 17.FerreiraC.S.FrenzkeM.LeonardV.H.WelsteadG.G.RichardsonC.D.CattaneoR.Measles Virus Infection of Alveolar Macrophages and"/>
   <result pre="19.MühlebachM.D.MateoM.SinnP.L.PrüferS.UhligK.M.LeonardV.H.J.NavaratnarajahC.K.FrenzkeM.WongX.X.SawatskyB.et al.Adherens junction protein nectin-4 is the epithelial receptor for" exact="measles" post="virusNature201148053053310.1038/nature1063922048310 20.RamachandranA.ParisienJ.-P.HorvathC.M.STAT2 Is a Primary Target for Measles Virus"/>
   <result pre="of the Measles Virus Hemagglutinin and Its ReceptorsViruses20181023610.3390/v10050236 89.ZhangX.LuG.QiJ.LiY.HeY.XuX.ShiJ.ZhangC.W.YanJ.GaoG.F.Structure of" exact="measles" post="virus hemagglutinin bound to its epithelial receptor nectin-4Nat. Struct."/>
   <result pre="Human ReceptorsJ. Virol.2013877170717510.1128/JVI.03479-1223596291 92.ChalmersW.BaxendaleW.A comparison of canine distemper vaccine and" exact="measles" post="vaccine for the prevention of canine distemper in young"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6834095\results\search\disease\results.xml">
   <result pre="group of conditions whose outcome is similar to that of" exact="amyotrophic lateral sclerosis," post="but with different characteristics in the initial phase and"/>
   <result pre="evidence of an association between amyotrophic lateral sclerosis-like syndrome and" exact="chikungunya" post="(CHK) infection in the literature. This report was intended"/>
   <result pre="arthralgia, myalgia, headache, and skin rash. Reports range from encephalitis," exact="optic neuritis," post="myeloradiculitis to Guillain-Barré syndrome, generating drastic sequelae such as"/>
   <result pre="case report of a possible association of ALS-like syndrome and" exact="chikungunya" post="infection. CHK infection may cause ALS-like syndrome. There is"/>
   <result pre="develop therapies for neurological complications such as that of CHK." exact="chikungunya" post="fever arbovirus amyotrophic lateral sclerosis diagnostic techniques critically ill"/>
   <result pre="neurological complications such as that of CHK. chikungunya fever arbovirus" exact="amyotrophic lateral sclerosis" post="diagnostic techniques critically ill The content published in Cureus"/>
   <result pre="within Cureus. Introduction Amyotrophic lateral sclerosis (ALS) is a progressive" exact="motor neuron disease" post="that is considered a neurodegenerative disease [1-3]. It has"/>
   <result pre="still no evidence of an association between ALS-like syndrome and" exact="chikungunya" post="(CHK) arbovirus infection in the literature. This report was"/>
   <result pre="New ENMG revealed a pattern consistent with diffuse axonal motor" exact="neuropathy" post="with no fasciculations and no conduction block, without bulbar"/>
   <result pre="Serology for Zika virus was negative. She presented signs of" exact="arthritis" post="in the hands, in agreement with arbovirus, and was"/>
   <result pre="similar manifestations are discarded. These include inflammatory demyelinating polyneuropathy, multifocal" exact="neuropathy" post="with conduction blockages, motor polyradiculopathy, multiple organic mitochondrial dysfunction"/>
   <result pre="multiple organic mitochondrial dysfunction syndrome, multifocal motor neuropathy, and cervical" exact="spondylosis" post="with myeloradiculopathy [7]. The case report in this article"/>
   <result pre="lymphadenopathy, pruritus, and digestive disorders. Severe cases can manifest with" exact="encephalopathy" post="and encephalitis, myocarditis, hepatitis and multiple organ failure, these"/>
   <result pre="disorders. Severe cases can manifest with encephalopathy and encephalitis, myocarditis," exact="hepatitis" post="and multiple organ failure, these rare forms can be"/>
   <result pre="in the ICU followed by death. Reports range from encephalitis," exact="optic neuritis," post="myeloradiculitis to Guillain-Barré syndrome, generating drastic sequelae such as"/>
   <result pre="all participants in this study References References 1Early diagnosis of" exact="amyotrophic lateral sclerosis" post="mimic syndromes: pros and cons of current clinical diagnostic"/>
   <result pre="patients with HIV-1 infectionJ Neurol SciVermaABergerJR5964240200616236322 10Atypical neurological manifestations of" exact="chikungunya" post="fever: two case reportsIndian J Crit Care MedMahtoSKGuptaPKSin ghAMeenaRC30630822201829743772"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6834195\results\search\disease\results.xml">
   <result pre="Clinical presentation includes a diverse disease spectrum, including hand-foot and" exact="mouth disease" post="(HFMD), aseptic meningitis, encephalitis, acute flaccid paralysis, and acute"/>
   <result pre="a diverse disease spectrum, including hand-foot and mouth disease (HFMD)," exact="aseptic meningitis," post="encephalitis, acute flaccid paralysis, and acute flaccid myelitis. HFMD"/>
   <result pre="important to reduce disease burden in pediatric populations. hand-foot and" exact="mouth disease" post="central nervous system complications encephalitis molecular characterization enterovirus A71"/>
   <result pre="pediatric populations. hand-foot and mouth disease central nervous system complications" exact="encephalitis" post="molecular characterization enterovirus A71 1. Introduction Multiple, highly contagious"/>
   <result pre="highly contagious Enterovirus A types are the etiological agents of" exact="infectious disease" post="outbreaks affecting pediatric populations worldwide [1,2]. Among these types,"/>
   <result pre="A16 (CV-A16), are most frequently associated with hand-foot-and-mouth disease (HFMD)," exact="aseptic meningitis" post="(AM) and encephalitis [2,3]. Despite the vast majority of"/>
   <result pre="(CV-A16), are most frequently associated with hand-foot-and-mouth disease (HFMD), aseptic" exact="meningitis" post="(AM) and encephalitis [2,3]. Despite the vast majority of"/>
   <result pre="frequently associated with hand-foot-and-mouth disease (HFMD), aseptic meningitis (AM) and" exact="encephalitis" post="[2,3]. Despite the vast majority of enterovirus infections being"/>
   <result pre="(Figure 2). Among these cases, the severe infections comprised brainstem" exact="encephalitis" post="and deaths from central pulmonary edema and heart failure"/>
   <result pre="the severe infections comprised brainstem encephalitis and deaths from central" exact="pulmonary edema" post="and heart failure [8]. As a consequence, HFMD outbreaks"/>
   <result pre="In addition, in the context of CNS infections, poliovirus causing" exact="poliomyelitis" post="(acute flaccid paralysis, AFP), which remarkably has almost achieved"/>
   <result pre="members are herpangina, AM, meningoencephalitis, acute flaccid paralysis, gastroenteritis, and" exact="encephalitis" post="[19,27]. 3. Enterovirus Infection EVs are predominantly transmitted through"/>
   <result pre="as 1 to 3 days, such as in acute hemorrhagic" exact="conjunctivitis" post="cases due to CV-A24 [29]. Viral shedding from the"/>
   <result pre="as an acute-onset, febrile viral infection with a characteristic maculopapular" exact="rash" post="and blisters observed on the hands, feet, and mouth"/>
   <result pre="fatigue, malaise, loss of appetite, irritability, upper respiratory tract infection," exact="gastroenteritis" post="and non-specific viral rashes [19,26,31]. Despite the highly infectious"/>
   <result pre="symptoms that could be misdiagnosed as varicella, such as vesiculobullous" exact="rash" post="of the trunk and extremities, and the characteristic spread"/>
   <result pre="CNS resulting in diverse pathologies. Among such pathologies, poliovirus acute" exact="poliomyelitis" post="caused by members of the species Enterovirus C has"/>
   <result pre="diseases. Poliomyelitis complications include spinal or bulbar paralysis with consequent" exact="respiratory failure" post="[27]. Nevertheless, as of 2019, poliovirus is close to"/>
   <result pre="emerged as the &quot;new polio�? in Asia [2,19,40]. AM and" exact="encephalitis" post="are among the most common manifestations of CNS infections"/>
   <result pre="infections by EVs. In the period between 2011 and 2012," exact="encephalitis" post="or encephalopathy was reported in 23 out of 2471"/>
   <result pre="EVs. In the period between 2011 and 2012, encephalitis or" exact="encephalopathy" post="was reported in 23 out of 2471 cases (0.93%)"/>
   <result pre="the Infectious Disease Survey in Japan. On the other hand," exact="encephalitis" post="or encephalopathy was reported in 10 out of 3202"/>
   <result pre="Disease Survey in Japan. On the other hand, encephalitis or" exact="encephalopathy" post="was reported in 10 out of 3202 patients (0.31%)"/>
   <result pre="during the same period. Although virus detection in patients with" exact="encephalitis" post="does not definitively indicate the causative infectious agent, this"/>
   <result pre="infectious agent, this figure suggests that CV-A16 may also cause" exact="encephalitis" post="and encephalopathy and warrants further investigation. Human fatalities and"/>
   <result pre="this figure suggests that CV-A16 may also cause encephalitis and" exact="encephalopathy" post="and warrants further investigation. Human fatalities and mice experiments"/>
   <result pre="small number of neurites and phagocytes [11]. Fulminant forms of" exact="pulmonary edema" post="are thought to be preceded by CNS symptoms and"/>
   <result pre="or cytokine storm influences the outcome. The concomitant occurrence of" exact="encephalitis" post="and HFMD is difficult to predict; moreover, encephalitis is"/>
   <result pre="occurrence of encephalitis and HFMD is difficult to predict; moreover," exact="encephalitis" post="is often unclear and prospective studies are difficult. EV"/>
   <result pre="EV infections are also reported to cause paralysis along with" exact="encephalitis" post="[17]. Before May 2018, Japanese surveillance lacked diagnosis and"/>
   <result pre="in 74% ± 15 of cases per year, with the" exact="mumps" post="paramyxovirus (which is not part of the routine Japanese"/>
   <result pre="the risks associated with outbreaks from this neurotropic EV. EV-induced" exact="meningitis" post="has a fundamentally favorable prognosis (particularly in comparison to"/>
   <result pre="in comparison to bacterial meningitis) so timely laboratory confirmation of" exact="aseptic meningitis" post="is crucial for clinical care. Although HFMD is reported"/>
   <result pre="comparison to bacterial meningitis) so timely laboratory confirmation of aseptic" exact="meningitis" post="is crucial for clinical care. Although HFMD is reported"/>
   <result pre="CNS infections, such as encephalitis, are more frequently judged as" exact="encephalitis" post="of unknown origin unless the pathogen is confirmed by"/>
   <result pre="EV-A71, the detection rate from CSF is low in EV-A71-associated" exact="meningitis" post="cases. Nevertheless, simultaneous viral testing in the acute phase"/>
   <result pre="associated with complications extending to the CNS, such as brainstem" exact="encephalitis" post="[85,86]. Moreover, severe cases with EV-A71 infections could be"/>
   <result pre="(p &amp;lt; 0.01, OR = 73.7), and (4) a maculopapular" exact="rash" post="(p &amp;lt; 0.01, OR = 84.4) [91]. Other reports"/>
   <result pre="Other reports also suggest the use of steroids in acute" exact="encephalitis" post="cases associated with EV-A71 clearly exacerbate central nervous system"/>
   <result pre="EV-associated HFMD and the development of CNS complications, such as" exact="encephalitis" post="and meningitis. HFMD is often caused by EV-A71, CV-A6,"/>
   <result pre="Asian countries. Nevertheless, baseline epidemiological surveillance in Japan of this" exact="infectious disease" post="provides insights into the infectious trends of EV-A71 to"/>
   <result pre="Neurological complications arising from a HFMD infection lead to brainstem" exact="encephalitis" post="and lesions in the thalamus, medulla oblongata and other"/>
   <result pre="the results. Abbreviations EV Enterovirus CV coxsackievirus HFMD hand-foot and" exact="mouth disease" post="AM aseptic meningitis CNS Central Nervous System NESID National"/>
   <result pre="EV Enterovirus CV coxsackievirus HFMD hand-foot and mouth disease AM" exact="aseptic meningitis" post="CNS Central Nervous System NESID National Epidemiological Surveillance of"/>
   <result pre="Enterovirus CV coxsackievirus HFMD hand-foot and mouth disease AM aseptic" exact="meningitis" post="CNS Central Nervous System NESID National Epidemiological Surveillance of"/>
   <result pre="and Mouth Disease, China, 2008–2015Emerg. Infect. Dis.20182410.3201/eid2403.17130329460747 5.WangJ.HuT.SunD.DingS.CarrM.J.XingW.LiS.WangX.ShiW.Epidemiological characteristics of" exact="hand, foot, and mouth disease" post="in Shandong, China, 2009–2016Sci. Rep.20177890010.1038/s41598-017-09196-z28827733 6.LeeK.Y.LeeY.-J.KimT.H.CheonD.-S.NamS.-O.Clinico-radiological spectrum in enterovirus"/>
   <result pre="China, 2008–2015Emerg. Infect. Dis.20182410.3201/eid2403.17130329460747 5.WangJ.HuT.SunD.DingS.CarrM.J.XingW.LiS.WangX.ShiW.Epidemiological characteristics of hand, foot, and" exact="mouth disease" post="in Shandong, China, 2009–2016Sci. Rep.20177890010.1038/s41598-017-09196-z28827733 6.LeeK.Y.LeeY.-J.KimT.H.CheonD.-S.NamS.-O.Clinico-radiological spectrum in enterovirus"/>
   <result pre="(Herpangina/Hand-Foot-and-Mouth Disease)Available online: http://www.niid.go.jp/niid/ja/iasr/510-surveillance/iasr/graphs/4892-iasrgnatus.html(accessed on 19 October 2019) 8.FujimotoT.ChikahiraM.YoshidaS.EbiraH.HasegawaA.TotsukaA.NishioO.Outbreak of" exact="central nervous system disease" post="associated with hand, foot, and mouth disease in Japan"/>
   <result pre="Disease)Available online: http://www.niid.go.jp/niid/ja/iasr/510-surveillance/iasr/graphs/4892-iasrgnatus.html(accessed on 19 October 2019) 8.FujimotoT.ChikahiraM.YoshidaS.EbiraH.HasegawaA.TotsukaA.NishioO.Outbreak of central" exact="nervous system disease" post="associated with hand, foot, and mouth disease in Japan"/>
   <result pre="October 2019) 8.FujimotoT.ChikahiraM.YoshidaS.EbiraH.HasegawaA.TotsukaA.NishioO.Outbreak of central nervous system disease associated with" exact="hand, foot, and mouth disease" post="in Japan during the summer of 2000: Detection and"/>
   <result pre="of central nervous system disease associated with hand, foot, and" exact="mouth disease" post="in Japan during the summer of 2000: Detection and"/>
   <result pre="neurotropic enteroviruses in Ireland, 2005–2014J. Med Virol.2017891550155810.1002/jmv.2476528071799 16.WangM.RenQ.ZhangZ.ZhangL.CarrM.J.LiJ.ZhouH.ShiW.Rapid detection of" exact="hand, foot and mouth disease" post="enterovirus genotypes by multiplex PCRJ. Virol. Methods201825871210.1016/j.jviromet.2018.05.00529758237 17.ObersteM.S.MaherK.KilpatrickD.R.FlemisterM.R.BrownB.A.PallanschM.A.Typing of"/>
   <result pre="Ireland, 2005–2014J. Med Virol.2017891550155810.1002/jmv.2476528071799 16.WangM.RenQ.ZhangZ.ZhangL.CarrM.J.LiJ.ZhouH.ShiW.Rapid detection of hand, foot and" exact="mouth disease" post="enterovirus genotypes by multiplex PCRJ. Virol. Methods201825871210.1016/j.jviromet.2018.05.00529758237 17.ObersteM.S.MaherK.KilpatrickD.R.FlemisterM.R.BrownB.A.PallanschM.A.Typing of"/>
   <result pre="features, diagnosis, and management of enterovirus 71Lancet Neurol.201091097110510.1016/S1474-4422(10)70209-X20965438 20.HatayamaK.GotoS.YashiroM.MoriH.FujimotoT.HanaokaN.Tanaka-TayaK.ZuzanT.InoueM.Acute flaccid" exact="myelitis" post="associated with enterovirus D68 in a non-epidemic settingIDCases201917e0054910.1016/j.idcr.2019.e0054931193053 21.FunakoshiY.ItoK.MorinoS.KinoshitaK.MorikawaY.KonoT.DoanY.H.ShimizuH.HanaokaN.KonagayaM.et"/>
   <result pre="2019) 30.LiX.W.NiX.QianS.Y.WangQ.JiangR.M.XuW.B.ZhangY.C.YuG.J.ChenQ.ShangY.X.et al.Chinese guidelines for the diagnosis and treatment of" exact="hand, foot and mouth disease" post="(2018 edition)World J. Pediatr.20181443744710.1007/s12519-018-0189-830280313 31.CoxJ.A.HiscoxJ.A.SolomonT.OoiM.-H.NgL.F.P.Immunopathogenesis and Virus–Host Interactions of"/>
   <result pre="guidelines for the diagnosis and treatment of hand, foot and" exact="mouth disease" post="(2018 edition)World J. Pediatr.20181443744710.1007/s12519-018-0189-830280313 31.CoxJ.A.HiscoxJ.A.SolomonT.OoiM.-H.NgL.F.P.Immunopathogenesis and Virus–Host Interactions of"/>
   <result pre="quantification of enterovirus 71 genome from cerebrospinal fluid of an" exact="encephalitis" post="patient by PCR applicationsJpn. J. Infect. Dis.20086149749919050366 33.ChongP.F.KiraR.MoriH.OkumuraA.TorisuH.YasumotoS.ShimizuH.FujimotoT.HanaokaN.KusunokiS.et al.Clinical"/>
   <result pre="August-December 2015Clin. Infect. Dis.20186665366410.1093/cid/cix86029028962 34.ShahV.A.ChongC.Y.ChanK.P.NgW.LingA.E.Clinical characteristics of an outbreak of" exact="hand, foot and mouth disease" post="in SingaporeAnn. Acad. Med. Singap.20033238138712854382 35.Pons-SalortM.GrasslyN.C.Serotype-specific immunity explains the"/>
   <result pre="Dis.20186665366410.1093/cid/cix86029028962 34.ShahV.A.ChongC.Y.ChanK.P.NgW.LingA.E.Clinical characteristics of an outbreak of hand, foot and" exact="mouth disease" post="in SingaporeAnn. Acad. Med. Singap.20033238138712854382 35.Pons-SalortM.GrasslyN.C.Serotype-specific immunity explains the"/>
   <result pre="of coxsackievirus A6 infection associated with a major outbreak of" exact="hand, foot, and mouth disease" post="in JapanJpn. J. Infect. Dis.20136626026110.7883/yoken.66.26023698493 37.MartinezM.ShuklaH.NikulinJ.WadoodM.Z.HadlerS.MbaeyiC.TangermannR.JorbaJ.EhrhardtD.Progress Toward Poliomyelitis Eradication-Afghanistan,"/>
   <result pre="infection associated with a major outbreak of hand, foot, and" exact="mouth disease" post="in JapanJpn. J. Infect. Dis.20136626026110.7883/yoken.66.26023698493 37.MartinezM.ShuklaH.NikulinJ.WadoodM.Z.HadlerS.MbaeyiC.TangermannR.JorbaJ.EhrhardtD.Progress Toward Poliomyelitis Eradication-Afghanistan,"/>
   <result pre="Mortal. Wkly. Rep.20176685485810.15585/mmwr.mm6632a528817551 38.NathansonN.KewO.M.From emergence to eradication: The epidemiology of" exact="poliomyelitis" post="deconstructedAm. J. Epidemiol.20101721213122910.1093/aje/kwq32020978089 39.XingW.LiaoQ.ViboudC.ZhangJ.SunJ.WuJ.T.ChangZ.LiuF.FangV.J.ZhengY.et al.Hand, foot, and mouth disease"/>
   <result pre="epidemiology of poliomyelitis deconstructedAm. J. Epidemiol.20101721213122910.1093/aje/kwq32020978089 39.XingW.LiaoQ.ViboudC.ZhangJ.SunJ.WuJ.T.ChangZ.LiuF.FangV.J.ZhengY.et al.Hand, foot, and" exact="mouth disease" post="in China, 2008–2012: An epidemiological studyLancet Infect. Dis.20141430831810.1016/S1473-3099(13)70342-624485991 40.Casas-AlbaD.de"/>
   <result pre="An epidemiological studyLancet Infect. Dis.20141430831810.1016/S1473-3099(13)70342-624485991 40.Casas-AlbaD.de SevillaM.F.Valero-RelloA.FortunyC.Garcia-GarciaJ.J.OrtezC.MuchartJ.ArmangueT.JordanI.LuacesC.et al.Outbreak of brainstem" exact="encephalitis" post="associated with enterovirus-A71 in Catalonia, Spain (2016): A clinical"/>
   <result pre="VanT.ChanY.-F.FarrarJ.J.OishiK.et al.Epidemic dynamics, interactions and predictability of enteroviruses associated with" exact="hand, foot and mouth disease" post="in JapanJ. R. Soc. Interface2018152018050710.1098/rsif.2018.050730209044 45.RaoD.C.NaiduJ.R.MaiyaP.P.BabuA.BaillyJ.-L.Large-scale HFMD epidemics caused"/>
   <result pre="interactions and predictability of enteroviruses associated with hand, foot and" exact="mouth disease" post="in JapanJ. R. Soc. Interface2018152018050710.1098/rsif.2018.050730209044 45.RaoD.C.NaiduJ.R.MaiyaP.P.BabuA.BaillyJ.-L.Large-scale HFMD epidemics caused"/>
   <result pre="and Mouth Disease in BeijingSci. Rep.201661924710.1038/srep1924726755102 47.SecondJ.VelterC.CalèsS.TruchetetF.LipskerD.CribierB.Clinicopathologic analysis of atypical" exact="hand, foot, and mouth disease" post="in adult patientsJ. Am. Acad. Dermatol.20177672272910.1016/j.jaad.2016.10.02228027826 48.Ramirez-FortM.K.DowningC.DoanH.Q.BenoistF.ObersteM.S.KhanF.TyringS.K.Coxsackievirus A6 associated"/>
   <result pre="in BeijingSci. Rep.201661924710.1038/srep1924726755102 47.SecondJ.VelterC.CalèsS.TruchetetF.LipskerD.CribierB.Clinicopathologic analysis of atypical hand, foot, and" exact="mouth disease" post="in adult patientsJ. Am. Acad. Dermatol.20177672272910.1016/j.jaad.2016.10.02228027826 48.Ramirez-FortM.K.DowningC.DoanH.Q.BenoistF.ObersteM.S.KhanF.TyringS.K.Coxsackievirus A6 associated"/>
   <result pre="disease in adult patientsJ. Am. Acad. Dermatol.20177672272910.1016/j.jaad.2016.10.02228027826 48.Ramirez-FortM.K.DowningC.DoanH.Q.BenoistF.ObersteM.S.KhanF.TyringS.K.Coxsackievirus A6 associated" exact="hand, foot and mouth disease" post="in adults: Clinical presentation and review of the literatureJ."/>
   <result pre="patientsJ. Am. Acad. Dermatol.20177672272910.1016/j.jaad.2016.10.02228027826 48.Ramirez-FortM.K.DowningC.DoanH.Q.BenoistF.ObersteM.S.KhanF.TyringS.K.Coxsackievirus A6 associated hand, foot and" exact="mouth disease" post="in adults: Clinical presentation and review of the literatureJ."/>
   <result pre="71 encephalitis: A new vaccine on the horizon?Lancet201338197697710.1016/S0140-6736(13)60286-X23668563 54.IshimaruY.NakanoS.YamaokaK.TakamiS.Outbreaks of" exact="hand, foot, and mouth disease" post="by enterovirus 71. High incidence of complication disorders of"/>
   <result pre="new vaccine on the horizon?Lancet201338197697710.1016/S0140-6736(13)60286-X23668563 54.IshimaruY.NakanoS.YamaokaK.TakamiS.Outbreaks of hand, foot, and" exact="mouth disease" post="by enterovirus 71. High incidence of complication disorders of"/>
   <result pre="enterovirus 71 in TaiwanArch. Virol.200114658960010.1007/s00705017016411338392 57.SabanathanS.ThwaitesL.WillsB.QuiP.T.van DoornH.R.Enterovirus 71 related severe" exact="hand, foot and mouth disease" post="outbreaks in South-East Asia: Current situation and ongoing challengesJ."/>
   <result pre="TaiwanArch. Virol.200114658960010.1007/s00705017016411338392 57.SabanathanS.ThwaitesL.WillsB.QuiP.T.van DoornH.R.Enterovirus 71 related severe hand, foot and" exact="mouth disease" post="outbreaks in South-East Asia: Current situation and ongoing challengesJ."/>
   <result pre="and Mouth Disease, FinlandEmerg. Infect. Dis.2009151485148810.3201/eid1509.09043819788821 60.FujimotoT.IizukaS.EnomotoM.AbeK.YamashitaK.HanaokaN.OkabeN.YoshidaH.YasuiY.KobayashiM.et al.Hand, foot, and" exact="mouth disease" post="caused by coxsackievirus A6, Japan, 2011Emerg. Infect. Dis.20121833733910.3201/eid1802.11114722304983 61.BianL.WangY.YaoX.MaoQ.XuM.LiangZ.Coxsackievirus"/>
   <result pre="2011Emerg. Infect. Dis.20121833733910.3201/eid1802.11114722304983 61.BianL.WangY.YaoX.MaoQ.XuM.LiangZ.Coxsackievirus A6: A new emerging pathogen causing" exact="hand, foot and mouth disease" post="outbreaks worldwideExpert Rev. Anti-Infect. Ther.2015131061107110.1586/14787210.2015.105815626112307 62.YangB.LiuF.LiaoQ.WuP.ChangZ.HuangJ.LongL.LuoL.LiY.LeungG.M.et al.Epidemiology of hand,"/>
   <result pre="61.BianL.WangY.YaoX.MaoQ.XuM.LiangZ.Coxsackievirus A6: A new emerging pathogen causing hand, foot and" exact="mouth disease" post="outbreaks worldwideExpert Rev. Anti-Infect. Ther.2015131061107110.1586/14787210.2015.105815626112307 62.YangB.LiuF.LiaoQ.WuP.ChangZ.HuangJ.LongL.LuoL.LiY.LeungG.M.et al.Epidemiology of hand,"/>
   <result pre="mouth disease outbreaks worldwideExpert Rev. Anti-Infect. Ther.2015131061107110.1586/14787210.2015.105815626112307 62.YangB.LiuF.LiaoQ.WuP.ChangZ.HuangJ.LongL.LuoL.LiY.LeungG.M.et al.Epidemiology of" exact="hand, foot and mouth disease" post="in China, 2008 to 2015 prior to the introduction"/>
   <result pre="worldwideExpert Rev. Anti-Infect. Ther.2015131061107110.1586/14787210.2015.105815626112307 62.YangB.LiuF.LiaoQ.WuP.ChangZ.HuangJ.LongL.LuoL.LiY.LeungG.M.et al.Epidemiology of hand, foot and" exact="mouth disease" post="in China, 2008 to 2015 prior to the introduction"/>
   <result pre="vaccineEurosurveillance2017225010.2807/1560-7917.ES.2017.22.50.16-00824 63.MaoQ.-Y.WangY.BianL.XuM.LiangZ.EV71 vaccine, a new tool to control outbreaks of" exact="hand, foot and mouth disease" post="(HFMD)Expert Rev. Vaccines20161559960610.1586/14760584.2016.113886226732723 64.AntonaD.KossorotoffM.SchuffeneckerI.MirandA.Leruez-VilleM.BassiC.AubartM.MoulinF.Levy-BruhlD.HenquellC.et al.Severe paediatric conditions linked with"/>
   <result pre="a new tool to control outbreaks of hand, foot and" exact="mouth disease" post="(HFMD)Expert Rev. Vaccines20161559960610.1586/14760584.2016.113886226732723 64.AntonaD.KossorotoffM.SchuffeneckerI.MirandA.Leruez-VilleM.BassiC.AubartM.MoulinF.Levy-BruhlD.HenquellC.et al.Severe paediatric conditions linked with"/>
   <result pre="France, May to October 2016Eurosurveillance2016213040210.2807/1560-7917.ES.2016.21.46.30402 65.NhanL.N.T.HongN.T.T.NhuL.N.T.NguyetL.A.NyN.T.H.ThanhT.T.HanD.D.K.VanH.M.T.ThwaitesC.L.HienT.T.et al.Severe enterovirus A71 associated" exact="hand, foot and mouth disease," post="Vietnam, 2018: Preliminary report of an impending outbreakEurosurveillance201823180059010.2807/1560-7917.ES.2018.23.46.1800590 66.WangY.-F.YuC.-K.Animal"/>
   <result pre="October 2016Eurosurveillance2016213040210.2807/1560-7917.ES.2016.21.46.30402 65.NhanL.N.T.HongN.T.T.NhuL.N.T.NguyetL.A.NyN.T.H.ThanhT.T.HanD.D.K.VanH.M.T.ThwaitesC.L.HienT.T.et al.Severe enterovirus A71 associated hand, foot and" exact="mouth disease," post="Vietnam, 2018: Preliminary report of an impending outbreakEurosurveillance201823180059010.2807/1560-7917.ES.2018.23.46.1800590 66.WangY.-F.YuC.-K.Animal"/>
   <result pre="high degree of plasticitySci. Rep.201663883110.1038/srep3883127958320 69.GonzalezG.YawataN.AokiK.KitaichiN.Challenges in management of epidemic" exact="keratoconjunctivitis" post="with emerging recombinant human adenovirusesJ. Clin. Virol.20191121910.1016/j.jcv.2019.01.00430654207 70.AndrésC.PiñanaM.VilaJ.EsperalbaJ.Trejo-ZahínosJ.CodinaM.G.MartínM.C.FuentesF.RubioS.PumarolaT.et al.The"/>
   <result pre="predictors for the risk of neurological involvement in children with" exact="hand, foot, and mouth disease" post="in SarawakBMC Infect. Dis.20099310.1186/1471-2334-9-319152683 86.AswathyrajS.ArunkumarG.AlidjinouE.K.HoberD.Hand, foot and mouth disease"/>
   <result pre="risk of neurological involvement in children with hand, foot, and" exact="mouth disease" post="in SarawakBMC Infect. Dis.20099310.1186/1471-2334-9-319152683 86.AswathyrajS.ArunkumarG.AlidjinouE.K.HoberD.Hand, foot and mouth disease"/>
   <result pre="and mouth disease in SarawakBMC Infect. Dis.20099310.1186/1471-2334-9-319152683 86.AswathyrajS.ArunkumarG.AlidjinouE.K.HoberD.Hand, foot and" exact="mouth disease" post="(HFMD): Emerging epidemiology and the need for a vaccine"/>
   <result pre="need for a vaccine strategyMed Microbiol. Immunol.201620539740710.1007/s00430-016-0465-y27406374 87.ChongC.Y.ChanK.P.ShahV.A.NgW.Y.M.LauG.TeoT.E.S.LaiS.H.LingA.E.Hand, foot and" exact="mouth disease" post="in Singapore: A comparison of fatal and non-fatal casesActa"/>
   <result pre="Virol.201791e02450-1610.1128/JVI.02450-1628250116 Figure 1 Distribution of the number of hand-foot and" exact="mouth disease" post="(HFMD) cases per week in each year between July"/>
   <result pre="shown next to the branches. ijms-20-05201-t001_Table 1Table 1 HFMD and" exact="aseptic meningitis" post="(AM) cases detected per year and the causative agents."/>
   <result pre="next to the branches. ijms-20-05201-t001_Table 1Table 1 HFMD and aseptic" exact="meningitis" post="(AM) cases detected per year and the causative agents."/>
   <result pre="based on sampled cases by the NESID. + The paramyxovirus" exact="mumps" post="is also a causative agent of aseptic meningitis in"/>
   <result pre="+ The paramyxovirus mumps is also a causative agent of" exact="aseptic meningitis" post="in Japan and is included in this table for"/>
   <result pre="The paramyxovirus mumps is also a causative agent of aseptic" exact="meningitis" post="in Japan and is included in this table for"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6834551\results\search\disease\results.xml">
   <result pre="joint and muscle pain in humans. Though the fever and" exact="rash" post="resolve, joint and muscle pain can be long lasting."/>
   <result pre="Two preclinical vaccines, the live-attenuated CHIKV/IRES vaccine and the modified" exact="vaccinia virus" post="Ankara (MVA) vectored vaccine, assessed the impact of vaccine-induced"/>
   <result pre="not protect A129 mice from CHIKV (18). However, a modified" exact="vaccinia virus" post="ankara (MVA) vaccine vector that expresses E3/E2 was shown"/>
   <result pre="of C57BL/6 mice with CHIKV results in edema, arthritis, and" exact="tenosynovitis" post="in the ankle joint, as well as necrosis in"/>
   <result pre="cells may protect against Venezuelan Equine Encephalitis virus (VEEV) -induced" exact="encephalitis" post="in mice (28). In the current study, we utilized"/>
   <result pre="patients who recovered from CHIKV and patients with chronic CHIKV-induced" exact="arthritis" post="both had roughly equal frequencies of CHIKV-specific IFNγ-producing T"/>
   <result pre="(2013) 7:e2137. 10.1371/journal.pntd.000213723556021 4.CouturierEGuilleminFMuraMLéonLVirionJMLetortMJet al.. Impaired quality of life after" exact="chikungunya" post="virus infection: a 2-year follow-up study. Rheumatology. (2012) 51:1315–22."/>
   <result pre="follow-up study. Rheumatology. (2012) 51:1315–22. 10.1093/rheumatology/kes01522427407 5.PowersAMLogueCH. Changing patterns of" exact="chikungunya" post="virus: re-emergence of a zoonotic arbovirus. J Gen Virol."/>
   <result pre="arbovirus. J Gen Virol. (2007) 88:2363–77. 10.1099/vir.0.82858-017698645 6.WeaverSC. Arrival of" exact="chikungunya" post="virus in the new world: prospects for spread and"/>
   <result pre="of a recombinant human monoclonal antibody reduces the severity of" exact="chikungunya" post="virus disease in rhesus macaques. PLoS Negl Trop Dis."/>
   <result pre="Dis. (2017) 11:e0005637. 10.1371/journal.pntd.000563728628616 12.ChangLJDowdKAMendozaFHSaundersJGSitarSPlummerSHet al.. Safety and tolerability of" exact="chikungunya" post="virus-like particle vaccine in healthy adults: a phase 1"/>
   <result pre="Assessment of immunogenicity and neutralisation efficacy of viral-vectored vaccines against" exact="chikungunya" post="virus. Viruses. (2019) 11:E322. 10.3390/v1104032230987160 15.ReisingerECTschismarovRBeublerEWiedermannUFirbasCLoebermannMet al.. Immunogenicity, safety,"/>
   <result pre="10.3390/v1104032230987160 15.ReisingerECTschismarovRBeublerEWiedermannUFirbasCLoebermannMet al.. Immunogenicity, safety, and tolerability of the measles-vectored" exact="chikungunya" post="virus vaccine MV-CHIK: a double-blind, randomised, placebo-controlled and active-controlled"/>
   <result pre="PLoS Negl Trop Dis. (2019) 13:e0006919. 10.1371/journal.pntd.000691930653504 17.PlanteKWangEPartidosCDWegerJGorchakovRTsetsarkinKet al.. Novel" exact="chikungunya" post="vaccine candidate with an IRES-based attenuation and host range"/>
   <result pre="Dis. (2014) 8:e2970. 10.1371/journal.pntd.000297025058320 21.MorrisonTEOkoLMontgomerySAWhitmoreACLotsteinARGunnBMet al.. A mouse model of" exact="chikungunya" post="virus-induced musculoskeletal inflammatory disease: evidence of arthritis, tenosynovitis, myositis,"/>
   <result pre="J Immunol. (2013) 190:259–69. 10.4049/jimmunol.120217723209328 23.TeoTHChanYHLeeWWLumFMAmrunSNHerZet al.. Fingolimod treatment abrogates" exact="chikungunya" post="virus-induced arthralgia. Sci Transl Med. (2017) 9:eaal1333. 10.1126/scitranslmed.aal133328148838 24.MinerJJCookLEHongJPSmithAMRichnerJMShimakRMet"/>
   <result pre="al.. Therapy with CTLA4-Ig and an antiviral monoclonal antibody controls" exact="chikungunya" post="virus arthritis. Sci Transl Med. (2017) 9:eaah3438. 10.1126/scitranslmed.aah343828148840 25.PooYSRuddPAGardnerJWilsonJALarcherTColleMAet"/>
   <result pre="Multiple immune factors are involved in controlling acute and chronic" exact="chikungunya" post="virus infection. PLoS Negl Trop Dis. (2014) 8:e3354. 10.1371/journal.pntd.000335425474568"/>
   <result pre="28.YunNEPengBHBertkeASBorisevichVSmithJKSmithJNet al.. CD4+ T cells provide protection against acute lethal" exact="encephalitis" post="caused by Venezuelan equine encephalitis virus. Vaccine. (2009) 27:4064–73."/>
   <result pre="provide protection against acute lethal encephalitis caused by Venezuelan equine" exact="encephalitis" post="virus. Vaccine. (2009) 27:4064–73. 10.1016/j.vaccine.2009.04.01519446933 29.MatthewsDACummingsDEveleghCGrahamFLPrevecL. Development and use"/>
   <result pre="for the rescue of recombinant adenoviruses expressing high levels of" exact="rabies" post="virus glycoprotein. J Gen Virol. (1999) 80:345–53. 10.1099/0022-1317-80-2-34510073694 30.MesserleMCrnkovicIHammerschmidtWZieglerHKoszinowskiUH."/>
   <result pre="RRV Ross River virus SINV Sindbis virus VEEV Venezquelan equine" exact="encephalitis" post="virus MCMV mouse cytomegalovirus AdV Adenovirus 5 ELISA enzyme-linked"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6838024\results\search\disease\results.xml">
   <result pre="Hepatitis E virus (HEV), a water-borne pathogen that causes acute" exact="hepatitis" post="in humans, is responsible for epidemics in developing countries."/>
   <result pre="host-protein interactions protein interactions network system biology gene ontology analysis" exact="hepatitis" post="E virus viral RNA viral polymerase fig-count: table-count: equation-count:"/>
   <result pre="that is transmitted via contaminated drinking water to cause acute" exact="hepatitis" post="in humans. Although prevalence of HEV has been mainly"/>
   <result pre="et al., 2007; LaPointe et al., 2018). HNRNPK binds to" exact="hepatitis" post="C virus RNA near the miR-122 binding site to"/>
   <result pre="binds to the negative regulator of splicing elements in Rous" exact="sarcoma" post="virus to regulate the splicing and polyadenylation machinery (Fogel"/>
   <result pre="References References AderemA.AdkinsJ. N.AnsongC.GalaganJ.KaiserS. (2011). A systems biology approach to" exact="infectious disease" post="research: innovating the pathogen-host research paradigm.mBio2:e00325-310. 10.1128/mBio.00325-31021285433 AhlquistP.NoueiryA. O.LeeW."/>
   <result pre="F.BramY.HellerB.SchwartzR. E.et al. (2018). Identification of the intragenomic promoter controlling" exact="hepatitis" post="E virus subgenomic RNA transcription.mBio9:e00769-18. 10.1128/mBio.00769-1829739903 FanB.SutandyF. X. R.SyuG."/>
   <result pre="binds to the negative regulator of splicing element from Rous" exact="sarcoma" post="virus.J. Biol. Chem.27532371–32378. 10.1074/jbc.m00500020010934202 GellerR.TaguwaS.FrydmanJ. (2012). Broad action of"/>
   <result pre="Acta1823698–706. 10.1016/j.bbamcr.2011.11.00722154817 HimmelsbachK.BenderD.HildtE. (2018). Life cycle and morphogenesis of the" exact="hepatitis" post="E virus.Emerg. Microb. Infect.7:196. 10.1038/s41426-018-0198-730498191 JohnL.ThomasS.HerchenröderO.PützerB. M.SchaeferS. (2011). Hepatitis"/>
   <result pre="of stress granule, DDX3X and IKK-α mediates multiple functions in" exact="hepatitis" post="C virus infection.J. Virol.895462–5477. 10.1128/JVI.03197-1425740981 PengX.ChanE. Y.LiY.DiamondD. L.KorthM. J.KatzeM."/>
   <result pre="particle production.PLoS Pathog.11:e1004573. 10.1371/journal.ppat.100457325569684 RehmanS.KapurN.DurgapalH.PandaS. K. (2008). Subcellular localization of" exact="hepatitis" post="E virus (HEV) replicase.Virology37077–92. 10.1016/j.virol.2007.07.03617904184 ReinekeL. C.LloydR. E. (2013)."/>
   <result pre="al. (2015). Quantitative proteomics identifies host factors modulated during acute" exact="hepatitis" post="E virus infection in the swine model.J. Virol.89129–143. 10.1128/JVI.02208-1425320303"/>
   <result pre="shock protein 70 and heat shock protein 90 synergistically increase" exact="hepatitis" post="B viral capsid assembly.Biochem. Biophys. Res. Commun.5032892–2898. 10.1016/j.bbrc.2018.08.06530115382 ShannonP.MarkielA.OzierO.BaligaN."/>
   <result pre="involvement of multiple host processes in the life cycle of" exact="hepatitis" post="E virus.mSystems3:e00135-17. 10.1128/mSystems.00135-1729404423 SurjitM.JameelS.LalS. K. (2007). Cytoplasmic localization of"/>
   <result pre="SurjitM.JameelS.LalS. K. (2007). Cytoplasmic localization of the ORF2 protein of" exact="hepatitis" post="E virus is dependent on its ability to undergo"/>
   <result pre="al. (2018). Co-regulatory activity of hnRNP K and NS1-BP in" exact="influenza" post="and human mRNA splicing.Nat. Commun.9:2407. 10.1038/s41467-018-04779-429921878 vande Garde MDBPasS."/>
   <result pre="infection.Clin. Transl. Immunol.7:e1014. 10.1002/cti2.101429632667 WangY.ZhouJ.DuY. (2014). hnRNP A2/B1 interacts with" exact="influenza" post="A viral protein NS1 and inhibits virus replication potentially"/>
   <result pre="10.1101/cshperspect.a00370721441581 XuJ.WuF.TianD.WangJ.ZhengZ.XiaN. (2014). Open reading frame 3 of genotype 1" exact="hepatitis" post="E virus inhibits nuclear factor-κappa B signaling induced by"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6839921\results\search\disease\results.xml">
   <result pre="spread, and disease severity. We find that multiple alphaviruses, including" exact="chikungunya" post="(CHIKV), Ross River (RRV), and o’nyong ‘nyong (ONNV) viruses,"/>
   <result pre="leading to global outbreaks of diseases such as Zika or" exact="chikungunya" post="fever. The severity of these diseases and how easily"/>
   <result pre="as MARCO revealed that this receptor is needed to clear" exact="chikungunya" post="viral particles. When MARCO was genetically deleted this led"/>
   <result pre="During the past several decades, multiple arboviruses, including dengue (DENV)," exact="chikungunya" post="(CHIKV), and Zika (ZIKV) viruses, have re-emerged to cause"/>
   <result pre="red blood cells as well as some pathogens, such as" exact="malaria" post="parasites (Borges da Silva et al., 2015). Similar to"/>
   <result pre="more susceptible to infection with L. monocytogenes, S. aureus, S." exact="pneumonia" post="and N. meningitides, and MARCO-/- mice have enhanced sensitivity"/>
   <result pre="and MARCO-/- mice have enhanced sensitivity to infection with S." exact="pneumonia" post="(Areschoug and Gordon, 2009). However, less is known about"/>
   <result pre="during viral infections. SR-A1 has a protective role during systemic" exact="herpes simplex" post="virus type 1 (HSV-1) infection of mice (Suzuki et"/>
   <result pre="and entry into epithelial cells (MacLeod et al., 2013). Similarly," exact="vaccinia virus" post="(VacV) binding to MARCO on keratinocytes enhances infection of"/>
   <result pre="data, prior studies found that some strains of Venezuelan equine" exact="encephalitis" post="virus accumulated in the liver following i.v. inoculation of"/>
   <result pre="scavenger receptor MARCO is required for lung defense against pneumococcal" exact="pneumonia" post="and inhaled particlesThe Journal of Experimental Medicine20026727210.1084/jem.2004073115263032 AshbrookAWBurrackKSSilvaLAMontgomerySAHeiseMTMorrisonTEDermodyTS2014Residue 82"/>
   <result pre="the Chikungunya virus E2 attachment protein modulates viral dissemination and" exact="arthritis" post="in miceJournal of Virology88121801219210.1128/JVI.01672-1425142598 AzevedoCSaiardiA2016Why always lysine? the ongoing"/>
   <result pre="Diseases4746947510.1086/59000318611153 BowdishDMSakamotoKLackNAHillPCSirugoGNewportMJGordonSHillAVVannbergFO2013Genetic variants of MARCO are associated with susceptibility to" exact="pulmonary tuberculosis" post="in a gambian populationBMC Medical Genetics144710.1186/1471-2350-14-4723617307 BowdishDMGordonS2009Conserved domains of"/>
   <result pre="BowdishDMSakamotoKLackNAHillPCSirugoGNewportMJGordonSHillAVVannbergFO2013Genetic variants of MARCO are associated with susceptibility to pulmonary" exact="tuberculosis" post="in a gambian populationBMC Medical Genetics144710.1186/1471-2350-14-4723617307 BowdishDMGordonS2009Conserved domains of"/>
   <result pre="Adult Wild-Type MiceJournal of Virology848021803210.1128/JVI.02603-0920519386 GardnerCLEbelGDRymanKDKlimstraWB2011Heparan sulfate binding by natural" exact="eastern equine encephalitis" post="viruses promotes neurovirulencePNAS108160261603110.1073/pnas.111061710821896745 GérardinPFianuAMalvyDMussardCBoussaïdKRollotOMichaultAGaüzereBABréartGFavierF2011Perceived morbidity and community burden after"/>
   <result pre="MiceJournal of Virology848021803210.1128/JVI.02603-0920519386 GardnerCLEbelGDRymanKDKlimstraWB2011Heparan sulfate binding by natural eastern equine" exact="encephalitis" post="viruses promotes neurovirulencePNAS108160261603110.1073/pnas.111061710821896745 GérardinPFianuAMalvyDMussardCBoussaïdKRollotOMichaultAGaüzereBABréartGFavierF2011Perceived morbidity and community burden after"/>
   <result pre="and macrophagesNature Reviews Immunology149410810.1038/nri358224445665 HawmanDWStoermerKAMontgomerySAPalPOkoLDiamondMSMorrisonTE2013Chronic joint disease caused by persistent" exact="chikungunya" post="virus infection is controlled by the adaptive immune responseJournal"/>
   <result pre="in human infantsEBioMedicine11738410.1016/j.ebiom.2016.08.01127554839 JahrlingPBGorelkinL1975Selective clearance of a benign clone of" exact="venezuelan equine encephalitis" post="virus from hamster plasma by hepatic reticuloendothelial cellsJournal of"/>
   <result pre="infantsEBioMedicine11738410.1016/j.ebiom.2016.08.01127554839 JahrlingPBGorelkinL1975Selective clearance of a benign clone of venezuelan equine" exact="encephalitis" post="virus from hamster plasma by hepatic reticuloendothelial cellsJournal of"/>
   <result pre="Immunology14996100610.1038/ni.269124048121 JonesJELongKMWhitmoreACSandersWThurlowLRBrownJAMorrisonCRVincentHPeckKMBrowningCMoormanNLimJKHeiseMT2017Disruption of the opal stop Codon attenuates Chikungunya Virus-Induced" exact="arthritis" post="and pathologymBio811610.1128/mBio.01456-17 JupilleHJOkoLStoermerKAHeiseMTMahalingamSGunnBMMorrisonTE2011Mutations in nsP1 and PE2 are critical"/>
   <result pre="genetic characterization of the virusVirology25225826810.1006/viro.1998.94379875334 LanciottiRSValadereAM2014Transcontinental movement of asian genotype" exact="chikungunya" post="virusEmerging Infectious Diseases201400140210.3201/eid2008.14026825076384 LaoWKangHJinGChenLChuYSunJSunB2017Evaluation of the relationship between MARCO"/>
   <result pre="relationship between MARCO and CD36 single-nucleotide polymorphisms and susceptibility to" exact="pulmonary tuberculosis" post="in a chinese han populationBMC Infectious Diseases1748810.1186/s12879-017-2595-228693442 LeeWYMoriartyTJWongCHZhouHStrieterRMvan RooijenNChaconasGKubesP2010An"/>
   <result pre="between MARCO and CD36 single-nucleotide polymorphisms and susceptibility to pulmonary" exact="tuberculosis" post="in a chinese han populationBMC Infectious Diseases1748810.1186/s12879-017-2595-228693442 LeeWYMoriartyTJWongCHZhouHStrieterRMvan RooijenNChaconasGKubesP2010An"/>
   <result pre="MaMJWangHBLiHYangJHYanYXieLPQiYCLiJLChenMJLiuWCaoWC2011Genetic variants in MARCO are associated with the susceptibility to" exact="pulmonary tuberculosis" post="in chinese han populationPLOS One6e2406910.1371/journal.pone.002406921886847 MacLeodDTNakatsujiTYamasakiKKobzikLGalloRL2013HSV-1 exploits the innate"/>
   <result pre="variants in MARCO are associated with the susceptibility to pulmonary" exact="tuberculosis" post="in chinese han populationPLOS One6e2406910.1371/journal.pone.002406921886847 MacLeodDTNakatsujiTYamasakiKKobzikLGalloRL2013HSV-1 exploits the innate"/>
   <result pre="spread in the americasNature54641141510.1038/nature2240228538734 MetzSWGeertsemaCMartinaBEAndradePHeldensJGvan OersMMGoldbachRWVlakJMPijlmanGP2011Functional processing and secretion of" exact="chikungunya" post="virus E1 and E2 glycoproteins in insect cellsVirology Journal835310.1186/1743-422X-8-35321762510"/>
   <result pre="tropism and virus-induced inflammation in a mouse model of viral" exact="arthritis" post="and myositisJournal of Virology8073774910.1128/JVI.80.2.737-749.200616378976 MorrisonTEOkoLMontgomerySAWhitmoreACLotsteinARGunnBMElmoreSAHeiseMT2011A mouse model of chikungunya"/>
   <result pre="viral arthritis and myositisJournal of Virology8073774910.1128/JVI.80.2.737-749.200616378976 MorrisonTEOkoLMontgomerySAWhitmoreACLotsteinARGunnBMElmoreSAHeiseMT2011A mouse model of" exact="chikungunya" post="Virus–Induced Musculoskeletal Inflammatory DiseaseAJPA178324010.1016/j.ajpath.2010.11.018 MorrisonTE2014Reemergence of Chikungunya virusJournal of"/>
   <result pre="zone macrophages and marginal zone metallophils in the clearance of" exact="lymphocytic choriomeningitis" post="virus infectionEuropean Journal of Immunology272626263310.1002/eji.18302710239368619 SilvaLAKhomandiakSAshbrookAWWellerRHeiseMTMorrisonTEDermodyTS2014A single-amino-acid polymorphism in"/>
   <result pre="overviewNature Reviews Rheumatology842042910.1038/nrrheum.2012.6422565316 SuzukiHKuriharaYTakeyaMKamadaNKataokaMJishageKUedaOSakaguchiHHigashiTSuzukiTTakashimaYKawabeYCynshiOWadaYHondaMKuriharaHAburataniHDoiTMatsumotoAAzumaSNodaTToyodaYItakuraHYazakiYKodamaT1997A role for macrophage scavenger receptors in" exact="atherosclerosis" post="and susceptibility to infectionNature38629229610.1038/386292a09069289 collab: Tabula Muris Consortiumcollab: Overall"/>
   <result pre="South-West indian oceanPLOS Neglected Tropical Diseases7e200410.1371/journal.pntd.000200423350006 TsetsarkinKHiggsSMcGeeCEDe LamballerieXCharrelRNVanlandinghamDL2006Infectious clones of" exact="chikungunya" post="virus (La réunion isolate) for vector competence studiesVector-Borne and"/>
   <result pre="Medicine and Hygiene7261662110.4269/ajtmh.2005.72.61615891138 VanlandinghamDLTsetsarkinKHongCKlinglerKMcElroyKLLehaneMJHiggsS2005bDevelopment and characterization of a double subgenomic" exact="chikungunya" post="virus infectious clone to express heterologous genes in aedes"/>
   <result pre="epidemics and various evolutionary ratesJournal of Virology846497650410.1128/JVI.01603-0920410280 VossJEVaneyMCDuquerroySVonrheinCGirard-BlancCCrubletEThompsonABricogneGReyFA2010Glycoprotein organization of" exact="chikungunya" post="virus particles revealed by X-ray crystallographyNature46870971210.1038/nature0955521124458 WaggonerJJGreshLVargasMJBallesterosGTellezYSodaKJSahooMKNuñezABalmasedaAHarrisEPinskyBA2016Viremia and clinical"/>
   <result pre="WesthausSDeestMNguyenATXStankeFHecklDCostaRSchambachAMannsMPBergTVondranFWRSarrazinCCiesekSvon HahnT2017Scavenger receptor class B member 1 (SCARB1) variants modulate" exact="hepatitis" post="C virus replication cycle and viral loadJournal of Hepatology6723724510.1016/j.jhep.2017.03.02028363797"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6841724\results\search\disease\results.xml">
   <result pre="with mild clinical manifestations; however, increased numbers of cases of" exact="microcephaly" post="and birth defects have been recently reported. To date,"/>
   <result pre="mild clinical manifestations such as fever, macular or papular rash," exact="arthritis" post="and arthralgia, nonpurulent conjunctivitis, myalgia, headache, edema, orbital pain"/>
   <result pre="observed7–9. Strong evidence suggests a link between ZIKV infection and" exact="microcephaly" post="once the viral genome has been detected in the"/>
   <result pre="metabolites13. Flavonoids are known to have antiviral activity against HIV-1," exact="herpes simplex" post="1 and 2, influenza, dengue and yellow fever14–18. Additionally,"/>
   <result pre="of flavonoids has been tested against numerous viruses such as" exact="herpes simplex" post="viruses, hepatitis B and human cytomegalovirus14,53,54. Additionally, the flavanone"/>
   <result pre="been tested against numerous viruses such as herpes simplex viruses," exact="hepatitis" post="B and human cytomegalovirus14,53,54. Additionally, the flavanone NAR presents"/>
   <result pre="viruses from the Flaviviridae family such as HCV, dengue and" exact="yellow fever" post="virus strain 17D17,18,55. It appears that some flavonoids are"/>
   <result pre="Furthermore, some treatments available for flaviviruses, like IFN-α 2A for" exact="hepatitis" post="C present several adverse effects, such as pain and"/>
   <result pre="binding, as shown for the flavonol called kaempferol against Japanese" exact="encephalitis" post="virus49. Furthermore, flavonoids seems to impair the activity of"/>
   <result pre="sequencing of Zika virus from amniotic fluid of fetuses with" exact="microcephaly" post="in Brazil: A case studyLancet Infect. Dis.201616665366010.1016/S1473-3099(16)00095-526897108 10.MS, 2018a"/>
   <result pre="Ministério da Saúde. Monitoramento dos casos de dengue, febre de" exact="chikungunya" post="e febre pelo vírus Zika até a Semana Epidemiológica"/>
   <result pre="of high pharmacological potencyBiochem. Pharmacol.19833271141114810.1016/0006-2952(83)90262-96342623 14.LyuS-YRhimJ-YParkWBAntiherpetic activities of flavonoids against" exact="herpes simplex" post="virus type 1 (HSV-1) and type 2 (HSV-2) in"/>
   <result pre="Res.2005281293130110.1007/BF0297821516350858 15.GrienkeUet al.Discovery of prenylated flavonoids with dual activity against" exact="influenza" post="virus and Streptococcus pneumoniaeSci. Rep.201662715610.1038/srep2715627257160 16.PasettoSPardiVMirataRMAnti-HIV-1 activity of flavonoid"/>
   <result pre="glycosides forms on the replication of the 17D strain of" exact="yellow fever" post="virusAv. Biomed.2014426978 18.FrabasileSet al.The citrus flavanone naringenin impairs dengue"/>
   <result pre="activity relationshipBiotechnol. Lett.20173941542110.1007/s10529-016-2261-627885509 29.DongWet al.A dual character of flavonoids in" exact="influenza" post="A virus replication and spread through modulating cell-autonomous immunity"/>
   <result pre="of chitosan nanoparticles containing naringenin and their cytotoxicity effects in" exact="lung cancer" post="cellsInt. J. Biol. Macromol.201578879510.1016/j.ijbiomac.2015.03.04525840152 51.BreinholtVMSvendsenGWDragstedLOHossainiAThe Citrus-derived Flavonoid Naringenin Exerts"/>
   <result pre="chitosan nanoparticles containing naringenin and their cytotoxicity effects in lung" exact="cancer" post="cellsInt. J. Biol. Macromol.201578879510.1016/j.ijbiomac.2015.03.04525840152 51.BreinholtVMSvendsenGWDragstedLOHossainiAThe Citrus-derived Flavonoid Naringenin Exerts"/>
   <result pre="55.GoldwasserJet al.Naringenin inhibits the assembly and long-term production of infectious" exact="hepatitis" post="C virus particles through a PPAR-mediated mechanismJ. Hepatol.20115596397110.1016/j.jhep.2011.02.01121354229 56.GoebelSet"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6842947\results\search\disease\results.xml">
   <result pre="Abstract Innate immunity is critical in the early containment of" exact="influenza" post="A virus (IAV) infection and surfactant protein D (SP-D)"/>
   <result pre="recovery from respiratory (pandemic) IAV infections in humans. antiviral agent" exact="influenza" post="A virus innate immunity surfactant protein D collectin pandemics"/>
   <result pre="table-count: equation-count: ref-count: page-count: word-count: Introduction Influenza is an infectious" exact="respiratory disease," post="caused by influenza A viruses (IAVs), that affects a"/>
   <result pre="word-count: Introduction Influenza is an infectious respiratory disease, caused by" exact="influenza" post="A viruses (IAVs), that affects a wide range of"/>
   <result pre="650.000 deaths (1). Moreover, novel IAVs have potential to cause" exact="influenza" post="pandemics like the most recent outbreak in 2009 that"/>
   <result pre="drugs as a novel therapeutic or prophylactic approach to fight" exact="influenza" post="in humans more effectively. Furthermore, recombinant approaches provide a"/>
   <result pre="ng/ml). Table 2 Hemagglutination inhibition of IAV by SP-Ds. H1N1" exact="influenza" post="A viruses SP-D preparation H3N2 influenza A viruses SP-D"/>
   <result pre="IAV by SP-Ds. H1N1 influenza A viruses SP-D preparation H3N2" exact="influenza" post="A viruses SP-D preparation pSP-D hSP-D iSP-D pSP-D hSP-D"/>
   <result pre="(4) A/USSR/90/77 4 (4) 3 (1) 3 (4) Avian H5N1" exact="influenza" post="A viruses (n=1) A/mallard/Netherlands/15/05 146 (95) &amp;gt;1,000 (0) 208*"/>
   <result pre="in vivo was assessed by using a mouse model for" exact="influenza" post="and to demonstrate the protective potential against a human-derived"/>
   <result pre="hematoxylin-stained tissue sections and immunohistochemically stained sections for detection of" exact="influenza" post="viral nucleoprotein from mice infected with a clinical isolate"/>
   <result pre="different batches of iSP-D were equally effective in protecting from" exact="influenza" post="disease symptoms and virus growth in the lungs. In"/>
   <result pre="viral antigens. Results indicated that H1N1pdm09 infection in mice induced" exact="bronchiolitis" post="but also alveolitis, with virus-staining in epithelial cells lining"/>
   <result pre="(H1N1) Virus Investigation TeamDawoodFSJainSFinelliLShawMWLindstromSet al.. Emergence of a novel swine-origin" exact="influenza" post="A (H1N1) virus in humans. N Engl J Med."/>
   <result pre="(2009) 360:2605–15. 10.1056/NEJMoa090381019423869 4.TripathiSWhiteMRHartshornKL. The amazing innate immune response to" exact="influenza" post="A virus infection. Innate Immun. (2015) 21:73–98. 10.1177/175342591350899224217220 5.PitzerVEAguasRRileySLoeffenWLAWoodJLNGrenfellBT."/>
   <result pre="(2015) 21:73–98. 10.1177/175342591350899224217220 5.PitzerVEAguasRRileySLoeffenWLAWoodJLNGrenfellBT. High turnover drives prolonged persistence of" exact="influenza" post="in managed pig herds. J R Soc Interface. (2016)"/>
   <result pre="recombinant human pulmonary surfactant protein D and SP-D multimers with" exact="influenza" post="A. Am J Physiol. (1996) 271:L753–62. 10.1152/ajplung.1996.271.5.L7538944718 9.HartshornKLWhiteMRVoelkerDRCoburnJZanerKCrouchEC. Mechanism"/>
   <result pre="10.1152/ajplung.1996.271.5.L7538944718 9.HartshornKLWhiteMRVoelkerDRCoburnJZanerKCrouchEC. Mechanism of binding of surfactant protein D to" exact="influenza" post="A viruses: importance of binding to haemagglutinin to antiviral"/>
   <result pre="EijkMWhiteMRCrouchECBatenburgJJVaandragerABvan GoldeLMGet al.. Porcine pulmonary collectins show distinct interactions with" exact="influenza" post="A viruses; role of the N-linked oligosaccharides in the"/>
   <result pre="D informed by evolution and x-ray crystallography enhances defenses against" exact="influenza" post="A virus in vivo. J Biol Chem. (2011) 286:40681–92."/>
   <result pre="Loss of a single N-linked glycan from the hemagglutinin of" exact="influenza" post="virus is associated with resistance to collectins and increased"/>
   <result pre="Chem. (1996) 271:13724–30. 10.1074/jbc.271.23.137248662732 15.QiLKashJCDuganVGJaggerBWLauYFShengZMet al.. The ability of pandemic" exact="influenza" post="virus hemagglutinins to induce lower respiratory pathology is associated"/>
   <result pre="of the antiviral properties of recombinant porcine SP-D against various" exact="influenza" post="A viruses in vitro. PLoS ONE. (2011) 6:e25005. 10.1371/journal.pone.002500521935489"/>
   <result pre="of the antiviral properties of recombinant surfactant protein D against" exact="influenza" post="B virus in vitro. Virus Res. (2015) 195:43–6. 10.1016/j.virusres.2014.08.01925200748"/>
   <result pre="Biol. (2002) 26:739–47. 10.1165/ajrcmb.26.6.452012034574 20.van EijkMWhiteMRBatenburgJJVaandragerABvan GoldeLMHaagsmanHPet al.. Interactions of" exact="influenza" post="A virus with sialic acids present on porcine surfactant"/>
   <result pre="lectin domain of surfactant protein D: impact on interactions with" exact="influenza" post="A viruses. J Biol Chem. (2011) 286:20137–51. 10.1074/jbc.M111.22446921489996 22.van"/>
   <result pre="EijkM. Pulmonary surfactant protein D in first-line innate defence against" exact="influenza" post="A virus infections. J Innate Immun. (2013) 5:197–208. 10.1159/00034637423391661"/>
   <result pre="binding and sialoglycans of porcine surfactant protein D synergistically neutralize" exact="influenza" post="A virus. J Biol Chem. (2018) 293:10646–62. 10.1074/jbc.RA117.00143029769321 28.DurocherYPerretSKamenA."/>
   <result pre="titration of infectious virus and immunofluorescence as methods for monitoring" exact="influenza" post="virus replication in vitro. J Virol Methods. (1998) 74:57–66."/>
   <result pre="Virol Methods. (1998) 74:57–66. 10.1016/S0166-0934(98)00071-89763129 31.KeawcharoenJSpronkenMIJVuongOBestebroerTMMunsterVJOsterhausADMEet al.. Repository of Eurasian" exact="influenza" post="A virus hemagglutinin and neuraminidase reverse genetics vectors and"/>
   <result pre="(2010) 28:5803–9. 10.1016/j.vaccine.2010.06.07220600474 32.HartshornKLSastryKBrownDWhiteMROkarmaTBLeeYMTauberAI. Conglutinin acts as an opsonin for" exact="influenza" post="A viruses. J Immunol. (1993) 151:6265–73. 8245465 33.de WitESiegersJYCroninJMWeathermanSvan"/>
   <result pre="(1993) 151:6265–73. 8245465 33.de WitESiegersJYCroninJMWeathermanSvan den BrandJMLeijtenLMet al.. 1918 H1N1" exact="influenza" post="virus replicates and induces proinflammatory cytokine responses in extrarespiratory"/>
   <result pre="site of surfactant protein D confer antiviral activity for pandemic" exact="influenza" post="A viruses. Am J Physiol. (2014) 306:L1036–44. 10.1152/ajplung.00035.201424705721 35.CrouchETuYBrinerDMcDonaldBSmithKHolmskovUet"/>
   <result pre="of a mutant trimeric collectin that shows enhanced interactions with" exact="influenza" post="A virus. J Biol Chem. (2005) 280:17046–56. 10.1074/jbc.M41393220015711012 36.CrouchECSmithKMcDonaldBBrinerDLindersBMcDonaldJet"/>
   <result pre="J Biol Chem. (1995) 270:14725–32. 10.1074/jbc.270.24.147257782337 38.JobERDengYMTateMDBottazziBCrouchECDeanMMet al.. Pandemic H1N1" exact="influenza" post="A viruses are resistant to the antiviral activities of"/>
   <result pre="action of surfactant protein D in innate host defense against" exact="influenza" post="A virus. Front Immunol. (2018) 9:1368. 10.3389/fimmu.2018.0136829951070 40.Atochina-VassermanENBeersMFGowAJ. Chemical"/>
   <result pre="(1997) 273:L1156–66. 10.1152/ajplung.1997.273.6.L11569435570 42.LeVineAMWhitsettJAHartshornKLCrouchECKorfhagenTR. Surfactant protein D enhances clearance of" exact="influenza" post="A virus from the lung in vivo. J Immunol."/>
   <result pre="Immunol. (2001) 167:5868–73. 10.4049/jimmunol.167.10.586811698462 43.HawgoodSBrownCEdmondsonJStumbaughAAllenLGoerkeJet al.. Pulmonary collectins modulate strain-specific" exact="influenza" post="a virus infection and host responses. J Virol. (2004)"/>
   <result pre="10.1074/jbc.M20163220011956209 46.TateMDJobERDengY-MGunalanVMaurer-StrohSReadingPC. Playing hide and seek: how glycosylation of the" exact="influenza" post="virus hemagglutinin can modulate the immune response to infection."/>
   <result pre="10.3390/v603129424638204 47.GillJRShengZ-MElySFGuineeDGBeasleyMBSuhJet al.. Pulmonary pathologic findings of fatal 2009 pandemic" exact="influenza" post="A/H1N1 viral infections. Arch Pathol Lab Med. (2010) 134:235–43."/>
   <result pre="Pathol Lab Med. (2010) 134:235–43. 10.1043/1543-2165-134.2.23520121613 48.KuikenTTaubenbergerJK. Pathology of human" exact="influenza" post="revisited. Vaccine. (2008) 26(Suppl. 4):D59–66. 10.1016/j.vaccine.2008.07.02519230162 Abbreviations 326GSS pSP-D-specific"/>
   <result pre="HAI hemagglutination inhibition HAU hemagglutinating units hSP-D human SP-D IAV" exact="influenza" post="A virus iSP-D improved SP-D MDCK Madin-Darby canine kidney"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6843141\results\search\disease\results.xml">
   <result pre="(http://creativecommons.org/licenses/by/4.0/). Abstract Poultry farmers face a dual risk when mutant" exact="avian influenza" post="(AI) virus exhibits zoonotic characteristics. A/H5N1 and A/H7N9 are"/>
   <result pre="Abstract Poultry farmers face a dual risk when mutant avian" exact="influenza" post="(AI) virus exhibits zoonotic characteristics. A/H5N1 and A/H7N9 are"/>
   <result pre="be effective in improving implementation of BPBs and PPBs. Avian" exact="influenza" post="coping behavior Chinese poultry farmer comparative analysis risk perception"/>
   <result pre="Chinese poultry farmer comparative analysis risk perception 1. Introduction Avian" exact="influenza" post="(AI) has captured the attention of the public in"/>
   <result pre="China since 2004 [2]. However, only after China changed its" exact="infectious disease" post="policy in 2013 [21] was information on human infection"/>
   <result pre="that live poultry markets (LPMs) were the predominant source of" exact="influenza" post="A/H7N9 exposure in China, and that the closing of"/>
   <result pre="Animal Industry Yearbook 2017China Agriculture Press PublishingBeijing, China2017203204 5.YangP.MaC.CuiS.ZhangD.ShiW.PanY.SunY.LuG.PengX.ZhaoJ.et al.Avian" exact="influenza" post="A(H7N9) and (H5N1) infections among poultry and swine workers"/>
   <result pre="2013–2015Sci. Rep.201663387710.1038/srep3387727670286 6.Van KerkhoveM.D.Brief literature review for the WHO global" exact="influenza" post="research agenda—highly pathogenic avian influenza H5N1 risk in humansInfluenza"/>
   <result pre="literature review for the WHO global influenza research agenda—highly pathogenic" exact="avian influenza" post="H5N1 risk in humansInfluenza Other Respir. Viruses20137Suppl. 2263310.1111/irv.1207724034480 7.LiQ.ZhouL.ZhouM.ChenZ.LiF.WuH.XiangN.ChenE.TangF.WangD.et"/>
   <result pre="review for the WHO global influenza research agenda—highly pathogenic avian" exact="influenza" post="H5N1 risk in humansInfluenza Other Respir. Viruses20137Suppl. 2263310.1111/irv.1207724034480 7.LiQ.ZhouL.ZhouM.ChenZ.LiF.WuH.XiangN.ChenE.TangF.WangD.et"/>
   <result pre="Other Respir. Viruses20137Suppl. 2263310.1111/irv.1207724034480 7.LiQ.ZhouL.ZhouM.ChenZ.LiF.WuH.XiangN.ChenE.TangF.WangD.et al.Epidemiology of human infections with" exact="avian influenza" post="A(H7N9) virus in ChinaN. Engl. J. Med.201437052053210.1056/NEJMoa130461723614499 8.HuangZ.ZengD.WangJ.Factors affecting"/>
   <result pre="Respir. Viruses20137Suppl. 2263310.1111/irv.1207724034480 7.LiQ.ZhouL.ZhouM.ChenZ.LiF.WuH.XiangN.ChenE.TangF.WangD.et al.Epidemiology of human infections with avian" exact="influenza" post="A(H7N9) virus in ChinaN. Engl. J. Med.201437052053210.1056/NEJMoa130461723614499 8.HuangZ.ZengD.WangJ.Factors affecting"/>
   <result pre="Chinese Poultry FarmersAvian Dis.20166048048610.1637/11361-010116-Reg27309291 11.NeupaneD.KhanalV.GhimireK.AroA.R.LeppinA.Knowledge, attitudes and practices related to" exact="avian influenza" post="among poultry workers in Nepal: A cross sectional studyBMC"/>
   <result pre="Poultry FarmersAvian Dis.20166048048610.1637/11361-010116-Reg27309291 11.NeupaneD.KhanalV.GhimireK.AroA.R.LeppinA.Knowledge, attitudes and practices related to avian" exact="influenza" post="among poultry workers in Nepal: A cross sectional studyBMC"/>
   <result pre="sectional studyBMC Infect. Dis.2012127610.1186/1471-2334-12-7622458535 12.MaX.LiaoQ.YuanJ.LiuY.LiuY.ChenJ.LiuJ.CaiW.CowlingB.J.DiB.Knowledge, attitudes and practices relating to" exact="influenza" post="A(H7N9) risk among live poultry traders in Guangzhou City,"/>
   <result pre="live poultry traders in Guangzhou City, ChinaBMC Infect. Dis.20141411210.1186/s12879-014-0554-824380631 13.CuiB.LiaoQ.Y.LamW.W.T.LiuZ.P.FieldingR.Avian" exact="influenza" post="A/H7N9 risk perception, information trust and adoption of protective"/>
   <result pre="in Mainland ChinaInt. J. Environ. Res. Public Health2015125026504510.3390/ijerph12050502626006118 16.KuchipudiS.V.TellabatiM.SebastianS.LondtB.Z.JansenC.VerveldeL.BrookesS.M.BrownI.H.DunhamS.P.ChangK.C.Highly pathogenic" exact="avian influenza" post="virus infection in chickens but not ducks is associated"/>
   <result pre="Mainland ChinaInt. J. Environ. Res. Public Health2015125026504510.3390/ijerph12050502626006118 16.KuchipudiS.V.TellabatiM.SebastianS.LondtB.Z.JansenC.VerveldeL.BrookesS.M.BrownI.H.DunhamS.P.ChangK.C.Highly pathogenic avian" exact="influenza" post="virus infection in chickens but not ducks is associated"/>
   <result pre="Res.2012824010.1186/1746-6148-8-24023216706 19.MetrasR.StevensK.B.AbduP.OkikeI.RandolphT.GraceD.PfeifferD.U.CostardS.Identification of potential risk factors associated with highly pathogenic" exact="avian influenza" post="subtype H5N1 outbreak occurrence in Lagos and Kano States,"/>
   <result pre="19.MetrasR.StevensK.B.AbduP.OkikeI.RandolphT.GraceD.PfeifferD.U.CostardS.Identification of potential risk factors associated with highly pathogenic avian" exact="influenza" post="subtype H5N1 outbreak occurrence in Lagos and Kano States,"/>
   <result pre="Disease ControlAnn. Glob. Health20168218018810.1016/j.aogh.2016.01.02427325075 22.VongS.O’LearyM.FengZ.Early response to the emergence of" exact="influenza" post="A(H7N9) virus in humans in China: The central role"/>
   <result pre="Organ.20149230330810.2471/BLT.13.12598924700999 23.LiR.XieR.YangC.FrostM.Perceptions on the risk communication strategy during the 2013" exact="avian influenza" post="A/H7N9 outbreak in humans in China: A focus group"/>
   <result pre="23.LiR.XieR.YangC.FrostM.Perceptions on the risk communication strategy during the 2013 avian" exact="influenza" post="A/H7N9 outbreak in humans in China: A focus group"/>
   <result pre="studyWestern Pac. Surveill. Response20167212810.5365/wpsar.2016.7.1.005 24.ChenY.LiangW.YangS.WuN.GaoH.ShengJ.YaoH.WoJ.FangQ.CuiD.et al.Human infections with the emerging" exact="avian influenza" post="A H7N9 virus from wet market poultry: Clinical analysis"/>
   <result pre="Pac. Surveill. Response20167212810.5365/wpsar.2016.7.1.005 24.ChenY.LiangW.YangS.WuN.GaoH.ShengJ.YaoH.WoJ.FangQ.CuiD.et al.Human infections with the emerging avian" exact="influenza" post="A H7N9 virus from wet market poultry: Clinical analysis"/>
   <result pre="the risk of exposure to contaminated environmentsBiosci. Trends2013716817110.5582/bst.2013.v7.4.16824056166 26.LeeS.S.WongN.S.LeungC.C.Exposure to" exact="avian influenza" post="H7N9 in farms and wet marketsLancet2013381181510.1016/S0140-6736(13)60949-6 27.YuH.WuJ.T.CowlingB.J.LiaoQ.FangV.J.ZhouS.WuP.ZhouH.LauE.H.Y.GuoD.et al.Effect of"/>
   <result pre="risk of exposure to contaminated environmentsBiosci. Trends2013716817110.5582/bst.2013.v7.4.16824056166 26.LeeS.S.WongN.S.LeungC.C.Exposure to avian" exact="influenza" post="H7N9 in farms and wet marketsLancet2013381181510.1016/S0140-6736(13)60949-6 27.YuH.WuJ.T.CowlingB.J.LiaoQ.FangV.J.ZhouS.WuP.ZhouH.LauE.H.Y.GuoD.et al.Effect of"/>
   <result pre="of closure of live poultry markets on poultry-to-person transmission of" exact="avian influenza" post="A H7N9 virus: An ecological studyLancet201438354154810.1016/S0140-6736(13)61904-224183056 28.CuiB.LiuZ.P.Factors Associated with"/>
   <result pre="closure of live poultry markets on poultry-to-person transmission of avian" exact="influenza" post="A H7N9 virus: An ecological studyLancet201438354154810.1016/S0140-6736(13)61904-224183056 28.CuiB.LiuZ.P.Factors Associated with"/>
   <result pre="Percentage of respondents reporting adoption of biosecurity preventive behaviors against" exact="avian influenza" post="(AI). Figure 4 Percentage of respondents reporting adoption of"/>
   <result pre="of respondents reporting adoption of biosecurity preventive behaviors against avian" exact="influenza" post="(AI). Figure 4 Percentage of respondents reporting adoption of"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6844409\results\search\disease\results.xml">
   <result pre="focused specifically on the intersection between the scientific efforts in" exact="hepatitis" post="B virus (HBV) and HIV-1 cure research and sought"/>
   <result pre="tissue samples required for the study of persistent virus HBV:" exact="hepatitis" post="B virus; cccDNA: covalently closed circular DNA. The keynote"/>
   <result pre="hepatic fibrosis and inflammation; •Decreased but not eliminated risk of" exact="hepatocellular carcinoma;" post="and •High cost and adverse effects of prolonged therapy."/>
   <result pre="clones (&amp;gt;10%), HIV-1 ISs were found to be enriched in" exact="cancer" post="genes, a result also consistent with the expansion resulting"/>
   <result pre="HBV DNA Viral genome in virus Active viral replication HBV:" exact="hepatitis" post="B virus. The loss of HBsAg is currently the"/>
   <result pre="advancing CAR-T cell therapy, which has rapidly gained popularity in" exact="cancer" post="[32] and antiviral therapy [33]. Indeed, lentivector-transduced T cells"/>
   <result pre="pre-screening for viral sensitivity [48] showed a more prolonged viral" exact="suppression" post="(median of 21 weeks) after ART interruption in antibody-sensitive"/>
   <result pre="Antibody-resistant viruses did not emerge and two individuals showed viral" exact="suppression" post="long after both bNAbs had been cleared (&amp;gt;30 months)."/>
   <result pre="same two bNAbs during acute HIV-1 infection resulted in sustained" exact="suppression" post="of viremia in a subset of animals. The effect"/>
   <result pre="viral load set-point. 5.1.4  Restoring or replacing adaptive immunity in" exact="hepatitis" post="B Turning the focus to HBV, Dr Mala Maini"/>
   <result pre="how an immunotherapeutic approach towards a functional cure for chronic" exact="hepatitis" post="B (CHB) should and could be tackled. Dr Maini"/>
   <result pre="of regulatory B cells mediates anti-HBV CD8 T cell response" exact="suppression" post="through IL-10 secretion [59]. Also, although HBsAg-specific B cells"/>
   <result pre="by T cell recognition. The platform has been developed for" exact="cancer" post="immunotherapy [66,67] and has multiple infectious disease applications in"/>
   <result pre="has been developed for cancer immunotherapy [66,67] and has multiple" exact="infectious disease" post="applications in development. Promising proof of concept from the"/>
   <result pre="on FX1, an inhibitor of the transcription factor B cell" exact="lymphoma" post="6 (BCL6) [70], Dr Yanhui Cai (Wistar Institute, Philadelphia,"/>
   <result pre="initiation. This compound is a sphingosine-1-phosphate receptor modulator used in" exact="multiple sclerosis" post="[73,74] that promotes the retention of several types of"/>
   <result pre="nonfunctional in mice and rats, but testing in the woodchuck" exact="hepatitis" post="model achieved lower levels of HBV surface antigen associated"/>
   <result pre="results from a dose escalation cohort in individuals with advanced" exact="hepatocellular carcinoma" post="offer some insight [80]. Overall, these results showed that"/>
   <result pre="5. Common community misconceptions about an HIV cure: •Complete viral" exact="suppression" post="is a cure and people may stop taking their"/>
   <result pre="is being developed. Relationships with potential clinical consequences such as" exact="hepatocellular carcinoma" post="in HBV carriers need to be taken into consideration."/>
   <result pre="Healthcare, the French National Agency for Research on AIDS and" exact="viral hepatitis" post="(ANRS), MSD and the Mexican Social Security Institute (IMSS)."/>
   <result pre="the French National Agency for Research on AIDS and viral" exact="hepatitis" post="(ANRS), MSD and the Mexican Social Security Institute (IMSS)."/>
   <result pre="formation of the covalently closed circular DNA persistence reservoir of" exact="hepatitis" post="B viruses. Proc Natl Acad Sci USA2014; 111(40): E4244–"/>
   <result pre="389.26983541 3.LuciforaJ, XiaY, ReisingerFet al.Specific and nonhepatotoxic degradation of nuclear" exact="hepatitis" post="B virus cccDNA. Science2014; 343(6176): 1221– 1228.24557838 4.UrbanS, BartenschlagerR,"/>
   <result pre="822.29045846 22.RevillPA, ChisariFV, BlockJMet al.A global scientific strategy to cure" exact="hepatitis" post="B. Lancet Gastroenterol Hepatol2019; 4(7): 545– 558.30981686 23.HuJ, ChengJ,"/>
   <result pre="23.HuJ, ChengJ, TangLet al.Virological basis for the cure of chronic" exact="hepatitis" post="B. ACS Infect Dis2019; 5(5): 659– 674.29893548 24.CoffinCS, ZhouK"/>
   <result pre="TerraultNA.New and old biomarkers for diagnosis and management of chronic" exact="hepatitis" post="B virus infection. Gastroenterology2019; 156(2): 355– 368. e353.30472225 25.BlockTM,"/>
   <result pre="of current and new endpoints in the evaluation of experimental" exact="hepatitis" post="B therapeutics. Clin Infect Dis2017; 64(9): 1283– 1288.28200098 26.RiddellJ,"/>
   <result pre="treatment of chronically infected patients and chimpanzees reveals that integrated" exact="hepatitis" post="B virus DNA is a source of HBsAg. Sci"/>
   <result pre="Nat Med2019; 25(2): 249– 254.30692695 39.BloomK, ElyA, MussolinoCet al.Inactivation of" exact="hepatitis" post="B virus replication in cultured cells and in vivo"/>
   <result pre="1897.23883864 40.ChenJ, ZhangW, LinJet al.An efficient antiviral strategy for targeting" exact="hepatitis" post="B virus genome using transcription activator-like effector nucleases. Mol"/>
   <result pre="ChettyS and BarthS.Principles of immunotherapy: implications for treatment strategies in" exact="cancer" post="and infectious diseases. Front Microbiol2018; 9: 3158.30622524 42.ShataMTM, Abdel-HameedEA,"/>
   <result pre="Hepatol2016; 64(1 Suppl): S71– S83.27084039 58.LewandowskaM and PiekarskaA.New directions in" exact="hepatitis" post="B therapy research. Clin Exp Hepatol2017; 3(3): 119– 126.29062901"/>
   <result pre="PallantCet al.IL-10-producing regulatory B cells in the pathogenesis of chronic" exact="hepatitis" post="B virus infection. J Immunol2012; 189(8): 3925– 3935.22972930 60.BurtonAR,"/>
   <result pre="McCoyLEet al.Circulating and intrahepatic antiviral B cells are defective in" exact="hepatitis" post="B. J Clin Invest2018; 128(10): 4588– 4603.30091725 61.BoniC, BariliV,"/>
   <result pre="E2754.31195619 62.MainiMK and PeppaD.NK cells: a double-edged sword in chronic" exact="hepatitis" post="B virus infection. Front Immunol2013; 4: 57.23459859 63.FabozziG, PeguA,"/>
   <result pre="73.CohenJA, BarkhofF, ComiGet al.Oral fingolimod or intramuscular interferon for relapsing" exact="multiple sclerosis." post="N Engl J Med2010; 362(5): 402– 415.20089954 74.KapposL, RadueEW,"/>
   <result pre="RadueEW, O’ConnorPet al.A placebo-controlled trial of oral fingolimod in relapsing" exact="multiple sclerosis." post="N Engl J Med2010; 362(5): 387– 401.20089952 75.MainiMK and"/>
   <result pre="Med2010; 362(5): 387– 401.20089952 75.MainiMK and PallettLJ.Defective T-cell immunity in" exact="hepatitis" post="B virus infection: why therapeutic vaccination needs a helping"/>
   <result pre="can be restored by blocking programmed death-1 pathway in chronic" exact="hepatitis" post="B. Gastroenterology2010; 138(2): 682– 693, 693.19800335 80.GaneE, VerdonDJ, BrooksAEet"/>
   <result pre="nivolumab with and without therapeutic vaccination for virally suppressed chronic" exact="hepatitis" post="B: a pilot study. J Hepatol2019: S0168-8278(19)30400-3 ( Epub"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6849232\results\search\disease\results.xml">
   <result pre="viruses and it regulates nuclear replication in viruses such as" exact="influenza" post="A virus, simian virus 40, Rous sarcoma virus, avian"/>
   <result pre="viruses such as influenza A virus, simian virus 40, Rous" exact="sarcoma" post="virus, avian sarcoma virus, and adenovirus [35–38]. In recent"/>
   <result pre="influenza A virus, simian virus 40, Rous sarcoma virus, avian" exact="sarcoma" post="virus, and adenovirus [35–38]. In recent years, numerous studies"/>
   <result pre="on HIV have lagged behind other known viruses such as" exact="influenza" post="virus, adenovirus, Rous sarcoma virus, and simian virus 40"/>
   <result pre="behind other known viruses such as influenza virus, adenovirus, Rous" exact="sarcoma" post="virus, and simian virus 40 for almost 40 years [35–38].Recently,"/>
   <result pre="young children, and is one of the etiologic agents of" exact="hand, foot, and mouth disease" post="(HFMD) characterized with fever, sores in mouth and a"/>
   <result pre="is one of the etiologic agents of hand, foot, and" exact="mouth disease" post="(HFMD) characterized with fever, sores in mouth and a"/>
   <result pre="disease (HFMD) characterized with fever, sores in mouth and a" exact="rash" post="with blisters [56]. Since the discovery of EV71 in"/>
   <result pre="tract infections, posing a huge threat to human health. Currently," exact="influenza" post="prevention and treatment strategies include annual vaccination and antiviral"/>
   <result pre="viral surface was caused by antigenic shift and drift, allowing" exact="influenza" post="viruses to escape antibody-mediated immunity following vaccination [59]. Therefore,"/>
   <result pre="drugs to replace the traditional methods for effective control of" exact="influenza" post="virus diseases. Previously, it was demonstrated that the influenza"/>
   <result pre="of influenza virus diseases. Previously, it was demonstrated that the" exact="influenza" post="virus mRNAs contain internal m6Amodification that is required for"/>
   <result pre="KSHV is the causative agent for multiple malignancies including Kaposi’s" exact="sarcoma" post="(KS), primary effusion lymphoma (PEL) and multicentric Castleman’s disease"/>
   <result pre="agent for multiple malignancies including Kaposi’s sarcoma (KS), primary effusion" exact="lymphoma" post="(PEL) and multicentric Castleman’s disease (MCD) [61–63]. Latency is"/>
   <result pre="virus belonging to the Hepadnaviridae family. HBV infection causes chronic" exact="hepatitis" post="and increases the risk of developing cirrhosis and hepatocellular"/>
   <result pre="infection causes chronic hepatitis and increases the risk of developing" exact="cirrhosis" post="and hepatocellular carcinoma [67]. Recently, researchers have demonstrated that"/>
   <result pre="chronic hepatitis and increases the risk of developing cirrhosis and" exact="hepatocellular carcinoma" post="[67]. Recently, researchers have demonstrated that the life cycle"/>
   <result pre="infection with HBV and HCV is the most cause of" exact="hepatocellular carcinoma" post="(HCC) [45, 68]. Accumulating evidence indicates that HBV and"/>
   <result pre="8 kb belonging to Papillomavirus genus of the Papillomavirus family. Cervical" exact="cancer" post="(CC) is the fourth most prevalent cancer in women"/>
   <result pre="Papillomavirus family. Cervical cancer (CC) is the fourth most prevalent" exact="cancer" post="in women and is one of the most common"/>
   <result pre="worldwide [69, 70]. Although significant advances have been made in" exact="cancer" post="detection and treatment during the past few decades, the"/>
   <result pre="study revealed that m6A methylation participates in the oncogenesis of" exact="cervical cancer." post="The study found that m6A plays a negative role"/>
   <result pre="they found that the m6A level was significantly lower in" exact="cervical cancer" post="tissues compared with adjacent non-cancerous tissues. Moreover, for patients"/>
   <result pre="found that the m6A level was significantly lower in cervical" exact="cancer" post="tissues compared with adjacent non-cancerous tissues. Moreover, for patients"/>
   <result pre="tissues compared with adjacent non-cancerous tissues. Moreover, for patients with" exact="cervical cancer," post="the disease-free survival (DFS) and overall survival (OS) were"/>
   <result pre="level of m6A methylation could be a prognostic marker of" exact="cervical cancer." post="Knockdown of erasers (FTO and ALKBH5) or overexpression of"/>
   <result pre="and METTL14) suppressed the cellular proliferation and tumor formation of" exact="cervical cancer" post="cells both in vitro and in vivo. Interestingly, Zhou"/>
   <result pre="METTL14) suppressed the cellular proliferation and tumor formation of cervical" exact="cancer" post="cells both in vitro and in vivo. Interestingly, Zhou"/>
   <result pre="in cervical squamous cell carcinoma (CSCC), the major type of" exact="cervical cancer" post="[50]. Unfortunately, FTO-mediated upregulation of β-catenin via mRNA demethylation"/>
   <result pre="cervical squamous cell carcinoma (CSCC), the major type of cervical" exact="cancer" post="[50]. Unfortunately, FTO-mediated upregulation of β-catenin via mRNA demethylation"/>
   <result pre="associated with poor prognosis. Understanding the role of m6A in" exact="cervical cancer" post="is expected to provide clues for optimal treatment of"/>
   <result pre="with poor prognosis. Understanding the role of m6A in cervical" exact="cancer" post="is expected to provide clues for optimal treatment of"/>
   <result pre="(ZIKV), which causes Zika virus disease (ZVD)-a type of acute" exact="infectious disease," post="was firstly isolated from the serum of apyrexial rhesus"/>
   <result pre="human primary brain tumors, malignant mesotheliomas, bone cancers, and non-Hodgkin’s" exact="lymphoma" post="[75, 76]. In 1979, it was reported that late"/>
   <result pre="an oncogenic virus first isolated and identified from a Burkitt’s" exact="lymphoma" post="patient in 1964 [77]. As one of the most"/>
   <result pre="As one of the most common human viruses, EBV causes" exact="infectious mononucleosis" post="and is associated with specific forms of lymphoma. There"/>
   <result pre="specific forms of lymphoma. There are about 200,000 cases of" exact="cancer" post="associated with this virus, with about 140,000 deaths reported"/>
   <result pre="health. Some viruses RNA undergo m6A modification such as Rous" exact="sarcoma" post="virus (RSV) [79], vesicular stomatitis virus (VSV) [80], and"/>
   <result pre="m6A modification such as Rous sarcoma virus (RSV) [79], vesicular" exact="stomatitis" post="virus (VSV) [80], and adenoviruses [37], and are less"/>
   <result pre="is associated with the development of various cancers, such as" exact="acute myeloid leukemia" post="[81, 82], lung cancer [83], and hepatocellular carcinoma [47,"/>
   <result pre="associated with the development of various cancers, such as acute" exact="myeloid leukemia" post="[81, 82], lung cancer [83], and hepatocellular carcinoma [47,"/>
   <result pre="with the development of various cancers, such as acute myeloid" exact="leukemia" post="[81, 82], lung cancer [83], and hepatocellular carcinoma [47,"/>
   <result pre="of various cancers, such as acute myeloid leukemia [81, 82]," exact="lung cancer" post="[83], and hepatocellular carcinoma [47, 48]. Particularly, m6A has"/>
   <result pre="various cancers, such as acute myeloid leukemia [81, 82], lung" exact="cancer" post="[83], and hepatocellular carcinoma [47, 48]. Particularly, m6A has"/>
   <result pre="as acute myeloid leukemia [81, 82], lung cancer [83], and" exact="hepatocellular carcinoma" post="[47, 48]. Particularly, m6A has been detected in viral"/>
   <result pre="AIDS acquired immunodeficiency syndrome ALKBH5 alkB homologue 5 CC Cervical" exact="cancer" post="co-IP co-immunoprecipitation CSCC cervical squamous cell carcinoma DAA 3-deazaadenosine"/>
   <result pre="IGF2BPs the insulin-like growth factor 2 mRNA-binding proteins KS Kaposi’s" exact="sarcoma" post="KSHV Kaposi’s sarcoma-associated herpesvirus m6A N6-methyladenosine m6Am N6,2′-O-dimethyladenosine m6A-seq"/>
   <result pre="sequencing PAR-CLIP photoactivatable ribonucleoside-enhanced crosslinking and immunoprecipitation PEL primary effusion" exact="lymphoma" post="RBM15 RNA binding motif protein 15 RdRp RNA-dependent RNA"/>
   <result pre="polymerase RRE Rev response element rRNA ribosomal RNA RSV Rous" exact="sarcoma" post="virus RTA replication transcription activator SOCS2 suppressors of cytokine"/>
   <result pre="2 SV40 Simian Virus 40 tRNA transfer RNA VSV vesicular" exact="stomatitis" post="virus WTAP Wilms’ tumor 1-associating protein ZIKV Zika virus"/>
   <result pre="40 RNANucleic Acids Res197962879289910.1093/nar/6.8.2879223130 36.BeemonKKeithJLocalization of N6-methyladenosine in the Rous" exact="sarcoma" post="virus genomeJ Mol Biol197711316517910.1016/0022-2836(77)90047-X196091 37.HashimotoSIGreenMMultiple methylated cap sequences in"/>
   <result pre="METTL3 modulate enterovirus 71 replicationNucleic Acids Res20194736237410.1093/nar/gky100730364964 42.CourtneyDGKennedyEMDummREBogerdHPTsaiKHeatonNSCullenBREpitranscriptomic enhancement of" exact="influenza" post="a virus gene expression and replicationCell Host Microbe20172237738610.1016/j.chom.2017.08.00428910636 43.Ye"/>
   <result pre="expression during Kaposi's sarcoma-associated herpesvirus infectionPLoS Pathog201814e100699510.1371/journal.ppat.100699529659627 45.ImamHKhanMGokhaleNSMcIntyreAKimGWJangJYKimSJMasonCEHornerSMSiddiquiAN6-methyladenosine modification of" exact="hepatitis" post="B virus RNA differentially regulates the viral life cycleProc"/>
   <result pre="regulates infectionCell Host Microbe20162065466510.1016/j.chom.2016.09.01527773535 47.ChenMWeiLLawCTTsangFHShenJChengCLTsangLHHoDWChiuDKLeeJMet al.RNA N6-methyladenosine methyltransferase-like 3 promotes" exact="liver cancer" post="progression through YTHDF2-dependent posttranscriptional silencing of SOCS2Hepatology.2018672254227010.1002/hep.2968329171881 48.MaJZYangFZhouCCLiuFYuanJHWangFWangTTXuQGZhouWPSunSHMETTL14 suppresses"/>
   <result pre="infectionCell Host Microbe20162065466510.1016/j.chom.2016.09.01527773535 47.ChenMWeiLLawCTTsangFHShenJChengCLTsangLHHoDWChiuDKLeeJMet al.RNA N6-methyladenosine methyltransferase-like 3 promotes liver" exact="cancer" post="progression through YTHDF2-dependent posttranscriptional silencing of SOCS2Hepatology.2018672254227010.1002/hep.2968329171881 48.MaJZYangFZhouCCLiuFYuanJHWangFWangTTXuQGZhouWPSunSHMETTL14 suppresses"/>
   <result pre="posttranscriptional silencing of SOCS2Hepatology.2018672254227010.1002/hep.2968329171881 48.MaJZYangFZhouCCLiuFYuanJHWangFWangTTXuQGZhouWPSunSHMETTL14 suppresses the metastatic potential of" exact="hepatocellular carcinoma" post="by modulating N6-methyladenosine-dependent primary MicroRNA processingHepatology.20166552954310.1002/hep.2888527774652 49.WangXLiZKongBSongCCongJHouJWangSReduced m(6)a mRNA"/>
   <result pre="and Public Health201613989010.3390/ijerph13090890 58.ToEELuongRDiaoJJJOLBrooksDAVlahosRSelemidisSNovel endosomal NOX2 oxidase inhibitor ameliorates pandemic" exact="influenza" post="A virus-induced lung inflammation in miceRespirology2019241011101710.1111/resp.1352430884042 59.SunJBracialeTJRole of T"/>
   <result pre="in miceRespirology2019241011101710.1111/resp.1352430884042 59.SunJBracialeTJRole of T cell immunity in recovery from" exact="influenza" post="virus infectionCurr Opin Virol2013342542910.1016/j.coviro.2013.05.00123721865 60.BarryPAWilliamCWPrimate betaherpesviruses2007 61.ChangYCesarmanEPessinMSLeeFCulpepperJKnowlesDMMoorePSIdentification of herpesvirus-like"/>
   <result pre="the KSHV life cycleNat Microbiol2018310812010.1038/s41564-017-0056-829109479 67.LevreroMPollicinoTPetersenJBelloniLRaimondoGDandriMControl of cccDNA function in" exact="hepatitis" post="B virus infectionJ Hepatol20095158159210.1016/j.jhep.2009.05.02219616338 68.RazaSACliffordGMFranceschiSWorldwide variation in the relative"/>
   <result pre="virus infectionJ Hepatol20095158159210.1016/j.jhep.2009.05.02219616338 68.RazaSACliffordGMFranceschiSWorldwide variation in the relative importance of" exact="hepatitis" post="B and hepatitis C viruses in hepatocellular carcinoma: a"/>
   <result pre="68.RazaSACliffordGMFranceschiSWorldwide variation in the relative importance of hepatitis B and" exact="hepatitis" post="C viruses in hepatocellular carcinoma: a systematic reviewBr J"/>
   <result pre="Surveill. 2014;19. 74.Schuler-FacciniLRibeiroEMFeitosaIMHorovitzDDCavalcantiDPPessoaADoriquiMJNeriJINetoJMWanderleyHYet al.Possible association between Zika virus infection and" exact="microcephaly" post="- Brazil, 2015MMWR Morb Mortal Wkly Rep201665596210.15585/mmwr.mm6503e226820244 75.LiddingtonRCYanYMoulaiJSahliRBenjaminTLHarrisonSCStructure of"/>
   <result pre="cells and epithelial cellsImmunity.2019501305131610.1016/j.immuni.2019.03.01030979688 79.KaneSEBeemonKPrecise localization of m6A in Rous" exact="sarcoma" post="virus RNA reveals clustering of methylation sites: implications for"/>
   <result pre="the nucleusNat Immunol201718136110.1038/ni1217-1361a29144498 81.LiZWengHSuRWengXZuoZLiCHuangHNachtergaeleSDongLHuCet al.FTO plays an oncogenic role in" exact="acute myeloid leukemia" post="as a N(6)-Methyladenosine RNA DemethylaseCancer Cell20173112714110.1016/j.ccell.2016.11.01728017614 82.KwokCTMarshallADRaskoJEWongJJGenetic alterations of"/>
   <result pre="nucleusNat Immunol201718136110.1038/ni1217-1361a29144498 81.LiZWengHSuRWengXZuoZLiCHuangHNachtergaeleSDongLHuCet al.FTO plays an oncogenic role in acute" exact="myeloid leukemia" post="as a N(6)-Methyladenosine RNA DemethylaseCancer Cell20173112714110.1016/j.ccell.2016.11.01728017614 82.KwokCTMarshallADRaskoJEWongJJGenetic alterations of"/>
   <result pre="Immunol201718136110.1038/ni1217-1361a29144498 81.LiZWengHSuRWengXZuoZLiCHuangHNachtergaeleSDongLHuCet al.FTO plays an oncogenic role in acute myeloid" exact="leukemia" post="as a N(6)-Methyladenosine RNA DemethylaseCancer Cell20173112714110.1016/j.ccell.2016.11.01728017614 82.KwokCTMarshallADRaskoJEWongJJGenetic alterations of"/>
   <result pre="(m(6)a)-forming enzyme METTL3 controls myeloid differentiation of normal hematopoietic and" exact="leukemia" post="cellsNat Med2017231369137610.1038/nm.441628920958"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6853075\results\search\disease\results.xml">
   <result pre="CHIKV include neurological disease in the acute phase, and longstanding" exact="arthritis" post="and myalgia. The acute phase of the three arboviral"/>
   <result pre="no identifiable source (respiratory, urinary, abdominal, soft tissue), a pruritic" exact="rash" post="and/or non-purulent conjunctivitis were included in the study as"/>
   <result pre="(respiratory, urinary, abdominal, soft tissue), a pruritic rash and/or non-purulent" exact="conjunctivitis" post="were included in the study as suspected ZIKV cases."/>
   <result pre="146 suspected ZIKV cases, two symptoms were the most frequent:" exact="rash" post="occurred in 99 (67.8%) in 2015 and 614 (79.0"/>
   <result pre="Brazil, several cases of the congenital syndrome, mainly associated with" exact="microcephaly" post="in newborns, have been reported with the detection of"/>
   <result pre="sequencing of Zika virus from amniotic fluid of fetuses with" exact="microcephaly" post="in Brazil: a case studyLancet Infect Dis20161665366010.1016/S1473-3099(16)00095-526897108 7collab: BrasilBoletim"/>
   <result pre="Ministério da Saúde Monitoramento dos casos de dengue, febre de" exact="chikungunya" post="e febre pelo vírus zika até a semana epidemiológica"/>
   <result pre="aegypti (Diptera: Culicidae) mosquito in El Salvador, vector of dengue," exact="yellow fever," post="chikungunya and ZikaParasit Vectors20181163710.1186/s13071-018-3226-530547835 14collab: BrasilProcedimentos a serem adotados"/>
   <result pre="Culicidae) mosquito in El Salvador, vector of dengue, yellow fever," exact="chikungunya" post="and ZikaParasit Vectors20181163710.1186/s13071-018-3226-530547835 14collab: BrasilProcedimentos a serem adotados para"/>
   <result pre="Med Hyg19521305010.4269/ajtmh.1952.1.3014903434 24ChompoosrJThavaraUTawatsinABoonsermRPhumeeASangkitpornSet al.Vertical transmission of Indian Ocean Lineage of" exact="chikungunya" post="virus in Aedes aegypti and Aedes albopictus mosquitoesParasit Vectors201692210.1186/s13071-016-1303-126775291"/>
   <result pre="in Aedes aegypti and Aedes albopictus mosquitoesParasit Vectors201692210.1186/s13071-016-1303-126775291 25SilvaNMDTeixeiraRAGCardosoCGSiqueiraJBJuniorCoelhoGEOliveiraESFVigilância de" exact="chikungunya" post="no Brasil: desafios no contexto da Saúde PúblicaEpidemiol Serv"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6854512\results\search\disease\results.xml">
   <result pre="(NW) (9). The OW family of arenaviruses includes LASV and" exact="lymphocytic choriomeningitis" post="virus (LCMV), a neglected human pathogen distributed worldwide (10,"/>
   <result pre="for maintaining normal viral GP functions. For example, glycosylation of" exact="influenza" post="hemagglutinin (HA) directs the proper folding and trafficking of"/>
   <result pre="OW arenaviruses (A) and two NW arenaviruses (B) or VSV-G," exact="influenza" post="A virus HA, and HIV-1 GP160 (C) were transfected"/>
   <result pre="knockout of STT3A or STT3B on the glycoproteins of vesicular" exact="stomatitis" post="virus (VSV), influenza A virus, and human immunodeficiency virus"/>
   <result pre="or STT3B on the glycoproteins of vesicular stomatitis virus (VSV)," exact="influenza" post="A virus, and human immunodeficiency virus 1 (HIV-1). As"/>
   <result pre="human immunodeficiency virus 1 (HIV-1). As shown in Fig. 10C," exact="influenza" post="HA was only affected by knockout of STT3B, whereas"/>
   <result pre="STT3A and STT3B for N-glycosylation were also found in VSV-G," exact="influenza" post="HA, and HIV-1 GP160 proteins, indicating the diverse mechanisms"/>
   <result pre="chemically synthesized by Sangon Biotech (China). The cDNA sequences of" exact="influenza" post="A virus HA (A/Puerto Rico/8/1934(H1N1), GenBank MH785011.1) and HIV-1"/>
   <result pre="by a T7 promoter in their 5′ termini and a" exact="hepatitis" post="delta riboenzyme sequence in their 3′ termini, respectively. Then,"/>
   <result pre="FEBS Lett538:203–206. doi:10.1016/s0014-5793(03)00160-1.12633879 18.FroeschkeM, BaslerM, GroettrupM, DobbersteinB2003Long-lived signal peptide of" exact="lymphocytic choriomeningitis" post="virus glycoprotein pGP-C. J Biol Chem278:41914–41920. doi:10.1074/jbc.M302343200.12917426 19.HastieKM, IgonetS,"/>
   <result pre="NicholST, CompansRW, CampbellKP, OldstoneMB1998Identification of alpha-dystroglycan as a receptor for" exact="lymphocytic choriomeningitis" post="virus and Lassa fever virus. Science282:2079–2081. doi:10.1126/science.282.5396.2079.9851928 24.RaabenM, JaeLT,"/>
   <result pre="KurowskiB, JohnsonAE, HebertDN2003N-linked glycans direct the cotranslational folding pathway of" exact="influenza" post="hemagglutinin. Mol Cell11:79–90. doi:10.1016/S1097-2765(02)00821-3.12535523 31.WagnerR, WolffT, HerwigA, PleschkaS, KlenkHD2000Interdependence"/>
   <result pre="PleschkaS, KlenkHD2000Interdependence of hemagglutinin glycosylation and neuraminidase as regulators of" exact="influenza" post="virus growth: a study by reverse genetics. J Virol74:6316–6323."/>
   <result pre="an N-linked glycosylation motif in the glycoprotein of the live-attenuated" exact="argentine hemorrhagic fever" post="vaccine, Candid #1, results in its improper processing, and"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6855045\results\search\disease\results.xml">
   <result pre="the case of an HIV-negative examinee having a Kaposi's Sarcoma-associated" exact="pulmonary tuberculosis." post="2. Case Report Our 70-year-old male patient is followed"/>
   <result pre="(Figure 1(b)). Papillomatous, palmoplantar skin lesions, as well as important" exact="lymphedema" post="of the extremities were also observed (Figures 1(c) and"/>
   <result pre="had no peculiarities. Biologically, the patient had a normochromic, normocytic" exact="anemia" post="with a hemoglobin level of 10, 5 g/dl, a white"/>
   <result pre="5 g/dl, a white blood cell count of 8520/mm3 and a" exact="lymphocytopenia" post="level of 700 per mm3. The C-reactive protein was"/>
   <result pre="on direct examination was negative. Serological assays for HBV (viral" exact="hepatitis" post="B), HCV (viral hepatitis C), and HIV (human immunodeficiency"/>
   <result pre="negative. Serological assays for HBV (viral hepatitis B), HCV (viral" exact="hepatitis" post="C), and HIV (human immunodeficiency virus) were negative as"/>
   <result pre="the extent of skin lesions' and a partial regression of" exact="lymphedema" post="starting from the fourth month of treatment. 3. Discussion"/>
   <result pre="to immunosuppressive agents, lymphoproliferative disorders (LPDs), and far less frequently" exact="tuberculosis" post="[4, 5]. Our case was an HIV-negative patient with"/>
   <result pre="[4, 5]. Our case was an HIV-negative patient with both" exact="pulmonary tuberculosis" post="and Kaposi's Sarcoma. Wang et al. [4] described the"/>
   <result pre="5]. Our case was an HIV-negative patient with both pulmonary" exact="tuberculosis" post="and Kaposi's Sarcoma. Wang et al. [4] described the"/>
   <result pre="was HIV-positive while the other was seronegative. Both had multi-focal" exact="tuberculosis" post="with the lung, the liver, and the spleen involvement,"/>
   <result pre="Sarcoma that had developed in an HIV-negative subject suffering from" exact="pulmonary tuberculosis." post="Ajili [8] and Chen [9] studies concerned the emergence"/>
   <result pre="on a ground of ganglionic if not cutaneous, or even" exact="miliary tuberculosis" post="inducing immunosuppression through cellular immune deficiency [10]. The clinical"/>
   <result pre="a ground of ganglionic if not cutaneous, or even miliary" exact="tuberculosis" post="inducing immunosuppression through cellular immune deficiency [10]. The clinical"/>
   <result pre="Sarcoma (KS) is a pathological entity, its presence along with" exact="tuberculosis" post="in immunocompromised patients have been reported only rarely in"/>
   <result pre="disease, the research of immunosuppressive factors are in order. Although" exact="tuberculosis" post="has very rarely been reported, this affection should be"/>
   <result pre="pathologie exotique2003962868912836521 4WangA. Y.LiP. K.ToK. F.LaiF. M.LaiK. N.Coexistence of Kaposi’s" exact="sarcoma" post="and tuberculosis in a renal transplant recipientTransplantation199866111511810.1097/00007890-199807150-000189679831 5LanjewarD. N.LanjewarS."/>
   <result pre="4WangA. Y.LiP. K.ToK. F.LaiF. M.LaiK. N.Coexistence of Kaposi’s sarcoma and" exact="tuberculosis" post="in a renal transplant recipientTransplantation199866111511810.1097/00007890-199807150-000189679831 5LanjewarD. N.LanjewarS. D.ChavanG.Coexistent lymphoma"/>
   <result pre="and tuberculosis in a renal transplant recipientTransplantation199866111511810.1097/00007890-199807150-000189679831 5LanjewarD. N.LanjewarS. D.ChavanG.Coexistent" exact="lymphoma" post="with tuberculosis and Kaposi’s sarcoma with tuberculosis occurring in"/>
   <result pre="in a renal transplant recipientTransplantation199866111511810.1097/00007890-199807150-000189679831 5LanjewarD. N.LanjewarS. D.ChavanG.Coexistent lymphoma with" exact="tuberculosis" post="and Kaposi’s sarcoma with tuberculosis occurring in lymph node"/>
   <result pre="transplant recipientTransplantation199866111511810.1097/00007890-199807150-000189679831 5LanjewarD. N.LanjewarS. D.ChavanG.Coexistent lymphoma with tuberculosis and Kaposi’s" exact="sarcoma" post="with tuberculosis occurring in lymph node in patients with"/>
   <result pre="5LanjewarD. N.LanjewarS. D.ChavanG.Coexistent lymphoma with tuberculosis and Kaposi’s sarcoma with" exact="tuberculosis" post="occurring in lymph node in patients with AIDS: a"/>
   <result pre="disséminée chez un individu séronégatifThe Lancet19923398797p. 86810.1016/0140-6736(92)90308-p 7GulerZ. M.KanbayA.CiftciB.et al.Kaposi" exact="sarcoma" post="secondary to pulmonary tuberculosis: a rare caseSouth Medical Journal200598993293310.1097/01.smj.0000170728.19052.c9"/>
   <result pre="la tuberculose!Pan African Medical Journal201316p. 8110.11604/pamj.2013.16.81.2787 9ChenY. J.ShiehP. P.ShenJ. L.Orificial" exact="tuberculosis" post="and Kaposi’s sarcoma in an HIV-negative individualClinical and Experimental"/>
   <result pre="Medical Journal201316p. 8110.11604/pamj.2013.16.81.2787 9ChenY. J.ShiehP. P.ShenJ. L.Orificial tuberculosis and Kaposi’s" exact="sarcoma" post="in an HIV-negative individualClinical and Experimental Dermatology200025539339710.1046/j.1365-2230.2000.00672.x11012593 10KonstantinovG. S.Kaposi’s"/>
   <result pre="sarcoma in an HIV-negative individualClinical and Experimental Dermatology200025539339710.1046/j.1365-2230.2000.00672.x11012593 10KonstantinovG. S.Kaposi’s" exact="sarcoma" post="combined with generalized miliary tuberculosisArkhiv Pathologii198850125861 11EmmanoulidesC.MilesS. A.MitsuyasuR. T.Pathogenesis"/>
   <result pre="11EmmanoulidesC.MilesS. A.MitsuyasuR. T.Pathogenesis of AIDS-related Kaposi’s sarcomaOncology19961033353418820448 12BeralV.PetermanT.BerkelmanA. R.JaffeH. W.Kaposi’s" exact="sarcoma" post="among persons with AIDS 2 a sexually transmitted infection?The"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6855448\results\search\disease\results.xml">
   <result pre="millions of dengue virus (DENV) infections every year. In China," exact="dengue fever" post="mainly occurs in coastal areas. Recurring dengue outbreaks were"/>
   <result pre="for opening up in China, understanding the epidemiological characteristics of" exact="dengue fever" post="in the city can hopefully provide a significant basis"/>
   <result pre="a blood samples drawn from patients who were diagnosed with" exact="dengue fever" post="by hospitals in Guangzhou during 2018. To explore the"/>
   <result pre="in Guangzhou during 2018. To explore the epidemiological characteristics of" exact="dengue fever," post="the envelope (E) gene obtained from the isolates was"/>
   <result pre="fever, also known as &quot;break-bone fever&quot;, is an acute mosquito-borne" exact="viral disease" post="caused by dengue virus (DENV) [1]. Patients infected with"/>
   <result pre="In a small proportion of cases, the disease develops into" exact="dengue hemorrhagic fever" post="(DHF) or dengue shock syndrome (DSS) [2, 3]. Dengue"/>
   <result pre="and humid climate indicates favorable mosquito habitat. In other words," exact="dengue fever" post="is also a seasonal infectious disease, and mosquito densities"/>
   <result pre="habitat. In other words, dengue fever is also a seasonal" exact="infectious disease," post="and mosquito densities and climatic conditions are strongly associated"/>
   <result pre="and climatic conditions are strongly associated with the incidence of" exact="dengue fever." post="In recent decades, dengue fever, as a growing threat"/>
   <result pre="associated with the incidence of dengue fever. In recent decades," exact="dengue fever," post="as a growing threat to human health, has presented"/>
   <result pre="In fact, as early as 1978, a case of imported" exact="dengue fever" post="was discovered in Xiamen, after which the Chinese mainland"/>
   <result pre="Control and Prevention, as it has been frequently attacked by" exact="dengue fever" post="since the first outbreak [12]. Despite the absence of"/>
   <result pre="since the first outbreak [12]. Despite the absence of reported" exact="dengue fever" post="cases between 1982 and 1984, 1988 and 1989, and"/>
   <result pre="in the DENV-infected patients [12, 15]. There were over 46000" exact="dengue fever" post="cases notified nationwide throughout the year, including up to"/>
   <result pre="travel records. Dengue epidemics refer to continued widespread outbreaks of" exact="dengue fever" post="in areas where DENV affects a large population and"/>
   <result pre="and the greenhouse effect, there were many patients infected with" exact="dengue fever" post="in Guangdong Province, and a serious outbreak occurred in"/>
   <result pre="blood samples drawn from DENV-infected patients who were diagnosed with" exact="dengue fever" post="by hospitals in Guangzhou during 2018. We described the"/>
   <result pre="infection [21]. A total of 170 samples suspected of having" exact="dengue fever" post="occurred during the 2018 outbreak. 55 blood samples were"/>
   <result pre="samples were drawn from DENV-infected patients who were diagnosed with" exact="dengue fever" post="by hospitals in Guangzhou during 2018, and an analysis"/>
   <result pre="isolated and treated properly to reduce the risk of imported" exact="dengue fever." post="In addition, health education also plays an important role"/>
   <result pre="strains were imported from endemic countries and regions and caused" exact="dengue fever" post="without further propagation in China; some evolved from imported"/>
   <result pre="in Guangzhou, previous phylogenetic analyses indicated possible local transmission of" exact="dengue fever" post="in the city. Since Aedes albopictus is the main"/>
   <result pre="should strive to improve the diagnostic accuracy and efficiency of" exact="dengue fever." post="Suspected DENV-infected patients should be isolated to prevent further"/>
   <result pre="for DENV in China and exploring the epidemiological characteristics of" exact="dengue fever" post="to provide a basis for dengue prevention strategies. As"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6856673\results\search\disease\results.xml">
   <result pre="suspicion of two diseases of interest in Switzerland: bovine viral" exact="diarrhea" post="(ALIS_BVD) and infectious bovine rhinotracheitis (ALIS_IBR). Suspicious cases were"/>
   <result pre="online at: https://webgate.ec.europa.eu/chafea_pdb/assets/files/pdb/20091112/20091112_d08_giss_en_ps.pdf (accessed October 25, 2019). 7.ChoiJChoYShimEWooHSchlipköterULombardoMet al.. Web-based" exact="infectious disease" post="surveillance systems and public health perspectives: a systematic review."/>
   <result pre="Alternative scan-based approaches to identify space-time clusters of highly pathogenic" exact="avian influenza" post="virus H5N1 in wild birds in Denmark and Sweden"/>
   <result pre="scan-based approaches to identify space-time clusters of highly pathogenic avian" exact="influenza" post="virus H5N1 in wild birds in Denmark and Sweden"/>
   <result pre="(2004) 11:141–50. 10.1197/jamia.M135614633933 44.UnkelSFarringtonCPGarthwaitePHRobertsonCAndrewsNStatistical methods for the prospective detection of" exact="infectious disease" post="outbreaks: a review. J R Stat Soc Ser A."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6857389\results\search\disease\results.xml">
   <result pre="and also by Aedes albopictus.[2] Aedes Aegypti also transmits Chikungunya," exact="yellow fever," post="and Zika infections.[1] Dengue also referred to as &quot;water"/>
   <result pre="or &quot;break bone fever�?[2] is the most rapidly spreading mosquito-borne" exact="viral disease" post="in the world. In the last 50 years, incidence"/>
   <result pre="severity of disease. The very first report of existence of" exact="dengue fever" post="in India was way back in 1946.[8] Notable epidemics"/>
   <result pre="in a spectrum of clinical outcomes, ranging from self-limiting, uncomplicated" exact="dengue fever" post="(characterized by a sudden onset of fever and one"/>
   <result pre="nausea and vomiting, weakness, and rash) to the more severe" exact="dengue hemorrhagic fever" post="(DHF). The critical stage in DHF is at the"/>
   <result pre="signs of circulatory failure and hemorrhagic manifestations, primarily skin hemorrhages," exact="thrombocytopenia" post="(&amp;lt;100 000/mm3), and elevated hematocrit being the prominent features."/>
   <result pre="entomological tools to standardize and classify the vectors. Surveillance in" exact="dengue fever" post="Surveillance is a prerequisite for monitoring the dengue situation"/>
   <result pre="transmission. Treatment and prevention There is no specific treatment for" exact="dengue fever" post="or for severe dengue though medical care by experienced"/>
   <result pre="present, and scenarios for the futureLancet Infect Dis20141412718025172160 5KutsunaSKatoYMoiMLKotakiAOtaMShinoharaKet al.Autochthonous" exact="dengue fever," post="Tokyo, Japan, 2014Emerg Infect Dis2015215172025695200 6National Dengue Day 2019"/>
   <result pre="(DENV-1) and its co-circulation with predominant DENV-3 during the 2006" exact="dengue fever" post="outbreak in DelhiInt J Infect Dis200812542918495513 18BharajPChaharHSPandeyADiddiKDarLGuleriaRet al.Concurrent infections"/>
   <result pre="of dengue in 2006 in Delhi, IndiaVirol J20085118182120 19ChaharHSBharajPDarLGuleriaRKabraSKBroorSCo-infections with" exact="chikungunya" post="virus and dengue virus in Delhi, IndiaEmerg Infect Dis20091510778019624923"/>
   <result pre="review of the evidencePLoS Negl Trop Dis20148e284824810901 34MurhekarMJoshuaVKanagasabaiKSheteVRaviMRamachandranRet al.Epidemiology of" exact="dengue fever" post="in India, based on laboratory surveillance data, 2014-2017Int J"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6858332\results\search\disease\results.xml">
   <result pre="seem to play a key role in Iquitos, Peru16. Related" exact="malaria" post="studies show that human mobility, which is estimated from"/>
   <result pre="which is estimated from cell-phone networks, drives the dissemination of" exact="malaria" post="parasites as well12. Recently Wesolowski et al. studied the"/>
   <result pre="dengue especially in cities, many authors studied the effect of" exact="dengue fever" post="in urban environments7,11,17–20. While these work generally assume that"/>
   <result pre="can give real-time mobility information that can be combined with" exact="infectious disease" post="surveillance data and seasonally varying environmental data to map"/>
   <result pre="to consider different mosquito-borne diseases such as dengue, chikungunya, malaria," exact="yellow fever" post="and different sources and models of human mobility, having"/>
   <result pre="outbreak in Singapore, a significant rise in the number of" exact="dengue fever" post="cases was reported in Singapore and caused 8 victims"/>
   <result pre="the years 2010, 2011 and 2012. The number of weekly" exact="dengue fever" post="cases has exceeded the epidemic threshold of 237. Similarly"/>
   <result pre="dataPLoS One20149e9618010.1371/journal.pone.009618024933264 9.Wesolowski, A. et al. Quantifying travel behavior for" exact="infectious disease" post="research: a comparison of data from surveys and mobile"/>
   <result pre="M. et al. Can human movements explain heterogeneous propagation of" exact="dengue fever" post="in cambodia? PLoS Neglected tropical diseases (2012). 14.Wesolowski, A."/>
   <result pre="for global dengue epidemic potentialPloS one20149e8978310.1371/journal.pone.008978324603439 34.HapuarachchiHCet al.Epidemic resurgence of" exact="dengue fever" post="in singapore in 2013-2014: A virological and entomological perspectiveBMC"/>
   <result pre="delhi on dispersal of aedes aegypti mosquitoes, vector of dengue," exact="chikungunya" post="and zika viruses. Cybergeo: European Journal of Geography (2017)."/>
   <result pre="08-14-2019). 44.Mobile penetration rate in singapore, https://data.gov.sg/dataset/mobile-penetration-rate?view_id=3f352003-35f9-44ce-be61-2b3a98ddea28&amp;amp;resource_id=26e9766b-a42d-468c-9c25-88d89b850823 (Accessed: 08-16-2019). 45.Weekly" exact="infectious disease" post="bulletin, https://data.gov.sg/dataset/weekly-infectious-disease-bulletin-cases (Accessed: 05-20-2019). 46.Sgcharts, http://www.sgcharts.com/ (Accessed: 05-20-2019). 47.HiiYien"/>
   <result pre="of dengueEpidemiology and infection20091371188120210.1017/S095026880900204019192322 50.NewtonEReiterPA model of the transmission of" exact="dengue fever" post="with an evaluation of the impact of ultra-low volume"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6858468\results\search\disease\results.xml">
   <result pre="variety of manifestations from mild upper respiratory tract illnesses or" exact="otitis media" post="to severe and potentially life-threatening lower respiratory tract illnesses"/>
   <result pre="PIV1 and PIV2 are best known as the cause of" exact="croup" post="whereas PIV3 is a common cause of bronchiolitis and"/>
   <result pre="cause of croup whereas PIV3 is a common cause of" exact="bronchiolitis" post="and pneumonia [7]. PIV4 infection has low prevalence [13]."/>
   <result pre="croup whereas PIV3 is a common cause of bronchiolitis and" exact="pneumonia" post="[7]. PIV4 infection has low prevalence [13]. HMPV was"/>
   <result pre="dyspnea during the previous week. Patients who were diagnosed with" exact="pneumonia" post="by chest radiography during the previous week were also"/>
   <result pre="RSV, PIV1–4, HMPV, and other 12 common respiratory pathogens, including" exact="influenza" post="A virus (infA), influenza B virus (infB), human rhinovirus"/>
   <result pre="other 12 common respiratory pathogens, including influenza A virus (infA)," exact="influenza" post="B virus (infB), human rhinovirus (HRV), enterovirus (EV), four"/>
   <result pre="acute respiratory-tract infections in all age groupsJ Infect Dis200218691330133410.1086/34431912402203 16.FalseyARWalshEEViral" exact="pneumonia" post="in older adultsClin Infect Dis200642451852410.1086/49995516421796 17.KahnJSEpidemiology of human metapneumovirusClin"/>
   <result pre="Anestesiol201278778222415435 20.ChuHYEnglundJAPodczervinskiSKuypersJCampbellAPBoeckhMPergamSACasperCNosocomial transmission of respiratory syncytial virus in an outpatient" exact="cancer" post="centerBiol Blood Marrow Transplant201420684485110.1016/j.bbmt.2014.02.02424607551 21.BontLNosocomial RSV infection control and"/>
   <result pre="in Guangzhou, southern ChinaBMC Infect Dis20111134510.1186/1471-2334-11-34522168387 31.WalkerCLRudanILiuLNairHTheodoratouEBhuttaZAO’BrienKLCampbellHBlackREGlobal burden of childhood" exact="pneumonia" post="and diarrhoeaLancet201338198751405141610.1016/S0140-6736(13)60222-623582727 32.LuksicIKearnsPKScottFRudanICampbellHNairHViral etiology of hospitalized acute lower respiratory"/>
   <result pre="on RSV infection in PortugalInt J Biometeorol201660121807181710.1007/s00484-016-1168-127059367 36.WangTLChenZMTangHFTangLFZouCCViral etiology of" exact="pneumonia" post="in childrenZhejiang Da Xue Xue Bao Yi Xue Ban200534656656916331823"/>
   <result pre="developing countriesTropical Med Int Health19983426828010.1046/j.1365-3156.1998.00213.x 38.MathisenMStrandTASharmaBNChandyoRKValentiner-BranthPBasnetSAdhikariRKHvidstenDShresthaPSSommerfeltHRNA viruses in community-acquired childhood" exact="pneumonia" post="in semi-urban Nepal; a cross-sectional studyBMC Med200973510.1186/1741-7015-7-3519635124 39.Garcia-GarciaMLCalvoCReyCDiazBMolineroMDPozoFCasasIHuman metapnuemovirus"/>
   <result pre="with other respiratory viruses. 2005-2014 prospective studyPloS one2017123e017350410.1371/journal.pone.017350428301570 40.PeirisJSTangWHChanKHKhongPLGuanYLauYLChiuSSChildren with" exact="respiratory disease" post="associated with metapneumovirus in Hong KongEmerg Infect Dis20039662863310.3201/eid0906.03000912781000 41.MaggiFPifferiMVatteroniMFornaiCTempestiniEAnzilottiSLaniniLAndreoliERagazzoVPistelloMSpecterSBendinelliMHuman"/>
   <result pre="Dis2003188101571157710.1086/37920014624384 43.IwaneMKEdwardsKMSzilagyiPGWalkerFJGriffinMRWeinbergGACoulenCPoehlingKAShoneLPBalterSHallCBErdmanDDWootenKSchwartzBPopulation-based surveillance for hospitalizations associated with respiratory syncytial virus," exact="influenza" post="virus, and parainfluenza viruses among young childrenPediatrics200411361758176410.1542/peds.113.6.175815173503 44.ShayDKHolmanRCNewmanRDLiuLLStoutJWAndersonLJBronchiolitis-associated hospitalizations"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6862093\results\search\disease\results.xml">
   <result pre="the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). Abstract Seasonal" exact="influenza" post="epidemics occur each winter season in temperate zones, involving"/>
   <result pre="globally. A published study demonstrated that the circulation of one" exact="influenza" post="virus type during early influenza season in the United"/>
   <result pre="that the circulation of one influenza virus type during early" exact="influenza" post="season in the United States interferes with the activity"/>
   <result pre="in the United States interferes with the activity of other" exact="influenza" post="virus types. However, this finding has yet to be"/>
   <result pre="In the present work, we investigated the interaction among seasonal" exact="influenza" post="viruses (A/H1N1, A/H3N2 and B) in Japan. Sentinel and"/>
   <result pre="particular virus type before the epidemic peak. The peak of" exact="influenza" post="type B took place later in the season than"/>
   <result pre="B took place later in the season than that of" exact="influenza" post="A, although the epidemic peaks of influenza A/H1N1 and"/>
   <result pre="than that of influenza A, although the epidemic peaks of" exact="influenza" post="A/H1N1 and A/H3N2 nearly coincided. Given the interaction among"/>
   <result pre="A/H1N1 and A/H3N2 nearly coincided. Given the interaction among different" exact="influenza" post="viruses, underlying mechanisms including age and spatial dependence should"/>
   <result pre="including age and spatial dependence should be explored in future." exact="influenza" post="viral interference epidemics statistical model epidemiology 1. Introduction Influenza"/>
   <result pre="statistical model epidemiology 1. Introduction Influenza is an acute viral" exact="respiratory disease" post="that is involved in approximately one billion infections worldwide"/>
   <result pre="involved in approximately one billion infections worldwide [1]. Symptoms of" exact="influenza" post="are often self-limiting, with recovery occurring within 7 days."/>
   <result pre="occurring within 7 days. Typical clinical signs and symptoms of" exact="influenza" post="include sudden onset of fever or upper respiratory symptoms"/>
   <result pre="such as sore throat, cough, and runny nose [2]. However," exact="influenza" post="infection in high-risk individuals, including older people with underlying"/>
   <result pre="650,000 deaths each year [1,3]. There are four types of" exact="influenza" post="viruses, including A, B, C, and D [4], among"/>
   <result pre="cause annual epidemics in humans. Currently circulating virus types include" exact="influenza" post="A/H1N1, influenza A/H3N2, and influenza B (which is further"/>
   <result pre="epidemics in humans. Currently circulating virus types include influenza A/H1N1," exact="influenza" post="A/H3N2, and influenza B (which is further subdivided into"/>
   <result pre="Currently circulating virus types include influenza A/H1N1, influenza A/H3N2, and" exact="influenza" post="B (which is further subdivided into B/Victoria and B/Yamagata)"/>
   <result pre="effectiveness of existing vaccines is limited because antigenic drift in" exact="influenza" post="viruses over time requires annual immunization and that vaccines"/>
   <result pre="reported that Japanese high school students who were infected with" exact="influenza" post="had a lower risk of subsequent infection with A/H1N1"/>
   <result pre="A/H3N2 co-circulation, indicating short-term cross-subtype protection induced by the initial" exact="influenza" post="infection. In observational studies, Skowronski et al. [10] found"/>
   <result pre="studies, Skowronski et al. [10] found that people who received" exact="influenza" post="vaccination during 2008–2009 were more likely to have symptoms"/>
   <result pre="during 2008–2009 were more likely to have symptoms owing to" exact="influenza" post="A/H1N1pdm in 2009 than those who did not receive"/>
   <result pre="influenza A/H1N1pdm in 2009 than those who did not receive" exact="influenza" post="vaccination during 2008–2009. Cowling et al. [11] reported that"/>
   <result pre="et al. [11] reported that the risk of infection with" exact="influenza" post="A/H1N1pdm in 2009 among people who were infected with"/>
   <result pre="A/H1N1pdm in 2009 among people who were infected with seasonal" exact="influenza" post="A during 2008–2009 was significantly lower than that among"/>
   <result pre="2008–2009 was significantly lower than that among people without seasonal" exact="influenza" post="A infection; those authors believed that the temporary nonspecific"/>
   <result pre="temporary nonspecific immunity theory could explain short-term protection induced by" exact="influenza" post="infection [12]. Several modeling studies [13,14,15,16] have applied the"/>
   <result pre="[13,14,15,16] have applied the temporary nonspecific immunity theory to describe" exact="influenza" post="virus dynamics and evolution, although biological evidence is limited."/>
   <result pre="Goldstein et al. [17] showed that possible interference among three" exact="influenza" post="virus types, A/H1N1, A/H3N2, and B, as a consequence"/>
   <result pre="virus type, could lead to reduced incidence of other co-circulating" exact="influenza" post="viruses. Additionally, those authors indicated that routine surveillance data"/>
   <result pre="could be used to predict the epidemic size for each" exact="influenza" post="virus type. The interference among different virus types is"/>
   <result pre="stockpiles to prepare for possible simultaneous epidemics caused by seasonal" exact="influenza" post="viruses. If influenza viruses do not independently cause epidemics,"/>
   <result pre="for possible simultaneous epidemics caused by seasonal influenza viruses. If" exact="influenza" post="viruses do not independently cause epidemics, such arguments require"/>
   <result pre="virus type using epidemic data from early phases of the" exact="influenza" post="season has been explored using state-specific datasets from the"/>
   <result pre="continuously implemented so called virus surveillance as well as sentinel" exact="influenza" post="surveillance [21]. Virus surveillance can detect virus types and"/>
   <result pre="and subtypes over time whereas sentinel surveillance collects notifications of" exact="influenza" post="diagnoses from physicians at designated health care facilities. In"/>
   <result pre="of influenza-like illness) undergo rapid diagnostic testing (RDT). This detects" exact="influenza" post="virus (with virus typing information) from nasopharyngeal swabs on"/>
   <result pre="surveillance system provides an opportunity to examine the interaction among" exact="influenza" post="virus types and subtypes. In the present study, we"/>
   <result pre="the present study, we aimed to investigate the interaction between" exact="influenza" post="A/H1N1, A/H3N2, and B in Japan with respect to"/>
   <result pre="Materials and Methods 2.1. Epidemiological Data To estimate the type-specific" exact="influenza" post="incidence, the present study analyzed two datasets: sentinel surveillance"/>
   <result pre="the percentage of each virus type with sentinel reports of" exact="influenza" post="notifications, we obtain type-specific proxy of influenza incidence. Adhering"/>
   <result pre="sentinel reports of influenza notifications, we obtain type-specific proxy of" exact="influenza" post="incidence. Adhering to the Infectious Disease Law and under"/>
   <result pre="under the National Epidemiological Surveillance for Infectious Diseases (NESID) program," exact="influenza" post="cases are notified to local health centers via health"/>
   <result pre="health centers via health care facilities. The weekly number of" exact="influenza" post="cases is reported from approximately 5000 sentinel health care"/>
   <result pre="Untyped A viruses are not reported. Diagnostic criteria for notified" exact="influenza" post="cases are either a positive RDT for influenza and/or"/>
   <result pre="for notified influenza cases are either a positive RDT for" exact="influenza" post="and/or the presence of symptoms of influenza-like illness (ILI),"/>
   <result pre="physicians in Japan regularly use RDT in patients with suspected" exact="influenza" post="infection, because the use of RDT is financially covered"/>
   <result pre="under their universal health coverage. Thus, most notified cases of" exact="influenza" post="are considered to represent the true influenza diagnoses using"/>
   <result pre="notified cases of influenza are considered to represent the true" exact="influenza" post="diagnoses using RDT, mirroring the influenza incidence in a"/>
   <result pre="to represent the true influenza diagnoses using RDT, mirroring the" exact="influenza" post="incidence in a more appropriate manner than ILI-based surveillance"/>
   <result pre="incidence as the product of the weekly number of reported" exact="influenza" post="cases and the proportion of virus type identification for"/>
   <result pre="the other two virus types as the complementary incidence. Japanese" exact="influenza" post="surveillance monitors influenza trends from calendar week 36 to"/>
   <result pre="virus types as the complementary incidence. Japanese influenza surveillance monitors" exact="influenza" post="trends from calendar week 36 to calendar week 35"/>
   <result pre="in this study was to investigate the interference among seasonal" exact="influenza" post="viruses, we analyzed data from calendar week 36 in"/>
   <result pre="To assess the interaction of epidemic sizes among the three" exact="influenza" post="viruses, we used the Spearman rank-order method to explore"/>
   <result pre="and pattern of epidemics are quite different among the three" exact="influenza" post="virus types, thresholds h and hc were chosen for"/>
   <result pre="of the degrees of freedom, calculated as the number of" exact="influenza" post="seasons minus 1. h and hc for each virus"/>
   <result pre="has become predictable. To investigate the interaction among the three" exact="influenza" post="viruses (A/H1N1, A/H3N2, and B) with respect to the"/>
   <result pre="reached the peak (i.e., the maximum value during a single" exact="influenza" post="season) among the three influenza virus types. 2.3. Ethical"/>
   <result pre="maximum value during a single influenza season) among the three" exact="influenza" post="virus types. 2.3. Ethical Considerations This study used publicly"/>
   <result pre="show the temporal distribution of the weekly incidence of three" exact="influenza" post="viruses (A/H1N1, A/H3N2 B) from 2010 to 2019. The"/>
   <result pre="2 shows the temporal distribution of the weekly incidence for" exact="influenza" post="A/H3N2. Vertical lines indicate the week s of each"/>
   <result pre="size took place. The distribution of the weekly incidence of" exact="influenza" post="A/H1N1 and B and the prediction timings are shown"/>
   <result pre="Using the optimization process with equation (2), selected thresholds for" exact="influenza" post="A/H1N1, A/H3N2, and B were h = 250,000 and"/>
   <result pre="value in four seasons (2010–2011, 2013–2014, 2015–2016, and 2018–2019) for" exact="influenza" post="A/H1N, in five seasons (2011–2012, 2012–2013, 2014–2015, 2016–2017, and"/>
   <result pre="in five seasons (2011–2012, 2012–2013, 2014–2015, 2016–2017, and 2018–2019) for" exact="influenza" post="A/H3N2, and in two seasons (2015–2016 and 2017–2018) for"/>
   <result pre="influenza A/H3N2, and in two seasons (2015–2016 and 2017–2018) for" exact="influenza" post="B. In these seasons, we observed large epidemics of"/>
   <result pre="as the epidemic peak except in the 2012–2013 season for" exact="influenza" post="A/H1N1 and the 2012–2013 and 2013–2014 seasons for influenza"/>
   <result pre="for influenza A/H1N1 and the 2012–2013 and 2013–2014 seasons for" exact="influenza" post="A/H3N2 and B. Details of the prediction timing and"/>
   <result pre="the proposed simplistic linear model against the observed data of" exact="influenza" post="A/H1N1, A/H3N2, and B from 2010 to 2019. Detailed"/>
   <result pre="incidence is observed among the three virus types. When comparing" exact="influenza" post="type A viruses (i.e., A/H1N1 vs. A/H3N2), the mean"/>
   <result pre="at 0.11 weeks. Comparing the timing of peak weeks between" exact="influenza" post="type A and B viruses, the mean differences were"/>
   <result pre="viruses, the mean differences were 2.22 and 2.11 weeks between" exact="influenza" post="type B and A/H1N1 and influenza type B and"/>
   <result pre="and 2.11 weeks between influenza type B and A/H1N1 and" exact="influenza" post="type B and A/H3N2, respectively. Standard deviations ranged from"/>
   <result pre="weeks. 4. Discussion In the present study, we explored seasonal" exact="influenza" post="epidemic data in Japan from 2010 to 2019, combining"/>
   <result pre="of nine epidemic seasons. We investigated statistical interactions between different" exact="influenza" post="virus types during the course of and at the"/>
   <result pre="complementary viruses. Specifying the index virus type in a single" exact="influenza" post="season, this index virus was found to be predictable"/>
   <result pre="the epidemic peak was also examined across different types of" exact="influenza" post="virus. We did not identify interacting timing between influenza"/>
   <result pre="of influenza virus. We did not identify interacting timing between" exact="influenza" post="A/H1N1 and A/H3N2, and the peak timing was likely"/>
   <result pre="A/H3N2, and the peak timing was likely different when comparing" exact="influenza" post="type A and B viruses (type A virus tended"/>
   <result pre="to precede type B). The present study verifies that seasonal" exact="influenza" post="virus types interact with each other, and negative correlations"/>
   <result pre="of viruses during real-time prediction of any type of seasonal" exact="influenza" post="because the incidences interfere with each other. As long"/>
   <result pre="the incidences interfere with each other. As long as different" exact="influenza" post="virus types continue to co-circulate, it must be remembered"/>
   <result pre="[17] first conducted an epidemiological analysis of interference among co-circulating" exact="influenza" post="viruses in a state-specific setting of the United States"/>
   <result pre="study adds to the literature regarding the interference among different" exact="influenza" post="virus types, identifiable using prefecture-specific datasets in Japan, another"/>
   <result pre="underlying mechanisms of interactions might differ for the interaction between" exact="influenza" post="A/H3N2 and A/H1N1 and that between influenza type A"/>
   <result pre="the interaction between influenza A/H3N2 and A/H1N1 and that between" exact="influenza" post="type A and B viruses. As for the latter"/>
   <result pre="viruses. As for the latter interaction, the consistent pattern of" exact="influenza" post="type A virus predominance, followed by predominance of influenza"/>
   <result pre="of influenza type A virus predominance, followed by predominance of" exact="influenza" post="type B virus, is indicative of differential seasonal preference"/>
   <result pre="peak of pandemic virus may coincide with that of another" exact="influenza" post="type A virus, although the epidemic peak of pandemic"/>
   <result pre="peak of pandemic virus may not coincide with that of" exact="influenza" post="type B virus. Nevertheless, it must be remembered that"/>
   <result pre="their emergence and perhaps more susceptible in comparison with seasonal" exact="influenza" post="virus of the same subtype. Thus, the interference between"/>
   <result pre="the same subtype. Thus, the interference between pandemic and seasonal" exact="influenza" post="viruses (type A) could be more abrupt than the"/>
   <result pre="more abrupt than the interactions among seasonal viruses. In fact," exact="influenza" post="A/H3N2 was seldom observed during the course of the"/>
   <result pre="used for virus surveillance data. For instance, severe cases with" exact="influenza" post="A/H3N2 might have been more frequently sampled at hospitals"/>
   <result pre="A/H3N2 might have been more frequently sampled at hospitals than" exact="influenza" post="A/H1N1; thus, the examined empirical data cannot reveal the"/>
   <result pre="only older people with underlying comorbidities receive routine vaccination against" exact="influenza" post="in Japan. Homologous vaccines could have modified our results."/>
   <result pre="identified a strong signature of interactions among different types of" exact="influenza" post="viruses, the exact mechanisms behind our observations have yet"/>
   <result pre="limitations, we believe that the present study sufficiently characterizes interacting" exact="influenza" post="virus type structures, using data from 47 prefectures during"/>
   <result pre="virus type structures, using data from 47 prefectures during nine" exact="influenza" post="seasons in Japan. Such interaction among seasonal influenza viruses"/>
   <result pre="during nine influenza seasons in Japan. Such interaction among seasonal" exact="influenza" post="viruses allowed us to predict the size of influenza"/>
   <result pre="seasonal influenza viruses allowed us to predict the size of" exact="influenza" post="epidemics during the early phase of the season. Our"/>
   <result pre="phase of the season. Our findings provide useful insight into" exact="influenza" post="forecasting and preparedness for future influenza pandemics. 5. Conclusions"/>
   <result pre="provide useful insight into influenza forecasting and preparedness for future" exact="influenza" post="pandemics. 5. Conclusions We examined the interaction among seasonal"/>
   <result pre="influenza pandemics. 5. Conclusions We examined the interaction among seasonal" exact="influenza" post="viruses (influenza A/H1N1, A/H3N2, and B) using sentinel and"/>
   <result pre="B) using sentinel and virus surveillance data in Japan. Co-circulating" exact="influenza" post="viruses interact with each other as far as the"/>
   <result pre="Figure S1: Temporal distribution of the weekly incidence proxies for" exact="influenza" post="A/H1N1 from 2010 to 2019. Figure S2: Temporal distribution"/>
   <result pre="Figure S2: Temporal distribution of the weekly incidence proxies for" exact="influenza" post="B from 2010 to 2019.Figure S3: Residual standard error"/>
   <result pre="timing of week s and the epidemic peak weeks of" exact="influenza" post="A/H1N1, A/H3N2, and B. LINK Click here for additional"/>
   <result pre="September 2019) 7.SmithD.J.LapedesA.S.de JongJ.C.BestebroerT.M.RimmelzwaanG.F.OsterhausA.D.FouchierR.A.Mapping the antigenic and genetic evolution of" exact="influenza" post="virusScience200430537137610.1126/science.109721115218094 8.AmpofoW.K.Azziz-BaumgartnerE.BashirU.CoxN.J.FasceR.GiovanniM.GrohmannG.HuangS.KatzJ.MironenkoA.et al.Strengthening the influenza vaccine virus selection and"/>
   <result pre="antigenic and genetic evolution of influenza virusScience200430537137610.1126/science.109721115218094 8.AmpofoW.K.Azziz-BaumgartnerE.BashirU.CoxN.J.FasceR.GiovanniM.GrohmannG.HuangS.KatzJ.MironenkoA.et al.Strengthening the" exact="influenza" post="vaccine virus selection and development process: Report of the"/>
   <result pre="sequential, overlapping, and/or concurrent epidemics caused by H3N2 and H1N1" exact="influenza" post="virusesJ. Infect. Dis.1985151818810.1093/infdis/151.1.813965596 10.SkowronskiD.M.De SerresG.CrowcroftN.S.JanjuaN.Z.BoulianneN.HottesT.S.RosellaL.C.DickinsonJ.A.GilcaR.SethiP.et al.Association between the 2008-09"/>
   <result pre="virusesJ. Infect. Dis.1985151818810.1093/infdis/151.1.813965596 10.SkowronskiD.M.De SerresG.CrowcroftN.S.JanjuaN.Z.BoulianneN.HottesT.S.RosellaL.C.DickinsonJ.A.GilcaR.SethiP.et al.Association between the 2008-09 seasonal" exact="influenza" post="vaccine and pandemic H1N1 illness during Spring-Summer 2009: Four"/>
   <result pre="observational studies from CanadaPLoS Med.20107e100025810.1371/journal.pmed.100025820386731 11.CowlingB.J.NgS.MaE.S.ChengC.K.Y.WaiW.FangV.J.ChanK.-H.IpD.K.M.ChiuS.S.PeirisJ.S.M.et al.Protective efficacy of seasonal" exact="influenza" post="vaccination against seasonal and pandemic influenza virus infection during"/>
   <result pre="al.Protective efficacy of seasonal influenza vaccination against seasonal and pandemic" exact="influenza" post="virus infection during 2009 in Hong KongClin. Infect. Dis.2010511370137910.1086/65731121067351"/>
   <result pre="in Hong KongClin. Infect. Dis.2010511370137910.1086/65731121067351 12.CowlingB.J.NgS.MaE.S.FangV.J.SoH.C.WaiW.ChengC.K.Y.WongJ.Y.ChanK.-H.IpD.K.M.et al.Protective efficacy against pandemic" exact="influenza" post="of seasonal influenza vaccination in children in Hong Kong:"/>
   <result pre="Infect. Dis.2010511370137910.1086/65731121067351 12.CowlingB.J.NgS.MaE.S.FangV.J.SoH.C.WaiW.ChengC.K.Y.WongJ.Y.ChanK.-H.IpD.K.M.et al.Protective efficacy against pandemic influenza of seasonal" exact="influenza" post="vaccination in children in Hong Kong: A randomized controlled"/>
   <result pre="randomized controlled trialClin. Infect. Dis.20125569570210.1093/cid/cis51822670050 13.FergusonN.M.GalvaniA.P.BushR.M.Ecological and immunological determinants of" exact="influenza" post="evolutionNature200342242843310.1038/nature0150912660783 14.TriaF.LässigM.PelitiL.FranzS.A minimal stochastic model for influenza evolutionJ. Stat."/>
   <result pre="immunological determinants of influenza evolutionNature200342242843310.1038/nature0150912660783 14.TriaF.LässigM.PelitiL.FranzS.A minimal stochastic model for" exact="influenza" post="evolutionJ. Stat. Mech.20052005700810.1088/1742-5468/2005/07/P07008 15.OmoriR.AdamsB.SasakiA.Coexistence conditions for strains of influenza"/>
   <result pre="for influenza evolutionJ. Stat. Mech.20052005700810.1088/1742-5468/2005/07/P07008 15.OmoriR.AdamsB.SasakiA.Coexistence conditions for strains of" exact="influenza" post="with immune cross-reactionJ. Theor. Biol.2010262485710.1016/j.jtbi.2009.09.01519766659 16.MercerG.N.BarryS.I.KellyH.Modelling the association of"/>
   <result pre="with immune cross-reactionJ. Theor. Biol.2010262485710.1016/j.jtbi.2009.09.01519766659 16.MercerG.N.BarryS.I.KellyH.Modelling the association of seasonal" exact="influenza" post="vaccination and the risk of infection with pandemic influenzaBMC"/>
   <result pre="with pandemic influenzaBMC Public Health.2010Forthcoming 17.GoldsteinE.CobeyS.TakahashiS.MillerJ.C.LipsitchM.Predicting the epidemic sizes of" exact="influenza" post="A/H1N1, A/H3N2, and B: A statistical methodPLoS Med.20118e100105110.1371/journal.pmed.100105121750666 18.National"/>
   <result pre="Figure 1 Temporal distribution of the weekly incidence of three" exact="influenza" post="virus types, A/H1N1 (orange), A/H3N2 (blue), and B (red)"/>
   <result pre="Figure 2 Temporal distribution of the weekly incidence proxies for" exact="influenza" post="A/H3N2 from 2010 to 2019. Epidemic week 1 corresponds"/>
   <result pre="the time at which the sum of the incidence of" exact="influenza" post="A/H3N2 in the past 5 weeks exceeds the statistically"/>
   <result pre="700,000 cases. Figure 3 Dynamic and cumulative correlations among different" exact="influenza" post="viruses. (A) Correlation between the cumulative incidence of influenza"/>
   <result pre="different influenza viruses. (A) Correlation between the cumulative incidence of" exact="influenza" post="A/H1N1 and the cumulative incidence of the complementary viruses"/>
   <result pre="epidemiological weeks 22–24. (B) Correlation between the cumulative incidence of" exact="influenza" post="A/H3N2 and the cumulative incidence of the complementary viruses"/>
   <result pre="epidemiological weeks 22–24. (C) Correlation between the cumulative incidence of" exact="influenza" post="B and cumulative incidence of the complementary viruses by"/>
   <result pre="epidemiological weeks 22–24. (D) Correlation between the cumulative incidence of" exact="influenza" post="A/H1N1 and the cumulative complementary incidence. (E) Correlation between"/>
   <result pre="cumulative complementary incidence. (E) Correlation between the cumulative incidence of" exact="influenza" post="A/H3N2 and the cumulative complementary incidence. (F) Correlation between"/>
   <result pre="cumulative complementary incidence. (F) Correlation between the cumulative incidence of" exact="influenza" post="B and the cumulative complementary incidence. Figure 4 Visual"/>
   <result pre="(A) Correlation between the predicted and observed epidemic sizes of" exact="influenza" post="A/H1N1. The chosen thresholds were h = 250,000 and"/>
   <result pre="(C) Correlation between the predicted and observed epidemic sizes for" exact="influenza" post="B. The statistically chosen thresholds were h = 310,000"/>
   <result pre="the differences between the week of peak incidence for two" exact="influenza" post="virus types. (A) Comparison of the peak timing for"/>
   <result pre="influenza virus types. (A) Comparison of the peak timing for" exact="influenza" post="A/H1N1 versus A/H3N2 (peak epidemic week of A/H3N2 minus"/>
   <result pre="that of A/H1N1). (B) Comparison of the peak timing for" exact="influenza" post="B versus A/H1N1 (peak epidemic week of A/H1N1 minus"/>
   <result pre="minus that B). (C) Comparison of the peak timing for" exact="influenza" post="B versus A/H3N2 (peak epidemic week of A/H3N2 minus"/>
   <result pre="ijerph-16-04179-t001_Table 1Table 1 Prediction models of the epidemic sizes of" exact="influenza" post="A/H1N1, A/H3N2, and B. Influenza A/H1N1 Influenza A/H3N2 Influenza"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6862117\results\search\disease\results.xml">
   <result pre="disease. Neurotropic flaviviruses, such as West Nile virus (WNV), Japanese" exact="encephalitis" post="virus (JEV), and tick-borne encephalitis virus (TBEV), are maintained"/>
   <result pre="as West Nile virus (WNV), Japanese encephalitis virus (JEV), and" exact="tick-borne encephalitis" post="virus (TBEV), are maintained in nature in transmission cycles"/>
   <result pre="West Nile virus (WNV), Japanese encephalitis virus (JEV), and tick-borne" exact="encephalitis" post="virus (TBEV), are maintained in nature in transmission cycles"/>
   <result pre="Infection during pregnancy, especially during the first trimester, causes fetal" exact="microcephaly" post="and other developmental anomalies, defined as congenital Zika virus"/>
   <result pre="defined as congenital Zika virus syndrome [3]. Guillain–Barré syndrome and" exact="meningoencephalitis" post="are rare complications of ZIKV infection in adult individuals."/>
   <result pre="complications caused by viruses, such as dengue virus (DENV) and" exact="yellow fever" post="virus (YFV), which usually are associated with hemorrhagic disease"/>
   <result pre="and yellow fever virus (YFV), which usually are associated with" exact="hemorrhagic disease" post="[6,7]. One of the central questions in the search"/>
   <result pre="6.Carod-ArtalF.J.WichmannO.FarrarJ.GascónJ.Neurological complications of dengue virus infectionLancet Neurol.20131290691910.1016/S1474-4422(13)70150-923948177 7.MarinhoP.E.S.AlvarengaP.P.M.CrispimA.P.C.CandianiT.M.S.AlvarengaA.M.BechlerI.M.AlvesP.A.DornasF.P.de OliveiraD.B.BentesA.A.et al.Wild-type" exact="yellow fever" post="virus RNA in cerebrospinal fluid of childEmerg. Infect. Dis.2019251567157010.3201/eid2508.18147931310221"/>
   <result pre="Zika syndromeEBioMedicine201610657010.1016/j.ebiom.2016.06.02627364784 26.ShrestaB.GottliebD.DiamondM.S.Infection and injury of neurons by West Nile" exact="encephalitis" post="virusJ. Virol.200373132031321310.1128/JVI.77.24.13203-13213.2003 27.LucasM.MashimoT.FrenkielM.P.Simon-ChazottesD.MontagutelliX.CeccaldiP.E.GuénetJ.L.DesprèsP.Infection of mouse neurons by West Nile"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6862669\results\search\disease\results.xml">
   <result pre="of cytokine profiles induced by nonlethal and lethal doses of" exact="influenza" post="A virus in mice TurianováLucia1LachováVeronika1SvetlíkovaDarina1KostrábováAnna2BetákováTatiana12[1], [2], Correspondence to: Dr"/>
   <result pre="and mortality. To investigate the immunological factors associated with severe" exact="influenza" post="infection, the immune responses in mice infected with nonlethal"/>
   <result pre="in mice infected with nonlethal (LD0) doses of A/PR/8/34 (H1N1)" exact="influenza" post="virus were compared with those of mice infected with"/>
   <result pre="present study identified key cytokines involved in the pathogenicity of" exact="influenza" post="infection, and demonstrated that lethal influenza virus infection induces"/>
   <result pre="in the pathogenicity of influenza infection, and demonstrated that lethal" exact="influenza" post="virus infection induces a mixed Th1/Th2 response. influenza virus"/>
   <result pre="that lethal influenza virus infection induces a mixed Th1/Th2 response." exact="influenza" post="virus cytokine interleukin chemokine immune response lungs mice Introduction"/>
   <result pre="virus cytokine interleukin chemokine immune response lungs mice Introduction The" exact="influenza" post="A virus is a major human pathogen. The severity"/>
   <result pre="deaths (1). In order to effectively diagnose and treat severe" exact="influenza" post="virus infections, it is important to determine the infection"/>
   <result pre="for predicting disease severity is required (2). Identifying biomarkers of" exact="influenza" post="A infection is challenging, as many viral and cellular"/>
   <result pre="and adaptive immune responses are crucial for the control of" exact="influenza" post="infection. The activity of innate and adaptive immune cells"/>
   <result pre="LD0. The results provide novel insights into the pathology of" exact="influenza" post="A infection and may have applications for the improvement"/>
   <result pre="A infection and may have applications for the improvement of" exact="influenza" post="diagnosis and therapy. Materials and methods Cells and viruses"/>
   <result pre="we did not examine histological changes in the lungs after" exact="influenza" post="infection. We would like to do it in the"/>
   <result pre="lungs of mice infected with nonlethal and lethal doses of" exact="influenza" post="virus. Nevertheless, infection with LD100 induced the expression of"/>
   <result pre="the profiles previously observed in sera from patients with severe" exact="influenza" post="infection and influenza virus-associated encephalopathy (11,12,20). IFN-γ, IL-4, IL-7,"/>
   <result pre="observed in sera from patients with severe influenza infection and" exact="influenza" post="virus-associated encephalopathy (11,12,20). IFN-γ, IL-4, IL-7, IL-10, IL-11, IL-12p40,"/>
   <result pre="sera from patients with severe influenza infection and influenza virus-associated" exact="encephalopathy" post="(11,12,20). IFN-γ, IL-4, IL-7, IL-10, IL-11, IL-12p40, IL-13 and"/>
   <result pre="function as anti-inflammatory macrophages and serve key roles in the" exact="suppression" post="of Th1 cell responses, wound healing and tissue repair"/>
   <result pre="of chemokines and the Th2 phenotype serve central roles in" exact="influenza" post="pathogenesis (36). The results of the present study therefore"/>
   <result pre="CCL2 and CCL12 mediate acute lung injury induced by lethal" exact="influenza" post="infection, as well as by the γ-herpesvirus or fungal"/>
   <result pre="is an important mechanism underlying multiple organ failure during severe" exact="influenza" post="infection. A previous study in mouse models demonstrated that"/>
   <result pre="PCSK9 and TIM-1, correlated with extensive lung damage following lethal" exact="influenza" post="infection. These proteins modulate infection response, inflammation and tissue"/>
   <result pre="exacerbates multi-organ damage, and MMP3 contributes to the pathogenesis of" exact="acute respiratory distress syndrome" post="(54,55). M-CSF promotes the differentiation and survival of macrophages,"/>
   <result pre="M-CSF, PTX2, PTX3, WISP-1, MMP-2, MMP-3, PCSK9 and TIM-1 in" exact="influenza" post="pathogenicity. It is possible that these factors are released"/>
   <result pre="has been implicated in the pathogenesis of granulomatous diseases and" exact="pulmonary fibrosis" post="(57,58). By comparing the cytokine profiles obtained from the"/>
   <result pre="from the lungs of mice infected with nonlethal and lethal" exact="influenza" post="doses, the authors of the present study hypothesize that"/>
   <result pre="response. A previous study demonstrated that Th2-dominated immune responses to" exact="influenza" post="virus infection exacerbate lung tissue damage and delay viral"/>
   <result pre="basophils may serve a greater role in the pathogenesis of" exact="influenza" post="infection than previously thought. However, the mechanisms by which"/>
   <result pre="which Th1 and Th2 cells influence the inflammatory response during" exact="influenza" post="virus infection require further investigation in future studies. Acknowledgements"/>
   <result pre="Island, FL2019https://www.ncbi.nlm.nih.gov/books/NBK537197/ 2KollmusHPilznerCLeistSRHeiseMGeffersRSchughartKOf mice and men: The host response to" exact="influenza" post="virus infectionMamm Genome29446470201810.1007/s00335-018-9750-y29947965 3BaskinCRBielefeldt-OhmannHTumpeyTMSabourinPJLongJPGarcía-SastreATolnayAEAlbrechtRPylesJAOlsonPHet al.Early and sustained innate immune"/>
   <result pre="pathology and death in nonhuman primates infected by highly pathogenic" exact="influenza" post="virusProc Natl Acad Sci USA10634553460200910.1073/pnas.081323410619218453 4LycettSJWardMJLewisFIPoonAFKosakovsky PondSLBrownAJDetection of mammalian"/>
   <result pre="USA10634553460200910.1073/pnas.081323410619218453 4LycettSJWardMJLewisFIPoonAFKosakovsky PondSLBrownAJDetection of mammalian virulence determinants in highly pathogenic" exact="avian influenza" post="H5N1 viruses: Multivariate analysis of published dataJ Virol8399019910200910.1128/JVI.00608-0919625397 5de"/>
   <result pre="4LycettSJWardMJLewisFIPoonAFKosakovsky PondSLBrownAJDetection of mammalian virulence determinants in highly pathogenic avian" exact="influenza" post="H5N1 viruses: Multivariate analysis of published dataJ Virol8399019910200910.1128/JVI.00608-0919625397 5de"/>
   <result pre="of published dataJ Virol8399019910200910.1128/JVI.00608-0919625397 5de WitEKawaokaYde JongMDFouchierRAPathogenicity of highly pathogenic" exact="avian influenza" post="virus in mammalsVaccine26Suppl 4D54D58200810.1016/j.vaccine.2008.07.07219230161 6PingJKeletaLForbesNEDankarSStechoWTylerSZhouYBabiukLWeingartlHHalpinRAet al.Genomic and protein structural"/>
   <result pre="published dataJ Virol8399019910200910.1128/JVI.00608-0919625397 5de WitEKawaokaYde JongMDFouchierRAPathogenicity of highly pathogenic avian" exact="influenza" post="virus in mammalsVaccine26Suppl 4D54D58200810.1016/j.vaccine.2008.07.07219230161 6PingJKeletaLForbesNEDankarSStechoWTylerSZhouYBabiukLWeingartlHHalpinRAet al.Genomic and protein structural"/>
   <result pre="al.Genomic and protein structural maps of adaptive evolution of human" exact="influenza" post="A virus to increased virulence in the mousePLoS One6e21740201110.1371/journal.pone.002174021738783"/>
   <result pre="to increased virulence in the mousePLoS One6e21740201110.1371/journal.pone.002174021738783 7TumpeyTMGarcía-SastreATaubenbergerJKPalesePSwayneDEPantin-JackwoodMJSchultz-CherrySSolórzanoAVan RooijenNKatzJMBaslerCFPathogenicity of" exact="influenza" post="viruses with genes from the 1918 pandemic virus: Functional"/>
   <result pre="a virulent PB2 E627K variant during adaptation of highly pathogenic" exact="avian influenza" post="H7N7 virus to miceVirol J10276201310.1186/1743-422X-10-27624007444 9BetakovaTKostrabovaALachovaVTurianovaLCytokines induced during influenza"/>
   <result pre="virulent PB2 E627K variant during adaptation of highly pathogenic avian" exact="influenza" post="H7N7 virus to miceVirol J10276201310.1186/1743-422X-10-27624007444 9BetakovaTKostrabovaALachovaVTurianovaLCytokines induced during influenza"/>
   <result pre="avian influenza H7N7 virus to miceVirol J10276201310.1186/1743-422X-10-27624007444 9BetakovaTKostrabovaALachovaVTurianovaLCytokines induced during" exact="influenza" post="virus infectionCurr Pharm Des2326162622201710.2174/138161282366617031612373628302021 10ChiYZhuYWenTCuiLGeYJiaoYWuTGeAJiHXuKet al.Cytokine and chemokine levels"/>
   <result pre="al.Cytokine and chemokine levels in patients infected with the novel" exact="avian influenza" post="A (H7N9) virus in ChinaJ Infect Dis20819621967201310.1093/infdis/jit44023990573 11Bradley-StewartAJollyLAdamsonWGunsonRFrew-GillespieCTempletonKAitkenCCarmanWCameronSMcSharryCCytokine responses"/>
   <result pre="and chemokine levels in patients infected with the novel avian" exact="influenza" post="A (H7N9) virus in ChinaJ Infect Dis20819621967201310.1093/infdis/jit44023990573 11Bradley-StewartAJollyLAdamsonWGunsonRFrew-GillespieCTempletonKAitkenCCarmanWCameronSMcSharryCCytokine responses"/>
   <result pre="Infect Dis20819621967201310.1093/infdis/jit44023990573 11Bradley-StewartAJollyLAdamsonWGunsonRFrew-GillespieCTempletonKAitkenCCarmanWCameronSMcSharryCCytokine responses in patients with mild or severe" exact="influenza" post="A(H1N1)pdm09J Clin Virol58100107201310.1016/j.jcv.2013.05.01123790455 12SunGOtaCKitaokaSChibaYTakayanagiMKitamuraTYamamotoKFujieHMikamiHUematsuMet al.Elevated serum levels of neutrophil"/>
   <result pre="12SunGOtaCKitaokaSChibaYTakayanagiMKitamuraTYamamotoKFujieHMikamiHUematsuMet al.Elevated serum levels of neutrophil elastase in patients with" exact="influenza" post="virus-associated encephalopathyJ Neurol Sci349190195201510.1016/j.jns.2015.01.01725626769 13AhnMYZhangZGTsangWChoppMEndogenous plasminogen activator expression after"/>
   <result pre="cerebral ischemia in miceBrain Res837169176199910.1016/S0006-8993(99)01645-510433999 14PeirisJSYuWCLeungCWCheungCYNgWFNichollsJMNgTKChanKHLaiSTLimWLet al.Re-emergence of fatal human" exact="influenza" post="A subtype H5N1 diseaseLancet363617619200410.1016/S0140-6736(04)15595-514987888 15ChanMCCheungCYChuiWHTsaoSWNichollsJMChanYOChanRWLongHTPoonLLGuanYPeirisJSProinflammatory cytokine responses induced by"/>
   <result pre="influenza A subtype H5N1 diseaseLancet363617619200410.1016/S0140-6736(04)15595-514987888 15ChanMCCheungCYChuiWHTsaoSWNichollsJMChanYOChanRWLongHTPoonLLGuanYPeirisJSProinflammatory cytokine responses induced by" exact="influenza" post="A (H5N1) viruses in primary human alveolar and bronchial"/>
   <result pre="16WalshKBTeijaroJRRosenHOldstoneMBQuelling the storm: Utilization of sphingosine-1-phosphate receptor signaling to ameliorate" exact="influenza" post="virus-induced cytokine stormImmunol Res511525201110.1007/s12026-011-8240-z21901448 17VogelAJHarrisSMarstellerNCondonSABrownDMEarly cytokine dysregulation and viral"/>
   <result pre="dysregulation and viral replication are associated with mortality during lethal" exact="influenza" post="infectionViral Immunol27214224201410.1089/vim.2013.009524787235 18SvancarovaPSvetlikovaDBetakovaTSynergic and antagonistic effect of small hairpin"/>
   <result pre="of small hairpin RNAs targeting the NS gene of the" exact="influenza" post="A virus in cells and miceVirus Res195100111201510.1016/j.virusres.2014.08.00425192613 19JablonskiKAAmiciSAWebbLMRuiz-Rosado JdeDPopovichPGPartida-SanchezSGuerau-de-ArellanoMNovel"/>
   <result pre="20DaveyRTJrLynfieldRDwyerDELossoMHCozzi-LepriAWentworthDLaneHCDewarRRupertAMetcalfJAet al.The association between serum biomarkers and disease outcome in" exact="influenza" post="A(H1N1)pdm09 virus infection: Results of two international observational cohort"/>
   <result pre="ligand 2 (CCL2) mediates acute lung injury induced by lethal" exact="influenza" post="H7N9 VirusFront Microbiol8587201710.3389/fmicb.2017.0058728421067 45WolfSJohnsonSPerwitasariOMahalingamSTrippRATargeting the pro-inflammatory factor CCL2 (MCP-1)"/>
   <result pre="Microbiol8587201710.3389/fmicb.2017.0058728421067 45WolfSJohnsonSPerwitasariOMahalingamSTrippRATargeting the pro-inflammatory factor CCL2 (MCP-1) with bindarit for" exact="influenza" post="A (H7N9) treatmentClin Transl Immunology6e135201710.1038/cti.2017.828435679 46SakaiSKawamataHMantaniNKogureTShimadaYTerasawaKSakaiTImanishiNOchiaiHTherapeutic effect of anti-macrophage"/>
   <result pre="Immunology6e135201710.1038/cti.2017.828435679 46SakaiSKawamataHMantaniNKogureTShimadaYTerasawaKSakaiTImanishiNOchiaiHTherapeutic effect of anti-macrophage inflammatory protein 2 antibody on" exact="influenza" post="virus-induced pneumonia in miceJ Virol7424722476200010.1128/JVI.74.5.2472-2476.200010666283 47CampJVBagciUChuYKSquierBFraigMUriarteSMGuoHMolluraDJJonssonCBLower respiratory tract infection"/>
   <result pre="effect of anti-macrophage inflammatory protein 2 antibody on influenza virus-induced" exact="pneumonia" post="in miceJ Virol7424722476200010.1128/JVI.74.5.2472-2476.200010666283 47CampJVBagciUChuYKSquierBFraigMUriarteSMGuoHMolluraDJJonssonCBLower respiratory tract infection of the"/>
   <result pre="respiratory tract infection of the ferret by 2009 H1N1 pandemic" exact="influenza" post="A Virus triggers biphasic, systemic, and local recruitment of"/>
   <result pre="changes in the lungs and heart of mice infected with" exact="influenza" post="A virusComp Immunol Microbiol Infect Dis56613201810.1016/j.cimid.2017.11.00229406285 51PillingDGomerRHThe development of"/>
   <result pre="profile in lung granulomatosis of unexplained etiologyHum Pathol75104115201810.1016/j.humpath.2018.01.01829410258 58WuCLuoZPangBWangWDengMJinRMuhataerXLiYLiQYangXAssociations of" exact="pulmonary fibrosis" post="with peripheral blood Th1/Th2 cell imbalance and EBF3 gene"/>
   <result pre="Mice were infected with LD0 and LD100 doses of H1N1" exact="influenza" post="virus. (A) Lungs were harvested prior to infection and"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6863562\results\search\disease\results.xml">
   <result pre="reproduction number (R0) and eco-environmental variables in Colombian municipalities with" exact="chikungunya" post="outbreaks during 2014-2016 Eco-environmental variables and Chikungunya basic reproduction"/>
   <result pre="is reported on a weekly basis, i.e. weekly number of" exact="chikungunya" post="cases per city reporting. Population projections developed by the"/>
   <result pre="R0 from CHIKV incidence data From 846 municipalities that reported" exact="chikungunya" post="cases between 2014 and 2016 we selected 85 that"/>
   <result pre="which was 589 cases. Fig 1 General behavior of the" exact="chikungunya" post="epidemic that occurred in Colombia from 2014 to 2016."/>
   <result pre="BhimalaKR, KumaraswamyS, KadiriMR, et al.Temperature dependent transmission potential model for" exact="chikungunya" post="in India. Sci Total Environ. 2018;647:66–74. Epub 2018/08/01. 10.1016/j.scitotenv.2018.07.461"/>
   <result pre="22AltoBW, WigginsK, EastmondB, VelezD, LounibosLP, LordCC. Transmission risk of two" exact="chikungunya" post="lineages by invasive mosquito vectors from Florida and the"/>
   <result pre="BhimalaKR, KumaraswamyS, KadiriMR, et al.Temperature dependent transmission potential model for" exact="chikungunya" post="in India. Sci Total Environ. 2019;647:66–74. Epub 2018/08/06. 10.1016/j.scitotenv.2018.07.461"/>
   <result pre="the impact of temperature on transmission of Zika, dengue, and" exact="chikungunya" post="using mechanistic models. PLoS Negl Trop Dis. 2017;11(4):e0005568 Epub"/>
   <result pre="CasasI. A spatial model of socioeconomic and environmental determinants of" exact="dengue fever" post="in Cali, Colombia. Acta Trop. 2016;164:169–76. Epub 2016/10/30. 10.1016/j.actatropica.2016.08.028"/>
   <result pre="space, and behaviors shape the spread of infectious diseases using" exact="chikungunya" post="as a case study. Proc Natl Acad Sci U"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6863851\results\search\disease\results.xml">
   <result pre="areas as well. ZIKV is related to other arboviruses like" exact="chikungunya" post="and dengue. Beside the major source of transmission (mosquito"/>
   <result pre="lead to Congenital Zika Syndrome the symptoms of which include" exact="microcephaly" post="and a specific pattern of brain damage. The virus"/>
   <result pre="virus disease, shares clinical signs and symptoms with dengue and" exact="chikungunya" post="fever, including mild fever, rash, conjunctivitis and joint pain."/>
   <result pre="symptoms with dengue and chikungunya fever, including mild fever, rash," exact="conjunctivitis" post="and joint pain. It has also been linked to"/>
   <result pre="October 2015, Brazil reported an increase in the number of" exact="microcephaly" post="cases among newborns. In November, Zika virus genome was"/>
   <result pre="in the blood and tissues of a baby born with" exact="microcephaly" post="in Brazil. In January 2016, intrauterine transmission of Zika"/>
   <result pre="of Zika virusJ. Infect. Dis.2017216S875S88310.1093/infdis/jix39629267909 7.World Health Organization, Zika virus," exact="microcephaly" post="and Guillain–Barré syndrome. Situation report. 7 April 2016, http://apps.who.int/iris/bitstream/handle/10665/204961/zikasitrep_7Apr2016_eng.pdf"/>
   <result pre="the impact of temperature on transmission of Zika, dengue, and" exact="chikungunya" post="using mechanistic modelsPLoS Negl. Trop. Dis.201711e000556810.1371/journal.pntd.000556828448507 23.GuzzettaGet al.Assessing the"/>
   <result pre="from a computer codeTechnometrics197921239245 37.GuzzettaGet al.Effectiveness of contact investigations for" exact="tuberculosis" post="control in ArkansasJ. Theor. Biol.201538023824610.1016/j.jtbi.2015.05.03126051196 38.BlowerSMDowlatabadiHSensitivity and uncertainty analysis"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6863932\results\search\disease\results.xml">
   <result pre="permitted which does not comply with these terms. Abstract Current" exact="influenza" post="vaccines manufactured using eggs have considerable limitations, both in"/>
   <result pre="emerging pandemic strain. Here we explore the production of recombinant" exact="influenza" post="haemagglutinin using the ciliated protozoan Tetrahymena thermophila. For the"/>
   <result pre="time we were able to produce haemagglutinin from both seasonal" exact="influenza" post="A and B strains. This ciliate derived material was"/>
   <result pre="with ciliate derived haemagglutinin were protected against challenge with homologous" exact="influenza" post="A or B viruses. The antigen could also be"/>
   <result pre="economic burden worldwide (1). The World Health Organization (WHO) estimates" exact="influenza" post="epidemics to result in about 3 to 5 million"/>
   <result pre="globally each year, leading to 290,000 to 650,000 deaths. Annual" exact="influenza" post="vaccination is considered by the WHO to be the"/>
   <result pre="the most effective strategy to prevent disease caused by the" exact="influenza" post="A and B viruses currently co-circulating in humans. Vaccination"/>
   <result pre="vaccines are produced using embryonated chicken eggs (3). However, egg-based" exact="influenza" post="vaccine production is complex to scale up and work"/>
   <result pre="a limited supply of embryonated eggs due to effects of" exact="influenza" post="virus on poultry (7). Alternative approaches that can generate"/>
   <result pre="has been on cell culture-based technologies for mass production of" exact="influenza" post="vaccines and there is a licensed cell culture-based vaccine:"/>
   <result pre="of age and older (9). Completely cell cultured virus in" exact="influenza" post="vaccines, which was not propagated in eggs, can avoid"/>
   <result pre="propagated in eggs, can avoid the egg-adaptation changes of the" exact="influenza" post="virus (10). But cell lines can induce mutations, reducing"/>
   <result pre="Furthermore, cell culture-based technologies using mammalian systems for manufacturing of" exact="influenza" post="vaccine from whole virus still involve chemical virus inactivation"/>
   <result pre="is to manufacture vaccines derived from recombinant protein. For example," exact="influenza" post="antigens can be produced in insect cells using baculoviral"/>
   <result pre="antigens. However, the current market share of this approved recombinant" exact="influenza" post="antigen produced in insect cells (Flublok™ from Sanofi, Swiftwater,"/>
   <result pre="low at 1–2%. Other approaches for the production of recombinant" exact="influenza" post="antigen are being investigated, for example the expression of"/>
   <result pre="candidates for vaccines against protozoan pathogenic agents, for example the" exact="malaria" post="agent Plasmodium falciparum (18). Furthermore, it has been shown,"/>
   <result pre="also suitable as expression host for the recombinant production of" exact="influenza" post="virus proteins (19). One other consideration is post-translational modification,"/>
   <result pre="heterogeneity (16). Here we describe the production of a recombinant" exact="influenza" post="subunit vaccine by overexpression of the surface protein HA"/>
   <result pre="subunit vaccine by overexpression of the surface protein HA from" exact="influenza" post="virus A and B strains using the ciliate T."/>
   <result pre="necessary to confer immunity (3, 21), we also combined the" exact="influenza" post="antigens with PLA-Nod2 particles, a promising vaccine vehicle (22,"/>
   <result pre="HA2 including the transmembrane region and the cytoplasmic tale) of" exact="influenza" post="virus A/California/07/2009 (A/Cal; accession # EPI177294, 567 amino acids),"/>
   <result pre="were anesthetized using isoflurane and infected i.n. with 100 μl" exact="influenza" post="virus or sterile PBS. Mice were culled using 100"/>
   <result pre="a non-lethal model, to match refinement guidelines. Influenza Viruses The" exact="influenza" post="infectious viruses used for HA inhibition, virus neutralization in"/>
   <result pre="neutralization in vitro assays and in vivo challenge were seasonal" exact="influenza" post="strains obtained from NIBSC: A/California/7/2009 (H1N1, 15/252) and B/Brisbane/60/2008"/>
   <result pre="thermophila as an expression host for production of different recombinant" exact="influenza" post="HA expression vectors coding for full length HA, codon-optimized,"/>
   <result pre="immunization (Figure 2A). Both s.c. and i.m. immunization induced significant" exact="influenza" post="specific IgG already after the primary immunization, with GMT"/>
   <result pre="immunized at 3 weekly intervals with a quadrivalent mixture of" exact="influenza" post="antigens containing 45 μg each of A/NC, A/Uru, B/Jia"/>
   <result pre="were compared to 15 μg positive control egg derived inactivated" exact="influenza" post="antigen (IIV). After 3 doses of vaccine, mice immunized"/>
   <result pre="low dose of antigen had a high level of HA" exact="influenza" post="specific antibody in serum (Figure 4A). Mice were then"/>
   <result pre="1.5 μg ciliate derived A/Cal, or 15 μg control inactivated" exact="influenza" post="antigen (IIV) by the intramuscular (i.m.) route. Two weeks"/>
   <result pre="or low dose of antigen had a high level of" exact="influenza" post="B specific antibody in serum (Figure 5A). Mice were"/>
   <result pre="serum (Figure 5A). Mice were then challenged i.n. with B/Bri" exact="influenza" post="strain; there was a significant difference between vaccinated and"/>
   <result pre="post test. Discussion In the current study we show that" exact="influenza" post="HA can be produced in the ciliate T. thermophila."/>
   <result pre="antigen was immunogenic and able to protect against infection with" exact="influenza" post="A or B viruses in mice. In a small"/>
   <result pre="we show that Tetrahymena can be used to produce immunogenic" exact="influenza" post="antigens. One advantage of recombinant protein-based influenza vaccines is"/>
   <result pre="to produce immunogenic influenza antigens. One advantage of recombinant protein-based" exact="influenza" post="vaccines is the avoidance of infectious viral propagation which"/>
   <result pre="further limitation of insect cells for the production of recombinant" exact="influenza" post="vaccines is the large volume of virus needed on"/>
   <result pre="looked at comparative efficacy compared to other platforms for generating" exact="influenza" post="vaccines, and the animal models may not necessarily enable"/>
   <result pre="or interpretation. EM works for Vismederi srl, which analyses responses" exact="influenza" post="vaccines and infection, Vismederi analyzed data from the project."/>
   <result pre="https://www.frontiersin.org/articles/10.3389/fimmu.2019.02661/full#supplementary-material Figure S1 SDS-PAGE of ciliate produced, purified rHA from" exact="influenza" post="virus A and B strains. Each purified rHA was"/>
   <result pre="References References 1.SomesMPTurnerRMDwyerLJNewallAT. Estimating the annual attack rate of seasonal" exact="influenza" post="among unvaccinated individuals: a systematic review and meta-analysis. Vaccine."/>
   <result pre="changes with aging. Semin Immunol. (2018) 40:83–94. 10.1016/j.smim.2018.10.01030501873 3.TregoningJSRussellRFKinnearE. Adjuvanted" exact="influenza" post="vaccines. Human Vaccines Immunotherapeut. (2018) 14:550–64. 10.1080/21645515.2017.141568429232151 4.SubbaraoKBarrI. A"/>
   <result pre="of two mutations: beginning to understand the problems with egg-based" exact="influenza" post="vaccines?Cell Host Microbe. (2019) 25:773–5. 10.1016/j.chom.2019.05.01231194938 5.ParkerLWhartonSAMartinSRCrossKLinYLiuYet al.. Effects"/>
   <result pre="Effects of egg-adaptation on receptor-binding and antigenic properties of recent" exact="influenza" post="A (H3N2) vaccine viruses. J Gen Virol. (2016) 97:1333–44."/>
   <result pre="J Gen Virol. (2016) 97:1333–44. 10.1099/jgv.0.00045726974849 6.SkowronskiDMJanjuaNZDe SerresGSabaiducSEshaghiADickinsonJAet al.Low 2012–13" exact="influenza" post="vaccine effectiveness associated with mutation in the egg-adapted H3N2"/>
   <result pre="(2014) 9:e9215310.1371/journal.pone.009215324667168 7.PandeyASinghNSambharaSMittalSK. Egg-independent vaccine strategies for highly pathogenic H5N1" exact="influenza" post="viruses. Human Vaccines. (2010) 6:178–88. 10.4161/hv.6.2.989919875936 8.BarrIGDonisROKatzJMMcCauleyJWOdagiriTTrusheimHet al.. Cell"/>
   <result pre="viruses. Human Vaccines. (2010) 6:178–88. 10.4161/hv.6.2.989919875936 8.BarrIGDonisROKatzJMMcCauleyJWOdagiriTTrusheimHet al.. Cell culture-derived" exact="influenza" post="vaccines in the severe 2017–2018 epidemic season: a step"/>
   <result pre="in the severe 2017–2018 epidemic season: a step towards improved" exact="influenza" post="vaccine effectiveness. NPJ Vaccines. (2018) 3:44. 10.1038/s41541-018-0079-z30323955 9.IzurietaHSChillarigeYKelmanJWeiYLuYXuWet al.."/>
   <result pre="3:44. 10.1038/s41541-018-0079-z30323955 9.IzurietaHSChillarigeYKelmanJWeiYLuYXuWet al.. Relative effectiveness of cell-cultured and egg-based" exact="influenza" post="vaccines among elderly persons in the United States, 2017–2018."/>
   <result pre="characteristics of qualified cell lines for isolation and propagation of" exact="influenza" post="viruses for vaccine manufacturing. Vaccine. (2014) 32:6583–90. 10.1016/j.vaccine.2014.06.04524975811 11.LeeHKTangJWKongDHLohTPChiangDKLamTTet"/>
   <result pre="10.1016/j.vaccine.2014.06.04524975811 11.LeeHKTangJWKongDHLohTPChiangDKLamTTet al.. Comparison of mutation patterns in full-genome A/H3N2" exact="influenza" post="sequences obtained directly from clinical samples and the same"/>
   <result pre="passage. PLoS ONE. (2013) 8:e79252. 10.1371/journal.pone.007925224223916 12.SheYMChengKFarnsworthALiXCyrTD. Surface modifications of" exact="influenza" post="proteins upon virus inactivation by beta-propiolactone. Proteomics. (2013) 13:3537–47."/>
   <result pre="Appl Microbiol Biotechnol. (1999) 51:447–55. 10.1007/s00253005141510341428 18.CowanGJBockauUEleni-MuusJAldagISamuelKCreaseyAMet al.. A novel" exact="malaria" post="vaccine candidate antigen expressed in Tetrahymena thermophila. PLoS ONE."/>
   <result pre="System for the heterologous expression of NS1 protein of H9N2" exact="avian influenza" post="virus in the ciliate Tetrahymena thermophila. J Vet Med"/>
   <result pre="for the heterologous expression of NS1 protein of H9N2 avian" exact="influenza" post="virus in the ciliate Tetrahymena thermophila. J Vet Med"/>
   <result pre="induce influenza-specific CD8+ T cell responses, enabling faster resolution of" exact="influenza" post="disease. Front Immunol. (2016) 7:321. 10.3389/fimmu.2016.0032127602032 30.GrovesHTMcDonaldJULangatPKinnearEKellamPMcCauleyJet al.. Mouse"/>
   <result pre="Front Immunol. (2016) 7:321. 10.3389/fimmu.2016.0032127602032 30.GrovesHTMcDonaldJULangatPKinnearEKellamPMcCauleyJet al.. Mouse models of" exact="influenza" post="infection with circulating strains to test seasonal vaccine efficacy."/>
   <result pre="a simple and high-yielding fed-batch process for the production of" exact="influenza" post="vaccines. Vaccine. (2009) 28:309–16. 10.1016/j.vaccine.2009.10.04819879996 38.ChalmersJJ. Shear sensitivity of"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6868920\results\search\disease\results.xml">
   <result pre="Article Molecular characteristics and replication mechanism of dengue, zika and" exact="chikungunya" post="arboviruses, and their treatments with natural extracts from plants:"/>
   <result pre="human diseases with worldwide distribution; including dengue (DENV), zika (ZIKV)," exact="yellow fever" post="(YFV), and chikungunya (CHIKV) viruses. These viruses are especially"/>
   <result pre="distribution; including dengue (DENV), zika (ZIKV), yellow fever (YFV), and" exact="chikungunya" post="(CHIKV) viruses. These viruses are especially important in tropical"/>
   <result pre="(Diptera: Culicidae) are primary vectors for arboviruses such as dengue," exact="yellow fever," post="zika and chikungunya viruses guaranteeing their permanence and circulation"/>
   <result pre="vectors for arboviruses such as dengue, yellow fever, zika and" exact="chikungunya" post="viruses guaranteeing their permanence and circulation in the population"/>
   <result pre="view, to deepen the studies related to dengue virus (DENV)," exact="yellow fever" post="virus (YFV), zika virus (ZIKV) and chikungunya virus (CHIKV)"/>
   <result pre="virus (DENV), yellow fever virus (YFV), zika virus (ZIKV) and" exact="chikungunya" post="virus (CHIKV) that lead to the development of effective,"/>
   <result pre="by four genera: Hepacivirus, one of the representatives being the" exact="hepatitis" post="C virus (HCV); Pestivirus, for which Bovine viral diarrhea"/>
   <result pre="the hepatitis C virus (HCV); Pestivirus, for which Bovine viral" exact="diarrhea" post="virus (BVDV) is a representative; Pegivirus, to which belongs"/>
   <result pre="and the Alphavirus genus. Currently there are four genotypes of" exact="chikungunya" post="reported: The East-Central-South Africa, West Africa, Asian, and Indian"/>
   <result pre="Virus, all of them are known as causative agents of" exact="arthritis" post="(Vu et al., 2017[91]). Since 1950, CHIKV was found"/>
   <result pre="reported. Myocarditis, liver failure in patients with antecedents of chronic" exact="liver disease," post="endocrine alterations, pancreatitis, and respiratory failure have also been"/>
   <result pre="with antecedents of chronic liver disease, endocrine alterations, pancreatitis, and" exact="respiratory failure" post="have also been reported, although less frequently (Simon et"/>
   <result pre="strains, can be involved in the developmental complications such as" exact="microcephaly" post="in fetuses and also severe neurological manifestations in adults."/>
   <result pre="and a biomarker for the diagnostics of dengue, zika and" exact="chikungunya" post="infections (Cecchetto et al., 2017[17]). The NS2 protein, is"/>
   <result pre="zika virus and the polyprotein conformed by C-E3-E2-6K-E1 proteins of" exact="chikungunya" post="virus, having as a result that a single dose"/>
   <result pre="and Alphavirus. Concluding Remarks Arbovirus, such as dengue, zika, and" exact="chikungunya" post="viruses, are an important threat to global public health,"/>
   <result pre="dengue virus NS5 polymerase inhibitorsJ Nat Prod2011742446–5322050318 5AllisonSLSchalichJStiasnyKMandlCWKunzCHeinzFXOligomeric rearrangement of" exact="tick-borne encephalitis" post="virus envelope proteins induced by an acidic pHJ Virol199569695–7007529335"/>
   <result pre="virus NS5 polymerase inhibitorsJ Nat Prod2011742446–5322050318 5AllisonSLSchalichJStiasnyKMandlCWKunzCHeinzFXOligomeric rearrangement of tick-borne" exact="encephalitis" post="virus envelope proteins induced by an acidic pHJ Virol199569695–7007529335"/>
   <result pre="Americas, May 2015-January 2016Am J Transplant2016161031–4 29HigueraARamírezJDMolecular epidemiology of dengue," exact="yellow fever," post="Zika and Chikungunya arboviruses: An updateActa Trop201919099–11130444971 30HubálekZRudolfINowotnyNArboviruses pathogenic"/>
   <result pre="perspective of alphavirus replication and assemblyFuture Microbiol20094837–5619722838 32KaurPThiruchelvanMLeeRCHChenHChenKCNgMLet al.Inhibition of" exact="chikungunya" post="virus replication by harringtonine, a novel antiviral that suppresses"/>
   <result pre="and enhances virus replicationJ Biol Chem201128622147–5921511946 49MounceBCCesaroTCarrauLValletTVignuzziMCurcumin inhibits Zika and" exact="chikungunya" post="virus infection by inhibiting cell bindingAntiviral Res2017142148–5728343845 50MurrayCLJonesCTRiceCMArchitects of"/>
   <result pre="56OliveiraAFTeixeiraRROliveiraASSouzaAPSilvaMLPaulaSOPotential antivirals: Natural products targeting replication enzymes of dengue and" exact="chikungunya" post="virusesMolecules2017223E50528327521 57collab: PAHO-CHA-IRVector born diseases (VBD) in the region"/>
   <result pre="single vector construct multi-pathogen vaccine protects against both Zika and" exact="chikungunya" post="virusesNat Commun201891123029581442 64Puerta-GuardoHGlasnerDRHarrisEDengue virus NS1 disrupts the endothelial glycocalyx,"/>
   <result pre="leading to hyperpermeabilityPLoS Pathog2016127e100573827416066 65RanaJGulatiSRajasekharanSGuptaAChaudharyVGuptaSIdentification of potential molecular associations between" exact="chikungunya" post="virus non-structural protein 2 and human host proteinsActa Virol20176139–4728105853"/>
   <result pre="viruses causing the Indian ocean outbreakPLoS Med20063e26316700631 71SharmaRKesariPKumarPTomarSStructure-function insights into" exact="chikungunya" post="virus capsid protein: Small molecules targeting capsid hydrophobic pocketVirology2018515223–3429306785"/>
   <result pre="protein domain III of dengue-4 virusVirology2007364147–5417395234 90VolkDEMayFJGandhamSHAAndersonAVon LindernJJBeasleyDWCet al.Structure of" exact="yellow fever" post="virus envelope protein domain IIIVirology200939412–819818466 91VuDMJungkindDLaBeaudADChikungunya VirusClin Lab Med201737371–8228457355"/>
   <result pre="molecular pathogenesisEmerg Microbes Infect20176e1328325921 93WangDChenCLiuSZhouHYangKZhaoQet al.A mutation identified in neonatal" exact="microcephaly" post="destabilizes Zika virus NS1 assembly in vitroSci Rep201774258028198446 94WangHHanMQiJHilgenfeldRLuoTShiYet"/>
   <result pre="al.Crystal structure of the C-terminal fragment of NS1 protein from" exact="yellow fever" post="virusSci China Life Sci2017601403–629285718 95WeaverSCReisenWKPresent and future arboviral threatsAntiviral"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6872174\results\search\disease\results.xml">
   <result pre="outcomes and reduce vaccination efficacy for viral pathogens such as" exact="influenza" post="and measles. Given the increasing rates of malnutrition and"/>
   <result pre="studies. Here, we infect obese or undernourished mice with different" exact="arthritis" post="inducing viruses in the genus Alphavirus and measure disease"/>
   <result pre="and have been responsible for several recent large outbreaks. Notably," exact="chikungunya" post="virus (CHIKV) re-emerged in 2004 to cause a massive"/>
   <result pre="changes in human health have also facilitated spread. Specifically, worldwide" exact="obesity" post="has tripled since 1975, and the World Health Organization"/>
   <result pre="same country or even within the same family [13]. Both" exact="obesity" post="and undernutrition are known to alter immunity and can"/>
   <result pre="risk of infection from several pathogens (reviewed in [14]). Additionally," exact="obesity" post="and undernutrition have been shown to increase disease severity"/>
   <result pre="increase disease severity and decrease the protective immune response for" exact="influenza" post="virus [15–18]. For arthropod-borne viruses (arboviruses), some epidemiological reports"/>
   <result pre="[15–18]. For arthropod-borne viruses (arboviruses), some epidemiological reports suggest that" exact="obesity" post="is associated with a higher likelihood of being seropositive"/>
   <result pre="that undernourishment may result in a decreased risk of contracting" exact="dengue fever" post="[22]. In addition to susceptibility to infection, obesity has"/>
   <result pre="contracting dengue fever [22]. In addition to susceptibility to infection," exact="obesity" post="has been identified as a risk factor for greater"/>
   <result pre="disease [28]. While the epidemiological data are quite clear that" exact="obesity" post="is associated with more severe disease outcomes for various"/>
   <result pre="nonessential amino acids, and 1% P/S. An Asian genotype of" exact="chikungunya" post="virus (CHIKV) was rescued from an infectious clone of"/>
   <result pre="by adipocytes, is a blood marker that generally increases during" exact="obesity" post="and decreases in severe undernourishment [45]. Obese mice had"/>
   <result pre="of either Mayaro virus (MAYV, 7 mice per group) or" exact="chikungunya" post="virus (CHIKV, 14 mice per group) or 103 PFU"/>
   <result pre="Mice were then infected with either Mayaro virus (MAYV, A-B)," exact="chikungunya" post="virus (CHIKV, C), or Ross River virus (RRV, D)."/>
   <result pre="More explicitly, we aimed to examine the role of both" exact="obesity" post="and undernutrition on infection, transmission, and evolution of arthritogenic"/>
   <result pre="and RRV. We fed mice different diets leading to either" exact="obesity" post="or undernutrition and compared them to lean control mice."/>
   <result pre="undernutrition did not result in more severe morbidity in acute" exact="arthritis" post="models of infection with either CHIKV or MAYV. Our"/>
   <result pre="increased susceptibility to [22] DENV disease. We next showed that" exact="obesity" post="alters viral replication. For MAYV and CHIKV infection, we"/>
   <result pre="early replication in the joint. Given the inflammatory nature of" exact="obesity" post="(reviewed in [49]) and the fact that obesity alters"/>
   <result pre="nature of obesity (reviewed in [49]) and the fact that" exact="obesity" post="alters epithelial cell permeability [50], it is possible that"/>
   <result pre="a 2% protein diet found increased viral replication with both" exact="influenza" post="virus [15] and Sendai virus [51]. However, this was"/>
   <result pre="or other factors in the blood that are altered in" exact="obesity" post="or lipid changes in the virions themselves altered rates"/>
   <result pre="et al. observed similar results in selenium-deficient mice infected with" exact="influenza" post="virus, as a new virulent strain emerged from a"/>
   <result pre="of pro-inflammatory cytokines but not necessarily viral RNA [74]. Therefore," exact="obesity" post="may be involved in persistent alphavirus replication, which may"/>
   <result pre="weeks. Mice were then infected with Mayaro virus (MAYV, A)," exact="chikungunya" post="virus (CHIKV, B), or Ross River virus (RRV, C)."/>
   <result pre="(Lean) diet for 8–10 weeks. Mice were then infected with" exact="chikungunya" post="virus (CHIKV). Nine days post-infection, the left hind footpad"/>
   <result pre="(Lean) diet for 8–10 weeks. Mice were then infected with" exact="chikungunya" post="virus (CHIKV). Nine days post-infection, the left hind footpad"/>
   <result pre="8FreitasARR, GérardinP, KassarL, DonalisioMR. Excess deaths associated with the 2014" exact="chikungunya" post="epidemic in Jamaica. Pathog Glob Health. 2019; 1–5. 9FreitasARR,"/>
   <result pre="10MavalankarD, ShastriP, BandyopadhyayT, ParmarJ, RamaniKV. Increased mortality rate associated with" exact="chikungunya" post="epidemic, Ahmedabad, India. Emerg Infect Dis. 2008;14: 412–415. 10.3201/eid1403.07072018325255"/>
   <result pre="AcuinC, et al.Worldwide trends in body-mass index, underweight, overweight, and" exact="obesity" post="from 1975 to 2016: a pooled analysis of 2416"/>
   <result pre="et al.Protein energy malnutrition decreases immunity and increases susceptibility to" exact="influenza" post="infection in mice. J Infect Dis. 2013;207: 501–510. 10.1093/infdis/jis52722949306"/>
   <result pre="17MoserJ-AS, Galindo-FragaA, Ortiz-HernándezAA, GuW, HunsbergerS, Galán-HerreraJ-F, et al.Underweight, overweight, and" exact="obesity" post="as independent risk factors for hospitalization in adults and"/>
   <result pre="independent risk factors for hospitalization in adults and children from" exact="influenza" post="and other respiratory viruses. Influenza Other Respi Viruses. 2019;13:"/>
   <result pre="SammonAB, et al.Obesity is associated with impaired immune response to" exact="influenza" post="vaccination in humans. Int J Obes. 2012;36: 1072–1077. 19SchwarzNG,"/>
   <result pre="2005;36: 378–384. 15916044 23PadmakumarB, JayanJB, MenonR, KottaratharaAJ. Clinical profile of" exact="chikungunya" post="sequelae, association with obesity and rest during acute phase."/>
   <result pre="JayanJB, MenonR, KottaratharaAJ. Clinical profile of chikungunya sequelae, association with" exact="obesity" post="and rest during acute phase. Southeast Asian J Trop"/>
   <result pre="2010;41: 85–91. 20578486 24ThisyakornU, NimmannityaS. Nutritional status of children with" exact="dengue hemorrhagic fever." post="Clin Infect Dis. 1993;16: 295–297. 10.1093/clind/16.2.2958443312 25LibratyDH, ZhangL, WodaM,"/>
   <result pre="LeBL, HuangK-J, et al.Association between sex, nutritional status, severity of" exact="dengue hemorrhagic fever," post="and immune status in infants with dengue hemorrhagic fever."/>
   <result pre="of dengue hemorrhagic fever, and immune status in infants with" exact="dengue hemorrhagic fever." post="Am J Trop Med Hyg. 2005;72: 370–374. 15827272 29StaplefordKA,"/>
   <result pre="J Virol. 2014;88: 2035–2046. 10.1128/JVI.02990-1324307590 32CoffeyLL, VignuzziM. Host alternation of" exact="chikungunya" post="virus increases fitness while restricting population diversity and adaptability"/>
   <result pre="1708810.1038/nmicrobiol.2017.8828581455 44DavisNL, WillisLV, SmithJF, JohnstonRE. In vitro synthesis of infectious" exact="venezuelan equine encephalitis" post="virus RNA from a cDNA clone: analysis of a"/>
   <result pre="WillisLV, SmithJF, JohnstonRE. In vitro synthesis of infectious venezuelan equine" exact="encephalitis" post="virus RNA from a cDNA clone: analysis of a"/>
   <result pre="48BorgheriniG, PoubeauP, StaikowskyF, LoryM, Le MoullecN, BecquartJP, et al.Outbreak of" exact="chikungunya" post="on Reunion Island: early clinical and laboratory features in"/>
   <result pre="Clin Infect Dis. 2007;44: 1401–1407. 10.1086/51753717479933 49ReillySM, SaltielAR. Adapting to" exact="obesity" post="with adipose tissue inflammation. Nat Rev Endocrinol. 2017;13: 633–643."/>
   <result pre="10.1016/j.cmet.2014.03.02924807222 59AratakiK, KumadaH, ToyotaK, OhishiW, TakahashiS, TazumaS, et al.Evolution of" exact="hepatitis" post="C virus quasispecies during ribavirin and interferon-alpha-2b combination therapy"/>
   <result pre="Pathog. 2008;4: e2910.1371/journal.ppat.004002918282093 65SourisseauM, SchilteC, CasartelliN, TrouilletC. Characterization of reemerging" exact="chikungunya" post="virus. PLoS. 2007; Available: https://journals.plos.org/plospathogens/article?id = 10.1371/journal.ppat.003008917604450 66VignuzziM, StoneJK,"/>
   <result pre="infectious etiologies of Keshan disease. Insights from coxsackie virus B-induced" exact="myocarditis" post="in mice deficient in selenium or vitamin E. Biol"/>
   <result pre="et al.Host nutritional selenium status as a driving force for" exact="influenza" post="virus mutations1. The FASEB Journal. 2001; 10.1096/fj.01-0115fje 73HawmanDW, StoermerKA,"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6872792\results\search\disease\results.xml">
   <result pre="doi: 10.1016/j.csbj.2019.09.007 : Review Article Mode and tempo of human" exact="hepatitis" post="virus evolution CaglianiRachele1ForniDiego1SironiManuelamanuela.sironi@bp.lnf.it�?�[], �?�Corresponding author. manuela.sironi@bp.lnf.it 1These authors equally"/>
   <result pre="under the CC BY license (http://creativecommons.org/licenses/by/4.0/). Graphical abstract Abstract Human" exact="viral hepatitis," post="a major cause of morbidity and mortality worldwide, is"/>
   <result pre="knowledge on the host range and evolutionary history of human" exact="hepatitis" post="viruses. Thus, with the exclusion of hepatitis D virus,"/>
   <result pre="history of human hepatitis viruses. Thus, with the exclusion of" exact="hepatitis" post="D virus, close or distant relatives of these human"/>
   <result pre="ecological contexts that determined the origin and spread of human" exact="hepatitis" post="viruses. Keywords Human hepatitis virus Zoonosis Molecular dating Host"/>
   <result pre="the origin and spread of human hepatitis viruses. Keywords Human" exact="hepatitis" post="virus Zoonosis Molecular dating Host switch Abbreviations ORF, open"/>
   <result pre="RNA-dependent RNA polymerase 1 General introduction The worldwide burden of" exact="viral hepatitis" post="in terms of death and disability is enormous. In"/>
   <result pre="RNA polymerase 1 General introduction The worldwide burden of viral" exact="hepatitis" post="in terms of death and disability is enormous. In"/>
   <result pre="in terms of death and disability is enormous. In 2015," exact="viral hepatitis" post="caused 1.34 million deaths, the majority of which imputable"/>
   <result pre="terms of death and disability is enormous. In 2015, viral" exact="hepatitis" post="caused 1.34 million deaths, the majority of which imputable"/>
   <result pre="compared to HBV monoinfection [1]. Less than 5% of overall" exact="hepatitis" post="mortality is caused by HAV (hepatitis A virus) and"/>
   <result pre="and effective vaccine, HAV remains a common cause of acute" exact="viral hepatitis" post="in many regions of the world [4]. Human hepatitis"/>
   <result pre="effective vaccine, HAV remains a common cause of acute viral" exact="hepatitis" post="in many regions of the world [4]. Human hepatitis"/>
   <result pre="viral hepatitis in many regions of the world [4]. Human" exact="hepatitis" post="viruses are extremely diverse and consequently belong to different"/>
   <result pre="availability of high-throughput technologies has revealed that relatives of human" exact="hepatitis" post="viruses can be found in a wide variety of"/>
   <result pre="ecological contexts that determined the origin and spread of human" exact="hepatitis" post="viruses. A short presentation of the most widely used"/>
   <result pre="contextualize recent research efforts on these viruses. Table 1 Human" exact="hepatitis" post="viruses: taxonomic classification and general features. Family Genus Genome"/>
   <result pre="[18], [19]. HAV was identified as the etiologic agent of" exact="hepatitis" post="A by Feinstone and colleagues [20] in 1973. Unlike"/>
   <result pre="hepatoviruses. 4 Hepatitis B virus HBV was the first human" exact="hepatitis" post="virus to be isolated and identified in 1970 [32]."/>
   <result pre="Houghton and colleagues as a cause of non-A and non-B" exact="hepatitis" post="[61]. If left untreated, HCV can persist lifelong in"/>
   <result pre="untreated, HCV can persist lifelong in humans, often resulting in" exact="cirrhosis" post="and hepatocellular carcinoma. Presently, the HCV worldwide seroprevalence is"/>
   <result pre="can persist lifelong in humans, often resulting in cirrhosis and" exact="hepatocellular carcinoma." post="Presently, the HCV worldwide seroprevalence is estimated to be"/>
   <result pre="propagation, at least in vitro (e.g. HCV, dengue virus, vesicular" exact="stomatitis" post="virus) [95]. Genetic heterogeneity among strains is quite high"/>
   <result pre="first indications that a virus was responsible for waterborne, epidemic" exact="hepatitis" post="came from studies of Asian outbreaks in the 1950–70s"/>
   <result pre="Conversely, genotypes 3 and 4 account for the majority of" exact="hepatitis" post="E human cases in industrialized countries. HEV-3 and HEV-4"/>
   <result pre="clade, mainly detected in rabbits (HEV-3ra), can also cause human" exact="hepatitis" post="E [114], [115], [116], [117] (Fig. 4A). The remaining"/>
   <result pre="and −4) or human-restricted/anthropotropic (HEV-1 and -2). Although several human" exact="hepatitis" post="E cases have a zoonotic origin and orthohepeviruses A"/>
   <result pre="include other RNA viruses such as rotaviruses, enteroviruses, and human" exact="influenza" post="viruses [122], [123], [124], [125]. For both swine influenza"/>
   <result pre="human influenza viruses [122], [123], [124], [125]. For both swine" exact="influenza" post="A viruses and swine vesicular disease virus onward transmission"/>
   <result pre="expanded our knowledge on the evolution and origin of human" exact="hepatitis" post="viruses. These insights have been paralleled by the development"/>
   <result pre="with the possible exception of HDV, viruses related to human" exact="hepatitis" post="viruses infect several other mammalian and non mammalian vertebrates."/>
   <result pre="in this paper. References References 1World Health Organization (WHO). Global" exact="hepatitis" post="report 2017. https://www.who.int/hepatitis/publications/global-hepatitis-report2017/en/. 2DoceulV.BagdassarianE.DemangeA.PavioN.Zoonotic hepatitis E virus: classification, animal"/>
   <result pre="1World Health Organization (WHO). Global hepatitis report 2017. https://www.who.int/hepatitis/publications/global-hepatitis-report2017/en/. 2DoceulV.BagdassarianE.DemangeA.PavioN.Zoonotic" exact="hepatitis" post="E virus: classification, animal reservoirs and transmission routesViruses82016E27027706110 3CuthbertJ.A.Hepatitis"/>
   <result pre="Ecol2520161911192426880113 7ZhouY.HolmesE.C.Bayesian estimates of the evolutionary rate and age of" exact="hepatitis" post="B virusJ Mol Evol65200719720517684696 8ZehenderG.EbranatiE.GabanelliE.SorrentinoC.Lo PrestiA.TanziE.Enigmatic origin of hepatitis"/>
   <result pre="of hepatitis B virusJ Mol Evol65200719720517684696 8ZehenderG.EbranatiE.GabanelliE.SorrentinoC.Lo PrestiA.TanziE.Enigmatic origin of" exact="hepatitis" post="B virus: an ancient travelling companion or a recent"/>
   <result pre="ancient travelling companion or a recent encounter?World J Gastroenterol2020147622763424976700 9MuhlemannB.JonesT.C.DamgaardP.B.AllentoftM.E.ShevninaI.LogvinA.Ancient" exact="hepatitis" post="B viruses from the Bronze Age to the Medieval"/>
   <result pre="of viral lineagesMol Biol Evol2820113355336521705379 16WertheimJ.O.SmithM.D.SmithD.M.SchefflerK.Kosakovsky PondS.L.Evolutionary origins of human" exact="herpes simplex" post="viruses 1 and 2Mol Biol Evol3120142356236424916030 17McKnightK.L.LemonS.M.Hepatitis A virus"/>
   <result pre="as the driving force of codon usage bias in the" exact="hepatitis" post="A virus capsidPLoS Pathog62010e1000797 20FeinstoneS.M.KapikianA.Z.PurceliR.H.Hepatitis A: detection by immune"/>
   <result pre="testing in epidemiologic surveillanceAm J Epidemiol1051977140147189600 22WongD.C.PurcellR.H.RosenL.Prevalence of antibody to" exact="hepatitis" post="A and hepatitis B viruses in selected populations of"/>
   <result pre="surveillanceAm J Epidemiol1051977140147189600 22WongD.C.PurcellR.H.RosenL.Prevalence of antibody to hepatitis A and" exact="hepatitis" post="B viruses in selected populations of the South PacificAm"/>
   <result pre="South PacificAm J Epidemiol1101979227236224696 23CristinaJ.Costa-MattioliM.Genetic variability and molecular evolution of" exact="hepatitis" post="A virusVirus Res127200715115717328982 24DrexlerJ.F.CormanV.M.LukashevA.N.van den BrandJ.M.GmylA.P.BruninkS.Evolutionary origins of hepatitis"/>
   <result pre="of hepatitis A virusVirus Res127200715115717328982 24DrexlerJ.F.CormanV.M.LukashevA.N.van den BrandJ.M.GmylA.P.BruninkS.Evolutionary origins of" exact="hepatitis" post="A virus in small mammalsProc Natl Acad Sci USA1122015151901519526575627"/>
   <result pre="of a novel hepatovirus (phopivirus of seals) related to human" exact="hepatitis" post="A virusMBio62015 26YuJ.M.LiL.L.ZhangC.Y.LuS.AoY.Y.GaoH.C.A novel hepatovirus identified in wild woodchuck"/>
   <result pre="wild woodchuck Marmota himalayanaSci Rep620162236126924426 27de OliveiraCarneiro I.SanderA.L.SilvaN.Moreira-SotoA.NormannA.FlehmigB.A novel marsupial" exact="hepatitis" post="A virus corroborates complex evolutionary patterns shaping the genus"/>
   <result pre="evolutionary history of vertebrate RNA virusesNature556201819720229618816 29SanderA.L.CormanV.M.LukashevA.N.DrexlerJ.F.Evolutionary origins of enteric" exact="hepatitis" post="virusesCold Spring Harb Perspect Med82018 30GuoW.P.LinX.D.WangW.TianJ.H.CongM.L.ZhangH.L.Phylogeny and origins of"/>
   <result pre="a remarkable replication strategyAntiviral Res1582018344430059722 35KramvisA.Genotypes and genetic variability of" exact="hepatitis" post="B virusIntervirology57201414115025034481 36CastelhanoN.AraujoN.M.ArenasM.Heterogeneous recombination among Hepatitis B virus genotypesInfect"/>
   <result pre="Hepatitis B virus genotypesInfect Genet Evol54201748649028827173 37TatematsuK.TanakaY.KurbanovF.SugauchiF.ManoS.MaeshiroT.A genetic variant of" exact="hepatitis" post="B virus divergent from known human and ape genotypes"/>
   <result pre="new genotype JJ Virol832009105381054719640977 38LocarniniS.LittlejohnM.AzizM.N.YuenL.Possible origins and evolution of the" exact="hepatitis" post="B virus (HBV)Semin Cancer Biol23201356157524013024 39VelkovS.OttJ.J.ProtzerU.MichlerT.The global hepatitis B"/>
   <result pre="of the hepatitis B virus (HBV)Semin Cancer Biol23201356157524013024 39VelkovS.OttJ.J.ProtzerU.MichlerT.The global" exact="hepatitis" post="B virus genotype distribution approximated from available genotyping dataGenes"/>
   <result pre="approximated from available genotyping dataGenes (Basel)92018 40LittlejohnM.LocarniniS.YuenL.Origins and evolution of" exact="hepatitis" post="B virus and hepatitis D virusCold Spring Harb Perspect"/>
   <result pre="dataGenes (Basel)92018 40LittlejohnM.LocarniniS.YuenL.Origins and evolution of hepatitis B virus and" exact="hepatitis" post="D virusCold Spring Harb Perspect Med62016a021360 41de Carvalho Dominguez"/>
   <result pre="Harb Perspect Med62016a021360 41de Carvalho Dominguez SouzaB.F.KonigA.RascheA.de Oliveira CarneiroI.StephanN.CormanVMA novel" exact="hepatitis" post="B virus species discovered in capuchin monkeys sheds new"/>
   <result pre="primate hepadnavirusesJ Hepatol6820181114112229428874 42RascheA.SouzaB.F.C.D.DrexlerJ.F.Bat hepadnaviruses and the origins of primate" exact="hepatitis" post="B virusesCurr Opin Virol162016869426897577 43LauberC.SeitzS.MatteiS.SuhA.BeckJ.HersteinJ.Deciphering the origin and evolution"/>
   <result pre="B virusesCurr Opin Virol162016869426897577 43LauberC.SeitzS.MatteiS.SuhA.BeckJ.HersteinJ.Deciphering the origin and evolution of" exact="hepatitis" post="B viruses by means of a family of non-enveloped"/>
   <result pre="new world evolutionary originJ Hepatol28199896 49SimmondsP.Reconstructing the origins of human" exact="hepatitis" post="virusesPhilos Trans R Soc Lond B Biol Sci35620011013102611516379 50Kahila"/>
   <result pre="virusesPhilos Trans R Soc Lond B Biol Sci35620011013102611516379 50Kahila Bar-GalG.KimM.J.KleinA.ShinD.H.OhC.S.KimJ.W.Tracing" exact="hepatitis" post="B virus to the 16th century in a Korean"/>
   <result pre="phylogenetic relatedness, and structural proteins of six strains of the" exact="hepatitis" post="B virus, four of which represent two new genotypesVirology19819944895038291231"/>
   <result pre="two new genotypesVirology19819944895038291231 52MagniusL.O.NorderH.Subtypes, genotypes and molecular epidemiology of the" exact="hepatitis" post="B virus as reflected by sequence variability of the"/>
   <result pre="variability of the S-geneIntervirology38199524348666521 53ParaskevisD.MagiorkinisG.MagiorkinisE.HoS.Y.BelshawR.AllainJ.P.Dating the origin and dispersal of" exact="hepatitis" post="B virus infection in humans and primatesHepatology57201390891622987324 54ParaskevisD.AngelisK.MagiorkinisG.KostakiE.HoS.Y.HatzakisA.Dating the"/>
   <result pre="virus infection in humans and primatesHepatology57201390891622987324 54ParaskevisD.AngelisK.MagiorkinisG.KostakiE.HoS.Y.HatzakisA.Dating the origin of" exact="hepatitis" post="B virus reveals higher substitution rate and adaptation on"/>
   <result pre="medieval virus genomes reveal complex evolution of hepatitisBElife72018 56MacDonaldD.M.HolmesE.C.LewisJ.C.SimmondsP.Detection of" exact="hepatitis" post="B virus infection in wild-born chimpanzees (Pan troglodytes verus):"/>
   <result pre="16th century mummyPLoS Pathog142018e1006750 58ForbiJ.C.VaughanG.PurdyM.A.CampoD.S.XiaG.L.Ganova-RaevaL.M.Epidemic history and evolutionary dynamics of" exact="hepatitis" post="B virus infection in two remote communities in rural"/>
   <result pre="two remote communities in rural NigeriaPLoS One52010e11615 59MojsiejczukL.N.TorresC.SevicI.BadanoI.MalanR.FlichmanD.M.Molecular epidemiology of" exact="hepatitis" post="B virus in Misiones, ArgentinaInfect Genet Evol442016344227321439 60SagnelliC.CiccozziM.CoppolaN.MinichiniC.Lo PrestiA.StaraceM.Molecular"/>
   <result pre="of a cDNA clone derived from a blood-borne non-A, non-B" exact="viral hepatitis" post="genomeScience24419893593622523562 62JackowiakP.KulsK.BudzkoL.ManiaA.FiglerowiczM.FiglerowiczM.Phylogeny and molecular evolution of the hepatitis C"/>
   <result pre="a cDNA clone derived from a blood-borne non-A, non-B viral" exact="hepatitis" post="genomeScience24419893593622523562 62JackowiakP.KulsK.BudzkoL.ManiaA.FiglerowiczM.FiglerowiczM.Phylogeny and molecular evolution of the hepatitis C"/>
   <result pre="non-B viral hepatitis genomeScience24419893593622523562 62JackowiakP.KulsK.BudzkoL.ManiaA.FiglerowiczM.FiglerowiczM.Phylogeny and molecular evolution of the" exact="hepatitis" post="C virusInfect Genet Evol212014678224200590 63PybusO.G.CharlestonM.A.GuptaS.RambautA.HolmesE.C.HarveyP.H.The epidemic behavior of the"/>
   <result pre="hepatitis C virusInfect Genet Evol212014678224200590 63PybusO.G.CharlestonM.A.GuptaS.RambautA.HolmesE.C.HarveyP.H.The epidemic behavior of the" exact="hepatitis" post="C virusScience29220012323232511423661 64SimmondsP.The origin of hepatitis C virusCurr Top"/>
   <result pre="epidemic behavior of the hepatitis C virusScience29220012323232511423661 64SimmondsP.The origin of" exact="hepatitis" post="C virusCurr Top Microbiol Immunol369201311523463195 65RayS.C.ArthurR.R.CarellaA.BukhJ.ThomasD.L.Genetic epidemiology of hepatitis"/>
   <result pre="of hepatitis C virusCurr Top Microbiol Immunol369201311523463195 65RayS.C.ArthurR.R.CarellaA.BukhJ.ThomasD.L.Genetic epidemiology of" exact="hepatitis" post="C virus throughout EgyptJ Infect Dis182200069870710950762 66MessinaJ.P.HumphreysI.FlaxmanA.BrownA.CookeG.S.PybusO.G.Global distribution and"/>
   <result pre="virus throughout EgyptJ Infect Dis182200069870710950762 66MessinaJ.P.HumphreysI.FlaxmanA.BrownA.CookeG.S.PybusO.G.Global distribution and prevalence of" exact="hepatitis" post="C virus genotypesHepatology612015778725069599 67BorgiaS.M.HedskogC.ParhyB.HylandR.H.StammL.M.BrainardD.M.Identification of a novel hepatitis C"/>
   <result pre="prevalence of hepatitis C virus genotypesHepatology612015778725069599 67BorgiaS.M.HedskogC.ParhyB.HylandR.H.StammL.M.BrainardD.M.Identification of a novel" exact="hepatitis" post="C virus genotype from Punjab, India: expanding classification of"/>
   <result pre="hepatitis C virus genotype from Punjab, India: expanding classification of" exact="hepatitis" post="C virus into 8 genotypesJ Infect Dis21820181722172929982508 68HedskogC.ParhyB.ChangS.ZeuzemS.MorenoC.ShafranS.D.Identification of"/>
   <result pre="virus into 8 genotypesJ Infect Dis21820181722172929982508 68HedskogC.ParhyB.ChangS.ZeuzemS.MorenoC.ShafranS.D.Identification of 19 novel" exact="hepatitis" post="C virus subtypes-further expanding HCV classificationOpen Forum Infect Dis62019ofz076"/>
   <result pre="subtypes-further expanding HCV classificationOpen Forum Infect Dis62019ofz076 69ShepardC.W.FinelliL.AlterM.J.Global epidemiology of" exact="hepatitis" post="C virus infectionLancet Infect Dis5200555856716122679 70ForniD.CaglianiR.PontremoliC.PozzoliU.VertemaraJ.De GioiaL.Evolutionary analysis provides"/>
   <result pre="into the origin and adaptation of HCVFront Microbiol9201885429765366 71ChanD.P.SunH.Y.WongH.T.LeeS.S.HungC.C.Sexually acquired" exact="hepatitis" post="C virus infection: a reviewInt J Infect Dis492016475827270138 72DobsonA.P.CarperE.R.Infectious"/>
   <result pre="and human population historyBioscience461996115126 73PybusO.G.MarkovP.V.WuA.TatemA.J.Investigating the endemic transmission of the" exact="hepatitis" post="C virusInt J Parasitol37200783984917521655 74HouldsworthA.Exploring the possibility of arthropod"/>
   <result pre="from African cattleJ Virol8920155876588225787289 76KapoorA.SimmondsP.GeroldG.QaisarN.JainK.HenriquezJ.A.Characterization of a canine homolog of" exact="hepatitis" post="C virusProc Natl Acad Sci USA1082011116081161321610165 77KapoorA.SimmondsP.ScheelT.K.HjelleB.CullenJ.M.BurbeloP.D.Identification of rodent"/>
   <result pre="virusProc Natl Acad Sci USA1082011116081161321610165 77KapoorA.SimmondsP.ScheelT.K.HjelleB.CullenJ.M.BurbeloP.D.Identification of rodent homologs of" exact="hepatitis" post="C virus and pegivirusesMBio42013e002161323572554 78ScheelT.K.SimmondsP.KapoorA.Surveying the global virome: identification"/>
   <result pre="UK dogsVirology48420159310226086431 85PybusO.G.ThezeJ.Hepacivirus cross-species transmission and the origins of the" exact="hepatitis" post="C virusCurr Opin Virol1620161726517843 86GrayR.R.TanakaY.TakebeY.MagiorkinisG.BuskellZ.SeeffL.Evolutionary analysis of hepatitis C"/>
   <result pre="of the hepatitis C virusCurr Opin Virol1620161726517843 86GrayR.R.TanakaY.TakebeY.MagiorkinisG.BuskellZ.SeeffL.Evolutionary analysis of" exact="hepatitis" post="C virus gene sequences from 1953Philos Trans R Soc"/>
   <result pre="1953Philos Trans R Soc Lond B Biol Sci36820132013016823938759 87LiC.LuL.MurphyD.G.NegroF.OkamotoH.Origin of" exact="hepatitis" post="C virus genotype 3 in Africa as estimated through"/>
   <result pre="sequenced 3d and 3eJ Gen Virol9520141677168824795446 88LuL.LiC.XuY.MurphyD.G.Full-length genomes of 16" exact="hepatitis" post="C virus genotype 1 isolates representing subtypes 1c, 1d,"/>
   <result pre="reveal ancestral relationships among subtypesJ Gen Virol9520141479148724718832 89SmithD.B.PathiranaS.DavidsonF.LawlorE.PowerJ.YapP.L.The origin of" exact="hepatitis" post="C virus genotypesJ Gen Virol78Pt 219973213289018053 90MuhlemannB.MargaryanA.DamgaardP.B.AllentoftM.E.VinnerL.HansenA.J.Ancient human parvovirus"/>
   <result pre="management with extensive ancient genome time seriesCell1771419–14352019e31 93RizzettoM.CaneseM.G.GerinJ.L.LondonW.T.SlyD.L.PurcellR.H.Transmission of the" exact="hepatitis" post="B virus-associated delta antigen to chimpanzeesJ Infect Dis14119805906026989929 94HughesS.A.WedemeyerH.HarrisonP.M.Hepatitis"/>
   <result pre="delta virusLancet3782011738521511329 95Perez-VargasJ.AmiracheF.BosonB.MialonC.FreitasN.SureauC.Enveloped viruses distinct from HBV induce dissemination of" exact="hepatitis" post="D virus in vivoNat Commun1020192098–019-10117-z 96DelfinoC.M.CerrudoC.S.BiglioneM.OubinaJ.R.GhiringhelliP.D.MathetV.L.A comprehensive bioinformatic analysis"/>
   <result pre="D virus in vivoNat Commun1020192098–019-10117-z 96DelfinoC.M.CerrudoC.S.BiglioneM.OubinaJ.R.GhiringhelliP.D.MathetV.L.A comprehensive bioinformatic analysis of" exact="hepatitis" post="D virus full-length genomesJ Viral Hepat25201886086929406571 97Le GalF.BrichlerS.DruganT.AllouiC.RoulotD.PawlotskyJ.M.Genetic diversity"/>
   <result pre="deltavirus genus: a study of 2,152 clinical strainsHepatology6620171826184128992360 98WilleM.NetterH.J.LittlejohnM.YuenL.ShiM.EdenJ.S.A divergent" exact="hepatitis" post="D-like agent in birdsViruses10201810.3390/v10120720 99HetzelU.SziroviczaL.SmuraT.PrahauserB.VapalahtiO.KiparA.Identification of a novel deltavirus"/>
   <result pre="99HetzelU.SziroviczaL.SmuraT.PrahauserB.VapalahtiO.KiparA.Identification of a novel deltavirus in boa constrictorsMBio102019 100ChangW.PetterssonJ.H.Le LayC.ShiM.LoN.WilleM.Novel" exact="hepatitis" post="D-like agents in vertebrates and invertebratesve20195 101CunhaC.TavanezJ.P.GudimaS.Hepatitis delta virus:"/>
   <result pre="an epidemic of non-A, non-B hepatitis. possibility of another human" exact="hepatitis" post="virus distinct from post-transfusion non-A, non-B typeAm J Med6819808188246770682"/>
   <result pre="virus distinct from post-transfusion non-A, non-B typeAm J Med6819808188246770682 103ViswanathanR.Infectious" exact="hepatitis" post="in Delhi (1955-56): a critical study-epidemiology. 1957Natl Med J"/>
   <result pre="a critical study-epidemiology. 1957Natl Med J India26201336237725074004 104WongD.C.PurcellR.H.SreenivasanM.A.PrasadS.R.PavriK.M.Epidemic and endemic" exact="hepatitis" post="in India: evidence for a non-A, non-B hepatitis virus"/>
   <result pre="and endemic hepatitis in India: evidence for a non-A, non-B" exact="hepatitis" post="virus aetiologyLancet219808768796107544 105ReyesG.R.PurdyM.A.KimJ.P.LukK.C.YoungL.M.FryK.E.Isolation of a cDNA from the virus"/>
   <result pre="of a novel viral factor mediates efficient replication of genotype-1" exact="hepatitis" post="E virusPLoS Pathog122016e1005521 108SmithD.B.SimmondsP.International Committee on Taxonomy of Viruses"/>
   <result pre="proposals for classification of the family HepeviridaeJ Gen Virol9520142223223224989172 109LinJ.NorderH.UhlhornH.BelakS.WidenF.Novel" exact="hepatitis" post="E like virus found in Swedish mooseJ Gen Virol95201455757024296469"/>
   <result pre="in Swedish mooseJ Gen Virol95201455757024296469 110SpancernieneU.GrigasJ.BuitkuvieneJ.ZymantieneJ.JuozaitieneV.StankeviciuteM.Prevalence and phylogenetic analysis of" exact="hepatitis" post="E virus in pigs, wild boars, roe deer, red"/>
   <result pre="deer and moose in LithuaniaActa Vet Scand60201813–018-0367-7 111LinJ.KarlssonM.OlofsonA.S.BelakS.MalmstenJ.DalinA.M.High prevalence of" exact="hepatitis" post="e virus in Swedish moose – a phylogenetic characterization"/>
   <result pre="virus from different regionsPLoS One102015e0122102 112BouquetJ.TesseS.LunazziA.EloitM.RoseN.NicandE.Close similarity between sequences of" exact="hepatitis" post="E virus recovered from humans and swine, France, 2008–2009Emerg"/>
   <result pre="and swine, France, 2008–2009Emerg Infect Dis1720112018202522099089 113BrayneA.B.DearloveB.L.LesterJ.S.Kosakovsky PondS.L.FrostS.D.Genotype-specific evolution of" exact="hepatitis" post="E virusJ Virol912017Print 2017 May 1 114AbravanelF.LhommeS.El CostaH.SchvartzB.PeronJ.M.KamarN.Rabbit hepatitis"/>
   <result pre="of hepatitis E virusJ Virol912017Print 2017 May 1 114AbravanelF.LhommeS.El CostaH.SchvartzB.PeronJ.M.KamarN.Rabbit" exact="hepatitis" post="E virus infections in humans, FranceEmerg Infect Dis2320171191119328628452 115SahliR.FragaM.SemelaD.MoradpourD.GouttenoireJ.Rabbit"/>
   <result pre="humans, FranceEmerg Infect Dis2320171191119328628452 115SahliR.FragaM.SemelaD.MoradpourD.GouttenoireJ.Rabbit HEV in immunosuppressed patients with" exact="hepatitis" post="E acquired in SwitzerlandJ Hepatol7020191023102530803864 116LiuP.BuQ.N.WangL.HanJ.DuR.J.LeiY.X.Transmission of hepatitis E"/>
   <result pre="patients with hepatitis E acquired in SwitzerlandJ Hepatol7020191023102530803864 116LiuP.BuQ.N.WangL.HanJ.DuR.J.LeiY.X.Transmission of" exact="hepatitis" post="E virus from rabbits to cynomolgus macaquesEmerg Infect Dis19201355956523628346"/>
   <result pre="closely related strain in humans, FranceEmerg Infect Dis1820121274128122840216 118LiT.C.BaiH.YoshizakiS.AmiY.SuzakiY.DoanY.H.Genotype 5" exact="hepatitis" post="E virus produced by a reverse genetics system has"/>
   <result pre="potential for zoonotic infectionHepatol Commun3201816017230620002 119LiT.C.ZhouX.YoshizakiS.AmiY.SuzakiY.NakamuraT.Production of infectious dromedary camel" exact="hepatitis" post="E virus by a reverse genetic system: potential for"/>
   <result pre="system: potential for zoonotic infectionJ Hepatol6520161104111127449916 120LeeG.H.TanB.H.TeoE.C.LimS.G.DanY.Y.WeeA.Chronic infection with camelid" exact="hepatitis" post="E virus in a liver transplant recipient who regularly"/>
   <result pre="regularly consumes camel meat and milkGastroenterology150355–72016e3 121ForniD.CaglianiR.ClericiM.SironiM.Origin and dispersal of" exact="hepatitis" post="E virusEmerg Microbes Infect7201811-017-0009-6 122MessengerA.M.BarnesA.N.GrayG.C.Reverse zoonotic disease transmission (zooanthroponosis):"/>
   <result pre="seldom-documented human biological threats to animalsPLoS One92014e89055 123NelsonM.I.VincentA.L.Reverse zoonosis of" exact="influenza" post="to swine: new perspectives on the human-animal interfaceTrends Microbiol23201514215325564096"/>
   <result pre="the specious origins of domesticationTrends Ecol Evol33201814915229454669 135PavioN.DoceulV.BagdassarianE.JohneR.Recent knowledge on" exact="hepatitis" post="E virus in Suidae reservoirs and transmission routes to"/>
   <result pre="Ther18201345946523792558 138Polaris Observatory HCV CollaboratorsGlobal prevalence and genotype distribution of" exact="hepatitis" post="C virus infection in 2015: a modelling studyLancet Gastroenterol"/>
   <result pre="and post-analysis of large phylogeniesBioinformatics3020141312131324451623 140AkanbiO.A.HarmsD.WangB.OpaleyeO.O.AdesinaO.OsundareF.A.Complete genome sequence of a" exact="hepatitis" post="E virus genotype 1e strain from an outbreak in"/>
   <result pre="domestic consumption in Central ItalyFood Microbiol82201919420131027773 144JemersicL.PrpicJ.BrnicD.KerosT.PandakN.DakovicRode O.Genetic diversity of" exact="hepatitis" post="E virus (HEV) strains derived from humans, swine and"/>
   <result pre="a domestic pigArch Virol16320183403340730220034 146Realpe-QuinteroM.MirazoS.Viera-SeguraO.Copado-VillagranaE.D.PanduroA.RomanS.Hepatitis E virus genotype 1 and" exact="hepatitis" post="A virus dual infection in pediatric patients with a"/>
   <result pre="status from MexicoIntervirology61201810511030278455 147SuinV.KlamerS.E.HutseV.WautierM.JacquesM.AbadyM.Epidemiology and genotype 3 subtype dynamics of" exact="hepatitis" post="E virus in Belgium, 2010 to 2017Euro Surveill242019 148Viera-SeguraO.Realpe-QuinteroM.PanduroA.RomanS.Jose-AbregoA.Gonzalez-AldacoK.First"/>
   <result pre="virus in Belgium, 2010 to 2017Euro Surveill242019 148Viera-SeguraO.Realpe-QuinteroM.PanduroA.RomanS.Jose-AbregoA.Gonzalez-AldacoK.First detection of" exact="hepatitis" post="E virus genotype 3 as a common infectious agent"/>
   <result pre="patients with chronic liver damage in MexicoAnn Hepatol2019 149WangB.AkanbiO.A.HarmsD.AdesinaO.OsundareF.A.NaidooD.A new" exact="hepatitis" post="E virus genotype 2 strain identified from an outbreak"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6874066\results\search\disease\results.xml">
   <result pre="and Informatics Methods : Bioinformatics: Sequence Analysis First evidence of" exact="hepatitis" post="E virus infection in a small mammal (yellow-necked mouse)"/>
   <result pre="credited.pone.0225583.pdf Abstract Since the role of wild rodents/small mammals in" exact="hepatitis" post="E virus (HEV) epidemiology has been a subject of"/>
   <result pre="(up to 15%) [7, 8, 9]. In contrast to other" exact="hepatitis" post="viruses, experimental models other than nonhuman primates have been"/>
   <result pre="HEV-3 host range and its zoonotic potential. The detection of" exact="hepatitis" post="E infections is arising in Croatia, with the occasional"/>
   <result pre="SimmondsP, IzopetJ, Oliveira-FilhoEF, UlrichRG, JohneR, et al.Proposed reference sequences for" exact="hepatitis" post="E virus subtypes. J Gen Virol. 2016;97: 537–542. 10.1099/jgv.0.00039326743685"/>
   <result pre="disease. J Hepatol. 2008;48(3): 494–503. 10.1016/j.jhep.2007.12.00818192058 5AggarwalR, NaikS. Epidemiology of" exact="hepatitis" post="e: Current status. J Gastroenterol Hepatol. 2009;24: 1484–1493. 10.1111/j.1440-1746.2009.05933.x19686410"/>
   <result pre="10.1111/j.1440-1746.2009.05933.x19686410 6JemeršićL, PrpićJ, BrnićD, KerosT, PandakN, �?aković-RodeO. Genetic diversity of" exact="hepatitis" post="E virus (HEV) strains derived from humans, swine and"/>
   <result pre="8LipejZ, NovoselD, VojtaL, RoićB, ŠimpragaM, VojtaA. Detection and characterisation of" exact="hepatitis" post="E virus in naturally infected swine in Croatia. Acta"/>
   <result pre="10.1556/AVet.2013.03123974940 9BalayanMS, UsmanovRK, ZamyatinaNA, DjumalievaDI, KarasFR. 1990. Brief report: experimental" exact="hepatitis" post="E infection in domestic pigs. J Med Virol. 1990;32:"/>
   <result pre="AlymbaevaDB, ZamiatinaNA, KazachkovIUA, et al.An experimental infection in lambs by" exact="hepatitis" post="E virus. VoprVirusol. 1994;39: 165–168. 11FavorovMO, NazarovaOK, YashinaTL, McCaustlandK,"/>
   <result pre="YashinaTL, McCaustlandK, FieldsHA, MargolisHS. Cattle as a possible reservoir of" exact="hepatitis" post="E virus infection. Ninth Triennial International Symposium on Viral"/>
   <result pre="novel virus in swine is closely related to the human" exact="hepatitis" post="E virus. Proc Natl Acad Sci U S A."/>
   <result pre="ShapiroMS. Genetic and experimental evidence for cross-species infection by swine" exact="hepatitis" post="E virus. J Virol. 1998;72: 9714–9721. 9811705 14FavorovMO, KosoyMY,"/>
   <result pre="9811705 14FavorovMO, KosoyMY, TsarevSA, ChildsJE, MargolisHS. Prevalence of antibody to" exact="hepatitis" post="E virus among rodents in the United States. J"/>
   <result pre="DiwanA, et al.Evidence for widespread infection of wild rats with" exact="hepatitis" post="E virus in the United States. Am J Trop"/>
   <result pre="LiTC, TakedaN, KawabataH, KoizumiN, et al.Evidence for widespread infection of" exact="hepatitis" post="E virus among wild rats in Japan. Hepatol Res."/>
   <result pre="ShimizuK, YoshimatsuK, HasebeF, HottaK, IsozumiR, et al.Epizootiological study of rodent-borne" exact="hepatitis" post="E virus HEV-C1 in small mammals in Hanoi, Vietnam.J"/>
   <result pre="XiongY, ZhangM, ChengM, ChenQ. The prevalence and genomic characteristics of" exact="hepatitis" post="E virus in murine rodents and house shrews from"/>
   <result pre="22SimanaviciusM, JuskaiteK, VerbickaiteA, JasiulionisM, TamosiunasPL, Petraityte-BurneikieneR, et al.Detection of rat" exact="hepatitis" post="E virus, but not human pathogenic hepatitis E virus"/>
   <result pre="al.Detection of rat hepatitis E virus, but not human pathogenic" exact="hepatitis" post="E virus genotype 1–4 infections in wild rats from"/>
   <result pre="10.1016/j.vetmic.2018.06.01429981698 23SayedIM, VerhoyeL, CocquerelL, AbravanelF, FoquetL, MontpellierC, et al.Study of" exact="hepatitis" post="E virus infection of genotype1 and 3 in mice"/>
   <result pre="EngleRE, FaulkK, DaltonHR, et al.Cross-species infections of cultured cells by" exact="hepatitis" post="E virus and discovery of an infectious virus-host recombinant."/>
   <result pre="one-step real-time RT-PCR assay for rapid and sensitive detection of" exact="hepatitis" post="E virus. J Virol Methods. 2006;131: 65–71. 10.1016/j.jviromet.2005.07.00416125257 28Van"/>
   <result pre="HIV-infected patients in Croatia: is one diagnostic method enough for" exact="hepatitis" post="E diagnosis?Eur J Clin Microbiol Infect Dis. 2014;33: 2231–2236."/>
   <result pre="10.1007/s10096-014-2187-725005459 35Vilibić-ČavlekT, VilibićM, KolarićB, JemeršićL, Ku�?inarJ, BarbićLj, et al.Seroepidemiology of" exact="hepatitis" post="E in selected population groups in Croatia: a prospective"/>
   <result pre="10.1111/zph.1225426776465 36JemeršićL, KerosT, MaltarLj, BarbićLj, Vilibić-ČavlekT, Jeli�?ićP, et al.Differences in" exact="hepatitis" post="E virus (HEV) presence in naturally infected seropositive domestic"/>
   <result pre="37FischerC, HofmannM, DanzerM, HoferK, KaarJ, GabrielC. Seroprevalence and Incidence of" exact="hepatitis" post="E in Blood Donors in Upper Austria. PLoS One."/>
   <result pre="PLoS One. 2015;10(3): e011957610.1371/journal.pone.011957625751574 38DebingY, MoradpourD, NeytsJ, GouttenoireJ. Update on" exact="hepatitis" post="E virology: Implications for clinical practice. J Hepatol. 2016;65(1):"/>
   <result pre="TothTE, et al.Evidence of extrahepatic sites of replication of the" exact="hepatitis" post="E virus in a swine model. J Clin Microbiol."/>
   <result pre="HarrisonTJ, ZhangH, GengK, et al.Detection and assessment of infectivity of" exact="hepatitis" post="E virus in urine. J Hepatol. 2016;64: 37–43. 10.1016/j.jhep.2015.08.03426362822"/>
   <result pre="YoungGD, InnisBL. Experimental infection of the laboratory rat with the" exact="hepatitis" post="E virus. J Med Virol. 1996;48: 121–8. 10.1002/(SICI)1096-9071(199602)48:2&amp;lt;121::AID-JMV1&amp;gt;3.0.CO;2-B8835343 42PurcellRH,"/>
   <result pre="43JohneR, Plenge-BonigA, HessM, UlrichRG, ReetzJ, SchielkeA. Detection of a novel" exact="hepatitis" post="E-like virus in faeces of wild rats using a"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6874238\results\search\disease\results.xml">
   <result pre="China; email: pcywoo@hku.hk or skplau@hku.hk ppub: 2019-12251223032306 Abstract We report" exact="influenza" post="A(H1N1)pdm09 virus infection in a captive giant panda in"/>
   <result pre="Genome analysis showed 99.3%–99.9% nucleotide identity between the virus and" exact="influenza" post="A(H1N1)pdm09 virus circulating in Hong Kong. Keywords: influenza A(H1N1)pdm09"/>
   <result pre="virus and influenza A(H1N1)pdm09 virus circulating in Hong Kong. Keywords:" exact="influenza" post="A(H1N1)pdm09 giant panda influenza Hong Kong viruses respiratory infections"/>
   <result pre="virus circulating in Hong Kong. Keywords: influenza A(H1N1)pdm09 giant panda" exact="influenza" post="Hong Kong viruses respiratory infections Since 2009, influenza A(H1N1)pdm09"/>
   <result pre="giant panda influenza Hong Kong viruses respiratory infections Since 2009," exact="influenza" post="A(H1N1)pdm09 virus (pH1N1) has been circulating seasonally worldwide and"/>
   <result pre="measures included placing rat traps to test resident rodents for" exact="influenza" post="and increased biosecurity to limit contact between the breeding"/>
   <result pre="nasal swab specimen collected on day 1 was positive for" exact="influenza" post="A virus. The viral load (± SD) in the"/>
   <result pre="by RT-PCR. Figure 1 Viral load and serologic response to" exact="influenza" post="A(H1N1)pdm09 in nasal and serum samples from an infected"/>
   <result pre="SD (log10 M gene copies/mL). Whole-genome sequence analysis showed that the" exact="influenza" post="virus we isolated from the giant panda (A/giant panda/Hong"/>
   <result pre="position 271 in polymerase protein 2 (1). Table Comparison of" exact="influenza" post="A(H1N1)pdm09 isolated from a giant panda (A/giant panda/Hong Kong/MISO20/2018)"/>
   <result pre="analyses of (A) hemagglutinin and (B) neuraminidase gene sequences of" exact="influenza" post="A(H1N1)pdm09 (A/giant panda/Hong Kong/MISO20/2018) isolated from a giant panda"/>
   <result pre="nucleotide substitutions per site. Conclusions We documented a case of" exact="influenza" post="infection caused by pH1N1 virus in a captive giant"/>
   <result pre="the pH1N1 virus from the giant panda differed from the" exact="influenza" post="virus circulating in Hong Kong at that time by"/>
   <result pre="circulating in humans during 2009 (1). These findings show that" exact="influenza" post="A virus infection in this giant panda was not"/>
   <result pre="not only in mainland China. Our findings indicate that the" exact="influenza" post="virus in giant pandas was most likely directly or"/>
   <result pre="result in high fatalities. Transmission of a new strain of" exact="influenza" post="from birds and poultry to humans has resulted in"/>
   <result pre="should not work near the animals. Appendix Additional information about" exact="influenza" post="A(H1N1)pdm09 in a giant panda, Hong Kong. LINK Suggested"/>
   <result pre="2. BoedekerNC, NelsonMI, KillianML, TorchettiMK, BarthelT, MurrayS. Pandemic (H1N1) 2009" exact="influenza" post="A virus infection associated with respiratory signs in sloth"/>
   <result pre="bears (Melursus ursinus).Zoonoses Public Health. 2017;64:566–71. 10.1111/zph.1237028646559 3. KeenlisideJ. Pandemic" exact="influenza" post="A H1N1 in swine and other animals. In: Richt"/>
   <result pre="et al.Viral load in patients infected with pandemic H1N1 2009" exact="influenza" post="A virus.J Med Virol. 2010;82:1–7. 10.1002/jmv.2166419950247 6. ChanKH, ToKK,"/>
   <result pre="virological parameters on the level of neutralizing antibody against pandemic" exact="influenza" post="A virus H1N1 2009.Clin Infect Dis. 2010;51:274–9. 10.1086/65394020575664 8."/>
   <result pre="FahimM, RoguskiK, ElazizHA, et al.Increased number of human cases of" exact="influenza" post="virus A(H5N1) infection, Egypt, 2014–15.Emerg Infect Dis. 2015;21:2171–3. 10.3201/eid2112.15088526584397"/>
   <result pre="WeiSH, YangJR, WuHS, ChangMC, LinJS, LinCY, et al.Human infection with" exact="avian influenza" post="A H6N1 virus: an epidemiological analysis.Lancet Respir Med. 2013;1:771–8."/>
   <result pre="YangJR, WuHS, ChangMC, LinJS, LinCY, et al.Human infection with avian" exact="influenza" post="A H6N1 virus: an epidemiological analysis.Lancet Respir Med. 2013;1:771–8."/>
   <result pre="Med. 2013;1:771–8. 10.1016/S2213-2600(13)70221-224461756 12. GoneauLW, MehtaK, WongJ, L’HuillierAG, GubbayJB. Zoonotic" exact="influenza" post="and human health—part 1: virology and epidemiology of zoonotic"/>
   <result pre="KeC, LuJ, WuJ, GuanD, ZouL, SongT, et al.Circulation of reassortant" exact="influenza" post="A(H7N9) viruses in poultry and humans, Guangdong Province, China,"/>
   <result pre="ZhangT, BiY, TianH, LiX, LiuD, WuY, et al.Human infection with" exact="influenza" post="virus A(H10N8) from live poultry markets, China, 2014.Emerg Infect"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6874249\results\search\disease\results.xml">
   <result pre="ppub: 2019-12251222152225 Abstract To determine the seroprevalence and seroconversion of" exact="avian influenza" post="virus (AIV) antibodies in poultry workers, we conducted a"/>
   <result pre="2019-12251222152225 Abstract To determine the seroprevalence and seroconversion of avian" exact="influenza" post="virus (AIV) antibodies in poultry workers, we conducted a"/>
   <result pre="H7N9 and H9N2 infection among poultry workers. Keywords: seroepidemiology seroprevalence" exact="avian influenza" post="virus poultry worker viruses China influenza influenza A occupational"/>
   <result pre="and H9N2 infection among poultry workers. Keywords: seroepidemiology seroprevalence avian" exact="influenza" post="virus poultry worker viruses China influenza influenza A occupational"/>
   <result pre="Keywords: seroepidemiology seroprevalence avian influenza virus poultry worker viruses China" exact="influenza" post="influenza A occupational health respiratory infections zoonoses Human infection"/>
   <result pre="seroepidemiology seroprevalence avian influenza virus poultry worker viruses China influenza" exact="influenza" post="A occupational health respiratory infections zoonoses Human infection with"/>
   <result pre="influenza A occupational health respiratory infections zoonoses Human infection with" exact="avian influenza" post="viruses (AIVs) has been reported in China since the"/>
   <result pre="A occupational health respiratory infections zoonoses Human infection with avian" exact="influenza" post="viruses (AIVs) has been reported in China since the"/>
   <result pre="and retail live poultry markets are recognized incubators for novel" exact="influenza" post="virus subtypes (6–9). Because of special occupational characteristics, poultry"/>
   <result pre="of AIV prevalence in live poultry markets (15). Low pathogenicity" exact="avian influenza" post="A(H9N2) virus is distributed widely in domestic poultry around"/>
   <result pre="AIV prevalence in live poultry markets (15). Low pathogenicity avian" exact="influenza" post="A(H9N2) virus is distributed widely in domestic poultry around"/>
   <result pre="H7N9 infection outbreak in China, caused by a novel reassortant" exact="influenza" post="A(H7N9) virus and associated with severe human infections, seroprevalence"/>
   <result pre="Figure 1 Temporal and spatial distribution of human infections with" exact="avian influenza" post="A virus subtypes before and during serosurveillance, China. A)"/>
   <result pre="1 Temporal and spatial distribution of human infections with avian" exact="influenza" post="A virus subtypes before and during serosurveillance, China. A)"/>
   <result pre="subtypes before and during serosurveillance, China. A) Geographic distribution of" exact="avian influenza" post="A(H7N9) virus infection among humans in China during May"/>
   <result pre="before and during serosurveillance, China. A) Geographic distribution of avian" exact="influenza" post="A(H7N9) virus infection among humans in China during May"/>
   <result pre="China (http://www.nhc.gov.cn/jkj/s2907/new_list.shtml?tdsourcetag=s_pcqq_aiomsg). Density of shading represents the number of reported" exact="avian influenza" post="H7N9 cases in humans in each province. Cases of"/>
   <result pre="(http://www.nhc.gov.cn/jkj/s2907/new_list.shtml?tdsourcetag=s_pcqq_aiomsg). Density of shading represents the number of reported avian" exact="influenza" post="H7N9 cases in humans in each province. Cases of"/>
   <result pre="infection are noted with symbols as in panel A. AIV," exact="avian influenza" post="virus. We used a standardized questionnaire to collect information"/>
   <result pre="are noted with symbols as in panel A. AIV, avian" exact="influenza" post="virus. We used a standardized questionnaire to collect information"/>
   <result pre="within the previous month, and whether they received a seasonal" exact="influenza" post="vaccination within the previous 12 months (Appendix). Some poultry"/>
   <result pre="distribution in 7 areas of China in a study of" exact="avian influenza" post="virus seroprevalence during December 2014–April 2016. We also recruited"/>
   <result pre="in 7 areas of China in a study of avian" exact="influenza" post="virus seroprevalence during December 2014–April 2016. We also recruited"/>
   <result pre="H10N8 virus subtypes, as well as for antibodies against seasonal" exact="influenza" post="A(H1N1)pdm09 (pH1N1) and H3N2 viruses, to exclude cross-reactivity. We"/>
   <result pre="of hemagglutinin (HA) genes (Appendix Figures 1–5). Table 1 Avian" exact="influenza" post="A antigens used in serologic hemagglutinin inhibition and microneutralization"/>
   <result pre="and microneutralization assays, China* Subtype Virus strain GISAID number Avian" exact="influenza" post="H5N1 clade 2.3.2.1c A/chicken/Shanghai/02.12 HZ199-P/2015 (SH199) EPI1544294 H5N1 clade"/>
   <result pre="EPI666285 H9N2 A/chicken/Guangdong/04.15 SZBAXQ005/2015 EPI661935 H10N8 A/chicken/Jiangxi /B18/2014 EPI1544302 Seasonal" exact="influenza" post="H1N1(pdm09) A/California/04/2009 EPI176470 H3N2 A/Beijing/CAS0001/2007 EPI1544286 *GISAID, https://www.gisaid.org. We"/>
   <result pre="commonly is used and generally is an accepted value for" exact="influenza" post="serologic assays used in detection of seasonal influenza and"/>
   <result pre="value for influenza serologic assays used in detection of seasonal" exact="influenza" post="and avian influenza H9 infection (24). We considered participants"/>
   <result pre="influenza serologic assays used in detection of seasonal influenza and" exact="avian influenza" post="H9 infection (24). We considered participants to have seroconversion"/>
   <result pre="serologic assays used in detection of seasonal influenza and avian" exact="influenza" post="H9 infection (24). We considered participants to have seroconversion"/>
   <result pre="oropharyngeal and cloacal swabs from apparently healthy poultry. We isolated" exact="avian influenza" post="viruses in 9- to 10-day-old specific pathogen–free chicken embryos"/>
   <result pre="and cloacal swabs from apparently healthy poultry. We isolated avian" exact="influenza" post="viruses in 9- to 10-day-old specific pathogen–free chicken embryos"/>
   <result pre="Data Analysis Our analyses were based on seroepidemiologic studies for" exact="influenza" post="published by Horby et al. (26). We assigned each"/>
   <result pre="processing, selling, transporting, and feeding poultry; and seropositivity to human" exact="influenza" post="pH1N1 or H3N2 viruses. For logistic regression analysis, we"/>
   <result pre="samples came from poultry workers who reported receiving a seasonal" exact="influenza" post="vaccine within the previous 12 months (Table 2). Table"/>
   <result pre="2). Table 2 Characteristics of study participants in serosurveys for" exact="avian influenza" post="viruses, China, 2014–2016* Variables 2014 Dec,  n = 700"/>
   <result pre="Table 2 Characteristics of study participants in serosurveys for avian" exact="influenza" post="viruses, China, 2014–2016* Variables 2014 Dec,  n = 700"/>
   <result pre="(Table 3). Table 3 Seroprevalence among poultry workers surveyed for" exact="avian influenza" post="viruses, China, 2014–2016* Antigen No. (%, 95% CI) seropositive"/>
   <result pre="3). Table 3 Seroprevalence among poultry workers surveyed for avian" exact="influenza" post="viruses, China, 2014–2016* Antigen No. (%, 95% CI) seropositive"/>
   <result pre="2016 Apr, n = 437 Total, n = 2124 Avian" exact="influenza" post="serotype H5N1-SH199 6 (0.9, 0.2–1.5) 6 (1.2, 0.2–2.1) 10"/>
   <result pre="64 (13.3, 10.3–16.3) 66 (15.1, 11.7–18.5) 237 (11.2, 9.8–12.5) Seasonal" exact="influenza" post="serotype H1N1(pdm09) 94 (13.4, 10.9–16.0) 85 (16.8, 13.5–20.1) 90"/>
   <result pre="participant tested positive for the H7N9 subtype. Figure 3 Avian" exact="influenza" post="virus seroprevalence in the studied regions of China during"/>
   <result pre="Guangdong, Henan, Jiangsu, Jiangxi, Shandong, and Sichuan. B) Seroprevalence against" exact="avian influenza" post="A virus subtypes in 4 cross-sectional surveys. Colors on"/>
   <result pre="Henan, Jiangsu, Jiangxi, Shandong, and Sichuan. B) Seroprevalence against avian" exact="influenza" post="A virus subtypes in 4 cross-sectional surveys. Colors on"/>
   <result pre="Colors on map correspond to colors in bar graphs. *Seasonal" exact="influenza" post="virus subtype. Seroprevalence of H5 and H6 subtypes among"/>
   <result pre="4, panel A). Figure 4 Seroconversion and persistent positivity for" exact="avian influenza" post="virus (AIV) A subtypes based on HI titers in"/>
   <result pre="panel A). Figure 4 Seroconversion and persistent positivity for avian" exact="influenza" post="virus (AIV) A subtypes based on HI titers in"/>
   <result pre="hemagglutinin inhibition. Table 4 Seroconversion and persistently positive findings for" exact="avian influenza" post="virus among 652 participants with paired or serial serum"/>
   <result pre="inhibition. Table 4 Seroconversion and persistently positive findings for avian" exact="influenza" post="virus among 652 participants with paired or serial serum"/>
   <result pre="Table 5 Risk analysis for seropositive participants in surveys for" exact="avian influenza" post="subtypes among poultry workers, China, 2014–2016* Subtypes and variables"/>
   <result pre="5 Risk analysis for seropositive participants in surveys for avian" exact="influenza" post="subtypes among poultry workers, China, 2014–2016* Subtypes and variables"/>
   <result pre="revealed a correlation between the presence of antibodies and seasonal" exact="influenza" post="virus infection. We saw an association between the presence"/>
   <result pre="H9N2 (aOR 2.6, 95% CI 1.4–5.0) subtypes (Table 5). Seasonal" exact="influenza" post="vaccination history was not a significant risk factor for"/>
   <result pre="for seroprevalence to avoid overestimation and reduce cross-reactivity with seasonal" exact="influenza" post="viruses (32). The higher seroprevalence in Shandong Province could"/>
   <result pre="in poultry workers. We also noted that the low seasonal" exact="influenza" post="vaccination rate (2.8%) in poultry workers might have a"/>
   <result pre="measures. The measures, such as closing live poultry markets during" exact="influenza" post="season, cleaning and disinfecting live poultry markets daily, and"/>
   <result pre="poultry workers and corresponding AIV infection risk factors. Because novel" exact="influenza" post="viruses continue to emerge, our results show the need"/>
   <result pre="for active surveillance to foresee dynamic AIV epidemics and inform" exact="influenza" post="vaccine development. Appendix Additional information on avian influenza A"/>
   <result pre="epidemics and inform influenza vaccine development. Appendix Additional information on" exact="avian influenza" post="A viruses among occupationally exposed populations, China, 2014–2016. LINK"/>
   <result pre="and inform influenza vaccine development. Appendix Additional information on avian" exact="influenza" post="A viruses among occupationally exposed populations, China, 2014–2016. LINK"/>
   <result pre="J, Zhao M, Dai Q, Huang T, et al. Avian" exact="influenza" post="A viruses among occupationally exposed populations, China, 2014–2016. Emerg"/>
   <result pre="Infectious Diseases (no. 2016ZX10004222-003), and the intramural special grant for" exact="influenza" post="virus research from the Chinese Academy of Sciences (no."/>
   <result pre="study. His primary research interests include etiology and serology of" exact="influenza" post="viruses and other emerging and reemerging viruses. References References"/>
   <result pre="WongG, GrayGC, GaoGF, LiS. Epidemiology, evolution, and recent outbreaks of" exact="avian influenza" post="virus in China.J Virol. 2015;89:8671–6. 10.1128/JVI.01034-1526063419 2. GaoGF. From"/>
   <result pre="GrayGC, GaoGF, LiS. Epidemiology, evolution, and recent outbreaks of avian" exact="influenza" post="virus in China.J Virol. 2015;89:8671–6. 10.1128/JVI.01034-1526063419 2. GaoGF. From"/>
   <result pre="QiX, ZhouM, et al.Severe human infection with a novel avian-origin" exact="influenza" post="A(H7N4) virus.Sci Bull (Beijing). 2018;63:1043–50. 10.1016/j.scib.2018.07.003 4. WeiSH, YangJR,"/>
   <result pre="WeiSH, YangJR, WuHS, ChangMC, LinJS, LinCY, et al.Human infection with" exact="avian influenza" post="A H6N1 virus: an epidemiological analysis.Lancet Respir Med. 2013;1:771–8."/>
   <result pre="YangJR, WuHS, ChangMC, LinJS, LinCY, et al.Human infection with avian" exact="influenza" post="A H6N1 virus: an epidemiological analysis.Lancet Respir Med. 2013;1:771–8."/>
   <result pre="ShiY, WangD, XiaoH, LiW, et al.Origin and diversity of novel" exact="avian influenza" post="A H7N9 viruses causing human infection: phylogenetic, structural, and"/>
   <result pre="WangD, XiaoH, LiW, et al.Origin and diversity of novel avian" exact="influenza" post="A H7N9 viruses causing human infection: phylogenetic, structural, and"/>
   <result pre="XiaoH, WuY, LiuD, QiX, ShiY, et al.H7N9: a low pathogenic" exact="avian influenza" post="A virus infecting humans.Curr Opin Virol. 2014;5:91–7. 10.1016/j.coviro.2014.03.00124705093 8."/>
   <result pre="WuY, LiuD, QiX, ShiY, et al.H7N9: a low pathogenic avian" exact="influenza" post="A virus infecting humans.Curr Opin Virol. 2014;5:91–7. 10.1016/j.coviro.2014.03.00124705093 8."/>
   <result pre="ChenX, ZhangJ, WangQ, ZhangC, et al.Genomic characterizations of H4 subtype" exact="avian influenza" post="viruses from live poultry markets in Sichuan province of"/>
   <result pre="ZhangJ, WangQ, ZhangC, et al.Genomic characterizations of H4 subtype avian" exact="influenza" post="viruses from live poultry markets in Sichuan province of"/>
   <result pre="trade.Science. 2014;344:235. 10.1126/science.125466424744345 10. CuiB, LiaoQ, LamWWT, LiuZP, FieldingR. Avian" exact="influenza" post="A/H7N9 risk perception, information trust and adoption of protective"/>
   <result pre="Health. 2017;17:463–76. 10.1186/s12889-017-4364-y28521760 11. BaiT, ZhouJ, ShuY. Serologic study for" exact="influenza" post="A (H7N9) among high-risk groups in China.N Engl J"/>
   <result pre="10.1056/NEJMc130586523718151 12. WangM, FuC-X, ZhengB-J. Antibodies against H5 and H9" exact="avian influenza" post="among poultry workers in China.N Engl J Med. 2009;360:2583–4."/>
   <result pre="12. WangM, FuC-X, ZhengB-J. Antibodies against H5 and H9 avian" exact="influenza" post="among poultry workers in China.N Engl J Med. 2009;360:2583–4."/>
   <result pre="10.1056/NEJMc090035819516044 13. MaC, CuiS, SunY, ZhaoJ, ZhangD, ZhangL, et al.Avian" exact="influenza" post="A (H9N2) virus infections among poultry workers, swine workers,"/>
   <result pre="14. XinL, BaiT, ZhouJF, ChenYK, LiXD, ZhuWF, et al.Seropositivity for" exact="avian influenza" post="H6 virus among humans, China.Emerg Infect Dis. 2015;21:1267–9. 10.3201/eid2107.15013526079934"/>
   <result pre="XinL, BaiT, ZhouJF, ChenYK, LiXD, ZhuWF, et al.Seropositivity for avian" exact="influenza" post="H6 virus among humans, China.Emerg Infect Dis. 2015;21:1267–9. 10.3201/eid2107.15013526079934"/>
   <result pre="BruinE, KoopmansM. Weighing serological evidence of human exposure to animal" exact="influenza" post="viruses - a literature review.Euro Surveill. 2016;21:30388. 10.2807/1560-7917.ES.2016.21.44.3038827874827 16."/>
   <result pre="GrayGC. A systematic review and meta-analysis of the seroprevalence of" exact="influenza" post="A(H9N2) infection among humans.J Infect Dis. 2015;212:562–9. 10.1093/infdis/jiv10925712969 17."/>
   <result pre="10.1093/infdis/jiv10925712969 17. YangS, ChenY, CuiD, YaoH, LouJ, HuoZ, et al.Avian-origin" exact="influenza" post="A(H7N9) infection in influenza A(H7N9)-affected areas of China: a"/>
   <result pre="CuiD, YaoH, LouJ, HuoZ, et al.Avian-origin influenza A(H7N9) infection in" exact="influenza" post="A(H7N9)-affected areas of China: a serological study.J Infect Dis."/>
   <result pre="18. WangX, FangS, LuX, XuC, CowlingBJ, TangX, et al.Seroprevalence to" exact="avian influenza" post="A(H7N9) virus among poultry workers and the general population"/>
   <result pre="WangX, FangS, LuX, XuC, CowlingBJ, TangX, et al.Seroprevalence to avian" exact="influenza" post="A(H7N9) virus among poultry workers and the general population"/>
   <result pre="LiLH, YuZ, ChenWS, LiuSL, LuY, ZhangYJ, et al.Evidence for H5" exact="avian influenza" post="infection in Zhejiang province, China, 2010-2012: a cross-sectional study.J"/>
   <result pre="YuZ, ChenWS, LiuSL, LuY, ZhangYJ, et al.Evidence for H5 avian" exact="influenza" post="infection in Zhejiang province, China, 2010-2012: a cross-sectional study.J"/>
   <result pre="QiW, SuS, XiaoC, ZhouP, LiH, KeC, et al.Antibodies against H10N8" exact="avian influenza" post="virus among animal workers in Guangdong Province before November"/>
   <result pre="SuS, XiaoC, ZhouP, LiH, KeC, et al.Antibodies against H10N8 avian" exact="influenza" post="virus among animal workers in Guangdong Province before November"/>
   <result pre="22. GomaaMR, KayedAS, ElabdMA, ZeidDA, ZakiSA, El RifayAS, et al.Avian" exact="influenza" post="A(H5N1) and A(H9N2) seroprevalence and risk factors for infection"/>
   <result pre="23. LiuWJ, TanS, ZhaoM, QuanC, BiY, WuY, et al.Cross-immunity against" exact="avian influenza" post="A(H7N9) virus in the healthy population is affected by"/>
   <result pre="LiuWJ, TanS, ZhaoM, QuanC, BiY, WuY, et al.Cross-immunity against avian" exact="influenza" post="A(H7N9) virus in the healthy population is affected by"/>
   <result pre="10.1093/infdis/jiw47127738054 24. PawarSD, TandaleBV, RautCG, ParkhiSS, BardeTD, GuravYK, et al.Avian" exact="influenza" post="H9N2 seroprevalence among poultry workers in Pune, India, 2010.PLoS"/>
   <result pre="ChenJ, JinT, WongG, et al.Genesis, evolution and prevalence of H5N6" exact="avian influenza" post="viruses in China.Cell Host Microbe. 2016;20:810–21. 10.1016/j.chom.2016.10.02227916476 26. HorbyPW,"/>
   <result pre="JinT, WongG, et al.Genesis, evolution and prevalence of H5N6 avian" exact="influenza" post="viruses in China.Cell Host Microbe. 2016;20:810–21. 10.1016/j.chom.2016.10.02227916476 26. HorbyPW,"/>
   <result pre="Committee. CONSISE statement on the reporting of Seroepidemiologic Studies for" exact="influenza" post="(ROSES-I statement): an extension of the STROBE statement.Influenza Other"/>
   <result pre="statement.Influenza Other Respir Viruses. 2017;11:2–14. 10.1111/irv.1241127417916 27. SunY, LiuJ. H9N2" exact="influenza" post="virus in China: a cause of concern.Protein Cell. 2015;6:18–25."/>
   <result pre="LiuP, ZhouJ, LvX, LiL, et al.Serological and virological surveillance of" exact="avian influenza" post="A virus H9N2 subtype in humans and poultry in"/>
   <result pre="ZhouJ, LvX, LiL, et al.Serological and virological surveillance of avian" exact="influenza" post="A virus H9N2 subtype in humans and poultry in"/>
   <result pre="et al.A comprehensive retrospective study of the seroprevalence of H9N2" exact="avian influenza" post="viruses in occupationally exposed populations in China.PLoS One. 2017;12:e0178328."/>
   <result pre="al.A comprehensive retrospective study of the seroprevalence of H9N2 avian" exact="influenza" post="viruses in occupationally exposed populations in China.PLoS One. 2017;12:e0178328."/>
   <result pre="YuQ, LiuL, PuJ, ZhaoJ, SunY, ShenG, et al.Risk perceptions for" exact="avian influenza" post="virus infection among poultry workers, China.Emerg Infect Dis. 2013;19:313–6."/>
   <result pre="LiuL, PuJ, ZhaoJ, SunY, ShenG, et al.Risk perceptions for avian" exact="influenza" post="virus infection among poultry workers, China.Emerg Infect Dis. 2013;19:313–6."/>
   <result pre="Dis. 2013;19:313–6. 10.3201/eid1901.12025123343592 31. LiS, ZhouY, SongW, PangQ, MiaoZ. Avian" exact="influenza" post="virus H9N2 seroprevalence and risk factors for infection in"/>
   <result pre="World Health Organization. Recommendations and laboratory procedures for detection of" exact="avian influenza" post="A(H5N1) virus in specimens from suspected human cases. Geneva:"/>
   <result pre="Health Organization. Recommendations and laboratory procedures for detection of avian" exact="influenza" post="A(H5N1) virus in specimens from suspected human cases. Geneva:"/>
   <result pre="JiangS, et al. Genotypic evolution and epidemiological characteristics of H9N2" exact="influenza" post="virus in Shandong Province, China. Poult Sci. 2019;98(9):3488-95. 35."/>
   <result pre="2019;98(9):3488-95. 35. MaMJ, ZhaoT, ChenSH, XiaX, YangXX, WangGL, et al.Avian" exact="influenza" post="A virus infection among workers at live poultry markets,"/>
   <result pre="KhuntiratBP, YoonIK, BlairPJ, KruegerWS, ChittaganpitchM, PutnamSD, et al.Evidence for subclinical" exact="avian influenza" post="virus infections among rural Thai villagers.Clin Infect Dis. 2011;53:e107–16."/>
   <result pre="YoonIK, BlairPJ, KruegerWS, ChittaganpitchM, PutnamSD, et al.Evidence for subclinical avian" exact="influenza" post="virus infections among rural Thai villagers.Clin Infect Dis. 2011;53:e107–16."/>
   <result pre="et al.Structure and function analysis of an antibody recognizing all" exact="influenza" post="A subtypes.Cell. 2016;166:596–608. 10.1016/j.cell.2016.05.07327453466 38. YuanJ, LauEH, LiK, LeungYH,"/>
   <result pre="YangZ, XieC, et al.Effect of live poultry market closure on" exact="avian influenza" post="A(H7N9) virus activity in Guangzhou, China, 2014.Emerg Infect Dis."/>
   <result pre="XieC, et al.Effect of live poultry market closure on avian" exact="influenza" post="A(H7N9) virus activity in Guangzhou, China, 2014.Emerg Infect Dis."/>
   <result pre="YuH, et al.Interventions to reduce zoonotic and pandemic risks from" exact="avian influenza" post="in Asia.Lancet Infect Dis. 2016;16:252–8. 10.1016/S1473-3099(15)00502-226654122 40. FourniéG, GuitianJ,"/>
   <result pre="et al.Interventions to reduce zoonotic and pandemic risks from avian" exact="influenza" post="in Asia.Lancet Infect Dis. 2016;16:252–8. 10.1016/S1473-3099(15)00502-226654122 40. FourniéG, GuitianJ,"/>
   <result pre="40. FourniéG, GuitianJ, DesvauxS, CuongVC, DungH, PfeifferDU, et al.Interventions for" exact="avian influenza" post="A (H5N1) risk management in live bird market networks.Proc"/>
   <result pre="FourniéG, GuitianJ, DesvauxS, CuongVC, DungH, PfeifferDU, et al.Interventions for avian" exact="influenza" post="A (H5N1) risk management in live bird market networks.Proc"/>
   <result pre="YangL, ZhuW, ZhangY, ZouS, BoH, et al.Two outbreak sources of" exact="influenza" post="A (H7N9) viruses have been established in China.J Virol."/>
   <result pre="43. TianH, ZhouS, DongL, Van BoeckelTP, CuiY, NewmanSH, et al.Avian" exact="influenza" post="H5N1 viral and bird migration networks in Asia.Proc Natl"/>
   <result pre="ChenQ, MaZ, WongG, et al.CASCIRE surveillance network and work on" exact="avian influenza" post="viruses.Sci China Life Sci. 2017;60:1386–91. 10.1007/s11427-017-9251-229294220"/>
   <result pre="MaZ, WongG, et al.CASCIRE surveillance network and work on avian" exact="influenza" post="viruses.Sci China Life Sci. 2017;60:1386–91. 10.1007/s11427-017-9251-229294220"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6876883\results\search\disease\results.xml">
   <result pre="Places : Geographical Locations : Oceania: Australia Forecasting type-specific seasonal" exact="influenza" post="after 26 weeks in the United States using influenza"/>
   <result pre="seasonal influenza after 26 weeks in the United States using" exact="influenza" post="activities in other countries Forecasting type-specific influenza after 26"/>
   <result pre="United States using influenza activities in other countries Forecasting type-specific" exact="influenza" post="after 26 weeks in the U.S. ChoiSoo BeomConceptualizationData curationFormal"/>
   <result pre="that have seasonal patterns similar to the time series of" exact="influenza" post="surveillance data in the United States and other countries,"/>
   <result pre="States and other countries, and to forecast the 2018–2019 seasonal" exact="influenza" post="outbreak in the U.S., we collected the surveillance data"/>
   <result pre="between two time-series which were weekly surveillances for ILI, total" exact="influenza" post="(Total INF), influenza A (INF A), and influenza B"/>
   <result pre="which were weekly surveillances for ILI, total influenza (Total INF)," exact="influenza" post="A (INF A), and influenza B (INF B) viruses"/>
   <result pre="ILI, total influenza (Total INF), influenza A (INF A), and" exact="influenza" post="B (INF B) viruses between two countries using cross-correlation"/>
   <result pre="the countries located in northern and southern hemisphere, the seasonal" exact="influenza" post="patterns in Australia and Chile showed a high correlation"/>
   <result pre="and less severe than those in 2017–2018, judging from the" exact="influenza" post="activity for Australia and Chile in 2018. It allows"/>
   <result pre="It allows to estimate peak timing, peak intensity, and type-specific" exact="influenza" post="activities for next season at 40th week. The correlation"/>
   <result pre="for next season at 40th week. The correlation between seasonal" exact="influenza" post="patterns in the U.S., Australia, and Chile could be"/>
   <result pre="and Chile could be used to forecast the next seasonal" exact="influenza" post="pattern, which can help to determine influenza vaccine strategy"/>
   <result pre="the next seasonal influenza pattern, which can help to determine" exact="influenza" post="vaccine strategy approximately six months ahead in the U.S."/>
   <result pre="not have any special privileges accessing the data. Introduction Seasonal" exact="influenza" post="viruses are a significant public-health problem that causes a"/>
   <result pre="seasonal epidemics is attributed to the continued evolution of seasonal" exact="influenza" post="viruses, which enables them to escape the immunity that"/>
   <result pre="respiratory droplets, direct contact, and fomites [1]. Currently, the human" exact="influenza" post="A subtypes H1N1 and H3N2, as well as influenza"/>
   <result pre="human influenza A subtypes H1N1 and H3N2, as well as" exact="influenza" post="B viruses, are the most commonly encountered variants worldwide"/>
   <result pre="the most commonly encountered variants worldwide [2]. Vaccination for seasonal" exact="influenza" post="is the primary tool for reducing its morbidity and"/>
   <result pre="to four weeks [5–7], and few studies have predicted seasonal" exact="influenza" post="epidemics by using influenza information from neighboring regions [8,9]."/>
   <result pre="and few studies have predicted seasonal influenza epidemics by using" exact="influenza" post="information from neighboring regions [8,9]. Because influenza epidemics are"/>
   <result pre="epidemics by using influenza information from neighboring regions [8,9]. Because" exact="influenza" post="epidemics are acute, the long-term circulation of influenza viruses"/>
   <result pre="[8,9]. Because influenza epidemics are acute, the long-term circulation of" exact="influenza" post="viruses in the human population is driven by the"/>
   <result pre="been of interest since at least the 1800s [1]. High-quality" exact="influenza" post="surveillance systems are needed to enable countries to better"/>
   <result pre="surveillance systems are needed to enable countries to better understand" exact="influenza" post="epidemiology, including disease incidence and severity, and help them"/>
   <result pre="most recently available vaccine formulation with respect to local peak" exact="influenza" post="timing, as long as the vaccine is available at"/>
   <result pre="Northern Hemisphere formulation) [13]. Previous studies forecasting the next seasonal" exact="influenza" post="were based on the previous influenza patterns using time-series"/>
   <result pre="forecasting the next seasonal influenza were based on the previous" exact="influenza" post="patterns using time-series prediction models, such as the autoregressive"/>
   <result pre="or a simple humidity-forced susceptible–infectious–recovered–susceptible mathematical model [14,15]. Although the" exact="influenza" post="season occurs annually, unique characteristics particular to each influenza"/>
   <result pre="the influenza season occurs annually, unique characteristics particular to each" exact="influenza" post="season make forecasting difficult. Each year, the geographical location,"/>
   <result pre="is important to find factors related to the next seasonal" exact="influenza" post="pattern and to make a long-term prediction model. To"/>
   <result pre="long-term prediction model. To identify countries with seasonal patterns and" exact="influenza" post="outbreaks that are similar to but precede those of"/>
   <result pre="other countries, in terms of time-series of the ILI, total" exact="influenza" post="(Total INF), influenza A (INF A), and influenza B"/>
   <result pre="terms of time-series of the ILI, total influenza (Total INF)," exact="influenza" post="A (INF A), and influenza B (INF B) viruses."/>
   <result pre="ILI, total influenza (Total INF), influenza A (INF A), and" exact="influenza" post="B (INF B) viruses. Our hypothesis was that similar"/>
   <result pre="B) viruses. Our hypothesis was that similar seasonal patterns of" exact="influenza" post="outbreaks between two countries over the years are associated"/>
   <result pre="outbreaks between two countries over the years are associated with" exact="influenza" post="activity in the following year. Knowing about such an"/>
   <result pre="an association may help clinicians to predict the pattern of" exact="influenza" post="incidence in the next season. The prediction model allows"/>
   <result pre="model allows to estimate peak timing, peak intensity, and type-specific" exact="influenza" post="activities for next season at 40th week. Methods Data"/>
   <result pre="FluNet database contains the following variables, reported by 164 countries:" exact="influenza" post="transmission zone, number of specimens, number of INF A"/>
   <result pre="the starting point for our research data in 2010, because" exact="influenza" post="season during 2009 was an atypical season, with the"/>
   <result pre="because some countries conducted surveillance only during weeks with high" exact="influenza" post="activity. Total INF, INF A, and INF B were"/>
   <result pre="A, and INF B were defined as the number of" exact="influenza" post="subtypes detected among processed specimens. Google Trends (GT) (https://trends.google.com/trends/)"/>
   <result pre="Maximum correlation coefficient and time lag with time series of" exact="influenza" post="surveillance data in the United States and input variables."/>
   <result pre="regression analysis (LR) was used to evaluate the relationship between" exact="influenza" post="surveillances in the U.S. after 26 weeks and those"/>
   <result pre="2010 to the 40th week in 2018. LR 1 used" exact="influenza" post="data from the U.S. after 26 weeks as dependent"/>
   <result pre="data from the U.S. as independent variable. LR 2 used" exact="influenza" post="activities from selected countries, and LR 3 used GT"/>
   <result pre="1, and these input variables were used to forecast seasonal" exact="influenza" post="after 26 weeks in the U.S. All statistical analyses"/>
   <result pre="&amp;lt; 0.05 was considered statistically significant. Prediction model Forecasting seasonal" exact="influenza" post="after 26 weeks was defined as forecasting influenza pattern"/>
   <result pre="Forecasting seasonal influenza after 26 weeks was defined as forecasting" exact="influenza" post="pattern after six months (26 weeks) with data available"/>
   <result pre="2015–2019 were selected to validate the prediction models for seasonal" exact="influenza" post="patterns. This is done because the training set accounted"/>
   <result pre="for 2010–2018. For example, the prediction model for the seasonal" exact="influenza" post="pattern during 2015–2016 used the influenza surveillance data from"/>
   <result pre="model for the seasonal influenza pattern during 2015–2016 used the" exact="influenza" post="surveillance data from the 40th week in 2010 to"/>
   <result pre="set (Fig 4). Fig 3 The explanation for forecasting seasonal" exact="influenza" post="after 26 weeks. Fig 4 The explanation for the"/>
   <result pre="set at the 40th week and output for forecasting seasonal" exact="influenza" post="after 26 weeks. The prediction model is a single-output"/>
   <result pre="weeks. The prediction model is a single-output model for seasonal" exact="influenza" post="patterns after 26 weeks using the four historical values"/>
   <result pre="ANN model. Prediction models of LR were calculated to forecast" exact="influenza" post="surveillance after 26 weeks in the U.S. per each"/>
   <result pre="after 26 weeks in the U.S. per each year. The" exact="influenza" post="time series is characterized by an autocorrelation, so we"/>
   <result pre="(RMSE) was calculated using real values and predicted values for" exact="influenza" post="activities in the validation set from the 41th week"/>
   <result pre="in 2015 to 14th week in 2019. The onset of" exact="influenza" post="weeks for ILI is defined as the weighted percentage"/>
   <result pre="defined as the maximum value and that week in seasonal" exact="influenza" post="week. Results Cross–correlation analysis Table 1 shows the maximum"/>
   <result pre="the maximum correlation coefficient and time lag between the seasonal" exact="influenza" post="outbreaks in the U.S. and the input variables. The"/>
   <result pre="between ILI in the U.S. and the number of positive" exact="influenza" post="viruses worldwide. In Table 1, Australia had the highest"/>
   <result pre="The -22 week time lag meant that the country’s seasonal" exact="influenza" post="outbreak 22 weeks earlier was highly correlated with the"/>
   <result pre="outbreak 22 weeks earlier was highly correlated with the seasonal" exact="influenza" post="outbreak in the U.S. In the analysis of the"/>
   <result pre="to 2 weeks, which were not eligible variables to forecast" exact="influenza" post="after 26 weeks. However, GT with the keyword &quot;influenza"/>
   <result pre="was shifted forward 28 weeks, the waveforms also similar. Therefore," exact="influenza" post="surveillance data in Australia and Chile could be valuable"/>
   <result pre="in Australia and Chile could be valuable for predicting an" exact="influenza" post="outbreak after 26 weeks in the U.S. Fig 5"/>
   <result pre="weeks in the U.S. Fig 5 The surveillance data for" exact="influenza" post="A (a) and B (b) viruses in the U.S."/>
   <result pre="shifted forward 22 weeks in 2010–2018. The surveillance data for" exact="influenza" post="A (c) viruses in the U.S. and Chile; the"/>
   <result pre="of the H1N1 and H3 viruses, is the number of" exact="influenza" post="viruses (not subtyped). Linear regression analysis Table 2 shows"/>
   <result pre="Linear regression analysis Table 2 shows results of LR for" exact="influenza" post="after 26 weeks (ILI, Total INF, INF A, and"/>
   <result pre="INF, INF A, and INF B) in the U.S. using" exact="influenza" post="activities for the previous season in the U.S, influenza"/>
   <result pre="using influenza activities for the previous season in the U.S," exact="influenza" post="activities in Australia and Chile, GT with the keyword"/>
   <result pre="of LR 2 demonstrated that the adjusted R2 values for" exact="influenza" post="surveillance at present in the selected countries were higher"/>
   <result pre="results for the final selection of input variables to forecast" exact="influenza" post="activities after 26 weeks in the U.S. 10.1371/journal.pone.0220423.t002Table 2"/>
   <result pre="weeks in the U.S. 10.1371/journal.pone.0220423.t002Table 2 Linear regression analysis for" exact="influenza" post="activities of previous season in the U.S. and input"/>
   <result pre="3 shows the performance of the prediction models for seasonal" exact="influenza" post="outbreaks in the U.S. after 26 weeks using previous"/>
   <result pre="the highest. 10.1371/journal.pone.0220423.t003Table 3 Performance of prediction models for seasonal" exact="influenza" post="outbreaks after 26 weeks in the United States from"/>
   <result pre="of visits for influenza-like illness and number of total influenza," exact="influenza" post="A, and influenza B viruses. Units for the RMSE"/>
   <result pre="influenza-like illness and number of total influenza, influenza A, and" exact="influenza" post="B viruses. Units for the RMSE (Peak timing) are"/>
   <result pre="of visits for influenza-like illness and number of total influenza," exact="influenza" post="A, and influenza B viruses. Fig 6 shows the"/>
   <result pre="influenza-like illness and number of total influenza, influenza A, and" exact="influenza" post="B viruses. Fig 6 shows the prediction of ANN"/>
   <result pre="and Chile. Moreover, the forecast prediction by ARIMAX for type-specific" exact="influenza" post="activities in the U.S. (blue line) and the 95%"/>
   <result pre="Fig 7. The pattern of peak timing and amplitude of" exact="influenza" post="activity for the 2015–2016 season was different from the"/>
   <result pre="2012–2015 season, but our models forecasted later and less severe" exact="influenza" post="activity. Moreover, the predicted INF B activity for the"/>
   <result pre="6 The prediction of ANN for ILI (a) and Total" exact="influenza" post="(b), influenza A and influenza B viruses (c) after"/>
   <result pre="prediction of ANN for ILI (a) and Total influenza (b)," exact="influenza" post="A and influenza B viruses (c) after 26 weeks"/>
   <result pre="for ILI (a) and Total influenza (b), influenza A and" exact="influenza" post="B viruses (c) after 26 weeks from 2015 to"/>
   <result pre="Auto Regressive Integrated Moving Average for ILI (a) and Total" exact="influenza" post="(b), influenza A (c) and influenza B viruses (d)"/>
   <result pre="Integrated Moving Average for ILI (a) and Total influenza (b)," exact="influenza" post="A (c) and influenza B viruses (d) from 2015"/>
   <result pre="ILI (a) and Total influenza (b), influenza A (c) and" exact="influenza" post="B viruses (d) from 2015 to 2019 in the"/>
   <result pre="this study was to identify countries with seasonal patterns and" exact="influenza" post="outbreaks that were similar to but preceded those of"/>
   <result pre="to but preceded those of the United States. We used" exact="influenza" post="activities in Australia and Chile, GT with the keyword"/>
   <result pre="Chile, and temperature in the U.S. to forecast for seasonal" exact="influenza" post="after 26 weeks in the U.S. The seasonal influenza"/>
   <result pre="seasonal influenza after 26 weeks in the U.S. The seasonal" exact="influenza" post="patterns in Australia before 22 weeks and Chile before"/>
   <result pre="high correlation with those of the U.S. In Table 2," exact="influenza" post="surveillance and GT in Australia and Chile at present"/>
   <result pre="and Chile at present were more useful than previous seasonal" exact="influenza" post="in the U.S. for forecasting next seasonal influenza in"/>
   <result pre="previous seasonal influenza in the U.S. for forecasting next seasonal" exact="influenza" post="in the U.S. ANN models showed better performance for"/>
   <result pre="in the U.S. ANN models showed better performance for forecasting" exact="influenza" post="activities after 26 weeks in the U.S than previous"/>
   <result pre="later and less severe than that in 2017–2018. The seasonal" exact="influenza" post="patterns in the U.S. were highly correlated with those"/>
   <result pre="shown in Table 1. Moreover, the period of the primary" exact="influenza" post="peak in the Southern Hemisphere countries was July and"/>
   <result pre="in Table 1. For these reasons, the correlations for seasonal" exact="influenza" post="between countries could be caused by characteristics of influenza,"/>
   <result pre="study did not prove the causality of correlations for seasonal" exact="influenza" post="between countries. Although we do not know the reasons,"/>
   <result pre="we do not know the reasons, the patterns for seasonal" exact="influenza" post="in the U.S., Australia, and Chile were similar, and"/>
   <result pre="influenza in the U.S., Australia, and Chile were similar, and" exact="influenza" post="surveillance in Australia and Chile can be used to"/>
   <result pre="in Australia and Chile can be used to predict seasonal" exact="influenza" post="outbreaks after 26 week in the U.S. A study"/>
   <result pre="Their study analyzed the correlation of peak timing for seasonal" exact="influenza" post="between countries, and gave a time-series graph for influenza"/>
   <result pre="seasonal influenza between countries, and gave a time-series graph for" exact="influenza" post="surveillance from 2000 to 2012 in the U.S. and"/>
   <result pre="of human viruses [30]. Viboud et al. analyzed correlations for" exact="influenza" post="epidemics from 1972 to 1997 in the U.S., France,"/>
   <result pre="study, France and the U.S. had a high correlation for" exact="influenza" post="epidemics, but there was no significant correlation between the"/>
   <result pre="the U.S. and Australia. In the scenario in which the" exact="influenza" post="season in Australia was systematically six months in advance"/>
   <result pre="not [31]. The previous studies for prediction models for seasonal" exact="influenza" post="have focused on social networking service data, search engine"/>
   <result pre="and environmental factors [32–34]. These predictors are correlated with present" exact="influenza" post="cases with a relatively short-term gap, of about one"/>
   <result pre="short-term gap, of about one to four weeks. However, the" exact="influenza" post="surveillance data in Australia had a time gap of"/>
   <result pre="in the U.S., which can help to establish a data-driven" exact="influenza" post="vaccine strategy about six months ahead. Kandula et al."/>
   <result pre="ahead. Kandula et al. analyzed whether forecasts targeted to predict" exact="influenza" post="by type and subtype during 2003–2015 in the U.S."/>
   <result pre="predictions of Total INF [35]. Our prediction models for type-specific" exact="influenza" post="is valuable as well as those for ILI, which"/>
   <result pre="for ILI, which could provide an important, richer picture of" exact="influenza" post="activity. To our best knowledge, this is the first"/>
   <result pre="our best knowledge, this is the first study to use" exact="influenza" post="surveillance in Australia and Chile for predicting influenza cases"/>
   <result pre="to use influenza surveillance in Australia and Chile for predicting" exact="influenza" post="cases after 26 weeks in the U.S. However, our"/>
   <result pre="enough data on other potential covariates to show relationships between" exact="influenza" post="outbreaks in Australia, Chile, and the U.S., such as"/>
   <result pre="the medical facilities, economic level, and medical records of the" exact="influenza" post="virus. Furthermore, we included only data from laboratory-confirmed cases,"/>
   <result pre="from laboratory-confirmed cases, which may underestimate the true incidence of" exact="influenza" post="in the population [36]. Further research to explain underlying"/>
   <result pre="Further research to explain underlying mechanisms for the relationship of" exact="influenza" post="activities between these countries is warranted. Conclusions Our study"/>
   <result pre="countries is warranted. Conclusions Our study forecasts the 2018–2019 seasonal" exact="influenza" post="after 26 weeks in the U.S. using the 2018"/>
   <result pre="after 26 weeks in the U.S. using the 2018 seasonal" exact="influenza" post="in Australia and Chile. The correlation between the seasonal"/>
   <result pre="influenza in Australia and Chile. The correlation between the seasonal" exact="influenza" post="patterns in the U.S., Australia, and Chile could be"/>
   <result pre="and Chile could be used to forecast the next seasonal" exact="influenza" post="pattern, which can help to determine influenza vaccine strategy"/>
   <result pre="the next seasonal influenza pattern, which can help to determine" exact="influenza" post="vaccine strategy approximately six months ahead in the U.S."/>
   <result pre="model allows to estimate peak timing, peak intensity, and type-specific" exact="influenza" post="activities for next season at 40th week. Supporting information"/>
   <result pre="40th week. Supporting information S1 Table Linear regression models for" exact="influenza" post="surveillance after 26 weeks in the U.S. (DOCX) LINK"/>
   <result pre="Table Auto regressive integrated moving average including exogenous variables for" exact="influenza" post="surveillance after 26 weeks in the U.S. (DOCX) LINK"/>
   <result pre="System (GISRS). References References 1PetrovaVN, RussellCA. The evolution of seasonal" exact="influenza" post="viruses. Nat Rev Microbiol2018;16:47–60. 10.1038/nrmicro.2017.11829081496 2XuC, ChanKH, TsangTK, FangVJ,"/>
   <result pre="Households. Am J Epidemiol2015;182:705–13. 10.1093/aje/kwv11026400854 3NewmanLP, BhatN, FlemingJA, NeuzilKM. Global" exact="influenza" post="seasonality to inform country–level vaccine programs: An analysis of"/>
   <result pre="to inform country–level vaccine programs: An analysis of WHO FluNet" exact="influenza" post="surveillance data between 2011 and 2016. PLoS One2018;13:e019326310.1371/journal.pone.019326329466459 4ChretienJP,"/>
   <result pre="5ChoS, SohnCH, JoMW, ShinSY, LeeJH, RyooSM, et al.Correlation between national" exact="influenza" post="surveillance data and google trends in South Korea. PLoS"/>
   <result pre="ShamanJ, AlonsoWJ, Bloom-FeshbachK, UejioCK, ComrieA, et al.Environmental predictors of seasonal" exact="influenza" post="epidemics across temperate and tropical climates. PLoS Pathog2013;9:e100319410.1371/journal.ppat.100319423505366 8Xi"/>
   <result pre="10OrtizJR, SotomayorV, UezOC, OlivaO, BettelsD, McCarronM, et al.Strategy to enhance" exact="influenza" post="surveillance worldwide. Emerg Infect Dis2009;15:1271–8. 10.3201/eid1508.08142219751590 11ViboudC, VespignaniA. The"/>
   <result pre="worldwide. Emerg Infect Dis2009;15:1271–8. 10.3201/eid1508.08142219751590 11ViboudC, VespignaniA. The future of" exact="influenza" post="forecasts. Proc Natl Acad Sci U S A. 2019;116:2802–4."/>
   <result pre="2019;116:2802–4. 10.1073/pnas.182216711630737293 12AgorJK, ÖzaltınOY. Models for predicting the evolution of" exact="influenza" post="to inform vaccine strain selection. Hum Vaccin Immunother2018;14:678–83. 10.1080/21645515.2017.142315229337643"/>
   <result pre="ViboudC, RichardSA, Schuck-PaimC, SimonsenL, et al.A global map of hemispheric" exact="influenza" post="vaccine recommendations based on local patterns of viral circulation."/>
   <result pre="Inform2017;9:e18710.5210/ojphi.v9i2.800429026453 16PolgreenPM, NelsonFD, NeumannGR. Use of prediction markets to forecast" exact="infectious disease" post="activity. Clin Infect Dis2007;44:272–9. 10.1086/51042717173231 17DuX, PascualM. Incidence Prediction"/>
   <result pre="of Asian Researchers on Influenza (GARI). Divergent seasonal patterns of" exact="influenza" post="types A and B across latitude gradient in Tropical"/>
   <result pre="10.1111/irv.1237226781162 19CainiS, AlonsoWJ, SéblainCE, SchellevisF, PagetJ. The spatiotemporal characteristics of" exact="influenza" post="A and B in the WHO European Region: can"/>
   <result pre="and B in the WHO European Region: can one define" exact="influenza" post="transmission zones in Europe?Euro Surveill2017;22:1–11. 20AroraVS, McKeeM, StucklerD. Google"/>
   <result pre="Health Policy2019;123:338–41. 10.1016/j.healthpol.2019.01.00130660346 21PáscoaR, RodriguesAP, SilvaS, NunesB, MartinsC. Comparison between" exact="influenza" post="coded primary care consultations and national influenza incidence obtained"/>
   <result pre="MartinsC. Comparison between influenza coded primary care consultations and national" exact="influenza" post="incidence obtained by the General Practitioners Sentinel Network in"/>
   <result pre="2012 to 2017. PLoS One2018;13:e019268110.1371/journal.pone.019268129438406 22ZhangJ, NawataK. Multi–step prediction for" exact="influenza" post="outbreak by an adjusted long short–term memory. Epidemiol Infect2018;146:809–16."/>
   <result pre="Sci Math Sci2016;5:43–7. 26SoebiyantoRP, AdimiF, KiangRK. Modeling and predicting seasonal" exact="influenza" post="transmission in warm regions using climatological parameters. PLoS One2010;5:e945010.1371/journal.pone.000945020209164"/>
   <result pre="BarrIG, BroorS, ChadhaM, CoxNJ, et al.Global circulation patterns of seasonal" exact="influenza" post="viruses vary with antigenic drift. Nature2015;523:217–20. 10.1038/nature1446026053121 31ViboudC, BoëllePY,"/>
   <result pre="Infect Dis2004;10:32–9. 10.3201/eid1001.02070515078594 32GinsbergJ, MohebbiMH, PatelRS, BrammerL, SmolinskiMS, BrilliantL. Detecting" exact="influenza" post="epidemics using search engine query data. Nature2009;457:1012–4. 10.1038/nature0763419020500 33HickmannKS,"/>
   <result pre="33HickmannKS, FairchildG, PriedhorskyR, GenerousN, HymanJM, DeshpandeA, et al.Forecasting the 2013–2014" exact="influenza" post="season using Wikipedia. PLoS Comput Biol2015;11:e100423910.1371/journal.pcbi.100423925974758 34HuH, WangH, WangF,"/>
   <result pre="Am J Epidemiol2017;185:395–402. 10.1093/aje/kww21128174833 36MoaAM, MuscatelloDJ, TurnerRM, MacIntyreCR. Epidemiology of" exact="influenza" post="B in Australia: 2001–2014 influenza seasons. Influenza Other Respir"/>
   <result pre="MuscatelloDJ, TurnerRM, MacIntyreCR. Epidemiology of influenza B in Australia: 2001–2014" exact="influenza" post="seasons. Influenza Other Respir Viruses2017;11:102–9. 10.1111/irv.1243227650482"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6877935\results\search\disease\results.xml">
   <result pre="cross-sectional study. 2922 patients aged 18 years or more with" exact="dengue fever" post="in National Hospital for Tropical Diseases (NHTD) in the"/>
   <result pre="in all ages were affected. The number of patients with" exact="dengue fever" post="was 1675 (57.3%), dengue with warning signs 914 (31.3%),"/>
   <result pre="Vietnam has also been successfully recorded in controlling mortality from" exact="dengue fever" post="[9]. Although the disease is now endemic in Vietnam,"/>
   <result pre="Such data will also provide useful information for establishing the" exact="dengue fever" post="prevention program in Vietnam. In the early year of"/>
   <result pre="Vietnam. In the early year of 2017, an outbreak of" exact="dengue fever" post="transmitted throughout the country with much higher number of"/>
   <result pre="pregnancy and 245/2922 (8.4%) patients with underlying diseases such as" exact="liver disease" post="(chronic hepatitis and cirrhosis), kidney disease (chronic nephritis and"/>
   <result pre="(8.4%) patients with underlying diseases such as liver disease (chronic" exact="hepatitis" post="and cirrhosis), kidney disease (chronic nephritis and renal failure),"/>
   <result pre="as liver disease (chronic hepatitis and cirrhosis), kidney disease (chronic" exact="nephritis" post="and renal failure), diabetes, hyperthyroidism, cardiovascular disease, and hypertension"/>
   <result pre="cirrhosis), kidney disease (chronic nephritis and renal failure), diabetes, hyperthyroidism," exact="cardiovascular disease," post="and hypertension (Table 1). 3.2. Clinical Presentations In this"/>
   <result pre="were shock, severe organ impairment, and severe bleeding. Outcome of" exact="dengue fever" post="patients was related to a number of factors such"/>
   <result pre="Demographics 4.1.1. Geographically Dispersed In Vietnam, the first cases of" exact="dengue fever" post="were recorded in 1959 in the North and in"/>
   <result pre="has been assessed by some studies as the spread of" exact="dengue fever" post="is associated with climate characteristics in different areas in"/>
   <result pre="areas in Vietnam [10, 11]. However, during the outbreak of" exact="dengue fever" post="in 2017, dengue fever patients were present in 4/5"/>
   <result pre="11]. However, during the outbreak of dengue fever in 2017," exact="dengue fever" post="patients were present in 4/5 of the provinces, cities"/>
   <result pre="dengue prevention program guideline. Similarly, some studies have shown that" exact="dengue fever" post="was only reported in patients under 60 years of"/>
   <result pre="virus in daily activities [6, 15]. Our findings showed that" exact="dengue fever" post="has affected all ages, especially in the age group"/>
   <result pre="we found that, in the South, the clinical manifestations of" exact="dengue fever" post="was more serious with the signs of hemorrhage, hepatomegaly,"/>
   <result pre="is a note in comparison with the previous reports of" exact="dengue fever," post="death mainly in the Southern and common in children"/>
   <result pre="also reported that, in adults, the factors associated with severe" exact="dengue fever" post="are age over 40 years [16–18], comorbidities [17, 18],"/>
   <result pre="with warning signs in the South. Second, the classification between" exact="dengue fever," post="dengue fever with warning signs, and severe dengue fever"/>
   <result pre="signs in the South. Second, the classification between dengue fever," exact="dengue fever" post="with warning signs, and severe dengue fever sometimes has"/>
   <result pre="between dengue fever, dengue fever with warning signs, and severe" exact="dengue fever" post="sometimes has no clear boundaries. Third, in the context"/>
   <result pre="tropical diseases in Vietnam, so it provides more information for" exact="dengue fever" post="situation in Vietnam. 5. Conclusion Dengue fever is becoming"/>
   <result pre="control. In the future, more studies are requested to monitor" exact="dengue fever" post="surveillance across the whole country and determine the biomarkers"/>
   <result pre="Namhttp://www.wpro.who.int/vietnam/vi/ 10VuH. H.OkumuraJ.HashizumeM.TranD. N.YamamotoT.Regional differences in the growing incidence of" exact="dengue fever" post="in Vietnam explained by weather variabilityTropical Medicine and Health2014421253310.2149/tmh.2013-24"/>
   <result pre="Medicine and Health2014421253310.2149/tmh.2013-24 11DoT. T. T.MartensP.LuuN. H.WrightP.ChoisyM.Climatic-driven seasonality of emerging" exact="dengue fever" post="in Hanoi, VietnamBMC Public Health2014141p. 107810.1186/1471-2458-14-1078 12GublerD. J.DuaneJ.GublerE. E."/>
   <result pre="and Dengue Hemorrhagic Fever20142ndCroydon, UKCPI Group Ltd.129 13ÅströmC.RocklövJ.HalesS.BéguinA.LouisV.SauerbornR.Potential distribution of" exact="dengue fever" post="under scenarios of climate change and economic developmentEco Health20129444845410.1007/s10393-012-0808-023408100"/>
   <result pre="developmentEco Health20129444845410.1007/s10393-012-0808-023408100 14Thi Tuyet-HanhT.Nhat CamN.Thi Thanh HuongL.et al.Climate variability and" exact="dengue hemorrhagic fever" post="in Hanoi, Viet Nam, during 2008 to 2015Asia Pacific"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6881000\results\search\disease\results.xml">
   <result pre=": Landforms: Wetlands Spatiotemporal analysis of historical records (2001–2012) on" exact="dengue fever" post="in Vietnam and development of a statistical model for"/>
   <result pre="of a statistical model for forecasting risk Spatial analysis of" exact="dengue fever" post="occurrence patterns in Vietnam http://orcid.org/0000-0001-9376-2941BettBernardConceptualizationData curationFormal analysisMethodologyVisualizationWriting – original"/>
   <result pre="are credited.pone.0224353.pdf Abstract Background Dengue fever is the most widespread" exact="infectious disease" post="of humans transmitted by Aedes mosquitoes. It is the"/>
   <result pre="data portal: data.ilri.org/portal/dataset/surveillance_climate_sensitive_diseases. Introduction Dengue fever (dengue) is a major" exact="infectious disease" post="of humans in the tropics and sub-tropics caused by"/>
   <result pre="headache, retro-orbital pain, nausea, vomiting, myalgia, arthralgia, haemorrhagic manifestations, and" exact="leukopenia" post="[1][28]. Before 2002, a few cases were confirmed using"/>
   <result pre="harmonize their dimensions. These data were then merged with the" exact="dengue fever" post="records, meteorological variables and human population using the province"/>
   <result pre="estimated from a parsimonious hierarchical Bayesian spatial model fitted to" exact="dengue fever" post="data from Vietnam (2001–2010). Variable Levels Mean SD Quantile"/>
   <result pre="for 2010–2012, with 2.5% and 95% quantiles. Discussion We analyzed" exact="dengue fever" post="surveillance records collected between 2001–2012 in Vietnam and developed"/>
   <result pre="the country [11] and with climate, the spatial range of" exact="dengue fever" post="virus is likely to expand to areas that are"/>
   <result pre="with a decline in dengue incidence. Evidence from studies on" exact="malaria" post="vectors show that high rainfall is known to cause"/>
   <result pre="made for a broad range of vector-borne diseases including Japanese" exact="encephalitis" post="[58] and malaria [58], among others. Apart from influencing"/>
   <result pre="broad range of vector-borne diseases including Japanese encephalitis [58] and" exact="malaria" post="[58], among others. Apart from influencing climate patterns, altitude"/>
   <result pre="have been associated with endemicity of other vector-borne diseases including" exact="malaria" post="[59], schistosomiasis [60], Rift Valley fever [61], and West"/>
   <result pre="associated with endemicity of other vector-borne diseases including malaria [59]," exact="schistosomiasis" post="[60], Rift Valley fever [61], and West Nile fever"/>
   <result pre="169–178. 10.1016/S1995-7645(14)60016-X 5AcharyaBK, CaoC, LakesT, ChenW, NaeemS. Spatiotemporal analysis of" exact="dengue fever" post="in Nepal from 2010 to 2014. BMC Public Health."/>
   <result pre="11LeeHS, Nguyen-VietH, NamVS, LeeM, WonS, DucPP, et al.Seasonal patterns of" exact="dengue fever" post="and associated climate factors in 4 provinces in Vietnam"/>
   <result pre="McIverL, HashizumeM, ChanV, AbeyasingheRR, et al.Effects of weather factors on" exact="dengue fever" post="incidence and implications for interventions in Cambodia. BMC Public"/>
   <result pre="ToanT, HuW, ThaiPQ. Hot spot detection and spatio-temporal dispersion of" exact="dengue fever" post="in Hanoi, Vietnam. 2013;1: 1–9. 15AnDTM, RocklövJ. Epidemiology of"/>
   <result pre="fever in Hanoi, Vietnam. 2013;1: 1–9. 15AnDTM, RocklövJ. Epidemiology of" exact="dengue fever" post="in hanoi from 2002 to 2010 and its meteorological"/>
   <result pre="ThiP, BriantL, GavotteL, LabbeP, Perriat-sanguinetM, et al.Incidence of dengue and" exact="chikungunya" post="viruses in mosquitoes and human patients in border provinces"/>
   <result pre="27collab: Anonymous. Guidelines on the surveillance, diagnosis, and treatment of" exact="dengue hemorrhagic fever." post="Hanoi, Vietnam: Ministry of Health; 1999. 28Handique BK, Khan"/>
   <result pre="28Handique BK, Khan SA, Mahanta J, Sudhakar S. Forecasting Japanese" exact="encephalitis" post="incidence from historical morbidity patterns: Statistical analysis with 27"/>
   <result pre="AnhDD, DuongTN, LeeM, GraceD, et al.Geographical and temporal patterns of" exact="rabies" post="post exposure prophylaxis (PEP) incidence in humans in the"/>
   <result pre="PetersonAT. Climate change influences on global distributions of dengue and" exact="chikungunya" post="virus vectors. Philos Trans R Soc B Biol Sci."/>
   <result pre="54Herrera-BastoE, PrevotsDR, ZarateML, SilvaJL, Sepulveda-AmorJ. First reported outbreak of classical" exact="dengue fever" post="at 1,700 meters above sea level in Guerrero State,"/>
   <result pre="KisinzaW, MsangeniHA, PedersenEM, et al.Relationship between altitude and intensity of" exact="malaria" post="transmission in the Usambara Mountains, Tanzania. J Med Entomol."/>
   <result pre="10.1603/0022-2585-40.5.70614596287 59MuriukiJM, KitalaP, MuchemiG, NjeruI, KaranjaJ, BettB. A comparison of" exact="malaria" post="prevalence, control and management strategies in irrigated and non-irrigated"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6881067\results\search\disease\results.xml">
   <result pre="in Southeast Asia, and are also the main vectors of" exact="chikungunya" post="(CHIKV) [5] and Zika virus (ZIKV) [6]. DENV is"/>
   <result pre="sylvatic DENV-1 virus was also isolated from a patient with" exact="dengue fever" post="in the country, and it was suggested that the"/>
   <result pre="2 from a sylvatic lineage isolated from a patient with" exact="dengue hemorrhagic fever." post="PLoS Negl Trop Dis3: e42310.1371/journal.pntd.000042319399166 15TeohB-T, SamS-S, Abd-JamilJ, AbuBakarS"/>
   <result pre="future distributions of the sylvatic cycles of dengue virus and" exact="yellow fever" post="virus. Infect Genet Evol19: 292–311. 10.1016/j.meegid.2013.03.00823523817 43DialloM, SallAA, MoncayoAC,"/>
   <result pre="reservoirs for flaviviruses (yellow fever, dengue 2 and St Louis" exact="encephalitis" post="viruses) in French Guiana. Trans R Soc Trop Med"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6881073\results\search\disease\results.xml">
   <result pre="author and source are credited.ppat.1007863.pdf Abstract Enterovirus A71 (EV-A71) causes" exact="hand, foot and mouth disease" post="epidemics with neurological complications and fatalities. However, the neuropathogenesis"/>
   <result pre="are credited.ppat.1007863.pdf Abstract Enterovirus A71 (EV-A71) causes hand, foot and" exact="mouth disease" post="epidemics with neurological complications and fatalities. However, the neuropathogenesis"/>
   <result pre="Author summary Enterovirus A71 (EV-A71) is the primary cause of" exact="hand, foot and mouth disease," post="and it can also infect the central nervous system"/>
   <result pre="A71 (EV-A71) is the primary cause of hand, foot and" exact="mouth disease," post="and it can also infect the central nervous system"/>
   <result pre="Information files. Introduction Enterovirus A71 (EV-A71) causes cyclical outbreaks of" exact="hand, foot and mouth disease" post="(HFMD) in the Asia-Pacific region [1]. HFMD primarily affects"/>
   <result pre="Enterovirus A71 (EV-A71) causes cyclical outbreaks of hand, foot and" exact="mouth disease" post="(HFMD) in the Asia-Pacific region [1]. HFMD primarily affects"/>
   <result pre="cases, infection also results in severe neurological complications, including encephalitis," exact="aseptic meningitis," post="acute flaccid paralysis and death [4]. There are no"/>
   <result pre="reported to cause attenuation in viruses such as Theiler's murine" exact="encephalomyelitis" post="virus [31], Japanese encephalitis virus [32], Murray Valley encephalitis"/>
   <result pre="in viruses such as Theiler's murine encephalomyelitis virus [31], Japanese" exact="encephalitis" post="virus [32], Murray Valley encephalitis virus [32], West Nile"/>
   <result pre="murine encephalomyelitis virus [31], Japanese encephalitis virus [32], Murray Valley" exact="encephalitis" post="virus [32], West Nile virus [33], yellow fever virus"/>
   <result pre="[32], Murray Valley encephalitis virus [32], West Nile virus [33]," exact="yellow fever" post="virus [34] and tick-borne encephalitis virus [35]. In contrast,"/>
   <result pre="[32], West Nile virus [33], yellow fever virus [34] and" exact="tick-borne encephalitis" post="virus [35]. In contrast, virus variants with weak heparin-binding"/>
   <result pre="West Nile virus [33], yellow fever virus [34] and tick-borne" exact="encephalitis" post="virus [35]. In contrast, virus variants with weak heparin-binding"/>
   <result pre="mortality in mice, as shown for Sindbis virus [36] and" exact="eastern equine encephalitis" post="virus (EEEV) [37]. Interestingly, variants with strong heparin-binding can"/>
   <result pre="mice, as shown for Sindbis virus [36] and eastern equine" exact="encephalitis" post="virus (EEEV) [37]. Interestingly, variants with strong heparin-binding can"/>
   <result pre="observed in other viruses, including Sindbis virus [36], Venezuelan equine" exact="encephalitis" post="virus [59], West Nile virus [33], yellow fever virus"/>
   <result pre="[36], Venezuelan equine encephalitis virus [59], West Nile virus [33]," exact="yellow fever" post="virus [34] and Japanese encephalitis virus [61]. Using a"/>
   <result pre="West Nile virus [33], yellow fever virus [34] and Japanese" exact="encephalitis" post="virus [61]. Using a monkey model, Zhang et al."/>
   <result pre="Appendix). Detection of VP1-145E in the sequences of a fatal" exact="encephalitis" post="autopsy specimen [79] further reinforces our view that weak"/>
   <result pre="of Malaya (reference number: 2016-190908/R/TCW). Cell lines and viruses Human" exact="rhabdomyosarcoma" post="(RD, ATCC no.: CCL-136) was propagated in Dulbecco’s Modified"/>
   <result pre="1NikNadiaN, SamIC, RampalS, WanNorAmalinaW, NurAtifahG, VerasahibK, et al.Cyclical patterns of" exact="hand, foot and mouth disease" post="caused by Enterovirus A71 in Malaysia. PLoS Negl Trop"/>
   <result pre="WanNorAmalinaW, NurAtifahG, VerasahibK, et al.Cyclical patterns of hand, foot and" exact="mouth disease" post="caused by Enterovirus A71 in Malaysia. PLoS Negl Trop"/>
   <result pre="et al.Cell surface sialylation affects binding of enterovirus 71 to" exact="rhabdomyosarcoma" post="and neuroblastoma cells. BMC Microbiol. 2012;12:162 Epub 2012/08/03. 10.1186/1471-2180-12-162"/>
   <result pre="surface sialylation affects binding of enterovirus 71 to rhabdomyosarcoma and" exact="neuroblastoma" post="cells. BMC Microbiol. 2012;12:162 Epub 2012/08/03. 10.1186/1471-2180-12-162 .22853823 12YangB,"/>
   <result pre="E protein determinants for attenuation of glycosaminoglycan-binding variants of Japanese" exact="encephalitis" post="and West Nile viruses. J Virol. 2004;78(15):8271–80. Epub 2004/07/16."/>
   <result pre="10.1128/JVI.78.15.8271-8280.2004 .15254199 34LeeE, LobigsM. E protein domain III determinants of" exact="yellow fever" post="virus 17D vaccine strain enhance binding to glycosaminoglycans, impede"/>
   <result pre=".18400851 35MandlCW, KroschewskiH, AllisonSL, KoflerR, HolzmannH, MeixnerT, et al.Adaptation of" exact="tick-borne encephalitis" post="virus to BHK-21 cells results in the formation of"/>
   <result pre="35MandlCW, KroschewskiH, AllisonSL, KoflerR, HolzmannH, MeixnerT, et al.Adaptation of tick-borne" exact="encephalitis" post="virus to BHK-21 cells results in the formation of"/>
   <result pre=".10623725 37GardnerCL, EbelGD, RymanKD, KlimstraWB. Heparan sulfate binding by natural" exact="eastern equine encephalitis" post="viruses promotes neurovirulence. Proc Natl Acad Sci U S"/>
   <result pre="EbelGD, RymanKD, KlimstraWB. Heparan sulfate binding by natural eastern equine" exact="encephalitis" post="viruses promotes neurovirulence. Proc Natl Acad Sci U S"/>
   <result pre="al.Natural variation in the heparan sulfate binding domain of the" exact="eastern equine encephalitis" post="virus E2 glycoprotein alters interactions with cell surfaces and"/>
   <result pre="in the heparan sulfate binding domain of the eastern equine" exact="encephalitis" post="virus E2 glycoprotein alters interactions with cell surfaces and"/>
   <result pre="KlimstraWB, JohnstonRE. Mutations in the E2 glycoprotein of Venezuelan equine" exact="encephalitis" post="virus confer heparan sulfate interaction, low morbidity, and rapid"/>
   <result pre="LiS-H, ZhuL, NianQ-G, YuanS, GaoQ, et al.Near-atomic structure of Japanese" exact="encephalitis" post="virus reveals critical determinants of virulence and stability. Nature"/>
   <result pre="et al.Correlation analysis of EV71 detection and case severity in" exact="hand, foot, and mouth disease" post="in the Hunan Province of China. PLoS One. 2014;9(6):e100003"/>
   <result pre="of EV71 detection and case severity in hand, foot, and" exact="mouth disease" post="in the Hunan Province of China. PLoS One. 2014;9(6):e100003"/>
   <result pre="ThwaitesL, WillsB, QuiPT, Rogier van DoornH. Enterovirus 71 related severe" exact="hand, foot and mouth disease" post="outbreaks in South-East Asia: current situation and ongoing challenges."/>
   <result pre="Rogier van DoornH. Enterovirus 71 related severe hand, foot and" exact="mouth disease" post="outbreaks in South-East Asia: current situation and ongoing challenges."/>
   <result pre="82XingW, LiaoQ, ViboudC, ZhangJ, SunJ, WuJT, et al.Hand, foot, and" exact="mouth disease" post="in China, 2008–12: an epidemiological study. Lancet Infect Dis."/>
   <result pre="10.1016/S1473-3099(13)70342-6 .24485991 83ZhangJ, SunJ, ChangZ, ZhangW, WangZ, FengZ. Characterization of" exact="hand, foot, and mouth disease" post="in China between 2008 and 2009. Biomed Environ Sci."/>
   <result pre="SunJ, ChangZ, ZhangW, WangZ, FengZ. Characterization of hand, foot, and" exact="mouth disease" post="in China between 2008 and 2009. Biomed Environ Sci."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6881638\results\search\disease\results.xml">
   <result pre=": Article E and prM proteins of genotype V Japanese" exact="encephalitis" post="virus are required for its increased virulence in mice"/>
   <result pre="BY license (http://creativecommons.org/licenses/by/4.0/). Abstract We previously showed that the Japanese" exact="encephalitis" post="virus (JEV) genotype V (GV) strain Muar exhibits significantly"/>
   <result pre="highly virulent characteristics of GV JEV. Genetics; Microbiology; Virology; Japanese" exact="encephalitis" post="virus; Genotype V; E protein; prM protein; Pathogenicity; Reverse"/>
   <result pre="Reverse genetics; Infectious cDNA clone Keywords Genetics Microbiology Virology Japanese" exact="encephalitis" post="virus Genotype V E protein prM protein Pathogenicity Reverse"/>
   <result pre="protein Pathogenicity Reverse genetics Infectious cDNA clone 1 Introduction Japanese" exact="encephalitis" post="(JE) is a severe central nervous system disease caused"/>
   <result pre="cDNA clone 1 Introduction Japanese encephalitis (JE) is a severe" exact="central nervous system disease" post="caused by infection with the Japanese encephalitis virus (JEV)."/>
   <result pre="clone 1 Introduction Japanese encephalitis (JE) is a severe central" exact="nervous system disease" post="caused by infection with the Japanese encephalitis virus (JEV)."/>
   <result pre="central nervous system disease caused by infection with the Japanese" exact="encephalitis" post="virus (JEV). JE represents a significant public health problem"/>
   <result pre="GV JEV (Muar strain) was isolated from a patient with" exact="encephalitis" post="in Malaysia in 1952; however, no other GV JEV"/>
   <result pre="African green monkey kidney Vero cells (strain 9013) and human" exact="neuroblastoma" post="IMR-32 cells were cultured at 37 °C in 5%"/>
   <result pre="fetal bovine serum (FBS) (Sigma-Aldrich) and 100 U/mL penicillin-streptomycin. Mouse" exact="neuroblastoma" post="N18 cells were cultured at 37 °C in 5%"/>
   <result pre="accession no. HM596272), which was isolated from a patient with" exact="encephalitis" post="in Malaysia in 1952, were used (Tajima et al.,"/>
   <result pre="Schematic representation of the genomic structure of the mutant Japanese" exact="encephalitis" post="viruses (JEVs) used in this study. The regions derived"/>
   <result pre="have shown that the growth ability of Muar in mouse" exact="neuroblastoma" post="N18 cells is significantly lower than that of Mie/41/2002"/>
   <result pre="than those observed for Muar (Fig. 2A). However, in human" exact="neuroblastoma" post="IMR-32 cells, no significant difference was observed in the"/>
   <result pre="of GI Mie/41/2002, GV Muar, and mutant rJEV-5NCMEMuar-M41 in mouse" exact="neuroblastoma" post="N18 (A) and human neuroblastoma IMR-32 (B) cells. Values"/>
   <result pre="and mutant rJEV-5NCMEMuar-M41 in mouse neuroblastoma N18 (A) and human" exact="neuroblastoma" post="IMR-32 (B) cells. Values represent the mean and standard"/>
   <result pre="Fig. 5 Alignment of partial amino acid sequences of Japanese" exact="encephalitis" post="virus (JEV) strains. A partial sequence of the E"/>
   <result pre="that the ES123R mutation increases the proliferative capacity in mouse" exact="neuroblastoma" post="N18 cells (Tajima et al., 2010). However, the proliferation"/>
   <result pre="virulence in mice. Fig. 6 Molecular graphics of the Japanese" exact="encephalitis" post="virus (JEV) E protein (SA-14-14-2 strain, PDB accession code"/>
   <result pre="this paper. References References BaeW.KimJ.H.KimJ.LeeJ.HwangE.S.Changes of epidemiological characteristics of Japanese" exact="encephalitis" post="viral infection and birds as a potential viral transmitter"/>
   <result pre="World Health Organ.892011766774774A-774E22084515 CaoL.FuS.GaoX.LiM.CuiS.LiX.CaoY.LeiW.LuZ.HeY.WangH.YanJ.GaoG.F.LiangG.Low protective efficacy of the current Japanese" exact="encephalitis" post="vaccine against the emerging genotype 5 Japanese encephalitis virusPLoS"/>
   <result pre="current Japanese encephalitis vaccine against the emerging genotype 5 Japanese" exact="encephalitis" post="virusPLoS Neglected Trop. Dis.102016e0004686 ChambersT.J.DrollD.A.JiangX.WoldW.S.NickellsJ.A.JE Nakayama/JE SA14-14-2 virus structural"/>
   <result pre="in the mouse model of neuroinvasive diseaseVirology3662007516117521693 ChiouS.S.LiuH.ChuangC.K.LinC.C.ChenW.J.Fitness of Japanese" exact="encephalitis" post="virus to Neuro-2a cells is determined by interactions of"/>
   <result pre="fusionJ. Cell Biol.183200835336118936253 GaoX.LiuH.WangH.FuS.GuoZ.LiangG.Southernmost Asia is the source of Japanese" exact="encephalitis" post="virus (genotype 1) diversity from which the viruses disperse"/>
   <result pre="evolve throughout AsiaPLoS Neglected Trop. Dis.72013e2459 GromowskiG.D.FirestoneC.Y.WhiteheadS.S.Genetic determinants of Japanese" exact="encephalitis" post="virus vaccine strain SA14-14-2 that govern attenuation of virulence"/>
   <result pre="the Zika virus clinical isolate ZIKV/Hu/S36/Chiba/2016Sci. Rep.720171616029170504 KimH.ChaG.W.JeongY.E.LeeW.G.ChangK.S.RohJ.Y.YangS.C.ParkM.Y.ParkC.ShinE.H.Detection of Japanese" exact="encephalitis" post="virus genotype V in Culex orientalis and Culex pipiens"/>
   <result pre="KoreaPLoS One102015e0116547 KimJ.M.YunS.I.SongB.H.HahnY.S.LeeC.H.OhH.W.LeeY.M.A single N-linked glycosylation site in the Japanese" exact="encephalitis" post="virus prM protein is critical for cell type-specific prM"/>
   <result pre="and mapping of conformational epitopes of envelope glycoprotein of Japanese" exact="encephalitis" post="virusVirology2611999314210441554 KonishiE.MasonP.W.Proper maturation of the Japanese encephalitis virus envelope"/>
   <result pre="glycoprotein of Japanese encephalitis virusVirology2611999314210441554 KonishiE.MasonP.W.Proper maturation of the Japanese" exact="encephalitis" post="virus envelope glycoprotein requires cosynthesis with the premembrane proteinJ."/>
   <result pre="cosynthesis with the premembrane proteinJ. Virol.671993167216758437237 LiM.H.FuS.H.ChenW.X.WangH.Y.GuoY.H.LiuQ.Y.LiY.X.LuoH.M.DaW.Duo JiD.Z.YeX.M.LiangG.D.Genotype v Japanese" exact="encephalitis" post="virus is emergingPLoS Neglected Trop. Dis.52011e1231 LiangJ.J.LiaoC.L.LiaoJ.T.LeeY.L.LinY.L.A Japanese encephalitis"/>
   <result pre="Japanese encephalitis virus is emergingPLoS Neglected Trop. Dis.52011e1231 LiangJ.J.LiaoC.L.LiaoJ.T.LeeY.L.LinY.L.A Japanese" exact="encephalitis" post="virus vaccine candidate strain is attenuated by decreasing its"/>
   <result pre="by decreasing its interferon antagonistic abilityVaccine2720092746275419366580 LorenzI.C.AllisonS.L.HeinzF.X.HeleniusA.Folding and dimerization of" exact="tick-borne encephalitis" post="virus envelope proteins prM and E in the endoplasmic"/>
   <result pre="decreasing its interferon antagonistic abilityVaccine2720092746275419366580 LorenzI.C.AllisonS.L.HeinzF.X.HeleniusA.Folding and dimerization of tick-borne" exact="encephalitis" post="virus envelope proteins prM and E in the endoplasmic"/>
   <result pre="in the endoplasmic reticulumJ. Virol.7620025480549111991976 LucaV.C.AbiMansourJ.NelsonC.A.FremontD.H.Crystal structure of the Japanese" exact="encephalitis" post="virus envelope proteinJ. Virol.8620122337234622156523 MonathT.P.ArroyoJ.LevenbookI.ZhangZ.X.CatalanJ.DraperK.GuirakhooF.Single mutation in the flavivirus"/>
   <result pre="testing of live, attenuated vaccinesJ. Virol.7620021932194311799188 MoriY.OkabayashiT.YamashitaT.ZhaoZ.WakitaT.YasuiK.HasebeF.TadanoM.KonishiE.MoriishiK.MatsuuraY.Nuclear localization of Japanese" exact="encephalitis" post="virus core protein enhances viral replicationJ. Virol.7920053448345815731239 NelsonS.PoddarS.LinT.Y.PiersonT.C.Protonation of"/>
   <result pre="the &quot;histidine switch&quot; hypothesisJ. Virol.832009126311263519776132 NeromeR.TajimaS.TakasakiT.YoshidaT.KotakiA.LimC.K.ItoM.SugiyamaA.YamauchiA.YanoT.KameyamaT.MorishitaI.KuwayamaM.OgawaT.SaharaK.IkegayaA.KandaM.HosoyaY.ItokazuK.OnishiH.ChiyaS.YoshidaY.TabeiY.KatsukiK.TabataK.HaradaS.KuraneI.Molecular epidemiological analyses of Japanese" exact="encephalitis" post="virus isolates from swine in Japan from 2002 to"/>
   <result pre="2002 to 2004J. Gen. Virol.8820072762276817872529 NiH.BarrettA.D.Molecular differences between wild-type Japanese" exact="encephalitis" post="virus strains of high and low mouse neuroinvasivenessJ. Gen."/>
   <result pre="and low mouse neuroinvasivenessJ. Gen. Virol.77Pt 71996144914558757986 NiH.BarrettA.D.Attenuation of Japanese" exact="encephalitis" post="virus by selection of its mouse brain membrane receptor"/>
   <result pre="M.Fields Virology6 ed.2013Lippincott Williams &amp;amp; WilkinsPhiladelphia747794 ReyF.A.HeinzF.X.MandlC.KunzC.HarrisonS.C.The envelope glycoprotein from" exact="tick-borne encephalitis" post="virus at 2 A resolutionNature37519952912987753193 SchuhA.J.WardM.J.Leigh BrownA.J.BarrettA.D.Dynamics of the"/>
   <result pre="Virology6 ed.2013Lippincott Williams &amp;amp; WilkinsPhiladelphia747794 ReyF.A.HeinzF.X.MandlC.KunzC.HarrisonS.C.The envelope glycoprotein from tick-borne" exact="encephalitis" post="virus at 2 A resolutionNature37519952912987753193 SchuhA.J.WardM.J.Leigh BrownA.J.BarrettA.D.Dynamics of the"/>
   <result pre="emergence and establishment of a newly dominant genotype of Japanese" exact="encephalitis" post="virus throughout AsiaJ. Virol.8820144522453224501419 ShiratoK.MiyoshiH.KariwaH.TakashimaI.Detection of West Nile virus"/>
   <result pre="throughout AsiaJ. Virol.8820144522453224501419 ShiratoK.MiyoshiH.KariwaH.TakashimaI.Detection of West Nile virus and Japanese" exact="encephalitis" post="virus using real-time PCR with a probe common to"/>
   <result pre="to both virusesJ. Virol. Methods126200511912515847927 SolomonT.NiH.BeasleyD.W.EkkelenkampM.CardosaM.J.BarrettA.D.Origin and evolution of Japanese" exact="encephalitis" post="virus in southeast AsiaJ. Virol.7720033091309812584335 SumiyoshiH.TignorG.H.ShopeR.E.Characterization of a highly"/>
   <result pre="in southeast AsiaJ. Virol.7720033091309812584335 SumiyoshiH.TignorG.H.ShopeR.E.Characterization of a highly attenuated Japanese" exact="encephalitis" post="virus generated from molecularly cloned cDNAJ. Infect. Dis.1711995114411517751689 TajimaS.NeromeR.NukuiY.KatoF.TakasakiT.KuraneI.A"/>
   <result pre="cloned cDNAJ. Infect. Dis.1711995114411517751689 TajimaS.NeromeR.NukuiY.KatoF.TakasakiT.KuraneI.A single mutation in the Japanese" exact="encephalitis" post="virus E protein (S123R) increases its growth rate in"/>
   <result pre="virus E protein (S123R) increases its growth rate in mouse" exact="neuroblastoma" post="cells and its pathogenicity in miceVirology396201029830419913862 TajimaS.NukuiY.ItoM.TakasakiT.KuraneI.Nineteen nucleotides in"/>
   <result pre="TajimaS.YagasakiK.KotakiA.TomikawaT.NakayamaE.MoiM.L.LimC.K.SaijoM.KuraneI.TakasakiT.In vitro growth, pathogenicity and serological characteristics of the Japanese" exact="encephalitis" post="virus genotype V Muar strainJ. Gen. Virol.9620152661266926048886 TakhampunyaR.KimH.C.TippayachaiB.KengluechaA.KleinT.A.LeeW.J.GriecoJ.EvansB.P.Emergence of"/>
   <result pre="virus genotype V Muar strainJ. Gen. Virol.9620152661266926048886 TakhampunyaR.KimH.C.TippayachaiB.KengluechaA.KleinT.A.LeeW.J.GriecoJ.EvansB.P.Emergence of Japanese" exact="encephalitis" post="virus genotype V in the Republic of KoreaVirol. J.8201144921943222"/>
   <result pre="of KoreaVirol. J.8201144921943222 TsaiT.F.New initiatives for the control of Japanese" exact="encephalitis" post="by vaccination: minutes of a WHO/CVI meeting, Bangkok, Thailand,"/>
   <result pre="Bangkok, Thailand, 13-15 October 1998Vaccine18Suppl 2200012510821969 UchilP.D.SatchidanandamV.Phylogenetic analysis of Japanese" exact="encephalitis" post="virus: envelope gene based analysis reveals a fifth genotype,"/>
   <result pre="antibody: solution structure of the domain III of the Japanese" exact="encephalitis" post="virus envelope proteinJ. Biol. Chem.2782003460074601312952958 WuS.C.LeeS.C.Complete nucleotide sequence and"/>
   <result pre="cell-line multiplication pattern of the attenuated variant CH2195LA of Japanese" exact="encephalitis" post="virusVirus Res.7320019110211163647 YamaguchiY.NukuiY.KotakiA.SawabeK.SaijoM.WatanabeH.KuraneI.TakasakiT.TajimaS.Characterization of a serine-to-asparagine substitution at position"/>
   <result pre="of a serine-to-asparagine substitution at position 123 in the Japanese" exact="encephalitis" post="virus E proteinJ. Gen. Virol.942013909623052392 YangJ.YangH.LiZ.WangW.LinH.LiuL.NiQ.LiuX.ZengX.WuY.LiY.Envelope Protein Mutations L107F"/>
   <result pre="Virus SA14-14-2 Strain2017Viruses 9 YuY.Phenotypic and genotypic characteristics of Japanese" exact="encephalitis" post="attenuated live vaccine virus SA14-14-2 and their stabilitiesVaccine2820103635364120226891 YuanL.HuangX.Y.LiuZ.Y.ZhangF.ZhuX.L.YuJ.Y.JiX.XuY.P.LiG.LiC.WangH.J.DengY.Q.WuM.ChengM.L.YeQ.XieD.Y.LiX.F.WangX.ShiW.HuB.ShiP.Y.XuZ.QinC.F.A"/>
   <result pre="fetal microcephalyScience358201793393628971967 ZhaoZ.DateT.LiY.KatoT.MiyamotoM.YasuiK.WakitaT.Characterization of the E-138 (Glu/Lys) mutation in Japanese" exact="encephalitis" post="virus by using a stable, full-length, infectious cDNA cloneJ."/>
   <result pre="stable, full-length, infectious cDNA cloneJ. Gen. Virol.8620052209222016033968 ZhengX.ZhengH.TongW.LiG.WangT.LiL.GaoF.ShanT.YuH.ZhouY.QiuY.MaZ.TongG.Acidity/alkalinity of Japanese" exact="encephalitis" post="virus E protein residue 138 alters neurovirulence in miceJ."/>
   <result pre="ZhouY.WuR.ZhaoQ.ChangY.F.WenX.FengY.HuangX.WenY.YanQ.HuangY.MaX.HanX.CaoS.Mutation of I176R in the E coding region weakens Japanese" exact="encephalitis" post="virus neurovirulence, but not its growth rate in BHK-21"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6882728\results\search\disease\results.xml">
   <result pre="ZIKV infection is the ability of the virus to cause" exact="microcephaly" post="and congenital malformation to the newborn baby if the"/>
   <result pre="Flaviviridae, which includes 52 other viral species including dengue and" exact="chikungunya" post="viruses [1,2]. It is synonymous to Zika fever or"/>
   <result pre="infection occurred in Brazil in 2015 with increase cases of" exact="microcephaly" post="[21]. The ZIKV cases have been sporadically reported in"/>
   <result pre="However, it may cause severe diseases such as multi-organs failure," exact="thrombocytopenia" post="and thrombocytopenic purpura, meningitis, encephalitis, and Guillain-Barre syndrome [36,37]."/>
   <result pre="having no evidence of transmission to human [46]. Though no" exact="microcephaly" post="has been reported in the Zika endemic areas, further"/>
   <result pre="further research is needed for better learning the ZIKV and" exact="microcephaly" post="in animal pregnancy as suggested by the Centers for"/>
   <result pre="of the patient were fever for 5 days and maculopapular" exact="rash" post="on body having no overseas travel history within last"/>
   <result pre="Isolations and serological specificityTrans R Soc Trop Med Hyg195246550920https://doi.org/10.1016/0035-9203(52)90042-412995440 [3]PaixaoESTeixeiraMGRodriguesLCZika," exact="chikungunya" post="and dengue: the causes and threats of new and"/>
   <result pre="Island, Federated States of MicronesiaN Engl J Med200936024253643https://doi.org/10.1056/NEJMoa080571519516034 [5]FaizanMIAbdullahMAliSNaqviIHAhmedAParveenSZika virus-induced" exact="microcephaly" post="and its possible molecular mechanismIntervirology20165931528https://doi.org/10.1159/00045295028081529 [6]do RosarioMSde JesusPAVasilakisNFariasDSNovaesMARodriguesSGet al.Guillain-Barre"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6882796\results\search\disease\results.xml">
   <result pre="n°ANR-10-LABX-62-IBEID) Introduction Recent epidemics involving several arboviral diseases such as" exact="chikungunya" post="(CHIKV), dengue (DENV) and Zika (ZIKV) have received global"/>
   <result pre="growing number of imported cases7 led to local transmissions of" exact="chikungunya" post="and dengue fever in Croatia8,9, France10–14, and Italy15. The"/>
   <result pre="of imported cases7 led to local transmissions of chikungunya and" exact="dengue fever" post="in Croatia8,9, France10–14, and Italy15. The 2017 CHIKV outbreak"/>
   <result pre="Europe. Results Southern European Ae. albopictus are highly susceptible to" exact="chikungunya" post="and to a lesser extent, to dengue, and Zika"/>
   <result pre="Unexpectedly, severe symptoms have been described including neurological disorders and" exact="microcephaly" post="in newborns leading to a global drive to limit"/>
   <result pre="interests The authors declare no competing interests. References References 1.PaixaoESTeixeiraMGRodriguesLCZika," exact="chikungunya" post="and dengue: the causes and threats of new and"/>
   <result pre="Microbiol2019485486310.1038/s41564-019-0376-y30833735 7.EnserinkMEpidemiology. Tropical disease follows mosquitoes to EuropeScience2007317148510.1126/science.317.5844.1485a17872417 8.Gjenero-MarganIet al.Autochthonous" exact="dengue fever" post="in Croatia, August-September 2010Euro surveillance: bulletin Europeen sur les"/>
   <result pre="European communicable disease bulletin21, 10.2807/1560-7917.ES.2016.21.21.30240 (2016). 15.AngeliniRet al.An outbreak of" exact="chikungunya" post="fever in the province of Ravenna, ItalyEuro Surveill200712E070906070901 16.Rezza,"/>
   <result pre="Negl Trop Dis201711e000533210.1371/journal.pntd.000533228135274 23.Venturi, G. et al. Detection of a" exact="chikungunya" post="outbreak in Central Italy, August to September 2017. Euro"/>
   <result pre="which is colonizing Mediterranean countriesHeredity (Edinb)200084Pt 333133710.1046/j.1365-2540.2000.00676.x10762403 29.RezzaGet al.Infection with" exact="chikungunya" post="virus in Italy: an outbreak in a temperate regionLancet20073701840184610.1016/S0140-6736(07)61779-618061059"/>
   <result pre="2007Parassitologia200850979818693568 31.Calba, C. et al. Preliminary report of an autochthonous" exact="chikungunya" post="outbreak in France, July to September 2017. Euro surveillance:"/>
   <result pre="Appl20191257258610.1111/eva.1274030828375 35.Vega-RuaAet al.High efficiency of temperate Aedes albopictus to transmit" exact="chikungunya" post="and dengue viruses in the Southeast of FrancePLoS One20138e5971610.1371/journal.pone.005971623527259"/>
   <result pre="36.SeveriniFet al.Vector competence of Italian Aedes albopictus populations for the" exact="chikungunya" post="virus (E1-226V)PLoS Negl Trop Dis201812e000643510.1371/journal.pntd.000643529672511 37.Cassadou, S. et al."/>
   <result pre="(E1-226V)PLoS Negl Trop Dis201812e000643510.1371/journal.pntd.000643529672511 37.Cassadou, S. et al. Emergence of" exact="chikungunya" post="fever on the French side of Saint Martin island,"/>
   <result pre="40.ZouacheKarimaFontaineAlbinVega-RuaAnubisMoussonLaurenceThibergeJean-MichelLourenco-De-OliveiraRicardoCaroValérieLambrechtsLouisFaillouxAnna-BellaThree-way interactions between mosquito population, viral strain and temperature underlying" exact="chikungunya" post="virus transmission potentialProceedings of the Royal Society B: Biological"/>
   <result pre="aegypti and Ae. albopictusBMJ Glob Health20183e00080110.1136/bmjgh-2018-00080130233829 55.SchuffeneckerIet al.Genome microevolution of" exact="chikungunya" post="viruses causing the Indian Ocean outbreakPLoS Med20063e26310.1371/journal.pmed.003026316700631 56.DonaldCLet al.Full"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6883514\results\search\disease\results.xml">
   <result pre="available in this article, unless otherwise stated. Abstract Background Aseptic" exact="meningitis" post="epidemics may pose various health care challenges. Methods We"/>
   <result pre="various health care challenges. Methods We describe the German enterovirus" exact="meningitis" post="epidemics in the university hospital centers of Düsseldorf, Cologne"/>
   <result pre="31st, 2013 in order to scrutinize clinical differences from other" exact="aseptic meningitis" post="cases. Results A total of 72 enterovirus (EV-positive) meningitis"/>
   <result pre="2013 in order to scrutinize clinical differences from other aseptic" exact="meningitis" post="cases. Results A total of 72 enterovirus (EV-positive) meningitis"/>
   <result pre="aseptic meningitis cases. Results A total of 72 enterovirus (EV-positive)" exact="meningitis" post="cases were detected in our multicenter cohort, corresponding to"/>
   <result pre="33 (1), echovirus 9 (4)). At the same time, 45" exact="aseptic meningitis" post="cases in our cohort were excluded to be due"/>
   <result pre="(1), echovirus 9 (4)). At the same time, 45 aseptic" exact="meningitis" post="cases in our cohort were excluded to be due"/>
   <result pre="for varicella zoster virus (VZV) and 1 EV-negative patient for" exact="herpes simplex" post="virus 2. Hospitalization was significantly longer in EV-negative cases."/>
   <result pre="valuable tool for epidemiological research. Our analyses suggest that EV-positive" exact="meningitis" post="predominantly affects younger patients and may be associated with"/>
   <result pre="to EV-negative cases. Keywords Meningitis Echovirus Epidemic Surveillance Background Periodic" exact="aseptic meningitis" post="epidemics can be a challenge in patient- and health"/>
   <result pre="EV-negative cases. Keywords Meningitis Echovirus Epidemic Surveillance Background Periodic aseptic" exact="meningitis" post="epidemics can be a challenge in patient- and health"/>
   <result pre="cohort revealed that in 21% of cases the etiology of" exact="aseptic meningitis" post="remains unknown [1]. Aseptic meningitis is defined [2] by"/>
   <result pre="revealed that in 21% of cases the etiology of aseptic" exact="meningitis" post="remains unknown [1]. Aseptic meningitis is defined [2] by"/>
   <result pre="cases the etiology of aseptic meningitis remains unknown [1]. Aseptic" exact="meningitis" post="is defined [2] by an inflammation of the leptomeninx"/>
   <result pre="and a droplet infection are also possible. In previous studies," exact="viral meningitis" post="in adults was rather associated with herpes simplex and"/>
   <result pre="a droplet infection are also possible. In previous studies, viral" exact="meningitis" post="in adults was rather associated with herpes simplex and"/>
   <result pre="previous studies, viral meningitis in adults was rather associated with" exact="herpes simplex" post="and West Nile virus, whereas children were more likely"/>
   <result pre="and 30th of June 2016 revealed an unfavorable outcome of" exact="viral meningitis" post="in 17% of all patients [6]. According to a"/>
   <result pre="30th of June 2016 revealed an unfavorable outcome of viral" exact="meningitis" post="in 17% of all patients [6]. According to a"/>
   <result pre="[6]. According to a UK study, the infection rates of" exact="viral meningitis" post="are mainly driven by an EV predominance of echovirus"/>
   <result pre="According to a UK study, the infection rates of viral" exact="meningitis" post="are mainly driven by an EV predominance of echovirus"/>
   <result pre="driven by an EV predominance of echovirus 30 [7]. EV" exact="meningitis" post="epidemics in Shandong (People’s Republic of China, 2014 [8])"/>
   <result pre="disease [13]. Cerebrospinal fluid (CSF) and clinical features of EV-positive" exact="meningitis" post="patients in Germany [14] and the differences in adult"/>
   <result pre="Germany [14] and the differences in adult and pediatric EV-positive" exact="meningitis" post="patients in Switzerland [15] have already been analyzed, but"/>
   <result pre="still a paucity of data describing the differences in EV-positive" exact="meningitis" post="and EV-negative meningitis patients. Methods We conducted a retrospective"/>
   <result pre="of data describing the differences in EV-positive meningitis and EV-negative" exact="meningitis" post="patients. Methods We conducted a retrospective chart review study"/>
   <result pre="classified elsewhere; Meningitis due to other and unspecified causes; Encephalitis," exact="myelitis" post="and encephalomyelitis; Encephalitis, myelitis and encephalomyelitis in diseases classified"/>
   <result pre="to other and unspecified causes; Encephalitis, myelitis and encephalomyelitis; Encephalitis," exact="myelitis" post="and encephalomyelitis in diseases classified elsewhere, Table 1). Virological"/>
   <result pre="and unspecified causes; Encephalitis, myelitis and encephalomyelitis; Encephalitis, myelitis and" exact="encephalomyelitis" post="in diseases classified elsewhere, Table 1). Virological testing of"/>
   <result pre="1 List of ICD-10 codes utilized to identify patients with" exact="aseptic meningitis" post="from the clinical databases of each hospital participating in"/>
   <result pre="List of ICD-10 codes utilized to identify patients with aseptic" exact="meningitis" post="from the clinical databases of each hospital participating in"/>
   <result pre="A85 Other viral encephalitis, not elsewhere classified A86 Unspecified viral" exact="encephalitis" post="A87 Viral meningitis A88 Other viral infections of central"/>
   <result pre="encephalitis, not elsewhere classified A86 Unspecified viral encephalitis A87 Viral" exact="meningitis" post="A88 Other viral infections of central nervous system, not"/>
   <result pre="G03 Meningitis due to other and unspecified causes G04 Encephalitis," exact="myelitis" post="and encephalomyelitis G05 Encephalitis, myelitis and encephalomyelitis in diseases"/>
   <result pre="due to other and unspecified causes G04 Encephalitis, myelitis and" exact="encephalomyelitis" post="G05 Encephalitis, myelitis and encephalomyelitis in diseases classified elsewhere"/>
   <result pre="and unspecified causes G04 Encephalitis, myelitis and encephalomyelitis G05 Encephalitis," exact="myelitis" post="and encephalomyelitis in diseases classified elsewhere Case definition After"/>
   <result pre="causes G04 Encephalitis, myelitis and encephalomyelitis G05 Encephalitis, myelitis and" exact="encephalomyelitis" post="in diseases classified elsewhere Case definition After the above-mentioned"/>
   <result pre="patient records were individually evaluated to exclusively select cases of" exact="aseptic meningitis" post="defined according to the Centers for Disease Control and"/>
   <result pre="records were individually evaluated to exclusively select cases of aseptic" exact="meningitis" post="defined according to the Centers for Disease Control and"/>
   <result pre="prehospital time / duration of clinical manifestation before confirmation of" exact="aseptic meningitis" post="by CSF analyses, results of CSF diagnostics (cell count,"/>
   <result pre="time / duration of clinical manifestation before confirmation of aseptic" exact="meningitis" post="by CSF analyses, results of CSF diagnostics (cell count,"/>
   <result pre="the Robert Koch Institute (RKI; EVSurv) [17] of all EV-positive" exact="meningitis" post="cases in 2013. Data was obtained in the context"/>
   <result pre="as not enough CSF was available for further analysis. EV-positive" exact="meningitis" post="cases peaked in July/August (Fig. 1). Furthermore, we identified"/>
   <result pre="cases, three were related to varicella zoster infection, one to" exact="herpes simplex" post="2 and no virus could be identified in the"/>
   <result pre="identified in the other patients. Fig. 1 Monthly distribution of" exact="meningitis" post="cases in 2013 (Düsseldorf, Cologne, Berlin). These data were"/>
   <result pre="respectively). Therapy The cases diagnosed with varicella zoster virus and" exact="herpes simplex" post="virus 2 received specific therapy. No child received specific"/>
   <result pre="enteroviral infections were associated with meningitis. The prevalence of enteroviral" exact="meningitis" post="is high worldwide (estimated 75,000 cases annually in the"/>
   <result pre="in the United States) [11], which makes this type of" exact="meningitis" post="highly relevant to both caregivers and patients. We were"/>
   <result pre="and August; Fig. 1). With age, the incidence of enteroviral" exact="meningitis" post="decreases. Therefore, the incidence is highest in infants and"/>
   <result pre="significant interest, as they stress differences between EV-positive and EV-negative" exact="meningitis" post="and may be of relevance for the treating physician:"/>
   <result pre="physician: Overall, caregivers may expect shorter hospitalization times in EV-positive" exact="meningitis" post="cases. Furthermore, routine CSF parameters that may already be"/>
   <result pre="and EV-negative meningitis. When caregivers experience an unusual accumulation of" exact="aseptic meningitis" post="cases in the summer and early autumn, patients should"/>
   <result pre="EV-negative meningitis. When caregivers experience an unusual accumulation of aseptic" exact="meningitis" post="cases in the summer and early autumn, patients should"/>
   <result pre="be reported to the authorities. Contrary to previous studies regarding" exact="viral meningitis" post="in general our data show that EV-positive meningitis is"/>
   <result pre="reported to the authorities. Contrary to previous studies regarding viral" exact="meningitis" post="in general our data show that EV-positive meningitis is"/>
   <result pre="regarding viral meningitis in general our data show that EV-positive" exact="meningitis" post="is rather associated with a benign disease course. In"/>
   <result pre="work and the necessary resources for medical treatment [26], although" exact="meningitis" post="caused by enteroviruses usually has a relatively benign course."/>
   <result pre="our knowledge, the economic burden for society due to EV-positive" exact="meningitis" post="has not been determined so far; and our data"/>
   <result pre="to work. Our data indicate that the course of EV-positive" exact="meningitis" post="is predominantly benign, and that hospitalization time was significantly"/>
   <result pre="also the case, when we did not consider the above-mentioned" exact="meningitis" post="cases that received specific antiviral therapy (varicella zoster virus,"/>
   <result pre="meningitis cases that received specific antiviral therapy (varicella zoster virus," exact="herpes simplex" post="virus 2). Moreover, a higher ratio of affected children"/>
   <result pre="of stay in hospital. Despite the generally excellent outcome of" exact="aseptic meningitis," post="there are rare instances of complicated courses that may"/>
   <result pre="infections were detected as the most common cause for an" exact="aseptic meningitis" post="in our cohort, driven by a high prevalence of"/>
   <result pre="were detected as the most common cause for an aseptic" exact="meningitis" post="in our cohort, driven by a high prevalence of"/>
   <result pre="worldwide. Overall, this entity remains a rather benign form of" exact="meningitis" post="with a rather short length of stay in hospital,"/>
   <result pre="care system. Therefore, we recommend rigorous testing and reporting of" exact="aseptic meningitis" post="cases. Within the National Enterovirussurveillance (EVSurv) all pediatric and"/>
   <result pre="system. Therefore, we recommend rigorous testing and reporting of aseptic" exact="meningitis" post="cases. Within the National Enterovirussurveillance (EVSurv) all pediatric and"/>
   <result pre="Germany are offered free-of-charge enterovirus diagnostics in patients with suspected" exact="aseptic meningitis" post="/ encephalitis or acute flaccid paralysis. This health care"/>
   <result pre="are offered free-of-charge enterovirus diagnostics in patients with suspected aseptic" exact="meningitis" post="/ encephalitis or acute flaccid paralysis. This health care"/>
   <result pre="free-of-charge enterovirus diagnostics in patients with suspected aseptic meningitis /" exact="encephalitis" post="or acute flaccid paralysis. This health care concept is"/>
   <result pre="Sanofi-Aventis/Genzyme, outside the submitted work. References References 1.HasbunRRosenthalNBalada-LlasatJMet al.Epidemiology of" exact="meningitis" post="and encephalitis in the United States, 2011-2014Clin Infect Dis20176535936310.1093/cid/cix31928419350"/>
   <result pre="the submitted work. References References 1.HasbunRRosenthalNBalada-LlasatJMet al.Epidemiology of meningitis and" exact="encephalitis" post="in the United States, 2011-2014Clin Infect Dis20176535936310.1093/cid/cix31928419350 2.WrightWFPintoCNPalisocKet al.Viral"/>
   <result pre="2.WrightWFPintoCNPalisocKet al.Viral (aseptic) meningitis: a reviewJ Neurol Sci201939817618310.1016/j.jns.2019.01.05030731305 3.ConnollyKJHammerSMThe acute" exact="aseptic meningitis" post="syndromeInfect Dis Clin N Am19904599622 4.LeeBEDaviesHDAseptic meningitisCurr Opin Infect"/>
   <result pre="al.Viral (aseptic) meningitis: a reviewJ Neurol Sci201939817618310.1016/j.jns.2019.01.05030731305 3.ConnollyKJHammerSMThe acute aseptic" exact="meningitis" post="syndromeInfect Dis Clin N Am19904599622 4.LeeBEDaviesHDAseptic meningitisCurr Opin Infect"/>
   <result pre="Clin N Am19904599622 4.LeeBEDaviesHDAseptic meningitisCurr Opin Infect Dis20072027227710.1097/QCO.0b013e3280ad467217471037 5.ShuklaBAguileraEASalazarLet al.Aseptic" exact="meningitis" post="in adults and children: diagnostic and management challengesJ Clin"/>
   <result pre="adults and children: diagnostic and management challengesJ Clin Virol20179411011410.1016/j.jcv.2017.07.01628806629 6.BodilsenJ.StorgaardMereteLarsenL.WieseL.Helweg-LarsenJ.LebechA.-M.BrandtC.ØstergaardC.NielsenH.Infectious" exact="meningitis" post="and encephalitis in adults in Denmark: a prospective nationwide"/>
   <result pre="children: diagnostic and management challengesJ Clin Virol20179411011410.1016/j.jcv.2017.07.01628806629 6.BodilsenJ.StorgaardMereteLarsenL.WieseL.Helweg-LarsenJ.LebechA.-M.BrandtC.ØstergaardC.NielsenH.Infectious meningitis and" exact="encephalitis" post="in adults in Denmark: a prospective nationwide observational cohort"/>
   <result pre="al.Predominance of enterovirus B and echovirus 30 as cause of" exact="viral meningitis" post="in a UK populationJ Clin Virol201681909310.1016/j.jcv.2016.06.00727367546 8.ChenPLinXLiuGet al.Analysis of"/>
   <result pre="of enterovirus B and echovirus 30 as cause of viral" exact="meningitis" post="in a UK populationJ Clin Virol201681909310.1016/j.jcv.2016.06.00727367546 8.ChenPLinXLiuGet al.Analysis of"/>
   <result pre="8.ChenPLinXLiuGet al.Analysis of enterovirus types in patients with symptoms of" exact="aseptic meningitis" post="in 2014 in Shandong, ChinaVirology201851619620110.1016/j.virol.2018.01.02229407377 9.ÖsterbackRKalliokoskiTLähdesmäkiTet al.Echovirus 30 meningitis"/>
   <result pre="al.Analysis of enterovirus types in patients with symptoms of aseptic" exact="meningitis" post="in 2014 in Shandong, ChinaVirology201851619620110.1016/j.virol.2018.01.02229407377 9.ÖsterbackRKalliokoskiTLähdesmäkiTet al.Echovirus 30 meningitis"/>
   <result pre="aseptic meningitis in 2014 in Shandong, ChinaVirology201851619620110.1016/j.virol.2018.01.02229407377 9.ÖsterbackRKalliokoskiTLähdesmäkiTet al.Echovirus 30" exact="meningitis" post="epidemic followed by an outbreak-specific RT-qPCRJ Clin Virol20156971110.1016/j.jcv.2015.05.01226209368 10.CalleriGLibanoreVCorcioneSet"/>
   <result pre="24.RhoadesRETabor-GodwinJMTsuengGet al.Enterovirus infections of the central nervous systemVirology201141128830510.1016/j.virol.2010.12.01421251690 25.RotbartHABrennanPJFifeKHet al.Enterovirus" exact="meningitis" post="in adultsClin Infect Dis19982789689810.1086/5171629798053 26.KhetsurianiNQuirozESHolmanRCet al.Viral meningitis-associated hospitalizations in"/>
   <result pre="Med20073561226123410.1056/NEJMoa06595417377160 28.DourmashkinRRDunnGCastanoVet al.Evidence for an enterovirus as the cause of" exact="encephalitis" post="lethargicaBMC Infect Dis20121213610.1186/1471-2334-12-13622715890 29.HuangCCLiuCCChangYCet al.Neurologic complications in children with"/>
   <result pre="al.Comparison of cerebrospinal fluid cytokine levels in children of Enteroviral" exact="meningitis" post="with versus without PleocytosisJ Interf Cytokine Res20183834835510.1089/jir.2018.0002 32.KhetsurianiNLamonte-FowlkesAOberstSet al.Enterovirus"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6884470\results\search\disease\results.xml">
   <result pre="then it crosses the blood-brain barrier and infects neurons, producing" exact="encephalitis" post="in more susceptible individuals5. Nevertheless, OROV fever is usually"/>
   <result pre="dizziness (54%), myalgia (48%), photophobia (39%), nausea (34%), vomiting (33%)," exact="arthritis" post="(18%), epigastric pain (8%), and exanthema (4%). Diarrhea and"/>
   <result pre="of circulating levels of IL-1Ra, CXCL10/IP-10, CCL4/MIP-1β and CCL2/MCP-1 in" exact="dengue fever" post="and parvovirosisMem Inst Oswaldo Cruz.2012107485610.1590/S0074-0276201200010000722310535 13.FigueiredoLTEmergent arboviruses in BrazilRev"/>
   <result pre="15.Luiza-SilvaMet al.Cytokine signatures of innate and adaptive immunity in 17DD" exact="yellow fever" post="vaccinated children and its association with the level of"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6884537\results\search\disease\results.xml">
   <result pre="pmcid: 688453754059 doi: 10.1038/s41598-019-54059-4 : Article Respiratory syncytial, parainfluenza and" exact="influenza" post="virus infection in young children with acute lower respiratory"/>
   <result pre="selected to test for respiratory syncytial (RSV), parainfluenza (PIV) and" exact="influenza" post="viruses. The expected number of viral-associated ALRI cases in"/>
   <result pre="for the sampling design. RSV G and F proteins and" exact="influenza" post="hemagglutinin genes were sequenced. 2385 children with ALRI were"/>
   <result pre="The expected incidence of ALRI associated with RSV, PIV or" exact="influenza" post="was 140 cases (95% CI, 131–149) per 1000 person-years;"/>
   <result pre="CI, 102–122) per 1000 person-years. Multiple strains of RSV and" exact="influenza" post="circulated during the year. RSV circulated throughout most of"/>
   <result pre="Streptococcus pneumoniae in many countries has contributed to reductions in" exact="pneumonia" post="deaths over the last two decades1,2. The introduction of"/>
   <result pre="etiologic association between ALRI and respiratory syncytial (RSV), parainfluenza (PIV)," exact="influenza" post="(IV) and human metapneumo viruses4,5. However, these studies could"/>
   <result pre="hospital, and excluded if the surveillance diagnosis was septicemia or" exact="meningitis" post="alone without suspected pneumonia. Children with ALRI and proven"/>
   <result pre="alone without suspected pneumonia. Children with ALRI and proven invasive" exact="bacterial disease" post="were included. Specimen processing Validation of STGG media for"/>
   <result pre="of STGG and GLY were included. Sequencing of RSV and" exact="influenza" post="virus We sequenced the length of the G-protein gene"/>
   <result pre="half of the year (Fig. 1). A small number of" exact="influenza" post="A(H1N1)pdm09 cases (n = 5) were detected early in the year"/>
   <result pre="IV, in rural Gambia. No virus detected &amp;amp; no radiologic" exact="pneumonia" post="or bacteremia(N = 185) ≥1 virus detected &amp;amp; no radiologic pneumonia"/>
   <result pre="radiologic pneumonia or bacteremia(N = 185) ≥1 virus detected &amp;amp; no radiologic" exact="pneumonia" post="or bacteremia(N = 274) Radiologic consolidation with or without viral detection(N = 52)"/>
   <result pre="prevalence of RSV in children aged &amp;lt;5 years hospitalized with" exact="pneumonia" post="from 2002–2007 was 15% (20% among infants) and 27%"/>
   <result pre="RSV prevalence was 36% in active case detection of clinical" exact="pneumonia" post="in children aged &amp;lt;2 years in Mirzapur, Bangladesh in"/>
   <result pre="conduct of the PERCH study of the etiology of childhood" exact="pneumonia" post="in 2012/13 in Basse, the prevalence of RSV in"/>
   <result pre="the introduction of RSV immunization in The Gambia. Currently, no" exact="influenza" post="vaccines are used in The Gambia. Given the IV"/>
   <result pre="3.MackenzieGAet al.Impact of the introduction of pneumococcal conjugate vaccination on" exact="pneumonia" post="in The Gambia: population-based surveillance and case-control studiesLancet Infect."/>
   <result pre="surveillance and case-control studiesLancet Infect. Dis.20171796597310.1016/S1473-3099(17)30321-328601421 4.BenetTet al.Microorganisms associated aith" exact="pneumonia" post="in children &amp;lt;5 years of age in developing and"/>
   <result pre="years of age in developing and emerging countries: the GABRIEL" exact="pneumonia" post="multicenter, prospective, case-control studyClin. Infect. Dis.20176560461228605562 5.FeikinDRet al.Is higher"/>
   <result pre="modelling studyLancet.201739094695810.1016/S0140-6736(17)30938-828689664 7.NokesDJet al.Incidence and severity of respiratory syncytial virus" exact="pneumonia" post="in rural Kenyan children identified through hospital surveillanceClin. Infect."/>
   <result pre="in Bamako, MaliClin. Infect. Dis.2019Feb 2718 24.HasanKet al.Viral etiology of" exact="pneumonia" post="in a cohort of newborns till 24 months of"/>
   <result pre="25.RSV infection in childhood cases of severe and very severe" exact="pneumonia" post="and controls in rural Gambia, West Africa. RSV16 10th"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6884810\results\search\disease\results.xml">
   <result pre="pmcid: 688481099 doi: 10.1186/s40794-019-0099-3 : Case Report Dengue fever and" exact="chikungunya" post="virus infections: identification in travelers in Uganda – 2017"/>
   <result pre="febrile illness that may be accompanied by rash, arthralgia and" exact="arthritis" post="and/or with neurological or hemorrhagic syndromes. The broad range"/>
   <result pre="infections in Uganda. These include a patient from Bangladesh with" exact="chikungunya" post="virus infection and two cases of dengue fever from"/>
   <result pre="from Bangladesh with chikungunya virus infection and two cases of" exact="dengue fever" post="from Ethiopia. Early detection of travel-imported cases by public"/>
   <result pre="of localized outbreaks of arboviruses such as dengue virus and" exact="chikungunya" post="virus. Because of the global public health importance and"/>
   <result pre="expansion [3]. Dengue virus (DENV), genus flavivirus, family Flaviviridae, and" exact="chikungunya" post="virus (CHIKV), genus alphavirus, family Togaviridae, are transmitted to"/>
   <result pre="(Ae.) aegypti and Ae. albopictus mosquito. Dengue fever (DF) and" exact="chikungunya" post="are typically characterized by fever, myalgia, arthralgia, rash, with"/>
   <result pre="of DENV and CHIKV competent transmission vectors [12–14]. Dengue and" exact="chikungunya" post="while endemic in Uganda, are increasingly being detected in"/>
   <result pre="medical history, was on no regular medication, and had received" exact="yellow fever" post="specific travel-related vaccination. The patient, whose final destination was"/>
   <result pre="febrile patients for malaria. However, with improved and easily accessed" exact="malaria" post="diagnostics in recent years, a substantial proportion of acutely"/>
   <result pre="patients in sub-Saharan Africa have been shown not to have" exact="malaria" post="[18, 19]. Clinical differentiation of infections caused by alphaviruses"/>
   <result pre="order to distinguish infections with similar clinical manifestations such as" exact="dengue fever" post="and other arboviruses. Most low- and middle-income countries do"/>
   <result pre="of dengueAsian Pacific Journal of Tropical Medicine20147316917810.1016/S1995-7645(14)60016-X24507635 8.KrastinovaEQuatresousITarantolaAImported cases of" exact="chikungunya" post="in metropolitan France: update to June 20062006 9.StaplesEBreimanRFAnnMPowers, Chikungunya"/>
   <result pre="Re-Emerging Infectious Disease2009 10.ReiterPaulFontenilleDidierPaupyChristopheAedes albopictus as an epidemic vector of" exact="chikungunya" post="virus: another emerging problem?The Lancet Infectious Diseases20066846346410.1016/S1473-3099(06)70531-X16870524 11.RaoTRPaulSDSinghKRExperimental studies"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6886976\results\search\disease\results.xml">
   <result pre="scoping review on vulnerability assessment tools in the field of" exact="infectious disease" post="outbreaks and antimicrobial resistance (AMR) crises. The scoping review"/>
   <result pre="methodologies to identify local level vulnerabilities in the context of" exact="infectious disease" post="outbreaks and AMR. Due to this focus on infectious"/>
   <result pre="will pilot one of these tools. Vulnerable groups vulnerability assessment" exact="infectious disease" post="outbreaks one health medical anthropology Funding European Union’s Horizon"/>
   <result pre="them. Such attention remains particularly important when instability (caused by" exact="infectious disease" post="outbreaks, conflicts or other stresses) exaggerates local inequalities, hampering"/>
   <result pre="threats that specifically affect SoNAR-Global partner countries, such as influenza," exact="measles" post="and certain viral haemorrhagic fevers (Ebola virus disease, Lassa"/>
   <result pre="focus on author, article type, type of threat (natural hazard," exact="infectious disease" post="or AMR), year, country and type of intervention. As"/>
   <result pre="and regional stakeholders will pilot the tool best suited to" exact="infectious disease" post="or AMR-related emergencies. Supplementary Material Reviewer comments LINK Author's"/>
   <result pre="commissioned; externally peer reviewed. References References 1InhornMC, BrownPJThe anthropology of" exact="infectious disease." post="Annu Rev Anthropol1990;19:89–117. 10.1146/annurev.an.19.100190.000513 2KellyAH, KeckF, LynterisCThe anthropology of"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6889554\results\search\disease\results.xml">
   <result pre="Currently, norovirus (NoV) is associated with one-fifth of all acute" exact="gastroenteritis" post="(AGE) cases worldwide. The NoV GII.17_2014 variant has been"/>
   <result pre="cases worldwide. The NoV GII.17_2014 variant has been associated with" exact="gastroenteritis" post="outbreaks in several Asian countries, replacing the previously dominant"/>
   <result pre="Nowadays, norovirus (NoV) is associated with one-fifth of all acute" exact="gastroenteritis" post="(AGE) cases worldwide and accounts for approximately 200,000 deaths"/>
   <result pre="developing countries. NoV is also implicated in outbreaks of non-bacterial" exact="gastroenteritis" post="in closed communities, such as schools, hospitals, camps, cruise"/>
   <result pre="[6, 7]. Globally, GII.4 genotype has been responsible for most" exact="gastroenteritis" post="outbreaks and sporadic cases related to NoV since the"/>
   <result pre="every two or 3 years and cause multiple epidemics of" exact="gastroenteritis" post="[8]. During the 2014–2015 season, the GII.17_2014 (Kawasaki) pandemic"/>
   <result pre="2014–2015 season, the GII.17_2014 (Kawasaki) pandemic variant emerged and caused" exact="gastroenteritis" post="outbreaks in schools, colleges, factories, and kindergartens in the"/>
   <result pre="2013–2014, a GII.17_2014 variant has been associated with outbreaks of" exact="gastroenteritis" post="in several countries and in some cases replacing the"/>
   <result pre="Brazilian Ministry of Health. This program includes epidemiological surveillance of" exact="diarrhea" post="cases, which was obtained from inpatients who attended the"/>
   <result pre="genotype and its variants were mainly responsible for the numerous" exact="gastroenteritis" post="outbreaks and sporadic cases for the last 20 years [33]."/>
   <result pre="circulated in Asian countries [13]. The GII.17 circulation caused several" exact="gastroenteritis" post="outbreaks replacing even the GII.4 variant. Several studies have"/>
   <result pre="and scores are generated using VERIFY 3D. Abbreviations AGE Acute" exact="gastroenteritis" post="BLAST Basic Local Alignment Search Tool CD-Hit program Cluster"/>
   <result pre="characterization of the emergent GII.17_2014 norovirus genotype among children with" exact="gastroenteritis" post="from northern BrazilInfect Genet Evol2017481327923768 12.AndradeJSRFumianTMLeiteJPGAssisMRBelloGMirDMiagostovichMPDetection and molecular characterization"/>
   <result pre="in TaiwanClin Infect Dis201561111762176426306886 35.CuiCPanLWangYXueCZhuWZhuLYeCLuXSongHFuYSunQAn outbreak of acute GII.17 norovirus" exact="gastroenteritis" post="in a long-termcare facility in China: the role of"/>
   <result pre="of a new GII.17 norovirus variant in patients with acute" exact="gastroenteritis" post="in Jiangsu, China, September 2014 to March 2015Eurosurveillance201520242115726111236 41.LindesmithLCKocherJFDonaldsonEFDebbinkKMalloryMLSwannEWBrewer-JensenPDBaricRSEmergence"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6890994\results\search\disease\results.xml">
   <result pre="a public health emergency following the linkage between infection and" exact="microcephaly" post="in fetuses of ZIKV-infected mothers (3–5). Since ZIKV and"/>
   <result pre="4.de OliveiraWK, de FrancaGVA, CarmoEH, DuncanBB, de Souza KuchenbeckerR, SchmidtMI2017Infection-related" exact="microcephaly" post="after the 2015 and 2016 Zika virus outbreaks in"/>
   <result pre="AdamsDJ, XavierRJ, FarzanM, ElledgeSJ2009The IFITM proteins mediate cellular resistance to" exact="influenza" post="A H1N1 virus, West Nile virus, and dengue virus."/>
   <result pre="is required for both IFITM protein association and inhibition of" exact="influenza" post="A virus and dengue virus replication. J Virol87:7837–7852. doi:10.1128/JVI.00481-13.23658454"/>
   <result pre="Italian.)3228497 25.OvertonET, NurutdinovaD, SungkanuparphS, SeyfriedW, GrogerRK, PowderlyWG2007Predictors of immunity after" exact="hepatitis" post="A vaccination in HIV-infected persons. J Viral Hepat14:189–193. doi:10.1111/j.1365-2893.2006.00822.x.17305885"/>
   <result pre="GezmuM, FollmannD, VodeikoGM, LevandowskiRA, MicanJM, FauciAS2005Compromised B cell responses to" exact="influenza" post="vaccination in HIV-infected individuals. J Infect Dis191:1442–1450. doi:10.1086/429298.15809902 27.KlattNR,"/>
   <result pre="PetrovasC, PahwaS2018Altered immune cell follicular dynamics in HIV infection following" exact="influenza" post="vaccination. J Clin Invest128:3171–3185. doi:10.1172/JCI99884.29911996 30.MoysiE, PetrovasC, KoupRA2018The role"/>
   <result pre="DimopoulosY, HeTF, ChavakisT, SaloustrosE, LeePP, PetrovasC2018Lymph node cellular dynamics in" exact="cancer" post="and HIV: what can we learn for the follicular"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6892364\results\search\disease\results.xml">
   <result pre="10.1038/s10038-019-0675-4 : Review Article Portable sequencer in the fight against" exact="infectious disease" post="MonganArthur Elia1TudaJosef Sem Berth1RuntuweneLucky Ronaldluckyruntuwene@edu.k.u-tokyo.ac.jpluckyruntuwene@yahoo.co.id2[1], 0000 0001 0702 3254grid.412381.dFaculty"/>
   <result pre="pressure, such as antimicrobials, encouraged the emergence and reemergence of" exact="infectious disease." post="The fight with infectious disease starts with prevention, diagnosis,"/>
   <result pre="the emergence and reemergence of infectious disease. The fight with" exact="infectious disease" post="starts with prevention, diagnosis, and treatment. Diagnosis can be"/>
   <result pre="to utilize a portable sequencer, MinION, in various aspects of" exact="infectious disease" post="management. Subject terms Genetics research Bacterial infection Infectious disease"/>
   <result pre="Poliomyelitis was already documented in Egyptian papyrus. Leprosy, plague, cholera," exact="yellow fever," post="influenza epidemics, or pandemics were the norm [1]. As"/>
   <result pre="already documented in Egyptian papyrus. Leprosy, plague, cholera, yellow fever," exact="influenza" post="epidemics, or pandemics were the norm [1]. As the"/>
   <result pre="of microorganisms for the first time, changing the paradigm of" exact="infectious disease" post="[2]. Soon, the discovery of pathogenic agents displaced the"/>
   <result pre="pathogenic agents displaced the preexisting theories of the cause of" exact="infectious disease." post="Vaccines were developed to prevent contracting or spreading the"/>
   <result pre="to hold the key for the emergence or reemergence of" exact="infectious disease." post="The acquisition of drug resistance, for example malaria parasites"/>
   <result pre="of infectious disease. The acquisition of drug resistance, for example" exact="malaria" post="parasites to chloroquine or the mosquito vector to insecticide,"/>
   <result pre="is one of the factors that prevent the eradication of" exact="malaria" post="worldwide in 1955–1978 [3]. Other example is the human"/>
   <result pre="coincidental transmission to humans [4–6] and the 2009 H1N1 pandemic" exact="influenza" post="virus that emerged from pigs, is a legacy of"/>
   <result pre="influenza virus that emerged from pigs, is a legacy of" exact="influenza" post="A virus causing pandemic in 1918 [7]. The definitive"/>
   <result pre="microscopic examination of acid-fast bacilli remains the main tool for" exact="tuberculosis" post="detection, yet the technique sensitivity varies on smearing, staining,"/>
   <result pre="can be applied to other pathogens as well, such as" exact="malaria" post="[35, 36] and chikungunya [37]. Table 1 An outline"/>
   <result pre="other pathogens as well, such as malaria [35, 36] and" exact="chikungunya" post="[37]. Table 1 An outline of MinION sequencing methods"/>
   <result pre="used in many clinical studies. Chikungunya virus (CHIKV), EBOV, and" exact="hepatitis" post="C virus can be detected from clinical samples after"/>
   <result pre="coronavirus [61], an mRNA that accumulates late in infection of" exact="herpes simplex" post="virus-1 [62], and the discovery of novel RNA molecules"/>
   <result pre="virus [63]. Advanced application of MinION in the field of" exact="infectious disease" post="is the epigenetic sequencing. Epigenetics is the study of"/>
   <result pre="number of infection-related epigenetic researches are still low compared with" exact="cancer" post="epigenomics [65]. MinION has a high potential assisting epigenetic"/>
   <result pre="field or clinical setting to assist in the fight against" exact="infectious disease." post="Publisher’s note Springer Nature remains neutral with regard to"/>
   <result pre="SIV. bioRxiv. 2017. 10.1101/190769. 7.MorensDTaunbenbergerJFauciAThe persistent legacy of the 1918" exact="influenza" post="virusN Engl J Med2009261225910.1056/NEJMp0904819 8.FarniaPet al.Improving sensitivity of direct"/>
   <result pre="Res. 2017;1–10. 10.1101/gr.214270.116.5. 26.RuntuweneLRet al.Nanopore sequencing of drug-resistance-associated genes in" exact="malaria" post="parasites, Plasmodium falciparumSci Rep2018811310.1038/s41598-018-26334-329311619 27.MénardDet al.A worldwide map of"/>
   <result pre="Targeted sequencing workflows for comprehensive drug resistance profiling of Mycobacterium" exact="tuberculosis" post="cultures using Illumina MiSeq and Nanopore MinION: Comparison of"/>
   <result pre="a portable sequencerSci Rep2017711010.1038/s41598-016-0028-x28127051 35.ImaiKet al.A novel diagnostic method for" exact="malaria" post="using loop-mediated isothermal amplification (LAMP) and MinIONTM nanopore sequencerBMC"/>
   <result pre="MinION nanopore sequencerMalar J20181711110.1186/s12936-018-2362-x29291736 37.HayashidaKet al.Field diagnosis and genotyping of" exact="chikungunya" post="virus using a dried reverse transcription loop-mediated isothermal amplification"/>
   <result pre="Nanopore and Illumina sequencing for recovering whole genome sequences of" exact="chikungunya" post="and dengue viruses directly from clinical samplesEurosurveillance20182311310.2807/1560-7917.ES.2018.23.50.1800228 40.ImaiKTamuraKTanigakiTTakizawaMNakayamaEWhole genome"/>
   <result pre="dengue viruses directly from clinical samplesEurosurveillance20182311310.2807/1560-7917.ES.2018.23.50.1800228 40.ImaiKTamuraKTanigakiTTakizawaMNakayamaEWhole genome sequencing of" exact="influenza" post="A and B viruses with the MinION sequencer in"/>
   <result pre="displacement amplification from single cellsNat Protoc2006119657110.1038/nprot.2006.32617487184 51.WangYNairSNostenFAndersonTMultiple displacement amplification for" exact="malaria" post="parasite DNAJ Parasitol200995253510.1645/GE-1706.118601578 52.George, S et al. MinION nanopore"/>
   <result pre="from sputum. bioRxiv. 2018. 10.1101/490417. 53.PendletonKet al.Rapid pathogen identification in" exact="bacterial pneumonia" post="using real-time metagenomicsAm J Respir Crit Care Med20171961610210.1164/rccm.201703-0537LE28475350 54.Payne"/>
   <result pre="sputum. bioRxiv. 2018. 10.1101/490417. 53.PendletonKet al.Rapid pathogen identification in bacterial" exact="pneumonia" post="using real-time metagenomicsAm J Respir Crit Care Med20171961610210.1164/rccm.201703-0537LE28475350 54.Payne"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6892805\results\search\disease\results.xml">
   <result pre="of this license, visit http://creativecommons.org/licenses/by/4.0/. Abstract A key question for" exact="infectious disease" post="dynamics is the impact of the climate on future"/>
   <result pre="has been paid to directly-transmitted infections, despite key work on" exact="influenza" post="demonstrating the significant role climatic variables can play in"/>
   <result pre="transmission of these types of infections. Experimental studies show that" exact="influenza" post="transmission increases in conditions of low humidity6–8. Observational studies"/>
   <result pre="in temperate climates support this finding; while in tropical locations," exact="influenza" post="peaks have been observed to occur in the rainy"/>
   <result pre="season when humidity increases9,10. The rapid evolution of the seasonal" exact="influenza" post="virus and the consequent complexity of dynamics makes projections"/>
   <result pre="leading cause of lower respiratory tract infections in infants, particularly" exact="bronchiolitis" post="and pneumonia, and has also been implicated in the"/>
   <result pre="in the United States and combine these observations with weekly" exact="bronchiolitis" post="hospitalization data from all 32 states in Mexico. The"/>
   <result pre="for RSV so we rely on mechanistic understanding developed from" exact="influenza" post="experiments to inform our choice of climate variables (Supplementary"/>
   <result pre="such patterns have been previously observed in both RSV and" exact="influenza" post="time series in tropical countries9,23, our results provide evidence"/>
   <result pre="striking similarity in the role of specific humidity for both" exact="influenza" post="and RSV suggests that parallel mechanisms are at play"/>
   <result pre="correspondence appears to hold even though the population dynamics of" exact="influenza" post="and RSV are palpably different. Influenza disappears at high"/>
   <result pre="work. Precipitation has also been hypothesized to be important for" exact="influenza" post="transmission, although this has not been tested in laboratory"/>
   <result pre="transmission for both RSV and influenza. Fig. 4 Comparison with" exact="influenza" post="results. Removing precipitation from our regression model and including"/>
   <result pre="reveals a very similar response (a) to earlier work on" exact="influenza" post="(b adapted from Tamerius et al.9, Fig 3a) suggesting"/>
   <result pre="diseases. Predicted minimum transmission for RSV occurs at 11.16 g/kg, with" exact="influenza" post="found to be similarly 11–12 g/kg9. Tamerius et al. suggest"/>
   <result pre="airborne transmission. More broadly, our preliminary comparison between RSV and" exact="influenza" post="reveals the potential for comparative studies to elucidate the"/>
   <result pre="Secretaría de Salud. We take data from all cases of" exact="bronchiolitis" post="(ICD-10 codes J21.0, J21.1, J21.8, J21.9), a serious respiratory"/>
   <result pre="E.WalterKatharine S.WesolowskiAmyBuckeeCaroline O.ShevliakovaElenaTatemAndrew J.BoosWilliam R.WeinbergerDaniel M.PitzerVirginia E.Identifying climate drivers of" exact="infectious disease" post="dynamics: recent advances and challenges aheadProceedings of the Royal"/>
   <result pre="the Royal Society B: Biological Sciences201728418602017090110.1098/rspb.2017.0901 2.MordecaiEAet al.Optimal temperature for" exact="malaria" post="transmission is dramatically lower than previously predictedEcol. Lett.201316223010.1111/ele.1201523050931 3.PascualMRodóXEllnerSPColwellRBoumaMJCholera"/>
   <result pre="5.CaminadeCyrilKovatsSariRocklovJoacimTompkinsAdrian M.MorseAndrew P.Colón-GonzálezFelipe J.StenlundHansMartensPimLloydSimon J.Impact of climate change on global" exact="malaria" post="distributionProceedings of the National Academy of Sciences201411193286329110.1073/pnas.1302089111 6.LowenACMubarekaSSteelJPalesePInfluenza virus"/>
   <result pre="and temperaturePLoS Pathog.20073e15110.1371/journal.ppat.0030151 7.LowenACSteelJRoles of humidity and temperature in shaping" exact="influenza" post="seasonalityJ. Virol.2014887692769510.1128/JVI.03544-1324789791 8.Shaman, J. &amp;amp; Kohn, M. Absolute humidity"/>
   <result pre="seasonalityJ. Virol.2014887692769510.1128/JVI.03544-1324789791 8.Shaman, J. &amp;amp; Kohn, M. Absolute humidity modulates" exact="influenza" post="survival, transmission, and seasonality. Proc. Natl Acad. Sci. USA106,"/>
   <result pre="Acad. Sci. USA106, 3243–3248 (2009). 9.TameriusJDet al.Environmental predictors of seasonal" exact="influenza" post="epidemics across temperate and tropical climatesPLoS Pathog.20139e100319410.1371/journal.ppat.100319423505366 10.ShamanJPitzerVEViboudCGrenfellBTLipsitchMAbsolute humidity"/>
   <result pre="tropical climatesPLoS Pathog.20139e100319410.1371/journal.ppat.100319423505366 10.ShamanJPitzerVEViboudCGrenfellBTLipsitchMAbsolute humidity and the seasonal onset of" exact="influenza" post="in the continental United StatesPLoS Biol.20108e100031610.1371/journal.pbio.100031620186267 11.Shaman, J. &amp;amp;"/>
   <result pre="of influenza. Proc. Natl Acad. Sci. USA109, 20425–20430 (2012). 12.ShamanJKarspeckAYangWTameriusJLipsitchMReal-time" exact="influenza" post="forecasts during the 2012–2013 seasonNat. Commun.20134283710.1038/ncomms383724302074 13.EarnDJRohaniPBolkerBMGrenfellBTA simple model"/>
   <result pre="virus disease in a tropical island populationEpidemiol. Infec.20081361319132710.1017/S095026880700001518177515 26.TameriusJet al.Global" exact="influenza" post="seasonality: reconciling patterns across temperate and tropical regionsEnviron. Health"/>
   <result pre="modelsMath. Biosci.200720922223910.1016/j.mbs.2006.08.01817335858 31.DalzielBDet al.Urbanization and humidity shape the intensity of" exact="influenza" post="epidemics in US citiesScience2018362757910.1126/science.aat603030287659 32.FerrariMJet al.The dynamics of measles"/>
   <result pre="of influenza epidemics in US citiesScience2018362757910.1126/science.aat603030287659 32.FerrariMJet al.The dynamics of" exact="measles" post="in sub-Saharan AfricaNature200845167910.1038/nature0650918256664 33.TaylorKEStoufferRJMeehlGAAn overview of CMIP5 and the"/>
   <result pre="syncytial virusClin. Infect. Dis.20156150651410.1093/cid/civ33125904370 38.HervásDet al.Epidemiology of hospitalization for acute" exact="bronchiolitis" post="in children: differences between RSV and non-RSV bronchiolitisEur. J."/>
   <result pre="stations—a new environmental record for monitoring extremesSci. Data2015215006610.1038/sdata.2015.6626646728 41.BjørnstadONFinkenstädtBFGrenfellBTDynamics of" exact="measles" post="epidemics: estimating scaling of transmission rates using a time"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6892822\results\search\disease\results.xml">
   <result pre="pmcid: 689282213520 doi: 10.1038/s41467-019-13520-8 : Article The dynamic proteome of" exact="influenza" post="A virus infection identifies M segment splicing as a"/>
   <result pre="view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/. Abstract Pandemic" exact="influenza" post="A virus (IAV) outbreaks occur when strains from animal"/>
   <result pre="segment RNA splicing as a viral host range determinant. Avian" exact="influenza" post="A virus (IAV) strains replicate poorly in mammalian hosts,"/>
   <result pre="do not infect mammals and vice versa. Pandemics occur when" exact="influenza" post="strains of avian origin with novel antigenicity acquire the"/>
   <result pre="intracellular restriction is still incomplete. One well-established factor is the" exact="influenza" post="RNA-dependent RNA polymerase (RdRP): this enzyme catalyzes replication of"/>
   <result pre="of viral transcripts. This suggests that mRNAs from human and" exact="avian influenza" post="virus strains access the translational machinery with comparable efficiency,"/>
   <result pre="viral transcripts. This suggests that mRNAs from human and avian" exact="influenza" post="virus strains access the translational machinery with comparable efficiency,"/>
   <result pre="overlapping protein-coding regions, for example, in viral genomes such as" exact="hepatitis" post="C and HIV52,53. Importantly, RNA-Decoder captures evidence on conserved"/>
   <result pre="were maintained at 37 °C and 5% CO2. Stocks of the" exact="avian influenza" post="virus A/Mallard/439/2004 (H3N2) (Mal) (GISAID accession numbers EPI859640-EPI859647) were"/>
   <result pre="maintained at 37 °C and 5% CO2. Stocks of the avian" exact="influenza" post="virus A/Mallard/439/2004 (H3N2) (Mal) (GISAID accession numbers EPI859640-EPI859647) were"/>
   <result pre="remaining reads were then mapped to the human and Pan/Mal" exact="influenza" post="A reference genome using Tophat2 (v2.0.10) with parameters: -N"/>
   <result pre="The authors declare no competing interests. References References 1.NeumannGKawaokaYTransmission of" exact="influenza" post="A virusesVirology2015479-48023424610.1016/j.virol.2015.03.00925812763 2.MatrosovichMNet al.Avian influenza A viruses differ from"/>
   <result pre="interests. References References 1.NeumannGKawaokaYTransmission of influenza A virusesVirology2015479-48023424610.1016/j.virol.2015.03.00925812763 2.MatrosovichMNet al.Avian" exact="influenza" post="A viruses differ from human viruses by recognition of"/>
   <result pre="RNA synthesisNat. Rev. Microbiol.20161447949310.1038/nrmicro.2016.8727396566 4.LongJSet al.Species difference in ANP32A underlies" exact="influenza" post="A virus polymerase host restrictionNature201652910110410.1038/nature1647426738596 5.MairCMLudwigKHerrmannASiebenCReceptor binding and pH"/>
   <result pre="A virus polymerase host restrictionNature201652910110410.1038/nature1647426738596 5.MairCMLudwigKHerrmannASiebenCReceptor binding and pH stability—how" exact="influenza" post="A virus hemagglutinin affects host-specific virus infectionBiochimica et. Biophysica"/>
   <result pre="affects host-specific virus infectionBiochimica et. Biophysica Acta (BBA)201418381153116810.1016/j.bbamem.2013.10.00424161712 6.MänzBSchwemmleMBrunotteLAdaptation of" exact="avian influenza" post="A virus polymerase in mammals to overcome the host"/>
   <result pre="host-specific virus infectionBiochimica et. Biophysica Acta (BBA)201418381153116810.1016/j.bbamem.2013.10.00424161712 6.MänzBSchwemmleMBrunotteLAdaptation of avian" exact="influenza" post="A virus polymerase in mammals to overcome the host"/>
   <result pre="and mRNA splicing: doing more with lessMBio20145e000701410.1128/mBio.00070-1424825008 10.MartinKHeleniusANuclear transport of" exact="influenza" post="virus ribonucleoproteins: the viral matrix protein (M1) promotes export"/>
   <result pre="protein (M1) promotes export and inhibits importCell19916711713010.1016/0092-8674(91)90576-K1913813 11.BuiMWillsEGHeleniusAWhittakerGRRole of the" exact="influenza" post="virus M1 protein in nuclear export of viral ribonucleoproteinsJ."/>
   <result pre="on the infected-cell surfaceVirus Res.19853410.1016/0168-1702(85)90260-6 14.ValcárcelJPortelaAOrtínJRegulated M1 mRNA splicing in" exact="influenza" post="virus-infected cellsJ. Gen. Virol.199172Part 61301130810.1099/0022-1317-72-6-13011710647 15.KönigRStertzSRecent strategies and progress"/>
   <result pre="virus replicationCurr. Opin. Microbiol.201526798810.1016/j.mib.2015.06.00126112615 16.KarlasAMachuyNMeyerTFHuman host cell factors crucial for" exact="influenza" post="virus replication identified by genome-wide RNAi screenNat. Biotechnol.201027S84 17.KönigRet"/>
   <result pre="genome-wide RNAi screenNat. Biotechnol.201027S84 17.KönigRet al.Human host factors required for" exact="influenza" post="virus replicationNature201046381381710.1038/nature0869920027183 18.BrassALet al.The IFITM proteins mediate cellular resistance"/>
   <result pre="virus replicationNature201046381381710.1038/nature0869920027183 18.BrassALet al.The IFITM proteins mediate cellular resistance to" exact="influenza" post="A H1N1 virus, West Nile virus, and dengue virusCell20091391243125410.1016/j.cell.2009.12.01720064371"/>
   <result pre="a platform for antiviral drug developmentCell Host Microbe20141679580510.1016/j.chom.2014.11.00225464832 20.WangLet al.Comparative" exact="influenza" post="protein interactomes identify the role of plakophilin 2 in"/>
   <result pre="Proteomics mcp.RA117.000364 (2018). 23.SimonPFet al.Highly pathogenic H5N1 and novel H7N9" exact="influenza" post="A viruses induce more profound proteomic host responses than"/>
   <result pre="al.Proteome alterations in primary human alveolar macrophages in response to" exact="influenza" post="A virus infectionJ. Proteome Res.2012114091410110.1021/pr300133222709384 25.KroekerALEzzatiPHalaykoAJCoombsKMResponse of primary human"/>
   <result pre="Proteome Res.2012114091410110.1021/pr300133222709384 25.KroekerALEzzatiPHalaykoAJCoombsKMResponse of primary human airway epithelial cells to" exact="influenza" post="infection: a quantitative proteomic studyJ. Proteome Res.2012114132414610.1021/pr300239r22694362 26.WuXet al.Subcellular"/>
   <result pre="proteomic analysis of human host cells infected with H3N2 swine" exact="influenza" post="virusProteomics2013133309332610.1002/pmic.20130018024115376 27.SadewasserAet al.Quantitative proteomic approach identifies Vpr binding protein"/>
   <result pre="approach identifies Vpr binding protein as novel host factor supporting" exact="influenza" post="A virus infections in human cellsMol. Cell. Proteom.20171672874210.1074/mcp.M116.065904 28.InglisSCBrownCMDifferences"/>
   <result pre="of virus mRNA splicing during permissive or abortive infection with" exact="influenza" post="A (fowl plague) virusJ. Gen. Virol.198465Part 115316410.1099/0022-1317-65-1-1536546394 29.ShapiroGIGurneyTJrKrugRMInfluenza virus"/>
   <result pre="mammalian gene expression controlNature201147333734210.1038/nature1009821593866 38.RivasHGSchmalingSKGagliaMMShutoff of host gene expression in" exact="influenza" post="A virus and herpesviruses: similar mechanisms and common themesViruses2016810210.3390/v804010227092522"/>
   <result pre="Virol.2007815315532410.1128/JVI.02129-0617344288 40.KhaperskyyDASchmalingSLarkins-FordJMcCormickCGagliaMMSelective degradation of host RNA polymerase II transcripts by" exact="influenza" post="A virus PA-X host shutoff proteinPLoS Pathog.201612e100542710.1371/journal.ppat.100542726849127 41.Bercovich-Kinori, A."/>
   <result pre="proteinPLoS Pathog.201612e100542710.1371/journal.ppat.100542726849127 41.Bercovich-Kinori, A. et al. A systematic view on" exact="influenza" post="induced host shutoff. Elife5, 10.7554/eLife.18311 (2016). 42.ParkYWKatzeMGTranslational control by"/>
   <result pre="influenza induced host shutoff. Elife5, 10.7554/eLife.18311 (2016). 42.ParkYWKatzeMGTranslational control by" exact="influenza" post="virus. Identification of cis-acting sequences and trans-acting factors which"/>
   <result pre="43.ZhouTGuWMaJSunXLuZAnalysis of synonymous codon usage in H5N1 virus and other" exact="influenza" post="A virusesBiosystems200581778610.1016/j.biosystems.2005.03.00215917130 44.GabrielGet al.The viral polymerase mediates adaptation of"/>
   <result pre="A virusesBiosystems200581778610.1016/j.biosystems.2005.03.00215917130 44.GabrielGet al.The viral polymerase mediates adaptation of an" exact="avian influenza" post="virus to a mammalian hostProc. Natl Acad. Sci. USA2005102185901859510.1073/pnas.050741510216339318"/>
   <result pre="virusesBiosystems200581778610.1016/j.biosystems.2005.03.00215917130 44.GabrielGet al.The viral polymerase mediates adaptation of an avian" exact="influenza" post="virus to a mammalian hostProc. Natl Acad. Sci. USA2005102185901859510.1073/pnas.050741510216339318"/>
   <result pre="Natl Acad. Sci. USA2005102185901859510.1073/pnas.050741510216339318 45.HutchinsonECet al.Conserved and host-specific features of" exact="influenza" post="virion architectureNat. Commun.20145481610.1038/ncomms581625226414 46.KillipMJFodorERandallREInfluenza virus activation of the interferon"/>
   <result pre="of the interferon systemVirus Res.2015209112210.1016/j.virusres.2015.02.00325678267 47.ShihSRSuenPCChenYSChangSCA novel spliced transcript of" exact="influenza" post="A/WSN/33 virusVirus Genes19981717918310.1023/A:10080249092229857991 48.WiseHMet al.Identification of a novel splice"/>
   <result pre="48.WiseHMet al.Identification of a novel splice variant form of the" exact="influenza" post="A virus M2 ion channel with an antigenically distinct"/>
   <result pre="ectodomainPLoS Pathog.20128e100299810.1371/journal.ppat.100299823133386 49.ShihSRNemeroffMEKrugRMThe choice of alternative 5’ splice sites in" exact="influenza" post="virus M1 mRNA is regulated by the viral polymerase"/>
   <result pre="Natl Acad. Sci. USA1995926324632810.1073/pnas.92.14.63247541537 50.MossWNet al.The 3′ splice site of" exact="influenza" post="A segment 7 mRNA can exist in two conformations:"/>
   <result pre="a hairpinPLoS ONE20127e3832310.1371/journal.pone.003832322685560 51.ShihSRKrugRMNovel exploitation of a nuclear function by" exact="influenza" post="virus: the cellular SF2/ASF splicing factor controls the amount"/>
   <result pre="54.WorobeyMHanG-ZRambautAA synchronized global sweep of the internal genes of modern" exact="avian influenza" post="virusNature201450825425710.1038/nature1301624531761 55.Backström WinquistEet al.Inefficient splicing of segment 7 and"/>
   <result pre="synchronized global sweep of the internal genes of modern avian" exact="influenza" post="virusNature201450825425710.1038/nature1301624531761 55.Backström WinquistEet al.Inefficient splicing of segment 7 and"/>
   <result pre="segment 7 and 8 mRNAs is an inherent property of" exact="influenza" post="virus A/Brevig Mission/1918/1 (H1N1) that causes elevated expression of"/>
   <result pre="et al. Dysregulation of M segment gene expression contributes to" exact="influenza" post="A virus host restriction. PLoS Pathog. 15, e1007892 (2019)."/>
   <result pre="restriction. PLoS Pathog. 15, e1007892 (2019). 10.1371/journal.ppat. 57.GarfinkelMSKatzeMGTranslational control by" exact="influenza" post="virus. Selective translation is mediated by sequences within the"/>
   <result pre="regionJ. Biol. Chem.199326822223222268226725 58.HuangXet al.An NS-segment exonic splicing enhancer regulates" exact="influenza" post="A virus replication in mammalian cellsNat. Commun.201781475110.1038/ncomms1475128323816 59.MorAet al.Influenza"/>
   <result pre="Microbiol201611606910.1038/nmicrobiol.2016.6927572970 60.ThompsonMGet al.Co-regulatory activity of hnRNP K and NS1-BP in" exact="influenza" post="and human mRNA splicingNat. Commun.20189240710.1038/s41467-018-04779-429921878 61.RobbNCFodorEThe accumulation of influenza"/>
   <result pre="in influenza and human mRNA splicingNat. Commun.20189240710.1038/s41467-018-04779-429921878 61.RobbNCFodorEThe accumulation of" exact="influenza" post="A virus segment 7 spliced mRNAs is regulated by"/>
   <result pre="62.TsaiP-Let al.Cellular RNA binding proteins NS1-BP and hnRNP K regulate" exact="influenza" post="A virus RNA splicingPLoS Pathog.20139e100346010.1371/journal.ppat.100346023825951 63.MorensDMTaubenbergerJKFauciASThe persistent legacy of"/>
   <result pre="virus RNA splicingPLoS Pathog.20139e100346010.1371/journal.ppat.100346023825951 63.MorensDMTaubenbergerJKFauciASThe persistent legacy of the 1918" exact="influenza" post="virusN. Engl. J. Med.200936122522910.1056/NEJMp090481919564629 64.ReidAHFanningTGJanczewskiTAMcCallSTaubenbergerJKCharacterization of the 1918 ‘Spanish’"/>
   <result pre="influenza virusN. Engl. J. Med.200936122522910.1056/NEJMp090481919564629 64.ReidAHFanningTGJanczewskiTAMcCallSTaubenbergerJKCharacterization of the 1918 ‘Spanish’" exact="influenza" post="virus matrix gene segmentJ. Virol.200276107171072310.1128/JVI.76.21.10717-10723.200212368314 65.DodtMRoehrJTAhmedRDieterichCFLEXBAR—flexible barcode and adapter"/>
   <result pre="Res.201442W373W37610.1093/nar/gku29224810851 70.ZhangYet al.Influenza Research Database: an integrated bioinformatics resource for" exact="influenza" post="virus researchNucleic Acids Res.201745D466D47410.1093/nar/gkw85727679478"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6893414\results\search\disease\results.xml">
   <result pre="Ery-Est also showed inhibitory activity against dengue virus (DENV) and" exact="yellow fever" post="virus (YFV). Thus, Ery-Est may be a promising drug"/>
   <result pre="also contains other enveloped viruses, such as dengue virus (DENV)," exact="yellow fever" post="virus (YFV), West Nile virus, and Japanese encephalitis virus,"/>
   <result pre="(DENV), yellow fever virus (YFV), West Nile virus, and Japanese" exact="encephalitis" post="virus, which have resulted in epidemics and threatened public"/>
   <result pre="detected by the plaque assay. The pseudotyped MERS-CoV and vesicular" exact="stomatitis" post="virus (VSV) were chosen as control enveloped viruses and"/>
   <result pre="consequences of abortion, premature birth, or having a baby with" exact="microcephaly" post="[48,49,50,51]. Meanwhile, as the sexual transmission of ZIKV was"/>
   <result pre="and epididymis of immunodeficient miceNat. Commun.20189535010.1038/s41467-018-07782-x30559387 8.De MoraesC.G.PettitoM.YepezJ.B.SakuntabhaiA.Simon-LoriereE.ZaidiM.B.ProtM.RuffieC.KimS.S.AllikmetsR.et al.Corrigendum: Optic" exact="neuropathy" post="and congenital glaucoma associated with probable Zika virus infection"/>
   <result pre="of immunodeficient miceNat. Commun.20189535010.1038/s41467-018-07782-x30559387 8.De MoraesC.G.PettitoM.YepezJ.B.SakuntabhaiA.Simon-LoriereE.ZaidiM.B.ProtM.RuffieC.KimS.S.AllikmetsR.et al.Corrigendum: Optic neuropathy and" exact="congenital glaucoma" post="associated with probable Zika virus infection in Venezuelan patientsJMM"/>
   <result pre="immunodeficient miceNat. Commun.20189535010.1038/s41467-018-07782-x30559387 8.De MoraesC.G.PettitoM.YepezJ.B.SakuntabhaiA.Simon-LoriereE.ZaidiM.B.ProtM.RuffieC.KimS.S.AllikmetsR.et al.Corrigendum: Optic neuropathy and congenital" exact="glaucoma" post="associated with probable Zika virus infection in Venezuelan patientsJMM"/>
   <result pre="Virus Associated with MeningoencephalitisN. Engl. J. Med.20163741595159610.1056/NEJMc160296426958738 11.WoodsC.G.BondJ.EnardW.Autosomal recessive primary" exact="microcephaly" post="(MCPH): A review of clinical, molecular, and evolutionary findingsAm."/>
   <result pre="virus production in Vero cellsSci. Rep.201991146110.1038/s41598-019-47956-131391514 30.MounceB.C.CesaroT.CarrauL.ValletT.VignuzziM.Curcumin inhibits Zika and" exact="chikungunya" post="virus infection by inhibiting cell bindingAntivir. Res.201714214815710.1016/j.antiviral.2017.03.01428343845 31.LuL.LiuQ.ZhuY.ChanK.H.QinL.LiY.WangQ.ChanJ.F.JiangS.YuF.et al.Structure-based"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6893437\results\search\disease\results.xml">
   <result pre="(Boulder, CO, USA) [18,19,20], and have been used to examine" exact="cancer" post="biomarkers [45], Alzheimer′s disease biomarkers [46] and biomarkers in"/>
   <result pre="version, capable of detecting 1128 proteins, reliably measured differences in" exact="influenza" post="PR8-infected A549 cells over a time course. We subsequently"/>
   <result pre="virus-induced proteomic alterations in Vero cells [23] and in U251" exact="astrocytoma" post="cells [48]. Application of this targeted aptamer-based approach, which"/>
   <result pre="and mRNA microarray screens identified &amp;gt;1500 cellular genes and proteins" exact="influenza" post="virus may depend upon [28,29,30,31]. For example, Konig and"/>
   <result pre="Konig and colleagues identified 295 genes that were required for" exact="influenza" post="virus replication as defined by replicase activity [29] and"/>
   <result pre="colleagues identified 287 genes required for replication of two different" exact="influenza" post="viruses, including the pdm09 strain [28]. Collectively, these two"/>
   <result pre="out in A549 cells, identified 552 potential genes important for" exact="influenza" post="replication, with 30 genes found in common. The low"/>
   <result pre="should be more extensively analyzed as potential targets to ameliorate" exact="influenza" post="virus infection. Some of our observed dysregulated proteins also"/>
   <result pre="HealthBoston, MA, USA1996990 2.TaubenbergerJ.K.HultinJ.V.MorensD.M.Discovery and characterization of the 1918 pandemic" exact="influenza" post="virus in historical contextAntivir. Ther.20071258159117944266 3.PaleseP.ShawM.L.Orthomyxoviridae: The viruses and"/>
   <result pre="&amp;amp; WilkinsPhiladelphia, PA, USA200716471689 4.JaggerB.W.WiseH.M.KashJ.C.WaltersK.A.WillsN.M.XiaoY.L.DunfeeR.L.SchwartzmanL.M.OzinskyA.BellG.L.et al.An overlapping protein-coding region in" exact="influenza" post="A virus segment 3 modulates the host responseScience201233719920410.1126/science.122221322745253 5.RahimM.N.SelmanM.SauderP.J.ForbesN.E.StechoW.XuW.LebarM.BrownE.G.CoombsK.M.Generation"/>
   <result pre="Influenza A virusJ. Gen. Virol.20139459260410.1099/vir.0.046649-023223621 6.TongS.X.LiY.RivaillerP.ConrardyC.CastilloD.A.A.ChenL.M.RecuencoS.EllisonJ.A.DavisC.T.YorkI.A.et al.A distinct lineage of" exact="influenza" post="A virus from batsProc. Natl. Acad. Sci. USA20121094269427410.1073/pnas.111620010922371588 7.AlexanderD.J.An"/>
   <result pre="and evidence of limited intercontinental virus exchangePLoS Path.200731684169310.1371/journal.ppat.0030167 9.RichardM.de GraafM.HerfstS.Avian" exact="influenza" post="A viruses: From zoonosis to pandemicFuture Virol.2014951352410.2217/fvl.14.3025214882 10.CoombsK.M.BerardA.XuW.KrokhinO.MengX.CortensJ.P.KobasaD.WilkinsJ.BrownE.G.Quantitative proteomic"/>
   <result pre="viruses: From zoonosis to pandemicFuture Virol.2014951352410.2217/fvl.14.3025214882 10.CoombsK.M.BerardA.XuW.KrokhinO.MengX.CortensJ.P.KobasaD.WilkinsJ.BrownE.G.Quantitative proteomic analyses of" exact="influenza" post="virus-infected cultured human lung cellsJ. Virol.201084108881090610.1128/JVI.00431-1020702633 11.KroekerA.L.EzzatiP.CoombsK.M.HalaykoA.J.Influenza A infection"/>
   <result pre="proteomic studyJ. Proteome Res.2012114132413610.1021/pr300239r22694362 13.SimonP.F.McCorristerS.HuP.Z.ChongP.SilaghiA.WestmacottG.CoombsK.M.KobasaD.Highly pathogenic H5N1 and novel H7N9" exact="influenza" post="A viruses induce more profound proteomic host responses than"/>
   <result pre="Proteome Res.2015144511452310.1021/acs.jproteome.5b0019626381135 14.VesterD.RappE.GadeD.GenzelY.ReichlU.Quantitative analysis of cellular proteome alterations in human" exact="influenza" post="A virus-infected mammalian cell linesProteomics200993316332710.1002/pmic.20080089319504497 15.DoveB.K.SurteesR.BeanT.J.MundayD.WiseH.M.DigardP.CarrollM.W.AjuhP.BarrJ.N.HiscoxJ.A.A quantitative proteomic analysis"/>
   <result pre="analysis of lung epithelial (A549) cells infected with 2009 pandemic" exact="influenza" post="A virus using stable isotope labelling with amino acids"/>
   <result pre="16.LiuL.ZhouJ.WangY.MasonR.J.FunkC.J.DuY.Proteome alterations in primary human alveolar macrophages in response to" exact="influenza" post="a virus infectionJ. Proteome Res.2012114091410110.1021/pr300133222709384 17.CheungC.Y.ChanE.Y.KrasnoselskyA.PurdyD.NavareA.T.BryanJ.T.LeungC.K.L.HuiK.P.Y.PeirisJ.S.M.KatzeM.G.H5N1 virus causes significant"/>
   <result pre="scale with the SOMAscan proteomics platformNew Bio.20122954354910.1016/j.nbt.2011.11.016 20.WebberJ.StoneT.C.KatiliusE.SmithB.C.GordonB.MasonM.D.TabiZ.BrewisI.A.ClaytonA.Proteomics analysis of" exact="cancer" post="exosomes using a novel modified aptamer-based array (SOMAscan(TM)) PlatformMol."/>
   <result pre="Zika virus infectionProteomics201919e180030910.1002/pmic.20180030930578658 24.XieH.WanX.F.YeZ.P.PlantE.P.ZhaoY.Q.XuY.F.LiX.FinchC.ZhaoN.KawanoT.et al.H3N2 mismatch of 2014–2015 Northern hemisphere" exact="influenza" post="vaccines and head-to-head comparison between human and ferret antisera"/>
   <result pre="and ferret antisera derived antigenic mapsSci. Rep.201551527910.1038/srep1527926472175 25.LewnardJ.A.CobeyS.Immune history and" exact="influenza" post="vaccine effectivenessVaccines201862810.3390/vaccines602002829883414 26.LackenbyA.ThompsonC.I.DemocratisJ.The potential impact of neuraminidase inhibitor resistant"/>
   <result pre="Inf. Dis.20082162663810.1097/QCO.0b013e328319979718978531 27.HurtA.C.BesselaarT.G.DanielsR.S.ErmetalB.FryA.GubarevaL.HuangW.J.LackenbyA.LeeR.T.C.LoJ.et al.Global update on the susceptibility of human" exact="influenza" post="viruses to neuraminidase inhibitors, 2014–2015Antivir. Res.201613217818510.1016/j.antiviral.2016.06.00127265623 28.KarlasA.MachuyN.ShinY.PleissnerK.P.ArtariniA.HeuerD.BeckerD.KhalilH.OgilvieL.A.HessS.et al.Genome-wide RNAi"/>
   <result pre="28.KarlasA.MachuyN.ShinY.PleissnerK.P.ArtariniA.HeuerD.BeckerD.KhalilH.OgilvieL.A.HessS.et al.Genome-wide RNAi screen identifies human host factors crucial for" exact="influenza" post="virus replicationNature201046381882210.1038/nature0876020081832 29.KonigR.StertzS.ZhouY.InoueA.HoffmannH.H.BhattacharyyaS.AlamaresJ.G.TscherneD.M.OrtigozaM.B.LiangY.et al.Human host factors required for influenza"/>
   <result pre="for influenza virus replicationNature201046381882210.1038/nature0876020081832 29.KonigR.StertzS.ZhouY.InoueA.HoffmannH.H.BhattacharyyaS.AlamaresJ.G.TscherneD.M.OrtigozaM.B.LiangY.et al.Human host factors required for" exact="influenza" post="virus replicationNature201046381381710.1038/nature0869920027183 30.WatanabeT.WatanabeS.KawaokaY.Cellular networks involved in the Influenza virus"/>
   <result pre="cycleCell Host Microbe2010742743910.1016/j.chom.2010.05.00820542247 31.TranA.T.RahimM.N.RanadheeraC.KroekerA.CortensJ.P.OpanubiK.J.WilkinsJ.A.CoombsK.M.Knockdown of specific host factors protects against" exact="influenza" post="virus-induced cell deathCell Death Dis.20134e76910.1038/cddis.2013.29623949218 32.DhingraV.LiQ.AllisonA.B.StallknechtD.E.FuZ.F.Proteomic profiling and neurodegeneration"/>
   <result pre="against influenza virus-induced cell deathCell Death Dis.20134e76910.1038/cddis.2013.29623949218 32.DhingraV.LiQ.AllisonA.B.StallknechtD.E.FuZ.F.Proteomic profiling and" exact="neurodegeneration" post="in West-Nile-virus-infected neuronsJ. Biomed. Biotechnol.2005200527127910.1155/JBB.2005.27116192685 33.ZhangM.C.ZhengX.Y.WuY.GanM.HeA.LiZ.Y.ZhangD.J.WuX.S.ZhanX.M.Differential proteomics of Aedes"/>
   <result pre="dengue virus infectionVirology201344410911810.1016/j.virol.2013.06.00123816433 34.ZhangL.K.ChaiF.LiH.Y.XiaoG.F.GuoL.Identification of host proteins involved in Japanese" exact="encephalitis" post="virus infection by quantitative proteomics analysisJ. Proteome Res.2013122666267810.1021/pr400011k23647205 35.YangR.W.KlimentovaJ.Gockel-KrzikallaE.LyR.GmelinN.Hotz-WagenblattA.RehulkovaH.StulikJ.RoslF.NieblerM.Combined"/>
   <result pre="proteomic analysis reveals unfolded-protein response involved in severe fever with" exact="thrombocytopenia" post="syndrome virus infectionJ. Virol.201993e00308e0031910.1128/JVI.00308-1930842332 39.LuberC.A.CoxJ.LauterbachH.FanckeB.SelbachM.TschoppJ.AkiraS.WiegandM.HochreinH.O’KeeffeM.et al.Quantitative proteomics reveals subset-specific"/>
   <result pre="and data independent acquisitionAnal. Chim. Acta201796472310.1016/j.aca.2017.01.05928351641 45.MehanM.R.AyersD.ThirstrupD.XiongW.OstroffR.M.BrodyE.N.WalkerJ.J.GoldL.JarvisT.C.JanjicN.et al.Protein signature of" exact="lung cancer" post="tissuesPLoS ONE20127e3515710.1371/journal.pone.003515722509397 46.SattleckerM.KiddleS.J.NewhouseS.ProitsiP.NelsonS.WilliamsS.JohnstonC.KillickR.SimmonsA.WestmanE.et al.Alzheimer’s disease biomarker discovery using SOMAscan"/>
   <result pre="data independent acquisitionAnal. Chim. Acta201796472310.1016/j.aca.2017.01.05928351641 45.MehanM.R.AyersD.ThirstrupD.XiongW.OstroffR.M.BrodyE.N.WalkerJ.J.GoldL.JarvisT.C.JanjicN.et al.Protein signature of lung" exact="cancer" post="tissuesPLoS ONE20127e3515710.1371/journal.pone.003515722509397 46.SattleckerM.KiddleS.J.NewhouseS.ProitsiP.NelsonS.WilliamsS.JohnstonC.KillickR.SimmonsA.WestmanE.et al.Alzheimer’s disease biomarker discovery using SOMAscan"/>
   <result pre="multiplexed protein technologyAlzheimers Dement.20141072473410.1016/j.jalz.2013.09.01624768341 47.MarionT.ElbaheshH.ThomasP.G.DeVincenzoJ.P.WebbyR.SchughartK.Respiratory mucosal proteome quantification in human" exact="influenza" post="infectionsPLoS ONE201611e015367410.1371/journal.pone.015367427088501 48.SherA.A.GloverK.K.M.CoombsK.M.Zika virus infection disrupts astrocytic proteins involved"/>
   <result pre="involved in synapse control and axon guidanceFront. Microbiol.20191059610.3389/fmicb.2019.0059630984137 49.MenacheryV.D.EisfeldA.J.SchaferA.JossetL.SimsA.C.ProllS.FanS.F.LiC.J.NeumannG.TiltonS.C.et al.Pathogenic" exact="influenza" post="viruses and coronaviruses utilize similar and contrasting approaches to"/>
   <result pre="interferon-stimulated gene responsesMbio20145e01174-1410.1128/mBio.01174-1424846384 50.BavagnoliL.MagaG.Identification of host cell factors involved in" exact="influenza" post="A virus infectionFuture Virol.2013819520810.2217/fvl.12.133 Figure 1 Protein dysregulation characteristics"/>
   <result pre="viruses-11-01028-t002_Table 2Table 2 A549 proteins dysregulated by infection by indicated" exact="influenza" post="strains. EntrezGene Symbol Protein Fold-Change Compared to Sham-Infected H1N1"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6893470\results\search\disease\results.xml">
   <result pre="genotype, viral genotype and temperature have been completed with dengue," exact="chikungunya" post="and Zika viruses [52,53,54,55,56,57,58,59]. A recent study by Tesla"/>
   <result pre="as has been shown by increased transmission of dengue and" exact="chikungunya" post="at lower temperatures in some mosquito populations [53,55,56]. Given"/>
   <result pre="in Aedes spp. than Culex spp. Studies with Venezuelan equine" exact="encephalitis" post="virus (VEEV), RVFV, chikungunya virus and Ross River virus"/>
   <result pre="Culex spp. Studies with Venezuelan equine encephalitis virus (VEEV), RVFV," exact="chikungunya" post="virus and Ross River virus (RRV) demonstrated an inverse"/>
   <result pre="was measured for RVFV in Cx. pipiens [49] Murray valley" exact="encephalitis" post="virus (MVEV) in Cx. annulirostris [61] or West Nile"/>
   <result pre="studies have demonstrated that enzootic arboviruses including WNV, Eastern equine" exact="encephalitis" post="virus (EEEV) and La Crosse Virus (LACV) can have"/>
   <result pre="(Table 3). Models have been reviewed for WNV [15,149,163,168], Japanese" exact="encephalitis" post="virus (JEV) [15,16,20], RVFV [14,15], RRV [7], and Barmah"/>
   <result pre="LACV [13], MVEV [3], Sindbis virus (SINV) [3,172,173], St. Louis" exact="encephalitis" post="virus (SLEV) [3,174], and Western equine encephalitis virus (WEEV)"/>
   <result pre="[3,172,173], St. Louis encephalitis virus (SLEV) [3,174], and Western equine" exact="encephalitis" post="virus (WEEV) ([174,175,176] and citations therein, [3]). Note that"/>
   <result pre="Acad. Sci.2019143615717310.1111/nyas.1395030120891 3.MordecaiE.A.CaldwellJ.M.GrossmanM.K.LippiC.A.JohnsonL.R.NeiraM.RohrJ.R.RyanS.J.SavageV.ShocketM.S.Thermal biology of mosquito-borne diseaseEcol. Lett.2019221690170810.1111/ele.1333531286630 4.LindseyN.P.StaplesJ.E.FischerM.Eastern equine" exact="encephalitis" post="virus in the United States, 2003–2016Am. J. Trop. Med."/>
   <result pre="VirusAnnu. Rev. Microbiol.19864039541410.1146/annurev.mi.40.100186.0021432877613 20.YiL.XuX.GeW.XueH.LiJ.LiD.WangC.WuH.LiuX.ZhengD.et al.The impact of climate variability on" exact="infectious disease" post="transmission in China: Current knowledge and further directionsEnviron. Res.201917325526110.1016/j.envres.2019.03.04330928856"/>
   <result pre="So Recent, OutbreaksAnnu. Rev. Entomol.20014611113810.1146/annurev.ento.46.1.11111112165 24.HubalekZ.HalouzkaJ.West Nile fever—A reemerging mosquito-borne" exact="viral disease" post="in EuropeEmerg. Infect. Dis.1999564365010.3201/eid0505.99050510511520 25.ReisenW.K.Ecology of West Nile virus"/>
   <result pre="pipiens quinquefasciatus Say (Diptera: Culicidae) vector competence for Saint Louis" exact="encephalitis" post="virusAm. J. Trop. Med. Hyg.20098126427210.4269/ajtmh.2009.81.26419635881 31.DanforthM.E.ReisenW.K.BarkerC.M.Extrinsic incubation rate is"/>
   <result pre="of Aedes taeniorhynchus for Rift Valley fever and Venezuelan equine" exact="encephalitis" post="virusesAm. J. Trop. Med. Hyg.19934967267610.4269/ajtmh.1993.49.6728279634 37.KilpatrickA.M.MeolaM.A.MoudyR.M.KramerL.D.Temperature, viral genetics, and"/>
   <result pre="of Culex tritaeniorhynchus on the pattern of transmission of Japanese" exact="encephalitis" post="virusJ. Med. Entomol.19761327528410.1093/jmedent/13.3.2751011230 43.DohmD.J.O’GuinnM.L.TurellM.J.Effect of environmental temperature on the"/>
   <result pre="on the vector competence of Culex tarsalis for western equine" exact="encephalomyelitis" post="virusAm. J. Trop. Med. Hyg.1983321130113910.4269/ajtmh.1983.32.11306625067 47.ChamberlainR.SudiaW.D.The effects of temperature"/>
   <result pre="Hyg.1983321130113910.4269/ajtmh.1983.32.11306625067 47.ChamberlainR.SudiaW.D.The effects of temperature upon the extrinsic incubation of" exact="eastern equine encephalitis" post="in mosquitoesAm. J. Trop. Med. Hyg.195562295305 48.DanforthM.E.ReisenW.K.BarkerC.M.The impact of"/>
   <result pre="effects of temperature upon the extrinsic incubation of eastern equine" exact="encephalitis" post="in mosquitoesAm. J. Trop. Med. Hyg.195562295305 48.DanforthM.E.ReisenW.K.BarkerC.M.The impact of"/>
   <result pre="susceptibility in Culex mosquitoesBMC Ecol.2011112310.1186/1472-6785-11-2321975028 51.KramerL.D.HardyJ.L.PresserS.B.HoukE.J.Dissemination barriers for western equine" exact="encephalomyelitis" post="virus in Culex tarsalis infected after ingestion of low"/>
   <result pre="viral dosesAm. J. Trop. Med. Hyg.19813019019710.4269/ajtmh.1981.30.1907212166 52.AltoB.W.WigginsK.EastmondB.OrtizS.ZirbelK.LounibosL.P.Diurnal temperature range and" exact="chikungunya" post="virus infection in invasive mosquito vectorsJ. Med. Entomol.20185521722410.1093/jme/tjx18229040730 53.CiotaA.T.ChinP.A.EhrbarD.J.MicieliM.V.FonsecaD.M.KramerL.D.Differential"/>
   <result pre="56.ZouacheK.FontaineA.Vega-RuaA.MoussonL.ThibergeJ.-M.Lourenco-De-OliveiraR.CaroV.LambrechtsL.FaillouxA.-B.Three-way interactions between mosquito population, viral strain and temperature underlying" exact="chikungunya" post="virus transmission potentialProc. Biol. Sci.20142812014107810.1098/rspb.2014.107825122228 57.LambrechtsL.PaaijmansK.P.FansiriT.CarringtonL.B.KramerL.D.ThomasM.B.ScottT.W.Impact of daily temperature"/>
   <result pre="longevity, fecundity, and gonotrophic cycles of Aedes albopictus, vector of" exact="chikungunya" post="and dengue in the Indian OceanJ. Med. Entomol.200946334110.1603/033.046.010519198515 88.RuybalJ.E.KramerL.D.KilpatrickA.M.Geographic"/>
   <result pre="Vet. Entomol.20112527628810.1111/j.1365-2915.2010.00939.x21294759 94.ScottT.W.LorenzL.H.Reduction of Culiseta melanura fitness by eastern equine" exact="encephalomyelitis" post="virusAm. J. Trop. Med. Hyg.19985934134610.4269/ajtmh.1998.59.3419715958 95.MoncayoA.C.EdmanJ.D.TurellM.J.Effect of eastern equine"/>
   <result pre="encephalomyelitis virusAm. J. Trop. Med. Hyg.19985934134610.4269/ajtmh.1998.59.3419715958 95.MoncayoA.C.EdmanJ.D.TurellM.J.Effect of eastern equine" exact="encephalomyelitis" post="virus on the survival of Aedes albopictus, Anopheles quadrimaculatus,"/>
   <result pre="viruseLife20165e1527210.7554/eLife.1527227090089 137.CampbellL.P.LutherC.Moo-LlanesD.RamseyJ.M.Danis-LozanoR.PetersonA.T.Climate change influences on global distributions of dengue and" exact="chikungunya" post="virus vectorsPhilos. Trans. Royal Soc. B20153702014013510.1098/rstb.2014.0135 138.CapinhaC.RochaJ.SousaC.A.Macroclimate Determines the"/>
   <result pre="J. Trop. Med. Hyg.20036850851810.4269/ajtmh.2003.68.50812812335 175.SellersR.MaaroufA.Weather factors in the prediction of" exact="western equine encephalitis" post="epidemics in ManitobaEpidemiol. Infect.199311137339010.1017/S09502688000570718405163 176.BarkerC.M.JohnsonW.O.EldridgeB.F.ParkB.K.MeltonF.ReisenW.K.Temporal connections between Culex tarsalis"/>
   <result pre="Med. Hyg.20036850851810.4269/ajtmh.2003.68.50812812335 175.SellersR.MaaroufA.Weather factors in the prediction of western equine" exact="encephalitis" post="epidemics in ManitobaEpidemiol. Infect.199311137339010.1017/S09502688000570718405163 176.BarkerC.M.JohnsonW.O.EldridgeB.F.ParkB.K.MeltonF.ReisenW.K.Temporal connections between Culex tarsalis"/>
   <result pre="CaliforniaAm. J. Trop. Med. Hyg.2010821185119310.4269/ajtmh.2010.09-032420519621 177.UnnaschR.S.SprengerT.KatholiC.R.CuppE.W.HillG.E.UnnaschT.R.A dynamic transmission model of" exact="eastern equine encephalitis" post="virusEcol. Model200619242544010.1016/j.ecolmodel.2005.07.011 178.SkaffN.K.ArmstrongP.M.AndreadisT.G.CheruvelilK.S.Wetland characteristics linked to broad-scale patterns in"/>
   <result pre="Trop. Med. Hyg.2010821185119310.4269/ajtmh.2010.09-032420519621 177.UnnaschR.S.SprengerT.KatholiC.R.CuppE.W.HillG.E.UnnaschT.R.A dynamic transmission model of eastern equine" exact="encephalitis" post="virusEcol. Model200619242544010.1016/j.ecolmodel.2005.07.011 178.SkaffN.K.ArmstrongP.M.AndreadisT.G.CheruvelilK.S.Wetland characteristics linked to broad-scale patterns in"/>
   <result pre="characteristics linked to broad-scale patterns in Culiseta melanura abundance and" exact="eastern equine encephalitis" post="virus infectionParasit Vectors20171050110.1186/s13071-017-2482-029047412 179.HahnM.B.MonaghanA.J.HaydenM.H.EisenR.J.DeloreyM.J.LindseyN.P.NasciR.S.FischerM.Meteorological conditions associated with increased incidence"/>
   <result pre="to broad-scale patterns in Culiseta melanura abundance and eastern equine" exact="encephalitis" post="virus infectionParasit Vectors20171050110.1186/s13071-017-2482-029047412 179.HahnM.B.MonaghanA.J.HaydenM.H.EisenR.J.DeloreyM.J.LindseyN.P.NasciR.S.FischerM.Meteorological conditions associated with increased incidence"/>
   <result pre="Three Gorges DamPLoS ONE20149e8432610.1371/journal.pone.008432624404159 195.MogiM.Relationship between number of human Japanese" exact="encephalitis" post="cases and summer meteorological conditions in Nagasaki, JapanAm. J."/>
   <result pre="Nagasaki, JapanAm. J. Trop. Med. Hyg.19833217017410.4269/ajtmh.1983.32.1706297324 196.BiP.ZhangY.PartonK.A.Weather variables and Japanese" exact="encephalitis" post="in the metropolitan area of Jinan city, ChinaJ. Infect.20075555155610.1016/j.jinf.2007.07.00417714787"/>
   <result pre="of Jinan city, ChinaJ. Infect.20075555155610.1016/j.jinf.2007.07.00417714787 197.LinH.YangL.LiuQ.WangT.HossainS.R.HoS.C.TianL.Time series analysis of Japanese" exact="encephalitis" post="and weather in Linyi City, ChinaInt. J. Public Health20125728929610.1007/s00038-011-0236-x21308477"/>
   <result pre="Raton, FL, USA1988Volume 1245255 201.ReisenW.LothropH.ChilesR.CusackR.GreenE.FangY.KensingtonM.Persistence and amplification of St. Louis" exact="encephalitis" post="virus in the Coachella Valley of California, 2000–2001J. Med."/>
   <result pre="California, 1986–1990J. Med. Entomol.19922951252410.1093/jmedent/29.3.5121352557 203.BiP.TongS.DonaldK.PartonK.NiJ.Climate variability and transmission of Japanese" exact="encephalitis" post="in Eastern ChinaVector Borne Zoonotic Dis.2003311111510.1089/15303660376839580714511580 204.WangL.HuW.MagalhaesR.J.S.BiP.DingF.SunH.LiS.YinW.WeiL.LiuQ.et al.The role"/>
   <result pre="role of environmental factors in the spatial distribution of Japanese" exact="encephalitis" post="in mainland ChinaEnviron. Int.2014731910.1016/j.envint.2014.07.00425072160 205.ProwN.The changing epidemiology of Kunjin"/>
   <result pre="214.HessA.CherubinC.LaMotteL.Relation of temperature to activity of western and St. Louis" exact="encephalitis" post="virusesAm. J. Trop. Med. Hyg.19631265766710.4269/ajtmh.1963.12.657 215.BorahJ.DuttaP.KhanS.A.MahantaJ.Association of Weather and"/>
   <result pre="of climatic factors on the distribution and abundance of Japanese" exact="encephalitis" post="vectors in Kurnool district of Andhra Pradesh, IndiaJ. Vector"/>
   <result pre="Dis.2010472632 217.UpadhyayulaS.M.MutheneniS.R.NayanooriH.K.NatarajanA.GoswamiP.Impact of weather variables on mosquitoes infected with Japanese" exact="encephalitis" post="virus in Kurnool district, Andhra PradeshAsian Pac. J. Trop."/>
   <result pre="MalaysiaPLoS Negl. Trop. Dis.20137e233410.1371/journal.pntd.000233423951373 219.HardyJ.L.RosenL.ReevesW.C.ScrivaniR.P.PresserS.B.Experimental transovarial transmission of St. Louis" exact="encephalitis" post="virus by Culex and Aedes mosquitoesAm. J. Trop. Med."/>
   <result pre="in peninsular FloridaJ. Med. Entomol.20084545846510.1603/0022-2585(2008)45[458:UHCTFT]2.0.CO;218533440 232.ShamanJ.DayJ.F.StieglitzM.Drought-induced amplification of Saint Louis" exact="encephalitis" post="virus, FloridaEmerg Infect. Dis.2002857558010.3201/eid0806.01041712023912 233.ReisenW.MeyerR.MilbyM.PresserS.EmmonsR.HardyJ.ReevesW.Ecological observations on the 1989"/>
   <result pre="Peninsular FloridaJ. Med. Entomol.2009461498150610.1603/033.046.063819960704 235.DayJ.F.StarkL.M.Avian serology in a St. Louis" exact="encephalitis" post="epicenter before, during, and after a widespread epidemic in"/>
   <result pre="ChinaEmerg Infect. Dis.20111793493610.3201/eid1705.10141721529419 238.HoS.H.SpeldewindeP.CookA.A Bayesian Belief Network for Murray Valley" exact="encephalitis" post="virus risk assessment in Western AustraliaInt. J. Health Geogr.201615610.1186/s12942-016-0036-x26823368"/>
   <result pre="Primary Hosts Distribution 1 Human Disease Togaviridae: alphaviruses Eastern equine" exact="encephalitis" post="virus (EEEV) [4] mosquito (Culiseta, Culex) bird NA, C/SA"/>
   <result pre="(EEEV) [4] mosquito (Culiseta, Culex) bird NA, C/SA febrile illness," exact="encephalitis" post="Western equine encephalitis virus (WEEV) [5] mosquito (Culiseta, Culex)"/>
   <result pre="(Culiseta, Culex) bird NA, C/SA febrile illness, encephalitis Western equine" exact="encephalitis" post="virus (WEEV) [5] mosquito (Culiseta, Culex) bird NA, C/SA"/>
   <result pre="(WEEV) [5] mosquito (Culiseta, Culex) bird NA, C/SA febrile illness," exact="encephalitis" post="Sindbis virus (SINV) [6] mosquito (Culex) bird AF, EU,"/>
   <result pre="mosquito (Aedes) mammals (marsupials) AU febrile illness, arthralgia Venezuelan equine" exact="encephalitis" post="virus (VEEV) [11] mosquito (Aedes, Culex) small mammal, equids"/>
   <result pre="mosquito (Aedes, Culex) small mammal, equids NA, C/SA febrile illness," exact="encephalitis" post="Mayaro virus (MAV) [12] mosquito (Haemagous) non-human primate C/SA"/>
   <result pre="virus (LACV) [13] mosquito (Aedes) small mammal NA febrile illness," exact="encephalitis" post="Bunyaviridae: phleboviruses Rift Valley fever virus (RVFV) [14,15] mosquito"/>
   <result pre="(Aedes/Culex), phlebotomus flies mammal (ruminants) AF febrile illness, hemorrhagic fever," exact="encephalitis" post="Flaviviidae: flaviviruses Japanese encephalitis virus (JEV) [15,16,17,18,19,20] mosquito (Culex)"/>
   <result pre="(ruminants) AF febrile illness, hemorrhagic fever, encephalitis Flaviviidae: flaviviruses Japanese" exact="encephalitis" post="virus (JEV) [15,16,17,18,19,20] mosquito (Culex) bird, swine AS febrile"/>
   <result pre="virus (JEV) [15,16,17,18,19,20] mosquito (Culex) bird, swine AS febrile illness," exact="encephalitis" post="Murray valley encephalitis virus (MVEV) [21] mosquito (Culex) bird"/>
   <result pre="mosquito (Culex) bird, swine AS febrile illness, encephalitis Murray valley" exact="encephalitis" post="virus (MVEV) [21] mosquito (Culex) bird AU febrile illness,"/>
   <result pre="encephalitis virus (MVEV) [21] mosquito (Culex) bird AU febrile illness," exact="encephalitis" post="St. Louis encephalitis virus (SLEV) [22,23] mosquito (Culex) bird"/>
   <result pre="[21] mosquito (Culex) bird AU febrile illness, encephalitis St. Louis" exact="encephalitis" post="virus (SLEV) [22,23] mosquito (Culex) bird NA, C/SA febrile"/>
   <result pre="virus (SLEV) [22,23] mosquito (Culex) bird NA, C/SA febrile illness," exact="encephalitis" post="West Nile virus (WNV) [15,24,25,26,27] mosquito (Culex) bird NA,"/>
   <result pre="bird NA, C/SA, AF, EU, ME, AS, AU febrile illness," exact="encephalitis" post="1 NA = N. America, C/SA = C./S. America,"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6893508\results\search\disease\results.xml">
   <result pre="calves, lambs and kids, as well as an arthrogryposis and" exact="hydranencephaly" post="syndrome [8]. SBV quickly spread to the rest of"/>
   <result pre="transient disease, with anorexia, hyperthermia, and in some animals with" exact="diarrhea" post="and reduced milk yield (up to 50%) [1,45]. In"/>
   <result pre="cattle, 3% sheep and 1% goats) [46]. Clinical signs of" exact="diarrhea" post="and reduced milk yield have been reported at least"/>
   <result pre="not been clearly established, there have been reports of fever," exact="diarrhea" post="and reduced milk yield in sheep [46]. Under experimental"/>
   <result pre="include arthrogryposis, lordosis, scoliosis, torticollis and brachygnathia inferior [37,50]. Sacral" exact="spina bifida" post="and cleft palate are also observed in stillborn lambs."/>
   <result pre="scoliosis, torticollis and brachygnathia inferior [37,50]. Sacral spina bifida and" exact="cleft palate" post="are also observed in stillborn lambs. Meanwhile, musculoskeletal defects"/>
   <result pre="or neonates led to the description of the arthrogryposis and" exact="hydranencephaly" post="syndrome (AG-HE syndrome) [14]. 4. Immunity Infections of Schmallenberg"/>
   <result pre="infections; however, occasionally, especially in cattle, clinical signs of fever," exact="diarrhea" post="and a reduction in milk yield are not uncommon"/>
   <result pre="syndrome, aplasia or hypoplasia of the cerebrum or cerebellum and" exact="hydranencephaly" post="are observed [33,45,49]. Virological and/or serological diagnosis is needed"/>
   <result pre="to Experimental Schmallenberg Virus InfectionVector Borne Zoonotic Dis.20181869770310.1089/vbz.2018.2297 50.TsudaT.YoshidaK.OhashiS.YanaseT.YanaseT.SueyoshiM.KamimuraS.MisumiK.HamanaK.SakamotoH.et al.Arthrogryposis," exact="hydranencephaly" post="and cerebellar hypoplasia syndrome in neonatal calves resulting from"/>
   <result pre="Gc delivered by recombinant equine herpesvirus type 1 and modified" exact="vaccinia virus" post="Ankara: Immunogenicity and protective efficacy in cattleVaccine2018365116512310.1016/j.vaccine.2018.07.04730049630 75. Schmallenberg"/>
   <result pre="in cattleVaccine2018365116512310.1016/j.vaccine.2018.07.04730049630 75. Schmallenberg virus vaccineVet. Rec.2015177321 76.KonoR.HirataM.KajiM.GotoY.IkedaS.YanaseT.KatoT.TanakaS.TsutsuiT.ImadaT.et al.Bovine epizootic" exact="encephalomyelitis" post="caused by Akabane virus in southern JapanBMC Vet. Res.200842010.1186/1746-6148-4-2018554406"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6893532\results\search\disease\results.xml">
   <result pre="Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). Abstract A novel" exact="avian influenza" post="virus (A/wild duck/Korea/K102/2018) (H2N9) was isolated from wild birds"/>
   <result pre="Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). Abstract A novel avian" exact="influenza" post="virus (A/wild duck/Korea/K102/2018) (H2N9) was isolated from wild birds"/>
   <result pre="the A/wild duck/Korea/K102/2018 (H2N9) isolate was a typical low pathogenicity" exact="avian influenza" post="(LPAI). Nucleotide sequence similarity analysis of HA revealed that"/>
   <result pre="A/wild duck/Korea/K102/2018 (H2N9) isolate was a typical low pathogenicity avian" exact="influenza" post="(LPAI). Nucleotide sequence similarity analysis of HA revealed that"/>
   <result pre="newly isolated A/wild duck/Korea/K102/2018 (H2N9) strain is the first reported" exact="avian influenza" post="virus in Korea, and may have evolved from multiple"/>
   <result pre="isolated A/wild duck/Korea/K102/2018 (H2N9) strain is the first reported avian" exact="influenza" post="virus in Korea, and may have evolved from multiple"/>
   <result pre="wild birds and ducks in Mongolia, China, and Japan. novel" exact="avian influenza" post="virus isolate H2N9 Korea wild duck 1. Introduction Influenza"/>
   <result pre="birds and ducks in Mongolia, China, and Japan. novel avian" exact="influenza" post="virus isolate H2N9 Korea wild duck 1. Introduction Influenza"/>
   <result pre="HA (H1–H16) and 9 subtypes of NA (N1–N9) belong to" exact="avian influenza" post="viruses (AIV), while H17N10 and H18N11 subtypes are only"/>
   <result pre="(H1–H16) and 9 subtypes of NA (N1–N9) belong to avian" exact="influenza" post="viruses (AIV), while H17N10 and H18N11 subtypes are only"/>
   <result pre="HA plays a central role in the life cycle of" exact="influenza" post="A viruses through its involvement in receptor recognition, virus"/>
   <result pre="subtypes such as H5, H7, and H9, [6] but H2" exact="influenza" post="viruses are found in wild birds [7], swine [8],"/>
   <result pre="[7], swine [8], and humans. The Asian pandemic of H2N2" exact="influenza" post="A virus resulted from reassortment of previously circulating human"/>
   <result pre="shared 84–85% similarity with the H2N2 viruses of the 1957" exact="influenza" post="pandemic [9,10]. In wild waterfowl birds, the H2 subtype"/>
   <result pre="H7 subtype was suggested as the origin of highly pathogenic" exact="avian influenza" post="(HPAI) H7N9 2013 [13]. H7N9 AIV has all three"/>
   <result pre="subtype was suggested as the origin of highly pathogenic avian" exact="influenza" post="(HPAI) H7N9 2013 [13]. H7N9 AIV has all three"/>
   <result pre="co-circulating in Korea [18,19,20]. The NA gene of the H7N9" exact="influenza" post="virus is more closely related to that of H2N9"/>
   <result pre="next-generation sequencing (NGS) is ideal, as the mutation rate of" exact="influenza" post="A viruses has been traditionally determined by sequencing different"/>
   <result pre="cDNA clones obtained from multiple plaques descending from a plaque-purified" exact="influenza" post="A virus [21]. In addition, NGS has the advantage"/>
   <result pre="instead of the specimen. 2.4. Subtyping Using PCR To evaluate" exact="influenza" post="growth and determine the subtype, conventional real-time RT-PCR for"/>
   <result pre="influenza growth and determine the subtype, conventional real-time RT-PCR for" exact="influenza" post="A virus that amplifies the matrix gene coding sequence"/>
   <result pre="(Daejeon, Korea) using HiSeq X as previously reported [26,27]. Briefly," exact="influenza" post="RNA was evaluated using an Agilent RNA 6000 Pico"/>
   <result pre="spectrophotometer of BioPhotometer® (Eppendorf, Hamburg, Germany). The cDNA library of" exact="influenza" post="RNA was generated using QIAseq FX Single Cell RNA"/>
   <result pre="DeconSeq (iden = 60) using a database created by downloading" exact="influenza" post="virus sequences from the National Center for Biotechnology Information"/>
   <result pre="(NA), and 8 (NS1), known to have high variability among" exact="influenza" post="virus segments, was examined by Basic Local Alignment Search"/>
   <result pre="Basic Local Alignment Search Tool for nucleotides (BLASTn) in the" exact="influenza" post="virus database. Among the results, the most homologous and"/>
   <result pre="as the reference of this study. Sequence reads classified as" exact="influenza" post="virus were mapped to the selected reference sequence using"/>
   <result pre="that are associated with the increased virulence factor of the" exact="influenza" post="virus A H5N1 strain in mice, such as N30D"/>
   <result pre="trypsin-like serine protease and this requirement restricts the tropism of" exact="influenza" post="viruses to the types of tissues that express the"/>
   <result pre="acids in the 220 loop (Table 3). In avian H2" exact="influenza" post="viruses, HA receptor-binding-site residues corresponding to the amino acids"/>
   <result pre="Korea [15,16]. Therefore, our study emphasizes the importance of understanding" exact="avian influenza" post="genetic diversity as a H7N9 outbreak may occur in"/>
   <result pre="[15,16]. Therefore, our study emphasizes the importance of understanding avian" exact="influenza" post="genetic diversity as a H7N9 outbreak may occur in"/>
   <result pre="the hemagglutinin (HA) cleavage site sequence of H5 and H7" exact="avian influenza" post="viruses: Amino acid sequence at the HA cleavage site"/>
   <result pre="hemagglutinin (HA) cleavage site sequence of H5 and H7 avian" exact="influenza" post="viruses: Amino acid sequence at the HA cleavage site"/>
   <result pre="pathogenicity potentialAvian Dis.19964042543710.2307/15922418790895 4.de GraafM.FouchierR.A.Role of receptor binding specificity in" exact="influenza" post="A virus transmission and pathogenesisEMBO J.20143382384110.1002/embj.20138744224668228 5.HaY.StevensD.J.SkehelJ.J.WileyD.C.X-ray structures of"/>
   <result pre="pathogenesisEMBO J.20143382384110.1002/embj.20138744224668228 5.HaY.StevensD.J.SkehelJ.J.WileyD.C.X-ray structures of H5 avian and H9 swine" exact="influenza" post="virus hemagglutinins bound to avian and human receptor analogsProc."/>
   <result pre="receptor analogsProc. Natl. Acad. Sci. USA200198111811118610.1073/pnas.20140119811562490 6.VerhagenJ.H.LexmondP.VuongO.SchuttenM.GuldemeesterJ.OsterhausA.D.ElbersA.R.SlaterusR.HornmanM.KochG.et al.Discordant detection of" exact="avian influenza" post="virus subtypes in time and space between poultry and"/>
   <result pre="analogsProc. Natl. Acad. Sci. USA200198111811118610.1073/pnas.20140119811562490 6.VerhagenJ.H.LexmondP.VuongO.SchuttenM.GuldemeesterJ.OsterhausA.D.ElbersA.R.SlaterusR.HornmanM.KochG.et al.Discordant detection of avian" exact="influenza" post="virus subtypes in time and space between poultry and"/>
   <result pre="and wild birds; Towards improvement of surveillance programsPLoS ONE20179e017347010.1371/journal.pone.017347028278281 7.KishidaN.SakodaY.ShiromotoM.BaiG.R.IsodaN.TakadaA.LaverG.KidaH.H2N5" exact="influenza" post="virus isolates from terns in Australia: Genetic reassortants between"/>
   <result pre="of the Eurasian and American lineagesVirus Genes200837162110.1007/s11262-008-0235-z18454312 8.MaW.VincentA.L.GramerM.R.BrockwellC.B.LagerK.M.JankeB.H.GaugerP.C.PatnayakD.P.WebbyR.J.RichtJ.A.Identification of H2N3" exact="influenza" post="A viruses from swine in the United StatesProc. Natl."/>
   <result pre="United StatesProc. Natl. Acad. Sci. USA2007104209492095410.1073/pnas.071028610418093945 9.JosephU.LinsterM.SuzukiY.KraussS.HalpinR.A.VijaykrishnaD.FabrizioT.P.BestebroerT.M.Maurer-StrohS.WebbyR.J.Adaptation of pandemic H2N2" exact="influenza" post="A viruses in humansJ. Virol.2015892442244710.1128/JVI.02590-1425505070 10.BeaudoinA.GramerM.GrayG.C.CapuanoA.SetterquistS.BenderJ.Serologic survey of swine"/>
   <result pre="10.BeaudoinA.GramerM.GrayG.C.CapuanoA.SetterquistS.BenderJ.Serologic survey of swine workers for exposure to H2N3 swine" exact="influenza" post="AInflu. Other Respir. Viruses2010416317010.1111/j.1750-2659.2009.00127.x 11.KillianM.L.ZhangY.PanigrahyB.TrampelD.YoonK.J.Identification and characterization of H2N3"/>
   <result pre="influenza AInflu. Other Respir. Viruses2010416317010.1111/j.1750-2659.2009.00127.x 11.KillianM.L.ZhangY.PanigrahyB.TrampelD.YoonK.J.Identification and characterization of H2N3" exact="avian influenza" post="virus from backyard poultry and comparison with novel H2N3"/>
   <result pre="AInflu. Other Respir. Viruses2010416317010.1111/j.1750-2659.2009.00127.x 11.KillianM.L.ZhangY.PanigrahyB.TrampelD.YoonK.J.Identification and characterization of H2N3 avian" exact="influenza" post="virus from backyard poultry and comparison with novel H2N3"/>
   <result pre="virus from backyard poultry and comparison with novel H2N3 swine" exact="influenza" post="virusAvian Dis.20115561161910.1637/9749-040111-Reg.122312981 12.JonassenC.M.HandelandK.Avian influenza virus screening in wild waterfowl"/>
   <result pre="and comparison with novel H2N3 swine influenza virusAvian Dis.20115561161910.1637/9749-040111-Reg.122312981 12.JonassenC.M.HandelandK.Avian" exact="influenza" post="virus screening in wild waterfowl in Norway, 2005Avian Dis.20075142542810.1637/7555-033106R1.117494599"/>
   <result pre="Norway, 2005Avian Dis.20075142542810.1637/7555-033106R1.117494599 13.GaoR.CaoB.HuY.FengZ.WangD.HuW.ChenJ.JieZ.QiuH.XuK.et al.Human infection with a novel avian-origin" exact="influenza" post="A (H7N9) virusN. Engl. J. Med.20133681888189710.1056/NEJMoa130445923577628 14.LinsterM.SchrauwenE.J.A.van der VlietS.BurkeD.F.LexmondP.BestebroerT.M.SmithD.J.HerfstS.KoelB.F.FouchierR.A.M.The"/>
   <result pre="VirusesJ. Virol.201993e01907-1810.1128/JVI.01907-1830700609 15.LeeY.N.CheonS.H.LeeE.K.HeoG.B.BaeY.C.JohS.J.LeeM.H.LeeY.J.Pathogenesis and genetic characteristics of novel reassortant low-pathogenic" exact="avian influenza" post="H7 viruses isolated from migratory birds in the Republic"/>
   <result pre="Virol.201993e01907-1810.1128/JVI.01907-1830700609 15.LeeY.N.CheonS.H.LeeE.K.HeoG.B.BaeY.C.JohS.J.LeeM.H.LeeY.J.Pathogenesis and genetic characteristics of novel reassortant low-pathogenic avian" exact="influenza" post="H7 viruses isolated from migratory birds in the Republic"/>
   <result pre="in the winter of 2016–2017Emerg. Microbes Infect.2018718210.1038/s41426-018-0181-330442892 16.KangH.M.ParkH.Y.LeeK.J.ChoiJ.G.LeeE.K.SongB.M.LeeH.S.LeeY.J.Characterization of H7" exact="influenza" post="A virus in wild and domestic birds in KoreaPLoS"/>
   <result pre="online: http://www.fao.org/3/CA3206EN/ca3206en.pdf(accessed on 28 February 2019) 18.KimH.R.ParkC.K.LeeY.J.OemJ.K.KangH.M.ChoiJ.G.LeeO.S.BaeY.C.Low pathogenic H7 subtype" exact="avian influenza" post="viruses isolated from domestic ducks in South Korea and"/>
   <result pre="http://www.fao.org/3/CA3206EN/ca3206en.pdf(accessed on 28 February 2019) 18.KimH.R.ParkC.K.LeeY.J.OemJ.K.KangH.M.ChoiJ.G.LeeO.S.BaeY.C.Low pathogenic H7 subtype avian" exact="influenza" post="viruses isolated from domestic ducks in South Korea and"/>
   <result pre="Virol.2012931278128710.1099/vir.0.041269-022422062 19.KangM.JangH.K.Genetics and biological property analysis of Korea lineage of" exact="influenza" post="A H9N2 virusesVet. Microbiol.20172049610310.1016/j.vetmic.2017.04.01428532813 20.LeT.B.LeeI.H.KimH.S.OhS.K.SeoS.H.Genetic analysis of a novel"/>
   <result pre="2016Virus Genes20175365666010.1007/s11262-017-1453-z28386784 21.Van den HoeckeS.VerhelstJ.VuylstekeM.SaelensX.Analysis of the genetic diversity of" exact="influenza" post="A viruses using next-generation DNA sequencingBMC Genom.2015167910.1186/s12864-015-1284-z 22.CrovilleG.SoubiesS.M.BarbieriJ.KloppC.MarietteJ.BouchezO.Camus-BouclainvilleC.GuerinJ.L.Field monitoring"/>
   <result pre="A viruses using next-generation DNA sequencingBMC Genom.2015167910.1186/s12864-015-1284-z 22.CrovilleG.SoubiesS.M.BarbieriJ.KloppC.MarietteJ.BouchezO.Camus-BouclainvilleC.GuerinJ.L.Field monitoring of" exact="avian influenza" post="viruses: Whole-genome sequencing and tracking of neuraminidase evolution using"/>
   <result pre="viruses using next-generation DNA sequencingBMC Genom.2015167910.1186/s12864-015-1284-z 22.CrovilleG.SoubiesS.M.BarbieriJ.KloppC.MarietteJ.BouchezO.Camus-BouclainvilleC.GuerinJ.L.Field monitoring of avian" exact="influenza" post="viruses: Whole-genome sequencing and tracking of neuraminidase evolution using"/>
   <result pre="Birds through DNA BarcodesPLoS Biol.20042e31210.1371/journal.pbio.002031215455034 26.LeeD.H.LeeH.J.LeeY.J.KangH.M.JeongO.M.KimM.C.KwonJ.S.KwonJ.H.KimC.B.LeeJ.B.et al.DNA barcoding techniques for" exact="avian influenza" post="virus surveillance in migratory bird habitatsJ. Wildl. Dis.20104664965410.7589/0090-3558-46.2.64920688667 27.AmbardarS.GuptaR.TrakrooD.LalR.VakhluJ.High"/>
   <result pre="through DNA BarcodesPLoS Biol.20042e31210.1371/journal.pbio.002031215455034 26.LeeD.H.LeeH.J.LeeY.J.KangH.M.JeongO.M.KimM.C.KwonJ.S.KwonJ.H.KimC.B.LeeJ.B.et al.DNA barcoding techniques for avian" exact="influenza" post="virus surveillance in migratory bird habitatsJ. Wildl. Dis.20104664965410.7589/0090-3558-46.2.64920688667 27.AmbardarS.GuptaR.TrakrooD.LalR.VakhluJ.High"/>
   <result pre="consensusBioinformatics2014303004301110.1093/bioinformatics/btu39225015988 29.SkehelJ.J.WileyD.C.Receptor binding and membrane fusion in virus entry: The" exact="influenza" post="hemagglutininAnnu. Rev. Biochem.20006953156910.1146/annurev.biochem.69.1.53110966468 30.LazniewskiM.DawsonW.K.SzczepinskaT.PlewczynskiD.The structural variability of the influenza"/>
   <result pre="The influenza hemagglutininAnnu. Rev. Biochem.20006953156910.1146/annurev.biochem.69.1.53110966468 30.LazniewskiM.DawsonW.K.SzczepinskaT.PlewczynskiD.The structural variability of the" exact="influenza" post="A hemagglutinin receptor-binding siteBrief. Funct. Genom.201817415427 31.LamT.T.-Y.WangJ.ShenY.ZhouB.DuanL.CheungC.-L.MaC.LycettS.J.LeungC.Y.-H.ChenX.et al.The genesis"/>
   <result pre="Funct. Genom.201817415427 31.LamT.T.-Y.WangJ.ShenY.ZhouB.DuanL.CheungC.-L.MaC.LycettS.J.LeungC.Y.-H.ChenX.et al.The genesis and source of the H7N9" exact="influenza" post="viruses causing human infections in ChinaNature201350224124410.1038/nature1251523965623 32.NaoN.YamagishiJ.MiyamotoH.IgarashiM.ManzoorR.OhnumaA.TsudaY.FuruyamaW.ShigenoA.KajiharaM.et al.Genetic Predisposition"/>
   <result pre="in MiceJ. Virol.2016902142214910.1128/JVI.02553-1526656694 34.BlumenkrantzD.RobertsK.L.SheltonH.LycettS.BarclayW.S.The short stalk length of highly pathogenic" exact="avian influenza" post="H5N1 virus neuraminidase limits transmission of pandemic H1N1 virus"/>
   <result pre="MiceJ. Virol.2016902142214910.1128/JVI.02553-1526656694 34.BlumenkrantzD.RobertsK.L.SheltonH.LycettS.BarclayW.S.The short stalk length of highly pathogenic avian" exact="influenza" post="H5N1 virus neuraminidase limits transmission of pandemic H1N1 virus"/>
   <result pre="and additional glycosylation of the hemagglutinin influence the virulence of" exact="influenza" post="H5N1 viruses for miceJ. Virol.2009834704470810.1128/JVI.01987-0819225004 36.HaiR.SchmolkeM.Leyva-GradoV.H.ThangavelR.R.MargineI.JaffeE.L.KrammerF.SolórzanoA.García-SastreA.PaleseP.et al.Influenza A(H7N9) virus"/>
   <result pre="Dis.20182474675010.3201/eid2404.17150929553313 38.KageyamaT.FujisakiS.TakashitaE.XuH.YamadaS.UchidaY.NeumannG.SaitoT.KawaokaY.TashiroM.Rapid communication Genetic analysis of novel avian A (H7N9)" exact="influenza" post="viruses isolated from patients in China, February to April"/>
   <result pre="from patients in China, February to April 2013Euro Surveill.2013182045323594575 39.HusainM.Avian" exact="influenza" post="A (H7N9) virus infection in humans: Epidemiology, evolution, and"/>
   <result pre="humans: Epidemiology, evolution, and pathogenesisInfect. Genet. Evol.20142830431210.1016/j.meegid.2014.10.01625446940 40.KatzJ.M.LuX.TumpeyT.M.SmithC.B.ShawM.W.SubbaraoK.Molecular correlates of" exact="influenza" post="A H5N1 virus pathogenesis in miceJ. Virol.200074108071081010.1128/JVI.74.22.10807-10810.200011044127 41.ProkopyevaE.SobolevI.ProkopyevM.ShestopalovA.Adaptation of"/>
   <result pre="influenza A H5N1 virus pathogenesis in miceJ. Virol.200074108071081010.1128/JVI.74.22.10807-10810.200011044127 41.ProkopyevaE.SobolevI.ProkopyevM.ShestopalovA.Adaptation of" exact="influenza" post="A (H1N1) pdm09 virus in experimental mouse modelsInfect. Genet."/>
   <result pre="experimental mouse modelsInfect. Genet. Evol.20163926527110.1016/j.meegid.2016.01.02226829383 42.GovorkovaE.A.RehgJ.E.KraussS.YenH.-L.GuanY.PeirisM.NguyenT.D.HanhT.H.PuthavathanaP.LongH.T.Lethality to ferrets of H5N1" exact="influenza" post="viruses isolated from humans and poultry in 2004J. Virol.2005792191219810.1128/JVI.79.4.2191-2198.200515681421"/>
   <result pre="in 2004J. Virol.2005792191219810.1128/JVI.79.4.2191-2198.200515681421 43.GabrielG.DauberB.WolffT.PlanzO.KlenkH.-D.StechJ.The viral polymerase mediates adaptation of an" exact="avian influenza" post="virus to a mammalian hostProc. Natl. Acad. Sci. USA2005102185901859510.1073/pnas.050741510216339318"/>
   <result pre="2004J. Virol.2005792191219810.1128/JVI.79.4.2191-2198.200515681421 43.GabrielG.DauberB.WolffT.PlanzO.KlenkH.-D.StechJ.The viral polymerase mediates adaptation of an avian" exact="influenza" post="virus to a mammalian hostProc. Natl. Acad. Sci. USA2005102185901859510.1073/pnas.050741510216339318"/>
   <result pre="genes (PA and PB1) associated with high pathogenicity of H5N1" exact="influenza" post="virus in mallard ducksJ. Virol.2007818515852410.1128/JVI.00435-0717553873 45.TaubenbergerJ.K.ReidA.H.LourensR.M.WangR.JinG.FanningT.G.Characterization of the 1918"/>
   <result pre="influenza virus in mallard ducksJ. Virol.2007818515852410.1128/JVI.00435-0717553873 45.TaubenbergerJ.K.ReidA.H.LourensR.M.WangR.JinG.FanningT.G.Characterization of the 1918" exact="influenza" post="virus polymerase genesNature200543788910.1038/nature0423016208372 46.LeungB.W.ChenH.BrownleeG.G.Correlation between polymerase activity and pathogenicity"/>
   <result pre="46.LeungB.W.ChenH.BrownleeG.G.Correlation between polymerase activity and pathogenicity in two duck H5N1" exact="influenza" post="viruses suggests that the polymerase contributes to pathogenicityVirology20104019610610.1016/j.virol.2010.01.03620211480 47.MeiK.LiuG.ChenZ.GaoZ.ZhaoL.JinT.YuX.ChenQ.Deep"/>
   <result pre="NP protein enhance polymerase activities and potential replication of novel" exact="influenza" post="(H7N9) viruses at low temperatureVirol. J.2015127110.1186/s12985-015-0304-625940512 49.WasilenkoJ.L.SarmentoL.Pantin-JackwoodM.J.A single substitution"/>
   <result pre="the NP protein alters the replication and pathogenicity of H5N1" exact="avian influenza" post="viruses in chickensArch. Virol.200915496997910.1007/s00705-009-0399-419475480 50.LycettS.WardM.LewisF.PoonA.PondS.K.BrownA.L.Detection of mammalian virulence determinants"/>
   <result pre="NP protein alters the replication and pathogenicity of H5N1 avian" exact="influenza" post="viruses in chickensArch. Virol.200915496997910.1007/s00705-009-0399-419475480 50.LycettS.WardM.LewisF.PoonA.PondS.K.BrownA.L.Detection of mammalian virulence determinants"/>
   <result pre="chickensArch. Virol.200915496997910.1007/s00705-009-0399-419475480 50.LycettS.WardM.LewisF.PoonA.PondS.K.BrownA.L.Detection of mammalian virulence determinants in highly pathogenic" exact="avian influenza" post="H5N1 viruses: Multivariate analysis of published dataJ. Virol.2009839901991010.1128/JVI.00608-0919625397 51.JiaoP.TianG.LiY.DengG.JiangY.LiuC.LiuW.BuZ.KawaokaY.ChenH.A"/>
   <result pre="Virol.200915496997910.1007/s00705-009-0399-419475480 50.LycettS.WardM.LewisF.PoonA.PondS.K.BrownA.L.Detection of mammalian virulence determinants in highly pathogenic avian" exact="influenza" post="H5N1 viruses: Multivariate analysis of published dataJ. Virol.2009839901991010.1128/JVI.00608-0919625397 51.JiaoP.TianG.LiY.DengG.JiangY.LiuC.LiuW.BuZ.KawaokaY.ChenH.A"/>
   <result pre="substitution in the NS1 protein changes the pathogenicity of H5N1" exact="avian influenza" post="viruses in miceJ. Virol.2008821146115410.1128/JVI.01698-0718032512 52.FanS.DengG.SongJ.TianG.SuoY.JiangY.GuanY.BuZ.KawaokaY.ChenH.Two amino acid residues in"/>
   <result pre="in the NS1 protein changes the pathogenicity of H5N1 avian" exact="influenza" post="viruses in miceJ. Virol.2008821146115410.1128/JVI.01698-0718032512 52.FanS.DengG.SongJ.TianG.SuoY.JiangY.GuanY.BuZ.KawaokaY.ChenH.Two amino acid residues in"/>
   <result pre="matrix protein M1 contribute to the virulence difference of H5N1" exact="avian influenza" post="viruses in miceVirology2009384283210.1016/j.virol.2008.11.04419117585 53.TseL.V.HamiltonA.M.FrilingT.WhittakerG.R.A novel activation mechanism of avian"/>
   <result pre="protein M1 contribute to the virulence difference of H5N1 avian" exact="influenza" post="viruses in miceVirology2009384283210.1016/j.virol.2008.11.04419117585 53.TseL.V.HamiltonA.M.FrilingT.WhittakerG.R.A novel activation mechanism of avian"/>
   <result pre="avian influenza viruses in miceVirology2009384283210.1016/j.virol.2008.11.04419117585 53.TseL.V.HamiltonA.M.FrilingT.WhittakerG.R.A novel activation mechanism of" exact="avian influenza" post="virus H9N2 by furinJ. Virol.2014881673168310.1128/JVI.02648-1324257604 54.El-SheshenyR.KandeilA.BagatoO.MaatouqA.M.MoatasimY.RubrumA.SongM.S.WebbyR.J.AliM.A.KayaliG.Molecular characterization of avian"/>
   <result pre="influenza viruses in miceVirology2009384283210.1016/j.virol.2008.11.04419117585 53.TseL.V.HamiltonA.M.FrilingT.WhittakerG.R.A novel activation mechanism of avian" exact="influenza" post="virus H9N2 by furinJ. Virol.2014881673168310.1128/JVI.02648-1324257604 54.El-SheshenyR.KandeilA.BagatoO.MaatouqA.M.MoatasimY.RubrumA.SongM.S.WebbyR.J.AliM.A.KayaliG.Molecular characterization of avian"/>
   <result pre="avian influenza virus H9N2 by furinJ. Virol.2014881673168310.1128/JVI.02648-1324257604 54.El-SheshenyR.KandeilA.BagatoO.MaatouqA.M.MoatasimY.RubrumA.SongM.S.WebbyR.J.AliM.A.KayaliG.Molecular characterization of" exact="avian influenza" post="H5N1 virus in Egypt and the emergence of a"/>
   <result pre="influenza virus H9N2 by furinJ. Virol.2014881673168310.1128/JVI.02648-1324257604 54.El-SheshenyR.KandeilA.BagatoO.MaatouqA.M.MoatasimY.RubrumA.SongM.S.WebbyR.J.AliM.A.KayaliG.Molecular characterization of avian" exact="influenza" post="H5N1 virus in Egypt and the emergence of a"/>
   <result pre="55.ConnorR.J.KawaokaY.WebsterR.G.PaulsonJ.C.Receptor specificity in human, avian, and equine H2 and H3" exact="influenza" post="virus isolatesVirology1994205172310.1006/viro.1994.16157975212 56.WatanabeT.WatanabeS.MaherE.A.NeumannG.KawaokaY.Pandemic potential of avian influenza A (H7N9)"/>
   <result pre="equine H2 and H3 influenza virus isolatesVirology1994205172310.1006/viro.1994.16157975212 56.WatanabeT.WatanabeS.MaherE.A.NeumannG.KawaokaY.Pandemic potential of" exact="avian influenza" post="A (H7N9) virusesTrends Microbiol.20142262363110.1016/j.tim.2014.08.00825264312 57.HedenströmA.Extreme endurance migration: What is"/>
   <result pre="H2 and H3 influenza virus isolatesVirology1994205172310.1006/viro.1994.16157975212 56.WatanabeT.WatanabeS.MaherE.A.NeumannG.KawaokaY.Pandemic potential of avian" exact="influenza" post="A (H7N9) virusesTrends Microbiol.20142262363110.1016/j.tim.2014.08.00825264312 57.HedenströmA.Extreme endurance migration: What is"/>
   <result pre="is the limit to non-stopflight?PLoS Biol.20104e1000362 58.RameyA.M.PearceJ.M.ElyC.R.GuyL.M.IronsD.B.DerksenD.V.IpH.S.Transmission and reassortment of" exact="avian influenza" post="viruses at the Asian-North American interfaceVirology201040635235910.1016/j.virol.2010.07.03120709346 59.LiY.ShiJ.ZhongG.DengG.TianG.GeJ.ZengX.SongJ.ZhaoD.LiuL.et al.Continued evolution"/>
   <result pre="the limit to non-stopflight?PLoS Biol.20104e1000362 58.RameyA.M.PearceJ.M.ElyC.R.GuyL.M.IronsD.B.DerksenD.V.IpH.S.Transmission and reassortment of avian" exact="influenza" post="viruses at the Asian-North American interfaceVirology201040635235910.1016/j.virol.2010.07.03120709346 59.LiY.ShiJ.ZhongG.DengG.TianG.GeJ.ZengX.SongJ.ZhaoD.LiuL.et al.Continued evolution"/>
   <result pre="at the Asian-North American interfaceVirology201040635235910.1016/j.virol.2010.07.03120709346 59.LiY.ShiJ.ZhongG.DengG.TianG.GeJ.ZengX.SongJ.ZhaoD.LiuL.et al.Continued evolution of H5N1" exact="influenza" post="viruses in wild birds, domestic poultry, and humans in"/>
   <result pre="and humans in China from 2004 to 2009J Virol.2010848389839710.1128/JVI.00413-1020538856 60.PearceJ.M.RameyA.M.FlintP.L.KoehlerA.V.FleskesJ.P.FransonJ.C.HallJ.S.DerksenD.V.IpH.S.Avian" exact="influenza" post="at both ends of a migratory flyway: Characterizing viral"/>
   <result pre="homology of the whole genome of the A/wild duck/Korea/K102/2018 (H2N9)" exact="avian influenza" post="virus (AIV) compared to influenza sequences available in NCBI."/>
   <result pre="of the whole genome of the A/wild duck/Korea/K102/2018 (H2N9) avian" exact="influenza" post="virus (AIV) compared to influenza sequences available in NCBI."/>
   <result pre="the A/wild duck/Korea/K102/2018 (H2N9) avian influenza virus (AIV) compared to" exact="influenza" post="sequences available in NCBI. Gene A/Wild Duck/Korea/K102/2018 (H2N9)(GenBank Accession"/>
   <result pre="sequence in HA receptor-binding sites of human and avian H2" exact="influenza" post="virus isolates. Strains HA Receptor-Binding Residues (H3 Numbering) 138"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6893686\results\search\disease\results.xml">
   <result pre="linked to the growing number of imported cases of dengue," exact="chikungunya" post="or Zika viruses into continental Europe and to the"/>
   <result pre="Aedes Culex Anopheles Culiseta transmission West Nile Usutu dengue Zika" exact="chikungunya" post="1. Introduction Emerging or re-emerging disease outbreaks caused by"/>
   <result pre="the last two decades, arboviruses such as dengue, Zika or" exact="chikungunya" post="achieved incursions in European countries [1,2,3], causing autochthonous human"/>
   <result pre="as the vector species in autochthonous outbreaks of dengue and" exact="chikungunya" post="in France [5]. While the vector competence of invasive"/>
   <result pre="the vector competence for dengue virus (DENV), Zika virus (ZIKV)," exact="chikungunya" post="virus (CHIKV), West Nile virus (WNV) and Usutu virus"/>
   <result pre="in our study area [74]. The first autochthonous cases of" exact="dengue fever" post="were reported in our area of interest (France) in"/>
   <result pre="occurred in southern European countries such as the occurrence of" exact="chikungunya" post="in Italy [73] and dengue in France [5]. Established"/>
   <result pre="new European invader Aedes (Finlaya) koreicus: A potential vector of" exact="chikungunya" post="virusPathog. Glob. Health201811210711410.1080/20477724.2018.146478029737236 10.VeronesiE.PaslaruA.SilaghiC.ToblerK.GlavinicU.TorgersonP.MathisA.Experimental evaluation of infection, dissemination, and"/>
   <result pre="fluctuating temperature regimeParasitol. Res.20181171925193210.1007/s00436-018-5886-729705877 11.SchaffnerF.VazeilleM.KaufmannC.FaillouxA.B.MathisA.Vector competence of Aedes japonicus for" exact="chikungunya" post="and dengue virusesJ. Eur. Mosq. Control Assoc.201129141142 12.BlagroveM.S.SherlockK.ChapmanG.E.ImpoinvilD.E.McCallP.J.MedlockJ.M.LycettG.SolomonT.BaylisM.Evaluation of"/>
   <result pre="a native UK mosquito Ochlerotatus detritus (Aedes detritus) for dengue," exact="chikungunya" post="and West Nile virusesParasit. Vectors2016945210.1186/s13071-016-1739-327527700 13.TalbalaghiA.MoutaillerS.VazeilleM.FaillouxA.B.Are Aedes albopictus or"/>
   <result pre="2019) 35.PrudhommeJ.FontaineA.LacourG.GantierJ.C.DiancourtL.VeloE.BinoS.ReiterP.MercierA.The native European Aedes geniculatus mosquito species can transmit" exact="chikungunya" post="virusEmerg. Microbes Infect.2019896297210.1080/22221751.2019.163448931259662 36.VermeilC.LavillaureixJ.ReebE.Survival and transmission of West Nile"/>
   <result pre="japonicus (Diptera: Culicidae) from Germany have vector competence for Japan" exact="encephalitis" post="virus but are refractory to infection with West Nile"/>
   <result pre="Austria to GermanyTransbound. Emerg. Dis.2019661033103610.1111/tbed.1307930462884 40.HubalekZ.HalouzkaJ.West nile fever-a reemerging mosquito-borne" exact="viral disease" post="in EuropeEmerg. Infect. Dis.1999564365010.3201/eid0505.99050510511520 41.BalenghienT.VazeilleM.GrandadamM.SchaffnerF.ZellerH.ReiterP.SabatierP.FouqueF.BicoutD.J.Vector competence of some French"/>
   <result pre="albopictus and Aedes aegypti in the emergence of dengue and" exact="chikungunya" post="in Central AfricaVector Borne Zoonotic Dis.20101025926610.1089/vbz.2009.000519725769 45.Lourenco-de-OliveiraR.MoussonL.VazeilleM.FuchsS.YebakimaA.GustaveJ.GirodR.DusfourI.Leparc-GoffartI.VanlandinghamD.L.et al.Chikungunya virus"/>
   <result pre="67.AmraouiF.FaillouxA.B.Chikungunya: An unexpected emergence in EuropeCurr. Opin. Virol.20162114615010.1016/j.coviro.2016.09.01427771517 68.VazeilleM.MoutaillerS.CoudrierD.RousseauxC.KhunH.HuerreM.ThiriaJ.DehecqJ.S.FontenilleD.SchuffeneckerI.et al.Two" exact="chikungunya" post="isolates from the outbreak of la Réunion (Indian ocean)"/>
   <result pre="Prevention and ControlStockholm, Sweden2018 72.CalbaC.Guerbois-GallaM.FrankeF.JeanninC.Auzet-CaillaudM.GrardG.PigaglioL.DecoppetA.WeicherdingJ.SavaillM.C.et al.Preliminary report of an autochthonous" exact="chikungunya" post="outbreak in France, july to september 2017Eurosurveillance20172251010.2807/1560-7917.ES.2017.22.39.17-00647 73.VenturiG.Di LucaM.FortunaC.RemoliM.E.RiccardoF.SeveriniF.TomaL.Del"/>
   <result pre="july to september 2017Eurosurveillance20172251010.2807/1560-7917.ES.2017.22.39.17-00647 73.VenturiG.Di LucaM.FortunaC.RemoliM.E.RiccardoF.SeveriniF.TomaL.Del MansoM.BenedettiE.CaporaliM.G.et al.Detection of a" exact="chikungunya" post="outbreak in central Italy, august to september 2017Eurosurveillance201722170064610.2807/1560-7917.ES.2017.22.39.17-00646 74.collab:"/>
   <result pre="European mosquitoes for West Nile virusEmerg. Microbes Infect.20176e9610.1038/emi.2017.8229116220 105.DialloM.ThonnonJ.Traore-LamizanaM.FontenilleD.Vectors of" exact="chikungunya" post="virus in Senegal: Current data and transmission cyclesAm. J."/>
   <result pre="of West Nile virus and a potential vector of human" exact="malaria" post="in BelgiumJ. Med. Entomol.20114892492810.1603/ME1023521845955 113.RabelP.O.PlanitzerC.B.FarcetM.R.OrlingerK.K.IlkR.BarrettP.N.KreilT.R.Increasing West Nile virus antibody"/>
   <result pre="Europe; W: elsewhere in the world. Since no capture of" exact="chikungunya" post="virus (CHIKV), dengue virus (DENV) and Zika virus (ZIKV)"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6893747\results\search\disease\results.xml">
   <result pre="(CC BY) license (http://creativecommons.org/licenses/by/4.0/). Abstract Victoria and Yamagata lineages of" exact="influenza" post="B viruses are globally circulating in seasonal epidemics. Madin–Darby"/>
   <result pre="for viral isolation and vaccine manufacture. Nevertheless, the interplay between" exact="influenza" post="B viruses and host microRNAs has not been investigated"/>
   <result pre="at high-throughput analysis of canine microRNA profile upon infection of" exact="influenza" post="B viruses. Briefly, MDCK cells were infected with Victoria"/>
   <result pre="of cfa-miR-197. This study provides canine microRNA responses to seasonal" exact="influenza" post="B viruses, suggesting that virus-mediated microRNAs might play crucial"/>
   <result pre="microRNAs might play crucial roles in host gene regulation. microRNAs" exact="influenza" post="B viruses Yamagata Victoria MDCK next-generation sequencing Canis lupus"/>
   <result pre="next-generation sequencing Canis lupus familiaris 1. Introduction Seasonal influenza—a respiratory" exact="infectious disease" post="with a high transmissibility rate and worldwide distribution—is caused"/>
   <result pre="with a high transmissibility rate and worldwide distribution—is caused by" exact="influenza" post="A and B viruses [1]. Influenza A viruses have"/>
   <result pre="genetic variability and severe pandemics [2]. On the other hand," exact="influenza" post="B viruses were divided into two genetically and antigenically"/>
   <result pre="and Yamagata, in the 1980s [3]. However, molecular characterization of" exact="influenza" post="B viruses has been little documented because a smaller"/>
   <result pre="viruses has been little documented because a smaller impact of" exact="influenza" post="B virus infection on public health was believed in"/>
   <result pre="[4]. Recently, epidemiological investigations have revealed a massive effect of" exact="influenza" post="B on the mortality rate and the severity [5,6]."/>
   <result pre="[5,6]. This evidence has highlighted the need to study the" exact="influenza" post="B infections in order to understand the pathogenesis. The"/>
   <result pre="of viruses is an essential process needed to further study" exact="influenza" post="viruses, e.g., molecular characterization, in vitro and in vivo"/>
   <result pre="kidney (MDCK) cell line is utilized as permissive cells for" exact="influenza" post="viruses [7,8]. In addition to viral isolation, MDCK cell"/>
   <result pre="viral isolation, MDCK cell line has also been used for" exact="influenza" post="vaccine manufacturing [9,10]. Nevertheless, mechanisms of influenza infections into"/>
   <result pre="been used for influenza vaccine manufacturing [9,10]. Nevertheless, mechanisms of" exact="influenza" post="infections into permissive MDCK cells are little studied. More"/>
   <result pre="is to investigate microRNA profile of permissive MDCK cells upon" exact="influenza" post="B virus infections. 2. Materials and Methods 2.1. Cell"/>
   <result pre="the media were removed. The cells were infected with mock" exact="influenza" post="B virus Victoria lineage (B/Thailand/CU-B5522/2011), or Yamagata lineage (B/Massachusetts/2/2012)"/>
   <result pre="B Viruses To identify canine microRNAs which were associated with" exact="influenza" post="B virus infection, MDCK cells infected with Victoria lineage,"/>
   <result pre="of differentially expressed microRNAs with 2-fold or greater change in" exact="influenza" post="B viruses-versus mock-infected cells. As shown in Figure 1A,"/>
   <result pre="comparative investigation of microRNAs in response to both lineages of" exact="influenza" post="B viruses demonstrated that 38 and 13 unique microRNAs"/>
   <result pre="the Predicted Target Genes The analysis of microRNAs’ response to" exact="influenza" post="B virus infection showed that five microRNAs were commonly"/>
   <result pre="and 24 hpi in order to determine viral titer during" exact="influenza" post="B virus infection (Figure 2B). The result showed that"/>
   <result pre="cells were transfected with pSilencer-miR-197 and cfa-miR-197 inhibitor, followed by" exact="influenza" post="B virus infection for multiple time points (Figure 4C,D)."/>
   <result pre="indicated that KPNA6 might be directly regulated by cfa-miR-197, affecting" exact="influenza" post="B virus replication. 4. Discussion Nowadays MDCK cells are"/>
   <result pre="Discussion Nowadays MDCK cells are known to be permissive to" exact="influenza" post="virus infection and replication. As a result of that,"/>
   <result pre="MDCK cells are widely used for identification and diagnosis of" exact="influenza" post="viruses from clinical specimens. In addition, this permissive cell"/>
   <result pre="addition, this permissive cell line could be utilized to produce" exact="influenza" post="vaccines. Moreover, in vitro study is a cost-effective and"/>
   <result pre="microRNA profile of permissive MDCK cells upon infection of seasonal" exact="influenza" post="B viruses was investigated. Recently, it has been evident"/>
   <result pre="For instance, several microRNAs impair the production of interferons during" exact="hepatitis" post="C virus infection [23,24,25]. In addition, apoptosis is regulated"/>
   <result pre="production against enterovirus 71 [28], dengue virus [29], and Japanese" exact="encephalitis" post="virus [30]. Interestingly, our result demonstrated that cfa-miR-146b were"/>
   <result pre="our result demonstrated that cfa-miR-146b were upregulated during infection of" exact="influenza" post="B virus (Yamagata lineage). According to the microRNA database"/>
   <result pre="Nevertheless, the function of cfa-miR-146b in the immune response to" exact="influenza" post="B virus might be further explored. In the previous"/>
   <result pre="explored. In the previous years, microRNAs’ response to infection of" exact="influenza" post="A viruses has been extensively studied in human cells."/>
   <result pre="suggested that some microRNAs modulated pro-apoptotic and anti-apoptotic effects during" exact="influenza" post="A viruses infected in A549 cell line [31,32]. Furthermore,"/>
   <result pre="lung epithelial cells and dendritic cells were controlled by several" exact="influenza" post="A virus-mediated microRNAs [33,34,35]. In addition to human cells,"/>
   <result pre="and in vitro microRNA expression in dogs infected with canine" exact="influenza" post="A viruses [36,37]. Nonetheless, canine microRNAs’ response to seasonal"/>
   <result pre="A viruses [36,37]. Nonetheless, canine microRNAs’ response to seasonal human" exact="influenza" post="virus infection has not been reported yet. Intriguingly, this"/>
   <result pre="that cfa-miR-29c were increased when the cells were infected with" exact="influenza" post="B virus (Victoria lineage). Similarly, the infection of seasonal"/>
   <result pre="influenza B virus (Victoria lineage). Similarly, the infection of seasonal" exact="influenza" post="A (H1N1) virus could induce the expression of hsa-miR-29c,"/>
   <result pre="[38]. However, the effect of cfa-miR-29c on innate immunity against" exact="influenza" post="B virus infection should be further investigated. On the"/>
   <result pre="further investigated. On the other hand, microRNAs’ profile upon seasonal" exact="influenza" post="B virus infection has been little studied. Our result"/>
   <result pre="upregulation of cfa-miR-183 and downregulation of cfa-miR-486 were expressed in" exact="influenza" post="B (Victoria lineage) virus-infected MDCK cells. This finding is"/>
   <result pre="tripartite motif-containing 22 (TRIM22), inhibiting NF-κB signaling, resulted in enhanced" exact="hepatitis" post="C virus replication [22]. In addition, microRNA-197 and microRNA-215"/>
   <result pre="it might be feasible that both microRNAs are involved in" exact="influenza" post="virus-mediated apoptosis. In this study, the gene targets of"/>
   <result pre="In addition, the role of KPNA6 has been studied in" exact="influenza" post="A viruses, which are more closely related to seasonal"/>
   <result pre="influenza A viruses, which are more closely related to seasonal" exact="influenza" post="B viruses. Recent studies indicated that KPNA6 interacts with"/>
   <result pre="B viruses. Recent studies indicated that KPNA6 interacts with some" exact="influenza" post="A viral proteins, affecting viral replication and pathogenicity. Viral"/>
   <result pre="basic 2 (PB2) is considered a major virulent determinant of" exact="influenza" post="A viruses, which involves in host adaptation [46]. In"/>
   <result pre="play a key part in the replication and transcription of" exact="influenza" post="viruses. Therefore, KPNA6 is also essential for propagation of"/>
   <result pre="influenza viruses. Therefore, KPNA6 is also essential for propagation of" exact="influenza" post="A viruses [49,50,51,52]. Furthermore, viral nucleoprotein (NP) is another"/>
   <result pre="another important multifunctional protein interacting with KPNA6, leading to enhancing" exact="influenza" post="A virus replication [46,53]. A recent study has shown"/>
   <result pre="study has shown that a long N-terminal tail of the" exact="influenza" post="B virus NP bound to human KPNA6 [54]. Although"/>
   <result pre="NP bound to human KPNA6 [54]. Although the NP of" exact="influenza" post="B viruses could possibly be imported into canine nucleus"/>
   <result pre="into canine nucleus by KPNA6, the interaction between NP of" exact="influenza" post="B virus and canine KPNA6 should be experimentally investigated."/>
   <result pre="pathway, affecting IFNα antiviral response, oxidative stress, and autophagy during" exact="hepatitis" post="C virus infection [56,57]. In conclusion, this investigation provides"/>
   <result pre="permissive MDCK cell line infected with two different lineages of" exact="influenza" post="B viruses, which are responsible for seasonal epidemics. Five"/>
   <result pre="emerging virus diseaseIntervirology199335162510.1159/0001502928407243 3.RotaP.A.WallisT.R.HarmonM.W.RotaJ.S.KendalA.P.NeromeK.Cocirculation of two distinct evolutionary lineages of" exact="influenza" post="type B virus since 1983Virology1990175596810.1016/0042-6822(90)90186-U2309452 4.JacksonD.ElderfieldR.A.BarclayW.S.Molecular studies of influenza"/>
   <result pre="of influenza type B virus since 1983Virology1990175596810.1016/0042-6822(90)90186-U2309452 4.JacksonD.ElderfieldR.A.BarclayW.S.Molecular studies of" exact="influenza" post="B virus in the reverse genetics eraJ. Gen. Virol.20119211710.1099/vir.0.026187-020926635"/>
   <result pre="genetics eraJ. Gen. Virol.20119211710.1099/vir.0.026187-020926635 5.CainiS.HuangQ.S.CiblakM.A.KusznierzG.OwenR.WangchukS.HenriquesC.M.NjouomR.FasceR.A.YuH.et al.Epidemiological and virological characteristics of" exact="influenza" post="B: Results of the global influenza B studyInfluenza Other"/>
   <result pre="and virological characteristics of influenza B: Results of the global" exact="influenza" post="B studyInfluenza Other Respir. Viruses20159313210.1111/irv.1231926256293 6.LapinsckiB.PereiraL.A.NogueiraM.B.VidalL.R.RiedigerI.DeburM.C.PresibellaM.RaboniS.M.Molecular epidemiology of influenza"/>
   <result pre="global influenza B studyInfluenza Other Respir. Viruses20159313210.1111/irv.1231926256293 6.LapinsckiB.PereiraL.A.NogueiraM.B.VidalL.R.RiedigerI.DeburM.C.PresibellaM.RaboniS.M.Molecular epidemiology of" exact="influenza" post="B virus and implications in immunization strategy, Southern BrazilVaccine20183610711310.1016/j.vaccine.2017.11.03329174679"/>
   <result pre="kidney (Vero) cells provide an alternative host cell system for" exact="influenza" post="A and B virusesJ. Virol.199670551955248764064 9.AggarwalK.JingF.MarangaL.LiuJ.Bioprocess optimization for cell"/>
   <result pre="and B virusesJ. Virol.199670551955248764064 9.AggarwalK.JingF.MarangaL.LiuJ.Bioprocess optimization for cell culture based" exact="influenza" post="vaccine productionVaccine2011293320332810.1016/j.vaccine.2011.01.08121335031 10.UgiyadiM.TanM.I.Giri-RachmanE.A.ZuhairiF.R.SumarsonoS.H.The expression of essential components for human"/>
   <result pre="influenza vaccine productionVaccine2011293320332810.1016/j.vaccine.2011.01.08121335031 10.UgiyadiM.TanM.I.Giri-RachmanE.A.ZuhairiF.R.SumarsonoS.H.The expression of essential components for human" exact="influenza" post="virus internalisation in Vero and MDCK cellsCytotechnology20146651552310.1007/s10616-013-9602-223912187 11.GirardiE.LopezP.PfefferS.On the"/>
   <result pre="sequencing dataNucl. Acids Res.20144210.1093/nar/gkt118124275495 15.MakkochJ.PoomipakW.SaengchoowongS.KhongnomnanK.PraianantathavornK.JinatoT.PoovorawanY.PayungpornS.Human microRNAs profiling in response to" exact="influenza" post="A viruses (subtypes pH1N1, H3N2, and H5N1)Exp. Biol. Med.201624140942010.1177/1535370215611764"/>
   <result pre="targeting TRAF6J. Infect.20136732934110.1016/j.jinf.2013.05.00323685241 30.SharmaN.VermaR.KumawatK.L.BasuA.SinghS.K.MiR-146a suppresses cellular immune response during Japanese" exact="encephalitis" post="virus JaOArS982 strain infection in human microglial cellsJ. Neuroinflamm.2015123010.1186/s12974-015-0249-0"/>
   <result pre="lung epithelial cells is modulated by miRNA-548an on exposure to" exact="influenza" post="A virusVirology2013447849410.1016/j.virol.2013.08.03124210102 32.OthumpangatS.NotiJ.D.BeezholdD.H.Lung epithelial cells resist influenza A infection"/>
   <result pre="on exposure to influenza A virusVirology2013447849410.1016/j.virol.2013.08.03124210102 32.OthumpangatS.NotiJ.D.BeezholdD.H.Lung epithelial cells resist" exact="influenza" post="A infection by inducing the expression of cytochrome c"/>
   <result pre="modulated by miRNA 4276Virology201410.1016/j.virol.2014.08.00725203353 33.IngleH.KumarS.RautA.A.MishraA.KulkarniD.D.KameyamaT.TakaokaA.AkiraS.KumarH.The microRNA miR-485 targets host and" exact="influenza" post="virus transcripts to regulate antiviral immunity and restrict viral"/>
   <result pre="viral replicationSci. Signal20158ra12610.1126/scisignal.aab318326645583 34.RosenbergerC.M.PodyminoginR.L.NavarroG.ZhaoG.W.AskovichP.S.WeissM.J.AderemA.MiR-451 regulates dendritic cell cytokine responses to" exact="influenza" post="infectionJ. Immunol.20121895965597510.4049/jimmunol.120143723169590 35.DongC.SunX.GuanZ.ZhangM.DuanM.Modulation of influenza A virus replication by"/>
   <result pre="dendritic cell cytokine responses to influenza infectionJ. Immunol.20121895965597510.4049/jimmunol.120143723169590 35.DongC.SunX.GuanZ.ZhangM.DuanM.Modulation of" exact="influenza" post="A virus replication by microRNA-9 through targeting MCPIP1J. Med."/>
   <result pre="in dog lungs infected with the H3N2 and H5N1 canine" exact="influenza" post="virusesMicrob. Pathog.201812125226110.1016/j.micpath.2018.05.01529772263 37.ZhouP.TuL.LinX.HaoX.ZhengQ.ZengW.ZhangX.ZhengY.WangL.LiS.Cfa-miR-143 promotes apoptosis via the p53 pathway"/>
   <result pre="Pathog.201812125226110.1016/j.micpath.2018.05.01529772263 37.ZhouP.TuL.LinX.HaoX.ZhengQ.ZengW.ZhangX.ZhengY.WangL.LiS.Cfa-miR-143 promotes apoptosis via the p53 pathway in canine" exact="influenza" post="virus H3N2-infected cellsViruses2017910.3390/v9120360 38.ZhangX.DongC.SunX.LiZ.ZhangM.GuanZ.DuanM.Induction of the cellular miR-29c by"/>
   <result pre="influenza virus H3N2-infected cellsViruses2017910.3390/v9120360 38.ZhangX.DongC.SunX.LiZ.ZhangM.GuanZ.DuanM.Induction of the cellular miR-29c by" exact="influenza" post="virus inhibits the innate immune response through protection of"/>
   <result pre="A20 mRNABiochem. Biophys. Res. Commun.201445075576110.1016/j.bbrc.2014.06.05924953694 39.KhongnomnanK.PoomipakW.PraianantathavornK.SaengchoowongS.PisitkunT.PoovorawanY.PayungpornS.Human MicroRNAs expression profiles in" exact="influenza" post="B virus-infected cells based on Illumina MiSeq platformMicrorna2018720421410.2174/221153660766618051511104829766833 40.ChenY.YangC.MiR1973pinduced"/>
   <result pre="Med. Rep.2018173921392710.3892/mmr.2017.833329286108 41.GeG.Q.ZhangW.NiuL.G.YanY.RenY.ZouY.L.MiR-215 functions as a tumor suppressor in epithelial" exact="ovarian cancer" post="through regulation of the X-chromosome-linked inhibitor of apoptosisOncol. Rep.2016351816182210.3892/or.2015.448226676658"/>
   <result pre="Rep.2018173921392710.3892/mmr.2017.833329286108 41.GeG.Q.ZhangW.NiuL.G.YanY.RenY.ZouY.L.MiR-215 functions as a tumor suppressor in epithelial ovarian" exact="cancer" post="through regulation of the X-chromosome-linked inhibitor of apoptosisOncol. Rep.2016351816182210.3892/or.2015.448226676658"/>
   <result pre="stabilityJ. Virol.20179110.1128/JVI.01715-1627974555 46.Resa-InfanteP.GabrielG.The nuclear import machinery is a determinant of" exact="influenza" post="virus host adaptationBioessays201335232710.1002/bies.20120013823239226 47.PumroyR.A.KeS.HartD.J.ZachariaeU.CingolaniG.Molecular determinants for nuclear import of"/>
   <result pre="influenza virus host adaptationBioessays201335232710.1002/bies.20120013823239226 47.PumroyR.A.KeS.HartD.J.ZachariaeU.CingolaniG.Molecular determinants for nuclear import of" exact="influenza" post="A PB2 by importin alpha isoforms 3 and 7Structure20152337438410.1016/j.str.2014.11.01525599645"/>
   <result pre="with importin alpha1 is a determinant of host range of" exact="influenza" post="A virusPLoS Pathog.20084e1110.1371/journal.ppat.004001118248089 49.Resa-InfanteP.ThiemeR.ErnstT.ArckP.C.IttrichH.ReimerR.GabrielG.Importin-alpha7 is required for enhanced influenza"/>
   <result pre="of influenza A virusPLoS Pathog.20084e1110.1371/journal.ppat.004001118248089 49.Resa-InfanteP.ThiemeR.ErnstT.ArckP.C.IttrichH.ReimerR.GabrielG.Importin-alpha7 is required for enhanced" exact="influenza" post="A virus replication in the alveolar epithelium and severe"/>
   <result pre="and severe lung damage in miceJ. Virol.2014888166817910.1128/JVI.00270-1424829333 50.BertramS.ThieleS.DreierC.Resa-InfanteP.PreussA.van RielD.MokC.K.P.SchwalmF.PeirisJ.S.M.KlenkH.D.et al.H7N9" exact="influenza" post="a virus exhibits importin-alpha7-mediated replication in the mammalian respiratory"/>
   <result pre="in the mammalian respiratory tractAm. J. Pathol.201718783184010.1016/j.ajpath.2016.12.01728189564 51.HudjetzB.GabrielG.Human-like PB2 627K" exact="influenza" post="virus polymerase activity is regulated by importin-alpha1 and -alpha7PLoS"/>
   <result pre="-alpha7PLoS Pathog.20128e100248810.1371/journal.ppat.100248822275867 52.Resa-InfanteP.PatersonD.BonetJ.OtteA.OlivaB.FodorE.GabrielG.Targeting importin-alpha7 as a therapeutic approach against pandemic" exact="influenza" post="virusesJ. Virol.2015899010902010.1128/JVI.00583-1526085167 53.WuW.SankhalaR.S.FlorioT.J.ZhouL.NguyenN.L.T.LokareddyR.K.CingolaniG.PanteN.Synergy of two low-affinity NLSs determines the"/>
   <result pre="53.WuW.SankhalaR.S.FlorioT.J.ZhouL.NguyenN.L.T.LokareddyR.K.CingolaniG.PanteN.Synergy of two low-affinity NLSs determines the high avidity of" exact="influenza" post="A virus nucleoprotein NP for human importin alpha isoformsSci."/>
   <result pre="importin alpha isoformsSci. Rep.201771138110.1038/s41598-017-11018-128900157 54.LabaronneA.MillesS.DonchetA.JensenM.R.BlackledgeM.BourhisJ.M.RuigrokR.W.H.CrepinT.Structural analysis of the complex between" exact="influenza" post="B nucleoprotein and human importin-alphaSci. Rep.2017710.1038/s41598-017-17458-z 55.SunZ.WuT.ZhaoF.LauA.BirchC.M.ZhangD.D.KPNA6 (Importin {alpha}7)-mediated"/>
   <result pre="Figure 1 The miRNA expression profiles in each lineage of" exact="influenza" post="B virus infection. Madin–Darby canine kidney (MDCK) cells were"/>
   <result pre="by RT-qPCR. Although both cfa-miR-197 and cfa-miR-215 were upregulated upon" exact="influenza" post="B virus infection, the expressions of both microRNAs found"/>
   <result pre="were used as a calibrator sample. (B) Viral replication of" exact="influenza" post="B viruses, Victoria and Yamagata lineages. Viral titers were"/>
   <result pre="The number of predicted microRNA target genes in response to" exact="influenza" post="B viruses. Biological Processes 1 The Number and the"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6893760\results\search\disease\results.xml">
   <result pre="unidentified viruses in 1956 in the USA from children with" exact="diarrhea" post="[16]. They were initially classified as EVs, echovirus 22"/>
   <result pre="associated with acute gastroenteritis, upper respiratory tract symptoms, fever, and" exact="rash" post="in children between 6 months to 5 years [14,15,45]."/>
   <result pre="system (CNS) syndromes such as acute flaccid paralysis, meningitis, and" exact="encephalitis" post="have been reported for PeV-A1 and A3 [2,4,25,101]. However,"/>
   <result pre="long-term outcomes [106,107,108]. Epidemics of myalgia and a case of" exact="myocarditis" post="in PeV-A3 infected adults have been reported but overall,"/>
   <result pre="than 5 years of age, presenting with symptoms of acute" exact="gastroenteritis" post="[38,45,47,113,114]. Furthermore, some published reports focus on children with"/>
   <result pre="a PeV-A1 infection in a child presenting with severe dilated" exact="cardiomyopathy" post="[127]. In animal studies, PeV-A1 VP1 C terminus has"/>
   <result pre="cytokine storm is well established for respiratory pathogens such as" exact="influenza" post="virus and human coronavirus [135,136]. Neonatal sepsis, also known"/>
   <result pre="of infecting neuronal cell lines and PeV-A3 isolates replicated human" exact="neuroblastoma" post="cell lines more efficiently than PeV-A1, suggesting a neural"/>
   <result pre="parechoviruses as an important viral cause of sepsislike illness and" exact="meningitis" post="in young childrenClin. Infect. Dis.20084735836310.1086/58975218558876 3.WildenbeestJ.G.HarvalaH.PajkrtD.WolthersK.C.The need for treatment"/>
   <result pre="virus and salivirus in fecal samples from hospitalized children with" exact="gastroenteritis" post="in Hong KongVirol. J.20141118210.1186/1743-422X-11-18225326707 46.BubbaL.MartinelliM.PellegrinelliL.PrimacheV.TanziE.ParianiE.BindaS.A 4-year Study on Epidemiologic"/>
   <result pre="2008 and 2009J. Med. Virol.2011831428143410.1002/jmv.2211421618555 48.AlamM.M.KhurshidA.ShaukatS.RanaM.S.SharifS.AngezM.NisarN.AamirU.B.NaeemM.ZaidiS.S.Viral etiologies of acute dehydrating" exact="gastroenteritis" post="in pakistani children: Confounding role of parechovirusesViruses2015737839310.3390/v701037825609308 49.PatilP.R.GanorkarN.N.GopalkrishnaV.Epidemiology and"/>
   <result pre="diversity of human parechoviruses circulating among children hospitalised with acute" exact="gastroenteritis" post="in Pune, Western India: A 5-years studyEpidemiol. Infect.2018146111810.1017/S095026881700262X29173223 50.AlamM.M.KhurshidA.ShaukatS.RanaM.S.SharifS.AngezM.NisarN.NaeemM.Zahoor"/>
   <result pre="1 IsolatesPLoS ONE201611e014716810.1371/journal.pone.014716826785353 89.WardT.PowellR.M.PipkinP.A.EvansD.J.MinorP.D.AlmondJ.W.Role for beta2-microglobulin in echovirus infection of" exact="rhabdomyosarcoma" post="cellsJ. Virol.199872536053659620989 90.TriantafilouM.TriantafilouK.WilsonK.M.TakadaY.FernandezN.StanwayG.Involvement of beta2-microglobulin and integrin alphavbeta3 molecules"/>
   <result pre="in 2008Jpn. J. Infect. Dis.20096224424519468194 101.Verboon-MaciolekM.A.GroenendaalF.HahnC.D.HellmannJ.van LoonA.M.BoivinG.de VriesL.S.Human parechovirus causes" exact="encephalitis" post="with white matter injury in neonatesAnn. Neurol.20086426627310.1002/ana.2144518825694 102.BrittonP.N.KhandakerG.KhatamiA.TeutschS.FrancisS.McMullanB.J.JonesC.A.High prevalence"/>
   <result pre="in Neonates and InfantsPediatr. Infect. Dis. J.201938e36e3810.1097/INF.000000000000214530001232 107.KadambariS.BraccioS.RibeiroS.AllenD.J.PebodyR.BrownD.CunneyR.SharlandM.LadhaniS.Enterovirus and parechovirus" exact="meningitis" post="in infants younger than 90 days old in the"/>
   <result pre="studyArch. Dis. Child.201910455255710.1136/archdischild-2018-31564330530486 108.RennaS.BergaminoL.PirloD.RossiA.FurioneM.PirallaA.MascarettiM.CristinaE.MarazziM.G.Di PietroP.A case of neonatal human parechovirus" exact="encephalitis" post="with a favourable outcomeBrain Dev.201436707310.1016/j.braindev.2012.12.00623347531 109.MizutaK.KurodaM.KurimuraM.YahataY.SekizukaT.AokiY.IkedaT.AbikoC.NodaM.KimuraH.et al.Epidemic myalgia in"/>
   <result pre="J. Infect. Dis.201759222410.1016/j.ijid.2017.03.01828347852 113.HanT.H.KimC.H.ParkS.H.ChungJ.Y.HwangE.S.Detection of human parechoviruses in children with" exact="gastroenteritis" post="in South KoreaArch. Virol.20111561471147510.1007/s00705-011-0995-y21479947 114.PhamN.T.TakanashiS.TranD.N.TrinhQ.D.AbeysekeraC.AbeygunawardeneA.KhamrinP.OkitsuS.ShimizuH.MizuguchiM.et al.Human parechovirus infection in"/>
   <result pre="Virol.20111561471147510.1007/s00705-011-0995-y21479947 114.PhamN.T.TakanashiS.TranD.N.TrinhQ.D.AbeysekeraC.AbeygunawardeneA.KhamrinP.OkitsuS.ShimizuH.MizuguchiM.et al.Human parechovirus infection in children hospitalized with acute" exact="gastroenteritis" post="in Sri LankaJ. Clin. Microbiol.20114936436610.1128/JCM.02151-1021048003 115.VollbachS.MullerA.DrexlerJ.F.SimonA.DrostenC.Eis-HubingerA.M.PanningM.Prevalence, type and concentration"/>
   <result pre="period: A retrospective studyVirol. J.20151219910.1186/s12985-015-0427-926607060 116.PellegrinelliL.BubbaL.GalliC.AnselmiG.PrimacheV.BindaS.ParianiE.Epidemiology and molecular characterization of" exact="influenza" post="viruses, human parechoviruses and enteroviruses in children up to"/>
   <result pre="proteinsJ. Clin. Microbiol.2003412294229910.1128/JCM.41.6.2294-2299.200312791839 126.Van de VenA.A.DoumaJ.W.RademakerC.van LoonA.M.WensingA.M.BoelensJ.J.SandersE.A.van MontfransJ.M.Pleconaril-resistant chronic parechovirus-associated" exact="enteropathy" post="in agammaglobulinaemiaAntivir. Ther.20111661161410.3851/IMP179221685550 127.WildenbeestJ.G.WolthersK.C.StraverB.PajkrtD.Successful IVIG treatment of human parechovirus-associated"/>
   <result pre="in agammaglobulinaemiaAntivir. Ther.20111661161410.3851/IMP179221685550 127.WildenbeestJ.G.WolthersK.C.StraverB.PajkrtD.Successful IVIG treatment of human parechovirus-associated dilated" exact="cardiomyopathy" post="in an infantPediatrics2013132e243e24710.1542/peds.2012-113623776125 128.ShakeelS.WesterhuisB.M.OraA.KoenG.BakkerA.Q.ClaassenY.WagnerK.BeaumontT.WolthersK.C.ButcherS.J.Structural Basis of Human Parechovirus Neutralization"/>
   <result pre="early recognition and therapyActa Paediatr.20029163263510.1111/j.1651-2227.2002.tb03292.x12162592 133.WangS.M.LeiH.Y.HuangK.J.WuJ.M.WangJ.R.YuC.K.SuI.J.LiuC.C.Pathogenesis of enterovirus 71 brainstem" exact="encephalitis" post="in pediatric patients: Roles of cytokines and cellular immune"/>
   <result pre="central nervous systemClin. Infect. Dis.20033626927410.1086/34590512539066 135.GuoX.J.ThomasP.G.New fronts emerge in the" exact="influenza" post="cytokine stormSemin. Immunopathol.20173954155010.1007/s00281-017-0636-y28555383 136.ChannappanavarR.PerlmanS.Pathogenic human coronavirus infections: Causes and"/>
   <result pre="enterovirus 71 brain stem encephalitisClin. Dev. Immunol.2012201287624110.1155/2012/87624122956971 141.HarvalaH.GriffithsM.SolomonT.SimmondsP.Distinct systemic and" exact="central nervous system disease" post="patterns in enterovirus and parechovirus infected childrenJ. Infect.201469697410.1016/j.jinf.2014.02.01724662038 142.Verboon-MaciolekM.A.KredietT.G.GerardsL.J.de"/>
   <result pre="71 brain stem encephalitisClin. Dev. Immunol.2012201287624110.1155/2012/87624122956971 141.HarvalaH.GriffithsM.SolomonT.SimmondsP.Distinct systemic and central" exact="nervous system disease" post="patterns in enterovirus and parechovirus infected childrenJ. Infect.201469697410.1016/j.jinf.2014.02.01724662038 142.Verboon-MaciolekM.A.KredietT.G.GerardsL.J.de"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6893775\results\search\disease\results.xml">
   <result pre="Kreidl et al. discussed methods for identifying susceptible sub-populations during" exact="measles" post="vaccination campaigns [10], which may provide a useful tool"/>
   <result pre="multi-host virusViruses20191158210.3390/v1107058231247987 6.Muñoz-AlíaM.A.RussellS.J.Probing morbillivirus antisera neutralization using functional chimerism between" exact="measles" post="virus and canine distemper virus envelope glycoproteinsViruses20191168810.3390/v1108068831357579 7.SiegM.BuschJ.EschkeM.BöttcherD.HeenemannK.VahlenkampA.ReinertA.SeegerJ.HeilmannR.SchefflerK.et al.A"/>
   <result pre="the lung, kidney, brain and peripheral bloodViruses20191114610.3390/v1102014630744110 8.TiwarekarV.FehrholzM.Schneider-SchauliesJ.KDELR2 competes with" exact="measles" post="virus envelope proteins for cellular chaperones reducing their chaperone-mediated"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6893791\results\search\disease\results.xml">
   <result pre="diseases. Recent decline in vaccination coverage resulted in re-emergence of" exact="measles" post="outbreaks. Measles virus (MeV) infection causes an acute systemic"/>
   <result pre="disease. Early following MeV infection some patients develop acute post-infectious" exact="measles" post="encephalitis (APME), which is not associated with direct infection"/>
   <result pre="Early following MeV infection some patients develop acute post-infectious measles" exact="encephalitis" post="(APME), which is not associated with direct infection of"/>
   <result pre="and cause sub-acute sclerosing panencephalitis (SSPE) in immunocompetent people or" exact="measles" post="inclusion-body encephalitis (MIBE) in immunocompromised patients. To date, cellular"/>
   <result pre="sub-acute sclerosing panencephalitis (SSPE) in immunocompetent people or measles inclusion-body" exact="encephalitis" post="(MIBE) in immunocompromised patients. To date, cellular and molecular"/>
   <result pre="advanced therapeutic approaches potentially applicable to treat MeV CNS infection." exact="measles" post="virus central nervous system tropism treatments 1. Measles Virus"/>
   <result pre="Epidemiology Measles virus (MeV) is the etiologic agent responsible for" exact="measles" post="disease. Humans are the only known reservoir for MeV."/>
   <result pre="MeV. Despite the availability of a very efficient vaccine [1]," exact="measles" post="remains one of the most contagious diseases with a"/>
   <result pre="After decades of emergences mainly restricted to the poorest countries," exact="measles" post="has made a strong comeback and re-emerged in industrialized"/>
   <result pre="there are 7 to 20 million people getting infected by" exact="measles" post="each year [7,8]. In most developed countries measles was"/>
   <result pre="infected by measles each year [7,8]. In most developed countries" exact="measles" post="was considered eliminated, in recent years. However the rate"/>
   <result pre="the decreased herd immunity led to large outbreaks and today" exact="measles" post="is considered re-emerged [4,9]. This year, in many developed"/>
   <result pre="[24], and through a nectin-4-mediated macropinocytosis pathway, in breast and" exact="colon cancer" post="cell lines (MCF7, HTB-20, and DLD-1) [25]. It was"/>
   <result pre="and through a nectin-4-mediated macropinocytosis pathway, in breast and colon" exact="cancer" post="cell lines (MCF7, HTB-20, and DLD-1) [25]. It was"/>
   <result pre="A highly efficient live-attenuated virus vaccine is available to prevent" exact="measles" post="outbreaks. MeV transmissibility is very high and 95% of"/>
   <result pre="the Centers for Disease Control (CDC), the experts agreed that" exact="measles" post="eradication was technically feasible by 2005–2010. Nevertheless, vaccination coverage"/>
   <result pre="Nevertheless, vaccination coverage decreased and led to a re-emergence of" exact="measles" post="infection. Nowadays, measles global eradication is one of the"/>
   <result pre="decreased and led to a re-emergence of measles infection. Nowadays," exact="measles" post="global eradication is one of the top priorities of"/>
   <result pre="the WHO. The Global Vaccine Action Plan aims to eliminate" exact="measles" post="in five WHO Regions by 2020. Based on confirmed"/>
   <result pre="cases reported by the WHO, the countries with the most" exact="measles" post="cases in 2018 were India, Ukraine, Philippines, Brazil, and"/>
   <result pre="in 2018 were India, Ukraine, Philippines, Brazil, and Yemen. Recently," exact="measles" post="strongly re-emerged in industrialized countries due to the significant"/>
   <result pre="Tanabe (Japan, 1968) strain. All vaccines strains belong to the" exact="measles" post="virus genotype A [45]. Measles vaccine is usually combined"/>
   <result pre="virus genotype A [45]. Measles vaccine is usually combined with" exact="mumps" post="and rubella vaccines, known as MMR (Measles, Mumps, and"/>
   <result pre="A [45]. Measles vaccine is usually combined with mumps and" exact="rubella" post="vaccines, known as MMR (Measles, Mumps, and Rubella) vaccine,"/>
   <result pre="(Measles, Mumps, Rubella, and Varicella) vaccine. MMR is a live-attenuated" exact="measles" post="virus [46]. MMR vaccination is given in a two-dose"/>
   <result pre="who received the two vaccine doses do not produce protective" exact="measles" post="antibodies. However, most of them remain protected by their"/>
   <result pre="regulatory cells homeostasis by increasing their frequency and attenuating the" exact="hypersensitivity" post="cellular response [55]. A more recent study suggests a"/>
   <result pre="response [55]. A more recent study suggests a MeV-induced immune" exact="amnesia" post="relying on the depletion of pre-existing memory lymphocytes [50]."/>
   <result pre="complications such as pneumonia, which is the main cause of" exact="measles" post="mortality [56] or to central nervous system (CNS) complications,"/>
   <result pre="such as malnutrition and vitamin A deficiency seem to increase" exact="measles" post="associated morbidity and mortality. Indeed, regardless of vaccination coverage,"/>
   <result pre="vaccination, hearing loss was observed in 5% to 10% of" exact="measles" post="cases in the USA. This remains highly frequent in"/>
   <result pre="low [70]. One possible explanation is that otitis associated with" exact="measles" post="in up to 25% of infected patients could cause"/>
   <result pre="after the acute phase of the infection or later following" exact="measles" post="acute encephalitis (described in paragraph 6.1) with typical bilateral"/>
   <result pre="acute phase of the infection or later following measles acute" exact="encephalitis" post="(described in paragraph 6.1) with typical bilateral and moderate"/>
   <result pre="in paragraph 6.1) with typical bilateral and moderate to profound" exact="sensorineural hearing loss" post="[69]. The mechanism associated with MeV-induced hearing loss remains"/>
   <result pre="inner ear [57]. 5.2. Blindness Eye related symptoms such as" exact="conjunctivitis" post="or corneal inflammation (keratitis) are commonly associated with measles"/>
   <result pre="as conjunctivitis or corneal inflammation (keratitis) are commonly associated with" exact="measles" post="[57]. Corneal complications are often more serious when superinfection"/>
   <result pre="measles-induced blindness. Indeed, vitamin A deficiency is associated with severe" exact="keratitis" post="and considerably increases the risk of xerophthalmia, corneal ulceration,"/>
   <result pre="xerophthalmia, corneal ulceration, and blindness [72]. This may explain why" exact="measles" post="related blindness is more common in areas where children"/>
   <result pre="latter being subdivided in two sub-types, the first as a" exact="measles" post="inclusion-body encephalitis (MIBE) in immunocompromised patients and the second"/>
   <result pre="subdivided in two sub-types, the first as a measles inclusion-body" exact="encephalitis" post="(MIBE) in immunocompromised patients and the second as a"/>
   <result pre="encephalitis (MIBE) in immunocompromised patients and the second as a" exact="subacute sclerosing panencephalitis" post="(SSPE) occurring in immunocompetent patients [79,80] (Figure 2B). 6.1."/>
   <result pre="patients [79,80] (Figure 2B). 6.1. Acute Encephalitis The acute post-infectious" exact="measles" post="encephalitis (APME) occurs in 0.1% of measles cases, about"/>
   <result pre="[79,80] (Figure 2B). 6.1. Acute Encephalitis The acute post-infectious measles" exact="encephalitis" post="(APME) occurs in 0.1% of measles cases, about a"/>
   <result pre="The acute post-infectious measles encephalitis (APME) occurs in 0.1% of" exact="measles" post="cases, about a week following the appearance of first"/>
   <result pre="of first clinical signs. The APME is also called post-infection" exact="encephalitis" post="(PIE), acute demyelinating encephalomyelitis, or acute disseminated encephalomyelitis. APME"/>
   <result pre="is also called post-infection encephalitis (PIE), acute demyelinating encephalomyelitis, or" exact="acute disseminated encephalomyelitis." post="APME is associated with 20% mortality and severe neurological"/>
   <result pre="contribute to this inflammatory immune reaction [88]. Overall, MeV acute" exact="encephalitis" post="is poorly described in the recent literature. Note that"/>
   <result pre="detection in certain cases, multiple groups have suggested that the" exact="encephalitis" post="could be caused by an autoimmune-like response [89]. While"/>
   <result pre="11 cases per 100,000 [97,98] in immunocompetent patients that contracted" exact="measles" post="in their childhood, with a mortality rate close to"/>
   <result pre="and S103I/N462S/N465S) also confer hyperfusogenicity and can spread in human" exact="neuroblastoma" post="cell lines and suckling hamster brains in the absence"/>
   <result pre="block [29,96,145,146] (Table 1). Non-human primates represent faithful models of" exact="measles" post="since they are fully susceptible to wild-type MeV infection"/>
   <result pre="the acute pathogenesis [20,65,66,68,148,149,150]. These studies highlighted numerous similarities between" exact="measles" post="pathogenesis in humans and primates. Particularly, they allowed confirming"/>
   <result pre="in one monkey and two monkeys showed neuronal inclusions with" exact="measles" post="antigens [152] but no infectious viral particle has been"/>
   <result pre="reported that rhesus monkeys infected intracerebrally with hamster-brain-adapted strain developed" exact="encephalitis" post="with morphological characteristics similar to those observed in the"/>
   <result pre="Additionally, other hyperfusogenic mutants more stable and also observed in" exact="encephalitis" post="cases were shown to conserve there dependence on H"/>
   <result pre="immunocompetent OBC. Astrogliosis and microgliosis have been observed in MeV" exact="encephalitis" post="[144,187,188]. These data could explain why infection of astrocytes"/>
   <result pre="Dissemination? Neuronal cell lines such as human cells NT2, human" exact="astrocytoma" post="cells, or mouse neuroblastoma cells were also used, but"/>
   <result pre="such as human cells NT2, human astrocytoma cells, or mouse" exact="neuroblastoma" post="cells were also used, but their relevance remains difficult"/>
   <result pre="to 79% protection to unvaccinated patients having close contact with" exact="measles" post="infected patients [200]. More recently, effectiveness of immune serum"/>
   <result pre="prophylaxis was estimated from 50% to 69% during the 2014" exact="measles" post="outbreak in British Columbia in Canada. However, this estimation"/>
   <result pre="the vaccine compared to the acquisition from a wild type" exact="measles" post="infection [202]. This led to the necessity to increase"/>
   <result pre="serum globulin in order to maintain a protective level of" exact="measles" post="antibodies [201]. However, as mentioned in paragraph 7.3, SSPE"/>
   <result pre="via intracerebral route led to persistency of MeV infection and" exact="encephalitis" post="[204,205,206]. Thus, the use of immunoglobulins to treat measles"/>
   <result pre="and encephalitis [204,205,206]. Thus, the use of immunoglobulins to treat" exact="measles" post="infection should be very carefully thought before introduction in"/>
   <result pre="effectiveness [210]. Many clinical reports show that Ribavirin can decrease" exact="measles" post="antibody titers in cerebrospinal fluid (CSF) of SSPE patients"/>
   <result pre="11.2.3. Vitamin A Vitamin A deficiency is highly related to" exact="measles" post="complications and the supplementation of vitamin A has been"/>
   <result pre="may not act as a therapeutic cure and prevent from" exact="encephalitis" post="in this particular case [237]. 11.3. Transcription/Replication Inhibitors In"/>
   <result pre="emergence of escape mutant virus [244]. While already used in" exact="cancer" post="treatment, antivirals directly targeting the chaperon activity of HSP90"/>
   <result pre="there is a high probability that Remdesivir may also inhibit" exact="measles" post="virus polymerase activity. Interestingly, pharmakokinetic studies performed in non-human"/>
   <result pre="of MeV studies, especially because of the recent re-emergences of" exact="measles" post="and the increasing number of associated fatal encephalitis [44,256]."/>
   <result pre="re-emergences of measles and the increasing number of associated fatal" exact="encephalitis" post="[44,256]. While the vaccine remains the most efficient prevention"/>
   <result pre="further propagation in the brain. Regardless of the type of" exact="encephalitis" post="or MeV variant invading the brain, the high mortality"/>
   <result pre="variant invading the brain, the high mortality rate associated to" exact="measles" post="virus CNS complication highlight the requirement to validate antiviral"/>
   <result pre="the cytoplasm. Figure 2 Course of MeV infection leading to" exact="measles" post="encephalitis. (A) Initially, MeV infects myeloid cells in the"/>
   <result pre="of transient immunosuppression or autoimmunity, patients can develop acute post-infectious" exact="measles" post="encephalitis (APME) shortly after exposure without systematic central nervous"/>
   <result pre="transient immunosuppression or autoimmunity, patients can develop acute post-infectious measles" exact="encephalitis" post="(APME) shortly after exposure without systematic central nervous system"/>
   <result pre="after exposure without systematic central nervous system (CNS) infection. However," exact="measles" post="inclusion-body encephalitis (MIBE) and subacute sclerosing panencephalitis (SSPE) are"/>
   <result pre="without systematic central nervous system (CNS) infection. However, measles inclusion-body" exact="encephalitis" post="(MIBE) and subacute sclerosing panencephalitis (SSPE) are associated with"/>
   <result pre="nervous system (CNS) infection. However, measles inclusion-body encephalitis (MIBE) and" exact="subacute sclerosing panencephalitis" post="(SSPE) are associated with MeV infection of the CNS."/>
   <result pre="MeV infection of the CNS. (B) The occurrence of MeV" exact="encephalitis" post="may range from one day to 15 years following"/>
   <result pre="Innate immune response i.p.i.n. CD46 IFN-α/βKO [163] Induction of MeV" exact="encephalitis" post="with Edmonston i.c. CD46 RagKO [96,103] Study of the"/>
   <result pre="rat (Sigmodon hispidus) [12,172,173] Treatment development.Respiratory infectionMeV induced immunosuppressionCNS infectionImmune" exact="suppression" post="i.n. CD46 Sprague-Dawley rat [174] permissiveness Multiple Brown Norway"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6893968\results\search\disease\results.xml">
   <result pre="epidemics. The unavailability of a specific antiviral drug against the" exact="chikungunya" post="virus (CHIKV) disease has created an alarming situation to"/>
   <result pre="remedial management to preclude CHIKV infection. Introduction The cases of" exact="chikungunya" post="viral fever are burgeoning every year. Infections are not"/>
   <result pre="only limited to Asia and Africa; recently, the epidemics of" exact="chikungunya" post="have been reported from Central and South America.1,2 Concerning"/>
   <result pre="studies have shown that there is considerable resource burden from" exact="chikungunya" post="outbreaks, which escalates in monsoon and post-monsoon seasons. Therefore,"/>
   <result pre="which escalates in monsoon and post-monsoon seasons. Therefore, cases of" exact="chikungunya" post="viral fever have increased in the continent of Asia"/>
   <result pre="of Asia and various parts of the world. The name" exact="chikungunya" post="originates from &quot;Makonde�?, meaning &quot;to become twisted�?. It denotes"/>
   <result pre="of those going through joint ache as a result of" exact="chikungunya" post="infection. Chikungunya virus (CHIKV) spreads by mosquito vectors Aedes"/>
   <result pre="manifestation is one of the bases for the diagnosis of" exact="chikungunya" post="infection, but the confirmation of disease can only be"/>
   <result pre="viruses like Ross River virus, Sindbis virus (SINV), Western equine" exact="encephalitis" post="virus (WEEV), Semiliki Forest virus (SFV), Venezuelan equine encephalitis"/>
   <result pre="equine encephalitis virus (WEEV), Semiliki Forest virus (SFV), Venezuelan equine" exact="encephalitis" post="virus (VEEV), etc. They are furthermore categorized into Old"/>
   <result pre="regressed the catalytically inactivated mutants. Despite the increasing number of" exact="chikungunya" post="patients, haplessly, to date, no antiviral remedy or vaccine"/>
   <result pre="to curb CHIKV progress have failed to produce noteworthy therapeutic" exact="aids" post="in clinical samples.21−24 In the recent past, high-throughput assays"/>
   <result pre="obtained dihydrorugosaflavonoids (Scheme 1).30,31 We had screened these compounds for" exact="tuberculosis" post="in our previous studies, and we found that halogenated"/>
   <result pre="analogues. In positive-strand RNA viruses such as alphaviruses, coronaviruses, and" exact="hepatitis" post="E virus, the macrodomains are the integral part of"/>
   <result pre="antigen. One of the two envelope glycoproteins present in the" exact="chikungunya" post="virus named E2 glycoprotein has been used as the"/>
   <result pre="clearly show the potential of these two compounds in the" exact="suppression" post="of viral RNA levels in infected cells. Furthermore, the"/>
   <result pre="treat. Curr. Opin. Virol.2017, 24, 25–30. 10.1016/j.coviro.2017.03.016.28414993 MorrisonT. E.Reemergence of" exact="chikungunya" post="virus. J. Virol.2014, 88, 11644–11647. 10.1128/JVI.01432-14.25078691 National Vector Borne"/>
   <result pre="709–712. 10.1038/nature09555.21124458 ShermanM. B.; WeaverS. C.Structure of the recombinant alphavirus" exact="western equine encephalitis" post="virus revealed by cryoelectron microscopy. J. Virol.2010, 84, 9775–9782."/>
   <result pre="ShermanM. B.; WeaverS. C.Structure of the recombinant alphavirus western equine" exact="encephalitis" post="virus revealed by cryoelectron microscopy. J. Virol.2010, 84, 9775–9782."/>
   <result pre="276, 148–160. 10.1006/viro.2000.0544.11022003 SharmaR.; KesariP.; KumarP.; TomarS.Structure function insights into" exact="chikungunya" post="virus capsid protein: Small molecules targeting capsid hydrophobic pocket."/>
   <result pre="synthesis of rugosaflavonoid and its derivatives and their activatity agahinst" exact="breast cancer." post="RSC Adv.2017, 7, 33052–33060. 10.1039/C7RA04971D. PuranikN. V.; SrivastavaP.; SwamiS.;"/>
   <result pre="MeritsA.; AholaT.; McInerneyG. M.Differential PI3K-Akt-mTOR activation by Semliki Forest and" exact="chikungunya" post="virus, dependent on nsP3 and connected to replication complex"/>
   <result pre="W.Computer-assisted assignment of functional domains in the nonstructural polyprotein of" exact="hepatitis" post="E virus: delineation of an additional group of positive-strand"/>
   <result pre="Rev. Biochem.2016, 85, 431–454. 10.1146/annurev-biochem-060815-014935.26844395 ErikssonK. K.; Cervantes-BarragánL.; LudewigB.; ThielV.Mouse" exact="hepatitis" post="virus liver pathology is dependent on ADP-ribose-1″-phosphatase, a viral"/>
   <result pre="DavidsonA. D.; SiddellS. G.; ThielV.; ZiebuhrJ.; WeberF.The ADP-ribose-1″-monophosphatase domains of" exact="severe acute respiratory syndrome" post="coronavirus and human coronavirus 229E mediate resistance to antiviral"/>
   <result pre="macrodomain promotes virulence and suppresses the innate immune response during" exact="severe acute respiratory syndrome" post="coronavirus infection. mBio2016, 7, e01721-1610.1128/mBio.01721-16.27965448 RungrotmongkolT.; NunthabootN.; MalaisreeaM.; KaiyawetN.;"/>
   <result pre="specific binding of ADP-ribose to the nsP3 macro domains of" exact="chikungunya" post="and venezuelan equine encephalitis viruses: Molecular dynamics simulations and"/>
   <result pre="of ADP-ribose to the nsP3 macro domains of chikungunya and" exact="venezuelan equine encephalitis" post="viruses: Molecular dynamics simulations and free energy calculations. J."/>
   <result pre="to the nsP3 macro domains of chikungunya and venezuelan equine" exact="encephalitis" post="viruses: Molecular dynamics simulations and free energy calculations. J."/>
   <result pre="protease. Biochimie2018, 149, 51–61. 10.1016/j.biochi.2018.04.004.29635044 KaurR.; MudgalR.; JoseJ.; KumarP.; TomarS.Glycan-dependent" exact="chikungunya" post="viral infection divulged by antiviral activity of NAG specific"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6894787\results\search\disease\results.xml">
   <result pre="Control: Infectious Disease Surveillance Clinical and epidemiological characteristics of imported" exact="dengue fever" post="among inbound passengers: Infrared thermometer–based active surveillance at an"/>
   <result pre="However, advances in modern air transportation allow the spread of" exact="dengue fever" post="to non-endemic countries via infected passengers [4, 5]. Travel-related,"/>
   <result pre="to non-endemic countries via infected passengers [4, 5]. Travel-related, imported" exact="dengue fever" post="can cause regional outbreaks in previously non-endemic regions. For"/>
   <result pre="outbreaks in the United States and Japan [8, 9]. Imported" exact="dengue fever" post="cases frequently caused disastrous epidemics with thousands of patients"/>
   <result pre="clinical and epidemiological information can be used to differentiate imported" exact="dengue fever" post="from other causes of febrile illness in surveillance of"/>
   <result pre="dengue-positive cases among tested passengers during 2007–2012. The 2009 H1N1" exact="influenza" post="pandemic affected passengers during 2009–2010. After further considering the"/>
   <result pre="self-reported fever (aOR, 2.5; 95% confidence interval [CI], 1.5–4.1), skin" exact="rash" post="(aOR, 10.1; 95% CI, 3.4–35.2), and tympanic temperature ≥39°C"/>
   <result pre="providing them with adequate treatment. Following the global outbreak of" exact="severe acute respiratory syndrome" post="in 2003, many countries started to establish entry screening"/>
   <result pre="the incubation period of relevant possible infections [4, 38]. Typical" exact="dengue fever" post="is an acute febrile illness accompanied by headache, skin"/>
   <result pre="other respiratory pathogens that could cause febrile illness, for example," exact="influenza" post="virus. Hence, in a primary care setting or at"/>
   <result pre="2013;11(5):274–84. 10.1016/j.tmaid.2013.07.00623962447 8KutsunaS, KatoY, MoiML, KotakiA, OtaM, ShinoharaK, et al.Autochthonous" exact="dengue fever," post="Tokyo, Japan, 2014. Emerg Infect Dis. 2015;21(3):517–20. 10.3201/eid2103/14166225695200 9AdaljaAA,"/>
   <result pre="Dis. 2010;4(8):e77510.1371/journal.pntd.000077520689820 11WangSF, WangWH, ChangK, ChenYH, TsengSP, YenCH, et al.Severe" exact="dengue fever" post="outbreak in Taiwan. Am J Trop Med Hyg. 2016;94(1):193–7."/>
   <result pre="the effect of airport fever screening on prevention of domestic" exact="dengue fever" post="outbreaks in Taiwan, 1998–2007. Int J Infect Dis. 2010;14(8):e693–7."/>
   <result pre="Dis. 2015; 21(2):197–201. 10.3201/eid2102.13161025625224 16NishiuraH, KamiyaK. Fever screening during the" exact="influenza" post="(H1N1-2009) pandemic at Narita International Airport, Japan. BMC Infect"/>
   <result pre="2006;12(7):1058–1065. 10.3201/eid1207.05149716836821 22PriestPC, DuncanAR, JenningsLC, BakerMG. Thermal image scanning for" exact="influenza" post="border screening: results of an airport screening study. PLoS"/>
   <result pre="40LeeMS, HwangKP, ChenTC, LuPL, ChenTP. Clinical characteristics of dengue and" exact="dengue hemorrhagic fever" post="in a medical center of southern Taiwan during the"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6895170\results\search\disease\results.xml">
   <result pre="network density. Interestingly, the covariance relations were primarily intra-protein in" exact="avian influenza" post="and inter-protein in HIV. The degree distributions showed two"/>
   <result pre="density. Interestingly, the covariance relations were primarily intra-protein in avian" exact="influenza" post="and inter-protein in HIV. The degree distributions showed two"/>
   <result pre="chosen for analysis: HIV-1 subtype B (referred to as HIV)," exact="hepatitis" post="subtype B (referred to as hepatitis), dengue, avian influenza"/>
   <result pre="as HIV), hepatitis subtype B (referred to as hepatitis), dengue," exact="avian influenza" post="and human influenza subtype A (referred to as human"/>
   <result pre="HIV), hepatitis subtype B (referred to as hepatitis), dengue, avian" exact="influenza" post="and human influenza subtype A (referred to as human"/>
   <result pre="B (referred to as hepatitis), dengue, avian influenza and human" exact="influenza" post="subtype A (referred to as human influenza); however, the"/>
   <result pre="each cluster has a mixed representation from all the proteins," exact="avian influenza" post="clusters are mainly from intraprotein covariance relations. Network representations"/>
   <result pre="cluster has a mixed representation from all the proteins, avian" exact="influenza" post="clusters are mainly from intraprotein covariance relations. Network representations"/>
   <result pre="basing the analysis at an amino acid level. For dengue," exact="hepatitis" post="and human influenza also the clusters have residues from"/>
   <result pre="at an amino acid level. For dengue, hepatitis and human" exact="influenza" post="also the clusters have residues from multiple proteins. Node"/>
   <result pre="power-law n(k) ~ k−γ, γ ~ 1, was significantly observed, while dengue and human" exact="influenza" post="show random distribution (Fig. 2). Hepatitis and avian influenza"/>
   <result pre="and human influenza show random distribution (Fig. 2). Hepatitis and" exact="avian influenza" post="on the other hand showed a mixed behavior including"/>
   <result pre="human influenza show random distribution (Fig. 2). Hepatitis and avian" exact="influenza" post="on the other hand showed a mixed behavior including"/>
   <result pre="and human influenza). The dashed line in the panels for" exact="hepatitis" post="and HIV is shown for reference and corresponds to"/>
   <result pre="separately. Figure 3 Node degree distribution sensitivity was studied in" exact="hepatitis" post="network by changing the cut-off value used for defining"/>
   <result pre="analysis on the data set which is most abundant, human" exact="influenza" post="(subtype A). We divided the complete genome data from"/>
   <result pre="(subtype A). We divided the complete genome data from human" exact="influenza" post="into periods where the number of sequences is similar"/>
   <result pre="Targeted removal has the highest effect on HIV followed by" exact="avian influenza." post="For these two virus covariance data sets, the difference"/>
   <result pre="distribution, and a transition to the powerlaw, as seen in" exact="hepatitis" post="(Fig. 3). For example, for HIV, the conclusion is"/>
   <result pre="couplings to host-virus interactions, with the interactomes from dengue, human" exact="influenza" post="and HIV-1. Two different comparisons were made: (i) the"/>
   <result pre="that the viral proteins are clustered closely in dengue and" exact="influenza" post="interactomes because many of the host proteins interact with"/>
   <result pre="the interactomes of human protein with HIV, dengue and human" exact="influenza" post="(details in Methods section). The networks of interactions are"/>
   <result pre="of the higher number of effective sequences of HIV and" exact="avian influenza," post="the covariance analysis was repeated using randomly selected 200"/>
   <result pre="nature of the couplings did not change for HIV and" exact="avian influenza." post="The characteristics of the distribution remained the same for"/>
   <result pre="the network characteristic - network density. Richter scale data for" exact="avian influenza" post="was not available and hence was not included in"/>
   <result pre="network characteristic - network density. Richter scale data for avian" exact="influenza" post="was not available and hence was not included in"/>
   <result pre="the time since when they infected the hosts: Influenza and" exact="hepatitis" post="infections go back to thousands of years, the youngest"/>
   <result pre="serotype strains is about 200 years old and HIV and" exact="avian influenza" post="are relatively younger with less than hundred years of"/>
   <result pre="strains is about 200 years old and HIV and avian" exact="influenza" post="are relatively younger with less than hundred years of"/>
   <result pre="on the shape of phylogenetic tree and found HIV and" exact="hepatitis" post="C virus clustered together while dengue and human influenza"/>
   <result pre="and hepatitis C virus clustered together while dengue and human" exact="influenza" post="A appeared in another cluster along with many other"/>
   <result pre="number of covariance connections for protein pairs for HIV, human" exact="influenza" post="and dengue (Methods section) and is shown in Supplementary"/>
   <result pre="interactome, we could observe (Fig. 6) that dengue and human" exact="influenza" post="have host proteins which interact with more than one"/>
   <result pre="format were downloaded from different sources: HIV (http://www.hiv.lanl.gov), dengue (https://www.viprbrc.org/brc/home.spg?decorator=flavi_dengue)," exact="hepatitis" post="(https://hbvdb.ibcp.fr/HBVdb/HBVdbDataset?seqtype=2), human and avian influenza (http://platform.gisaid.org/). Any sequence where"/>
   <result pre="different sources: HIV (http://www.hiv.lanl.gov), dengue (https://www.viprbrc.org/brc/home.spg?decorator=flavi_dengue), hepatitis (https://hbvdb.ibcp.fr/HBVdb/HBVdbDataset?seqtype=2), human and" exact="avian influenza" post="(http://platform.gisaid.org/). Any sequence where information about all the proteins"/>
   <result pre="sources: HIV (http://www.hiv.lanl.gov), dengue (https://www.viprbrc.org/brc/home.spg?decorator=flavi_dengue), hepatitis (https://hbvdb.ibcp.fr/HBVdb/HBVdbDataset?seqtype=2), human and avian" exact="influenza" post="(http://platform.gisaid.org/). Any sequence where information about all the proteins"/>
   <result pre="interactions we found the most comprehensive data for: HIV, human" exact="influenza" post="and dengue and we present the analyses for the"/>
   <result pre="virus-host system was downloaded from virus mentha46 (https://virusmentha.uniroma2.it/) for human" exact="influenza" post="and HIV. For dengue virus the interactions with human"/>
   <result pre="protein interaction network for pluripotency of embryonic stem cellsNat.200644436436810.1038/nature05284 4.KarGGursoyAKeskinOHuman" exact="cancer" post="protein-protein interaction network: a structural perspectivePLoS Comput. Biol20095e100060110.1371/journal.pcbi.100060120011507 5.Shen-OrrSSMiloRManganSAlonUNetwork"/>
   <result pre="representation of protein structures: implications for protein stabilityBiophys. J.2005894159417010.1529/biophysj.105.06448516150969 16.AuroraRDonlinMJCannonNATavisJEGrpV-CSGenome-wide" exact="hepatitis" post="C virus amino acid covariance networks can predict response"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6896411\results\search\disease\results.xml">
   <result pre="10.1080/20008686.2019.1696632 : Research Article Complete genome sequencing of H1N1pdm09 swine" exact="influenza" post="isolates from Nigeria reveals likely reverse zoonotic transmission at"/>
   <result pre="the human-animal interface. However, molecular epidemiology studies of zoonotic swine" exact="influenza" post="viruses in this region are limited. In this study,"/>
   <result pre="this region are limited. In this study, isolates of pandemic" exact="influenza" post="virus (H1N1pdm09) obtained from pigs in Nigeria were fully"/>
   <result pre="from pigs in Nigeria were fully sequenced. BLAST of swine" exact="influenza" post="virus genes from Nigeria was carried out in GenBank"/>
   <result pre="trees were constructed to infer genomic clusters and relationship. Swine" exact="influenza" post="viruses isolated and sequenced in this study were monophyletic"/>
   <result pre="A/H1N1pdm09 viruses circulating in pigs that are also exposed to" exact="avian influenza" post="in the same epidemiological zones could engender emergence of"/>
   <result pre="viruses circulating in pigs that are also exposed to avian" exact="influenza" post="in the same epidemiological zones could engender emergence of"/>
   <result pre="fig-count: table-count: ref-count: page-count: Introduction Pigs are mixing vessels of" exact="influenza" post="viruses and known reservoirs of virus genes capable of"/>
   <result pre="reservoirs of virus genes capable of causing emergence of novel" exact="influenza" post="virus strains with potential adverse economic and public health"/>
   <result pre="economic and public health consequences [1]. Although the pandemic H1N1pdm09" exact="influenza" post="virus was first reported in human in Mexico in"/>
   <result pre="spillover transmission into the human population [3]. Surveillance for swine" exact="influenza" post="in animals have also shown that the human pandemic"/>
   <result pre="is a dearth of epidemiologic and genomic data on swine" exact="influenza" post="viruses in the country and in sub-Saharan Africa [6]."/>
   <result pre="a product of gene reassortment of avian, swine and human" exact="influenza" post="viruses [3]. The ecological and biological elements that engendered"/>
   <result pre="butchers) predispose to inter and intra-species transmission and exchange of" exact="influenza" post="viruses at the human-animal interface thus favouring the emergence"/>
   <result pre="emerging strains may possess markers of molecular changes in the" exact="influenza" post="virus genome that may be important for transmission and"/>
   <result pre="complete genome sequencing and phylogenetic study of isolates of swine" exact="influenza" post="virus obtained from embryonated egg culture of samples collected"/>
   <result pre="Out of 227 samples analysed, 31 (13.7%) were positive for" exact="influenza" post="A matrix gene by real-time RT-PCR. Virus isolation yielded"/>
   <result pre="(12%) isolates out of which 18 (18%) were identified as" exact="influenza" post="A/H1N1 by Heamaglutination Inhibition test against H1 antisera. Reverse"/>
   <result pre="Gene sequences were thereafter compared with corresponding genes of other" exact="influenza" post="virus strains obtained from GenBank and Global Initiative on"/>
   <result pre="Initiative on Sharing All Influenza Data (GISAID). These include human" exact="influenza" post="sequences from Nigeria, Ghana and Cameroon, viz.: A/Nigeria/4280/2011, A/Ghana/601/2011"/>
   <result pre="of the phylogeny [10]. Nucleotides and amino acid substitutions of" exact="influenza" post="H1N1pdm09 isolates from Nigeria were compared with prototype A/California/07/2009(H1N1)"/>
   <result pre="construct the tree for such gene. Results The pandemic Swine" exact="influenza" post="virus that were isolated from the piggery complex in"/>
   <result pre="JX482559-PA and JX48260-NS (www.ncbi.nlm.nih.gov). Figure 1. Phylogenetic tree of H1N1pdm09" exact="influenza" post="A virus (A/swine/Nigeria/12VIR4047/2011) isolated in Nigeria (HA, NA, MA,"/>
   <result pre="deposited in GISAID, all of which are human isolates of" exact="influenza" post="H1N1pdm09 virus clustering together in the phylogenetic tree (Figure"/>
   <result pre="matrix gene except S31N that has been described for most" exact="influenza" post="A/H1N1pdm09 isolates as the predominant amantadine-resistant mutation in M2."/>
   <result pre="that were analysed in this study were most similar to" exact="influenza" post="H1N1pdm09 sequences from human hosts as obtained in GenBank"/>
   <result pre="transboundary transmission of infectious pathogens. Interestingly, earlier detection of H1N1pdm09" exact="influenza" post="virus in pig was reported in Cameroon [11], but"/>
   <result pre="detected from pigs in Africa). The human isolate of H1N1pdm09" exact="influenza" post="virus (A/Nigeria/4280/2011(H1N1)) detected from nasal swab sample by molecular"/>
   <result pre="prove because there were no sufficient surveillance data on swine" exact="influenza" post="or H1N1pdm09 in the country prior to 2009 global"/>
   <result pre="animals within the country. The observed transmission and circulation of" exact="influenza" post="H1N1pdm09 from humans to pigs resulted in the emergence"/>
   <result pre="about 5% of cases (Matrosovich et al., 2000). Most H1N1pdm09" exact="influenza" post="virus circulating globally including those detected in human host"/>
   <result pre="GenBank from Africa and provides baseline genomic data on swine" exact="influenza" post="virus circulating in pigs in Nigeria and probably the"/>
   <result pre="revealed the epidemiological intricacies in the circulation and transmission of" exact="influenza" post="virus at the human-animal interface whereas infectious pathogens can"/>
   <result pre="public have limited knowledge of the risk of transmission of" exact="influenza" post="virus from animals to human and from human to"/>
   <result pre="human to animals [20] Conclusion Given the genetic characteristics of" exact="influenza" post="viruses, the continued circulation of H1N1pdm09 viruses in pigs"/>
   <result pre="drift and shift and co-circulating with human, avian or swine" exact="influenza" post="viruses. This increases the risk of emergence of influenza"/>
   <result pre="swine influenza viruses. This increases the risk of emergence of" exact="influenza" post="virus variants with enhanced intra and interspecies transmission and"/>
   <result pre="Fredrich-Loefler-Institut, Insel Riems, Germany for research on avian and swine" exact="influenza" post="virus. He returned back to the National Veterinary Research"/>
   <result pre="to Dr Clement Meseko for the molecular characterisation of swine" exact="influenza" post="virus at IZSVe, Padova Italy. We gratefully acknowledge the"/>
   <result pre="be accessed here. Supplemental Material LINK References References [1]CapuaI, AlexanderDJ.Avian" exact="influenza" post="and human health. Acta Trop. 2002;83(1):1–10.12062786 [2]GartenRJC, Todd DavisCA,"/>
   <result pre="Genetic characteristics of the early isolates of swine-origin 2009 A(H1N1)" exact="influenza" post="viruses circulating in humans. Science. 2009;325(5937):197–201.19465683 [3]PaddleAEPandemic 2009 (H1N1)"/>
   <result pre="viruses circulating in humans. Science. 2009;325(5937):197–201.19465683 [3]PaddleAEPandemic 2009 (H1N1) swine" exact="influenza" post="virus is mild compared to the 1918 (H1N1) virus"/>
   <result pre="et alOrigins and evolutionary genomics of the 2009 swine-origin H1N1" exact="influenza" post="A epidemic. Nature. 2009;459:1122–1125.19516283 [5]VijaykrishnaD, SmithGJ, PybusOG, et alLong-term"/>
   <result pre="SmithGJ, PybusOG, et alLong-term evolution and transmission dynamics of swine" exact="influenza" post="A. Nature. 2011;473(7348):519–522.21614079 [6]MesekoC, OlaleyeD, CapuaI, et alSwine influenza"/>
   <result pre="swine influenza A. Nature. 2011;473(7348):519–522.21614079 [6]MesekoC, OlaleyeD, CapuaI, et alSwine" exact="influenza" post="in sub Saharan Africa, current knowledge and emerging insights."/>
   <result pre="chain reaction (PCR) methods for detection of pandemic (H1N1) 2009" exact="influenza" post="virus and European swine influenza A virus infections in"/>
   <result pre="detection of pandemic (H1N1) 2009 influenza virus and European swine" exact="influenza" post="A virus infections in pigs. Influenza Other Respir Viruses."/>
   <result pre="Viruses. 2010;4(5):277–293.20716157 [9]MesekoCA, OdaiboGN, OlaleyeDODetection and isolation of 2009 pandemic" exact="influenza" post="A/H1N1 virus in commercial pigs, Lagos Nigeria. Vet Microbiol."/>
   <result pre="Acad Sci USA. 2004;101:11030–11035.15258291 [11]NjaboKY, FullerTL, ChasarA, et alPandemic A/H1N1/2009" exact="influenza" post="virus in swine, cameroon, 2010. Vet Microbiol. 2011;156(1–2):189–192.21963416 [12]DalhatuIT,"/>
   <result pre="2009–2010: results from the first 17 months of a national" exact="influenza" post="sentinel surveillance system. J Infect Dis. 2012;206(S1):S121–128.23169957 [13]MatrosovichM, TuzikovA,"/>
   <result pre="alterations of the receptor-binding properties of H1, H2, and H3" exact="avian influenza" post="virus hemagglutinins after their introduction into mammals. J Virol."/>
   <result pre="of the receptor-binding properties of H1, H2, and H3 avian" exact="influenza" post="virus hemagglutinins after their introduction into mammals. J Virol."/>
   <result pre="TuzikovA, PazyninaG, et alEvolution of the receptor binding phenotype of" exact="influenza" post="A (H5) viruses. Virology. 2006;344:432–438.16226289 [15]collab: HurtThe epidemiologyand spread"/>
   <result pre="Virology. 2006;344:432–438.16226289 [15]collab: HurtThe epidemiologyand spread of drug resistant human" exact="influenza" post="viruses. Curr Opin Virol. 2014;8:22–29.24866471 [16]MesekoC, GlobigA, IjomantaJ, et"/>
   <result pre="et alEvidence of exposure of domestic pigs to highly pathogenic" exact="avian influenza" post="H5N1 in Nigeria. Sci Rep. 2018;12;8(1):5900. [17]DucatezMF, AwoumeF, WebbyRJInfluenza"/>
   <result pre="alEvidence of exposure of domestic pigs to highly pathogenic avian" exact="influenza" post="H5N1 in Nigeria. Sci Rep. 2018;12;8(1):5900. [17]DucatezMF, AwoumeF, WebbyRJInfluenza"/>
   <result pre="Microbiol. 2015;15;177(1–2):201–205. [18]MunyuaP, OnyangoC, MwasiL, et alIdentification and characterization of" exact="influenza" post="A viruses in selected domestic animals in Kenya, 2010-2012."/>
   <result pre="PLoS One. 2018;13(2):e0192721.29425232 [19]AdeolaOA, OlugasaBO, EmikpeBODetection of pandemic strain of" exact="influenza" post="virus (A/H1N1/pdm09) in pigs, West Africa: implications and considerations"/>
   <result pre="pigs, West Africa: implications and considerations for prevention of future" exact="influenza" post="pandemics at the source. Infect Ecol Epidemiol. 2015;1228;5: 30227."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6896758\results\search\disease\results.xml">
   <result pre="RNA viruses such as Porcine epidemic diarrhoea virus (PEDV), Transmissible" exact="gastroenteritis" post="virus (TGEV), Porcine deltacoronavirus (PDCoV) or Rotavirus A, B,"/>
   <result pre="RVC Rotavirus C RVH Rotavirus H SAV Sapovirus TGEV Transmissible" exact="gastroenteritis" post="virus Publisher’s Note Springer Nature remains neutral with regard"/>
   <result pre="References References 1.ChanGFarzanADeLayJMcEwenBPrescottJFFriendshipRMA retrospective study on the etiological diagnoses of" exact="diarrhea" post="in neonatal piglets in Ontario, Canada, between 2001 and"/>
   <result pre="and differentiation of virulent and variant strains of porcine epidemic" exact="diarrhea" post="viruses from the United StatesJ Virol Methods201420715415710.1016/j.jviromet.2014.07.00525019169 10.AnbalaganSPetersonJWassmanBElstonJSchwartzKGenome sequence"/>
   <result pre="sequence of Torovirus identified from a pig with porcine epidemic" exact="diarrhea" post="virus from the United StatesGenome Announc20142e01291e0121425523767 11.GoeckeNBHjulsagerCKKongstedHBoyeMRasmussenSGranbergFFischerTKMidgleySERasmussenLDAngenØNielsenJPJorsalSELarsenLENo evidence of"/>
   <result pre="virome indicates high diversity in pigs infected by porcine endemic" exact="diarrhea" post="virus in the United StatesVirol J2018159510.1186/s12985-018-1001-z29801460 20.SachsenröderJTwardziokSHammerlJAJanczykPWredePHertwigSJohneRSimultaneous identification of"/>
   <result pre="genetic characterization of porcine astroviruses in piglets with and without" exact="diarrhea" post="in ThailandArch Virol20181631823182910.1007/s00705-018-3806-x29569070 33.De BenedictisPSchultz-CherrySBurnhamACattoliGAstrovirus infections in humans and"/>
   <result pre="TP, Rossow S, Saif LJ, Marthaler DG. Decline of transmissible" exact="gastroenteritis" post="virus and its complex evolutionary relationship with porcine respiratory"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6896812\results\search\disease\results.xml">
   <result pre="Public Health[Internet]2011Sep 5 2018101353153810.2105/AJPH.2010.19760821233431 15MattsonCLFreedmanMFaganJLFrazierELBeerLHuangPet al.Sexual risk behaviour and viral" exact="suppression" post="among HIV-infected adults receiving medical care in the United"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6896946\results\search\disease\results.xml">
   <result pre="and Future Development of More Efficacious Preventative and Therapeutic Interventions" exact="influenza" post="virus vaccine efficacy therapeutics prevention fig-count: table-count: equation-count: ref-count:"/>
   <result pre="needed. Both the innate and adaptive immune systems contribute to" exact="influenza" post="virus control and the virus itself employs various mechanisms"/>
   <result pre="review article add to our understanding of limitations of current" exact="influenza" post="vaccine and disease intervention strategies. In a mini-review by"/>
   <result pre="Out of 15 candidate compounds, four were able to inhibit" exact="influenza" post="virus infection 10- to 100-fold in vitro without toxicity."/>
   <result pre="on how &quot;Peritoneal cells mediate immune responses and cross-protection against" exact="influenza" post="A virus�? demonstrated that intraperitoneal inoculation with live influenza"/>
   <result pre="against influenza A virus�? demonstrated that intraperitoneal inoculation with live" exact="influenza" post="A virus confers protection against intranasal challenge in mice"/>
   <result pre="responses in the peritoneal cavity are critical for protection against" exact="influenza" post="A virus infection. The study shows that immunological responses"/>
   <result pre="Kedzierska's lab on &quot;Downregulation of MHC class I expression by" exact="influenza" post="A and B viruses�? suggests that both IAV and"/>
   <result pre="influenza A and B viruses�? suggests that both IAV and" exact="influenza" post="B virus (IBV) subtypes downregulate MHC I surface expression"/>
   <result pre="interactions and inform the design of novel vaccine strategies against" exact="influenza" post="viruses. Finally, an article by Hornick et al. from"/>
   <result pre="&quot;Kinetics and phenotype of the CD4 T cell response to" exact="influenza" post="virus infections�? describe the characterization of the full antigen-specific"/>
   <result pre="of the CD4+ T cell response associated with immunity following" exact="influenza" post="virus infection and suggests that we consider all responses"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6897401\results\search\disease\results.xml">
   <result pre="in Kinshasa between 1950–1960 [2], similar to the spread of" exact="hepatitis" post="C virus in Kinshasa [47]. The results presented here"/>
   <result pre="transportation data to predict the global transmission dynamics of human" exact="influenza" post="H3N2. PLoS pathogens. 2014;10(2):e1003932 Epub 2014/03/04. 10.1371/journal.ppat.100393224586153 64NunesMR, PalaciosG,"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6902501\results\search\disease\results.xml">
   <result pre="6902501608 doi: 10.1186/s40249-019-0608-7 : Research Article Reduction patterns of Japanese" exact="encephalitis" post="incidence following vaccine introduction into long-term expanded program on"/>
   <result pre="available in this article, unless otherwise stated. Abstract Background Japanese" exact="encephalitis" post="(JE) is a leading cause of childhood viral encephalitis"/>
   <result pre="Japanese encephalitis (JE) is a leading cause of childhood viral" exact="encephalitis" post="both at global level and in China. Vaccination is"/>
   <result pre="five official working languages of the United Nations. Background Japanese" exact="encephalitis" post="(JE) is a leading cause of childhood viral encephalitis."/>
   <result pre="Culex mosquitoes. It is related to the viruses causing dengue," exact="yellow fever," post="and West Nile fevers [1]. The first case of"/>
   <result pre="In Asia, the virus is the main cause of viral" exact="encephalitis" post="resulting into an estimated 68 000 clinical cases every year"/>
   <result pre="salivation, lisping, vision loss, hearing loss), mental state, and with/without" exact="epilepsy" post="[21]. Data analysis For this report, the case-based JE"/>
   <result pre="326 6.8  Unknown 2392 50.0 Fig. 1 Incidence of Japanese" exact="encephalitis" post="and coverage of vaccine before and after introduction of"/>
   <result pre="2nd dose JE vaccination Fig. 2 Monthly distribution of Japanese" exact="encephalitis" post="cases in Yunnan Province, 2005–2017 Epidemiological characteristics of the"/>
   <result pre="of JE symptoms. Fig. 3 The spatial distribution of Japanese" exact="encephalitis" post="cases in Yunnan Province, 2005–2017 The majority (97%) of"/>
   <result pre="48% in 2017. Fig. 4 Incidence and proportion of Japanese" exact="encephalitis" post="cases by age-group in Yunnan Province, 2005–2017. Notes: EPI"/>
   <result pre="denominator (data not shown). Fig. 5 Treatment outcomes of Japanese" exact="encephalitis" post="cases in Yunnan Province, 2005–2017 Discussion Our analysis of"/>
   <result pre="declare that they have no competing interests. References References 1.BharatiKVratiSJapanese" exact="encephalitis" post="vaccines: current status and future prospectsProc Nat’l Acad Sci"/>
   <result pre="- Section B: Biolog Sci201080179189 2.LiuXinyuZhaoXinNaRuiLiLiliWarkentinEberhardWittJenniferLuXuYuYongxinWeiYuquanPengGuohongLiYuhuaWangJunzhiThe structure differences of Japanese" exact="encephalitis" post="virus SA14 and SA14-14-2 E proteins elucidate the virulence"/>
   <result pre="a systematic reviewBull World Health Organ201189766774E10.2471/BLT.10.08523322084515 5.DanWUNingGJYinZDEpidemiological characteristics of Japanese" exact="encephalitis" post="in China, 2011-2013Chin J Vaccin Immun201521486490 6.ZhuQYHuXTKongYZhangLDingZRSeasonal distribution of"/>
   <result pre="in China, 2011-2013Chin J Vaccin Immun201521486490 6.ZhuQYHuXTKongYZhangLDingZRSeasonal distribution of Japanese" exact="encephalitis" post="of Yunnan, 1952–2015Modern Prev Med20164342364239 7.SohnYMJapanese encephalitis immunization in"/>
   <result pre="distribution of Japanese encephalitis of Yunnan, 1952–2015Modern Prev Med20164342364239 7.SohnYMJapanese" exact="encephalitis" post="immunization in South Korea: past, present, and futureEmerg Infect"/>
   <result pre="Infect Dis20006172410.3201/eid0601.00010310653564 8.YenNTLiuWHanhHDChangNYDuongTNGibbonsRVet al.A model immunization programme to control Japanese" exact="encephalitis" post="in Viet NamJ Health Popul Nutr20153320721325995736 9.Kumar PantDTenzinTChandRKumar SharmaBRajBPSpatio-temporal"/>
   <result pre="NamJ Health Popul Nutr20153320721325995736 9.Kumar PantDTenzinTChandRKumar SharmaBRajBPSpatio-temporal epidemiology of Japanese" exact="encephalitis" post="in Nepal, 2007-2015PLoS One201712e018059110.1371/journal.pone.018059128746354 10.UpretiSRLindseyNPBoharaRChoudharyGRShakyaSGautamMet al.Updated estimation of the"/>
   <result pre="One201712e018059110.1371/journal.pone.018059128746354 10.UpretiSRLindseyNPBoharaRChoudharyGRShakyaSGautamMet al.Updated estimation of the impact of a Japanese" exact="encephalitis" post="immunization program with live, attenuated SA 14-14-2 vaccine in"/>
   <result pre="vaccine in NepalPLoS Negl Trop Dis201711e000586610.1371/journal.pntd.000586628934197 11.LopezALAldabaJGRoqueVGTandocAOSyAKEspinoFEet al.Epidemiology of Japanese" exact="encephalitis" post="in the Philippines: a systematic reviewPLoS Negl Trop Dis20159e000363010.1371/journal.pntd.000363025794009"/>
   <result pre="SAGE Working Group on Japanese Encephalitis VaccinesBackground paper on Japanese" exact="encephalitis" post="vaccines—SAGE working group2014GenevaWorld Health Organization 17.HeffelfingerJDLiXBatmunkhNGrabovacVDiorditsaSLiyanageJBet al.Japanese encephalitis surveillance"/>
   <result pre="on Japanese encephalitis vaccines—SAGE working group2014GenevaWorld Health Organization 17.HeffelfingerJDLiXBatmunkhNGrabovacVDiorditsaSLiyanageJBet al.Japanese" exact="encephalitis" post="surveillance and immunization - Asia and Western Pacific regions,"/>
   <result pre="Xue Za Zhi201132384121518539 20.KakotiGDuttaPRam DasBBorahJMahantaJClinical profile and outcome of Japanese" exact="encephalitis" post="in children admitted with acute encephalitis syndromeBiomed Res Int2013201315265624490147"/>
   <result pre="and outcome of Japanese encephalitis in children admitted with acute" exact="encephalitis" post="syndromeBiomed Res Int2013201315265624490147 21.YinZWangXLiLLiHZhangXLiJNingGLiFLiangXGaoLLiangXLiYNeurological sequelae of hospitalized Japanese encephalitis"/>
   <result pre="acute encephalitis syndromeBiomed Res Int2013201315265624490147 21.YinZWangXLiLLiHZhangXLiJNingGLiFLiangXGaoLLiangXLiYNeurological sequelae of hospitalized Japanese" exact="encephalitis" post="cases in Gansu province, ChinaAm J Trop Med Hyg2015921125112910.4269/ajtmh.14-014825918213"/>
   <result pre="26.GaoXLiXLiMFuSWangHZhiLet al.Vaccine strategies for the control and prevention of Japanese" exact="encephalitis" post="in mainland China, 1951–2011PLoS Negl Trop Dis20148e301510.1371/journal.pntd.000301525121596 27.YangYLiangNTanYXieZEpidemiological trends"/>
   <result pre="1951–2011PLoS Negl Trop Dis20148e301510.1371/journal.pntd.000301525121596 27.YangYLiangNTanYXieZEpidemiological trends and characteristics of Japanese" exact="encephalitis" post="changed based on the vaccination program between 1960 and"/>
   <result pre="region, southern ChinaInt J Infect Dis20164513513810.1016/j.ijid.2016.03.00426972041 28.YaoNWangQZhouCBEpidemiological analysis of Japanese" exact="encephalitis" post="before and after expanded program on immunization in Chongqing"/>
   <result pre="ChinaChin J Viral Dis201774347 29.DengSZZhangHLLiuXQAnalysis of epidemiological characteristics of Japanese" exact="encephalitis" post="in Yunnan Province from 1976 to 2007Endemic Dis Bull20092417"/>
   <result pre="for South East Asia 31.PanjaPMondalSKChattopadhyayJStability and bifurcation analysis of Japanese" exact="encephalitis" post="model with/without effects of some control parametersJ Comp Appl"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6904267\results\search\disease\results.xml">
   <result pre="symptoms in humans, including sore throat, pneumonia, fever, and acute" exact="otitis media," post="with most cases involving gastrointestinal symptoms that vary with"/>
   <result pre="but outbreaks of acute respiratory diseases (ARDs), such as community-acquired" exact="pneumonia" post="(CAP), can occur in newborns, school students, and military"/>
   <result pre="inactivated HAdV-7 and HAdV-55 were used as antigens, and inactivated" exact="influenza" post="virus H3N2 (A/swine/Colorado/1/77) (Karasin et al., 2000) and a"/>
   <result pre="The synthetic polypeptide antigen of foot-and-mouth disease virus (FMDV) and" exact="influenza" post="A virus H3N2 (A/swine/Colorado/1/77) served as negative controls. HAdV-55"/>
   <result pre="MMAb 10G12 bound to inactivated HAdV-7, but not to inactivated" exact="influenza" post="virus H3N2, the synthetic polypeptide antigen of FMDV, or"/>
   <result pre="al.. (2010). Genomic characterization of human adenovirus 36, a putative" exact="obesity" post="agent. Virus Res.149, 152–161. 10.1016/j.virusres.2010.01.01120109503 BradleyR. R.MaxfieldL. F.LynchD. M.IampietroM."/>
   <result pre="adenovirus types (HAdV-8, HAdV-37, HAdV-4, HAdV-3) in an epidemic of" exact="keratoconjunctivitis" post="occurred in Pune, Maharashtra, Western India. J. Med. Virol.88,"/>
   <result pre="M.CooperL. A.SmithC. B.SubbaraoK.AndersonG. A.et al.. (2000). Genetic characterization of H3N2" exact="influenza" post="viruses isolated from pigs in North America, 1977-1999: evidence"/>
   <result pre="protein. J. Immunol.174, 7179–7185. 10.4049/jimmunol.174.11.717915905562 TanD.ZhuH.FuY.TongF.YaoD.WallineJ.et al.. (2016). Severe community-acquired" exact="pneumonia" post="caused by human adenovirus in immunocompetent adults: a multicenter"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6904818\results\search\disease\results.xml">
   <result pre="virus (ZIKV) is a mosquito-borne flavivirus that can cause devastating" exact="microcephaly" post="and other congenital syndromes in infants born to infected"/>
   <result pre="several devastating epidemics of zoonotic RNA viral diseases, such as" exact="severe acute respiratory syndrome" post="(SARS), middle east respiratory syndrome (MERS), Ebola, Nipah, chikungunya,"/>
   <result pre="middle east respiratory syndrome (MERS), Ebola, Nipah, chikungunya, West Nile," exact="yellow fever," post="and ZIKV. Given the unpredictable nature of emerging pathogens,"/>
   <result pre="if rilpivirine also inhibits closely related flaviviruses, such as dengue," exact="yellow fever," post="West Nile, and Japanese encephalitis viruses. Nevertheless, the authors"/>
   <result pre="flaviviruses, such as dengue, yellow fever, West Nile, and Japanese" exact="encephalitis" post="viruses. Nevertheless, the authors have established the antiviral activity"/>
   <result pre="in vivo potency of rilpivirine seems better than sofosbuvir, a" exact="hepatitis" post="C virus (HCV) nucleoside drug that was reported with"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6905541\results\search\disease\results.xml">
   <result pre="in the state of Rio de Janeiro, and since then," exact="dengue fever" post="became a public health burden for Brazil [7]. By"/>
   <result pre="the state, however, since late 2014, different arboviruses such as" exact="chikungunya" post="virus (CHIKV), Zika virus (ZIKV), and yellow fever virus"/>
   <result pre="arboviruses such as chikungunya virus (CHIKV), Zika virus (ZIKV), and" exact="yellow fever" post="virus (YFV), joined alternating their circulation [19]. DENV-2 cases"/>
   <result pre="was low, and the focus was mostly on surveillance of" exact="yellow fever" post="cases and epizootics, and immunization actions as well [22]."/>
   <result pre="samples Sera samples were obtained from ten patients with suspected" exact="dengue fever" post="from the districts of Vassouras, Volta Redonda, Nova Iguaçu"/>
   <result pre="years-old male patient from the district of Volta Redonda manifesting" exact="dengue fever" post="in mid-March. Phylogenetic analysis performed over the two generated"/>
   <result pre="study, corresponded to young adults’ patients, both presenting a classic" exact="dengue fever" post="(Clinical end epidemiological characteristics are available in S2 Table)."/>
   <result pre="It is important to mention that also during 2019, a" exact="chikungunya" post="outbreak of great magnitude is scourging the state of"/>
   <result pre="49—N° 7, 2018. Monitoramento dos casos de dengue, febre de" exact="chikungunya" post="e febre pelo vírus Zika até a Semana Epidemiológica"/>
   <result pre="50, Jan 2019. Monitoramento dos casos de dengue, febre de" exact="chikungunya" post="e doença aguda pelo vírus Zika até a Semana"/>
   <result pre="Monitoramento dos casos de arboviroses urbanas transmitidas pelo Aedes (dengue," exact="chikungunya" post="e Zika) até a Semana Epidemiológica 12 de 2019"/>
   <result pre="Emerging and Zoonotic Infectious Diseases, CDC. Notes from the field:" exact="chikungunya" post="virus spreads in the Americas—Caribbean and South America, 2013–2014."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6906739\results\search\disease\results.xml">
   <result pre="as effective drugs to ameliorate murine acute lung injury after" exact="influenza" post="A H5N1 virus infection. mSystems 4:e00431-19. https://doi.org/10.1128/mSystems.00431-19. epub: 2019-12-12collection:"/>
   <result pre="new therapies with approved drugs. H5N1 is a highly pathogenic" exact="avian influenza" post="virus subtype that can cause severe acute lung injury"/>
   <result pre="therapies with approved drugs. H5N1 is a highly pathogenic avian" exact="influenza" post="virus subtype that can cause severe acute lung injury"/>
   <result pre="the anticancer drug flavopiridol could effectively ameliorate murine ALI after" exact="influenza" post="A H5N1 virus infection, suggesting that they might be"/>
   <result pre="indications. Abstract ABSTRACT Due to the limitations of effective treatments," exact="avian influenza" post="A H5N1 virus is the most lethal influenza virus"/>
   <result pre="Abstract ABSTRACT Due to the limitations of effective treatments, avian" exact="influenza" post="A H5N1 virus is the most lethal influenza virus"/>
   <result pre="treatments, avian influenza A H5N1 virus is the most lethal" exact="influenza" post="virus strain that causes severe acute lung injury (ALI)."/>
   <result pre="new therapies with approved drugs. H5N1 is a highly pathogenic" exact="avian influenza" post="virus subtype that can cause severe acute lung injury"/>
   <result pre="therapies with approved drugs. H5N1 is a highly pathogenic avian" exact="influenza" post="virus subtype that can cause severe acute lung injury"/>
   <result pre="the anticancer drug flavopiridol could effectively ameliorate murine ALI after" exact="influenza" post="A H5N1 virus infection, suggesting that they might be"/>
   <result pre="is the most common type among the viruses that cause" exact="influenza" post="epidemics, and influenza A viruses can be divided into"/>
   <result pre="common type among the viruses that cause influenza epidemics, and" exact="influenza" post="A viruses can be divided into various subtypes based"/>
   <result pre="on the viral surface (1). H5N1 is a highly pathogenic" exact="avian influenza" post="virus subtype that can cause severe acute lung injury"/>
   <result pre="the viral surface (1). H5N1 is a highly pathogenic avian" exact="influenza" post="virus subtype that can cause severe acute lung injury"/>
   <result pre="reliable approach to identify genes important in diseases such as" exact="acute myeloid leukemia," post="epithelial ovarian cancer, and schistosomiasis (5–7). Genomewide RNAi screening"/>
   <result pre="approach to identify genes important in diseases such as acute" exact="myeloid leukemia," post="epithelial ovarian cancer, and schistosomiasis (5–7). Genomewide RNAi screening"/>
   <result pre="genes important in diseases such as acute myeloid leukemia, epithelial" exact="ovarian cancer," post="and schistosomiasis (5–7). Genomewide RNAi screening has been used"/>
   <result pre="diseases such as acute myeloid leukemia, epithelial ovarian cancer, and" exact="schistosomiasis" post="(5–7). Genomewide RNAi screening has been used to identify"/>
   <result pre="host genes involved in the replication of the moderately pathogenic" exact="influenza" post="H1N1 virus (8–15). Data mining using public databases such"/>
   <result pre="RNAi screen of 19,424 genes to identify those important in" exact="influenza" post="A H5N1 virus infection. (B) Heat map of cell"/>
   <result pre="and Fig. S3C; Table S3). FIG 2 Drugs effective against" exact="influenza" post="A H5N1 virus infection in vitro and in vivo."/>
   <result pre="which, at low doses, are used in conventional treatments against" exact="influenza" post="virus-induced ALI (18, 19). Therefore, we focused on the"/>
   <result pre="revealed for the first time that ifenprodil is effective in" exact="avian influenza" post="A H5N1 virus infection and lung injury. FIG 4"/>
   <result pre="for the first time that ifenprodil is effective in avian" exact="influenza" post="A H5N1 virus infection and lung injury. FIG 4"/>
   <result pre="neoplasms; LI, lung diseases (interstitial); LO, lung diseases (obstructive); PF," exact="pulmonary fibrosis;" post="T, traditional indication; SLE, systemic lupus erythematosus; NETosis, neutrophil"/>
   <result pre="lung diseases (obstructive); PF, pulmonary fibrosis; T, traditional indication; SLE," exact="systemic lupus erythematosus;" post="NETosis, neutrophil extracellular trap-associated cell death; PR, progesterone receptor;"/>
   <result pre="diseases (obstructive); PF, pulmonary fibrosis; T, traditional indication; SLE, systemic" exact="lupus erythematosus;" post="NETosis, neutrophil extracellular trap-associated cell death; PR, progesterone receptor;"/>
   <result pre="signal-regulated kinase; PI3K, phosphatidylinositol 3-kinase; MAPK, mitogen-activated protein kinase; COPD," exact="chronic obstructive pulmonary disease." post="Detailed information about the enriched pathways and objects is"/>
   <result pre="for the treatment of several types of cancers, including leukemia," exact="liver cancer," post="and renal cancer, in clinical phase 2 trials (24–26)."/>
   <result pre="by blocking leukocyte adhesion and migration and that flavopiridol inhibited" exact="avian influenza" post="H7N9 virus replication in A549 cells but that its"/>
   <result pre="blocking leukocyte adhesion and migration and that flavopiridol inhibited avian" exact="influenza" post="H7N9 virus replication in A549 cells but that its"/>
   <result pre="treatment group, 5 are related to the immune response of" exact="lung disease" post="and 2 are involved in cancer (Fig. 4D). We"/>
   <result pre="immune response of lung disease and 2 are involved in" exact="cancer" post="(Fig. 4D). We found that dozens of genes in"/>
   <result pre="are widely used in large-scale experiments for the study of" exact="influenza" post="A virus based on convenience and economic considerations (11,"/>
   <result pre="Most genomewide RNAi screens use replication of the moderately pathogenic" exact="influenza" post="H1N1 virus as the readout of interference (8–15). Since"/>
   <result pre="as the readout of interference (8–15). Since the highly pathogenic" exact="avian influenza" post="H5N1 virus can cause significant cell death (28) and"/>
   <result pre="the readout of interference (8–15). Since the highly pathogenic avian" exact="influenza" post="H5N1 virus can cause significant cell death (28) and"/>
   <result pre="the anticancer drug flavopiridol as potential novel effective remedies for" exact="avian influenza" post="A H5N1 virus-infected lung injury. The mechanisms by which"/>
   <result pre="anticancer drug flavopiridol as potential novel effective remedies for avian" exact="influenza" post="A H5N1 virus-infected lung injury. The mechanisms by which"/>
   <result pre="of leukocytes such as NK cells and neutrophils could alleviate" exact="influenza" post="A virus-induced ALI (29, 30). We found that both"/>
   <result pre="was reported in the blood samples of patients with lethal" exact="avian influenza" post="A virus infection, and plasma cytokine and chemokine levels"/>
   <result pre="reported in the blood samples of patients with lethal avian" exact="influenza" post="A virus infection, and plasma cytokine and chemokine levels"/>
   <result pre="with traditional drug development strategies) for identifying novel remedies against" exact="avian influenza" post="virus-induced lung injury. This approach could be generalized for"/>
   <result pre="traditional drug development strategies) for identifying novel remedies against avian" exact="influenza" post="virus-induced lung injury. This approach could be generalized for"/>
   <result pre="At 24 h after transfection, A549 cells were infected with H5N1" exact="influenza" post="virus (multiplicity of infection [MOI], 3.0) or administered an"/>
   <result pre="therapeutically (3 h after infection) to A549 cells infected with H5N1" exact="influenza" post="virus, and cell viabilities were measured by MTS assay"/>
   <result pre="and bilateral lungs were collected to assess lung injury and" exact="pulmonary edema" post="(33). The animal experiments in this work were approved"/>
   <result pre="UyekiTM, YangW2008Clinical characteristics of 26 human cases of highly pathogenic" exact="avian influenza" post="A (H5N1) virus infection in China. PLoS One3:e2985. doi:10.1371/journal.pone.0002985.18716658"/>
   <result pre="YangW2008Clinical characteristics of 26 human cases of highly pathogenic avian" exact="influenza" post="A (H5N1) virus infection in China. PLoS One3:e2985. doi:10.1371/journal.pone.0002985.18716658"/>
   <result pre="screens identify KPNB1 as a new druggable oncogene in epithelial" exact="ovarian cancer." post="Proc Natl Acad Sci U S A114:E7301–E7310. doi:10.1073/pnas.1705441114.28811376 7.ZuberJ,"/>
   <result pre="AdamsDJ, XavierRJ, FarzanM, ElledgeSJ2009The IFITM proteins mediate cellular resistance to" exact="influenza" post="A H1N1 virus, West Nile virus, and dengue virus."/>
   <result pre="NewtonMA, AhlquistP, KawaokaY2008Drosophila RNAi screen identifies host genes important for" exact="influenza" post="virus replication. Nature454:890–893. doi:10.1038/nature07151.18615016 10.KarlasA, MachuyN, ShinY, PleissnerKP, ArtariniA,"/>
   <result pre="RudelT, MeyerTF2010Genome-wide RNAi screen identifies human host factors crucial for" exact="influenza" post="virus replication. Nature463:818–822. doi:10.1038/nature08760.20081832 11.KonigR, StertzS, ZhouY, InoueA, HoffmannHH,"/>
   <result pre="IdekerT, Garcia-SastreA, YoungJA, PaleseP, ShawML, ChandaSK2010Human host factors required for" exact="influenza" post="virus replication. Nature463:813–817. doi:10.1038/nature08699.20027183 12.ShapiraSD, Gat-ViksI, ShumBO, DricotA, de"/>
   <result pre="LaiMM2013Pooled RNAi screen identifies ubiquitin ligase Itch as crucial for" exact="influenza" post="A virus release from the endosome during virus entry."/>
   <result pre="Intensive Care Med42:829–840. doi:10.1007/s00134-015-4095-4.26508525 19. 2017Erratum: clinical practice guideline of" exact="acute respiratory distress syndrome." post="Tuberc Respir Dis (Seoul)80:95. doi:10.4046/trd.2017.80.1.95.28119754 20.TajimaN, KarakasE, GrantT, SimorowskiN,"/>
   <result pre="22.SaidSI, BerishaHI, PakbazH1996Excitotoxicity in the lung: N-methyl- d-aspartate-induced, nitric oxide-dependent," exact="pulmonary edema" post="is attenuated by vasoactive intestinal peptide and by inhibitors"/>
   <result pre="study of sequential irinotecan and flavopiridol in patients with advanced" exact="hepatocellular carcinoma." post="Gastrointest Cancer Res5:185–189.23293699 25.StadlerWM, VogelzangNJ, AmatoR, SosmanJ, TaberD, LiebowitzD,"/>
   <result pre="O'DonnellJ, JohnsonS, TrippRA2015Repurposing kinase inhibitors as antiviral agents to control" exact="influenza" post="A virus replication. Assay Drug Dev Technol13:638–649. doi:10.1089/adt.2015.0003.drrr.26192013 28.SunY,"/>
   <result pre="JinN, JiangC2012Inhibition of autophagy ameliorates acute lung injury caused by" exact="avian influenza" post="A H5N1 infection. Sci Signal5:ra16. doi:10.1126/scisignal.2001931.22355189 29.WangJ, LiF, SunR,"/>
   <result pre="JiangC2012Inhibition of autophagy ameliorates acute lung injury caused by avian" exact="influenza" post="A H5N1 infection. Sci Signal5:ra16. doi:10.1126/scisignal.2001931.22355189 29.WangJ, LiF, SunR,"/>
   <result pre="and neutrophil extracellular traps contribute to acute lung injury of" exact="influenza" post="pneumonitis. Am J Pathol179:199–210. doi:10.1016/j.ajpath.2011.03.013.21703402 31.de JongMD, SimmonsCP, ThanhTT,"/>
   <result pre="Ha doQ, GuanY, PeirisJS, ChinhNT, HienTT, FarrarJ2006Fatal outcome of human" exact="influenza" post="A (H5N1) is associated with high viral load and"/>
   <result pre="LiN, LiD, JinN, PenningerJM, JiangC2014Angiotensin-converting enzyme 2 protects from lethal" exact="avian influenza" post="A H5N1 infections. Nat Commun5:3594. doi:10.1038/ncomms4594.24800825"/>
   <result pre="LiD, JinN, PenningerJM, JiangC2014Angiotensin-converting enzyme 2 protects from lethal avian" exact="influenza" post="A H5N1 infections. Nat Commun5:3594. doi:10.1038/ncomms4594.24800825"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6906816\results\search\disease\results.xml">
   <result pre="variable was determined by analyzing the statistics corresponding to the" exact="influenza" post="and viral pneumonia in 2009 since that year was"/>
   <result pre="determined by analyzing the statistics corresponding to the influenza and" exact="viral pneumonia" post="in 2009 since that year was critical for these"/>
   <result pre="by analyzing the statistics corresponding to the influenza and viral" exact="pneumonia" post="in 2009 since that year was critical for these"/>
   <result pre="the rate of transmitted diseases through the air such as" exact="influenza" post="and common cold [3]. An overcrowding study indicates that"/>
   <result pre="of transmitted diseases through the air such as influenza and" exact="common cold" post="[3]. An overcrowding study indicates that different levels exist:"/>
   <result pre="is that of respiratory health, measured by the presence of" exact="respiratory disease" post="or by lung function�? [7]. This kind of housing"/>
   <result pre="with physical and mental health outcomes�? [25]. On the contrary," exact="influenza" post="is &quot;… an acute respiratory infectious disease related to"/>
   <result pre="[25]. On the contrary, influenza is &quot;… an acute respiratory" exact="infectious disease" post="related to climate and seasonal clustering cycles�? [26], which"/>
   <result pre="seasonal epidemics occur mainly during winter, while in tropical regions," exact="influenza" post="may occur throughout the year, causing outbreaks more irregularly�?"/>
   <result pre="occur throughout the year, causing outbreaks more irregularly�? [26]. Most" exact="influenza" post="infections are spread by droplets of several microns in"/>
   <result pre="&quot;the airborne route is a potentially important transmission pathway for" exact="influenza" post="in indoor environments, especially in unventilated conditions�? [28]. It"/>
   <result pre="in unventilated conditions�? [28]. It supposed that most cases of" exact="influenza" post="are transmitted by aerosol &quot;suspensions in air (or in"/>
   <result pre="housing during the night. A study about the transmission of" exact="influenza" post="A(H1N1)pdm09 in the pandemic and postpandemic seasons in a"/>
   <result pre="being the children the most affected [30]. The percentage of" exact="influenza" post="contagion is very high worldwide so that the development"/>
   <result pre="is very high worldwide so that the development of symptomatic" exact="influenza" post="A or B each year in children represents about"/>
   <result pre="relative humidity is 20–70% (ideal relative humidity is 40–50%). Although" exact="influenza" post="is a common illness, it can condition the daily"/>
   <result pre="the daily activities of an affected person. In addition, new" exact="influenza" post="viruses which threaten the human life have been identified,"/>
   <result pre="have been identified, such as the one that caused the" exact="influenza" post="pandemic [33] in 2009 [34]. The World Health Organization"/>
   <result pre="[34]. The World Health Organization (WHO) reported that &quot;… H5N1" exact="influenza" post="virus has caused the infection of 650 people and"/>
   <result pre="386 since 2003�? [35]. The routes of transmission of the" exact="influenza" post="virus in humans have not been defined, but evidence"/>
   <result pre="bird-to-human, possibly environment-to-human, and, in limited cases, human-to-human transmission human" exact="influenza" post="A (H5N1) infections are limited [36]. The rapid transmission"/>
   <result pre="projects and respiratory diseases in Ecuador. Specifically, the relation between" exact="influenza" post="virus transmission, temperature, and relative humidity (RH), as potential"/>
   <result pre="some relations exist. In relation to the risk factors for" exact="influenza" post="virus transmission by contagion, the threshold encountered in one"/>
   <result pre="Respiratory Diseases Registry Definition The database used to obtain the" exact="influenza" post="morbidity was the hospital registry made available by the"/>
   <result pre="selected included the J09-influenza, related to the zoonotic or pandemic" exact="influenza" post="virus, the J10-influenza related to the seasonal influenza virus,"/>
   <result pre="or pandemic influenza virus, the J10-influenza related to the seasonal" exact="influenza" post="virus, the J11-influenza, which is a not identified virus,"/>
   <result pre="has been included since its propagation is similar to the" exact="influenza" post="(other pneumonia have bacterial cause). 2.4. Definition of the"/>
   <result pre="included since its propagation is similar to the influenza (other" exact="pneumonia" post="have bacterial cause). 2.4. Definition of the Indoor Conditions"/>
   <result pre="constructed by counting how many parishes with high rate of" exact="influenza" post="also have, either an indoor temperature over 20°C and"/>
   <result pre="&quot;b�?); on the contrary, the parishes with low rate of" exact="influenza" post="are also divided between housing with an indoor temperature"/>
   <result pre="to discriminate between parishes with exposure to adequate conditions for" exact="influenza" post="transmission from parishes with less exposure. The map in"/>
   <result pre="the indicators used to determine the severity of a possible" exact="influenza" post="pandemic is the transmissibility of an influenza virus, revealing"/>
   <result pre="of a possible influenza pandemic is the transmissibility of an" exact="influenza" post="virus, revealing the importance of finding a method to"/>
   <result pre="those of social housing. Statistically, these conditions could contribute to" exact="influenza" post="virus contagion, particularly during August and October, as a"/>
   <result pre="their inhabitants is affected. In addition, an increased rate of" exact="influenza" post="spreading, in combination with overcrowding, converts these housings in"/>
   <result pre="(Seasonal)2018Geneva, SwitzerlandWHOhttp://www.who.int/news-room/fact-sheets/detail/influenza-%28seasonal%29 27NicholsonK. G.WoodJ. M.ZambonM.InfluenzaThe Lancet200336293971733174510.1016/S0140-6736(03)14854-4 28WeberT. P.StilianakisN. I.Inactivation of" exact="influenza" post="A viruses in the environment and modes of transmission:"/>
   <result pre="a critical reviewJournal of Infection200857536137310.1016/j.jinf.2008.08.01318848358 29TellierR.Review of aerosol transmission of" exact="influenza" post="a virusEmerging Infectious Diseases200612111657166210.3201/eid1211.06042617283614 30CasadoI.Martínez-BazI.BurguiR.et al.Household transmission of influenza"/>
   <result pre="of influenza a virusEmerging Infectious Diseases200612111657166210.3201/eid1211.06042617283614 30CasadoI.Martínez-BazI.BurguiR.et al.Household transmission of" exact="influenza" post="A(H1N1)pdm09 in the pandemic and post-pandemic seasonsPloS One20149910.1371/journal.pone.0108485 31WeitzmanM.BatenA.RosenthalD."/>
   <result pre="associated socio- economic outcomesCochrane Database of Systematic Reviews2013210.1002/14651858.CD008657.pub2 33KatayamaY.OhgiT.MitomaY.HifumiE.EgashiraN.Detection of" exact="influenza" post="virus by a biosensor based on the method combining"/>
   <result pre="36collab: World Health Organization (WHO)The writing committee, consultation on human" exact="influenza" post="a/H5, avian influenza a (H5N1) infection in humansThe New"/>
   <result pre="Health Organization (WHO)The writing committee, consultation on human influenza a/H5," exact="avian influenza" post="a (H5N1) infection in humansThe New England Journal of"/>
   <result pre="Organization (WHO)The writing committee, consultation on human influenza a/H5, avian" exact="influenza" post="a (H5N1) infection in humansThe New England Journal of"/>
   <result pre="en epidemiología, primera parteRevista Mexicana de Pediatría19986527683https://www.medigraphic.com/pdfs/pediat/sp-1998/sp982i.pdf 57HagbomM.NordgrenJ.NybomR.HedlundK.-O.WigzellH.SvenssonL.Ionizing air affects" exact="influenza" post="virus infectivity and prevents airborne-transmissionScientific Reports20155111010.1038/srep11431 58LifshitzA.El diagnóstico clínico"/>
   <result pre="and the registered cases of J09, J10, J11-influenza, and J12-viral" exact="pneumonia" post="assuming that &quot;the relationship between climate variability and illness"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6908683\results\search\disease\results.xml">
   <result pre="adults, ZIKV infection is associated with Guillain-Barré syndrome (GBS), an" exact="autoimmune disease" post="that can lead to paralysis4,5. One out of seven"/>
   <result pre="two licensed, live-attenuated flavivirus vaccines (yellow fever 17D and Japanese" exact="encephalitis" post="SA 14-14-2)13. Despite the above promising progress, a number"/>
   <result pre="availability of clinically licensed vaccines for four flaviviruses (yellow fever," exact="tick-borne encephalitis," post="Japanese encephalitis, and dengue). Compared with the licensed flavivirus"/>
   <result pre="this idea, maternal vaccination is recommended by the WHO for" exact="yellow fever" post="and Japanese encephalitis vaccines during outbreaks in endemic regions"/>
   <result pre="is recommended by the WHO for yellow fever and Japanese" exact="encephalitis" post="vaccines during outbreaks in endemic regions or when the"/>
   <result pre="successful maternal vaccines, such as Tetanus-Diphtheria-Pertussis (Tdap) vaccine and inactivated" exact="influenza" post="vaccine (IIV), are recommended by the Center for Disease"/>
   <result pre="and antibodies to dengue virus promote infection and Zika virus-induced" exact="microcephaly" post="in fetusesSci. Adv.20195eaav320810.1126/sciadv.aav320830820456 36.CamargosVNet al.In-depth characterization of congenital Zika"/>
   <result pre="after Zika virus infectionScience Immunology2018319eaao168010.1126/sciimmunol.aao168029305462 44.collab: WHO.Vaccines and vaccination against" exact="yellow fever." post="WHO position paper–June 2013Wkly Epidemiol Rec.2013269283 45.collab: WHO.Japanese Encephalitis"/>
   <result pre="position paper—February 2015Wkly. Epidemiol. Rec.201590698725726573 46.SawyerMLiangJLMessonnierNClarkTAUpdated recommendations for use of" exact="tetanus" post="toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine (Tdap)"/>
   <result pre="Epidemiol. Rec.201590698725726573 46.SawyerMLiangJLMessonnierNClarkTAUpdated recommendations for use of tetanus toxoid, reduced" exact="diphtheria" post="toxoid, and acellular pertussis vaccine (Tdap) in pregnant women—Advisory"/>
   <result pre="for use of tetanus toxoid, reduced diphtheria toxoid, and acellular" exact="pertussis" post="vaccine (Tdap) in pregnant women—Advisory Committee on Immunization Practices"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6908948\results\search\disease\results.xml">
   <result pre="by pathology laboratories in Australia. Others, such as Murray Valley" exact="encephalitis" post="(MVEV) and Kunjin (KUNV) virus infections may be diagnosed"/>
   <result pre="epidemics and intercontinental spread of hitherto obscure diseases such as" exact="chikungunya" post="and Zika have highlighted the significant threat to global"/>
   <result pre="(Fraser, 1986; Phillips et al., 1990). The flaviviruses Murray Valley" exact="encephalitis" post="(MVEV) and West Nile virus (Kunjin strain, KUNV) cause"/>
   <result pre="the possibility that blood donors had been vaccinated against either" exact="yellow fever" post="or Japanese encephalitis. However, neither yellow fever nor Japanese"/>
   <result pre="vaccinated against either yellow fever or Japanese encephalitis. However, neither" exact="yellow fever" post="nor Japanese encephalitis is endemic to Australia so immunisation"/>
   <result pre="fever or Japanese encephalitis. However, neither yellow fever nor Japanese" exact="encephalitis" post="is endemic to Australia so immunisation would be recommended"/>
   <result pre="Trop. Med. Hyg.62430–438. 10.1016/0035-9203(68)90095-34385483 EvansI. A.HuestonL.DoggettS. L. (2009). Murray Valley" exact="encephalitis" post="virus.NSW Public Health Bull.20195–196. FaddyH.DunfordM.SeedC.OldsA.HarleyD.DeanM.et al. (2015). Seroprevalence of"/>
   <result pre="analysis of the envelope and non-structural glycoproteins of Murray Valley" exact="encephalitis" post="virus.J. Gen. Virol.712923–2930. 10.1099/0022-1317-71-12-29231703213 HalsteadS. �?NimmannityaS.CohenS. N. (1970). Observations"/>
   <result pre="10.1099/0022-1317-71-12-29231703213 HalsteadS. �?NimmannityaS.CohenS. N. (1970). Observations related to pathogenesis of" exact="dengue hemorrhagic fever." post="IV. relation of disease severity to antibody response and"/>
   <result pre="antibodies and host cells in plaque enhancement of Murray Valley" exact="encephalitis" post="virus.J. Virol.46394–404. 6842678 MarshallI. D.WoodroofeG. M.HirschS. (1982). Viruses recovered"/>
   <result pre="A.RichardsJ. S.FaddyH. M.LeydonJ.MoranR.NicholsonS.et al. (2013). Low seroprevalence of Murray Valley" exact="encephalitis" post="and Kunjin viruses in an opportunistic serosurvey, victoria 2011.Aust."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6912104\results\search\disease\results.xml">
   <result pre="modulation of innate immune responses in human primary cells by" exact="influenza" post="A viruses carrying human or avian nonstructural protein 1."/>
   <result pre="different cellular localization dynamics in infected cells. Abstract ABSTRACT The" exact="influenza" post="A virus (IAV) nonstructural protein 1 (NS1) contributes to"/>
   <result pre="in infected cells. KEYWORDS NS1 protein dendritic cells epithelial cells" exact="influenza" post="innate immunity interferons Funding HHS | NIH | National"/>
   <result pre="replication and represents an early barrier against viruses such as" exact="influenza" post="A virus (IAV). Mammalian cells have developed sophisticated antiviral"/>
   <result pre="proteins (11–13). Different mechanisms have been reported by which the" exact="influenza" post="NS1 protein counteracts the innate immune responses (reviewed in"/>
   <result pre="proteins from different hosts. RESULTS Characterization of recombinant A/Puerto Rico/08/34" exact="influenza" post="viruses expressing different NS1 proteins. To assess the impact"/>
   <result pre="and representation of the wild-type (WT) segments of eight of" exact="influenza" post="A vRNAs which encode two proteins (NS1 and NEP)"/>
   <result pre="sequences representative of the global diversity of NS1 proteins from" exact="influenza" post="A viruses. Sequences used in this study are shown"/>
   <result pre="firefly luciferase (FF-Luc) IFN-β promoter reporter plasmid (p125Luc) and a" exact="herpes simplex" post="virus-thymidine kinase promoter-driven Renilla luciferase (Ren-Luc) plasmid. At 24"/>
   <result pre="of the determinants associated with highly virulent features of some" exact="influenza" post="A viruses in mammalian hosts (58–60). As NS1 proteins"/>
   <result pre="different patterns of innate immune responses. These data suggest that" exact="avian influenza" post="viruses might be more efficient at antagonizing innate immune"/>
   <result pre="patterns of innate immune responses. These data suggest that avian" exact="influenza" post="viruses might be more efficient at antagonizing innate immune"/>
   <result pre="Multiple NS1 functions occur in the nucleus and cytoplasm during" exact="influenza" post="infection (41, 57, 67); therefore, its intracellular localization dynamics"/>
   <result pre="1. For the detection of viral segments of A/Puerto Rico/8/34" exact="influenza" post="virus, we used specific primers for M1, NP, HA,"/>
   <result pre="reagents and insightful discussions. References REFERENCES 1.IwasakiA, PillaiPS2014Innate immunity to" exact="influenza" post="virus infection. Nat Rev Immunol14:315–328. doi:10.1038/nri3665.24762827 2.GuillotL, Le GofficR,"/>
   <result pre="immune response of lung epithelial cells to double-stranded RNA and" exact="influenza" post="A virus. J Biol Chem280:5571–5580. doi:10.1074/jbc.M410592200.15579900 3.LundJM, AlexopoulouL, SatoA,"/>
   <result pre="DoyleSE, KotenkoSV, ThanopoulouK, AndreakosE2017Interferon-lambda mediates non-redundant front-line antiviral protection against" exact="influenza" post="virus infection without compromising host fitness. Immunity46:875–890.e6. doi:10.1016/j.immuni.2017.04.025.28514692 7.OnoguchiK,"/>
   <result pre="Biol Chem282:7576–7581. doi:10.1074/jbc.M608618200.17204473 8.HaleBG, AlbrechtRA, Garcia-SastreA2010Innate immune evasion strategies of" exact="influenza" post="viruses. Future Microbiol5:23–41. doi:10.2217/fmb.09.108.20020828 9.KlemmC, BoergelingY, LudwigS, EhrhardtC2018Immunomodulatory nonstructural"/>
   <result pre="Future Microbiol5:23–41. doi:10.2217/fmb.09.108.20020828 9.KlemmC, BoergelingY, LudwigS, EhrhardtC2018Immunomodulatory nonstructural proteins of" exact="influenza" post="A viruses. Trends Microbiol26:624–636. doi:10.1016/j.tim.2017.12.006.29373257 10.AyllonJ, Garcia-SastreA2015The NS1 protein:"/>
   <result pre="doi:10.1007/82_2014_400.25007846 11.SuarezDL, PerdueML1998Multiple alignment comparison of the non-structural genes of" exact="influenza" post="A viruses. Virus Res54:59–69. doi:10.1016/s0168-1702(98)00011-2.9660072 12.HaleBG, BarclayWS, RandallRE, RussellRJ2008Structure"/>
   <result pre="viruses. Virus Res54:59–69. doi:10.1016/s0168-1702(98)00011-2.9660072 12.HaleBG, BarclayWS, RandallRE, RussellRJ2008Structure of an" exact="avian influenza" post="A virus NS1 protein effector domain. Virology378:1–5. doi:10.1016/j.virol.2008.05.026.18585749 13.DundonWG,"/>
   <result pre="Virus Res54:59–69. doi:10.1016/s0168-1702(98)00011-2.9660072 12.HaleBG, BarclayWS, RandallRE, RussellRJ2008Structure of an avian" exact="influenza" post="A virus NS1 protein effector domain. Virology378:1–5. doi:10.1016/j.virol.2008.05.026.18585749 13.DundonWG,"/>
   <result pre="Virology378:1–5. doi:10.1016/j.virol.2008.05.026.18585749 13.DundonWG, CapuaI2009A closer look at the NS1 of" exact="influenza" post="virus. Viruses1:1057–1072. doi:10.3390/v1031057.21994582 14.HaleBG, RandallRE, OrtinJ, JacksonD2008The multifunctional NS1"/>
   <result pre="Viruses1:1057–1072. doi:10.3390/v1031057.21994582 14.HaleBG, RandallRE, OrtinJ, JacksonD2008The multifunctional NS1 protein of" exact="influenza" post="A viruses. J Gen Virol89:2359–2376. doi:10.1099/vir.0.2008/004606-0.18796704 15.MarcD2014Influenza virus non-structural"/>
   <result pre="I-mediated induction of beta interferon by the NS1 protein of" exact="influenza" post="A virus. J Virol81:514–524. doi:10.1128/JVI.01265-06.17079289 17.JurekaAS, KleinpeterAB, CornilescuG, CornilescuCC,"/>
   <result pre="novel interaction between the NS1 protein derived from the 1918" exact="influenza" post="virus and RIG-I. Structure23:2001–2010. doi:10.1016/j.str.2015.08.007.26365801 18.GackMU, AlbrechtRA, UranoT, InnKS,"/>
   <result pre="GackMU2012Species-specific inhibition of RIG-I ubiquitination and IFN induction by the" exact="influenza" post="A virus NS1 protein. PLoS Pathog8:e1003059. doi:10.1371/journal.ppat.1003059.23209422 20.TalonJ, HorvathCM,"/>
   <result pre="Garcia-SastreA2000Activation of interferon regulatory factor 3 is inhibited by the" exact="influenza" post="A virus NS1 protein. J Virol74:7989–7996. doi:10.1128/jvi.74.17.7989-7996.2000.10933707 21.WangX, LiM,"/>
   <result pre="doi:10.1128/jvi.74.24.11566-11573.2000.11090154 22.MinJY, KrugRM2006The primary function of RNA binding by the" exact="influenza" post="A virus NS1 protein in infected cells: inhibiting the"/>
   <result pre="PKR-mediated inhibition of replication. J Virol74:6203–6206. doi:10.1128/jvi.74.13.6203-6206.2000.10846107 24.HatadaE, SaitoS, FukudaR1999Mutant" exact="influenza" post="viruses with a defective NS1 protein cannot block the"/>
   <result pre="infected cells. J Virol73:2425–2433.9971827 25.LuY, WambachM, KatzeMG, KrugRM1995Binding of the" exact="influenza" post="virus NS1 protein to double-stranded RNA inhibits the activation"/>
   <result pre="factor. Virology214:222–228. doi:10.1006/viro.1995.9937.8525619 26.MinJY, LiS, SenGC, KrugRM2007A site on the" exact="influenza" post="A virus NS1 protein mediates both inhibition of PKR"/>
   <result pre="27.TanSL, KatzeMG1998Biochemical and genetic evidence for complex formation between the" exact="influenza" post="A virus NS1 protein and the interferon-induced PKR protein"/>
   <result pre="AraminiJ, ZhaoL, MarklundJ, KuoRL, TwuKY, ArnoldE, KrugRM, MontelioneGT2008Structural basis for" exact="suppression" post="of a host antiviral response by influenza A virus."/>
   <result pre="MontelioneGT2008Structural basis for suppression of a host antiviral response by" exact="influenza" post="A virus. Proc Natl Acad Sci U S A105:13093–13098."/>
   <result pre="S A105:13093–13098. doi:10.1073/pnas.0805213105.18725644 29.KochsG, García-SastreA, Martínez-SobridoL2007Multiple anti-interferon actions of the" exact="influenza" post="A virus NS1 protein. J Virol81:7011–7021. doi:10.1128/JVI.02581-06.17442719 30.NoahDL, TwuKY,"/>
   <result pre="protein. J Virol81:7011–7021. doi:10.1128/JVI.02581-06.17442719 30.NoahDL, TwuKY, KrugRM2003Cellular antiviral responses against" exact="influenza" post="A virus are countered at the posttranscriptional level by"/>
   <result pre="and blocks mRNA nucleocytoplasmic transport. EMBO J13:704–712. doi:10.1002/j.1460-2075.1994.tb06310.x.8313914 34.QiuY, KrugRM1994The" exact="influenza" post="virus NS1 protein is a poly(A)-binding protein that inhibits"/>
   <result pre="a cellular target for NS1 protein, a translational activator of" exact="influenza" post="virus. Mol Cell Biol20:6259–6268. doi:10.1128/mcb.20.17.6259-6268.2000.10938102 36.BurguiI, AragonT, OrtinJ, NietoA2003PABP1"/>
   <result pre="Biol20:6259–6268. doi:10.1128/mcb.20.17.6259-6268.2000.10938102 36.BurguiI, AragonT, OrtinJ, NietoA2003PABP1 and eIF4GI associate with" exact="influenza" post="virus NS1 protein in viral mRNA translation initiation complexes."/>
   <result pre="J Gen Virol84:3263–3274. doi:10.1099/vir.0.19487-0.14645908 37.FalconAM, FortesP, MarionRM, BelosoA, OrtinJ1999Interaction of" exact="influenza" post="virus NS1 protein and the human homologue of Staufen"/>
   <result pre="KillipMJ, RandallRE, RussellRJ2010Structural insights into phosphoinositide 3-kinase activation by the" exact="influenza" post="A virus NS1 protein. Proc Natl Acad Sci U"/>
   <result pre="Sci U S A107:1954–1959. doi:10.1073/pnas.0910715107.20133840 40.ZhirnovOP, KlenkHD2007Control of apoptosis in" exact="influenza" post="virus-infected cells by up-regulation of Akt and p53 signaling."/>
   <result pre="Apoptosis12:1419–1432. doi:10.1007/s10495-007-0071-y.17468837 41.GreenspanD, PaleseP, KrystalM1988Two nuclear location signals in the" exact="influenza" post="virus NS1 nonstructural protein. J Virol62:3020–3026.2969057 42.LiY, YamakitaY, KrugRM1998Regulation"/>
   <result pre="by an adjacent inhibitory sequence: the effector domain of the" exact="influenza" post="virus NS1 protein. Proc Natl Acad Sci U S"/>
   <result pre="Sci U S A95:4864–4869. doi:10.1073/pnas.95.9.4864.9560194 43.RamosI, Fernandez-SesmaA2012Innate immunity to H5N1" exact="influenza" post="viruses in humans. Viruses4:3363–3388. doi:10.3390/v4123363.23342363 44.Fernandez-SesmaA, MarukianS, EbersoleBJ, KaminskiD,"/>
   <result pre="45.HayeK, BurmakinaS, MoranT, Garcia-SastreA, Fernandez-SesmaA2009The NS1 protein of a human" exact="influenza" post="virus inhibits type I interferon production and the induction"/>
   <result pre="conventional and plasmacytoid human dendritic cells enhances their activation by" exact="influenza" post="virus. PLoS Pathog4:e1000193. doi:10.1371/journal.ppat.1000193.18974865 47.RamosI, CarneroE, Bernal-RubioD, SeibertCW, WesteraL,"/>
   <result pre="García-SastreA, Fernandez-SesmaA2013Contribution of double-stranded RNA and CPSF30 binding domains of" exact="influenza" post="virus NS1 to the inhibition of type I interferon"/>
   <result pre="species reveal multiple evolutionary lines for the NS1 gene of" exact="influenza" post="A viruses. Cell Host Microbe doi:10.2139/ssrn.3380257. 49.DonelanNR, BaslerCF, Garcia-SastreA2003A"/>
   <result pre="A viruses. Cell Host Microbe doi:10.2139/ssrn.3380257. 49.DonelanNR, BaslerCF, Garcia-SastreA2003A recombinant" exact="influenza" post="A virus expressing an RNA-binding-defective NS1 protein induces high"/>
   <result pre="MontelioneGT, KrugRM1999RNA binding by the novel helical domain of the" exact="influenza" post="virus NS1 protein requires its dimer structure and a"/>
   <result pre="LagerKM, JankeBH, Garcia-SastreA, RichtJA2005Mutations in the NS1 protein of swine" exact="influenza" post="virus impair anti-interferon activity and confer attenuation in pigs."/>
   <result pre="of normal human bronchial epithelial cells as a model for" exact="influenza" post="A infections in human distal trachea. J Histochem Cytochem63:312–328."/>
   <result pre="55.KlinkhammerJ, SchnepfD, YeL, SchwaderlappM, GadHH, HartmannR, GarcinD, MahlakoivT, StaeheliP2018IFN-λ prevents" exact="influenza" post="virus spread from the upper airways to the lungs"/>
   <result pre="CloutierA, MaroisI, ColomboE, DesiletsA, VerreaultC, LeducR, MarsaultE, RichterMV2013Matriptase proteolytically activates" exact="influenza" post="virus and promotes multicycle replication in the human airway"/>
   <result pre="J Virol87:4237–4251. doi:10.1128/JVI.03005-12.23365447 57.NewbyCM, SabinL, PekoszA2007The RNA binding domain of" exact="influenza" post="A virus NS1 protein affects secretion of tumor necrosis"/>
   <result pre="Iwatsuki-HorimotoK, HorimotoT, KawaokaY2010The HA and NS genes of human H5N1" exact="influenza" post="A virus contribute to high virulence in ferrets. PLoS"/>
   <result pre="SalvatoreM, PerdueML, SwayneDE, Garcia-SastreA, PaleseP, TaubenbergerJK2001Sequence of the 1918 pandemic" exact="influenza" post="virus nonstructural gene (NS) segment and characterization of recombinant"/>
   <result pre="Acad Sci U S A98:2746–2751. doi:10.1073/pnas.031575198.11226311 60.SeoSH, HoffmannE, WebsterRG2002Lethal H5N1" exact="influenza" post="viruses escape host anti-viral cytokine responses. Nat Med8:950–954. doi:10.1038/nm757.12195436"/>
   <result pre="cytokine responses. Nat Med8:950–954. doi:10.1038/nm757.12195436 61.KoutsakosM, KedzierskaK, SubbaraoK2019Immune responses to" exact="avian influenza" post="viruses. J Immunol202:382–391. doi:10.4049/jimmunol.1801070.30617120 62.CarrilloB, ChoiJM, BornholdtZA, SankaranB, RiceAP,"/>
   <result pre="responses. Nat Med8:950–954. doi:10.1038/nm757.12195436 61.KoutsakosM, KedzierskaK, SubbaraoK2019Immune responses to avian" exact="influenza" post="viruses. J Immunol202:382–391. doi:10.4049/jimmunol.1801070.30617120 62.CarrilloB, ChoiJM, BornholdtZA, SankaranB, RiceAP,"/>
   <result pre="viruses. J Immunol202:382–391. doi:10.4049/jimmunol.1801070.30617120 62.CarrilloB, ChoiJM, BornholdtZA, SankaranB, RiceAP, PrasadBV2014The" exact="influenza" post="A virus protein NS1 displays structural polymorphism. J Virol88:4113–4122."/>
   <result pre="GonzalezJ, PrietoK, Rosas-AcostaG2013SUMOylation affects the interferon blocking activity of the" exact="influenza" post="A nonstructural protein NS1 without affecting its stability or"/>
   <result pre="SelmanM, PelchatM, JiaJJ, StintziA, BrownEG2013Identification of adaptive mutations in the" exact="influenza" post="A virus non-structural 1 gene that increase cytoplasmic localization"/>
   <result pre="KinnunenL, FagerlundR, IkonenN, TwuKY, KrugRM, JulkunenI2007Nuclear and nucleolar targeting of" exact="influenza" post="A virus NS1 protein: striking differences between different virus"/>
   <result pre="different virus subtypes. J Virol81:5995–6006. doi:10.1128/JVI.01714-06.17376915 68.RobbNC, FodorE2012The accumulation of" exact="influenza" post="A virus segment 7 spliced mRNAs is regulated by"/>
   <result pre="Nat Microbiol1:16069. doi:10.1038/nmicrobiol.2016.69.27572970 70.TonnessenR, HaugeAG, HansenEF, RimstadE, JonassenCM2013Host restrictions of" exact="avian influenza" post="viruses: in silico analysis of H13 and H16 specific"/>
   <result pre="Microbiol1:16069. doi:10.1038/nmicrobiol.2016.69.27572970 70.TonnessenR, HaugeAG, HansenEF, RimstadE, JonassenCM2013Host restrictions of avian" exact="influenza" post="viruses: in silico analysis of H13 and H16 specific"/>
   <result pre="LuX, LiJ, BerubeN, GiestKL, LiuQ, AndersonDH, ZhouY2010Genetically engineered, biarsenically labeled" exact="influenza" post="virus allows visualization of viral NS1 protein in living"/>
   <result pre="ChenH2017The role of nuclear NS1 protein in highly pathogenic H5N1" exact="influenza" post="viruses. Microbes Infect19:587–596. doi:10.1016/j.micinf.2017.08.011.28903072 73.MelenK, TynellJ, FagerlundR, RousselP, Hernandez-VerdunD,"/>
   <result pre="ZhangXE2010New regulatory mechanisms for the intracellular localization and trafficking of" exact="influenza" post="A virus NS1 protein revealed by comparative analysis of"/>
   <result pre="Gen Virol91:2907–2917. doi:10.1099/vir.0.024943-0.20826615 75.FodorE, DevenishL, EngelhardtOG, PaleseP, BrownleeGG, Garcia-SastreA1999Rescue of" exact="influenza" post="A virus from recombinant DNA. J Virol73:9679–9682.10516084 76.RobinsonJT, ThorvaldsdottirH,"/>
   <result pre="WatanabeT, FujiiK, GotoH, WatanabeS, NodaT, KawaokaY2011Strand-specific real-time RT-PCR for distinguishing" exact="influenza" post="vRNA, cRNA, and mRNA. J Virol Methods173:1–6. doi:10.1016/j.jviromet.2010.12.014.21185869 78.LivakKJ,"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6912272\results\search\disease\results.xml">
   <result pre="flavivirus belonging to the Flaviviridae family, like Dengue virus (DENV)," exact="yellow fever" post="virus (YFV) or West Nile virus (WNV), has become"/>
   <result pre="features of the disease have been reported. Complications such as" exact="microcephaly" post="in newborns or Guillain–Barré syndrome (GBS) in adults were"/>
   <result pre="to their advantage [11]. One example is the case of" exact="chikungunya" post="virus (CHIKV), an arbovirus of the alphavirus family, which"/>
   <result pre="relatively slow. For several of them such as DENV, Japanese" exact="encephalitis" post="virus (JEV) and WNV, apoptosis has been shown to"/>
   <result pre="persistence in the brain has been reported to explain the" exact="microcephaly" post="observed in infected newborns [19]. In this study we"/>
   <result pre="roles of apoptosis, autophagy and unfolded protein response in arbovirus," exact="influenza" post="virus, and HIV infectionsVirulence20191037641310.1080/21505594.2019.160580330966844 11.RoulstonA.MarcellusR.C.BrantonP.E.Viruses and ApoptosisAnnu. Rev. Microbiol.19995357762810.1146/annurev.micro.53.1.57710547702"/>
   <result pre="progenitors similar to mutations involved in severe forms of genetic" exact="microcephaly" post="and p53Cell Death Dis.20167e244010.1038/cddis.2016.26627787521 34.LeeC.-J.LiaoC.-L.LinY.-L.Flavivirus Activates Phosphatidylinositol 3-Kinase Signaling"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6912530\results\search\disease\results.xml">
   <result pre="Mosquito-borne Zika (ZIKV), dengue (DENV), Yellow fever (YFV) and Japanese" exact="encephalitis" post="(JEV) viruses belonging to flavivirus genus (Flaviviridae family), are"/>
   <result pre="determinant of ZIKV virulence in a mouse model of viral" exact="encephalitis" post="[22,26]. In invertebrate vectors, ZIKV bearing an unglycosylated E"/>
   <result pre="RNA) or E reverse primer (virus particles) and moloney mouse" exact="leukemia" post="virus reverse transcriptase (Life Technologies, Carlsbad, CA, USA) at"/>
   <result pre="Microbiol.20182691392810.1016/j.tim.2018.05.01229933925 4.LindquistL.Recent and historical trends in the epidemiology of Japanese" exact="encephalitis" post="and its implication for risk assessment in travellersJ. Travel"/>
   <result pre="mechanisms of flavivirus membrane fusionAmino Acids2011411159116310.1007/s00726-009-0370-419882217 15.ReyF.A.HeinzF.X.MandlC.KunzC.HarrisonS.C.The envelope glycoprotein from" exact="tick-borne encephalitis" post="virus at 2 Å resolutionNature199537529129810.1038/375291a07753193 16.PiersonT.C.DiamondM.S.Degrees of maturity: The"/>
   <result pre="of flavivirus membrane fusionAmino Acids2011411159116310.1007/s00726-009-0370-419882217 15.ReyF.A.HeinzF.X.MandlC.KunzC.HarrisonS.C.The envelope glycoprotein from tick-borne" exact="encephalitis" post="virus at 2 Å resolutionNature199537529129810.1038/375291a07753193 16.PiersonT.C.DiamondM.S.Degrees of maturity: The"/>
   <result pre="and Safety Testing of Live, Attenuated VaccinesJ. Virol.2002761932194310.1128/JVI.76.4.1932-1943.200211799188 18.BradtV.MalafaS.von BraunA.JarmerJ.TsouchnikasG.MeditsI.WankeK.KarrerU.StiasnyK.HeinzF.X.Pre-existing" exact="yellow fever" post="immunity impairs and modulates the antibody response to tick-borne"/>
   <result pre="yellow fever immunity impairs and modulates the antibody response to" exact="tick-borne encephalitis" post="vaccinationnpj Vaccines201943810.1038/s41541-019-0133-531508246 19.ZaidiM.B.Cedillo-BarronL.González y AlmeidaM.E.Garcia-CorderoJ.CamposF.D.Namorado-TonixK.PerezF.Serological tests reveal significant cross-reactive"/>
   <result pre="fever immunity impairs and modulates the antibody response to tick-borne" exact="encephalitis" post="vaccinationnpj Vaccines201943810.1038/s41541-019-0133-531508246 19.ZaidiM.B.Cedillo-BarronL.González y AlmeidaM.E.Garcia-CorderoJ.CamposF.D.Namorado-TonixK.PerezF.Serological tests reveal significant cross-reactive"/>
   <result pre="on the Three-Dimensional Structure of the ProteinVirology199723228129010.1006/viro.1997.85709191841 42.YoshiiK.YanagiharaN.IshizukaM.SakaiM.KariwaH.N-linked glycan in" exact="tick-borne encephalitis" post="virus envelope protein affects viral secretion in mammalian cells,"/>
   <result pre="the Three-Dimensional Structure of the ProteinVirology199723228129010.1006/viro.1997.85709191841 42.YoshiiK.YanagiharaN.IshizukaM.SakaiM.KariwaH.N-linked glycan in tick-borne" exact="encephalitis" post="virus envelope protein affects viral secretion in mammalian cells,"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6913311\results\search\disease\results.xml">
   <result pre="medium, provided the original work is properly cited. Abstract An" exact="influenza" post="virus epidemic is an important issue in public hygiene,"/>
   <result pre="treatment of respiratory symptoms including symptoms caused by influenza, on" exact="influenza" post="virus replication in cultured cells. Culture media of influenza"/>
   <result pre="on influenza virus replication in cultured cells. Culture media of" exact="influenza" post="virus-infected MDCK(+) cells were tested for hemagglutination and infectivity"/>
   <result pre="viruses with segmented, single-stranded, negative-sense RNA genomes [1]. In seasonal" exact="influenza" post="epidemics, mortality is a particular concern in the elderly"/>
   <result pre="require inpatient care [3]. In addition, a new type of" exact="influenza" post="virus may emerge and cause a pandemic. Several antiviral"/>
   <result pre="which are prescribed for respiratory symptoms including symptoms caused by" exact="influenza" post="and common cold, on influenza virus replication in vitro."/>
   <result pre="prescribed for respiratory symptoms including symptoms caused by influenza and" exact="common cold," post="on influenza virus replication in vitro. A similar study"/>
   <result pre="symptoms including symptoms caused by influenza and common cold, on" exact="influenza" post="virus replication in vitro. A similar study was also"/>
   <result pre="Pharma, Tokyo, Japan), and streptomycin (100 µg/ml, Meiji Seika Pharma). Human" exact="influenza" post="virus strain A/Udorn/72 (H3N2) was propagated in 10-day-old embryonated"/>
   <result pre="in a 96-well plate as described previously [10]. Antiserum against" exact="influenza" post="virus was prepared by immunizing a rabbit with purified"/>
   <result pre="reading) are used hereafter throughout this paper. Their indications include" exact="common cold," post="influenza, and respiratory symptoms including cough and sputum, and"/>
   <result pre="no cytotoxicity of the drugs. MDCK(+) cells were infected with" exact="influenza" post="virus at an m.o.i. of 0.2 or 5, and"/>
   <result pre="These results suggest that maoto inhibited the replication stages of" exact="influenza" post="virus in the cells such as protein synthesis and"/>
   <result pre="Kampo drugs that were tested for their ability to inhibit" exact="influenza" post="virus replication. Maoto and kakkonto, both of which inhibited"/>
   <result pre="shown in Figure 2, when MDCK(+) cells were infected with" exact="influenza" post="virus at an m.o.i. of 5, strong inhibitory activity"/>
   <result pre="Cnidii rhizome was also examined. MDCK(+) cells were infected with" exact="influenza" post="virus at an m.o.i. of 5 and cultured in"/>
   <result pre="from the beginning, and almost all of the current seasonal" exact="influenza" post="viruses and avian H5N1 viruses have acquired resistance to"/>
   <result pre="patients with respiratory symptoms were examined for their effects on" exact="influenza" post="virus replication in cultured cells. Four of the five"/>
   <result pre="in infected cells. Kakkonto also weakly inhibited the growth of" exact="influenza" post="virus at an m.o.i. of 5. At infection with"/>
   <result pre="to be effective for reducing fever in children infected with" exact="influenza" post="viruses [5, 6]. Infection experiments with an influenza virus"/>
   <result pre="infected with influenza viruses [5, 6]. Infection experiments with an" exact="influenza" post="virus in cultured cells have also shown that maoto"/>
   <result pre="vitro [7]. It has also been reported that maoto inhibited" exact="influenza" post="virus replication in the lungs of mice and exhibited"/>
   <result pre="effects [13]. Although no direct inhibition of the growth of" exact="influenza" post="viruses by kakkonto has been reported, toll-like receptor 4-dependent"/>
   <result pre="[16] and the possibility of kakkonto inhibiting the onset of" exact="influenza" post="encephalopathy by acting on the blood-brain barrier [17] have"/>
   <result pre="and the possibility of kakkonto inhibiting the onset of influenza" exact="encephalopathy" post="by acting on the blood-brain barrier [17] have been"/>
   <result pre="and senkyuchachosan have not been reported to be associated with" exact="influenza" post="viruses, and this is the first report about the"/>
   <result pre="first report about the effects of those Kampo drugs on" exact="influenza" post="virus. A Kampo drug is a mixture of crude"/>
   <result pre="herba. Mantani et al. (1999) showed that Ephedrae herba inhibited" exact="influenza" post="virus A/PR8 replication in MDCK(+) cells. In this study,"/>
   <result pre="activity of Glycyrrhizae radix was reported to be effective against" exact="influenza" post="virus A/H2N2 in mice infection experiments but not in"/>
   <result pre="had strong anti-influenza virus activity and that it selectively inhibited" exact="influenza" post="virus protein synthesis. The exact acting point of Glycyrrhizae"/>
   <result pre="affect virus particles or increase the pH in endosomes, where" exact="influenza" post="virus envelope fusion occurs. The drug thus seems to"/>
   <result pre="Polymerase acidic (PA) protein, one of the three polymerases of" exact="influenza" post="virus that works for cap snatching and mRNA synthesis,"/>
   <result pre="Shirayama et al. [22] reported that PA endonuclease activity of" exact="influenza" post="virus PA protein was inhibited by Kampo drugs in"/>
   <result pre="to be considered. In the search for new drugs against" exact="influenza" post="viruses, Kampo drugs could be used as seeds for"/>
   <result pre="Virology20131Philadelphia, PA, USALippincott Williams &amp;amp; Wilkins11511185 2ThompsonW. W.Mortality associated with" exact="influenza" post="and respiratory syncytial virus in the United StatesJama2003289217918610.1001/jama.289.2.17912517228 3PoehlingK."/>
   <result pre="United StatesJama2003289217918610.1001/jama.289.2.17912517228 3PoehlingK. A.EdwardsK. M.WeinbergG. A.et al.The underrecognized burden of" exact="influenza" post="in young childrenNew England Journal of Medicine20063551314010.1056/nejmoa05486916822994 4collab: Tumura"/>
   <result pre="Mao-to, a Japanese herbal medicine, for treatment of type A" exact="influenza" post="infection in childrenPhytomedicine2007142-39610110.1016/j.phymed.2006.09.01517141491 6ToriumiY.KameiT.MurataK.TakahashiI.SuzukiN.MazdaO.Utility of maoto in an influenza"/>
   <result pre="A influenza infection in childrenPhytomedicine2007142-39610110.1016/j.phymed.2006.09.01517141491 6ToriumiY.KameiT.MurataK.TakahashiI.SuzukiN.MazdaO.Utility of maoto in an" exact="influenza" post="season where reduced effectiveness of oseltamivir was observed—a clinical,"/>
   <result pre="Complementary Medicine201219417918610.1159/00034154722964983 7MiyazakiT.Chinese herbal medicines to inhibit the replication of" exact="influenza" post="virusesFolia Pharmacologica Japonica20121402626510.1254/fpj.140.6222878568 8NomaK.KiyotaniK.KouchiH.et al.Endogenous protease-dependent replication of human"/>
   <result pre="influenza virusesFolia Pharmacologica Japonica20121402626510.1254/fpj.140.6222878568 8NomaK.KiyotaniK.KouchiH.et al.Endogenous protease-dependent replication of human" exact="influenza" post="viruses in two MDCK cell linesArchives of Virology1998143101893190910.1007/s0070500504289856079 9KawaharaT.AkibaI.SakouM.SakaguchiT.TaniguchiH.Inactivation"/>
   <result pre="two MDCK cell linesArchives of Virology1998143101893190910.1007/s0070500504289856079 9KawaharaT.AkibaI.SakouM.SakaguchiT.TaniguchiH.Inactivation of human and" exact="avian influenza" post="viruses by potassium oleate of natural soap component through"/>
   <result pre="MDCK cell linesArchives of Virology1998143101893190910.1007/s0070500504289856079 9KawaharaT.AkibaI.SakouM.SakaguchiT.TaniguchiH.Inactivation of human and avian" exact="influenza" post="viruses by potassium oleate of natural soap component through"/>
   <result pre="Ephedrae herba, an oriental traditional medicine, on the growth of" exact="influenza" post="A/PR/8 virus in MDCK cellsAntiviral Research199944319320010.1016/s0166-3542(99)00067-410651070 13NagaiT.KataokaE.AokiY.HokariR.KiyoharaH.YamadaH.Alleviative effects of"/>
   <result pre="Japanese herbal) medicine &quot;maoto (Ma-Huang-Tang)�? on the early phase of" exact="influenza" post="virus infection and its possible mode of actionEvidence-Based Complementary"/>
   <result pre="resistanceInfluenza and Other Respiratory Viruses201371253610.1111/irv.1204723279894 15O’HanlonR.ShawM. L.Baloxavir marboxil: the new" exact="influenza" post="drug on the marketCurrent Opinion in Virology201935141810.1016/j.coviro.2019.01.00630852344 16IshijimaY.KawamuraT.KimuraA.et al.Toll-like"/>
   <result pre="of cinnamaldehyde, derived from Cinnamomi cortex, on the growth of" exact="influenza" post="A/PR/8 virus in vitro and in vivoAntiviral Research20077411810.1016/j.antiviral.2007.01.00317303260 19JiS.LiZ.SongW.et"/>
   <result pre="B.SuzukiF.Antiviral effect of gingyo-san, a traditional Chinese herbal medicine, on" exact="influenza" post="A2 virus infection in miceThe American Journal of Chinese"/>
   <result pre="Journal of Chinese Medicine1999271536210.1142/s0192415x9900008210354817 22ShirayamaR.ShojiM.SriwilaijaroenN.HiramatsuH.SuzukiY.KuzuharaT.Inhibition of PA endonuclease activity of" exact="influenza" post="virus RNA polymerase by Kampo medicinesDrug Discoveries &amp;amp; Therapeutics201610210911310.5582/ddt.2016.0101026902927"/>
   <result pre="from Kampo drug-treated, virus-infected cells. MDCK(+) cells were infected with" exact="influenza" post="virus at an input m.o.i. of 0.2 or 5"/>
   <result pre="from crude drug-treated, virus-infected cells. MDCK(+) cells were infected with" exact="influenza" post="virus at an input m.o.i. of 0.2 or 5"/>
   <result pre="protein synthesis by crude drugs. MDCK(+) cells were infected with" exact="influenza" post="virus at an input m.o.i. of 5 and maintained"/>
   <result pre="Name (Chinese read) Indications 麻黄湯 27 Maoto Ma-Huang-Tang Common cold," exact="influenza" post="(in the early stage), rheumatoid arthritis, asthma, nasal obstruction"/>
   <result pre="27 Maoto Ma-Huang-Tang Common cold, influenza (in the early stage)," exact="rheumatoid arthritis," post="asthma, nasal obstruction in sucking infants, and suckling difficulty"/>
   <result pre="the initial stage of febrile diseases, inflammatory diseases (conjunctivitis, keratitis," exact="otitis media," post="tonsillitis, mastitis, and lymphadenitis), shoulder stiffness, neuralgia in the"/>
   <result pre="and lymphadenitis), shoulder stiffness, neuralgia in the upper body, and" exact="urticaria" post="滋陰�?�?�湯 93 Jiinkokato Zi-Yin-Jiang-Huo-Tang Dry cough �?芎茶調散 124 Senkyuchachosan"/>
   <result pre="Mai-Men-Dong-Tang Coughing with a hard, obstructive sputum, bronchitis, and bronchial" exact="asthma" post="Table 2 Crude drugs configuring kampo drugs∗. #27 maoto"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6913923\results\search\disease\results.xml">
   <result pre="rodent hosts and associated to fatal human diseases, such as" exact="hemorrhagic fever with renal syndrome" post="(HFRS) and orthohantavirus cardiopulmonary syndrome (HCPS). Circulation of HFRS-associated"/>
   <result pre="etiological agents of serious rodent-borne neglected human diseases named as" exact="hemorrhagic fever with renal syndrome" post="(HFRS) and orthohantavirus cardiopulmonary syndrome (HCPS). These distinct clinical"/>
   <result pre="associated with serious and fatal diseases in humans, such as" exact="hemorrhagic fever with renal syndrome" post="(HFRS) and orthohantavirus cardiopulmonary syndrome (HCPS). The clinical manifestations"/>
   <result pre="present on the five continents, which are also implicated in" exact="leptospirosis" post="outbreaks [6]. In Americas, we highlight that SEOV has"/>
   <result pre="could be misdiagnosed as other tropical infectious diseases like dengue," exact="yellow fever" post="and leptospirosis. This data combined with the absence of"/>
   <result pre="be misdiagnose as viral or bacterial hemorrhagic diseases, like dengue," exact="yellow fever" post="or leptospirosis, especially in countries where these diseases are"/>
   <result pre="[36] and is considered the most prevalent pathogen associated with" exact="nephropathia epidemica" post="[37], a mild form of HFRS. This epidemics is"/>
   <result pre="This epidemics is characterized by acute kidney injury (AKI) and" exact="thrombocytopenia" post="[5], suggesting differences among species associated to HFRS. Besides,"/>
   <result pre="Dis. 2014;14(1):33–40. 10.1089/vbz.2013.137824359425 10ClementJ, NeildG, HinrichsenSL, CrescenteJA, Van RanstM. Urban" exact="leptospirosis" post="versus urban hantavirus infection in Brazil. Lancet. 1999;354(9194):2003–4. 10.1016/S0140-6736(05)76782-9"/>
   <result pre="HofmannJ, SchnitzlerP, et al.Clinical characterization of two severe cases of" exact="hemorrhagic fever with renal syndrome" post="(HFRS) caused by hantaviruses Puumala and Dobrava-Belgrade genotype Sochi."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6914775\results\search\disease\results.xml">
   <result pre="1.5 for 2009 H1N1 influenza7, at 3 for the 2003" exact="severe acute respiratory syndrome" post="(SARS) outbreak8, and at 12–18 for historical measles outbreaks9."/>
   <result pre="acute respiratory syndrome (SARS) outbreak8, and at 12–18 for historical" exact="measles" post="outbreaks9. As an epidemic unfolds, however, the depletion and"/>
   <result pre="https://cran.r-project.org). Dengue data Dengue fever is listed as a notifiable" exact="infectious disease" post="in Taiwan. This means that physicians are mandated to"/>
   <result pre="individual-level transmission potential of other acute contagious diseases, such as" exact="influenza" post="and Zika virus infection, with observed generation interval and"/>
   <result pre="around the infected cases for human infectious diseases, such as" exact="influenza" post="and dengue fever. Other studies have also explored spatial"/>
   <result pre="infected cases for human infectious diseases, such as influenza and" exact="dengue fever." post="Other studies have also explored spatial heterogeneity by performing"/>
   <result pre="medical research19932234110.1177/0962280293002001038261248 3.Vynnycky, E. &amp;amp; White, R. An introduction to" exact="infectious disease" post="modelling. OUP oxford, (2010). 4.HeffernanJMSmithRJWahlLMPerspectives on the basic reproductive"/>
   <result pre="in parasitology (2019). 7.FraserCet al.Pandemic potential of a strain of" exact="influenza" post="A (H1N1): early findingsScience20093241557156110.1126/science.117606219433588 8.LipsitchMet al.Transmission dynamics and control"/>
   <result pre="forward projectionsNew England Journal of Medicine20143711481149510.1056/NEJMoa141110025244186 15.WallingaJTeunisPDifferent epidemic curves for" exact="severe acute respiratory syndrome" post="reveal similar impacts of control measuresAmerican Journal of epidemiology200416050951610.1093/aje/kwh25515353409"/>
   <result pre="the spread of influenzaScience200631244745110.1126/science.112523716574822 23.SavillNJet al.Topographic determinants of foot and" exact="mouth disease" post="transmission in the UK 2001 epidemicBMC Veterinary Research20062310.1186/1746-6148-2-316412245 24.KraayANTrostleJBrouwerAFCevallosWEisenbergJNDeterminants"/>
   <result pre="32.CowlingBJFangVJRileySPeirisJMLeungGMEstimation of the serial interval of influenzaEpidemiology20092034410.1097/EDE.0b013e31819d109219279492 33.MeyerSHeldLPower-law models for" exact="infectious disease" post="spreadThe Annals of Applied Statistics201481612163910.1214/14-AOAS743 34.ShiXSelection of bandwidth type"/>
   <result pre="AfricaPLoS computational biology201612e100521010.1371/journal.pcbi.100521027930675 41.YamauchiTTakeuchiSYamanoYKurodaYNakadateTEstimation of the effective reproduction number of" exact="influenza" post="based on weekly reports in Miyazaki PrefectureScientific reports20199253910.1038/s41598-019-39057-w30796315 42.CumminsBCortezRFoppaIMWalbeckJHymanJMA"/>
   <result pre="and migration patternsNature20124849610.1038/nature1085622367540 45.KisslerSMet al.Geographic transmission hubs of the 2009" exact="influenza" post="pandemic in the United StatesEpidemics201926869410.1016/j.epidem.2018.10.00230327253 46.KulldorffMHeffernanRHartmanJAssunçaoRMostashariFA space–time permutation scan"/>
   <result pre="Shandong Province, ChinaPloS one20138e6344710.1371/journal.pone.006344723704909 50.RenHWuWLiTYangZUrban villages as transfer stations for" exact="dengue fever" post="epidemic: A case study in the Guangzhou, ChinaPLoS neglected"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6915707\results\search\disease\results.xml">
   <result pre="Associations between ZIKV infection and severe disease outcomes such as" exact="microcephaly" post="and Guillain-Barré syndrome were recognized by the WHO in"/>
   <result pre="primary ZIKV vectors, Aedes aegypti and Aedes albopictus2,3,29, also transmit" exact="chikungunya" post="virus (CHIKV) and DENV. In contrast to CHIKV (an"/>
   <result pre="of Zika. For a baseline, we also fit models incorporating" exact="chikungunya" post="incidence. CHIKV shares climate and vector determinants as DENV"/>
   <result pre="effect coefficients for Brazil (a) and Colombia (c). Zika and" exact="chikungunya" post="coefficients are estimated from autoregressive dengue models. Positive (negative)"/>
   <result pre="and indirectly as effects on transmission for the Zika and" exact="chikungunya" post="models. Shared year multipliers for expected dengue incidence are"/>
   <result pre="and biweekly (mean coefficient: 0.11, 95% CrI: 0.04–0.17, Fig. 3a)" exact="chikungunya" post="incidence were positively associated with expected dengue transmission in"/>
   <result pre="c, Supplementary Fig. 7). No significant association were found between" exact="chikungunya" post="incidence and dengue transmission potential in Colombia. In Brazil,"/>
   <result pre="Zika on dengue transmission potential often observed positive effects of" exact="chikungunya" post="on dengue (Supplementary Fig. 7). Totals of suspected Zika"/>
   <result pre="dengue (Supplementary Fig. 7). Totals of suspected Zika and suspected" exact="chikungunya" post="cases at state- and department-level were positively correlated (Supplementary"/>
   <result pre="than the assumed one-year duration of cross-protection. In all scenarios," exact="suppression" post="of DENV transmission resulted in subsequent increases in DENV"/>
   <result pre="and unconfirmed cases) in all of our analyses. Zika and" exact="chikungunya" post="case counts were first reported in the Epidemiological bulletins"/>
   <result pre="to the preceding historical data. Analogous updated probable Zika and" exact="chikungunya" post="case counts were first reported in 2017 and 2016"/>
   <result pre="analyses. We also use data on the cumulative number of" exact="microcephaly" post="cases and other central nervous system disorders in newborns40"/>
   <result pre="reported separately. We extracted additional data for probable Zika and" exact="chikungunya" post="cases from the weekly Epidemiological Bulletins36 for 2015–2017. According"/>
   <result pre="We construct biweekly time series for probable dengue, Zika, and" exact="chikungunya" post="case counts for each state in Brazil and department"/>
   <result pre="2016, 2017) or a multiplicative effect of either Zika or" exact="chikungunya" post="case counts (previous biweek or total count recorded up"/>
   <result pre="year-specific subnational population size (Ni,t). Xi,t represents either: Zika or" exact="chikungunya" post="incidence (either at biweek t or the cumulative total"/>
   <result pre="competing interests. References References 1.World Health Organization. Situation Report-Zika virus," exact="microcephaly" post="and Guillain-Barré syndrome. http://origin.searo.who.int/entity/bhutan/who-zika-28-7-16.pdf. (2016). 2.AyresCFJIdentification of Zika virus"/>
   <result pre="da Saude Brasil. Monitoramento dos casos de dengue, febre de" exact="chikungunya" post="e febre pelo vírus Zika até a Semana Epidemiológica"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6917806\results\search\disease\results.xml">
   <result pre="691780655254 doi: 10.1038/s41598-019-55254-z : Article Re-evaluation of the evolution of" exact="influenza" post="H1 viruses using direct PCA http://orcid.org/0000-0003-4826-6265KonishiTomokazukonishi@akita-pu.ac.jp[], 0000 0004 1761"/>
   <result pre="copy of this license, visit http://creativecommons.org/licenses/by/4.0/. Abstract The history of" exact="influenza" post="H1 virus was re-evaluated by applying a new methodology"/>
   <result pre="Subject terms Evolutionary genetics Taxonomy Immunogenetics Immunopathogenesis Introduction Although most" exact="influenza" post="viruses infect waterfowl exclusively, some of them target humans"/>
   <result pre="changed. This article reports the changes that occurred in the" exact="influenza" post="H1N1 type from 1977 to 2017, which were analysed"/>
   <result pre="particular, they are inappropriate for studying the evolution of human" exact="influenza" post="viruses, because they are polyphyletic. They not only change"/>
   <result pre="the risk of keeping groups of swine that have different" exact="influenza" post="strains in adjacent farms because new viruses may be"/>
   <result pre="humans. Therefore, the present system of vaccine production to control" exact="influenza" post="infections, which uses eggs, has a critical defect: i.e.,"/>
   <result pre="declares no competing interests. References References 1.PetrovaVNRussellCAThe evolution of seasonal" exact="influenza" post="virusesNature Reviews Microbiology2017164710.1038/nrmicro.2017.11829081496 2.World Health Organization. Avian influenza: assessing"/>
   <result pre="Adaptation, and Pandemic FormationCell Host &amp;amp; Microbe2010744045110.1016/j.chom.2010.05.00920542248 4.ZimmerSMBurkeDSHistorical perspective–Emergence of" exact="influenza" post="A (H1N1) virusesN Engl J Med200936127928510.1056/NEJMra090432219564632 5.MaWKahnRERichtJAThe pig as"/>
   <result pre="Engl J Med200936127928510.1056/NEJMra090432219564632 5.MaWKahnRERichtJAThe pig as a mixing vessel for" exact="influenza" post="viruses: Human and veterinary implicationsJournal of molecular and genetic"/>
   <result pre="8.SmithGJDet al.Origins and evolutionary genomics of the 2009 swine-origin H1N1" exact="influenza" post="A epidemicNature2009459112210.1038/nature0818219516283 9.GartenRJet al.Antigenic and genetic characteristics of swine-origin"/>
   <result pre="epidemicNature2009459112210.1038/nature0818219516283 9.GartenRJet al.Antigenic and genetic characteristics of swine-origin 2009 A(H1N1)" exact="influenza" post="viruses circulating in humansScience200932519720110.1126/science.117622519465683 10.MarthaINRejaneSDanielleGMaurício EgídioCJanice ReisC-ZInfluenza A Viruses"/>
   <result pre="journal201521133910.3201/eid2108.141891 11.Mena, I. et al. Origins of the 2009 H1N1" exact="influenza" post="pandemic in swine in Mexico. Elife5, 10.7554/eLife.16777 (2016). 12.NelsonMIet"/>
   <result pre="swine in Mexico. Elife5, 10.7554/eLife.16777 (2016). 12.NelsonMIet al.Global migration of" exact="influenza" post="A viruses in swineNat Commun20156669610.1038/ncomms769625813399 13.MorensDMTaubenbergerJKFauciASThe persistent legacy of"/>
   <result pre="viruses in swineNat Commun20156669610.1038/ncomms769625813399 13.MorensDMTaubenbergerJKFauciASThe persistent legacy of the 1918" exact="influenza" post="virusN Engl J Med200936122522910.1056/NEJMp090481919564629 14.Thornton, S. In The Stanford"/>
   <result pre="in molecular biologyChem-Bio Inf. J.20181817318310.1273/cbij.18.173 16.TaubenbergerJKet al.Characterization of the 1918" exact="influenza" post="virus polymerase genesNature200543788989310.1038/nature0423016208372 17.ZhouNNet al.Genetic reassortment of avian, swine,"/>
   <result pre="polymerase genesNature200543788989310.1038/nature0423016208372 17.ZhouNNet al.Genetic reassortment of avian, swine, and human" exact="influenza" post="A viruses in American pigsJ Virol1999738851885610482643 18.WertheimJOThe Re-Emergence of"/>
   <result pre="V.Role for migratory wild birds in the global spread of" exact="avian influenza" post="H5N8Science201635421321710.1126/science.aaf885227738169 20.EdgarRCMUSCLE: multiple sequence alignment with high accuracy and"/>
   <result pre="for migratory wild birds in the global spread of avian" exact="influenza" post="H5N8Science201635421321710.1126/science.aaf885227738169 20.EdgarRCMUSCLE: multiple sequence alignment with high accuracy and"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6917977\results\search\disease\results.xml">
   <result pre="a mosquito�?transmitted alphavirus, and its infection can cause long�?term debilitating" exact="arthritis" post="in humans. Currently, there are no licensed vaccines or"/>
   <result pre="of in vivo activity by controlling Fc glycosylation. monoclonal antibody" exact="chikungunya" post="virus plant�?made therapeutics glycosylation neutralization glycoengineering plant�?made antibody Funding"/>
   <result pre="models of CHIKV infection, WT mice (i.e. WT C57BL/6) develop" exact="arthritis" post="symptoms similar to those observed in humans (Broeckel et"/>
   <result pre="et al., 2013). However, these mice do not develop the" exact="arthritis" post="observed in humans. In contrast, CHIKV infection in WT"/>
   <result pre="humans. In contrast, CHIKV infection in WT C57BL/6 mice causes" exact="arthritis" post="and swelling in feet and ankles (Broeckel et al.,"/>
   <result pre="mAbs against CHIKV. Our results warrant future studies in mouse" exact="arthritis" post="models that mimic symptoms of human CHIKV infection. In"/>
   <result pre="Loss of glycosaminoglycan receptor binding after mosquito cell passage reduces" exact="chikungunya" post="virus infectivity. PLoS Negl. Trop Dis.9, e0004139.26484530 Arntzen, C."/>
   <result pre="of a recombinant human monoclonal antibody reduces the severity of" exact="chikungunya" post="virus disease in rhesus macaques. PLoS Negl. Trop Dis.11,"/>
   <result pre="L.G. (2016) Plant expression systems, a budding way to confront" exact="chikungunya" post="and Zika in developing countries?F1000Res, 5, 2121.27781090 Chen, Q."/>
   <result pre="Lai, H. (2014b) Plant�?derived monoclonal antibodies as human biologics for" exact="infectious disease" post="and cancer In Plant�?derived Pharmaceuticals: Principles and Applications for"/>
   <result pre="Plant�?derived monoclonal antibodies as human biologics for infectious disease and" exact="cancer" post="In Plant�?derived Pharmaceuticals: Principles and Applications for Developing Countries(HefferonK.L.,"/>
   <result pre="Early appearance of neutralizing immunoglobulin G3 antibodies is associated with" exact="chikungunya" post="virus clearance and long�?term clinical protection. J. Infect. Dis.205,"/>
   <result pre="Lee, W.W.L., Leo, Y.�?S.et al (2015) Sero�?prevalence and cross�?reactivity of" exact="chikungunya" post="virus specific anti�?E2EP3 antibodies in arbovirus�?infected patients. PLoS Negl."/>
   <result pre="Development of a highly protective combination monoclonal antibody therapy against" exact="chikungunya" post="virus. PLoS Pathog.9, e1003312.23637602 collab: Prevail, II Writing Group"/>
   <result pre="broad and ultrapotent human monoclonal antibodies with therapeutic activity against" exact="chikungunya" post="virus. Cell. Host. Microbe.18, 86–95.26159721 Strasser, R., Altmann, F."/>
   <result pre="Fernandez, S., Thaisomboonsuk, B.et al (2015) High rate of subclinical" exact="chikungunya" post="virus infection and association of neutralizing antibody with protection"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6919333\results\search\disease\results.xml">
   <result pre="asthmatic who presented with respiratory distress and pneumonitis during peak" exact="influenza" post="season, and recovered after a prolonged hospital stay. The"/>
   <result pre="who presented with diarrhoea, vomiting, and general malaise outside of" exact="influenza" post="season, developed respiratory compromise, and died. Adenovirus type 7"/>
   <result pre="tract adenoviral infection are similar to other infectious causes of" exact="pneumonia" post="and ARDS, including severe influenza. This can create diagnostic"/>
   <result pre="including severe influenza. This can create diagnostic uncertainty, especially during" exact="influenza" post="season. Positive adenovirus polymerase chain reaction results can support"/>
   <result pre="considered in the differential diagnoses of immunocompetent patients presenting with" exact="pneumonia" post="and ARDS. Highlights •Severe lower respiratory tract adenovirus infection"/>
   <result pre="•Immunocompetent patients with adenovirus sLRTI may present with pneumonitis and" exact="acute respiratory distress syndrome" post="(ARDS) •Clinical features of sLRTI are difficult to distinguish"/>
   <result pre="denied related hospital admissions. Other medical history included obesity, schizophrenia," exact="personality disorder," post="depression and self-harm. She was a smoker, did not"/>
   <result pre="rhonchi and severe respiratory distress. A diagnosis of a life-threatening" exact="asthma" post="exacerbation precipitated by LRTI was made. Antimicrobial treatment commenced"/>
   <result pre="treatment commenced included oseltamivir (due to presentation during peak of" exact="influenza" post="season and risk factors for viral pneumonitis including chronic"/>
   <result pre="influenza season and risk factors for viral pneumonitis including chronic" exact="lung disease" post="and obesity), benzylpenicillin and clarithromycin. Respiratory distress was treated"/>
   <result pre="liver and kidney function. Arterial blood gas showed type 1" exact="respiratory failure." post="Chest radiograph showed bilateral patchy consolidation. Blood-borne virus (BBV)"/>
   <result pre="recruitment, the patient continued to desaturate and developed type 2" exact="respiratory failure." post="In an attempt to improve ventilation, inhaled nitric oxide"/>
   <result pre="illness 4 day history of URTI and LRTI symptomsPresented in peak" exact="influenza" post="season Lymphopenia, mildly raised CRPNo initial renal dysfunctiona CXR:"/>
   <result pre="level care on day 65 Case 2:73 year old male Hypertension," exact="nephrolithiasis" post="3 day history of generalised and gastrointestinal symptomsPresented outside of"/>
   <result pre="nephrolithiasis 3 day history of generalised and gastrointestinal symptomsPresented outside of" exact="influenza" post="season Lymphopenia, mildly raised CRPNo initial renal dysfunctiona CT"/>
   <result pre="Lymphopenia, mildly raised CRPNo initial renal dysfunctiona CT chest: left-sided" exact="pneumonia" post="and bilateral pleural effusions (Fig. 1) Throat swab: adenovirus"/>
   <result pre="symptoms. He was a non-smoker who had amlodipine-controlled hypertension and" exact="nephrolithiasis" post="but was normally well and regularly hill-walked, including an"/>
   <result pre="radiograph demonstrated left middle-zone consolidation. He was diagnosed with community-acquired" exact="pneumonia" post="and benzylpenicillin and clarithromycin were started. By day 2,"/>
   <result pre="started. By day 2, he had deteriorated with type 1" exact="respiratory failure." post="Benzylpenicillin was switched to piperacillin/tazobactam and he was transferred"/>
   <result pre="outbreaks in immunocompetent people,2., 5., 6., 7. similar to recent" exact="influenza" post="epidemics, fever, cough, and myalgia were the most common"/>
   <result pre="chest signs (e.g. crepitations), and hypoxia.7 Rarely, patients can develop" exact="acute respiratory distress syndrome" post="(ARDS).8 With regard to diagnosis, standard blood tests are"/>
   <result pre="10., 11.; one review of 21 immunocompetent patients with adenovirus" exact="pneumonia" post="found lymphopenia in 11 (52%) and raised transaminases in"/>
   <result pre="With regard to our patients, Case 1 presented during England's" exact="influenza" post="season with respiratory symptoms and signs of pneumonitis followed"/>
   <result pre="consolidation; Case 2 presented with generalised and gastrointestinal symptoms following" exact="influenza" post="season and was found to have unilateral pneumonia and"/>
   <result pre="symptoms following influenza season and was found to have unilateral" exact="pneumonia" post="and pleural effusions (Fig. 1). Ultimately, from reflection on"/>
   <result pre="with their training.6 In addition, it has been suggested that" exact="obesity" post="may be associated with adenovirus disease in immunocompetent individuals"/>
   <result pre="patients but equally it could have related to obesity, chronic" exact="lung disease," post="smoking, and social risk factors including unstable housing as"/>
   <result pre="radiological features are similar to other infective causes of LRTI," exact="pneumonia" post="and ARDS (including severe influenza) but, as in Case"/>
   <result pre="influenza) but, as in Case 2 and similar to recent" exact="influenza" post="epidemics, presenting symptoms can be non-specific. Positive adenovirus PCR"/>
   <result pre="Mar 29Epub ahead of print 2.KlingerJ.R.SanchezM.P.CurtinL.A.DurkinM.MatyasB.Multiple cases of life-threatening adenovirus" exact="pneumonia" post="in a mental health care centreAm J Respir Crit"/>
   <result pre="3 in healthy young adultsClin Infect Dis34200257758211803503 7.ClarkT.FleetD.H.WiselkaM.J.Severe community-acquired adenovirus" exact="pneumonia" post="in an immunocompetent 44-year-old woman: a case report and"/>
   <result pre="and review of the literatureJ Med Case Reports52011259 8.LowS.Y.TanT.T.LeeC.H.K.LooC.M.ChewH.C.Severe adenovirus" exact="pneumonia" post="requiring extracorporeal membrane oxygenation support – serotype 7 revisitedRespiratory"/>
   <result pre="patients with severe adenovirus pneumoniaPLoS One1042015 Apr 15e0122642[eCollection 2015] 10.LeersW.D.SarinM.K.KasupakiG.J.Lobar" exact="pneumonia" post="associated with adenovirus type 7CMA JournalVol.125198110031004 11.ChaM.J.ChungM.J.LeeK.S.KimT.J.KimT.S.ChongS.Clinical features and"/>
   <result pre="type 7CMA JournalVol.125198110031004 11.ChaM.J.ChungM.J.LeeK.S.KimT.J.KimT.S.ChongS.Clinical features and radiological findings of adenovirus" exact="pneumonia" post="associated with progression to acute respiratory distress syndrome: a"/>
   <result pre="patientsClin Microbiol Rev273201444146224982316 19.von Lilienfeld-ToalM.BergerA.ChristopeitM.Community acquired respiratory virus infections in" exact="cancer" post="patients-guideline on diagnosis and management by the Infectious Diseases"/>
   <result pre="OncologyEur J Cancer672016 Nov200212Epub 2016 Sep 2527681877 20.LeeM.KimS.KwonO.J.Treatment of adenoviral" exact="acute respiratory distress syndrome" post="using cidofovir with extracorporeal membrane oxygenationJ Intensive Care Med3232017"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6920831\results\search\disease\results.xml">
   <result pre="to be more susceptible to viral infections such as during" exact="influenza" post="and dengue epidemics. We examined the co-factorial role of"/>
   <result pre="anti-inflammation and anti-obesity activity. persistent viral infection interferon lipid metabolism" exact="obesity" post="1. Viral Infectobesity: The Association of Chronic Viral Infections"/>
   <result pre="Infections with Obesity According to recent statistics, the prevalence of" exact="obesity" post="was 39.8% and affected about 93.3 million US adults"/>
   <result pre="2015~2016 [1]. Similarly, in many other countries worldwide, overweight and" exact="obesity" post="are also dramatically on the rise, particularly in urban"/>
   <result pre="the rise, particularly in urban areas [2]. We face an" exact="obesity" post="epidemic that has a complex and multifactorial etiology [3]."/>
   <result pre="epidemic that has a complex and multifactorial etiology [3]. While" exact="obesity" post="is multifactorial, a simplified thermo-dynamic model, rather than a"/>
   <result pre="thermo-dynamic model, rather than a biological model, has prevailed in" exact="obesity" post="clinics for over 90 years [3]. A key suggestion"/>
   <result pre="calorie intake and exercise more. While addressing proximate causes of" exact="obesity" post="serves as a global health priority, it seems incomplete"/>
   <result pre="global health priority, it seems incomplete or ineffective to control" exact="obesity" post="given that the epidemic has continued to worsen at"/>
   <result pre="obesity. In this regard, we review the biological complex of" exact="obesity" post="and interpret its etiology from the interaction between immune"/>
   <result pre="fundamental requirements and are highly inter-dependent for species survival. Sequentially," exact="obesity" post="displays itself as a metabolic overload (shown by excess"/>
   <result pre="overload (shown by excess adipose tissue) in addition to an" exact="immune disorder," post="which accompanies a low-grade inflammatory state known as &quot;meta-inflammation�?"/>
   <result pre="pathogenic persistence [4,11,12,13,14]. In this context, recent studies have associated" exact="obesity" post="with numerous microbial agents in both humans and animal"/>
   <result pre="we recap the evidence of viral agents in association with" exact="obesity" post="and relevant metabolic syndrome [13,14,15,16,17]. In addition to examination"/>
   <result pre="evidence of viral agents in association with obesity and relevant" exact="metabolic syndrome" post="[13,14,15,16,17]. In addition to examination of the major viruses"/>
   <result pre="biochemical mechanism to understand the interaction of viral infection and" exact="obesity" post="[4,5,11,19]. As shown in Table 1, the major viruses"/>
   <result pre="the major viruses and VLA that have been associated with" exact="obesity" post="in both humans and animal models include members of"/>
   <result pre="obesity-associated immune suppression. This, in turn, underlies reciprocal causality between" exact="obesity" post="and higher susceptibility of obese individuals to viral infections"/>
   <result pre="and several serotypes of human Ad have been associated with" exact="obesity" post="regarding epidemiological correlation in certain subsets of humans and"/>
   <result pre="-9, 31, -36, and -37 have been observed to cause" exact="obesity" post="at different levels. First, these five Ad serotypes induced"/>
   <result pre="and marmosets (Ad-36). Third, Ad-5 has been associated with child" exact="obesity" post="and Ad-36 in both adults and children [15,24]. Mechanistically,"/>
   <result pre="VLA listed in Table 1 have also been associated with" exact="obesity" post="in animals and humans through pathological studies or epidemiological"/>
   <result pre="[11,12,46,47,48,49]. Such as in mice infected by norovirus (MNV) and" exact="lymphocytic choriomeningitis" post="virus (LCMV), IFN-α/β played a systemic role in control"/>
   <result pre="partly, the immune dysfunction [11,12] that triggers metabolic disorders and" exact="obesity" post="(Table 1) [4,13,14,15,16,17,63]. 3. Gut Microbiota and Intrinsic Interferon"/>
   <result pre="Response Current studies link gut microbiota to the development of" exact="obesity" post="and its related comorbidities in the following aspects [64,65,66,67]."/>
   <result pre="with obesity. The association of some bacterial taxonomic groups with" exact="obesity" post="and relevant comorbidities was observed such as lower content"/>
   <result pre="the disorder of gut microflora could be a drive to" exact="obesity" post="development. Second, germ-free (GF) animal models provide eloquent evidence"/>
   <result pre="eloquent evidence to address the role of gut microbiota in" exact="obesity" post="induction. Without gut microbiota colonization, GF mice were highly"/>
   <result pre="Without gut microbiota colonization, GF mice were highly resistant to" exact="obesity" post="induced by a high-fat diet than normal mice despite"/>
   <result pre="and cholesterol in young mice [64,65,66,67]. Mechanistically, gut microbiota affect" exact="obesity" post="development in an inter-systemic manner. Locally in the gut,"/>
   <result pre="of eukaryotic viruses and bacterial phages. While phages potentially affect" exact="obesity" post="indirectly through modulating bacterial composition, eukaryotic viruses can directly"/>
   <result pre="is a missing link underlying human diseases like cancers and" exact="obesity" post="[68,69,71]. Further studies are needed to decipher the composition"/>
   <result pre="lack of studies to correlate certain viral taxonomic groups with" exact="obesity" post="in humans and animals, they may have an overlapping"/>
   <result pre="have an overlapping spectrum with most persistent viruses associated with" exact="obesity" post="(Table 1) [13,14,15,16,17,68,69,70,71]. Evolutionarily, the IFN system represents a"/>
   <result pre="anti-inflammatory microenvironment, which buffers a homeostatic resistance to meta-inflammation in" exact="obesity" post="(Figure 1) [76,77,78]. Using hydrodynamic gene transfer to increase"/>
   <result pre="cellular immune responses and was recently shown to directly inactivate" exact="influenza" post="virus replication [87]. On the other hand, viral infections"/>
   <result pre="human cells including macrophages, DCs, T cells, keratinocytes, and some" exact="cancer" post="cell lines [18,80,81,91,92,93,94]. Particularly in macrophages, IFNs also act"/>
   <result pre="the cell antimicrobial activity against engulfed pathogens [82,89,95,96,97,98]. The IFN" exact="suppression" post="of lipid metabolism is multifaceted, and can occur by"/>
   <result pre="and obesity, and molecular manipulation of body ceramide to control" exact="obesity" post="was illuminated by a recent elegant study [104]. Notably,"/>
   <result pre="might be an adipogenic drive and could lead to immune" exact="suppression" post="mostly in obesity patients (see Figure 3 and the"/>
   <result pre="adipogenic drive and could lead to immune suppression mostly in" exact="obesity" post="patients (see Figure 3 and the next section) [80,81]."/>
   <result pre="Causality of Obesity and Persistent Viral Infections The association of" exact="obesity" post="with various viral infections has always faced a &quot;chicken"/>
   <result pre="[13,14,15,16,17]. Do viral infections trigger the infectobesity first, or does" exact="obesity" post="lead to higher susceptibility to viral infections that manifest"/>
   <result pre="above, we reinforced the reciprocal causality of viral infections and" exact="obesity" post="underlying the infectobesity [14]. First, multiple viruses and VLAs"/>
   <result pre="First, multiple viruses and VLAs have been epidemiologically associated with" exact="obesity" post="and some with identified mechanisms in adipogenic or lipogenic"/>
   <result pre="obesogenesis and complicate into infectobesity [4,7,64,66]. On the other hand," exact="obesity" post="also provokes an aberration in the immune system including"/>
   <result pre="relevant to T cells and B cells in people with" exact="obesity" post="[4,14,19,77,106]. IFN signaling occurs via the same JAK–STAT pathway"/>
   <result pre="obese patients, showing that basal SOCS-3 expression was increased in" exact="obesity" post="and correlated to the reduction of type I IFN"/>
   <result pre="infections [5,108]. More severe lung inflammation and lung damage from" exact="viral pneumonia" post="as well as prolonged viral shedding were observed in"/>
   <result pre="[5,108]. More severe lung inflammation and lung damage from viral" exact="pneumonia" post="as well as prolonged viral shedding were observed in"/>
   <result pre="be among the risk factors for severe outcomes in pandemic" exact="influenza" post="infection [5,14,108]. In one report, the incidence of DENV"/>
   <result pre="that persistent viral infection and perturbation of IFN signaling exacerbate" exact="obesity" post="development. Regarding systemic interaction in animal and human bodies,"/>
   <result pre="persistent viral infections and underlie the systemic inflammation observed in" exact="obesity" post="[4,11,12,13,14,15,16,17]. A recent study by Ghazarian et al. (2017)"/>
   <result pre="correlates with insulin resistance in obesity-linked fat liver (termed nonalcoholic" exact="fatty liver disease," post="NAFLD) in obese patients [107]. This study also critically"/>
   <result pre="with insulin resistance in obesity-linked fat liver (termed nonalcoholic fatty" exact="liver disease," post="NAFLD) in obese patients [107]. This study also critically"/>
   <result pre="[107]. It is likely that the dysbiotic microbiome in the" exact="obesity" post="and NAFLD patients may harbor persistent infections. In turn,"/>
   <result pre="of long-chain fatty acid (LFA) and leptin by expanding adipocytes," exact="obesity" post="is accompanied with general immune suppression including aberration of"/>
   <result pre="leptin by expanding adipocytes, obesity is accompanied with general immune" exact="suppression" post="including aberration of antiviral IFN signaling, which leads to"/>
   <result pre="infections (Figure 3) [4,11,48,107,109]. Therefore, in most cases of infectobesity," exact="obesity" post="and viral infections may interact dynamically as a reciprocal"/>
   <result pre="The emerging theme of IFNs as a critical regulator of" exact="obesity" post="has been demonstrated by several reports targeting therapeutic development"/>
   <result pre="has been demonstrated by several reports targeting therapeutic development against" exact="obesity" post="in both cell and animal models. McGillicuddy et al."/>
   <result pre="adipose tissue, but not hepatocyte-specific deletion of Ifnar1 worsened HFD-induced" exact="metabolic syndrome." post="Conversely, improved metabolic control in laparoscopic adjustable gastric banding"/>
   <result pre="improved metabolic control in laparoscopic adjustable gastric banding patients with" exact="obesity" post="was associated with stimulation of type I IFN-regulated genes"/>
   <result pre="(particularly adipocytes/hepatocytes) that are closely relevant to the development of" exact="obesity" post="and metabolic disorders [111]. Again, using hydrodynamic gene transfer"/>
   <result pre="that targeting IFN signaling represents a promising strategy to block" exact="obesity" post="development and its related pathologies. So, how about other"/>
   <result pre="may provide more IFN-based options for therapeutic optimization against current" exact="obesity" post="prevalence and reveal IFN subtypes that bear superior activity"/>
   <result pre="with IFN signaling provides another rationale to associate IFNs with" exact="obesity" post="[29,48]. However, more direct evidence such as using IFN-signaling"/>
   <result pre="if and how fundamental IFN signaling plays a role in" exact="obesity" post="development. Remarkably, all immune responses are a double-edged sword,"/>
   <result pre="cause of overeating?JAMA20143112167216810.1001/jama.2014.413324839118 4.HotamisligilG.S.Inflammation, metaflammation and immunometabolic disordersNature201754217718510.1038/nature2136328179656 5.HonceR.Schultz-CherryS.Impact of" exact="obesity" post="on influenza A virus pathogenesis, immune response, and evolutionFront"/>
   <result pre="overeating?JAMA20143112167216810.1001/jama.2014.413324839118 4.HotamisligilG.S.Inflammation, metaflammation and immunometabolic disordersNature201754217718510.1038/nature2136328179656 5.HonceR.Schultz-CherryS.Impact of obesity on" exact="influenza" post="A virus pathogenesis, immune response, and evolutionFront Immunol.201910107110.3389/fimmu.2019.0107131134099 6.PrevedenT.ScarpelliniE.MilićN.LuzzaF.AbenavoliL.Gut"/>
   <result pre="immune response, and evolutionFront Immunol.201910107110.3389/fimmu.2019.0107131134099 6.PrevedenT.ScarpelliniE.MilićN.LuzzaF.AbenavoliL.Gut microbiota changes and chronic" exact="hepatitis" post="C virus infectionExpert Rev. Gastroenterol. Hepatol.20171181381910.1080/17474124.2017.134366328621554 7.ManS.M.Inflammasomes in the"/>
   <result pre="infectionExpert Rev. Gastroenterol. Hepatol.20171181381910.1080/17474124.2017.134366328621554 7.ManS.M.Inflammasomes in the gastrointestinal tract: Infection," exact="cancer" post="and gut microbiota homeostasisNat. Rev. Gastroenterol. Hepatol.20181572173710.1038/s41575-018-0054-130185915 8.DebédatJ.ClémentK.Aron-WisnewskyJ.Gut Microbiota"/>
   <result pre="norovirus persistence despite enhanced adaptive immunityPLoS Pathog.201612e100568410.1371/journal.ppat.100568427327515 20.TanV.P.K.NgimC.F.LeeE.Z.RamadasA.PongL.Y.NgJ.I.HassanS.S.NgX.Y.DhanoaA.The association between" exact="obesity" post="and dengue virus (DENV) infection in hospitalised patientsPLoS ONE201813e020069810.1371/journal.pone.020069830016369"/>
   <result pre="infection in hospitalised patientsPLoS ONE201813e020069810.1371/journal.pone.020069830016369 21.BadawiA.VelummailumR.RyooS.G.SenthinathanA.YaghoubiS.VasilevaD.OstermeierE.PlishkaM.SoosaipillaiM.AroraP.Prevalence of chronic comorbidities in" exact="dengue fever" post="and West Nile virus: A systematic review and meta-analysisPLoS"/>
   <result pre="HIV/AIDS Rep.20171421121910.1007/s11904-017-0368-629043609 23.LakeJ.E.StanleyT.L.ApovianC.M.BhasinS.BrownT.T.CapeauJ.CurrierJ.S.DubeM.P.FalutzJ.GrinspoonS.K.et al.Practical review of recognition and management of" exact="obesity" post="and lipohypertrophy in human immunodeficiency virus infectionClin. Infect. Dis.2017641422142910.1093/cid/cix17828329372"/>
   <result pre="of cellular metabolismVirology2015479–48060961810.1016/j.virol.2015.02.03825812764 31.RidauraV.K.FaithJ.J.ReyF.E.ChengJ.DuncanA.E.KauA.L.GriffinN.W.LombardV.HenrissatB.BainJ.R.et al.Gut microbiota from twins discordant for" exact="obesity" post="modulate metabolism in miceScience2013341125121410.1126/science.124121424009397 32.MillsS.ShanahanF.StantonC.HillC.CoffeyA.RossR.P.Movers and shakers: Influence of"/>
   <result pre="gain is mediated through shifts in the gut microbiome and" exact="suppression" post="of energy expenditureEBioMedicine201521725173410.1016/j.ebiom.2015.10.01826870798 34.GogokhiaL.BuhrkeK.BellR.HoffmanB.BrownD.G.Hanke-GogokhiaC.AjamiN.J.WongM.C.GhazaryanA.ValentineJ.F.et al.Expansion of bacteriophages is linked"/>
   <result pre="Endocrinol. Metab.20161011680168510.1210/jc.2015-420826863425 37.LiberskiP.P.GajosA.SikorskaB.LindenbaumS.Kuru, the first human prion diseaseViruses201911E23210.3390/v1103023230866511 38.KimY.S.CarpR.I.CallahanS.M.WisniewskiH.M.Scrapie induced" exact="obesity" post="in miceJ. Infect. Dis.198715640240510.1093/infdis/156.2.4023598239 39.CarpR.I.CallahanS.M.SersenE.A.MoretzR.C.Preclinical changes in weight of"/>
   <result pre="obesityProc. Soc. Exp. Biol. Med.1988189212710.3181/00379727-189-427743141932 41.StromA.YutzyB.KruipC.OomsM.SchlootN.C.RodenM.ScottF.W.LoewerJ.HolznagelE.Foodborne transmission of bovine spongiform" exact="encephalopathy" post="to non-human primates results in preclinical rapid-onset obesityPLoS ONE20149e10434310.1371/journal.pone.010434325090610"/>
   <result pre="resistance, and steatosisJ. Clin. Transl. Hepatol.20164667527047774 44.LazoM.NwankwoC.DayaN.R.ThomasD.L.MehtaS.H.JuraschekS.WillisK.SelvinE.Confluence of epidemics of" exact="hepatitis" post="C, diabetes, obesity, and chronic kidney disease in the"/>
   <result pre="Hepatol.20164667527047774 44.LazoM.NwankwoC.DayaN.R.ThomasD.L.MehtaS.H.JuraschekS.WillisK.SelvinE.Confluence of epidemics of hepatitis C, diabetes, obesity, and" exact="chronic kidney disease" post="in the United States populationClin. Gastroenterol. Hepatol.2017151957196410.1016/j.cgh.2017.04.04628579183 45.YenY.H.KeeK.M.ChenC.H.HuT.H.LuS.N.WangJ.H.HungC.H.Sustained virological"/>
   <result pre="risk factors are associated with mortality in patients with chronic" exact="hepatitis" post="CPLoS ONE201914e020885810.1371/journal.pone.020885830625158 46.ShieldsL.E.JenningsJ.LiuQ.LeeJ.MaW.BlechaF.MillerL.C.SangY.Cross-species genome-wide analysis reveals molecular and functional"/>
   <result pre="I interferon responsesNat. Rev. Immunol.201414364910.1038/nri358124362405 52.XieY.HeS.WangJ.MicroRNA-373 facilitates HSV-1 replication through" exact="suppression" post="of type I IFN response by targeting IRF1Biomed. Pharmacother.2018971409141610.1016/j.biopha.2017.11.07129156530"/>
   <result pre="IRF1Biomed. Pharmacother.2018971409141610.1016/j.biopha.2017.11.07129156530 53.RuJ.SunH.FanH.WangC.LiY.LiuM.TangH.MiR-23a facilitates the replication of HSV-1 through the" exact="suppression" post="of interferon regulatory factor 1PLoS ONE20149e11402110.1371/journal.pone.011402125461762 54.ClementM.MarsdenM.StaceyM.A.Abdul-KarimJ.GimenoBriasS.Costa BentoD.ScurrM.J.GhazalP.WeaverC.T.CarlessoG.et al.Cytomegalovirus-specific"/>
   <result pre="infection and slow disease progressionNature201451160160510.1038/nature1355425043006 60.ScagnolariC.MonteleoneK.CacciottiG.AntonelliG.Role of interferons in chronic" exact="hepatitis" post="C infectionCurr. Drug Targets20171884485010.2174/138945011766616020111263226844564 61.NanY.WuC.ZhangY.J.Interplay between Janus kinase/signal transducer"/>
   <result pre="physiology and diseaseNat. Med.2016221079108910.1038/nm.418527711063 65.MeijnikmanA.S.GerdesV.E.NieuwdorpM.HerremaH.Evaluating causality of gut microbiota in" exact="obesity" post="and diabetes in humansEndocr. Rev.20173913315310.1210/er.2017-0019229309555 66.SunL.MaL.MaY.ZhangF.ZhaoC.NieY.Insights into the role"/>
   <result pre="A multifaceted majorityFront. Microbiol.2015691810.3389/fmicb.2015.0091826441861 70.YadavH.JainS.NagpalR.MarottaF.Increased fecal viral content associated with" exact="obesity" post="in miceWorld J. Diabetes2016731632010.4239/wjd.v7.i15.31627555892 71.MukhopadhyaI.SegalJ.P.CardingS.R.HartA.L.HoldG.L.The gut virome: The ‘missing"/>
   <result pre="79.AlsaggarM.MillsM.LiuD.Interferon beta overexpression attenuates adipose tissue inflammation and high-fat diet-induced" exact="obesity" post="and maintains glucose homeostasisGene Ther.201724606610.1038/gt.2016.7627858942 80.FritschS.D.WeichhartT.Effects of interferons and"/>
   <result pre="activationNat. Immunol.20151683884910.1038/ni.320526147685 95.VlahosR.StambasJ.SelemidisS.Suppressing production of reactive oxygen species (ROS) for" exact="influenza" post="A virus therapyTrends Pharm. Sci.2012333810.1016/j.tips.2011.09.00121962460 96.WuT.MaF.MaX.JiaW.PanE.ChengG.ChenL.SunC.Regulating innate and adaptive"/>
   <result pre="steatosisScience201936538639210.1126/science.aav372231273070 105.OttenlingerF.M.MayerC.A.FerreirósN.SchreiberY.SchwiebsA.SchmidtK.G.AckermannH.PfeilschifterJ.M.RadekeH.H.Interferon-beta increases plasma ceramides of specific chain length in" exact="multiple sclerosis" post="patients, unlike fingolimod or natalizumabFront. Pharmacol.2016741210.3389/fphar.2016.0041227857690 106.O’SheaD.HoganA.E.Dysregulation of natural"/>
   <result pre="to non-obese mice during infection with the 2009 pandemic H1N1" exact="influenza" post="virusInfluenza Other Respir. Viruses2011541842510.1111/j.1750-2659.2011.00254.x21668672 109.WeberK.J.SauerM.HeL.TycksenE.KalugotlaG.RazaniB.SchillingJ.D.PPARγ deficiency suppresses the release"/>
   <result pre="Intrinsic interferon (IFN) response to microbiota tonic induction may suppress" exact="obesity" post="in addition to its role in potentiating rapid antiviral"/>
   <result pre="a general arrest of protein and lipid metabolism. The IFN" exact="suppression" post="of lipid metabolism is multifaceted such as directly repressing"/>
   <result pre="during acute phases of antiviral responses, is unlikely to induce" exact="obesity" post="and meta-inflammation underlying obesity; however, the prolonged IFN responses"/>
   <result pre="[80,81] with a permission. Figure 3 A reciprocal causality of" exact="obesity" post="and chronic viral infections. High-fat diet and viral infection"/>
   <result pre="of long-chain fatty acid (LFA) and leptin by expanding adipocytes," exact="obesity" post="is accompanied with meta-inflammation (enhanced by LFA) and susceptibility"/>
   <result pre="meta-inflammation (enhanced by LFA) and susceptibility to viral infections (through" exact="suppression" post="of IFN antiviral signaling by leptin induction of SOCS3"/>
   <result pre="chickens Obesity-association in humans Ad-5: childhood obesity, Ad-36: childhood, adult" exact="obesity" post="and BMISMAM-1: BMI Adipogenic gutmicrobe transferassociated with heavierhuman donor"/>
   <result pre="BMI Adipogenic gutmicrobe transferassociated with heavierhuman donor CMV: metabolicSyndromeHSV-1: adult" exact="obesity" post="Kuru obesity and/orbulimia duringearly disease inhumans HCV genotype 3:insulin"/>
   <result pre="gutmicrobe transferassociated with heavierhuman donor CMV: metabolicSyndromeHSV-1: adult obesity Kuru" exact="obesity" post="and/orbulimia duringearly disease inhumans HCV genotype 3:insulin resistance in"/>
   <result pre="disease inhumans HCV genotype 3:insulin resistance in humansDENV: children obesityHIV:" exact="obesity" post="in patients on ART Obesity during persistent viral infections?"/>
   <result pre="borna disease virus; BMI, body mass index; CMV, cytomegalovirus; DENV," exact="dengue fever" post="virus; HHV, human herpesvirus; HCV, hepatitis C virus; HSV-1,"/>
   <result pre="CMV, cytomegalovirus; DENV, dengue fever virus; HHV, human herpesvirus; HCV," exact="hepatitis" post="C virus; HSV-1, herpes simplex virus 1; IL, interleukin;"/>
   <result pre="fever virus; HHV, human herpesvirus; HCV, hepatitis C virus; HSV-1," exact="herpes simplex" post="virus 1; IL, interleukin; RAV, Rous-associated virus; SMAM, an"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6921433\results\search\disease\results.xml">
   <result pre="for future outbreaks of emerging infectious diseases. Yet when an" exact="infectious disease" post="is emerging, there is often substantial risk and uncertainty"/>
   <result pre="to accelerate testing of interventions. One prominent example was the" exact="yellow fever" post="experiments conducted by Walter Reed and colleagues in the"/>
   <result pre="Reed and colleagues in the early 1900s that proved that" exact="yellow fever" post="was transmitted by mosquitoes [1]. Over the last few"/>
   <result pre="by mosquitoes [1]. Over the last few decades, controlled human" exact="malaria" post="infection studies have enrolled approximately 2000 participants, with no"/>
   <result pre="coordinate the development of new vaccines to prevent and contain" exact="infectious disease" post="epidemics�? [7]. For epidemics that loom on the horizon,"/>
   <result pre="to determine whether and when an HCT of an emerging" exact="infectious disease" post="could be permissible. Through this analysis, we isolate several"/>
   <result pre="it ethically acceptable to conduct an HCT on an emerging" exact="infectious disease." post="Recognizing that, for many high priority diseases, an HCT"/>
   <result pre="not limited to Guillain–Barré syndrome, which is an acute, progressive" exact="neuropathy" post="that can result in paralysis [10, 11]. It can"/>
   <result pre="can cause congenital Zika syndrome. Congenital Zika syndrome typically involves" exact="microcephaly" post="and potentially significant abnormalities in neurological development, visual impairment,"/>
   <result pre="other viruses in the same family (flaviviruses such as dengue," exact="yellow fever," post="West Nile) would have been an exclusion criterion for"/>
   <result pre="research with pregnant women), a neurologist, two obstetrician/gynecologists, and an" exact="infectious disease" post="physician. Panel members were vetted to ensure there were"/>
   <result pre="stakeholders are likely to be interested in addressing an emerging" exact="infectious disease" post="in the midst of an outbreak, making it difficult"/>
   <result pre="this exception was included in order not to condemn the" exact="yellow fever" post="HCTs conducted by Walter Reed and colleagues, in which"/>
   <result pre="the research team were enrolled, and one investigator died from" exact="yellow fever." post="However, because the Nuremberg Code’s statement does not provide"/>
   <result pre="HCTs: &quot;[A] study that involves deliberately infecting healthy individuals with" exact="anthrax" post="or Ebola - both of which pose a very"/>
   <result pre="Joffe and Miller give the example of an epidemic of" exact="avian influenza" post="and note that, just as firefighters or rescue workers"/>
   <result pre="and Miller give the example of an epidemic of avian" exact="influenza" post="and note that, just as firefighters or rescue workers"/>
   <result pre="[6]. Accordingly, another possible way an HCT on an emerging" exact="infectious disease" post="could be ethically acceptable is if the HCT was"/>
   <result pre="exposure to fetuses can be catastrophic [31]. If an emerging" exact="infectious disease" post="was not transmissible to fetuses, then, an HCT of"/>
   <result pre="not transmissible to fetuses, then, an HCT of an emerging" exact="infectious disease" post="might be easier to justify. Similarly, if a disease"/>
   <result pre="monitoring throughout the study, then an HCT on an emerging" exact="infectious disease" post="could be relatively straightforward to justify ethically (provided of"/>
   <result pre="to illustrate a possible use of HCT with an emerging" exact="infectious disease;" post="this is one way to flesh out the WHO’s"/>
   <result pre="illustrates a scenario in which an HCT on an emerging" exact="infectious disease" post="might be relatively straightforward to justify ethically because the"/>
   <result pre="Ecol201742220822210.1111/jvec.1226129125246 2.RoestenbergMHoogerwerfMAFerreiraDMMordmüllerBYazdanbakhshMExperimental infection of human volunteersLancet Infect Dis20181810e312e32210.1016/S1473-3099(18)30177-429891332 3.SpringMPolhemusMOckenhouseCControlled human" exact="malaria" post="infectionJ Infect Dis2014209Suppl 2S40S4510.1093/infdis/jiu06324872394 4.BeecherHKEthics and clinical researchN Engl"/>
   <result pre="Zika Virus Infection in ColombiaN Engl J Med2016375161513152310.1056/NEJMoa160556427705091 12.AlettiMLecoulesSKanczugaVSolerCMaquartMSimonFet al.Transient" exact="myocarditis" post="associated with acute Zika virus infectionClin Infect Dis201764567867927940942 13.de"/>
   <result pre="Health Department of Pernambuco. Association between Zika virus infection and" exact="microcephaly" post="in Brazil, January to May, 2016: Preliminary report of"/>
   <result pre="resource settings: Experiences and perceptions of study participants in a" exact="malaria" post="Challenge study in KenyaWellcome Open Research201833910.12688/wellcomeopenres.14439.229806038 40.StunkelLGradyCMore than the"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6923192\results\search\disease\results.xml">
   <result pre="surveillance and control programs. Rift valley fever virus (RVFV), Japanese" exact="encephalitis" post="virus (JEV), and African swine fever virus (ASFV) represent"/>
   <result pre="fever virus (RVFV), African swine fever virus (ASFV), and Japanese" exact="encephalitis" post="virus (JEV), are three vector-borne veterinary pathogens with the"/>
   <result pre="the invasion and establishment of Rift Valley fever virus, Japanese" exact="encephalitis" post="virus, and African swine fever virus into the United"/>
   <result pre="fever virus into the United States. Rift Valley fever Japanese" exact="encephalitis" post="African swine fever Human pathogen Yes Yes No Vaccine"/>
   <result pre="available at the time this model was developed (16). Japanese" exact="encephalitis" post="virus strains have a history of invasion and establishment"/>
   <result pre="Guidelines and control recommendations for Rift Valley fever virus, Japanese" exact="encephalitis" post="virus, and African swine fever virus. Pathogen Available Guidelines"/>
   <result pre="animals Wildlife management Vector control (40) Japanese Encephalitis Virus &quot;Japanese" exact="encephalitis" post="virus infection, diagnosis and control in domestic animals�? Vaccination"/>
   <result pre="Assessment of the impact of vaccination Syndromic surveillance for acute" exact="encephalitis" post="syndrome Standardized, aggregate, data reporting (42) Manual for the"/>
   <result pre="Disease Preparedness and Response Plan (FAD PReP)—Disease Response Strategy: Japanese" exact="encephalitis" post="virus Quarantine and movement control Stamping out—swine depopulation on"/>
   <result pre="National Veterinary Services Laboratories (NVSL) (40). Japanese Encephalitis Globally, Japanese" exact="encephalitis" post="virus (JEV) is one of the most prevalent encephalitic"/>
   <result pre="found in eastern and southern regions of Asia (71). Japanese" exact="encephalitis" post="virus is primarily recognized as a human pathogen, but"/>
   <result pre="considered dead-end hosts, as there is no human-to-human transmission. Japanese" exact="encephalitis" post="virus is comprised of five genotypes (GI–GV) which are"/>
   <result pre="are relatively less available than human vaccines (41). Surveillance Japanese" exact="encephalitis" post="virus (JEV), West Nile virus (WNV), and St. Louis"/>
   <result pre="encephalitis virus (JEV), West Nile virus (WNV), and St. Louis" exact="encephalitis" post="virus (SLE) share the same serocomplex (77). There is"/>
   <result pre="types of surveillance (Table 2). Comprehensive syndromic surveillance for acute" exact="encephalitis" post="syndrome (AES) is recommended for JEV (42). These resources"/>
   <result pre="2006 for laboratory-based surveillance of JE by the WHO Japanese" exact="encephalitis" post="(JE) laboratory network (86). Of the available MAC ELISA"/>
   <result pre="assay developed by Wang et al. targets; &quot;WNV, Saint Louis" exact="encephalitis" post="virus, Venezuelan equine encephalomyelitis virus, Western equine encephalomyelitis virus,"/>
   <result pre="et al. targets; &quot;WNV, Saint Louis encephalitis virus, Venezuelan equine" exact="encephalomyelitis" post="virus, Western equine encephalomyelitis virus, Eastern equine encephalomyelitis virus,"/>
   <result pre="Saint Louis encephalitis virus, Venezuelan equine encephalomyelitis virus, Western equine" exact="encephalomyelitis" post="virus, Eastern equine encephalomyelitis virus, Highlands J virus and"/>
   <result pre="Venezuelan equine encephalomyelitis virus, Western equine encephalomyelitis virus, Eastern equine" exact="encephalomyelitis" post="virus, Highlands J virus and JEV�? (91). African Swine"/>
   <result pre="detection of ASFV, classical swine fever virus, and foot and" exact="mouth disease" post="virus, and evaluated use of this assay on swine"/>
   <result pre="9.TurellMJWilsonWCBennettKE. Potential for North American mosquitoes (Diptera: Culicidae) to transmit" exact="rift valley fever" post="virus. J Med Entomol. (2010) 47:884–9. 10.1093/jmedent/47.5.88420939385 10.BergrenNAKadingRC. The"/>
   <result pre="7:e2515. 10.1371/journal.pntd.000251524244769 17.NabeshimaTLoanHTKInoueSSumiyoshiMHarutaYNgaPTet al.. Evidence of frequent introductions of Japanese" exact="encephalitis" post="virus from south-east Asia and continental east Asia to"/>
   <result pre="(2009) 90:827–32. 10.1099/vir.0.007617-019264633 18.NgaPTdel Carmen ParquetMCuongVDMaSPHasebeFInoueSet al.. Shift in Japanese" exact="encephalitis" post="virus (JEV) genotype circulating in northern Vietnam: implications for"/>
   <result pre="(2004) 85:1625–31. 10.1099/vir.0.79797-015166447 19.YoshikawaANabeshimaTInoueSAgohMMoritaK. Molecular and serological epidemiology of Japanese" exact="encephalitis" post="virus (JEV) in a remote island of western Japan:"/>
   <result pre="(2016) 44:8. 10.1186/s41182-016-0010-027433127 20.RitchieSARochesterW. Wind-blown mosquitoes and introduction of Japanese" exact="encephalitis" post="into Australia. Emerging Infect Dis. (2001) 7:900–3. 10.3201/eid0705.01752411747709 21.SolomonTThaoTTLewthwaitePOoiMHKneenRDungNMet"/>
   <result pre="al.. A cohort study to assess the new WHO Japanese" exact="encephalitis" post="surveillance standards. Bull World Health Organ. (2008) 86:178–86. 10.2471/BLT.07.04330718368204"/>
   <result pre="Health Organ. (2008) 86:178–86. 10.2471/BLT.07.04330718368204 22.TakashimaIWatanabeTOuchiNHashimotoN. Ecological studies of Japanese" exact="encephalitis" post="virus in Hokkaido: interepidemic outbreaks of swine abortion and"/>
   <result pre="Med Hyg. (1988) 38:420–7. 10.4269/ajtmh.1988.38.4202833128 23.OliveiraARSPiaggioJCohnstaedtLWMcVeyDSCernicchiaroN. Introduction of the Japanese" exact="encephalitis" post="virus (JEV) in the United States–a qualitative risk assessment."/>
   <result pre="Dis. (2019) 66:1558–74. 10.1111/tbed.1318130900804 24.HuangY-JSHettenbachSMParkSLHiggsSBarrettADTHsuW-Wet al.. Differential infectivities among different" exact="japanese encephalitis" post="virus genotypes in culex quinquefasciatus mosquitoes. PLoS Negl Trop"/>
   <result pre="(2019) 66:1558–74. 10.1111/tbed.1318130900804 24.HuangY-JSHettenbachSMParkSLHiggsSBarrettADTHsuW-Wet al.. Differential infectivities among different japanese" exact="encephalitis" post="virus genotypes in culex quinquefasciatus mosquitoes. PLoS Negl Trop"/>
   <result pre="al.. Susceptibility of a North American culex quinquefasciatus to Japanese" exact="encephalitis" post="virus. Vector Borne Zoonotic Dis. (2015) 15:709–11. 10.1089/vbz.2015.182126565775 26.LiXTianK."/>
   <result pre="Animal Plant Health Inspection Service, Veterinary Services (2013). 41.MansfieldKLHernández-TrianaLMBanyardACFooksARJohnsonN. Japanese" exact="encephalitis" post="virus infection, diagnosis and control in domestic animals. Vet"/>
   <result pre="Infect Dis. (2012) 16:564–73. 10.1016/j.bjid.2012.10.00423141974 72.SchererWFBuescherEL. Ecologic studies of Japanese" exact="encephalitis" post="firus in Japan. I Introduction. Am J Trop Med"/>
   <result pre="Med Hyg. (1959) 8:644–50. 10.4269/ajtmh.1959.8.64414442653 73.SugiuraTShimadaK. Seroepizootiological survey of Japanese" exact="encephalitis" post="virus and Getah virus in regional horse race tracks"/>
   <result pre="Med Sci. (1999) 61:877–81. 10.1292/jvms.61.87710487225 74.ChenWRTeshRBRico-HesseR. Genetic variation of Japanese" exact="encephalitis" post="virus in nature. J Gen Virol. (1990) 71:2915–22. 10.1099/0022-1317-71-12-29152273391"/>
   <result pre="in nature. J Gen Virol. (1990) 71:2915–22. 10.1099/0022-1317-71-12-29152273391 75.ZaninMPWebsterDEMartinJLWesselinghSL. Japanese" exact="encephalitis" post="vaccines: moving away from the mouse brain. Expert Rev"/>
   <result pre="76.NahJ-JYangD-KKimH-HSongJ-Y. The present and future of veterinary vaccines for Japanese" exact="encephalitis" post="in Korea. Clin Exp Vaccine Res. (2015) 4:130–6. 10.7774/cevr.2015.4.2.13026273571"/>
   <result pre="Flavivirus. J Virol. (1998) 72:73–83. 9420202 78.PhamTTMengSSunYLvWBahlJ. Inference of Japanese" exact="encephalitis" post="virus ecological and evolutionary dynamics from passive and active"/>
   <result pre="Evol. (2016) 2:vew009. 10.1093/ve/vew00927774302 79.CappelleJDuongVPringLKongLYakovleffMPrasetyoDBet al.. Intensive circulation of Japanese" exact="encephalitis" post="virus in peri-urban sentinel pigs near Phnom Penh, Cambodia."/>
   <result pre="10:e0005149. 10.1371/journal.pntd.000514927926937 80.RicklinMEGarcía-NicolásOBrechbühlDPythonSZumkehrBNougairedeAet al.. Vector-free transmission and persistence of Japanese" exact="encephalitis" post="virus in pigs. Nat Commun. (2016) 7:10832. 10.1038/ncomms1083226902924 81.YapGLimXFChanSHowCBHumaidiMYeoGet"/>
   <result pre="(2016) 7:10832. 10.1038/ncomms1083226902924 81.YapGLimXFChanSHowCBHumaidiMYeoGet al.. Serological evidence of continued Japanese" exact="encephalitis" post="virus transmission in Singapore nearly three decades after end"/>
   <result pre="for detection of immunoglobulin M antibodies in sera from Japanese" exact="encephalitis" post="and dengue hemorrhagic fever patients. J Virol Methods. (1985)"/>
   <result pre="of immunoglobulin M antibodies in sera from Japanese encephalitis and" exact="dengue hemorrhagic fever" post="patients. J Virol Methods. (1985) 11:15–22. 10.1016/0166-0934(85)90120-X2989309 84.InnisBLNisalakANimmannityaSKusalerdchariyaSChongswasdiVSuntayakornSet al.."/>
   <result pre="immunosorbent assay to characterize dengue infections where dengue and Japanese" exact="encephalitis" post="co-circulate. Am J Trop Med Hyg. (1989) 40:418–27. 10.4269/ajtmh.1989.40.4182540664"/>
   <result pre="Gen Virol. (1989) 70:37–43. 10.1099/0022-1317-70-1-372543738 86.JohnsonBWGoodmanCHJeeYFeatherstoneDA. Differential diagnosis of Japanese" exact="encephalitis" post="virus infections with the inbios JE Detect™ and DEN"/>
   <result pre="Dis. (2017) 64:1801–12. 10.1111/tbed.1256927633257 88.PanJYanJZhouJTangXHeHXieRet al.. Sero-molecular epidemiology of Japanese" exact="encephalitis" post="in Zhejiang, an Eastern Province of China. PLoS Negl"/>
   <result pre="PLoS Negl Trop Dis. (2016) 10:e0004936. 10.1371/journal.pntd.000493627560360 89.ChuHWuZChenHLiCGuoXLiuRet al.. Japanese" exact="encephalitis" post="virus infection rate and detection of genotype I from"/>
   <result pre="PCR and microfluidic electrophoresis to simultaneously detect seven mosquito-transmitted zoonotic" exact="encephalomyelitis" post="viruses. Vet J. (2016) 212:27–35. 10.1016/j.tvjl.2015.10.04027256022 92.ChenaisEDepnerKGubertiVDietzeKViltropAStåhlK. Epidemiological considerations"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6924880\results\search\disease\results.xml">
   <result pre="ppub: 2020-1261125128 Abstract During 2016–2018, we conducted surveillance for Japanese" exact="encephalitis" post="virus (JEV) in mosquitoes and pigs in Japan, Thailand,"/>
   <result pre="years ago. Indigenous JEV strains persist in Asia. Keywords: Japanese" exact="encephalitis" post="virus Culex tritaeniorhynchus pig wild boar vector-borne infections mosquitoborne"/>
   <result pre="transmit a variety of viral pathogens (e.g., dengue, Zika, and" exact="chikungunya" post="viruses) and have caused a number of arboviral epidemics"/>
   <result pre="a number of arboviral epidemics throughout the world (1). Japanese" exact="encephalitis" post="virus (JEV; family Flaviviridae, genus Flavivirus) is a mosquitoborne"/>
   <result pre="is a mosquitoborne arbovirus that causes a severe form of" exact="encephalitis" post="in humans. JEV is distributed across most of Asia,"/>
   <result pre="Health Organization has estimated that the annual number of Japanese" exact="encephalitis" post="cases worldwide exceeds 60,000 (2). JEV is transmitted primarily"/>
   <result pre="Bali Pig serum sample 2017 Oct 17 LC461962† *JEV, Japanese" exact="encephalitis" post="virus. †Envelope gene sequence. ‡Full-genome sequence. A preliminary study we performed"/>
   <result pre="are provided. bo, bovine; eq, equine; hu, human; JEV, Japanese" exact="encephalitis" post="virus; MQ, mosquito; NA, data not available; sw, swine;"/>
   <result pre="campaign strategies. Appendix More information about the distribution of Japanese" exact="encephalitis" post="virus, Japan and Southeast Asia, 2016–2018. LINK Suggested citation"/>
   <result pre="Supriyono, Phichitraslip T, Prasertsincharoen N, et al. Distribution of Japanese" exact="encephalitis" post="virus, Japan and Southeast Asia, 2016–2018. Emerg Infect Dis."/>
   <result pre="4. NabeshimaT, MoritaK. Phylogeographic analysis of the migration of Japanese" exact="encephalitis" post="virus in Asia.Future Virol. 2010;5:343–54. 10.2217/fvl.10.21 5. NgaPT, del"/>
   <result pre="Carmen ParquetM, CuongVD, MaSP, HasebeF, InoueS, et al.Shift in Japanese" exact="encephalitis" post="virus (JEV) genotype circulating in northern Vietnam: implications for"/>
   <result pre="FangW, et al.Comparison of genotypes I and III in Japanese" exact="encephalitis" post="virus reveals distinct differences in their genetic and host"/>
   <result pre="LiX, FuS, CaoL, ShaoN, et al.Changing geographic distribution of Japanese" exact="encephalitis" post="virus genotypes, 1935–2017.Vector Borne Zoonotic Dis. 2019;19:35–44. 10.1089/vbz.2018.229130207876 8."/>
   <result pre="SugiyamaH, YonemitsuK, Van DungN, TeradaY, TaniguchiM, et al.Isolation of Japanese" exact="encephalitis" post="virus and a novel insect-specific flavivirus from mosquitoes collected"/>
   <result pre="NitatpattanaN, Dubot-PérèsA, GouilhMA, SourisM, BarbazanP, YoksanS, et al.Change in Japanese" exact="encephalitis" post="virus distribution, Thailand.Emerg Infect Dis. 2008;14:1762–5. 10.3201/eid1411.08054218976565 12. LopezAL,"/>
   <result pre="LopezAL, AldabaJG, RoqueVGJr, TandocAOIII, SyAK, EspinoFE, et al.Epidemiology of Japanese" exact="encephalitis" post="in the Philippines: a systematic review.PLoS Negl Trop Dis."/>
   <result pre="BalasubramanianR, YastiniNW, SuwarbaIGN, AndayaniAR, BuraV, et al.Protecting children against Japanese" exact="encephalitis" post="in Bali, Indonesia.Lancet. 2018;391:2500–1. 10.1016/S0140-6736(18)31191-729976465 14. GarjitoTA, Widiarti, AnggraeniYM,"/>
   <result pre="14. GarjitoTA, Widiarti, AnggraeniYM, AlfiahS, Tunggul SatotoTB, FarchannyA, et al.Japanese" exact="encephalitis" post="in Indonesia: An update on epidemiology and transmission ecology.Acta"/>
   <result pre="WatanabeM, HasegawaS, UedaY, MatsunoK, et al.Continuity and change of Japanese" exact="encephalitis" post="virus in Toyama Prefecture, Japan.Am J Trop Med Hyg."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6925274\results\search\disease\results.xml">
   <result pre="visit http://creativecommons.org/licenses/by/4.0/. Abstract Respiratory Syncytial Virus (RSV) can cause severe" exact="respiratory disease," post="yet a licensed vaccine is not available. We determined"/>
   <result pre="age of 65 are infected with RSV annually, leading to" exact="pneumonia" post="in 10–20% and death in 8% of those hospitalized"/>
   <result pre="obstacle of safety concerns raised after the occurrence of enhanced" exact="respiratory disease" post="(ERD) following natural RSV infection in RSV-naive infants that"/>
   <result pre="viral load, implying their capacity to protect against severe respiratory" exact="viral disease" post="when humoral immunity is insufficient.28 Based on these observations,"/>
   <result pre="under specific pathogen free conditions after screening negative for Mycobacterium" exact="tuberculosis" post="(by Mantoux test), for simian immunodeficiency virus, simian retrovirus,"/>
   <result pre="and polymerase chain reaction). Screening included Herpes B virus and" exact="measles" post="serology, but results were not included in the SPF"/>
   <result pre="based on the method described in ref. 61 A549 human" exact="lung carcinoma" post="cells (catalog number ATCC CCL-185, obtained from the American"/>
   <result pre="determined using a luciferase-based RSV VNA. Five thousand A549 human" exact="lung carcinoma" post="cells (catalog number ATCC CCL-185, obtained from the American"/>
   <result pre="elderly and high-risk adultsN. Engl. J. Med.20053521749175910.1056/NEJMoa04395115858184 6.HanLLAlexanderJPAndersonLJRespiratory syncytial virus" exact="pneumonia" post="among the elderly: an assessment of disease burdenJ. Infect."/>
   <result pre="assessment of disease burdenJ. Infect. Dis.1999179253010.1086/3145679841818 7.ThompsonWWet al.Mortality associated with" exact="influenza" post="and respiratory syncytial virus in the United StatesJAMA200328917918610.1001/jama.289.2.17912517228 8.PalivizumabAHumanized"/>
   <result pre="(rsv) vaccines–nonadjuvanted vaccine or vaccine adjuvanted with alum–given concomitantly with" exact="influenza" post="vaccine to high-risk elderly individualsJ. Infect. Dis.20081981317132610.1086/59216818855558 19.GroothuisJRet al.Prophylactic"/>
   <result pre="of a prime-boost vaccine schedule with distinct adenovirus vectors against" exact="malaria" post="in rhesus monkeysVaccine2009276226623310.1016/j.vaccine.2009.07.10619686691 34.HoftDFet al.A recombinant adenovirus expressing immunodominant"/>
   <result pre="reactogenicity and immunogenicity of an adenovirus type 35 based circumsporozoite" exact="malaria" post="vaccine in Burkinabe healthy adults 18 to 45 years"/>
   <result pre="in healthy adults (IPCAVD 001)J. Infect. Dis.201320724825610.1093/infdis/jis67123125443 37.AbelBet al.The novel" exact="tuberculosis" post="vaccine, AERAS-402, induces robust and polyfunctional CD4+ and CD8+"/>
   <result pre="of macaques with formalin-inactivated respiratory syncytial virus (RSV) induces interleukin-13-associated" exact="hypersensitivity" post="to subsequent RSV infectionJ. Virol.200276115611156910.1128/JVI.76.22.11561-11569.200212388717 43.MagroMet al.Neutralizing antibodies against"/>
   <result pre="immunogenicity to Plasmodium falciparum CS compared to that with either" exact="malaria" post="vaccine aloneInfect. Immun.2007752283229010.1128/IAI.01879-0617307942 56.KakukTJet al.A human respiratory syncytial virus"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6925897\results\search\disease\results.xml">
   <result pre="RNA secondary structure affect NS1 protein expression during early stage" exact="influenza" post="virus infection http://orcid.org/0000-0003-4573-8466BaranovskayaIrinairina.baranovskaja.1992@gmail.com12SergeevaMariiamari.v.sergeeva@gmail.com13FadeevArtemafadeew@gmail.com1KadirovaRenatarenakad87@mail.ru1IvanovaAnnaanna_e_svobodniy@mail.ru1RamsayEdwardwarmsunnyday@mail.ru1VasinAndreyinfluenza.spb@gmail.com123[1], 0000 0004 0494 5466grid.452514.3Smorodintsev Research Institute"/>
   <result pre="demonstrated in the life cycle of RNA-containing viruses, including the" exact="influenza" post="virus. At least two regions of conserved secondary structure"/>
   <result pre="in NS segment (+) RNA are predicted to vary among" exact="influenza" post="virus strains with respect to thermodynamic stability; both fall"/>
   <result pre="response to viral infection. Using a reverse genetics approach, four" exact="influenza" post="virus strains were constructed featuring mutations that have different"/>
   <result pre="protein Reverse genetics Funding Russian Science Foundation (RU)18-74-00130SergeevaMariia Introduction The" exact="influenza" post="A virus (IAV) poses a serious threat to human"/>
   <result pre="varies between IAV strains. The virus from the 1918 Spanish" exact="influenza" post="pandemic, A/Brevig Mission/1/1918 (H1N1), is characterized by a high"/>
   <result pre="NS mRNAs are less efficiently spliced in comparison to other" exact="influenza" post="viruses; this may be associated with higher NS1 protein"/>
   <result pre="predicted that the type of these structures can vary between" exact="influenza" post="A virus strains [12]. The first region (82–148) forms"/>
   <result pre="[14]. It has been noted that highly virulent avian H5N1" exact="influenza" post="viruses which appeared after the 2005 outbreak carry stable,"/>
   <result pre="the second region [15]. Other researchers have shown that mutant" exact="influenza" post="A viruses with altered RNA structure in the second"/>
   <result pre="497–564 have been previously predicted for a large number of" exact="influenza" post="A viruses [12]. In order to investigate whether these"/>
   <result pre="we chose sequences from A/Brevig Mission/1/1918 (H1N1)and A/Vietnam/1194/2004 (H5N1) pathogenic" exact="influenza" post="virus strains characterized by NS (+) RNA hairpin structure"/>
   <result pre="respectively. Based on our previous RNA structure analysis of human" exact="influenza" post="A viruses [12], we chose mutations that change hairpin"/>
   <result pre="G511A, G512A and C537G substitutions In order to obtain four" exact="influenza" post="virus strains that would differ only by NS RNA"/>
   <result pre="in the regions of interest, we used the well characterized" exact="influenza" post="virus A/PR/8/34 (H1N1) laboratory strain as the backbone and"/>
   <result pre="structure differences are involved in viral replication. We rescued 4" exact="influenza" post="viruses that have predicted combinations of NS gene RNA"/>
   <result pre="4: Figure S1. NS gene nucleotide alignment of the selected" exact="influenza" post="virus strains. LINK Additional file 5: Figure S2. Relative"/>
   <result pre="competing interests. References References 1.VasinAVTemkinaOAEgorovVVKlotchenkoSAPlotnikovaMAKiselevOIMolecular mechanisms enhancing the proteome of" exact="influenza" post="a viruses: an overview of recently discovered proteinsVirus Res2014185536310.1016/j.virusres.2014.03.01524675275"/>
   <result pre="overview of recently discovered proteinsVirus Res2014185536310.1016/j.virusres.2014.03.01524675275 2.PatersonDFodorEEmerging roles for the" exact="influenza" post="a virus nuclear export protein (NEP)PLoS Pathog20128e100301910.1371/journal.ppat.100301923236273 3.HaleBGRandallREOrtínJJacksonDThe multifunctional"/>
   <result pre="nuclear export protein (NEP)PLoS Pathog20128e100301910.1371/journal.ppat.100301923236273 3.HaleBGRandallREOrtínJJacksonDThe multifunctional NS1 protein of" exact="influenza" post="a virusesJ Gen Virol2008892359237610.1099/vir.0.2008/004606-018796704 4.García-SastreAEgorovAMatassovDBrandtSLevyDEDurbinJEet al.Influenza a virus lacking"/>
   <result pre="the NS1 gene replicates in interferon-deficient systemsVirology.199833032433010.1006/viro.1998.9508 5.YoungJFDesselbergerUPalesePFergusonBShatzmanARRosenbergMEfficient expression of" exact="influenza" post="virus NS1 nonstructural proteins in Escherichia coliProc Natl Acad"/>
   <result pre="Escherichia coliProc Natl Acad Sci U S A1983806105610910.1073/pnas.80.19.61056310615 6.EgorovABrandtSSereinigSRomanovaJFerkoBKatingerDet al.Transfectant" exact="influenza" post="a viruses with long deletions in the NS1 protein"/>
   <result pre="in Vero cellsJ Virol199872643764419658085 7.PetersenHMostafaATantawyMAIqbalAAHoffmannDTallamAet al.NS segment of a 1918" exact="influenza" post="a virus-descendent enhances replication of H1N1pdm09 and virus-induced cellular"/>
   <result pre="segment 7 and 8 mRNAs is an inherent property of" exact="influenza" post="virus a/Brevig Mission/1918/1 (H1N1) that causes elevated expression of"/>
   <result pre="NS1 proteinVirology.2012422465810.1016/j.virol.2011.10.00422036312 9.MossWNPrioreSFTurnerDHIdentification of potential conserved RNA secondary structure throughout" exact="influenza" post="a coding regionsRNA.201117991101110.1261/rna.261951121536710 10.ChursovAKopetzkySJLeshchinerIKondoferskyITheisFJFrishmanDet al.Specific temperature-induced perturbations of secondary"/>
   <result pre="mRNA structures are associated with the cold-adapted temperature-sensitive phenotype of" exact="influenza" post="a virusRNA Biol201291266127410.4161/rna.2208122995831 11.IlyinskiiPOSchmidtTLukashevDMeriinABThoidisGFrishmanDet al.Importance of mRNA secondary structural"/>
   <result pre="al.Importance of mRNA secondary structural elements for the expression of" exact="influenza" post="virus genesOmics20091342143010.1089/omi.2009.003619594376 12.VasinAVPetrovaAVEgorovVVPlotnikovaMAKlotchenkoSAKarpenkoMNet al.The influenza a virus NS genome"/>
   <result pre="elements for the expression of influenza virus genesOmics20091342143010.1089/omi.2009.003619594376 12.VasinAVPetrovaAVEgorovVVPlotnikovaMAKlotchenkoSAKarpenkoMNet al.The" exact="influenza" post="a virus NS genome segment displays lineage-specific patterns in"/>
   <result pre="al.Secondary structure of a conserved domain in the intron of" exact="influenza" post="a NS1 mRNAPLoS One201389e7061510.1371/journal.pone.007061524023714 14.GultyaevAPOlsthoornRCLA family of non-classical pseudoknots"/>
   <result pre="a NS1 mRNAPLoS One201389e7061510.1371/journal.pone.007061524023714 14.GultyaevAPOlsthoornRCLA family of non-classical pseudoknots in" exact="influenza" post="a and B virusesRNA Biol2010712512910.4161/rna.7.2.1128720200490 15.GultyaevAPHeusHAOlsthoornRCLAn RNA conformational shift"/>
   <result pre="B virusesRNA Biol2010712512910.4161/rna.7.2.1128720200490 15.GultyaevAPHeusHAOlsthoornRCLAn RNA conformational shift in recent H5N1" exact="influenza" post="a virusesBioinformatics.20072327227610.1093/bioinformatics/btl55917090581 16.JiangTNogalesABakerSFMartinez-SobridoLTurnerDHMutations designed by ensemble defect to Misfold"/>
   <result pre="designed by ensemble defect to Misfold conserved RNA structures of" exact="influenza" post="a segments 7 and 8 affect splicing and attenuate"/>
   <result pre="and attenuate viral replication in cell culturePLoS One201611e015690610.1371/journal.pone.015690627272307 17.BaoYBolotovPDernovoyDKiryutinBZaslavskyLTatusovaTet al.The" exact="influenza" post="virus resource at the National Center for biotechnology informationJ"/>
   <result pre="Virol20088259660110.1128/JVI.02005-0717942553 18.SquiresRBNoronhaJHuntVGarcía-SastreAMackenCBaumgarthNet al.Influenza research database: an integrated bioinformatics resource for" exact="influenza" post="research and surveillanceInfluenza Other Respir Viruses2012640441610.1111/j.1750-2659.2011.00331.x22260278 19.GruberA. R.LorenzR.BernhartS. H.NeubockR.HofackerI."/>
   <result pre="in polyacrylamide gelsElectrophoresis19878939910.1002/elps.1150080203 24.HoffmannENeumannGKawaokaYHobomGWebsterRGA DNA transfection system for generation of" exact="influenza" post="a virus from eight plasmidsProc Natl Acad Sci U"/>
   <result pre="sequencing and vaccine production for classical and swine origin human" exact="influenza" post="a virusesJ Virol200983103091031310.1128/JVI.01109-0919605485 27.HuangXZhengMWangPMokBWLiuSLauSYAn NS-segment exonic splicing enhancer regulates"/>
   <result pre="influenza a virusesJ Virol200983103091031310.1128/JVI.01109-0919605485 27.HuangXZhengMWangPMokBWLiuSLauSYAn NS-segment exonic splicing enhancer regulates" exact="influenza" post="A virus replication in mammalian cellsNat Commun201781475110.1038/ncomms1475128323816"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6926201\results\search\disease\results.xml">
   <result pre="having dengue with warning signs, and 43 patients as having" exact="dengue fever." post="Conclusion In this study, we found that the serum"/>
   <result pre="of 15 years [5]. Dengue virus infections can manifest as" exact="dengue fever" post="or DHF/dengue shock syndrome (DSS) and can also end"/>
   <result pre="that neopterin level in patients at the early stage of" exact="dengue fever" post="is a sensitive indicator for the estimation of the"/>
   <result pre="of the first and second samples by severe and nonsevere" exact="dengue fever" post="The mean (SD) neopterin levels in non-severe dengue and"/>
   <result pre="of the first and second samples of severe and nonsevere" exact="dengue fever." post="[alt-text] Table 3 Neopterin Samples Nonsevere Dengue Severe Dengue"/>
   <result pre="reduced specificity in a patient known to have a specific" exact="infectious disease." post="Neopterin level in the early stage of dengue infection"/>
   <result pre="OrganizationGenevaWHO/HTM/NTD/DEN/2009 11BharathK.R.LaksmanaR.VeerappaB.G.ShivanandaUltrasonography as a tool in predicting the severity of" exact="dengue fever" post="in children—a useful aid in a developing countryPediatr Radiol43201397197723455371"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6927920\results\search\disease\results.xml">
   <result pre="multiple animal species, including humans. There are four types of" exact="influenza" post="viruses: A, B, C, and D (IAV, IBV, ICV,"/>
   <result pre="a multifunctional protein encoded by the NS segment in all" exact="influenza" post="types. The main function of NS1 is to counteract"/>
   <result pre="Despite of homologous functions, the NS1 protein from the diverse" exact="influenza" post="types share little amino acid sequence identity, suggesting possible"/>
   <result pre="NS1, resulting in deficient viral replication and pathogenesis in vivo." exact="influenza" post="A virus (IAV) influenza B virus (IBV) influenza C"/>
   <result pre="viral replication and pathogenesis in vivo. influenza A virus (IAV)" exact="influenza" post="B virus (IBV) influenza C virus (ICV) influenza D"/>
   <result pre="in vivo. influenza A virus (IAV) influenza B virus (IBV)" exact="influenza" post="C virus (ICV) influenza D virus (IDV) non-structural protein"/>
   <result pre="virus (IAV) influenza B virus (IBV) influenza C virus (ICV)" exact="influenza" post="D virus (IDV) non-structural protein 1 (NS1) signal transducer"/>
   <result pre="2018; Blanco-Lobo et al., 2019). Currently, there are four recognized" exact="influenza" post="virus types: A, B, C, and D (IAV, IBV,"/>
   <result pre="et al., 2017; Asha and Kumar, 2019). Concerns associated with" exact="influenza" post="virus are further exacerbated by their ability to efficiently"/>
   <result pre="et al., 2019). Therefore, there are several functional characteristics of" exact="influenza" post="NS1 that remains elusive. To evaluate the ability of"/>
   <result pre="NS1 proteins to functionally complement IAV NS1, we engineered recombinant" exact="influenza" post="A/Puerto Rico/8/34 H1N1 (PR8) viruses expressing homotypic (IAV) or"/>
   <result pre="NS1 proteins for the development of safe and effective live-attenuated" exact="influenza" post="vaccines (LAIVs) for the prevention of IAV infections. Results"/>
   <result pre="Activation To evaluate the ability of NS1 proteins from different" exact="influenza" post="viruses to inhibit general host protein expression or IFN-dependent"/>
   <result pre="expression, similar to PR8 IAV NS1. FIGURE 1 Ability of" exact="influenza" post="NS1 proteins to inhibit host gene expression and ISRE"/>
   <result pre="(in kDa) are indicated on the left. (C,D) Ability of" exact="influenza" post="NS1 proteins to inhibit ISRE promoter activation upon SeV"/>
   <result pre="Recombinant PR8 Viruses in vitro Since the primary role of" exact="influenza" post="NS1 protein is to inhibit IFN and host antiviral"/>
   <result pre="Viral infections were evaluated by immunofluorescence using the antibody against" exact="influenza" post="NP. (C) Tissue culture supernatants from the same mock-"/>
   <result pre="the different recombinant PR8 viruses in a mouse model of" exact="influenza" post="viral infection (Figure 5). Groups of C57BL/6 WT mice"/>
   <result pre="et al., 2016b, 2018a,b). Currently, there are four types of" exact="influenza" post="viruses: IAV, IBV, ICV and the newly identified IDV"/>
   <result pre="divergence of their genomes and host range, all types of" exact="influenza" post="viruses express NS1 proteins. The NS1 protein of IAV"/>
   <result pre="could be different for the NS1 proteins of these diverse" exact="influenza" post="viruses. The IBV, ICV, and IDV NS1 proteins tested"/>
   <result pre="responses, one could postulate that the NS1 protein of an" exact="influenza" post="virus could be exchanged for that of other virus"/>
   <result pre="feasibility of conducting similar studies in the backbone of other" exact="influenza" post="types (e.g., IBV, ICV, and IDV) to evaluate the"/>
   <result pre="Plasmids Polymerase II expression plasmids containing the NS1 sequences from" exact="influenza" post="B/Brisbane/60/2008 (IBV), C/Taylor/1233/1947 (ICV), or D/Swine/Oklahoma/1334/2011 (IDV) fused to"/>
   <result pre="by an immunofluorescence assay (fluorescent forming units [FFU/ml]) using an" exact="influenza" post="virus anti-NP antibody (HB-65) as previously described (Nogales et"/>
   <result pre="Medicine at Mount Sinai (ISMMS) related to using live attenuated" exact="influenza" post="virus vaccines lacking the NS1 virulence gene, exclusively licensed"/>
   <result pre="Contract No. HHSN272201400008C to AG-S). References References AshaK.KumarB. (2019). Emerging" exact="influenza" post="D virus threat: what we know so far!J. Clin."/>
   <result pre="AydilloT.AyllonJ.PavlisinA.Martinez-RomeroC.TripathiS.MenaI.et al. (2018). Specific mutations in the PB2 protein of" exact="influenza" post="A virus compensate for the lack of efficient interferon"/>
   <result pre="of efficient interferon antagonism of the NS1 protein of bat" exact="influenza" post="A-like viruses.J. Virol.92:e002021-17. 10.1128/JVI.02021-17JVI.02021-1729321309 AyllonJ.DominguesP.RajsbaumR.MiorinL.SchmolkeM.HaleB. G.et al. (2014). A"/>
   <result pre="(2014). A single amino acid substitution in the novel H7N9" exact="influenza" post="A virus NS1 protein increases F30 binding and virulence.J."/>
   <result pre="Blanco-LoboP.NogalesA.RodriguezL.Martinez-SobridoL. (2019). Novel approaches for the development of live attenuated" exact="influenza" post="vaccines.Viruses11:E190. 10.3390/v1102019030813325 BlaszczykK.NowickaH.KostyrkoK.AntonczykA.WesolyJ.BluyssenH. A. (2016). The unique role of"/>
   <result pre="responses.Cytokine Growth Factor Rev.2971–81. 10.1016/j.cytogfr.2016.02.01027053489 BreenM.NogalesA.BakerS. F.PerezD. R.Martinez-SobridoL. (2016). Replication-competent" exact="influenza" post="A and B viruses expressing a fluorescent dynamic timer"/>
   <result pre="studies.PLoS One11:e0147723. 10.1371/journal.pone.014772326809059 BurguiI.AragonT.OrtinJ.NietoA. (2003). PABP1 and eIF4GI associate with" exact="influenza" post="virus NS1 protein in viral mRNA translation initiation complexes.J."/>
   <result pre="10.1093/intimm/dxt05024158954 ChaucheC.NogalesA.ZhuH.GoldfarbD.Ahmad ShanizzaA. I.GuQ.et al. (2018). Mammalian adaptation of an" exact="avian influenza" post="A virus involves stepwise changes in NS1.J. Virol.92:e01875-17. 10.1128/JVI.01875-1729237841"/>
   <result pre="ChaucheC.NogalesA.ZhuH.GoldfarbD.Ahmad ShanizzaA. I.GuQ.et al. (2018). Mammalian adaptation of an avian" exact="influenza" post="A virus involves stepwise changes in NS1.J. Virol.92:e01875-17. 10.1128/JVI.01875-1729237841"/>
   <result pre="Virol.92:e01875-17. 10.1128/JVI.01875-1729237841 ChenR.HolmesE. C. (2008). The evolutionary dynamics of human" exact="influenza" post="B virus.J. Mol. Evol.66655–663. 10.1007/s00239-008-9119-z18504518 ChengA. C.SubbaraoK. (2018). Epidemiological"/>
   <result pre="10.1007/s00239-008-9119-z18504518 ChengA. C.SubbaraoK. (2018). Epidemiological data on the effectiveness of" exact="influenza" post="vaccine-another piece of the puzzle.J. Infect Dis.218176–178. 10.1093/infdis/jix63529361111 ChuaM."/>
   <result pre="10.1016/j.celrep.2012.12.01023333274 CoxA.BakerS. F.NogalesA.Martinez-SobridoL.DewhurstS. (2015). Development of a mouse-adapted live attenuated" exact="influenza" post="virus that permits in vivo analysis of enhancements to"/>
   <result pre="vivo analysis of enhancements to the safety of live attenuated" exact="influenza" post="virus vaccine.J. Virol.893421–3426. 10.1128/JVI.02636-1425552727 DankarS. K.MirandaE.ForbesN. E.PelchatM.TavassoliA.SelmanM.et al. (2013)."/>
   <result pre="and CPSF30.Virol. J.10:243. 10.1186/1743-422X-10-24323886034 DauberB.SchneiderJ.WolffT. (2006). Double-stranded RNA binding of" exact="influenza" post="B virus nonstructural NS1 protein inhibits protein kinase R"/>
   <result pre="I64T affects interferon responses and virulence of circulating H3N2 human" exact="influenza" post="A viruses.J. Virol.909693–9711. 10.1128/JVI.01039-1627535054 Dela-MossL. I.MossW. N.TurnerD. H. (2014)."/>
   <result pre="N.TurnerD. H. (2014). Identification of conserved RNA secondary structures at" exact="influenza" post="B and C splice sites reveals similarities and differences"/>
   <result pre="B and C splice sites reveals similarities and differences between" exact="influenza" post="A, B, and C.BMC Res. Notes7:22. 10.1186/1756-0500-7-2224405943 FalconA. M.FortesP.MarionR."/>
   <result pre="C.BMC Res. Notes7:22. 10.1186/1756-0500-7-2224405943 FalconA. M.FortesP.MarionR. M.BelosoA.OrtinJ. (1999). Interaction of" exact="influenza" post="virus NS1 protein and the human homologue of Staufen"/>
   <result pre="income countries: a systematic review.PLoS One13:e0202787. 10.1371/journal.pone.020278730192781 Fernandez-SesmaA. (2007). The" exact="influenza" post="virus NS1 protein: inhibitor of innate and adaptive immunity.Infect."/>
   <result pre="J.RichH. E.RamananK.MandalapuS.et al. (2018). STAT2 signaling regulates macrophage phenotype during" exact="influenza" post="and bacterial super-infection.Front. Immunol.9:2151. 10.3389/fimmu.2018.0215130337919 GrantA.PoniaS. S.TripathiS.BalasubramaniamV.MiorinL.SourisseauM.et al. (2016)."/>
   <result pre="Microbe19882–890. 10.1016/j.chom.2016.05.00927212660 GuoZ.ChenL. M.ZengH.GomezJ. A.PlowdenJ.FujitaT.et al. (2007). NS1 protein of" exact="influenza" post="A virus inhibits the function of intracytoplasmic pathogen sensor,"/>
   <result pre="10.1128/JVI.01213-0818768976 HaleB. G.BarclayW. S.RandallR. E.RussellR. J. (2008a). Structure of an" exact="avian influenza" post="A virus NS1 protein effector domain.Virology3781–5. 10.1016/j.virol.2008.05.02618585749 HaleB. G.RandallR."/>
   <result pre="HaleB. G.BarclayW. S.RandallR. E.RussellR. J. (2008a). Structure of an avian" exact="influenza" post="A virus NS1 protein effector domain.Virology3781–5. 10.1016/j.virol.2008.05.02618585749 HaleB. G.RandallR."/>
   <result pre="10.1016/j.virol.2008.05.02618585749 HaleB. G.RandallR. E.OrtinJ.JacksonD. (2008b). The multifunctional NS1 protein of" exact="influenza" post="A viruses.J. Gen. Virol.89(Pt 10), 2359–2376. 10.1099/vir.0.2008/004606-018796704 HaleB. G.SteelJ.MedinaR."/>
   <result pre="control of host gene expression by the 2009 pandemic H1N1" exact="influenza" post="A virus NS1 protein.J. Virol.846909–6922. 10.1128/JVI.00081-1020444891 HatadaE.SaitoS.OkishioN.FukudaR. (1997). Binding"/>
   <result pre="virus NS1 protein.J. Virol.846909–6922. 10.1128/JVI.00081-1020444891 HatadaE.SaitoS.OkishioN.FukudaR. (1997). Binding of the" exact="influenza" post="virus NS1 protein to model genome RNAs.J. Gen. Virol.78(Pt"/>
   <result pre="Gen. Virol.78(Pt 5), 1059–1063. 10.1099/0022-1317-78-5-10599152423 HatadaE.TakizawaT.FukudaR. (1992). Specific binding of" exact="influenza" post="A virus NS1 protein to the virus minus-sense RNA"/>
   <result pre="al. (2015). Crystal structure of the RNA-dependent RNA polymerase from" exact="influenza" post="C virus.Nature527114–117. 10.1038/nature1552526503046 HerfstS.SchrauwenE. J.LinsterM.ChutinimitkulS.de WitE.MunsterV. J.et al. (2012)."/>
   <result pre="10.1038/nature1552526503046 HerfstS.SchrauwenE. J.LinsterM.ChutinimitkulS.de WitE.MunsterV. J.et al. (2012). Airborne transmission of" exact="influenza" post="A/H5N1 virus between ferrets.Science3361534–1541. 10.1126/science.121336222723413 IwasakiA.PillaiP. S. (2014). Innate"/>
   <result pre="virus between ferrets.Science3361534–1541. 10.1126/science.121336222723413 IwasakiA.PillaiP. S. (2014). Innate immunity to" exact="influenza" post="virus infection.Nat. Rev. Immunol.14315–328. 10.1038/nri366524762827 KimbleJ. B.SorrellE.ShaoH.MartinP. L.PerezD. R."/>
   <result pre="Immunol.14315–328. 10.1038/nri366524762827 KimbleJ. B.SorrellE.ShaoH.MartinP. L.PerezD. R. (2011). Compatibility of H9N2" exact="avian influenza" post="surface genes and 2009 pandemic H1N1 internal genes for"/>
   <result pre="10.1038/nri366524762827 KimbleJ. B.SorrellE.ShaoH.MartinP. L.PerezD. R. (2011). Compatibility of H9N2 avian" exact="influenza" post="surface genes and 2009 pandemic H1N1 internal genes for"/>
   <result pre="Sci. U.S.A.10812084–12088. 10.1073/pnas.110805810821730147 KochsG.Garcia-SastreA.Martinez-SobridoL. (2007). Multiple anti-interferon actions of the" exact="influenza" post="A virus NS1 protein.J. Virol.817011–7021. 10.1128/JVI.02581-0617442719 KochsG.Martinez-SobridoL.LienenklausS.WeissS.Garcia-SastreA.StaeheliP. (2009). Strong"/>
   <result pre="(2009). Strong interferon-inducing capacity of a highly virulent variant of" exact="influenza" post="A virus strain PR8 with deletions in the NS1"/>
   <result pre="Gen. Virol.90(Pt 12), 2990–2994. 10.1099/vir.0.015727-019726611 KrammerF.PaleseP.SteelJ. (2015). Advances in universal" exact="influenza" post="virus vaccine design and antibody mediated therapies based on"/>
   <result pre="for polypeptides NS1 and NS2 on RNA segment 8 of" exact="influenza" post="virus genome.Proc. Natl. Acad. Sci. U.S.A.771857–1861. 10.1073/pnas.77.4.18576246509 LiS.MinJ. Y.KrugR."/>
   <result pre="U.S.A.771857–1861. 10.1073/pnas.77.4.18576246509 LiS.MinJ. Y.KrugR. M.SenG. C. (2006). Binding of the" exact="influenza" post="A virus NS1 protein to PKR mediates the inhibition"/>
   <result pre="LongJ. S.MistryB.HaslamS. M.BarclayW. S. (2019). Host and viral determinants of" exact="influenza" post="A virus species specificity.Nat. Rev. Microbiol.1767–81. 10.1038/s41579-018-0115-z30487536 LuY.QianX. Y.KrugR."/>
   <result pre="species specificity.Nat. Rev. Microbiol.1767–81. 10.1038/s41579-018-0115-z30487536 LuY.QianX. Y.KrugR. M. (1994). The" exact="influenza" post="virus NS1 protein: a novel inhibitor of pre-mRNA splicing.Genes"/>
   <result pre="Dev.81817–1828. 10.1101/gad.8.15.18177958859 ManicassamyB.ManicassamyS.Belicha-VillanuevaA.PisanelliG.PulendranB.Garcia-SastreA. (2010). Analysis of in vivo dynamics of" exact="influenza" post="virus infection in mice using a GFP reporter virus.Proc."/>
   <result pre="Virol.78(Pt 10), 2447–2451. 10.1099/0022-1317-78-10-24479349463 Martinez-SobridoL.PeersenO.NogalesA. (2018). Temperature sensitive mutations in" exact="influenza" post="A viral ribonucleoprotein complex responsible for the attenuation of"/>
   <result pre="ribonucleoprotein complex responsible for the attenuation of the live attenuated" exact="influenza" post="vaccine.Viruses10:E560. 10.3390/v1010056030326610 Martinez-SobridoL.ZunigaE. I.RosarioD.Garcia-SastreA.de la TorreJ. C. (2006). Inhibition"/>
   <result pre="I interferon response by the nucleoprotein of the prototypic arenavirus" exact="lymphocytic choriomeningitis" post="virus.J. Virol.809192–9199. 10.1128/JVI.00555-0616940530 MatsuzakiY.SugawaraK.FuruseY.ShimotaiY.HongoS.OshitaniH.et al. (2016). Genetic lineage and"/>
   <result pre="Virol.809192–9199. 10.1128/JVI.00555-0616940530 MatsuzakiY.SugawaraK.FuruseY.ShimotaiY.HongoS.OshitaniH.et al. (2016). Genetic lineage and reassortment of" exact="influenza" post="C viruses circulating between 1947 and 2014.J. Virol.908251–8265. 10.1128/JVI.00969-1627384661"/>
   <result pre="I-mediated induction of beta interferon by the NS1 protein of" exact="influenza" post="A virus.J. Virol.81514–524. 10.1128/JVI.01265-0617079289 MonteagudoP. L.Munoz-MorenoR.FribourgM.PotlaU.MenaI.MarjanovicN.et al. (2019). Differential"/>
   <result pre="modulation of innate immune responses in human primary cells by" exact="influenza" post="A viruses carrying human or avian non-structural 1 proteins.J."/>
   <result pre="virus infection.JAKSTAT3:e27715. 10.4161/jkst.2771524778924 MostafaA.AbdelwhabE. M.MettenleiterT. C.PleschkaS. (2018). Zoonotic potential of" exact="influenza" post="A viruses: a comprehensive overview.Viruses10:E497. 10.3390/v1009049730217093 MuellerS. N.LangleyW. A.CarneroE.Garcia-SastreA.AhmedR."/>
   <result pre="overview.Viruses10:E497. 10.3390/v1009049730217093 MuellerS. N.LangleyW. A.CarneroE.Garcia-SastreA.AhmedR. (2010). Immunization with live attenuated" exact="influenza" post="viruses that express altered NS1 proteins results in potent"/>
   <result pre="M.et al. (2009). Pathogenesis and transmission of swine-origin 2009 A(H1N1)" exact="influenza" post="virus in ferrets.Science325481–483. 10.1126/science.117712719574348 MurakiY.FurukawaT.KohnoY.MatsuzakiY.TakashitaE.SugawaraK.et al. (2010). Influenza C"/>
   <result pre="splicing of viral mRNAs.J. Virol.841957–1966. 10.1128/JVI.01627-0920007279 NakadaS.GravesP. N.PaleseP. (1986). The" exact="influenza" post="C virus NS gene: evidence for a spliced mRNA"/>
   <result pre="formation of cellular pre-mRNAs.Mol. Cell1991–1000. 10.1016/s1097-2765(00)80099-49651582 NogalesA.BakerS. F.Martinez-SobridoL. (2014a). Replication-competent" exact="influenza" post="A viruses expressing a red fluorescent protein.Virology476C206–216. 10.1016/j.virol.2014.12.00625553516 NogalesA.BakerS."/>
   <result pre="al. (2017a). The K186E amino acid substitution in the canine" exact="influenza" post="virus H3N8 NS1 protein restores its ability to inhibit"/>
   <result pre="expression.J. Virol.91:e00877-17. 10.1128/JVI.00877-1728835506 NogalesA.HuangK.ChaucheC.DeDiegoM. L.MurciaP. R.ParrishC. R.et al. (2017b). Canine" exact="influenza" post="viruses with modified NS1 proteins for the development of"/>
   <result pre="of live-attenuated vaccines.Virology5001–10. 10.1016/j.virol.2016.10.00827750071 NogalesA.PerezD. R.SantosJ.FinchC.Martinez-SobridoL. (2017c). Reverse genetics of" exact="influenza" post="B viruses.Methods Mol. Biol.1602205–238. 10.1007/978-1-4939-6964-7_1428508223 NogalesA.RodriguezL.DeDiegoM. L.TophamD. J.Martinez-SobridoL. (2017d)."/>
   <result pre="in replication and pathogenesis of a temperature-sensitive 2009 pandemic H1N1" exact="influenza" post="A virus.J. Virol.91:e00720-17. 10.1128/JVI.00720-1728637750 NogalesA.DeDiegoM. L.TophamD. J.Martinez-SobridoL. (2016a). Rearrangement"/>
   <result pre="A virus.J. Virol.91:e00720-17. 10.1128/JVI.00720-1728637750 NogalesA.DeDiegoM. L.TophamD. J.Martinez-SobridoL. (2016a). Rearrangement of" exact="influenza" post="virus spliced segments for the development of live-attenuated vaccines.J."/>
   <result pre="affect interferon responses, thermosensitivity and virulence of circulating H3N2 human" exact="influenza" post="A viruses.J. Virol.91:e01930-16. 10.1128/JVI.01930-1628003482 NogalesA.Martinez-SobridoL. (2016). Reverse genetics approaches"/>
   <result pre="10.1128/JVI.01930-1628003482 NogalesA.Martinez-SobridoL. (2016). Reverse genetics approaches for the development of" exact="influenza" post="vaccines.Int. J. Mol. Sci.18:E20. 10.3390/ijms1801002028025504 NogalesA.Martinez-SobridoL.ChiemK.TophamD. J.DeDiegoM. L. (2018a)."/>
   <result pre="J.DeDiegoM. L. (2018a). Functional evolution of the 2009 pandemic H1N1" exact="influenza" post="virus NS1 and PA in humans.J. Virol.92:e01206-18. 10.1128/JVI.01206-1830021892 NogalesA.Martinez-SobridoL.TophamD."/>
   <result pre="J.DeDiegoM. L. (2018b). Modulation of innate immune responses by the" exact="influenza" post="A NS1 and PA-X proteins.Viruses10:E708. 10.3390/v1012070830545063 NogalesA.PiepenbrinkM. S.WangJ.OrtegaS.BasuM.FucileC. F.et"/>
   <result pre="monoclonal antibody.Sci. Rep.8:4374. 10.1038/s41598-018-22307-829531320 NogalesA.Rodriguez-SanchezI.MonteK.LenschowD. J.PerezD. R.Martinez-SobridoL. (2015). Replication-competent fluorescent-expressing" exact="influenza" post="B virus.Virus Res.21369–81. 10.1016/j.virusres.2015.11.01426590325 OpitzB.RejaibiA.DauberB.EckhardJ.VinzingM.SchmeckB.et al. (2007). IFNbeta induction"/>
   <result pre="B virus.Virus Res.21369–81. 10.1016/j.virusres.2015.11.01426590325 OpitzB.RejaibiA.DauberB.EckhardJ.VinzingM.SchmeckB.et al. (2007). IFNbeta induction by" exact="influenza" post="A virus is mediated by RIG-I which is regulated"/>
   <result pre="reservoirs and intermediate hosts: dogs, horses, and new possibilities for" exact="influenza" post="virus exposure of humans.J. Virol.892990–2994. 10.1128/JVI.03146-1425540375 PatzinaC.BottingC. H.Garcia-SastreA.RandallR. E.HaleB."/>
   <result pre="10.1128/JVI.03146-1425540375 PatzinaC.BottingC. H.Garcia-SastreA.RandallR. E.HaleB. G. (2017). Human interactome of the" exact="influenza" post="B virus NS1 protein.J. Gen. Virol.982267–2273. 10.1099/jgv.0.00090928869005 PaulesC. I.SullivanS."/>
   <result pre="Gen. Virol.982267–2273. 10.1099/jgv.0.00090928869005 PaulesC. I.SullivanS. G.SubbaraoK.FauciA. S. (2018). Chasing seasonal" exact="influenza" post="- the need for a universal influenza vaccine.N. Engl."/>
   <result pre="(2018). Chasing seasonal influenza - the need for a universal" exact="influenza" post="vaccine.N. Engl. J. Med.3787–9. 10.1056/NEJMp171491629185857 PicaN.LangloisR. A.KrammerF.MargineI.PaleseP. (2012). NS1-truncated"/>
   <result pre="PiepenbrinkM. S.NogalesA.BasuM.FucileC. F.LiesveldJ. L.KeeferM. C.et al. (2019). Broad and protective" exact="influenza" post="B virus neuraminidase antibodies in humans after vaccination and"/>
   <result pre="clonal persistence as plasma cells.mBio10:e00066-19. 10.1128/mBio.00066-1930862743 QiuY.KrugR. M. (1994). The" exact="influenza" post="virus NS1 protein is a poly(A)-binding protein that inhibits"/>
   <result pre="export of mRNAs containing poly(A).J. Virol.682425–2432.7908060 QiuY.NemeroffM.KrugR. M. (1995). The" exact="influenza" post="virus NS1 protein binds to a specific region in"/>
   <result pre="P.et al. (2017). Cost-effectiveness and public health impact of alternative" exact="influenza" post="vaccination strategies in high-risk adults.Vaccine355708–5713. 10.1016/j.vaccine.2017.07.06928890196 RichtJ. A.Garcia-SastreA. (2009)."/>
   <result pre="vaccination strategies in high-risk adults.Vaccine355708–5713. 10.1016/j.vaccine.2017.07.06928890196 RichtJ. A.Garcia-SastreA. (2009). Attenuated" exact="influenza" post="virus vaccines with modified NS1 proteins.Curr. Top. Microbiol. Immunol.333177–195."/>
   <result pre="Microbiol. Immunol.333177–195. 10.1007/978-3-540-92165-3_919768406 RobbN. C.ChaseG.BierK.VreedeF. T.ShawP. C.NaffakhN.et al. (2011). The" exact="influenza" post="A virus NS1 protein interacts with the nucleoprotein of"/>
   <result pre="ribonucleoprotein complexes.J. Virol.855228–5231. 10.1128/JVI.02562-10JVI.02562-1021411538 RobbN. C.JacksonD.VreedeF. T.FodorE. (2010). Splicing of" exact="influenza" post="A virus NS1 mRNA is independent of the viral"/>
   <result pre="acid residues responsible for inhibition of host gene expression by" exact="influenza" post="A H9N2 NS1 targeting of CPSF30.Front. Microbiol.9:2546. 10.3389/fmicb.2018.0254630405591 RodriguezL.NogalesA.Martinez-SobridoL."/>
   <result pre="A.SchwalmF.et al. (2010). Oseltamivir-resistant variants of the 2009 pandemic H1N1" exact="influenza" post="A virus are not attenuated in the guinea pig"/>
   <result pre="M.NjaaB. L.DavisC. T.et al. (2011). The virulence of 1997 H5N1" exact="influenza" post="viruses in the mouse model is increased by correcting"/>
   <result pre="their NS1 proteins.J. Virol.857048–7058. 10.1128/JVI.00417-11JVI.00417-1121593152 SteelJ.LowenA. C.MubarekaS.PaleseP. (2009a). Transmission of" exact="influenza" post="virus in a mammalian host is increased by PB2"/>
   <result pre="or 627E/701N.PLoS Pathog.5:e1000252. 10.1371/journal.ppat.100025219119420 SteelJ.LowenA. C.PenaL.AngelM.SolorzanoA.AlbrechtR.et al. (2009b). Live attenuated" exact="influenza" post="viruses containing NS1 truncations as vaccine candidates against H5N1"/>
   <result pre="Glycine 184 in nonstructural protein NS1 determines the virulence of" exact="influenza" post="A virus strain PR8 without affecting the host interferon"/>
   <result pre="affecting the host interferon response.J. Virol.8412761–12770. 10.1128/JVI.00701-1020926573 SuS.FuX.LiG.KerlinF.VeitM. (2017). Novel" exact="influenza" post="D virus: epidemiology, pathology, evolution and biological characteristics.Virulence81580–1591. 10.1080/21505594.2017.136521628812422"/>
   <result pre="Host microRNA molecular signatures associated with human H1N1 and H3N2" exact="influenza" post="A viruses reveal an unanticipated antiviral activity for miR-146a.J."/>
   <result pre="985–995. 10.1099/vir.0.049528-0vir.0.049528-023343627 TongS.ZhuX.LiY.ShiM.ZhangJ.BourgeoisM.et al. (2013). New world bats harbor diverse" exact="influenza" post="A viruses.PLoS Pathog.9:e1003657. 10.1371/journal.ppat.100365724130481 TurkingtonH. L.JuozapaitisM.KerryP. S.AydilloT.AyllonJ.Garcia-SastreA.et al. (2015)."/>
   <result pre="viruses.PLoS Pathog.9:e1003657. 10.1371/journal.ppat.100365724130481 TurkingtonH. L.JuozapaitisM.KerryP. S.AydilloT.AyllonJ.Garcia-SastreA.et al. (2015). Novel bat" exact="influenza" post="virus NS1 proteins bind double-stranded RNA and antagonize host"/>
   <result pre="10.1128/JVI.01430-15JVI.01430-1526246567 TurkingtonH. L.JuozapaitisM.TsolakosN.Corrales-AguilarE.SchwemmleM.HaleB. G. (2018). Unexpected functional divergence of bat" exact="influenza" post="virus NS1 proteins.J. Virol.92:e02097-17. 10.1128/JVI.02097-1729237829 TwuK. Y.NoahD. L.RaoP.KuoR. L.KrugR."/>
   <result pre="(2006). The CPSF30 binding site on the NS1A protein of" exact="influenza" post="A virus is a potential antiviral target.J. Virol.803957–3965. 10.1128/JVI.80.8.3957-3965.200616571812"/>
   <result pre="role of stearate attachment to the hemagglutinin-esterase-fusion glycoprotein HEF of" exact="influenza" post="C virus.Cell Microbiol.18692–704. 10.1111/cmi.1254126518983 WangW.KrugR. M. (1998). U6atac snRNA,"/>
   <result pre="specific target that mediates inhibition of AT-AC splicing by the" exact="influenza" post="virus NS1 protein.RNA455–64. 9436908 WanitchangA.NarkpukJ.Jaru-ampornpanP.JengarnJ.JongkaewwattanaA. (2012). Inhibition of influenza"/>
   <result pre="the influenza virus NS1 protein.RNA455–64. 9436908 WanitchangA.NarkpukJ.Jaru-ampornpanP.JengarnJ.JongkaewwattanaA. (2012). Inhibition of" exact="influenza" post="A virus replication by influenza B virus nucleoprotein: an"/>
   <result pre="9436908 WanitchangA.NarkpukJ.Jaru-ampornpanP.JengarnJ.JongkaewwattanaA. (2012). Inhibition of influenza A virus replication by" exact="influenza" post="B virus nucleoprotein: an insight into interference between influenza"/>
   <result pre="by influenza B virus nucleoprotein: an insight into interference between" exact="influenza" post="A and B viruses.Virology432194–203. 10.1016/j.virol.2012.06.01622770925 WatanabeT.KawaokaY. (2015). Influenza virus-host"/>
   <result pre="WIlkins). YoonS. W.WebbyR. J.WebsterR. G. (2014). Evolution and ecology of" exact="influenza" post="a viruses.Curr. Top. Microbiol. Immunol.385359–375. 10.1007/82_2014_39624990620 YuanW.KrugR. M. (2001)."/>
   <result pre="Genetic evolution and molecular selection of the HE gene of" exact="influenza" post="C virus.Viruses11:E167. 10.3390/v1102016730791465"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6928032\results\search\disease\results.xml">
   <result pre="or Non�?commissioned): Formal Systematic Review (Commissioned or Non�?commissioned) Nanoparticles in" exact="influenza" post="subunit vaccine development: Immunogenicity enhancement KHALAJ�?HEDAYATI et al. Khalaj�?HedayatiAtin1ChuaCaroline"/>
   <result pre="work is properly cited.file:IRV-14-92.pdf Abstract Abstract The threat of novel" exact="influenza" post="infections has sparked research efforts to develop subunit vaccines"/>
   <result pre="and types of nanoparticles (NPs) used in the preparation of" exact="influenza" post="subunit vaccine candidates to enhance humoral and cellular immune"/>
   <result pre="vaccine candidates to enhance humoral and cellular immune responses. immunogenicity" exact="influenza" post="vaccine nanoparticles subunit vaccine vaccine delivery Funding Taylor's Internal"/>
   <result pre="fig-count: table-count: page-count: word-count: Khalaj�?HedayatiA, ChuaCLL, SmookerP, LeeKW. Nanoparticles in" exact="influenza" post="subunit vaccine development: Immunogenicity enhancement. Influenza Other Respi Viruses."/>
   <result pre="650,000 deaths.1 Vaccination is the most effective method to prevent" exact="influenza" post="infection. Current influenza vaccines mainly rely on hemagglutinin (HA)"/>
   <result pre="is the most effective method to prevent influenza infection. Current" exact="influenza" post="vaccines mainly rely on hemagglutinin (HA) proteins as antigens"/>
   <result pre="These antibodies are mostly targeting the immunodominant epitopes of the" exact="influenza" post="virus that are highly variable between different virus strains."/>
   <result pre="variable between different virus strains. Each year, new variants of" exact="influenza" post="virus may emerge due to antigenic drift, which necessitates"/>
   <result pre="emerge due to antigenic drift, which necessitates the reformulation of" exact="influenza" post="vaccines on a yearly basis.2 Previously, mismatches between predicted"/>
   <result pre="cases.3 A &quot;universal�? vaccine that targets the conserved regions of" exact="influenza" post="viruses and induces a broadly protective immunity may dramatically"/>
   <result pre="protective immunity may dramatically improve protection against seasonal and pandemic" exact="influenza" post="viruses. Antibodies that target conserved sites in the HA"/>
   <result pre="and shown to confer protection in animals challenged with various" exact="influenza" post="virus strains and subtypes.4 However, it is noteworthy that"/>
   <result pre="given sufficient consideration during universal vaccine design and evaluation.5 Licensed" exact="influenza" post="vaccines are currently available as inactivated (whole inactivated virus"/>
   <result pre="boost immunogenicity. Adjuvants are particularly important in the development of" exact="influenza" post="vaccines for the elderly population who has decreased immune"/>
   <result pre="adjuvants are also required in the development of novel peptide�?based" exact="influenza" post="vaccines, which are known to have low immunogenicity. There"/>
   <result pre="six types of adjuvants that have been included in licensed" exact="influenza" post="vaccines; alum, AS03, AF03, MF59, heat labile enterotoxin, and"/>
   <result pre="virosome, which is a nanoparticle (NP). Table 1 Currently available" exact="influenza" post="vaccines for the 2019�?2020 influenza season in the United"/>
   <result pre="(NP). Table 1 Currently available influenza vaccines for the 2019�?2020" exact="influenza" post="season in the United States112 Vaccines Manufacturers Production Preparation"/>
   <result pre="their ability to deliver antigens and increase immune responses against" exact="influenza" post="antigens in vaccines. The current review focuses on the"/>
   <result pre="latest scientific advancement in the application of different NPs in" exact="influenza" post="subunit vaccine development to enhance immunogenicity (Table 2). Table"/>
   <result pre="enhance immunogenicity (Table 2). Table 2 Current development of nanoparticle�?based" exact="influenza" post="vaccines NPs Vaccine candidate composition Humoral response Cellular response"/>
   <result pre="N/A √ √ Mice Pre�?clinical 114 Recombinant A (H1N1) 2009" exact="influenza" post="VLP vaccine (HA) √ N/A N/A N/A Human Phase"/>
   <result pre="primary antigen�?presenting cells (APCs).17, 18 For efficient protection against influenza," exact="influenza" post="vaccines are required to induce specific antibody responses, such"/>
   <result pre="types of NPs have been employed in the design of" exact="influenza" post="subunit vaccines such as bacterial spores, virus�?like particles (VLPs),"/>
   <result pre="spores have been used in the design of an oral" exact="influenza" post="vaccine, where the spore coat protein of B subtilis"/>
   <result pre="the ectodomain of M2 protein, a proton channel of the" exact="influenza" post="virus, that is highly conserved across all human influenza"/>
   <result pre="the influenza virus, that is highly conserved across all human" exact="influenza" post="virus A strains, thus making it one of the"/>
   <result pre="thus making it one of the main targets for universal" exact="influenza" post="vaccine development. The authors reported that M2e was successfully"/>
   <result pre="responses. When immunized mice were further challenged with A/PR/8/34 (H1N1)" exact="influenza" post="virus, lung specimens revealed significantly lower levels of the"/>
   <result pre="in vaccine production due to their ability in binding to" exact="influenza" post="virions. In a previous study, mice that were intranasally"/>
   <result pre="Particularly interesting was the observation that in the absence of" exact="influenza" post="antigens, the killed spores alone were able to confer"/>
   <result pre="human papillomavirus (HPV) and the third generation Sci�?B�?Vac™ vaccine against" exact="hepatitis" post="B virus (HBV). VLP�?based approaches are also explored as"/>
   <result pre="as a promising approach for the development of a universal" exact="influenza" post="vaccine.37 To design a successful VLP�?based vaccine, the most"/>
   <result pre="particle�?based vaccines have been widely explored in the design of" exact="influenza" post="vaccines, with promising results in providing protection against the"/>
   <result pre="with promising results in providing protection against the infection. An" exact="influenza" post="VLP�?based vaccine candidate consisting of influenza HA, NA, and"/>
   <result pre="against the infection. An influenza VLP�?based vaccine candidate consisting of" exact="influenza" post="HA, NA, and matrix protein (M1) (H7N9 A/Shanghai/2/2013) was"/>
   <result pre="a lethal dose of H7N9 virus.38 Another study reported that" exact="influenza" post="H3N2�?VLPs expressing HA, NA, and M1 proteins induced protective"/>
   <result pre="tandem repeat of five M2e variants from human, swine, and" exact="avian influenza" post="A viruses. It was shown to protect infected mice"/>
   <result pre="repeat of five M2e variants from human, swine, and avian" exact="influenza" post="A viruses. It was shown to protect infected mice"/>
   <result pre="to protect infected mice against a lethal challenge from distinct" exact="influenza" post="A viruses (H3N2 and H5N1).40, 41 Additionally, M2e5x was"/>
   <result pre="and promote cross�?protection when tested in ferrets.42 Tandiflu1 is an" exact="influenza" post="VLP�?based vaccine candidate comprising of a hepatitis B virus"/>
   <result pre="Tandiflu1 is an influenza VLP�?based vaccine candidate comprising of a" exact="hepatitis" post="B virus core (HBc) VLPs fused to four conserved"/>
   <result pre="protective antibodies, which resulted in 100% protection from a lethal" exact="influenza" post="challenge with H1N1 in mice. In addition, serum transfer"/>
   <result pre="result in broad protection. Mice vaccinated with a mixture of" exact="influenza" post="VLPs containing 4 different HA subtypes of influenza A"/>
   <result pre="mixture of influenza VLPs containing 4 different HA subtypes of" exact="influenza" post="A viruses (H1, H3, H5, and H7) were protected"/>
   <result pre="that were not included in the vaccine.45 A few VLP" exact="influenza" post="vaccines have been tested in humans with promising results."/>
   <result pre="in humans with promising results. For example, VLP vaccines against" exact="influenza" post="A/California/04/2009 (H1N1) was tested in adults and showed good"/>
   <result pre="achieved ≥40 hemagglutinin inhibition (HAI) titer.46 For the recombinant VLP" exact="influenza" post="A (H7N9) vaccine, the presence of ISCOMATRIX™ adjuvant was"/>
   <result pre="the effect of adding a modified Salmonella flagellin protein to" exact="influenza" post="VLPs associated with HA and M1 proteins. They reported"/>
   <result pre="in a group of elderly population (≥65 years old).48 Another" exact="influenza" post="vaccine, STF2.4 × M2e (VAX102), which consists of Salmonella"/>
   <result pre="can be taken up by DCs as efficiently as the" exact="influenza" post="virus.53 Bacteriophage VLP systems employ phage capsid proteins to"/>
   <result pre="56 Several phages have been developed as antigen adjuvant for" exact="influenza" post="vaccine development. A previous study incorporated influenza conserved nucleoprotein"/>
   <result pre="antigen adjuvant for influenza vaccine development. A previous study incorporated" exact="influenza" post="conserved nucleoprotein (NP) into bacteriophage P22 through genetic engineering"/>
   <result pre="The vaccine candidate protected mice against both H1N1 and H3N2" exact="influenza" post="strains that were administered via intranasal challenge.57 Two previous"/>
   <result pre="completely protected the mice against a lethal challenge with the" exact="influenza" post="virus PR8.60 An example of bacteriophage VLPs that have"/>
   <result pre="responses.66, 67, 68 Chitosan NPs have been previously used in" exact="influenza" post="DNA vaccines and shown to exhibit high stability and"/>
   <result pre="rate that need to be considered before being used in" exact="influenza" post="subunit vaccine development.69 Alternatively, water�?soluble trimethyl chitosan and alginate"/>
   <result pre="preparation. When these materials were used to package whole inactivated" exact="influenza" post="virus and administered as vaccines, high IgG titers were"/>
   <result pre="against lethal viral challenges for a cationic liposome�?DNA complex (CLDC)�?adjuvanted" exact="influenza" post="vaccine candidate compared to un�?adjuvanted formulation.74, 75 A similar"/>
   <result pre="Fluzone/CLDC�?vaccinated animals had lower virus replication when challenged with H1N1" exact="influenza" post="viruses.76 In another study, vaccination with liposomes containing HA"/>
   <result pre="study, vaccination with liposomes containing HA and NA from various" exact="influenza" post="strains and IL�?2/GM�?CSF as an adjuvant (INFLUSOME�?VAC) resulted in"/>
   <result pre="HAI titers compared to the control groups that received commercial" exact="influenza" post="vaccines.77 Studies have shown that the dose of liposomes"/>
   <result pre="when used at a high dose (900 µg) with trivalent" exact="influenza" post="vaccine (TIV), while at 30 µg of Vaxfectin, antibody"/>
   <result pre="lower doses.71, 79 This immune�?modulatory property can be explored in" exact="influenza" post="vaccine development to produce the required immune responses just"/>
   <result pre="a virosome/DNA vaccine complex (consisting of NP�?encoding plasmid attached to" exact="influenza" post="virosomes) was reported to induce comparable T�?cell responses in"/>
   <result pre="all age�?groups, is an example of a commercially available virosome�?based" exact="influenza" post="vaccine.87 Immune�?stimulating complexes Immune�?stimulating complexes (ISCOMs) are particulate adjuvant"/>
   <result pre="in the vaccine preparation.92, 93 The use of ISCOM containing" exact="influenza" post="viral proteins has been reported to enhance the CD8+"/>
   <result pre="T cells.97 Furthermore, this vaccine elicited protection against highly pathogenic" exact="avian influenza" post="A (H5N1) virus challenge in pre�?clinical murine studies.98, 99"/>
   <result pre="cells.97 Furthermore, this vaccine elicited protection against highly pathogenic avian" exact="influenza" post="A (H5N1) virus challenge in pre�?clinical murine studies.98, 99"/>
   <result pre="100% survival rate in mice that were lethally challenged with" exact="influenza" post="A/PR/8/34 (H1N1).103 The immunogenicity of these NPs can be"/>
   <result pre="of AuNPs�?FliC improved mucosal B�?cell responses, as characterized by elevated" exact="influenza" post="specific IgA and IgG levels in nasal, tracheal, and"/>
   <result pre="There is great potential in the use of NPs in" exact="influenza" post="vaccine development as they can be used to deliver"/>
   <result pre="understanding on these issues, a safer, highly immunogenic and affordable" exact="influenza" post="vaccine can be expected in the near future. AUTHOR"/>
   <result pre="et al. Vaccine�?induced anti�?HA2 antibodies promote virus fusion and enhance" exact="influenza" post="virus respiratory disease. Sci Transl Med. 2013;5(200):200ra114. 6ZhouF, TrieuM�?C,"/>
   <result pre="Vaccine�?induced anti�?HA2 antibodies promote virus fusion and enhance influenza virus" exact="respiratory disease." post="Sci Transl Med. 2013;5(200):200ra114. 6ZhouF, TrieuM�?C, DaviesR, CoxRJ. Improving"/>
   <result pre="disease. Sci Transl Med. 2013;5(200):200ra114. 6ZhouF, TrieuM�?C, DaviesR, CoxRJ. Improving" exact="influenza" post="vaccines: challenges to effective implementation. Curr Opin Immunol. 2018;53:88�?95.29719276"/>
   <result pre="effective implementation. Curr Opin Immunol. 2018;53:88�?95.29719276 7TregoningJS, RussellRF, KinnearE. Adjuvanted" exact="influenza" post="vaccines. Hum Vaccin Immunother. 2018;14(3):550�?564.29232151 8ZhaoK, ShiX, ZhaoY, et"/>
   <result pre="ZhaoY, et al. Preparation and immunological effectiveness of a swine" exact="influenza" post="DNA vaccine encapsulated in chitosan nanoparticles. Vaccine. 2011;29(47):8549�?8556.21945253 9Laliberté�?GagnéM�?È,"/>
   <result pre="13SinghSM, AlkieTN, NagyÉ, KulkarniRR, HodginsDC, SharifS. Delivery of an inactivated" exact="avian influenza" post="virus vaccine adjuvanted with poly(D, L�?lactic�?co�?glycolic acid) encapsulated CpG"/>
   <result pre="AlkieTN, NagyÉ, KulkarniRR, HodginsDC, SharifS. Delivery of an inactivated avian" exact="influenza" post="virus vaccine adjuvanted with poly(D, L�?lactic�?co�?glycolic acid) encapsulated CpG"/>
   <result pre="ChiocchettiA, DianzaniUExploiting PLGA�?based biocompatible nanoparticles for next�?generation tolerogenic vaccines against" exact="autoimmune disease." post="Int J Mol Sci. 201920(1):204. 15PatiR, ShevtsovM, SonawaneA. Nanoparticle"/>
   <result pre="a heat�?stable and orally delivered recombinant M2e�?expressing B subtilis spore�?based" exact="influenza" post="vaccine. Hum Vaccin Immunother. 2014;10(12):3649�?3658.25483702 25FerreiraL, FerreiraR, SchumannW. Bacillus"/>
   <result pre="LiuJ, et al. Intramuscular and intranasal immunization with an H7N9" exact="influenza" post="virus�?like particle vaccine protects mice against lethal influenza virus"/>
   <result pre="an H7N9 influenza virus�?like particle vaccine protects mice against lethal" exact="influenza" post="virus challenge. Int Immunopharmacol. 2017;2018(58):109�?116.s 39BrightRA, CarterDM, DanilukS, et"/>
   <result pre="virus�?like particles elicit broader immune responses than whole virion inactivated" exact="influenza" post="virus or recombinant hemagglutinin. Vaccine. 2007;25(19):3871�?3878.17337102 40KimM�?C, SongJ�?M, EunjuO,"/>
   <result pre="MorrisS, MaucourantS, et al. A virus�?like particle vaccine candidate for" exact="influenza" post="A virus based on multiple conserved antigens presented on"/>
   <result pre="influenza A virus based on multiple conserved antigens presented on" exact="hepatitis" post="B tandem core particles. Vaccine. 2018;36:873�?880.29306508 44GaoX, WangW, LiY,"/>
   <result pre="virus�?like particle vaccine broadly protects mice from multiple subtypes of" exact="influenza" post="a virus. MBio. 2015;6(4):1�?9. 46López�?MacíasC, Ferat�?OsorioE, Tenorio�?CalvoA, et al."/>
   <result pre="et al. Safety and immunogenicity of a virus�?like particle pandemic" exact="influenza" post="A (H1N1) 2009 vaccine in a blinded, randomized, placebo�?controlled"/>
   <result pre="JohnsonC, et al. Safety and immunogenicity of a recombinant M2e–flagellin" exact="influenza" post="vaccine (STF2.4xM2e) in healthy adults. Vaccine. 2011;29(32):5145�?5152.21624416 52TaoP, ZhuJ,"/>
   <result pre="2012;7(9):e45765.23029232 59DengL, IbañezLI, Van Den BosscheV, et al. Protection against" exact="influenza" post="a virus challenge with M2e�?displaying filamentous Escherichia coli phages."/>
   <result pre="et al. Safety and immunogenicity of a virus�?like particle pandemic" exact="influenza" post="A (H1N1) 2009 vaccine: Results from a double�?blinded, randomized"/>
   <result pre="evaluation of alginate�?coated chitosan and trimethylchitosan nanoparticles loaded with PR8" exact="influenza" post="virus for nasal immunization. Asian J Pharm Sci. 2020;14(2):216�?221."/>
   <result pre="adjuvant enhances the immunogenicity and cross�?protective efficacy of a pre�?pandemic" exact="influenza" post="A H5N1 vaccine in mice. Vaccine. 2012;30(2):254�?264.22085545 75HongDK, ChangS,"/>
   <result pre="2012;30(2):254�?264.22085545 75HongDK, ChangS, BothamCM, GiffonTD, FairmanJ, LewisDB. Cationic lipid/DNA complex�?adjuvanted" exact="influenza" post="a virus vaccination induces robust cross�?protective immunity. J Virol."/>
   <result pre="CallejoB, ChangS, et al. Cationic lipid/DNA complexes (JVRS�?100) combined with" exact="influenza" post="vaccine (Fluzone®) increases antibody response, cellular immunity, and antigenically"/>
   <result pre="ZeiraE, et al. Immunogenicity and safety of a novel liposomal" exact="influenza" post="subunit vaccine (INFLUSOME�?VAC) in young adults. J Med Virol."/>
   <result pre="YangCK, et al. Vaxfectin®, a cationic lipid�?based adjuvant for protein�?based" exact="influenza" post="vaccines. Vaccine. 2009;27(46):6399�?6403.19552895 79LasicDD. Novel applications of liposomes. Trends"/>
   <result pre="Biotechnol. 1998;16(7):307�?321.9675915 80AlmeidaJ, EdwardsDC, BrandC, HeathT. Formation of virosomes from" exact="influenza" post="subunits and liposomes. Lancet. 1975;306(7941):899�?901. 81StegmannT, MorseltHW, BooyFP, BreemenJF,"/>
   <result pre="1975;306(7941):899�?901. 81StegmannT, MorseltHW, BooyFP, BreemenJF, ScherphofG, WilschutJ. Functional reconstitution of" exact="influenza" post="virus envelopes. EMBO J. 1987;6(9):2651�?2659.3678202 82CryzSJ, QueJU, GlückR. A"/>
   <result pre="2000;43(2):197�?205.10967226 84HuckriedeA, BungenerL, StegmannT, et al. The virosome concept for" exact="influenza" post="vaccines. Vaccine. 2005;23:S26�?S38.16026906 85MoserC, AmackerM, KammerAR, RasiS, WesterfeldN, ZurbriggenR."/>
   <result pre="complex as a new formulation to induce intra�?subtypic protection against" exact="influenza" post="virus challenge. Antiviral Res. 2012;95(3):229�?236.22809863 87MischlerR, MetcalfeIC. Inflexal®V a"/>
   <result pre="Antiviral Res. 2012;95(3):229�?236.22809863 87MischlerR, MetcalfeIC. Inflexal®V a trivalent virosome subunit" exact="influenza" post="vaccine: production. Vaccine. 2002;20:B17�?B23.12477413 88LovgrenK, MoreinB. The requirement of"/>
   <result pre="adults comparing cell mediated and humoral immune responses induced by" exact="influenza" post="ISCOMTM vaccines and conventional vaccines. Vaccine. 2000;19(9–10):1180�?1187.11137255 95SambharaS, KurichhA,"/>
   <result pre="2000;19(9–10):1180�?1187.11137255 95SambharaS, KurichhA, MirandaR, et al. Heterosubtypic immunity against human" exact="influenza" post="A viruses, including recently emerged avian H5 and H9"/>
   <result pre="Gold nanoparticle�?M2e conjugate coformulated with CpG induces protective immunity against" exact="influenza" post="A virus. Nanomedicine (Lond). 2014;9(2):237�?251.23829488 103IngroleRS, TaoW, TripathyJN, GillHS."/>
   <result pre="Synthesis and immunogenicity assessment of elastin�?like polypeptide�?M2e construct as an" exact="influenza" post="antigen. Nano Life. 2014;4(2):1450004.25825595 104WangC, ZhuW, LuoY, WangBZ. Gold"/>
   <result pre="Life. 2014;4(2):1450004.25825595 104WangC, ZhuW, LuoY, WangBZ. Gold nanoparticles conjugating recombinant" exact="influenza" post="hemagglutinin trimers and flagellin enhanced mucosal cellular immunity. Nanomedicine."/>
   <result pre="and PLGA nanoparticles enhance humoral, mucosal and cytokine responses to" exact="hepatitis" post="B vaccine. Mol Pharm. 2011;8(2):405�?415. 21189035 111TanZ, LiuW, LiuH,"/>
   <result pre="Immunizations with heterosubtypic virus�?like particles elicit cross protection against divergent" exact="influenza" post="A viruses in mice. Sci Rep. 2018;8(1):11�?13.29311646 115PilletS, AubinÉ,"/>
   <result pre="AubinÉ, TrépanierS, et al. A plant�?derived quadrivalent virus like particle" exact="influenza" post="vaccine induces cross�?reactive antibody and T cell response in"/>
   <result pre="Immunogenicity and safety of a quadrivalent plant�?derived virus like particle" exact="influenza" post="vaccine candidate—Two randomized Phase II clinical trials in 18"/>
   <result pre="RomeijnS, KrosA, JiskootW. Adjuvant effect of cationic liposomes for subunit" exact="influenza" post="vaccine: Influence of antigen loading method, cholesterol and immune"/>
   <result pre="KünziV, et al. Eleven years of Inflexal® V—a virosomal adjuvanted" exact="influenza" post="vaccine. Vaccine. 2009;27(33):4381�?4387.19450630"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6928059\results\search\disease\results.xml">
   <result pre="6928059 doi: 10.1111/irv.12670IRV12670 : Original Article: Original Articles Influenza and" exact="tuberculosis" post="co�?infection: A systematic review WALAZA et al. WalazaSibongilehttps://orcid.org/0000-0001-7588-248012sibongilew@nicd.ac.zaCohenCheryl12cherylc@nicd.ac.zaTempiaStefanohttps://orcid.org/0000-0003-4395-347X34MoyesJocelyn12NguwenezaAthermon1MadhiShabir A.156McMorrowMeredith347CohenAdam"/>
   <result pre="on risk of severe disease or outcomes in patients with" exact="influenza" post="and pulmonary tuberculosis (PTB) co�?infection compared to those with"/>
   <result pre="of severe disease or outcomes in patients with influenza and" exact="pulmonary tuberculosis" post="(PTB) co�?infection compared to those with single infection. Methods"/>
   <result pre="severe disease or outcomes in patients with influenza and pulmonary" exact="tuberculosis" post="(PTB) co�?infection compared to those with single infection. Methods"/>
   <result pre="a systematic review of published literature on the interaction of" exact="influenza" post="viruses and PTB. Studies were eligible for inclusion if"/>
   <result pre="data on prevalence, disease association, presentation or severity of laboratory�?confirmed" exact="influenza" post="among clinically diagnosed or laboratory�?confirmed PTB cases. We searched"/>
   <result pre="four analytical studies reported no association with disease severity of" exact="influenza" post="infection in those with PTB, whilst one study reported"/>
   <result pre="as a risk factor for influenza�?associated hospitalization. An association between" exact="influenza" post="infection and PTB disease was found in three of"/>
   <result pre="of PTB disease progression and complications among patients with seasonal" exact="influenza" post="co�?infection. Conclusion Human analytical studies of an association between"/>
   <result pre="and severe influenza�? or PTB�?associated disease or increased prevalence of" exact="influenza" post="co�?infection in individuals' hospitalized for PTB were not conclusive."/>
   <result pre="limited from large, high�?quality, analytical epidemiological studies with laboratory�?confirmed endpoints." exact="influenza" post="interaction tuberculosis fig-count: table-count: page-count: word-count: WalazaS, CohenC, TempiaS,"/>
   <result pre="large, high�?quality, analytical epidemiological studies with laboratory�?confirmed endpoints. influenza interaction" exact="tuberculosis" post="fig-count: table-count: page-count: word-count: WalazaS, CohenC, TempiaS, et al."/>
   <result pre="table-count: page-count: word-count: WalazaS, CohenC, TempiaS, et al. Influenza and" exact="tuberculosis" post="co�?infection: A systematic review. Influenza Other Respi Viruses. 2020;14:77–91."/>
   <result pre="humans worldwide.1, 2, 3 Globally, it is estimated that annual" exact="influenza" post="epidemics result in three to five million cases of"/>
   <result pre="2015, there were an estimated 10.4 million incident cases of" exact="tuberculosis" post="and 1.8 million tuberculosis deaths globally.6 In 2015, tuberculosis"/>
   <result pre="estimated 10.4 million incident cases of tuberculosis and 1.8 million" exact="tuberculosis" post="deaths globally.6 In 2015, tuberculosis was the most common"/>
   <result pre="of tuberculosis and 1.8 million tuberculosis deaths globally.6 In 2015," exact="tuberculosis" post="was the most common cause of infectious disease�?related deaths"/>
   <result pre="the majority of cases reported in Asia and Africa.6 Both" exact="influenza" post="and tuberculosis impair host immune responses. Specifically, influenza can"/>
   <result pre="of cases reported in Asia and Africa.6 Both influenza and" exact="tuberculosis" post="impair host immune responses. Specifically, influenza can impair T�?cell"/>
   <result pre="Africa.6 Both influenza and tuberculosis impair host immune responses. Specifically," exact="influenza" post="can impair T�?cell immunity and weaken innate immune responses"/>
   <result pre="result in increased risk of influenza�?associated mortality.13 Furthermore, individuals with" exact="pulmonary tuberculosis" post="(PTB) may be at increased risk for severe influenza"/>
   <result pre="in increased risk of influenza�?associated mortality.13 Furthermore, individuals with pulmonary" exact="tuberculosis" post="(PTB) may be at increased risk for severe influenza"/>
   <result pre="pulmonary tuberculosis (PTB) may be at increased risk for severe" exact="influenza" post="disease and death due to chronic lung disease and"/>
   <result pre="risk for severe influenza disease and death due to chronic" exact="lung disease" post="and immunosupression. Ecological studies and mathematical modelling of epidemiologic"/>
   <result pre="of epidemiologic data suggest an increase in the frequency of" exact="influenza" post="disease or severe influenza�?associated disease in individuals with PTB"/>
   <result pre="disease or severe influenza�?associated disease in individuals with PTB during" exact="influenza" post="pandemics14, 15, 16, 17, 18 or during seasonal influenza"/>
   <result pre="during influenza pandemics14, 15, 16, 17, 18 or during seasonal" exact="influenza" post="epidemics19 compared with otherwise healthy individuals. Influenza infection may"/>
   <result pre="individuals. Influenza infection may facilitate the progression of latent Mycobacterium" exact="tuberculosis" post="infection to tuberculosis disease and alter the clinical presentation"/>
   <result pre="may facilitate the progression of latent Mycobacterium tuberculosis infection to" exact="tuberculosis" post="disease and alter the clinical presentation of tuberculosis.20 It"/>
   <result pre="the clinical presentation of tuberculosis.20 It is also possible that" exact="influenza" post="infection may exacerbate PTB. Whilst chronic lung diseases are"/>
   <result pre="are a known risk factor for severe outcomes due to" exact="influenza" post="infection and influenza vaccination is recommended in this group,"/>
   <result pre="risk factor for severe outcomes due to influenza infection and" exact="influenza" post="vaccination is recommended in this group, PTB is not"/>
   <result pre="listed as a separate priority group.21 Understanding the interaction between" exact="influenza" post="and PTB may assist in determining whether individuals with"/>
   <result pre="in determining whether individuals with PTB should be prioritized for" exact="influenza" post="vaccination and treatment with antiviral medications. We conducted a"/>
   <result pre="systematic review of published literature on the association between laboratory�?confirmed" exact="influenza" post="and PTB, that is influenza in individuals with tuberculosis"/>
   <result pre="on the association between laboratory�?confirmed influenza and PTB, that is" exact="influenza" post="in individuals with tuberculosis and tuberculosis in individuals with"/>
   <result pre="laboratory�?confirmed influenza and PTB, that is influenza in individuals with" exact="tuberculosis" post="and tuberculosis in individuals with influenza infection, in order"/>
   <result pre="and PTB, that is influenza in individuals with tuberculosis and" exact="tuberculosis" post="in individuals with influenza infection, in order to summarize"/>
   <result pre="influenza in individuals with tuberculosis and tuberculosis in individuals with" exact="influenza" post="infection, in order to summarize whether co�?infection affects presentation,"/>
   <result pre="guidelines,22 to summarize whether individuals with co�?infection present with severe" exact="influenza" post="or PTB disease as compared to those with single"/>
   <result pre="the association (burden of disease, transmission and severity) between laboratory�?confirmed" exact="influenza" post="and clinically diagnosed or laboratory�?confirmed PTB. Due to the"/>
   <result pre="comparison groups, were included. Articles that included seasonal or pandemic" exact="influenza" post="and animal experimental studies were also included. For human"/>
   <result pre="For human studies, inclusion was limited to studies in which" exact="influenza" post="was laboratory�?confirmed and tuberculosis included PTB. Animal studies were"/>
   <result pre="was limited to studies in which influenza was laboratory�?confirmed and" exact="tuberculosis" post="included PTB. Animal studies were included as they may"/>
   <result pre="humans. Studies that modelled ecological data on the association between" exact="influenza" post="and tuberculosis, individual case reports, vaccine studies and influenza"/>
   <result pre="between influenza and tuberculosis, individual case reports, vaccine studies and" exact="influenza" post="antiviral therapy in patients with tuberculosis were not included."/>
   <result pre="reports, vaccine studies and influenza antiviral therapy in patients with" exact="tuberculosis" post="were not included. Study selection is summarized in Figure"/>
   <result pre="Figure 1. Figure 1 Flow diagram for systematic review of" exact="influenza" post="and tuberculosis co�?infection 2.2 Search strategy We conducted a"/>
   <result pre="Figure 1 Flow diagram for systematic review of influenza and" exact="tuberculosis" post="co�?infection 2.2 Search strategy We conducted a systematic review"/>
   <result pre="using online databases. For our search, we included terms for" exact="influenza" post="(&quot;influenza�? or &quot;flu�? or &quot;influenza virus�? or &quot;human influenza�?)"/>
   <result pre="or &quot;flu�? or &quot;influenza virus�? or &quot;human influenza�?) and for" exact="tuberculosis" post="(&quot;tuberculosis�? or &quot;TB�?). The Medline, Embase, PsycINFO, CINAHL, Web"/>
   <result pre="included. Studies that reported data on the association between laboratory�?confirmed" exact="influenza" post="and clinically diagnosed or laboratory�?confirmed PTB including the following"/>
   <result pre="Prevalence and risk for PTB�?associated severe disease among patients with" exact="influenza" post="infection; Effect of influenza on PTB disease progression Clinical"/>
   <result pre="PTB�?associated severe disease among patients with influenza infection; Effect of" exact="influenza" post="on PTB disease progression Clinical presentation of influenza and"/>
   <result pre="Effect of influenza on PTB disease progression Clinical presentation of" exact="influenza" post="and PTB co�?infection; and Immune response to co�?infection, presentation"/>
   <result pre="period of study, sample size, study setting (hospital/ICU/outpatient), type of" exact="influenza" post="testing, tuberculosis testing method (microscopy, culture, polymerase chain reaction"/>
   <result pre="study, sample size, study setting (hospital/ICU/outpatient), type of influenza testing," exact="tuberculosis" post="testing method (microscopy, culture, polymerase chain reaction [PCR]), results"/>
   <result pre="(microscopy, culture, polymerase chain reaction [PCR]), results (influenza and tuberculosis)," exact="influenza" post="strains, outcome and findings. In studies where only a"/>
   <result pre="We summarized data under two groups, PTB in patients with" exact="influenza" post="and influenza in patients with PTB; this was decided"/>
   <result pre="data under two groups, PTB in patients with influenza and" exact="influenza" post="in patients with PTB; this was decided after examination"/>
   <result pre="classified according to whether they fall among the 22 high" exact="tuberculosis" post="burden countries (HBC) that account for aproximately. 80% of"/>
   <result pre="burden countries (HBC) that account for aproximately. 80% of world's" exact="tuberculosis" post="cases.3 Review protocol attached (Appendix S2). 2.5 Ethics Since"/>
   <result pre="reaction (RT�?PCR) and three used unpaired serology to test for" exact="influenza" post="infection. A total of 27 566 individuals (range 1924�?12"/>
   <result pre="31, 32, 33 Eight studies had laboratory�?confirmed results for both" exact="influenza" post="and tuberculosis (Tables 1 and 2). Nine studies were"/>
   <result pre="33 Eight studies had laboratory�?confirmed results for both influenza and" exact="tuberculosis" post="(Tables 1 and 2). Nine studies were from high"/>
   <result pre="from Europe reported data from a period (1952�?1963) with high" exact="tuberculosis" post="prevalence. Three of the eight analytical studies were of"/>
   <result pre="individuals with influenza,24, 25, 27, 29, 34, 35 six on" exact="influenza" post="in individuals with the underlying PTB26, 28, 31, 32,"/>
   <result pre="2).30 Table 1 Summary of studies reporting on effect of" exact="tuberculosis" post="in individuals with influenza Study Country Year Descriptive/ analytical"/>
   <result pre="of studies reporting on effect of tuberculosis in individuals with" exact="influenza" post="Study Country Year Descriptive/ analytical Objective/hypothesis Setting Number studied"/>
   <result pre="Year Descriptive/ analytical Objective/hypothesis Setting Number studied Influenza type Laboratory�?confirmed" exact="influenza" post="TB diagnosis Findings Associationa Newcastle�?Ottawa Scoreb Archer, (2009)34 South"/>
   <result pre="(2009)34 South Africa 2009 Descriptive Describe epidemiology of lab�?confirmed pandemic" exact="influenza" post="cases in South Africa Hospital admissions 72 cases Pandemic"/>
   <result pre="reported by attending clinician 7/72 (10%) cases who died with" exact="influenza" post="A(H1N1)pdm09 had TB vs 1% TB prevalence in 2006"/>
   <result pre="Hospital admissions 442 cases Pandemic A(H1N1)2009 RT�?PCR/culture Not specified 8.8%" exact="influenza" post="A (H1N1)pdm09 cases had TB vs 0.4% TB prevalence"/>
   <result pre="hospitalization Hospital admission 3646 Seasonal and pandemic RT�?PCR Microscopy, M" exact="tuberculosis" post="culture/XPert MTB/RIF TB was a risk factor for influenza�?associated"/>
   <result pre="Korea 2009�? 2011 Descriptive Describe cases with concurrent TB and" exact="influenza" post="Hospital admissions 12 196 subjects Pandemic A(H1N1) 2009 RT�?PCR"/>
   <result pre="NA Ope (2011)29 Kenya 2007�?2009 Analytical Describe risk factors for" exact="influenza" post="hospitalization Hospital admissions 64 cases; 190 controls Seasonal (AH3N2"/>
   <result pre="Self�?report verified by clinician diagnosis and medication TB associated with" exact="influenza" post="hospitalization on bivariate (OR 12.0, 95% CI 1.3�?107.37) but"/>
   <result pre="not on multivariate (aOR not presented) analysis Adjusted for chronic" exact="lung disease," post="chronic heart disease, HIV infection, owns cattle and number"/>
   <result pre="(aOR not presented) analysis Adjusted for chronic lung disease, chronic" exact="heart disease," post="HIV infection, owns cattle and number of chickens owned."/>
   <result pre="of chickens owned. HIV�?infected more likely to be hospitalized for" exact="influenza" post="[aOR3.56 (95% CI 1.25�?10.07)] No 8 Roth (2013)30 Thailand"/>
   <result pre="Roth (2013)30 Thailand 2003�?2011 Analytical Compare characteristics of TB/influenza to" exact="influenza" post="and TB only Hospital admissions 7180 subjects Seasonal &amp;amp;"/>
   <result pre="increased severity/mortality. Deaths in 0/23 co�?infected vs 17/604 (2.8%) with" exact="influenza" post="only (P = 1.0) HIV prevalence among co�?infected 3/18"/>
   <result pre="clinical features and outcome of pandemic H1N1 cases complicated by" exact="respiratory failure" post="Intensive care unit admissions 19 cases Pandemic A(H1N1) 2009"/>
   <result pre="Lab methods not specified�?presence/absence of disease 4/19 ICU cases with" exact="influenza" post="A(H1N1)pdm09 had TB. TB in 4/13 (31%) who died"/>
   <result pre="America. aAssociation—Evidence of/or association (univariate/multivariable analysis) with increased severity of" exact="influenza" post="disease in those with vs without tuberculosis; or prevalence"/>
   <result pre="without tuberculosis; or prevalence of co�?infection in those with severe" exact="influenza" post="disease. bScore out of a possible score of 9."/>
   <result pre="Table 2 Summary of studies reporting on the effect of" exact="influenza" post="in individuals with tuberculosis (TB) Study Country Year Descriptive/"/>
   <result pre="studies reporting on the effect of influenza in individuals with" exact="tuberculosis" post="(TB) Study Country Year Descriptive/ analytical Objective/hypothesis Setting Number"/>
   <result pre="Year Descriptive/ analytical Objective/hypothesis Setting Number studied Influenza type Laboratory�?confirmed" exact="influenza" post="TB diagnosis Findings Associationa Newcastle�?Ottawa Scoreb Dijkman (1967)26 Netherlands"/>
   <result pre="infection (influenza) and unfavourable course of primary pulmonary and hilar" exact="tuberculosis" post="among children�? Tuberculosis sanatorium 36 subjects Seasonal, influenza A"/>
   <result pre="and hilar tuberculosis among children�? Tuberculosis sanatorium 36 subjects Seasonal," exact="influenza" post="A &amp;amp; B Serology, HI antibodies against influenza A."/>
   <result pre="subjects Seasonal, influenza A &amp;amp; B Serology, HI antibodies against" exact="influenza" post="A. ≥fourfold increase in antibody titres Clinical&amp;amp; radiological examination"/>
   <result pre="towards end of hospitalization 20% (5/20) of paediatric patients with" exact="influenza" post="developed segmental pulmonary lesions. Not evaluated statistically NA NA"/>
   <result pre="viral infection on existing TB TB sanatorium 31 subjects Pandemic," exact="influenza" post="A, 1957 HI antibodies to PR8 type A &amp;amp;"/>
   <result pre="&amp;amp; FMI type A Tuberculin conversion, X�?ray changes ± M" exact="tuberculosis" post="culture 2/31 TB cases with influenza had signs of"/>
   <result pre="X�?ray changes ± M tuberculosis culture 2/31 TB cases with" exact="influenza" post="had signs of worsening on X�?ray (increased perihilar nodes,"/>
   <result pre="cavity) NA NA Walaza (2015)32 South Africa 2010�?2011 Analytical Compare" exact="influenza" post="single infection &amp;amp; influenza�?TB co�?infection to TB single infection"/>
   <result pre="single infection Hospital admission 2959 subjects Seasonal RT�?PCR Microscopy, M" exact="tuberculosis" post="culture/XPert MTB/RIF Increased risk of death in cases with"/>
   <result pre="8 Espersen (1954)28 Denmark 1952 Analytical Describe the epidemic of" exact="influenza" post="B in a TB sanatorium Tuberculosis sanatorium 295 subjects"/>
   <result pre="B in a TB sanatorium Tuberculosis sanatorium 295 subjects Seasonal," exact="influenza" post="B HI Clinical, TB smear ± culture Radiological changes"/>
   <result pre="6 Dube (2016)33 South Africa 2011�?2012 Analytical Compare prevalence of" exact="influenza" post="in children with definite TB to unlikely TB Hospital"/>
   <result pre="94 Unlikely TB, 86 unconfirmed TB) Seasonal Multiplex PCR M" exact="tuberculosis" post="culture/XPert MTB/RIF Influenza C 18% (6/34) vs 4% (4/94),"/>
   <result pre="2001�?2004 Analytical Did newly diagnosed TB patients have a recent" exact="influenza" post="virus infection? Hypothesis—Influenza virus enhanced the susceptibility to develop"/>
   <result pre="susceptibility to develop active TB/ reactivated latent TB Cases from" exact="tuberculosis" post="clinic and community controls 111 TB cases; 111 community"/>
   <result pre="socio�?economic status Seasonal (AH3N2/AH1N1) Serology HI�?IG and IGM antibodies against" exact="influenza" post="A HI titre ≥10 WHO case definition (clinical +"/>
   <result pre="CXR changes positive microscopy and culture for Mtb) Prevalence of" exact="influenza" post="antibodies among TB cases vs controls was 46% vs"/>
   <result pre="Roth (2013)30 Thailand 2003�?2011 Analytical Compare characteristics of TB/influenza to" exact="influenza" post="and TB only Hospital admissions 7180 subjects Seasonal and"/>
   <result pre="frequency of co�?infection vs single infection in those with severe" exact="tuberculosis" post="disease. bScore out of a possible score of 9."/>
   <result pre="Sons, Ltd, 3.2 The effect of PTB in patients with" exact="influenza" post="Of the seven studies that reported on PTB in"/>
   <result pre="Three descriptive studies from HBC using data from the 2009" exact="influenza" post="pandemic reported the prevalence of PTB in individuals with"/>
   <result pre="influenza. Two of these studies reported a high frequency of" exact="tuberculosis" post="(9% and 10%) in cases hospitalized with influenza and"/>
   <result pre="frequency of tuberculosis (9% and 10%) in cases hospitalized with" exact="influenza" post="and among influenza deaths relative to expected community prevalence."/>
   <result pre="(9% and 10%) in cases hospitalized with influenza and among" exact="influenza" post="deaths relative to expected community prevalence. However, no inferences"/>
   <result pre="statistically.34, 35 In a report of individuals that died with" exact="influenza" post="A(H1N1)pdm09 virus infection in South Africa, the underlying PTB"/>
   <result pre="Similarly, in a hospital�?based case series of patients positive for" exact="influenza" post="A(H1N1)pdm09 virus in India, 9% of influenza cases had"/>
   <result pre="patients positive for influenza A(H1N1)pdm09 virus in India, 9% of" exact="influenza" post="cases had PTB compared with 0.4% tuberculosis prevalence in"/>
   <result pre="India, 9% of influenza cases had PTB compared with 0.4%" exact="tuberculosis" post="prevalence in general population (P &amp;lt; .001).35 In a"/>
   <result pre="&amp;lt; .001).35 In a case series of patients infected with" exact="influenza" post="A(H1N1)pdm09 virus in South Korea &amp;lt;1% (7/12 196) had"/>
   <result pre="disease among patients with influenza�?PTB co�?infection compared to patients with" exact="influenza" post="only.24, 29, 30 One analytical study reported PTB as"/>
   <result pre="illness (SARI) hospitalization.27 In this case�?population study from South Africa," exact="tuberculosis" post="was twice as prevalent among hospitalized influenza�?associated SARI cases"/>
   <result pre="CI 1.3�?107.37); however, the underlying PTB was not associated with" exact="influenza" post="hospitalization on multivariable analysis.29 Less than 1% (23/7180) of"/>
   <result pre="and enrolled in a study from Thailand were co�?infected with" exact="influenza" post="viruses and tuberculosis. There were no deaths among the"/>
   <result pre="whereas 17 (2.8%) deaths occurred among cases in whom only" exact="influenza" post="was identified, P = .1.30 In a review of"/>
   <result pre="= .1.30 In a review of 19 cases with laboratory�?confirmed" exact="influenza" post="A(H1N1)pdm09 virus infection with respiratory failure admitted to an"/>
   <result pre="of 19 cases with laboratory�?confirmed influenza A(H1N1)pdm09 virus infection with" exact="respiratory failure" post="admitted to an intensive care facility in South Africa,"/>
   <result pre="(0%) who survived P = .5.24 3.5 The effect of" exact="influenza" post="in patients with PTB Of the seven papers that"/>
   <result pre="with PTB Of the seven papers that reported data on" exact="influenza" post="in patients with PTB (Table 2),26, 28, 30, 31,"/>
   <result pre="2),26, 28, 30, 31, 32, 33, 36 four were from" exact="tuberculosis" post="HBCs and the other three were from Europe in"/>
   <result pre="other three were from Europe in a period with high" exact="tuberculosis" post="prevalence.30, 31, 32, 33 Four of these papers were"/>
   <result pre="review analytically. 3.6 Descriptive studies Two descriptive studies reported on" exact="influenza" post="in cases with tuberculosis housed at a sanatorium. Of"/>
   <result pre="studies Two descriptive studies reported on influenza in cases with" exact="tuberculosis" post="housed at a sanatorium. Of these, one study described"/>
   <result pre="sanatorium. Of these, one study described the effect of seasonal" exact="influenza" post="on tuberculosis disease progression and complications.26 This study, from"/>
   <result pre="these, one study described the effect of seasonal influenza on" exact="tuberculosis" post="disease progression and complications.26 This study, from the Netherlands"/>
   <result pre="from the Netherlands in 1967, among children institutionalized with primary" exact="tuberculosis" post="of the lungs and hilar lymphadenopathy reported a high"/>
   <result pre="children institutionalized with primary tuberculosis of the lungs and hilar" exact="lymphadenopathy" post="reported a high frequency of developing secondary segmental pulmonary"/>
   <result pre="segmental pulmonary lesions, suggesting progression of PTB following serologically diagnosed" exact="influenza" post="virus infection (defined as greater than fourfold rise in"/>
   <result pre="in anti�?influenza virus antibody titres).26 The other study in a" exact="tuberculosis" post="sanatorium in the United States described the effect of"/>
   <result pre="States described the effect of superimposed viral infection on existing" exact="tuberculosis" post="following an outbreak of the 1957 influenza A pandemic"/>
   <result pre="infection on existing tuberculosis following an outbreak of the 1957" exact="influenza" post="A pandemic virus, in which two of 31 TB"/>
   <result pre="virus, in which two of 31 TB paediatric cases with" exact="influenza" post="infection had evidence of worsening of tuberculosis on chest"/>
   <result pre="paediatric cases with influenza infection had evidence of worsening of" exact="tuberculosis" post="on chest radiography (Table 2).36 3.7 Analytical studies In"/>
   <result pre="Africa, hospitalized cases with influenza�?PTB co�?infection compared to cases with" exact="tuberculosis" post="only had increased risk of death (adjusted relative risk"/>
   <result pre="0.9, 95% CI 0.1�?8.6).32 In a case series during an" exact="influenza" post="B epidemic in a Danish tuberculosis sanatorium, 13% (7/53)"/>
   <result pre="case series during an influenza B epidemic in a Danish" exact="tuberculosis" post="sanatorium, 13% (7/53) of individuals co�?infected with influenza viruses"/>
   <result pre="a Danish tuberculosis sanatorium, 13% (7/53) of individuals co�?infected with" exact="influenza" post="viruses compared to 2% (3/142) of individuals with tuberculosis"/>
   <result pre="with influenza viruses compared to 2% (3/142) of individuals with" exact="tuberculosis" post="only developed tuberculosis complications which included radiological changes or"/>
   <result pre="compared to 2% (3/142) of individuals with tuberculosis only developed" exact="tuberculosis" post="complications which included radiological changes or sputum conversion back"/>
   <result pre="being positive (P = .005).28 Among children admitted with suspected" exact="tuberculosis" post="in a study from South Africa, a higher prevalence"/>
   <result pre="in a study from South Africa, a higher prevalence of" exact="influenza" post="C was detected in children with laboratory�?confirmed PTB compared"/>
   <result pre="was detected in children with laboratory�?confirmed PTB compared with unlikely" exact="tuberculosis" post="(18% [6/34] vs 4% [4/94], P = .04).33 A"/>
   <result pre="A case�?control study from Indonesia investigating the putative association between" exact="tuberculosis" post="and influenza virus infection reported no association between the"/>
   <result pre="study from Indonesia investigating the putative association between tuberculosis and" exact="influenza" post="virus infection reported no association between the development of"/>
   <result pre="development of clinically active PTB, either through reactivation of latent" exact="tuberculosis" post="or directly after exposure to M tuberculosis, and influenza"/>
   <result pre="latent tuberculosis or directly after exposure to M tuberculosis, and" exact="influenza" post="virus infection as measured by unpaired serology in cases"/>
   <result pre="as measured by unpaired serology in cases with newly diagnosed" exact="tuberculosis" post="and community controls. The proportion of individuals with influenza"/>
   <result pre="diagnosed tuberculosis and community controls. The proportion of individuals with" exact="influenza" post="virus antibody titres ≥10 against influenza A(H3N2) and A(H1N1)"/>
   <result pre="proportion of individuals with influenza virus antibody titres ≥10 against" exact="influenza" post="A(H3N2) and A(H1N1) viruses in patients with tuberculosis were"/>
   <result pre="≥10 against influenza A(H3N2) and A(H1N1) viruses in patients with" exact="tuberculosis" post="were similar to matched community controls; however, the antibody"/>
   <result pre="to matched community controls; however, the antibody titre levels for" exact="influenza" post="A(H3N2) virus at time of tuberculosis diagnosis were significantly"/>
   <result pre="antibody titre levels for influenza A(H3N2) virus at time of" exact="tuberculosis" post="diagnosis were significantly higher (1.7 times higher, P ="/>
   <result pre="was significantly higher than in cases with mild to moderate" exact="tuberculosis" post="and their controls.31 Among 23 patients with concurrent PTB"/>
   <result pre="and their controls.31 Among 23 patients with concurrent PTB and" exact="influenza" post="infection from Thailand, none died, compared with 30 (4.7%)"/>
   <result pre="an association between influenza�?PTB co�?infection and increased mortality compared with" exact="tuberculosis" post="only32 and two showed no association between co�?infection and"/>
   <result pre="only32 and two showed no association between co�?infection and severe" exact="influenza" post="disease29 or correlation between influenza infection and tuberculosis.31 Over"/>
   <result pre="association between co�?infection and severe influenza disease29 or correlation between" exact="influenza" post="infection and tuberculosis.31 Over a third of the studies"/>
   <result pre="tuberculosis.31 Over a third of the studies about PTB and" exact="influenza" post="virus co�?infection were descriptive case series that included univariate"/>
   <result pre="described. Among the studies that included laboratory�?confirmed PTB, screening for" exact="tuberculosis" post="was not done systematically. 3.9 Summary of findings from"/>
   <result pre="experimental animal models In murine models, five studies suggested that" exact="influenza" post="and tuberculosis co�?infection affected tuberculosis and influenza disease presentation"/>
   <result pre="models In murine models, five studies suggested that influenza and" exact="tuberculosis" post="co�?infection affected tuberculosis and influenza disease presentation or outcome,20"/>
   <result pre="models, five studies suggested that influenza and tuberculosis co�?infection affected" exact="tuberculosis" post="and influenza disease presentation or outcome,20 and one study"/>
   <result pre="studies suggested that influenza and tuberculosis co�?infection affected tuberculosis and" exact="influenza" post="disease presentation or outcome,20 and one study showed no"/>
   <result pre="Five of the murine studies reported on the effect of" exact="influenza" post="on tuberculosis, and one study reported on the effect"/>
   <result pre="on tuberculosis, and one study reported on the effect of" exact="influenza" post="on tuberculosis and the effect of tuberculosis on influenza."/>
   <result pre="and one study reported on the effect of influenza on" exact="tuberculosis" post="and the effect of tuberculosis on influenza. Table 3"/>
   <result pre="the effect of influenza on tuberculosis and the effect of" exact="tuberculosis" post="on influenza. Table 3 Summary of experimental animal studies"/>
   <result pre="3 Summary of experimental animal studies exploring the interaction between" exact="influenza" post="and tuberculosis Reference Objective Experiment Influenza strain/TB Period/ observation"/>
   <result pre="of experimental animal studies exploring the interaction between influenza and" exact="tuberculosis" post="Reference Objective Experiment Influenza strain/TB Period/ observation period Findings"/>
   <result pre="group 1 Experimental group Simultaneous TB bacilli given intraperitoneally and" exact="influenza" post="A virus (PR8) intra nasally Control group 1: Inoculated"/>
   <result pre="group 1: Inoculated with TB only Outcomes: Number of gross" exact="tuberculosis" post="pulmonary lesions measured at 3 wk Experiment group 2:"/>
   <result pre="3 wk Experiment group 2: Inoculation with TB bacilli and" exact="influenza" post="3 wk later Outcomes: Number of gross TB pulmonary"/>
   <result pre="lesions measured 6 wk after TB infection (3 wk after" exact="influenza" post="challenge) Influenza A PR8/ culture of tubercle bacilli 3"/>
   <result pre="lesions compared to control group Florido (2013)38 Assessed impact of" exact="influenza" post="A virus and mycobacterial respiratory co�?infection on development of"/>
   <result pre="Experiment 1 Experimental group: Mycobacterium bovis bacille Calmette�?Guerin (BCG) and" exact="influenza" post="A/PR8 at D1 Control groups: BCG only at D1"/>
   <result pre="D21 post�?infection Experiment 2: Experimental group: BCG at D1, and" exact="influenza" post="infection at 7 wk Control group: BCG at D1,"/>
   <result pre="D1, TB treatment at week 3 (for 4 wk) and" exact="influenza" post="infection at 7 wk Outcomes: BCG�?specific CD8 T�?cell response"/>
   <result pre="Redford (2014)39 1. Effect of prior IAV on susceptibility to" exact="tuberculosis" post="2. Effect of IAV/M tuberculosis co�?infection on control of"/>
   <result pre="prior IAV on susceptibility to tuberculosis 2. Effect of IAV/M" exact="tuberculosis" post="co�?infection on control of TB Model: mice 1. Experimental"/>
   <result pre="of viable MTB measured on D27 Influenza A Virus/ M" exact="tuberculosis" post="Model 1:120 d Model 1 Experimental group 1 had"/>
   <result pre="compared to control group Bernard, (1962)37 Assessed the effect of" exact="influenza" post="infection on TB�? infected mice. Measured TB bacilli per"/>
   <result pre="mice sacrificed 15 d post�?influenza challenge Group 6 (20 mice)�?" exact="influenza" post="only challenge at week 6 for all; Not sacrificed"/>
   <result pre="at week 1, 2, 3, 4 and 5, respectively. No" exact="influenza" post="challenge Outcomes: Number of TB bacilli per nodule in"/>
   <result pre="and had increased number of bacilli per nodules. Effect of" exact="influenza" post="infection on TB severity increased with increasing duration of"/>
   <result pre="TB severity increased with increasing duration of TB infection before" exact="influenza" post="challenge Among non�?sacrificed mice, death in 25/25 (100%) co�?infected"/>
   <result pre="death in 25/25 (100%) co�?infected vs 1/20 (5%) infected with" exact="influenza" post="only Massanari (40) Examined tuberculin hypersensitivity during superimposed acute"/>
   <result pre="1/20 (5%) infected with influenza only Massanari (40) Examined tuberculin" exact="hypersensitivity" post="during superimposed acute influenza infection Model: Mice Experimental groups"/>
   <result pre="influenza only Massanari (40) Examined tuberculin hypersensitivity during superimposed acute" exact="influenza" post="infection Model: Mice Experimental groups 1: Influenza virus, intranasal"/>
   <result pre="groups 1: Influenza virus, intranasal (i.n.) 4�?6 wk after M" exact="tuberculosis" post="infection Experimental group 2 Formalin�?inactivated influenza virus (i.n.) or"/>
   <result pre="4�?6 wk after M tuberculosis infection Experimental group 2 Formalin�?inactivated" exact="influenza" post="virus (i.n.) or intravenous (i.v.) live influenza virus 4�?6"/>
   <result pre="group 2 Formalin�?inactivated influenza virus (i.n.) or intravenous (i.v.) live" exact="influenza" post="virus 4�?6 wk after M tuberculosis infection Control group"/>
   <result pre="or intravenous (i.v.) live influenza virus 4�?6 wk after M" exact="tuberculosis" post="infection Control group Inoculated with PBS, 4�?6 wk after"/>
   <result pre="infection Control group Inoculated with PBS, 4�?6 wk after M" exact="tuberculosis" post="infection Outcomes: Tuberculin hypersensitivity (measured as footpad swelling) 6"/>
   <result pre="with PBS, 4�?6 wk after M tuberculosis infection Outcomes: Tuberculin" exact="hypersensitivity" post="(measured as footpad swelling) 6 d after influenza, PBS"/>
   <result pre="influenza, PBS challenge Number of circulating lymphocytes post�?influenza challenge M" exact="tuberculosis" post="and influenza A/PR8 4�?6 wk after TB infection Experimental"/>
   <result pre="challenge Number of circulating lymphocytes post�?influenza challenge M tuberculosis and" exact="influenza" post="A/PR8 4�?6 wk after TB infection Experimental group 1"/>
   <result pre="4�?6 wk after TB infection Experimental group 1 Suppressed tuberculin" exact="hypersensitivity" post="from D3 to D16 post–intranasal influenza infection. Suppression of"/>
   <result pre="group 1 Suppressed tuberculin hypersensitivity from D3 to D16 post–intranasal" exact="influenza" post="infection. Suppression of immune response preceded presentation of clinical"/>
   <result pre="Suppression of immune response preceded presentation of clinical signs of" exact="influenza" post="Reduction in lymphocytes on D 2, 5, 7 post�?influenza"/>
   <result pre="D 2, 5, 7 post�?influenza challenge compared to values before" exact="influenza" post="infection Experimental group 2 No immunosuppression in experimental group"/>
   <result pre="chronically infected with BCG and intranasal hen egg lysozyme (HEL�?flu)" exact="influenza" post="challenge 5 wk post�?BCG Mice chronically infected with BCG"/>
   <result pre="post�?BCG Mice chronically infected with BCG and wild type (wt)" exact="influenza" post="challenge 5 wk post�?BCG Control group: Mice infected with"/>
   <result pre="lesions and dissemination of mycobacteria from granuloma HEL�?flu or wt." exact="influenza" post="virus/ BCG 5 wk 6 d Experimental groups Increase"/>
   <result pre="group No dissemination of mycobacteria from granuloma Interpretation: Co�?infection with" exact="influenza" post="had little effect on mycobacterial load mycobacteria did not"/>
   <result pre="either group Abbreviations: BCG, Calmette�?Guerin; HEL, hen egg lysozyme; IAV," exact="influenza" post="A virus; IFN, interferon; M tuberculosis, Mycobacterium tuberculosis; TB,"/>
   <result pre="tuberculosis. (C) John Wiley &amp;amp; Sons, Ltd, 3.10 Effect of" exact="influenza" post="on tuberculosis Volkert et al20 showed that the course"/>
   <result pre="John Wiley &amp;amp; Sons, Ltd, 3.10 Effect of influenza on" exact="tuberculosis" post="Volkert et al20 showed that the course of experimental"/>
   <result pre="infection with tubercle bacillus in mice was worsened by simultaneous" exact="influenza" post="infection (influenza A virus and tubercle bacilli challenge at"/>
   <result pre="A virus and tubercle bacilli challenge at week 0) and" exact="influenza" post="infection superimposed on tuberculosis infection (influenza challenge 3 weeks"/>
   <result pre="bacilli challenge at week 0) and influenza infection superimposed on" exact="tuberculosis" post="infection (influenza challenge 3 weeks after TB challenge). Co�?infection"/>
   <result pre="were impaired in co�?infected mice. Concurrent infection of mice with" exact="influenza" post="virus and BCG (challenge on day 0) and sequential"/>
   <result pre="day 0) and sequential infection of mice with TB and" exact="influenza" post="virus (TB infection on day 0 and influenza virus"/>
   <result pre="TB and influenza virus (TB infection on day 0 and" exact="influenza" post="virus 7 weeks later) compared to infection with BCG"/>
   <result pre="compared with mice that had cleared TB. Concurrent infection with" exact="influenza" post="virus and tuberculosis reduced generation of protective T�?cell responses"/>
   <result pre="that had cleared TB. Concurrent infection with influenza virus and" exact="tuberculosis" post="reduced generation of protective T�?cell responses against intracellular mycobacteria"/>
   <result pre="against intracellular mycobacteria but did not affect control of pulmonary" exact="influenza" post="viral loads (no difference between co�?infected mice compared with"/>
   <result pre="viral loads (no difference between co�?infected mice compared with the" exact="influenza" post="only group).38 Redford et al39 demonstrated that influenza A"/>
   <result pre="with the influenza only group).38 Redford et al39 demonstrated that" exact="influenza" post="A virus infection of mice 28 days before or"/>
   <result pre="before or during (on day 1 or day 14) M" exact="tuberculosis" post="infection enhanced susceptibility to tuberculosis and impaired mycobacterium control"/>
   <result pre="1 or day 14) M tuberculosis infection enhanced susceptibility to" exact="tuberculosis" post="and impaired mycobacterium control and decreased host survival. Bernard"/>
   <result pre="survival. Bernard et al37 showed that in M tuberculosis�?infected mice," exact="influenza" post="virus challenge 1�?5 weeks after M tuberculosis infection, compared"/>
   <result pre="M tuberculosis�?infected mice, influenza virus challenge 1�?5 weeks after M" exact="tuberculosis" post="infection, compared with M tuberculosis�?only infected mice, resulted in"/>
   <result pre="and a higher case�?fatality rate. In addition, the effect of" exact="influenza" post="virus on tuberculosis severity, measured by amount of tissue"/>
   <result pre="case�?fatality rate. In addition, the effect of influenza virus on" exact="tuberculosis" post="severity, measured by amount of tissue damage, increased with"/>
   <result pre="by amount of tissue damage, increased with increasing time of" exact="tuberculosis" post="infection prior to the influenza virus challenge. Five per"/>
   <result pre="increased with increasing time of tuberculosis infection prior to the" exact="influenza" post="virus challenge. Five per cent of the mice infected"/>
   <result pre="virus challenge. Five per cent of the mice infected with" exact="influenza" post="alone died compared to 100% of the mice infected"/>
   <result pre="alone died compared to 100% of the mice infected with" exact="influenza" post="and tuberculosis. This was corroborated in a study by"/>
   <result pre="et al37 in which 5% of the mice infected with" exact="influenza" post="alone died compared to 100% of the mice infected"/>
   <result pre="alone died compared to 100% of the mice infected with" exact="influenza" post="and tuberculosis (Table 3). Massanari (40) reported that tuberculin"/>
   <result pre="compared to 100% of the mice infected with influenza and" exact="tuberculosis" post="(Table 3). Massanari (40) reported that tuberculin hypersensitivity in"/>
   <result pre="influenza and tuberculosis (Table 3). Massanari (40) reported that tuberculin" exact="hypersensitivity" post="in mice was temporarily suppressed following an intranasal influenza"/>
   <result pre="tuberculin hypersensitivity in mice was temporarily suppressed following an intranasal" exact="influenza" post="virus challenge; however, a normal response resumed after resolution"/>
   <result pre="virus challenge; however, a normal response resumed after resolution of" exact="influenza" post="virus infection. Tuberculin hypersensitivity, tested 4�?6 weeks after tuberculosis"/>
   <result pre="of influenza virus infection. Tuberculin hypersensitivity, tested 4�?6 weeks after" exact="tuberculosis" post="infection, was temporarily suppressed from day 3 to day"/>
   <result pre="suppressed from day 3 to day 16 post an intranasal" exact="influenza" post="virus challenge.40 In contrast, Co et al41 showed that"/>
   <result pre="influenza virus challenge.40 In contrast, Co et al41 showed that" exact="influenza" post="viruses had little effect on mycobacterial load and did"/>
   <result pre="effect on mycobacterial load and did not affect dissemination of" exact="tuberculosis" post="in a mouse model. They showed that T cells"/>
   <result pre="model. They showed that T cells responding to an acute" exact="influenza" post="virus infection can modulate host responses to an ongoing"/>
   <result pre="ongoing BCG infection. Though not statistically significant, acute infection with" exact="influenza" post="in mice with chronic Mycobacterium bovis BCG infection moderately"/>
   <result pre="review suggests that analytical studies exploring the interaction between laboratory�?confirmed" exact="influenza" post="virus infection and clinically diagnosed or laboratory�?confirmed PTB are"/>
   <result pre="influenza�?tuberculosis co�?infection in mice results in more severe disease than" exact="influenza" post="only or tuberculosis only disease. Observational studies among humans"/>
   <result pre="mice results in more severe disease than influenza only or" exact="tuberculosis" post="only disease. Observational studies among humans showed mixed results."/>
   <result pre="and severe influenza�? or tuberculosis�?associated disease or increased prevalence of" exact="influenza" post="co�?infection in individuals hospitalized for tuberculosis.27, 28, 32, 33"/>
   <result pre="high quality, showed no association between co�?infection and progression of" exact="tuberculosis" post="or influenza disease or severe outcomes, that is they"/>
   <result pre="showed no association between co�?infection and progression of tuberculosis or" exact="influenza" post="disease or severe outcomes, that is they did not"/>
   <result pre="or severe outcomes, that is they did not show that" exact="influenza" post="affected PTB presentation and outcomes, or that PTB affected"/>
   <result pre="influenza affected PTB presentation and outcomes, or that PTB affected" exact="influenza" post="presentation and outcomes. Three of the descriptive studies, although"/>
   <result pre="either a high prevalence of co�?infection in cases with severe" exact="influenza" post="disease34, 35 or increased severe disease or progression of"/>
   <result pre="in co�?infected individuals.26 Of the five studies reporting on pandemic" exact="influenza" post="only, two descriptive studies from HBCs reported a high"/>
   <result pre="two descriptive studies from HBCs reported a high prevalence of" exact="tuberculosis" post="in cases with severe influenza�?associated disease.34, 35 These studies"/>
   <result pre="influenza�?associated disease.34, 35 These studies presented limited univariate analyses. Pandemic" exact="influenza" post="may behave differently to seasonal influenza because of lack"/>
   <result pre="limited univariate analyses. Pandemic influenza may behave differently to seasonal" exact="influenza" post="because of lack of pre�?existing immunity, and the likely"/>
   <result pre="of lack of pre�?existing immunity, and the likely interaction between" exact="influenza" post="and tuberculosis might be immunologically mediated. High levels of"/>
   <result pre="of pre�?existing immunity, and the likely interaction between influenza and" exact="tuberculosis" post="might be immunologically mediated. High levels of cytokines produced"/>
   <result pre="studies have demonstrated a higher mortality due to 2009 pandemic" exact="influenza" post="as compared to seasonal influenza.43, 44, 45 High�?quality epidemiological"/>
   <result pre="recommendations and prevention strategies. However, even if the association between" exact="influenza" post="and PTB is less marked during seasonal influenza epidemics,"/>
   <result pre="association between influenza and PTB is less marked during seasonal" exact="influenza" post="epidemics, targeting individuals with active PTB for influenza vaccination"/>
   <result pre="during seasonal influenza epidemics, targeting individuals with active PTB for" exact="influenza" post="vaccination and antiviral treatment in HBCs could still potentially"/>
   <result pre="morbidity and mortality and might also prevent further spread of" exact="tuberculosis" post="during the intensive phase if influenza increases coughing. In"/>
   <result pre="prevent further spread of tuberculosis during the intensive phase if" exact="influenza" post="increases coughing. In this review, all the analytical studies"/>
   <result pre="countries. It is important to understand the background prevalence of" exact="tuberculosis" post="where studies are conducted for better interpretation of the"/>
   <result pre="for better interpretation of the results. In countries with low" exact="tuberculosis" post="burden, it is possible for studies not to identify"/>
   <result pre="severe outcomes, purely because of low numbers due to low" exact="tuberculosis" post="prevalence in the community. In some of the analytical"/>
   <result pre="patients with severe respiratory illness. Depending on the magnitude of" exact="tuberculosis" post="burden, results may have different implications for prioritization in"/>
   <result pre="prioritization in different settings. Since the 1950s, authors have recommended" exact="influenza" post="vaccination among patients with tuberculosis during influenza epidemics.28 Influenza"/>
   <result pre="the 1950s, authors have recommended influenza vaccination among patients with" exact="tuberculosis" post="during influenza epidemics.28 Influenza vaccination is the most effective"/>
   <result pre="authors have recommended influenza vaccination among patients with tuberculosis during" exact="influenza" post="epidemics.28 Influenza vaccination is the most effective way to"/>
   <result pre="has been shown to generate antibody response in patients with" exact="tuberculosis" post="that is similar to those without tuberculosis, although these"/>
   <result pre="1960s and did not include HIV�?infected individuals.36 Antiviral treatment for" exact="influenza" post="improves outcomes for patients with severe influenza�?associated disease.46 However,"/>
   <result pre="accessible in low�? to middle�?income countries where the burden of" exact="tuberculosis" post="and influenza are high.47 Identifying PTB patients as a"/>
   <result pre="low�? to middle�?income countries where the burden of tuberculosis and" exact="influenza" post="are high.47 Identifying PTB patients as a risk group"/>
   <result pre="in making decisions about prioritizing this group of patients for" exact="influenza" post="vaccination and treatment with influenza antiviral treatment. More high�?quality"/>
   <result pre="this group of patients for influenza vaccination and treatment with" exact="influenza" post="antiviral treatment. More high�?quality epidemiological data from high tuberculosis"/>
   <result pre="with influenza antiviral treatment. More high�?quality epidemiological data from high" exact="tuberculosis" post="burden settings are needed to address this question. In"/>
   <result pre="are needed to determine whether seasonal or pandemic vaccines or" exact="influenza" post="antivirals should be prioritized for PTB patients and whether"/>
   <result pre="with more chronic PTB are more at risk of severe" exact="influenza" post="disease, this might explain the lack of association in"/>
   <result pre="presentation, this may further assist in making decisions about which" exact="tuberculosis" post="cases to prioritize for interventions, especially in countries where"/>
   <result pre="cases to prioritize for interventions, especially in countries where the" exact="tuberculosis" post="burden is high and resources are limited. The mechanism"/>
   <result pre="al49 suggested that the underlying chronic lung diseases such as" exact="tuberculosis" post="may be an important factor in the increase in"/>
   <result pre="an important factor in the increase in frequency of secondary" exact="bacterial pneumonia" post="in persons with influenza, which in turn can lead"/>
   <result pre="important factor in the increase in frequency of secondary bacterial" exact="pneumonia" post="in persons with influenza, which in turn can lead"/>
   <result pre="increased frequency of complications. Some of the studies reported on" exact="tuberculosis" post="in patients from sanatorium.26, 28, 36 It is possible"/>
   <result pre="28, 36 It is possible that the high prevalence of" exact="influenza" post="reported in these studies is due to increased risk"/>
   <result pre="reported in these studies is due to increased risk of" exact="influenza" post="transmission resulting in high transmission rates in these closed"/>
   <result pre="high transmission rates in these closed settings. In addition, the" exact="influenza" post="transmission may not reflect community�?acquired influenza and results from"/>
   <result pre="settings. In addition, the influenza transmission may not reflect community�?acquired" exact="influenza" post="and results from these studies cannot be generalizable to"/>
   <result pre="resulting in poor outcomes, closed settings should be prioritized for" exact="influenza" post="vaccination. There were a number of limitations to this"/>
   <result pre="studies, an association could not be evaluated. The type of" exact="tuberculosis" post="included differed among the studies, with some studies reporting"/>
   <result pre="reporting newly diagnosed tuberculosis, some reporting on cases in a" exact="tuberculosis" post="sanatorium for a number of months and some included"/>
   <result pre="number of months and some included cases who had completed" exact="tuberculosis" post="treatment, thus making data less comparable. There were differences"/>
   <result pre="making data less comparable. There were differences in the population" exact="tuberculosis" post="incidences where studies were conducted which could affect the"/>
   <result pre="detect an association. However, the majority of studies were from" exact="tuberculosis" post="high burden countries or were conducted during the period"/>
   <result pre="high burden countries or were conducted during the period when" exact="tuberculosis" post="burden was high. We included animal studies although these"/>
   <result pre="and malnutrition. HIV infection is a risk factor for severe" exact="influenza" post="disease as well as for PTB, and it is"/>
   <result pre="is an important contributor to the overall burden of severe" exact="influenza" post="in high HIV�?prevalence settings.50, 51 However, only a few"/>
   <result pre="the individual infection. Other conditions such as malnutrition, which like" exact="tuberculosis" post="are prevalent in HBC, were not evaluated in included"/>
   <result pre="included articles and may be confounders in the association between" exact="influenza" post="and PTB. The numbers of participants in most studies"/>
   <result pre="that were not addressed by the studies reviewed include whether" exact="influenza" post="infection caused reactivation of latent tuberculosis or whether the"/>
   <result pre="studies reviewed include whether influenza infection caused reactivation of latent" exact="tuberculosis" post="or whether the acute viral infection precipitated a visit"/>
   <result pre="a visit to the doctor in patients who already had" exact="tuberculosis" post="disease. Studies in Chinese were not included in the"/>
   <result pre="animal studies suggested increased severity of disease with co�?infection of" exact="influenza" post="and PTB, only half of the analytical studies on"/>
   <result pre="influenza and PTB, only half of the analytical studies on" exact="influenza" post="and PTB in humans found the same. Descriptive studies,"/>
   <result pre="reported an increased prevalence of co�?infection among cases with severe" exact="influenza" post="or PTB disease. Data are limited from large epidemiological"/>
   <result pre="Data are limited from large epidemiological studies, studies with laboratory�?confirmed" exact="influenza" post="and PTB, studies from high tuberculosis burden settings and"/>
   <result pre="studies, studies with laboratory�?confirmed influenza and PTB, studies from high" exact="tuberculosis" post="burden settings and studies that include data on HIV."/>
   <result pre="data on HIV. In order to study the association between" exact="influenza" post="and PTB and make inferences about causal associations, more"/>
   <result pre="about causal associations, more epidemiological studies with systematic testing for" exact="influenza" post="and tuberculosis are needed. CONFLICT OF INTEREST No authors"/>
   <result pre="associations, more epidemiological studies with systematic testing for influenza and" exact="tuberculosis" post="are needed. CONFLICT OF INTEREST No authors have any"/>
   <result pre="et al. Global burden of respiratory infections due to seasonal" exact="influenza" post="in young children: a systematic review and meta�?analysis. Lancet."/>
   <result pre="and meta�?analysis. Lancet. 2011;378(9807):1917�?1930.22078723 3collab: World Health Organization . Global" exact="tuberculosis" post="report 2014; 2014. 4collab: World Health Organization . Seasonal"/>
   <result pre="modelling study. Lancet. 2018;391(10127):1285�?1300.29248255 6collab: World Health Organization . Global" exact="tuberculosis" post="report 2016. WHO;2016;1�?201. 7SmallC�?L, ShalerCR, McCormickS, et al. Influenza"/>
   <result pre="TianX, et al. Type I IFNs mediate development of postinfluenza" exact="bacterial pneumonia" post="in mice. J Clin Invest. 2009;119(7):1910�?1920.19487810 10BallingerMN, StandifordTJ. Postinfluenza"/>
   <result pre="et al. Type I IFNs mediate development of postinfluenza bacterial" exact="pneumonia" post="in mice. J Clin Invest. 2009;119(7):1910�?1920.19487810 10BallingerMN, StandifordTJ. Postinfluenza"/>
   <result pre="Res. 2010;30(9):643�?652.20726789 11GardnerID. Suppression of antibacterial immunity by infection with" exact="influenza" post="virus. J Infect Dis. 1981;144(3):225�?231.6974206 12SchlieheC, FlynnEK, VilagosB, et"/>
   <result pre="bacterial superinfection. Nat Immunol. 2015;16(1):67�?74.25419628 13McCullersJA, RehgJE. Lethal synergism between" exact="influenza" post="virus and Streptococcus pneumoniae: characterization of a mouse model"/>
   <result pre="platelet�?activating factor receptor. J Infect Dis. 2002;186(3):341�?350.12134230 14NoymerA. The 1918" exact="influenza" post="pandemic hastened the decline of tuberculosis in the United"/>
   <result pre="2002;186(3):341�?350.12134230 14NoymerA. The 1918 influenza pandemic hastened the decline of" exact="tuberculosis" post="in the United States: an age, period, cohort analysis."/>
   <result pre="cohort analysis. Vaccine. 2011;29(Suppl 2):B38�?41.21757102 15OeiW, NishiuraH. The relationship between" exact="tuberculosis" post="and influenza death during the influenza (H1N1) pandemic from"/>
   <result pre="Vaccine. 2011;29(Suppl 2):B38�?41.21757102 15OeiW, NishiuraH. The relationship between tuberculosis and" exact="influenza" post="death during the influenza (H1N1) pandemic from 1918–19. Comput"/>
   <result pre="NishiuraH. The relationship between tuberculosis and influenza death during the" exact="influenza" post="(H1N1) pandemic from 1918–19. Comput Math Methods Med. 2012;2012:1–9."/>
   <result pre="2009;68(9):1599�?1608.19304361 18ZürcherK, ZwahlenM, BallifM, RiederHL, EggerM, FennerL. Influenza pandemics and" exact="tuberculosis" post="mortality in 1889 and 1918: analysis of historical data"/>
   <result pre="2016;11(10):e0162575.27706149 19WalazaS, CohenC, NanooA, et al. Excess mortality associated with" exact="influenza" post="among tuberculosis deaths in South Africa, 1999–2009. PLoS ONE."/>
   <result pre="CohenC, NanooA, et al. Excess mortality associated with influenza among" exact="tuberculosis" post="deaths in South Africa, 1999–2009. PLoS ONE. 2015;10(6):e0129173.26076197 20VolkertM."/>
   <result pre="The enhancing effect of concurrent infection with pneumotropic viruses on" exact="pulmonary tuberculosis" post="in mice. J Exp Med. 1947;86(3):203�?214.19871671 21collab: World Health"/>
   <result pre="enhancing effect of concurrent infection with pneumotropic viruses on pulmonary" exact="tuberculosis" post="in mice. J Exp Med. 1947;86(3):203�?214.19871671 21collab: World Health"/>
   <result pre="Exp Med. 1947;86(3):203�?214.19871671 21collab: World Health Organization . Vaccines against" exact="influenza" post="WHO position paper – November 2012. Wkly Epidemiol Rec."/>
   <result pre="in Meta�?Analyses. 24KoegelenbergC, IrusenEM, CooperR, et al. High mortality from" exact="respiratory failure" post="secondary to swine�?origin influenza A (H1N1) in South Africa."/>
   <result pre="et al. High mortality from respiratory failure secondary to swine�?origin" exact="influenza" post="A (H1N1) in South Africa. QJM. 2010;103(5):319�?325.20219780 25NohJY, LeeJ,"/>
   <result pre="South Africa. QJM. 2010;103(5):319�?325.20219780 25NohJY, LeeJ, ChoiWS, et al. Concurrent" exact="tuberculosis" post="and influenza, South Korea. Emerg Infect Dis. 2013;19(1):165�?167.23260033 26DijkmanJH."/>
   <result pre="respiratory passages on the course of primary pulmonary and hilar" exact="tuberculosis" post="in children. Selected Papers of the Royal Netherlands Tuberculosis"/>
   <result pre="South Africa: a case�?population study. Vaccine. 2016;34(46):5649�?5655.27720448 28EspersenE. Epidemic of" exact="influenza" post="B among Green�?landic patients in a Danish tuberculosis sanatorium."/>
   <result pre="Epidemic of influenza B among Green�?landic patients in a Danish" exact="tuberculosis" post="sanatorium. Influenza and pulmonary tuberculosis. Acta Tuberc Scand. 1954;29(2):125�?139.13188754"/>
   <result pre="among Green�?landic patients in a Danish tuberculosis sanatorium. Influenza and" exact="pulmonary tuberculosis." post="Acta Tuberc Scand. 1954;29(2):125�?139.13188754 29OpeMO, KatzMA, AuraB, et al."/>
   <result pre="29OpeMO, KatzMA, AuraB, et al. Risk factors for hospitalized seasonal" exact="influenza" post="in rural Western Kenya. PLoS ONE. 2011;6(5):e20111.21637856 30RothS, WhiteheadS,"/>
   <result pre="Kenya. PLoS ONE. 2011;6(5):e20111.21637856 30RothS, WhiteheadS, ThamthitiwatS, et al. Concurrent" exact="influenza" post="virus infection and tuberculosis in patients hospitalized with respiratory"/>
   <result pre="30RothS, WhiteheadS, ThamthitiwatS, et al. Concurrent influenza virus infection and" exact="tuberculosis" post="in patients hospitalized with respiratory illness in Thailand. Influenza"/>
   <result pre="PausRA, van CrevelR, van BeekR, et al. The influence of" exact="influenza" post="virus infections on the development of tuberculosis. Tuberculosis. 2013;93(3):338�?342.23474302"/>
   <result pre="with increased risk of death amongst patients hospitalized with confirmed" exact="pulmonary tuberculosis" post="in South Africa, 2010–2011. BMC Infect Dis. 2015;15(1):26.25623944 33DubeFS,"/>
   <result pre="increased risk of death amongst patients hospitalized with confirmed pulmonary" exact="tuberculosis" post="in South Africa, 2010–2011. BMC Infect Dis. 2015;15(1):26.25623944 33DubeFS,"/>
   <result pre="microbes present in the nasopharynx of children hospitalised with suspected" exact="pulmonary tuberculosis" post="in Cape Town, South Africa. BMC Infect Dis. 2016;16(1):597.27776489"/>
   <result pre="present in the nasopharynx of children hospitalised with suspected pulmonary" exact="tuberculosis" post="in Cape Town, South Africa. BMC Infect Dis. 2016;16(1):597.27776489"/>
   <result pre="34ArcherBN, CohenC, NaidooD, et al. Interim report on pandemic H1N1" exact="influenza" post="virus infections in South Africa, April to October 2009:"/>
   <result pre="2011;59: 14�?16, 18. 36SellersMI, BlackJP, FromanS. An outbreak of Asian" exact="influenza" post="in tuberculous patients. Dis Chest. 1959;36:471�?477.14444747 37BernardE, KreisB, Le"/>
   <result pre="Dis Chest. 1959;36:471�?477.14444747 37BernardE, KreisB, Le QuangS. The influence of" exact="influenza" post="on tuberculosis. Bull Acad Nat Med. 1962;146(7/8):139�?145.13868007 38FlóridoM, GrimaMA,"/>
   <result pre="McNabFW, et al. Influenza A virus impairs control of Mycobacterium" exact="tuberculosis" post="coinfection through a Type I interferon receptor�?dependent pathway. J"/>
   <result pre="receptor�?dependent pathway. J Infect Dis. 2014;209(2):270�?274.23935205 40MassanariRM. Suppression of tuberculin" exact="hypersensitivity" post="during influenza infection in mice. Infect Immun. 1979;24(2):501�?507.457284 41CoDO,"/>
   <result pre="J Infect Dis. 2014;209(2):270�?274.23935205 40MassanariRM. Suppression of tuberculin hypersensitivity during" exact="influenza" post="infection in mice. Infect Immun. 1979;24(2):501�?507.457284 41CoDO, HoganLH, KarmanJ,"/>
   <result pre="al. Interactions between T cells responding to concurrent mycobacterial and" exact="influenza" post="infections. J Immunol. 2006;177(12):8456�?8465.17142743 42GuarnerJ, Falcon�?EscobedoR. Comparison of the"/>
   <result pre="Comparison of the pathology caused by H1N1, H5N1, and H3N2" exact="influenza" post="viruses. Arch Med Res. 2009;40(8):655�?661.20304252 43RabagliatiBR, SiriZL, PérezC, LabarcaLJ,"/>
   <result pre="Arch Med Res. 2009;40(8):655�?661.20304252 43RabagliatiBR, SiriZL, PérezC, LabarcaLJ, FerrésGM. [Pandemic" exact="influenza" post="A (H1N1) 2009: epidemiology, clinical features and differences with"/>
   <result pre="A (H1N1) 2009: epidemiology, clinical features and differences with seasonal" exact="influenza" post="in Chile]. Rev Chilena Infectol. 2011;28(6):546�?553.22286677 44ReedC, ChavesSS, PerezA,"/>
   <result pre="Complications among adults hospitalized with influenza: a comparison of seasonal" exact="influenza" post="and the 2009 H1N1 pandemic. Clin Infect Dis. 2014;59(2):166�?174.24785230"/>
   <result pre="inhibitors in reducing mortality in patients admitted to hospital with" exact="influenza" post="A H1N1pdm09 virus infection: a meta�?analysis of individual participant"/>
   <result pre="Lancet Respir Med. 2014;2(5):395�?404.24815805 47DuqueJ, McMorrowML, CohenAL. Influenza vaccines and" exact="influenza" post="antiviral drugs in Africa: are they available and do"/>
   <result pre="Health. 2014;14(1):1�?5.24383435 48WalazaS, CohenC. Recommendations pertaining to the use of" exact="influenza" post="vaccines and influenza antiviral drugs: influenza 2015. S Afr"/>
   <result pre="CohenC. Recommendations pertaining to the use of influenza vaccines and" exact="influenza" post="antiviral drugs: influenza 2015. S Afr Med J. 2015;105(2):90.26242521"/>
   <result pre="to the use of influenza vaccines and influenza antiviral drugs:" exact="influenza" post="2015. S Afr Med J. 2015;105(2):90.26242521 49SekiM, KosaiK, YanagiharaK,"/>
   <result pre="KosaiK, YanagiharaK, et al. Disease severity in patients with simultaneous" exact="influenza" post="and bacterial pneumonia. Intern Med. 2007;46(13):953�?958.17603232 50CohenC, MoyesJ, TempiaS,"/>
   <result pre="et al. Disease severity in patients with simultaneous influenza and" exact="bacterial pneumonia." post="Intern Med. 2007;46(13):953�?958.17603232 50CohenC, MoyesJ, TempiaS, et al. Severe"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6928875\results\search\disease\results.xml">
   <result pre="and coxsackievirus A16 (CV-A16) are the most common causes of" exact="hand, foot, and mouth disease." post="Severe EV-A71 and CV-A16 infections may be associated with"/>
   <result pre="(CV-A16) are the most common causes of hand, foot, and" exact="mouth disease." post="Severe EV-A71 and CV-A16 infections may be associated with"/>
   <result pre="of the most common causes of recurrent community outbreaks of" exact="hand, foot, and mouth disease" post="(HFMD) among children worldwide and particularly in the Asia–Pacific"/>
   <result pre="common causes of recurrent community outbreaks of hand, foot, and" exact="mouth disease" post="(HFMD) among children worldwide and particularly in the Asia–Pacific"/>
   <result pre="and CV-A16 infections are associated with life-threatening complications, such as" exact="aseptic meningitis," post="encephalitis, myocarditis, non-cardiogenic pulmonary edema with respiratory failure, and"/>
   <result pre="with life-threatening complications, such as aseptic meningitis, encephalitis, myocarditis, non-cardiogenic" exact="pulmonary edema" post="with respiratory failure, and death [1,5]. However, the pathogenic"/>
   <result pre="such as aseptic meningitis, encephalitis, myocarditis, non-cardiogenic pulmonary edema with" exact="respiratory failure," post="and death [1,5]. However, the pathogenic mechanisms underlying these"/>
   <result pre="the host lipidome changes induced by EV-A71 and CV-A16 in" exact="rhabdomyosarcoma" post="(RD) cells. We found that these enteroviruses perturbed the"/>
   <result pre="lipid mediator protectin D1 (PD1) was reported to markedly attenuate" exact="influenza" post="virus replication via interference with the virus RNA export"/>
   <result pre="6-desaturase enzyme or by treatment with a small-molecule inhibitor impaired" exact="hepatitis" post="C virus (HCV) production, indicating that PUFAs could also"/>
   <result pre="hand, foot and mouth diseaseEpidemiol Infect.20101381071108910.1017/S095026880999155520056019 2.XingW.LiaoQ.ViboudC.ZhangJ.SunJ.WuJ.T.ChangZ.LiuF.FangV.J.ZhengY.et al.Hand, foot, and" exact="mouth disease" post="in China, 2008-12: an epidemiological studyLancet Infect. Dis20141430831810.1016/S1473-3099(13)70342-624485991 3.ChangL.Y.LinT.Y.HsuK.H.HuangY.C.LinK.L.HsuehC.ShihS.R.NingH.C.HwangM.S.WangH.S.et"/>
   <result pre="inflammationIUBMB Life20156765966710.1002/iub.142826397837 32.HofmannS.KrajewskiM.SchererC.ScholzV.MordhorstV.TruschowP.SchobelA.ReimerR.SchwudkeD.HerkerE.Complex lipid metabolic remodeling is required for efficient" exact="hepatitis" post="C virus replicationBiochimica Et Biophysica Acta-Molecular and Cell Biology"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6929465\results\search\disease\results.xml">
   <result pre="Rule-based meta-analysis reveals the major role of PB2 in influencing" exact="influenza" post="A virus virulence in mice http://orcid.org/0000-0001-6491-6358IvanFransiskus Xaveriusfivan@ntu.edu.sgKwohChee Keongasckkwoh@ntu.edu.sg[], 0000"/>
   <result pre="H5N1, H5N6, H6N1, H7N2, H7N3, H7N7, H7N9, H9N2, and H10N8" exact="avian influenza" post="viruses [2, 3]. Among them, the H5N1 and H7N9"/>
   <result pre="H5N6, H6N1, H7N2, H7N3, H7N7, H7N9, H9N2, and H10N8 avian" exact="influenza" post="viruses [2, 3]. Among them, the H5N1 and H7N9"/>
   <result pre="last 50 years, the importance of many more host genes in" exact="influenza" post="pathogenesis has been discovered through experiments in mice, including"/>
   <result pre="HA and one mutation F35 L in PA of pandemic 2009" exact="influenza" post="H1N1 virus that causes lethality in the infected mice"/>
   <result pre="of contribution of viral protein sites to the virulence of" exact="influenza" post="infections could be better investigated through a meta-analysis approach,"/>
   <result pre="to investigate the viral protein sites important for virulence of" exact="influenza" post="H5N1 in mammals [15]. Nevertheless, a meta-analysis approach using"/>
   <result pre="the datasets or records for a specific mouse strain or" exact="influenza" post="subtype, and using the concatenated alignments of all IAV"/>
   <result pre="the corresponding site pair to the accuracy Discussion In this" exact="influenza" post="study, we systematically and extensively searched literature, collected infection"/>
   <result pre="strongly influences the virulence of both pandemic H1N1 and H5" exact="influenza" post="viruses in mice [51]. Experimental evidence for the contribution"/>
   <result pre="if there is a significant increase in the number of" exact="influenza" post="experiments carried out with mouse and IAV strains that"/>
   <result pre="will be beneficial for further understanding the molecular principles underlying" exact="influenza" post="mechanisms since mice have been a major animal model"/>
   <result pre="virulence classification. The thresholds are used by WHO when classifying" exact="influenza" post="virulence in mice in EID50 unit [64]. In this"/>
   <result pre="of the virus were/was BLASTed against GenBank database of all" exact="influenza" post="viruses and the top virus hit whose complete genome"/>
   <result pre="FFU focus forming unit HA hemagglutinin hi high virulence IAV" exact="influenza" post="A virus int intermediate virulence IP IAV protein dataset"/>
   <result pre="they have no competing interests. References References 1.MuramotoYNodaTKawakamiEAkkinaRKawaokaYIdentification of novel" exact="influenza" post="A virus proteins translated from PA mRNAJ Virol20138752455246210.1128/JVI.02656-1223236060 2.PoovorawanYPyungpornSPrachayangprechaSMakkochJGlobal"/>
   <result pre="virus proteins translated from PA mRNAJ Virol20138752455246210.1128/JVI.02656-1223236060 2.PoovorawanYPyungpornSPrachayangprechaSMakkochJGlobal alert to" exact="avian influenza" post="virus infection: from H5N1 to H7N9Pathog Glob Health2013107521722310.1179/2047773213Y.000000010323916331 3.SuSBiYWongGGrayGCGaoGFLiSEpidemiology,"/>
   <result pre="proteins translated from PA mRNAJ Virol20138752455246210.1128/JVI.02656-1223236060 2.PoovorawanYPyungpornSPrachayangprechaSMakkochJGlobal alert to avian" exact="influenza" post="virus infection: from H5N1 to H7N9Pathog Glob Health2013107521722310.1179/2047773213Y.000000010323916331 3.SuSBiYWongGGrayGCGaoGFLiSEpidemiology,"/>
   <result pre="to H7N9Pathog Glob Health2013107521722310.1179/2047773213Y.000000010323916331 3.SuSBiYWongGGrayGCGaoGFLiSEpidemiology, evolution, and recent outbreaks of" exact="avian influenza" post="virus in ChinaJ Virol201589178671867610.1128/JVI.01034-1526063419 4.MaMJLiuCWuMNZhaoTWangGLYangYet al.Influenza A(H7N9) virus antibody"/>
   <result pre="H7N9Pathog Glob Health2013107521722310.1179/2047773213Y.000000010323916331 3.SuSBiYWongGGrayGCGaoGFLiSEpidemiology, evolution, and recent outbreaks of avian" exact="influenza" post="virus in ChinaJ Virol201589178671867610.1128/JVI.01034-1526063419 4.MaMJLiuCWuMNZhaoTWangGLYangYet al.Influenza A(H7N9) virus antibody"/>
   <result pre="after infection, China, 2017Emerg Infect Dis201824466367210.3201/eid2404.17199529432091 5.LindenmannJInheritance of resistance to" exact="influenza" post="virus in miceProc Soc Exp Biol Med196411650650910.3181/00379727-116-2929214193387 6.VerhelstJParthoensESchepensBFiersWSaelensXInterferon-inducible protein"/>
   <result pre="in miceProc Soc Exp Biol Med196411650650910.3181/00379727-116-2929214193387 6.VerhelstJParthoensESchepensBFiersWSaelensXInterferon-inducible protein Mx1 inhibits" exact="influenza" post="virus by interfering with functional viral ribonucleoprotein complex assemblyJ"/>
   <result pre="with functional viral ribonucleoprotein complex assemblyJ Virol20128624134451345510.1128/JVI.01682-1223015724 7.KamalRPKatzJMYorkIAMolecular determinants of" exact="influenza" post="virus pathogenesis in miceCurr Top Microbiol Immunol201438524327425038937 8.MedinaRAGarcia-SastreAInfluenza A"/>
   <result pre="9.ImaiMKawaokaYThe role of receptor binding specificity in interspecies transmission of" exact="influenza" post="virusesCurr Opin Virol20122216016710.1016/j.coviro.2012.03.00322445963 10.ConenelloGMZamarinDPerroneLATumpeyTPalesePA single mutation in the PB1-F2"/>
   <result pre="single mutation in the PB1-F2 of H5N1 (HK/97) and 1918" exact="influenza" post="A viruses contributes to increased virulencePLoS Pathog20073101414142110.1371/journal.ppat.003014117922571 11.SongJXuJShiJLiYChenHSynergistic effect"/>
   <result pre="of S224P and N383D substitutions in the PA of H5N1" exact="avian influenza" post="virus contributes to mammalian adaptationSci Rep201551051010.1038/srep1051026000865 12.SeyerRHrinciusERRitzelDAbtMMellmannAMarjukiHet al.Synergistic adaptive"/>
   <result pre="S224P and N383D substitutions in the PA of H5N1 avian" exact="influenza" post="virus contributes to mammalian adaptationSci Rep201551051010.1038/srep1051026000865 12.SeyerRHrinciusERRitzelDAbtMMellmannAMarjukiHet al.Synergistic adaptive"/>
   <result pre="acidic protein lead to increased virulence of pandemic 2009 H1N1" exact="influenza" post="A virus in miceJ Infect Dis2012205226227110.1093/infdis/jir71622102733 13.Peng Y, Zhu"/>
   <result pre="Identification of genome-wide nucleotide sites associated with mammalian virulence in" exact="influenza" post="A viruses. bioRxiv. 2018;416586. 10.1101/416586. 14.York IA, Stevens J,"/>
   <result pre="2019;39(1):BSR20171505. 15.LycettSJWardMJLewisFIPoonAFKosakovsky PondSLBrownAJDetection of mammalian virulence determinants in highly pathogenic" exact="avian influenza" post="H5N1 viruses: multivariate analysis of published dataJ Virol200983199901991010.1128/JVI.00608-0919625397 16.Casadevall"/>
   <result pre="15.LycettSJWardMJLewisFIPoonAFKosakovsky PondSLBrownAJDetection of mammalian virulence determinants in highly pathogenic avian" exact="influenza" post="H5N1 viruses: multivariate analysis of published dataJ Virol200983199901991010.1128/JVI.00608-0919625397 16.Casadevall"/>
   <result pre="20.BreimanLRandom forestsMach Learn200145153210.1023/A:1010933404324 21.MairCMLudwigKHerrmannASiebenCReceptor binding and pH stability – how" exact="influenza" post="A virus hemagglutinin affects host-specific virus infectionBiochim Biophys Acta2014183841153116810.1016/j.bbamem.2013.10.00424161712"/>
   <result pre="polymerase gene mutations for human adaptation occurring in Asian H5N1" exact="influenza" post="virus clinical isolatesSci Rep2018811306610.1038/s41598-018-31397-330166556 23.Czudai-MatwichVOtteAMatrosovichMGabrielGKlenkHDPB2 mutations D701N and S714R"/>
   <result pre="Rep2018811306610.1038/s41598-018-31397-330166556 23.Czudai-MatwichVOtteAMatrosovichMGabrielGKlenkHDPB2 mutations D701N and S714R promote adaptation of an" exact="influenza" post="H5N1 virus to a mammalian hostJ Virol201488168735874210.1128/JVI.00422-1424899203 24.FanSHattaMKimJHHalfmannPImaiMMackenCAet al.Novel"/>
   <result pre="virus to a mammalian hostJ Virol201488168735874210.1128/JVI.00422-1424899203 24.FanSHattaMKimJHHalfmannPImaiMMackenCAet al.Novel residues in" exact="avian influenza" post="virus PB2 protein affect virulence in mammalian hostsNat Commun20145502110.1038/ncomms602125289523"/>
   <result pre="to a mammalian hostJ Virol201488168735874210.1128/JVI.00422-1424899203 24.FanSHattaMKimJHHalfmannPImaiMMackenCAet al.Novel residues in avian" exact="influenza" post="virus PB2 protein affect virulence in mammalian hostsNat Commun20145502110.1038/ncomms602125289523"/>
   <result pre="protein affect virulence in mammalian hostsNat Commun20145502110.1038/ncomms602125289523 25.WangJSunYXuQTanYPuJYangHet al.Mouse-adapted H9N2" exact="influenza" post="A virus PB2 protein M147L and E627K mutations are"/>
   <result pre="PB2 283M and 526R contributes to enhanced virulence of H5N8" exact="influenza" post="viruses in miceVet Res20174816710.1186/s13567-017-0471-029070059 27.SediriHThieleSSchwalmFGabrielGKlenkHDPB2 subunit of avian influenza"/>
   <result pre="of H5N8 influenza viruses in miceVet Res20174816710.1186/s13567-017-0471-029070059 27.SediriHThieleSSchwalmFGabrielGKlenkHDPB2 subunit of" exact="avian influenza" post="virus subtype H9N2: a pandemic risk factorJ Gen Virol2016971394810.1099/jgv.0.00033326560088"/>
   <result pre="H5N8 influenza viruses in miceVet Res20174816710.1186/s13567-017-0471-029070059 27.SediriHThieleSSchwalmFGabrielGKlenkHDPB2 subunit of avian" exact="influenza" post="virus subtype H9N2: a pandemic risk factorJ Gen Virol2016971394810.1099/jgv.0.00033326560088"/>
   <result pre="of the NS1 protein on virulence of an avian H5N1" exact="influenza" post="A virusJ Virol20138794861487110.1128/JVI.02608-1223408626 29.PuJWangJZhangYFuGBiYSunYet al.Synergism of co-mutation of two"/>
   <result pre="amino acid residues in NS1 protein increases the pathogenicity of" exact="influenza" post="virus in miceVirus Res2010151220020410.1016/j.virusres.2010.05.00720546807 30.ChenHBrightRASubbaraoKSmithCCoxNJKatzJMet al.Polygenic virulence factors involved"/>
   <result pre="virulence factors involved in pathogenesis of 1997 Hong Kong H5N1" exact="influenza" post="viruses in miceVirus Res20071281–215916310.1016/j.virusres.2007.04.01717521765 31.ChengKYuZChaiHSunWXinYZhangQet al.PB2-E627K and PA-T97I substitutions"/>
   <result pre="polymerase activity and confer a virulent phenotype to an H6N1" exact="avian influenza" post="virus in miceVirology2014468–47020721310.1016/j.virol.2014.08.01025194918 32.KatzJMLuXTumpeyTMSmithCBShawMWSubbaraoKMolecular correlates of influenza A H5N1"/>
   <result pre="activity and confer a virulent phenotype to an H6N1 avian" exact="influenza" post="virus in miceVirology2014468–47020721310.1016/j.virol.2014.08.01025194918 32.KatzJMLuXTumpeyTMSmithCBShawMWSubbaraoKMolecular correlates of influenza A H5N1"/>
   <result pre="an H6N1 avian influenza virus in miceVirology2014468–47020721310.1016/j.virol.2014.08.01025194918 32.KatzJMLuXTumpeyTMSmithCBShawMWSubbaraoKMolecular correlates of" exact="influenza" post="A H5N1 virus pathogenesis in miceJ Virol20007422108071081010.1128/JVI.74.22.10807-10810.200011044127 33.LiJLiYHuYChangGSunWYangYet al.PB1-mediated"/>
   <result pre="pathogenesis in miceJ Virol20007422108071081010.1128/JVI.74.22.10807-10810.200011044127 33.LiJLiYHuYChangGSunWYangYet al.PB1-mediated virulence attenuation of H5N1" exact="influenza" post="virus in mice is associated with PB2J Gen Virol201192Pt"/>
   <result pre="are major determinants of host range and virulence in mouse-adapted" exact="influenza" post="A virusJ Virol20108420106061061810.1128/JVI.01187-1020702632 35.SongMSPascuaPNLeeJHBaekYHParkKJKwonHIet al.Virulence and genetic compatibility of"/>
   <result pre="of polymerase reassortant viruses derived from the pandemic (H1N1) 2009" exact="influenza" post="virus and circulating influenza A virusesJ Virol201185136275628610.1128/JVI.02125-1021507962 36.ZhangXXuGWangCJiangMGaoWWangMet al.Enhanced"/>
   <result pre="derived from the pandemic (H1N1) 2009 influenza virus and circulating" exact="influenza" post="A virusesJ Virol201185136275628610.1128/JVI.02125-1021507962 36.ZhangXXuGWangCJiangMGaoWWangMet al.Enhanced pathogenicity and neurotropism of"/>
   <result pre="virusesJ Virol201185136275628610.1128/JVI.02125-1021507962 36.ZhangXXuGWangCJiangMGaoWWangMet al.Enhanced pathogenicity and neurotropism of mouse-adapted H10N7" exact="influenza" post="virus are mediated by novel PB2 and NA mutationsJ"/>
   <result pre="271 plays a key role in enhanced polymerase activity of" exact="influenza" post="A viruses in mammalian host cellsJ Virol20108494395440610.1128/JVI.02642-0920181719 38.HattaMGaoPHalfmannPKawaokaYMolecular basis"/>
   <result pre="Virol20108494395440610.1128/JVI.02642-0920181719 38.HattaMGaoPHalfmannPKawaokaYMolecular basis for high virulence of Hong Kong H5N1" exact="influenza" post="A virusesScience (New York, NY)200129355361840184210.1126/science.1062882 39.SunHCuiPSongYQiYLiXQiWet al.PB2 segment promotes"/>
   <result pre="(New York, NY)200129355361840184210.1126/science.1062882 39.SunHCuiPSongYQiYLiXQiWet al.PB2 segment promotes high-pathogenicity of H5N1" exact="avian influenza" post="viruses in miceFront Microbiol201567325713566 40.ParkSJKimEHKwonHISongMSKimSMKimYIet al.Altered virulence of highly"/>
   <result pre="York, NY)200129355361840184210.1126/science.1062882 39.SunHCuiPSongYQiYLiXQiWet al.PB2 segment promotes high-pathogenicity of H5N1 avian" exact="influenza" post="viruses in miceFront Microbiol201567325713566 40.ParkSJKimEHKwonHISongMSKimSMKimYIet al.Altered virulence of highly"/>
   <result pre="viruses in miceFront Microbiol201567325713566 40.ParkSJKimEHKwonHISongMSKimSMKimYIet al.Altered virulence of highly pathogenic" exact="avian influenza" post="(HPAI) H5N8 reassortant viruses in mammalian modelsVirulence20189113314810.1080/21505594.2017.136640828873012 41.BiYXieQZhangSLiYXiaoHJinTet al.Assessment"/>
   <result pre="in miceFront Microbiol201567325713566 40.ParkSJKimEHKwonHISongMSKimSMKimYIet al.Altered virulence of highly pathogenic avian" exact="influenza" post="(HPAI) H5N8 reassortant viruses in mammalian modelsVirulence20189113314810.1080/21505594.2017.136640828873012 41.BiYXieQZhangSLiYXiaoHJinTet al.Assessment"/>
   <result pre="in mammalian modelsVirulence20189113314810.1080/21505594.2017.136640828873012 41.BiYXieQZhangSLiYXiaoHJinTet al.Assessment of the internal genes of" exact="influenza" post="A (H7N9) virus contributing to high pathogenicity in miceJ"/>
   <result pre="Virol201589121310.1128/JVI.02390-1425320305 42.HuMYuanSZhangKSinghKMaQZhouJet al.PB2 substitutions V598T/I increase the virulence of H7N9" exact="influenza" post="A virus in mammalsVirology20175019210110.1016/j.virol.2016.11.00827889648 43.LiWLeeHHYLiRFZhuHMYiGPeirisJSMet al.The PB2 mutation with"/>
   <result pre="PB2 mutation with lysine at 627 enhances the pathogenicity of" exact="avian influenza" post="(H7N9) virus which belongs to a non-zoonotic lineageSci Rep201771235210.1038/s41598-017-02598-z28539661"/>
   <result pre="mutation with lysine at 627 enhances the pathogenicity of avian" exact="influenza" post="(H7N9) virus which belongs to a non-zoonotic lineageSci Rep201771235210.1038/s41598-017-02598-z28539661"/>
   <result pre="2 gene contribute to the pathogenicity of the novel A/H7N9" exact="influenza" post="virus in mammalian hostsJ Virol20148863568357610.1128/JVI.02740-1324403592 45.XiaoCMaWSunNHuangLLiYZengZet al.PB2-588 V promotes"/>
   <result pre="V promotes the mammalian adaptation of H10N8, H7N9 and H9N2" exact="avian influenza" post="virusesSci Rep201661947410.1038/srep1947426782141 46.WangCLeeHHYangZFMokCKZhangZPB2-Q591K mutation determines the pathogenicity of avian"/>
   <result pre="promotes the mammalian adaptation of H10N8, H7N9 and H9N2 avian" exact="influenza" post="virusesSci Rep201661947410.1038/srep1947426782141 46.WangCLeeHHYangZFMokCKZhangZPB2-Q591K mutation determines the pathogenicity of avian"/>
   <result pre="virusesSci Rep201661947410.1038/srep1947426782141 46.WangCLeeHHYangZFMokCKZhangZPB2-Q591K mutation determines the pathogenicity of avian H9N2" exact="influenza" post="viruses for mammalian speciesPLoS One2016119e016216310.1371/journal.pone.016216327684944 47.NeumannGH5N1 influenza virulence, pathogenicity"/>
   <result pre="of avian H9N2 influenza viruses for mammalian speciesPLoS One2016119e016216310.1371/journal.pone.016216327684944 47.NeumannGH5N1" exact="influenza" post="virulence, pathogenicity and transmissibility: what do we know?Future Virol201510897198010.2217/fvl.15.6226617665"/>
   <result pre="and transmissibility: what do we know?Future Virol201510897198010.2217/fvl.15.6226617665 48.BoivinSHartDJInteraction of the" exact="influenza" post="A virus polymerase PB2 C-terminal region with importin alpha"/>
   <result pre="assemblyJ Biol Chem201128612104391044810.1074/jbc.M110.18296421216958 49.GabrielGDauberBWolffTPlanzOKlenkHDStechJThe viral polymerase mediates adaptation of an" exact="avian influenza" post="virus to a mammalian hostProc Natl Acad Sci U"/>
   <result pre="Biol Chem201128612104391044810.1074/jbc.M110.18296421216958 49.GabrielGDauberBWolffTPlanzOKlenkHDStechJThe viral polymerase mediates adaptation of an avian" exact="influenza" post="virus to a mammalian hostProc Natl Acad Sci U"/>
   <result pre="A200510251185901859510.1073/pnas.050741510216339318 50.LeeCYAnSHKimIGoDMKimDYChoiJGet al.Prerequisites for the acquisition of mammalian pathogenicity by" exact="influenza" post="A virus with a prototypic avian PB2 geneSci Rep2017711020510.1038/s41598-017-09560-z28860593"/>
   <result pre="158 is a pathogenic determinant of pandemic H1N1 and H5" exact="influenza" post="A viruses in miceJ Virol201185135736510.1128/JVI.01694-1020962098 52.KatoYSFukuiKSuzukiKMechanism of a mutation"/>
   <result pre="a mutation in non-structural protein 1 inducing high pathogenicity of" exact="avian influenza" post="virus H5N1Protein Pept Lett201623437237810.2174/092986652366616020412440626845765 53.ChengJZhangCTaoJLiBShiYLiuHEffects of the S42 residue"/>
   <result pre="mutation in non-structural protein 1 inducing high pathogenicity of avian" exact="influenza" post="virus H5N1Protein Pept Lett201623437237810.2174/092986652366616020412440626845765 53.ChengJZhangCTaoJLiBShiYLiuHEffects of the S42 residue"/>
   <result pre="Lett201623437237810.2174/092986652366616020412440626845765 53.ChengJZhangCTaoJLiBShiYLiuHEffects of the S42 residue of the H1N1 swine" exact="influenza" post="virus NS1 protein on interferon responses and virus replicationVirol"/>
   <result pre="matrix protein M1 contribute to the virulence difference of H5N1" exact="avian influenza" post="viruses in miceVirology20093841283210.1016/j.virol.2008.11.04419117585 55.BlazejewskaPKoscinskiLViegasNAnhlanDLudwigSSchughartKPathogenicity of different PR8 influenza A"/>
   <result pre="protein M1 contribute to the virulence difference of H5N1 avian" exact="influenza" post="viruses in miceVirology20093841283210.1016/j.virol.2008.11.04419117585 55.BlazejewskaPKoscinskiLViegasNAnhlanDLudwigSSchughartKPathogenicity of different PR8 influenza A"/>
   <result pre="H5N1 avian influenza viruses in miceVirology20093841283210.1016/j.virol.2008.11.04419117585 55.BlazejewskaPKoscinskiLViegasNAnhlanDLudwigSSchughartKPathogenicity of different PR8" exact="influenza" post="A virus variants in mice is determined by both"/>
   <result pre="variation affects resistance to infection with a highly pathogenic H5N1" exact="influenza" post="A virus in miceJ Virol20098320104171042610.1128/JVI.00514-0919706712 57.DavidsonSCrottaSMcCabeTMWackAPathogenic potential of interferon"/>
   <result pre="in miceJ Virol20098320104171042610.1128/JVI.00514-0919706712 57.DavidsonSCrottaSMcCabeTMWackAPathogenic potential of interferon alphabeta in acute" exact="influenza" post="infectionNat Commun20145386410.1038/ncomms486424844667 58.PicaNIyerARamosIBouvierNMFernandez-SesmaAGarcia-SastreAet al.The DBA.2 mouse is susceptible to"/>
   <result pre="disease following infection with a broad, but limited, range of" exact="influenza" post="A and B virusesJ Virol20118523128251282910.1128/JVI.05930-1121917963 59.SrivastavaBBlazejewskaPHessmannMBruderDGeffersRMauelSet al.Host genetic background"/>
   <result pre="Virol20118523128251282910.1128/JVI.05930-1121917963 59.SrivastavaBBlazejewskaPHessmannMBruderDGeffersRMauelSet al.Host genetic background strongly influences the response to" exact="influenza" post="A virus infectionsPLoS One200943e485710.1371/journal.pone.000485719293935 60.YeJSorrellEMCaiYShaoHXuKPenaLet al.Variations in the hemagglutinin"/>
   <result pre="and strong NK cell responses protect 129 mice against high-dose" exact="influenza" post="virus infectionJ Immunol201619641842185410.4049/jimmunol.150148626773146 62.EisfeldAJGasperDJSureshMKawaokaYC57BL/6J and C57BL/6NJ mice are differentially"/>
   <result pre="C57BL/6NJ mice are differentially susceptible to inflammation-associated disease caused by" exact="influenza" post="A virusFront Microbiol20189330710.3389/fmicb.2018.0330730713529 63.ReedLJMuenchHA simple method of estimating fifty"/>
   <result pre="Epidemiol193827349349710.1093/oxfordjournals.aje.a118408 64.collab: World Health OrganizationProduction of pilot lots of inactivated" exact="influenza" post="vaccine in response to a pandemic threat: an interim"/>
   <result pre="threat: an interim biosafety risk assessmentReleve epidemiologique hebdomadaire2003784740540814677515 65.BaoYBolotovPDernovoyDKiryutinBZaslavskyLTatusovaTet al.The" exact="influenza" post="virus resource at the National Center for Biotechnology InformationJ"/>
   <result pre="67.Shu Y, McCauley J. GISAID: global initiative on sharing all" exact="influenza" post="data – from vision to reality. Euro Surveill. 2017;22(13)."/>
   <result pre="to reality. Euro Surveill. 2017;22(13). 68.Ivan FX. Virulence information for" exact="influenza" post="virus infections (VI2VI) in mice. DR-NTU (Data); 2019. 69.HornikKBuchtaCZeileisAOpen-source"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6935926\results\search\disease\results.xml">
   <result pre="DW, Walker AS, Matthews PC. 2020. Metagenomic Nanopore sequencing of" exact="influenza" post="virus direct from clinical respiratory samples. J Clin Microbiol"/>
   <result pre="viral sequencing offers the potential for a diagnostic test for" exact="influenza" post="virus which also provides insights on transmission, evolution, and"/>
   <result pre="viral sequencing offers the potential for a diagnostic test for" exact="influenza" post="virus which also provides insights on transmission, evolution, and"/>
   <result pre="sequencing method to metagenomic sequencing of respiratory samples. We generated" exact="influenza" post="virus reads down to a limit of detection of"/>
   <result pre="strong relationship between the viral titer and the proportion of" exact="influenza" post="virus reads (P = 4.7 × 10−5). Applying our methods to clinical throat"/>
   <result pre="(P = 4.7 × 10−5). Applying our methods to clinical throat swabs, we generated" exact="influenza" post="virus reads for 27/27 samples with mid-to-high viral titers"/>
   <result pre="30 to 40). No false-positive reads were generated from 10" exact="influenza" post="virus-negative samples. Thus, Nanopore sequencing operated with 83% sensitivity"/>
   <result pre="influenced by increased host and bacterial reads. However, at high" exact="influenza" post="virus titers, we were able to reconstruct &amp;gt;99% complete"/>
   <result pre="to be used in the diagnosis and genetic analysis of" exact="influenza" post="virus and other respiratory viruses. Keywords influenza Nanopore metagenomic"/>
   <result pre="genetic analysis of influenza virus and other respiratory viruses. Keywords" exact="influenza" post="Nanopore metagenomic diagnosis epidemiology sequencing DNA sequencing diagnostics metagenomics"/>
   <result pre="WHO list of &quot;ten threats to global health�? (7). Seasonal" exact="influenza" post="causes an estimated 650,000 deaths globally each year, and"/>
   <result pre="older adults, infants, young children, pregnant women, those with underlying" exact="lung disease," post="and the immunocompromised (9). The burden of disease disproportionately"/>
   <result pre="neuraminidase inhibitors (NAI) (9). Currently, most clinical diagnostic tests for" exact="influenza" post="virus depend on detecting viral antigen or on PCR"/>
   <result pre="nonquantitative (binary) diagnostic result, and the data routinely generated for" exact="influenza" post="diagnosis have limited capacity to inform insights into epidemiological"/>
   <result pre="application of Oxford Nanopore Technologies (ONT) sequencing to generate full-length" exact="influenza" post="virus sequences from clinical respiratory samples can address these"/>
   <result pre="range of viruses (20, 22–24). To date, Nanopore sequencing of" exact="influenza" post="virus has been reported using high-titer virus from an"/>
   <result pre="using targeted enrichment by either hybridization of cDNA (26) or" exact="influenza" post="virus-specific PCR amplification (27). We therefore aimed to optimize"/>
   <result pre="We therefore aimed to optimize a metagenomic protocol for detecting" exact="influenza" post="viruses directly from clinical samples using Nanopore sequencing. We"/>
   <result pre="(Illumina) sequencing, using clinical samples from hospital patients during an" exact="influenza" post="season and samples from a controlled laboratory infection in"/>
   <result pre="a PCR-based test using the GeneXpert assay (Cepheid) to detect" exact="influenza" post="A and B viruses and respiratory syncytial virus (RSV)."/>
   <result pre="were generated by the GeneXpert assay, and we used the" exact="influenza" post="virus CT value to estimate the viral titers in"/>
   <result pre="to show processing protocol through clinical and research pipelines for" exact="influenza" post="diagnosis. (A) Clinical sample collection (orange), clinical diagnostic testing"/>
   <result pre="and processing of sequence data (purple). (B) Outline of pooled" exact="influenza" post="virus-positive samples into an influenza virus-negative background to generate"/>
   <result pre="(purple). (B) Outline of pooled influenza virus-positive samples into an" exact="influenza" post="virus-negative background to generate various titers of influenza virus"/>
   <result pre="into an influenza virus-negative background to generate various titers of" exact="influenza" post="virus (from 0 to 106 genome copies/ml), undertaken in"/>
   <result pre="titer of Hazara virus control at 104 genome copies/ml. FluA," exact="influenza" post="A virus. For methodological assessment, we focused on four"/>
   <result pre="pooled 19 throat swab samples that had tested positive for" exact="influenza" post="A virus in the clinical diagnostic laboratory to provide"/>
   <result pre="pools of throat swab samples that had tested negative for" exact="influenza" post="virus (consisting of 24, 38, and 38 individual samples)"/>
   <result pre="swabs and 5 nasal swabs) that had tested positive for" exact="influenza" post="A or B virus, selected to represent the widest"/>
   <result pre="samples, we selected 10 individual throat swab samples that were" exact="influenza" post="virus negative. Quantification of viral RNA in samples. We"/>
   <result pre="We quantified viral titers in Hazara virus stocks and pooled" exact="influenza" post="A virus-positive throat swabs by quantitative reverse transcription-PCR (qRT-PCR),"/>
   <result pre="consensus sequences were subjected to a BLAST search against an" exact="influenza" post="virus sequence database that included &amp;gt;2,000 H1N1 and H3N2"/>
   <result pre="virus sequence database that included &amp;gt;2,000 H1N1 and H3N2 seasonal" exact="influenza" post="virus sequences between 2018 and 2019 and were downloaded"/>
   <result pre="SAMtools v1.5 (34) and Pysam (https://github.com/pysam-developers/pysam). The subtype of the" exact="influenza" post="A virus derived from each clinical sample was determined"/>
   <result pre="time course, from 3 days prior to first exposure with" exact="influenza" post="H1N1pdm09 virus and at days 1, 2, 3, and"/>
   <result pre="protocol is shown in Fig. 1A. We first sequenced five" exact="influenza" post="A virus-positive and five influenza virus-negative throat swabs, each"/>
   <result pre="1A. We first sequenced five influenza A virus-positive and five" exact="influenza" post="virus-negative throat swabs, each spiked with Hazara virus control"/>
   <result pre="extraction from the supernatant. We used a pooled set of" exact="influenza" post="A virus-positive samples (concentration, 106 genome copies/ml) to provide"/>
   <result pre="virus control spiked in at 104 genome copies/ml. Enrichment for" exact="influenza" post="virus and Hazara virus was similar for filtration versus"/>
   <result pre="original protocol, using triplicate extractions from the pooled set of" exact="influenza" post="A virus-positive samples demonstrated no significant loss in performance"/>
   <result pre="retrieval of Hazara virus by Nanopore sequencing. Starting with an" exact="influenza" post="A virus-positive sample pool (106 genome copies/ml), we made"/>
   <result pre="copies/ml), we made three volumetric dilution series using three independent" exact="influenza" post="virus-negative pools (Fig. 1B). The total quantity of cDNA"/>
   <result pre="throat swab samples. FIG 2 Characteristics of three pools of" exact="influenza" post="virus-negative throat swabs and Nanopore sequence results following spiking"/>
   <result pre="virus-negative throat swabs and Nanopore sequence results following spiking with" exact="influenza" post="A virus. (A) Total concentration of cDNA produced per"/>
   <result pre="undiluted material, represented by the black bars. Samples diluted to" exact="influenza" post="virus titers of 104, 103, and 102 contain more"/>
   <result pre="generated by Nanopore sequencing of samples with different titers of" exact="influenza" post="A virus and a consistent titer of Hazara virus"/>
   <result pre="Graphs show reads per million of total reads mapping to" exact="influenza" post="A or Hazara virus genomes, across the three individual"/>
   <result pre="from all three dilution series by Nanopore sequencing, independently of" exact="influenza" post="virus titer in the sample (Fig. 2B). Sequencing from"/>
   <result pre="nonviral RNA was introduced from this high-background pool. Limit of" exact="influenza" post="virus detection by Nanopore sequencing from pooled samples. Nanopore"/>
   <result pre="samples. Nanopore sequencing of the triplicate SISPA preparations of the" exact="influenza" post="A virus-positive pool produced mean ± standard deviation of"/>
   <result pre="standard deviation of 5.3 × 104 ± 3.6 × 104 RPM mapping to the" exact="influenza" post="A virus genome (Fig. 2B). Across the dilution series,"/>
   <result pre="genome (Fig. 2B). Across the dilution series, the proportion of" exact="influenza" post="virus reads was strongly associated with influenza virus titer"/>
   <result pre="the proportion of influenza virus reads was strongly associated with" exact="influenza" post="virus titer (P value = 4.7 × 10−5) but was also"/>
   <result pre="Hazara virus control. Sequencing the negative controls (pools with no" exact="influenza" post="virus spike) generated no reads mapping to influenza virus."/>
   <result pre="with no influenza virus spike) generated no reads mapping to" exact="influenza" post="virus. At influenza virus titers of &amp;lt;103 copies/ml, influenza"/>
   <result pre="virus spike) generated no reads mapping to influenza virus. At" exact="influenza" post="virus titers of &amp;lt;103 copies/ml, influenza virus reads were"/>
   <result pre="to influenza virus. At influenza virus titers of &amp;lt;103 copies/ml," exact="influenza" post="virus reads were inconsistently detected across the samples (Fig."/>
   <result pre="that the limit of detection is between 102 and 103" exact="influenza" post="virus copies/ml. Retrieval and reconstruction of complete influenza virus"/>
   <result pre="and 103 influenza virus copies/ml. Retrieval and reconstruction of complete" exact="influenza" post="virus genomes from pooled/spiked samples. For the Hazara virus"/>
   <result pre="in all samples (Fig. 3A). At 104 genome copies/ml of" exact="influenza" post="virus, a mean 1× coverage per segment was 90.3%"/>
   <result pre="in the high-background pool 3 to 5.7% (Fig. 3A). At" exact="influenza" post="virus titers of &amp;lt;104 copies/ml, coverage was highly varied"/>
   <result pre="correct subtyping as H3N2 (Table 1). FIG 3 Coverage of" exact="influenza" post="virus and Hazara virus genome segments achieved by Nanopore"/>
   <result pre="pooled samples (A) Data from three dilution series of pooled" exact="influenza" post="virus-positive samples, diluted with three separate negative-sample pools to"/>
   <result pre="with three separate negative-sample pools to generate different titers of" exact="influenza" post="virus. Each individual dilution was spiked with Hazara virus"/>
   <result pre="at 1× depth is shown for each of the eight" exact="influenza" post="virus genome segments (encoding PB2 [polymerase subunit 2], PB1"/>
   <result pre="of all three genome segments. (B) Representative coverage plots of" exact="influenza" post="A virus genome segments from the dilution series 1"/>
   <result pre="genome segments from the dilution series 1 sample at 104" exact="influenza" post="virus copies per ml. TABLE 1 Summary of results"/>
   <result pre="Nanopore sequencing based on pooled samples with various titers of" exact="influenza" post="A virus and a consistent titer of Hazara virus"/>
   <result pre="copies/ml) Dilution pool no. Total no. of reads No. of" exact="influenza" post="A virus reads (reads per million) Influenza A virus"/>
   <result pre="from individual clinical samples. Having demonstrated our ability to retrieve" exact="influenza" post="virus sequences from pooled influenza virus-positive material diluted with"/>
   <result pre="demonstrated our ability to retrieve influenza virus sequences from pooled" exact="influenza" post="virus-positive material diluted with negative samples, we next applied"/>
   <result pre="methods to individual anonymized clinical samples, with 40 samples testing" exact="influenza" post="virus positive and 10 samples testing influenza virus negative"/>
   <result pre="40 samples testing influenza virus positive and 10 samples testing" exact="influenza" post="virus negative in the clinical diagnostic laboratory. Data yield"/>
   <result pre="(median, 3.8 × 105 reads) (Table S1). Reads mapping to either the" exact="influenza" post="A or B virus genome were present in all"/>
   <result pre="274,955 reads). At a CT of &amp;gt;30, 6/13 samples generated" exact="influenza" post="virus reads (range, 6 to 92,057 reads) (difference between"/>
   <result pre="P &amp;lt; 0.0001; Fig. 4). The highest CT value at which any" exact="influenza" post="virus reads were detected was 36.8 (sample 37; 17"/>
   <result pre="reads were detected was 36.8 (sample 37; 17 reads of" exact="influenza" post="A virus). No reads classified as influenza virus were"/>
   <result pre="17 reads of influenza A virus). No reads classified as" exact="influenza" post="virus were obtained from sequencing the 10 GeneXpert assay-negative"/>
   <result pre="CT value and both the reads per sample classified as" exact="influenza" post="virus (R2 = 0.60) and the number of influenza"/>
   <result pre="as influenza virus (R2 = 0.60) and the number of" exact="influenza" post="virus reads per million reads (R2 = 0.62) (Fig."/>
   <result pre="generated (at 10× minimum depth) covered over 90% of the" exact="influenza" post="virus genome for 17 samples, with another two generating"/>
   <result pre="CT value of a sample from which &amp;gt;90% of an" exact="influenza" post="virus genome sequence was generated was 27.5 (Fig. S4)."/>
   <result pre="was 27.5 (Fig. S4). FIG 4 Total and proportion of" exact="influenza" post="virus reads derived by Nanopore sequencing of individual samples"/>
   <result pre="laboratory. Left, correlation between CT value and total number of" exact="influenza" post="virus reads generated. R2 = 0.604, P = 2.47e−08."/>
   <result pre="= 2.47e−08. Right, correlation between CT value and number of" exact="influenza" post="virus reads per million reads. R2 = 0.623, P"/>
   <result pre="no detectable Hazara virus reads, two with high numbers of" exact="influenza" post="virus reads (for sample 1, CT of 13.5 and"/>
   <result pre="virus reads (for sample 1, CT of 13.5 and 1.5 × 105" exact="influenza" post="B virus reads, and for sample 6, CT of"/>
   <result pre="reads, and for sample 6, CT of 18.4 and 1.5 × 104" exact="influenza" post="A virus reads) acting to dilute the control signal."/>
   <result pre="the control signal. The other two samples contained no detectable" exact="influenza" post="virus reads (for sample 34, CT of 35.9, and"/>
   <result pre="(for sample 34, CT of 35.9, and for sample 46," exact="influenza" post="virus negative). The lack of control detection therefore indicates"/>
   <result pre="platform. The proportions of reads generated that mapped to the" exact="influenza" post="virus genome were similar between the two sequencing technologies"/>
   <result pre="sequences, as expected within one geographic setting in a single" exact="influenza" post="season. FIG 5 Phylogenetic trees of consensus influenza virus"/>
   <result pre="a single influenza season. FIG 5 Phylogenetic trees of consensus" exact="influenza" post="virus HA gene derived by Nanopore and Illumina sequencing."/>
   <result pre="109 reads mapping to human coronavirus in addition to &amp;gt;1.5 × 104" exact="influenza" post="A virus reads, suggesting coinfection. We also derived &amp;gt;4.0 × 104"/>
   <result pre="We also derived &amp;gt;4.0 × 104 reads from human metapneumovirus from an" exact="influenza" post="virus-negative sample, providing a nearly complete genome (99.8% coverage)"/>
   <result pre="reproducibility of our methods across a time course model of" exact="influenza" post="A virus infection (three ferrets swabbed preinfection [day −3]"/>
   <result pre="days 1, 2, 3, and 5 following laboratory infection with" exact="influenza" post="A virus). The proportion of viral reads present at"/>
   <result pre="same cDNA (Table S2). FIG 6 Time course experiment showing" exact="influenza" post="A virus infection in three laboratory ferrets. Infection was"/>
   <result pre="proportion of total Nanopore reads (linear scale) (B) mapping to" exact="influenza" post="A virus from metagenomic sequencing of ferret nasal washes"/>
   <result pre="metagenomic sequencing of ferret nasal washes taken before and after" exact="influenza" post="virus challenge. DISCUSSION To our knowledge, this is the"/>
   <result pre="applying metagenomic Nanopore sequencing directly to respiratory samples to detect" exact="influenza" post="virus and generate influenza virus sequences. The approach demonstrates"/>
   <result pre="directly to respiratory samples to detect influenza virus and generate" exact="influenza" post="virus sequences. The approach demonstrates excellent specificity. Sensitivity varies"/>
   <result pre="to be further optimized and validated to improve sensitivity for" exact="influenza" post="virus, identify other RNA viruses, detect drug resistance mutations,"/>
   <result pre="demonstrating the ability of metagenomics to produce sufficient data for" exact="influenza" post="virus diagnostics and genome characterization, while also detecting and"/>
   <result pre="Society of America (IDSA) guidelines (9) recommend nasal/nasopharyngeal specimens for" exact="influenza" post="diagnosis, but throat swabs are easier to collect in"/>
   <result pre="virus; however, half of these contained a high titer of" exact="influenza" post="virus, so only 4% were true sensitivity failures. This"/>
   <result pre="Nanopore reads confirms semiquantitative output. Using samples from the ferret" exact="influenza" post="virus model, collected under standardized laboratory conditions, we demonstrated"/>
   <result pre="clinical diagnostics to further assess sensitivity and specificity, and using" exact="influenza" post="virus sequence data to investigate transmission events. Identifying instances"/>
   <result pre="the method is robust for the identification of commonly circulating" exact="influenza" post="virus strains in human populations, but further investigation is"/>
   <result pre="strains. Comparison with existing/alternative approaches. The current standard assay for" exact="influenza" post="diagnosis employed within the large tertiary referral teaching hospital"/>
   <result pre="study was performed is the GeneXpert assay (Cepheid), which detects" exact="influenza" post="A and B viruses and respiratory syncytial virus (RSV)."/>
   <result pre="purchasing 48 flow cells together. The cost of the current" exact="influenza" post="A/B and RSV GeneXpert test is ∼£56, and the"/>
   <result pre="approaches to generate sequence data include amplicon-based sequencing of the" exact="influenza" post="virus genome (51, 52). However, this approach detects only"/>
   <result pre="Illumina sequencing instead of Nanopore sequencing for metagenomic sequencing of" exact="influenza" post="virus (53) provides the current gold standard of sequence"/>
   <result pre="further work is needed, our methods show promise for generating" exact="influenza" post="virus sequences directly from respiratory samples. The &quot;pathogen-agnostic�? metagenomic"/>
   <result pre="doi:10.1038/s41572-018-0002-y.29955068 2.JosephU, SuYCF, VijaykrishnaD, SmithG2017The ecology and adaptive evolution of" exact="influenza" post="A interspecies transmission. Influenza Other Respir Viruses11:74–84. doi:10.1111/irv.12412.27426214 3.HumphreysM2018The"/>
   <result pre="influenza A interspecies transmission. Influenza Other Respir Viruses11:74–84. doi:10.1111/irv.12412.27426214 3.HumphreysM2018The" exact="influenza" post="of 1918: evolutionary perspectives in a historical context. Evol"/>
   <result pre="GuanY, RambautA2009Origins and evolutionary genomics of the 2009 swine-origin H1N1" exact="influenza" post="A epidemic. Nature459:1122–1125. doi:10.1038/nature08182.19516283 5.SuttonTC2018The pandemic threat of emerging"/>
   <result pre="Nature459:1122–1125. doi:10.1038/nature08182.19516283 5.SuttonTC2018The pandemic threat of emerging H5 and H7" exact="avian influenza" post="viruses. Viruses10:E461. doi:10.3390/v10090461.30154345 6.XiangD, PuZ, LuoT, GuoF, LiX, ShenX,"/>
   <result pre="doi:10.1038/nature08182.19516283 5.SuttonTC2018The pandemic threat of emerging H5 and H7 avian" exact="influenza" post="viruses. Viruses10:E461. doi:10.3390/v10090461.30154345 6.XiangD, PuZ, LuoT, GuoF, LiX, ShenX,"/>
   <result pre="LuoT, GuoF, LiX, ShenX, IrwinDM, MurphyRW, LiaoM, ShenY2018Evolutionary dynamics of" exact="avian influenza" post="A H7N9 virus across five waves in mainland China,"/>
   <result pre="GuoF, LiX, ShenX, IrwinDM, MurphyRW, LiaoM, ShenY2018Evolutionary dynamics of avian" exact="influenza" post="A H7N9 virus across five waves in mainland China,"/>
   <result pre="GosticKM, PompeiS, BedfordT, �?ukszaM, NeherRA, GrenfellBT, LässigM, McCauleyJW2018Predictive modeling of" exact="influenza" post="shows the promise of applied evolutionary biology. Trends Microbiol26:102–118."/>
   <result pre="Microbiol26:102–118. doi:10.1016/j.tim.2017.09.004.29097090 12.BlancoN, EisenbergMC, StillwellT, FoxmanB2016What transmission precautions best control" exact="influenza" post="spread in a hospital?Am J Epidemiol183:1045–1054. doi:10.1093/aje/kwv293.27188950 13.SansoneM, WimanÅ,"/>
   <result pre="BohlinL, AnderssonL-M, WestinJ, NordénR2019Molecular characterization of a nosocomial outbreak of" exact="influenza" post="B virus in an acute care hospital setting. J"/>
   <result pre="ThomsonRBJr, KaulK, DasS2019Clinical impact of rapid point-of-care polymerase chain reaction" exact="influenza" post="testing in an urgent care setting: a single center"/>
   <result pre="PCR-based point-of-care method facilitates rapid, efficient, and sensitive diagnosis of" exact="influenza" post="virus infection. Clin Microbiol Infect25:1032–1037. doi:10.1016/j.cmi.2018.12.017.30583060 18.VotintsevaAA, BradleyP, PankhurstL,"/>
   <result pre="WyllieDH, WalkerAS, PetoTEA, CrookDW, IqbalZ2017Same-day diagnostic and surveillance data for" exact="tuberculosis" post="via whole-genome sequencing of direct respiratory samples. J Clin"/>
   <result pre="JiaX-J, WangH-H, FuX-F, JiJ-M, HeP-Y, ChenL-X, LuoJ-Y, ChenZ-W2016Dynamic quantification of" exact="avian influenza" post="H7N9(A) virus in a human infection during clinical treatment"/>
   <result pre="WangH-H, FuX-F, JiJ-M, HeP-Y, ChenL-X, LuoJ-Y, ChenZ-W2016Dynamic quantification of avian" exact="influenza" post="H7N9(A) virus in a human infection during clinical treatment"/>
   <result pre="Nanopore and Illumina sequencing for recovering whole genome sequences of" exact="chikungunya" post="and dengue viruses directly from clinical samples. Euro Surveill23:pii=1800228https://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2018.23.50.1800228."/>
   <result pre="BarnesE, MatthewsPC2018Illumina and Nanopore methods for whole genome sequencing of" exact="hepatitis" post="B virus (HBV). bioRxivhttps://www.biorxiv.org/content/biorxiv/suppl/2018/11/14/470633.DC1/470633-1.pdf. 25.KellerMW, Rambo-MartinBL, WilsonMM, RidenourCA, ShepardSS,"/>
   <result pre="NeuhausEB, DuganVG, WentworthDE, BarnesJR2018Direct RNA sequencing of the coding complete" exact="influenza" post="A virus genome. Sci Rep8:14408. doi:10.1038/s41598-018-32615-8.30258076 26.EckertSE, ChanJ-M, HounietD,"/>
   <result pre="JangY, NeuhausEB, Todd DavisC, BowmanAS, WentworthDE, BarnesJR2019Mitigating pandemic risk with" exact="influenza" post="A virus field surveillance at a swine-human interface. bioRxivhttps://www.biorxiv.org/content/10.1101/585588v1."/>
   <result pre="DowallS, PlankJ, NewmanE, BarclayWS, DimmockNJ, EastonAJ, HallisB, SilmanNJ, CarrollMW2014Low dose" exact="influenza" post="virus challenge in the ferret leads to increased virus"/>
   <result pre="DeitrichJ, KlemE, ScheuermannRH2012Influenza research database: an integrated bioinformatics resource for" exact="influenza" post="research and surveillance. Influenza Other Respir Viruses6:404–416. doi:10.1111/j.1750-2659.2011.00331.x.22260278 34.LiH,"/>
   <result pre="AladinF, BrownKE2015Assessment of the utility of whole genome sequencing of" exact="measles" post="virus in the characterisation of outbreaks. PLoS One10:e0143081. doi:10.1371/journal.pone.0143081.26569100"/>
   <result pre="bioRxivhttps://www.biorxiv.org/node/147782.full. 45.MeinelDM, HeinzingerS, EberleU, AckermannN, SchönbergerK, SingA2018Whole genome sequencing identifies" exact="influenza" post="A H3N2 transmission and offers superior resolution to classical"/>
   <result pre="NelsonMI, ViboudC, TaubenbergerJK, HolmesEC2008The genomic and epidemiological dynamics of human" exact="influenza" post="A virus. Nature453:615–619. doi:10.1038/nature06945.18418375 47.ThompsonCP, LourençoJ, WaltersAA, ObolskiU, EdmansM,"/>
   <result pre="GilbertSC, GuptaS2018A naturally protective epitope of limited variability as an" exact="influenza" post="vaccine target. Nat Commun9:3859. doi:10.1038/s41467-018-06228-8.30242149 48.KafetzopoulouLE, PullanST, LemeyP, SuchardMA,"/>
   <result pre="OkamotoM, NishiyamaY, TarumotoN, MitsutakeK, MurakamiT, MaesakiS, MaedaT2018Whole genome sequencing of" exact="influenza" post="A and B viruses with the MinION sequencer in"/>
   <result pre="doi:10.3389/fmicb.2018.02748.30483243 52.WangJ, MooreNE, DengY-M, EcclesDA, HallRJ2015MinION Nanopore sequencing of an" exact="influenza" post="genome. Front Microbiol6:766. doi:10.3389/fmicb.2015.00766.26347715 53.GreningerAL, ChenEC, SittlerT, ScheinermanA, RoubinianN,"/>
   <result pre="AriasCF, HackettJJr, SchochetmanG, MillerS, TangP, ChiuCY2010A metagenomic analysis of pandemic" exact="influenza" post="A (2009 H1N1) infection in patients from North America."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6936527\results\search\disease\results.xml">
   <result pre="Cross-genotype protection of live-attenuated vaccine candidate for severe fever with" exact="thrombocytopenia" post="syndrome virus in a ferret model YuKwang-MinabParkSu-JinabYuMin-AhabKimYoung-IlabChoiYounhocJungJae U.chttp://orcid.org/0000-0003-4707-726XBrennanBenjamind1ChoiYoung Kiab1[],"/>
   <result pre="Commons Attribution License 4.0 (CC BY).pnas.201914704.pdf Significance Severe fever with" exact="thrombocytopenia" post="syndrome virus (SFTSV) is an emerging viral pathogen discovered"/>
   <result pre="the animals from a lethal challenge. Abstract Severe fever with" exact="thrombocytopenia" post="syndrome (SFTS) virus (SFTSV) is an emerging tick-borne virus"/>
   <result pre="since 2009 and is characterized by high fever, thrombocytopenia, and" exact="leukopenia" post="and has a 12 to 30% case fatality rate."/>
   <result pre="Institutes of Health (NIH)100000002AI140705Younho ChoiJae Jung page-count: Severe fever with" exact="thrombocytopenia" post="syndrome (SFTS) virus (SFTSV) is an emerging viral pathogen"/>
   <result pre="the N or NSs proteins (42) or a recombinant vesicular" exact="stomatitis" post="virus (rVSV)-based vaccine candidate expressing the SFTSV Gn/Gc glycoproteins"/>
   <result pre="the hematological pathologies’ characteristic of SFTS disease is a marked" exact="thrombocytopenia" post="in infected patients and animals (2, 40). We examined"/>
   <result pre="the animals infected with either of the NSs-mutant viruses developed" exact="thrombocytopenia" post="over the course of infection, and recorded mean platelet"/>
   <result pre="3 B and C). CB8/2016-infected animals developed a statistically significant" exact="thrombocytopenia" post="by 6 d p.i., and this continued until 8"/>
   <result pre="fever was detected the rHB2912aaNSs-immunized ferrets (Fig. 5C). Further, no" exact="thrombocytopenia" post="was detected in the immunized and challenged animals at"/>
   <result pre="evidenced by a lack of clinical manifestations, an absence of" exact="thrombocytopenia" post="and reduced virus replication and dissemination to the surrounding"/>
   <result pre="SFTSV strain HB29 antigenome segments flanked by T7 promoter and" exact="hepatitis" post="delta ribozyme sequences. Plasmid pTVT7-HB29S12aaNSs, which was previously described"/>
   <result pre="2019. Arch. Virol.164, 1949–1965 (2019).31065850 2YuX. J.et al., Fever with" exact="thrombocytopenia" post="associated with a novel bunyavirus in China. N. Engl."/>
   <result pre="Infect. Dis.209, 816–827 (2014).24231186 4KimK. H.et al., Severe fever with" exact="thrombocytopenia" post="syndrome, South Korea, 2012. Emerg. Infect. Dis.19, 1892–1894 (2013).24206586"/>
   <result pre="Infect. Dis.19, 1892–1894 (2013).24206586 5ParkS. W.et al., Severe fever with" exact="thrombocytopenia" post="syndrome virus, South Korea, 2013. Emerg. Infect. Dis.20, 1880–1882"/>
   <result pre="1880–1882 (2014).25341085 6ParkS. W.et al., Prevalence of severe fever with" exact="thrombocytopenia" post="syndrome virus in Haemaphysalis longicornis ticks in South Korea."/>
   <result pre="Dis.5, 975–977 (2014).25164614 7TranX. C.et al., Endemic severe fever with" exact="thrombocytopenia" post="syndrome, Vietnam. Emerg. Infect. Dis.25, 1029–1031 (2019).31002059 8collab: World"/>
   <result pre="A case-control study of risk sources for severe fever with" exact="thrombocytopenia" post="syndrome in Hubei Province, China. Int. J. Infect. Dis.55,"/>
   <result pre="86–91 (2017).28088586 12ZhanJ.et al., Current status of severe fever with" exact="thrombocytopenia" post="syndrome in China. Virol. Sin.32, 51–62 (2017).28251515 13GaiZ.et al.,"/>
   <result pre="51–62 (2017).28251515 13GaiZ.et al., Person-to-person transmission of severe fever with" exact="thrombocytopenia" post="syndrome bunyavirus through blood contact. Clin. Infect. Dis.54, 249–252"/>
   <result pre="249–252 (2012).22095565 14LiuY.et al., Person-to-person transmission of severe fever with" exact="thrombocytopenia" post="syndrome virus. Vector Borne Zoonotic Dis.12, 156–160 (2012).21955213 15TangX.et"/>
   <result pre="156–160 (2012).21955213 15TangX.et al., Human-to-human transmission of severe fever with" exact="thrombocytopenia" post="syndrome bunyavirus through contact with infectious blood. J. Infect."/>
   <result pre="of cases of human-to-human transmission caused by severe fever with" exact="thrombocytopenia" post="syndrome bunyavirus. Int. J. Infect. Dis.17, e206–e208 (2013).23218674 17LiD."/>
   <result pre="J. Infect. Dis.17, e206–e208 (2013).23218674 17LiD. X., Severe fever with" exact="thrombocytopenia" post="syndrome: A newly discovered emerging infectious disease. Clin. Microbiol."/>
   <result pre="X., Severe fever with thrombocytopenia syndrome: A newly discovered emerging" exact="infectious disease." post="Clin. Microbiol. Infect.21, 614–620 (2015).25769426 18ZhangY. Z.et al., Hemorrhagic"/>
   <result pre="research group-Japan, Epidemiological and clinical features of severe fever with" exact="thrombocytopenia" post="syndrome in Japan, 2013–2014. PLoS One11, e0165207 (2016).27776187 20ElliottR."/>
   <result pre="50–57 (2014).24607799 23LiZ.et al., Increased prevalence of severe fever with" exact="thrombocytopenia" post="syndrome in eastern China clustered with multiple genotypes and"/>
   <result pre="6503 (2017).28747674 24FuY.et al., Phylogeographic analysis of severe fever with" exact="thrombocytopenia" post="syndrome virus from Zhoushan Islands, China: Implication for transmission"/>
   <result pre="interferon responses. J. Virol.88, 4572–4585 (2014).24478431 26NingY. J.et al., Viral" exact="suppression" post="of innate immunity via spatial isolation of TBK1/IKKε from"/>
   <result pre="III IFN signalling by NSs protein of severe fever with" exact="thrombocytopenia" post="syndrome virus through inhibition of STAT1 phosphorylation and activation."/>
   <result pre="interferon signaling by the nonstructural protein of severe fever with" exact="thrombocytopenia" post="syndrome virus via the hijacking of STAT2 and STAT1"/>
   <result pre="nonstructural proteins. mSphere2, e00234-17 (2017).28680969 31ChoiY.et al., Severe fever with" exact="thrombocytopenia" post="syndrome phlebovirus non-structural protein activates TPL2 signalling pathway for"/>
   <result pre="conserved amino acids within the NSs of severe fever with" exact="thrombocytopenia" post="syndrome phlebovirus are essential for anti-interferon activity. J. Virol.92,"/>
   <result pre="104 (2017).28194148 35LiuY.et al., The pathogenesis of severe fever with" exact="thrombocytopenia" post="syndrome virus infection in alpha/beta interferon knockout mice: Insights"/>
   <result pre="effect of post-exposure treatment with antiserum on severe fever with" exact="thrombocytopenia" post="syndrome (SFTS) in a mouse model of SFTS virus"/>
   <result pre="1288–1293 (2012).22357748 38JinC.et al., Pathogenesis of emerging severe fever with" exact="thrombocytopenia" post="syndrome virus in C57/BL6 mouse model. Proc. Natl. Acad."/>
   <result pre="40ParkS. J.et al., Ferret animal model of severe fever with" exact="thrombocytopenia" post="syndrome phlebovirus for human lethal infection and pathogenesis. Nat."/>
   <result pre="a rVSV-based vaccine elicits complete protection against severe fever with" exact="thrombocytopenia" post="syndrome virus. NPJ Vaccines4, 5 (2019).30701094 44KimK. H.et al.,"/>
   <result pre="convalescent patient potently inhibits the infection of severe fever with" exact="thrombocytopenia" post="syndrome virus. PLoS Pathog.15, e1007375 (2019).30707748 45YunS. M.et al.,"/>
   <result pre="Molecular genomic characterization of tick- and human-derived severe fever with" exact="thrombocytopenia" post="syndrome virus isolates from South Korea. PLoS Negl. Trop."/>
   <result pre="Plasma exchange and ribavirin for rapidly progressive severe fever with" exact="thrombocytopenia" post="syndrome. Int. J. Infect. Dis.18, 84–86 (2014).24161209 49JiaZ.et al.,"/>
   <result pre="Identification of a candidate standard strain of severe fever with" exact="thrombocytopenia" post="syndrome virus for vaccine quality control in China using"/>
   <result pre="92–98 (2017).28173977 50YunY.et al., Phylogenetic analysis of severe fever with" exact="thrombocytopenia" post="syndrome virus in South Korea and migratory bird routes"/>
   <result pre="(2015).26033016 51DingN. Z.et al., Identification of two severe fever with" exact="thrombocytopenia" post="syndrome virus strains originating from reassortment. Virus Res.178, 543–546"/>
   <result pre="HanH. J., ParkS.-J., ChoiY. K., Epidemiology of severe fever and" exact="thrombocytopenia" post="syndrome virus infection and the need for therapeutics for"/>
   <result pre="(2014).24550727 54KaulA., WoerzI., MeulemanP., Leroux-RoelsG., BartenschlagerR., Cell culture adaptation of" exact="hepatitis" post="C virus and in vivo viability of an adapted"/>
   <result pre="(2007).17881454 55BrennanB.et al., Reverse genetics system for severe fever with" exact="thrombocytopenia" post="syndrome virus. J. Virol.89, 3026–3037 (2015).25552716 56YuM.-A.et al., Evaluation"/>
   <result pre="of two different enzyme-linked immunosorbent assay for severe fever with" exact="thrombocytopenia" post="syndrome virus diagnosis. Clin. Exp. Vaccine Res.7, 82–86 (2018).29399584"/>
   <result pre="57YuK.-M.et al., Seroprevalence and genetic characterization of severe fever with" exact="thrombocytopenia" post="syndrome virus in domestic goats in South Korea. Ticks"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6936719\results\search\disease\results.xml">
   <result pre="Population BiologyPNAS Plus Virus–virus interactions impact the population dynamics of" exact="influenza" post="and the common cold NickbakhshSemaaMairColetteabhttp://orcid.org/0000-0003-4420-8367MatthewsLouisec1http://orcid.org/0000-0003-2589-8091ReeveRichardcJohnsonPaul C. D.cThorburnFionadvon WissmannBeatrixeReynoldsArlenefMcMenaminJamesfGunsonRory N.ghttp://orcid.org/0000-0002-4352-394XMurciaPablo"/>
   <result pre="Virus–virus interactions impact the population dynamics of influenza and the" exact="common cold" post="NickbakhshSemaaMairColetteabhttp://orcid.org/0000-0003-4420-8367MatthewsLouisec1http://orcid.org/0000-0003-2589-8091ReeveRichardcJohnsonPaul C. D.cThorburnFionadvon WissmannBeatrixeReynoldsArlenefMcMenaminJamesfGunsonRory N.ghttp://orcid.org/0000-0002-4352-394XMurciaPablo R.a1[], aUniversity of GlasgowUnited"/>
   <result pre="simulations, we found that very short-lived interferences may explain why" exact="common cold" post="infections are less frequent during flu seasons. Improved understanding"/>
   <result pre="obtain strong support for the existence of negative interactions between" exact="influenza" post="and noninfluenza viruses and positive interactions among noninfluenza viruses."/>
   <result pre="role of innate immunity in driving the asynchronous circulation of" exact="influenza" post="A and rhinovirus. These findings have important implications for"/>
   <result pre="of respiratory infections, a well-known example is the coseasonality of" exact="influenza" post="and pneumococcus, driven by an enhanced susceptibility to secondary"/>
   <result pre="by an enhanced susceptibility to secondary bacterial colonization subsequent to" exact="influenza" post="infection (3, 4). Indeed, respiratory bacteria–bacteria and bacteria–virus interactions,"/>
   <result pre="of infection in respiratory virus outbreaks (9–11). More recently, the" exact="influenza" post="A virus (IAV) pandemic of 2009 further galvanized interest"/>
   <result pre="(18, 19). For example, antibody-driven cross-immunity is believed to restrict" exact="influenza" post="virus strain diversity, leading to sequential strain replacement over"/>
   <result pre="respiratory virus peaked during winter, with the exception of the" exact="influenza" post="A H1N1 pandemic in the summer of 2009 (Fig."/>
   <result pre="the summer of 2009 (Fig. 1A). Nevertheless, even during the" exact="influenza" post="pandemic, the overall viral infection prevalence among patients remained"/>
   <result pre="across viruses. During the first wave of the United Kingdom’s" exact="influenza" post="A pandemic [A(H1N1)pdm09] in 2009, infections with influenza A"/>
   <result pre="United Kingdom’s influenza A pandemic [A(H1N1)pdm09] in 2009, infections with" exact="influenza" post="A virus were relatively more prevalent among the patient"/>
   <result pre="(highlighted by black box). RV = rhinoviruses (A–C); IAV =" exact="influenza" post="A virus (H1N1 and H3N2); IBV = influenza B"/>
   <result pre="IAV = influenza A virus (H1N1 and H3N2); IBV =" exact="influenza" post="B virus; RSV = respiratory syncytial virus; CoV ="/>
   <result pre="absolute infection counts. Fig. 3. Negative and positive interactions among" exact="influenza" post="and noninfluenza viruses at population scale. Significant unadjusted correlations"/>
   <result pre="interactions, with negative interactions between IAV and RV and between" exact="influenza" post="B virus (IBV) and adenovirus (AdV) (Fig. 3, blue"/>
   <result pre="negative interactions (OR &amp;lt; 1) among 3 virus pairs involving" exact="influenza" post="and 13 positive interactions (OR &amp;gt; 1) among 8"/>
   <result pre="human rubulaviruses (2 and 4). Fig. 4. Host-scale interactions among" exact="influenza" post="and noninfluenza viruses. (A) Statistically supported negative (OR &amp;lt;"/>
   <result pre="the prevalence of RV among the patient population during peak" exact="influenza" post="activity (Fig. 2A). To address this question, we performed"/>
   <result pre="the presence (blue) and absence (green) of interference with the" exact="influenza" post="like virus. This example assumes a strong interaction (φ"/>
   <result pre="model supports the hypothesis that temporary nonspecific protection elicited by" exact="influenza" post="explains the periodic decline in rhinovirus frequency during peak"/>
   <result pre="influenza explains the periodic decline in rhinovirus frequency during peak" exact="influenza" post="activity (Fig. 2A). Discussion In this study, we demonstrated"/>
   <result pre="patterns of individual patients, our analyses support an interference between" exact="influenza" post="and noninfluenza viruses operating at the host scale. This"/>
   <result pre="support of immune-driven interference between H1N1 and H3N2 subtypes of" exact="influenza" post="A (46, 47). Our data did not permit reliable"/>
   <result pre="level of virus differentiation because low and inconsistent numbers of" exact="influenza" post="cases were routinely subtyped. Age patterns of infection may"/>
   <result pre="and MPV, are known to enhance the incidence of pneumococcal" exact="pneumonia" post="(6, 52). It is possible that we are observing"/>
   <result pre="individual host scales. Our findings imply that the incidence of" exact="influenza" post="infections is interlinked with the incidence of noninfluenza viral"/>
   <result pre="and time period of sample collection with respect to the" exact="influenza" post="A(H1N1)pdm09 virus pandemic (PANDEMIC). In addition, we ensured that"/>
   <result pre="Biol. Sci.368, 20120150 (2013).23798698 3ShresthaS.et al., Identifying the interaction between" exact="influenza" post="and pneumococcal pneumonia using incidence data. Sci. Transl. Med.5,"/>
   <result pre="(2013).23798698 3ShresthaS.et al., Identifying the interaction between influenza and pneumococcal" exact="pneumonia" post="using incidence data. Sci. Transl. Med.5, 191ra84 (2013). 4ShresthaS.,"/>
   <result pre="Pathog.14, e1006770 (2018).29447284 8McCullersJ. A., RehgJ. E., Lethal synergism between" exact="influenza" post="virus and Streptococcus pneumoniae: Characterization of a mouse model"/>
   <result pre="(2002).12134230 9AnestadG., Interference between outbreaks of respiratory syncytial virus and" exact="influenza" post="virus infection. Lancet1, 502 (1982). 10BangF. B., Epidemiological interference."/>
   <result pre="13CasalegnoJ. S.et al., Rhinoviruses delayed the circulation of the pandemic" exact="influenza" post="A (H1N1) 2009 virus in France. Clin. Microbiol. Infect.16,"/>
   <result pre="Infect.16, 326–329 (2010).20121829 14CasalegnoJ. S.et al., Impact of the 2009" exact="influenza" post="A(H1N1) pandemic wave on the pattern of hibernal respiratory"/>
   <result pre="C., WongA. H., HoW. Y., LimW., The impact of pandemic" exact="influenza" post="A (H1N1) 2009 on the circulation of respiratory viruses"/>
   <result pre="BarrèsB., ValeP. F., LaineA. L., Co-infection alters population dynamics of" exact="infectious disease." post="Nat. Commun.6, 5975 (2015).25569306 19FergusonN., AndersonR., GuptaS., The effect"/>
   <result pre="M., GalvaniA. P., BushR. M., Ecological and immunological determinants of" exact="influenza" post="evolution. Nature422, 428–433 (2003).12660783 21BhattacharyyaS., GestelandP. H., KorgenskiK., BjørnstadO."/>
   <result pre="growth profiles of respiratory syncytial virus in the presence of" exact="influenza" post="virus. Acta Virol.44, 91–97 (2000).10989700 23ChanK. F.et al., Investigating"/>
   <result pre="Virol.44, 91–97 (2000).10989700 23ChanK. F.et al., Investigating viral interference between" exact="influenza" post="A virus and human respiratory syncytial virus in a"/>
   <result pre="24GonzalezA. J., IjezieE. C., BalembaO. B., MiuraT. A., Attenuation of" exact="influenza" post="A virus disease severity by viral coinfection in a"/>
   <result pre="Br. Med. Bull.15, 185–188 (1959).13853040 26GotoH.et al., Enhanced growth of" exact="influenza" post="A virus by coinfection with human parainfluenza virus type"/>
   <result pre="Microbiol. Immunol. (Berl.)205, 209–218 (2016).26582554 27ViboudC.et al., Risk factors of" exact="influenza" post="transmission in households. Br. J. Gen. Pract.54, 684–689 (2004).15353055"/>
   <result pre="FlahaultA., FergusonN. M., Estimating the impact of school closure on" exact="influenza" post="transmission from Sentinel data. Nature452, 750–754 (2008).18401408 29ShamanJ., KohnM.,"/>
   <result pre="Sentinel data. Nature452, 750–754 (2008).18401408 29ShamanJ., KohnM., Absolute humidity modulates" exact="influenza" post="survival, transmission, and seasonality. Proc. Natl. Acad. Sci. U.S.A.106,"/>
   <result pre="W., Dybdahl-SissokoN., EvansD., Apoptosis: A mechanism of cell killing by" exact="influenza" post="A and B viruses. J. Virol.68, 3667–3673 (1994).8189504 37TelferS.et"/>
   <result pre="(1975).778995 42NobusawaE., SatoK., Comparison of the mutation rates of human" exact="influenza" post="A and B viruses. J. Virol.80, 3675–3678 (2006).16537638 43PeltolaV.,"/>
   <result pre="Infect. Dis.36, 299–305 (2003).12539071 44YapJ.et al., Differing clinical characteristics between" exact="influenza" post="strains among young healthy adults in the tropics. BMC"/>
   <result pre="BMC Infect. Dis.12, 12 (2012).22264216 45IhaY.et al., Comparative epidemiology of" exact="influenza" post="A and B viral infection in a subtropical region:"/>
   <result pre="Infect. Dis.16, 650 (2016).27821090 46HeD.et al., Global spatio-temporal patterns of" exact="influenza" post="in the post-pandemic era. Sci. Rep.5, 11013 (2015).26046930 47FinkelmanB."/>
   <result pre="(2015).26046930 47FinkelmanB. S.et al., Global patterns in seasonal activity of" exact="influenza" post="A/H3N2, A/H1N1, and B from 1997 to 2005: Viral"/>
   <result pre="A., Cross-reactive human B cell and T cell epitopes between" exact="influenza" post="A and B viruses. Virol. J.10, 244 (2013).23886073 49O’DonnellC."/>
   <result pre="244 (2013).23886073 49O’DonnellC. D.et al., Effect of priming with H1N1" exact="influenza" post="viruses of variable antigenic distances on challenge with 2009"/>
   <result pre="51ZambonM. C., StocktonJ. D., ClewleyJ. P., FlemingD. M., Contribution of" exact="influenza" post="and respiratory syncytial virus to community cases of influenza-like"/>
   <result pre="G.et al., Local and systemic cytokine responses during experimental human" exact="influenza" post="A virus infection. Relation to symptom formation and host"/>
   <result pre="(1998).9449698 65RichmanD. D., MurphyB. R., BaronS., UhlendorfC., Three strains of" exact="influenza" post="A virus (H3N2): Interferon sensitivity in vitro and interferon"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6936826\results\search\disease\results.xml">
   <result pre="States by meta-analysis to calculate national rates of HIV and" exact="hepatitis" post="C virus infections. PLoS One. 2014;9(5): e9759610.1371/journal.pone.009759624840662 5Des JarlaisDC,"/>
   <result pre="2008726;372(9635): 314–320. 10.1016/S0140-6736(08)61115-018657710 32PassaroDJ, WernerSB, McGeeJ, Mac KenzieWR, VugiaDJ. Wound" exact="botulism" post="associated with black tar heroin among injecting drug users."/>
   <result pre="243210.1038/s41598-018-20864-629402964 47DombrowskiK, CurtisR, FriedmanS, KhanB. Topological and historical considerations for" exact="infectious disease" post="transmission among injecting drug users in Bushwick, Brooklyn (USA)."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6937093\results\search\disease\results.xml">
   <result pre="the impact of a routine molecular point-of-care ‘test-and-treat’ strategy for" exact="influenza" post="in adults hospitalised with acute respiratory illness (FluPOC): trial"/>
   <result pre="routine testing. When tested for, the diagnosis and treatment of" exact="influenza" post="are often delayed due to the slow turnaround times"/>
   <result pre="(POCTs). High-quality evidence for the impact of routine POCT for" exact="influenza" post="on clinical outcomes is, however, currently lacking. This large"/>
   <result pre="a district general hospital with an acute respiratory illness, during" exact="influenza" post="season and defined by Public Health England. Up to"/>
   <result pre="to 840 patients will be recruited over up to three" exact="influenza" post="seasons, and randomised (1:1) to receive either POCT using"/>
   <result pre="be informed of the results in real time and where" exact="influenza" post="is detected clinical teams will be encouraged to offer"/>
   <result pre="presented at national and international conferences. Trial registration number ISRCTN17197293" exact="influenza" post="adult hospitalised point-of-care test neuraminidase inhibitors Funding NIHR Post-doctoral"/>
   <result pre="highly relevant clinical question currently given the variable use of" exact="influenza" post="testing and neuraminidase inhibitors in clinical practice, the ongoing"/>
   <result pre="neuraminidase inhibitors in clinical practice, the ongoing threat of further" exact="influenza" post="pandemics, the recent development of novel influenza antivirals and"/>
   <result pre="threat of further influenza pandemics, the recent development of novel" exact="influenza" post="antivirals and the undefined role of influenza point-of-care testing"/>
   <result pre="development of novel influenza antivirals and the undefined role of" exact="influenza" post="point-of-care testing in acute respiratory illness during seasonal influenza."/>
   <result pre="detected pathogens in adults hospitalised with acute respiratory illness.2 Seasonal" exact="influenza" post="epidemics lead to excess hospitalisations and death due to"/>
   <result pre="lead to excess hospitalisations and death due to complications including" exact="pneumonia" post="and exacerbation of underlying cardiopulmonary conditions, and occur mainly"/>
   <result pre="comorbidity.3–5 Influenza: widespread but underdiagnosed Estimates of the burden of" exact="influenza" post="virus infection in hospitalised adults have traditionally been based"/>
   <result pre="than on laboratory-confirmed influenza.6–9 Patients may also present as decompensated" exact="cardiovascular disease," post="collapse or diabetic emergencies.10 11 A recent Canadian study"/>
   <result pre="around 1 in 14 emergency department (ED) visits due to" exact="influenza" post="virus infection was correctly attributed to influenza.12 Sampling for"/>
   <result pre="studies suggest that in lower respiratory tract syndromes (such as" exact="pneumonia" post="and exacerbation of chronic obstructive pulmonary disease (COPD)) testing"/>
   <result pre="lower respiratory tract syndromes (such as pneumonia and exacerbation of" exact="chronic obstructive pulmonary disease" post="(COPD)) testing of upper respiratory tract samples for viruses"/>
   <result pre="For these reasons, it is likely that the burden of" exact="influenza" post="and other respiratory viruses among hospitalised adults and its"/>
   <result pre="WHO guidelines for all hospitalised adults with suspected and proven" exact="influenza" post="infection.15 Although there have been no randomised controlled trial"/>
   <result pre="this group, well-controlled observational data suggest that the treatment of" exact="influenza" post="with NAIs reduces mortality in hospitalised adults, especially when"/>
   <result pre="rapidly.16 17 Therefore, it is important that hospitalised patients with" exact="influenza" post="are all identified and treated as soon as possible"/>
   <result pre="soon as possible after presentation. Previous point-of-care tests (POCTs) for" exact="influenza" post="Rapid diagnostic tests for influenza, based on antigen detection"/>
   <result pre="viral pathogens detected by the FilmArray respiratory panel 2 include:" exact="influenza" post="A (H1 and H3), influenza B, adenovirus, coronaviruses (HKU1,"/>
   <result pre="FilmArray respiratory panel 2 include: influenza A (H1 and H3)," exact="influenza" post="B, adenovirus, coronaviruses (HKU1, NL63, 229E, OC43) human metapneumovirus,"/>
   <result pre="rapid molecular viral testing might reduce antibiotic use and improve" exact="influenza" post="antiviral use.31 32 We have recently shown in a"/>
   <result pre="a reduced length of hospital stay. It also suggested improved" exact="influenza" post="detection and antiviral use and better side room utilisation,"/>
   <result pre="side room utilisation, although the number of patients infected with" exact="influenza" post="was small and the study was not powered to"/>
   <result pre="to definitively evaluate the impact of routine molecular POCT for" exact="influenza" post="on the detection of patients infected with influenza, their"/>
   <result pre="influenza, their clinical care and outcome. Accepting the unpredictability of" exact="influenza" post="activity year on year, this study is designed to"/>
   <result pre="control group allows a direct assessment of missed diagnosis of" exact="influenza" post="in hospitalised adults. Alignment with global research priorities In"/>
   <result pre="will be generated by this trial regarding the impact of" exact="influenza" post="POCT on antibiotic prescribing is highly aligned with this"/>
   <result pre="impact of a routine molecular point-of-care (POC) ‘test-and-treat’ strategy for" exact="influenza" post="in adults hospitalised with acute respiratory illness during influenza"/>
   <result pre="for influenza in adults hospitalised with acute respiratory illness during" exact="influenza" post="season. Objectives To evaluate the impact of routine molecular"/>
   <result pre="impact of routine molecular POCT on the clinical management of" exact="influenza" post="including: the detection rate of influenza, the adherence to"/>
   <result pre="the detection rate of influenza, the adherence to national (PHE)" exact="influenza" post="guidelines, the speed and appropriateness of NAI use and"/>
   <result pre="POCT on measures of clinical effectiveness in adults hospitalised with" exact="influenza" post="including: time to clinical stability, time on supplementary oxygen,"/>
   <result pre="statement.37 The study will take place across up to three" exact="influenza" post="seasons (as defined by national PHE surveillance programmes). Participants,"/>
   <result pre="exacerbation of a chronic respiratory illness (including exacerbation of COPD," exact="asthma" post="or bronchiectasis). For the study, acute respiratory illness as"/>
   <result pre="the result within 4 hours of testing. In the event of" exact="influenza" post="A or B being detected, clinical teams will be"/>
   <result pre="5 days of admission). Secondary outcomes Proportion of cases of" exact="influenza" post="identified. Proportion of all NAI use occurring in influenza-positive"/>
   <result pre="side room. Median duration of isolation facility use. Proportion of" exact="influenza" post="cases correctly isolated. Median time from admission to isolation"/>
   <result pre="mm Hg for at least 24 hours.38 Exploratory outcomes Difference in" exact="influenza" post="detection between upper and lower respiratory tract samples. Difference"/>
   <result pre="detection between upper and lower respiratory tract samples. Difference in" exact="influenza" post="viral load between upper and lower respiratory tract samples."/>
   <result pre="load between upper and lower respiratory tract samples. Proportion with" exact="influenza" post="RNA detected in blood. Changes in influenza viral load"/>
   <result pre="samples. Proportion with influenza RNA detected in blood. Changes in" exact="influenza" post="viral load over time (kinetics) in respiratory tract samples"/>
   <result pre="to 840 patient–participants: about 280 per season for three consecutive" exact="influenza" post="seasons. With 1:1 allocation to groups, there will be"/>
   <result pre="On the conservative assumption of a 25% positivity rate for" exact="influenza" post="during influenza season (ie, ~100 influenza-positive patients in each"/>
   <result pre="conservative assumption of a 25% positivity rate for influenza during" exact="influenza" post="season (ie, ~100 influenza-positive patients in each group), the"/>
   <result pre="run for up to 3 years to include three seasonal" exact="influenza" post="seasons between December 2017 and May 2020. Consent The"/>
   <result pre="of proportions for binary data (eg, proportion of cases of" exact="influenza" post="detected) and using independent-sample t-tests or non-parametric equivalent as"/>
   <result pre="Primary outcome The primary outcome (proportion of patients infected with" exact="influenza" post="treated with NAIs) will be measured only in patients"/>
   <result pre="logistic regression to control for the following covariates: age, sex," exact="influenza" post="vaccine status, receipt of antibiotics prior to admission, duration"/>
   <result pre="the use of a routine molecular POC ‘test-and-treat’ strategy for" exact="influenza" post="in adults hospitalised with acute respiratory illness will improve"/>
   <result pre="will improve adherence to national guidelines for the management of" exact="influenza" post="and may improve patient outcomes. We expect increased, timely"/>
   <result pre="may improve patient outcomes. We expect increased, timely detection of" exact="influenza" post="and that this will lead to improved use of"/>
   <result pre="NAI treatment. Rapid and appropriate use of NAI treatment in" exact="influenza" post="may also lead to decreased complication and mortality and"/>
   <result pre="J Infect2014;69:507–15. 10.1016/j.jinf.2014.07.02325108123 3ThompsonWW, ShayDK, WeintraubE, et al.Mortality associated with" exact="influenza" post="and respiratory syncytial virus in the United States. JAMA2003;289:179–86."/>
   <result pre="Serv Res2001;1:810.1186/1472-6963-1-811580874 6van den DoolC, HakE, WallingaJ, et al.Symptoms of" exact="influenza" post="virus infection in hospitalized patients. Infect Control Hosp Epidemiol2008;29:314–9."/>
   <result pre="7BabcockHM, MerzLR, DubberkeER, et al.Case-control study of clinical features of" exact="influenza" post="in hospitalized patients. Infect Control Hosp Epidemiol2008;29:921–6. 10.1086/59066318754739 8BabcockHM,"/>
   <result pre="hospitalized patients. Infect Control Hosp Epidemiol2008;29:921–6. 10.1086/59066318754739 8BabcockHM, MerzLR, FraserVJIs" exact="influenza" post="an influenza-like illness? Clinical presentation of influenza in hospitalized"/>
   <result pre="8BabcockHM, MerzLR, FraserVJIs influenza an influenza-like illness? Clinical presentation of" exact="influenza" post="in hospitalized patients. Infect Control Hosp Epidemiol2006;27:266–70. 10.1086/50153916532414 9CallSA,"/>
   <result pre="J Med2005;352:1749–59. 10.1056/NEJMoa04395115858184 11Warren-GashC, SmeethL, HaywardACInfluenza as a trigger for" exact="acute myocardial infarction" post="or death from cardiovascular disease: a systematic review. Lancet"/>
   <result pre="Lancet Infect Dis2009;9:601–10. 10.1016/S1473-3099(09)70233-619778762 12SchanzerDL, SchwartzBImpact of seasonal and pandemic" exact="influenza" post="on emergency department visits, 2003-2010, Ontario, Canada. Acad Emerg"/>
   <result pre="Emerg Med2013;20:388–97. 10.1111/acem.1211123701347 13López RoaP, Rodríguez-SánchezB, CatalánP, et al.Diagnosis of" exact="influenza" post="in intensive care units: lower respiratory tract samples are"/>
   <result pre="of antiviral agents for the treatment and prophylaxis of seasonal" exact="influenza" post="(version 6.0, 2015. 16MuthuriSG, VenkatesanS, MylesPR, et al.Effectiveness of"/>
   <result pre="inhibitors in reducing mortality in patients admitted to hospital with" exact="influenza" post="A H1N1pdm09 virus infection: a meta-analysis of individual participant"/>
   <result pre="18collab: Centers for Disease Control and Prevention (CDC)Evaluation of rapid" exact="influenza" post="diagnostic tests for detection of novel influenza A (H1N1)"/>
   <result pre="(CDC)Evaluation of rapid influenza diagnostic tests for detection of novel" exact="influenza" post="A (H1N1) Virus - United States, 2009. MMWR Morb"/>
   <result pre="Mortal Wkly Rep2009;58:826–9.19661856 19ChartrandC, LeeflangMMG, MinionJ, et al.Accuracy of rapid" exact="influenza" post="diagnostic tests: a meta-analysis. Ann Intern Med2012;156:500–11. 10.7326/0003-4819-156-7-201204030-0040322371850 20NicholsonKG,"/>
   <result pre="Infect Dis2015;212:1692–700. 10.1093/infdis/jiv25225910632 32DugasAF, ValsamakisA, AtreyaMR, et al.Clinical diagnosis of" exact="influenza" post="in the ED. Am J Emerg Med2015;33:770–5. 10.1016/j.ajem.2015.03.00825827595 33BrendishNJ,"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6940900\results\search\disease\results.xml">
   <result pre="(CC BY) license (http://creativecommons.org/licenses/by/4.0/). Abstract The currently available drugs against" exact="influenza" post="A virus primarily target neuraminidase (NA) or the matrix"/>
   <result pre="termed NC-5, was found to possess antiviral activity. NC-5 inhibited" exact="influenza" post="A viruses A/FM/1/47 (H1N1), A/Beijing/32/92 (H3N2) and oseltamivir-resistant mutant"/>
   <result pre="regarded as a promising drug candidate to treat infection with" exact="influenza" post="viruses, including oseltamivir-resistant viruses. benzoic acid derivatives antiviral activity"/>
   <result pre="acid derivatives antiviral activity neuraminidase inhibition oseltamivir-resistant 1. Introduction The" exact="influenza" post="A virus belongs to the Orthomyxoviridae family and is"/>
   <result pre="severe epidemics of respiratory illness [1]. The genome of the" exact="influenza" post="virus contains eight segmented and negative-stranded RNAs, encoding for"/>
   <result pre="cells [6,7]. However, due to the frequent emergence of drug-resistant" exact="influenza" post="viruses, the usage of these drugs has been greatly"/>
   <result pre="molecule, was reported to show sub-micromolar antiviral potency against the" exact="influenza" post="A virus [11,12]. Some compounds have been successfully designed"/>
   <result pre="designed a series of benzoic acid derivatives to obtain potential" exact="influenza" post="virus inhibitors with improved antiviral activity. In our research,"/>
   <result pre="possess a triazole substituent had been reported to inhibit the" exact="influenza" post="virus via insertion into the 150-cavity near the active"/>
   <result pre="compounds that displayed a reduction in the CPE on the" exact="influenza" post="H1N1 virus at 10 μM and 100 μM (Table"/>
   <result pre="as the CHO-K1 expression of NA proteins of highly pathogenic" exact="avian influenza" post="viruses H5N1 (Figure 2D) and H7N9 (Figure 2C) were"/>
   <result pre="the CHO-K1 expression of NA proteins of highly pathogenic avian" exact="influenza" post="viruses H5N1 (Figure 2D) and H7N9 (Figure 2C) were"/>
   <result pre="of the CPE reduction assay (Table 1), we tested other" exact="influenza" post="virus strains including an oseltamivir-resistant strain to confirm the"/>
   <result pre="h post-infection in a dose-dependent manner, indicating that NC-5 inhibits" exact="influenza" post="virus infection by interfering with viral replication. This result"/>
   <result pre="indicate that NC-5 effectively inhibits both wild-type and oseltamivir-resistant mutant" exact="influenza" post="viruses in vitro and could reduce the level of"/>
   <result pre="was designed to evaluate the efficacy of NC-5 against the" exact="influenza" post="virus in vivo. Body weight, survival and clinical manifestations"/>
   <result pre="demonstrates potent therapeutic efficacy in vivo against wild-type and oseltamivir-resistant" exact="influenza" post="viruses. 2.5. NC-5 Suppressed Influenza Virus A/FM/1/47 (H1N1) in"/>
   <result pre="tried to explore the potential mechanisms by which NC-5 inhibits" exact="influenza" post="infection. The complete life cycle of the influenza virus"/>
   <result pre="NC-5 inhibits influenza infection. The complete life cycle of the" exact="influenza" post="virus is approximately 8–10 h and it is divided"/>
   <result pre="displays anti-influenza virus activity in vitro and in vivo. The" exact="influenza" post="virus produces clear and rapid CPE following cell death"/>
   <result pre="(EC50) values of 33.6 μM and 32.8 μΜ. However, for" exact="influenza" post="virus H3N2, the EC50 value was greater than 160"/>
   <result pre="All the data demonstrate that NC-5 possesses potent activity against" exact="influenza" post="viruses, including oseltamivir-resistant viruses. Nucleoprotein (NP) and matrix protein"/>
   <result pre="mechanism of antiviral activity, we found that the activity against" exact="influenza" post="virus took effect in the biosynthesis stage with the"/>
   <result pre="respectively. It has been reported that the resistance mutations of" exact="influenza" post="virus H1N1 mostly occur at His275 and Arg292 sites"/>
   <result pre="in DMEM/F12 medium supplemented with 10% FBS. Virus production: The" exact="influenza" post="A virus used in this study, containing A/FM/1/47 (H1N1),"/>
   <result pre="Lipofectamine® 2000 Reagent (Invitrogen™, Carlsbad, CA, USA). Expression plasmids for" exact="influenza" post="A virus A/WSN/33 (H1N1) proteins (PB1, PB2, PA and"/>
   <result pre="virus A/WSN/33 (H1N1) proteins (PB1, PB2, PA and NP), an" exact="influenza" post="virus-like RNA encoding firefly luciferase (vNS-Luc), and pCMV β-gal"/>
   <result pre="stock solution. 4.3. Determination of Influenza a Virus TCID50 The" exact="influenza" post="A virus was serially diluted and added to specific"/>
   <result pre="of a suspension of 8 × LD50 of the mouse-adapted" exact="influenza" post="A/FM1/1/47 (H1N1), A/FM/1/47-H275Y virus diluted in phosphate-buffered saline (PBS)."/>
   <result pre="were infected with 1.5 × 103 TCID50 of the H1N1" exact="influenza" post="virus and treated with NC-5 (10 μM, 40 μM,"/>
   <result pre="24-well plate and then transfected with plasmids to express the" exact="influenza" post="A virus A/WSN/33 (H1N1) PB1, PB2, PA, NP and"/>
   <result pre="and infected with 1.5 × 103 TCID50 of the H1N1" exact="influenza" post="virus for 2 h followed by the addition of"/>
   <result pre="and infected with 1.5 × 103 TCID50 of the H1N1" exact="influenza" post="virus for 2 h then treated with NC-5 (10"/>
   <result pre="diethyl triazole benzoic acid derivative, NC-5. This compound can inhibit" exact="influenza" post="A viruses A/FM/1/47 (H1N1), A/Beijing/32/92 (H3N2) and oseltamivir-resistant mutant"/>
   <result pre="Therefore, it can be regarded as a promising candidate for" exact="influenza" post="virus infection therapy. Its modification to improve the efficacy,"/>
   <result pre="Abbreviations NC-5 4-[2,2-bis(hydroxymethyl)-5-oxopyrrolidin-l-yl]-3-(5-cyclohexyl-4H-1, 2,4-triazol-3-yl) amino) benzoic acid NA neuraminidase H1N1" exact="influenza" post="A virus A/FM/1/47 (H1N1) H1N1-H275Y influenza A virus A/FM/1/47-H275Y"/>
   <result pre="acid NA neuraminidase H1N1 influenza A virus A/FM/1/47 (H1N1) H1N1-H275Y" exact="influenza" post="A virus A/FM/1/47-H275Y (H1N1-H275Y) H3N2 influenza A virus A/Beijing/32/92"/>
   <result pre="virus A/FM/1/47 (H1N1) H1N1-H275Y influenza A virus A/FM/1/47-H275Y (H1N1-H275Y) H3N2" exact="influenza" post="A virus A/Beijing/32/92 (H3N2) H5N1 influenza A virus A/Vietnam/1203/2004"/>
   <result pre="virus A/FM/1/47-H275Y (H1N1-H275Y) H3N2 influenza A virus A/Beijing/32/92 (H3N2) H5N1" exact="influenza" post="A virus A/Vietnam/1203/2004 (H5N1) H7N9 influenza A virus A/Anhui/1/2013"/>
   <result pre="virus A/Beijing/32/92 (H3N2) H5N1 influenza A virus A/Vietnam/1203/2004 (H5N1) H7N9" exact="influenza" post="A virus A/Anhui/1/2013 (H7N9) H7N9-R294K influenza A virus A/Anhui/1/2013-R294K"/>
   <result pre="virus A/Vietnam/1203/2004 (H5N1) H7N9 influenza A virus A/Anhui/1/2013 (H7N9) H7N9-R294K" exact="influenza" post="A virus A/Anhui/1/2013-R294K (H7N9-R294K MDCK Madin–Darby canine kidney cells"/>
   <result pre="Pentacyclic Triterpenoids as Potential Entry Inhibitors of InfluenzaViruses201457100581007110.1021/jm501406725383779 2.SuzukiY.Sialobiology of" exact="influenza" post="molecular mechanism of host range variation of influenza virusesBiol."/>
   <result pre="2.SuzukiY.Sialobiology of influenza molecular mechanism of host range variation of" exact="influenza" post="virusesBiol. Pharm. Bull.20052839940810.1248/bpb.28.39915744059 3.LeeS.M.Y.YenH.L.Targeting the host or the virus:"/>
   <result pre="the virus: Current and novel concepts for antiviral approaches against" exact="influenza" post="virus infectionAntivir. Res.20129639140410.1016/j.antiviral.2012.09.01323022351 4.RudrawarS.DyasonJ.C.Rameix-WeltiM.A.RoseF.J.KerryP.S.RussellR.J.van der WerfS.ThomsonR.J.NaffakhN.von ItzsteinM.Novel sialic acid"/>
   <result pre="ItzsteinM.Novel sialic acid derivatives lock open the 150-loop of an" exact="influenza" post="A virus group-1 sialidaseNat. Commun.2010111310.1038/ncomms111421081911 5.RussellR.J.HaireL.F.StevensD.J.CollinsP.J.LinY.P.BlackburnG.M.HayA.J.GamblinS.J.SkehelJ.J.J.N.The structure of H5N1"/>
   <result pre="influenza A virus group-1 sialidaseNat. Commun.2010111310.1038/ncomms111421081911 5.RussellR.J.HaireL.F.StevensD.J.CollinsP.J.LinY.P.BlackburnG.M.HayA.J.GamblinS.J.SkehelJ.J.J.N.The structure of H5N1" exact="avian influenza" post="neuraminidase suggests new opportunities for drug designNature2006443454910.1038/nature0511416915235 6.VonitzsteinM.WuW.Y.KokG.B.PeggM.S.DyasonJ.C.JinB.PhanT.V.SmytheM.L.WhiteH.F.OliverS.W.et al.Rational"/>
   <result pre="A virus group-1 sialidaseNat. Commun.2010111310.1038/ncomms111421081911 5.RussellR.J.HaireL.F.StevensD.J.CollinsP.J.LinY.P.BlackburnG.M.HayA.J.GamblinS.J.SkehelJ.J.J.N.The structure of H5N1 avian" exact="influenza" post="neuraminidase suggests new opportunities for drug designNature2006443454910.1038/nature0511416915235 6.VonitzsteinM.WuW.Y.KokG.B.PeggM.S.DyasonJ.C.JinB.PhanT.V.SmytheM.L.WhiteH.F.OliverS.W.et al.Rational"/>
   <result pre="anti-influenza activityJ. Am. Chem Soc.199711968169010.1021/ja963036t16526129 8.BrightR.A.MedinaM.J.XuX.Y.Perez-OronozG.WallisT.R.DavisX.H.M.PovinelliL.CoxN.J.KlimovA.I.Incidence of adamantane resistance among" exact="influenza" post="A (H3N2) viruses isolated worldwide from 1994 to 2005:"/>
   <result pre="A cause for concernLancet20053661175118110.1016/S0140-6736(05)67338-216198766 9.DeydeV.M.XuX.Y.BrightR.A.ShawM.SmithC.B.ZhangY.ShuY.L.GubarevaL.V.CoxN.J.KlimovA.I.Surveillance of resistance to adamantanes among" exact="influenza" post="A(H3N2) and A(H1N1) viruses isolated worldwideJ. Infect. Dis.200719624925710.1086/51893617570112 10.MosconaA.Global"/>
   <result pre="Oseltamivir-Resistant InfluenzaNew Engl. J. Med.200936095395610.1056/NEJMp090064819258250 11.SunC.W.HuangH.FengM.Q.ShiX.L.ZhangX.D.ZhouP.A novel class of potent" exact="influenza" post="virus inhibitors: Polysubstituted acylthiourea and its fused heterocycle derivativesBioorg."/>
   <result pre="13.TarbetE.B.HamiltonS.VollmerA.H.LuttickA.NgW.C.PryorM.HurstB.L.CrawfordS.SmeeD.F.TuckerS.P.A zanamivir dimer with prophylactic and enhanced therapeutic activity against" exact="influenza" post="virusesJ. Antimicrob. Chemoth.2014692164217410.1093/jac/dku12724777908 14.LiuK.C.FangJ.M.JanJ.T.ChengT.J.R.WangS.Y.YangS.T.ChengY.S.E.WongC.H.Enhanced Anti-influenza Agents Conjugated with Anti-inflammatory"/>
   <result pre="Conjugated with Anti-inflammatory ActivityJ. Med. Chem.2012558493850110.1021/jm300984422963087 15.AtigaddaV.R.BrouilletteW.J.DuarteF.AliS.M.BabuY.S.BantiaS.ChandP.ChuN.MontgomeryJ.A.WalshD.A.et al.Potent inhibition of" exact="influenza" post="sialidase by a benzoic acid containing a 2-pyrrolidinone substituentJ."/>
   <result pre="and nuclear-cytoplasmic transport of virus-specific RNAsJ. Virol.1987617647733806797 17.AtkinsC.EvansC.W.WhiteE.L.NoahJ.W.Screening methods for" exact="influenza" post="antiviral drug discoveryExpert. Opin. Drug. Dis.2012742943810.1517/17460441.2012.674510 18.AmaroR.E.SwiftR.V.VotapkaL.LiW.W.WalkerR.C.BushR.M.Mechanism of 150-cavity"/>
   <result pre="drug discoveryExpert. Opin. Drug. Dis.2012742943810.1517/17460441.2012.674510 18.AmaroR.E.SwiftR.V.VotapkaL.LiW.W.WalkerR.C.BushR.M.Mechanism of 150-cavity formation in" exact="influenza" post="neuraminidaseNat. Commun.2011210.1038/ncomms1390 19.WangW.L.LiR.Q.DengY.LuN.ChenH.MengX.WangW.WangX.P.YanK.X.QiX.R.et al.Protective Efficacy of the Conserved NP,"/>
   <result pre="Vaccine. Immunol.20152261863010.1128/CVI.00091-1525834017 20.HurtA.C.The epidemiology and spread of drug resistant human" exact="influenza" post="virusesCurr. Opin. Virol.20148222910.1016/j.coviro.2014.04.00924866471 21.YuJ.WangD.C.JinJ.XuJ.LiM.W.WangH.DouJ.ZhouC.L.Antiviral activity of SA-2 against influenza"/>
   <result pre="human influenza virusesCurr. Opin. Virol.20148222910.1016/j.coviro.2014.04.00924866471 21.YuJ.WangD.C.JinJ.XuJ.LiM.W.WangH.DouJ.ZhouC.L.Antiviral activity of SA-2 against" exact="influenza" post="A virus in vitro/vivo and its inhibition of RNA"/>
   <result pre="of RNA polymeraseAntivir. Res.2016127687810.1016/j.antiviral.2016.01.01126802558 22.ZhangJ.J.LiuT.TongX.M.LiG.YanJ.H.YeX.Identification of novel virus inhibitors by" exact="influenza" post="A virus specific reporter cell based screeningAntivir. Res.201293485410.1016/j.antiviral.2011.10.01422057306 23.ZhouC.L.JinJ.ZhangH.X.DouJ.WangD.C.JiaY.B.Synthesis"/>
   <result pre="cells during mouse embryogenesisNat. Genet.20033317217610.1038/ng107212524542 25.DingY.DouJ.TengZ.J.YuJ.WangT.T.LuN.WangH.ZhouC.L.Antiviral activity of baicalin against" exact="influenza" post="A (H1N1/H3N2) virus in cell culture and in mice"/>
   <result pre="inhibition of neuraminidaseArch. Virol.20141593269327810.1007/s00705-014-2192-225078390 26.DongW.J.WeiX.L.ZhangF.Y.HaoJ.F.HuangF.ZhangC.L.LiangW.A dual character of flavonoids in" exact="influenza" post="A virus replication and spread through modulating cell-autonomous immunity"/>
   <result pre="benzoic acid. Figure 2 The inhibitory activity of NC-5 on" exact="influenza" post="A virus neuraminidase (NA). (A) NA-inhibitory effect on A/FM/1/47"/>
   <result pre="Figure 3 Inhibitory effect of NC-5 on wild-type and oseltamivir-resistant" exact="influenza" post="A virus in Madin–Darby canine kidney (MDCK) cells. (A)"/>
   <result pre="cells. (B) The inhibition rate of NC-5 (10–160 μM) on" exact="influenza" post="A virus A/FM/1/47 (H1N1) and A/Beijing/32/92 (H3N2). MDCK cells"/>
   <result pre="control. (C) The inhibition rate of NC-5 (20–80 μM) against" exact="influenza" post="A virus H1N1 in MDCK cells at different TCID50."/>
   <result pre="TCID50. (D) The inhibition rate of NC-5 (20–80 μM) against" exact="influenza" post="A virus H3N2 in MDCK cells at different TCID50."/>
   <result pre="mean ± S.D. of three independent experiments. Figure 4 NC-5" exact="suppression" post="of A/FM/1/47 (H1N1) influenza viral replication and its effect"/>
   <result pre="three independent experiments. Figure 4 NC-5 suppression of A/FM/1/47 (H1N1)" exact="influenza" post="viral replication and its effect on NP and M1"/>
   <result pre="with A/FM/1/47 (H1N1) virus. The ICR mice were infected with" exact="influenza" post="A virus (8 × LD50), and ten mice in"/>
   <result pre="Therapeutic effect of NC-5 on mice infected with the oseltamivir-resistant" exact="influenza" post="A virus A/FM/1/47-H275Y (H1N1-H275Y). The ICR mice were intranasally"/>
   <result pre="&amp;lt;0.001 compared with the placebo group. Figure 7 NC-5 suppressed" exact="influenza" post="A virus replication by inhibiting NP and M1 protein"/>
   <result pre="293T cells transfected with plasmids containing PB1, PB2, PA, NP," exact="influenza" post="virus-like RNA encoding firefly luciferase (vNS-Luc) and pCMV β-gal"/>
   <result pre="compared with the DMSO control. ijms-20-06261-t001_Table 1Table 1 Structures and" exact="influenza" post="A virus inhibition rates of newly synthesized compounds at"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6941257\results\search\disease\results.xml">
   <result pre="be the result of bacterial cell wall depolarization [36]. Mycobacterium" exact="tuberculosis" post="(MTB), the bacterium that causes tuberculosis, is another important"/>
   <result pre="an anti-biofilm agent. Aptamer has led to an early stage" exact="suppression" post="of biofilm formation. In the absence of aptamer, flagella-mediated"/>
   <result pre="bacterial pneumonias and is the major cause of meningitis, septicemia," exact="otitis media" post="and sinusitis. All wild-type strains are able to form"/>
   <result pre="Moreover, enterotoxin B (SEB) from S. aureus can cause staphylococcal" exact="toxic shock syndrome" post="(TSS), which is rarely observed with other enterotoxins types."/>
   <result pre="The virulence of B. anthracis depends on the production of" exact="anthrax" post="toxin. The anthrax toxins consist of three components. One"/>
   <result pre="B. anthracis depends on the production of anthrax toxin. The" exact="anthrax" post="toxins consist of three components. One of them is"/>
   <result pre="gp120 aptamer -LTR-362 siRNA conjugates induced TGS with a ~ 10-fold" exact="suppression" post="of viral p24 levels and also, reduced CD4+ T"/>
   <result pre="enterica serovar typhi (S. typhi) produces a feverish disease called" exact="typhoid fever." post="IVB pili is expressed by S. typhi, which is"/>
   <result pre="is the main character in the development of epidemics of" exact="typhoid fever." post="Monocytes and macrophages are critical effector molecules that play"/>
   <result pre="by inhibiting nucleocapsid assembly that reduces extracellular DNA. Apt.No.28 against" exact="hepatitis" post="B virus (HBV) exhibited this feature [82]. Aptamers can"/>
   <result pre="impede virus binding to host cells. As an example, the" exact="influenza" post="virus hemagglutinin binds to the sialic acid receptor of"/>
   <result pre="in initiating of viral infections. A DNA aptamer, A22, obstructed" exact="influenza" post="virus infection by blocking the virus attachment to host"/>
   <result pre="to host cells [83]. Also, T14 and F34 aptamers prevent" exact="rabies" post="virus from entering the host cells by blocking the"/>
   <result pre="host cell receptors [84]. Moreover, in the penetration process of" exact="herpes simplex" post="virus, the gD protein is a major determinant of"/>
   <result pre="simplex virus, the gD protein is a major determinant of" exact="herpes simplex" post="virus-1 (HSV) entry. Two aptamers were selected, which interfered"/>
   <result pre="the enzyme activity of HIV tat and reverse transcriptase [86]," exact="hepatitis" post="C virus (HCV) NS3 protease/helicase [87], NS5B RNA-dependent RNA"/>
   <result pre="the helicase [89] Rabies virus DNA Blocking the interaction between" exact="rabies" post="virus and permissive host cell receptors -Reduced viral replication"/>
   <result pre="microbial pathogen growthFuture Microbiol20138338740110.2217/fmb.12.14923464374 29.BayraçATDonmezSISelection of DNA aptamers to Streptococcus" exact="pneumonia" post="and fabrication of graphene oxide based fluorescent assayAnal Biochem2018556919810.1016/j.ab.2018.06.02429964028"/>
   <result pre="staphylococcal enterotoxin a by an aptamer antagonistToxicon.2016119212710.1016/j.toxicon.2016.05.00627179422 34.LahousseMParkH-CLeeS-CHaN-RJungI-PSchlesingerSRet al.Inhibition of" exact="anthrax" post="lethal factor by ssDNA aptamersArch Biochem Biophys2018646162310.1016/j.abb.2018.03.02829580944 35.HuangYChenXDuanNWuSWangZWeiXet al.Selection"/>
   <result pre="Chem20135641564157210.1021/jm301856j23387511 37.ChuangY-MBelchisDAKarakousisPCThe polyphosphate kinase gene ppk2 is required for Mycobacterium" exact="tuberculosis" post="inorganic polyphosphate regulation and virulenceMBio201343e00039e0001310.1128/mBio.00039-1323695835 38.ShumKTLuiELHWongSCKYeungPSamLWangYet al.Aptamer-mediated inhibition of"/>
   <result pre="inorganic polyphosphate regulation and virulenceMBio201343e00039e0001310.1128/mBio.00039-1323695835 38.ShumKTLuiELHWongSCKYeungPSamLWangYet al.Aptamer-mediated inhibition of mycobacterium" exact="tuberculosis" post="polyphosphate kinase 2Biochem201150153261327110.1021/bi200145521381755 39.HallCWMahT-FMolecular mechanisms of biofilm-based antibiotic resistance"/>
   <result pre="of biofilm formation in surgical infectionBr J Surg20171042e85e9410.1002/bjs.1043328121033 41.NingYChengLLingMFengXChenLWuMet al.Efficient" exact="suppression" post="of biofilm formation by a nucleic acid aptamerPathog Dis2015736ftv03410.1093/femspd/ftv03426025307"/>
   <result pre="69.RobertsonCAEvansDHAbrahamseHPhotodynamic therapy (PDT): a short review on cellular mechanisms and" exact="cancer" post="research applications for PDTJ Photochem Photobiol B Biol20099611810.1016/j.jphotobiol.2009.04.001 70.MallikaratchyPTangZTanWCell"/>
   <result pre="Biointerfaces2017159162210.1016/j.colsurfb.2017.07.05628778062 74.GagneuxSEcology and evolution of mycobacterium tuberculosisNat Rev Microbiol201816420210.1038/nrmicro.2018.829456241 75.RohdeKHAbramovitchRBRussellDGMycobacterium" exact="tuberculosis" post="invasion of macrophages: linking bacterial gene expression to environmental"/>
   <result pre="gene expression to environmental cuesCell Host Microbe20072535236410.1016/j.chom.2007.09.00618005756 76.ChenFZhangXZhouJLiuSLiuJAptamer inhibits mycobacterium" exact="tuberculosis" post="(H37Rv) invasion of macrophageMol Biol Rep20123932157216210.1007/s11033-011-0963-321643749 77.Khan TA, Mazhar"/>
   <result pre="Muhammad N, Abbas MN. Interferon-gamma improves macrophages function against M." exact="tuberculosis" post="in multidrug-resistant tuberculosis patients. Chemother Res Pract. 2016:7295390. 78.MaeurerMJTrinderPHommelGWalterWFreitagKAtkinsDet"/>
   <result pre="MN. Interferon-gamma improves macrophages function against M. tuberculosis in multidrug-resistant" exact="tuberculosis" post="patients. Chemother Res Pract. 2016:7295390. 78.MaeurerMJTrinderPHommelGWalterWFreitagKAtkinsDet al.Interleukin-7 or interleukin-15"/>
   <result pre="tuberculosis-infected miceInfect Immun20006852962297010.1128/IAI.68.5.2962-2970.200010768995 79.ChenXZhangMLiaoMGranerMWWuCYangQet al.Reduced Th17 response in patients with" exact="tuberculosis" post="correlates with IL-6R expression on CD4+ T cellsAm J"/>
   <result pre="HepG2. 2.15 cellsInt J Mol Med20143451423142910.3892/ijmm.2014.190825174447 83.JeonSHKayhanBBen-YedidiaTArnonRA DNA aptamer prevents" exact="influenza" post="infection by blocking the receptor binding region of the"/>
   <result pre="hemagglutininJ Biol Chem200427946484104841910.1074/jbc.M40905920015358767 84.LiangH-RHuG-QZhangTYangY-JZhaoL-LQiYLet al.Isolation of ssDNA aptamers that inhibit" exact="rabies" post="virusInt Immunopharmacol201214334134710.1016/j.intimp.2012.06.01922771543 85.GopinathSCHayashiKKumarPKAptamer that binds to the gD protein"/>
   <result pre="virusInt Immunopharmacol201214334134710.1016/j.intimp.2012.06.01922771543 85.GopinathSCHayashiKKumarPKAptamer that binds to the gD protein of" exact="herpes simplex" post="virus 1 and efficiently inhibits viral entryJ Virol201286126732674410.1128/JVI.00377-1222514343 86.YamamotoRKatahiraMNishikawaSBabaTTairaKKumarPKA"/>
   <result pre="87.FukudaKVishnuvardhanDSekiyaSHwangJKakiuchiNTairaKet al.Isolation and characterization of RNA aptamers specific for the" exact="hepatitis" post="C virus nonstructural protein 3 proteaseEur J Biochem2000267123685369410.1046/j.1432-1327.2000.01400.x10848986 88.KanamoriHYuhashiKUchiyamaYKodamaTOhnishiSIn"/>
   <result pre="of RNA aptamers that bind the RNA-dependent RNA polymerase of" exact="hepatitis" post="C virus: a possible role of GC-rich RNA motifs"/>
   <result pre="motifs in NS5B bindingVirol200938819110210.1016/j.virol.2009.02.032 89.JangKJLeeN-RYeoW-SJeongY-JKimD-EIsolation of inhibitory RNA aptamers against" exact="severe acute respiratory syndrome" post="(SARS) coronavirus NTPase/helicaseBiochem Biophys Res Commun2008366373874410.1016/j.bbrc.2007.12.02018082623 90.YangDMengXYuQXuLLongYLiuBet al.Inhibition of"/>
   <result pre="syndrome (SARS) coronavirus NTPase/helicaseBiochem Biophys Res Commun2008366373874410.1016/j.bbrc.2007.12.02018082623 90.YangDMengXYuQXuLLongYLiuBet al.Inhibition of" exact="hepatitis" post="C virus infection by DNA aptamer against envelope proteinAntimicrob"/>
   <result pre="vaccinia virus-infected cellsAnal Chem201082208642864910.1021/ac101801j20873781 94.GopinathSCSakamakiYKawasakiKKumarPKAn efficient RNA aptamer against human" exact="influenza" post="B virus hemagglutininJ Biochem2006139583784610.1093/jb/mvj09516751591 95.Auwardt SL. Use of RNA"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6943315\results\search\disease\results.xml">
   <result pre="samples from 112 cats were tested for antigens against feline" exact="leukemia" post="virus (FeLV antigen-ELISA) and antibodies against feline immunodeficiency virus"/>
   <result pre="jackals (Canis mesomelas) [25]. Likewise, possible cross-species transmission of feline" exact="leukemia" post="virus (FeLV) from domestic cats has been recorded in"/>
   <result pre="Negative NE, not explored; FIV, feline immunodeficiency virus; FeLV, feline" exact="leukemia" post="virus; CDV, canine distemper virus. ). Serum analysis Of"/>
   <result pre="test; C.I.,Confidence intervals (lower-upper); FIV, feline immunodeficiency virus; FeLV, feline" exact="leukemia" post="virus; CDV, canine distemper virus. ). No coinfections or"/>
   <result pre="areas. Canine distemper virus is one of the most important" exact="infectious disease" post="of carnivores worldwide and has the second highest fatality"/>
   <result pre="worldwide and has the second highest fatality rate of any" exact="infectious disease" post="after rabies in domestic dogs [17]. Evidence of CDV"/>
   <result pre="the second highest fatality rate of any infectious disease after" exact="rabies" post="in domestic dogs [17]. Evidence of CDV infection has"/>
   <result pre="this study, is one of the three species associated with" exact="cat-scratch disease" post="and other syndromes in humans [9, 11]. In Chile,"/>
   <result pre="is not required. Nevertheless, more than 200 human cases of" exact="bartonellosis" post="were diagnosed between 1997 and 2000 in Chile [20],"/>
   <result pre="[60], Venezuela [28] and Japan [46], causing infectious canine cyclic" exact="thrombocytopenia" post="[18]. The tick Rhipicephalus sanguineus sensu lato is suspected"/>
   <result pre="doi: 10.1590/S0074-0276201200060001122990968 11BreitschwerdtE. B.MaggiR. G.ChomelB. B.LappinM. R.2010. Bartonellosis: an emerging" exact="infectious disease" post="of zoonotic importance to animals and human beings. J."/>
   <result pre="N.LevyJ. K.ScottH. M.CrandallM. M.TuckerS. J.WoodE. G.FosterJ. D.2017. Seroprevalences of feline" exact="leukemia" post="virus and feline immunodeficiency virus infection in cats in"/>
   <result pre="doi: 10.1016/j.vetmic.2013.09.03424176254 14ChiuE. S.KrabergerS.CunninghamM.CusackL.RoelkeM.VandeWoudeS.2019. Multiple introductions of domestic cat Feline" exact="leukemia" post="virus in endangered Florida panthers. Emerg. Infect. Dis.25: 92–101."/>
   <result pre="doi: 10.3201/eid1311.07078218217575 31LevyJ. K.ScottH. M.LachtaraJ. L.CrawfordP. C.2006. Seroprevalence of feline" exact="leukemia" post="virus and feline immunodeficiency virus infection among cats in"/>
   <result pre="Vet. Res.12: 78. doi: 10.1186/s12917-016-0702-z27170307 40MeliM. L.CattoriV.MartínezF.LópezG.VargasA.SimónM. A.ZorrillaI.MuñozA.PalomaresF.López-BaoJ. V.PastorJ.TandonR.WilliB.Hofmann-LehmannR.LutzH.2009. Feline" exact="leukemia" post="virus and other pathogens as important threats to the"/>
   <result pre="Res.106: 183–188. doi: 10.1007/s00436-009-1647-y19841943 45MoraM.NapolitanoC.OrtegaR.PoulinE.Pizarro-LuceroJ.2015. Feline immunodeficiency virus and feline" exact="leukemia" post="virus infection in free-ranging guignas (Leopardus guigna) and sympatric"/>
   <result pre="Mycoplasma haemominutum’ in a cat diagnosed with splenic plasmacytosis and" exact="multiple myeloma." post="J. Feline Med. Surg.16: 713–720. doi: 10.1177/1098612X1351963224445821 55RampersadJ. N.WatkinsJ."/>
   <result pre="808–815. doi: 10.1111/j.1523-1739.2011.01690.x21658128 65SleemanJ. M.KeaneJ. M.JohnsonJ. S.BrownR. J.WoudeS. V.2001. Feline" exact="leukemia" post="virus in a captive bobcat. J. Wildl. Dis.37: 194–200."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6943894\results\search\disease\results.xml">
   <result pre=": Research Genetic variations on 31 and 450 residues of" exact="influenza" post="A nucleoprotein affect viral replication and translation HungSu-Jhen1HsuYin-Mei1HuangSheng-Wen2TsaiHuey-Pin13LeeLeo Yi"/>
   <result pre="which cause severe epidemics and occasional pandemics [1]. These pandemic" exact="influenza" post="strains then persistently circulate in the human population and"/>
   <result pre="it is essential to better understand the evolutionary mechanisms of" exact="influenza" post="A viruses. Replication and transcription of influenza viruses rely"/>
   <result pre="evolutionary mechanisms of influenza A viruses. Replication and transcription of" exact="influenza" post="viruses rely on the functional unit, ribonucleoprotein (RNP) complex"/>
   <result pre="escape immunity, or regulate apoptosis [11]. Most previous studies on" exact="influenza" post="A have focused on the change of viral surface"/>
   <result pre="over time might also be meaningful. Thus, we evaluated the" exact="influenza" post="virus NP, a major multi-functional protein in the virion,"/>
   <result pre="have shown that the evolution rates of viral genomes in" exact="influenza" post="A are different with the rate in H3N2 greater"/>
   <result pre="rate in H3N2 greater than in H1N1 and also than" exact="influenza" post="B viruses [13, 14]. Clinical reports also showed that"/>
   <result pre="viruses led to high mortality in the 1991–1998 and 2003–2004" exact="influenza" post="seasons, in which the latter was associated with an"/>
   <result pre="that the H3N2 caused more severe diseases than H1N1 and" exact="influenza" post="B viruses [15–17]. In Taiwan, H3N2 influenza viruses were"/>
   <result pre="than H1N1 and influenza B viruses [15–17]. In Taiwan, H3N2" exact="influenza" post="viruses were monitored as the main circulating subtype, its"/>
   <result pre="novel determinants on NP that may play a role in" exact="influenza" post="virus evolution. Methods Cell lines and virus isolates MDCK"/>
   <result pre="FBS, 2% P/S and 1X sodium pyruvate. Clinical isolates of" exact="influenza" post="A virus H3N2 subtypes were collected from the Virology"/>
   <result pre="amino acid sequences by BioEdit software. Analysis of sequences from" exact="influenza" post="research database To expand the evolutional analysis, we collected"/>
   <result pre="2.7 × 104 cells/0.1 mL. After 24 h of culture, cells were transfected with" exact="influenza" post="PB2, PB1, PA expression plasmids (A/Taiwan/3446/02 strain in pHW2000"/>
   <result pre="reporter plasmid contains 3′ and 5′ noncoding region of the" exact="influenza" post="virus and is under the control of Pol-I promoter"/>
   <result pre="cells/2 mL. After 24 h of culture, cells were transfected with 7" exact="influenza" post="gene expression plasmids (A/Taiwan/3446/02 strain) and different NP expression"/>
   <result pre="extracted at 6 h post-infection and treated with DNase. Oligo-dT and" exact="influenza" post="universal primer, uni-12, for mRNA and virus vRNA, respectively,"/>
   <result pre="PCR, cDNAs were treated with RNase H, then amplified both" exact="influenza" post="virus M gene (GACCRATCCTGTCACCTCTGAC and AGGGCATTYTGGACAAAKCGTCTA) and β-actin (CCAACCGCGAGAAGATGA"/>
   <result pre="Virus infection and immunoblot analysis A549 cells were infected with" exact="influenza" post="viruses and whole-cell lysates were extracted with 1X lysis"/>
   <result pre="seronegative by haemagglutination inhibition assay for antibodies to currently circulating" exact="influenza" post="viruses before use in experiments. The hemagglutination inhibition (HI)"/>
   <result pre="ensure the ferrets have not been exposed to human seasonal" exact="influenza" post="viruses. Influenza virus strains used in HI assay were"/>
   <result pre="viruses To understand the evolution pattern of the NP gene," exact="influenza" post="H3N2 clinical isolates from 1999 to 2017 from the"/>
   <result pre="of H3N2 viruses from 1999 to 2017. Phylogenetic analysis of" exact="influenza" post="virus NP gene (nucleotide 16 to 1473 bases) was"/>
   <result pre="human, these produced genetic variations in the internal genes of" exact="influenza" post="virus and may play an important role in modulating"/>
   <result pre="alanine mutation and reverse genetics system, 74 conserved residues among" exact="influenza" post="viruses were analyzed and their impact on virus replication"/>
   <result pre="investigate whether this enhancement of viral properties correlated with larger" exact="influenza" post="outbreaks or disease severity, we looked at the human"/>
   <result pre="outbreaks or disease severity, we looked at the human seasonal" exact="influenza" post="(H3N2) epidemiology for Taiwan. Notably, viruses with NP-450G was"/>
   <result pre="the dominant circulating strain since 1968, whereas in the 2006–2007" exact="influenza" post="virus season, NP-450S appeared temporarily in Taiwan (Additional file"/>
   <result pre="with epidemiology reports, whereby NP-450S reduce morbidity in the 2006–2007" exact="influenza" post="virus season, however, there are still many concerns and/or"/>
   <result pre="pathogenicity in chicken by a duck origin, low pathogenic H7N1" exact="influenza" post="virus [27]. Positions 105 and 184 of NP contribute"/>
   <result pre="NP contribute to virus replication and pathogenicity of avian H5N1" exact="influenza" post="virus [28, 29]. The substitution NP-D375N of 2009 pandemic"/>
   <result pre="required to better understand the role of NP in human" exact="influenza" post="evolution and fitness. Avian influenza infection is a great"/>
   <result pre="role of NP in human influenza evolution and fitness. Avian" exact="influenza" post="infection is a great threat to humans and it"/>
   <result pre="case where a single mutation contributes to enhancing replication of" exact="avian influenza" post="in mammals [33]. The NP-N319K mutation affects the interaction"/>
   <result pre="where a single mutation contributes to enhancing replication of avian" exact="influenza" post="in mammals [33]. The NP-N319K mutation affects the interaction"/>
   <result pre="analysis and have tried to understand the complicated mechanisms of" exact="influenza" post="virus evolution and clinical outcome. For instance, the severe"/>
   <result pre="resistance [40]. Epistasis was found in the NA protein of" exact="influenza" post="H1N1 virus and contributed to the emergence of resistant"/>
   <result pre="Instead of analyzing surface proteins of HA and NA of" exact="influenza" post="A(H3N2) viruses, we analyzed the NP gene of human"/>
   <result pre="influenza A(H3N2) viruses, we analyzed the NP gene of human" exact="influenza" post="A H3N2 viruses that have circulated from 1999 to"/>
   <result pre="acquired from evolution appear to have an impact on some" exact="influenza" post="viral properties. Hence, we suggest that the evolutional genetic"/>
   <result pre="viruses from 1999 to 2017 in Taiwan. Isolated cases of" exact="influenza" post="A H3N2 viruses from Virology Laboratory of National Cheng"/>
   <result pre="no competing interests. References References 1.SchrauwenEJFouchierRAHost adaptation and transmission of" exact="influenza" post="A viruses in mammalsEmerg Microbes Infect20143e910.1038/emi.2014.926038511 2.WendelIMatrosovichMKlenkHDSnapShot: evolution of"/>
   <result pre="A viruses in mammalsEmerg Microbes Infect20143e910.1038/emi.2014.926038511 2.WendelIMatrosovichMKlenkHDSnapShot: evolution of human" exact="influenza" post="A virusesCell Host Microbe201517416.e41110.1016/j.chom.2015.02.00125766297 3.Song W, Wang P, Mok"/>
   <result pre="in viral protein PB2 enhances the effects of E627K on" exact="influenza" post="virus replication. Nat Commun. 2014;5:5509. 4.TurrellLLyallJWTileyLSFodorEVreedeFTThe role and assembly"/>
   <result pre="Commun. 2014;5:5509. 4.TurrellLLyallJWTileyLSFodorEVreedeFTThe role and assembly mechanism of nucleoprotein in" exact="influenza" post="A virus ribonucleoprotein complexesNat Commun20134159110.1038/ncomms258923481399 5.ShenYFChenYHChuSYLinMIHsuHTWuPYWuCJLiuHWLinFYLinGHsuPHYangASChengYSWuYTWongCHTsaiMDE339...R416 salt bridge of"/>
   <result pre="5.ShenYFChenYHChuSYLinMIHsuHTWuPYWuCJLiuHWLinFYLinGHsuPHYangASChengYSWuYTWongCHTsaiMDE339...R416 salt bridge of nucleoprotein as a feasible target for" exact="influenza" post="virus inhibitorsProc Natl Acad Sci U S A2011108165151652010.1073/pnas.111310710821930946 6.EltonDMedcalfEBishopKDigardPOligomerization"/>
   <result pre="inhibitorsProc Natl Acad Sci U S A2011108165151652010.1073/pnas.111310710821930946 6.EltonDMedcalfEBishopKDigardPOligomerization of the" exact="influenza" post="virus nucleoprotein: identification of positive and negative sequence elementsVirology199926019020010.1006/viro.1999.981810405371"/>
   <result pre="positive and negative sequence elementsVirology199926019020010.1006/viro.1999.981810405371 7.BiswasSKBoutzPLNayakDPInfluenza virus nucleoprotein interacts with" exact="influenza" post="virus polymerase proteinsJ Virol1998725493550110.1128/JVI.72.7.5493-5501.19989621005 8.EltonDMedcalfLBishopKHarrisonDDigardPIdentification of amino acid residues"/>
   <result pre="virus polymerase proteinsJ Virol1998725493550110.1128/JVI.72.7.5493-5501.19989621005 8.EltonDMedcalfLBishopKHarrisonDDigardPIdentification of amino acid residues of" exact="influenza" post="virus nucleoprotein essential for RNA bindingJ Virol1999737357736710.1128/JVI.73.9.7357-7367.199910438825 9.OzawaMFujiiKMuramotoYYamadaSYamayoshiSTakadaAGotoHHorimotoTKawaokaYContributions of"/>
   <result pre="RNA bindingJ Virol1999737357736710.1128/JVI.73.9.7357-7367.199910438825 9.OzawaMFujiiKMuramotoYYamadaSYamayoshiSTakadaAGotoHHorimotoTKawaokaYContributions of two nuclear localization signals of" exact="influenza" post="A virus nucleoprotein to viral replicationJ Virol200781304110.1128/JVI.01434-0617050598 10.LiZWatanabeTHattaMWatanabeSNanboAOzawaMKakugawaSShimojimaMYamadaSNeumannGKawaokaYMutational analysis"/>
   <result pre="replicationJ Virol200781304110.1128/JVI.01434-0617050598 10.LiZWatanabeTHattaMWatanabeSNanboAOzawaMKakugawaSShimojimaMYamadaSNeumannGKawaokaYMutational analysis of conserved amino acids in the" exact="influenza" post="A virus nucleoproteinJ Virol2009834153416210.1128/JVI.02642-0819225007 11.TripathiSBatraJCaoWSharmaKPatelJRRanjanPKumarAKatzJMCoxNJLalRBSambharaSLalSKInfluenza A virus nucleoprotein induces"/>
   <result pre="and host protein ClusterinCell Death Dis20134e56210.1038/cddis.2013.8923538443 12.SmithDJPredictability and preparedness in" exact="influenza" post="controlScience200631239239410.1126/science.112266516627736 13.FergusonNMGalvaniAPBushRMEcological and immunological determinants of influenza evolutionNature200342242843310.1038/nature0150912660783 14.RambautAPybusOGNelsonMIViboudCTaubenbergerJKHolmesECThe"/>
   <result pre="and preparedness in influenza controlScience200631239239410.1126/science.112266516627736 13.FergusonNMGalvaniAPBushRMEcological and immunological determinants of" exact="influenza" post="evolutionNature200342242843310.1038/nature0150912660783 14.RambautAPybusOGNelsonMIViboudCTaubenbergerJKHolmesECThe genomic and epidemiological dynamics of human influenza"/>
   <result pre="of influenza evolutionNature200342242843310.1038/nature0150912660783 14.RambautAPybusOGNelsonMIViboudCTaubenbergerJKHolmesECThe genomic and epidemiological dynamics of human" exact="influenza" post="A virusNature200845361561910.1038/nature0694518418375 15.JohnsonBFWilsonLEEllisJElliotAJBarclayWSPebodyRGMcMenaminJFlemingDMZambonMCFatal cases of influenza a in childhoodPLoS"/>
   <result pre="epidemiological dynamics of human influenza A virusNature200845361561910.1038/nature0694518418375 15.JohnsonBFWilsonLEEllisJElliotAJBarclayWSPebodyRGMcMenaminJFlemingDMZambonMCFatal cases of" exact="influenza" post="a in childhoodPLoS One20094e767110.1371/journal.pone.000767119876396 16.GalianoMJohnsonBFMyersREllisJDanielsRZambonMFatal cases of influenza A(H3N2)"/>
   <result pre="cases of influenza a in childhoodPLoS One20094e767110.1371/journal.pone.000767119876396 16.GalianoMJohnsonBFMyersREllisJDanielsRZambonMFatal cases of" exact="influenza" post="A(H3N2) in children: insights from whole genome sequence analysisPLoS"/>
   <result pre="insights from whole genome sequence analysisPLoS One20127e3316610.1371/journal.pone.003316622412998 17.ThompsonWWShayDKWeintraubEBrammerLCoxNAndersonLJFukudaKMortality associated with" exact="influenza" post="and respiratory syncytial virus in the United StatesJAMA200328917918610.1001/jama.289.2.17912517228 18.JianJWChenGWLaiCTHsuLCChenPJKuoSHWuHSShihSRGenetic"/>
   <result pre="virus in the United StatesJAMA200328917918610.1001/jama.289.2.17912517228 18.JianJWChenGWLaiCTHsuLCChenPJKuoSHWuHSShihSRGenetic and epidemiological analysis of" exact="influenza" post="virus epidemics in Taiwan during 2003 to 2006J Clin"/>
   <result pre="to 2006J Clin Microbiol2008461426143410.1128/JCM.01560-0718256223 19.LinJHChiuSCChengJCChangHWHsiaoKLLinYCWuHSLiuHFMolecular epidemiology and antigenic analyses of" exact="influenza" post="A viruses H3N2 in TaiwanClin Microbiol Infect20111721422210.1111/j.1469-0691.2010.03228.x20370800 20.ZhangYAevermannBDAndersonTKBurkeDFDauphinGGuZHeSKumarSLarsenCNLeeAJLiXMackenCMahaffeyCPickettBEReardonBSmithTStewartLSulowayCSunGTongLVincentALWaltersBZarembaSZhaoHZhouLZmasekCKlemEBScheuermannRHInfluenza research"/>
   <result pre="Microbiol Infect20111721422210.1111/j.1469-0691.2010.03228.x20370800 20.ZhangYAevermannBDAndersonTKBurkeDFDauphinGGuZHeSKumarSLarsenCNLeeAJLiXMackenCMahaffeyCPickettBEReardonBSmithTStewartLSulowayCSunGTongLVincentALWaltersBZarembaSZhaoHZhouLZmasekCKlemEBScheuermannRHInfluenza research database: an integrated bioinformatics resource for" exact="influenza" post="virus researchNucleic Acids Res201745D466d47410.1093/nar/gkw85727679478 21.Chan KF, Carolan LA, Druce"/>
   <result pre="infections and viral hierarchy are determinants of viral interference following" exact="influenza" post="virus infection in a ferret modelJ Infect Dis20152121701171010.1093/infdis/jiv26025943206 23.MarklundJKYeQDongJTaoYJKrugRMSequence"/>
   <result pre="infection in a ferret modelJ Infect Dis20152121701171010.1093/infdis/jiv26025943206 23.MarklundJKYeQDongJTaoYJKrugRMSequence in the" exact="influenza" post="A virus nucleoprotein required for viral polymerase binding and"/>
   <result pre="viral polymerase binding and RNA synthesisJ Virol2012867292729710.1128/JVI.00014-1222532672 24.XuJChristmanMCDonisROLuGEvolutionary dynamics of" exact="influenza" post="A nucleoprotein (NP) lineages revealed by large-scale sequence analysesInfect"/>
   <result pre="large-scale sequence analysesInfect Genet Evol2011112125213210.1016/j.meegid.2011.07.00221763464 25.LinJHChiuSCChengJCChangHWHsiaoKLLinYCWuHSSalemiMLiuHFPhylodynamics and molecular evolution of" exact="influenza" post="A virus nucleoprotein genes in Taiwan between 1979 and"/>
   <result pre="and PB2 contribute to increased virulence of H5N1 highly pathogenic" exact="avian influenza" post="viruses in chickensJ Virol2011851834184610.1128/JVI.01648-1021123376 29.WasilenkoJLSarmentoLPantin-JackwoodMJA single substitution in amino"/>
   <result pre="PB2 contribute to increased virulence of H5N1 highly pathogenic avian" exact="influenza" post="viruses in chickensJ Virol2011851834184610.1128/JVI.01648-1021123376 29.WasilenkoJLSarmentoLPantin-JackwoodMJA single substitution in amino"/>
   <result pre="the NP protein alters the replication and pathogenicity of H5N1" exact="avian influenza" post="viruses in chickensArch Virol200915496997910.1007/s00705-009-0399-419475480 30.SakabeSOzawaMTakanoRIwastuki-HorimotoKKawaokaYMutations in PA, NP, and"/>
   <result pre="NP protein alters the replication and pathogenicity of H5N1 avian" exact="influenza" post="viruses in chickensArch Virol200915496997910.1007/s00705-009-0399-419475480 30.SakabeSOzawaMTakanoRIwastuki-HorimotoKKawaokaYMutations in PA, NP, and"/>
   <result pre="in PA, NP, and HA of a pandemic (H1N1) 2009" exact="influenza" post="virus contribute to its adaptation to miceVirus Res201115812412910.1016/j.virusres.2011.03.02221458512 31.TadaTSuzukiKSakuraiYKuboMOkadaHItohTTsukamotoKEmergence"/>
   <result pre="virus contribute to its adaptation to miceVirus Res201115812412910.1016/j.virusres.2011.03.02221458512 31.TadaTSuzukiKSakuraiYKuboMOkadaHItohTTsukamotoKEmergence of" exact="avian influenza" post="viruses with enhanced transcription activity by a single amino"/>
   <result pre="contribute to its adaptation to miceVirus Res201115812412910.1016/j.virusres.2011.03.02221458512 31.TadaTSuzukiKSakuraiYKuboMOkadaHItohTTsukamotoKEmergence of avian" exact="influenza" post="viruses with enhanced transcription activity by a single amino"/>
   <result pre="potential for strains with altered virulence phenotype?PLoS Pathog20106e100114510.1371/journal.ppat.100114520976194 33.ManzBSchwemmleMBrunotteLAdaptation of" exact="avian influenza" post="A virus polymerase in mammals to overcome the host"/>
   <result pre="for strains with altered virulence phenotype?PLoS Pathog20106e100114510.1371/journal.ppat.100114520976194 33.ManzBSchwemmleMBrunotteLAdaptation of avian" exact="influenza" post="A virus polymerase in mammals to overcome the host"/>
   <result pre="with importin alpha1 is a determinant of host range of" exact="influenza" post="A virusPLoS Pathog20084e1110.1371/journal.ppat.004001118248089 35.AhnISonHSEvolutionary analysis of human-origin influenza A"/>
   <result pre="range of influenza A virusPLoS Pathog20084e1110.1371/journal.ppat.004001118248089 35.AhnISonHSEvolutionary analysis of human-origin" exact="influenza" post="A virus (H3N2) genes associated with the codon usage"/>
   <result pre="1993Virus Genes20124419820610.1007/s11262-011-0687-422086505 36.LinJHChiuSCLinYCChengJCWuHSSalemiMLiuHFExploring the molecular epidemiology and evolutionary dynamics of" exact="influenza" post="A virus in TaiwanPLoS One20138e6195710.1371/journal.pone.006195723613982 37.WestgeestKBRussellCALinXSpronkenMIBestebroerTMBahlJvan BeekRSkepnerEHalpinRAde JongJCRimmelzwaanGFOsterhausADSmithDJWentworthDEFouchierRAde GraafMGenomewide"/>
   <result pre="BeekRSkepnerEHalpinRAde JongJCRimmelzwaanGFOsterhausADSmithDJWentworthDEFouchierRAde GraafMGenomewide analysis of reassortment and evolution of human" exact="influenza" post="A(H3N2) viruses circulating between 1968 and 2011J Virol2014882844285710.1128/JVI.02163-1324371052 38.HutchinsonECDenhamEMThomasBTrudgianDCHesterSSRidlovaGYorkATurrellLFodorEMapping"/>
   <result pre="circulating between 1968 and 2011J Virol2014882844285710.1128/JVI.02163-1324371052 38.HutchinsonECDenhamEMThomasBTrudgianDCHesterSSRidlovaGYorkATurrellLFodorEMapping the phosphoproteome of" exact="influenza" post="A and B viruses by mass spectrometryPLoS Pathog20128e100299310.1371/journal.ppat.100299323144613 39.LehnerBMolecular"/>
   <result pre="between neuraminidase mutations facilitated the emergence of the oseltamivir-resistant H1N1" exact="influenza" post="viruses. Nat Commun. 2014;5:5029. 42.GongLISuchardMABloomJDStability-mediated epistasis constrains the evolution"/>
   <result pre="Nat Commun. 2014;5:5029. 42.GongLISuchardMABloomJDStability-mediated epistasis constrains the evolution of an" exact="influenza" post="proteinElife20132e0063110.7554/eLife.0063123682315"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6948741\results\search\disease\results.xml">
   <result pre="Life Sciences : Genetics : Genomics: Genome Analysis Persistence of" exact="chikungunya" post="ECSA genotype and local outbreak in an upper medium"/>
   <result pre="provided the original author and source are credited.pone.0226098.pdf Abstract The" exact="chikungunya" post="East/Central/South/Africa virus lineage (CHIKV-ECSA) was first detected in Brazil"/>
   <result pre="that Bahia state reported a total of 50,880 cases of" exact="chikungunya" post="fever in 2016 and 1,524 chikungunya cases, until the"/>
   <result pre="of 50,880 cases of chikungunya fever in 2016 and 1,524" exact="chikungunya" post="cases, until the 2019 25th epidemiological week (June/2019). In"/>
   <result pre="= 25), backache (n = 24), exanthema (n = 22)," exact="conjunctivitis" post="(n = 17), retro-orbital pain (n = 16), nausea"/>
   <result pre="years during distinct epidemic seasons. Fig 1 Phylogenetic analysis of" exact="chikungunya" post="virus human samples from Feira de Santana, Bahia, Brazil."/>
   <result pre="of cryptic transmission of arboviruses such as Zika, dengue and" exact="chikungunya" post="before the first case detection [48–50]. On this way"/>
   <result pre="WongHV, ChanYF, SamIC. An amino acid change in nsP4 of" exact="chikungunya" post="virus confers fitness advantage in human cell lines rather"/>
   <result pre="4SchuffeneckerI, ItemanI, MichaultA, MurriS, FrangeulL, VaneyMC, et al.Genome microevolution of" exact="chikungunya" post="viruses causing the Indian Ocean outbreak. PLoS Med. 2006;3(7):e26310.1371/journal.pmed.003026316700631"/>
   <result pre="9Brasil. Boletim Epidemiológico: Monitoramento dos casos de dengue, febre de" exact="chikungunya" post="e febre pelo vírus Zika até a Semana Epidemiológica"/>
   <result pre="Dos, NetoDF de L, SchanoskiAS, PourSZ, PassosSD, et al.Outbreak of" exact="chikungunya" post="virus in a vulnerable population of Sergipe, Brazil-A molecular"/>
   <result pre="Microbiol Spectr. 20166;4(3). 10.1128/microbiolspec.EI10-0017-2016 ; PMCID: PMC6488301.27337473 25MorrisonTE. Reemergence of" exact="chikungunya" post="virus. J Virol. 201410;88(20):11644–7. 10.1128/JVI.01432-14 Epub 2014 Jul 30."/>
   <result pre="PMC4178719.25078691 26MussoD, TeissierA, RouaultE, TeururaiS, de PinaJ-J, NhanT-X. Detection of" exact="chikungunya" post="virus in saliva and urine. Virology Journal. 2016;13: 10210.1186/s12985-016-0556-927306056"/>
   <result pre="34Brasil. Boletim Epidemiológico: Monitoramento dos casos de dengue, febre de" exact="chikungunya" post="e febre pelo vírus Zika até a Semana Epidemiológica"/>
   <result pre="40SchuffeneckerI, ItemanI, MichaultA, MurriS, FrangeulL, VaneyM-C, et al.Genome microevolution of" exact="chikungunya" post="viruses causing the Indian Ocean outbreak. PLoS medicine. 2006/05/23."/>
   <result pre="44FrosJJ, van der MatenE, VlakJM, PijlmanGP. The C-terminal domain of" exact="chikungunya" post="virus nsP2 independently governs viral RNA replication, cytopathicity, and"/>
   <result pre="10.1128/JVI.00884-1323864632 45JonesPH, MaricM, MadisonMN, MauryW, RollerRJ, OkeomaCM. BST-2/tetherin-mediated restriction of" exact="chikungunya" post="(CHIKV) VLP budding is counteracted by CHIKV non-structural protein"/>
   <result pre="e000706510.1371/journal.pntd.000706530845267 48XavierJ, GiovanettiM, FonsecaV, ThezeJ, GrafT, FabriA, et al.Circulation of" exact="chikungunya" post="virus East/Central/South African lineage in Rio de Janeiro, Brazil."/>
   <result pre="da vigilância epidemiológica no enfrentamento da tríplice epidemia de dengue," exact="chikungunya" post="e Zika: desatando nós e buscando caminhos. Patologia das"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6948816\results\search\disease\results.xml">
   <result pre="women in the first semester of pregnancy [28]  Risk of" exact="microcephaly" post="Upon infection during exposure time (3 levels of risk)"/>
   <result pre="S1. Risk of adverse congenital outcomes The estimated number of" exact="microcephaly" post="cases resulting from the reintroduction of ZIKV depended on"/>
   <result pre="given time. We explored three different levels of risk of" exact="microcephaly" post="in births to pregnant woman with ZIKV infection during"/>
   <result pre="vaccine, given to 15-year-old-girls. This vaccination strategy was used for" exact="rubella" post="virus, which also causes congenital abnormalities, before the vaccine"/>
   <result pre="congenital abnormalities, before the vaccine was included in the measles," exact="mumps" post="and rubella vaccine given in early childhood [35]. The"/>
   <result pre="before the vaccine was included in the measles, mumps and" exact="rubella" post="vaccine given in early childhood [35]. The main objective"/>
   <result pre="successful introductions is 3.6% (IQR: 2.0–6.2). Risk of infection and" exact="microcephaly" post="births in women of reproductive age The differences between"/>
   <result pre="across ages. Assuming different values for the added risk of" exact="microcephaly" post="after a ZIKV infection during the first trimester, we"/>
   <result pre="the first trimester, we expect the mean number of additional" exact="microcephaly" post="cases due to ZIKV infection resulting from the reintroduction"/>
   <result pre="in 2060 (Fig 3B). Fig 3 Risk of infection and" exact="microcephaly" post="births in women of reproductive age. (A) Relative risk"/>
   <result pre="by year (median, interquartile range). (B) Expected number of additional" exact="microcephaly" post="events associated with ZIKV infection during pregnancy per 100,000"/>
   <result pre="outbreak in the population. The reduction in the number of" exact="microcephaly" post="cases would then exceed what would be expected by"/>
   <result pre="BompardP, DubT, Guillemette-ArturP, Eyrolle-GuignotD, et al.Association between Zika virus and" exact="microcephaly" post="in French Polynesia, 2013-15: A retrospective study. Lancet. 2016;387(10033):2125–2132."/>
   <result pre="BrownDWG, CohenBJ, et al.Evolution of surveillance of measles, mumps, and" exact="rubella" post="in England and Wales: Providing the platform for evidence-based"/>
   <result pre="al.An online decision tree for vaccine efficacy trial design during" exact="infectious disease" post="epidemics: The InterVax-Tool. Vaccine. 2019;37(31):4376–4381. 10.1016/j.vaccine.2019.06.01931242963"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6948821\results\search\disease\results.xml">
   <result pre="of arboviruses such as Zika virus (ZIKV), dengue virus, and" exact="chikungunya" post="virus is critical for prevention and control activities. Previous"/>
   <result pre="and control of arboviruses such as ZIKV, dengue virus, and" exact="chikungunya" post="virus is dependent on timely and accurate detection of"/>
   <result pre="case identification [9, 10]. However, transmission of Zika, dengue, and" exact="chikungunya" post="viruses occurs mainly between Aedes mosquitoes and human hosts."/>
   <result pre="2018 October 3]. Available from: http://www.cdc.gov/zika/pdfs/zika-key-messages.pdf. 2PaixãoES, TeixeiraMG, RodriguesLC. Zika," exact="chikungunya" post="and dengue: the causes and threats of new and"/>
   <result pre="2018;9:8710.3389/fmicb.2018.0008729472902 8collab: World Health Organization. Surveillance for Zika virus infection," exact="microcephaly" post="and Guillain-Barré syndrome: Interim guidance: World Health Organization; 2016"/>
   <result pre="Trioplex real-time RT-PCR assay for detection of Zika, dengue, and" exact="chikungunya" post="viruses. Nature Communications. 2018;9(1):139110.1038/s41467-018-03772-129643334 17BarreraR, AmadorM, AcevedoV, BeltranM, MuñozJ."/>
   <result pre="2017;11(7):e000568310.1371/journal.pntd.000568328672006 20JohanssonMA, PowersAM, PesikN, CohenNJ, StaplesJE. Nowcasting the spread of" exact="chikungunya" post="virus in the Americas. PloS One. 2014;9(8):e10491510.1371/journal.pone.010491525111394 21FocksDA, BrennerRJ,"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6949906\results\search\disease\results.xml">
   <result pre="vectors, and shows the epidemiological risk in the area for" exact="chikungunya" post="cases and a possible increase of severe dengue cases,"/>
   <result pre="increase of severe dengue cases, associated with the occurrence of" exact="dengue hemorrhagic fever." post="Aedes Chikungunya virus Dengue virus arbovirus 1. Introduction Arboviral"/>
   <result pre="and clinical management [6]. In addition, congenital abnormalities, such as" exact="microcephaly" post="and Guillain–Barré syndrome, were associated with infection by ZIKV"/>
   <result pre="with ZIKV and DENV in 2016, a total of 185,593" exact="chikungunya" post="probable cases were reported in 2017, however, a decrease"/>
   <result pre="when two cases were confirmed. In 2017, the number of" exact="chikungunya" post="confirmed cases reached 46, showing that the virus has"/>
   <result pre="Monitoramento dos casos de arboviroses urbanas transmitidas pelo Aedes (dengue," exact="chikungunya" post="e Zika): Semanas Epidemiológicas 1 a 36Available online: https://portalarquivos2.saude.gov.br/images/pdf/2019/outubro/04/BE-multitematico-n28.pdf(accessed"/>
   <result pre="dengue até a semana epidemiológica (SE) 38 e febre de" exact="chikungunya" post="até a SE 39 de 2014Available online: http://portalarquivos2.saude.gov.br/images/pdf/2014/outubro/03/BE-2014-45--23----Dengue--SE38--e-CHIKV--SE39-.pdf(accessed on"/>
   <result pre="potential for spread of Chikungunya virus in BrazilBMC Med.20151310210.1186/s12916-015-0348-x25976325 16.BandeiraA.C.CamposG.S.SardiS.I.RochaV.F.D.RochaG.C.M.Neonatal" exact="encephalitis" post="due to Chikungunya vertical transmission: First report in BrazilIDCases20165575910.1016/j.idcr.2016.07.00827500084"/>
   <result pre="21.MehtaR.SoaresC.N.Medialdea-CarreraR.EllulM.SilvaM.T.T.Rosala-HallasA.JardimM.R.BurnsideG.PamplonaL.BhojakM.et al.The spectrum of neurological disease associated with Zika and" exact="chikungunya" post="viruses in adults in Rio de Janeiro, Brazil: A"/>
   <result pre="Vigilância em Saúde. Monitoramento dos casos de dengue, febre de" exact="chikungunya" post="e doença aguda pelo vírus Zika até a Semana"/>
   <result pre="2018Available online: http://portalarquivos2.saude.gov.br/images/pdf/2019/janeiro/28/2019-002.pdf(accessed on 2 February 2019) 26.WahidB.AliA.RafiqueS.IdreesM.Global expansion of" exact="chikungunya" post="virus: mapping the 64-year historyInt. J. Infect. Dis.201758697610.1016/j.ijid.2017.03.00628288924 27.CarvalhoF.D.MoreiraL.A.Why"/>
   <result pre="Aedes aegypti to Brazil, the major vector of the dengue," exact="chikungunya" post="and Zika virusesPLoS Negl. Trop. Dis.201711e000565310.1371/journal.pntd.000565328742801 29.collab: Instituto Brasileiro"/>
   <result pre="J. Trop. Med. Hyg.2007761182118810.4269/ajtmh.2007.76.118217556633 75.DelatteH.PaupyC.DehecqJ.S.ThiriaJ.FaillouxA.B.FontenilleD.Aedes albopictus, vecteur des virus du" exact="chikungunya" post="et de la dengue à la Réunion: biologie et"/>
   <result pre="la dengue à la Réunion: biologie et contrôleParasite20081531310.1051/parasite/200815100318416242 76.LeroyE.M.NkogheD.OllomoB.Nze-nkogueC.BecquartP.GrardG.PourrutX.CharrelR.MoureauG.Ndjoyi-MbguinoA.et al.Concurrent" exact="chikungunya" post="and dengue virus infections during simultaneous outbreaks, Gabon, 2007Emerg."/>
   <result pre="Negl. Trop. Dis.20148e268110.1371/journal.pntd.000268124516683 79.ReiterP.FontenilleD.PaupyC.Aedes albopictus as an epidemic vector of" exact="chikungunya" post="virus: another emerging problem?Lancet Infect. Dis.2006646346410.1016/S1473-3099(06)70531-X16870524 80.RatsitorahinaM.HarisoaJ.RatovonjatoJ.BiacabeS.ReynesJ.-M.ZellerH.RaoelinaY.TalarminA.RichardV.SoaresJ.L.Outbreak of Dengue"/>
   <result pre="Vigilância em Saúde. Monitoramento dos casos de dengue, febre de" exact="chikungunya" post="e febre pelo vírus Zika até a Semana Epidemiológica"/>
   <result pre="Vigilância em Saúde. Monitoramento dos casos de dengue, febre de" exact="chikungunya" post="e febre pelo vírus Zika até a Semana Epidemiológica"/>
   <result pre="2019) 87.Costa-da-SilvaA.L.IoshinoR.S.PetersenV.LimaA.F.CunhaM.d.P.WileyM.R.LadnerJ.T.PrietoK.PalaciosG.CostaD.D.et al.First report of naturally infected Aedes aegypti with" exact="chikungunya" post="virus genotype ECSA in the AmericasPLoS Negl. Trop. Dis.201711e000563010.1371/journal.pntd.000563028614394"/>
   <result pre="Bahia, BrazilMem. Inst. Oswaldo Cruz2019114e18059710.1590/0074-0276018059730843962 91.ContevilleL.C.ZanellaL.MarínM.A.de FilippisA.M.B.NogueiraR.M.R.VicenteA.C.P.de MendonçaM.C.L.Phylogenetic analyses of" exact="chikungunya" post="virus among travelers in Rio De Janeiro, Brazil, 2014-2015Mem."/>
   <result pre="BrazilEpidemiol. Infect.20181462056205810.1017/S095026881800246730182863 96.MachadoL.C.de Morais-SobralM.C.CamposT.d.L.PereiraM.R.de AlbuquerqueM.d.F.P.M.GilbertC.FrancaR.F.O.WallauG.L.Genome sequencing reveals coinfection by multiple" exact="chikungunya" post="virus genotypes in a recent outbreak in BrazilPLoS Negl."/>
   <result pre="Vigilância em Saúde. Monitoramento dos casos de dengue, febre de" exact="chikungunya" post="e febre pelo vírus Zika até a Semana Epidemiológica"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6950258\results\search\disease\results.xml">
   <result pre="to harmful ultra-violet radiation. This may cause conditions such as" exact="skin cancer," post="cataracts, and blindness [5]. The health and well-being of"/>
   <result pre="thus, leading to outbreaks of waterborne diseases such as cholera," exact="typhoid fever," post="or hepatitis A [13]. In addition, stress and trauma"/>
   <result pre="outbreaks of waterborne diseases such as cholera, typhoid fever, or" exact="hepatitis" post="A [13]. In addition, stress and trauma caused by"/>
   <result pre="including those transmitted by mosquitoes, mention can be made to;" exact="dengue fever," post="chikungunya fever, Zika, Lymphatic Filariasis, Japanese encephalitis, Murray Valley"/>
   <result pre="transmitted by mosquitoes, mention can be made to; dengue fever," exact="chikungunya" post="fever, Zika, Lymphatic Filariasis, Japanese encephalitis, Murray Valley encephalitis,"/>
   <result pre="Valley encephalitis, Barmah forest virus disease, Ross River fever, and" exact="malaria" post="[21]. In a global context, these diseases are more"/>
   <result pre="vector of several viruses, primarily Zika (ZIKV), dengue (DENV) and" exact="chikungunya" post="virus (CHIKV). Development and life cycles of mosquitoes, and"/>
   <result pre="(types one to four), but newly emerging Aedes-borne Zika and" exact="chikungunya" post="transmission [28]. Regular DENV outbreaks had been reported since"/>
   <result pre="genera in the Pacific region include Alphaviruses (family Togaviridae), e.g.," exact="chikungunya" post="virus, and Flaviviruses (family Flaviviridae), e.g., Zika and dengue"/>
   <result pre="River virus (closely related to CHIKV), West Nile virus, and" exact="yellow fever" post="virus (closely related to DENV and ZIKV). They primarily"/>
   <result pre="Disease: A Cross-Disciplinary ReviewClin. Microbiol. Rev.20011490993210.1128/CMR.14.4.909-932.200111585790 39.RothA.MercierA.LepersC.HoyD.DuituturagaS.BenyonE.GuillaumotL.SouarèsY.Concurrent outbreaks of dengue," exact="chikungunya" post="and Zika virus infections—An unprecedented epidemic wave of mosquito-borne"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6950424\results\search\disease\results.xml">
   <result pre="host factors myxovirus (Mx) proteins are key features in regulating" exact="influenza" post="A virus (IAV) infections. Viral polymerases are essential for"/>
   <result pre="influence of polymerase activity and providing interspecies restriction. The equine" exact="influenza" post="virus has evolved as an independent lineage to influenza"/>
   <result pre="equine influenza virus has evolved as an independent lineage to" exact="influenza" post="viruses from other species. We estimated the differences in"/>
   <result pre="the pandemic potential of lately evolving IAVs. MxA equine Mx1" exact="influenza" post="A viruses polymerase activity interspecies transmission nucleoprotein equine influenza"/>
   <result pre="Mx1 influenza A viruses polymerase activity interspecies transmission nucleoprotein equine" exact="influenza" post="1. Introduction Influenza A viruses (IAVs), commonly termed flu"/>
   <result pre="the Orthmyxoviridae family and are broadly associated with acute febrile" exact="respiratory disease" post="in many animals. Wild aquatic birds are believed to"/>
   <result pre="pathogens including DNA and RNA viruses (mainly Orthomyxoviruses such as" exact="influenza" post="[9,10], measles [11], La Crosse [12], and Hantaan viruses"/>
   <result pre="DNA and RNA viruses (mainly Orthomyxoviruses such as influenza [9,10]," exact="measles" post="[11], La Crosse [12], and Hantaan viruses [13]). HuMxA"/>
   <result pre="Hantaan viruses [13]). HuMxA is a potent interspecies barrier for" exact="influenza" post="viruses from other species [8,10,14]. MxA is a dynamin-like"/>
   <result pre="stalk [15,16]. Although the exact mechanism of Mx1-mediated immunity to" exact="influenza" post="viruses is still unclear, a proposed possible mechanism suggests"/>
   <result pre="MxA represents a considerable barrier against the zoonotic introduction of" exact="avian influenza" post="viruses into the human population [7]. Interestingly, several investigations"/>
   <result pre="represents a considerable barrier against the zoonotic introduction of avian" exact="influenza" post="viruses into the human population [7]. Interestingly, several investigations"/>
   <result pre="in transgenic mice than the parental virus [29]. The equine" exact="influenza" post="virus underwent an independent evolution pattern that can be"/>
   <result pre="study were kindly provided by the following personals: H1N1 human" exact="influenza" post="virus A/WSN/1933 (WSN) by Dr. Kawoaka, and plasmids of"/>
   <result pre="human IAV A/Sichuan/01/2009 (H1N1SC09) by Dr. Hualan Chen. The equine" exact="influenza" post="viruses H3N8XJ07 (A/equine/Xinjiang/1/2007) and H3N8JL89 were acquired from the"/>
   <result pre="gene linked with non-coding regions of the HA gene of" exact="influenza" post="containing human polI as the promoter and a mice"/>
   <result pre="and NP is crucial for the establishment of an enzymatically-active" exact="influenza" post="RdRp in RNP complexes [42], and that enzymatically-active Mx1"/>
   <result pre="result supported the model in which eqMx1 interacts with the" exact="influenza" post="RNP and affects its assembly by disturbing the PB2-NP"/>
   <result pre="from equines and suggests that its antiviral activity against the" exact="influenza" post="virus was similar to Mx1 from water buffalo [14]."/>
   <result pre="equine origin and most closely related to European equine H3N8" exact="influenza" post="viruses from the early 1990s [47]. All this evidence"/>
   <result pre="HEK293T cells are well used in previous studies [6,38,49,50]. Since" exact="influenza" post="viruses are the pathogens that cause major respiratory tract"/>
   <result pre="Zhenyu Zhang for the project &quot;The study on mechanism of" exact="influenza" post="A virus NS1 protein binding with host protein LRPPRC"/>
   <result pre="adaptation, and pandemic formationCell Host Microbe2010744045110.1016/j.chom.2010.05.00920542248 2.HorimotoT.KawaokaY.Pandemic threat posed by" exact="avian influenza" post="A virusesClin. Microbiol. Rev.20011412914910.1128/CMR.14.1.129-149.200111148006 3.ShortK.R.RichardM.VerhagenJ.H.van RielD.SchrauwenE.J.van den BrandJ.M.MänzB.BodewesR.HerfstS.One health,"/>
   <result pre="and pandemic formationCell Host Microbe2010744045110.1016/j.chom.2010.05.00920542248 2.HorimotoT.KawaokaY.Pandemic threat posed by avian" exact="influenza" post="A virusesClin. Microbiol. Rev.20011412914910.1128/CMR.14.1.129-149.200111148006 3.ShortK.R.RichardM.VerhagenJ.H.van RielD.SchrauwenE.J.van den BrandJ.M.MänzB.BodewesR.HerfstS.One health,"/>
   <result pre="RielD.SchrauwenE.J.van den BrandJ.M.MänzB.BodewesR.HerfstS.One health, multiple challenges: The inter-species transmission of" exact="influenza" post="A virusOne Health2015111310.1016/j.onehlt.2015.03.00126309905 4.WebsterR.G.BeanW.J.GormanO.T.ChambersT.M.KawaokaY.Evolution and ecology of influenza A"/>
   <result pre="transmission of influenza A virusOne Health2015111310.1016/j.onehlt.2015.03.00126309905 4.WebsterR.G.BeanW.J.GormanO.T.ChambersT.M.KawaokaY.Evolution and ecology of" exact="influenza" post="A virusesMicrobiol. Mol. Biol. Rev.199256152179 5.MostafaA.AbdelwhabE.M.MettenleiterT.C.PleschkaS.Zoonotic potential of influenza"/>
   <result pre="of influenza A virusesMicrobiol. Mol. Biol. Rev.199256152179 5.MostafaA.AbdelwhabE.M.MettenleiterT.C.PleschkaS.Zoonotic potential of" exact="influenza" post="A viruses: A comprehensive overviewViruses20181049710.3390/v10090497 6.VerhelstJ.ParthoensE.SchepensB.FiersW.SaelensX.Interferon-inducible protein Mx1 inhibits"/>
   <result pre="influenza A viruses: A comprehensive overviewViruses20181049710.3390/v10090497 6.VerhelstJ.ParthoensE.SchepensB.FiersW.SaelensX.Interferon-inducible protein Mx1 inhibits" exact="influenza" post="virus by interfering with functional viral ribonucleoprotein complex assemblyJ."/>
   <result pre="Rev.20137755156610.1128/MMBR.00024-1324296571 9.XiaoH.KillipM.J.StaeheliP.RandallR.E.JacksonD.The human interferon-induced MxA protein inhibits early stages of" exact="influenza" post="A virus infection by retaining the incoming viral genome"/>
   <result pre="10.PavlovicJ.HallerO.StaeheliP.Human and mouse Mx proteins inhibit different steps of the" exact="influenza" post="virus multiplication cycleJ. Virol.199266256425691548781 11.Schneider-SchauliesS.Schneider-SchauliesJ.SchusterA.BayerM.PavlovicJ.Ter MeulenV.Cell type-specific MxA-mediated inhibition"/>
   <result pre="virus multiplication cycleJ. Virol.199266256425691548781 11.Schneider-SchauliesS.Schneider-SchauliesJ.SchusterA.BayerM.PavlovicJ.Ter MeulenV.Cell type-specific MxA-mediated inhibition of" exact="measles" post="virus transcription in human brain cellsJ. Virol.199468691069177933071 12.KochsG.JanzenC.HohenbergH.HallerO.Antivirally active"/>
   <result pre="protein is inhibited by overexpression of the PB2 protein of" exact="influenza" post="virusVirology199319764265110.1006/viro.1993.16398249287 19.HuangT.PavlovicJ.StaeheliP.KrystalM.Overexpression of the influenza virus polymerase can titrate"/>
   <result pre="of the PB2 protein of influenza virusVirology199319764265110.1006/viro.1993.16398249287 19.HuangT.PavlovicJ.StaeheliP.KrystalM.Overexpression of the" exact="influenza" post="virus polymerase can titrate out inhibition by the murine"/>
   <result pre="titrate out inhibition by the murine Mx1 proteinJ. Virol.199266415441601602538 20.MänzB.DornfeldD.GötzV.ZellR.ZimmermannP.HallerO.KochsG.SchwemmleM.Pandemic" exact="influenza" post="A viruses escape from restriction by human MxA through"/>
   <result pre="stable transgenic vero cell line interferes with replication of vesicular" exact="stomatitis" post="virusJ. Interferon Cytokine Res.20042451352110.1089/jir.2004.24.51315450127 26.YamadaK.NakatsuY.OnogiA.UedaJ.WatanabeT.Specific intracellular localization and antiviral"/>
   <result pre="in bovine Mx1Viral Immunol.20092238939510.1089/vim.2009.005019951175 27.RieggerD.HaiR.DornfeldD.MänzB.Leyva-GradoV.Sánchez-AparicioM.T.AlbrechtR.A.PaleseP.HallerO.SchwemmleM.The nucleoprotein of newly emerged H7N9" exact="influenza" post="A virus harbors a unique motif conferring resistance to"/>
   <result pre="nuclear vRNP importSci. Rep.201662313810.1038/srep2313826988202 29.DeegC.M.HassanE.MutzP.RheinemannL.GötzV.MagarL.SchillingM.KallfassC.NürnbergerC.SoubiesS.In vivo evasion of MxA by" exact="avian influenza" post="viruses requires human signature in the viral nucleoproteinJ. Exp."/>
   <result pre="vRNP importSci. Rep.201662313810.1038/srep2313826988202 29.DeegC.M.HassanE.MutzP.RheinemannL.GötzV.MagarL.SchillingM.KallfassC.NürnbergerC.SoubiesS.In vivo evasion of MxA by avian" exact="influenza" post="viruses requires human signature in the viral nucleoproteinJ. Exp."/>
   <result pre="of an Autochthonous LineageJ. Virol.20199310.1128/JVI.00116-19 31.SovinovaO.TumovaB.PouskaF.NemecJ.Isolation of a virus causing" exact="respiratory disease" post="in horsesActa Virol.195825213533033 32.GormanO.BeanW.KawaokaY.DonatelliI.GuoY.WebsterR.Evolution of influenza A virus nucleoprotein"/>
   <result pre="a virus causing respiratory disease in horsesActa Virol.195825213533033 32.GormanO.BeanW.KawaokaY.DonatelliI.GuoY.WebsterR.Evolution of" exact="influenza" post="A virus nucleoprotein genes: Implications for the origins of"/>
   <result pre="virusesJ. Virol.199165370437142041090 33.LinY.-Z.CaoX.-Z.LiL.LiL.JiangC.-G.WangX.-F.MaJ.ZhouJ.-H.The pathogenic and vaccine strains of equine infectious" exact="anemia" post="virus differentially induce cytokine and chemokine expression and apoptosis"/>
   <result pre="in macrophagesVirus Res.201116027428210.1016/j.virusres.2011.06.02821782860 34.ZimmermannP.MänzB.HallerO.SchwemmleM.KochsG.The viral nucleoprotein determines Mx sensitivity of" exact="influenza" post="A virusesJ. Virol.2011858133814010.1128/JVI.00712-1121680506 35.PleschkaS.JaskunasR.EngelhardtO.G.ZürcherT.PaleseP.Garcia-SastreA.A plasmid-based reverse genetics system for"/>
   <result pre="influenza A virusesJ. Virol.2011858133814010.1128/JVI.00712-1121680506 35.PleschkaS.JaskunasR.EngelhardtO.G.ZürcherT.PaleseP.Garcia-SastreA.A plasmid-based reverse genetics system for" exact="influenza" post="A virusJ. Virol.199670418841928648766 36.ReedL.J.MuenchH.A simple method of estimating fifty"/>
   <result pre="contribution and host range determination of ANP32 protein family in" exact="influenza" post="A virus polymerase activitybioRxiv2019529412 38.VerhelstJ.De VliegerD.SaelensX.Co-immunoprecipitation of the mouse"/>
   <result pre="activitybioRxiv2019529412 38.VerhelstJ.De VliegerD.SaelensX.Co-immunoprecipitation of the mouse Mx1 protein with the" exact="influenza" post="a virus nucleoproteinJoVE (J. Vis. Exp.)2015e5287110.3791/52871 39.WangM.ZhangZ.WangX.Strain-specific antagonism of"/>
   <result pre="nucleoproteinJoVE (J. Vis. Exp.)2015e5287110.3791/52871 39.WangM.ZhangZ.WangX.Strain-specific antagonism of the human H1N1" exact="influenza" post="A virus against equine tetherinViruses20181026410.3390/v10050264 40.KumarS.TamuraK.NeiM.MEGA3: Integrated software for"/>
   <result pre="and sequence alignmentBrief. Bioinform.2004515016310.1093/bib/5.2.15015260895 41.AshenbergO.PadmakumarJ.DoudM.B.BloomJ.D.Deep mutational scanning identifies sites in" exact="influenza" post="nucleoprotein that affect viral inhibition by MxAPLoS Pathog.201713e100628810.1371/journal.ppat.100628828346537 42.BiswasS.K.BoutzP.L.NayakD.P.Influenza"/>
   <result pre="viral inhibition by MxAPLoS Pathog.201713e100628810.1371/journal.ppat.100628828346537 42.BiswasS.K.BoutzP.L.NayakD.P.Influenza virus nucleoprotein interacts with" exact="influenza" post="virus polymerase proteinsJ. Virol.199872549355019621005 43.LearT.BreenM.Ponce de LeonF.CoogleL.FergusonE.ChambersT.BaileyE.Cloning and chromosomal"/>
   <result pre="of H5N1Rev. Sci. Tech. (Int. Off. Epizoot.)20092818710.20506/rst.28.1.1879 46.CrawfordP.DuboviE.J.CastlemanW.L.StephensonI.GibbsE.ChenL.SmithC.HillR.C.FerroP.PompeyJ.Transmission of equine" exact="influenza" post="virus to dogsScience200531048248510.1126/science.111795016186182 47.TuJ.ZhouH.JiangT.LiC.ZhangA.GuoX.ZouW.ChenH.JinM.Isolation and molecular characterization of equine"/>
   <result pre="virus to dogsScience200531048248510.1126/science.111795016186182 47.TuJ.ZhouH.JiangT.LiC.ZhangA.GuoX.ZouW.ChenH.JinM.Isolation and molecular characterization of equine H3N8" exact="influenza" post="viruses from pigs in ChinaArch. Virol.200915488789010.1007/s00705-009-0381-119396578 48.EngelhardtO.G.UllrichE.KochsG.HallerO.Interferon-induced antiviral Mx1"/>
   <result pre="is associated with components of the SUMO-1 system and promyelocytic" exact="leukemia" post="protein nuclear bodiesExp. Cell Res.200127128629510.1006/excr.2001.538011716541 49.PatzinaC.HallerO.KochsG.Structural requirements for the"/>
   <result pre="antiviral activity of the human MxA protein against Thogoto and" exact="influenza" post="A virusJ. Biol. Chem.20142896020602710.1074/jbc.M113.54389224448803 50.GieseS.CiminskiK.BolteH.MoreiraÉ.A.LakdawalaS.HuZ.DavidQ.KolesnikovaL.GötzV.ZhaoY.Role of influenza A virus"/>
   <result pre="against Thogoto and influenza A virusJ. Biol. Chem.20142896020602710.1074/jbc.M113.54389224448803 50.GieseS.CiminskiK.BolteH.MoreiraÉ.A.LakdawalaS.HuZ.DavidQ.KolesnikovaL.GötzV.ZhaoY.Role of" exact="influenza" post="A virus NP acetylation on viral growth and replicationNat."/>
   <result pre="tag and flag tag. (C,D) Relative luciferase activities of different" exact="influenza" post="A virus (IAV) strains. Human embryonic kidney 293T (HEK293T)"/>
   <result pre="representative experiment). Figure 2 Phylogenetic analysis demonstrates the relationship of" exact="influenza" post="A virus NP from distinct hosts. Molecular phylogenetic analysis"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6952674\results\search\disease\results.xml">
   <result pre="P, Nair N, De Jong A. 2020. Genome sequences of" exact="chikungunya" post="virus strains from Bangladesh and Thailand. Microbiol Resour Announc"/>
   <result pre="Attribution 4.0 International license.MRA.01452-19.pdf We sequenced the genomes of two" exact="chikungunya" post="virus isolates obtained from viremic patients who had traveled"/>
   <result pre="African genotype. Abstract ABSTRACT We sequenced the genomes of two" exact="chikungunya" post="virus isolates obtained from viremic patients who had traveled"/>
   <result pre="20 years, the reemergence and global spread of the arthropod-borne" exact="chikungunya" post="virus (CHIKV) (genus Alphavirus, family Togaviridae) have resulted in"/>
   <result pre="Human Ethics Committee. References REFERENCES 1.PykeAT, MoorePR, McMahonJ2018New insights into" exact="chikungunya" post="virus emergence and spread from Southeast Asia. Emerg Microbes"/>
   <result pre="PhumeeA, BoonsermR, Sor-SuwanS, BuathongR, WacharapluesadeeS, BrownellN, PoovorawanY, SiriyasatienP2019Genetic characterization of" exact="chikungunya" post="virus in field-caught Aedes aegypti mosquitoes collected during the"/>
   <result pre="HurkAF, Hall-MendelinS, PykeAT, SmithGA, MackenzieJS2010Vector competence of Australian mosquitoes for" exact="chikungunya" post="virus. Vector Borne Zoonotic Dis10:489–495. doi:10.1089/vbz.2009.0106.19877822 5.HuangB, PykeAT, McMahonJ,"/>
   <result pre="5.HuangB, PykeAT, McMahonJ, WarrilowD2017Complete coding sequence of a case of" exact="chikungunya" post="virus imported into Australia. Genome Announc5:e00310-17. doi:10.1128/genomeA.00310-17.28495775 6.PykeAT, HuangB,"/>
   <result pre="PLoS One5:e9490. doi:10.1371/journal.pone.0009490.20224823 9.TsetsarkinKA, VanlandinghamDL, McGeeCE, HiggsS2007A single mutation in" exact="chikungunya" post="virus affects vector specificity and epidemic potential. PLoS Pathog3:e201."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6955097\results\search\disease\results.xml">
   <result pre="al. 2017a; Kellner et al. 2018), including spillover of feline" exact="leukemia" post="virus from domestic cats to the endangered Florida panther"/>
   <result pre="bobcat (Lynx rufus) to puma (Lee et al. 2017a), feline" exact="leukemia" post="virus transmission from domestic cat to puma (Cunningham et"/>
   <result pre="feline viral infections such as feline immunodeficiency virus and feline" exact="leukemia" post="virus (Mochizuki, Akuzawa, and Nagatomo 1990), thereby supporting an"/>
   <result pre="model more virulent disease, such as that caused by feline" exact="leukemia" post="virus, which is a major threat to the endangered"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6955252\results\search\disease\results.xml">
   <result pre="C. 2020. The G protein-coupled receptor FFAR2 promotes internalization during" exact="influenza" post="A virus entry. J Virol 94:e01707-19. https://doi.org/10.1128/JVI.01707-19. epreprint: 2019-11-11epub:"/>
   <result pre="for antiviral drug development. KEYWORDS β-arrestin1 AP2B1 FFAR2 GRK entry" exact="influenza" post="A virus internalization Funding National Key Research and Development"/>
   <result pre="epidemics caused by H1 or H3 IAVs and occasional pandemics," exact="avian influenza" post="viruses, such as those of the H5N1, H7N9, and"/>
   <result pre="caused by H1 or H3 IAVs and occasional pandemics, avian" exact="influenza" post="viruses, such as those of the H5N1, H7N9, and"/>
   <result pre="glutamate receptor 2 (mGluR2) is a novel cellular receptor for" exact="rabies" post="virus (RABV) through interaction with RABV G protein (20)."/>
   <result pre="the effect of FFAR2 knockdown on the replication of vesicular" exact="stomatitis" post="virus encoding an enhanced green fluorescent protein reporter gene"/>
   <result pre="pretreatment of A549 cells with 100 μM 4-CMTB led to significant" exact="suppression" post="of viral NP expression at the early time points"/>
   <result pre="data suggest that FFAR2 is a crucial host factor for" exact="influenza" post="virus entry into host cells. FIG 10 Model of"/>
   <result pre="followed by further interaction with AP2B1. Ultimately, the FFAR2–β-arrestin1–AP2B1 complex" exact="aids" post="in the internalization of IAV via clathrin-mediated endocytosis. MATERIALS"/>
   <result pre="METHODS Cells and viruses. Human embryonic kidney cells (HEK293T), human" exact="lung carcinoma" post="cells (A549), Madin-Darby canine kidney (MDCK) cells, and murine"/>
   <result pre="contained 100 U/ml penicillin and 100 μg/ml streptomycin (Life Technologies). Venus-expressing reporter" exact="influenza" post="viruses, H1N1 NA-Venus, H5N1 NA-Venus, and H9N2 NA-Venus, were"/>
   <result pre="JiangL, GuanY, XinX, JiangY, TianG, WangX, QiaoC, LiC, BuZ, ChenH2013H7N9" exact="influenza" post="viruses are transmissible in ferrets by respiratory droplet. Science341:410–414."/>
   <result pre="KawakamiE, YamadaS, KisoM, SuzukiY, MaherEA, NeumannG, KawaokaY2012Experimental adaptation of an" exact="influenza" post="H5 HA confers respiratory droplet transmission to a reassortant"/>
   <result pre="ferrets. Nature486:420–428. doi:10.1038/nature10831.22722205 3.KimbleJB, SorrellE, ShaoHX, MartinPL, PerezDR2011Compatibility of H9N2" exact="avian influenza" post="surface genes and 2009 pandemic H1N1 internal genes for"/>
   <result pre="Nature486:420–428. doi:10.1038/nature10831.22722205 3.KimbleJB, SorrellE, ShaoHX, MartinPL, PerezDR2011Compatibility of H9N2 avian" exact="influenza" post="surface genes and 2009 pandemic H1N1 internal genes for"/>
   <result pre="MunsterVJ, SorrellEM, BestebroerTM, BurkeDF, SmithDJ, RimmelzwaanGF, OsterhausADME, FouchierRAM2012Airborne transmission of" exact="influenza" post="A/H5N1 virus between ferrets. Science336:1534–1541. doi:10.1126/science.1213362.22723413 5.LiXY, ShiJZ, GuoJ,"/>
   <result pre="binding property, and transmissibility in mammals of naturally isolated H9N2" exact="avian influenza" post="viruses. PLoS Pathog10:e1004508. doi:10.1371/journal.ppat.1004508.25411973 6.ZhangY, ZhangQY, KongHH, JiangYP, GaoYW,"/>
   <result pre="property, and transmissibility in mammals of naturally isolated H9N2 avian" exact="influenza" post="viruses. PLoS Pathog10:e1004508. doi:10.1371/journal.ppat.1004508.25411973 6.ZhangY, ZhangQY, KongHH, JiangYP, GaoYW,"/>
   <result pre="droplet. Science340:1459–1463. doi:10.1126/science.1229455.23641061 7.RogersGN, PaulsonJC1983Receptor determinants of human and animal" exact="influenza" post="virus isolates: differences in receptor specificity of the H3"/>
   <result pre="doi:10.1016/0042-6822(83)90150-2.6868370 8.RustMJ, LakadamyaliM, ZhangF, ZhuangX2004Assembly of endocytic machinery around individual" exact="influenza" post="viruses during viral entry. Nat Struct Mol Biol11:567–573. doi:10.1038/nsmb769.15122347"/>
   <result pre="TscherneDM, WienholtsMJ, Cobos-JiménezV, ScholteF, García-SastreA, RottierPJM, de HaanCAM2011Dissection of the" exact="influenza" post="A virus endocytic routes reveals macropinocytosis as an alternative"/>
   <result pre="is a cargo-specific adaptor for the clathrin-mediated endocytosis of the" exact="influenza" post="virus. Proc Natl Acad Sci U S A105:11790–11795. doi:10.1073/pnas.0803711105.18689690"/>
   <result pre="LudwigS, EhrhardtC2010The epidermal growth factor receptor (EGFR) promotes uptake of" exact="influenza" post="A viruses (IAV) into host cells. PLoS Pathog6:e1001099. doi:10.1371/journal.ppat.1001099.20844577"/>
   <result pre="NurnbergB, PlanzO, PleschkaS, LudwigS2006Bivalent role of the phosphatidylinositol-3-kinase (PI3K) during" exact="influenza" post="virus infection and host cell defence. Cell Microbiol8:1336–1348. doi:10.1111/j.1462-5822.2006.00713.x.16882036"/>
   <result pre="signaling plays a subtype-specific role in postbinding cell entry of" exact="influenza" post="A virus. J Virol88:417–424. doi:10.1128/JVI.02591-13.24155396 16.HeJ, SunE, BujnyMV, KimD,"/>
   <result pre="16.HeJ, SunE, BujnyMV, KimD, DavidsonMW, ZhuangX2013Dual function of CD81 in" exact="influenza" post="virus uncoating and budding. PLoS Pathog9:e1003701. doi:10.1371/journal.ppat.1003701.24130495 17.SuWC, ChenYC,"/>
   <result pre="LaiMM2013Pooled RNAi screen identifies ubiquitin ligase Itch as crucial for" exact="influenza" post="A virus release from the endosome during virus entry."/>
   <result pre="BuZ2018Metabotropic glutamate receptor subtype 2 is a cellular receptor for" exact="rabies" post="virus. PLoS Pathog14:e1007189. doi:10.1371/journal.ppat.1007189.30028877 21.ChengH, Lear-RooneyCM, JohansenL, VarhegyiE, ChenZW,"/>
   <result pre="KisoM, YamashitaM, MaekawaT, KubotaM, SuganoS, KawaokaY2018Stimulation of alpha2-adrenergic receptors impairs" exact="influenza" post="virus infection. Sci Rep8:4631. doi:10.1038/s41598-018-22927-0.29545586 23.YanY, LiuQ, LiN, DuJ,"/>
   <result pre="as a novel therapy in acute lung injury induced by" exact="avian influenza" post="A H5N1 virus infection in mouse. Sci China Life"/>
   <result pre="a novel therapy in acute lung injury induced by avian" exact="influenza" post="A H5N1 virus infection in mouse. Sci China Life"/>
   <result pre="LiC2018Generation and application of replication-competent Venus-expressing H5N1, H7N9, and H9N2" exact="influenza" post="A viruses. Sci Bull63:176–186. doi:10.1016/j.scib.2018.01.002. 39.SmithNJ, WardRJ, StoddartLA, HudsonBD,"/>
   <result pre="PaulsonJC1990Sialyloligosaccharides of the respiratory epithelium in the selection of human" exact="influenza" post="virus receptor specificity. Acta Histochem Suppl40:35–38.2091044 42.KrupnickJG, BenovicJL1998The role"/>
   <result pre="doi:10.1016/S0898-6568(03)00099-8.14499340 50.SieczkarskiSB, BrownHA, WhittakerGR2003Role of protein kinase C βII in" exact="influenza" post="virus entry via late endosomes. J Virol77:460–469. doi:10.1128/jvi.77.1.460-469.2003.12477851 51.EdingerTO,"/>
   <result pre="via late endosomes. J Virol77:460–469. doi:10.1128/jvi.77.1.460-469.2003.12477851 51.EdingerTO, PohlMO, StertzS2014Entry of" exact="influenza" post="A virus: host factors and antiviral targets. J Gen"/>
   <result pre="J Virol92:e00196-18. doi:10.1128/JVI.00196-18.29514909 62.LiS, AhmadI, ShiJ, WangB, YuC, ZhangL, ZhengYH2019Murine" exact="leukemia" post="virus glycosylated Gag reduces murine SERINC5 protein expression at"/>
   <result pre="ZhangJ, WangG, JiangL, ChenH, LiC2017Host cellular protein TRAPPC6AΔ interacts with" exact="influenza" post="A virus M2 protein and regulates viral propagation by"/>
   <result pre="JiangY, DengG, BuZ, LiC, JiangL, ChenH2018Phospholipid scramblase 1 interacts with" exact="influenza" post="A virus NP, impairing its nuclear import and thereby"/>
   <result pre="drives the acquisition of the PB2 E627K mutation of H7N9" exact="avian influenza" post="virus in mammals. mBio10:e01162-19. doi:10.1128/mBio.01162-19.31213560 69.MaL, LiF, ZhangJW, LiW,"/>
   <result pre="the acquisition of the PB2 E627K mutation of H7N9 avian" exact="influenza" post="virus in mammals. mBio10:e01162-19. doi:10.1128/mBio.01162-19.31213560 69.MaL, LiF, ZhangJW, LiW,"/>
   <result pre="WangH, HuaRH, BuZG2018Host factor SPCS1 regulates the replication of Japanese" exact="encephalitis" post="virus through interactions with transmembrane domains of NS2B. J"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6955267\results\search\disease\results.xml">
   <result pre="for other globally prevalent arboviruses such as dengue virus and" exact="chikungunya" post="virus (CHIKV) (11, 28, 29). Considerable increases in virus"/>
   <result pre="significant alphaviruses in the past. The E1-A226V transition in the" exact="chikungunya" post="virus (CHIKV) genome enhanced transmission of this variant by"/>
   <result pre="for other alphaviruses, including SINV (40), CHIKV (28), Eastern equine" exact="encephalitis" post="virus (EEEV) (41), and Venezuelan equine encephalitis virus (42)."/>
   <result pre="(28), Eastern equine encephalitis virus (EEEV) (41), and Venezuelan equine" exact="encephalitis" post="virus (42). Making meaningful comparisons of these timescales is"/>
   <result pre="in the structural E gene (E 332) of Murray Valley" exact="encephalitis" post="virus that likely played a role in immune evasion,"/>
   <result pre="collab: National Arbovirus and Malaria Advisory Committee. 2014Arboviral diseases and" exact="malaria" post="in Australia, 2011–12: annual report of the National Arbovirus"/>
   <result pre="KoenraadtCJM, van OersMM, PijlmanP2018Conserved motifs in the hypervariable domain of" exact="chikungunya" post="virus nsP3 required for transmission by Aedes aegypti mosquitoes."/>
   <result pre="LimJK, HeiseMT2017Disruption of the opal stop codon attenuates Chikungunya virus-induced" exact="arthritis" post="and pathology. mBio8:e01456-17. doi:10.1128/mBio.01456-17.29138302 35.MylesKM, KellyCLH, LedermannJP, PowersAM2006Effects of"/>
   <result pre="UnnaschTR, CiotaAT, KramerLD, DasSR2018Large-scale complete-genome sequencing and phylodynamic analysis of" exact="eastern equine encephalitis" post="virus reveals source-sink transmission dynamics in the United States."/>
   <result pre="KramerLD, DasSR2018Large-scale complete-genome sequencing and phylodynamic analysis of eastern equine" exact="encephalitis" post="virus reveals source-sink transmission dynamics in the United States."/>
   <result pre="WentworthDE, SmithMD, Kosakovsky PondSL, WeaverSC2017Evolution and spread of Venezuelan equine" exact="encephalitis" post="complex alphavirus in the Americas. PLoS Negl Trop Dis11:e0005693."/>
   <result pre="DoggettSL, JohansenCA, MackenzieJS2015The molecular epidemiology and evolution of Murray Valley" exact="encephalitis" post="virus: recent emergence of distinct sub-lineages of the dominant"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6955377\results\search\disease\results.xml">
   <result pre="doi: 10.1073/pnas.1916585116 : Biological Sciences: Microbiology Divergent evolutionary trajectories of" exact="influenza" post="B viruses underlie their contemporaneous epidemic activity VirkRamandeep K.aJayakumarJayanthiahttp://orcid.org/0000-0003-4250-6459MendenhallIan"/>
   <result pre="under Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND).pnas.201916585.pdf Significance Two" exact="influenza" post="B viruses (Victoria and Yamagata) cocirculate in humans and"/>
   <result pre="to the estimated 290,000–650,000 annual influenza-attributed deaths. Here, we analysed" exact="influenza" post="B genomic data to understand the causes of a"/>
   <result pre="to understand the causes of a recent surge in human" exact="influenza" post="B infections. We found that evolution is acting differently"/>
   <result pre="has led to the cocirculation of a diverse group of" exact="influenza" post="B viruses. If this phenomenon continues, we could potentially"/>
   <result pre="could potentially witness the emergence of 3 or more distinct" exact="influenza" post="B viruses that could require their own vaccine component,"/>
   <result pre="viruses that could require their own vaccine component, thereby complicating" exact="influenza" post="vaccine formulation and highlighting the urgency of developing universal"/>
   <result pre="influenza vaccine formulation and highlighting the urgency of developing universal" exact="influenza" post="vaccines. Abstract Influenza B viruses have circulated in humans"/>
   <result pre="the reasons for which are unclear. By analyzing over 12,000" exact="influenza" post="B virus genomes, we describe the processes enabling the"/>
   <result pre="the long-term success and recent resurgence of epidemics due to" exact="influenza" post="B virus. We show that following prolonged diversification, both"/>
   <result pre="should be employed to monitor and develop robust protection against" exact="influenza" post="B morbidity and mortality. Overall, we show that long-term"/>
   <result pre="neuraminidase, are factors that contributed to successful circulation of diverse" exact="influenza" post="B clades. Further divergence of hemagglutinin variants with poor"/>
   <result pre="could potentially lead to circulation of 3 or more distinct" exact="influenza" post="B viruses, further complicating influenza vaccine formulation and highlighting"/>
   <result pre="of 3 or more distinct influenza B viruses, further complicating" exact="influenza" post="vaccine formulation and highlighting the urgent need for universal"/>
   <result pre="influenza vaccine formulation and highlighting the urgent need for universal" exact="influenza" post="vaccines. phylogeny genetic diversity natural selection antigenic vaccine Funding"/>
   <result pre="Siew-Chuan KoayDhanasekaran VijaykrishnaGavin JD SmithYvonne Su page-count: Two lineages of" exact="influenza" post="B viruses (&quot;B/Victoria/2/87-like�? and &quot;B/Yamagata/16/88-like,�? respectively, referred to as"/>
   <result pre="and the elderly being more susceptible to infection (1–3). Unlike" exact="influenza" post="A viruses, which periodically emerge from animals to cause"/>
   <result pre="and Yamagata lineages emerged as antigenic variants following divergence of" exact="influenza" post="B viruses during the 1970s, and both lineages have"/>
   <result pre="frequently mismatched with respect to the circulation of the dominant" exact="influenza" post="B lineage in a given season, resulting in low"/>
   <result pre="and Yamagata viruses evolve at a slower pace than in" exact="influenza" post="A virus lineages, although the Victoria lineage undergoes faster"/>
   <result pre="1A and 1B) (11). The development of greater diversity of" exact="influenza" post="B lineages raises a challenge to the existing quadrivalent"/>
   <result pre="diversity, reassortment plays a crucial role in the evolution of" exact="influenza" post="B viruses (9–11, 13). While Yamagata and Victoria viruses"/>
   <result pre="compatibility (9), as confirmed by in vitro experiments (14). Historically," exact="influenza" post="B virus epidemics have been characteristically low to sporadic"/>
   <result pre="low to sporadic in most countries during a year, with" exact="influenza" post="A viruses predominant in most countries. Since the first"/>
   <result pre="predominant in most countries. Since the first reports of high" exact="influenza" post="B virus activity in Europe in 2015, substantial epidemics"/>
   <result pre="indicating major changes in the evolutionary and epidemiological dynamics of" exact="influenza" post="B viruses (12, 15–19). Here, we analyzed all available"/>
   <result pre="influenza B viruses (12, 15–19). Here, we analyzed all available" exact="influenza" post="B genomic data (&amp;gt;12,000) in combination with 158 genomes"/>
   <result pre="the processes enabling the recent resurgence of epidemics due to" exact="influenza" post="B virus (see global epidemic activity in SI Appendix,"/>
   <result pre="sum, our results show that increases in epidemic dominance by" exact="influenza" post="B viruses is determined by a diverse set of"/>
   <result pre="than in the previous decades. Fig. 1. Phylodynamics of global" exact="influenza" post="B virus. Relative genetic diversities and temporal phylogenies of"/>
   <result pre="mutations within and between gene segments, and selection pressure of" exact="influenza" post="B viruses. (A) HA phylogeny of the Victoria lineage."/>
   <result pre="Victoria and Yamagata lineages is consistent with observations in seasonal" exact="influenza" post="A viruses, where emergence of between-subtype reassortants (e.g., between"/>
   <result pre="showing a correlation between reassortment and relative genetic diversity of" exact="influenza" post="B viruses. Selection Pressure of Victoria and Yamagata Lineages."/>
   <result pre="that the NA is contributing significantly to the evolution of" exact="influenza" post="B virus. Viral Migration Dynamics. We reconstructed the global"/>
   <result pre="virus. Viral Migration Dynamics. We reconstructed the global phylogeography of" exact="influenza" post="B viruses using the Markov fields model (20). We"/>
   <result pre="Appendix, Fig. S26). Fig. 4. Phylogeography and age distribution of" exact="influenza" post="B viruses. (A) Proportion of ancestral geographical location states"/>
   <result pre="(SA), and Southeast Asia (SEA). (C) Age density distribution of" exact="influenza" post="B virus by lineage. The violin plot indicates the"/>
   <result pre="2 decades reveal a dynamic pattern of evolution of seasonal" exact="influenza" post="viruses that were not observed previously using shorter time"/>
   <result pre="significant changes in the evolutionary landscapes of the 2 cocirculating" exact="influenza" post="B lineages, Victoria and Yamagata. For the Victoria lineage,"/>
   <result pre="The observation of HA deletion variants is not unprecedented in" exact="influenza" post="B viruses; the influenza B prototype strain B/Lee/1940 possessed"/>
   <result pre="deletion variants is not unprecedented in influenza B viruses; the" exact="influenza" post="B prototype strain B/Lee/1940 possessed an amino acid deletion"/>
   <result pre="HA protein, they may be crucial for antigenic properties of" exact="influenza" post="B viruses (24). At the time of writing, the"/>
   <result pre="B viruses (24). At the time of writing, the current" exact="influenza" post="vaccine strain selected for the Victoria lineage was the"/>
   <result pre="antigenically distinct variants. The circulation of 3 or more distinct" exact="influenza" post="B viruses would drastically complicate influenza vaccine formulation. We"/>
   <result pre="3 or more distinct influenza B viruses would drastically complicate" exact="influenza" post="vaccine formulation. We found that the NA of Yamagata"/>
   <result pre="that coincide with global epidemics of Yamagata viruses (16–19). The" exact="influenza" post="vaccine strain for the Yamagata lineage (B/Phuket/3073/2013-like) has remain"/>
   <result pre="cross-react with older viruses. Increasing awareness of the importance of" exact="influenza" post="virus NA immunity has prompted recent efforts to understand"/>
   <result pre="anti-NA antibodies can significantly reduce virus titers and shedding of" exact="influenza" post="B viruses (27) and lower the duration of illness"/>
   <result pre="B viruses (27) and lower the duration of illness in" exact="influenza" post="A/H1N1 virus (28). Crucially, anti-NA antibodies can broadly cross-react"/>
   <result pre="broadly cross-react against H1N1 and H3N2 subtype viruses, but current" exact="influenza" post="vaccines cannot induce an efficient NA response (29). Furthermore,"/>
   <result pre="we have revealed key molecular processes affecting the evolution of" exact="influenza" post="B virus that have contributed to immune escape and"/>
   <result pre="on the antigenic and genetic evolution and global circulation of" exact="influenza" post="B virus. Addressing these aspects can potentially aid modeling"/>
   <result pre="of epidemic outbreaks, and also inform the development of universal" exact="influenza" post="vaccines that are the cornerstone of current research efforts"/>
   <result pre="RT-PCR. Influenza A virus was detected in 1,493 samples and" exact="influenza" post="B in 654 samples. A subset of influenza B"/>
   <result pre="samples and influenza B in 654 samples. A subset of" exact="influenza" post="B samples was selected for full genome sequencing using"/>
   <result pre="swabs and followed by RT-PCR amplification of whole genome of" exact="influenza" post="B (32, 33). The PCR products were quantified using"/>
   <result pre="UGENE, and consensus sequences were obtained. A total of 158" exact="influenza" post="B genomes (76 Victoria and 82 Yamagata) were generated."/>
   <result pre="Genomic Analysis of Influenza B Viruses. We downloaded &amp;gt;12,000 global" exact="influenza" post="B genomes (as of May 30, 2019) from National"/>
   <result pre="2008 to 2019. To investigate the evolutionary dynamics of recent" exact="influenza" post="B outbreaks, we first reconstructed the global evolution using"/>
   <result pre="phylogenies. Reassortment Analysis. Based on the global HA phylogeny of" exact="influenza" post="B lineages, the Victoria and Yamagata split into 2"/>
   <result pre="Influenza B Viruses. To infer the spatial-temporal dynamics of each" exact="influenza" post="B lineage, a Bayesian Stochastic Search Variable Selection (BSSVS)"/>
   <result pre="Global Host Age Distribution. We downloaded the global sequences of" exact="influenza" post="B viruses (Victoria: 5,302 and Yamagata: 7,360) from 2008"/>
   <result pre="Proportion Positive (GRIPP) Working Group, Global role and burden of" exact="influenza" post="in pediatric respiratory hospitalizations, 1982-2012: A systematic analysis. PLoS"/>
   <result pre="network, Clinical characteristics are similar across type A and B" exact="influenza" post="virus infections. PLoS One10, e0136186 (2015).26325069 4ShawM. W.et al.,"/>
   <result pre="4ShawM. W.et al., Reappearance and global spread of variants of" exact="influenza" post="B/Victoria/2/87 lineage viruses in the 2000-2001 and 2001-2002 seasons."/>
   <result pre="2000-2001 and 2001-2002 seasons. Virology303, 1–8 (2002).12482653 5TisaV.et al., Quadrivalent" exact="influenza" post="vaccine: A new opportunity to reduce the influenza burden."/>
   <result pre="al., Quadrivalent influenza vaccine: A new opportunity to reduce the" exact="influenza" post="burden. J. Prev. Med. Hyg.57, E28–E33 (2016).27346937 6HeikkinenT., IkonenN.,"/>
   <result pre="Prev. Med. Hyg.57, E28–E33 (2016).27346937 6HeikkinenT., IkonenN., ZieglerT., Impact of" exact="influenza" post="B lineage-level mismatch between trivalent seasonal influenza vaccines and"/>
   <result pre="ZieglerT., Impact of influenza B lineage-level mismatch between trivalent seasonal" exact="influenza" post="vaccines and circulating viruses, 1999-2012. Clin. Infect. Dis.59, 1519–1524"/>
   <result pre="1999-2012. Clin. Infect. Dis.59, 1519–1524 (2014).25139969 7SunW.et al., Development of" exact="influenza" post="B universal vaccine candidates using the &quot;Mosaic�? hemagglutinin approach."/>
   <result pre="Virol.93, e00333-19 (2019).30944178 8BedfordT.et al., Global circulation patterns of seasonal" exact="influenza" post="viruses vary with antigenic drift. Nature523, 217–220 (2015).26053121 9DudasG.,"/>
   <result pre="drift. Nature523, 217–220 (2015).26053121 9DudasG., BedfordT., LycettS., RambautA., Reassortment between" exact="influenza" post="B lineages and the emergence of a coadapted PB1-PB2-HA"/>
   <result pre="Evol.32, 162–172 (2015).25323575 10VijaykrishnaD.et al., The contrasting phylodynamics of human" exact="influenza" post="B viruses. eLife4, e05055 (2015).25594904 11LangatP.et al., Genome-wide evolutionary"/>
   <result pre="viruses. eLife4, e05055 (2015).25594904 11LangatP.et al., Genome-wide evolutionary dynamics of" exact="influenza" post="B viruses on a global scale. PLoS Pathog.13, e1006749"/>
   <result pre="(2017).29284042 12BarrI. G., VijaykrishnaD., SullivanS. G., Differential age susceptibility to" exact="influenza" post="B/Victoria lineage viruses in the 2015 Australian influenza season."/>
   <result pre="susceptibility to influenza B/Victoria lineage viruses in the 2015 Australian" exact="influenza" post="season. Euro Surveill.21, 30118 (2016). 13ChenR., HolmesE. C., The"/>
   <result pre="30118 (2016). 13ChenR., HolmesE. C., The evolutionary dynamics of human" exact="influenza" post="B virus. J. Mol. Evol.66, 655–663 (2008).18504518 14KimJ. I.et"/>
   <result pre="compatibility between PB1, PB2, and HA genes of the two" exact="influenza" post="B virus lineages in mammalian cells. Sci. Rep.6, 27480"/>
   <result pre="15collab: World Health Organization, WHO recommendations on the composition of" exact="influenza" post="virus vaccines. https://www.who.int/influenza/vaccines/virus/recommendations/en/. Accessed 9 September 2019. 16AdlhochC., SnackenR.,"/>
   <result pre="MelidouA., IonescuS., PenttinenP.; collab: The European Influenza Surveillance Network, Dominant" exact="influenza" post="A(H3N2) and B/Yamagata virus circulation in EU/EEA, 2016/17 and"/>
   <result pre="States during the 2017-18 season and composition of the 2018-19" exact="influenza" post="vaccine. MMWR Morb. Mortal. Wkly. Rep.67, 634–642 (2018).29879098 18SkowronskiD."/>
   <result pre="Rep.67, 634–642 (2018).29879098 18SkowronskiD. M.et al., Early season co-circulation of" exact="influenza" post="A(H3N2) and B(Yamagata): Interim estimates of 2017/18 vaccine effectiveness,"/>
   <result pre="2018. Euro Surveill.23, 18-00035 (2018). 19KorsunN. S.et al., Predominance of" exact="influenza" post="B/Yamagata lineage viruses in Bulgaria during the 2017/2018 season."/>
   <result pre="Comput. Biol.5, e1000520 (2009).19779555 21TanY.et al., Differing epidemiological dynamics of" exact="influenza" post="B virus lineages in Guangzhou, southern China, 2009-2010. J."/>
   <result pre="J. Virol.87, 12447–12456 (2013).24027322 22SkowronskiD. M.et al., Age-related differences in" exact="influenza" post="B infection by lineage in a community-based sentinel system,"/>
   <result pre="J. Infect. Dis.216, 697–702 (2017).28934439 23NeromeR.et al., Evolutionary characteristics of" exact="influenza" post="B virus since its first isolation in 1940: Dynamic"/>
   <result pre="with amino acid deletions clarify a neutralizing epitope specific for" exact="influenza" post="B virus Victoria group strains. J. Gen. Virol.82, 2169–2172"/>
   <result pre="September 2019. 26collab: Centers for Disease Control and Prevention, Seasonal" exact="influenza" post="vaccine effectiveness, 2017-2018. https://www.cdc.gov/flu/vaccines-work/2017-2018.html. Accessed 9 September 2019. 27McMahonM.et"/>
   <result pre="9 September 2019. 27McMahonM.et al., Mucosal immunity against neuraminidase prevents" exact="influenza" post="B virus transmission in Guinea Pigs. MBio10, e00560-19 (2019).31113896"/>
   <result pre="al., Pre-existing anti-neuraminidase antibodies are associated with shortened duration of" exact="influenza" post="A (H1N1)pdm virus shedding and illness in naturally infected"/>
   <result pre="changes to the lateral surface of the neuraminidase head of" exact="influenza" post="A virus. Nat. Microbiol.4, 1024–1034 (2019).30886361 31HoffmannE.et al., Rescue"/>
   <result pre="A virus. Nat. Microbiol.4, 1024–1034 (2019).30886361 31HoffmannE.et al., Rescue of" exact="influenza" post="B virus from eight plasmids. Proc. Natl. Acad. Sci."/>
   <result pre="Proc. Natl. Acad. Sci. U.S.A.99, 11411–11416 (2002).12172012 32ZhouB.et al., Universal" exact="influenza" post="B virus genomic amplification facilitates sequencing, diagnostics, and reverse"/>
   <result pre="LohT. P., KoayE. S., Contamination-controlled high-throughput whole genome sequencing for" exact="influenza" post="A viruses using the MiSeq sequencer. Sci. Rep.6, 33318"/>
   <result pre="8 July 2019. 44SuY. C. F.et al., Phylodynamics of H1N1/2009" exact="influenza" post="reveals the transition from host adaptation to immune-driven selection."/>
   <result pre="Commun.6, 7952 (2015).26245473 45NagarajanN., KingsfordC., GiRaF: Robust, computational identification of" exact="influenza" post="reassortments via graph mining. Nucleic Acids Res.39, e34 (2011).21177643"/>
   <result pre="(2008).17874105 52BahlJ.et al., Temporally structured metapopulation dynamics and persistence of" exact="influenza" post="A H3N2 virus in humans. Proc. Natl. Acad. Sci."/>
   <result pre="PascualM., Global migration dynamics underlie evolution and persistence of human" exact="influenza" post="A (H3N2). PLoS Pathog.6, e1000918 (2010).20523898"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6956197\results\search\disease\results.xml">
   <result pre="aggression levels among colonies may represent one contributor in shaping" exact="viral disease" post="transmission in A. gracilipes. Future study should examine if"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6956279\results\search\disease\results.xml">
   <result pre="Fever Sicilian virus SFSV UVE/SFSV/1943/IT/Sabin (10 6,82) 001v-EVA77 Flavivirus Japanese" exact="encephalitis" post="virus JEV UVE/JEV/2009/LA/CNS769 (10 5,57) 001v-02217 Saint-Louis encephalitis virus"/>
   <result pre="Flavivirus Japanese encephalitis virus JEV UVE/JEV/2009/LA/CNS769 (10 5,57) 001v-02217 Saint-Louis" exact="encephalitis" post="virus SLEV UVE/SLEV/UNK/US/MSI-7 (10 4,82) 001v-EVA128 Tick-borne encephalitis virus"/>
   <result pre="001v-02217 Saint-Louis encephalitis virus SLEV UVE/SLEV/UNK/US/MSI-7 (10 4,82) 001v-EVA128 Tick-borne" exact="encephalitis" post="virus TBEV UVE/TBEV/2013/FR/32.11 WT-PCR (10 8,82) 001v-02352 West-Nile virus"/>
   <result pre="Dengue virus DENV-1 UVE/DENV-1/2013/NC/CNR_17132 (10 7,57) 001v-03151 Alphavirus Venezuelan equine" exact="encephalitis" post="virus VEEV UVE/VEEV/UNK/XX/TC83 vaccine (10 9,42) 001v-EVA1459 Western equine"/>
   <result pre="encephalitis virus VEEV UVE/VEEV/UNK/XX/TC83 vaccine (10 9,42) 001v-EVA1459 Western equine" exact="encephalitis" post="virus WEEV UVE/WEEV/UNK/XX/47a (10 8,32) 001v-EVA1479 Eastern equine encephalitis"/>
   <result pre="equine encephalitis virus WEEV UVE/WEEV/UNK/XX/47a (10 8,32) 001v-EVA1479 Eastern equine" exact="encephalitis" post="virus EEEV UVE/EEEV/1999/XX/H178_99 (10 7,82) 001v-EVA1480 O’nyong-nyong virus ONNV"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6958409\results\search\disease\results.xml">
   <result pre="Ninety years after the discovery of the virus causing the" exact="influenza" post="disease, this malady remains one of the biggest public"/>
   <result pre="viral infections and host–pathogen interactions. Even the functions of the" exact="influenza" post="proteins, their mechanisms of action and interaction with host"/>
   <result pre="to various genetic, molecular and biochemical approaches. The fact that" exact="influenza" post="remains an unsolved problem, in combination with the limitations"/>
   <result pre="cultures. In this review, we summarized the efforts to study" exact="influenza" post="in yeast, Drosophila, zebrafish and primary human tissue cultures"/>
   <result pre="has for better comprehending virus–host interactions and viral protein function." exact="influenza" post="MDCK A549 ferrets mice pigs macaque yeast S. cerevisiae"/>
   <result pre="Eradicated Almost ninety years after the virus causing the disastrous" exact="influenza" post="epidemics was identified [1], 3–5 million people are still"/>
   <result pre="more successful at tackling other viral maladies such as smallpox," exact="measles" post="and polio [4], and developed efficient drugs and vaccines"/>
   <result pre="made in vaccination and therapy [7,8]. However, the fact that" exact="influenza" post="still prevails demonstrates, unambiguously and painfully, that these drugs"/>
   <result pre="mutations could also account for the rapid evolution of drug-resistant" exact="influenza" post="strainsb (C8)(C9) [6]. Given that influenza is a RNA"/>
   <result pre="rapid evolution of drug-resistant influenza strainsb (C8)(C9) [6]. Given that" exact="influenza" post="is a RNA virus, its RNA polymerase lacks proofreading"/>
   <result pre="lacks proofreading activity and is more error-prone [9]. Also, as" exact="influenza" post="is able to infect a variety of hosts, this"/>
   <result pre="the function and mechanisms of action of several of the" exact="influenza" post="viral proteins. These latter aspects are being approached in"/>
   <result pre="therapy or comprehensive vaccination, combined with the many questions regarding" exact="influenza" post="pathology that are still open, has motivated investigators to"/>
   <result pre="to the simple animal models, another less used system in" exact="influenza" post="research is that of primary human tissue cultures [12]."/>
   <result pre="extract from them for better comprehending the intricacies of the" exact="influenza" post="virus and developing tools for devising novel anti-influenza therapies."/>
   <result pre="that cause respiratory diseases [13]. There are three types of" exact="influenza" post="viruses, named A, B and C. The most prolific"/>
   <result pre="and is the main cause of the seasonal and pandemic" exact="influenza" post="[3]. Its genome is composed of symmetrical helixes in"/>
   <result pre="nuclear export protein (NEP/non-structural protein NS2) [14]. Segments of some" exact="influenza" post="A virus strains may encode a second or third"/>
   <result pre="immunomodulatory, modulating the host response to the virus [16]. The" exact="influenza" post="A virus can be further classified into different subtypes"/>
   <result pre="and N2 subtypes have caused epidemics in humans [18]. The" exact="influenza" post="virus life cycle can be divided into the following"/>
   <result pre="Young children, the elderly, those with chronic conditions like diabetes," exact="heart disease" post="and kidney disease, and immunocompromised patients are especially vulnerable"/>
   <result pre="kidney disease, and immunocompromised patients are especially vulnerable to severe" exact="influenza" post="[2,20]. Severe influenza may result in complications such as"/>
   <result pre="immunocompromised patients are especially vulnerable to severe influenza [2,20]. Severe" exact="influenza" post="may result in complications such as acute bronchitis and"/>
   <result pre="may result in complications such as acute bronchitis and secondary" exact="bacterial pneumonia" post="[21]. Influenza viruses evolve constantly with antigenic shifts (reassortment"/>
   <result pre="result in complications such as acute bronchitis and secondary bacterial" exact="pneumonia" post="[21]. Influenza viruses evolve constantly with antigenic shifts (reassortment"/>
   <result pre="anti-influenza drugs, the major strategy to prevent or control seasonal" exact="influenza" post="epidemics is the annual influenza vaccination programme. Due to"/>
   <result pre="to prevent or control seasonal influenza epidemics is the annual" exact="influenza" post="vaccination programme. Due to its varied effectiveness year to"/>
   <result pre="antigenic strains. One of the main methods to produce the" exact="influenza" post="vaccine is through fertilized embryonated chicken eggs. First, the"/>
   <result pre="animals that investigators were able to infect with the human" exact="influenza" post="virus were ferrets [1] and this model remains in"/>
   <result pre="used [30]. Pigs are also used because the pathology of" exact="influenza" post="in their lungs is similar to its manifestation in"/>
   <result pre="be a logical first choice, under the assumption that the" exact="influenza" post="virus naturally infects these models. It is also further"/>
   <result pre="available resources such as antibodies limit its use. For mice," exact="influenza" post="virus could cause disease in mice if the virus"/>
   <result pre="available, mice might not be the ideal model for studying" exact="influenza" post="due to differences in disease pathogenesis and limited infective"/>
   <result pre="scope of infection and viral life cycle, new insights into" exact="influenza" post="could be derived from studying the intrinsic biochemical properties,"/>
   <result pre="afterward to be susceptible to infection by various strains of" exact="influenza" post="[46,47]. Apparently, other cell lines, such as kidney cells"/>
   <result pre="Since then, several MDCK derivatives have been developed to study" exact="influenza" post="in vitro [45,48,49,50,51], primarily as an alternative method to"/>
   <result pre="primarily as an alternative method to embryonated chicken eggs for" exact="influenza" post="virus propagation [50,52,53] and as a means of determining"/>
   <result pre="have also been used in almost 1000 papers to produce" exact="influenza" post="vaccines [57,58,59], study virus pathogenesis and replication kinetics and"/>
   <result pre="mice and is now approved in Japan for treatment of" exact="influenza" post="infection [62]. 2.2.2. Immortalized Lung Cells, e.g., A549 and"/>
   <result pre="bronchial epithelial cell line, have been widely used to study" exact="influenza" post="virus–host interactions [63,64,65,66,67,68,69,70,71,72,73,74,75,76,77,78], viral protein biochemistry [79,80], drug studies"/>
   <result pre="as a CRISPR activation screen, to identify genes that inhibit" exact="influenza" post="virus infection when they are overexpressed [82]. 2.2.3. HEK293"/>
   <result pre="and Vero cells are being studied for basic research regarding" exact="influenza" post="as well as for vaccine research (reviewed in Milian"/>
   <result pre="[44]). 2.3. Animal Models The use of animal models in" exact="influenza" post="research has been extensively discussed in previous reviews [29,30,33,87,88,89]."/>
   <result pre="readily available. Many inbred laboratory mice are also susceptible to" exact="influenza" post="virus infection [30]. However, a significant drawback of the"/>
   <result pre="is that wild mice are in fact not susceptible to" exact="influenza" post="because they express the antiviral protein Mx1 which is"/>
   <result pre="strains do not display disease following infection with primary human" exact="influenza" post="virus isolates [30]. This is, in part, due to"/>
   <result pre="This is, in part, due to the preference of human" exact="influenza" post="A virus for α2,6-linked sialic acid receptors on the"/>
   <result pre="α2,6-linked sialic acid receptor in the upper respiratory tract, where" exact="influenza" post="virus commonly replicates, mice express the α2,3-linked sialic acid"/>
   <result pre="share many of the clinical symptoms presented by humans following" exact="influenza" post="infection and are susceptible to the human influenza virus"/>
   <result pre="humans following influenza infection and are susceptible to the human" exact="influenza" post="virus [88]. Thus, no prior adaptation of the virus"/>
   <result pre="in humans. Given the similarity of the physiological response to" exact="influenza" post="virus between ferrets and humans, ferrets have been used"/>
   <result pre="between ferrets and humans, ferrets have been used to study" exact="influenza" post="proteins [94,95] and to assess the effectiveness of anti-viral"/>
   <result pre="macaques) have similar immune responses to humans in regard to" exact="influenza" post="infection ([99] and reviewed in Bouvier et al., 2010"/>
   <result pre="and ethical issues make such primates less accessible for routine" exact="influenza" post="studies [30]. To date, there has not been any"/>
   <result pre="in virus binding sites in macaques and in humans for" exact="avian influenza" post="[100]. 2.3.4. Pigs Since influenza A is the main"/>
   <result pre="virus binding sites in macaques and in humans for avian" exact="influenza" post="[100]. 2.3.4. Pigs Since influenza A is the main"/>
   <result pre="and in humans for avian influenza [100]. 2.3.4. Pigs Since" exact="influenza" post="A is the main cause of respiratory disease in"/>
   <result pre="2.3.4. Pigs Since influenza A is the main cause of" exact="respiratory disease" post="in pigs, this animal can be used as a"/>
   <result pre="this animal can be used as a model to study" exact="influenza" post="(reviewed by Rajao et al., 2015 [31]). This is"/>
   <result pre="models, animals and cell lines, are obviously biologically relevant for" exact="influenza" post="studies but do possess serious limitations. Prominent drawbacks of"/>
   <result pre="C. elegans, have been used for other biological research, no" exact="influenza" post="studies have been attempted in these models and will"/>
   <result pre="of proteins [123]. It was used, as such, for studying" exact="influenza" post="proteins, including the vRNP complex that was reconstituted in"/>
   <result pre="the powerful tools that come with it have been assisting" exact="influenza" post="research in several ways. A common approach is expressing"/>
   <result pre="the usefulness of yeast for studying structure-function relationships of important" exact="influenza" post="proteins and the properties of mutated viral proteins. NS1"/>
   <result pre="re-establishment of the proton gradient by M2. Interestingly, when the" exact="influenza" post="PA-X protein was expressed in yeast, 29 unintended mutations"/>
   <result pre="toxic to MDCK cells and three showed no activity against" exact="influenza" post="virus replication. Of the other four, three were able"/>
   <result pre="to study human proteins known to be targets of the" exact="influenza" post="virus. Many of these proteins have homologs in yeast,"/>
   <result pre="[140]. Yeast could also be used to establish the entire" exact="influenza" post="replicon to study, in an isolated system, the transcription"/>
   <result pre="budding out of the cell [143]. As the effect of" exact="influenza" post="on host machinery is so dramatic and involves interactions"/>
   <result pre="[194]. Since yeasts have already been used to generate novel" exact="influenza" post="vaccines [195,196], there seems to be untapped potential in"/>
   <result pre="et al., 2018 [206]) and for investigating oncogenic pathways and" exact="cancer" post="(reviewed in Mirzoyan et al., 2019 [207]; Enomoto, 2018"/>
   <result pre="[216,220,221,222,223,224,225]. 3.2.3. Drosophila and Influenza Virus Infection Several of the" exact="influenza" post="proteins have been studied in fly culture cells or"/>
   <result pre="in fly culture cells or in the whole fly. The" exact="influenza" post="M2 was expressed in the wing and the eye,"/>
   <result pre="bafilomycin, a drug that targets the V1V0 ATPase, prior to" exact="influenza" post="infection and this reduced infectivity [226]. Thus, this shows"/>
   <result pre="activity and allows the identification of important host targets of" exact="influenza" post="M2. The Drosophila model was used to report that"/>
   <result pre="influenza M2. The Drosophila model was used to report that" exact="influenza" post="NS1 was able to suppress RNA-silencing-based antiviral response (RSAR),"/>
   <result pre="pFR1gfp plasmid could rescue GFP expression. This result shows that" exact="influenza" post="NS1 functions as a RNA silencing suppressor through its"/>
   <result pre="compared to WT A/NS1, which is associated with lethal H5N1" exact="influenza" post="A virus [229]. Using the same viral RNA silencing"/>
   <result pre="levels of Hh target gene induction may be protective against" exact="influenza" post="infection [231]. An RNAi screen in Drosophila cell culture"/>
   <result pre="the feasibility of using this system for genome screens in" exact="influenza" post="[232]. Notably, a particular disadvantage of fly cells with"/>
   <result pre="Notably, a particular disadvantage of fly cells with respect to" exact="influenza" post="is the fact that they do not express the"/>
   <result pre="influenza is the fact that they do not express the" exact="influenza" post="virus receptor α2,6-linked sialic acid, which is required for"/>
   <result pre="HA and NA genes were replaced to encode the vesicular" exact="stomatitis" post="virus (VSV) glycoprotein G. With these modifications, the influenza"/>
   <result pre="vesicular stomatitis virus (VSV) glycoprotein G. With these modifications, the" exact="influenza" post="virus was able to enter Drosophila cells. A screen"/>
   <result pre="importance of the Drosophila system in the discovery of novel" exact="influenza" post="virus–host targets. It seems that the use of Drosophila"/>
   <result pre="Drosophila as a model and as an experimental tool for" exact="influenza" post="studies is only in its infancy. However, the advances"/>
   <result pre="seen with M. marinum, a bacteria species used to model" exact="tuberculosis" post="(which is the same genus as M. marinum) in"/>
   <result pre="performed in adult zebrafish for other viral infections such as" exact="chikungunya" post="[238], herpes simplex virus 1 [239] and hepatitis C"/>
   <result pre="adult zebrafish for other viral infections such as chikungunya [238]," exact="herpes simplex" post="virus 1 [239] and hepatitis C [240,241]. In the"/>
   <result pre="such as chikungunya [238], herpes simplex virus 1 [239] and" exact="hepatitis" post="C [240,241]. In the context of the influenza A"/>
   <result pre="[239] and hepatitis C [240,241]. In the context of the" exact="influenza" post="A virus (IAV), zebrafish embryos were reported to have"/>
   <result pre="MAPK, Rho/ROCK and PKC pathways [244]. Finally, using a zebrafish" exact="muscular dystrophy" post="model (sapje/dmd), infected zebrafish were found to have severe"/>
   <result pre="These studies clearly display zebrafish as a relevant model for" exact="influenza" post="studies. 3.4. Primary Human Tissue Culture As described above,"/>
   <result pre="main cell lines that have been traditionally used for studying" exact="influenza" post="included the MDCK cells and cancer-derived lung cell lines"/>
   <result pre="immortal cell lines that are readily infectable and in which" exact="influenza" post="replicates is of obvious convenience. These systems contributed indeed"/>
   <result pre="These systems contributed indeed significantly to our current understanding of" exact="influenza" post="(reviewed in Powell et al., 2018,2018 [12,245]). Nevertheless, established"/>
   <result pre="cells that secrete a class of proteases that can cleave" exact="influenza" post="HA for viral entry [247], and when cultured at"/>
   <result pre="cell types that were preferentially infected by the virus. Different" exact="influenza" post="viruses (human and avian source) tended to infect different"/>
   <result pre="may reflect the pathogenicity of H5N6 viruses to cause severe" exact="influenza" post="in humans. 3.4.1. Human Nasal Epithelial Cells (NECs) The"/>
   <result pre="trachea) are important for the spread and infection of the" exact="influenza" post="virus [254]. Studies with primary human nasal epithelial cells"/>
   <result pre="nasal epithelial cells (NECs) have significantly assisted our understanding of" exact="influenza" post="in this tissue. For example, in normal tissue infected"/>
   <result pre="only way in which responses of smokers and patients to" exact="influenza" post="infection could have been tested. Adult human nasal epithelial"/>
   <result pre="nasal biopsy specimens of both healthy subjects and patients with" exact="allergic rhinitis" post="have been established [259]. The in vitro- passaged hNESPCs"/>
   <result pre="biopsy specimens of both healthy subjects and patients with allergic" exact="rhinitis" post="have been established [259]. The in vitro- passaged hNESPCs"/>
   <result pre="of hNECs has uncovered novel host signaling mechanisms which the" exact="influenza" post="virus can stimulate. For example, H3N2 infection of hNECs"/>
   <result pre="revealed perturbations in homeostasis and metabolic pathways in response to" exact="influenza" post="infection [262]. Other interesting observations using patient-derived NECs include"/>
   <result pre="the trachea and carina. While normally an upper respiratory infection," exact="influenza" post="is known to cause complications such as bronchitis in"/>
   <result pre="children [21]. Hence, NHBE cells may provide further knowledge to" exact="influenza" post="tropism, the host susceptibility to complications and response to"/>
   <result pre="cellular tropism, several studies have used them to compare various" exact="avian influenza" post="strains [265,266,267,268]. NHBE cells predominantly display α2,6 linkage sialic"/>
   <result pre="tropism, several studies have used them to compare various avian" exact="influenza" post="strains [265,266,267,268]. NHBE cells predominantly display α2,6 linkage sialic"/>
   <result pre="predictive ability of a novel viral strain in causing severe" exact="influenza" post="in humans. To better understand the effects and functions"/>
   <result pre="shown to have lower conductance of the chloride ion channel" exact="cystic fibrosis" post="transmembrane regulator (CFTR) [273]. This may be due to"/>
   <result pre="to provide a better understanding of the host response to" exact="influenza" post="infection in the bronchial tissues. Proteomic studies performed with"/>
   <result pre="to test DAS181 efficacy in removing sialic acid and inhibiting" exact="influenza" post="infection [286]. Given these results, DAS181 has currently reached"/>
   <result pre="are therefore a most valuable tool for personalized treatment of" exact="influenza" post="patients. 3.4.3. Human Alveolar Epithelial Cells (AECs) The alveolar"/>
   <result pre="portion of the lung, which is the main target for" exact="influenza" post="A pneumonia. The epithelium is made up of two"/>
   <result pre="lung [288]. The different cell tropism between various strains of" exact="influenza" post="was described, but it was found that the viruses"/>
   <result pre="from human lungs, and these cells were shown to support" exact="influenza" post="infection with PR8 and A/Philippines/1982 (H3N2) [296]. ATII cells"/>
   <result pre="compared to non-obese donors. The link between infection rates and" exact="obesity" post="could have been monitored only in the patients-derived primary"/>
   <result pre="different host processes can be elucidated in the context of" exact="influenza" post="to further understand host–virus interactions in specific cell types."/>
   <result pre="SP-D [302]. While some of these processes are known in" exact="influenza" post="infection, these studies with AECs confirm the role of"/>
   <result pre="not relevant on a first glance, when studying aspects of" exact="influenza" post="infection in yeast, Drosophila and zebrafish provide knowledge and"/>
   <result pre="are in their infancy of contributing to the field of" exact="influenza" post="research and the vast potential they hold in helping"/>
   <result pre="the vast potential they hold in helping better understand of" exact="influenza" post="awaits more extensive use of these models. Most of"/>
   <result pre="a specific host protein. And yet, only several of the" exact="influenza" post="proteins have been expressed in yeast, flies and fish."/>
   <result pre="a better treatment or vaccination. While the traditional models of" exact="influenza" post="have their advantages and usefulness, we believe that the"/>
   <result pre="alternative model. It is anticipated that many molecular mechanisms of" exact="influenza" post="and new therapies against this long-standing malady will be"/>
   <result pre="no conflicts of interest. References References 1.SmithW.AndrewesC.H.LaidlawP.P.A virus obtained from" exact="influenza" post="patientsLancet1933222666810.1016/S0140-6736(00)78541-2 2.HussainM.GalvinH.D.HawT.Y.NutsfordA.N.HusainM.Drug resistance in influenza A virus: The epidemiology"/>
   <result pre="References 1.SmithW.AndrewesC.H.LaidlawP.P.A virus obtained from influenza patientsLancet1933222666810.1016/S0140-6736(00)78541-2 2.HussainM.GalvinH.D.HawT.Y.NutsfordA.N.HusainM.Drug resistance in" exact="influenza" post="A virus: The epidemiology and managementInfect. Drug Resist.20171012113410.2147/IDR.S10547328458567 3.ShenZ.LouK.WangW.New"/>
   <result pre="Drug Resist.20171012113410.2147/IDR.S10547328458567 3.ShenZ.LouK.WangW.New small-molecule drug design strategies for fighting resistant" exact="influenza" post="AActa Pharm. Sin. B2015541943010.1016/j.apsb.2015.07.00626579472 4.GreenwoodB.The contribution of vaccination to"/>
   <result pre="Rev.2010329011910.1007/BF03391594 6.KrammerF.SmithG.J.D.FouchierR.A.M.PeirisM.KedzierskaK.DohertyP.C.PaleseP.ShawM.L.TreanorJ.WebsterR.G.et al.InfluenzaNat. Rev. Dis. Primers20184310.1038/s41572-018-0002-y29955068 7.BarberisI.MylesP.AultS.K.BragazziN.L.MartiniM.History and evolution of" exact="influenza" post="control through vaccination: From the first monovalent vaccine to"/>
   <result pre="21—OrthomyxoviridaeFenner’s Veterinary Virology5th ed.Academic PressBoston, MA, USA201738941010.1016/B978-0-12-800946-8.00021-0 14.NodaT.Native morphology of" exact="influenza" post="virionsFront. Microbiol.2012226910.3389/fmicb.2011.0026922291683 15.McCauleyJ.HongoS.KaverinN.KochsG.LambR.MatrosovichM.PerezD.PaleseP.PrestiR.RimstadE.Family—OrthomyxoviridaeVirus TaxonomyKingA.M.Q.AdamsM.J.CarstensE.B.LefkowitzE.J.ElsevierSan Diego, CA, USA201274976110.1016/B978-0-12-384684-6.00061-6 16.KlemmC.BoergelingY.LudwigS.EhrhardtC.Immunomodulatory Nonstructural"/>
   <result pre="Bats Harbor Diverse Influenza A VirusesPLoS Pathog.20139e100365710.1371/journal.ppat.100365724130481 18.BouvierN.M.PaleseP.The biology of" exact="influenza" post="virusesVaccine200826Suppl. 4D49D5310.1016/j.vaccine.2008.07.03919230160 19.SamjiT.Influenza A: Understanding the Viral Life CycleYale"/>
   <result pre="Understanding the Viral Life CycleYale J. Biol. Med.20098215315920027280 20.BarkerW.H.MulloolyJ.P.Pneumonia and" exact="influenza" post="deaths during epidemics: Implications for preventionArch. Intern. Med.1982142858910.1001/archinte.1982.003401400870167053739 21.TaubenbergerJ.K.MorensD.M.The"/>
   <result pre="Virus InfectionsAnnu. Rev. Pathol.2008349952210.1146/annurev.pathmechdis.3.121806.15431618039138 22.AriasC.F.Escalera-ZamudioM.Soto-Del Rio MdeL.Cobian-GuemesA.G.IsaP.LopezS.Molecular anatomy of 2009" exact="influenza" post="virus A (H1N1)Arch. Med. Res.20094064365410.1016/j.arcmed.2009.10.00720304251 23.HaydenF.G.ShindoN.Influenza virus polymerase inhibitors"/>
   <result pre="REDD1 as a host defense factorNat. Chem. Biol.2011771271910.1038/nchembio.64521909097 26.BarrI.G.DonisR.O.KatzJ.M.McCauleyJ.W.OdagiriT.TrusheimH.TsaiT.F.WentworthD.E.Cell culture-derived" exact="influenza" post="vaccines in the severe 2017–2018 epidemic season: A step"/>
   <result pre="in the severe 2017–2018 epidemic season: A step towards improved" exact="influenza" post="vaccine effectivenessNpj Vaccines201834410.1038/s41541-018-0079-z30323955 27.CherfG.M.CochranJ.R.Applications of Yeast Surface Display for"/>
   <result pre="vaccine proteins and immunotherapeutic moleculesHum. Vaccines Immunother.20161394796110.1080/21645515.2016.126079527905833 29.BouvierN.M.Animal models for" exact="influenza" post="virus transmission studies: A historical perspectiveCurr. Opin. Virol.20151310110810.1016/j.coviro.2015.06.00226126082 30.BouvierN.M.LowenA.C.Animal"/>
   <result pre="for Influenza Virus Exposure of HumansJ. Virol.2015892990299410.1128/JVI.03146-1425540375 33.ThangavelR.R.BouvierN.M.Animal models for" exact="influenza" post="virus pathogenesis, transmission, and immunologyJ. Immunol. Methods2014410607910.1016/j.jim.2014.03.02324709389 34.ZhongL.WangX.LiQ.LiuD.ChenH.ZhaoM.GuX.HeL.LiuX.GuM.et al.Molecular"/>
   <result pre="ChickensJ. Virol.2014889568957810.1128/JVI.00943-1424920791 35.BelserJ.A.KatzJ.M.TumpeyT.M.The ferret as a model organism to study" exact="influenza" post="A virus infectionDis. Models Mech.2011457557910.1242/dmm.007823 36.BoivinS.CusackS.RuigrokR.W.H.HartD.J.Influenza A Virus Polymerase:"/>
   <result pre="40.von ItzsteinM.WuW.-Y.KokG.B.PeggM.S.DyasonJ.C.JinB.Van PhanT.SmytheM.L.WhiteH.F.OliverS.W.et al.Rational design of potent sialidase-based inhibitors of" exact="influenza" post="virus replicationNature199336341842310.1038/363418a08502295 41.ChoppinP.W.Plaque formation by influenza A2 virus in"/>
   <result pre="potent sialidase-based inhibitors of influenza virus replicationNature199336341842310.1038/363418a08502295 41.ChoppinP.W.Plaque formation by" exact="influenza" post="A2 virus in monkey kidney cellsVirology19621833233410.1016/0042-6822(62)90023-514021004 42.GreenI.J.LiebermanM.MogabgabW.J.PeterkinW.G.PhillipsI.A.The Behavior of"/>
   <result pre="Mol. Sci.2016182010.3390/ijms1801002028025504 44.MiliánE.KamenA.A.Current and emerging cell culture manufacturing technologies for" exact="influenza" post="vaccinesBiomed. Res. Int.2015201550483110.1155/2015/50483125815321 45.DukesJ.D.WhitleyP.ChalmersA.D.The MDCK variety pack: Choosing the"/>
   <result pre="pack: Choosing the right strainBMC Cell Biol.2011124310.1186/1471-2121-12-4321982418 46.GreenI.J.Serial propagation of" exact="influenza" post="B (Lee) virus in a transmissible line of canine"/>
   <result pre="line of canine kidney cellsScience1962138424310.1126/science.138.3536.4213901412 47.GaushC.R.SmithT.F.Replication and plaque assay of" exact="influenza" post="virus in an established line of canine kidney cellsAppl."/>
   <result pre="characterization of a Madin-Darby canine kidney reporter cell line for" exact="influenza" post="A virus assaysJ. Clin. Microbiol.2010482515252310.1128/JCM.02286-0920504984 49.LinS.C.KappesM.A.ChenM.C.LinC.C.WangT.T.Distinct susceptibility and applicability"/>
   <result pre="Clin. Microbiol.2010482515252310.1128/JCM.02286-0920504984 49.LinS.C.KappesM.A.ChenM.C.LinC.C.WangT.T.Distinct susceptibility and applicability of MDCK derivatives for" exact="influenza" post="virus researchPLoS ONE201712e017229910.1371/journal.pone.017229928207898 50.TakadaK.KawakamiC.FanS.ChibaS.ZhongG.GuC.ShimizuK.TakasakiS.Sakai-TagawaY.LopesT.J.S.et al.A humanized MDCK cell line"/>
   <result pre="cell line for the efficient isolation and propagation of human" exact="influenza" post="virusesNat. Microbiol.201910.1038/s41564-019-0433-6 51.TsaiH.C.LehmanC.W.LinC.C.TsaiS.W.ChenC.M.Functional evaluation for adequacy of MDCK-lineage cells"/>
   <result pre="virusesNat. Microbiol.201910.1038/s41564-019-0433-6 51.TsaiH.C.LehmanC.W.LinC.C.TsaiS.W.ChenC.M.Functional evaluation for adequacy of MDCK-lineage cells in" exact="influenza" post="researchBMC Res. Notes20191210110.1186/s13104-019-4134-230808400 52.HamamotoI.TakakuH.TashiroM.YamamotoN.High Yield Production of Influenza Virus"/>
   <result pre="of suspension MDCK cells enable high cell concentrations and efficient" exact="influenza" post="A virus productionVaccine201910.1016/j.vaccine.2019.04.054 54.IlyushinaN.A.IkizlerM.R.KawaokaY.RudenkoL.G.TreanorJ.J.SubbaraoK.WrightP.F.Comparative study of influenza virus replication"/>
   <result pre="concentrations and efficient influenza A virus productionVaccine201910.1016/j.vaccine.2019.04.054 54.IlyushinaN.A.IkizlerM.R.KawaokaY.RudenkoL.G.TreanorJ.J.SubbaraoK.WrightP.F.Comparative study of" exact="influenza" post="virus replication in MDCK cells and in primary cells"/>
   <result pre="ScharrenburgG.J.Influvac: A safe Madin Darby Canine Kidney (MDCK) cell culture-based" exact="influenza" post="vaccineDev. Biol. Stand.1999989310010494962 58.GhendonY.Z.MarkushinS.G.AkopovaI.I.KoptiaevaI.B.NechaevaE.A.MazurkovaL.A.RadaevaI.F.KolokoltsevaT.D.Development of cell culture (MDCK) live"/>
   <result pre="Stand.1999989310010494962 58.GhendonY.Z.MarkushinS.G.AkopovaI.I.KoptiaevaI.B.NechaevaE.A.MazurkovaL.A.RadaevaI.F.KolokoltsevaT.D.Development of cell culture (MDCK) live cold-adapted (CA) attenuated" exact="influenza" post="vaccineVaccine2005234678468410.1016/j.vaccine.2005.04.03916026905 59.ManiniI.DomnichA.AmiciziaD.RossiS.PozziT.GaspariniR.PanattoD.MontomoliE.Flucelvax (Optaflu) for seasonal influenzaExpert Rev. Vaccines20151478980410.1586/14760584.2015.103952025968069 60.JonesJ.C.MaratheB.M.LernerC.KreisL.GasserR.PascuaP.N.Q.NajeraI.GovorkovaE.A.A"/>
   <result pre="in vitroAntimicrob. Agents Chemother.201660550410.1128/AAC.00888-1627381402 61.LenevaI.A.FalynskovaI.N.MakhmudovaN.R.PoromovA.A.YatsyshinaS.B.MaleevV.V.Umifenovir susceptibility monitoring and characterization of" exact="influenza" post="viruses isolated during ARBITR clinical studyJ. Med. Virol.20199158859710.1002/jmv.2535830431664 62.FurutaY.KomenoT.NakamuraT.Favipiravir"/>
   <result pre="68.KumarD.TiwariK.RajalaM.S.Analysis of A549 cell proteome alteration in response to recombinant" exact="influenza" post="A virus nucleoprotein and its interaction with cellular proteins,"/>
   <result pre="d’OrengianiA.P.MinJ.Y.Acid phosphatase 2 (ACP2) is required for membrane fusion during" exact="influenza" post="virus entrySci. Rep.201774389310.1038/srep4389328272419 70.McAuleyJ.L.CorciliusL.TanH.X.PayneR.J.McGuckinM.A.BrownL.E.The cell surface mucin MUC1 limits"/>
   <result pre="Rep.201774389310.1038/srep4389328272419 70.McAuleyJ.L.CorciliusL.TanH.X.PayneR.J.McGuckinM.A.BrownL.E.The cell surface mucin MUC1 limits the severity of" exact="influenza" post="A virus infectionMucosal Immunol.2017101581159310.1038/mi.2017.1628327617 71.RialdiA.HultquistJ.Jimenez-MoralesD.PeraltaZ.CampisiL.FenouilR.MoshkinaN.WangZ.Z.LaffleurB.KaakeR.M.et al.The RNA Exosome Syncs"/>
   <result pre="CellsMol. Cell. Proteom.20171672874210.1074/mcp.M116.065904 73.SeongR.K.ChoiY.K.ShinO.S.MDA7/IL-24 is an anti-viral factor that inhibits" exact="influenza" post="virus replicationJ. Microbiol.20165469570010.1007/s12275-016-6383-227687232 74.TannerL.B.ChngC.GuanX.L.LeiZ.RozenS.G.WenkM.R.Lipidomics identifies a requirement for peroxisomal"/>
   <result pre="replicationJ. Microbiol.20165469570010.1007/s12275-016-6383-227687232 74.TannerL.B.ChngC.GuanX.L.LeiZ.RozenS.G.WenkM.R.Lipidomics identifies a requirement for peroxisomal function during" exact="influenza" post="virus replicationJ. Lipid Res.2014551357136510.1194/jlr.M04914824868094 75.TerrierO.CarronC.De ChasseyB.DuboisJ.TraversierA.JulienT.CartetG.ProustA.HacotS.RessnikoffD.et al.Nucleolin interacts with"/>
   <result pre="influenza virus replicationJ. Lipid Res.2014551357136510.1194/jlr.M04914824868094 75.TerrierO.CarronC.De ChasseyB.DuboisJ.TraversierA.JulienT.CartetG.ProustA.HacotS.RessnikoffD.et al.Nucleolin interacts with" exact="influenza" post="A nucleoprotein and contributes to viral ribonucleoprotein complexes nuclear"/>
   <result pre="and contributes to viral ribonucleoprotein complexes nuclear trafficking and efficient" exact="influenza" post="viral replicationSci. Rep.201662900610.1038/srep2900627373907 76.WangC.LiuH.LuoJ.ChenL.LiM.SuW.ZhaoN.LiuS.XieL.JiaY.et al.HA Triggers the Switch from"/>
   <result pre="mutagenesis to explore conserved residues in the RNA-binding groove of" exact="influenza" post="A virus nucleoprotein for antiviral drug developmentSci. Rep.201662166210.1038/srep2166226916998 81.CourtinN.FotsoA.F.FautradP.MasF.AlessiM.C.RiteauB.Antiviral"/>
   <result pre="Rep.201662166210.1038/srep2166226916998 81.CourtinN.FotsoA.F.FautradP.MasF.AlessiM.C.RiteauB.Antiviral activity of formyl peptide receptor 2 antagonists against" exact="influenza" post="virusesAntivir. Res.201714325226110.1016/j.antiviral.2017.05.00128483551 82.HaasbachE.MullerC.EhrhardtC.SchreiberA.PleschkaS.LudwigS.PlanzO.The MEK-inhibitor CI-1040 displays a broad anti-influenza"/>
   <result pre="kidney (Vero) cells provide an alternative host cell system for" exact="influenza" post="A and B virusesJ. Virol.199670551955248764064 86.MacfarlaneD.E.SommervilleR.G.VERO cells (cercopithecus aethiops"/>
   <result pre="in diagnostic virologyArchiv für die gesamte Virusforschung19692737938510.1007/BF012496594313210 87.MargineI.KrammerF.Animal models for" exact="influenza" post="viruses: Implications for universal vaccine developmentPathogens2014384587410.3390/pathogens304084525436508 88.OhD.Y.HurtA.C.Using the Ferret"/>
   <result pre="Investigating Influenza Antiviral EffectivenessFront. Microbiol.201678010.3389/fmicb.2016.0008026870031 89.MifsudE.J.TaiC.M.K.HurtA.C.Animal models used to assess" exact="influenza" post="antiviralsExpert Opin. Drug Discov.2018131131113910.1080/17460441.2018.154058630362841 90.RodriguezL.NogalesA.Martínez-SobridoL.Influenza A Virus Studies in"/>
   <result pre="Mouse Model of InfectionJoVE2017e5589810.3791/55898 91.AshenbergO.PadmakumarJ.DoudM.B.BloomJ.D.Deep mutational scanning identifies sites in" exact="influenza" post="nucleoprotein that affect viral inhibition by MxAPLoS Pathog.201713e100628810.1371/journal.ppat.100628828346537 92.DeegC.M.HassanE.MutzP.RheinemannL.GötzV.MagarL.SchillingM.KallfassC.NürnbergerC.SoubiesS.et"/>
   <result pre="by MxAPLoS Pathog.201713e100628810.1371/journal.ppat.100628828346537 92.DeegC.M.HassanE.MutzP.RheinemannL.GötzV.MagarL.SchillingM.KallfassC.NürnbergerC.SoubiesS.et al.In vivo evasion of MxA by" exact="avian influenza" post="viruses requires human signature in the viral nucleoproteinJ. Exp."/>
   <result pre="MxAPLoS Pathog.201713e100628810.1371/journal.ppat.100628828346537 92.DeegC.M.HassanE.MutzP.RheinemannL.GötzV.MagarL.SchillingM.KallfassC.NürnbergerC.SoubiesS.et al.In vivo evasion of MxA by avian" exact="influenza" post="viruses requires human signature in the viral nucleoproteinJ. Exp."/>
   <result pre="95.MeunierI.von MesslingV.NS1-mediated delay of type I interferon induction contributes to" exact="influenza" post="A virulence in ferretsJ. Gen. Virol.2011921635164410.1099/vir.0.032193-021411677 96.GovorkovaE.A.IlyushinaN.A.BoltzD.A.DouglasA.YilmazN.WebsterR.G.Efficacy of Oseltamivir"/>
   <result pre="powder delivery system for laninamivir in a ferret model of" exact="influenza" post="infectionAntivir. Res.2015120667110.1016/j.antiviral.2015.05.00726022199 99.MessaoudiI.EstepR.RobinsonB.WongS.W.Nonhuman primate models of human immunologyAntioxid. Redox"/>
   <result pre="models of human immunologyAntioxid. Redox Signal.20111426127310.1089/ars.2010.324120524846 100.Van RielD.MunsterV.J.de WitE.RimmelzwaanG.F.FouchierR.A.M.OsterhausA.D.M.E.KuikenT.Human and" exact="avian influenza" post="viruses target different cells in the lower respiratory tract"/>
   <result pre="of human immunologyAntioxid. Redox Signal.20111426127310.1089/ars.2010.324120524846 100.Van RielD.MunsterV.J.de WitE.RimmelzwaanG.F.FouchierR.A.M.OsterhausA.D.M.E.KuikenT.Human and avian" exact="influenza" post="viruses target different cells in the lower respiratory tract"/>
   <result pre="Yeast Pichia pastorisJ. Virol.2000744074408410.1128/JVI.74.9.4074-4084.200010756019 125.KoperaE.DwornykA.KossonP.FlorysK.SaczynskaV.DebskiJ.Cecuda-AdamczewskaV.SzewczykB.Zagorski-OstojaW.GrzelakK.Expression, purification and characterization of glycosylated" exact="influenza" post="H5N1 hemagglutinin produced in Pichia pastorisActa Biochim. Pol.20146159760210.18388/abp.2014_188225210934 126.JabbarM.A.SivasubramanianN.NayakD.P.Influenza"/>
   <result pre="processing, glycosylation, and secretion of mutant hemagglutinins of a human" exact="influenza" post="virus by Saccharomyces cerevisiaeMol. Cell Biol.198771476148510.1128/MCB.7.4.14763037322 128.WardA.C.AzadA.A.MacreadieI.G.Expression and characterisation"/>
   <result pre="by Saccharomyces cerevisiaeMol. Cell Biol.198771476148510.1128/MCB.7.4.14763037322 128.WardA.C.AzadA.A.MacreadieI.G.Expression and characterisation of the" exact="influenza" post="A virus non-structural protein NS1 in yeastArch. Virol.199413829931410.1007/BF013791337998836 129.WardA.C.CastelliL.A.LucantoniA.C.WhiteJ.F.AzadA.A.MacreadieI.G.Expression"/>
   <result pre="yeastArch. Virol.199413829931410.1007/BF013791337998836 129.WardA.C.CastelliL.A.LucantoniA.C.WhiteJ.F.AzadA.A.MacreadieI.G.Expression and analysis of the NS2 protein of" exact="influenza" post="A virusArch. Virol.19951402067207310.1007/BF013226937503702 130.HahnenbergerK.M.KrystalM.EspositoK.TangW.KurtzS.Use of microphysiometry for analysis of"/>
   <result pre="in yeastNat. Biotechnol.19961488088310.1038/nbt0796-8809631015 131.OishiK.YamayoshiS.KawaokaY.Identification of novel amino acid residues of" exact="influenza" post="virus PA-X that are important for PA-X shutoff activity"/>
   <result pre="of a convenient system for easily screening inhibitors of mutated" exact="influenza" post="virus neuraminidasesFEBS Open Bio2013348448910.1016/j.fob.2013.10.007 133.BasuD.WalkiewiczM.P.FriemanM.BaricR.S.AubleD.T.EngelD.A.Novel Influenza Virus NS1 Antagonists"/>
   <result pre="Innate Immune FunctionJ. Virol.2009831881189110.1128/JVI.01805-0819052087 134.KurtzS.LuoG.HahnenbergerK.M.BrooksC.GechaO.IngallsK.NumataK.KrystalM.Growth impairment resulting from expression of" exact="influenza" post="virus M2 protein in Saccharomyces cerevisiae: Identification of a"/>
   <result pre="protein in Saccharomyces cerevisiae: Identification of a novel inhibitor of" exact="influenza" post="virusAntimicrob. Agents Chemother.1995392204220910.1128/AAC.39.10.22048619568 135.BalgiA.D.WangJ.ChengD.Y.H.MaC.PfeiferT.A.ShimizuY.AndersonH.J.PintoL.H.LambR.A.DeGradoW.F.et al.Inhibitors of the Influenza A"/>
   <result pre="Growth Restoration AssayPLoS ONE20138e5527110.1371/journal.pone.005527123383318 136.ArnsS.BalgiA.D.ShimizuY.PfeiferT.A.KumarN.ShidmoossaveeF.S.SunS.TaiS.S.H.AgafiteiO.JaquithJ.B.et al.Novel spirothiazamenthane inhibitors of the" exact="influenza" post="A M2 proton channelEur. J. Med. Chem.2016120647310.1016/j.ejmech.2016.05.00827187859 137.YuY.TangQ.XuZ.LiS.JinM.ZhaoZ.DongC.WuS.ZhouH.-B.Synthesis and"/>
   <result pre="141.HookerL.StrongR.AdamsR.HandaB.MerrettJ.H.MartinJ.A.KlumppK.A sensitive, single-tube assay to measure the enzymatic activities of" exact="influenza" post="RNA polymerase and other poly(A) polymerases: Application to kinetic"/>
   <result pre="inhibitor analysisNucleic Acids Res.2001292691269810.1093/nar/29.13.269111433013 142.ParkY.W.WiluszJ.KatzeM.G.Regulation of eukaryotic protein synthesis: Selective" exact="influenza" post="viral mRNA translation is mediated by the cellular RNA-binding"/>
   <result pre="the Golgi ApparatusJ. Biol. Chem.1996271169521696110.1074/jbc.271.28.169528663371 144.De ChasseyB.Aublin-GexA.RuggieriA.Meyniel-SchicklinL.PradezynskiF.DavoustN.ChantierT.TafforeauL.MangeotP.E.CianciaC.et al.The interactomes of" exact="influenza" post="virus NS1 and NS2 proteins identify new host factors"/>
   <result pre="replicationPLoS Pathog.20139e100344010.1371/journal.ppat.100344023853584 145.LeeJ.H.KimS.H.PascuaP.N.SongM.S.BaekY.H.JinX.ChoiJ.K.KimC.J.KimH.ChoiY.K.Direct interaction of cellular hnRNP-F and NS1 of" exact="influenza" post="A virus accelerates viral replication by modulation of viral"/>
   <result pre="gene expressionVirology2010397899910.1016/j.virol.2009.10.04119926108 146.LiW.WangG.ZengJ.ZhangD.ZhangH.ChenX.ChenY.LiK.Differential transcription-activating capability of NS1 proteins from different" exact="influenza" post="virus subtypes expressed in yeastSci. China Ser. C Life"/>
   <result pre="Virol.20095315315910.4149/av_2009_03_15319941396 149.TanS.L.KatzeM.G.Biochemical and genetic evidence for complex formation between the" exact="influenza" post="A virus NS1 protein and the interferon-induced PKR protein"/>
   <result pre="with the PDZ binding motif of highly pathogenic avian H5N1" exact="influenza" post="A virus NS1PLoS ONE20116e1951110.1371/journal.pone.001951121625420 151.ZhangH.LiW.WangG.SuY.ZhangC.ChenX.XuY.LiK.The distinct binding properties between"/>
   <result pre="A virus NS1PLoS ONE20116e1951110.1371/journal.pone.001951121625420 151.ZhangH.LiW.WangG.SuY.ZhangC.ChenX.XuY.LiK.The distinct binding properties between avian/human" exact="influenza" post="A virus NS1 and Postsynaptic density protein-95 (PSD-95), and"/>
   <result pre="human protein that binds to the nonstructural NS1 proteins of" exact="influenza" post="A and B virusesJ. Virol.199670536353728764047 153.WolffT.O’NeillR.E.PaleseP.NS1-Binding protein (NS1-BP): A"/>
   <result pre="protein (NS1-BP): A novel human protein that interacts with the" exact="influenza" post="A virus nonstructural NS1 protein is relocalized in the"/>
   <result pre="relocalized in the nuclei of infected cellsJ. Virol.199872717071809696811 154.FalcónA.M.FortesP.MariónR.M.BelosoA.OrtínJ.Interaction of" exact="influenza" post="virus NS1 protein and the human homologue of Staufen"/>
   <result pre="mRNA nuclear exportJ. Cell Biol.201219631532610.1083/jcb.20110705822312003 156.MirandaE.ForafonovF.TavassoliA.Deciphering interactions used by the" exact="influenza" post="virus NS1 protein to silence the host antiviral sensor"/>
   <result pre="two-hybrid systemMol. Biosyst.201171042104510.1039/c0mb00318b21264376 157.XuK.KlenkC.LiuB.KeinerB.ChengJ.ZhengB.J.LiL.HanQ.WangC.LiT.et al.Modification of nonstructural protein 1 of" exact="influenza" post="A virus by SUMO1J. Virol.2011851086109810.1128/JVI.00877-1021047957 158.FournierG.ChiangC.MunierS.TomoiuA.DemeretC.VidalainP.O.JacobY.NaffakhN.Recruitment of RED-SMU1 complex"/>
   <result pre="facilitates the switch from ubiquitination to SUMOylation of M1 in" exact="influenza" post="A virus-infected cellsJ. Virol.20158930031110.1128/JVI.02170-1425320310 160.ChenJ.HuangS.ChenZ.Human cellular protein nucleoporin hNup98"/>
   <result pre="virus-infected cellsJ. Virol.20158930031110.1128/JVI.02170-1425320310 160.ChenJ.HuangS.ChenZ.Human cellular protein nucleoporin hNup98 interacts with" exact="influenza" post="A virus NS2/nuclear export protein and overexpression of its"/>
   <result pre="GLFG repeat domain can inhibit virus propagationJ. Gen. Virol.2010912474248410.1099/vir.0.022681-020554795 161.O’NeillR.E.TalonJ.PaleseP.The" exact="influenza" post="virus NEP (NS2 protein) mediates the nuclear export of"/>
   <result pre="mediates the nuclear export of viral ribonucleoproteinsEMBO J.19981728829610.1093/emboj/17.1.2889427762 162.BalasubramaniamV.R.WaiT.H.TejoB.A.OmarA.R.HassanS.S.Highly pathogenic" exact="avian influenza" post="virus nucleoprotein interacts with TREX complex adaptor protein Aly/REFPLoS"/>
   <result pre="the nuclear export of viral ribonucleoproteinsEMBO J.19981728829610.1093/emboj/17.1.2889427762 162.BalasubramaniamV.R.WaiT.H.TejoB.A.OmarA.R.HassanS.S.Highly pathogenic avian" exact="influenza" post="virus nucleoprotein interacts with TREX complex adaptor protein Aly/REFPLoS"/>
   <result pre="Aly/REFPLoS ONE20138e7242910.1371/journal.pone.007242924073193 163.GenerousA.ThorsonM.BarcusJ.JacherJ.BuschM.SleisterH.Identification of putative interactions between swine and human" exact="influenza" post="A virus nucleoprotein and human host proteinsVirol. J.20141122810.1186/s12985-014-0228-625547032 164.MomoseF.BaslerC.F.O’NeillR.E.IwamatsuA.PaleseP.NagataK.Cellular"/>
   <result pre="host proteinsVirol. J.20141122810.1186/s12985-014-0228-625547032 164.MomoseF.BaslerC.F.O’NeillR.E.IwamatsuA.PaleseP.NagataK.Cellular splicing factor RAF-2p48/NPI-5/BAT1/UAP56 interacts with the" exact="influenza" post="virus nucleoprotein and enhances viral RNA synthesisJ. Virol.2001751899190810.1128/JVI.75.4.1899-1908.200111160689 165.NailwalH.SharmaS.MayankA.K.LalS.K.The"/>
   <result pre="nucleoprotein and enhances viral RNA synthesisJ. Virol.2001751899190810.1128/JVI.75.4.1899-1908.200111160689 165.NailwalH.SharmaS.MayankA.K.LalS.K.The nucleoprotein of" exact="influenza" post="A virus induces p53 signaling and apoptosis via attenuation"/>
   <result pre="activationPLoS ONE20116e2021510.1371/journal.pone.002021521698289 167.WangP.PaleseP.O’NeillR.E.The NPI-1/NPI-3 (karyopherin alpha) binding site on the" exact="influenza" post="a virus nucleoprotein NP is a nonconventional nuclear localization"/>
   <result pre="nuclear localization signalJ. Virol.199771185018569032315 168.LuoW.ZhangJ.LiangL.WangG.LiQ.ZhuP.ZhouY.LiJ.ZhaoY.SunN.et al.Phospholipid scramblase 1 interacts with" exact="influenza" post="A virus NP, impairing its nuclear import and thereby"/>
   <result pre="replicationPLoS Pathog.201814e100685110.1371/journal.ppat.100685129352288 169.AlfonsoR.LutzT.RodriguezA.ChavezJ.P.RodriguezP.GutierrezS.NietoA.CHD6 chromatin remodeler is a negative modulator of" exact="influenza" post="virus replication that relocates to inactive chromatin upon infectionCell."/>
   <result pre="chromatin upon infectionCell. Microbiol.2011131894190610.1111/j.1462-5822.2011.01679.x21899694 170.HsuW.B.ShihJ.L.ShihJ.R.DuJ.L.TengS.C.HuangL.M.WangW.B.Cellular protein HAX1 interacts with the" exact="influenza" post="A virus PA polymerase subunit and impedes its nuclear"/>
   <result pre="subunit and impedes its nuclear translocationJ. Virol.20138711012310.1128/JVI.00939-1223055567 171.HuarteM.Sanz-EzquerroJ.J.RoncalF.OrtinJ.NietoA.PA subunit from" exact="influenza" post="virus polymerase complex interacts with a cellular protein with"/>
   <result pre="of transcriptional activatorsJ. Virol.2001758597860410.1128/JVI.75.18.8597-8604.200111507205 172.RodriguezA.Perez-GonzalezA.NietoA.Cellular human CLE/C14orf166 protein interacts with" exact="influenza" post="virus polymerase and is required for viral replicationJ. Virol.201185120621206610.1128/JVI.00684-1121900157"/>
   <result pre="for viral replicationJ. Virol.201185120621206610.1128/JVI.00684-1121900157 173.HondaA.OkamotoT.IshihamaA.Host factor Ebp1: Selective inhibitor of" exact="influenza" post="virus transcriptaseGenes Cells Devoted Mol. Cell. Mech.20071213314210.1111/j.1365-2443.2007.01047.x17295834 174.WeiX.LiuZ.WangJ.YangR.YangJ.GuoY.TanH.ChenH.LiuQ.LiuL.The interaction"/>
   <result pre="Mol. Cell. Mech.20071213314210.1111/j.1365-2443.2007.01047.x17295834 174.WeiX.LiuZ.WangJ.YangR.YangJ.GuoY.TanH.ChenH.LiuQ.LiuL.The interaction of cellular protein ANP32A with" exact="influenza" post="A virus polymerase component PB2 promotes vRNA synthesisArch. Virol.201910.1007/s00705-018-04139-z"/>
   <result pre="to stabilize itself and enhance cell survivalJ. Cell. Biochem.20191206449645810.1002/jcb.2793530335904 176.ReinhardtJ.WolffT.The" exact="influenza" post="A virus M1 protein interacts with the cellular receptor"/>
   <result pre="human general transcription factor IIICArch. Virol.20091541101111010.1007/s00705-009-0416-719521658 178.LiuX.SunL.YuM.WangZ.XuC.XueQ.ZhangK.YeX.KitamuraY.LiuW.Cyclophilin A interacts with" exact="influenza" post="A virus M1 protein and impairs the early stage"/>
   <result pre="to block host cell cycleCell. Microbiol.201921e1303810.1111/cmi.1303831050118 180.GuanZ.LiuD.MiS.ZhangJ.YeQ.WangM.GaoG.F.YanJ.Interaction of Hsp40 with" exact="influenza" post="virus M2 protein: Implications for PKR signaling pathwayProtein Cell2010194495510.1007/s13238-010-0115-x21204021"/>
   <result pre="Cell2010194495510.1007/s13238-010-0115-x21204021 181.MiS.LiY.YanJ.GaoG.F.Na(+)/K (+)-ATPase beta1 subunit interacts with M2 proteins of" exact="influenza" post="A and B viruses and affects the virus replicationSci."/>
   <result pre="Regulates Viral Propagation by Modulating M2 TraffickingJ. Virol.20179110.1016/j.virol.2016.10.014 185.MazurI.AnhlanD.MitznerD.WixlerL.SchubertU.LudwigS.The proapoptotic" exact="influenza" post="A virus protein PB1-F2 regulates viral polymerase activity by"/>
   <result pre="interaction with the PB1 proteinCell. Microbiol.2008101140115210.1111/j.1462-5822.2008.01116.x18182088 186.MitznerD.DudekS.E.StudtruckerN.AnhlanD.MazurI.WissingJ.JanschL.WixlerL.BrunsK.SharmaA.et al.Phosphorylation of the" exact="influenza" post="A virus protein PB1-F2 by PKC is crucial for"/>
   <result pre="functions in monocytesCell. Microbiol.2009111502151610.1111/j.1462-5822.2009.01343.x19523156 187.GuanZ.H.ZhangM.L.HouP.L.DuanM.CuiY.M.WangX.R.Identification of cellular proteins interacting with" exact="influenza" post="A virus PB1-F2 proteinActa Virol.20125619920710.4149/av_2012_03_19923043599 188.ReisA.L.McCauleyJ.W.The influenza virus protein"/>
   <result pre="proteins interacting with influenza A virus PB1-F2 proteinActa Virol.20125619920710.4149/av_2012_03_19923043599 188.ReisA.L.McCauleyJ.W.The" exact="influenza" post="virus protein PB1-F2 interacts with IKKbeta and modulates NF-kappaB"/>
   <result pre="RNA-Dependent RNA PolymeraseFront. Microbiol.2017816210.3389/fmicb.2017.0016228232820 191.TafforeauL.ChantierT.PradezynskiF.PelletJ.MangeotP.E.VidalainP.O.AndreP.Rabourdin-CombeC.LotteauV.Generation and comprehensive analysis of an" exact="influenza" post="virus polymerase cellular interaction networkJ. Virol.201185130101301810.1128/JVI.02651-1021994455 192.ShapiraS.D.Gat-ViksI.ShumB.O.DricotA.de GraceM.M.WuL.GuptaP.B.HaoT.SilverS.J.RootD.E.et al.A"/>
   <result pre="reveals pathways in H1N1 infectionCell20091391255126710.1016/j.cell.2009.12.01820064372 193.TamuraD.NguyenH.T.SleemanK.LevineM.MishinV.P.YangH.GuoZ.Okomo-AdhiamboM.XuX.StevensJ.et al.Cell culture-selected substitutions in" exact="influenza" post="A(H3N2) neuraminidase affect drug susceptibility assessmentAntimicrob. Agents Chemother.2013576141614610.1128/AAC.01364-1324080660 194.LeeY.J.JeongK.J.Challenges"/>
   <result pre="220.MuellerS.GaussonV.VodovarN.DeddoucheS.TroxlerL.PerotJ.PfefferS.HoffmannJ.A.SalehM.-C.ImlerJ.-L.RNAi-mediated immunity provides strong protection against the negative-strand RNA vesicular" exact="stomatitis" post="virus in DrosophilaProc. Natl. Acad. Sci. USA2010107193901939510.1073/pnas.101437810720978209 221.CherryS.VSV infection"/>
   <result pre="222.ShellyS.LukinovaN.BambinaS.BermanA.CherryS.Autophagy is an essential component of Drosophila immunity against vesicular" exact="stomatitis" post="virusImmunity20093058859810.1016/j.immuni.2009.02.00919362021 223.SalehM.-C.TassettoM.van RijR.P.GoicB.GaussonV.BerryB.JacquierC.AntoniewskiC.AndinoR.Antiviral immunity in Drosophila requires systemic RNA"/>
   <result pre="DrosophilaCurr. Opin. Immunol.2010224910.1016/j.coi.2010.01.00720137906 226.AdamsonA.L.ChohanK.SwensonJ.LaJeunesseD.A Drosophila model for genetic analysis of" exact="influenza" post="viral/host interactionsGenetics201118949550610.1534/genetics.111.13229021775472 227.LiW.-X.LiH.LuR.LiF.DusM.AtkinsonP.BrydonE.W.A.JohnsonK.L.García-SastreA.BallL.A.et al.Interferon antagonist proteins of influenza and"/>
   <result pre="analysis of influenza viral/host interactionsGenetics201118949550610.1534/genetics.111.13229021775472 227.LiW.-X.LiH.LuR.LiF.DusM.AtkinsonP.BrydonE.W.A.JohnsonK.L.García-SastreA.BallL.A.et al.Interferon antagonist proteins of" exact="influenza" post="and vaccinia viruses are suppressors of RNA silencingProc. Natl."/>
   <result pre="AP organiserDevelopment20021294261426912183378 232.HaoL.SakuraiA.WatanabeT.SorensenE.NidomC.A.NewtonM.A.AhlquistP.KawaokaY.Drosophila RNAi screen identifies host genes important for" exact="influenza" post="virus replicationNature200845489089310.1038/nature0715118615016 233.Van der SarA.M.AppelmelkB.J.Vandenbroucke-GraulsC.M.J.E.BitterW.A star with stripes: Zebrafish"/>
   <result pre="Plants, Animals, and HumansHeineH.SpringerBerlin/Heidelberg, Germany200811313310.1007/978-3-540-73930-2_6 237.SullivanC.KimC.H.Zebrafish as a model for" exact="infectious disease" post="and immune functionFish. Shellfish Immunol.20082534135010.1016/j.fsi.2008.05.00518640057 238.PalhaN.Guivel-BenhassineF.BriolatV.LutfallaG.SourisseauM.EllettF.WangC.-H.LieschkeG.J.HerbomelP.SchwartzO.et al.Real-Time Whole-Body Visualization"/>
   <result pre="Response in ZebrafishPLoS Pathog.20139e100361910.1371/journal.ppat.100361924039582 239.BurgosJ.S.Ripoll-GomezJ.AlfaroJ.M.SastreI.ValdiviesoF.Zebrafish as a new model for" exact="herpes simplex" post="virus type 1 infectionZebrafish2008532333310.1089/zeb.2008.055219133831 240.DingC.B.ZhaoY.ZhangJ.P.PengZ.G.SongD.Q.JiangJ.D.A zebrafish model for subgenomic"/>
   <result pre="simplex virus type 1 infectionZebrafish2008532333310.1089/zeb.2008.055219133831 240.DingC.B.ZhaoY.ZhangJ.P.PengZ.G.SongD.Q.JiangJ.D.A zebrafish model for subgenomic" exact="hepatitis" post="C virus replicationInt. J. Mol. Med.20153579179710.3892/ijmm.2015.206325572289 241.DingC.-B.ZhangJ.-P.ZhaoY.PengZ.-G.SongD.-Q.JiangJ.-D.Zebrafish as a"/>
   <result pre="ProspectsPathogens201762510.3390/pathogens6020025 246.KaurG.DufourJ.M.Cell lines: Valuable tools or useless artifactsSpermatogenesis201221510.4161/spmg.1988522553484 247.Böttcher-FriebertshäuserE.KlenkH.-D.GartenW.Activation of" exact="influenza" post="viruses by proteases from host cells and bacteria in"/>
   <result pre="JamiliN.H.BosquillonC.SayersI.Evaluation of differentiated human bronchial epithelial cell culture systems for" exact="asthma" post="researchJ. Allergy2012201294398210.1155/2012/94398222287976 249.RamosI.Fernandez-SesmaA.Cell Receptors for Influenza a Viruses and"/>
   <result pre="al.Tropism and innate host responses of the 2009 pandemic H1N1" exact="influenza" post="virus in ex vivo and in vitro cultures of"/>
   <result pre="tractAm. J. Pathol.20101761828184010.2353/ajpath.2010.09108720110407 251.HuiK.P.ChanL.L.KuokD.I.MokC.K.YangZ.F.LiR.F.LukG.S.LeeE.F.LaiJ.C.YenH.L.et al.Tropism and innate host responses of" exact="influenza" post="A/H5N6 virus: An analysis of ex vivo and in"/>
   <result pre="from smokers modify dendritic cell responses in the context of" exact="influenza" post="infectionAm. J. Respir. Cell Mol. Biol.20114523724510.1165/rcmb.2010-0190OC20935192 259.YanY.TanK.S.LiC.TranT.ChaoS.S.SugrueR.J.ShiL.ChowV.T.WangD.-Y.Human nasal epithelial"/>
   <result pre="cells derived from multiple subjects exhibit differential responses to H3N2" exact="influenza" post="virus infection in vitroJ. Allergy Clin. Immunol.201613827628110.1016/j.jaci.2015.11.01626806046 260.TianT.ZiX.PengY.WangZ.HongH.YanY.GuanW.TanK.S.LiuJ.OngH.H.et al.H3N2"/>
   <result pre="influenza virus infection in vitroJ. Allergy Clin. Immunol.201613827628110.1016/j.jaci.2015.11.01626806046 260.TianT.ZiX.PengY.WangZ.HongH.YanY.GuanW.TanK.S.LiuJ.OngH.H.et al.H3N2" exact="influenza" post="virus infection enhances oncostatin M expression in human nasal"/>
   <result pre="expression in human nasal epitheliumExp. Cell Res.201837132232910.1016/j.yexcr.2018.08.02230142324 261.DengY.YanY.TanK.S.LiuJ.ChowV.T.TaoZ.-Z.WangD.-Y.MicroRNA-146a induction during" exact="influenza" post="H3N2 virus infection targets and regulates TRAF6 levels in"/>
   <result pre="Multiple Individuals Reveal Specific Nasal-Initiated SignaturesFront. Microbiol.20189268510.3389/fmicb.2018.0268530487780 263.PeretzJ.PekoszA.LaneA.P.KleinS.L.Estrogenic compounds reduce" exact="influenza" post="A virus replication in primary human nasal epithelial cells"/>
   <result pre="of human airway epithelium by human and avian strains of" exact="influenza" post="a virusJ. Virol.2006808060806810.1128/JVI.00384-0616873262 266.OshanskyC.M.PickensJ.A.BradleyK.C.JonesL.P.Saavedra-EbnerG.M.BarberJ.P.CrabtreeJ.M.SteinhauerD.A.TompkinsS.M.TrippR.A.Avian Influenza Viruses Infect Primary Human"/>
   <result pre="both sialyl(alpha2-3)Gal receptor for human parainfluenza virus type 1 and" exact="avian influenza" post="viruses, and sialyl(alpha2-6)Gal receptor for human influenza virusesGlycoconj. J.20062310110610.1007/s10719-006-5442-z16575527"/>
   <result pre="sialyl(alpha2-3)Gal receptor for human parainfluenza virus type 1 and avian" exact="influenza" post="viruses, and sialyl(alpha2-6)Gal receptor for human influenza virusesGlycoconj. J.20062310110610.1007/s10719-006-5442-z16575527"/>
   <result pre="1 and avian influenza viruses, and sialyl(alpha2-6)Gal receptor for human" exact="influenza" post="virusesGlycoconj. J.20062310110610.1007/s10719-006-5442-z16575527 270.NichollsJ.M.BourneA.J.ChenH.GuanY.PeirisJ.S.M.Sialic acid receptor detection in the human"/>
   <result pre="for widespread distribution of potential binding sites for human and" exact="avian influenza" post="virusesRespir. Res.200787310.1186/1465-9921-8-7317961210 271.SuzukiY.Sialobiology of influenza: Molecular mechanism of host"/>
   <result pre="widespread distribution of potential binding sites for human and avian" exact="influenza" post="virusesRespir. Res.200787310.1186/1465-9921-8-7317961210 271.SuzukiY.Sialobiology of influenza: Molecular mechanism of host"/>
   <result pre="271.SuzukiY.Sialobiology of influenza: Molecular mechanism of host range variation of" exact="influenza" post="virusesBiol. Pharm. Bull.20052839940810.1248/bpb.28.39915744059 272.DanzyS.StuddardL.R.ManicassamyB.SolorzanoA.MarshallN.García-SastreA.SteelJ.LowenA.C.Mutations to PB2 and NP Proteins"/>
   <result pre="in Primary Human Respiratory CellsJ. Virol.201488134361344610.1128/JVI.01093-1425210184 273.LondinoJ.D.LazrakA.NoahJ.W.AggarwalS.BaliV.WoodworthB.A.BebokZ.MatalonS.Influenza virus M2 targets" exact="cystic fibrosis" post="transmembrane conductance regulator for lysosomal degradation during viral infectionFASEB"/>
   <result pre="infectionFASEB J.2015292712272510.1096/fj.14-26875525795456 274.WanH.PerezD.R.Amino acid 226 in the hemagglutinin of H9N2" exact="influenza" post="viruses determines cell tropism and replication in human airway"/>
   <result pre="replication in human airway epithelial cellsJ. Virol.2007815181519110.1128/JVI.02827-0617344280 275.Ayora-TalaveraG.SheltonH.ScullM.A.RenJ.JonesI.M.PicklesR.J.BarclayW.S.Mutations in H5N1" exact="influenza" post="virus hemagglutinin that confer binding to human tracheal airway"/>
   <result pre="receptor specificity does not affect the neuraminidase-inhibitor susceptibility of H5N1" exact="influenza" post="virusesPLoS Pathog.20084e100004310.1371/journal.ppat.100004318404209 278.IlyushinaN.A.BovinN.V.WebsterR.G.Decreased neuraminidase activity is important for the"/>
   <result pre="278.IlyushinaN.A.BovinN.V.WebsterR.G.Decreased neuraminidase activity is important for the adaptation of H5N1" exact="influenza" post="virus to human airway epitheliumJ. Virol.2012864724473310.1128/JVI.06774-1122379077 279.SitS.-T.ManserE.Rho GTPases and"/>
   <result pre="Proteome Res.2017163287329710.1021/acs.jproteome.7b0028628745058 281.KroekerA.L.EzzatiP.HalaykoA.J.CoombsK.M.Response of primary human airway epithelial cells to" exact="influenza" post="infection: A quantitative proteomic studyJ. Proteome Res.2012114132414610.1021/pr300239r22694362 282.LeeS.HirohamaM.NoguchiM.NagataK.KawaguchiA.Influenza A"/>
   <result pre="al.DAS181, a sialidase fusion protein, protects human airway epithelium against" exact="influenza" post="virus infection: An in vitro pharmacodynamic analysisJ. Antimicrob. Chemother.20106527528410.1093/jac/dkp42119942616"/>
   <result pre="291.KosmiderB.MessierE.M.JanssenW.J.NahreiniP.WangJ.HartshornK.L.MasonR.J.Nrf2 protects human alveolar epithelial cells against injury induced by" exact="influenza" post="A virusRespir. Res.2012134310.1186/1465-9921-13-4322672594 292.ZhouB.PearceM.B.LiY.WangJ.MasonR.J.TumpeyT.M.WentworthD.E.Asparagine substitution at PB2 residue 701"/>
   <result pre="the replication, pathogenicity, and transmission of the 2009 pandemic H1N1" exact="influenza" post="A virusPLoS ONE20138e6761610.1371/journal.pone.006761623799150 293.GaoY.ZhangY.ShinyaK.DengG.JiangY.LiZ.GuanY.TianG.LiY.ShiJ.et al.Identification of amino acids in"/>
   <result pre="in HA and PB2 critical for the transmission of H5N1" exact="avian influenza" post="viruses in a mammalian hostPLoS Pathog.20095e100070910.1371/journal.ppat.100070920041223 294.SteelJ.LowenA.C.MubarekaS.PaleseP.Transmission of influenza"/>
   <result pre="HA and PB2 critical for the transmission of H5N1 avian" exact="influenza" post="viruses in a mammalian hostPLoS Pathog.20095e100070910.1371/journal.ppat.100070920041223 294.SteelJ.LowenA.C.MubarekaS.PaleseP.Transmission of influenza"/>
   <result pre="avian influenza viruses in a mammalian hostPLoS Pathog.20095e100070910.1371/journal.ppat.100070920041223 294.SteelJ.LowenA.C.MubarekaS.PaleseP.Transmission of" exact="influenza" post="virus in a mammalian host is increased by PB2"/>
   <result pre="or 627E/701NPLoS Pathog.20095e100025210.1371/journal.ppat.100025219119420 295.LiZ.ChenH.JiaoP.DengG.TianG.LiY.HoffmannE.WebsterR.G.MatsuokaY.YuK.Molecular basis of replication of duck H5N1" exact="influenza" post="viruses in a mammalian mouse modelJ. Virol.200579120581206410.1128/JVI.79.18.12058-12064.200516140781 296.WangJ.Oberley-DeeganR.WangS.NikradM.FunkC.J.HartshornK.L.MasonR.J.Differentiated Human"/>
   <result pre="sequencing of primary human lung epithelial cells challenged with H5N1" exact="influenza" post="virus reveals a proviral role for CEACAM1Sci. Rep.201881546810.1038/s41598-018-33605-630341336 302.WangJ.NikradM.P.PhangT.GaoB.AlfordT.ItoY.EdeenK.TravantyE.A.KosmiderB.HartshornK.et"/>
   <result pre="II CellsAm. J. Respir. Cell Mol. Biol.20114558259110.1165/rcmb.2010-0108OC21239608 303.RüdigerD.KupkeS.Y.LaskeT.ZmoraP.ReichlU.Multiscale modeling of" exact="influenza" post="A virus replication in cell cultures predicts infection dynamics"/>
   <result pre="physiologically relevant as these cells secrete proteases that can cleave" exact="influenza" post="HA for viral entry [247] Cultured at ALI which"/>
   <result pre="cells are derived from Compared to known cell models of" exact="influenza" post="Yes Yes No Yes Yes Yes Compared to known"/>
   <result pre="No Yes Yes Yes Compared to known animal models of" exact="influenza" post="No Yes No No No Yes"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6958434\results\search\disease\results.xml">
   <result pre="order to safeguard the public against major events, such as" exact="influenza" post="pandemics. Since posting warnings of the epidemic influenza in"/>
   <result pre="such as influenza pandemics. Since posting warnings of the epidemic" exact="influenza" post="in 1918, to the mass media communications available a"/>
   <result pre="monitor the spread of disease, and evaluate the most threatening" exact="influenza" post="strains by means of risk assessment, to be able"/>
   <result pre="for New York State preparedness and response to the 2009" exact="influenza" post="pandemic, and the re-evaluation of preparedness plans is recommended"/>
   <result pre="address the emergence and spread of a future novel virulent" exact="influenza" post="strain. emergency preparedness influenza pandemic surge support just-in-time training"/>
   <result pre="spread of a future novel virulent influenza strain. emergency preparedness" exact="influenza" post="pandemic surge support just-in-time training incident management system 1."/>
   <result pre="York State (NYS) public health response to the 1918 &quot;Spanish�?" exact="influenza" post="pandemic was the State Health Commissioner, Hermann M. Biggs"/>
   <result pre="and punishable by a fine or imprisonment or both. Epidemic" exact="influenza" post="is conveyed solely from the discharges from the nose"/>
   <result pre="Public Health Council amended the Sanitary Code and declared epidemic" exact="influenza" post="a reportable disease, effective 14 October 1918. Efforts were"/>
   <result pre="physical restrictions constituted the only preventative measures, as the bacillus" exact="influenza" post="vaccine was ineffective, except to diminish some secondary bacterial"/>
   <result pre="and newspaper articles documented the devastation of the disease. The" exact="influenza" post="epidemic subsided after an estimated 50 million deaths worldwide"/>
   <result pre="the time, retrospective analyses identified the causative agent to be" exact="influenza" post="A/H1N1 [4]. 2. Early Preparedness Efforts: Diagnostics, Surveillance and"/>
   <result pre="Surveillance and Vaccines Essential to pandemic preparedness are components of" exact="influenza" post="surveillance that detect the emergence and spread of influenza"/>
   <result pre="of influenza surveillance that detect the emergence and spread of" exact="influenza" post="virus strains, as well as monitor morbidity and mortality."/>
   <result pre="mortality. The efforts to surveil and control the spread of" exact="influenza" post="were hampered until the discovery of the virus. First"/>
   <result pre="development of laboratory procedures for the culture and identification of" exact="influenza" post="from clinical specimens also facilitated major research applications. Beginning"/>
   <result pre="as the Wadsworth Center, initiated laboratory research and diagnosis of" exact="viral disease." post="The construction of a new laboratory building for virology"/>
   <result pre="of services for infectious viral agents. The laboratory responded to" exact="influenza" post="outbreaks by isolating the virus and analyzing its antigenic"/>
   <result pre="hemagglutination-inhibition assays [6,7], and immunofluorescence assays for the identification of" exact="influenza" post="viruses propagated in tissue culture [8]. Influenza vaccines were"/>
   <result pre="Canine Kidney (MDCK) cell line [12] and a trivalent recombinant" exact="influenza" post="vaccine produced from a baculovirus expression vector in the"/>
   <result pre="1956 [14]. For surveillance in NYS during the 1957 &quot;Asian�?" exact="influenza" post="A/H2N2 pandemic and 1968 Hong Kong influenza A/H3N2 pandemic"/>
   <result pre="the 1957 &quot;Asian�? influenza A/H2N2 pandemic and 1968 Hong Kong" exact="influenza" post="A/H3N2 pandemic [4], influenza activity was tracked by school"/>
   <result pre="A/H2N2 pandemic and 1968 Hong Kong influenza A/H3N2 pandemic [4]," exact="influenza" post="activity was tracked by school and workplace absenteeism and"/>
   <result pre="department [15]. As the networks for surveillance and investigation of" exact="influenza" post="were then global [16], and since the WHO tool"/>
   <result pre="were then global [16], and since the WHO tool for" exact="influenza" post="virologic surveillance FluNet began in 1997, the surveillance data"/>
   <result pre="virologic surveillance FluNet began in 1997, the surveillance data for" exact="influenza" post="types, subtypes and lineages is updated weekly from 138"/>
   <result pre="Services issued $175 million to assist in preparedness for an" exact="influenza" post="pandemic [18]. There was elevated concern for this due"/>
   <result pre="the high case fatality rate in avian to human transmitted" exact="influenza" post="A/H5N1 cases and the global spread of highly pathogenic"/>
   <result pre="cases and the global spread of highly pathogenic avian H5N1" exact="influenza" post="virus. In 2006, as part the national Pandemic Influenza"/>
   <result pre="health care providers in preparedness and response to a potential" exact="influenza" post="pandemic. One of the thirteen sections in this plan"/>
   <result pre="the need for rapid and accurate laboratory testing of emerging" exact="influenza" post="virus strains that may cause a pandemic. 3. The"/>
   <result pre="Influenza Laboratory Surge Drill To evaluate laboratory preparedness for an" exact="influenza" post="pandemic response, the Wadsworth Center designed and executed a"/>
   <result pre="the participating PHLs estimated their maximum daily laboratory capacity for" exact="influenza" post="testing. Mock influenza specimens, of which approximately 30% were"/>
   <result pre="estimated their maximum daily laboratory capacity for influenza testing. Mock" exact="influenza" post="specimens, of which approximately 30% were positive, were prepared"/>
   <result pre="national governments were primarily focused on the threat of an" exact="influenza" post="pandemic with avian A/H5N1 from Asia, a novel A/H1N1"/>
   <result pre="pandemic with avian A/H5N1 from Asia, a novel A/H1N1 swine" exact="influenza" post="strain emerged in Mexico with sustained human to human"/>
   <result pre="human to human transmission in 2009 (Figure 2). The novel" exact="influenza" post="A/H1N1 outbreak was declared a public health emergency in"/>
   <result pre="in the USA, the CDC developed a panel of human" exact="influenza" post="real-time RT-PCR assays to detect influenza types A and"/>
   <result pre="a panel of human influenza real-time RT-PCR assays to detect" exact="influenza" post="types A and B and distinguish subtypes A/H1N1 (seasonal)"/>
   <result pre="to distinguish this virus from the previously circulating seasonal A/H1N1" exact="influenza" post="virus [21,22]. To assure reagent consistency and maintain supply,"/>
   <result pre="testing panels. 4.2. State and Federal Reporting In 1918, epidemic" exact="influenza" post="was made a reportable disease in New York State."/>
   <result pre="reportable disease in New York State. On 1 December 2004," exact="influenza" post="was added to the NYSDOH reportable diseases list, requiring"/>
   <result pre="list, requiring all NYS licensed clinical laboratories to report positive" exact="influenza" post="test results to the NYSDOH via the Electronic Clinical"/>
   <result pre="During the 2009 pandemic, additional advisories directed that all &quot;swine-origin" exact="influenza" post="virus�? [subsequently novel influenza A (H1N1)] test results from"/>
   <result pre="additional advisories directed that all &quot;swine-origin influenza virus�? [subsequently novel" exact="influenza" post="A (H1N1)] test results from licensed clinical laboratories, whether"/>
   <result pre="4.4. Second Wave By the second wave of the 2009" exact="influenza" post="pandemic in the Northern Hemisphere, clinical and commercial laboratories"/>
   <result pre="methods than the distribution of posters used during the 1918" exact="influenza" post="pandemic, in 2009, mass media campaigns through television, radio,"/>
   <result pre="distribution of pamphlets, educated the public on the prevention of" exact="influenza" post="transmission through good hygiene practices and vaccination. This was"/>
   <result pre="for severe disease, such as pregnant women. However, the novel" exact="influenza" post="A 2009 pandemic quickly spread throughout America and the"/>
   <result pre="Disease Control database showed a total of 53,930 laboratory confirmed" exact="influenza" post="cases for 2009 [24]. These included 45,166 influenza A"/>
   <result pre="laboratory confirmed influenza cases for 2009 [24]. These included 45,166" exact="influenza" post="A cases from 1 April to 31 December, the"/>
   <result pre="1 April to 31 December, the majority of which were" exact="influenza" post="A/H1pdm09. The total influenza-associated fatalities in the USA during"/>
   <result pre="USA during the first 12 months following the emergence of" exact="influenza" post="A/H1N1pdm09 has been estimated at 12,469 [25], approximately 2%"/>
   <result pre="to review the New York State response to the 2009" exact="influenza" post="pandemic. Central in the coordination of efforts and communication"/>
   <result pre="Communicable Disease Control to clinicians gave weekly updates of statewide" exact="influenza" post="surveillance; directives for electronic reporting of positive cases; guidelines"/>
   <result pre="The discussions addressed the advantages and disadvantages of the rapid" exact="influenza" post="diagnostic tests (RIDT), the culture of influenza viruses as"/>
   <result pre="of the rapid influenza diagnostic tests (RIDT), the culture of" exact="influenza" post="viruses as well as molecular laboratory developed tests, and"/>
   <result pre="Good relations between state and local health departments, epidemiologists and" exact="infectious disease" post="staff in hospitals and community settings were necessary to"/>
   <result pre="May 2009 [10], the availability of vaccines targeting the novel" exact="influenza" post="A/H1N1pdm09 virus was too delayed to be an effective"/>
   <result pre="other private sector partners [20,26,27]. 6. Present-Day Preparedness The 2009" exact="influenza" post="pandemic demonstrated how preparedness plans and efforts are key"/>
   <result pre="use; community mitigation; communications, training and education; workforce support; emerging" exact="influenza" post="strains; and public health preparedness informatics [20]. The implementation"/>
   <result pre="the waves of pandemic influenza, post-pandemic and interpandemic levels of" exact="influenza" post="activity, and to the legal, ethical and policy issues"/>
   <result pre="within the jurisdictions [28]. The national and international networks for" exact="influenza" post="surveillance for early detection continue to evolve. The World"/>
   <result pre="three centers which provide extensive analysis on approximately 3,000 positive" exact="influenza" post="samples per season collected from all U.S. states and"/>
   <result pre="and territories. For all specimens submitted to these reference centers," exact="influenza" post="viruses are sequenced directly with next generation sequencing, enabling"/>
   <result pre="as well as to detect the emergence of a novel" exact="influenza" post="strain. Influenza viruses are also cultured and analyzed with"/>
   <result pre="Public health agencies must address the ongoing threats of potential" exact="influenza" post="pandemics, such as the persistence of the highly pathogenic"/>
   <result pre="influenza pandemics, such as the persistence of the highly pathogenic" exact="avian influenza" post="virus A/H5N1 [30,31], and emergence of influenza A/H7N9 in"/>
   <result pre="pandemics, such as the persistence of the highly pathogenic avian" exact="influenza" post="virus A/H5N1 [30,31], and emergence of influenza A/H7N9 in"/>
   <result pre="highly pathogenic avian influenza virus A/H5N1 [30,31], and emergence of" exact="influenza" post="A/H7N9 in 2013 [32,33]. Five H7N9 epidemics have occurred"/>
   <result pre="occurred in China, the most severe arising in the 2016-2017" exact="influenza" post="season [34], although an extensive vaccination program appears to"/>
   <result pre="to have controlled the situation at this time [35]. The" exact="influenza" post="risk assessment tool (IRAT) has rated the Asian H7N9"/>
   <result pre="as having the greatest potential pandemic risk amongst the novel" exact="influenza" post="A viruses [36]. The indicators warn that the world"/>
   <result pre="critical in influencing the intensity and duration of the next" exact="influenza" post="pandemic and its impact on public safety. In addition"/>
   <result pre="1918 Influenza VirusN. Engl. J. Med.200936122522910.1056/NEJMp090481919564629 5.SmithW.AndrewesC.H.LaidlawP.P.A virus obtained from" exact="influenza" post="patientsLancet1933222666810.1016/S0140-6736(00)78541-2 6.collab: New York State Department of HealthSeventieth Annual"/>
   <result pre="of HealthAlbany, NY, USA194933 7.WidelockD.KleinS.SimonovicO.PeizerL.R.A laboratory analysis of the 1957–1958" exact="influenza" post="outbreak in New York city: II. A seroepidemiological studyAm."/>
   <result pre="http://www.immunize.org/timeline/(accessed on 8 March 2019) 11.StanleyW.M.The preparation and properties of" exact="influenza" post="virus vaccines concentrated and purified by differential centrifugationJ. Exp."/>
   <result pre="Cellular substrates for viral vaccinesViruses2014616721700167210.3390/v604167224732259 13.McPhersonC.E.Development of a Novel recombinant" exact="influenza" post="vaccine in insect cellsBiologicals20083635035310.1016/j.biologicals.2008.08.00118804387 14.ZieglerT.MamahitA.CoxN.J.65 Years of influenza surveillance"/>
   <result pre="Novel recombinant influenza vaccine in insect cellsBiologicals20083635035310.1016/j.biologicals.2008.08.00118804387 14.ZieglerT.MamahitA.CoxN.J.65 Years of" exact="influenza" post="surveillance by a world health organization-coordinated global networkInfluenza Respir."/>
   <result pre="online: https://www.questar.org/wp-content/uploads/2017/08/Pandemic_influenza_plan.pdf(accessed on 14 February 2019) 21.JerniganD.B.LindstromS.L.JohnsonJ.R.MillerJ.D.HoelscherM.HumesR.ShivelyR.BrammerL.BurkeS.A.VillanuevaJ.M.et al.Detecting 2009 pandemic" exact="influenza" post="a (H1N1) virus infection: Availability of diagnostic testing led"/>
   <result pre="26 February 2019) 25.ShresthaS.S.SwerdlowD.L.BorseR.H.PrabhuV.S.FinelliL.AtkinsC.Y.Owusu-EduseiK.BellB.MeadP.S.BiggerstaffM.et al.Estimating the burden of 2009 pandemic" exact="influenza" post="A (H1N1) in the United States (April 2009–April 2010)Clin."/>
   <result pre="on 14 February 2019) 29.JesterB.SchwerzmannJ.MustaquimD.AdenT.BrammerL.HumesR.ShultP.ShahangianS.GubarevaL.XuX.et al.Mapping of the US domestic" exact="influenza" post="virologic surveillance landscapeEmerg. Infect. Dis.2018241300130610.3201/eid2407.18002829715078 30.MountsA.W.KwongH.IzurietaH.S.HoY.-Y.AuT.-K.LeeM.BridgesC.B.WilliamsS.W.MakK.H.KatzJ.M.et al.Case-control study of"/>
   <result pre="landscapeEmerg. Infect. Dis.2018241300130610.3201/eid2407.18002829715078 30.MountsA.W.KwongH.IzurietaH.S.HoY.-Y.AuT.-K.LeeM.BridgesC.B.WilliamsS.W.MakK.H.KatzJ.M.et al.Case-control study of risk factors for" exact="avian influenza" post="A (H5N1) disease, Hong Kong, 1997J. Infect. Dis.199918050550810.1086/31490310395870 31.collab:"/>
   <result pre="Infect. Dis.2018241300130610.3201/eid2407.18002829715078 30.MountsA.W.KwongH.IzurietaH.S.HoY.-Y.AuT.-K.LeeM.BridgesC.B.WilliamsS.W.MakK.H.KatzJ.M.et al.Case-control study of risk factors for avian" exact="influenza" post="A (H5N1) disease, Hong Kong, 1997J. Infect. Dis.199918050550810.1086/31490310395870 31.collab:"/>
   <result pre="with H7N9 virus in ChinaSci. China Life Sci.2018611465147310.1007/s11427-018-9420-130414008 36.BurkeS.A.TrockS.C.Use of" exact="influenza" post="risk assessment tool for prepandemic preparednessEmerg Infect. Dis.20182447147710.3201/eid2403.17185229460739 37.JesterB.UyekiT.JerniganD.Readiness"/>
   <result pre="Division of Laboratories and Research, preparing eggs for inoculation with" exact="influenza" post="A virus, to produce vaccines during the 1957–1958 influenza"/>
   <result pre="with influenza A virus, to produce vaccines during the 1957–1958" exact="influenza" post="pandemic [9]. Figure 2 The timeline of the 2009"/>
   <result pre="influenza pandemic [9]. Figure 2 The timeline of the 2009" exact="influenza" post="pandemic and the emergency response by the international World"/>
   <result pre="Figure 3 Testing by the Wadsworth Center in 2009 for" exact="influenza" post="types and subtypes, identifying the pandemic influenza A/H1N1pdm09 strain"/>
   <result pre="in 2009 for influenza types and subtypes, identifying the pandemic" exact="influenza" post="A/H1N1pdm09 strain once the specific CDC assay became available."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6958466\results\search\disease\results.xml">
   <result pre="virus attracted a heightened international attention following huge incidence of" exact="microcephaly" post="in neo-natal cases in the Latin Americas in 2015"/>
   <result pre="notified WHO of reports of an illness characterized by skin" exact="rash" post="in the northeastern states. From February 2015 to 29"/>
   <result pre="29 April 2015, nearly 7000 cases of illness with skin" exact="rash" post="were reported in these states. All cases were mild,"/>
   <result pre="that the recent association of Zika infection with clusters of" exact="microcephaly" post="and other neurological disorders constituted a Public Health Emergency"/>
   <result pre="disease-causing viruses of this genus are Dengue fever virus, Tick-borne" exact="encephalitis" post="virus, West Nile virus, Japanese encephalitis virus, and Zika"/>
   <result pre="Dengue fever virus, Tick-borne encephalitis virus, West Nile virus, Japanese" exact="encephalitis" post="virus, and Zika virus [10]. These viruses possess a"/>
   <result pre="infection is its association with the Guillain–Barré syndrome (GBS), a" exact="neurological disorder" post="[22,23]. 3.2. Modes of Transmission The current CDC website"/>
   <result pre="precedents in the human history. The first incidences of possibly" exact="smallpox" post="in Europe was the Antonine Plague of 165 to"/>
   <result pre="was carried there by the Spanish conquistadores [26]; in turn" exact="syphilis" post="was carried eastward from the New World to Europe"/>
   <result pre="organisms. In the Flaviviridae family, vaccines are available for the" exact="yellow fever" post="virus (YFV) and Japanese encephalitis virus (JEV). There are"/>
   <result pre="are available for the yellow fever virus (YFV) and Japanese" exact="encephalitis" post="virus (JEV). There are two types of JEV vaccine"/>
   <result pre="Watson is reported to be already more efficient in detecting" exact="cancer" post="symptoms than humans; precision vaccine design by AI may"/>
   <result pre="heightened because of babies born from ZIKV infected mothers showed" exact="microcephaly" post="and neurological complications [84]. Since neither any drug nor"/>
   <result pre="50% of the infected mice from death without symptoms of" exact="neurological disorder" post="[129], the compound was discarded to other undesirable toxic"/>
   <result pre="to identify potential anti–ZIKV compounds. The CDK pharmacophore model on" exact="malaria" post="allowed identification of several new antimalarial CDK inhibitors [136]."/>
   <result pre="an FDA-approved drug, mainly used in the treatment of intestinal" exact="helminthiasis" post="and also in pregnancy. However, the drug has not"/>
   <result pre="for use as live virus vaccinesVaccine1985335536910.1016/0264-410X(85)90124-03909681 45.CateT.R.CouchR.B.KaselJ.A.SixH.R.Clinical trials of monovalent" exact="influenza" post="A/New Jersey/76 virus vaccines in adults: Reactogenicity, antibody response,"/>
   <result pre="YFV 17D-based chimeric vaccines against dengue, West Nile and Japanese" exact="encephalitis" post="virusesVaccine20102863264910.1016/j.vaccine.2009.09.09819808029 48.WHO Vaccine Pipeline TrackerAvailable online: https://docs.google.com/spreadsheets/d/19otvINcayJURCMg76xWO4KvuyedYbMZDcXqbyJGdcZM/pubhtml#(accessed on 15"/>
   <result pre="Clin. Investig.20021101765176810.1172/JCI1740512488425 64.LiuF.FeuerR.HassettD.E.WhittonJ.L.Peptide vaccination of mice immune to LCMV or" exact="vaccinia virus" post="causes serious CD8+ T cell mediated, TNF-dependent immunopathologyJ. Clin."/>
   <result pre="Antiviral compounds active against pathogenic flavivirusesAntivir. Res.200358737910.1016/S0166-3542(02)00185-712719009 127.XieY.OgahC.A.JiangX.LiJ.ShenJ.Nucleoside inhibitors of" exact="hepatitis" post="C virus NS5B polymerase: A systematic reviewCurr. Drug Targets2016171560157610.2174/138945011766615120912375126648061"/>
   <result pre="153.OliveiraA.F.TeixeiraR.R.OliveiraA.S.SouzaA.P.SilvaM.L.PaulaS.O.Potential antivirals: Natural products targeting replication enzymes of dengue and" exact="chikungunya" post="virusesMolecules20172250510.3390/molecules22030505 154.ValadaoA.L.AguiarR.S.de ArrudaL.B.Interplay between inflammation and cellular stress triggered"/>
   <result pre="FDA-approved drug, prevents Zika Virus infection and its associated congenital" exact="microcephaly" post="in miceEBioMedicine20172418919410.1016/j.ebiom.2017.09.03429033372 156.ShiryaevS.A.MesciP.PintoA.FernandesI.SheetsN.ShrestaS.FarhyC.HuangC.-T.StronginA.Y.MuotriA.R.et al.Repurposing of the anti-malaria drug chloroquine"/>
   <result pre="French Polynesia Second reported outbreak of ZIKV infections. Connection with" exact="microcephaly" post="and neurological disorders established later. 2013–2014 Chile, Cook Islands,New"/>
   <result pre="Central and South America Brazil reported 141 suspected cases of" exact="microcephaly" post="and declared a national public health emergency. Brazil reported"/>
   <result pre="and Ivermectin Hybrid drugs against co-infections of ZIKV, dengue and" exact="chikungunya" post="[100] 20-Cmethylated nucleosides Inhibitors of RNA-dependent RNA polymerase (RdRp)"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6959858\results\search\disease\results.xml">
   <result pre="infection of influenza, adenovirus, or RSV during 2 recent consecutive" exact="influenza" post="seasons. Remnant respiratory specimens were used for bacterial PCR"/>
   <result pre="7.6% for those with adenovirus to 0% for those with" exact="influenza" post="viruses. The overall viral–bacterial codetection rate was 59.8% (61/102);"/>
   <result pre="viral–bacterial coinfection KEY POINTS Among young children with solo-infections of" exact="influenza" post="viruses, adenoviruses, and RSV, the overall viral–bacterial codetection rate"/>
   <result pre="M catarrhalis in RSV infection (34.2%), and S pneumoniae in" exact="influenza" post="(50.0%; 5/10). Although the presence of viral–bacterial coinfection was"/>
   <result pre="involvement. Among diverse respiratory viruses, respiratory syncytial virus (RSV) and" exact="influenza" post="virus are the most common pathogens during the winter"/>
   <result pre="causes of lower respiratory tract infections in infants leading to" exact="respiratory failure;" post="internationally 200,000 deaths and 3,000,000 hospitalizations each year are"/>
   <result pre="to RSV infection by either direct or nondirect impacts.[1–3] Although" exact="influenza" post="viruses are far less common than RSV infection, except"/>
   <result pre="aggravating factor for disease severity as formerly shown during the" exact="influenza" post="pandemics in which mortality cases were vastly attributed to"/>
   <result pre="aureus (S aureus).[6,9,10] Although most coinfection research has focused on" exact="influenza" post="viruses, other viruses also participate in viral–bacterial coinfections, including"/>
   <result pre="which is responsible for most cases of community-acquired pneumonia, sinusitis," exact="otitis media," post="and meningitis.[11] Evidence is accumulating that bacterial colonization or"/>
   <result pre="coinfection dynamics between bacteria and respiratory viruses especially focused on" exact="influenza" post="viruses, adenoviruses, and RSV and the clinical significance of"/>
   <result pre="at Asan Medical Center Children‘s Hospital during 2 recent consecutive" exact="influenza" post="seasons (November 2015 to April 2016 and November 2016"/>
   <result pre="aged under 5 years with community-acquired single viral infections of" exact="influenza" post="A/B, RSV A/B, or adenovirus detected by real-time multiplex"/>
   <result pre="excluded: healthcare-associated infection, coexistence of ≥ 2 different respiratory viruses," exact="influenza" post="cases confirmed only by rapid influenza antigen test, and"/>
   <result pre="2 different respiratory viruses, influenza cases confirmed only by rapid" exact="influenza" post="antigen test, and respiratory viral infections other than adenovirus,"/>
   <result pre="was defined as need for advanced respiratory support due to" exact="respiratory failure" post="(i.e., invasive or noninvasive mechanical ventilation), or need for"/>
   <result pre="pediatric intensive care unit (PICU) admission for reasons other than" exact="respiratory failure" post="(i.e., hemodynamic instability, lethargy, reduced level of consciousness, convulsions),"/>
   <result pre="respiratory tract infection (LRTI) including acute bronchitis, acute bronchiolitis, and" exact="pneumonia" post="was defined as the presence of wheezing, rales, hypoxia,"/>
   <result pre="identification With the exception of respiratory specimens only for rapid" exact="influenza" post="antigen testing which were obtained by nasopharyngeal swabs, respiratory"/>
   <result pre="(Seeplex), which differentiated 15 species of common respiratory viruses including" exact="influenza" post="A and B, RSV A and B, and adenovirus."/>
   <result pre="any respiratory viruses using real-time multiplex PCR during 2 consecutive" exact="influenza" post="seasons, 51.5% (410/796) comprised of adenovirus (n = 114), influenza viruses"/>
   <result pre="2 consecutive influenza seasons, 51.5% (410/796) comprised of adenovirus (n = 114)," exact="influenza" post="viruses (n = 53), or RSV (n = 271); 50.2% (206/410) of these"/>
   <result pre="5 years with community-acquired single viral infections of adenovirus (n = 13)," exact="influenza" post="A (n = 7), influenza B (n = 3), and RSV (n = 79) were"/>
   <result pre="community-acquired single viral infections of adenovirus (n = 13), influenza A (n = 7)," exact="influenza" post="B (n = 3), and RSV (n = 79) were included in this"/>
   <result pre="under age 5, with proven single viral infections of adenovirus," exact="influenza" post="A and B viruses, and respiratory syncytial virus (RSV)."/>
   <result pre="manifestation was present more frequently with adenovirus (81.8%) than with" exact="influenza" post="(60.0%) or RSV (53.1%). Overall median length of hospital"/>
   <result pre="adenovirus and RSV, and 3 days (IQR 2.0–5.0 d) in" exact="influenza" post="viruses, respectively. Table 2 Demographic data and clinical characteristics"/>
   <result pre="years old with community-acquired single viral infections during 2 consecutive" exact="influenza" post="seasons. The occurrence of severe clinical outcome requiring PICU"/>
   <result pre="7.6% for those with adenovirus to 0% for those with" exact="influenza" post="viruses. Overall, 6.8% (7/102) of cases were classified as"/>
   <result pre="RSV infection, in which a 4-month-old boy newly diagnosed with" exact="acute myeloid leukemia" post="progressed to acute respiratory distress syndrome and expired despite"/>
   <result pre="infection, in which a 4-month-old boy newly diagnosed with acute" exact="myeloid leukemia" post="progressed to acute respiratory distress syndrome and expired despite"/>
   <result pre="in which a 4-month-old boy newly diagnosed with acute myeloid" exact="leukemia" post="progressed to acute respiratory distress syndrome and expired despite"/>
   <result pre="4-month-old boy newly diagnosed with acute myeloid leukemia progressed to" exact="acute respiratory distress syndrome" post="and expired despite ICU stay and ventilator care. 3.2"/>
   <result pre="to the clinical diagnosis of LRTI and non-LRTI. Patients with" exact="influenza" post="viruses showed higher bacterial coinfection rates (80.0%; 8/10) compared"/>
   <result pre="influenzae (46.2%; 6/13), RSV and M catarrhalis (34.2%; 27/79), and" exact="influenza" post="viruses and S pneumoniae (50.0%; 5/10). Pneumococcal coinfection rate"/>
   <result pre="S pneumoniae (50.0%; 5/10). Pneumococcal coinfection rate was 50% in" exact="influenza" post="viral infection, which was higher than that of adenovirus"/>
   <result pre="adenoviral infection, 5 of the children infected with RSV or" exact="influenza" post="virus were colonized with 3 different bacteria. However, none"/>
   <result pre="association with the severity of LRTIs compared with adenoviral or" exact="influenza" post="viral infections (OR 0.97; 95% CI 0.26–3.68). Although codetection"/>
   <result pre="the clinical severity. 4 Discussion This study over 2 consecutive" exact="influenza" post="seasons showed that 60% of single respiratory viral infections"/>
   <result pre="showed that 60% of single respiratory viral infections including adenovirus," exact="influenza" post="viruses, and RSV occurred in the setting of coexistence"/>
   <result pre="aggravating factor of disease severity as formerly shown during the" exact="influenza" post="pandemics,[9,10,27] pneumococcal coinfection in the upper respiratory tract was"/>
   <result pre="It can be partly explained by the small number of" exact="influenza" post="cases; influenza cases diagnosed only by rapid influenza antigen"/>
   <result pre="be partly explained by the small number of influenza cases;" exact="influenza" post="cases diagnosed only by rapid influenza antigen test were"/>
   <result pre="number of influenza cases; influenza cases diagnosed only by rapid" exact="influenza" post="antigen test were not included in this study because"/>
   <result pre="were available for bacterial PCR assays. In addition, only seasonal" exact="influenza" post="epidemics were observed during this study period, and none"/>
   <result pre="this study period, and none of the patients infected with" exact="influenza" post="ended up with a severe clinical outcome. Dynamics of"/>
   <result pre="postviral wheeze; especially, higher risk of developing persistent wheezing and" exact="asthma" post="in the presence of M catarrhalis in viral infection.[33,34]"/>
   <result pre="viral–bacterial coinfection. Even though the study period included 2 consecutive" exact="influenza" post="seasons in Korea, the number of influenza cases was"/>
   <result pre="included 2 consecutive influenza seasons in Korea, the number of" exact="influenza" post="cases was too small to analyze the synergism of"/>
   <result pre="influenza cases was too small to analyze the synergism of" exact="influenza" post="virus and pneumococci or S aureus. Secondly, respiratory specimens"/>
   <result pre="review the individual histories of immunization including pneumococcal and H" exact="influenza" post="type b (Hib) vaccines. However, in Korea, Hib and"/>
   <result pre="reduced severity of viral LRTIs. Despite the small study population," exact="influenza" post="virus most frequently detected with S pneumoniae, RSV with"/>
   <result pre="Microbiol Lett2015;362: fnv062. [7]MichelowICOlsenKLozanoJet al.Epidemiology and clinical characteristics of community-acquired" exact="pneumonia" post="in hospitalized children. Pediatrics2004;113:701–7.15060215 [8]SmithCMSandriniSDattaSet al.Respiratory syncytial virus increases"/>
   <result pre="Influenza Other Respir Viruses2013;7: suppl 2: 105–13.24034494 [10]McCullersJAThe co-pathogenesis of" exact="influenza" post="viruses with bacteria in the lung. Nat Rev Microbiol2014;12:252–62.24590244"/>
   <result pre="microbiome impacts severity of lower respiratory infection and risk of" exact="asthma" post="development. Cell Host Microbe2015;17:704–15.25865368 [21]Cebey-LopezMHerbergJPardo-SecoJet al.Does viral co-infection influence"/>
   <result pre="to their younger siblings. J Infect Dis2002;186:1608–14.12447737 [23]HiranoTKuronoYIchimiyaIet al.Effects of" exact="influenza" post="A virus on lectin-binding patterns in murine nasopharyngeal mucosa"/>
   <result pre="I Streptococcus pneumoniae to tracheal epithelium of mice infected with" exact="influenza" post="A/PR8 virus. Am Rev Respir Dis1986;134:1040–4.3777666 [25]GhaffarFFriedlandIRMcCrackenGHJrDynamics of nasopharyngeal"/>
   <result pre="do we know?Paediatr Child Health2004;9:21–4.19654976 [27]McCullersJAInsights into the interaction between" exact="influenza" post="virus and pneumococcus. Clin Microbiol Rev2006;19:571–82.16847087 [28]DeMuriGPGernJEEickhoffJCet al.Dynamics of"/>
   <result pre="on pneumococcal colonization of the nasopharynx. Trends Microbiol2013;21:129–35.23273566 [33]BisgaardHHermansenMNBuchvaldFet al.Childhood" exact="asthma" post="after bacterial colonization of the airway in neonates. N"/>
   <result pre="Infect2012;18:300–7.21851481 [36]BhuiyanMUSnellingTLWestRet al.Role of viral and bacterial pathogens in causing" exact="pneumonia" post="among Western Australian children: a case-control study protocol. BMJ"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6963280\results\search\disease\results.xml">
   <result pre="heart [20,21,22,23,24]. Dengue renal involvement varies from elevated serum creatinine," exact="acute tubular necrosis," post="hemolytic uremic syndrome, proteinuria, glomerulopathy, nephrotic syndrome, and acute"/>
   <result pre="serum creatinine, acute tubular necrosis, hemolytic uremic syndrome, proteinuria, glomerulopathy," exact="nephrotic syndrome," post="and acute renal injury [25]. Despite the remarkable evidence"/>
   <result pre="were identified. Histological analysis revealed circulatory and parenchymal damage, presenting" exact="acute tubular necrosis," post="characterized by desquamation of necrotic cells and loss of"/>
   <result pre="fatal cases, Póvoa et al. [20] described the presence of" exact="acute tubular necrosis," post="characterized by desquamation of necrotic cells and loss of"/>
   <result pre="occur earlier and more intensely in cases of hypertension and" exact="diabetes mellitus." post="However, this is the first study to describe this"/>
   <result pre="may result in the reduction of renal perfusion leading to" exact="acute tubular necrosis," post="and involvement of multiple organ failure in severe dengue"/>
   <result pre="2018) 8.SVS/MS Monitoramento dos casos de dengue e febre de" exact="chikungunya" post="até a Semana Epidemiológica (SE) 53 de 2014Minist. SAÚDE"/>
   <result pre="24.PagliariC.Simões QuaresmaJ.A.Kanashiro-GaloL.de CarvalhoL.V.VitoriaW.O.da SilvaW.L.F.PennyR.VasconcelosB.C.B.da Costa VasconcelosP.F.DuarteM.I.S.Human kidney damage in fatal" exact="dengue hemorrhagic fever" post="results of glomeruli injury mainly induced by IL17J. Clin."/>
   <result pre="Int.2012811254126210.1038/ki.2012.2322418979 27.KularatneS.A.M.GawarammanaI.B.KumarasiriP.R.V.Epidemiology, clinical features, laboratory investigations and early diagnosis of" exact="dengue fever" post="in adults: A descriptive study in Sri LankaSoutheast Asian"/>
   <result pre="in dengue virus infectionClin. Kidney J.2012539039410.1093/ckj/sfs11726019813 31.MehraN.PatelA.AbrahamG.ReddyY.N.V.ReddyY.N.V.Acute kidney injury in" exact="dengue fever" post="using Acute Kidney Injury Network criteria: Incidence and risk"/>
   <result pre="with non-hemorrhagic Dengue fever: A case reportRen. Fail.20093173673910.3109/0886022090300340419814641 37.UpadhayaB.K.SharmaA.KhairaA.DindaA.K.AgarwalS.K.TiwariS.C.Transient IgA" exact="nephropathy" post="with acute kidney injury in a patient with dengue"/>
   <result pre="patient with dengue feverSaudi J. Kidney Dis. Transpl.20102152152520427882 38.RepizoL.P.MalheirosD.M.YuL.BarrosR.T.BurdmannE.A.Biopsy proven" exact="acute tubular necrosis" post="due to rhabdomyolysis in a dengue fever patient: A"/>
   <result pre="38.RepizoL.P.MalheirosD.M.YuL.BarrosR.T.BurdmannE.A.Biopsy proven acute tubular necrosis due to rhabdomyolysis in a" exact="dengue fever" post="patient: A case report and review of literatureRev. Inst."/>
   <result pre="Pract. Nephrol.2006262262310.1038/ncpneph032217066053 45.FinkJ.GuF.VasudevanS.G.Role of T cells, cytokines and antibody in" exact="dengue fever" post="and dengue haemorrhagic feverRev. Med. Virol.20061626327510.1002/rmv.50716791836 46.GuzmánM.G.AlvarezM.RodríguezR.RosarioD.VázquezS.Vald sL.CabreraM.V.KouríG.Fatal dengue"/>
   <result pre="dengue fever and dengue haemorrhagic feverRev. Med. Virol.20061626327510.1002/rmv.50716791836 46.GuzmánM.G.AlvarezM.RodríguezR.RosarioD.VázquezS.Vald sL.CabreraM.V.KouríG.Fatal" exact="dengue hemorrhagic fever" post="in Cuba, 1997Int. J. Infect. Dis.1999313013510.1016/S1201-9712(99)90033-410460923 47.WiwanitkitV.Acute renal failure"/>
   <result pre="Infect. Dis.1999313013510.1016/S1201-9712(99)90033-410460923 47.WiwanitkitV.Acute renal failure in the fatal cases of" exact="dengue hemorrhagic fever," post="a summary in Thai death casesRen. Fail.20052764710.1080/0886022050020091616153008 48.HommelD.TalarminA.ReynesJ.M.HulinA.Acute renal"/>
   <result pre="in Thai death casesRen. Fail.20052764710.1080/0886022050020091616153008 48.HommelD.TalarminA.ReynesJ.M.HulinA.Acute renal failure associated with" exact="dengue fever" post="in French GuianaNephron19998318310.1159/00004550610516508 49.LanciottiR.S.CalisherC.H.GublerD.J.ChangG.J.VorndamA.V.Rapid detection and typing of dengue"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6963298\results\search\disease\results.xml">
   <result pre="license (http://creativecommons.org/licenses/by/4.0/). Abstract Yellow fever is a potentially fatal, mosquito-borne" exact="viral disease" post="that appears to be experiencing a resurgence in endemic"/>
   <result pre="to areas in Asia with ecological conditions that can sustain" exact="yellow fever" post="virus transmission. In this article, we provide a broad"/>
   <result pre="transmission. In this article, we provide a broad overview of" exact="yellow fever" post="burden of disease, natural history, treatment, vaccine, prevention and"/>
   <result pre="and control initiatives, and vaccine and therapeutic agent development efforts." exact="yellow fever" post="vaccine flavivirus mosquito-borne acute febrile illness 1. Background Yellow"/>
   <result pre="caused by a member of the family Flaviviridae, genus Flavivirus," exact="yellow fever" post="virus (YFV) [1]. The disease is endemic in equatorial"/>
   <result pre="epigastric pain, jaundice, oliguria, and hemorrhagic manifestations. Patients may develop" exact="metabolic acidosis" post="and organ impairment involving the liver, pancreas, kidneys and"/>
   <result pre="disease require intensive care management to prevent and treat shock," exact="metabolic acidosis," post="hypoglycemia, stress-induced gastritis, bleeding, hepatic dysfunction, renal failure, and"/>
   <result pre="trials. For example, sofosbuvir, a uridine analog used to treat" exact="hepatitis" post="C, has shown antiviral activity against YFV in cell-based"/>
   <result pre="YF vaccine is comparable to the rate of vaccine-associated paralytic" exact="poliomyelitis" post="with oral polio vaccine [97,98]. In addition, because YF"/>
   <result pre="support sustained replication of the 17D strain [108]. Encephalitis and" exact="meningoencephalitis" post="associated with 17D vaccine administration in infants was first"/>
   <result pre="to direct viral invasion of the central nervous system (e.g.," exact="encephalitis" post="and meningitis) but also autoimmune-mediated demyelination and neuropathy including"/>
   <result pre="system (e.g., encephalitis and meningitis) but also autoimmune-mediated demyelination and" exact="neuropathy" post="including Guillain-Barre´ syndrome, acute disseminated encephalomyelitis, myelitis, and cranial"/>
   <result pre="meningitis) but also autoimmune-mediated demyelination and neuropathy including Guillain-Barre´ syndrome," exact="acute disseminated encephalomyelitis," post="myelitis, and cranial neuropathies. YEL-AND typically occurs 2-56 days"/>
   <result pre="≥60 years old [110,111,112]. In 2009, the first case of" exact="encephalitis" post="in an infant was confirmed to be caused by"/>
   <result pre="[133]. 10. Summary Points YF is a potentially fatal, mosquito-borne" exact="viral disease" post="that appears to be experiencing a resurgence in endemic"/>
   <result pre="Virol.20193410410910.1016/j.coviro.2019.01.00130743191 2.HamletA.JeanK.PereaW.YactayoS.BieyJ.Van KerkhoveM.FergusonN.GarskeT.The seasonal influence of climate and environment on" exact="yellow fever" post="transmission across AfricaPLoS Negl. Trop. Dis.201812e000628410.1371/journal.pntd.000628429543798 3.WeetmanD.KamgangB.BadoloA.MoyesC.L.ShearerF.M.CoulibalyM.PintoJ.LambrechtsL.McCallP.J.Aedes Mosquitoes and"/>
   <result pre="Public Health20181522010.3390/ijerph1502022029382107 4.HamrickP.N.AldighieriS.MachadoG.LeonelD.G.VilcaL.M.UrionaS.SchneiderM.C.Geographic patterns and environmental factors associated with human" exact="yellow fever" post="presence in the AmericasPLoS Negl. Trop. Dis.20171110.1371/journal.pntd.0005897 5.AbreuF.V.S.RibeiroI.P.Ferreira-de-BritoA.SantosA.MirandaR.M.BonellyI.S.NevesM.BersotM.I.SantosT.P.D.GomesM.Q.et al.Haemagogus"/>
   <result pre="and Haemagogus janthinomys are the primary vectors in the major" exact="yellow fever" post="outbreak in Brazil, 2016–2018Emerg. Microbes Infect.2019821823110.1080/22221751.2019.156818030866775 6.BarrettA.D.T.The reemergence of"/>
   <result pre="of yellow feverScience201836184784810.1126/science.aau822530139914 7.WamalaJ.F.MalimboM.OkotC.L.Atai-OmorutoA.D.TenywaE.MillerJ.R.BalinandiS.ShoemakerT.OyooC.OmonyE.O.et al.Epidemiological and laboratory characterization of a" exact="yellow fever" post="outbreak in northern Uganda, October 2010–January 2011Int. J. Infect."/>
   <result pre="Uganda, October 2010–January 2011Int. J. Infect. Dis.201216e536e54210.1016/j.ijid.2012.03.00422575876 8.KwagonzaL.MasiiraB.Kyobe-BosaH.KadoberaD.AtuheireE.B.LubwamaB.KagiritaA.KatushabeE.KayiwaJ.T.LutwamaJ.J.et al.Outbreak of" exact="yellow fever" post="in central and southwestern Uganda, February-may 2016BMC Infect. Dis.20181810.1186/s12879-018-3440-y"/>
   <result pre="and southwestern Uganda, February-may 2016BMC Infect. Dis.20181810.1186/s12879-018-3440-y 9.LilayA.AsameneN.BekeleA.MengeshaM.WendabekuM.TarekeI.GirmayA.WuletawY.AdossaA.BaY.et al.Reemergence of" exact="yellow fever" post="in Ethiopia after 50 years, 2013: Epidemiological and entomological"/>
   <result pre="Yellow Fever in Angola, 2015–2016Emerg. Infect. Dis.2016221854185510.3201/eid2210.16081827536787 11.KraemerM.U.G.FariaN.R.ReinerR.C.Jr.GoldingN.NikolayB.StasseS.JohanssonM.A.SaljeH.FayeO.WintG.R.W.et al.Spread of" exact="yellow fever" post="virus outbreak in Angola and the Democratic Republic of"/>
   <result pre="Epidemiological Report, Week 52Nigeria Centre for Disease ControlAbuja, Nigeria2018 13.IngelbeenB.WeregemereN.A.NoelH.TshapendaG.P.MossokoM.NsioJ.RonsseA.Ahuka-MundekeS.CohuetS.KebelaB.I.Urban" exact="yellow fever" post="outbreak-Democratic Republic of the Congo, 2016: Towards more rapid"/>
   <result pre="China from Angola, March 2016Emerg. Infect. Dis.2016221317131810.3201/eid2207.16046927314417 16.CuiS.J.PanY.LyuY.N.LiangZ.C.LiJ.SunY.L.DouX.F.TianL.L.HuoD.ChenL.J.et al.Detection of" exact="yellow fever" post="virus genomes from four imported cases in ChinaInt. J."/>
   <result pre="Salud Pública201943e2910.26633/RPSP.2019.2931093253 21.GossnerC.M.HaussigJ.M.de Bellegarde de Saint LaryC.Kaasik AaslavK.SchlagenhaufP.SudreB.Increased risk of" exact="yellow fever" post="infections among unvaccinated European travellers due to ongoing outbreak"/>
   <result pre="Brazilian Regions from 2015 to 2018Front. Microbiol.201910107910.3389/fmicb.2019.0107931178835 23.AmakuM.CoutinhoF.A.MassadE.Why dengue and" exact="yellow fever" post="coexist in some areas of the world and not"/>
   <result pre="populations from dengue incidence data: Implications for the risk of" exact="yellow fever" post="outbreaksInfect. Dis. Model.2017244145410.1016/j.idm.2017.12.00130137722 26.DorigattiI.HamletA.AguasR.CattarinoL.CoriA.DonnellyC.A.GarskeT.ImaiN.FergusonN.M.International risk of yellow fever spread"/>
   <result pre="risk of yellow fever outbreaksInfect. Dis. Model.2017244145410.1016/j.idm.2017.12.00130137722 26.DorigattiI.HamletA.AguasR.CattarinoL.CoriA.DonnellyC.A.GarskeT.ImaiN.FergusonN.M.International risk of" exact="yellow fever" post="spread from the ongoing outbreak in Brazil, December 2016"/>
   <result pre="Wkly. Rep.20186734034110.15585/mmwr.mm6711e129565840 28.BrentS.E.WattsA.CetronM.GermanM.KraemerM.U.BogochI.I.BradyO.J.HayS.I.CreatoreM.I.KhanK.International travel between global urban centres vulnerable to" exact="yellow fever" post="transmissionBull. World Health Organ.201896343B354B10.2471/BLT.17.20565829875519 29.VasconcelosP.F.Yellow fever in Brazil: Thoughts"/>
   <result pre="Vaccine Shortage - United States, 2016–2017Morb. Mortal. Wkly. Rep.20176645745910.15585/mmwr.mm6617e2 32.RoukensA.H.E.VisserL.G.Fractional-dose" exact="yellow fever" post="vaccination: An expert reviewJ. Travel Med.20192610.1093/jtm/taz024 33.collab: World Health"/>
   <result pre="vaccination: An expert reviewJ. Travel Med.20192610.1093/jtm/taz024 33.collab: World Health OrganizationEliminate" exact="yellow fever" post="epidemics (EYE): A global strategy, 2017–2026Wkly. Epidemiol. Rec.201716193204 34.collab:"/>
   <result pre="Trop. Med. Hyg.20108318318810.4269/ajtmh.2010.09-078220595499 38.JohanssonM.A.VasconcelosP.F.StaplesJ.E.The whole iceberg: Estimating the incidence of" exact="yellow fever" post="virus infection from the number of severe casesTrans. R."/>
   <result pre="studyLancet Infect. Dis.20191975075810.1016/S1473-3099(19)30125-231104909 40.TuboiS.H.CostaZ.G.da Costa VasconcelosP.F.HatchD.Clinical and epidemiological characteristics of" exact="yellow fever" post="in Brazil: Analysis of reported cases 1998-2002Trans. R. Soc."/>
   <result pre="viral load) are prognostic factors for the evolution of severe" exact="yellow fever" post="casesMemórias do Instituto Oswaldo Cruz2019114e19003310.1590/0074-0276019003331116245 42.Duarte-NetoA.N.CunhaM.D.P.MarcilioI.SongA.T.W.de MartinoR.B.HoY.L.PourS.Z.DolhnikoffM.SaldivaP.H.N.DuarteM.I.S.et al.Yellow fever"/>
   <result pre="feverTrans. R. Soc. Trop. Med. Hyg.19817528228610.1016/0035-9203(81)90335-77029803 45.MiyajiK.T.Avelino-SilvaV.I.SimoesM.FreireM.D.MedeirosC.R.BragaP.E.NevesM.A.LopesM.H.KallasE.G.SartoriA.M.Prevalence and titers of" exact="yellow fever" post="virus neutralizing antibodies in previously vaccinated adultsRev. Inst. Med."/>
   <result pre="against Yellow FeverJ. Exp. Med.19315453355510.1084/jem.54.4.53319869938 48.BauerJ.H.HudsonN.P.Duration of immunity in human" exact="yellow fever" post="as shown by protective power of serumJ. Prev. Med.19304177178"/>
   <result pre="protective power of serumJ. Prev. Med.19304177178 49.BlakeL.E.Garcia-BlancoM.A.Human genetic variation and" exact="yellow fever" post="mortality during 19th century U.S. epidemicsmBio20145e01253-1410.1128/mBio.01253-1424895309 50.OliveiraR.A.de Oliveira-FilhoE.F.FernandesA.I.BritoC.A.MarquesE.T.TenorioM.C.GilL.H.Previous dengue"/>
   <result pre="Glob. Infect. Dis.2009111111610.4103/0974-777X.5625720300401 52.MonathT.P.Treatment of yellow feverAntivir. Res.20087811612410.1016/j.antiviral.2007.10.00918061688 53.HoY.L.JoelsonsD.LeiteG.F.C.MalbouissonL.M.S.SongA.T.W.PerondiB.AndradeL.C.PintoL.F.D’AlbuquerqueL.A.C.SeguradoA.A.C.et al.Severe" exact="yellow fever" post="in Brazil: Clinical characteristics and managementJ. Travel Med.20192610.1093/jtm/taz040 54.ZandiK.AmblardF.AmichaiS.BassitL.TaoS.JiangY.ZhouL.Ollinger"/>
   <result pre="nucleoside analogue BCX4430Nature201450840240510.1038/nature1302724590073 59.JulanderJ.G.BantiaS.TaubenheimB.R.MinningD.M.KotianP.MorreyJ.D.SmeeD.F.SheridanW.P.BabuY.S.BCX4430, a novel nucleoside analog, effectively treats" exact="yellow fever" post="in a Hamster modelAntimicrob. Agents Chemother.2014586607661410.1128/AAC.03368-1425155605 60.collab: ClinicalTrials.govA Study"/>
   <result pre="for International TravelBrunetteG.W.NemhauserJ.B.Oxford University PressOxford, UK2019 70.KaulR.B.EvansM.V.MurdockC.C.DrakeJ.M.Spatio-temporal spillover risk of" exact="yellow fever" post="in BrazilParasites Vectors20181148810.1186/s13071-018-3063-630157908 71.MorenoE.S.SpinolaR.TenganC.H.BrasilR.A.SicilianoM.M.CoimbraT.L.SilveiraV.R.RoccoI.M.BisordiI.SouzaR.P.et al.Yellow fever epizootics in non-human"/>
   <result pre="77.ShearerF.M.LongbottomJ.BrowneA.J.PigottD.M.BradyO.J.KraemerM.U.G.MarinhoF.YactayoS.de AraujoV.E.M.da NobregaA.A.et al.Existing and potential infection risk zones of" exact="yellow fever" post="worldwide: A modelling analysisLancet Glob. Health20186e270e27810.1016/S2214-109X(18)30024-X29398634 78.HamletA.JeanK.YactayoS.BenzlerJ.CibrelusL.FergusonN.GarskeT.POLICI: A web"/>
   <result pre="Glob. Health20186e270e27810.1016/S2214-109X(18)30024-X29398634 78.HamletA.JeanK.YactayoS.BenzlerJ.CibrelusL.FergusonN.GarskeT.POLICI: A web application for visualising and extracting" exact="yellow fever" post="vaccination coverage in AfricaVaccine2019371384138810.1016/j.vaccine.2019.01.07430770224 79.PolonskyJ.A.BaidjoeA.KamvarZ.N.CoriA.DurskiK.EdmundsW.J.EggoR.M.FunkS.KaiserL.KeatingP.et al.Outbreak analytics: A developing"/>
   <result pre="emerging pathogensPhilos. Trans. R. Soc. B201937410.1098/rstb.2018.027631104603 80.KraemerM.U.G.CummingsD.A.T.FunkS.ReinerR.C.FariaN.R.PybusO.G.CauchemezS.Reconstruction and prediction of" exact="viral disease" post="epidemicsEpidemiol. Infect.201914710.1017/S095026881800288130394230 81.ChildsM.L.NovaN.ColvinJ.MordecaiE.A.Mosquito and primate ecology predict human risk"/>
   <result pre="epidemicsEpidemiol. Infect.201914710.1017/S095026881800288130394230 81.ChildsM.L.NovaN.ColvinJ.MordecaiE.A.Mosquito and primate ecology predict human risk of" exact="yellow fever" post="virus spillover in BrazilPhilos. Trans. R. Soc. Lond. B"/>
   <result pre="Virus to Cultivation in VitroJ. Exp. Med.19376580180810.1084/jem.65.6.80119870635 83.StokesA.BauerJ.H.HudsonX.P.Experimental transmission of" exact="yellow fever" post="to laboratory animalsAm. J. Trop. Med.1928810316410.4269/ajtmh.1928.s1-8.103 84.TheilerM.SmithH.H.The Effect of"/>
   <result pre="of Vaccine Supply and DemandN. Engl. J. Med.201637530130310.1056/NEJMp160699727276108 87.ShearerF.M.MoyesC.L.PigottD.M.BradyO.J.MarinhoF.DeshpandeA.LongbottomJ.BrowneA.J.KraemerM.U.G.O’ReillyK.M.et al.Global" exact="yellow fever" post="vaccination coverage from 1970 to 2016: An adjusted retrospective"/>
   <result pre="of Imported Stamaril VaccineMorb. Mortal. Wkly. Rep.20176678010.15585/mmwr.mm6629a4 89.WuJ.T.PeakC.M.LeungG.M.LipsitchM.Fractional dosing of" exact="yellow fever" post="vaccine to extend supply: A modelling studyLancet20163882904291110.1016/S0140-6736(16)31838-427837923 90.collab: World"/>
   <result pre="of fractional doses—June 2017, addendum to vaccines and vaccination against" exact="yellow fever" post="WHO: Position paper—June 2013Vaccine2017355751575210.1016/j.vaccine.2017.06.08728689653 91.ChenL.H.HamerD.H.Vaccination Challenges in Confronting the"/>
   <result pre="Fever Outbreak—Final ReportN. Engl. J. Med.201938144445410.1056/NEJMoa171043029443626 94.LindseyN.P.RabeI.B.MillerE.R.FischerM.StaplesJ.E.Adverse event reports following" exact="yellow fever" post="vaccination, 2007–2013J. Travel Med.20162310.1093/jtm/taw045 95.LindseyN.P.SchroederB.A.MillerE.R.BraunM.M.HinckleyA.F.MaranoN.SladeB.A.BarnettE.D.BrunetteG.W.HoranK.et al.Adverse event reports following"/>
   <result pre="fever vaccination, 2007–2013J. Travel Med.20162310.1093/jtm/taw045 95.LindseyN.P.SchroederB.A.MillerE.R.BraunM.M.HinckleyA.F.MaranoN.SladeB.A.BarnettE.D.BrunetteG.W.HoranK.et al.Adverse event reports following" exact="yellow fever" post="vaccinationVaccine2008266077608210.1016/j.vaccine.2008.09.00918809449 96.MonathT.P.Review of the risks and benefits of yellow"/>
   <result pre="yellow fever vaccinationVaccine2008266077608210.1016/j.vaccine.2008.09.00918809449 96.MonathT.P.Review of the risks and benefits of" exact="yellow fever" post="vaccination including some new analysesExpert Rev. Vaccines20121142744810.1586/erv.12.622551029 97.HayesE.B.Is it"/>
   <result pre="new analysesExpert Rev. Vaccines20121142744810.1586/erv.12.622551029 97.HayesE.B.Is it time for a new" exact="yellow fever" post="vaccine?Vaccine2010288073807610.1016/j.vaccine.2010.10.01520971115 98.AmannaI.J.SlifkaM.K.Questions regarding the safety and duration of immunity"/>
   <result pre="98.AmannaI.J.SlifkaM.K.Questions regarding the safety and duration of immunity following live" exact="yellow fever" post="vaccinationExpert Rev. Vaccines2016151519153310.1080/14760584.2016.119825927267203 99.collab: Centers for Disease Control and"/>
   <result pre="IFNAR1 deficiency in otherwise healthy patients with adverse reaction to" exact="measles" post="and yellow fever live vaccinesJ. Exp. Med.20192162057207010.1084/jem.2018229531270247 102.DeSilvaM.SharmaA.StaplesE.ArndtB.ShiehW.J.ShamesJ.CieslakP.Notes from"/>
   <result pre="in otherwise healthy patients with adverse reaction to measles and" exact="yellow fever" post="live vaccinesJ. Exp. Med.20192162057207010.1084/jem.2018229531270247 102.DeSilvaM.SharmaA.StaplesE.ArndtB.ShiehW.J.ShamesJ.CieslakP.Notes from the field: Fatal"/>
   <result pre="fever live vaccinesJ. Exp. Med.20192162057207010.1084/jem.2018229531270247 102.DeSilvaM.SharmaA.StaplesE.ArndtB.ShiehW.J.ShamesJ.CieslakP.Notes from the field: Fatal" exact="yellow fever" post="vaccine-associated viscerotropic disease—Oregon, September 2014Morb. Mortal. Wkly. Rep.201564279281 103.SeligmanS.J.Risk"/>
   <result pre="viscerotropic disease—Oregon, September 2014Morb. Mortal. Wkly. Rep.201564279281 103.SeligmanS.J.Risk groups for" exact="yellow fever" post="vaccine-associated viscerotropic disease (YEL-AVD)Vaccine2014325769577510.1016/j.vaccine.2014.08.05125192973 104.HayesE.B.Acute viscerotropic disease following vaccination"/>
   <result pre="subjects have a delayed antibody response and prolonged viraemia following" exact="yellow fever" post="vaccination: A prospective controlled cohort studyPLoS ONE20116e2775310.1371/journal.pone.002775322163273 106.MeierK.C.GardnerC.L.KhoretonenkoM.V.KlimstraW.B.RymanK.D.A mouse"/>
   <result pre="ONE20116e2775310.1371/journal.pone.002775322163273 106.MeierK.C.GardnerC.L.KhoretonenkoM.V.KlimstraW.B.RymanK.D.A mouse model for studying viscerotropic disease caused by" exact="yellow fever" post="virus infectionPLoS Pathog.20095e100061410.1371/journal.ppat.100061419816561 107.EricksonA.K.PfeifferJ.K.Dynamic viral dissemination in mice infected"/>
   <result pre="virus infectionPLoS Pathog.20095e100061410.1371/journal.ppat.100061419816561 107.EricksonA.K.PfeifferJ.K.Dynamic viral dissemination in mice infected with" exact="yellow fever" post="virus strain 17DJ. Virol.201387123921239710.1128/JVI.02149-1324027319 108.DhimanG.AbrahamR.GriffinD.E.Human Schwann cells are susceptible"/>
   <result pre="108.DhimanG.AbrahamR.GriffinD.E.Human Schwann cells are susceptible to infection with Zika and" exact="yellow fever" post="viruses, but not dengue virusSci. Rep.20199995110.1038/s41598-019-46389-031289325 109.StuartG.Rections Folowing Vaccination"/>
   <result pre="109.StuartG.Rections Folowing Vaccination against Yellow FeverWorld Health OrganizationGeneva, Switzerland1956 110.BartolK.D.AguirreJ.L.LabruzzoS.V.HenrietR.P.Transverse" exact="myelitis" post="associated with yellow fever vaccinationBayl. Univ. Med Cent. Proc.20193228328510.1080/08998280.2019.1573405"/>
   <result pre="against Yellow FeverWorld Health OrganizationGeneva, Switzerland1956 110.BartolK.D.AguirreJ.L.LabruzzoS.V.HenrietR.P.Transverse myelitis associated with" exact="yellow fever" post="vaccinationBayl. Univ. Med Cent. Proc.20193228328510.1080/08998280.2019.1573405 111.GoldsteinE.J.BellD.J.GunsonR.N.Yellow fever vaccine-associated neurological"/>
   <result pre="at riskBMJ Case Rep.20191210.1136/bcr-2019-22955831088820 112.McMahonA.W.EidexR.B.MarfinA.A.RussellM.SejvarJ.J.MarkoffL.HayesE.B.ChenR.T.BallR.BraunM.M.et al.Neurologic disease associated with 17D-204" exact="yellow fever" post="vaccination: A report of 15 casesVaccine2007251727173410.1016/j.vaccine.2006.11.02717240001 113.TraiberC.Coelho-AmaralP.RitterV.R.WingeA.Infant meningoencephalitis caused"/>
   <result pre="17D-204 yellow fever vaccination: A report of 15 casesVaccine2007251727173410.1016/j.vaccine.2006.11.02717240001 113.TraiberC.Coelho-AmaralP.RitterV.R.WingeA.Infant" exact="meningoencephalitis" post="caused by yellow fever vaccine virus transmitted via breastmilkJ."/>
   <result pre="vaccination: A report of 15 casesVaccine2007251727173410.1016/j.vaccine.2006.11.02717240001 113.TraiberC.Coelho-AmaralP.RitterV.R.WingeA.Infant meningoencephalitis caused by" exact="yellow fever" post="vaccine virus transmitted via breastmilkJ. Pediatr.20118726927210.2223/JPED.206721461453 114.KuhnS.Twele-MontecinosL.MacDonaldJ.WebsterP.LawB.Case report: Probable"/>
   <result pre="breastmilkJ. Pediatr.20118726927210.2223/JPED.206721461453 114.KuhnS.Twele-MontecinosL.MacDonaldJ.WebsterP.LawB.Case report: Probable transmission of vaccine strain of" exact="yellow fever" post="virus to an infant via breast milkCMAJ2011183E243E24510.1503/cmaj.10061921324845 115.collab: Centers"/>
   <result pre="breast milkCMAJ2011183E243E24510.1503/cmaj.10061921324845 115.collab: Centers for Disease Control and PreventionTransmission of" exact="yellow fever" post="vaccine virus through breast-feeding-Brazil, 2009Morb. Mortal. Wkly. Rep.201059130132 116.MonathT.P.VasconcelosP.F.Yellow"/>
   <result pre="116.MonathT.P.VasconcelosP.F.Yellow feverJ. Clin. Virol.20156416017310.1016/j.jcv.2014.08.03025453327 117.GotuzzoE.YactayoS.CordovaE.Efficacy and duration of immunity after" exact="yellow fever" post="vaccination: Systematic review on the need for a booster"/>
   <result pre="Required to Guarantee Protective Immunity in ChildrenFront. Immunol.201910219210.3389/fimmu.2019.0219231616412 120.PatoT.P.SouzaM.C.O.MattosD.A.CarideE.FerreiraD.F.GasparL.P.FreireM.S.CastilhoL.R.Purification of" exact="yellow fever" post="virus produced in Vero cells for inactivated vaccine manufactureVaccine2019373214322010.1016/j.vaccine.2019.04.07731047674"/>
   <result pre="in Vero cells for inactivated vaccine manufactureVaccine2019373214322010.1016/j.vaccine.2019.04.07731047674 121.RoukensA.H.VossenA.C.BredenbeekP.J.van DisselJ.T.VisserL.G.Intradermally administered" exact="yellow fever" post="vaccine at reduced dose induces a protective immune response:"/>
   <result pre="randomized controlled non-inferiority trialPLoS ONE20083e199310.1371/journal.pone.000199318431480 122.RoukensA.H.GelinckL.B.VisserL.G.Intradermal vaccination to protect against" exact="yellow fever" post="and influenzaCurr. Top. Microbiol. Immunol.201235115917910.1007/82_2011_12421416266 123.WatsonA.M.LamL.K.KlimstraW.B.RymanK.D.The 17D-204 Vaccine Strain-Induced"/>
   <result pre="CellsPLoS Pathog.201612e100578610.1371/journal.ppat.100578627463517 124.Perdomo-CelisF.SalvatoM.S.Medina-MorenoS.ZapataJ.C.T-Cell Response to Viral Hemorrhagic FeversVaccines201971110.3390/vaccines701001130678246 125.SouzaM.C.FreireM.S.SchulzeE.A.GasparL.P.CastilhoL.R.Production of" exact="yellow fever" post="virus in microcarrier-based Vero cell culturesVaccine2009276420642310.1016/j.vaccine.2009.06.02319559120 126.MonathT.P.LeeC.K.JulanderJ.G.BrownA.BeasleyD.W.WattsD.M.HaymanE.GuertinP.MakowieckiJ.CrowellJ.et al.Inactivated yellow"/>
   <result pre="yellow fever virus in microcarrier-based Vero cell culturesVaccine2009276420642310.1016/j.vaccine.2009.06.02319559120 126.MonathT.P.LeeC.K.JulanderJ.G.BrownA.BeasleyD.W.WattsD.M.HaymanE.GuertinP.MakowieckiJ.CrowellJ.et al.Inactivated" exact="yellow fever" post="17D vaccine: Development and nonclinical safety, immunogenicity and protective"/>
   <result pre="vaccine: Development and nonclinical safety, immunogenicity and protective activityVaccine2010283827384010.1016/j.vaccine.2010.03.02320347059 127.GasparL.P.MendesY.S.YamamuraA.M.AlmeidaL.F.CarideE.GoncalvesR.B.SilvaJ.L.OliveiraA.C.GallerR.FreireM.S.Pressure-inactivated" exact="yellow fever" post="17DD virus: Implications for vaccine developmentJ. Virol. Methods2008150576210.1016/j.jviromet.2008.03.00218420285 128.PereiraR.C.SilvaA.N.SouzaM.C.SilvaM.V.NevesP.P.SilvaA.A.MatosD.D.HerreraM.A.YamamuraA.M.FreireM.S.et"/>
   <result pre="virus: Implications for vaccine developmentJ. Virol. Methods2008150576210.1016/j.jviromet.2008.03.00218420285 128.PereiraR.C.SilvaA.N.SouzaM.C.SilvaM.V.NevesP.P.SilvaA.A.MatosD.D.HerreraM.A.YamamuraA.M.FreireM.S.et al.An inactivated" exact="yellow fever" post="17DD vaccine cultivated in Vero cell culturesVaccine2015334261426810.1016/j.vaccine.2015.03.07725862300 129.BeasleyD.W.MorinM.LambA.R.HaymanE.WattsD.M.LeeC.K.TrentD.W.MonathT.P.Adaptation of"/>
   <result pre="fever 17DD vaccine cultivated in Vero cell culturesVaccine2015334261426810.1016/j.vaccine.2015.03.07725862300 129.BeasleyD.W.MorinM.LambA.R.HaymanE.WattsD.M.LeeC.K.TrentD.W.MonathT.P.Adaptation of" exact="yellow fever" post="virus 17D to Vero cells is associated with mutations"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6963304\results\search\disease\results.xml">
   <result pre="of the Herpesviridae, is the causative agent of an acute" exact="infectious disease" post="in a variety of animals. The emergence of a"/>
   <result pre="PRV germacrone antiviral 1. Introduction Pseudorabies (PR), an acute, febrile" exact="infectious disease" post="caused by pseudorabies virus (PRV), usually occurs in sows"/>
   <result pre="promoting apoptosis [19]. In terms of antiviral activity, germacrone inhibits" exact="influenza" post="virus (IAV), Porcine parvovirus (PPV), Feline calicivirus (FCV), and"/>
   <result pre="(PRRSV) replication [16,20,21,22]. Germacrone has inhibitory effects on H1N1, H3N2" exact="influenza" post="viruses, and Influenza B viruses in the early stages"/>
   <result pre="oseltamivir combination has a synergistic effect on the inhibition of" exact="influenza" post="virus. On the other hand, there are no reports"/>
   <result pre="Negative control NC Lithium chloride LiCl Diammonium glycyrrhizinate DG Inhibits" exact="influenza" post="virus IAV Porcine parvovirus PPV Feline calicivirus FCV Porcine"/>
   <result pre="and promoting apoptosisEur. J. Pharmacol.20136989510210.1016/j.ejphar.2012.10.01323117090 20.LiaoQ.QianZ.LiuR.AnL.ChenX.Germacrone inhibits early stages of" exact="influenza" post="virus infectionAntivir. Res.201310057858824095670 21.ChenY.DongY.JiaoY.HouL.ShiY.GuT.ZhouP.ShiZ.XuL.WangC.In vitro antiviral activity of germacrone"/>
   <result pre="geographic regionsVirology2017506929810.1016/j.virol.2017.03.01328363130 24.PanJ.MiaoD.ChenL.Germacrone reverses adriamycin resistance in human chronic myelogenous" exact="leukemia" post="K562/ADM cells by suppressing MDR1 gene/P-glycoprotein expressionChem. Biol. Interact.2018288323710.1016/j.cbi.2018.04.01229655913"/>
   <result pre="in neonatal ratsCell. Mol. Biol.20146081225399081 33.LiuB.GaoY.Q.WangX.M.WangY.C.FuL.Q.Germacrone inhibits the proliferation of" exact="glioma" post="cells by promoting apoptosis and inducing cell cycle arrestMol."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6963365\results\search\disease\results.xml">
   <result pre="under 5 years old. They can lead to complications, super-infection," exact="respiratory failure," post="and even compromised respiratory function in adulthood. For some"/>
   <result pre="highlight the available strategies to reduce the burden of paediatric" exact="respiratory disease." post="The optimal use of influenza, pneumococcal, pertussis and measles"/>
   <result pre="of paediatric respiratory disease. The optimal use of influenza, pneumococcal," exact="pertussis" post="and measles vaccines is required in order to reduce"/>
   <result pre="respiratory disease. The optimal use of influenza, pneumococcal, pertussis and" exact="measles" post="vaccines is required in order to reduce ARI burden."/>
   <result pre="According to estimates made by the World Health Organization (WHO)," exact="pneumonia" post="kills more children worldwide than any other disease, even"/>
   <result pre="other disease, even more than acquired immune deficiency syndrome (AIDS)," exact="malaria" post="and measles combined [9,10,11]. In healthy children, nasopharyngeal colonization"/>
   <result pre="even more than acquired immune deficiency syndrome (AIDS), malaria and" exact="measles" post="combined [9,10,11]. In healthy children, nasopharyngeal colonization with respiratory"/>
   <result pre="are important determinants of bacterial colonization [13,14]. Respiratory viruses including" exact="influenza" post="viruses, respiratory syncytial virus (RSV), human rhinoviruses (HRV), human"/>
   <result pre="children ranges from 1% to 44% [21], and studies on" exact="influenza" post="pandemics over the last 100 years have strengthened the"/>
   <result pre="100 years have strengthened the association of bacterial super-infections and" exact="influenza" post="infections [2,22]. In addition, pertussis and measles still represent"/>
   <result pre="association of bacterial super-infections and influenza infections [2,22]. In addition," exact="pertussis" post="and measles still represent serious medical issues with lower"/>
   <result pre="bacterial super-infections and influenza infections [2,22]. In addition, pertussis and" exact="measles" post="still represent serious medical issues with lower respiratory tract"/>
   <result pre="highlight the available strategies to reduce the burden of paediatric" exact="respiratory disease." post="2. Respiratory Pathogens and Available Vaccines 2.1. Influenza Vaccination"/>
   <result pre="number of medical visits, drug prescriptions, and hospital admissions for" exact="respiratory disease" post="[34,35,36]. Influenza-related complications seem to be more common in"/>
   <result pre="authorities worldwide have long recommended that these children receive the" exact="influenza" post="vaccine every year. However, recently collected data clearly demonstrate"/>
   <result pre="demonstrate that otherwise healthy children can also suffer from severe" exact="influenza" post="and that the annual number of deaths is not"/>
   <result pre="children with chronic severe diseases [34,35]. Every year during the" exact="influenza" post="season, together with the two subtypes of influenza A"/>
   <result pre="during the influenza season, together with the two subtypes of" exact="influenza" post="A virus (A/H1N1 and A/H3N2), two lineages of influenza"/>
   <result pre="of influenza A virus (A/H1N1 and A/H3N2), two lineages of" exact="influenza" post="B viruses (B/Victoria/2/87-like and B/Yamagata/16/88-like) simultaneously circulate; in some"/>
   <result pre="viruses (B/Victoria/2/87-like and B/Yamagata/16/88-like) simultaneously circulate; in some years, the" exact="influenza" post="B viruses are responsible for the major disease burden"/>
   <result pre="viruses are responsible for the major disease burden [37,38,39]. Unlike" exact="influenza" post="A viruses, humans are the sole host with epidemiological"/>
   <result pre="viruses, humans are the sole host with epidemiological relevance for" exact="influenza" post="B viruses. Influenza B viruses evolve mainly through genetic"/>
   <result pre="of the ability to cause disease. Regardless of the lineage," exact="influenza" post="B infection can cause severe disease and death [39]."/>
   <result pre="B infection can cause severe disease and death [39]. During" exact="influenza" post="season, influenza C virus can circulate infecting humans, dogs,"/>
   <result pre="can cause severe disease and death [39]. During influenza season," exact="influenza" post="C virus can circulate infecting humans, dogs, and pigs,"/>
   <result pre="and pigs, sometimes causing severe illness and local epidemics; however," exact="influenza" post="C virus is less common than the other types"/>
   <result pre="C virus is less common than the other types of" exact="influenza" post="viruses and usually it only causes mild disease in"/>
   <result pre="in children. In the past, recommended vaccines included only one" exact="influenza" post="B lineage, chosen by the World Health Organization (WHO)"/>
   <result pre="in the previous year; however, currently, quadrivalent vaccines containing both" exact="influenza" post="B lineages represent the best influenza prevention strategy [40,41,42]."/>
   <result pre="quadrivalent vaccines containing both influenza B lineages represent the best" exact="influenza" post="prevention strategy [40,41,42]. Studies have shown that the administration"/>
   <result pre="the administration of quadrivalent inactivated (IIV) and live attenuated (LAIV)" exact="influenza" post="vaccines to healthy children is effective at reducing the"/>
   <result pre="[43,44,45]. The USA Advisory Committee on Immunization Practices (ACIP) recommends" exact="influenza" post="vaccination for the entire paediatric population, regardless of age"/>
   <result pre="ACIP highlights the importance of administering 1 dose of any" exact="influenza" post="vaccine annually to prevent influenza disease and complications, with"/>
   <result pre="administering 1 dose of any influenza vaccine annually to prevent" exact="influenza" post="disease and complications, with 2 doses separated by at"/>
   <result pre="years who did not receive at least 2 doses of" exact="influenza" post="vaccine before 1 July 2018 [46]. Within Europe, there"/>
   <result pre="July 2018 [46]. Within Europe, there are huge variations in" exact="influenza" post="vaccine recommendations; for example, in Italy, as in some"/>
   <result pre="for example, in Italy, as in some other countries, the" exact="influenza" post="vaccine is recommended only for at-risk people and not"/>
   <result pre="and infants in the first 6 months of life from" exact="influenza" post="is so important that many health authorities have recommended"/>
   <result pre="influenza is so important that many health authorities have recommended" exact="influenza" post="vaccinations of pregnant women [49,50,51]. Studies have shown that"/>
   <result pre="have shown that vaccination during pregnancy is effective in reducing" exact="influenza" post="cases for at least one influenza season [52,53]. Experts"/>
   <result pre="is effective in reducing influenza cases for at least one" exact="influenza" post="season [52,53]. Experts agree that the available influenza vaccines"/>
   <result pre="least one influenza season [52,53]. Experts agree that the available" exact="influenza" post="vaccines can significantly reduce the risk of contracting influenza"/>
   <result pre="available influenza vaccines can significantly reduce the risk of contracting" exact="influenza" post="in healthy or immunocompromised subjects of any age [54]."/>
   <result pre="in healthy or immunocompromised subjects of any age [54]. Preventing" exact="influenza" post="infection through vaccination may decrease the subsequent burden of"/>
   <result pre="the bacterial pathogens, reduce hospitalizations, and reduce antibiotic prescriptions for" exact="influenza" post="complications in children and adolescents [55,56]. Moreover, a reduction"/>
   <result pre="complications in children and adolescents [55,56]. Moreover, a reduction in" exact="influenza" post="cases can have an impact on the abuse of"/>
   <result pre="and invasive infections in children and adults, most commonly acute" exact="otitis media" post="(AOM), community-acquired pneumonia (CAP), and invasive pneumococcal diseases (IPD),"/>
   <result pre="children and adults, most commonly acute otitis media (AOM), community-acquired" exact="pneumonia" post="(CAP), and invasive pneumococcal diseases (IPD), such as bacteraemia"/>
   <result pre="(CAP), and invasive pneumococcal diseases (IPD), such as bacteraemia and" exact="meningitis" post="[60,61,62,63,64]. In the late 1970s, a 14-valent Pneumococcal Polysaccharide"/>
   <result pre="use one over the other [70]. 2.3. Pertussis Vaccination Bordetella" exact="pertussis" post="is a Gram-negative coccobacillus that causes whooping cough and"/>
   <result pre="[73,74]. There has been an increase in the incidence of" exact="pertussis" post="in the European Union from 2011 onwards [75]. The"/>
   <result pre="the European Union from 2011 onwards [75]. The resurgence of" exact="pertussis" post="observed in recent years seems to be a complex"/>
   <result pre="to a number of reasons, including the use of acellular" exact="pertussis" post="(aP) vaccines in many locales. Lack of mucosal immune"/>
   <result pre="earlier waning of protective immunity and the circulation of B." exact="pertussis" post="variants depleted of vaccine-included antigens further favor the increase"/>
   <result pre="variants depleted of vaccine-included antigens further favor the increase in" exact="pertussis" post="disease [74]. Studies in immunized children have reported that"/>
   <result pre="and protective immunity wane 3–5 years after immunization with acellular" exact="pertussis" post="(aP) vaccines, which may reflect poor induction of memory"/>
   <result pre="years during adulthood [79,80]. Recently, in several countries vaccination against" exact="pertussis" post="in the 2nd and 3rd vaccination during pregnancy is"/>
   <result pre="3rd vaccination during pregnancy is recommended in order to prevent" exact="pertussis" post="in the first 6 months of life [81,82]. Studies"/>
   <result pre="months of life [81,82]. Studies showed &amp;gt; 90% effectiveness of" exact="pertussis" post="vaccination of mothers against pertussis in the first 6"/>
   <result pre="showed &amp;gt; 90% effectiveness of pertussis vaccination of mothers against" exact="pertussis" post="in the first 6 months of life. Vaccine administration"/>
   <result pre="for both mother and foetus [81,82]. In conclusion, prevention of" exact="pertussis" post="with currently available vaccines reaching high vaccination coverage rates"/>
   <result pre="colonization, and transmission. However, present knowledge seems to indicate that" exact="pertussis" post="toxin, particularly if genetically detoxified, represents the main antigen"/>
   <result pre="protection from disease even if not from infection. The optimal" exact="pertussis" post="vaccine would be one that induces both mucosal and"/>
   <result pre="lead to severe complications, which can deeply impact children, and" exact="pneumonia" post="represents one of the most common [84,85]. It is"/>
   <result pre="for more than 100,000 deaths every year [84,85]. Although the" exact="measles" post="vaccine was introduced in national vaccination schedules in the"/>
   <result pre="[86,87]. Every month, despite the availability of the vaccine, many" exact="measles" post="cases continue to be reported worldwide, with episodic clusters."/>
   <result pre="of 2019 through May [86]. In Europe, twenty-seven countries reported" exact="measles" post="data for March 2019, with 1,548 cases reported by"/>
   <result pre="importance of maintaining high vaccination coverage with two doses of" exact="measles" post="vaccine administered in the first years of life, the"/>
   <result pre="life [90]. Prematurity, low birth weight, male sex, broncho-pulmonary dysplasia," exact="congenital heart disease," post="immunodeficiency, cerebral palsy, and Down’s syndrome are risk factors"/>
   <result pre="[90]. Prematurity, low birth weight, male sex, broncho-pulmonary dysplasia, congenital" exact="heart disease," post="immunodeficiency, cerebral palsy, and Down’s syndrome are risk factors"/>
   <result pre="birth weight, male sex, broncho-pulmonary dysplasia, congenital heart disease, immunodeficiency," exact="cerebral palsy," post="and Down’s syndrome are risk factors for severe RSV"/>
   <result pre="under 5 years old. They can lead to complications, super-infection," exact="respiratory failure," post="and even compromised respiratory function in adulthood. For some"/>
   <result pre="about vaccines against respiratory pathogens. The use of influenza, pneumococcal," exact="pertussis" post="and measles vaccines is essential to reduce ARIs burden."/>
   <result pre="against respiratory pathogens. The use of influenza, pneumococcal, pertussis and" exact="measles" post="vaccines is essential to reduce ARIs burden. Vaccination coverage"/>
   <result pre="Dis.2004414415410.1016/S1473-3099(04)00938-714998500 13.NairH.BrooksW.A.KatzM.RocaA.BerkleyJ.A.MadhiS.A.SimmermanJ.M.GordonA.SatoM.HowieS.et al.Global burden of respiratory infections due to seasonal" exact="influenza" post="in young children: A systematic review and meta-analysisLancet20113781917193010.1016/S0140-6736(11)61051-922078723 14.VerhagenL.M.LuesinkM.WarrisA.de"/>
   <result pre="the Emergency DepartmentCochrane Database Syst. Rev.20141500645210.1002/14651858.CD006452.pub4 16.BashirU.NisarN.ArshadY.AlamM.M.AshrafA.SadiaH.KaziB.M.ZaidiS.S.Respiratory syncytial virus and" exact="influenza" post="are the key viral pathogens in children &amp;lt;2 years"/>
   <result pre="the key viral pathogens in children &amp;lt;2 years hospitalized with" exact="bronchiolitis" post="and pneumonia in Islamabad PakistanArch Virol.201716276377327885562 17.García-GarcíaM.L.CalvoC.ReyC.DíazB.MolineroM.D.PozoF.CasasI.Human metapnuemovirus infections"/>
   <result pre="viral pathogens in children &amp;lt;2 years hospitalized with bronchiolitis and" exact="pneumonia" post="in Islamabad PakistanArch Virol.201716276377327885562 17.García-GarcíaM.L.CalvoC.ReyC.DíazB.MolineroM.D.PozoF.CasasI.Human metapnuemovirus infections in hospitalized"/>
   <result pre="viral respiratory infectionExpert Rev. Anti Infect. Ther.20121090991610.1586/eri.12.8023030330 22.McCullersJ.A.The co-pathogenesis of" exact="influenza" post="viruses with bacteria in the lungNat. Rev. Microbiol.20141225226210.1038/nrmicro323124590244 23.McCarthyN.L.GeeJ.SukumaranL.WeintraubE.DuffyJ.KharbandaE.O.BaxterR.IrvingS.KingJ.DaleyM.F.et"/>
   <result pre="26.EspositoS.PrincipiN.Influenza vaccination in pediatric ageExpert. Rev. Vaccines20151478578710.1586/14760584.2015.103729025872557 27.AntonovaE.N.RycroftC.E.AmbroseC.S.HeikkinenT.PrincipiN.Burden of paediatric" exact="influenza" post="in Western Europe: A systematic reviewBMC Public Health20121296810.1186/1471-2458-12-96823146107 28.EspositoS.MencacciA.CenciE.CamilloniB.SilvestriE.PrincipiN.Multiplex"/>
   <result pre="Practice?Front. Cell. Infect. Microbiol.2019919610.3389/fcimb.2019.0019631275863 29.LafondK.E.NairH.RasoolyM.H.ValenteF.BooyR.RahmanM.KitsutaniP.YuH.GuzmanG.CoulibalyD.et al.Global role and burden of" exact="influenza" post="in pediatric respiratory hospitalizations, 1982–2012: A systematic analysisPLoS Med.201613e100197710.1371/journal.pmed.100197727011229"/>
   <result pre="analysisPLoS Med.201613e100197710.1371/journal.pmed.100197727011229 30.HeikkinenT.SilvennoinenH.HeinonenS.VuorinenT.Clinical and socioeconomic impact of moderate-to-severe versus mild" exact="influenza" post="in childrenEur. J. Clin. Microbiol. Infect. Dis.2016351107111310.1007/s10096-016-2641-927086364 31.PrincipiN.EspositoS.Protection of"/>
   <result pre="in influenza-like illnessesPediatrics201413468469010.1542/peds.2014-0505 35.NakamuraS.DavisK.M.WeiserJ.N.Synergistic stimulation of type I interferons during" exact="influenza" post="virus coinfection promotes Streptococcus pneumoniae colonization in miceJ. Clin."/>
   <result pre="epidemic profile: A key role for mathematical modellingPLoS Pathog.201814e100677010.1371/journal.ppat.100677029447284 37.PrincipiN.EspositoS.Severe" exact="influenza" post="in children: Incidence and risk factorsExpert Rev. Anti Infect."/>
   <result pre="and socioeconomic impact of different types and subtypes of seasonal" exact="influenza" post="viruses in children during influenza seasons 2007/2008 and 2008/2009BMC"/>
   <result pre="types and subtypes of seasonal influenza viruses in children during" exact="influenza" post="seasons 2007/2008 and 2008/2009BMC Infect. Dis.20111127110.1186/1471-2334-11-27121992699 39.EspositoS.CantaruttiL.MolteniC.G.DalenoC.ScalaA.TagliabueC.PelucchiC.GiaquintoC.PrincipiN.Clinical manifestations and"/>
   <result pre="and 2008/2009BMC Infect. Dis.20111127110.1186/1471-2334-11-27121992699 39.EspositoS.CantaruttiL.MolteniC.G.DalenoC.ScalaA.TagliabueC.PelucchiC.GiaquintoC.PrincipiN.Clinical manifestations and socio-economic impact of" exact="influenza" post="among healthy children in the communityJ. Infect.20116237938710.1016/j.jinf.2011.02.01521414357 40.PirallaA.LunghiG.RuggieroL.GirelloA.BianchiniS.RovidaF.CaimmiS.MarsegliaG.L.PrincipiN.BaldantiF.et al.Molecular"/>
   <result pre="healthy children in the communityJ. Infect.20116237938710.1016/j.jinf.2011.02.01521414357 40.PirallaA.LunghiG.RuggieroL.GirelloA.BianchiniS.RovidaF.CaimmiS.MarsegliaG.L.PrincipiN.BaldantiF.et al.Molecular epidemiology of" exact="influenza" post="B virus among hospitalized pediatric patients in Northern Italy"/>
   <result pre="during the 2015-16 seasonPLoS ONE201712e018589310.1371/journal.pone.018589329049310 41.EspositoS.100 years since the 1918" exact="influenza" post="pandemicHum. Vaccin. Immunother.20181450450710.1080/21645515.2018.144659129553916 42.ChongY.IkematsuH.Is seasonal vaccination a contributing factor"/>
   <result pre="42.ChongY.IkematsuH.Is seasonal vaccination a contributing factor to the selection of" exact="influenza" post="epidemic variants?Hum. Vaccin. Immunother.20181451852210.1080/21645515.2017.137322828857677 43.TreanorJ.J.TalbotH.K.OhmitS.E.ColemanL.A.ThompsonM.G.ChengP.Y.PetrieJ.G.LofthusG.MeeceJ.K.WilliamsJ.V.et al.US Flu-VE Network. Effectiveness"/>
   <result pre="variants?Hum. Vaccin. Immunother.20181451852210.1080/21645515.2017.137322828857677 43.TreanorJ.J.TalbotH.K.OhmitS.E.ColemanL.A.ThompsonM.G.ChengP.Y.PetrieJ.G.LofthusG.MeeceJ.K.WilliamsJ.V.et al.US Flu-VE Network. Effectiveness of seasonal" exact="influenza" post="vaccines in the United States during a season with"/>
   <result pre="Acute Lung Injury and Sepsis Investigators (PALISI) Network. Effectiveness of" exact="influenza" post="vaccine against life-threatening RT-PCR-confirmed influenza illness in US children,"/>
   <result pre="Investigators (PALISI) Network. Effectiveness of influenza vaccine against life-threatening RT-PCR-confirmed" exact="influenza" post="illness in US children, 2010–2012J. Infect. Dis.201421067468310.1093/infdis/jiu18524676207 45.PrincipiN.SenatoreL.EspositoS.Protection of"/>
   <result pre="US children, 2010–2012J. Infect. Dis.201421067468310.1093/infdis/jiu18524676207 45.PrincipiN.SenatoreL.EspositoS.Protection of young children from" exact="influenza" post="through universal vaccinationHum. Vaccin. Immunother.2015112350235810.1080/21645515.2015.105542826090704 46.Centers for Disease Control"/>
   <result pre="49.PoehlingK.A.SzilagyiP.G.StaatM.A.SnivelyB.M.PayneD.C.BridgesC.B.ChuS.Y.LightL.S.PrillM.M.FinelliL.et al.New Vaccine Surveillance Network. Impact of maternal immunization on" exact="influenza" post="hospitalizations in infantsAm. J. Obstet. Gynecol.201120414114810.1016/j.ajog.2011.02.042 50.EickA.A.UyekiT.M.KlimovA.HallH.ReidR.SantoshamM.O’BrienK.L.Maternal influenza vaccination"/>
   <result pre="immunization on influenza hospitalizations in infantsAm. J. Obstet. Gynecol.201120414114810.1016/j.ajog.2011.02.042 50.EickA.A.UyekiT.M.KlimovA.HallH.ReidR.SantoshamM.O’BrienK.L.Maternal" exact="influenza" post="vaccination and effect on influenza virus infection in young"/>
   <result pre="infantsAm. J. Obstet. Gynecol.201120414114810.1016/j.ajog.2011.02.042 50.EickA.A.UyekiT.M.KlimovA.HallH.ReidR.SantoshamM.O’BrienK.L.Maternal influenza vaccination and effect on" exact="influenza" post="virus infection in young infantsArch. Pediatr. Adolesc. Med.201116510411110.1001/archpediatrics.2010.19220921345 51.NunesM.C.CutlandC.L.JonesS.DownsS.WeinbergA.OrtizJ.R.NeuzilK.M.SimõesE.A.F.KlugmanK.P.MadhiS.A.Efficacy"/>
   <result pre="from a Randomized Controlled TrialClin. Infect. Dis.2017651066107110.1093/cid/cix49728575286 52.ZamanK.RoyE.ArifeenS.E.RahmanM.RaqibR.WilsonE.OmerS.B.ShahidN.S.BreimanR.F.SteinhoffM.C.Effectiveness of maternal" exact="influenza" post="immunization in mothers and infantsN. Engl. J. Med.20083591555156410.1056/NEJMoa070863018799552 53.EspositoS.BosisS.MorlacchiL.BaggiE.SabatiniC.PrincipiN.Can"/>
   <result pre="Pathogens of the Respiratory TractFront. Immunol.20189270010.3389/fimmu.2018.0270030515172 55.KnightG.M.ClarksonM.de SilvaT.I.Potential impact of" exact="influenza" post="vaccine roll-out on antibiotic use in AfricaJ. Antimicrob. Chemother.2018732197220010.1093/jac/dky17229746637"/>
   <result pre="Restrict Their Use?PLoS Biol.201513e100226610.1371/journal.pbio.100226626444324 57.RufB.R.KnufM.The burden of seasonal and pandemic" exact="influenza" post="in infants and childrenEur. J. Pediatr.201417326527610.1007/s00431-013-2023-623661234 58.EspositoS.PrincipiN.Different influenza vaccine"/>
   <result pre="and pandemic influenza in infants and childrenEur. J. Pediatr.201417326527610.1007/s00431-013-2023-623661234 58.EspositoS.PrincipiN.Different" exact="influenza" post="vaccine formulations and adjuvants for childhood influenza vaccinationVaccine2011297535754110.1016/j.vaccine.2011.08.01221820478 59.PrincipiN.Di"/>
   <result pre="J. Pediatr.201417326527610.1007/s00431-013-2023-623661234 58.EspositoS.PrincipiN.Different influenza vaccine formulations and adjuvants for childhood" exact="influenza" post="vaccinationVaccine2011297535754110.1016/j.vaccine.2011.08.01221820478 59.PrincipiN.Di CaraG.BizzarriI.IsidoriC.BorgiaP.MigniniC.SaponaraM.ArgentieroA.EspositoS.Prevention of Invasive Pneumococcal Disease: Problems Emerged"/>
   <result pre="and 13-Valent vaccines similar?Future Microbiol.201992192310.2217/fmb-2019-015131373218 71.Argondizo-CorreiaC.RodriguesA.K.S.de BritoC.A.Neonatal Immunity to Bordetella" exact="pertussis" post="Infection and Current Prevention StrategiesJ. Immunol. Res.20192019713416810.1155/2019/713416830882004 72.PrincipiN.LittD.TerranovaL.PiccaM.MalvasoC.VitaleC.FryN.K.EspositoS.The Italian"/>
   <result pre="Pertussis-associated persistent cough in previously vaccinated childrenJ. Med. Microbiol.2017661699170210.1099/jmm.0.00060728984566 73.MelvinJ.A.SchellerE.V.MillerJ.F.CotterP.A.Bordetella" exact="pertussis" post="pathogenesis: Current and future challengesNat. Rev. Microbiol.20141227428810.1038/nrmicro323524608338 74.PolinoriI.EspositoS.Clinical Findings"/>
   <result pre="Serum Antibodies and Memory B CellsFront. Immunol.20178115810.3389/fimmu.2017.0115828966622 77.KauhlB.HeilJ.HoebeC.J.SchweikartJ.KrafftT.Dukers-MuijrersN.H.Is the current" exact="pertussis" post="incidence only the results of testing? A spatial and"/>
   <result pre="the results of testing? A spatial and space-time analysis of" exact="pertussis" post="surveillance data using cluster detection methods and geographically weightedregression"/>
   <result pre="weightedregression modellingPLoS ONE201712e017238310.1371/journal.pone.017238328278180 78.WilkM.M.BorknerL.MisiakA.CurhamL.AllenA.C.MillsK.H.G.Immunization with whole cell but not acellular" exact="pertussis" post="vaccines primes CD4 TRM cells that sustain protective immunity"/>
   <result pre="PertussisAvailable online: http://vaccine-schedule.ecdc.europa.eu/pages/scheduler.aspx(accessed on 22 May 2019) 81.AmirthalingamG.AndrewsN.CampbellH.RibeiroS.KaraE.DoneganK.FryN.K.MillerE.RamsayM.Effectiveness of maternal" exact="pertussis" post="vaccination in England: An observational studyLancet20143841521152810.1016/S0140-6736(14)60686-325037990 82.RomaninV.AcostaA.M.JuarezM.D.V.BriereE.SanchezS.M.CordobaB.L.SevillaM.E.LucionM.F.UrrutiaA.SagradiniS.et al.Maternal Vaccination"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6963570\results\search\disease\results.xml">
   <result pre="(http://creativecommons.org/licenses/by/4.0/). Abstract Despite efforts to improve surveillance and vaccination coverage," exact="measles" post="virus (MeV) continues to cause outbreaks also in high-income"/>
   <result pre="Veneto Region, Italy, we analyzed changes in population immunity, described" exact="measles" post="outbreaks, investigated MeV genetic diversity, and evaluated cross-protection of"/>
   <result pre="measles outbreaks, investigated MeV genetic diversity, and evaluated cross-protection of" exact="measles" post="vaccination against MeV epidemic strains. Like most European areas,"/>
   <result pre="strains. Like most European areas, the Veneto Region has suboptimal" exact="measles" post="vaccination coverage and is facing a growing public mistrust"/>
   <result pre="a growing public mistrust of vaccination. A progressive decline of" exact="measles" post="vaccine uptake was observed during the last decade in"/>
   <result pre="that were circulating in other European countries. Eleven cases of" exact="measles" post="were observed in immunized subjects. These cases were not"/>
   <result pre="of the current measles-containing vaccines and strategies to strengthen vaccination." exact="measles" post="epidemiology vaccine uptake vaccine hesitancy cross-protection whole-genome sequencing secondary"/>
   <result pre="1. Introduction Despite efforts to improve surveillance and vaccination coverage," exact="measles" post="virus (MeV) continues to cause outbreaks not only in"/>
   <result pre="and neighboring countries reported a dramatic increase in the number" exact="measles" post="cases, with 25,475 and 59,578 cases reported in 2017"/>
   <result pre="World Health Organization (WHO) European region, compared with the 5273" exact="measles" post="cases reported in 2016 [2]. Among European countries, Romania,"/>
   <result pre="vaccination coverage below the 95% target defined by WHO for" exact="measles" post="elimination [3]. The increasing distrust of vaccination among people"/>
   <result pre="has been hypothesized to account for the current resurge of" exact="measles" post="is the emergence of new viral strains characterized by"/>
   <result pre="escape from vaccine-induced immunity [7]. Actually, the recent and ongoing" exact="measles" post="outbreaks have been mainly caused by two MeV genotypes,"/>
   <result pre="the Midterm Review, which recommended research on susceptibility profiles for" exact="measles" post="and research related to outbreaks in high-vaccine-coverage settings [12],"/>
   <result pre="aim of this study was to investigate multiple aspects of" exact="measles" post="infection and population immunity by an integrated analysis of"/>
   <result pre="during the last two decades in the Veneto Region, described" exact="measles" post="outbreaks and cases of MeV infection among supposedly immunized"/>
   <result pre="investigated MeV genetic diversity within transmission clusters, and evaluated if" exact="measles" post="vaccination provided cross-protection against MeV epidemic strains. The Veneto"/>
   <result pre="the risk of population exposure to vaccine-preventable infectious diseases like" exact="measles" post="[14,15]. 2. Materials and Methods 2.1. Study Design All"/>
   <result pre="Region, following routine procedures according to the national and regional" exact="measles" post="surveillance and elimination plans. 2.1.1. Seroprevalence Study To determine"/>
   <result pre="a subgroup of the above subjects, for whom records on" exact="measles" post="vaccination were available, MeV IgG antibody titers determined by"/>
   <result pre="were analyzed according to the time interval since the second" exact="measles" post="vaccine dose. 2.1.3. Measles Cases Specimens of serum, urine,"/>
   <result pre="serum, urine, and throat swabs collected from suspected cases of" exact="measles" post="in the Veneto Region were referred to the Subnational"/>
   <result pre="wild-type MeV epidemic strains might result in reduced efficacy of" exact="measles" post="vaccination, we compared the titers of neutralizing antibodies against"/>
   <result pre="was evaluated by microneutralization assays with the Edmonston A Schwarz" exact="measles" post="vaccine strain and clinical isolates of MeV in B95-A"/>
   <result pre="population toward vaccination represent key factors for the resurgence of" exact="measles" post="epidemics in industrialized countries. In Italy, measles vaccination is"/>
   <result pre="the resurgence of measles epidemics in industrialized countries. In Italy," exact="measles" post="vaccination is recommended since 1979, but the Veneto Region"/>
   <result pre="if the suspension led to changes in population protection against" exact="measles" post="during the last decade, we analyzed data on measles"/>
   <result pre="against measles during the last decade, we analyzed data on" exact="measles" post="vaccination uptake and seroprevalence. Data on measles vaccination uptake"/>
   <result pre="analyzed data on measles vaccination uptake and seroprevalence. Data on" exact="measles" post="vaccination uptake were retrieved from reports of the Ministry"/>
   <result pre="the mandatory childhood vaccines from 4 to 10, including mandatory" exact="measles" post="vaccination [26]. This led to a slight increase of"/>
   <result pre="measles vaccination [26]. This led to a slight increase of" exact="measles" post="vaccination uptake, which, however, remained below the 95% coverage"/>
   <result pre="remained below the 95% coverage target defined by the WHO" exact="measles" post="elimination plan (Figure 1a). Analysis of measles immunity was"/>
   <result pre="by the WHO measles elimination plan (Figure 1a). Analysis of" exact="measles" post="immunity was conducted on 11,506 subjects who were screened"/>
   <result pre="people with naturally acquired immunity. In the other age groups," exact="measles" post="IgG seroprevalence ranged from 74% to 89%. 3.2. Description"/>
   <result pre="the Veneto Region (population of about 5 million people), 1005" exact="measles" post="cases were reported in the period from January 2010"/>
   <result pre="During this period, large outbreaks occurred in 2010–2011, with 465" exact="measles" post="cases reported (66% were laboratory-confirmed), and in 2017–2018, with"/>
   <result pre="cases reported (66% were laboratory-confirmed), and in 2017–2018, with 322" exact="measles" post="cases (86% were laboratory-confirmed) (Figure 1c). In Italy, during"/>
   <result pre="laboratory-confirmed) (Figure 1c). In Italy, during the same period, 20,746" exact="measles" post="cases were notified, with peaks of incidence in 2010–2011,"/>
   <result pre="In the Veneto Region, as at the national level, most" exact="measles" post="cases were unvaccinated subjects (82.8%), 9.9% received only one"/>
   <result pre="affected age groups (Figure 1d). The estimated annual incidence of" exact="measles" post="was 5.9 cases/100,000 inhabitants in the general population and"/>
   <result pre="cases/100,000 in children ≤4 years of age. Overall, 58% of" exact="measles" post="cases were males, and the incidence of measles was"/>
   <result pre="58% of measles cases were males, and the incidence of" exact="measles" post="was slightly higher in males than in females (Figure"/>
   <result pre="34% of patients, respectively, were hospitalized; complications included kerato-conjunctivitis (16%)," exact="diarrhea" post="(15%), pneumonia (10%), laryngo-tracheo-bronchitis (9%), respiratory distress (6%), otitis"/>
   <result pre="patients, respectively, were hospitalized; complications included kerato-conjunctivitis (16%), diarrhea (15%)," exact="pneumonia" post="(10%), laryngo-tracheo-bronchitis (9%), respiratory distress (6%), otitis (5%), and"/>
   <result pre="pneumonia (10%), laryngo-tracheo-bronchitis (9%), respiratory distress (6%), otitis (5%), and" exact="hepatitis" post="(2%). Abortion occurred in a young female with measles"/>
   <result pre="and hepatitis (2%). Abortion occurred in a young female with" exact="measles" post="and without other risk factors. No measles-related deaths were"/>
   <result pre="not available (Table 2). At the time of diagnosis, these" exact="measles" post="cases had low or absent MeV IgM antibodies, high"/>
   <result pre="&amp;lt; 0.01). The MeV genotype distribution in cases with previous" exact="measles" post="immunity was similar to that in the general population"/>
   <result pre="in the general population (Table 2). To assess if these" exact="measles" post="infections were caused by MeV strains with mutations in"/>
   <result pre="Persistence of Measles Vaccine-Induced Immunity To evaluate the persistence of" exact="measles" post="vaccine-induced immunity, the titers of MeV IgG antibodies were"/>
   <result pre="analyzed in a group of subjects for whom information on" exact="measles" post="vaccination status was available and who had received ≥2"/>
   <result pre="presents an integrated analysis of field and laboratory data on" exact="measles" post="infection and population immunity in a typical European setting"/>
   <result pre="by suboptimal vaccination coverage and the occurrence of relatively large" exact="measles" post="outbreaks. In this context, this study analyzed changes in"/>
   <result pre="described the clinical features and the molecular epidemiology of the" exact="measles" post="outbreaks, investigated the genetic diversity and evolution of MeV"/>
   <result pre="cases of secondary vaccine failure, and, finally, it evaluated if" exact="measles" post="vaccination provided cross-protection against epidemic strains of MeV genotypes"/>
   <result pre="provide a coherent picture that supports strengthening vaccination programs for" exact="measles" post="eradication. Analysis of measles vaccination coverage, population immunity from"/>
   <result pre="that supports strengthening vaccination programs for measles eradication. Analysis of" exact="measles" post="vaccination coverage, population immunity from serological surveys, and the"/>
   <result pre="coverage, population immunity from serological surveys, and the demographics of" exact="measles" post="outbreaks during the last decade in the Veneto Region"/>
   <result pre="aged 20–39 years and a trend towards a decrease of" exact="measles" post="immunity among young children and subjects older than 40"/>
   <result pre="individuals older than 15 years, but no relevant changes in" exact="measles" post="susceptibility in children aged 0–4 years in Italy, because"/>
   <result pre="vaccination schedules and coverage remained unchanged [6]. The incidence of" exact="measles" post="was higher in males than in females, but differences"/>
   <result pre="age groups and years. In the literature, severe complications of" exact="measles" post="have been reported more frequently in males than in"/>
   <result pre="in females [31], and slightly higher antibody levels induced by" exact="measles" post="vaccination have been observed in girls than in boys"/>
   <result pre="Italian Regions and European countries. Measles is a highly contagious" exact="infectious disease," post="and MeV strains rapidly circulate with traveling people, causing"/>
   <result pre="B3 strain [2]. To get a more detailed picture of" exact="measles" post="transmission networks, we sequenced the full viral genome from"/>
   <result pre="of full viral genome sequencing for the epidemiological investigation of" exact="measles" post="outbreaks [33]. During the 2017–2018 outbreak, we observed 11"/>
   <result pre="[33]. During the 2017–2018 outbreak, we observed 11 cases of" exact="measles" post="in previously immunized subjects, probably representing cases of secondary"/>
   <result pre="MeV strains has been hypothesized to play a role in" exact="measles" post="reemergence [11,38]. In the case of mumps, infection in"/>
   <result pre="vaccinated individuals have been shown to neutralize the currently circulating" exact="mumps" post="virus genotype G less efficiently than other genotypes and"/>
   <result pre="[41]. Another factor that might contribute to the reemergence of" exact="measles" post="in vaccinated populations could be the progressive loss of"/>
   <result pre="by exposure to wild-type virus circulation. Therefore, population immunity to" exact="measles" post="should be monitored, especially in adult age groups, to"/>
   <result pre="in MeV infection, such as CD46, have been associated with" exact="measles" post="vaccine-induced neutralizing antibodies and T cell response [43,44]. In"/>
   <result pre="been identified in children who developed disseminated infection or fatal" exact="encephalitis" post="after inoculation of the live attenuated measles, mumps, and"/>
   <result pre="encephalitis after inoculation of the live attenuated measles, mumps, and" exact="rubella" post="vaccine. Thus, the role of an individual’s genetic background"/>
   <result pre="of protection against epidemic MeV strains. Pre-illness sera from twice-vaccinated" exact="measles" post="cases were tested in an outbreak study in the"/>
   <result pre="regions where vaccination coverage is below the WHO target for" exact="measles" post="elimination. The decrease of vaccination coverage and the decline"/>
   <result pre="should be promoted and enhanced to pursue the goal of" exact="measles" post="eradication. Author Contributions Conceptualization, L.B. and M.P.; methodology, M.P.,"/>
   <result pre="2018ECDCStockholm, Sweden2018Available online: https://www.ecdc.europa.eu/en/publications-data/monthly-measles-and-rubella-monitoring-report-december-2018(accessed on 2 November 2019) 4.HoltE.41 000" exact="measles" post="cases in Europe since the beginning of 2018Lancet201839272410.1016/S0140-6736(18)32031-230191821 5.BurkiT.Measles"/>
   <result pre="new vaccine approach needed?Lancet Infect. Dis.2018181060106110.1016/S1473-3099(18)30543-730303095 8.RotaP.A.BrownK.MankertzA.SantibanezS.ShulgaS.MullerC.P.HübschenJ.M.SiqueiraM.BeirnesJ.AhmedH.et al.Global distribution of" exact="measles" post="genotypes and measles molecular epidemiologyJ. Infect. Dis.2011204Suppl. 151452310.1093/infdis/jir11821666208 9.AckleyS.F.HackerJ.K.EnanoriaW.T.A.WordenL.BlumbergS.PorcoT.C.ZipprichJ.Genotype-specific"/>
   <result pre="needed?Lancet Infect. Dis.2018181060106110.1016/S1473-3099(18)30543-730303095 8.RotaP.A.BrownK.MankertzA.SantibanezS.ShulgaS.MullerC.P.HübschenJ.M.SiqueiraM.BeirnesJ.AhmedH.et al.Global distribution of measles genotypes and" exact="measles" post="molecular epidemiologyJ. Infect. Dis.2011204Suppl. 151452310.1093/infdis/jir11821666208 9.AckleyS.F.HackerJ.K.EnanoriaW.T.A.WordenL.BlumbergS.PorcoT.C.ZipprichJ.Genotype-specific measles transmissibility: A"/>
   <result pre="measles genotypes and measles molecular epidemiologyJ. Infect. Dis.2011204Suppl. 151452310.1093/infdis/jir11821666208 9.AckleyS.F.HackerJ.K.EnanoriaW.T.A.WordenL.BlumbergS.PorcoT.C.ZipprichJ.Genotype-specific" exact="measles" post="transmissibility: A branching process analysisClin. Infect. Dis.2018661270127510.1093/cid/cix97429228134 10.El MubarakH.S.YükselS.van"/>
   <result pre="(Macaca fascicularis) and rhesus macaques (Macaca mulatta) with different wild-type" exact="measles" post="virusesJ. Gen. Virol.2007882028203410.1099/vir.0.82804-017554037 11.Fatemi NasabG.S.SalimiV.AbbasiS.Adjami Nezhad FardF.Mokhtari AzadT.Comparison of"/>
   <result pre="NasabG.S.SalimiV.AbbasiS.Adjami Nezhad FardF.Mokhtari AzadT.Comparison of neutralizing antibody titers against outbreak-associated" exact="measles" post="genotypes (D4, H1 and B3) in IranPathog. Dis.20167410.1093/femspd/ftw08927777263 12.collab:"/>
   <result pre="dynamics of the ParamyxoviridaeJ. Mol. Evol.2008669810610.1007/s00239-007-9040-x18217182 29.De SwartR.L.YükselS.OsterhausA.D.Relative contributions of" exact="measles" post="virus hemagglutinin- and fusion protein-specific serum antibodies to virus"/>
   <result pre="antibodies to virus neutralizationJ. Virol.200579115471155110.1128/JVI.79.17.11547-11551.200516103210 30.DineM.S.HutchinsS.S.ThomasA.WilliamsI.BelliniW.J.ReddS.C.Persistence of vaccine-induced antibody to" exact="measles" post="26–33 year after vaccinationJ. Infect. Dis.2004189Suppl. 112313010.1086/380308 31.WendorfK.A.WinterK.ZipprichJ.SchechterR.HackerJ.K.PreasC.CherryJ.D.GlaserC.HarrimanK.Subacute sclerosing"/>
   <result pre="after vaccinationJ. Infect. Dis.2004189Suppl. 112313010.1086/380308 31.WendorfK.A.WinterK.ZipprichJ.SchechterR.HackerJ.K.PreasC.CherryJ.D.GlaserC.HarrimanK.Subacute sclerosing panencephalitis: The devastating" exact="measles" post="complication that might be more common than previously estimatedClin."/>
   <result pre="and childhood vaccinations in the NetherlandsVaccine2019374504451010.1016/j.vaccine.2019.06.05531279563 33.GardyL.J.MausM.AmlaniA.ChungW.KimH.TanM.SeveriniA.KrajdenM.PuddicombeD.SahniV.et al.Whole-genome sequencing of" exact="measles" post="virus genotypes H1 and D8 during outbreaks of infection"/>
   <result pre="Games reveals viral transmission routesJ. Infect. Dis.20152121574157810.1093/infdis/jiv27126153409 34.RosenJ.B.RotaJ.S.HickmanC.J.SowersS.B.MercaderS.RotaP.A.BelliniW.J.HuangA.J.DollM.K.ZuckerJ.R.et al.Outbreak of" exact="measles" post="among persons with prior evidence of immunity, New York"/>
   <result pre="immunity, New York City, 2011Clin. Infect. Dis.2014581205121010.1093/cid/ciu10524585562 35.CherryJ.D.ZahnM.Clinical characteristics of" exact="measles" post="in previously vaccinated and unvaccinated patients in CaliforniaClin. Infect."/>
   <result pre="France, October 2017 to July 2018Euro. Surveill.20182310.2807/1560-7917.ES.2018.23.30.1800373 37.GibneyK.B.AttwoodL.O.NicholsonS.TranT.DruceJ.HealyJ.StrachanJ.FranklinL.HallR.CrossG.B.Emergence of attenuated" exact="measles" post="illness among IgG positive/IgM negative measles cases, Victoria, Australia"/>
   <result pre="Surveill.20182310.2807/1560-7917.ES.2018.23.30.1800373 37.GibneyK.B.AttwoodL.O.NicholsonS.TranT.DruceJ.HealyJ.StrachanJ.FranklinL.HallR.CrossG.B.Emergence of attenuated measles illness among IgG positive/IgM negative" exact="measles" post="cases, Victoria, Australia 2008–2017Clin. Infect. Dis.201910.1093/cid/ciz363 38.Munoz-AliaM.A.MullerC.P.RussellS.J.Antigenic drift defines"/>
   <result pre="Infect. Dis.201910.1093/cid/ciz363 38.Munoz-AliaM.A.MullerC.P.RussellS.J.Antigenic drift defines a new D4 subgenotype of" exact="measles" post="virusJ. Virol.20179110.1128/JVI.00209-1728356529 39.VermeireT.BarbezangeC.FrancartA.HamoudaA.LitzrothA.HutseV.MartensL.VandermarliereE.Van GuchtS.Sera from different age cohorts in"/>
   <result pre="different age cohorts in Belgium show limited cross-neutralisation between the" exact="mumps" post="vaccine and outbreak strainsClin. Microbiol. Infect.20192510.1016/j.cmi.2018.11.01630502489 40.GoumaS.Ten HulscherH.I.Schurink-van ‘t"/>
   <result pre="ElsC.A.C.M.KoopmansM.P.G.van BinnendijkR.S.Mumps-specific cross-neutralization by MMR vaccine-induced antibodies predicts protection against" exact="mumps" post="virus infectionVaccine2016344166417110.1016/j.vaccine.2016.06.06327372154 41.TaharaM.BürckertJ.P.KanouK.MaenakaK.MullerC.P.TakedaM.Measles virus hemagglutinin protein epitopes: The basis"/>
   <result pre="virus hemagglutinin protein epitopes: The basis of antigenic stabilityViruses2016821610.3390/v808021627490564 42.GiddingH.F.QuinnH.E.HuestonL.DwyerD.E.McIntyreP.B.Declining" exact="measles" post="antibodies in the era of elimination: Australia’s experienceVaccine20183650751310.1016/j.vaccine.2017.12.00229269156 43.HaralambievaI.H.OvsyannikovaI.G.KennedyR.B.VierkantR.A.PankratzV.S.JacobsonR.M.PolandG.A.Associations"/>
   <result pre="haplotypes in cytokine and cytokine receptor genes and immunity to" exact="measles" post="vaccinationVaccine2011297883789510.1016/j.vaccine.2011.08.08321875636 44.HaralambievaI.H.KennedyR.B.OvsyannikovaI.G.SchaidD.J.PolandG.A.Current perspectives in assessing humoral immunity after measles"/>
   <result pre="to measles vaccinationVaccine2011297883789510.1016/j.vaccine.2011.08.08321875636 44.HaralambievaI.H.KennedyR.B.OvsyannikovaI.G.SchaidD.J.PolandG.A.Current perspectives in assessing humoral immunity after" exact="measles" post="vaccinationExpert Rev. Vaccin.201918758710.1080/14760584.2019.155906330585753 45.HernandezN.BucciolG.MoensL.Le PenJ.ShahrooeiM.GoudourisE.ShirkaniA.Changi-AshtianiM.Rokni-ZadehH.SayarE.H.et al.Inherited IFNAR1 deficiency in"/>
   <result pre="IFNAR1 deficiency in otherwise healthy patients with adverse reaction to" exact="measles" post="and yellow fever live vaccinesJ. Exp. Med.20192162057207010.1084/jem.2018229531270247 46.DuncanC.J.MohamadS.M.YoungD.F.SkeltonA.J.LeahyT.R.MundayD.C.ButlerK.M.MorfopoulouS.BrownJ.R.HubankM.et al.Human"/>
   <result pre="in otherwise healthy patients with adverse reaction to measles and" exact="yellow fever" post="live vaccinesJ. Exp. Med.20192162057207010.1084/jem.2018229531270247 46.DuncanC.J.MohamadS.M.YoungD.F.SkeltonA.J.LeahyT.R.MundayD.C.ButlerK.M.MorfopoulouS.BrownJ.R.HubankM.et al.Human IFNAR2 deficiency: Lessons"/>
   <result pre="severe viral illnessJ. Allergy Clin. Immunol.20171391995199710.1016/j.jaci.2016.10.03328087227 50.DurrheimD.N.OrensteinW.A.SchluterW.W.Assessing population immunity for" exact="measles" post="elimination—The promise and peril of serosurveysVaccine2018364001400310.1016/j.vaccine.2018.04.03629793892 51.HahnéS.J.Nic LochlainnL.M.van BurgelN.D.KerkhofJ.SaneJ.YapK.B.van"/>
   <result pre="(2009–2012 and 2014–2017) were compared. (c) Epidemic curve of 1005" exact="measles" post="cases in the Veneto Region, Italy, from January 2010"/>
   <result pre="Italy, from January 2010 to December 2018. (d) Distribution of" exact="measles" post="by age group during the 2010–2011 and the 2017–2018"/>
   <result pre="2017–2018 outbreaks in the Veneto Region, Italy. (e) Incidence of" exact="measles" post="by age and sex groups during the 2010–2011 and"/>
   <result pre="Italy. Figure 2 Phylogenetic trees of MeV sequences obtained from" exact="measles" post="cases, Veneto Region, 2010–2018. MeV genotypes B3 (a), D4"/>
   <result pre="as Neutralization) and of MeV sequences obtained from cases of" exact="measles" post="in previously immunized individuals (indicated as Secondary). The amino"/>
   <result pre="red. vaccines-07-00199-t001_Table 1Table 1 Evolutionary analysis on whole genomes of" exact="measles" post="virus (MeV) B3 and D8 isolates 1. Gene dN/dS"/>
   <result pre="were non-synonymous. vaccines-07-00199-t002_Table 2Table 2 Clinical and laboratory characteristics of" exact="measles" post="in previously immunized subjects. Measles Vaccine Doses Age (Years)"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6963661\results\search\disease\results.xml">
   <result pre="per year [1]) experience a spectrum typified initially by acute" exact="dengue fever" post="(DF) that after defervescence can develop into severe haemorrhagic"/>
   <result pre="fever (DF) that after defervescence can develop into severe haemorrhagic" exact="dengue fever" post="(DHF), characterised by dangerous plasma leakage and hypovolaemic shock"/>
   <result pre="a rudimental understanding appears only successful for some cases (e.g.," exact="smallpox" post="[48]) and may even lead to disease enhancement with"/>
   <result pre="regardless of age [174]. It is based on four chimeric" exact="yellow fever" post="viruses with the structural genes replaced by DENV structural"/>
   <result pre="lanatoside C against dengue virus infectionAntiviral Res.2014111939910.1016/j.antiviral.2014.09.00725251726 10.AbdelnabiR.NeytsJ.DelangL.Towards antivirals against" exact="chikungunya" post="virusAntiviral Res.2015121596810.1016/j.antiviral.2015.06.01726119058 11.LaniR.HassandarvishP.ChiamC.W.MoghaddamE.ChuJ.J.H.RausaluK.MeritsA.HiggsS.VanlandinghamD.BakarS.A.et al.Antiviral activity of silymarin against chikungunya"/>
   <result pre="against chikungunya virusAntiviral Res.2015121596810.1016/j.antiviral.2015.06.01726119058 11.LaniR.HassandarvishP.ChiamC.W.MoghaddamE.ChuJ.J.H.RausaluK.MeritsA.HiggsS.VanlandinghamD.BakarS.A.et al.Antiviral activity of silymarin against" exact="chikungunya" post="virusSci. Rep.201551142110.1038/srep1142126078201 12.Bin MasriM.F.RathoreA.P.S.JohnA.L.S.Therapeutics for DengueCurr. Treat. Options Infect."/>
   <result pre="Implications for Disease ControlCell201516248849210.1016/j.cell.2015.07.00526232221 16.HalsteadS.B.RussellP.K.Protective and immunological behavior of chimeric" exact="yellow fever" post="dengue vaccineVaccine2016341643164710.1016/j.vaccine.2016.02.00426873054 17.CapedingM.R.TranN.H.HadinegoroS.R.S.IsmailH.I.H.M.ChotpitayasunondhT.ChuaM.N.LuongC.Q.RusmilK.WirawanD.N.NallusamyR.et al.Clinical efficacy and safety of a"/>
   <result pre="virus NS2A proteinJ. Virol.2013874609462210.1128/JVI.02424-1223408612 48.RiedelS.Edward Jenner and the history of" exact="smallpox" post="and vaccinationProceedings (Baylor University. Medical Center)2005182168910.1080/08998280.2005.1192802816200144 49.DudasR.A.KarronR.A.Respiratory syncytial virus"/>
   <result pre="of third or fourth dengue infections resulting in admissions and" exact="dengue hemorrhagic fever," post="and serotype sequencesAm. J. Trop. Med. Hyg.20077791091310.4269/ajtmh.2007.77.91017984352 53.BurkeD.S.NisalakA.JohnsonD.E.ScottR.M.A prospective"/>
   <result pre="BangkokAm. J. Trop. Med. Hyg.19883817218010.4269/ajtmh.1988.38.1723341519 54.HalsteadS.B.Observations related to pathogensis of" exact="dengue hemorrhagic fever." post="VI. Hypotheses and discussionYale J. Biol. Med.1970423503625419208 55.SabinA.B.Research on"/>
   <result pre="that maternal dengue antibodies are important in the development of" exact="dengue hemorrhagic fever" post="in infantsAm. J. Trop. Med. Hyg.19883841141910.4269/ajtmh.1988.38.4113354774 63.HalsteadS.B.O’RourkeE.J.AllisonA.C.Dengue viruses and"/>
   <result pre="97.SunD.S.KingC.C.HuangH.S.ShihY.L.LeeC.C.TsaiW.J.YuC.C.ChangH.H.Antiplatelet autoantibodies elicited by dengue virus non-structural protein 1 cause" exact="thrombocytopenia" post="and mortality in miceJ. Throm. Haemostasis200752291229910.1111/j.1538-7836.2007.02754.x 98.LinC.F.LeiH.Y.LiuC.C.LiuH.S.YehT.M.WangS.T.YangT.I.SheuF.C.KuoC.F.LinY.S.Generation of IgM"/>
   <result pre="cellular immunity to dengue disease pathogenesisImmunol. Rev.200822530031310.1111/j.1600-065X.2008.00678.x18837790 134.KuraneI.RothmanA.L.LivingstonP.G.GreenS.GagnonS.J.JanusJ.InnisB.L.NimmannityaS.NisalakA.EnnisF.A.Immunopathologic mechanisms of" exact="dengue hemorrhagic fever" post="and dengue shock syndromeArch. Virol. Suppl.1994959648032282 135.MangadaM.M.EndyT.P.NisalakA.ChunsuttiwatS.VaughnD.W.LibratyD.H.GreenS.EnnisF.A.RothmanA.L.Dengue-specific T cell"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6963678\results\search\disease\results.xml">
   <result pre="severe illness affecting the central nervous system (CNS), such as" exact="encephalitis" post="and meningitis. The virus became recognized as a cause"/>
   <result pre="meningitis. The virus became recognized as a cause of human" exact="meningitis" post="or encephalitis in elderly patients during an outbreak in"/>
   <result pre="virus became recognized as a cause of human meningitis or" exact="encephalitis" post="in elderly patients during an outbreak in Israel in"/>
   <result pre="one of the most important causative agents of human viral" exact="encephalitis" post="worldwide. Since 1999, WNV has been estimated to cause"/>
   <result pre="Neuroinvasive disease cases present with more severe symptoms, including encephalitis," exact="meningitis" post="or acute flaccid paralysis [16]. Moreover, WNV infection has"/>
   <result pre="infection has also been indicated to cause longitudinally extensive transverse" exact="myelitis" post="[17], cognitive-behavioral impairment and irreversible sensorineural deafness [18], and"/>
   <result pre="City outbreak, more than 50% of patients with confirmed WNV" exact="encephalitis" post="had severe muscle weakness as a cardinal sign [12],"/>
   <result pre="etiologies, namely Guillain–Barré syndrome (GBS), motor axonopathy, or severe axonal" exact="polyneuropathy" post="[12,20,21]. In the 2002 and 2003 WNV epidemics, neuromuscular"/>
   <result pre="are actively involved in WNV clinical research now accept a" exact="poliomyelitis" post="to be the most common cause of WNV-associated acute"/>
   <result pre="common cause of WNV-associated acute flaccid paralysis. Patients with WNV" exact="poliomyelitis" post="commonly have associated signs of meningitis, encephalitis, or respiratory"/>
   <result pre="paralysis also may occur in the absence of fever or" exact="meningoencephalitis" post="[24,26,27]. Moreover, cases of WNV-poliomyelitis frequently occur in the"/>
   <result pre="severe cases associated with flaccid paralysis and fails to include" exact="poliomyelitis" post="cases with lesser degrees of motor neuron loss that"/>
   <result pre="matter, which may explain the infrequent occurrence of WNV-associated transverse" exact="myelitis" post="with clinical involvement of spinal sensory and motor pathways"/>
   <result pre="infection of hamsters has also been reported to cause electrophysiologic" exact="suppression" post="of the diaphragm either directly by producing neuronal injury"/>
   <result pre="cord [35]. Bladder dysfunction and changes in sweating, including hyperhidrosis," exact="anhidrosis" post="and segmental changes in sweating, have also been observed"/>
   <result pre="AXL receptor tyrosine kinase deficient (Axl−/−) mice during WNV and" exact="influenza" post="infection [70]. Recent studies showed that IL-1β, IFN regulatory"/>
   <result pre="which exhibited higher and extended viremia and accelerated development of" exact="encephalitis" post="and death [74]. However, excessive cytokine production and inflammation"/>
   <result pre="in the CNS and ultimately increases host resistance to lethal" exact="encephalitis" post="[75]. Neutrophil: Neutrophils are the most abundant leukocytes in"/>
   <result pre="of γδ T cells, had elevated viremia and more severe" exact="encephalitis" post="compared to the wild-type (WT) control mice, which may"/>
   <result pre="in the brain and a lower mortality rate to WNV" exact="encephalitis" post="[89]. In addition, Vγ4+ cells negatively regulate Vγ1+ T"/>
   <result pre="post-infectious pro-inflammatory state that may promote autoimmune diseases, such as" exact="myasthenia gravis." post="The illustration was created in Biorender.com. The BBB, composed"/>
   <result pre="WNV infection [40,131,132,133]. In addition, a study on Venezuelan equine" exact="encephalitis" post="virus (VEEV, a mosquito-transmitted alphavirus) infection indicated that the"/>
   <result pre="cohort showed that the majority of patients (86%, 30/35) with" exact="encephalitis" post="had abnormal neurological exam findings compared with uncomplicated fever"/>
   <result pre="neurological exam findings compared with uncomplicated fever (27%, 3/11) and" exact="meningitis" post="(36%, 5/14) cases during 1–3 years following WNV infection."/>
   <result pre="of West Nile meningitis, and 36% (5/14) of West Nile" exact="encephalitis" post="had developed new neurological complications [163]. Importantly, MRI (magnetic"/>
   <result pre="numerous WNV patients have developed autoinflammatory or autoimmune-related diseases, including" exact="myasthenia gravis" post="(MG) [165,166], suggesting that WNV infection may promote or"/>
   <result pre="neuropathies [31,171], brachial plexopathies [172], stiff-person syndrome [173], and autoimmune" exact="encephalitis" post="[174]. However, more clinical data and experimental evidence are"/>
   <result pre="treat a patient with WNV-associated acute flaccid paralysis and autoimmune" exact="encephalitis" post="[174,177]. Two patients with acute flaccid paralysis and brainstem"/>
   <result pre="of high dose corticosteroids in a semi-comatose woman with WNV" exact="encephalitis" post="highlights the success of this therapeutic approach [178]. Although"/>
   <result pre="pseudoknot in the NS2A-encoding sequence of West Nile and Japanese" exact="encephalitis" post="flaviviruses suggests NS1’ may derive from ribosomal frameshiftingVirol. J.200961410.1186/1743-422X-6-1419196463"/>
   <result pre="VirusAvailable online: https://www.cdc.gov/westnile/healthcareproviders/healthcareproviders-diagnostic.html(accessed on 10 December 2018) 17.MartinovicV.Kisic-TepavcevicD.KacarA.MesarosS.PekmezovicT.DrulovicJ.Longitudinally extensive transverse" exact="myelitis" post="in a patient infected with West Nile virusMult. Scler."/>
   <result pre="Dysfunction in Hamsters Infected with West Nile VirusPLoS ONE20116e1957510.1371/journal.pone.001957521573009 34.MorreyJ.D.SiddharthanV.WangH.HallJ.O.MotterN.E.SkinnerR.D.SkirpstunasR.T.Neurological" exact="suppression" post="of diaphragm electromyographs in hamsters infected with West Nile"/>
   <result pre="lethal encephalitisNat. Med.2004101366137310.1038/nm114015558055 41.TownT.BaiF.WangT.KaplanA.T.QianF.MontgomeryR.R.AndersonJ.F.FlavellR.A.FikrigE.Toll-like receptor 7 mitigates lethal West Nile" exact="encephalitis" post="via interleukin 23-dependent immune cell infiltration and homingImmunity20093024225310.1016/j.immuni.2008.11.01219200759 42.LiuJ.XuC.HsuL.C.LuoY.XiangR.ChuangT.H.A"/>
   <result pre="of interferon alpha-2b in a patient with West Nile virus" exact="meningoencephalitis" post="and acute flaccid paralysisScand. J. Infect. Dis.20053794494610.1080/0036554050026269016308241 65.DavisonA.M.KingN.J.Accelerated dendritic"/>
   <result pre="of MAVS signalingPLoS Pathog.20139e100311810.1371/annotation/4de7ddfd-52df-4f87-8ca4-d48afe646ca823300459 74.Ben-NathanD.HuitingaI.LustigS.Van RooijenN.KobilerD.West Nile virus neuroinvasion and" exact="encephalitis" post="induced by macrophage depletion in miceArch. Virol.199614145946910.1007/BF017183108645088 75.LuoH.WinkelmannE.R.ZhuS.RuW.MaysE.SilvasJ.A.VollmerL.L.GaoJ.PengB.-H.BoppN.E.et al.Peli1"/>
   <result pre="and CD8+ T cells to vaccine immunity against West Nile" exact="encephalitis" post="virusVaccine2008262020203310.1016/j.vaccine.2008.02.00918339459 124.LanteriM.C.O’BrienK.M.PurthaW.E.CameronM.J.LundJ.M.OwenR.E.HeitmanJ.W.CusterB.HirschkornD.F.ToblerL.H.et al.Tregs control the development of symptomatic West"/>
   <result pre="EvasionJ. Virol.2006809349936010.1128/JVI.01122-0616973541 144.BrehinA.C.MouriesJ.FrenkielM.P.DadaglioG.DespresP.LafonM.CoudercT.Dynamics of immune cell recruitment during West Nile" exact="encephalitis" post="and identification of a new CD19+B220-BST-2+ leukocyte populationJ. Immunol.20081806760676710.4049/jimmunol.180.10.676018453596"/>
   <result pre="findings in 250 patients with serologically confirmed West Nile virus" exact="meningitis" post="and encephalitisNeurology20066636136510.1212/01.wnl.0000195890.70898.1f16382032 147.YangJ.-S.RamanathanM.P.MuthumaniK.ChooA.Y.JinS.-H.YuQ.-C.HwangD.S.ChooD.K.LeeM.D.DangK.et al.Induction of Inflammation by West Nile"/>
   <result pre="a post-infectious pro-inflammatory state that explains transformation of stable ocular" exact="myasthenia gravis" post="to myasthenic crisesJ. Neurol. Sci.20183951310.1016/j.jns.2018.09.01530267806 167.MuL.ZhangY.SunB.WangJ.XieX.LiN.ZhangJ.KongQ.LiuY.HanZ.et al.Activation of the"/>
   <result pre="receptor for advanced glycation end products (RAGE) exacerbates experimental autoimmune" exact="myasthenia gravis" post="symptomsClin. Immunol.2011141364810.1016/j.clim.2011.04.01321570918 168.MoserB.BekosC.ZimprichF.NicklS.KlepetkoW.AnkersmitJ.The receptor for advanced glycation endproducts and"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6963679\results\search\disease\results.xml">
   <result pre="Infection by ZIKV is associated with neurological complications, such as" exact="microcephaly" post="in foetuses and Guillain–Barré syndrome (GBS) in adults, now"/>
   <result pre="in phase I or II clinical trials [11]. The modified" exact="vaccinia virus" post="Ankara (MVA) has been extensively studied as a vectored-vaccine"/>
   <result pre="Engl. J. Med.20163741552156310.1056/NEJMra160211327028561 8.CauchemezS.BesnardM.BompardP.DubT.Guillemette-ArturP.Eyrolle-GuignotD.SaljeH.Van KerkhoveM.D.AbadieV.GarelC.et al.Association between Zika virus and" exact="microcephaly" post="in French Polynesia, 2013–2015: A retrospective studyLancet20163872125213210.1016/S0140-6736(16)00651-626993883 9.MlakarJ.KorvaM.TulN.PopovićM.Poljšak-PrijateljM.MrazJ.KolencM.Resman RusK.Vesnaver"/>
   <result pre="13.DunachieS.J.WaltherM.VuolaJ.M.WebsterD.P.KeatingS.M.BerthoudT.AndrewsL.BejonP.PoultonI.ButcherG.et al.A clinical trial of prime-boost immunisation with the candidate" exact="malaria" post="vaccines RTS,S/AS02A and MVA-CSVaccine2006242850285910.1016/j.vaccine.2005.12.04116434127 14.BerthoudT.K.HamillM.LillieP.J.HwendaL.CollinsK.A.EwerK.J.MilicicA.PoyntzH.C.LambeT.FletcherH.A.et al.Potent CD8+ T-cell immunogenicity"/>
   <result pre="al.Potent CD8+ T-cell immunogenicity in humans of a novel heterosubtypic" exact="influenza" post="A vaccine, MVA-NP+M1Clin. Infect. Dis. Off. Publ. Infect. Dis."/>
   <result pre="Lethal Challenge ModelSci. Rep.201771476910.1038/s41598-017-15039-829116169 23.Reyes-SandovalA.BerthoudT.AlderN.SianiL.GilbertS.C.NicosiaA.CollocaS.CorteseR.HillA.V.S.Prime-boost immunization with adenoviral and modified" exact="vaccinia virus" post="Ankara vectors enhances the durability and polyfunctionality of protective"/>
   <result pre="virus Ankara vectors enhances the durability and polyfunctionality of protective" exact="malaria" post="CD8+ T-cell responsesInfect. Immun.20107814515310.1128/IAI.00740-0919858306 24.López-GilE.LorenzoG.HeviaE.BorregoB.EidenM.GroschupM.GilbertS.C.BrunA.A Single Immunization with MVA"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6963926\results\search\disease\results.xml">
   <result pre="SNPs that are important to understand the pathology derived from" exact="influenza" post="A virus (IAV) infections in humans and the susceptibility"/>
   <result pre="annual recurrent epidemics that affect the entire world [38,39]. Seasonal" exact="influenza" post="infections are prevented and controlled through annual vaccination campaigns"/>
   <result pre="the absent in melanoma 2 (AIM2) protein, recognizing not well-characterized" exact="influenza" post="stimuli [54]. The result of PRR detection of viral"/>
   <result pre="mentioned below, IFITM3 is an ISG playing antiviral roles against" exact="influenza" post="virus infection and other viruses [59]. Type I and"/>
   <result pre="lung injury (ALI) pathology induced by highly pathogenic viruses, including" exact="severe acute respiratory syndrome" post="(SARS) coronavirus and avian IAV H5N1, and H7N9 [80]."/>
   <result pre="be important for multiple human pathologies, such as cancer, diabetes," exact="heart disease," post="schizophrenia, blood-pressure homeostasis, and autoimmune or metabolic diseases, have"/>
   <result pre="examples of the presence of SNPs in host genes affecting" exact="influenza" post="severity (Table 1), which will be discussed in this"/>
   <result pre="was found in one out of three patients developing IAV-associated" exact="encephalopathy" post="(IAE), a neurological consequence of severe viral infection [98]."/>
   <result pre="TLR3 SNP was found in all the children developing IAV-associated" exact="pneumonia" post="(18 cases). However, the SNP was found in significantly"/>
   <result pre="responses show an elevated susceptibility to Herpes Simplex-1 Virus (HSV-1)-mediated" exact="encephalitis" post="by encoding TLR3-deficient alleles [102,103], or by encoding deficient"/>
   <result pre="The TLR3 rs5743314 C allele was also associated with HCV-related" exact="liver disease" post="progression (cirrhosis and hepatocellular carcinoma) [107]. However, the functional"/>
   <result pre="parents and living in France affected by a severe pulmonary" exact="influenza" post="infection [115]. In particular, the homozygous mutation (c.991G&amp;gt;A) occurred"/>
   <result pre="One of the clearest associations of SNPs in genes affecting" exact="influenza" post="severity is located in the ISG IFITM3. The human"/>
   <result pre="Different studies have described the effect of IFITM3 SNPs in" exact="influenza" post="disease severity. Northern European patients infected with IAV pH1N1"/>
   <result pre="According to these results suggesting that this SNP could affect" exact="influenza" post="disease, the minority (CC) variant rendered homozygous cells more"/>
   <result pre="21 amino acids of IFITM3 are relevant for attenuating vesicular" exact="stomatitis" post="virus (VSV) replication in vitro [119]. Moreover, the CC"/>
   <result pre="with more than 16,000 subjects, revealed increased risk of severe" exact="influenza" post="in both the East Asian and White populations in"/>
   <result pre="[122]. Another important SNP (rs34481144) associated with risk of severe" exact="influenza" post="in humans from the United States (US) infected with"/>
   <result pre="to less CD8+ T cells in the airways during natural" exact="influenza" post="infection in the carriers of the risk allele, and"/>
   <result pre="on the IL-1B promoter were associated with increased risk of" exact="influenza" post="disease in Chinese subjects [126]. This nucleotide change is"/>
   <result pre="with pH1N1 virus compared to control subjects [130], and developing" exact="pneumonia" post="was more uncommon in Greek and Mexican subjects with"/>
   <result pre="minor A allele was a risk factor to develop liver" exact="cirrhosis" post="and hepatocellular carcinoma following HBV infection in a Han"/>
   <result pre="allele was a risk factor to develop liver cirrhosis and" exact="hepatocellular carcinoma" post="following HBV infection in a Han Chinese population [133],"/>
   <result pre="rs1059046-A, leading to the mutation T9N) were associated with acute" exact="respiratory failure," post="mechanical ventilation, and acute respiratory distress syndrome after infection"/>
   <result pre="T9N) were associated with acute respiratory failure, mechanical ventilation, and" exact="acute respiratory distress syndrome" post="after infection with pH1N1 2009 virus in a Spanish"/>
   <result pre="lung [146]. Moreover, galectin-1 knockout mice showed increased susceptibility to" exact="influenza" post="virus infection than wild-type mice [146]. To study human"/>
   <result pre="deletion of Tmprss2 in mice impairs the spread of H1N1" exact="influenza" post="viruses, including the pH1N1 2009 swine IAV [148]. In"/>
   <result pre="type mice [148]. The genetic predisposition to severe pH1N1 2009" exact="influenza" post="virus was evaluated in Chinese human subjects, finding that"/>
   <result pre="expression of TMPRSS2, was a risk variant to severe pH1N1" exact="influenza" post="[149]. Furthermore, rs2070788 and rs383510, both of them associated"/>
   <result pre="before and 28 days after the administration of seasonal trivalent" exact="influenza" post="vaccine. A correlation between HLA class II alleles and"/>
   <result pre="HLA class II alleles and IAV HAI titers in the" exact="influenza" post="risk group was found. Moreover, a positive association between"/>
   <result pre="group was found. Moreover, a positive association between non-responsiveness to" exact="influenza" post="vaccine and HLA-DRB1*07 and a negative association with HLA-DRB1*13"/>
   <result pre="2). These data suggest that host SNPs affect responses to" exact="influenza" post="vaccine. Mannose-binding lectin 2 (MBL-2) is a protein that"/>
   <result pre="the presence of SNPs in subjects who received an inactivated" exact="influenza" post="vaccine. For that, authors classified the vaccine recipients in"/>
   <result pre="was linked with increased seroconversion in recipients of an inactivated" exact="influenza" post="vaccine (Table 2) [153]. Moreover, IAV-stimulated B- and T-cells"/>
   <result pre="conflict of interest. References References 1.HeldtF.S.FrensingT.ReichlU.Modeling the intracellular dynamics of" exact="influenza" post="virus replication to understand the control of viral RNA"/>
   <result pre="of the Live Attenuated Influenza VaccineViruses20181056010.3390/v1010056030326610 3.ArranzR.ColomaR.ChichonF.J.ConesaJ.J.CarrascosaJ.L.ValpuestaJ.M.OrtinJ.Martin-BenitoJ.The structure of native" exact="influenza" post="virion ribonucleoproteinsScience20123381634163710.1126/science.122817223180776 4.PflugA.GuilligayD.ReichS.CusackS.Structure of influenza A polymerase bound to"/>
   <result pre="VaccineViruses20181056010.3390/v1010056030326610 3.ArranzR.ColomaR.ChichonF.J.ConesaJ.J.CarrascosaJ.L.ValpuestaJ.M.OrtinJ.Martin-BenitoJ.The structure of native influenza virion ribonucleoproteinsScience20123381634163710.1126/science.122817223180776 4.PflugA.GuilligayD.ReichS.CusackS.Structure of" exact="influenza" post="A polymerase bound to the viral RNA promoterNature201451635536010.1038/nature1400825409142 5.PflugA.LukarskaM.Resa-InfanteP.ReichS.CusackS.Structural"/>
   <result pre="viral RNA promoterNature201451635536010.1038/nature1400825409142 5.PflugA.LukarskaM.Resa-InfanteP.ReichS.CusackS.Structural insights into RNA synthesis by the" exact="influenza" post="virus transcription-replication machineVirus Res.201723410311710.1016/j.virusres.2017.01.01328115197 6.Resa-InfanteP.JorbaN.ColomaR.OrtinJ.The influenza virus RNA synthesis"/>
   <result pre="RNA synthesis by the influenza virus transcription-replication machineVirus Res.201723410311710.1016/j.virusres.2017.01.01328115197 6.Resa-InfanteP.JorbaN.ColomaR.OrtinJ.The" exact="influenza" post="virus RNA synthesis machine: Advances in its structure and"/>
   <result pre="expression: Codon usage bias manipulation for the generation of novel" exact="influenza" post="A virus vaccinesFuture Virol.20151071573010.2217/fvl.15.3126213563 8.WiseH.M.FoegleinA.SunJ.DaltonR.M.PatelS.HowardW.AndersonE.C.BarclayW.S.DigardP.A complicated message: Identification of"/>
   <result pre="complicated message: Identification of a novel PB1-related protein translated from" exact="influenza" post="A virus segment 2 mRNAJ. Virol.2009838021803110.1128/JVI.00826-0919494001 9.JaggerB.W.WiseH.M.KashJ.C.WaltersK.A.WillsN.M.XiaoY.L.DunfeeR.L.SchwartzmanL.M.OzinskyA.BellG.L.et al.An overlapping"/>
   <result pre="segment 2 mRNAJ. Virol.2009838021803110.1128/JVI.00826-0919494001 9.JaggerB.W.WiseH.M.KashJ.C.WaltersK.A.WillsN.M.XiaoY.L.DunfeeR.L.SchwartzmanL.M.OzinskyA.BellG.L.et al.An overlapping protein-coding region in" exact="influenza" post="A virus segment 3 modulates the host responseScience201233719920410.1126/science.122221322745253 10.BouvierN.M.PaleseP.The"/>
   <result pre="virus segment 3 modulates the host responseScience201233719920410.1126/science.122221322745253 10.BouvierN.M.PaleseP.The biology of" exact="influenza" post="virusesVaccine200826D49D5310.1016/j.vaccine.2008.07.03919230160 11.Byrd-LeotisL.CummingsR.D.SteinhauerD.A.The Interplay between the Host Receptor and Influenza"/>
   <result pre="13.ImaiM.KawaokaY.The role of receptor binding specificity in interspecies transmission of" exact="influenza" post="virusesCurr. Opin. Virol.2012216016710.1016/j.coviro.2012.03.00322445963 14.McAuleyJ.L.GilbertsonB.P.TrifkovicS.BrownL.E.McKimm-BreschkinJ.L.Influenza Virus Neuraminidase Structure and FunctionsFront."/>
   <result pre="FunctionsFront. Microbiol.2019103910.3389/fmicb.2019.0003930761095 15.GaymardA.Le BriandN.FrobertE.LinaB.EscuretV.Functional balance between neuraminidase and haemagglutinin in" exact="influenza" post="virusesClin. Microbiol. Infect.20162297598310.1016/j.cmi.2016.07.00727424943 16.JagadeshA.SalamA.A.MudgalP.P.ArunkumarG.Influenza virus neuraminidase (NA): A target"/>
   <result pre="neuraminidase (NA): A target for antivirals and vaccinesArch. Virol.20161612087209410.1007/s00705-016-2907-727255748 17.ChenB.J.LeserG.P.JacksonD.LambR.A.The" exact="influenza" post="virus M2 protein cytoplasmic tail interacts with the M1"/>
   <result pre="budding of plasmid-derived virus-like particlesJ. Virol.2007817111712310.1128/JVI.00361-0717475660 20.NayakD.P.HuiE.K.BarmanS.Assembly and budding of" exact="influenza" post="virusVirus Res.200410614716510.1016/j.virusres.2004.08.01215567494 21.WardA.C.CastelliL.A.LucantoniA.C.WhiteJ.F.AzadA.A.MacreadieI.G.Expression and analysis of the NS2 protein"/>
   <result pre="virusVirus Res.200410614716510.1016/j.virusres.2004.08.01215567494 21.WardA.C.CastelliL.A.LucantoniA.C.WhiteJ.F.AzadA.A.MacreadieI.G.Expression and analysis of the NS2 protein of" exact="influenza" post="A virusArch. Virol.19951402067207310.1007/BF013226937503702 22.YasudaJ.NakadaS.KatoA.ToyodaT.IshihamaA.Molecular assembly of influenza virus: Association"/>
   <result pre="NS2 protein of influenza A virusArch. Virol.19951402067207310.1007/BF013226937503702 22.YasudaJ.NakadaS.KatoA.ToyodaT.IshihamaA.Molecular assembly of" exact="influenza" post="virus: Association of the NS2 protein with virion matrixVirology199319624925510.1006/viro.1993.14738356796"/>
   <result pre="of the NS2 protein with virion matrixVirology199319624925510.1006/viro.1993.14738356796 23.RichardsonJ.C.AkkinaR.K.NS2 protein of" exact="influenza" post="virus is found in purified virus and phosphorylated in"/>
   <result pre="and phosphorylated in infected cellsArch. Virol.1991116698010.1007/BF013192321825776 24.PatersonD.FodorE.Emerging roles for the" exact="influenza" post="A virus nuclear export protein (NEP)PLoS Pathog.20128e100301910.1371/journal.ppat.100301923236273 25.NogalesA.Martinez-SobridoL.TophamD.J.DeDiegoM.L.Modulation of"/>
   <result pre="acids at the C-terminus of PA-X are associated with increased" exact="influenza" post="A virus replication and pathogenicityJ. Gen. Virol.2015962036204910.1099/vir.0.00014325877935 28.HuJ.MoY.GaoZ.WangX.GuM.LiangY.ChengX.HuS.LiuW.LiuH.et al.PA-X-associated"/>
   <result pre="injury contributes to the attenuation of a highly pathogenic H5N1" exact="avian influenza" post="virus in miceMed. Microbiol. Immunol.201620538139510.1007/s00430-016-0461-227289459 29.HuJ.MoY.WangX.GuM.HuZ.ZhongL.WuQ.HaoX.HuS.LiuW.et al.PA-X decreases the"/>
   <result pre="contributes to the attenuation of a highly pathogenic H5N1 avian" exact="influenza" post="virus in miceMed. Microbiol. Immunol.201620538139510.1007/s00430-016-0461-227289459 29.HuJ.MoY.WangX.GuM.HuZ.ZhongL.WuQ.HaoX.HuS.LiuW.et al.PA-X decreases the"/>
   <result pre="Immunol.201620538139510.1007/s00430-016-0461-227289459 29.HuJ.MoY.WangX.GuM.HuZ.ZhongL.WuQ.HaoX.HuS.LiuW.et al.PA-X decreases the pathogenicity of highly pathogenic H5N1" exact="influenza" post="A virus in avian species by inhibiting virus replication"/>
   <result pre="ProteinPLoS Pathog.201612e100542710.1371/journal.ppat.100542726849127 31.BarrI.G.McCauleyJ.CoxN.DanielsR.EngelhardtO.G.FukudaK.GrohmannG.HayA.KelsoA.KlimovA.et al.Epidemiological, antigenic and genetic characteristics of seasonal" exact="influenza" post="A(H1N1), A(H3N2) and B influenza viruses: Basis for the"/>
   <result pre="and genetic characteristics of seasonal influenza A(H1N1), A(H3N2) and B" exact="influenza" post="viruses: Basis for the WHO recommendation on the composition"/>
   <result pre="viruses: Basis for the WHO recommendation on the composition of" exact="influenza" post="vaccines for use in the 2009-2010 northern hemisphere seasonVaccine2010281156116710.1016/j.vaccine.2009.11.04320004635"/>
   <result pre="Influenza with VaccinesMMWR Recomm. Rep.20166515410.15585/mmwr.rr6505a127560619 33.MolinariN.A.Ortega-SanchezI.R.MessonnierM.L.ThompsonW.W.WortleyP.M.WeintraubE.BridgesC.B.The annual impact of seasonal" exact="influenza" post="in the US: Measuring disease burden and costsVaccine2007255086509610.1016/j.vaccine.2007.03.04617544181 34.BaileyE.S.ChoiJ.Y.FieldhouseJ.K.BorkenhagenL.K.ZemkeJ.ZhangD.GrayG.C.The"/>
   <result pre="US: Measuring disease burden and costsVaccine2007255086509610.1016/j.vaccine.2007.03.04617544181 34.BaileyE.S.ChoiJ.Y.FieldhouseJ.K.BorkenhagenL.K.ZemkeJ.ZhangD.GrayG.C.The continual threat of" exact="influenza" post="virus infections at the human-animal interface: What is new"/>
   <result pre="reservoirs and intermediate hosts: Dogs, horses, and new possibilities for" exact="influenza" post="virus exposure of humansJ. Virol.2015892990299410.1128/JVI.03146-1425540375 36.TongS.ZhuX.LiY.ShiM.ZhangJ.BourgeoisM.YangH.ChenX.RecuencoS.GomezJ.et al.New world bats"/>
   <result pre="exposure of humansJ. Virol.2015892990299410.1128/JVI.03146-1425540375 36.TongS.ZhuX.LiY.ShiM.ZhangJ.BourgeoisM.YangH.ChenX.RecuencoS.GomezJ.et al.New world bats harbor diverse" exact="influenza" post="A virusesPLoS Pathog.20139e100365710.1371/journal.ppat.100365724130481 37.YoonS.W.WebbyR.J.WebsterR.G.Evolution and ecology of influenza A"/>
   <result pre="harbor diverse influenza A virusesPLoS Pathog.20139e100365710.1371/journal.ppat.100365724130481 37.YoonS.W.WebbyR.J.WebsterR.G.Evolution and ecology of" exact="influenza" post="A virusesCurr. Top. Microbiol. Immunol.201438535937510.1007/82_2014_39624990620 38.ClarkA.M.DeDiegoM.L.AndersonC.S.WangJ.YangH.NogalesA.Martinez-SobridoL.ZandM.S.SangsterM.Y.TophamD.J.Antigenicity of the 2015-2016"/>
   <result pre="Top. Microbiol. Immunol.201438535937510.1007/82_2014_39624990620 38.ClarkA.M.DeDiegoM.L.AndersonC.S.WangJ.YangH.NogalesA.Martinez-SobridoL.ZandM.S.SangsterM.Y.TophamD.J.Antigenicity of the 2015-2016 seasonal H1N1 human" exact="influenza" post="virus HA and NA proteinsPLoS ONE201712e018826710.1371/journal.pone.018826729145498 39.GrohskopfL.A.SokolowL.Z.BroderK.R.WalterE.B.BreseeJ.S.FryA.M.JerniganD.B.Prevention and Control"/>
   <result pre="Rep.20176612010.15585/mmwr.rr6602a128841201 40.GartenR.J.DavisC.T.RussellC.A.ShuB.LindstromS.BalishA.SessionsW.M.XuX.SkepnerE.DeydeV.et al.Antigenic and genetic characteristics of swine-origin 2009 A(H1N1)" exact="influenza" post="viruses circulating in humansScience200932519720110.1126/science.117622519465683 41.SmithG.J.VijaykrishnaD.BahlJ.LycettS.J.WorobeyM.PybusO.G.MaS.K.CheungC.L.RaghwaniJ.BhattS.et al.Origins and evolutionary genomics"/>
   <result pre="41.SmithG.J.VijaykrishnaD.BahlJ.LycettS.J.WorobeyM.PybusO.G.MaS.K.CheungC.L.RaghwaniJ.BhattS.et al.Origins and evolutionary genomics of the 2009 swine-origin H1N1" exact="influenza" post="A epidemicNature20094591122112510.1038/nature0818219516283 42.BakerS.F.NogalesA.SantiagoF.W.TophamD.J.Martinez-SobridoL.Competitive detection of influenza neutralizing antibodies using"/>
   <result pre="the 2009 swine-origin H1N1 influenza A epidemicNature20094591122112510.1038/nature0818219516283 42.BakerS.F.NogalesA.SantiagoF.W.TophamD.J.Martinez-SobridoL.Competitive detection of" exact="influenza" post="neutralizing antibodies using a novel bivalent fluorescence-based microneutralization assay"/>
   <result pre="for the Development of Influenza VaccinesInt. J. Mol. Sci.2016182010.3390/ijms1801002028025504 44.SchotsaertM.Garcia-SastreA.Inactivated" exact="influenza" post="virus vaccines: The future of TIV and QIVCurr. Opin."/>
   <result pre="Development of Live Attenuated Influenza VaccinesViruses20191119010.3390/v1102019030813325 47.LinT.Y.BrassA.L.Host genetic determinants of" exact="influenza" post="pathogenicityCurr. Opin. Virol.2013353153610.1016/j.coviro.2013.07.00523933004 48.BuiC.M.ChughtaiA.A.AdamD.C.MacIntyreC.R.An overview of the epidemiology and"/>
   <result pre="Opin. Virol.2013353153610.1016/j.coviro.2013.07.00523933004 48.BuiC.M.ChughtaiA.A.AdamD.C.MacIntyreC.R.An overview of the epidemiology and emergence of" exact="influenza" post="A infection in humans over timeArch. Public Health2017751510.1186/s13690-017-0182-z28352464 49.PerezD.R.Garcia-SastreA.H5N1,"/>
   <result pre="of knowledge to improve pandemic preparednessVirus Res.20131781210.1016/j.virusres.2013.11.00124238658 50.IwasakiA.PillaiP.S.Innate immunity to" exact="influenza" post="virus infectionNat. Rev. Immunol.20141431532810.1038/nri366524762827 51.GoffP.H.HayashiT.HeW.YaoS.CottamH.B.TanG.S.CrainB.KrammerF.MesserK.PuM.et al.Synthetic Toll-Like Receptor 4"/>
   <result pre="Virol.20179110.1128/JVI.01050-1728724768 52.Weber-GerlachM.WeberF.Standing on three legs: Antiviral activities of RIG-I against" exact="influenza" post="virusesCurr. Opin. Immunol.201642717510.1016/j.coi.2016.05.01627318973 53.SarvestaniS.T.McAuleyJ.L.The role of the NLRP3 inflammasome"/>
   <result pre="of the NLRP3 inflammasome in regulation of antiviral responses to" exact="influenza" post="A virus infectionAntivir. Res.2017148324210.1016/j.antiviral.2017.10.02029097227 54.ZhangH.LuoJ.AlcornJ.F.ChenK.FanS.PilewskiJ.LiuA.ChenW.KollsJ.K.WangJ.AIM2 Inflammasome Is Critical for"/>
   <result pre="a transcriptional signature in influenza-infected airway epitheliaPLoS Pathog.20139e100377310.1371/journal.ppat.100377324278020 59.DesaiT.M.MarinM.ChinC.R.SavidisG.BrassA.L.MelikyanG.B.IFITM3 restricts" exact="influenza" post="A virus entry by blocking the formation of fusion"/>
   <result pre="Immunol.20153612413810.1016/j.it.2015.01.00425704559 65.KosF.J.EnglemanE.G.Role of natural killer cells in the generation of" exact="influenza" post="virus-specific cytotoxic T cellsCell. Immunol.19961731610.1006/cimm.1996.02458871595 66.HeX.S.DraghiM.MahmoodK.HolmesT.H.KembleG.W.DekkerC.L.ArvinA.M.ParhamP.GreenbergH.B.T cell-dependent production of"/>
   <result pre="cell-dependent production of IFN-gamma by NK cells in response to" exact="influenza" post="A virusJ. Clin. Investig.20041141812181910.1172/JCI2279715599406 67.HashimotoY.MokiT.TakizawaT.ShiratsuchiA.NakanishiY.Evidence for phagocytosis of influenza"/>
   <result pre="to influenza A virusJ. Clin. Investig.20041141812181910.1172/JCI2279715599406 67.HashimotoY.MokiT.TakizawaT.ShiratsuchiA.NakanishiY.Evidence for phagocytosis of" exact="influenza" post="virus-infected, apoptotic cells by neutrophils and macrophages in miceJ."/>
   <result pre="Immunol.20111862529253410.4049/jimmunol.100272021257968 72.PothlichetJ.MeunierI.DavisB.K.TingJ.P.SkameneE.von MesslingV.VidalS.M.Type I IFN triggers RIG-I/TLR3/NLRP3-dependent inflammasome activation in" exact="influenza" post="A virus infected cellsPLoS Pathog.20139e100325610.1371/journal.ppat.100325623592984 73.LupferC.KannegantiT.D.The expanding role of"/>
   <result pre="Rev.2013255132410.1111/imr.1208923947344 74.AllenI.C.ScullM.A.MooreC.B.HollE.K.McElvania-TeKippeE.TaxmanD.J.GuthrieE.H.PicklesR.J.TingJ.P.The NLRP3 inflammasome mediates in vivo innate immunity to" exact="influenza" post="A virus through recognition of viral RNAImmunity20093055656510.1016/j.immuni.2009.02.00519362020 75.McAuleyJ.L.TateM.D.MacKenzie-KludasC.J.PinarA.ZengW.StutzA.LatzE.BrownL.E.MansellA.Activation of"/>
   <result pre="infectious diseasesClin. Exp. Immunol.201518016517710.1111/cei.1257825560985 85.HillA.V.The genomics and genetics of human" exact="infectious disease" post="susceptibilityAnnu. Rev. Genom. Hum. Genet.2001237340010.1146/annurev.genom.2.1.373 86.DaiW.YeZ.LuH.SuQ.LiH.LiL.Meta-analysis of the relationship"/>
   <result pre="diseaseOncotarget20189123431235010.18632/oncotarget.2390129552315 87.KoberleB.KochB.FischerB.M.HartwigA.Single nucleotide polymorphisms in DNA repair genes and putative" exact="cancer" post="riskArch Toxicol2016902369238810.1007/s00204-016-1771-227334373 88.LiX.ZhouJ.ChenH.WangF.MeiQ.SunH.The association between the UBQLN1 polymorphism and"/>
   <result pre="Determinants of Viral DiseasesAnnu. Rev. Genet.20175124126310.1146/annurev-genet-120116-02342528853921 96.MathewS.Abdel-HafizH.RazaA.FatimaK.QadriI.Host nucleotide polymorphism in" exact="hepatitis" post="B virus-associated hepatocellular carcinomaWorld J. Hepatol.2016848549810.4254/wjh.v8.i10.48527057306 97.RehmanS.U.RaufM.AbbasZ.HamedM.H.QadriI.Role of Some"/>
   <result pre="99.EspositoS.MolteniC.G.GilianiS.MazzaC.ScalaA.TagliaferriL.PelucchiC.FossaliE.PlebaniA.PrincipiN.Toll-like receptor 3 gene polymorphisms and severity of pandemic A/H1N1/2009" exact="influenza" post="in otherwise healthy childrenVirol J.2012927010.1186/1743-422X-9-27023151015 100.LeeN.CaoB.KeC.LuH.HuY.TamC.H.T.MaR.C.W.GuanD.ZhuZ.LiH.et al.IFITM3, TLR3, and"/>
   <result pre="antibody responseEMBO Mol. Med.20157244110.15252/emmm.20140445925452586 102.ZhangS.Y.JouanguyE.UgoliniS.SmahiA.ElainG.RomeroP.SegalD.Sancho-ShimizuV.LorenzoL.PuelA.et al.TLR3 deficiency in patients with" exact="herpes simplex" post="encephalitisScience20073171522152710.1126/science.113952217872438 103.LafailleF.G.PessachI.M.ZhangS.Y.CiancanelliM.J.HermanM.AbhyankarA.YingS.W.KerosS.GoldsteinP.A.MostoslavskyG.et al.Impaired intrinsic immunity to HSV-1 in human"/>
   <result pre="leads to impaired Toll-like receptor 3 response and susceptibility to" exact="herpes simplex" post="encephalitisImmunity20103340041110.1016/j.immuni.2010.08.01420832341 105.Sancho-ShimizuV.Perez de DiegoR.LorenzoL.HalwaniR.AlangariA.IsraelssonE.FabregaS.CardonA.MaluendaJ.TatematsuM.et al.Herpes simplex encephalitis in children"/>
   <result pre="susceptibility to herpes simplex encephalitisImmunity20103340041110.1016/j.immuni.2010.08.01420832341 105.Sancho-ShimizuV.Perez de DiegoR.LorenzoL.HalwaniR.AlangariA.IsraelssonE.FabregaS.CardonA.MaluendaJ.TatematsuM.et al.Herpes simplex" exact="encephalitis" post="in children with autosomal recessive and dominant TRIF deficiencyJ."/>
   <result pre="de DiegoR.AbhyankarA.IsraelssonE.et al.Heterozygous TBK1 mutations impair TLR3 immunity and underlie" exact="herpes simplex" post="encephalitis of childhoodJ. Exp. Med.20122091567158210.1084/jem.2011131622851595 107.Al-AnaziM.R.Matou-NasriS.AbdoA.A.SanaiF.M.AlkahtaniS.AlarifiS.AlkahtaneA.A.Al-YahyaH.AliD.AlessiaM.S.et al.Association of Toll-Like"/>
   <result pre="al.Heterozygous TBK1 mutations impair TLR3 immunity and underlie herpes simplex" exact="encephalitis" post="of childhoodJ. Exp. Med.20122091567158210.1084/jem.2011131622851595 107.Al-AnaziM.R.Matou-NasriS.AbdoA.A.SanaiF.M.AlkahtaniS.AlarifiS.AlkahtaneA.A.Al-YahyaH.AliD.AlessiaM.S.et al.Association of Toll-Like Receptor"/>
   <result pre="Res.20172017159065310.1155/2017/159065328127569 108.Al-QahtaniA.Al-AhdalM.AbdoA.SanaiF.Al-AnaziM.KhalafN.ViswanN.A.Al-AshgarH.Al-HumaidanH.Al-SuwayehR.et al.Toll-like receptor 3 polymorphism and its association with" exact="hepatitis" post="B virus infection in Saudi Arabian patientsJ. Med. Virol.2012841353135910.1002/jmv.2327122825813"/>
   <result pre="patientsJ. Med. Virol.2012841353135910.1002/jmv.2327122825813 109.JorgensenS.E.ChristiansenM.RyoL.B.GadH.H.GjedstedJ.StaeheliP.MikkelsenJ.G.StorgaardM.HartmannR.MogensenT.H.Defective RNA sensing by RIG-I in severe" exact="influenza" post="virus infectionClin. Exp. Immunol.201819236637610.1111/cei.1312029453856 110.HondaK.YanaiH.NegishiH.AsagiriM.SatoM.MizutaniT.ShimadaN.OhbaY.TakaokaA.YoshidaN.et al.IRF-7 is the master"/>
   <result pre="type III IFN (IFN-lambda) genesJ. Immunol.20071793434344210.4049/jimmunol.179.6.343417785777 113.CiancanelliM.J.HuangS.X.LuthraP.GarnerH.ItanY.VolpiS.LafailleF.G.TrouilletC.SchmolkeM.AlbrechtR.A.et al.Infectious disease. Life-threatening" exact="influenza" post="and impaired interferon amplification in human IRF7 deficiencyScience201534844845310.1126/science.aaa157825814066 114.ChangJ.LindsayR.J.KulkarniS.LifsonJ.D.CarringtonM.AltfeldM.Polymorphisms"/>
   <result pre="interferon-alpha responses of plasmacytoid dendritic cells to HIV-1AIDS20112571571710.1097/QAD.0b013e328343c18621297422 115.HernandezN.MelkiI.JingH.HabibT.HuangS.S.Y.DanielsonJ.KulaT.DrutmanS.BelkayaS.RattinaV.et al.Life-threatening" exact="influenza" post="pneumonitis in a child with inherited IRF9 deficiencyJ. Exp."/>
   <result pre="of lung tissue-resident memory CD8(+) T cells during infection with" exact="influenza" post="virus due to selective expression of IFITM3Nat. Immunol.20131423824510.1038/ni.252523354485 118.EverittA.R.ClareS.PertelT.JohnS.P.WashR.S.SmithS.E.ChinC.R.FeeleyE.M.SimsJ.S.AdamsD.J.et"/>
   <result pre="influenzaNature201248451952310.1038/nature1092122446628 119.WeidnerJ.M.JiangD.PanX.B.ChangJ.BlockT.M.GuoJ.T.Interferon-induced cell membrane proteins, IFITM3 and tetherin, inhibit vesicular" exact="stomatitis" post="virus infection via distinct mechanismsJ. Virol.201084126461265710.1128/JVI.01328-1020943977 120.ZhangY.H.ZhaoY.LiN.PengY.C.GiannoulatouE.JinR.H.YanH.P.WuH.LiuJ.H.LiuN.et al.Interferon-induced transmembrane"/>
   <result pre="al.Interferon-induced transmembrane protein-3 genetic variant rs12252-C is associated with severe" exact="influenza" post="in Chinese individualsNat. Commun.20134141810.1038/ncomms243323361009 121.YangX.TanB.ZhouX.XueJ.ZhangX.WangP.ShaoC.LiY.LiC.XiaH.et al.Interferon-Inducible Transmembrane Protein 3"/>
   <result pre="Severity: A Meta-AnalysisPLoS ONE201510e012498510.1371/journal.pone.012498525942469 122.PrabhuS.S.ChakrabortyT.T.KumarN.BanerjeeI.Association between IFITM3 rs12252 polymorphism and" exact="influenza" post="susceptibility and severity: A meta-analysisGene2018674707910.1016/j.gene.2018.06.07029940276 123.AllenE.K.RandolphA.G.BhangaleT.DograP.OhlsonM.OshanskyC.M.ZamoraA.E.ShannonJ.P.FinkelsteinD.DressenA.et al.SNP-mediated disruption of"/>
   <result pre="at the IFITM3 promoter is associated with risk of severe" exact="influenza" post="in humansNat. Med.20172397598310.1038/nm.437028714988 124.EisfeldA.J.KawaokaY.Calculated risk: A new single-nucleotide polymorphism"/>
   <result pre="Med.20172397598310.1038/nm.437028714988 124.EisfeldA.J.KawaokaY.Calculated risk: A new single-nucleotide polymorphism linked to severe" exact="influenza" post="diseaseNat. Med.20172391191210.1038/nm.438328777788 125.DinarelloC.A.IL-1: Discoveries, controversies and future directionsEur. J."/>
   <result pre="and IL1B contribute to the susceptibility to 2009 pandemic H1N1" exact="influenza" post="A virusBMC Immunol.2013143710.1186/1471-2172-14-3723927441 127.ZhangG.ZhouB.LiS.YueJ.YangH.WenY.ZhanS.WangW.LiaoM.ZhangM.et al.Allele-specific induction of IL-1beta expression"/>
   <result pre="of IL-1beta expression by C/EBPbeta and PU.1 contributes to increased" exact="tuberculosis" post="susceptibilityPLoS Pathog.201410e100442610.1371/journal.ppat.100442625329476 128.LindH.HaugenA.ZienolddinyS.Differential binding of proteins to the IL1B"/>
   <result pre="gene single nucleotide polymorphisms in the natural course of 2009" exact="influenza" post="A H1N1 virus infectionInt. J. Infect. Dis.201216e204e20810.1016/j.ijid.2011.11.01222269998 131.Garcia-RamirezR.A.Ramirez-VenegasA.Quintana-CarrilloR.CamarenaA.E.Falfan-ValenciaR.Mejia-ArangureJ.M.TNF, IL6,"/>
   <result pre="of TNF-alpha-238 and -308 polymorphisms with different outcomes of persistent" exact="hepatitis" post="B virus infection in ChinaPathology20104267468010.3109/00313025.2010.52369621080879 134.GlassW.G.McDermottD.H.LimJ.K.LekhongS.YuS.F.FrankW.A.PapeJ.CheshierR.C.MurphyP.M.CCR5 deficiency increases risk"/>
   <result pre="variation in CD55 increases the severity of 2009 pandemic H1N1" exact="influenza" post="A virus infectionJ. Infect. Dis.201220649550310.1093/infdis/jis37822693232 138.ChatzopoulouF.GioulaG.KioumisI.ChatzidimitriouD.ExindariM.Identification of complement-related host"/>
   <result pre="Dis.201220649550310.1093/infdis/jis37822693232 138.ChatzopoulouF.GioulaG.KioumisI.ChatzidimitriouD.ExindariM.Identification of complement-related host genetic risk factors associated with" exact="influenza" post="A(H1N1)pdm09 outcome: Challenges aheadMed. Microbiol. Immunol.201810.1007/s00430-018-0567-930306260 139.EwulonuU.K.RaviL.MedofM.E.Characterization of the"/>
   <result pre="Natl. Acad. Sci. USA1991884675467910.1073/pnas.88.11.46751711208 140.ZunigaJ.Buendia-RoldanI.ZhaoY.JimenezL.TorresD.RomoJ.RamirezG.CruzA.Vargas-AlarconG.SheuC.C.et al.Genetic variants associated with severe" exact="pneumonia" post="in A/H1N1 influenza infectionEur. Respir J20123960461010.1183/09031936.0002061121737555 141.NgW.C.TateM.D.BrooksA.G.ReadingP.C.Soluble host defense"/>
   <result pre="USA1991884675467910.1073/pnas.88.11.46751711208 140.ZunigaJ.Buendia-RoldanI.ZhaoY.JimenezL.TorresD.RomoJ.RamirezG.CruzA.Vargas-AlarconG.SheuC.C.et al.Genetic variants associated with severe pneumonia in A/H1N1" exact="influenza" post="infectionEur. Respir J20123960461010.1183/09031936.0002061121737555 141.NgW.C.TateM.D.BrooksA.G.ReadingP.C.Soluble host defense lectins in innate"/>
   <result pre="Respir J20123960461010.1183/09031936.0002061121737555 141.NgW.C.TateM.D.BrooksA.G.ReadingP.C.Soluble host defense lectins in innate immunity to" exact="influenza" post="virusJ Biomed Biotechnol2012201273219110.1155/2012/73219122665991 142.LeVineA.M.HartshornK.ElliottJ.WhitsettJ.KorfhagenT.Absence of SP-A modulates innate and"/>
   <result pre="of SP-A modulates innate and adaptive defense responses to pulmonary" exact="influenza" post="infectionAm. J. Physiol. Lung Cell. Mol. Physiol.2002282L563L57210.1152/ajplung.00280.200111839553 143.LiG.SiddiquiJ.HendryM.AkiyamaJ.EdmondsonJ.BrownC.AllenL.LevittS.PoulainF.HawgoodS.Surfactant protein-A--deficient"/>
   <result pre="an exaggerated early inflammatory response to a beta-resistant strain of" exact="influenza" post="A virusAm. J. Respir. Cell Mol. Biol.20022627728210.1165/ajrcmb.26.3.458411867335 144.HartshornK.L.WhiteM.R.ShepherdV.ReidK.JenseniusJ.C.CrouchE.C.Mechanisms of"/>
   <result pre="A genetic variants associate with severe respiratory insufficiency in pandemic" exact="influenza" post="A virus infectionCrit. Care201418R12710.1186/cc1393424950659 146.YangM.L.ChenY.H.WangS.W.HuangY.J.LeuC.H.YehN.C.ChuC.Y.LinC.C.ShiehG.S.ChenY.L.et al.Galectin-1 binds to influenza"/>
   <result pre="pandemic influenza A virus infectionCrit. Care201418R12710.1186/cc1393424950659 146.YangM.L.ChenY.H.WangS.W.HuangY.J.LeuC.H.YehN.C.ChuC.Y.LinC.C.ShiehG.S.ChenY.L.et al.Galectin-1 binds to" exact="influenza" post="virus and ameliorates influenza virus pathogenesisJ. Virol.201185100101002010.1128/JVI.00301-1121795357 147.ChenY.ZhouJ.ChengZ.YangS.ChuH.FanY.LiC.WongB.H.ZhengS.ZhuY.et al.Functional"/>
   <result pre="infectionCrit. Care201418R12710.1186/cc1393424950659 146.YangM.L.ChenY.H.WangS.W.HuangY.J.LeuC.H.YehN.C.ChuC.Y.LinC.C.ShiehG.S.ChenY.L.et al.Galectin-1 binds to influenza virus and ameliorates" exact="influenza" post="virus pathogenesisJ. Virol.201185100101002010.1128/JVI.00301-1121795357 147.ChenY.ZhouJ.ChengZ.YangS.ChuH.FanY.LiC.WongB.H.ZhengS.ZhuY.et al.Functional variants regulating LGALS1 (Galectin"/>
   <result pre="variants regulating LGALS1 (Galectin 1) expression affect human susceptibility to" exact="influenza" post="A(H7N9)Sci. Rep.20155851710.1038/srep0851725687228 148.HatesuerB.BertramS.MehnertN.BahgatM.M.NelsonP.S.PohlmannS.SchughartK.Tmprss2 is essential for influenza H1N1 virus"/>
   <result pre="human susceptibility to influenza A(H7N9)Sci. Rep.20155851710.1038/srep0851725687228 148.HatesuerB.BertramS.MehnertN.BahgatM.M.NelsonP.S.PohlmannS.SchughartK.Tmprss2 is essential for" exact="influenza" post="H1N1 virus pathogenesis in micePLoS Pathog.20139e100377410.1371/journal.ppat.100377424348248 149.ChengZ.ZhouJ.ToK.K.ChuH.LiC.WangD.YangD.ZhengS.HaoK.BosseY.et al.Identification of"/>
   <result pre="Pandemic A(H1N1) Influenza and A(H7N9) InfluenzaJ. Infect. Dis.20152121214122110.1093/infdis/jiv24625904605 150.BartoszkoJ.J.McNamaraI.F.ArasO.A.Z.HyltonD.A.ZhangY.B.MalhotraD.HyettS.L.MorassutR.E.RudziakP.LoebM.Does consecutive" exact="influenza" post="vaccination reduce protection against influenza: A systematic review and"/>
   <result pre="against influenza: A systematic review and meta-analysisVaccine2018363434344410.1016/j.vaccine.2018.04.04929724509 151.BelongiaE.A.SkowronskiD.M.McLeanH.Q.ChambersC.SundaramM.E.De SerresG.Repeated annual" exact="influenza" post="vaccination and vaccine effectiveness: Review of evidenceExpert Rev. Vaccines20171672373610.1080/14760584.2017.1334554"/>
   <result pre="influenzaPLoS Pathog.201410e100455610.1371/journal.ppat.100455625503988 154.GelderC.M.LambkinR.HartK.W.FlemingD.WilliamsO.M.BunceM.WelshK.I.MarshallS.E.OxfordJ.Associations between human leukocyte antigens and nonresponsiveness to" exact="influenza" post="vaccineJ. Infect. Dis.200218511411710.1086/33801411756990 155.LinnikJ.E.EgliA.Impact of host genetic polymorphisms on"/>
   <result pre="on vaccine induced antibody responseHum. Vaccin Immunother.20161290791510.1080/21645515.2015.111934526809773 156.PolandG.A.OvsyannikovaI.G.JacobsonR.M.Immunogenetics of seasonal" exact="influenza" post="vaccine responseVaccine200826D35D4010.1016/j.vaccine.2008.07.06519230157 157.BurlesonG.R.Immunological Variation Due to Genetics of Inflammatory"/>
   <result pre="diseaseMol. Immunol.20034042342910.1016/S0161-5890(03)00155-X14568388 165.TangY.W.LiH.WuH.ShyrY.EdwardsK.M.Host single-nucleotide polymorphisms and altered responses to inactivated" exact="influenza" post="vaccineJ. Infect. Dis.20071961021102510.1086/52137017763324 Figure 1 Influenza A virus structure"/>
   <result pre="1 Single nucleotide polymorphisms associated with susceptibility and severity of" exact="influenza" post="infections. Gene Function SNPs (Type) References TLR-3 Recognizes dsRNA,"/>
   <result pre="Deletion of Tmprss2 in mice impairs the spread of H1N1" exact="influenza" post="viruses, including the pH1N1. Moreover, body weight loss and"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6963929\results\search\disease\results.xml">
   <result pre="payoffs to those of a traditional vaccination game for seasonal" exact="influenza" post="and commercial livestock vaccination in a developed country context."/>
   <result pre="also play important roles. FMD is a highly contagious, non-zoonotic" exact="viral disease" post="that affects cloven-hoofed animals, including cattle, sheep, and goats"/>
   <result pre="and cost that closely resembles the vaccination game for seasonal" exact="influenza" post="with self-interested individuals [22]. The second game adapts the"/>
   <result pre="vaccination programs with one vaccine or even vaccination for seasonal" exact="influenza" post="where the vaccine may offer some protection [25]. In"/>
   <result pre="likelihood of the vaccine preventing or stopping infection. Similar to" exact="influenza" post="vaccination efforts that compile information early to predict the"/>
   <result pre="Implications for Outbreak Risk and Herd ImmunityPLoS ONE20149e8704210.1371/journal.pone.008704224505274 3.SchmidP.RauberD.BetschC.LidoltG.DenkerM.L.Barriers of" exact="influenza" post="vaccination intention and behavior—A systematic review of influenza vaccine"/>
   <result pre="3.SchmidP.RauberD.BetschC.LidoltG.DenkerM.L.Barriers of influenza vaccination intention and behavior—A systematic review of" exact="influenza" post="vaccine hesitancy, 2005–2016PLoS ONE2017122005201610.1371/journal.pone.017055028125629 4.MutuaE.De HaanN.TumusiimeD.JostC.BettB.A Qualitative Study on"/>
   <result pre="and temporal risk as drivers for adoption of foot and" exact="mouth disease" post="vaccinationVaccine2018365077508310.1016/j.vaccine.2018.06.06929997035 18.ChapmanG.B.LiM.VietriJ.IbukaY.ThomasD.YoonH.GalvaniA.P.Using Game Theory to Examine Incentives in Influenza"/>
   <result pre="21.IbukaY.LiM.VietriJ.ChapmanG.B.GalvaniA.P.Free-Riding Behavior in Vaccination Decisions: An Experimental StudyPLoS ONE20149e8716410.1371/journal.pone.008716424475246 22.GalvaniA.P.RelugaT.C.ChapmanG.B.Long-standing" exact="influenza" post="vaccination policy is in accord with individual self-interest but"/>
   <result pre="gamesProc. Natl. Acad. Sci. USA2004101133911339410.1073/pnas.040382310115329411 24.JemberuW.T.MouritsM.RushtonJ.HogeveenH.Cost-benefit analysis of foot and" exact="mouth disease" post="control in EthiopiaPrev. Vet. Med.2016132678210.1016/j.prevetmed.2016.08.00827664449 25.OsterholmM.T.KelleyN.S.SommerA.A BelongiaE.Efficacy and effectiveness"/>
   <result pre="control in EthiopiaPrev. Vet. Med.2016132678210.1016/j.prevetmed.2016.08.00827664449 25.OsterholmM.T.KelleyN.S.SommerA.A BelongiaE.Efficacy and effectiveness of" exact="influenza" post="vaccines: A systematic review and meta-analysisLancet Infect. Dis.201212364410.1016/S1473-3099(11)70295-X22032844 26.NowakG.J.ShenA.K.SchwartzJ.L.Using"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6964091\results\search\disease\results.xml">
   <result pre="6964091540 doi: 10.1186/s12992-019-0540-4 : Research Spatial and temporal distribution of" exact="infectious disease" post="epidemics, disasters and other potential public health emergencies in"/>
   <result pre="temporal analysis indicates that the risk of emerging and re-emerging" exact="infectious disease" post="epidemics has risen [1, 8]. This could partly be"/>
   <result pre="WHO Health Emergencies Programme from the website https://www.afro.who.int/health-topics/disease-outbreaks/outbreaks-and-other-emergencies-updates. Data on" exact="infectious disease" post="epidemics, disasters and other emergencies were compiled from the"/>
   <result pre="are published weekly in the DON website (https://www.who.int/csr/don/archive/year/2016/en/). Data on" exact="infectious disease" post="epidemics and other health emergencies were compiled from the"/>
   <result pre="the period 2016 to 2018. Assembly of the data for" exact="infectious disease" post="epidemics and other public health emergencies Most of the"/>
   <result pre="events by country for the period 2016–2018. Results Over 260" exact="infectious disease" post="epidemics, disasters and other potential public health emergencies were"/>
   <result pre="one epidemic per year (Fig. 1). These data demonstrate that" exact="infectious disease" post="epidemics continue to emerge and re-emerge predictably in certain"/>
   <result pre="1). Table 1 Prioritization of countries, based on frequency of" exact="infectious disease" post="epidemics, 2016–2018 Discussion This analysis demonstrates that the entire"/>
   <result pre="suggests that there is an increase in the frequency of" exact="infectious disease" post="epidemics, disasters and other potential public health emergencies in"/>
   <result pre="greater scale of epidemics. Some of the changes in the" exact="infectious disease" post="transmission patterns are likely a consequence of climate change,"/>
   <result pre="Ebola virus disease epidemic [1]). Second, several epidemics of meningococcal" exact="meningitis" post="recently occurred outside the meningitis belt, showing a high"/>
   <result pre="Second, several epidemics of meningococcal meningitis recently occurred outside the" exact="meningitis" post="belt, showing a high likelihood that the areas at"/>
   <result pre="constituting a dual threat. We explored the dual occurrence of" exact="infectious disease" post="epidemics, disasters and humanitarian crises. A comparison of data"/>
   <result pre="epidemics, disasters and humanitarian crises. A comparison of data on" exact="infectious disease" post="epidemics, disasters and other potential public health emergencies suggest"/>
   <result pre="emergencies suggest that certain countries have a high frequency of" exact="infectious disease" post="epidemics, as well as, a high frequency of other"/>
   <result pre="Africa highlight the negative compounding effects of humanitarian crisis and" exact="infectious disease" post="epidemics, suggesting obvious benefits of cross linkages and the"/>
   <result pre="Niche Modeling for Filoviruses: A risk map for ebola and" exact="marburg virus disease" post="outbreaks in uganda. PLoS Curr. 2017;5:9. 33.NyakarahukaLShoemakerTRBalinandiSChemosGKwesigaBet al.Marburg virus"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6964813\results\search\disease\results.xml">
   <result pre="of diverse and well-characterized antibodies exist against other arboviruses (eg" exact="chikungunya" post="and Zika, this work also provides a proof-of-concept principle"/>
   <result pre="its Supporting Information files Introduction Dengue fever is a devastating" exact="viral disease" post="caused by several antigenically distinct dengue viral (DENV) serotypes"/>
   <result pre="fever, headaches, and myalgia[3] and can advance to the life-threatening" exact="dengue hemorrhagic fever" post="and dengue shock syndrome[4]. Global incidences of DENV and"/>
   <result pre="vector of DENV and other epidemiologically significant viruses such as" exact="chikungunya" post="(CHIKV), yellow fever (YFV), and Zika (ZIKV), is a"/>
   <result pre="DENV and other epidemiologically significant viruses such as chikungunya (CHIKV)," exact="yellow fever" post="(YFV), and Zika (ZIKV), is a domestic endophilic mosquito[17]"/>
   <result pre="vector (GenScript, Piscataway, NJ). For OA984-HA, a 3’ 30-amino-acid human" exact="influenza" post="hemagglutinin (HA) epitope tag with a G(4)S linker[47] was"/>
   <result pre="1C19 scFv that was fused with a 3’ 30-amino-acid human" exact="influenza" post="hemagglutinin (HA) epitope tag, commonly used as a general"/>
   <result pre="scFv antibody-expressing transgenic mosquitoes are just as efficient at viral" exact="suppression" post="as—and homozygous mosquitoes are significantly more efficient than—Wolbachia-infected mosquitoes,"/>
   <result pre="previous efforts have demonstrated effective Cas9-mediated homing-based gene drives in" exact="malaria" post="vectors [70–72], and even Ae. aegypti [34]. Additionally, since"/>
   <result pre="10.1016/j.pt.2012.01.00122300806 18Gloria-SoriaA, BrownJE, KramerV, Hardstone YoshimizuM, PowellJR. Origin of the" exact="dengue fever" post="mosquito, Aedes aegypti, in California. PLoS Negl Trop Dis."/>
   <result pre="GhaniAC, GodfrayHCJ, et al.The importance of mosquito behavioural adaptations to" exact="malaria" post="control in Africa. Evolution. 2013;67: 1218–1230. 10.1111/evo.1206323550770 23MoyesCL, VontasJ,"/>
   <result pre="2006;103: 4198–4203. 10.1073/pnas.060047910316537508 37MathurG, Sanchez-VargasI, AlvarezD, OlsonKE, MarinottiO, JamesAA. Transgene-mediated" exact="suppression" post="of dengue viruses in the salivary glands of the"/>
   <result pre="suppression of dengue viruses in the salivary glands of the" exact="yellow fever" post="mosquito, Aedes aegypti. Insect Mol Biol. 2010;19: 753–763. 10.1111/j.1365-2583.2010.01032.x20738425"/>
   <result pre="10.1073/pnas.120773810922689959 42SumitaniM, KasashimaK, YamamotoDS, YagiK, YudaM, MatsuokaH, et al.Reduction of" exact="malaria" post="transmission by transgenic mosquitoes expressing an antisporozoite antibody in"/>
   <result pre="al.Activation of Akt signaling reduces the prevalence and intensity of" exact="malaria" post="parasite infection and lifespan in Anopheles stephensi mosquitoes. PLoS"/>
   <result pre="10895–10898. 10.1073/pnas.97.20.1089511005862 50KokozaV, AhmedA, WimmerEA, RaikhelAS. Efficient transformation of the" exact="yellow fever" post="mosquito Aedes aegypti using the piggyBac transposable element vector"/>
   <result pre="al.Highly efficient Cas9-mediated gene drive for population modification of the" exact="malaria" post="vector mosquito Anopheles stephensi. Proc Natl Acad Sci U"/>
   <result pre="al.A CRISPR-Cas9 gene drive system targeting female reproduction in the" exact="malaria" post="mosquito vector Anopheles gambiae [Internet]. Nature Biotechnology. 2016 pp."/>
   <result pre="et al.A CRISPR–Cas9 gene drive targeting doublesex causes complete population" exact="suppression" post="in caged Anopheles gambiae mosquitoes [Internet]. Nature Biotechnology. 2018"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6968261\results\search\disease\results.xml">
   <result pre="the Americas and the association with disease outcomes such as" exact="microcephaly" post="among infants and Guillain-Barre syndrome among adults necessitates the"/>
   <result pre="the impact of temperature on transmission of Zika, dengue, and" exact="chikungunya" post="using mechanistic models. PLoS Negl Trop Dis. 2017;11(4):e0005568. doi:"/>
   <result pre="longevity, fecundity, and gonotrophic cycles of Aedes albopictus, vector of" exact="chikungunya" post="and dengue in the Indian Ocean. J Med Entomol."/>
   <result pre="2014;9(3):e89783. doi: 10.1371/journal.pone.008978324603439 22MordecaiEA, PaaijmansKP, JohnsonLR, et al.Optimal temperature for" exact="malaria" post="transmission is dramatically lower than previously predicted. Ecol Lett."/>
   <result pre="2014;9(10):e110538. doi: 10.1371/journal.pone.011053825310016 44JohanssonMA, Arana-vizcarrondoN, BiggerstaffBJ, et al.Incubation periods of" exact="yellow fever" post="virus. Am J Trop Med Hyg. 2010;83(1):183–188. doi: 10.4269/ajtmh.2010.09-078220595499"/>
   <result pre="environmental temperature on the vector competence of Aedes taeniorhynchus for" exact="rift valley fever" post="and equine encephalitis viruses. Am J Trop Med Hyg."/>
   <result pre="competence of Aedes taeniorhynchus for rift valley fever and equine" exact="encephalitis" post="viruses. Am J Trop Med Hyg. 1993;49(6):672–676. doi: 10.4269/ajtmh.1993.49.6728279634"/>
   <result pre="and the susceptibility of Aedes albopictus Skuse (Diptera: Culicidae) to" exact="chikungunya" post="virus. Vector Borne Zoonotic Dis. 2010;10(3):241–247. doi: 10.1089/vbz.2009.003519725768 48LambrechtsL,"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6968431\results\search\disease\results.xml">
   <result pre="become a chronic condition, with persistent or relapse symptoms of" exact="arthropathy" post="[1]. Virus diversity can be classified into four distinct"/>
   <result pre="joint pain accompanied by edema, rash, skin and ocular manifestations," exact="plantar fasciitis" post="and morning joint stiffness. Using a combination of portable"/>
   <result pre="pain accompanied by edema, rash, skin and ocular manifestations, plantar" exact="fasciitis" post="and morning joint stiffness. Using a combination of portable"/>
   <result pre="co-circulation of different mosquito-borne viruses (i.e. zika, dengue, Mayaro, oropouche," exact="yellow fever" post="viruses) exanthematic disease is increasing in prevalence in Brazil,"/>
   <result pre="BrasilBoletim Epidemiológico - Monitoramento dos casos de dengue, febre de" exact="chikungunya" post="e doença aguda pelo vírus Zika até a Semana"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6968645\results\search\disease\results.xml">
   <result pre="pmid: 319000601708811 doi: 10.1080/22221751.2019.1708811 : Original Article Evidence of H10N8" exact="influenza" post="virus infection among swine in southern China and its"/>
   <result pre="is properly cited.TEMI_9_1708811.pdf Abstract ABSTRACT Infection with a novel H10N8" exact="influenza" post="virus in humans was first described in China in"/>
   <result pre="remains unclear. In the present study, antibody specific for H10N8" exact="influenza" post="virus was detected in swine herds in southern China"/>
   <result pre="swine herds in southern China during serological monitoring for swine" exact="influenza" post="virus. The pathogenicity and transmissibility of this H10N8 influenza"/>
   <result pre="swine influenza virus. The pathogenicity and transmissibility of this H10N8" exact="influenza" post="virus to swine was examined. The results showed that"/>
   <result pre="showed that swine are susceptible to infection with human-origin H10N8" exact="influenza" post="virus, which causes viral shedding, severe tissue lesions, and"/>
   <result pre="severe tissue lesions, and seroconversion, while infection with avian-origin H10N8" exact="influenza" post="virus causes only seroconversion and no viral shedding. Importantly,"/>
   <result pre="causes only seroconversion and no viral shedding. Importantly, human-origin H10N8" exact="influenza" post="virus can inefficiently be transmitted between swine and cause"/>
   <result pre="study provides a new perspective regarding the ecology of H10N8" exact="influenza" post="virus and highlights the importance of epidemiological monitoring of"/>
   <result pre="and highlights the importance of epidemiological monitoring of the H10N8" exact="influenza" post="virus in different animal species, which will be helpful"/>
   <result pre="preventing and controlling future infections by this virus. KEYWORDS H10N8" exact="influenza" post="virus infectivity pathogenicity transmissibility Funding National Key R&amp;amp;D Program2016YFD0-500707"/>
   <result pre="subtypes, H1N1 and H3N2 are currently responsible for causing seasonal" exact="influenza" post="virus epidemics [7]. In addition to these three subtypes,"/>
   <result pre="2013, China reported the first human infection with a H10N8" exact="avian influenza" post="virus in Jiangxi Province, with two of the three"/>
   <result pre="China reported the first human infection with a H10N8 avian" exact="influenza" post="virus in Jiangxi Province, with two of the three"/>
   <result pre="in death [12], raising concerns regarding the effects of H10N8" exact="influenza" post="viruses on public health. In China, H10N8 influenza viruses"/>
   <result pre="of H10N8 influenza viruses on public health. In China, H10N8" exact="influenza" post="viruses were previously isolated from the environment of Dongting"/>
   <result pre="other mammals. Several studies subsequently confirmed that the human H10N8" exact="influenza" post="virus originated from chickens in LPMs [15,16]. Additionally, a"/>
   <result pre="chickens in LPMs [15,16]. Additionally, a specific antibody for H10N8" exact="influenza" post="virus was detected in sera samples collected from animal"/>
   <result pre="first H10N8 infection cases were recognized [17,18]. Interspecies transmission of" exact="avian influenza" post="viruses to humans and other mammals has been consistently"/>
   <result pre="H10N8 infection cases were recognized [17,18]. Interspecies transmission of avian" exact="influenza" post="viruses to humans and other mammals has been consistently"/>
   <result pre="decades. Swine are susceptible to infection with both human and" exact="avian influenza" post="viruses. Influenza virus may undergo reassortment to generate novel"/>
   <result pre="Swine are susceptible to infection with both human and avian" exact="influenza" post="viruses. Influenza virus may undergo reassortment to generate novel"/>
   <result pre="swine [19]; thus, swine are considered as &quot;mixing vessels�? in" exact="influenza" post="ecology. Considering this important role, we conducted serological monitoring"/>
   <result pre="in swine herds. Eight serum samples were positive for H10N8" exact="influenza" post="virus based on hemagglutination inhibition (HI) and microneutralization (MN)"/>
   <result pre="in southern China. However, the pathogenicity and transmissibility of H10N8" exact="influenza" post="virus in swine remains unknown. Based on serological evidence,"/>
   <result pre="Based on serological evidence, pathogenicity and transmission analyses of H10N8" exact="influenza" post="virus in swine were conducted in this study, which"/>
   <result pre="infections and provide new perspectives regarding the transmission of H10N8" exact="influenza" post="virus. Materials and methods Viruses and serum samples Human-origin"/>
   <result pre="virus. Materials and methods Viruses and serum samples Human-origin H10N8" exact="influenza" post="virus strain A/Jiangxi-Donghu/346-1/2013 (JX346) and duck-origin strain A/duck/Guangdong/E1/2012 (GD-E1)"/>
   <result pre="Qi, College of Veterinary Medicine, South China Agricultural University. Swine" exact="influenza" post="virus A/swine/Guangdong/SS1/2012 (H1N1 Eurasian avian-like lineage) and A/swine/Guangdong/L22/2010 (H3N2)"/>
   <result pre="were collected from swine farms that were non-immunized for swine" exact="influenza" post="virus from July 2016 to June 2017 in southern"/>
   <result pre="to HI and MN assays against H1N1 and H3N2 swine" exact="influenza" post="viruses. In this serological study, serum samples with HI"/>
   <result pre="and pseudorabies virus. They were confirmed to be free from" exact="influenza" post="virus infection and were found to be seronegative for"/>
   <result pre="were found to be seronegative for H1N1 and H3N2 swine" exact="influenza" post="viruses by HI assay. The 19 pigs were randomly"/>
   <result pre="Additionally, to exclude the possibility of cross-reactions with other swine" exact="influenza" post="viruses, HI and MN assays for the H1N1 and"/>
   <result pre="HI and MN assays for the H1N1 and H3N2 swine" exact="influenza" post="viruses were conducted for the eight positive serum samples."/>
   <result pre="that all samples were negative for H1N1 and H3N2 swine" exact="influenza" post="virus (HI and MN titer &amp;lt; 1:10, Table 1)."/>
   <result pre="Results of serological assay for serum samples positive for H10N8" exact="influenza" post="virus. Farm Collection date Sample name H10N8 H1N1 H3N2"/>
   <result pre="HI, hemagglutination inhibition assay; MN, microneutralization assay. Infectivity of H10N8" exact="influenza" post="virus in swine To investigate whether H10N8 influenza virus"/>
   <result pre="of H10N8 influenza virus in swine To investigate whether H10N8" exact="influenza" post="virus can infect swine, two groups of pigs were"/>
   <result pre="seroconversion with low antibody levels. Thus, epidemiological monitoring of H10N8" exact="influenza" post="virus in swine herds should be further conducted to"/>
   <result pre="be further conducted to determine whether interspecies transmission of H10N8" exact="influenza" post="viruses has occurred in swine herds. Table 2. Seroconversion"/>
   <result pre="the HI and MN titer in pigs infected with H10N8" exact="influenza" post="virus. Strain Group Pig 7 dpi/dpc 14 dpi/dpc HI MN HI"/>
   <result pre="Note: dpi, days post-infection; dpc, days post-contact. Transmissibility of H10N8" exact="influenza" post="virus in swine To investigate whether H10N8 influenza virus"/>
   <result pre="of H10N8 influenza virus in swine To investigate whether H10N8" exact="influenza" post="virus can be transmitted between swine through physical contact,"/>
   <result pre="by direct contact. Pathological changes of pigs infected with H10N8" exact="influenza" post="virus One inoculated pig from each group was necropsied"/>
   <result pre="Discussion Rapid mutation and continuous reassortment are important features of" exact="influenza" post="virus, which accelerate adaptation and interspecies transmission in new"/>
   <result pre="accelerate adaptation and interspecies transmission in new hosts. Numerous zoonotic" exact="influenza" post="viruses that cause human infection have been documented in"/>
   <result pre="infection have been documented in recent years, such as high-pathogenic" exact="avian influenza" post="H5N1 infections in Hong Kong in 1997 [20], H1N1/2009"/>
   <result pre="have been documented in recent years, such as high-pathogenic avian" exact="influenza" post="H5N1 infections in Hong Kong in 1997 [20], H1N1/2009"/>
   <result pre="[20], H1N1/2009 as a worldwide pandemic in 2009 [21], H7N9" exact="avian influenza" post="infection in China since 2013 [22], and novel reassorted"/>
   <result pre="H1N1/2009 as a worldwide pandemic in 2009 [21], H7N9 avian" exact="influenza" post="infection in China since 2013 [22], and novel reassorted"/>
   <result pre="infection in China since 2013 [22], and novel reassorted H5N6" exact="avian influenza" post="virus infection in humans in 2014 [10]. In December"/>
   <result pre="in China since 2013 [22], and novel reassorted H5N6 avian" exact="influenza" post="virus infection in humans in 2014 [10]. In December"/>
   <result pre="in 2014 [10]. In December 2013, human infection with H10N8" exact="avian influenza" post="virus was first reported in China, which resulted in"/>
   <result pre="2014 [10]. In December 2013, human infection with H10N8 avian" exact="influenza" post="virus was first reported in China, which resulted in"/>
   <result pre="in China, which resulted in three deaths [12], and H10N8" exact="influenza" post="virus infection of human origin from LPMs was subsequently"/>
   <result pre="confirmed by several research groups [15,16]. During serological monitoring of" exact="influenza" post="virus in swine herds in 2016–2017 in southern China,"/>
   <result pre="in southern China, we detected a specific antibody for H10N8" exact="influenza" post="virus for the first time and confirmed the result"/>
   <result pre="the result by MN assay. Serological analysis indicated that H10N8" exact="influenza" post="virus infection occurs in swine herds in nature. Su"/>
   <result pre="swine herds in nature. Su et al. also reported H10N8" exact="influenza" post="virus infections in feral dogs in LPMs before the"/>
   <result pre="(such as swine and dog) are potential hosts of H10N8" exact="influenza" post="viruses. However, it is important to identify the origin"/>
   <result pre="in human infections. We further investigated the pathogenesis of H10N8" exact="influenza" post="virus in swine, which showed that the human-origin strain"/>
   <result pre="PB2 is critical for virus pathogenicity and mammalian adaptation of" exact="avian influenza" post="virus [24–26]. JX346 contained the 87E, 292 V, 340 K, 588 V,"/>
   <result pre="is critical for virus pathogenicity and mammalian adaptation of avian" exact="influenza" post="virus [24–26]. JX346 contained the 87E, 292 V, 340 K, 588 V,"/>
   <result pre="play a critical role in mammalian adaptation of human-origin H10N8" exact="influenza" post="virus [27]. These mutations may be responsible for the"/>
   <result pre="thus, swine are susceptible to infection with both human and" exact="avian influenza" post="virus [19]. In contrast, the human respiratory tract mainly"/>
   <result pre="swine are susceptible to infection with both human and avian" exact="influenza" post="virus [19]. In contrast, the human respiratory tract mainly"/>
   <result pre="α-2,6-galactose receptor [28]. Several studies have reported that human-origin H10N8" exact="influenza" post="viruses shows a strong preference for the avian receptor"/>
   <result pre="virus evolution remains unclear; thus, continuous epidemiological monitoring of H10N8" exact="influenza" post="virus in different animal species (such as avian and"/>
   <result pre="swine. In summary, we detected a specific antibody for H10N8" exact="influenza" post="virus in swine herds in southern China for the"/>
   <result pre="study provides a new perspective regarding the ecology of H10N8" exact="influenza" post="virus and highlights the importance of epidemiological monitoring of"/>
   <result pre="influenza virus and highlights the importance of epidemiological monitoring of" exact="influenza" post="viruses in different animal species, which will be helpful"/>
   <result pre="of Veterinary Medicine, South China Agricultural University to provide H10N8" exact="influenza" post="virus. Disclosure statement No potential conflict of interest was"/>
   <result pre="Nat Rev Microbiol. 2005;3(8):591–600. doi: 10.1038/nrmicro120816064053 2NelsonMI, VincentAL.Reverse zoonosis of" exact="influenza" post="to swine: new perspectives on the human-animal interface. Trends"/>
   <result pre="3SuS, GuM, LiuD, et al.Epidemiology, evolution, and pathogenesis of H7N9" exact="influenza" post="viruses in five epidemic waves since 2013 in China."/>
   <result pre="Lancet. 2017;390(10095):697–708. doi: 10.1016/S0140-6736(17)30129-028302313 5YoonSW, WebbyRJ, WebsterRG.Evolution and ecology of" exact="influenza" post="A viruses. Curr Top Microbiol Immunol. 2014;385:359–375.24990620 6WuY, WuY,"/>
   <result pre="Microbiol. 2014;22(4):183–191. doi: 10.1016/j.tim.2014.01.01024582528 7PetrovaVN, RussellCA.Erratum: the evolution of seasonal" exact="influenza" post="viruses. Nat Rev Microbiol. 2018;16(1):60. doi: 10.1038/nrmicro.2017.14629109554 8TongXC, WengSS,"/>
   <result pre="8TongXC, WengSS, XueF, et al.First human infection by a novel" exact="avian influenza" post="A(H7N4) virus. J Infec. 2018;77(3):249–257. doi: 10.1016/j.jinf.2018.06.002 9GaoR, CaoB,"/>
   <result pre="WengSS, XueF, et al.First human infection by a novel avian" exact="influenza" post="A(H7N4) virus. J Infec. 2018;77(3):249–257. doi: 10.1016/j.jinf.2018.06.002 9GaoR, CaoB,"/>
   <result pre="9GaoR, CaoB, HuY, et al.Human infection with a novel avian-origin" exact="influenza" post="A (H7N9) virus. N Engl J Med. 2013;368(20):1888–1897. doi:"/>
   <result pre="10ZhangY, ChenM, HuangY, et al.Human infections with novel reassortant H5N6" exact="avian influenza" post="viruses in China. Emerg Microbes Infect. 2017;6(6):e50.28588293 11LaiS, QinY,"/>
   <result pre="ChenM, HuangY, et al.Human infections with novel reassortant H5N6 avian" exact="influenza" post="viruses in China. Emerg Microbes Infect. 2017;6(6):e50.28588293 11LaiS, QinY,"/>
   <result pre="Microbes Infect. 2017;6(6):e50.28588293 11LaiS, QinY, CowlingBJ, et al.Global epidemiology of" exact="avian influenza" post="A H5N1 virus infection in humans, 1997–2015: a systematic"/>
   <result pre="Infect. 2017;6(6):e50.28588293 11LaiS, QinY, CowlingBJ, et al.Global epidemiology of avian" exact="influenza" post="A H5N1 virus infection in humans, 1997–2015: a systematic"/>
   <result pre="et al.Clinical and epidemiological characteristics of a fatal case of" exact="avian influenza" post="A H10N8 virus infection: a descriptive study. The Lancet."/>
   <result pre="al.Clinical and epidemiological characteristics of a fatal case of avian" exact="influenza" post="A H10N8 virus infection: a descriptive study. The Lancet."/>
   <result pre="doi: 10.1016/S0140-6736(14)60111-2 13ZhangH, XuB, ChenQ, et al.Characterization of an H10N8" exact="influenza" post="virus isolated from Dongting lake wetland. Virol J. 2011;8:42."/>
   <result pre="14JiaoP, CaoL, YuanR, et al.Complete genome sequence of an H10N8" exact="avian influenza" post="virus isolated from a live bird market in Southern"/>
   <result pre="CaoL, YuanR, et al.Complete genome sequence of an H10N8 avian" exact="influenza" post="virus isolated from a live bird market in Southern"/>
   <result pre="10.1128/JVI.00959-1222733881 15QiW, ZhouX, ShiW, et al.Genesis of the novel human-infecting" exact="influenza" post="A(H10N8) virus and potential genetic diversity of the virus"/>
   <result pre="2014;19(25):20841. doi: 10.2807/1560-7917.ES2014.19.25.2084124993558 16ZhangT, BiY, TianH, et al.Human infection with" exact="influenza" post="virus A(H10N8) from live poultry markets, China, 2014. Emerging"/>
   <result pre="2014;20(12):2076–2079. doi: 10.3201/eid2012.14091125425075 17QiW, SuS, XiaoC, et al.Antibodies against H10N8" exact="avian influenza" post="virus among animal workers in Guangdong Province before November"/>
   <result pre="doi: 10.3201/eid2012.14091125425075 17QiW, SuS, XiaoC, et al.Antibodies against H10N8 avian" exact="influenza" post="virus among animal workers in Guangdong Province before November"/>
   <result pre="10.1186/s12916-014-0205-325348464 18SuS, QiW, ZhouP, et al.First evidence of H10N8 Avian" exact="influenza" post="virus infections among feral dogs in live poultry markets"/>
   <result pre="KelmS, et al.Molecular basis for the generation in pigs of" exact="influenza" post="A viruses with pandemic potential. J Virol. 1998;72(9):7367–7373. doi:"/>
   <result pre="et al.Molecular basis for high virulence of Hong Kong H5N1" exact="influenza" post="A viruses. Science. 2001;293(5536):1840–1842. doi: 10.1126/science.106288211546875 21NeumannG, NodaT, KawaokaY.Emergence"/>
   <result pre="10.1126/science.106288211546875 21NeumannG, NodaT, KawaokaY.Emergence and pandemic potential of swine-origin H1N1" exact="influenza" post="virus. Nature. 2009;459(7249):931–939. doi: 10.1038/nature0815719525932 22LamTT, WangJ, ShenY, et"/>
   <result pre="WangJ, ShenY, et al.The genesis and source of the H7N9" exact="influenza" post="viruses causing human infections in China. Nature. 2013;502(7470):241–244. doi:"/>
   <result pre="23MaC, LamTT, ChaiY, et al.Emergence and evolution of H10 subtype" exact="influenza" post="viruses in poultry in China. J Virol. 2015;89(7):3534–3541. doi:"/>
   <result pre="E627 K and D701N mutations in the PB2 protein of A(H7N9)" exact="influenza" post="virus increased its virulence in mammalian models. Sci Rep."/>
   <result pre="LondonW, MurphyBR.A single amino acid in the PB2 gene of" exact="influenza" post="A virus is a determinant of host range. J"/>
   <result pre="DauberB, WolffT, et al.The viral polymerase mediates adaptation of an" exact="avian influenza" post="virus to a mammalian host. Proc Natl Acad Sci"/>
   <result pre="WolffT, et al.The viral polymerase mediates adaptation of an avian" exact="influenza" post="virus to a mammalian host. Proc Natl Acad Sci"/>
   <result pre="al.PB2-588 V promotes the mammalian adaptation of H10N8, H7N9 and H9N2" exact="avian influenza" post="viruses. Sci Rep. 2016;6:19474. doi: 10.1038/srep1947426782141 28ShinyaK, EbinaM, YamadaS,"/>
   <result pre="promotes the mammalian adaptation of H10N8, H7N9 and H9N2 avian" exact="influenza" post="viruses. Sci Rep. 2016;6:19474. doi: 10.1038/srep1947426782141 28ShinyaK, EbinaM, YamadaS,"/>
   <result pre="Rep. 2016;6:19474. doi: 10.1038/srep1947426782141 28ShinyaK, EbinaM, YamadaS, et al.Avian flu:" exact="influenza" post="virus receptors in the human airway. Nature. 2006;440(7083):435–436. doi:"/>
   <result pre="WohlboldTJ, et al.Hemagglutinin receptor binding of a human isolate of" exact="influenza" post="A(H10N8) virus. Emerging Infect. Dis.. 2015;21(7):1197–1201. doi: 10.3201/eid2107.14175526079843 30ZhangH,"/>
   <result pre="doi: 10.3201/eid2107.14175526079843 30ZhangH, de VriesRP, TzarumN, et al.A human-infecting H10N8" exact="influenza" post="virus retains a strong preference for avian-type receptors. Cell"/>
   <result pre="basis for preferential avian receptor binding by the human-infecting H10N8" exact="avian influenza" post="virus. Nat Commun. 2015;6:5600. doi: 10.1038/ncomms660025574798"/>
   <result pre="for preferential avian receptor binding by the human-infecting H10N8 avian" exact="influenza" post="virus. Nat Commun. 2015;6:5600. doi: 10.1038/ncomms660025574798"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6968865\results\search\disease\results.xml">
   <result pre="contains a large number of viral agents capable of causing" exact="encephalitis" post="and jaundice [1]. Most flaviviruses are arboviruses and transmitted"/>
   <result pre="Individual members such as dengue (DENV), yellow-fever virus (YFV), Japanese" exact="encephalitis" post="virus (JEV), tick-borne encephalitis virus (TBEV) and West Nile"/>
   <result pre="as dengue (DENV), yellow-fever virus (YFV), Japanese encephalitis virus (JEV)," exact="tick-borne encephalitis" post="virus (TBEV) and West Nile virus (WNV) cause significant"/>
   <result pre="dengue (DENV), yellow-fever virus (YFV), Japanese encephalitis virus (JEV), tick-borne" exact="encephalitis" post="virus (TBEV) and West Nile virus (WNV) cause significant"/>
   <result pre="infected mosquitoes. Notable viruses that infect the human population include" exact="chikungunya" post="(CHIKV), Barmah Forest virus (BFV), Mayaro virus (MAYV) [6],"/>
   <result pre="and the presence of pathogens, including Norovirus, in patients with" exact="gastrointestinal disease" post="[24]. We have utilised the method to produce pan-species"/>
   <result pre="YFV, TBEV and MVEV. Aphaviruses; CHIKV, BFV, RRV, Eastern equine" exact="encephalitis" post="virus (EEEV), Western equine encephalitis virus (WEEV), Venezuelan equine"/>
   <result pre="CHIKV, BFV, RRV, Eastern equine encephalitis virus (EEEV), Western equine" exact="encephalitis" post="virus (WEEV), Venezuelan equine encephalitis virus (VEEV), Middleburg virus"/>
   <result pre="encephalitis virus (EEEV), Western equine encephalitis virus (WEEV), Venezuelan equine" exact="encephalitis" post="virus (VEEV), Middleburg virus (MV) and Ndumu virus (NV)."/>
   <result pre="MBC024 SLEV Vircell MBC101 HHV-6 Vircell MBC025 TBEV Vircell MBC045" exact="influenza" post="H1 Vircell MBC028 VEEV Vircell MBC096 influenza H3 Vircell"/>
   <result pre="TBEV Vircell MBC045 influenza H1 Vircell MBC028 VEEV Vircell MBC096" exact="influenza" post="H3 Vircell MBC029 WEEV Vircell MBC098 influenza B Vircell"/>
   <result pre="VEEV Vircell MBC096 influenza H3 Vircell MBC029 WEEV Vircell MBC098" exact="influenza" post="B Vircell MBC03 WNV Vircell MBC069 parainfluenza-1 Vircell MBC037"/>
   <result pre="number) and 10μl of Vircell DENV-1, DENV-2, DENV-3, DENV-4 and" exact="chikungunya" post="RNA samples (again provided with a certificate specifying their"/>
   <result pre="(FA002-A), West Nile virus (FA002-B), Yellow Fever Virus (FA002-C), Tick-borne" exact="encephalitis" post="virus (FA002-D), St Louis encephalitis virus (FA002-E), Murray Valley"/>
   <result pre="Yellow Fever Virus (FA002-C), Tick-borne encephalitis virus (FA002-D), St Louis" exact="encephalitis" post="virus (FA002-E), Murray Valley encephalitis virus (FA002-F), dengue-1 (FA003-A),"/>
   <result pre="encephalitis virus (FA002-D), St Louis encephalitis virus (FA002-E), Murray Valley" exact="encephalitis" post="virus (FA002-F), dengue-1 (FA003-A), dengue-2 (FA003-B), dengue-3 (FA003-C), dengue-4"/>
   <result pre="virus (FA002-F), dengue-1 (FA003-A), dengue-2 (FA003-B), dengue-3 (FA003-C), dengue-4 (FA003-D)," exact="chikungunya" post="(FA004-A), Ross River virus (FA004-B), Barmah Forest virus (FA004-C),"/>
   <result pre="Ross River virus (FA004-B), Barmah Forest virus (FA004-C), Eastern equine" exact="encephalitis" post="virus (FA004-C), Western equine encephalitis virus (FA004-D) and Venezuelan"/>
   <result pre="Forest virus (FA004-C), Eastern equine encephalitis virus (FA004-C), Western equine" exact="encephalitis" post="virus (FA004-D) and Venezuelan equine encephalitis virus (FA004-E). Real-time"/>
   <result pre="virus (FA004-C), Western equine encephalitis virus (FA004-D) and Venezuelan equine" exact="encephalitis" post="virus (FA004-E). Real-time reverse transcription PCR Following sample extraction"/>
   <result pre="virus, Herpes Simplex virus 1, Herpes Simplex virus 2, HHV-6," exact="influenza" post="H1, influenza H3, influenza B, parainfluenza-1, parainfluenza-2, parainfluenza-3, parainfluenza-4A,"/>
   <result pre="Simplex virus 1, Herpes Simplex virus 2, HHV-6, influenza H1," exact="influenza" post="H3, influenza B, parainfluenza-1, parainfluenza-2, parainfluenza-3, parainfluenza-4A, Respiratory Syncytial"/>
   <result pre="1, Herpes Simplex virus 2, HHV-6, influenza H1, influenza H3," exact="influenza" post="B, parainfluenza-1, parainfluenza-2, parainfluenza-3, parainfluenza-4A, Respiratory Syncytial virus (subtype"/>
   <result pre="BuchtG, MosomtaiG, OtienoV, AhlmCet al.Global emergence of Alphaviruses that cause" exact="arthritis" post="in humans. Infect Ecol Epidemiol. 2015; 1218; 5:2985310.3402/iee.v5.2985326689654 7LaBeaudAD,"/>
   <result pre="Association of Tonate virus (subtype IIIB of the Venezuelan equine" exact="encephalitis" post="complex) with encephalitis in a human. Clin Infect Dis."/>
   <result pre="virus (subtype IIIB of the Venezuelan equine encephalitis complex) with" exact="encephalitis" post="in a human. Clin Infect Dis. 2000; 1; 30(1):188–90."/>
   <result pre="Atai-OmorutoAD, TenywaE, MillerJR, et al.Epidemiological and laboratory characterization of a" exact="yellow fever" post="outbreak in northern Uganda, October 2010-January 2011. Int J"/>
   <result pre="ChenPL, ChuangKT, ShuYC, ChienYW, PerngGC, et al.Symptoms associated with adverse" exact="dengue fever" post="prognoses at the time of reporting in the 2015"/>
   <result pre="DashS, SoniaT, MuthukumaravelS, SankariT, GunasekaranK, et al.Entomological investigation of Japanese" exact="encephalitis" post="outbreak in Malkangiri district of Odisha state, India. Mem"/>
   <result pre="20185; 14;113(6). 17KabirI, DhimalM, MüllerR, BanikS, HaqueU. The 2017 Dhaka" exact="chikungunya" post="outbreak. Lancet Infect Dis. 201711;17(11):111810.1016/S1473-3099(17)30564-9 18https://www.theage.com.au/national/victoria/ross-river-virus-150-more-victims-in-victoria-as-outbreak-tally-tops-1000-20170217-guf7bg.html 19Normile D. &quot;Tropical"/>
   <result pre="MercierA, LepersC, HoyD, DuituturagaS, BenyonE, et al.Concurrent outbreaks of dengue," exact="chikungunya" post="and Zika virus infections–an unprecedented epidemic wave of mosquito-borne"/>
   <result pre="34AnkerM, ArimaY. Male-female differences in the number of reported incident" exact="dengue fever" post="cases in six Asian countries. Western Pac Surveill Response"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6969489\results\search\disease\results.xml">
   <result pre="conventional methods. We validated this platform using different subtypes of" exact="avian influenza" post="A viruses and human samples with respiratory infections. This"/>
   <result pre="methods. We validated this platform using different subtypes of avian" exact="influenza" post="A viruses and human samples with respiratory infections. This"/>
   <result pre="human samples with respiratory infections. This technology successfully enriched rhinovirus," exact="influenza" post="virus, and parainfluenza viruses, and maintained the stoichiometric viral"/>
   <result pre="to 31.8% for parainfluenza and from 0.08 to 0.44% for" exact="influenza" post="virus. This enrichment method coupled to Raman virus identification"/>
   <result pre="and monitor viral outbreaks in real time. carbon nanotube microfabrication" exact="infectious disease" post="sequencing virus isolation Funding National Science Foundation (NSF)1000000011394977Yin-Ting YehKristen"/>
   <result pre="label-free optical virus identification. Images of electron microscopy showing captured" exact="avian influenza" post="virus H5N2 by CNxCNT arrays. (D) On-chip virus analysis"/>
   <result pre="optical virus identification. Images of electron microscopy showing captured avian" exact="influenza" post="virus H5N2 by CNxCNT arrays. (D) On-chip virus analysis"/>
   <result pre="efficacy of the VIRRION platform, we used a low pathogenic" exact="avian influenza" post="A virus (LPAIV), which is an RNA virus (Fig."/>
   <result pre="of the VIRRION platform, we used a low pathogenic avian" exact="influenza" post="A virus (LPAIV), which is an RNA virus (Fig."/>
   <result pre="particles captured (Figs. 1A and 4B). Fig. 4. Characterization of" exact="avian influenza" post="virus captured and detected by VIRRION. (A) A process"/>
   <result pre="captured (Figs. 1A and 4B). Fig. 4. Characterization of avian" exact="influenza" post="virus captured and detected by VIRRION. (A) A process"/>
   <result pre="detected by VIRRION. (A) A process flow of VIRRION for" exact="avian influenza" post="virus surveillance and discovery. (B) SEM showing H5N2 virus"/>
   <result pre="by VIRRION. (A) A process flow of VIRRION for avian" exact="influenza" post="virus surveillance and discovery. (B) SEM showing H5N2 virus"/>
   <result pre="nasopharyngeal swabs from patients who had been diagnosed with rhinovirus," exact="influenza" post="A virus, or human parainfluenza virus type 3 (HPIV"/>
   <result pre="spectrum. (C) Circos plots of coverage and variants of captured" exact="influenza" post="viruses. Genome segment sequencing and analysis of influenza A"/>
   <result pre="of captured influenza viruses. Genome segment sequencing and analysis of" exact="influenza" post="A mapped to strain A/New York/03/2016 (H3N2). Track 1:"/>
   <result pre="acid for NGS and determined that after VIRRION capture, the" exact="influenza" post="A and HPIV 3 viruses were significantly enriched (SI"/>
   <result pre="percentage of virus-specific reads increased from 0.08 to 0.44% for" exact="influenza" post="A and from 4.1 to 31.8% for HPIV 3."/>
   <result pre="Genome coverage also increased following enrichment. The percentage of the" exact="influenza" post="A genome increased from 33% before enrichment to 48%"/>
   <result pre="able to assemble large portions of each viral genome. No" exact="influenza" post="A contigs greater than 500 bp were identified following"/>
   <result pre="assembly in the unenriched sample. However, 4 contigs matching the" exact="influenza" post="A genome were found in both enrichment steps with"/>
   <result pre="159–171 (2013).29503665 5PeirisJ. S. M., de JongM. D., GuanY., Avian" exact="influenza" post="virus (H5N1): A threat to human health. Clin. Microbiol."/>
   <result pre="World Health Organization (WHO) Consultation on Human Influenza A/H5, Avian" exact="influenza" post="A (H5N1) infection in humans. N. Engl. J. Med.353,"/>
   <result pre="study of a novel dot-enzyme-linked immunosorbent assay for detection of" exact="avian influenza" post="virus. Avian Dis.47, 361–369 (2003).12887195 27SpackmanE.et al., Development of"/>
   <result pre="of a novel dot-enzyme-linked immunosorbent assay for detection of avian" exact="influenza" post="virus. Avian Dis.47, 361–369 (2003).12887195 27SpackmanE.et al., Development of"/>
   <result pre="of a real-time reverse transcriptase PCR assay for type A" exact="influenza" post="virus and the avian H5 and H7 hemagglutinin subtypes."/>
   <result pre="Exploiting the anti-aggregation of gold nanostars for rapid detection of" exact="hand, foot, and mouth disease" post="causing enterovirus 71 using surface-enhanced Raman spectroscopy. Anal. Chem.89,"/>
   <result pre="of gold nanostars for rapid detection of hand, foot, and" exact="mouth disease" post="causing enterovirus 71 using surface-enhanced Raman spectroscopy. Anal. Chem.89,"/>
   <result pre="Chem.89, 5373–5381 (2017).28414218 38LimJ. Y.et al., Identification of newly emerging" exact="influenza" post="viruses by surface-enhanced Raman spectroscopy. Anal. Chem.87, 11652–11659 (2015).26528878"/>
   <result pre="method using multiplex real-time PCR for diagnosis of infections by" exact="influenza" post="A and influenza B viruses, respiratory syncytial virus, and"/>
   <result pre="real-time PCR for diagnosis of infections by influenza A and" exact="influenza" post="B viruses, respiratory syncytial virus, and parainfluenza viruses 1,"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6971842\results\search\disease\results.xml">
   <result pre="the Americas, with recent epidemics occurring on both continents. The" exact="yellow fever" post="vaccine is effective, affordable and safe, providing life-long immunity"/>
   <result pre="epidemics, but there are no randomized controlled trials of fractional" exact="yellow fever" post="vaccine doses in Africa. Methods and analysis: We will"/>
   <result pre="will be randomized to receive fractional or standard doses of" exact="yellow fever" post="vaccine. Scheduled visits will include blood collection for serum"/>
   <result pre="least eight years. WHO recommends the use of fractional dose" exact="yellow fever" post="vaccination as an off-label use in response to emergency"/>
   <result pre="key questions the trials are answering? Can all four WHO-prequalified" exact="yellow fever" post="vaccines be used as fractional doses with non-inferior immunogenicity"/>
   <result pre="compared to the standard vaccine dose? What is the minimum" exact="yellow fever" post="vaccine dose that is non-inferior to the standard dose?"/>
   <result pre="is non-inferior to the standard dose? Can reduced doses of" exact="yellow fever" post="vaccine provide sufficient immunogenicity in infants and children under"/>
   <result pre="under the age of 5 years? Are reduced doses of" exact="yellow fever" post="vaccine sufficiently immunogenic in human immunodeficiency virus (HIV)-infected individuals"/>
   <result pre="longevity of the immunity provided by the reduced doses of" exact="yellow fever" post="vaccine? Introduction Yellow fever (YF) is caused by a"/>
   <result pre="few days after vaccination. Serious reactions are rare and include" exact="hypersensitivity" post="reactions to components of the vaccine, YF vaccine-associated neurologic"/>
   <result pre="symptomatic HIV/AIDS or other causes, known thymus disorder, such as" exact="thymoma" post="and myasthenia gravis and acute febrile diseases • Previous"/>
   <result pre="or other causes, known thymus disorder, such as thymoma and" exact="myasthenia gravis" post="and acute febrile diseases • Previous YF vaccination •"/>
   <result pre="doses - June 2017, addendum to vaccines and vaccination against" exact="yellow fever" post="WHO: Position paper - June 2013.Vaccine.2017;35(43):5751–5752. 10.1016/j.vaccine.2017.06.08728689653 2collab: SAGE"/>
   <result pre="paper - June 2013.Vaccine.2017;35(43):5751–5752. 10.1016/j.vaccine.2017.06.08728689653 2collab: SAGE WHO: Fractional dose" exact="yellow fever" post="vaccine as a dose-sparing option for outbreak response.2016Reference Source"/>
   <result pre="dose-sparing option for outbreak response.2016Reference Source 3MutebiJPBarrettAD: The epidemiology of" exact="yellow fever" post="in Africa.Microbes Infect.2002;4(14):1459–68. 10.1016/s1286-4579(02)00028-x12475636 4ShearerFMLongbottomJBrowneAJet al.: Existing and potential"/>
   <result pre="10.1016/s1286-4579(02)00028-x12475636 4ShearerFMLongbottomJBrowneAJet al.: Existing and potential infection risk zones of" exact="yellow fever" post="worldwide: a modelling analysis.Lancet Glob Health.2018;6(3):e270–e278. 10.1016/S2214-109X(18)30024-X29398634 5MonathTPVasconcelosPF: Yellow"/>
   <result pre="Fever, jaundice, and multiple organ system failure associated with 17D-derived" exact="yellow fever" post="vaccination, 1996-2001.MMWR Morb Mortal Wkly Rep.2001;50(30):643–5. 11787575 9GarskeTVan KerkhoveMDYactayoSet"/>
   <result pre="Virus Res.2003;60:343–95. 10.1016/s0065-3527(03)60009-614689698 11GotuzzoEYactayoSCórdovaE: Efficacy and duration of immunity after" exact="yellow fever" post="vaccination: systematic review on the need for a booster"/>
   <result pre="One.2016;11(3):e0149871. 10.1371/journal.pone.014987126977808 13MonathTP: Review of the risks and benefits of" exact="yellow fever" post="vaccination including some new analyses.Expert Rev Vaccines.2012;11(4):427–48. 10.1586/erv.12.622551029 14FoxJPPennaHA:"/>
   <result pre="some new analyses.Expert Rev Vaccines.2012;11(4):427–48. 10.1586/erv.12.622551029 14FoxJPPennaHA: Behavior of 17D" exact="yellow fever" post="virus in rhesus monkeys: relation to substrain, dose and"/>
   <result pre="controlling the disease.Vaccine.2017;35(44):5951–5955. 10.1016/j.vaccine.2017.03.03228366605 16Osei-KwasiMDunyoSKKoramKAet al.: Antibody response to 17D" exact="yellow fever" post="vaccine in Ghanaian infants.Bull World Health Organ.2001;79(11):1056–9. 11731813 17BeckASBarrettAD:"/>
   <result pre="Health Organ.2001;79(11):1056–9. 11731813 17BeckASBarrettAD: Current status and future prospects of" exact="yellow fever" post="vaccines.Expert Rev Vaccines.2015;14(11):1479–92. 10.1586/14760584.2015.108343026366673 18FergusonMShinJKnezevicIet al.: WHO Working Group"/>
   <result pre="Switzerland, 13-14 May 2009.Vaccine.2010;28(52):8236–45. 10.1016/j.vaccine.2010.10.07021055492 19WuJTPeakCMLeungGMet al.: Fractional dosing of" exact="yellow fever" post="vaccine to extend supply: a modelling study.Lancet.2016;388(10062):2904–2911. 10.1016/S0140-6736(16)31838-427837923 20BarrettAD:"/>
   <result pre="- Preliminary Report.N Engl J Med.2018Reference Source 22MonathTP: Stability of" exact="yellow fever" post="vaccine.Dev Biol Stand.1996;87:219–25. 8854020 23collab: World Health Organization (WHO):"/>
   <result pre="to assure the quality, safety and efficacy of live attenuated" exact="yellow fever" post="vaccines (Annex 5).2013Reference Source 24collab: PATH: Yellow Fever vaccination:"/>
   <result pre="(PAHO): Epidemiological Update: Yellow Fever.2018Reference Source 29MartinsRMMaia MdeLFariasRHet al.: 17DD" exact="yellow fever" post="vaccine: a double blind, randomized clinical trial of immunogenicity"/>
   <result pre="Vaccin Immunother.2013;9(4):879–88. 10.4161/hv.2298223364472 30Campi-AzevedoACde Almeida EstevamPCoelho-Dos-ReisJGet al.: Subdoses of 17DD" exact="yellow fever" post="vaccine elicit equivalent virological/immunological kinetics timeline.BMC Infect Dis.2014;14:391. 10.1186/1471-2334-14-39125022840"/>
   <result pre="virological/immunological kinetics timeline.BMC Infect Dis.2014;14:391. 10.1186/1471-2334-14-39125022840 31RoukensAHVossenACBredenbeekPJet al.: Intradermally administered" exact="yellow fever" post="vaccine at reduced dose induces a protective immune response:"/>
   <result pre="controlled non-inferiority trial.PLoS One.2008;3(4):e1993. 10.1371/journal.pone.000199318431480 32Lopes OdeSGuimarãesSSde CarvalhoR: Studies on" exact="yellow fever" post="vaccine. III--Dose response in volunteers.J Biol Stand.1988;16(2):77–82. 10.1016/0092-1157(88)90034-03372545 33VanniceKWilder-SmithAHombachJ:"/>
   <result pre="Advancing the Evidence Base.N Engl J Med.2018;379(7):603–605. 10.1056/NEJMp180343329995585 34RoukensAHEVisserLG: Fractional-dose" exact="yellow fever" post="vaccination: an expert review.J Travel Med.2019;26(6):pii: taz024. 10.1093/jtm/taz02430937437 35GoujonCGougeonMLTondeurLet"/>
   <result pre="al.: CHRONOVAC VOYAGEUR: A study of the immune response to" exact="yellow fever" post="vaccine among infants previously immunized against measles.Vaccine.2017;35(45):6166–6171. 10.1016/j.vaccine.2017.09.04728958813 36Luiza-SilvaMCampi-AzevedoACBatistaMAet"/>
   <result pre="al.: Cytokine signatures of innate and adaptive immunity in 17DD" exact="yellow fever" post="vaccinated children and its association with the level of"/>
   <result pre="antibody.J Infect Dis.2011;204(6):873–83. 10.1093/infdis/jir43921849284 37SidibeMYactayoSKalleAet al.: Immunogenicity and safety of" exact="yellow fever" post="vaccine among 115 HIV-infected patients after a preventive immunisation"/>
   <result pre="Uganda.figshare.201910.6084/m9.figshare.10283048.v2 40CohenBJDoblasDAndrewsN: Comparison of plaque reduction neutralisation test (PRNT) and" exact="measles" post="virus-specific IgG ELISA for assessing immunogenicity of measles vaccination.Vaccine.2008;26(50):6392–7."/>
   <result pre="(PRNT) and measles virus-specific IgG ELISA for assessing immunogenicity of" exact="measles" post="vaccination.Vaccine.2008;26(50):6392–7. 10.1016/j.vaccine.2008.08.07418834911 41WietenRWJonkerEFPierenDKet al.: Comparison of the PRNT and"/>
   <result pre="Comparison of the PRNT and an immune fluorescence assay in" exact="yellow fever" post="vaccinees receiving immunosuppressive medication.Vaccine.2016;34(10):1247–51. 10.1016/j.vaccine.2016.01.03726845742 42DomingoCPatelPYillahJet al.: Advanced yellow"/>
   <result pre="yellow fever vaccinees receiving immunosuppressive medication.Vaccine.2016;34(10):1247–51. 10.1016/j.vaccine.2016.01.03726845742 42DomingoCPatelPYillahJet al.: Advanced" exact="yellow fever" post="virus genome detection in point-of-care facilities and reference laboratories.J"/>
   <result pre="external quality assessment study on molecular and serological methods for" exact="yellow fever" post="diagnosis.PLoS One.2012;7(5):e36291. 10.1371/journal.pone.003629122570700 44FullertonTForrestALevyG: Pharmacodynamic analysis of sparse data"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6971860\results\search\disease\results.xml">
   <result pre="serious with associated mortality. This was the largest and unusual" exact="dengue fever" post="outbreak in the North of Vietnam over the past"/>
   <result pre="sylvatic cycles with little transmissibility to humans, other DENVs cause" exact="dengue fever" post="only [4, 11]. In contrast, many genotypes of DENV"/>
   <result pre="associated with the potential to also cause the more severe" exact="dengue hemorrhagic fever" post="and dengue shock syndrome [4, 11]. DENV has been"/>
   <result pre="often benign, non-fatal, with main manifestations of high fever and" exact="osteoarthritis" post="[14]. However, cases of severe progression and death have"/>
   <result pre="to pregnant women [23]. In this outbreak, there were 59,063" exact="dengue fever" post="cases in Northern Vietnam, approximately eight times higher than"/>
   <result pre="Vietnam, approximately eight times higher than in 2016 with 7289" exact="dengue fever" post="cases [24]. In this ourbreak in Hanoi, the number"/>
   <result pre="of 72 DENV-1 strains circulating in the unusual outbreak of" exact="dengue hemorrhagic fever" post="2017 in Northern Vietnam. We also analyzed the genetic"/>
   <result pre="from Cortez (USA). Blood samples (2–3 mL) of patients with acute" exact="dengue fever" post="were collected and centrifuged. The plasma was separated and"/>
   <result pre="the influence of the amino acid substitution of DENV and" exact="dengue hemorrhagic fever" post="severe. Studies on the genetic evolution of DENV shows"/>
   <result pre="relatively high, it is only slower than the HIV and" exact="influenza" post="viruses. In nature, DENV exists in two forms, sylvatic"/>
   <result pre="results constitute an important database to elucidate the mechanism of" exact="dengue hemorrhagic fever," post="genetic characteristics of the virus, and the development of"/>
   <result pre="literature and meta-analysisValue Health Reg Issues20132334735610.1016/j.vhri.2013.10.00229702769 18.LeeHSNguyen-VietHNamVSLeeMWonSDucPPet al.Seasonal patterns of" exact="dengue fever" post="and associated climate factors in 4 provinces in Vietnam"/>
   <result pre="of dengue epidemics, southern VietnamEmerg Infect Dis201319694595310.3201/eid1906.12132323735713 21.Minh AnDTRocklovJEpidemiology of" exact="dengue fever" post="in Hanoi from 2002 to 2010 and its meteorological"/>
   <result pre="meteorological determinantsGlob Health Action201472307410.3402/gha.v7.2307425511882 22.PhamLDPhungNHLeNTVoTQEconomic report on the cost of" exact="dengue fever" post="in Vietnam: case of a provincial hospitalClinicoecon Outcomes Res201791810.2147/CEOR.S12402328031723"/>
   <result pre="al.Role of Aedes aegypti and Aedes albopictus during the 2011" exact="dengue fever" post="epidemics in Hanoi, VietnamAsian Pac J Trop Med20158754354810.1016/j.apjtm.2015.06.00926276285 35.FoxALeNMSimmonsCPWolbersMWertheimHFPhamTKet"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6972593\results\search\disease\results.xml">
   <result pre="ARTICLES: Respiratory Infections Novel endosomal NOX2 oxidase inhibitor ameliorates pandemic" exact="influenza" post="A virus�?induced lung inflammation in mice Reactive oxygen species"/>
   <result pre="A virus�?induced lung inflammation in mice Reactive oxygen species and" exact="influenza" post="EE To et al. ToEunice E.1LuongRaymond1DiaoJiayin2O’ LearyJohn J.345BrooksDoug A.6VlahosRosshttps://orcid.org/0000-0001-8443-70711SelemidisStavroshttps://orcid.org/0000-0002-3989-761517stavros.selemidis@rmit.edu.au[1],"/>
   <result pre="inflammation and viral replication to infection with a low pathogenic" exact="influenza" post="A viral strain. Here, we determined whether suppression of"/>
   <result pre="low pathogenic influenza A viral strain. Here, we determined whether" exact="suppression" post="of endosome NOX2 oxidase prevents the lung inflammation following"/>
   <result pre="the pathogenesis caused during epidemics and pandemics. Lung inflammation to" exact="influenza" post="A virus (IAV) infection can be fatal when the"/>
   <result pre="inflammation and improved viral clearance. See related https://onlinelibrary.wiley.com/doi/10.1111/resp.13629 endosome inflammation" exact="influenza" post="NOX2 oxidase respiratory infections Funding Australian Research Council 10.13039/501100000923"/>
   <result pre="J, et al. Novel endosomal NOX2 oxidase inhibitor ameliorates pandemic" exact="influenza" post="A virus�?induced lung inflammation in mice. Respirology. 2019;24:1011–1017. 10.1111/resp.1352430884042"/>
   <result pre="systems. The current approaches to limit the pathogenesis associated with" exact="influenza" post="virus infections are vaccines and antiviral drugs. Despite vaccines"/>
   <result pre="Despite vaccines being relatively efficacious in containing the spread of" exact="influenza" post="viruses in some years, the demand for mass production"/>
   <result pre="drugs have also been demonstrated with some circulating strains of" exact="influenza" post="virus.2, 3 This highlights the unmet need for the"/>
   <result pre="altered metabolism has been directly implicated in the pathogenesis of" exact="influenza" post="virus infections.4, 5 The consensus is that excessive ROS"/>
   <result pre="revealed that the primary subcellular site of ROS generation to" exact="influenza" post="virus infection is the endosome.9 We previously showed that"/>
   <result pre="influenza virus infection is the endosome.9 We previously showed that" exact="influenza" post="A virus (IAV) triggers ROS production within the endosome"/>
   <result pre="limit ROS production could reduce the viral burden associated with" exact="influenza" post="infections. We developed an innovative molecular targeting system to"/>
   <result pre="limiting ROS production to restrict viral pathogenesis, using a mild" exact="influenza" post="viral strain, that is Hong Kong H3N2 X�?31 strain.9"/>
   <result pre="promotes a deleterious inflammatory immune response in the lung, following" exact="influenza" post="virus infection, and that this may be exploited as"/>
   <result pre="lung tissue of mRNA from the gene encoding polymerase of" exact="influenza" post="virus strain PR8; results were presented relative to those"/>
   <result pre="recently identified endosomes as key sites of ROS generation during" exact="influenza" post="virus infections.9, 16 To this end, we custom�?modified the"/>
   <result pre="Airway and lung parenchymal inflammation are important pathological characteristics of" exact="influenza" post="virus infections, particularly those due to highly pathogenic strains,"/>
   <result pre="a hallmark feature of the host innate immune response to" exact="influenza" post="virus infections17; however, there is conflicting evidence for what"/>
   <result pre="exhibited exacerbated amounts of pulmonary inflammation and respiratory dysfunction during" exact="influenza" post="virus infection,18 suggesting that these cells are critical for"/>
   <result pre="virus infection,18 suggesting that these cells are critical for minimizing" exact="influenza" post="virus�?induced pathology. By contrast, partial suppression of neutrophil infiltration"/>
   <result pre="are critical for minimizing influenza virus�?induced pathology. By contrast, partial" exact="suppression" post="of neutrophil infiltration was associated with a milder pathology"/>
   <result pre="infiltration following PR8 infection. Although the role of neutrophils in" exact="influenza" post="virus infections is debatable, our data suggest that a"/>
   <result pre="virus infections is debatable, our data suggest that a partial" exact="suppression" post="of neutrophil infiltration combined with inhibition of ROS resulted"/>
   <result pre="it from escaping the endosome. In contrast, it suggests that" exact="influenza" post="virus actually utilize NOX2�?derived ROS to promote their replication"/>
   <result pre="N�?acetyl�?l�?cysteine (NAC) and vitamins including C and E for reducing" exact="influenza" post="pathogenicity with some promising results.20, 21 Yet, this has"/>
   <result pre="H2O2 and peroxynitrite, all of which have been implicated in" exact="influenza" post="pathology, we suggest that a better alternative is to"/>
   <result pre="for endosome NOX2 inhibitors, particularly as a means for preventing" exact="influenza" post="pathology. Whilst our study shows a clear potential for"/>
   <result pre="a clear potential for prevention of this inflammation to pandemic" exact="influenza" post="by delivering an endosome NOX2 inhibitor prior to infection,"/>
   <result pre="of the effect of Cgp91ds�?TAT on the resolution of pandemic" exact="influenza" post="which should include a comprehensive analysis of critical arms"/>
   <result pre="infection that could provide novel and effective approaches to avoid/alleviate" exact="influenza" post="pathology. Abbreviations ANOVA analysis of variance BALF bronchoalveloar lavage"/>
   <result pre="bronchoalveloar lavage fluid Cgp91ds�?TAT cholestanol�?conjugated gp91dsTAT DMSO dimethyl sulphoxide IAV" exact="influenza" post="A virus IFN interferon NOX2 NADPH oxidase 2 PBS"/>
   <result pre="Nat. Commun.2013; 4: 2854.24326875 3Nitsch�?OsuchA, BrydakLB. Treatment and prophylaxis of" exact="influenza" post="and the problem of resistance to neuraminidase inhibitors. Postepy"/>
   <result pre="absence of reactive oxygen species improves the resolution of lung" exact="influenza" post="infection. Eur. J. Immunol.2006; 36: 1364–73.16703568 7VlahosR, StambasJ, BozinovskiS,"/>
   <result pre="BozinovskiS, BroughtonBRS, DrummondGR, SelemidisS. Inhibition of Nox2 oxidase activity ameliorates" exact="influenza" post="A virus�?induced lung inflammation. PLoS Pathog.2011; 7: e1001271.21304882 8VlahosR,"/>
   <result pre="e1001271.21304882 8VlahosR, SelemidisS. NADPH oxidases as novel pharmacologic targets against" exact="influenza" post="A virus infection. Mol. Pharmacol.2014; 86: 747–59.25301784 9ToEE, VlahosR,"/>
   <result pre="SeowHJ, BroughtonBR, VinhA, BozinovskiS, SobeyCG, DrummondGR, VlahosR. Nox1 oxidase suppresses" exact="influenza" post="A virus�?induced lung inflammation and oxidative stress. PLoS One2013;"/>
   <result pre="PeterhansE, StockerR. Oxidative stress in lungs of mice infected with" exact="influenza" post="A virus. Free Radic. Res.1992; 16: 99–110. 13ChandlerJD, HuX,"/>
   <result pre="of lung inflammation revealed by high�?resolution metabolomics (HRM) of H1N1" exact="influenza" post="virus infection in mice. Am. J. Physiol. Regul. Integr."/>
   <result pre="StambasJ, SelemidisS. Suppressing production of reactive oxygen species (ROS) for" exact="influenza" post="A virus therapy. Trends Pharmacol. Sci.2012; 33: 3–8.21962460 16SelemidisS."/>
   <result pre="PaleseP, SwayneDE, Pantin�?JackwoodMJ, Schultz�?CherryS, SolórzanoA, Van RooijenN, KatzJMet al.Pathogenicity of" exact="influenza" post="viruses with genes from the 1918 pandemic virus: functional"/>
   <result pre="ameliorate lung injury and the development of severe disease during" exact="influenza" post="infection. J. Immunol.2009; 183: 7441–50.19917678 19KelkkaT, KienhöferD, HoffmannM, LinjaM,"/>
   <result pre="pro�?inflammatory molecules in A549 cells infected with highly pathogenic H5N1" exact="influenza" post="A virus. Biochem. Pharmacol.2010; 79: 413–20.19732754 21ZhangRH, LiCH, WangCL,"/>
   <result pre="WeiD, LiuBJ, WangGH, TianSF. N�?acetyl�?l�?cystine (NAC) protects against H9N2 swine" exact="influenza" post="virus�?induced acute lung injury. Int. Immunopharmacol.2014; 22: 1–8.24968347"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6976597\results\search\disease\results.xml">
   <result pre="possible role for autoimmunity through molecular mimicry in alphavirus mediated" exact="arthritis" post="VenigallaSiva Sai KrishnaPremakumarSowmyaJanakiramanVanivani@iitm.ac.in[], 0000 0001 2315 1926grid.417969.4Department of Biotechnology,"/>
   <result pre="in causing debilitating clinical outcomes in humans characterized by rheumatic" exact="arthritis" post="like conditions. Though the presence of virus in joints"/>
   <result pre="conserved regions which share homology with human proteins implicated in" exact="rheumatoid arthritis" post="(RA). These conserved regions were predicted to exhibit binding"/>
   <result pre="regions which share homology with human proteins implicated in rheumatoid" exact="arthritis" post="(RA). These conserved regions were predicted to exhibit binding"/>
   <result pre="studies also report a simultaneous increase in alpha virus associated" exact="arthritis" post="lasting even after decrease in viral load7. While there"/>
   <result pre="viral load7. While there is a resurgence of alphavirus associated" exact="arthritis" post="cases, the knowledge about the molecular level events during"/>
   <result pre="a comparative study between CHIKV infection induced gene expression and" exact="rheumatoid arthritis" post="induced gene expression changes in mouse models showed similarity"/>
   <result pre="comparative study between CHIKV infection induced gene expression and rheumatoid" exact="arthritis" post="induced gene expression changes in mouse models showed similarity"/>
   <result pre="trigger for many autoimmune diseases14. In these scenarios, initiation of" exact="autoimmune disease" post="by an infectious pathogen is hypothesized to involve immune"/>
   <result pre="sp. may have a possible association with autoimmune diseases like" exact="ankylosing spondylitis," post="Systemic Lupus Erythematosus (SLE) and Lyme arthritis, respectively. A"/>
   <result pre="in clinical manifestation of an alphaviral infection induced arthralgia and" exact="rheumatoid arthritis" post="at both phenotypic and molecular levels suggests that alphaviral"/>
   <result pre="clinical manifestation of an alphaviral infection induced arthralgia and rheumatoid" exact="arthritis" post="at both phenotypic and molecular levels suggests that alphaviral"/>
   <result pre="suggests that alphaviral infections could be a causative link for" exact="rheumatoid arthritis." post="Overarching goal of this study is to explore the"/>
   <result pre="alphaviruses which may set off an autoimmune response resulting in" exact="rheumatoid arthritis" post="like symptoms in alphavirus infected patients. Structural polyproteins of"/>
   <result pre="which may set off an autoimmune response resulting in rheumatoid" exact="arthritis" post="like symptoms in alphavirus infected patients. Structural polyproteins of"/>
   <result pre="might share homology with sequences in human proteins implicated in" exact="rheumatoid arthritis." post="These conserved regions were validated in silico both at"/>
   <result pre="1 Computational pipeline for the prediction of possible induction of" exact="rheumatoid arthritis" post="through molecular mimicry post alphaviral infection. Multiple sequence alignment"/>
   <result pre="Computational pipeline for the prediction of possible induction of rheumatoid" exact="arthritis" post="through molecular mimicry post alphaviral infection. Multiple sequence alignment"/>
   <result pre="across alpha viruses share homology with human proteins implicated in" exact="arthritis" post="To deduce the possibility of autoimmune reactions involved in"/>
   <result pre="to 100%) with human proteins that have been implicated in" exact="arthritis" post="like conditions in humans (Table 1). Table 1 List"/>
   <result pre="to have antibodies developed against them in patients diagnosed with" exact="rheumatoid arthritis." post="Potential mimic regions harbor HLA binding motifs Human leukocyte"/>
   <result pre="to have antibodies developed against them in patients diagnosed with" exact="rheumatoid arthritis" post="(highlighted in bold in Table 1). To further validate"/>
   <result pre="have antibodies developed against them in patients diagnosed with rheumatoid" exact="arthritis" post="(highlighted in bold in Table 1). To further validate"/>
   <result pre="immunopathology observed at the site of infection and/or sites of" exact="autoimmune disease" post="and normally the infections precede the occurrence of inflammation"/>
   <result pre="common feature of the clinical picture of arthralgia and chronic" exact="arthritis" post="that closely resembles rheumatoid arthritis7,24,25. Further, more severe and"/>
   <result pre="rheumatoid arthritis7,24,25. Further, more severe and delayed recovery of alpha" exact="viral disease" post="in patients with pre-existing arthritic conditions has been reported26."/>
   <result pre="of auto antibodies specific to some of these proteins in" exact="rheumatoid arthritis" post="(Table 1). Serum and synovial fluid from RA patients"/>
   <result pre="auto antibodies specific to some of these proteins in rheumatoid" exact="arthritis" post="(Table 1). Serum and synovial fluid from RA patients"/>
   <result pre="The mouse injected with this peptide recapitulated the pathology seen" exact="chikungunya" post="infection29. These reports give further credibility to our findings"/>
   <result pre="of autoimmunity during alpha virus infections which could culminate in" exact="arthritis" post="like conditions in infected individuals. Figure 7 Highly conserved"/>
   <result pre="has been reported to be involved in the pathogenesis of" exact="rheumatoid arthritis." post="The Open Targets Platform server is a repository of"/>
   <result pre="viral replication complexesPLoS Pathog2016128e100581010.1371/journal.ppat.100581027509095 2.RulliNEMeltonJWilmesAEwartGMahalingamSThe molecular and cellular aspects of" exact="arthritis" post="due to alphavirus infections: lesson learned from Ross River"/>
   <result pre="emerging cause of arthritis?Current opinion in rheumatology200820448649010.1097/BOR.0b013e328303220b18525365 8.GardnerJet al.Chikungunya virus" exact="arthritis" post="in adult wild-type miceJournal of virology201084168021803210.1128/JVI.02603-0920519386 9.MorrisonTEet al.A mouse"/>
   <result pre="adult wild-type miceJournal of virology201084168021803210.1128/JVI.02603-0920519386 9.MorrisonTEet al.A mouse model of" exact="chikungunya" post="virus–induced musculoskeletal inflammatory disease: evidence of arthritis, tenosynovitis, myositis,"/>
   <result pre="tropism and virus-induced inflammation in a mouse model of viral" exact="arthritis" post="and myositisJournal of virology200680273774910.1128/JVI.80.2.737-749.200616378976 11.LidburyBAet al.Macrophage-derived proinflammatory factors contribute"/>
   <result pre="virology200680273774910.1128/JVI.80.2.737-749.200616378976 11.LidburyBAet al.Macrophage-derived proinflammatory factors contribute to the development of" exact="arthritis" post="and myositis after infection with an arthrogenic alphavirusThe Journal"/>
   <result pre="al.Macrophage-derived proinflammatory factors contribute to the development of arthritis and" exact="myositis" post="after infection with an arthrogenic alphavirusThe Journal of infectious"/>
   <result pre="Journal of infectious diseases2008197111585159310.1086/58784118433328 12.NakayaHIet al.Gene profiling of Chikungunya virus" exact="arthritis" post="in a mouse model reveals significant overlap with rheumatoid"/>
   <result pre="virus-induced diseaseJournal of virology200781105132514310.1128/JVI.02799-0617314163 14.BenedekTGThe history of bacteriologic concepts of" exact="rheumatic fever" post="and rheumatoid arthritisSeminars in arthritis and rheumatism200636210912310.1016/j.semarthrit.2006.05.00116884972 15.OlsonJKCroxfordJLCalenoffMADal CantoMCMillerSDA"/>
   <result pre="of bacteriologic concepts of rheumatic fever and rheumatoid arthritisSeminars in" exact="arthritis" post="and rheumatism200636210912310.1016/j.semarthrit.2006.05.00116884972 15.OlsonJKCroxfordJLCalenoffMADal CantoMCMillerSDA virus-induced molecular mimicry model of"/>
   <result pre="10.7861%2Fclinmedicine.16-2-129 (2016). 25.Wesula OliviaLet al.Global emergence of alphaviruses that cause" exact="arthritis" post="in humansInfection ecology &amp;amp; epidemiology2015512985310.3402/iee.v5.2985326689654 26.ChenWet al.Arthritogenic alphaviruses: new"/>
   <result pre="humansInfection ecology &amp;amp; epidemiology2015512985310.3402/iee.v5.2985326689654 26.ChenWet al.Arthritogenic alphaviruses: new insights into" exact="arthritis" post="and bone pathologyTrends in microbiology2015231354310.1016/j.tim.2014.09.00525449049 27.Assunção-MirandaIranaiaCruz-OliveiraChristineDa PoianAndrea T.Molecular Mechanisms"/>
   <result pre="Pathogenesis of Alphavirus-Induced ArthritisBioMed Research International2013201311110.1155/2013/973516 28.SchwartzOAlbertMLBiology and pathogenesis of" exact="chikungunya" post="virusNature Reviews Microbiology20108749110.1038/nrmicro236820551973 29.ReddyVDesaiAKrishnaSSVasanthapuramRMolecular mimicry between chikungunya virus and"/>
   <result pre="and pathogenesis of chikungunya virusNature Reviews Microbiology20108749110.1038/nrmicro236820551973 29.ReddyVDesaiAKrishnaSSVasanthapuramRMolecular mimicry between" exact="chikungunya" post="virus and host components: a possible mechanism for the"/>
   <result pre="44.BiswasSet al.Identification of novel autoantigen in the synovial fluid of" exact="rheumatoid arthritis" post="patients using an immunoproteomics approachPLoS One201382e5624610.1371/journal.pone.005624623418544 45.OokaSMatsuiTNishiokaKKatoTAutoantibodies to low-density-lipoprotein-receptor-related"/>
   <result pre="al.Identification of novel autoantigen in the synovial fluid of rheumatoid" exact="arthritis" post="patients using an immunoproteomics approachPLoS One201382e5624610.1371/journal.pone.005624623418544 45.OokaSMatsuiTNishiokaKKatoTAutoantibodies to low-density-lipoprotein-receptor-related"/>
   <result pre="layer protein in cartilage destruction in subsets of patients with" exact="osteoarthritis" post="and rheumatoid arthritisArthritis &amp;amp; Rheumatism200144483884510.1002/1529-0131(200104)44:4&amp;lt;838::AID-ANR140&amp;gt;3.0.CO;2-C11315923 51.TsuruhaJIet al.Autoimmunity against YKL-39,"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6977312\results\search\disease\results.xml">
   <result pre="in the laboratory [6]. As other arboviral infections including dengue," exact="chikungunya" post="and zika, RVF is emerging worldwide, due to the"/>
   <result pre="RVFV in humans are varied and unspecific including hepatitis, encephalitis," exact="hemorrhagic disease," post="and retinitis with potential dramatic consequences. The overall case"/>
   <result pre="are varied and unspecific including hepatitis, encephalitis, hemorrhagic disease, and" exact="retinitis" post="with potential dramatic consequences. The overall case fatality rate"/>
   <result pre="also reported [17, 37]. RVF differs from influenza, dengue and" exact="chikungunya" post="as to whether cough, skin involvement (i.e. rash or"/>
   <result pre="dengue and chikungunya as to whether cough, skin involvement (i.e." exact="rash" post="or pruritus) and arthritis are respectively uncommon signs. A"/>
   <result pre="to whether cough, skin involvement (i.e. rash or pruritus) and" exact="arthritis" post="are respectively uncommon signs. A slight meningism at the"/>
   <result pre="in 2007 [19] most of RVF severe cases presented with" exact="encephalopathy" post="(respectively 71% and 89%), whereas hemorrhagic manifestations predominated in"/>
   <result pre="in 11/16 (69%) severe cases, of whom 5 (45%) had" exact="encephalitis" post="with hemorrhagic symptoms which were lethal in 2/5 (40%),"/>
   <result pre="of incubation 50–90% of infected people – Prolonged asthenia Arboviruses," exact="influenza" post="virus, HIV (primary infection) Rickettsia spp., Coxiella burnetii, Salmonella"/>
   <result pre="spp., Coxiella burnetii, Salmonella spp., bacterial sepsis Malarial parasites Acute" exact="hepatitis" post="Day 2–21 1–2% of symptomatic cases High in icteric"/>
   <result pre="hepatitis Day 2–21 1–2% of symptomatic cases High in icteric" exact="hepatitis" post="None EBV, CMV, HIV, hepatitis viruses A, B, C,"/>
   <result pre="symptomatic cases High in icteric hepatitis None EBV, CMV, HIV," exact="hepatitis" post="viruses A, B, C, D, E, arboviruses (yellow fever,"/>
   <result pre="influenza, CMV, HSV, VZV, West Nile, chikungunya, dengue and various" exact="encephalitis" post="viruses Rickettsia spp., Borrelia burgdorferi, Treponema pallidum Acute encephalitis"/>
   <result pre="various encephalitis viruses Rickettsia spp., Borrelia burgdorferi, Treponema pallidum Acute" exact="encephalitis" post="Day 2–10 &amp;lt; 1% of symptomatic cases 50% Neurologic disorders"/>
   <result pre="symptomatic cases 50% Neurologic disorders Enteroviruses, measles, mumps, rubella, influenza," exact="rabies" post="viruses, arboviruses (West-Nile, dengue, regional encephalitis), HIV Listeria, Rickettsia,"/>
   <result pre="Rickettsia, Treponema pallidum, Brucella, Borrelia, Leptospirosa spp., Chlamydia, Mycoplasma, ±bacterial" exact="meningitis" post="(meningococcal, pneumococcal) Plasmodium falciparum, Trypanosoma spp., Toxoplasma gondii, Echinococcus,"/>
   <result pre="falciparum, Trypanosoma spp., Toxoplasma gondii, Echinococcus, Cryptococcus, Histoplasma capsulatum Delayed" exact="encephalitis" post="Day 4– 60 1–5% of symptomatic cases &amp;lt; 50% Neurologic"/>
   <result pre="human immunodeficiency virus, EBV Epstein Barr virus, CMV cytomegalovirus, HSV" exact="herpes simplex" post="viruses, VZV varicella zoster virus Risk factors for severe"/>
   <result pre="and RIG-I) were also associated with severe symptomatology [55]. Acute" exact="malaria" post="co-occurrence was observed in severe forms and HIV-positive status"/>
   <result pre="be independently associated with a high mortality rate [40]. Acute" exact="hepatitis" post="may complicate with prolonged blood coagulation times and may"/>
   <result pre="59, 60]. A RVF case with a co-existing condition of" exact="cirrhosis" post="after hepatitis B infection died as a result of"/>
   <result pre="A RVF case with a co-existing condition of cirrhosis after" exact="hepatitis" post="B infection died as a result of gastrointestinal bleeding"/>
   <result pre="infection died as a result of gastrointestinal bleeding and hepatic" exact="encephalitis" post="in Mayotte [28], and 4/31 (13%) severe cases described"/>
   <result pre="described during the epidemic in Mauritania in 2015 had chronic" exact="hepatitis" post="B [61], suggesting that patients with chronic hepatic disorders—mainly"/>
   <result pre="hepatitis B [61], suggesting that patients with chronic hepatic disorders—mainly" exact="hepatitis" post="B chronic infection—could be at higher risk of unfavorable"/>
   <result pre="a key early warning sign) [62], hematemesis or melaena, petechial/purpuric" exact="rash" post="or ecchymoses, menorrhagia, hematuria, or bleeding from venipuncture sites"/>
   <result pre="[64, 65]. Thrombocytopenia is invariably present. Hepato-renal failure with jaundice," exact="disseminated intravascular coagulation" post="and encephalitis can be associated [44, 66]. Overall prevalence"/>
   <result pre="invariably present. Hepato-renal failure with jaundice, disseminated intravascular coagulation and" exact="encephalitis" post="can be associated [44, 66]. Overall prevalence is estimated"/>
   <result pre="occurring on the endothelial surface [69]. Meningoencephalitis The onset of" exact="meningoencephalitis" post="usually occurs 1 to 4 weeks after the first"/>
   <result pre="memory, hallucinations, confusion, disorientation, vertigo, convulsions, ataxia, lethargy, decerebrate posturing," exact="locked-in syndrome" post="and coma [17, 35, 44, 70–73]. In a human"/>
   <result pre="Mauritania in 1989, up to 5% of observed infections had" exact="encephalitis" post="[71]. Two types of pure encephalitis were described: acute"/>
   <result pre="of observed infections had encephalitis [71]. Two types of pure" exact="encephalitis" post="were described: acute febrile forms with short duration and"/>
   <result pre="frequent sequelae [71]. Pulmonary complications may occur [71, 74], and" exact="malaria" post="can worsen the severity of neurologic symptoms [19]. Lethality"/>
   <result pre="clear a cellular CSF were documented in all cases with" exact="encephalitis" post="[71]. In a 18-year old woman treated for chronic"/>
   <result pre="with encephalitis [71]. In a 18-year old woman treated for" exact="chronic myeloid leukemia" post="with acute RVFV encephalitis acquired in Saudi Arabia, CSF"/>
   <result pre="encephalitis [71]. In a 18-year old woman treated for chronic" exact="myeloid leukemia" post="with acute RVFV encephalitis acquired in Saudi Arabia, CSF"/>
   <result pre="[71]. In a 18-year old woman treated for chronic myeloid" exact="leukemia" post="with acute RVFV encephalitis acquired in Saudi Arabia, CSF"/>
   <result pre="old woman treated for chronic myeloid leukemia with acute RVFV" exact="encephalitis" post="acquired in Saudi Arabia, CSF was documented predominantly with"/>
   <result pre="CT-scan of her brain appeared much later [70]. In delayed" exact="meningoencephalitis" post="normal glucose and protein concentrations will lymphocytic pleocytosis were"/>
   <result pre="in CSF [17]. In a kidney transplant recipient with cured" exact="hepatitis" post="B, presenting acute hepatitis followed by delayed pachymeningitis, specific"/>
   <result pre="a kidney transplant recipient with cured hepatitis B, presenting acute" exact="hepatitis" post="followed by delayed pachymeningitis, specific RVF-IgM were detected in"/>
   <result pre="In a mouse model of RVF infection, survivors to primarily" exact="hepatitis" post="cleared the virus from liver and blood, but exhibited"/>
   <result pre="virus from liver and blood, but exhibited neuro-invasion and fatal" exact="encephalitis" post="[57]. Active viral replication in brain leading to necrotizing"/>
   <result pre="encephalitis [57]. Active viral replication in brain leading to necrotizing" exact="encephalitis" post="was documented in several animal models [75, 76]. The"/>
   <result pre="and more severe neuropathology in the murine model and fatal" exact="encephalitis" post="in primates [75, 76]. In aerosol-infected rats with lethal"/>
   <result pre="defect in early T-cells, proinflammatory and antiviral responses in lethal" exact="encephalitis" post="[79]. Other immune disorders and alteration in vascular permeability"/>
   <result pre="creatinine levels may be secondary to hypovolemia, multiple-organ dysfunction, or" exact="hepatorenal syndrome" post="[39, 81]. Acute hepatonephritis, possibly related to direct RVFV"/>
   <result pre="Acute hepatonephritis, possibly related to direct RVFV injury, characterized by" exact="proteinuria" post="and oliguria were also reported with a bad prognosis"/>
   <result pre="in patients with acute renal failure, 25% in those with" exact="hepatorenal syndrome," post="and 31% in patients with primary hepatic involvement and"/>
   <result pre="seen [40, 47, 81]. In 2008 in Mayotte, an acute" exact="pericarditis" post="with symptoms of right-sided heart failure, relapsing at 1"/>
   <result pre="delayed, and may include decreased visual acuity, scotoma, acute hemorrhagic" exact="conjunctivitis" post="and retro-orbital pain [85]. The most frequent and most"/>
   <result pre="and most specific ocular lesion is a macular or paramacular" exact="retinitis" post="[86, 87]. The funduscopy by indirect ophthalmoscopy usually shows"/>
   <result pre="demarcated necrotic lesion with ill-defined creamy-white patchy lesions of macular" exact="retinitis" post="with hemorrhages [84]. The other retinal signs include arterial"/>
   <result pre="with hemorrhages [84]. The other retinal signs include arterial occlusions," exact="vasculitis" post="(mostly phlebitis and sometimes arteritis) [84], sheathing of the"/>
   <result pre="[84]. The other retinal signs include arterial occlusions, vasculitis (mostly" exact="phlebitis" post="and sometimes arteritis) [84], sheathing of the vessels, which"/>
   <result pre="in 15% of cases with retinal involvement, and no infectious" exact="optic neuropathy" post="was reported [84, 85]. Anterior uveitis was associated with"/>
   <result pre="15% of cases with retinal involvement, and no infectious optic" exact="neuropathy" post="was reported [84, 85]. Anterior uveitis was associated with"/>
   <result pre="and no infectious optic neuropathy was reported [84, 85]. Anterior" exact="uveitis" post="was associated with a posterior uveitis, defining a panuveitis"/>
   <result pre="Anterior uveitis was associated with a posterior uveitis, defining a" exact="panuveitis" post="with aqueous flare and fine non-granulomatous keratic precipitates [84,"/>
   <result pre="[84]. However, ophthalmoscopic and angiographic features of the RVFV associated" exact="retinitis" post="are not specific and can be encountered in several"/>
   <result pre="[85, 87–89]. Table 3 Main alternative infectious diagnoses for RVFV" exact="retinitis" post="and their characteristics Retinal lesions Absent lesions Localisation Vitreous"/>
   <result pre="Anterior lesions Keratic lesions Onset Specific treatment Measles virus Diffuse" exact="retinal edema," post="small hemorrhages, exudative stellate macular lesions, attenuate vessels, optic"/>
   <result pre="Retinal necrotic lesions Diffuse No No Punctuate epithelial erosions and" exact="keratitis" post="Few days after the skin rash or later with"/>
   <result pre="Punctuate epithelial erosions and keratitis Few days after the skin" exact="rash" post="or later with SSPE No Rubella virus Chorioretinitis, RPE"/>
   <result pre="later with SSPE No Rubella virus Chorioretinitis, RPE detachment, bullous" exact="retinal detachment" post="Retinal hemorrhages, vasculitis, optic disc edema Posterior pole Mild"/>
   <result pre="optic disc edema Posterior pole Mild vitreous reaction Mild anterior" exact="uveitis" post="Central epithelial keratitis – Topical or oral corticosteroids on"/>
   <result pre="Posterior pole Mild vitreous reaction Mild anterior uveitis Central epithelial" exact="keratitis" post="– Topical or oral corticosteroids on bullous retinal detachment"/>
   <result pre="Central epithelial keratitis – Topical or oral corticosteroids on bullous" exact="retinal detachment" post="Influenza virus Retinal edema, shiny vesicular dots at the"/>
   <result pre="dots at the termination of a capillary, small hemorrhages, serous" exact="retinal detachment," post="frosted branch angiitis, neuroretinitis, optic neuritis, uveal effusion Retinal"/>
   <result pre="capillary, small hemorrhages, serous retinal detachment, frosted branch angiitis, neuroretinitis," exact="optic neuritis," post="uveal effusion Retinal necrotic lesions Macular No Iridocyclitis Interstitial"/>
   <result pre="Interstitial keratitis, marginal corneal ulcers – Oral corticosteroids for serous" exact="retinal detachment," post="macular edema and frosted branch angiitis Borrelia burgdorferi Multifocal"/>
   <result pre="marginal corneal ulcers – Oral corticosteroids for serous retinal detachment," exact="macular edema" post="and frosted branch angiitis Borrelia burgdorferi Multifocal choroiditis, vasculitis,"/>
   <result pre="optic disc edema Retinal necrotic lesions Diffuse Posterior pole if" exact="neuroretinitis" post="Vitritis Granulomatous or non-granulomatous anterior uveitis Stromal keratitis Several"/>
   <result pre="Diffuse Posterior pole if neuroretinitis Vitritis Granulomatous or non-granulomatous anterior" exact="uveitis" post="Stromal keratitis Several weeks after inoculation Ceftriaxone Doxycycline Topical"/>
   <result pre="pole if neuroretinitis Vitritis Granulomatous or non-granulomatous anterior uveitis Stromal" exact="keratitis" post="Several weeks after inoculation Ceftriaxone Doxycycline Topical or systemic"/>
   <result pre="Rickettsia spp. White retinal lesions adjacent to retinal vessels, serous" exact="retinal detachment," post="retinal sheathing, hemorrhages, vascular leakage or occlusions, optic disc"/>
   <result pre="sheathing, hemorrhages, vascular leakage or occlusions, optic disc edema, neuroretinitis," exact="optic neuritis," post="choroidal involvement Retinal scarring Adjacent to retinal vessels Mild"/>
   <result pre="No No – Doxycycline Systemic corticosteroids Dengue virus Maculopathy with" exact="macular edema," post="focal chorioretinitis, yellow subretinal dots, foveolitis, hemorrhages, venular sheathing,"/>
   <result pre="– Doxycycline Systemic corticosteroids Dengue virus Maculopathy with macular edema," exact="focal chorioretinitis," post="yellow subretinal dots, foveolitis, hemorrhages, venular sheathing, disc edema,"/>
   <result pre="dots, foveolitis, hemorrhages, venular sheathing, disc edema, vascular occlusion, exudative" exact="retinal detachment" post="due to vascular leakage – Macular Vitreous hemorrhages –"/>
   <result pre="No Chikungunya virus Multifocal choroiditis, retinal whitening with retinal and" exact="macular edema," post="central retinal artery occlusion, ONH edema when optic neuritis"/>
   <result pre="virus Multifocal choroiditis, retinal whitening with retinal and macular edema," exact="central retinal artery occlusion," post="ONH edema when optic neuritis or neuroretinitis, exudative retinal"/>
   <result pre="and macular edema, central retinal artery occlusion, ONH edema when" exact="optic neuritis" post="or neuroretinitis, exudative retinal detachment – Posterior pole Mild"/>
   <result pre="artery occlusion, ONH edema when optic neuritis or neuroretinitis, exudative" exact="retinal detachment" post="– Posterior pole Mild vitritis Granulomatous or non granulomatous"/>
   <result pre="– Posterior pole Mild vitritis Granulomatous or non granulomatous Anterior" exact="uveitis" post="Keratitis 1 month to 1 year after diagnosis No"/>
   <result pre="pole Along retinal nerve fibers Mild to moderate vitritis Anterior" exact="uveitis" post="No Early, contemporary to the fever No CMV Yellow-white"/>
   <result pre="vascular sheathing, frosted branch angiitis, ONH edema with hemorrhages if" exact="optic neuritis" post="– Perivascular distribution, central (10%) Mild vitreous reaction Mild"/>
   <result pre="– Perivascular distribution, central (10%) Mild vitreous reaction Mild anterior" exact="uveitis" post="No – Ganciclovir Foscarnet HSV Retinal edema, ARN syndrome,"/>
   <result pre="edema, PORN syndrome – Macular, diffuse Mild vitreous reaction Anterior" exact="uveitis" post="with iris atrophy and elevated IOP Dendritic stromal ulcerations"/>
   <result pre="iris atrophy and elevated IOP Dendritic stromal ulcerations or disciform" exact="keratitis" post="– Aciclovir VZV Focal chorioretinitis with exudates and necrotic"/>
   <result pre="Dendritic stromal ulcerations or disciform keratitis – Aciclovir VZV Focal" exact="chorioretinitis" post="with exudates and necrotic lesions, occasional hemorrhages, sheathed vessels,"/>
   <result pre="chorioretinitis with exudates and necrotic lesions, occasional hemorrhages, sheathed vessels," exact="central retinal vein occlusion," post="ONH edema when optic neuritis, ARN syndrome, PORN syndrome"/>
   <result pre="hemorrhages, sheathed vessels, central retinal vein occlusion, ONH edema when" exact="optic neuritis," post="ARN syndrome, PORN syndrome – Usually peripheral, possible macular"/>
   <result pre="Usually peripheral, possible macular extension Vitritis when ARN syndrome Anterior" exact="uveitis" post="Punctuate epithelial keratitis – Acyclovir Treponema pallidum Multifocal chorioretinitis,"/>
   <result pre="macular extension Vitritis when ARN syndrome Anterior uveitis Punctuate epithelial" exact="keratitis" post="– Acyclovir Treponema pallidum Multifocal chorioretinitis, ASPPC with large"/>
   <result pre="Multifocal chorioretinitis, ASPPC with large pale yellowish subretinal lesion, retinitis," exact="vasculitis" post="(arteritis and phlebitis which can be occlusive), exudative retinal"/>
   <result pre="with large pale yellowish subretinal lesion, retinitis, vasculitis (arteritis and" exact="phlebitis" post="which can be occlusive), exudative retinal detachment, neuroretinitis –"/>
   <result pre="retinitis, vasculitis (arteritis and phlebitis which can be occlusive), exudative" exact="retinal detachment," post="neuroretinitis – Multifocal Posterior pole when ASPPC Vitritis or"/>
   <result pre="(arteritis and phlebitis which can be occlusive), exudative retinal detachment," exact="neuroretinitis" post="– Multifocal Posterior pole when ASPPC Vitritis or vitreous"/>
   <result pre="Multifocal Posterior pole when ASPPC Vitritis or vitreous reaction to" exact="chorioretinitis" post="Granulomatous or non- granulomatous anterior uveitis bilateral in 50%"/>
   <result pre="or vitreous reaction to chorioretinitis Granulomatous or non- granulomatous anterior" exact="uveitis" post="bilateral in 50% Stromal keratitis Several weeks after inoculation"/>
   <result pre="Granulomatous or non- granulomatous anterior uveitis bilateral in 50% Stromal" exact="keratitis" post="Several weeks after inoculation Penicillin G Topical or systemic"/>
   <result pre="necrosis, ASPPC acute syphilitic posterior placoid chorioretinopathy, CMV cytomegalovirus, HSV" exact="herpes simplex" post="viruses, VZV varicella zoster virus, SSPE subacute sclerosing panencephalitis"/>
   <result pre="cytomegalovirus, HSV herpes simplex viruses, VZV varicella zoster virus, SSPE" exact="subacute sclerosing panencephalitis" post="Ocular active lesions resolve spontaneously in 10 to 12"/>
   <result pre="12 weeks. Macular or paramacular scarring, vascular occlusions and post-infectious" exact="optic atrophy" post="associated to the central scarring lead to poor visual"/>
   <result pre="85]. No chronic anterior uveitis, posterior synechiae, iris nodules, uveitic" exact="glaucoma" post="nor cataract were described [38, 84, 85]. It is"/>
   <result pre="chronic anterior uveitis, posterior synechiae, iris nodules, uveitic glaucoma nor" exact="cataract" post="were described [38, 84, 85]. It is not known"/>
   <result pre="symptoms [9]. Prolonged and intense viremias were reported during acute" exact="encephalitis" post="and hemorrhagic fever. Thus, testing of serial patient specimens"/>
   <result pre="of a recent RVF infection. In case of delayed-onset of" exact="encephalitis" post="or ocular complications, imputation to RVFV may be difficult"/>
   <result pre="[84]. Aciclovir was used in eyes lesions of other mosquito-transmitted" exact="viral disease" post="notably chikungunya, dengue and West Nile (Table 2) [112]."/>
   <result pre="intraocular pressure, antiglaucoma medications could be useful. Ocular surgery including" exact="cataract" post="removal, retinal hole and detachment repair, vitrectomy, and laser"/>
   <result pre="requiring hospitalization for medical supervision, as we already proposed for" exact="chikungunya" post="[113]. Severe illness included hemorrhagic fever, neurological disorders or"/>
   <result pre="virus ELISA enzyme-linked immunosorbent assay HIV human immunodeficiency virus HSV" exact="herpes simplex" post="viruses HVFs hemorrhagic viral fevers Ig immunoglobulin IPC infection"/>
   <result pre="Rift Valley Fever virus sICAM-1 soluble intracellular adhesion molecule SSPE" exact="subacute sclerosing panencephalitis" post="TLR8 toll-like receptor tPA tissue plasminogen activator TRIF TIR-domain-containing"/>
   <result pre="could be construed as potential competing interests. References References 1.DaubneyRHudsonJRGarnhamPCEnzootic" exact="hepatitis" post="or rift valley fever. An undescribed virus disease of"/>
   <result pre="construed as potential competing interests. References References 1.DaubneyRHudsonJRGarnhamPCEnzootic hepatitis or" exact="rift valley fever." post="An undescribed virus disease of sheep cattle and man"/>
   <result pre="field quantitative real-time PCR test to rapidly identify highly viremic" exact="rift valley fever" post="casesJ Clin Microbiol2009471166117110.1128/JCM.01905-0819171680 55.HiseAGTraylorZHallNBSutherlandLJDahirSErmlerMEet al.Association of symptoms and severity"/>
   <result pre="casesJ Clin Microbiol2009471166117110.1128/JCM.01905-0819171680 55.HiseAGTraylorZHallNBSutherlandLJDahirSErmlerMEet al.Association of symptoms and severity of" exact="rift valley fever" post="with genetic polymorphisms in human innate immune pathwaysPLoS Negl"/>
   <result pre="the epidemic in MauritaniaBull Soc Pathol Exot198982620627 66.Al-KhuwaitirTSAl-MoghairiAMSherbeeniSMAl-GhamdiASRift Valley fever" exact="hepatitis" post="complicated by disseminated intravascular coagulation and hepatorenal syndromeSaudi Med"/>
   <result pre="MauritaniaBull Soc Pathol Exot198982620627 66.Al-KhuwaitirTSAl-MoghairiAMSherbeeniSMAl-GhamdiASRift Valley fever hepatitis complicated by" exact="disseminated intravascular coagulation" post="and hepatorenal syndromeSaudi Med J20042552853115083233 67.AnyanguASGouldLHSharifSKNgukuPMOmoloJOMutongaDet al.Risk factors for"/>
   <result pre="important implications for therapeutic developmentPLoS Negl Trop Dis.20137e215610.1371/journal.pntd.000215623593523 76.HartmanALPowellDSBethelLMCarolineALSchmidRJOuryTet al.Aerosolized" exact="rift valley fever" post="virus causes fatal encephalitis in african green monkeys and"/>
   <result pre="Trop Dis.20137e215610.1371/journal.pntd.000215623593523 76.HartmanALPowellDSBethelLMCarolineALSchmidRJOuryTet al.Aerosolized rift valley fever virus causes fatal" exact="encephalitis" post="in african green monkeys and common marmosetsJ Virol2014882235224510.1128/JVI.02341-1324335307 77.WileyCABhardwajNRossTMBisselSJEmerging"/>
   <result pre="green monkeys and common marmosetsJ Virol2014882235224510.1128/JVI.02341-1324335307 77.WileyCABhardwajNRossTMBisselSJEmerging infections of CNS:" exact="avian influenza" post="A virus, Rift Valley Fever Virus and human parechovirusBrain"/>
   <result pre="monkeys and common marmosetsJ Virol2014882235224510.1128/JVI.02341-1324335307 77.WileyCABhardwajNRossTMBisselSJEmerging infections of CNS: avian" exact="influenza" post="A virus, Rift Valley Fever Virus and human parechovirusBrain"/>
   <result pre="nervous system are inflammatory components of lethal Rift Valley fever" exact="encephalitis" post="in ratsPLoS Pathog201915e100783310.1371/journal.ppat.100783331220182 79.WonderlichERCarolineALMcMillenCMWaltersAWReedDSBarratt-BoyesSMet al.Peripheral blood biomarkers of disease"/>
   <result pre="is a late pathogenic event during Rift Valley fever virus" exact="encephalitis" post="in ratsVirology201952617317910.1016/j.virol.2018.10.02130396029 81.El ImamMEl SabiqMOmranMAbdalkareemAEl Gaili MohamedMAElbashirAet al.Acute renal"/>
   <result pre="etiologies for posterior uveitisOphthalmic Res201349667210.1159/00034400923258387 90.Galindo-CardielIBusquetsNVelardeRAbadFXSolanesDRivasRet al.Lymphoplasmacytic endotheliitis and anterior" exact="uveitis" post="in sheep infected experimentally with rift valley fever virusJ"/>
   <result pre="al.Lymphoplasmacytic endotheliitis and anterior uveitis in sheep infected experimentally with" exact="rift valley fever" post="virusJ Comp Pathol2012146404310.1016/j.jcpa.2011.03.01321601870 91.NiklassonBLiljestrandJBergströmSPetersCJRift Valley fever: a sero-epidemiological survey"/>
   <result pre="mosquito-transmitted diseasesMil Med201818345045810.1093/milmed/usx18329635625 113.SimonFJavelleECabieABouquillardETroisgrosOGentileGet al.French guidelines for the management of" exact="chikungunya" post="(acute and persistent presentations)Med Mal Infect.20154524326310.1016/j.medmal.2015.05.00726119684 114.HassanMMAgarwalAAfridiRMdaSilvaMJBKaracaISadiqMAet al.The role"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6977952\results\search\disease\results.xml">
   <result pre="is properly cited. Abstract At the moment, developing new broad-spectrum" exact="influenza" post="vaccines which would help avoid annual changes in a"/>
   <result pre="urgency. In addition, developing new vaccines based on highly conserved" exact="influenza" post="virus proteins could allow us to better prepare for"/>
   <result pre="a key aspect of the characterization of the effectiveness of" exact="influenza" post="vaccines. In the development of new broad-spectrum influenza vaccines,"/>
   <result pre="effectiveness of influenza vaccines. In the development of new broad-spectrum" exact="influenza" post="vaccines, it is important to study the mechanisms of"/>
   <result pre="antibody-dependent cellular phagocytosis (ADCP), and antibody-mediated complement-dependent cytotoxicity (CDC). The" exact="influenza" post="virus antigens that trigger these reactions are hemagglutinin (HA)"/>
   <result pre="and to the stem domain of hemagglutinin (HA) of the" exact="influenza" post="virus are considered. influenza virus broad-spectrum influenza vaccine antibody-dependent"/>
   <result pre="domain of hemagglutinin (HA) of the influenza virus are considered." exact="influenza" post="virus broad-spectrum influenza vaccine antibody-dependent cellular cytotoxicity antibody-dependent cellular"/>
   <result pre="(HA) of the influenza virus are considered. influenza virus broad-spectrum" exact="influenza" post="vaccine antibody-dependent cellular cytotoxicity antibody-dependent cellular phagocytosis antibody-mediated complement-dependent"/>
   <result pre="children and 5 to 10% of adults are infected with" exact="influenza" post="annually in the world and 250 to 500 thousand"/>
   <result pre="to 500 thousand people die from severe complications of the" exact="influenza" post="infection. In pandemics, the extent of complications and mortality"/>
   <result pre="various sources, around 50 to 100 million people died from" exact="influenza" post="during the 1918–1919 flu pandemic [1]. The most potent"/>
   <result pre="flu pandemic [1]. The most potent protective measure against the" exact="influenza" post="infection and its spread is vaccination. Modern influenza vaccines,"/>
   <result pre="against the influenza infection and its spread is vaccination. Modern" exact="influenza" post="vaccines, as a rule, induce the formation of antibodies"/>
   <result pre="as a rule, induce the formation of antibodies to the" exact="influenza" post="HA and NA surface antigens. The surface proteins of"/>
   <result pre="HA and NA surface antigens. The surface proteins of the" exact="influenza" post="virus undergo constant antigenic drift. Therefore, annual renewal of"/>
   <result pre="is required [2]. To date, the development of new broad-spectrum" exact="influenza" post="vaccines which would help avoid the necessity of annual"/>
   <result pre="addition, the creation of new vaccines based on highly conserved" exact="influenza" post="virus proteins would allow us to better prepare for"/>
   <result pre="damage they cause. The key to evaluating the effectiveness of" exact="influenza" post="vaccines is to determine the level of humoral response"/>
   <result pre="viral infection and undergird the protective mechanisms of all the" exact="influenza" post="vaccines available to date [3]. Most virus-neutralizing antibodies bind"/>
   <result pre="antibodies to cells that have been previously infected with the" exact="influenza" post="virus [7]. Fig. 1 Mechanisms of action of anti-influenza"/>
   <result pre="[7]. Fig. 1 Mechanisms of action of anti-influenza antibodies. The" exact="influenza" post="virus enters the body through respiratory tract mucosa, where"/>
   <result pre="the mucous layer (a). After penetrating the mucous layer, the" exact="influenza" post="virus binds to the sialic acids on the surface"/>
   <result pre="and enters the cell by endocytosis. Neutralizing antibodies bind to" exact="influenza" post="HA and block this process (b).The endosomes of the"/>
   <result pre="complement system (g) Antibodies against various conserved antigens of the" exact="influenza" post="virus (such as NP, M1, M2) are generally non-neutralizing"/>
   <result pre="evaluating the level of such antibodies after immunization with new" exact="influenza" post="vaccines, is relevant for the development of novel broad-spectrum"/>
   <result pre="influenza vaccines, is relevant for the development of novel broad-spectrum" exact="influenza" post="vaccines. ANTIBODIES TO CONSERVED ANTIGENS OF THE INFLUENZA VIRUS"/>
   <result pre="ANTIBODY-MEDIATED COMPLEMENT-DEPENDENT CYTOTOXICITY The ability of antibodies to neutralize the" exact="influenza" post="virus has traditionally been considered the most important mechanism"/>
   <result pre="cellular phagocytosis (ADCP), and antibody-mediated complement-dependent cytotoxicity (CDC) [8]. The" exact="influenza" post="virus antigens that trigger these reactions are HA, NA,"/>
   <result pre="antibody-dependent cellular cytotoxicity (ADCC) in a cell infected with an" exact="influenza" post="virus. IgG binds to the viral antigens on the"/>
   <result pre="is one of the most represented surface proteins of the" exact="influenza" post="virus. For instance, it has been shown that antibodies"/>
   <result pre="against the conserved HA stem protect mice from a lethal" exact="influenza" post="infection through a mechanism that involves an interaction with"/>
   <result pre="interaction with FcγR [11]. Furthermore, re-infection of macaques with the" exact="influenza" post="virus has led to a rapid appearance of ADCC"/>
   <result pre="viruses close to the strain that caused the 2009 swine" exact="influenza" post="pandemic and who retained a significant amount of titers"/>
   <result pre="but had no neutralizing antibodies were protected from the pandemic" exact="influenza" post="virus. Thus, non-neutralizing HA stem-specific antibodies capable of inducing"/>
   <result pre="are directly related to the level of protection against an" exact="influenza" post="virus [14]. In addition, according to published data, vaccines"/>
   <result pre="[14]. In addition, according to published data, vaccines against seasonal" exact="influenza" post="viruses weakly induce the production of antibodies that can"/>
   <result pre="over a lifetime as a result of re-infection with various" exact="influenza" post="virus strains [15]. Using a panel of 13 monoclonal"/>
   <result pre="[15]. Using a panel of 13 monoclonal antibodies to the" exact="influenza" post="virus HA protein (both neutralizing and non-neutralizing ones, both"/>
   <result pre="not only certain HA-specific antibodies, but also antibodies to other" exact="influenza" post="antigens exposed on the surface of an infected cell,"/>
   <result pre="amount of the antibody involved in the interaction with the" exact="influenza" post="virus. It should be noted that, during viral infection,"/>
   <result pre="(NP), also contribute to the ADCC response. For instance, the" exact="influenza" post="infection and vaccination induce the production of antibodies to"/>
   <result pre="involved in ADCC [17, 18]. It has been shown that" exact="influenza" post="virus NP is expressed on the surface of infected"/>
   <result pre="vaccination of laboratory mice with soluble recombinant NP of the" exact="influenza" post="A virus induces high titers of antibodies to NP"/>
   <result pre="vaccination reduced the manifestation of disease symptoms and decreased the" exact="influenza" post="virus titers in the lungs of the influenza-infected animals"/>
   <result pre="immunized mice to naive animals also provided protection against an" exact="influenza" post="infection [22]. Subsequent studies have demonstrated that the protective"/>
   <result pre="the protective effects of the serum of mice immunized with" exact="influenza" post="A recombinant NP upon passive transfer to animals with"/>
   <result pre="not infants) contains antibodies to various proteins of the H7N9" exact="influenza" post="A virus that are involved in the ADCC response,"/>
   <result pre="NA. The level of antibodies to NP of the seasonal" exact="influenza" post="A viruses that are involved in ADCC correlated with"/>
   <result pre="with the level of antibodies to NP of the H7N9" exact="influenza" post="A virus. Therefore, production of these antibodies that cross-react"/>
   <result pre="assumed to be triggered by vaccination and infection with seasonal" exact="influenza" post="A viruses [25]. The antibodies to influenza A virus"/>
   <result pre="infection with seasonal influenza A viruses [25]. The antibodies to" exact="influenza" post="A virus NP involved in ADCC were found in"/>
   <result pre="in ADCC were found in children vaccinated with seasonal inactivated" exact="influenza" post="virus vaccines. NP-specific antibodies that can interact with FcγRIIIa"/>
   <result pre="activation against virus-infected cells expressing NP [13, 26]. Another conserved" exact="influenza" post="protein found on the surface of infected cells is"/>
   <result pre="channel. Antibodies to this protein can protect mice from an" exact="influenza" post="virus infection in laboratory experiments. Moreover, in the immunization"/>
   <result pre="anti-M2e antibodies [28, 29]. The human monoclonal antibody against the" exact="influenza" post="A (Ab1-10) virus M2 protein was able to activate"/>
   <result pre="against both target cells expressing M2 and cells infected with" exact="influenza" post="[30]. Fig. 3 Evaluation of ADCC in the laboratory."/>
   <result pre="ADCC in the laboratory. (a) Evaluation of ADCC using immobilized" exact="influenza" post="virus antigens. Firstly, antigens are immobilized, washed, and incubated"/>
   <result pre="and interferon gamma are used). (b) Evaluation of ADCC using" exact="influenza" post="virus-infected cells or target cells expressing the major viral"/>
   <result pre="of the most important antibody-induced effector defense mechanisms against the" exact="influenza" post="virus. FcγR-/- mice have been shown to be highly"/>
   <result pre="FcγR-/- mice have been shown to be highly sensitive to" exact="influenza" post="even in the presence of influenza antibodies obtained from"/>
   <result pre="be highly sensitive to influenza even in the presence of" exact="influenza" post="antibodies obtained from FcγR+/+ mice. Moreover, the absence of"/>
   <result pre="some non-neutralizing human broad-spectrum monoclonal antibodies protect mice from an" exact="influenza" post="infection through Fc-mediated recruitment of effector cells, with the"/>
   <result pre="action of the antibodies binding to the ectodomain of the" exact="influenza" post="M2 ion channel. Respiratory tract epithelial cells infected with"/>
   <result pre="M2 ion channel. Respiratory tract epithelial cells infected with the" exact="influenza" post="A virus expose the HA, NA, and M2 viral"/>
   <result pre="experiments on protecting animals from infection with homologous and heterologous" exact="influenza" post="A virus strains [37]. Interestingly, the ability of alveolar"/>
   <result pre="alveolar macrophages to protect the lungs from damage during an" exact="influenza" post="infection is reduced in elderly mice [38]. In addition"/>
   <result pre="populations can also participate in the ADCP-mediated response to the" exact="influenza" post="virus. For instance, neutrophils, which are the largest in"/>
   <result pre="[40, 41]. A study of the ADCP mechanism in the" exact="influenza" post="infection showed that both macrophages and neutrophils are quickly"/>
   <result pre="in virus shedding [42]. It is assumed that each subsequent" exact="influenza" post="infection, as well as influenza vaccinations, slightly induces the"/>
   <result pre="is assumed that each subsequent influenza infection, as well as" exact="influenza" post="vaccinations, slightly induces the cross-reactive antibodies involved in ADCP,"/>
   <result pre="involved in ADCP, with their level increasing with each subsequent" exact="influenza" post="infection [17]. Various anti-influenza antibodies, including antibodies to the"/>
   <result pre="responsible for ADCP is studied as follows: target cells expressing" exact="influenza" post="antigens are labeled with an intravital dye, then the"/>
   <result pre="complement system is necessary to protect mice from a lethal" exact="influenza" post="infection [44]. In 1983, it was established that human"/>
   <result pre="established that human serum contains antibodies capable of neutralizing the" exact="influenza" post="virus by activating the classical complement pathway [45]. To"/>
   <result pre="classical complement pathway [45]. To date it is known that" exact="influenza" post="virions can activate both the classical and alternative complement"/>
   <result pre="virus-like particles carrying the M2e proteins of human, porcine, and" exact="avian influenza" post="A viruses, as well as virus-like particles carrying HA"/>
   <result pre="particles carrying the M2e proteins of human, porcine, and avian" exact="influenza" post="A viruses, as well as virus-like particles carrying HA"/>
   <result pre="as well as virus-like particles carrying HA of the H5-subtype" exact="influenza" post="A virus. It turned out that immunization with the"/>
   <result pre="M2e vaccine did not protect C3 knockout mice from the" exact="influenza" post="A viruses, while even low levels of antibodies to"/>
   <result pre="M2e protein were enough to protect wild-type animals from the" exact="influenza" post="A virus infection upon passive transfer. On the contrary,"/>
   <result pre="strain-specific neutralizing antibodies, were protected from infection with a homologous" exact="influenza" post="virus despite the low level of antibody response [47]."/>
   <result pre="Thus, one can state the ability of antibodies to the" exact="influenza" post="virus M2 ion channel to protect against influenza A"/>
   <result pre="to the influenza virus M2 ion channel to protect against" exact="influenza" post="A virus infection through the activation of the complement"/>
   <result pre="infected cells. For instance, vaccination with a seasonal trivalent inactivated" exact="influenza" post="vaccine led to an increase in the level of"/>
   <result pre="was not pronounced [48]. CDC-inducing antibodies were detected among both" exact="influenza" post="HA head-specific and stem-specific antibodies. Meanwhile, antibodies to the"/>
   <result pre="of action and were able to induce CDC against different" exact="influenza" post="A strains [49]. Antibodies of the IgG1 and IgM"/>
   <result pre="involved in CDC correlated with the protection against a seasonal" exact="influenza" post="virus in children [32]. The activity of antibodies in"/>
   <result pre="by the rate of death of target cells expressing the" exact="influenza" post="antigen or infected with an influenza virus in solutions"/>
   <result pre="target cells expressing the influenza antigen or infected with an" exact="influenza" post="virus in solutions containing complement components and antibodies. Cell"/>
   <result pre="serum of people who have been infected bind to different" exact="influenza" post="strains, providing ground for the development of broad-spectrum vaccines"/>
   <result pre="broad-spectrum vaccines based on this antigen [52]. Antibodies to the" exact="influenza" post="virus HA stem The HA stem is more conserved"/>
   <result pre="neutralizing HA stem-specific antibodies is detected in humans after an" exact="influenza" post="infection or vaccination, with the infection being more effective"/>
   <result pre="pseudotyped viral vectors [55]. The latter present chimeric viruses carrying" exact="influenza" post="virus surface antigens that do not contain any genetic"/>
   <result pre="pseudoviruses are usually derived from lentiviral vectors and the vesicular" exact="stomatitis" post="virus. They allow avoidance of highly pathogenic influenza strains"/>
   <result pre="the vesicular stomatitis virus. They allow avoidance of highly pathogenic" exact="influenza" post="strains when performing a neutralization reaction (which is especially"/>
   <result pre="stem-specific antibodies than the conventional neutralization assay [55]. Antibodies to" exact="influenza" post="virus neuraminidase Influenza virus neuraminidase is involved in various"/>
   <result pre="the sialylated glycans of another one [56]. Antibodies to the" exact="influenza" post="virus NA can interfere with any of these processes"/>
   <result pre="HA-specific antibodies, NA-specific antibodies can protect laboratory animals from an" exact="influenza" post="infection [57]. Moreover, the presence of NA-specific antibodies also"/>
   <result pre="presence of NA-specific antibodies also correlates with protection against an" exact="influenza" post="virus in humans. The titer of anti-NA antibody has"/>
   <result pre="The production of antibodies to neuraminidase is induced by an" exact="influenza" post="infection. However, their level is usually lower than that"/>
   <result pre="infection bind to a wide range of modern and historical" exact="influenza" post="strains, inhibit NA activity, and protect laboratory mice in"/>
   <result pre="of broad-spectrum vaccines that induce the formation of antibodies to" exact="influenza" post="NA exist. One of them is the creation of"/>
   <result pre="N7, N8, N9, and etc.) associated with human and zoonotic" exact="influenza" post="strains. It is also possible to include NA as"/>
   <result pre="NA as an additional antigen in vaccines based on conserved" exact="influenza" post="antigens: such as M2, NP, etc. [58]. ELISA is"/>
   <result pre="of these antibodies were considered. Antibodies can provide protection against" exact="influenza" post="via Fc-independent or Fc-dependent mechanisms. Fc-independent antibodies directly neutralize"/>
   <result pre="strain-specific, are mainly involved in the direct neutralization of the" exact="influenza" post="virus. As a rule, Fc-dependent antibodies are non-neutralizing but"/>
   <result pre="of the HA, NA, M2, or NP proteins of the" exact="influenza" post="virus, and most of them are broad-spectrum antibodies [11,"/>
   <result pre="of them are broad-spectrum antibodies [11, 21, 28, 58]. The" exact="influenza" post="vaccines currently being developed are aimed at generating an"/>
   <result pre="immune response not mainly to the conventional HA and NA" exact="influenza" post="antigens, but to various conserved viral antigens. When creating"/>
   <result pre="The traditional methods for assessing the humoral immune response to" exact="influenza" post="vaccines by hemagglutination and neutralization reactions will no longer"/>
   <result pre="that can provide protection against both seasonal and potentially pandemic" exact="influenza" post="virus strains. Abbreviations ADCC antibody-dependent cellular cytotoxicity ADCP antibody-dependent"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6979359\results\search\disease\results.xml">
   <result pre="Journal1743-422XBioMed CentralLondon pmcid: 69793591277 doi: 10.1186/s12985-019-1277-7 : Review Recent sylvatic" exact="yellow fever" post="virus transmission in Brazil: the news from an old"/>
   <result pre="unless otherwise stated. Abstract Yellow fever (YF) is an acute" exact="viral disease," post="affecting humans and non-human primates (NHP), caused by the"/>
   <result pre="disease, affecting humans and non-human primates (NHP), caused by the" exact="yellow fever" post="virus (YFV). Despite the existence of a safe vaccine,"/>
   <result pre="and Technological Development (CNPq)440593/2016-6 Background Yellow fever virus (YFV) causes" exact="yellow fever" post="(YF), an acute disease affecting humans and non-human primates"/>
   <result pre="fitness should be investigated [19, 22]. Recent clinical findings in" exact="yellow fever" post="patients YF has been described as a viscerotropic disease"/>
   <result pre="hemorrhagic signs [24–27]. Recently, in severe YF cases, a critical" exact="metabolic acidosis" post="leading to the need for hemodialysis [25], increased levels"/>
   <result pre="of serum lipase [25, 28] and a high prevalence of" exact="pancreatitis" post="were observed [25]. These studies highlighted the importance of"/>
   <result pre="pancreatitis were observed [25]. These studies highlighted the importance of" exact="pancreatitis" post="in the evolution of YF and the need for"/>
   <result pre="circulation, due to the loss of naïve sentinel NHP. Sylvatic" exact="yellow fever" post="in Brazil During the 18th and 19th centuries, YFV"/>
   <result pre="and North regions (Fig. 1) [55, 60–73]. Fig. 1 Sylvatic" exact="yellow fever" post="(YF) human cases and epizootics occurrence in Brazil, from"/>
   <result pre="Ministry of Health Brazil and State Health Departments [60–73]. YF:" exact="yellow fever." post="H: humans. NHP: non-human primates In Brazil, most of"/>
   <result pre="reaching extensive YF-free areas. Fig. 2 Historical series of sylvatic" exact="yellow fever" post="human cases in Brazil, from 1980 to June 2019."/>
   <result pre="group sizes of some monkeys lead to lower rates of" exact="malaria" post="in Amazonian NHP [106]. Some NHP species exhibiting less"/>
   <result pre="geographic distribution and behavioral patterns could favor infection. Pathogenesis of" exact="yellow fever" post="in non-human primates Most of the knowledge about the"/>
   <result pre="intestinal bleeding, liver injury with hemorrhagic and necrosis foci, and" exact="kidney failure" post="[33, 137, 142]. There are few descriptions of YF"/>
   <result pre="liver hemorrhage, inflammatory mononuclear cell infiltration of the liver, renal" exact="acute tubular necrosis," post="and interstitial nephritis [139]. Recent YF outbreaks in Brazil"/>
   <result pre="cell infiltration of the liver, renal acute tubular necrosis, and" exact="interstitial nephritis" post="[139]. Recent YF outbreaks in Brazil opened an opportunity"/>
   <result pre="infiltration of the liver, renal acute tubular necrosis, and interstitial" exact="nephritis" post="[139]. Recent YF outbreaks in Brazil opened an opportunity"/>
   <result pre="future distributions of the sylvatic cycles of dengue virus and" exact="yellow fever" post="virusInfect Genet Evol20131929231110.1016/j.meegid.2013.03.00823523817 8.KlittingRGouldEPaupyCde LamballerieXWhat Does the Future Hold"/>
   <result pre="of Yellow Fever Virus into the AmericasPLoS Pathogens200735e7510.1371/journal.ppat.003007517511518 17.MirDDelatorreEBonaldoMLourenço-De-OliveiraRVicenteACBelloGPhylodynamics of" exact="yellow fever" post="virus in the Americas: new insights into the origin"/>
   <result pre="RB, Rodrigues SG, Barrett ADT. Genetic divergence and dispersal of" exact="yellow fever" post="virus. Emerg Infect Dis. 2004;10(9):1578. 19.BonaldoMCGómezMMDos SantosAACDe AbreuFVSFerreira-de-BritoADe MirandaRMet"/>
   <result pre="Infect Dis. 2004;10(9):1578. 19.BonaldoMCGómezMMDos SantosAACDe AbreuFVSFerreira-de-BritoADe MirandaRMet al.Genome analysis of" exact="yellow fever" post="virus of the ongoing outbreak in Brazil reveals polymorphismsMem"/>
   <result pre="Oswaldo Cruz201711244745110.1590/0074-0276017013428591405 20.CunhaMSda CostaACde Azevedo FernandesNCCGuerraJMdos SantosFCPNogueiraJSet al.Epizootics due to" exact="yellow fever" post="virus in São Paulo state, Brazil: viral dissemination to"/>
   <result pre="RS, Iani FCM, et al. Genomic and epidemiological monitoring of" exact="yellow fever" post="virus transmission potential. Science. 2018;361:894–9. 22.GómezMMde AbreuFVSDos SantosAACde MelloISSantosMPRibeiroIPet"/>
   <result pre="22.GómezMMde AbreuFVSDos SantosAACde MelloISSantosMPRibeiroIPet al.Genomic and structural features of the" exact="yellow fever" post="virus from the 2016-2017 Brazilian outbreakJ Gen Virol20189953654810.1099/jgv.0.00103329469689 23.QuaresmaJASPagliariCMedeirosDBADuarteMISVasconcelosPFCImmunity"/>
   <result pre="HiromiCostaZouraide Guerra Antunesda Costa VasconcelosPedro FernandoHatchDouglasClinical and epidemiological characteristics of" exact="yellow fever" post="in Brazil: analysis of reported cases 1998–2002Transactions of the"/>
   <result pre="GFC, Malbouisson LMS, Song ATW, Perondi B, et al. Severe" exact="yellow fever" post="in Brazil: clinical characteristics and management. J Travel Med."/>
   <result pre="viral load) are prognostic factors for the evolution of severe" exact="yellow fever" post="cases. Mem Inst Oswaldo Cruz. 2019;114:e190033. 29.MarinhoPaula E.S.AlvarengaPedro P.M.CrispimAna"/>
   <result pre="NC, Simon F, et al. Hepatitis rebound after infection with" exact="yellow fever" post="virus. Emerg Infect Dis. 2019;25(6):1248. 32.MS-BR. GUIA DE VIGILÂNCIA"/>
   <result pre="única FA.pdf.[cited 2019 Jul 18]. 41.Collaborative group for studies on" exact="yellow fever" post="vaccines. Duration of post-vaccination immunity against yellow fever in"/>
   <result pre="studies on yellow fever vaccines. Duration of post-vaccination immunity against" exact="yellow fever" post="in adults. Vaccine. 2014;32(39):4977–84. 42.Campi-AzevedoACCosta-PereiraCAntonelliLRFonsecaCTTeixeira-CarvalhoAVillela-RezendeGet al.Booster dose after 10"/>
   <result pre="Diseases2018126e000646210.1371/journal.pntd.000646229879134 44.WHO. Detection and investigation of serious adverse events following" exact="yellow fever" post="vaccination - Guidance from an informal consultation of experts"/>
   <result pre="2019 Jul 2] 47.SelemaneIsmaelEpidemiological monitoring of the last outbreak of" exact="yellow fever" post="in Brazil – An outlook from PortugalTravel Medicine and"/>
   <result pre="57.de AbreuFVSDelatorreEDos SantosAACFerreira-de-BritoAde CastroMGRibeiroIPet al.Combination of surveillance tools reveals that" exact="yellow fever" post="virus can remain in the same Atlantic Forest area"/>
   <result pre="and Haemagogus janthinomys are the primary vectors in the major" exact="yellow fever" post="outbreak in Brazil, 2016–2018. Emerg Microbes Infect. 2019;8:218–31. 76.Cardoso"/>
   <result pre="[cited 2019 Jun 20] 82.DegallierNda Rosa APATHerveJPA comparative study of" exact="yellow fever" post="in Africa and South AmericaCienc Cult199244143151 83.AlencarJde MelloCFBarbosaLSGil-SantanaHRde AMDMarcondesCBet"/>
   <result pre="Africa and South AmericaCienc Cult199244143151 83.AlencarJde MelloCFBarbosaLSGil-SantanaHRde AMDMarcondesCBet al.Diversity of" exact="yellow fever" post="mosquito vectors in the Atlantic forest of Rio de"/>
   <result pre="Culicidae) do Brasil. Rev Biomed. 2010. 86.WHO. Risk assessment on" exact="yellow fever" post="virus circulation in endemic countries - WHO [Internet]. World"/>
   <result pre="BrazilJournal of the American Mosquito Control Association201632432933210.2987/16-6587.128206862 92.PinheiroGGRochaMNde OliveiraMAMoreiraLAFilhoJDADetection of" exact="yellow fever" post="virus in sylvatic mosquitoes during disease outbreaks of 2017-2018"/>
   <result pre="R.BallingerMary E.Aedes albopictus mosquitoes introduced into Brazil: vector competence for" exact="yellow fever" post="and dengue virusesTransactions of the Royal Society of Tropical"/>
   <result pre="Medicine and Hygiene198882347647710.1016/0035-9203(88)90168-X3232189 95.MassadEduardoCoutinhoFrancisco Antonio BezerraBurattiniMarcelo NascimentoLopezLuiz FernandesThe risk of" exact="yellow fever" post="in a dengue-infested areaTransactions of the Royal Society of"/>
   <result pre="of Brazilian Aedes aegypti and Ae. albopictus for a Brazilian" exact="yellow fever" post="virus isolateTransactions of the Royal Society of Tropical Medicine"/>
   <result pre="Brazil: genetically differentiated populations with high susceptibility to dengue and" exact="yellow fever" post="virusesTransactions of the Royal Society of Tropical Medicine and"/>
   <result pre="reaction of a species of colobus monkey to inoculation with" exact="yellow fever" post="virusAnnals of Tropical Medicine &amp;amp; Parasitology196862452853510.1080/00034983.1968.116865944389548 110.Taufflieb R, Robin"/>
   <result pre="ORSTOM Série Entomol Médicale Parasitol. 1971;9:351–71. 111.TaylorRMHaseebMAWorkTHA regional reconnaissance on" exact="yellow fever" post="in the Sudan. With special reference to primate hostsBull"/>
   <result pre="hostsBull World Health Organ19551271172514379007 112.DavisNCSusceptibility of capuchin (Cebus) monkeys to" exact="yellow fever" post="virusAm J Epidemiol19301132133410.1093/oxfordjournals.aje.a113835 113.DavisNCThe susceptibility of marmosets to yellow"/>
   <result pre="yellow fever virusAm J Epidemiol19301132133410.1093/oxfordjournals.aje.a113835 113.DavisNCThe susceptibility of marmosets to" exact="yellow fever" post="virusJ Exp Med19305240541610.1084/jem.52.3.40519869773 114.Davis NC. The transmission of yellow"/>
   <result pre="JI, Ferreyra H, Beldomenico P, di Bitetti MS. Impact of" exact="yellow fever" post="outbreaks on two howler monkey species (Alouatta Guariba clamitans"/>
   <result pre="HW, Ferreira LC, Taylor RM. An epidemiological Study of jungle" exact="yellow fever" post="in a endemic area in Brazil. Part II –"/>
   <result pre="Journal of Tropical Medicine and Hygiene1950s1-30572373110.4269/ajtmh.1950.s1-30.723 123.Galindo P. Monkeys and" exact="yellow fever." post="In: Nonhum Primates Med Res. 3rd ed: Academic Press,"/>
   <result pre="guariba clamitans and Alouatta caraya) in northeastern ArgentinaPrimates200849430430710.1007/s10329-008-0106-118855099 127.Vargas-MendezOEltonNWNaturally acquired" exact="yellow fever" post="in wild monkeys of Costa Rica1Am J Trop Med"/>
   <result pre="organization in howling monkeysAm Philos Soc195296143156 129.AugusteAJLemeyPBergrenNAGiambalvoDMoncadaMMorónDet al.Enzootic transmission of" exact="yellow fever" post="virusVenezuela Emerg Infect Dis2015219910210.3201/eid2101.14081425531105 130.RifakisPMBenitezJADe-La-Paz-PinedaJRodriguez-MoralesAJEpizootics of yellow fever in"/>
   <result pre="transmission of yellow fever virusVenezuela Emerg Infect Dis2015219910210.3201/eid2101.14081425531105 130.RifakisPMBenitezJADe-La-Paz-PinedaJRodriguez-MoralesAJEpizootics of" exact="yellow fever" post="in Venezuela (2004-2005): an emerging zoonotic diseaseAnn N Y"/>
   <result pre="Capture of Alouatta guariba clamitans for the surveillance of sylvatic" exact="yellow fever" post="and zoonotic malaria: Which is the best strategy in"/>
   <result pre="J Primatol. 2019: e23000. 137.FigueiredoPOSilvaATSOliveiraJSMarinhoPERochaFTDomingosGPet al.Detection and molecular characterization of" exact="yellow fever" post="virus, 2017Brazil Ecohealth20181586487010.1007/s10393-018-1364-z30117000 138.FernandesNCCCunhaMSGuerraJMRéssioRACirqueiraCSS.DIet al.Outbreak of yellow fever among"/>
   <result pre="characterization of yellow fever virus, 2017Brazil Ecohealth20181586487010.1007/s10393-018-1364-z30117000 138.FernandesNCCCunhaMSGuerraJMRéssioRACirqueiraCSS.DIet al.Outbreak of" exact="yellow fever" post="among nonhuman primates, Espirito Santo, Brazil, 2017Emerg Infect Dis2017232038204110.3201/eid2312.17068529148378"/>
   <result pre="changes in Howler monkeys ( Alouatta sp.) naturally infected with" exact="yellow fever" post="virus in BrazilRevista da Sociedade Brasileira de Medicina Tropical2016491293310.1590/0037-8682-0363-201527163561"/>
   <result pre="the American Medical Association192890425310.1001/jama.1928.02690310005002 141.BearcroftWGCThe histopathology of the liver of" exact="yellow fever" post="infected rhesus monkeysJ Pathol1957LXXI29530310.1002/path.1700740207 142.EngelmannFloraJossetLaurenceGirkeThomasParkByungBarronAlexDewaneJesseHammarlundErikaLewisAnneAxthelmMichael K.SlifkaMark K.MessaoudiIlhemPathophysiologic and Transcriptomic"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6981203\results\search\disease\results.xml">
   <result pre="are susceptible to RSV-induced lower respiratory tract infections (LRTI) causing" exact="bronchiolitis" post="and pneumonia. Severe RSV disease occurs most commonly in"/>
   <result pre="the cellular compartment of the bronchoalveolar lavage (BAL) during RSV-induced" exact="bronchiolitis" post="in infants11. Neutrophils are phagocytic cells that can be"/>
   <result pre="to minimize bystander damage, a cause of immunopathology during both" exact="infectious disease" post="and sterile inflammation16,17. Neutrophils are particularly important in the"/>
   <result pre="methods of attack. However, circulating neutrophils are a predictor of" exact="pneumonia" post="risk in patients with chronic obstructive pulmonary disease18 and,"/>
   <result pre="demonstrate that neutrophils can be both beneficial and detrimental during" exact="influenza" post="virus and pneumonia virus of mice (PVM) infection suggesting"/>
   <result pre="can be both beneficial and detrimental during influenza virus and" exact="pneumonia" post="virus of mice (PVM) infection suggesting that the role"/>
   <result pre="found to be more prevalent in infants hospitalized with RSV-induced" exact="bronchiolitis" post="compared to controls28. To study the contribution of neutrophils"/>
   <result pre="influences the severity of disease. In children with RSV induced" exact="bronchiolitis" post="airway neutrophils are prominent during the peak of disease24."/>
   <result pre="that neutrophils can influence adaptive and memory responses in other" exact="infectious disease" post="scenarios32,42. Humans are unable to generate lasting, effective antibody"/>
   <result pre="found that the release of mature IL-1β from AMs during" exact="influenza" post="infection requires a neutrophil-derived peptide22. Together these studies highlight"/>
   <result pre="did not reduce weight loss in RSV infected mice. During" exact="influenza" post="infection, neutrophils have been shown to guide the recruitment"/>
   <result pre="Indeed, neutrophils contribute to disease severity during infection with numerous" exact="influenza" post="virus strains20,59. However, not all studies on influenza virus"/>
   <result pre="with numerous influenza virus strains20,59. However, not all studies on" exact="influenza" post="virus infection after neutrophil depletion are in agreement on"/>
   <result pre="8.CarrollKecia N.WuPingshengGebretsadikTebebGriffinMarie R.DupontWilliam D.MitchelEdward F.HartertTina V.The severity-dependent relationship of infant" exact="bronchiolitis" post="on the risk and morbidity of early childhood asthmaJournal"/>
   <result pre="childhood asthmaJournal of Allergy and Clinical Immunology200912351055-1061.e110.1016/j.jaci.2009.02.02119361850 9.MDLBBet al.Determinants of" exact="asthma" post="after severe respiratory syncytial virus bronchiolitisJ. Allergy Clin. Immunol.201213091100.e310.1016/j.jaci.2012.02.01022444510"/>
   <result pre="NeutrophilsCell Host Microbe20141552653610.1016/j.chom.2014.04.01124832448 18.PascoeSJPapiAMidwinterDLettisSBarnesNCirculating neutrophils levels are a predictor of" exact="pneumonia" post="risk in chronic obstructive pulmonary diseaseRespiratory Reserach20192011010.1186/s12931-018-0967-9 19.ToussaintMet al.Host"/>
   <result pre="Reserach20192011010.1186/s12931-018-0967-9 19.ToussaintMet al.Host DNA released by NETosis promotes rhinovirus-induced type-2" exact="allergic asthma" post="exacerbationNat. Med.20172368169110.1038/nm.433228459437 20.TateMDet al.Neutrophils ameliorate lung injury and the"/>
   <result pre="19.ToussaintMet al.Host DNA released by NETosis promotes rhinovirus-induced type-2 allergic" exact="asthma" post="exacerbationNat. Med.20172368169110.1038/nm.433228459437 20.TateMDet al.Neutrophils ameliorate lung injury and the"/>
   <result pre="ameliorate lung injury and the development of severe disease during" exact="influenza" post="infectionJ. Immunol.20091837441745010.4049/jimmunol.090249719917678 21.TateMDBrooksAGReadingPCMinternJDNeutrophils sustain effective CD8(+) T-cell responses in"/>
   <result pre="sustain effective CD8(+) T-cell responses in the respiratory tract following" exact="influenza" post="infectionImmunol. Cell Biol.20129019720510.1038/icb.2011.2621483446 22.PeiróTet al.Neutrophils drive alveolar macrophage IL-1β"/>
   <result pre="is related to the severity of a first acute epidemic" exact="bronchiolitis" post="in young infantsPediatr. Allergy Immunol.20081915716510.1111/j.1399-3038.2007.00600.x18093085 28.HullJThomsonAKwiatkowskiDAssociation of respiratory syncytial"/>
   <result pre="in young infantsPediatr. Allergy Immunol.20081915716510.1111/j.1399-3038.2007.00600.x18093085 28.HullJThomsonAKwiatkowskiDAssociation of respiratory syncytial virus" exact="bronchiolitis" post="with the interleukin 8 gene region in UK familiesThorax2000551023102710.1136/thorax.55.12.102311083887"/>
   <result pre="Immunology201617172010.1038/nri.2016.11727890913 60.TateMDet al.The role of neutrophils during mild and severe" exact="influenza" post="virus infections of micePLoS ONE20116e1761810.1371/journal.pone.001761821423798 61.NarasarajuTet al.Excessive Neutrophils and"/>
   <result pre="neutrophil levels in the lung underlie the age-associated increase in" exact="influenza" post="mortalityMucosal immunology20191254555410.1038/s41385-018-0115-330617300 63.CortjensBet al.Neutrophil Extracellular Traps Cause Airway Obstruction"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6983437\results\search\disease\results.xml">
   <result pre="5-lipoxygenase product by daidzein is involved in the regulation of" exact="influenza" post="virus replication HorioYuka1†SogabeRiho1†ShichiriMototada23†IshidaNoriko2MorimotoRyosuke1OhshimaAtsushi4IsegawaYuji15*[1], [2], [3], [4], [5], †These authors"/>
   <result pre="This study was conducted to evaluate the regulation mechanism of" exact="influenza" post="virus replication following treatment of Madin-Darby canine kidney cells"/>
   <result pre="daidzein regulates virus replication via signal transduction through 5-lipoxygenase products." exact="influenza" post="virus daidzein lipid peroxide signal transduction lipoxygenase Introduction Influenza"/>
   <result pre="losses.(1) Influenza virus infections can cause severe complications such as" exact="pneumonia" post="and encephalitis and can increase the rate of hospitalization"/>
   <result pre="virus infections can cause severe complications such as pneumonia and" exact="encephalitis" post="and can increase the rate of hospitalization and mortality,"/>
   <result pre="neuraminidase inhibitors zanamivir and oseltamivir have been used to treat" exact="influenza" post="virus infections. Recently, neuraminidase inhibitor-resistant influenza A viruses were"/>
   <result pre="been used to treat influenza virus infections. Recently, neuraminidase inhibitor-resistant" exact="influenza" post="A viruses were reported and an antiviral reagent against"/>
   <result pre="reported and an antiviral reagent against RNA-dependent RNA polymerase in" exact="influenza" post="virus was developed.(4–7) We previously reported that soybean extract"/>
   <result pre="We previously reported that soybean extract exerted antiviral activity against" exact="influenza" post="virus growth.(8) During influenza infection, reactive oxygen species (ROS)"/>
   <result pre="soybean extract exerted antiviral activity against influenza virus growth.(8) During" exact="influenza" post="infection, reactive oxygen species (ROS) and lipid peroxides are"/>
   <result pre="an improvement in postprandial blood glucose levels and a significant" exact="suppression" post="of blood lipid peroxide can be achieved by single"/>
   <result pre="produce non-hormonal effects.(18–24) We found that daidzein and glycitein inhibited" exact="influenza" post="virus replication and suggested that the regulation by daidzein"/>
   <result pre="Louis, MO) containing 70 ml/L fetal bovine serum (FBS). The" exact="influenza" post="A virus H1N1 (PR/8/34) was used throughout the experiments."/>
   <result pre="infection period. Focus forming reduction assay for virucidal activity Sample" exact="influenza" post="viruses used in the virucidal activity assay were prepared"/>
   <result pre="24 h, the supernatants were harvested and used as the" exact="influenza" post="virus samples for focus forming reduction assay (FFRA). Focus"/>
   <result pre="production in MDCK cells by daidzein addition The titer of" exact="influenza" post="virus in the culture medium decreased in a dose-dependent"/>
   <result pre="dose-dependent manner following addition of daidzein (Fig. 1A). Daidzein inhibited" exact="influenza" post="virus multiplication at an IC50 of 51.2 µM (Fig."/>
   <result pre="µM. This concentration of daidzein in the culture medium inhibited" exact="influenza" post="virus multiplication by approximately 85% and did not exert"/>
   <result pre="enhances the enzymatic activity of 5-LOX. Effect of zileuton on" exact="influenza" post="virus replication in daidzein added virus-infected cells To confirm"/>
   <result pre="levels in MDCK cells were suppressed. We then measured the" exact="influenza" post="virus titer in the culture medium. In control siRNA-transfected"/>
   <result pre="The present study clarified the mechanism of daidzein-induced inhibition of" exact="influenza" post="virus replication. Daidzein showed no antioxidant activity under our"/>
   <result pre="anti-influenza activity. Additionally, 5-HpETE, the primary product of 5-LOX, inhibited" exact="influenza" post="virus replication (Fig. 5A). This is the first study"/>
   <result pre="al.(31) reported the effect of soy isoflavone administration to non-alcoholic" exact="fatty liver disease" post="model rat. And they showed that soy isoflavones affected"/>
   <result pre="reported the effect of soy isoflavone administration to non-alcoholic fatty" exact="liver disease" post="model rat. And they showed that soy isoflavones affected"/>
   <result pre="that the omega-3 PUFA-derived lipid mediator protectin D1 (PD1) attenuates" exact="influenza" post="virus replication. They performed a screen of PUFA-derived lipid"/>
   <result pre="lipid metabolites in human lung epithelial (A549) cells infected with" exact="influenza" post="A virus (PR8 virus) by using bioactive lipid libraries"/>
   <result pre="and other PUFA-derived metabolites.(34) They evaluated the antiviral effect by" exact="influenza" post="virus nucleoprotein mRNA expression at 8 h after infection"/>
   <result pre="enzymes and leukotrienes exert physiological functions in the pathophysiology of" exact="asthma" post="and inflammation.(35) Additionally, there is another 5-LOX associated arachidonate-derived"/>
   <result pre="activity. The duration of daidzein administration for the treatment of" exact="influenza" post="infection is thought to be 5 days. Further research"/>
   <result pre="dose administration of daidzein. The inhibitory mechanism of daidzein against" exact="influenza" post="replication does not involve the inhibition of viral enzymes,"/>
   <result pre="as neuraminidase and cap-dependent endonuclease, which are encoded by the" exact="influenza" post="virus genome, but rather involves enzyme activation in infected"/>
   <result pre="of action, as well as for developing preventive strategies against" exact="influenza" post="infection using food ingredients. Author Contributions YH, RS, MS,"/>
   <result pre="for Desease Control and Prevention (CDC). Prevention and control of" exact="influenza" post="with vaccines: recommendations of the Advisory Committee on Immunization"/>
   <result pre="1108.16228009 5BloomJD, GongLI, BaltimoreDPermissive secondary mutations enable the evolution of" exact="influenza" post="oseltamivir resistance. Science2010; 328: 1272–1275.20522774 6FurutaY, TakahashiK, FukudaY, et"/>
   <result pre="7KisoM, TakahashiK, Sakai-TagawaY, et al.T-705 (favipiravir) activity against lethal H5N1" exact="influenza" post="A viruses. Proc Natl Acad Sci U S A2010;"/>
   <result pre="S A2010; 107: 882–887.20080770 8NagaiE, IwaiM, KoketsuR, et al.Inhibition of" exact="influenza" post="virus replication by adlay tea. J Sci Food Agric2018;"/>
   <result pre="Biol Med1994; 16: 821–824.8070686 11AkaikeT, NoguchiY, IjiriS, et al.Pathogenesis of" exact="influenza" post="virus-induced pneumonia: involvement of both nitric oxide and oxygen"/>
   <result pre="al. Mitochondrial reactive oxygen species contribute to pathological inflammation during" exact="influenza" post="A virus infection in mice. Antioxid Redox Signal 2019."/>
   <result pre="Endocrinology1998; 139: 4252–4263.9751507 20UifäleanA, SchneiderS, IonescuC, LalkM, IugaCASoy isoflavones and" exact="breast cancer" post="cell lines: molecular mechanisms and future perspectives. Molecules2015; 21:"/>
   <result pre="139: 4252–4263.9751507 20UifäleanA, SchneiderS, IonescuC, LalkM, IugaCASoy isoflavones and breast" exact="cancer" post="cell lines: molecular mechanisms and future perspectives. Molecules2015; 21:"/>
   <result pre="al.Long-term fermented soybean paste improves metabolic parameters associated with non-alcoholic" exact="fatty liver disease" post="and insulin resistance in high-fat diet-induced obese mice. Biochem"/>
   <result pre="fermented soybean paste improves metabolic parameters associated with non-alcoholic fatty" exact="liver disease" post="and insulin resistance in high-fat diet-induced obese mice. Biochem"/>
   <result pre="34MoritaM, KubaK, IchikawaA, et al.The lipid mediator protectin D1 inhibits" exact="influenza" post="virus replication and improves severe influenza. Cell2013; 153: 112–125.23477864"/>
   <result pre="1 LINK Fig. 1 Effect of daidzein on multiplication of" exact="influenza" post="virus and on proliferation of MDCK cells. MDCK cells"/>
   <result pre="on proliferation of MDCK cells. MDCK cells were inoculated with" exact="influenza" post="A/PR/8/34 virus at a MOI of 0.001. (A) Concentration-dependent"/>
   <result pre="on production of lipid peroxide. MDCK cells were inoculated with" exact="influenza" post="A/PR/8/34 virus at a MOI of 0.001. Lipid fraction"/>
   <result pre="5-LOX inhibitor, zileuton, and 5-LOX siRNA transfection on multiplication of" exact="influenza" post="virus and production of 5-HETE. MDCK cells were inoculated"/>
   <result pre="virus and production of 5-HETE. MDCK cells were inoculated with" exact="influenza" post="A/PR/8/34 virus at a MOI of 0.001. Viral titers"/>
   <result pre="focus-forming assays. (A) Effect of zileuton on the titer of" exact="influenza" post="virus. (B) Effect of zileuton on 5-HETE production. (C)"/>
   <result pre="cells treated with or without daidzein and with or without" exact="influenza" post="virus infection. (D) Effect of 5-LOX siRNA on daidzein-induced"/>
   <result pre="***p&amp;lt;0.005, ****p&amp;lt;0.001. Fig. 5 Effect of 5-HpETE on multiplication of" exact="influenza" post="virus. MDCK cells were inoculated with influenza A/PR/8/34 virus"/>
   <result pre="on multiplication of influenza virus. MDCK cells were inoculated with" exact="influenza" post="A/PR/8/34 virus at a MOI of 0.001. (A) Concentration-dependent"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6986714\results\search\disease\results.xml">
   <result pre="2006;2:997–1018. 6MassadE, MaS, BurattiniMN, TunY, CoutinhoFAB, AngLW. The risk of" exact="chikungunya" post="fever in a dengue-endemic area. Journal of travel medicine."/>
   <result pre="10.1016/j.epidem.2017.06.00528803069 16QueyriauxB, SimonF, GrandadamM, MichelR, TolouH, BoutinJP. Clinical burden of" exact="chikungunya" post="virus infection. The Lancet infectious diseases. 2008;8(1):2–3. 10.1016/S1473-3099(07)70294-318156079 17ThibervilleSD,"/>
   <result pre="SoletJL, SissokoD, BalleydierE, LarrieuS, FilleulL, et al.A major epidemic of" exact="chikungunya" post="virus infection on Reunion Island, France, 2005–2006. The American"/>
   <result pre="10.1098/rsif.2009.0386 22HeesterbeekJ, RobertsM. The type-reproduction number T in models for" exact="infectious disease" post="control. Mathematical biosciences. 2007;206(1):3–10. 10.1016/j.mbs.2004.10.01316529777 23FraserC, RileyS, AndersonRM, FergusonNM."/>
   <result pre="2007;206(1):3–10. 10.1016/j.mbs.2004.10.01316529777 23FraserC, RileyS, AndersonRM, FergusonNM. Factors that make an" exact="infectious disease" post="outbreak controllable. Proceedings of the National Academy of Sciences."/>
   <result pre="new method for estimating the effort required to control an" exact="infectious disease." post="Proceedings of the Royal Society of London Series B:"/>
   <result pre="ChristophidesGK, ParhamPE. A large-scale stochastic spatiotemporal model for Aedes albopictus-borne" exact="chikungunya" post="epidemiology. PloS one. 2017;12(3):e017429310.1371/journal.pone.017429328362820 31LongKC, ZieglerSA, ThangamaniS, HausserNL, KochelTJ,"/>
   <result pre="tropical diseases. 2018;12(11):e000689510.1371/journal.pntd.000689530403665 34MassadE, CoutinhoFAB, BurattiniMN, LopezLF. The risk of" exact="yellow fever" post="in a dengue-infested area. Transactions of the Royal Society"/>
   <result pre="35MassadE, BurattiniMN, CoutinhoFAB, LopezLF. Dengue and the risk of urban" exact="yellow fever" post="reintroduction in Sao Paulo State, Brazil. Revista de Saúde"/>
   <result pre="2018;7(1):1–11. 10.1038/s41426-018-0163-529323102 42KantorA, GrantD, BalaramanV, WhiteT, FranzA. Ultrastructural analysis of" exact="chikungunya" post="virus dissemination from the midgut of the yellow fever"/>
   <result pre="analysis of chikungunya virus dissemination from the midgut of the" exact="yellow fever" post="mosquito, aedes aegypti. Viruses. 2018;10(10):57110.3390/v10100571 43WigginsK, EastmondB, AltoB. Transmission"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6986850\results\search\disease\results.xml">
   <result pre="to not notify the press of a death resulting from" exact="pneumonic plague." post="Appearing in the same year, The Killer That Stalked"/>
   <result pre="(1950, Earl McEvoy) was based on an actual threat of" exact="smallpox" post="that occurred in New York in 1947. In the"/>
   <result pre="Suspects (1963, Val Guest), the doctor tackling an outbreak of" exact="smallpox" post="uses a quarantining process with the explicitly mentioned goal"/>
   <result pre="in Florence in the mid-14th century and portrayed death from" exact="plague" post="as a response to immoral behavior and sexual debauchery."/>
   <result pre="(Nuova Cronica) and Giovanni Boccaccio (Decameron). In several films, the" exact="plague" post="became used as an explicit punishment for immorality and"/>
   <result pre="Leslie Megahey), and especially Anazapta (2002, Alberto Sciamma), in which" exact="plague" post="was a supposed consequence of the brutal rape of"/>
   <result pre="Muslims were blamed for poisoning water systems during the 1994" exact="plague" post="outbreak in Surat, India (14), and the HIV/AIDS pandemic"/>
   <result pre="of various Western cities were victimized in the wake of" exact="severe acute respiratory syndrome" post="(SARS) (19), and studies performed in Hong Kong revealed"/>
   <result pre="(not penned by Conan Doyle), Professor Moriarty prepares to import" exact="plague" post="to Britain by acquiring infected rats from Southeast Asia"/>
   <result pre="scenes of working class miners resisting medical authority during a" exact="tuberculosis" post="outbreak, and 1918 (1985, Ken Harrison), in which residents"/>
   <result pre="the Middle East during Second Pandemic plagues (25), and the" exact="influenza" post="pandemic of 1918–1920 has been cited as the foremost"/>
   <result pre="South Korea, which plays on recent experiences with SARS and" exact="influenza" post="by focusing on responses to an outbreak of a"/>
   <result pre="of a fictional disease with parallels to the strain of" exact="avian influenza" post="A(H5N1) virus. On the one hand, many scenes capture"/>
   <result pre="a fictional disease with parallels to the strain of avian" exact="influenza" post="A(H5N1) virus. On the one hand, many scenes capture"/>
   <result pre="persons with a disease that is wrongly assumed to be" exact="plague" post="(33,34) and media perpetuation of several recent misguided anxieties"/>
   <result pre="2009;15:743–7. 10.1111/j.1469-0691.2009.02947.x19754730 13. CohnSK. Epidemics: hate and compassion from the" exact="plague" post="of Athens to AIDS. Oxford (UK): Oxford University Press;"/>
   <result pre="Oxford (UK): Oxford University Press; 2018. 14. BarrettR. The 1994" exact="plague" post="in Western India: human ecology and the risks of"/>
   <result pre="10.1016/j.socscimed.2007.04.02217544189 20. LauJT, KimJH, TsuiH, GriffithsS. Perceptions related to human" exact="avian influenza" post="and their associations with anticipated psychological and behavioral responses"/>
   <result pre="20. LauJT, KimJH, TsuiH, GriffithsS. Perceptions related to human avian" exact="influenza" post="and their associations with anticipated psychological and behavioral responses"/>
   <result pre="SabraaT. Refugees of the Black Death: quantifying rural migration for" exact="plague" post="and other environmental disasters.Ann Demogr Hist (Paris). 2017;134:63–93. 10.3917/adh.134.0063"/>
   <result pre="Hist (Paris). 2017;134:63–93. 10.3917/adh.134.0063 26. CrosbyA. Americas forgotten pandemic: the" exact="influenza" post="of 1918. Cambridge (UK): Cambridge University Press; 1989. 27."/>
   <result pre="Press; 1989. 27. CohnSK. Fear and the corpse: cholera and" exact="plague" post="riots compared. In: Lynteris C, Evans NHA, editors. Histories"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6987159\results\search\disease\results.xml">
   <result pre="proteins, and can adhere to freshly-isolated thymocytes, as well as" exact="acute lymphoblastic leukemia" post="derived T cells16,18. In the first group of experiments,"/>
   <result pre="and can adhere to freshly-isolated thymocytes, as well as acute" exact="lymphoblastic leukemia" post="derived T cells16,18. In the first group of experiments,"/>
   <result pre="can adhere to freshly-isolated thymocytes, as well as acute lymphoblastic" exact="leukemia" post="derived T cells16,18. In the first group of experiments,"/>
   <result pre="with ZIKV (MOI = 1) and 72 hpi uninfected CEM acute T-cell" exact="leukemia" post="cell line was added to the culture. (b) Association"/>
   <result pre="to lymphoblastic T cells. For that, the CEM acute T-cell" exact="leukemia" post="cell line, previously known to adhere to human TEC16,"/>
   <result pre="tubules, retinal pigment epithelium, neural progenitors, and astrocytes, which reported" exact="suppression" post="of cell proliferation, as well as induction of antiviral"/>
   <result pre="authors that this lncRNA impairing proliferation42 and inducing apoptosis43 in" exact="lung cancer" post="cells. Another lncRNA, SENCR can stabilize the vascular endothelial"/>
   <result pre="that this lncRNA impairing proliferation42 and inducing apoptosis43 in lung" exact="cancer" post="cells. Another lncRNA, SENCR can stabilize the vascular endothelial"/>
   <result pre="cell line and ZIKV infection CEM is an acute T-cell" exact="lymphoblastic leukemia" post="cell line that was maintained in RPMI-1640 medium supplemented"/>
   <result pre="line and ZIKV infection CEM is an acute T-cell lymphoblastic" exact="leukemia" post="cell line that was maintained in RPMI-1640 medium supplemented"/>
   <result pre="described previously. After 72 h in culture, CEM cells (human T-cell" exact="acute lymphoblastic leukemia" post="cell line) were added to the infected culture in"/>
   <result pre="previously. After 72 h in culture, CEM cells (human T-cell acute" exact="lymphoblastic leukemia" post="cell line) were added to the infected culture in"/>
   <result pre="After 72 h in culture, CEM cells (human T-cell acute lymphoblastic" exact="leukemia" post="cell line) were added to the infected culture in"/>
   <result pre="Infection in retinal pigment epitheliumSci. Rep.2018811610.1038/s41598-017-17765-529311619 27.LiuLingChenZhenyuZhangXinLiShunHuiYiFengHexiDuYanhuaJinGuohuaZhouXiaohuiZhangXiaoqingProtection of ZIKV infection-induced" exact="neuropathy" post="by abrogation of acute antiviral response in human neural"/>
   <result pre="al.Long non-coding RNA PICART1 suppresses proliferation and promotes apoptosis in" exact="lung cancer" post="cells by inhibiting JAK2/STAT3 signalingNeoplasma20186577978910.4149/neo_2018_171130N77829940776 43.ZhangCet al.LncRNA PICART1 suppressed"/>
   <result pre="non-coding RNA PICART1 suppresses proliferation and promotes apoptosis in lung" exact="cancer" post="cells by inhibiting JAK2/STAT3 signalingNeoplasma20186577978910.4149/neo_2018_171130N77829940776 43.ZhangCet al.LncRNA PICART1 suppressed"/>
   <result pre="by inhibiting JAK2/STAT3 signalingNeoplasma20186577978910.4149/neo_2018_171130N77829940776 43.ZhangCet al.LncRNA PICART1 suppressed non-small cell" exact="lung cancer" post="cells proliferation and invasion by targeting AKT1 signaling pathwayAm."/>
   <result pre="inhibiting JAK2/STAT3 signalingNeoplasma20186577978910.4149/neo_2018_171130N77829940776 43.ZhangCet al.LncRNA PICART1 suppressed non-small cell lung" exact="cancer" post="cells proliferation and invasion by targeting AKT1 signaling pathwayAm."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6988203\results\search\disease\results.xml">
   <result pre="tissues and organs including the lungs resulting in a primary" exact="viral pneumonia." post="The acute stage of disease is characterised by high"/>
   <result pre="all cases of PPR can be distinguish from rinderpest, pneumonic" exact="pasteurellosis" post="and contagious caprine pleuropneumonia, based on clinical sigs [4]."/>
   <result pre="similar infectious diseases such as contagious caprine pleuropneumonia, bluetongue, contagious" exact="ecthyma" post="and foot-and-mouth disease. These multiplex assays may also be"/>
   <result pre="des petits ruminants in Arabian wildlifeEpidemiol Infect20101381211121410.1017/S095026880999159220067659 42.HamdyFMDardiriAHNduakaOBreeseSSJrIhemelanduECEtiology of the" exact="stomatitis" post="pneumoenteritis complex in Nigerian dwarf goatsCan J Comp Med.197640276284826310"/>
   <result pre="Methods2016227404610.1016/j.jviromet.2015.10.00826506137 122.LoganNDundonWGDialloABaronMDJames NyarobiMCleavelandSet al.Enhanced immunosurveillance for animal morbilliviruses using vesicular" exact="stomatitis" post="virus (VSV) pseudotypesVaccine.2016345736574310.1016/j.vaccine.2016.10.01027742221 123.MassonJFSurface plasmon resonance clinical biosensors for"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6988270\results\search\disease\results.xml">
   <result pre="World Health Organ. 2016;94(12):880-92. 10.2471/BLT.16.17595027994281 12FischerCde LamballerieXDrexlerJFEnhanced molecular surveillance of" exact="chikungunya" post="virus.MSphere. 2019;4(4):e00295-19. 10.1128/mSphere.00295-1931270168 13LiJDuanH-JChenH-YJiY-JZhangXRongY-Het al.Age and Ebola viral load"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6989424\results\search\disease\results.xml">
   <result pre="conserved and similarly targeted in other mosquito-borne flaviviruses, including dengue," exact="yellow fever," post="and Zika viruses. Together, these findings indicate a strong"/>
   <result pre="critical CD4 T cell epitopes in other flaviviruses, including Zika," exact="yellow fever" post="(YF) and tick-borne encephalitis (TBE) viruses (21–24). Crystallographic and"/>
   <result pre="epitopes in other flaviviruses, including Zika, yellow fever (YF) and" exact="tick-borne encephalitis" post="(TBE) viruses (21–24). Crystallographic and cryo-EM studies have shown"/>
   <result pre="in other flaviviruses, including Zika, yellow fever (YF) and tick-borne" exact="encephalitis" post="(TBE) viruses (21–24). Crystallographic and cryo-EM studies have shown"/>
   <result pre="rash, headache neg Pos 88 &amp;lt;20 50 513 Fever, headache," exact="rash" post="pos Pos 71 &amp;lt;20 53 514 Asymptomatic pos Pos"/>
   <result pre="42 516 Asymptomatic pos Pos 53 23 &amp;lt;20 517 Fever," exact="rash" post="pos Pos 30 &amp;lt;20 27 518 Fever, rash, ocular"/>
   <result pre="rash, ocular pain pos Pos 100 &amp;lt;20 50 519 Fever," exact="encephalitis" post="pos Pos 225 108 175 520 Asymptomatic neg Pos"/>
   <result pre="51 522 Asymptomatic pos Pos 149 &amp;lt;20 39 523 Fever," exact="rash" post="pos Pos 63 &amp;lt;20 43 524 Fever, rash, muscle"/>
   <result pre="C protein (PDB 1SFK) (36), as well as the Japanese" exact="encephalitis" post="(JE) virus E dimers (PDB 3P54 and 5WSN) (37,"/>
   <result pre="(PDB 3P54 and 5WSN) (37, 38) and the St. Louis" exact="encephalitis" post="(SLE) virus E trimer (PDB 4FG0) (39), all belonging"/>
   <result pre="of three domains (DI-DIII). (D) Surface representation of the Japanese" exact="encephalitis" post="virus pre-fusion sE dimer (top view, PDB 3P54) (37)"/>
   <result pre="PDB 5WSN) (38). (E) Surface depiction of the St. Louis" exact="encephalitis" post="virus post-fusion E protein trimer (PDB 4FG0; side view)"/>
   <result pre="YF viruses, but overlapped with those previously identified in Japanese" exact="encephalitis" post="virus, a closely related flavivirus of the same serocomplex"/>
   <result pre="cross-linking (24). There are many other well-known examples, such as" exact="influenza" post="virus or HIV, which undergo conformational changes that may"/>
   <result pre="in the preferential selection of certain epitopes. Moreover, studies with" exact="influenza" post="virus reported that some peptides are generated only during"/>
   <result pre="described in a significant percentage of patients with WN virus" exact="encephalitis" post="(73). Apart from this single case and in line"/>
   <result pre="are also frequently targeted in other clinically relevant flaviviruses, including" exact="yellow fever," post="dengue and Zika viruses. Together, these data provide novel"/>
   <result pre="system. J Virol. (2006) 80:12060–9. 10.1128/JVI.01650-0617035323 11.StadlerKAllisonSLSchalichJHeinzFX. Proteolytic activation of" exact="tick-borne encephalitis" post="virus by furin. J Virol. (1997) 71:8475–81. 10.1128/JVI.71.11.8475-8481.19979343204 12.HarrisonSCViral"/>
   <result pre="J Virol. (2006) 80:12060–9. 10.1128/JVI.01650-0617035323 11.StadlerKAllisonSLSchalichJHeinzFX. Proteolytic activation of tick-borne" exact="encephalitis" post="virus by furin. J Virol. (1997) 71:8475–81. 10.1128/JVI.71.11.8475-8481.19979343204 12.HarrisonSCViral"/>
   <result pre="structure determines the pattern of CD4(+) T-cell epitope dominance in" exact="influenza" post="virus hemagglutinin. J Virol. (2008) 82:1238–48. 10.1128/JVI.02026-0718057238 18.Mirano-BascosDTary-LehmannMLandrySJ. Antigen"/>
   <result pre="epitopes. Mol Immunol. (2007) 44:1159–68. 10.1016/j.molimm.2006.06.01416893568 20.EisenlohrLCLuckashenakNApcherSMillerMASinnathambyG. Beyond the classical:" exact="influenza" post="virus and the elucidation of alternative MHC class II-restricted"/>
   <result pre="structure shapes immunodominance in the CD4 T cell response to" exact="yellow fever" post="vaccination. Sci Rep. (2017) 7:8907. 10.1038/s41598-017-09331-w28827760 23.KoblischkeMStiasnyKAberleSWMalafaSTsouchnikasGSchwaigerJet al.Structural influence"/>
   <result pre="Virol J. (2018) 15:183. 10.1186/s12985-018-1092-630477514 30.ReyFAHeinzFXMandlCKunzCHarrisonSC. The envelope glycoprotein from" exact="tick-borne encephalitis" post="virus at 2 A resolution. Nature. (1995) 375:291–8. 10.1038/375291a07753193"/>
   <result pre="J. (2018) 15:183. 10.1186/s12985-018-1092-630477514 30.ReyFAHeinzFXMandlCKunzCHarrisonSC. The envelope glycoprotein from tick-borne" exact="encephalitis" post="virus at 2 A resolution. Nature. (1995) 375:291–8. 10.1038/375291a07753193"/>
   <result pre="Nature. (2005) 437:764–8. 10.1038/nature0395616193056 34.StiasnyKHolzmannHHeinzFX. Characteristics of antibody responses in" exact="tick-borne encephalitis" post="vaccination breakthroughs. Vaccine. (2009) 27:7021–6. 10.1016/j.vaccine.2009.09.06919789092 35.BradtVMalafaSvon BraunAJarmerJTsouchnikasGMeditsIet al.."/>
   <result pre="(2005) 437:764–8. 10.1038/nature0395616193056 34.StiasnyKHolzmannHHeinzFX. Characteristics of antibody responses in tick-borne" exact="encephalitis" post="vaccination breakthroughs. Vaccine. (2009) 27:7021–6. 10.1016/j.vaccine.2009.09.06919789092 35.BradtVMalafaSvon BraunAJarmerJTsouchnikasGMeditsIet al.."/>
   <result pre="vaccination breakthroughs. Vaccine. (2009) 27:7021–6. 10.1016/j.vaccine.2009.09.06919789092 35.BradtVMalafaSvon BraunAJarmerJTsouchnikasGMeditsIet al.. Pre-existing" exact="yellow fever" post="immunity impairs and modulates the antibody response to tick-borne"/>
   <result pre="yellow fever immunity impairs and modulates the antibody response to" exact="tick-borne encephalitis" post="vaccination. NPJ Vaccines. (2019) 4:38. 10.1038/s41541-019-0133-531508246 36.DoklandTWalshMMackenzieJMKhromykhAAEeKHWangS. West Nile"/>
   <result pre="fever immunity impairs and modulates the antibody response to tick-borne" exact="encephalitis" post="vaccination. NPJ Vaccines. (2019) 4:38. 10.1038/s41541-019-0133-531508246 36.DoklandTWalshMMackenzieJMKhromykhAAEeKHWangS. West Nile"/>
   <result pre="Structure. (2004) 12:1157–63. 10.1016/j.str.2004.04.02415242592 37.LucaVCAbiMansourJNelsonCAFremontDH. Crystal structure of the Japanese" exact="encephalitis" post="virus envelope protein. J Virol. (2012) 86:2337–46. 10.1128/JVI.06072-1122156523 38.WangXXLiSHZhuLNianQGYuanSGaoQet"/>
   <result pre="Virol. (2012) 86:2337–46. 10.1128/JVI.06072-1122156523 38.WangXXLiSHZhuLNianQGYuanSGaoQet al.. Near-atomic structure of Japanese" exact="encephalitis" post="virus reveals critical determinants of virulence and stability. Nat"/>
   <result pre="214:1117–24. 10.1093/infdis/jiw30927443615 47.TurtleLBaliTBuxtonGChibSChanSSoniMet al.. Human T cell responses to Japanese" exact="encephalitis" post="virus in health and disease. J Exp Med. (2016)"/>
   <result pre="variables affecting the repertoire of T cell specificities recognized after" exact="vaccinia virus" post="infection. J Immunol. (2007) 178:7890–901. 10.4049/jimmunol.178.12.789017548627 62.BackertLKohlbacherO. Immunoinformatics and"/>
   <result pre="10.1002/eji.18301912092481588 65.AberleJHSchwaigerJAberleSWStiasnyKScheinostOKundiMet al.. Human CD4(+) T helper cell responses after" exact="tick-borne encephalitis" post="vaccination and infection. PLoS ONE. (2015) 10:e140545. 10.1371/journal.pone.014054526465323 66.OliphantTEngleMNybakkenGEDoaneCJohnsonSHuangLet"/>
   <result pre="65.AberleJHSchwaigerJAberleSWStiasnyKScheinostOKundiMet al.. Human CD4(+) T helper cell responses after tick-borne" exact="encephalitis" post="vaccination and infection. PLoS ONE. (2015) 10:e140545. 10.1371/journal.pone.014054526465323 66.OliphantTEngleMNybakkenGEDoaneCJohnsonSHuangLet"/>
   <result pre="DEN Dengue E envelope HLA human leukocyte antigen JE Japanese" exact="encephalitis" post="M membrane MHC major histocompatibility complex PBMCs peripheral blood"/>
   <result pre="complex PBMCs peripheral blood mononuclear cells prM pre-membrane TBE Tick-borne" exact="encephalitis" post="WN West Nile WND West Nile virus disease YF"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6991954\results\search\disease\results.xml">
   <result pre="patients with viral infections—approaches that can be applied to any" exact="infectious disease." post="A second reason for the popularity of antibodies in"/>
   <result pre="distinguish between closely related molecular targets. In the case of" exact="infectious disease," post="this selectivity can be absolute, since antibodies can be"/>
   <result pre="[11]. The dramatic clinical effect in subgroups of otherwise treatment-refractory" exact="cancer" post="patients has led to products with prices well in"/>
   <result pre="of US$10,000 per month [12]. Another recent milestone for an" exact="infectious disease" post="was the global approval of ibalizumab, a humanized mAb"/>
   <result pre="mediators that are overexpressed in disease, such as cytokines in" exact="rheumatoid arthritis" post="or cell-surface markers in oncology. For the anti-tumor necrosis"/>
   <result pre="that are overexpressed in disease, such as cytokines in rheumatoid" exact="arthritis" post="or cell-surface markers in oncology. For the anti-tumor necrosis"/>
   <result pre="oncology. For the anti-tumor necrosis factor (anti-TNF) antibodies used in" exact="rheumatoid arthritis," post="although there is an initial loading dose to reduce"/>
   <result pre="delivery of the subcutaneous approach, with a reasonable dose. In" exact="infectious disease," post="the biggest success story has been the use of"/>
   <result pre="to US$80/g [18]. For a public health application against an" exact="infectious disease" post="in an LMIC, an intramuscular or subcutaneous delivery would"/>
   <result pre="costs is difficult, but as a comparison, the recently launched" exact="malaria" post="vaccine provides less than 50% protection for 3 injections"/>
   <result pre="US$5 each. The programmatic cost of protecting a child from" exact="malaria" post="for a year in the Sahel using existing low-cost"/>
   <result pre="developed and marketed for respiratory syncytial, varicella zoster, vaccinia, and" exact="hepatitis" post="B viruses (HBVs) [27, 28]. Historically, immune responses against"/>
   <result pre="understood, for instance, with therapeutic opportunities against viruses such as" exact="rabies" post="that rely on passive immunization. mAbs that target the"/>
   <result pre="is especially effective in infections, such as those with the" exact="rabies" post="virus, which avoids apoptosis of infected neurons while killing"/>
   <result pre="approved in the European Union or the US for cytomegalovirus," exact="hepatitis" post="viruses A and C, and postexposure prophylaxis against measles,"/>
   <result pre="and C, and postexposure prophylaxis against measles, rabies, rubella, and" exact="tetanus" post="[31]. These approaches appear most suitable for virus infections"/>
   <result pre="marketed antibodies that target bacteria, and these target toxins, namely" exact="anthrax" post="and Clostridium cytotoxin [27]. This paucity may be due"/>
   <result pre="[63]. Abbreviations: BCG, Bacillus Calmette–Guérin; CIS43, circumsporozoite protein 43; HBV," exact="hepatitis" post="B virus; mAb, monoclonal antibody; mutFc, mutated Fragment crystallizable"/>
   <result pre="monoclonal antibody; mutFc, mutated Fragment crystallizable region; TB, tuberculosis; VL," exact="visceral leishmaniasis" post="Schistosomiasis Human schistosomiasis is caused by infection, mainly with"/>
   <result pre="antibody; mutFc, mutated Fragment crystallizable region; TB, tuberculosis; VL, visceral" exact="leishmaniasis" post="Schistosomiasis Human schistosomiasis is caused by infection, mainly with"/>
   <result pre="Fragment crystallizable region; TB, tuberculosis; VL, visceral leishmaniasis Schistosomiasis Human" exact="schistosomiasis" post="is caused by infection, mainly with one of 4"/>
   <result pre="with schistosomal infections is difficult to calculate. Comorbidities linked to" exact="anemia" post="are common, and infection with S. haematobium can lead"/>
   <result pre="molecule inhibitor [66]. No target-product profile (TPP) for prophylaxis against" exact="schistosomiasis" post="has been published, but it is possible to start"/>
   <result pre="80 to 200 μg in mice [19]. Target identification for" exact="schistosomiasis" post="is not straightforward. Unlike malaria, the vaccine field offers"/>
   <result pre="a noninflammatory Th2 response. The clinical use of anti-IL17 in" exact="rheumatoid arthritis" post="clearly exacerbates fungal infection [91], although it remains to"/>
   <result pre="noninflammatory Th2 response. The clinical use of anti-IL17 in rheumatoid" exact="arthritis" post="clearly exacerbates fungal infection [91], although it remains to"/>
   <result pre="spreads hematogenously to the cerebrospinal fluid and brain to cause" exact="meningitis" post="and meningoencephalitis, adding the complexity of crossing the blood–brain"/>
   <result pre="kexin-like protein KEX1, was able to prevent transmission of Pneumocystis" exact="pneumonia" post="from infected to susceptible cohoused mice, demonstrating the feasibility"/>
   <result pre="significant morbidity and mortality, particularly in patients with HIV or" exact="tuberculosis" post="(TB) infection [114]. A recent paper demonstrated the cloning"/>
   <result pre="of the gap between a pathogen’s prevalence and burden. Mycobacterium" exact="tuberculosis" post="spreads easily among human populations; presently, about one-third of"/>
   <result pre="further consideration�? [128]. Malaria The role of protective antibodies in" exact="malaria" post="was demonstrated over 40 years ago with the finding"/>
   <result pre="development of infection in other mice [129]. The TPPs for" exact="malaria" post="are well described [130, 131]. These include a profile"/>
   <result pre="well described [130, 131]. These include a profile for seasonal" exact="malaria" post="chemoprevention, a treatment successfully launched in sub-Saharan Africa in"/>
   <result pre="monthly to children during the rainy season. Antibody therapeutics for" exact="malaria" post="could (1) prevent the entry (initial infection) of the"/>
   <result pre="transmission cycle). One difficulty in targeting the merozoites in symptomatic" exact="malaria" post="is that the extracellular phase of the pathogen is"/>
   <result pre="discovery of therapeutic mAbs [143]. Leishmaniasis In the case of" exact="visceral leishmaniasis" post="(VL), IL-10 and glucocorticoid-induced TNF-receptor–related protein have been considered"/>
   <result pre="of therapeutic mAbs [143]. Leishmaniasis In the case of visceral" exact="leishmaniasis" post="(VL), IL-10 and glucocorticoid-induced TNF-receptor–related protein have been considered"/>
   <result pre="conclusions Although mAbs have made a massive impact in controlling" exact="autoimmune disease," post="inflammation, and cancer, the relative impact in the world"/>
   <result pre="inflammation, and cancer, the relative impact in the world of" exact="infectious disease" post="has largely been confined to viral diseases. The use"/>
   <result pre="natural response to infection. Studies in animal models of chronic" exact="malaria" post="infection led to the observation that this results in"/>
   <result pre="and HBV infection [11]. This has important implications for any" exact="infectious disease" post="in which a single infection does not drive a"/>
   <result pre="dominate the human B cell response against 2009 pandemic H1N1" exact="influenza" post="virus infection. J Exp Med. 2011;208(1):181–93. 10.1084/jem.2010135221220454 10HayM, ThomasDW,"/>
   <result pre="as a Single Dose to Healthy Preterm Infants. The Pediatric" exact="infectious disease" post="journal. 2018;37(9):886–92. 10.1097/INF.000000000000191629373476 16KelleyB.Industrialization of mAb production technology: the"/>
   <result pre="to protect against malaria. Malar J. 2018;17(1):40210.1186/s12936-018-2549-1 .30384848 20UNITAID. Seasonal" exact="malaria" post="chemoprevention for children in the Sahel. https://unitaidorg/project/seasonal-malaria-chemo-prevention-children-sahel/#en. 2017. [cited"/>
   <result pre="BalthasarJP. Mechanistic considerations for the use of monoclonal antibodies for" exact="cancer" post="therapy. Cancer biology &amp;amp; medicine. 2014;11(1):20–33. 10.7497/j.issn.2095-3941.2014.01.00224738036 22KontermannRE. Strategies"/>
   <result pre="Vaccine. 2013;31(12):1553–9. 10.1016/j.vaccine.2013.01.025 .23370150 29LafonM.Immune evasion, a critical strategy for" exact="rabies" post="virus. Developments in biologicals. 2008;131:413–9. .18634503 30MimuraY, KatohT, SaldovaR,"/>
   <result pre="10.1086/507547 .16983626 52GaoY, ZhangTY, YuanQ, XiaNS. Antibody-mediated immunotherapy against chronic" exact="hepatitis" post="B virus infection. Human vaccines &amp;amp; immunotherapeutics. 2017;13(8):1768–73. 10.1080/21645515.2017.131902128521640"/>
   <result pre="RTS'S Clinical Trials Partnership. Efficacy and safety of the RTS,S/AS01" exact="malaria" post="vaccine during 18 months after vaccination: a phase 3"/>
   <result pre="WeidleC, Flores-GarciaY, FlynnBJ, SackBK, et al.A human monoclonal antibody prevents" exact="malaria" post="infection by targeting a new site of vulnerability on"/>
   <result pre="WeidleC, Flores-GarciaY, FlynnBJ, SackBK, et al.A human monoclonal antibody prevents" exact="malaria" post="infection by targeting a new site of vulnerability on"/>
   <result pre="65HotezPJ, HarrisonW, FenwickA, BustinduyAL, DuckerC, Sabina MbabaziP, et al.Female genital" exact="schistosomiasis" post="and HIV/AIDS: Reversing the neglect of girls and women."/>
   <result pre="CordingleyJS, DaltonPR, DunneDW, KariukiHC, et al.Immunity after treatment of human" exact="schistosomiasis" post="mansoni. II. Identification of resistant individuals, and analysis of"/>
   <result pre="al.Pilot-scale production and characterization of paramyosin, a vaccine candidate for" exact="schistosomiasis" post="japonica. Infect Immun. 2008;76(7):3164–9. 10.1128/IAI.00409-0818426875 80van DiepenA, Van der"/>
   <result pre="WongwitW, Pattara-ArechachaiJ, et al.Comparison of the protective efficacy on mekongi" exact="schistosomiasis" post="in mice induced by antigens derived from cercariae, schistosomulae"/>
   <result pre="10.1098/rstb.2015.046828080991 91SaunteDM, MrowietzU, PuigL, ZachariaeC. Candida infections in patients with" exact="psoriasis" post="and psoriatic arthritis treated with interleukin-17 inhibitors and their"/>
   <result pre="MrowietzU, PuigL, ZachariaeC. Candida infections in patients with psoriasis and" exact="psoriatic arthritis" post="treated with interleukin-17 inhibitors and their practical management. The"/>
   <result pre="PuigL, ZachariaeC. Candida infections in patients with psoriasis and psoriatic" exact="arthritis" post="treated with interleukin-17 inhibitors and their practical management. The"/>
   <result pre="93DromerF, CharreireJ, ContrepoisA, CarbonC, YeniP. Protection of mice against experimental" exact="cryptococcosis" post="by anti-Cryptococcus neoformans monoclonal antibody. Infect Immun. 1987;55(3):749–52. 3546140"/>
   <result pre="PiccoliL, BarbieriS, et al.A public antibody lineage that potently inhibits" exact="malaria" post="infection through dual binding to the circumsporozoite protein. Nat"/>
   <result pre="Dis. 2016;10(2):e000441510.1371/journal.pntd.000441526872334 145DyckL, MillsKHG. Immune checkpoints and their inhibition in" exact="cancer" post="and infectious diseases. Eur J Immunol. 2017;47(5):765–79. Epub 2017/04/11."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6992227\results\search\disease\results.xml">
   <result pre="are common and shared with other endemic diseases such as" exact="malaria" post="or typhoid fever. Current molecular diagnostic methods such as"/>
   <result pre="and shared with other endemic diseases such as malaria or" exact="typhoid fever." post="Current molecular diagnostic methods such as polymerase chain reaction"/>
   <result pre="is unknown. Overlapping symptoms with other endemic diseases, such as" exact="malaria" post="and cholera, make accurate diagnostic challenging. Outbreaks of Ebola"/>
   <result pre="infection [17]. Since early symptoms of EVD (fever, nausea, vomiting," exact="diarrhea" post="and weakness) are nonspecific and common, patients may expose"/>
   <result pre="silver amplification technology combined with immunochromatography methodology previously reported for" exact="influenza" post="H5 diagnosis to generate a blood-based diagnostic test for"/>
   <result pre="generate a blood-based diagnostic test for EBOV [21]. As for" exact="influenza" post="diagnosis, the silver amplification reaction was analyzed by an"/>
   <result pre="BD EDTA Vacutainer tube and tested against the following disease:" exact="typhoid fever" post="and malaria using RDTs. Blood samples from healthy African"/>
   <result pre="tube and tested against the following disease: typhoid fever and" exact="malaria" post="using RDTs. Blood samples from healthy African controls were"/>
   <result pre="edited by the Ebola virus polymerase and by T7 and" exact="vaccinia virus" post="polymerases. Virology. 1995;214(2):421–30. Epub 1995/12/20. 10.1006/viro.1995.0052 .8553543 5VolchkovVE, FeldmannH,"/>
   <result pre="Development of a highly sensitive immunochromatographic detection kit for H5" exact="influenza" post="virus hemagglutinin using silver amplification. Journal of virological methods."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6993346\results\search\disease\results.xml">
   <result pre="family [1]. It is the causative agents for both seasonal" exact="influenza" post="and pandemic influenza, posing major public health challenges [2,"/>
   <result pre="public health challenges [2, 3]. The annual epidemics of seasonal" exact="influenza" post="caused 3–5 million cases of severe illness worldwide. In"/>
   <result pre="3–5 million cases of severe illness worldwide. In addition, four" exact="influenza" post="pandemics have been recorded since the twentieth century: the"/>
   <result pre="neuraminidase inhibitors) are considered the best options for control of" exact="influenza" post="infection [11]. However, because of the easily occurrence of"/>
   <result pre="of the easily occurrence of antigenic drift and antigenic shift," exact="influenza" post="vaccines need to be updated annually and the number"/>
   <result pre="be updated annually and the number of reports of drug-resistant" exact="influenza" post="strains keeps increasing [12, 13]. Particularly, more than 95%"/>
   <result pre="current antiviral strategies underscore the urgent need for developing new" exact="influenza" post="therapies. MicroRNAs (miRNAs) are a class of ~ 22 nucleotides"/>
   <result pre="that miR-323, miR-491, and miR-654 inhibit replication of the H1N1" exact="influenza" post="A virus through binding to the same conserved region"/>
   <result pre="of the PB1 gene. Let-7c [27] was found to regulate" exact="influenza" post="virus replication through the degradation of viral gene (+)"/>
   <result pre="least one viral gene segment of both the human seasonal" exact="influenza" post="H3N2 and PR8 (H1N1) virus [29]. miR-122 [30] is"/>
   <result pre="and PR8 (H1N1) virus [29]. miR-122 [30] is essential for" exact="hepatitis" post="C virus replication in liver, and Lanford et al."/>
   <result pre="treatment of chronically infected chimpanzees with anti-miR-122 leads to long-lasting" exact="suppression" post="of HCV viremia, with no evidence of viral resistance"/>
   <result pre="analysis Sequence of Influenza A virus was downloaded from NCBI" exact="influenza" post="virus Resource (http://www.ncbi.nlm.nih.gov/genomes/FLU/FLU.html). The sequence of strains whose host"/>
   <result pre="transfection in cells. After 6 h, the cells were infected with" exact="influenza" post="A virus at a multiplicity of infection (MOI) of"/>
   <result pre="washed with phosphate-buffered saline (PBS) three times and infected with" exact="influenza" post="virus at a multiplicity of infection (MOI) of 0.01"/>
   <result pre="indicated significant differences. Results Screening of miRNAs that broad-spectrum targeting" exact="influenza" post="A virus It is well known that IAV is"/>
   <result pre="the sequence of IAV that can infected human from NCBI" exact="influenza" post="virus Resource, 28,124 records in total. Human mature miRNAs"/>
   <result pre="from NC miRNA group miRNAs overexpression suppresses the replication of" exact="influenza" post="A virus in A549 cells Since miR-188-3p, miR-345, miR-3183"/>
   <result pre="protein, we then investigated whether overexpression of these miRNAs affect" exact="influenza" post="A virus replication. A549 cells were tranfected with miRNA"/>
   <result pre="FM47 replication. Fig. 5 miRNAs inhibits the replication of H1N1" exact="influenza" post="A virus in A549 cells. a TCID50 values were"/>
   <result pre="that miR-188-3p may also suppress the replication of emerging human-infected" exact="influenza" post="A virus, such as H7N9 and H5N6 subtype. Table"/>
   <result pre="are very important for inhibitory activity. Discussion IAV is well-known" exact="infectious disease" post="that affects individuals of all ages in annual seasonal"/>
   <result pre="found that miR-188-3p might be a new potential therapy for" exact="atherosclerosis" post="by inhibiting macrophage proinflammatory response and oxidation. Pei et"/>
   <result pre="found that miR-188-3p inhibited the cell proliferation and motility in" exact="breast cancer" post="by targeting Transmembrane emp24 domain-containing protein 3 (TMED3). Pichler"/>
   <result pre="that miR-188-3p inhibited the cell proliferation and motility in breast" exact="cancer" post="by targeting Transmembrane emp24 domain-containing protein 3 (TMED3). Pichler"/>
   <result pre="Figure S1. miR-188-3p inhibits the replication of H7N9 and H5N6" exact="influenza" post="A virus in A549 cells. TCID50 values were used"/>
   <result pre="of miRNAs on replication of H7N9 (A) and H5N6 (B)" exact="influenza" post="A virus in A549 cells. The strains used were"/>
   <result pre="all pandemicsRev Biomed2006171697910.32776/revbiomed.v17i1.440 3.ShresthaSSSwerdlowDLBorseRHPrabhuVSFinelliLAtkinsCYet al.Estimating the burden of 2009 pandemic" exact="influenza" post="A (H1N1) in the United States (April 2009–April 2010)Clin"/>
   <result pre="(April 2009–April 2010)Clin Infect Dis201152suppl_1S75S8210.1093/cid/ciq01221342903 4.LiuJXiaoHWuYLiuDQiXShiYet al.H7N9: a low pathogenic" exact="avian influenza" post="A virus infecting humansCurr Opin Virol20145919710.1016/j.coviro.2014.03.00124705093 5.CoxNJSubbaraoKGlobal epidemiology of"/>
   <result pre="2009–April 2010)Clin Infect Dis201152suppl_1S75S8210.1093/cid/ciq01221342903 4.LiuJXiaoHWuYLiuDQiXShiYet al.H7N9: a low pathogenic avian" exact="influenza" post="A virus infecting humansCurr Opin Virol20145919710.1016/j.coviro.2014.03.00124705093 5.CoxNJSubbaraoKGlobal epidemiology of"/>
   <result pre="Med200051140742110.1146/annurev.med.51.1.40710774473 6.JohnsonNPMuellerJUpdating the accounts: global mortality of the 1918-1920 &quot;Spanish�?" exact="influenza" post="pandemicBull Hist Med200276110511510.1353/bhm.2002.002211875246 7.DawoodFSIulianoADReedCMeltzerMIShayDKChengPYet al.Estimated global mortality associated with"/>
   <result pre="mortality associated with the first 12 months of 2009 pandemic" exact="influenza" post="A H1N1 virus circulation: a modelling studyLancet Infect Dis201212968769510.1016/S1473-3099(12)70121-422738893"/>
   <result pre="H1N1 virus circulation: a modelling studyLancet Infect Dis201212968769510.1016/S1473-3099(12)70121-422738893 8.LiCChenHEnhancement of" exact="influenza" post="virus transmission by gene reassortmentInfluenza pathogenesis and control-volume I2014ChamSpringer185204"/>
   <result pre="reassortmentInfluenza pathogenesis and control-volume I2014ChamSpringer185204 9.YangZFMokCKPeirisJSZhongNSHuman infection with a novel" exact="avian influenza" post="A (H5N6) virusN Engl J Med2015373548748910.1056/NEJMc150298326222578 10.GaoRCaoBHuYFengZWangDHuWet al.Human infection"/>
   <result pre="pathogenesis and control-volume I2014ChamSpringer185204 9.YangZFMokCKPeirisJSZhongNSHuman infection with a novel avian" exact="influenza" post="A (H5N6) virusN Engl J Med2015373548748910.1056/NEJMc150298326222578 10.GaoRCaoBHuYFengZWangDHuWet al.Human infection"/>
   <result pre="Engl J Med2015373548748910.1056/NEJMc150298326222578 10.GaoRCaoBHuYFengZWangDHuWet al.Human infection with a novel avian-origin" exact="influenza" post="A (H7N9) virusN Engl J Med2013368201888189710.1056/NEJMoa130445923577628 11.LoregianAMercorelliBNannettiGCompagninCPalùGAntiviral strategies against"/>
   <result pre="influenza A (H7N9) virusN Engl J Med2013368201888189710.1056/NEJMoa130445923577628 11.LoregianAMercorelliBNannettiGCompagninCPalùGAntiviral strategies against" exact="influenza" post="virus: towards new therapeutic approachesCell Mol Life Sci201471193659368310.1007/s00018-014-1615-224699705 12.HayAJHaydenFGOseltamivir"/>
   <result pre="inhibitors that target the drug-resistant M2 proton channels from the" exact="influenza" post="A virusesPept Sci2015104429130910.1002/bip.22623 15.WienholdsEPlasterkRHMicroRNA function in animal developmentFEBS Lett2005579265911592210.1016/j.febslet.2005.07.07016111679"/>
   <result pre="microRNA-10b in breast cancerNature2007449716368268810.1038/nature0617417898713 21.TavazoieSFAlarcónCOskarssonTPaduaDWangQBosPDet al.Endogenous human microRNAs that suppress" exact="breast cancer" post="metastasisNature2008451717514715210.1038/nature0648718185580 22.HwangHWMendellJTMicroRNAs in cell proliferation, cell death, and tumorigenesisBr"/>
   <result pre="in breast cancerNature2007449716368268810.1038/nature0617417898713 21.TavazoieSFAlarcónCOskarssonTPaduaDWangQBosPDet al.Endogenous human microRNAs that suppress breast" exact="cancer" post="metastasisNature2008451717514715210.1038/nature0648718185580 22.HwangHWMendellJTMicroRNAs in cell proliferation, cell death, and tumorigenesisBr"/>
   <result pre="T lymphocytesNat Med20071310124110.1038/nm163917906637 26.SongLLiuHGaoSJiangWHuangWCellular microRNAs inhibit replication of the H1N1" exact="influenza" post="A virus in infected cellsJ Virol201084178849886010.1128/JVI.00456-1020554777 27.MaYJYangJFanXLZhaoHBHuWLiZPet al.Cellular micro"/>
   <result pre="micro RNA let-7c inhibits M1 protein expression of the H1N1" exact="influenza" post="A virus in infected human lung epithelial cellsJ Cell"/>
   <result pre="28.ZhangSWangRSuHWangBSizhuSLeiZet al.Sus scrofa miR-204 and miR-4331 negatively regulate swine H1N1/2009" exact="influenza" post="a virus replication by targeting viral HA and NS,"/>
   <result pre="Mol Sci201718474910.3390/ijms180407495412334 29.PengSWangJWeiSLiCZhouKHuJet al.Endogenous cellular MicroRNAs mediate antiviral defense against" exact="influenza" post="a virusMol Ther Nucleic Acids20181036137510.1016/j.omtn.2017.12.01629499948 30.JoplingCLYiMLancasterAMLemonSMSarnowPModulation of hepatitis C"/>
   <result pre="defense against influenza a virusMol Ther Nucleic Acids20181036137510.1016/j.omtn.2017.12.01629499948 30.JoplingCLYiMLancasterAMLemonSMSarnowPModulation of" exact="hepatitis" post="C virus RNA abundance by a liver-specific MicroRNAScience200530957401577158110.1126/science.111332916141076 31.LanfordREHildebrandt-EriksenESPetriAPerssonRLindowMMunkMEet"/>
   <result pre="MicroRNAScience200530957401577158110.1126/science.111332916141076 31.LanfordREHildebrandt-EriksenESPetriAPerssonRLindowMMunkMEet al.Therapeutic silencing of microRNA-122 in primates with chronic" exact="hepatitis" post="C virus infectionScience2010327596219820110.1126/science.117817819965718 32.EnrightAJJohnBGaulUTuschlTSanderCMarksDSMicroRNA targets in drosophilaGenome Biol200351R110.1186/gb-2003-5-1-r114709173 33.JohnBEnrightAJAravinATuschlTSanderCMarksDSHuman"/>
   <result pre="factor-β-regulated miR-24 promotes skeletal muscle differentiationNucleic Acids Res20083682690269910.1093/nar/gkn03218353861 35.ZhaoZGuoZZhangCLiuLChenLZhangCet al.Avian" exact="influenza" post="H5N6 viruses exhibit differing pathogenicities and transmissibilities in mammalsSci"/>
   <result pre="City; 2016. p. 423–44. 37.KeshavarzMDianat-MoghadamHSofianiVHKarimzadehMZargarMMoghoofeiMet al.miRNA-based strategy for modulation of" exact="influenza" post="A virus infectionEpigenomics201810682984410.2217/epi-2017-017029888954 38.ShiYWuYZhangWQiJGaoGFEnabling the ‘host jump’: structural determinants"/>
   <result pre="38.ShiYWuYZhangWQiJGaoGFEnabling the ‘host jump’: structural determinants of receptor-binding specificity in" exact="influenza" post="A virusesNat Rev Microbiol2014121282210.1038/nrmicro336225383601 39.AlboCValenciaAPortelaAIdentification of an RNA binding"/>
   <result pre="an RNA binding region within the N-terminal third of the" exact="influenza" post="A virus nucleoproteinJ Virol19956963799380610.1128/JVI.69.6.3799-3806.19957745727 40.BouloSAkarsuHRuigrokRWBaudinFNuclear traffic of influenza virus"/>
   <result pre="of the influenza A virus nucleoproteinJ Virol19956963799380610.1128/JVI.69.6.3799-3806.19957745727 40.BouloSAkarsuHRuigrokRWBaudinFNuclear traffic of" exact="influenza" post="virus proteins and ribonucleoprotein complexesVirus Res20071241–2122110.1016/j.virusres.2006.09.01317081640 41.ChenYLiangWYangSWuNGaoHShengJet al.Human infections"/>
   <result pre="and ribonucleoprotein complexesVirus Res20071241–2122110.1016/j.virusres.2006.09.01317081640 41.ChenYLiangWYangSWuNGaoHShengJet al.Human infections with the emerging" exact="avian influenza" post="A H7N9 virus from wet market poultry: clinical analysis"/>
   <result pre="ribonucleoprotein complexesVirus Res20071241–2122110.1016/j.virusres.2006.09.01317081640 41.ChenYLiangWYangSWuNGaoHShengJet al.Human infections with the emerging avian" exact="influenza" post="A H7N9 virus from wet market poultry: clinical analysis"/>
   <result pre="42.ChenHYuanHGaoRZhangJWangDXiongYet al.Clinical and epidemiological characteristics of a fatal case of" exact="avian influenza" post="A H10N8 virus infection: a descriptive studyLancet2014383991871472110.1016/S0140-6736(14)60111-224507376 43.PeirisMYuenKYLeungCWChanKHIpPLSLaiRWMet al.Human"/>
   <result pre="al.Clinical and epidemiological characteristics of a fatal case of avian" exact="influenza" post="A H10N8 virus infection: a descriptive studyLancet2014383991871472110.1016/S0140-6736(14)60111-224507376 43.PeirisMYuenKYLeungCWChanKHIpPLSLaiRWMet al.Human"/>
   <result pre="H10N8 virus infection: a descriptive studyLancet2014383991871472110.1016/S0140-6736(14)60111-224507376 43.PeirisMYuenKYLeungCWChanKHIpPLSLaiRWMet al.Human infection with" exact="influenza" post="H9N2Lancet1999354918291691710.1016/S0140-6736(99)03311-510489954 44.FouchierRASchneebergerPMRozendaalFWBroekmanJMKeminkSAMunsterVet al.Avian influenza A virus (H7N7) associated with"/>
   <result pre="descriptive studyLancet2014383991871472110.1016/S0140-6736(14)60111-224507376 43.PeirisMYuenKYLeungCWChanKHIpPLSLaiRWMet al.Human infection with influenza H9N2Lancet1999354918291691710.1016/S0140-6736(99)03311-510489954 44.FouchierRASchneebergerPMRozendaalFWBroekmanJMKeminkSAMunsterVet al.Avian" exact="influenza" post="A virus (H7N7) associated with human conjunctivitis and a"/>
   <result pre="H9N2Lancet1999354918291691710.1016/S0140-6736(99)03311-510489954 44.FouchierRASchneebergerPMRozendaalFWBroekmanJMKeminkSAMunsterVet al.Avian influenza A virus (H7N7) associated with human" exact="conjunctivitis" post="and a fatal case of acute respiratory distress syndromeProc"/>
   <result pre="syndromeProc Natl Acad Sci200410151356136110.1073/pnas.030835210014745020 45.De JongMDSimmonsCPThanhTTHienVMSmithGJChauTNBet al.Fatal outcome of human" exact="influenza" post="A (H5N1) is associated with high viral load and"/>
   <result pre="with high viral load and hypercytokinemiaNat Med20061210120310.1038/nm147716964257 46.XuFLiuGLiuQZhouYRNA interference of" exact="influenza" post="A virus replication by microRNA-adapted lentiviral loop short hairpin"/>
   <result pre="upregulation results in the inhibition of macrophage proinflammatory activities and" exact="atherosclerosis" post="in ApoE-deficient miceThromb Res2018171556110.1016/j.thromres.2018.09.04330253270 51.PeiJZhangJYangXWuZSunCWangZet al.TMED3 promotes cell proliferation"/>
   <result pre="miceThromb Res2018171556110.1016/j.thromres.2018.09.04330253270 51.PeiJZhangJYangXWuZSunCWangZet al.TMED3 promotes cell proliferation and motility in" exact="breast cancer" post="and is negatively modulated by miR-188-3pCancer Cell Int20191917510.1186/s12935-019-0791-430976199 52.PichlerMStiegelbauerVVychytilova-FaltejskovaPIvanCLingHWinterEet"/>
   <result pre="Res2018171556110.1016/j.thromres.2018.09.04330253270 51.PeiJZhangJYangXWuZSunCWangZet al.TMED3 promotes cell proliferation and motility in breast" exact="cancer" post="and is negatively modulated by miR-188-3pCancer Cell Int20191917510.1186/s12935-019-0791-430976199 52.PichlerMStiegelbauerVVychytilova-FaltejskovaPIvanCLingHWinterEet"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6993835\results\search\disease\results.xml">
   <result pre="6993835 doi: 10.12688/f1000research.20634.1 : Review: Articles Understanding and managing acute" exact="encephalitis" post="[version 1; peer review: 2 approved] KumarRashmiConceptualizationFunding AcquisitionWriting –"/>
   <result pre="In 2006, the World Health Organization coined the term &quot;acute" exact="encephalitis" post="syndrome�?, which simply means acute onset of fever with"/>
   <result pre="2013, the International Encephalitis Consortium set criteria for diagnosis of" exact="encephalitis" post="on basis of clinical and laboratory features. The most"/>
   <result pre="features. The most important infectious cause in the West is" exact="herpes simplex" post="virus, but globally Japanese encephalitis (JE) remains the single"/>
   <result pre="in the West is herpes simplex virus, but globally Japanese" exact="encephalitis" post="(JE) remains the single largest cause. Etiologic diagnosis is"/>
   <result pre="manifest with fever, convulsions, coma, neurologic deficits, and death. Autoimmune" exact="encephalitis" post="(AIE) includes two major categories: (i) classic paraneoplastic limbic"/>
   <result pre="encephalitis (AIE) includes two major categories: (i) classic paraneoplastic limbic" exact="encephalitis" post="(LE) with autoantibodies against intracellular neuronal antigens (Eg: Hu"/>
   <result pre="infections. Various forms of immunotherapy are used for AIE. Acute" exact="encephalitis" post="syndrome Japanese encephalitis autoimmune encephalitis Funding The author(s) declared"/>
   <result pre="of immunotherapy are used for AIE. Acute encephalitis syndrome Japanese" exact="encephalitis" post="autoimmune encephalitis Funding The author(s) declared that no grants"/>
   <result pre="are used for AIE. Acute encephalitis syndrome Japanese encephalitis autoimmune" exact="encephalitis" post="Funding The author(s) declared that no grants were involved"/>
   <result pre="common causes include metabolic, toxic, or ischemic disorders. The term" exact="encephalopathy" post="is also used for altered mentation due to any"/>
   <result pre="cause. Encephalopathy can also be acute or chronic. Encephalitis and" exact="meningitis" post="are overlapping syndromes. Pathologically, both viral and non-viral invasions"/>
   <result pre="no sensorial alteration 3. The magnitude of the problem of" exact="encephalitis" post="is difficult to assess because of a lack of"/>
   <result pre="varies. In the US, there were 73 hospitalizations due to" exact="encephalitis" post="per 100,000 population (95% confidence interval 7.1–7.6) 4 from"/>
   <result pre="Canada, between 2002 and 2013, the crude incidence of all-cause" exact="encephalitis" post="was estimated to be about 4.3 cases per 100,000"/>
   <result pre="variety of central nervous system disorders may mimic encephalitis. Infectious" exact="encephalitis" post="can occur in epidemic, endemic, or sporadic form. In"/>
   <result pre="In 2006, the World Health Organization coined the term &quot;acute" exact="encephalitis" post="syndrome�? (AES) for the purpose of surveillance of JE."/>
   <result pre="constitutes a public health problem. Table 1. Etiology of acute" exact="encephalitis" post="syndrome. I. Viral agents that are known to cause"/>
   <result pre="encephalitis syndrome. I. Viral agents that are known to cause" exact="encephalitis" post="Arboviruses, togaviruses, and alphaviruses • Western equine encephalitis virus"/>
   <result pre="to cause encephalitis Arboviruses, togaviruses, and alphaviruses • Western equine" exact="encephalitis" post="virus • Eastern equine encephalitis virus • Venezuelan equine"/>
   <result pre="and alphaviruses • Western equine encephalitis virus • Eastern equine" exact="encephalitis" post="virus • Venezuelan equine encephalitis virus Flaviviruses (mosquito-borne) •"/>
   <result pre="encephalitis virus • Eastern equine encephalitis virus • Venezuelan equine" exact="encephalitis" post="virus Flaviviruses (mosquito-borne) • Japanese encephalitis virus • St"/>
   <result pre="virus • Venezuelan equine encephalitis virus Flaviviruses (mosquito-borne) • Japanese" exact="encephalitis" post="virus • St Louis encephalitis virus • West Nile"/>
   <result pre="virus Flaviviruses (mosquito-borne) • Japanese encephalitis virus • St Louis" exact="encephalitis" post="virus • West Nile virus • Murray Valley encephalitis"/>
   <result pre="Louis encephalitis virus • West Nile virus • Murray Valley" exact="encephalitis" post="virus • Non-arthropod-borne togavirus – rubella virus Bunyaviruses •"/>
   <result pre="virus • Murray Valley encephalitis virus • Non-arthropod-borne togavirus –" exact="rubella" post="virus Bunyaviruses • California encephalitis virus Reoviruses • Colorado"/>
   <result pre="virus • Non-arthropod-borne togavirus – rubella virus Bunyaviruses • California" exact="encephalitis" post="virus Reoviruses • Colorado tick fever encephalitis virus Herpesviruses"/>
   <result pre="Bunyaviruses • California encephalitis virus Reoviruses • Colorado tick fever" exact="encephalitis" post="virus Herpesviruses • Herpes simplex 1 and 2 •"/>
   <result pre="echinococcus, cysticercus, schistosoma III.Non-infectious inflammation of brain • Acute disseminated" exact="encephalomyelitis" post="• Antibody-associated encephalitis • Collagen vascular disorders IV.Infectious encephalopathy"/>
   <result pre="III.Non-infectious inflammation of brain • Acute disseminated encephalomyelitis • Antibody-associated" exact="encephalitis" post="• Collagen vascular disorders IV.Infectious encephalopathy • Cerebral malaria"/>
   <result pre="disseminated encephalomyelitis • Antibody-associated encephalitis • Collagen vascular disorders IV.Infectious" exact="encephalopathy" post="• Cerebral malaria • Shigella encephalopathy • Dengue encephalopathy"/>
   <result pre="Antibody-associated encephalitis • Collagen vascular disorders IV.Infectious encephalopathy • Cerebral" exact="malaria" post="• Shigella encephalopathy • Dengue encephalopathy • Sepsis syndrome"/>
   <result pre="Collagen vascular disorders IV.Infectious encephalopathy • Cerebral malaria • Shigella" exact="encephalopathy" post="• Dengue encephalopathy • Sepsis syndrome • Enteric encephalopathy"/>
   <result pre="IV.Infectious encephalopathy • Cerebral malaria • Shigella encephalopathy • Dengue" exact="encephalopathy" post="• Sepsis syndrome • Enteric encephalopathy V. Structural causes"/>
   <result pre="Shigella encephalopathy • Dengue encephalopathy • Sepsis syndrome • Enteric" exact="encephalopathy" post="V. Structural causes of coma with associated fever due"/>
   <result pre="coma with associated fever due to another cause • Electrolyte" exact="encephalopathy" post="• Reye’s syndrome • Diabetic coma • Uremic coma"/>
   <result pre="Inborn error of metabolism • Chemicals • Toxins • Hypertensive" exact="encephalopathy" post="II.Non-viral agents • Rickettsia: Rocky mountain spotted fever, endemic"/>
   <result pre="Toxins • Hypertensive encephalopathy II.Non-viral agents • Rickettsia: Rocky mountain" exact="spotted fever," post="endemic and epidemictyphus, Coxiellaburnetti, Ehrlichiosis, scrub typhus • Bacterial:"/>
   <result pre="Rickettsia: Rocky mountain spotted fever, endemic and epidemictyphus, Coxiellaburnetti, Ehrlichiosis," exact="scrub typhus" post="• Bacterial: ○ Pyogenic (bacterial) meningitis The table is"/>
   <result pre="Rocky mountain spotted fever, endemic and epidemictyphus, Coxiellaburnetti, Ehrlichiosis, scrub" exact="typhus" post="• Bacterial: ○ Pyogenic (bacterial) meningitis The table is"/>
   <result pre="epidemictyphus, Coxiellaburnetti, Ehrlichiosis, scrub typhus • Bacterial: ○ Pyogenic (bacterial)" exact="meningitis" post="The table is based on data from 7. In"/>
   <result pre="Encephalitis Consortium (IEC) suggested consensus criteria for case definition of" exact="encephalitis" post="or encephalopathy of presumed infectious or autoimmune etiology 8."/>
   <result pre="(IEC) suggested consensus criteria for case definition of encephalitis or" exact="encephalopathy" post="of presumed infectious or autoimmune etiology 8. Neurologic dysfunction"/>
   <result pre="not differentiate infectious from post- or non-infectious processes 8. Acute" exact="encephalitis" post="syndrome etiology The most important cause is infection—both viral"/>
   <result pre="agents include primary neurotropic viruses such as arboviruses, herpesviruses, and" exact="rabies" post="virus as well as other &quot;incidental�? nervous system pathogens"/>
   <result pre="7. Worldwide, JE is the single largest cause of viral" exact="encephalitis" post="(VE) 9. Non-viral brain infectious agents include bacteria, mycoplasma,"/>
   <result pre="metazoa, and fungi. Non-infectious brain inflammation such as in AIE," exact="acute disseminated encephalomyelitis" post="(ADEM), and collagen vascular disorders is another group. In"/>
   <result pre="fungi. Non-infectious brain inflammation such as in AIE, acute disseminated" exact="encephalomyelitis" post="(ADEM), and collagen vascular disorders is another group. In"/>
   <result pre="infectious cause 10. The most common sporadic infectious encephalitisis is" exact="herpes simplex" post="virus encephalitis (HSVE) 11. The California Encephalitis Project enrolled"/>
   <result pre="The most common sporadic infectious encephalitisis is herpes simplex virus" exact="encephalitis" post="(HSVE) 11. The California Encephalitis Project enrolled 1570 patients"/>
   <result pre="11. The California Encephalitis Project enrolled 1570 patients with suspected" exact="encephalitis" post="over a 7-year period (1998–2005): &quot;A core battery of"/>
   <result pre="common pathogen was human enterovirus (EV) (27.7%). The etiology of" exact="viral meningitis" post="was identified in 42.8% of cases; the leading pathogen"/>
   <result pre="pathogen was human enterovirus (EV) (27.7%). The etiology of viral" exact="meningitis" post="was identified in 42.8% of cases; the leading pathogen"/>
   <result pre="of literature has emerged from various parts of India, implicating" exact="scrub typhus" post="(caused by Orientia tsutsugamushi) meningoencephalitis as an important cause"/>
   <result pre="literature has emerged from various parts of India, implicating scrub" exact="typhus" post="(caused by Orientia tsutsugamushi) meningoencephalitis as an important cause"/>
   <result pre="parts of India, implicating scrub typhus (caused by Orientia tsutsugamushi)" exact="meningoencephalitis" post="as an important cause of AES here 15– 18."/>
   <result pre="15– 18. Nipah virus, a paramyxovirus known to cause severe" exact="encephalitis" post="in Malaysian pig farmers, caused an outbreak of encephalitis"/>
   <result pre="severe encephalitis in Malaysian pig farmers, caused an outbreak of" exact="encephalitis" post="in the southern state of Kerela 19, 20. Dengue"/>
   <result pre="23. A recent study from Lucknow, described trend of infectious" exact="encephalitis" post="after immunization for JE was incorporated. Evidence of JE"/>
   <result pre="8.3%, dengue 7.8%, EVs 0.4%, HSV 0.8%, varicella zoster 0.4%," exact="scrub typhus" post="meningoencephalitis in 31.8%, Haemophilus influenza in 0.97%, and Streptococcus"/>
   <result pre="dengue 7.8%, EVs 0.4%, HSV 0.8%, varicella zoster 0.4%, scrub" exact="typhus" post="meningoencephalitis in 31.8%, Haemophilus influenza in 0.97%, and Streptococcus"/>
   <result pre="7.8%, EVs 0.4%, HSV 0.8%, varicella zoster 0.4%, scrub typhus" exact="meningoencephalitis" post="in 31.8%, Haemophilus influenza in 0.97%, and Streptococcus pmeumoniae"/>
   <result pre="0.8%, varicella zoster 0.4%, scrub typhus meningoencephalitis in 31.8%, Haemophilus" exact="influenza" post="in 0.97%, and Streptococcus pmeumoniae in 0.94% 24. So"/>
   <result pre="Western equine, eastern equine, Californian, and St. Louis encephalitis. Venezuelan" exact="encephalitis" post="is found in South America, and JE in Asia."/>
   <result pre="produces an explosive outbreak. HSVE is the commonest sporadic infectious" exact="encephalitis" post="in Western countries. It tends to occur worldwide with"/>
   <result pre="little seasonal or age and sex predilection 4. West Nile" exact="encephalitis" post="virus was introduced in the US in the 1990s"/>
   <result pre="and the illness is endemic there 26. Mumps, measles, and" exact="rabies" post="encephalitis have been largely eradicated from many developed countries"/>
   <result pre="the illness is endemic there 26. Mumps, measles, and rabies" exact="encephalitis" post="have been largely eradicated from many developed countries because"/>
   <result pre="or enter the brain by retrograde axonal transport (for example," exact="rabies" post="virus). Neuronal infection causes release of cytokines leading to"/>
   <result pre="to cytotoxicity, inflammation, and tissue damage 27. Another mechanism is" exact="vasculitis" post="leading to tissue ischemia as happens with varicella zoster"/>
   <result pre="that IL-1 antagonists should be investigated as adjunctive treatment in" exact="encephalitis" post="29. AIE includes two major categories: (i) classic paraneoplastic"/>
   <result pre="of immune-mediated disease may also coexist, as illustrated by HSV" exact="encephalitis" post="cases with subsequent or concurrent anti-NMDAR antibodies identified 33."/>
   <result pre="without sequelae 7. Examination should include a search for skin" exact="rash" post="often seen with enteroviral encephalitis, measles, dengue, varicella zoster,"/>
   <result pre="lesions like &quot;cold sore�?, believed to be a manifestation of" exact="herpes simplex" post="infection, have little diagnostic value. Concurrent upper respiratory infection"/>
   <result pre="Concurrent upper respiratory infection is characteristic of influenza. Patients with" exact="rabies" post="may have the characteristic hydrophobia or aerophobia. Neurologic signs"/>
   <result pre="have the characteristic hydrophobia or aerophobia. Neurologic signs in acute" exact="encephalitis" post="do not reliably identify the underlying etiology despite the"/>
   <result pre="and abnormal movements, especially in the convalescent stage 40. Cerebral" exact="malaria" post="presents as acute onset of fever with chills and"/>
   <result pre="are seen in dengue, rickettsial infection, enteric fever, leptospirosis, and" exact="cerebral malaria" post="42. In AIE, psychiatric manifestations are common early in"/>
   <result pre="seen in dengue, rickettsial infection, enteric fever, leptospirosis, and cerebral" exact="malaria" post="42. In AIE, psychiatric manifestations are common early in"/>
   <result pre="for detection of rickettsial IgM is used for diagnosis of" exact="scrub typhus" post="meningoencephalitis. Multiplex PCR panels for a variety of agents"/>
   <result pre="detection of rickettsial IgM is used for diagnosis of scrub" exact="typhus" post="meningoencephalitis. Multiplex PCR panels for a variety of agents"/>
   <result pre="picture may be seen with a few pathogens. Herpes simplex" exact="encephalitis" post="classically affects temporal and frontal lobes. Focal edema is"/>
   <result pre="blood transfusion. 5. The role of steroids in acute infectious" exact="encephalitis" post="is debatable. There are theoretical arguments for and against"/>
   <result pre="therapy Among the viral agents, specific therapy is recommended in" exact="encephalitis" post="due to the herpes group of viruses. Acyclovir in"/>
   <result pre="A combination of ganciclovir and foscarnet is recommended for cytomegaloviral" exact="encephalitis" post="59. Pleconaril is an investigational agent for enteroviral infections,"/>
   <result pre="viral attachment and uncoating 60. Oseltamivir can be considered for" exact="influenza" post="(H1N1) encephalitis/encephalopathy 59. Trials with interferon alpha and nasogastric"/>
   <result pre="Intravenous azithromycin or oral minocycline/doxycycline is currently recommended for rickettsial" exact="meningoencephalitis" post="64.Treatment of AIE is immunosuppression through high-dose methylprednisolone pulse"/>
   <result pre="the United States, 1988-1997.Clin Infect Dis.2002;35(2):175–82. 10.1086/34130112087524 3ShuklaBAguileraEASalazarLet al.: Aseptic" exact="meningitis" post="in adults and children: Diagnostic and management challenges.J Clin"/>
   <result pre="algorithms, and priorities in encephalitis: consensus statement of the international" exact="encephalitis" post="consortium.Clin Infect Dis.2013;57(8):1114–28. 10.1093/cid/cit45823861361 F1000 Recommendation 9WangHLiangG: Epidemiology of"/>
   <result pre="To what extent can clinical characteristics be used to distinguish" exact="encephalitis" post="from encephalopathy of other causes? Results from a prospective"/>
   <result pre="extent can clinical characteristics be used to distinguish encephalitis from" exact="encephalopathy" post="of other causes? Results from a prospective observational study.BMC"/>
   <result pre="F1000 Recommendation 12AiJXieZLiuGet al.: Etiology and prognosis of acute viral" exact="encephalitis" post="and meningitis in Chinese children: a multicentre prospective study.BMC"/>
   <result pre="12AiJXieZLiuGet al.: Etiology and prognosis of acute viral encephalitis and" exact="meningitis" post="in Chinese children: a multicentre prospective study.BMC Infect Dis.2017;17(1):"/>
   <result pre="features in children hospitalized during the 2005 epidemic of Japanese" exact="encephalitis" post="in Uttar Pradesh, India.Clin Infect Dis.2006;43(2):123–31. 10.1086/50512116779737 F1000 Recommendation"/>
   <result pre="Infect Dis.2006;43(2):123–31. 10.1086/50512116779737 F1000 Recommendation 14JainPSinghAKKhanDNet al.: Trend of Japanese" exact="encephalitis" post="in Uttar Pradesh, India from 2011 to 2013.Epidemiol Infect.2016;144(2):363–70."/>
   <result pre="India from 2011 to 2013.Epidemiol Infect.2016;144(2):363–70. 10.1017/S095026881500092826112391 15MeenaJKKhandelwalSGuptaPet al.: Scrub" exact="typhus" post="meningitis: An emerging infectious threat.IOSR Journal of Dental and"/>
   <result pre="true entity?Am J Trop Med Hyg.1996;54(3):256–9. 10.4269/ajtmh.1996.54.2568600761 22KumarRTripathiSTambeJJet al.: Dengue" exact="encephalopathy" post="in children in Northern India: clinical features and comparison"/>
   <result pre="dengue.J Neurol Sci.2008;269(1–2):41–8. 10.1016/j.jns.2007.12.01818222482 23ShrivastavaAKumarAThomasJDet al.: Association of acute toxic" exact="encephalopathy" post="with litchi consumption in an outbreak in Muzaffarpur, India,"/>
   <result pre="Glob Health.2017;5(4):e458–e466. 10.1016/S2214-109X(17)30035-928153514 F1000 Recommendation 24JainPPrakashSKhanDNet al.: Aetiology of acute" exact="encephalitis" post="syndrome in Uttar Pradesh, India from 2014 to 2016.J"/>
   <result pre="Encephalitis.J Clin Neurol.2016;12(1):1–13. 10.3988/jcn.2016.12.1.126754777 32DalmauJTüzünEWuHYet al.: Paraneoplastic anti- N-methyl-D-aspartate receptor" exact="encephalitis" post="associated with ovarian teratoma.Ann Neurol.2007;61(1):25–36. 10.1002/ana.2105017262855 F1000 Recommendation 33HermetterCFazekasFHochmeisterS:"/>
   <result pre="in Autoimmune Encephalitis.Front Neurol.2018;9:706. 10.3389/fneur.2018.0070630233481 F1000 Recommendation 34GulatiSSondhiVChakrabortyBet al.: Autoimmune" exact="encephalitis" post="in children: Clinical profile and outcome from a single"/>
   <result pre="Saunders Co, Pennsylvania, 14thedn1993;666–669. 37KalitaJMisraUKManiVEet al.: Can we differentiate between" exact="herpes simplex" post="encephalitis and Japanese encephalitis?J Neurol Sci.2016;366:110–5. 10.1016/j.jns.2016.05.01727288787 38SchlesingerYBullerRSBrunstromJEet al.:"/>
   <result pre="Pennsylvania, 14thedn1993;666–669. 37KalitaJMisraUKManiVEet al.: Can we differentiate between herpes simplex" exact="encephalitis" post="and Japanese encephalitis?J Neurol Sci.2016;366:110–5. 10.1016/j.jns.2016.05.01727288787 38SchlesingerYBullerRSBrunstromJEet al.: Expanded"/>
   <result pre="Japanese encephalitis?J Neurol Sci.2016;366:110–5. 10.1016/j.jns.2016.05.01727288787 38SchlesingerYBullerRSBrunstromJEet al.: Expanded spectrum of" exact="herpes simplex" post="encephalitis in childhood.J Pediatr.1995;126(2):234–41. 10.1016/s0022-3476(95)70550-37844669 39KumarS: Differentiating paralytic rabies"/>
   <result pre="Neurol Sci.2016;366:110–5. 10.1016/j.jns.2016.05.01727288787 38SchlesingerYBullerRSBrunstromJEet al.: Expanded spectrum of herpes simplex" exact="encephalitis" post="in childhood.J Pediatr.1995;126(2):234–41. 10.1016/s0022-3476(95)70550-37844669 39KumarS: Differentiating paralytic rabies from"/>
   <result pre="herpes simplex encephalitis in childhood.J Pediatr.1995;126(2):234–41. 10.1016/s0022-3476(95)70550-37844669 39KumarS: Differentiating paralytic" exact="rabies" post="from post antirabies vaccine polyradiculoneuropathy.Neurol India.2004;52(2):270; author reply 270–1."/>
   <result pre="al.: Clinical predictors of Japanese encephalitis.Neuroepidemiology.1994;13(3):97–102. 10.1159/0001103658015669 41MacCormickIJBeareNATaylorTEet al.: Cerebral" exact="malaria" post="in children: using the retina to study the brain.Brain.2014;137(Pt"/>
   <result pre="43LiLSunLDuRet al.: Application of the 2016 diagnostic approach for autoimmune" exact="encephalitis" post="from Lancet Neurology to Chinese patients.BMC Neurol.2017;17(1): 195. 10.1186/s12883-017-0974-329110638"/>
   <result pre="of reverse-transcriptase PCR as a diagnostic tool to confirm Japanese" exact="encephalitis" post="virus infection.Trans R Soc Trop Med Hyg.2009;103(4):403–6. 10.1016/j.trstmh.2009.01.02119249068 47SarkarATaraphdarDMukhopadhyaySKet"/>
   <result pre="10.1016/j.trstmh.2009.01.02119249068 47SarkarATaraphdarDMukhopadhyaySKet al.: Molecular evidence for the occurrence of Japanese" exact="encephalitis" post="virus genotype I and III infection associated with acute"/>
   <result pre="Use of clinical and neuroimaging characteristics to distinguish temporal lobe" exact="herpes simplex" post="encephalitis from its mimics.Clin Infect Dis.2015;60(9):1377–83. 10.1093/cid/civ05125637586 49MisraUKKalitaJJainSKet al.:"/>
   <result pre="clinical and neuroimaging characteristics to distinguish temporal lobe herpes simplex" exact="encephalitis" post="from its mimics.Clin Infect Dis.2015;60(9):1377–83. 10.1093/cid/civ05125637586 49MisraUKKalitaJJainSKet al.: Radiological"/>
   <result pre="involvement in Japanese encephalitis.J Neuroimaging.2009;19(3):280–2. 10.1111/j.1552-6569.2008.00271.x18811670 52MisraUKKalitaJ: Neurophysiological studies in" exact="herpes simplex" post="encephalitis.Electromyogr Clin Neurophysiol.1998;38(3):177–82. 9637944 53SankaranarayananMShahSThomasPet al.: Persistent extreme delta"/>
   <result pre="al.: Effect of high-dose dexamethasone on the outcome of acute" exact="encephalitis" post="due to Japanese encephalitis virus.J Infect Dis.1992;165(4):631–7. 10.1093/infdis/165.4.6311313068 56StanberryLR:"/>
   <result pre="dexamethasone on the outcome of acute encephalitis due to Japanese" exact="encephalitis" post="virus.J Infect Dis.1992;165(4):631–7. 10.1093/infdis/165.4.6311313068 56StanberryLR: Herpes simplex virus. In:"/>
   <result pre="administration.J Antimicrob Chemother.1983;12(Suppl B):29–37. 10.1093/jac/12.suppl_b.296355048 58BergmannMBeerRKoflerMet al.: Acyclovir resistance in" exact="herpes simplex" post="virus type I encephalitis: a case report.J Neurovirol.2017;23(2):335–7. 10.1007/s13365-016-0489-527787806"/>
   <result pre="62KumarRTripathiPBaranwalMet al.: Randomized, controlled trial of oral ribavirin for Japanese" exact="encephalitis" post="in children in Uttar Pradesh, India.Clin Infect Dis.2009;48(4):400–6. 10.1086/59630919143532"/>
   <result pre="Dis.2009;48(4):400–6. 10.1086/59630919143532 63KumarRBasuASinhaSet al.: Role of oral Minocycline in acute" exact="encephalitis" post="syndrome in India - a randomized controlled trial.BMC Infect"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6994196\results\search\disease\results.xml">
   <result pre="[7]. In a minority of patients, the infection progresses to" exact="encephalitis" post="or haemorrhagic fever, of which the latter is often"/>
   <result pre="scheduled at 6 dpi. All ewes showed a multifocal necrotizing" exact="hepatitis" post="which was most severe in the animal that died"/>
   <result pre="1F and 1G). Necropsy at 4 dpi revealed multifocal necrotizing" exact="hepatitis" post="in all ewes but no macroscopic abnormalities in placentas"/>
   <result pre="J Gen Virol98: 875–887. 10.1099/jgv.0.00076528555542 2DaubneyR, HudsonJR, GarnhamPC (1931) Enzootic" exact="hepatitis" post="or rift valley fever. An undescribed virus disease of"/>
   <result pre="Virol98: 875–887. 10.1099/jgv.0.00076528555542 2DaubneyR, HudsonJR, GarnhamPC (1931) Enzootic hepatitis or" exact="rift valley fever." post="An undescribed virus disease of sheep cattle and man"/>
   <result pre="(1931) Rift Valley fever. Lancet. 14DaubneyR, HudsonJR, GarnhamPC (1931) Enzootic" exact="hepatitis" post="or Rift Valley fever: An undescribed disease of sheep,"/>
   <result pre="et al. (2001) Genetic evidence for an interferon-antagonistic function of" exact="rift valley fever" post="virus nonstructural protein NSs. J Virol75: 1371–1377. 10.1128/JVI.75.3.1371-1377.200111152510 29HabjanM,"/>
   <result pre="PichlmairA, ElliottRM, OverbyAK, GlatterT, et al. (2009) NSs protein of" exact="rift valley fever" post="virus induces the specific degradation of the double-stranded RNA-dependent"/>
   <result pre="PLoS Pathog5: e100028710.1371/journal.ppat.100028719197350 31KalveramB, LihoradovaO, IkegamiT (2011) NSs protein of" exact="rift valley fever" post="virus promotes posttranslational downregulation of the TFIIH subunit p62."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6994851\results\search\disease\results.xml">
   <result pre="HeliyonHeliyonHeliyon2405-8440Elsevier pmcid: 6994851S2405-8440(20)30149-3 doi: 10.1016/j.heliyon.2020.e03304e03304 : Article Overview of seasonal" exact="influenza" post="and recommended vaccine during the 2016/2017 season in Nepal"/>
   <result pre="Influenza is a highly contagious viral respiratory infection caused by" exact="influenza" post="viruses whose epidemic and pandemic have resulted in significant"/>
   <result pre="resulted in significant morbidity and mortality. The annual epidemic of" exact="influenza" post="results in an estimated 3–5 million cases of severe"/>
   <result pre="improvement. This study was aimed to investigate the types of" exact="influenza" post="viruses prevailing in Nepal during 2016 and, to match"/>
   <result pre="from patients of different age group referred to NPHL for" exact="influenza" post="testing. The specimen was primarily stored at 4 °C"/>
   <result pre="using ABI 7500 RT PCR system for the identification of" exact="influenza" post="viruses. Results Of the total 1683 patients suspected of"/>
   <result pre="viruses. Results Of the total 1683 patients suspected of having" exact="influenza" post="infection, influenza viruses were isolated from 614 (36.5%) patients"/>
   <result pre="Of the total 1683 patients suspected of having influenza infection," exact="influenza" post="viruses were isolated from 614 (36.5%) patients with male"/>
   <result pre="male predominance. The highest number of infection was caused by" exact="influenza" post="A/H3 strain (51.0%) followed by influenza B (40.4%) and"/>
   <result pre="infection was caused by influenza A/H3 strain (51.0%) followed by" exact="influenza" post="B (40.4%) and influenza A (H1N1) pdm09 (8.6%). Two"/>
   <result pre="influenza A/H3 strain (51.0%) followed by influenza B (40.4%) and" exact="influenza" post="A (H1N1) pdm09 (8.6%). Two peaks of infection were"/>
   <result pre="lineage. Conclusion We concluded that Nepal experiences semiannual cycle of" exact="influenza" post="infection, firstly during the month of January–February and secondly"/>
   <result pre="need to be decided by national authority based on prevailing" exact="influenza" post="types to confer effective immunization. Microbiology, Genetics, Molecular biology,"/>
   <result pre="Influenza is a highly contagious viral respiratory infection caused by" exact="influenza" post="viruses whose epidemic and pandemic have resulted in significant"/>
   <result pre="in significant morbidity and mortality worldwide. The annual epidemic of" exact="influenza" post="results in an estimated 3–5 million cases of severe"/>
   <result pre="the family orthomyxoviridae and it is classified into four genera:" exact="influenza" post="A, B, C and D. Influenza A and B"/>
   <result pre="epidemics [4]. Influenza C virus causes only mild illness whereas" exact="influenza" post="D virus is not known to cause illness in"/>
   <result pre="two lineages: B/Yamagata and B/Victoria [4]. There are 131subtypes of" exact="influenza" post="A detected in nature among which A(H1N1) and A(H3N2)"/>
   <result pre="different time and place [5, 6]. A study on global" exact="influenza" post="activities suggests that 171 seasonal influenza epidemics have occurred"/>
   <result pre="A study on global influenza activities suggests that 171 seasonal" exact="influenza" post="epidemics have occurred from 1997 to 2005 in different"/>
   <result pre="Kong flu in 1968 by H3N2 [9]. Studies suggest that" exact="influenza" post="virus has an annual or semi-annual cycle based on"/>
   <result pre="involve annual, semi-annual or year-round activity [10]. The pattern of" exact="influenza" post="virus circulation varies or remains same throughout the year"/>
   <result pre="human population [6]. This further suggests that genetic characterization of" exact="influenza" post="viruses circulating around the world is important and timely"/>
   <result pre="and, control the spread of viruses. The first outbreak of" exact="influenza" post="in Nepal was detected in year 2004 at Bhutanese"/>
   <result pre="Bhutanese refugee camp in southeastern Nepal, which was caused by" exact="influenza" post="A/H3 serotype [12]. Since then, Nepal has an increasing"/>
   <result pre="serotype [12]. Since then, Nepal has an increasing number of" exact="influenza" post="positive cases with two major epidemics in year 2004"/>
   <result pre="and 2009 [13,14]. The epidemic in 2009 was due to" exact="influenza" post="A (H1N1) whose first case was seen in June"/>
   <result pre="16]. In the very preliminary phase of diagnostic services of" exact="influenza" post="virus in Nepal, we had very limited information about"/>
   <result pre="influenza virus in Nepal, we had very limited information about" exact="influenza" post="infection and its types. In addition, it was also"/>
   <result pre="two central objectives: 1. to determine the seasonal activity of" exact="influenza" post="virus in Nepal in year 2016 and, 2. to"/>
   <result pre="till further processing. Patients included in the study had either" exact="influenza" post="like illness (ILI) that includes fever (&amp;gt;38 °C), cough,"/>
   <result pre="and sore throat or, severe acute respiratory infection (SARI) or" exact="pneumonia" post="which was in accordance with WHO case definition for"/>
   <result pre="the other was stored at -70 °C. The identification of" exact="influenza" post="virus was carried out by Applied Biosystems™ 7500 Real-Time"/>
   <result pre="AgPath-ID™ One-step RT-PCR Kit (Thermo Fisher Scientific, USA). RNA of" exact="influenza" post="viruse was extracted using QIAamp® Viral RNA Mini Kit"/>
   <result pre="The extracted RNA was first tested for the presence of" exact="influenza" post="A and B viruses. The sample showing positive for"/>
   <result pre="influenza A and B viruses. The sample showing positive for" exact="influenza" post="A/B was further differentiated into sub types and lineages."/>
   <result pre="screened for Pdm A, Pdm H1, A/H3 whereas samples showing" exact="influenza" post="B positive were tested for B/Yamagata and B/Victoria lineage."/>
   <result pre="lineage. Due to limited number of PCR kit, only 106" exact="influenza" post="B positive samples were processed to identify their lineages."/>
   <result pre="mixture for identification of different types, subtypes and lineages of" exact="influenza" post="virus (H1N1, H3N2, H1N1pdm09, Influenza B, B/Victoria, B/Yamagata) were"/>
   <result pre="registered at National Public Health Laboratory to test for suspected" exact="influenza" post="infection among which influenza virus was identified in 614"/>
   <result pre="Health Laboratory to test for suspected influenza infection among which" exact="influenza" post="virus was identified in 614 cases. A relatively higher"/>
   <result pre="were male in comparison to female. Age-group distribution of both" exact="influenza" post="suspected cases as well as influenza positive cases showed"/>
   <result pre="Age-group distribution of both influenza suspected cases as well as" exact="influenza" post="positive cases showed that higher number were from adult"/>
   <result pre="data also revealed that higher number of suspected cases had" exact="influenza" post="like illness (64%) followed by severe acute respiratory infection"/>
   <result pre="illness (64%) followed by severe acute respiratory infection (26%) and" exact="pneumonia" post="(10%) (Figure 1). Table 1 Age wise distribution of"/>
   <result pre="614 (100) Figure 1 Clinical signs of patients suspected for" exact="influenza" post="infection (N = 1683). National Public Health Laboratory being"/>
   <result pre="National Public Health Laboratory being only one diagnosis center for" exact="influenza" post="infection in Nepal during 2016, patients from all over"/>
   <result pre="from 63 districts of the country. However, positive cases for" exact="influenza" post="infection were confirmed from 44 districts only. The highest"/>
   <result pre="(Figure 2). Figure 2 Map of Nepal showing districts with" exact="influenza" post="cases in year 2016. 3.2 Prevalence of influenza viruses"/>
   <result pre="districts with influenza cases in year 2016. 3.2 Prevalence of" exact="influenza" post="viruses Out of total 1683 suspected cases for having"/>
   <result pre="influenza viruses Out of total 1683 suspected cases for having" exact="influenza" post="infection, we identified influenza viruses from 614 (36.5%) cases"/>
   <result pre="total 1683 suspected cases for having influenza infection, we identified" exact="influenza" post="viruses from 614 (36.5%) cases (Figure 3). Influenza type"/>
   <result pre="type A accounted for 364 (59.3%) cases of infection whereas" exact="influenza" post="type B was found in 248 (40.4%) cases. More"/>
   <result pre="half number of patients 313 (51.0%) were found infected with" exact="influenza" post="A/H3 strain alone. Among the 248 cases of influenza"/>
   <result pre="with influenza A/H3 strain alone. Among the 248 cases of" exact="influenza" post="B infection, 106 isolates were further differentiated into lineage"/>
   <result pre="(11.1%) in comparison to B/Victoria lineage (6.2%). Interestingly, co-infection of" exact="influenza" post="B and influenza A/H3 strain was found in two"/>
   <result pre="to B/Victoria lineage (6.2%). Interestingly, co-infection of influenza B and" exact="influenza" post="A/H3 strain was found in two cases during the"/>
   <result pre="the period of study (Table 2). Figure 3 Incidence of" exact="influenza" post="infection among suspected cases (N = 1683). Table 2"/>
   <result pre="suspected cases (N = 1683). Table 2 Viruses identified in" exact="influenza" post="positive cases in year 2016 (N = 614). [alt-text]"/>
   <result pre="B 2 0.3 Total 614 100 3.3 Seasonal distribution of" exact="influenza" post="viruses Figure 4 illustrates the distribution of cases of"/>
   <result pre="influenza viruses Figure 4 illustrates the distribution of cases of" exact="influenza" post="in different months throughout the year 2016. It can"/>
   <result pre="year 2016. It can be seen that higher number of" exact="influenza" post="cases were reported two times during the year 2016,"/>
   <result pre="of July–August. The highest number of cases suspected of having" exact="influenza" post="infection and, influenza positive cases both were recorded in"/>
   <result pre="highest number of cases suspected of having influenza infection and," exact="influenza" post="positive cases both were recorded in the month of"/>
   <result pre="than half of the total cases. The least number of" exact="influenza" post="positive cases were reported in the months of May,"/>
   <result pre="and November (Figure 4). Figure 4 Month wise analysis of" exact="influenza" post="cases in year 2016 (N = 1683). In addition,"/>
   <result pre="in year 2016 (N = 1683). In addition, infection with" exact="influenza" post="A/H3 strain was found predominant in the months of"/>
   <result pre="trend was found reversed in the month of August making" exact="influenza" post="B predominant. Overall, influenza A/H3 was responsible for majority"/>
   <result pre="in the month of August making influenza B predominant. Overall," exact="influenza" post="A/H3 was responsible for majority of infection in the"/>
   <result pre="for majority of infection in the month of January–February while" exact="influenza" post="B was the major cause of infection in the"/>
   <result pre="infection in the peak season of July–August. Few cases of" exact="influenza" post="A(H1N1)pdm09 were reported during beginning and end of the"/>
   <result pre="of the year2016. 4 Discussion Since the first outbreak of" exact="influenza" post="in 1580, the virus has continued to cause epidemic"/>
   <result pre="time scale. It has been observed that following an outbreak" exact="influenza" post="virus tend to re-assort with different kinds of genetic"/>
   <result pre="Health Organization reports that in the European region, the 2018/19" exact="influenza" post="season is dominated by influenza A virus; co-circulation of"/>
   <result pre="the European region, the 2018/19 influenza season is dominated by" exact="influenza" post="A virus; co-circulation of both subtypes (H1N1pdm09 and H3N2)"/>
   <result pre="H3N2) however, the past season (2014/15–2016/17) was dominated either by" exact="influenza" post="A(H1N1)pdm09 or by A(H3N2) [19]. The re-emergence of influenza"/>
   <result pre="by influenza A(H1N1)pdm09 or by A(H3N2) [19]. The re-emergence of" exact="influenza" post="virus in every season with some genetic modification or,"/>
   <result pre="according to the predominating strain to confer maximum protection against" exact="influenza" post="infection. The findings of our study suggest that influenza"/>
   <result pre="against influenza infection. The findings of our study suggest that" exact="influenza" post="A/H3 was the predominant strain circulating in Nepal in"/>
   <result pre="Upadhyay et al. also reported similar finding according to which" exact="influenza" post="A/H3 was responsible for 60.1% of the total infection"/>
   <result pre="[14]. A study from countries in tropical Asia also reports" exact="influenza" post="A dominant over influenza B during 2007–2013 which is"/>
   <result pre="countries in tropical Asia also reports influenza A dominant over" exact="influenza" post="B during 2007–2013 which is in correspondence to this"/>
   <result pre="2007–2013 which is in correspondence to this study [20]. Among" exact="influenza" post="type B virus, we noticed B/Yamagata lineage dominant over"/>
   <result pre="might be reason for high prevalence of dissimilar subtypes of" exact="influenza" post="virus in different study. This study illustrates that Nepal"/>
   <result pre="study. This study illustrates that Nepal observes two peaks of" exact="influenza" post="infection round the year; first in the month of"/>
   <result pre="further supported by a study from India which reports maximum" exact="influenza" post="activity during the rainy season [24]. A study carried"/>
   <result pre="et al. from mainland China also reported two peak of" exact="influenza" post="activity; first in winter and then in Spring in"/>
   <result pre="which lies in temperate region experience only one peak of" exact="influenza" post="activity in winter season [26]. Similarly, a study from"/>
   <result pre="a study from Hong Kong also reports annual cycle of" exact="influenza" post="A(H3N2) during the study period [27]. This suggests that"/>
   <result pre="during the study period [27]. This suggests that seasonality of" exact="influenza" post="appears to be country specific despite of similar type"/>
   <result pre="country specific despite of similar type of climatic conditions. Though" exact="influenza" post="A/H3 was the predominant circulating strain in year 2016"/>
   <result pre="second peak of infection in July–August that was marked by" exact="influenza" post="B despite of A/H3 strain. The possible explanation behind"/>
   <result pre="of virus. The findings from this study also suggest that" exact="influenza" post="prevalence was higher in Kathmandu and nearby districts. These"/>
   <result pre="of Central Bureau of Statistics [28]. Because the transmission of" exact="influenza" post="virus mainly occur by aerosol inhalation and spread more"/>
   <result pre="rapidly in crowded areas, these districts had higher prevalence of" exact="influenza" post="in comparison to other districts of Nepal [28, 29]."/>
   <result pre="As higher temperature enhances defense mechanism and decreases replication of" exact="influenza" post="virus, Kathmandu valley having lower temperature favors influenza virus"/>
   <result pre="replication of influenza virus, Kathmandu valley having lower temperature favors" exact="influenza" post="virus replication which might also be the reason for"/>
   <result pre="for higher prevalence rate [31]. Our study suggests that 2016" exact="influenza" post="season was dominated by influenza A/H3 strain. Besides that,"/>
   <result pre="Our study suggests that 2016 influenza season was dominated by" exact="influenza" post="A/H3 strain. Besides that, influenza B infection was also"/>
   <result pre="influenza season was dominated by influenza A/H3 strain. Besides that," exact="influenza" post="B infection was also found in higher number of"/>
   <result pre="or regional authorities in accordance to their seasonability pattern of" exact="influenza" post="virus circulation [21, 32]. In Nepal, influenza vaccine was"/>
   <result pre="seasonability pattern of influenza virus circulation [21, 32]. In Nepal," exact="influenza" post="vaccine was not provided to the public at government"/>
   <result pre="find any guidelines made by national authorities in Nepal regarding" exact="influenza" post="vaccine use. However, clinician preferred to use trivalent vaccine"/>
   <result pre="confer effective immunization. Furthermore, when we consider the timing for" exact="influenza" post="vaccination, the vaccine needs to be introduced within 4"/>
   <result pre="in the month of July–August. Because we observe only 2016" exact="influenza" post="season, the recommendation for vaccination twice a year should"/>
   <result pre="set out to determine that Nepal experience semiannual cycle of" exact="influenza" post="infection firstly, during the winter month of January–February and"/>
   <result pre="month of July–August following rainy season. Despite few cases of" exact="influenza" post="B and influenza A(H1N1)pdm09, influenza A/H3 remained predominant throughout"/>
   <result pre="following rainy season. Despite few cases of influenza B and" exact="influenza" post="A(H1N1)pdm09, influenza A/H3 remained predominant throughout the year 2016."/>
   <result pre="season. Despite few cases of influenza B and influenza A(H1N1)pdm09," exact="influenza" post="A/H3 remained predominant throughout the year 2016. This paper"/>
   <result pre="Nepal must be decided by national authority based on prevailing" exact="influenza" post="types. There is abundant space for further progress in"/>
   <result pre="for further progress in recommending the timing and composition of" exact="influenza" post="vaccine to be introduced in Nepal by the national"/>
   <result pre="information is available for this paper. References References 1KorsunN.AngelovaS.TrifonovaI.GeorgievaI.TzotchevaI.MilevaS.Predominance of" exact="influenza" post="B/Yamagata lineage viruses in Bulgaria during the 2017/2018 seasonEpidemiol."/>
   <result pre="August 27, 2018]. Available from:https://www.cdc.gov/flu/highrisk/index.htm 3ScorzaF.B.Advancing new vaccines against pandemic" exact="influenza" post="in low-resource countriesVaccine354020175397540228410815 4Centers for Disease Control and PreventionNational"/>
   <result pre="Influenza Viruses [English][updated November 18, 2019]. Available from:https://www.cdc.gov/flu/about/viruses/types.htm 5KhadkaM.Novel swine" exact="influenza" post="A/H1N1 and the phase six pandemicJNMA - J. Nepal"/>
   <result pre="and future pandemicPubl. Health Rep.1253_suppl20101526 7KawakamiC.YamayoshiS.AkimotoM.NakamuraK.MiuraH.FujisakiS.Genetic and antigenic characterisation of" exact="influenza" post="A (H3N2) viruses isolated in Yokohama during the 2016/17"/>
   <result pre="(H3N2) viruses isolated in Yokohama during the 2016/17 and 2017/18" exact="influenza" post="seasonsEuro Surveill.2462019 8WuC.WangM.H.LuX.ChongK.C.HeJ.YauC.-Y.Concurrent epidemics of influenza A/H3N2 and A/H1N1pdm"/>
   <result pre="the 2016/17 and 2017/18 influenza seasonsEuro Surveill.2462019 8WuC.WangM.H.LuX.ChongK.C.HeJ.YauC.-Y.Concurrent epidemics of" exact="influenza" post="A/H3N2 and A/H1N1pdm in Southern China: a serial cross-sectional"/>
   <result pre="China: a serial cross-sectional studyJ. Infect.723201636937626747013 9BragstadK.NielsenL.P.FomsgaardA.The evolution of human" exact="influenza" post="A viruses from 1999 to 2006: a complete genome"/>
   <result pre="studyVirol. J.5120084018325125 10PanM.YangH.JianJ.KuangY.XuJ.LiT.Association of meteorological factors with seasonal activity of" exact="influenza" post="A subtypes and B lineages in subtropical western ChinaEpidemiol."/>
   <result pre="in subtropical western ChinaEpidemiol. Infect.1472019 11GuiomarR.da SilvaS.P.CondeP.CristóvãoP.MaiaA.C.PechirraP.Cross-protection to new drifted" exact="influenza" post="A (H3) viruses and prevalence of protective antibodies to"/>
   <result pre="Med. Assoc. JNMA521882012 14UpadhyayB.P.GhimireP.TashiroM.BanjaraM.R.Molecular epidemiology and antigenic characterization of seasonal" exact="influenza" post="viruses circulating in NepalJ. Nepal Health Res. Counc.1512017445028714491 15NeopaneA.The"/>
   <result pre="15NeopaneA.The swine flu pandemic in NepalKathmandu Univ. Med. J.742009339340 16MahatoR.BhandariG.ShresthaJ.BasnetP.Pandemic" exact="influenza" post="A (H1N1) 2009 outbreak investigation in NepalJ. Nepal Health"/>
   <result pre="A (H1N1)2009Centers for Disease Control and PreventionAtlanta, GA 19SegaloffH.MelidouA.AdlhochC.PereyaslovD.RobesynE.PenttinenP.Co-circulation of" exact="influenza" post="A (H1N1) pdm09 and influenza A (H3N2) viruses, world"/>
   <result pre="and PreventionAtlanta, GA 19SegaloffH.MelidouA.AdlhochC.PereyaslovD.RobesynE.PenttinenP.Co-circulation of influenza A (H1N1) pdm09 and" exact="influenza" post="A (H3N2) viruses, world Health organization (WHO) European region,"/>
   <result pre="to february 2019Euro Surveill.2492019 20SahaS.ChadhaM.ShuY.collab: Influenza GoARoLijieW.ChittaganpitchM.Divergent seasonal patterns of" exact="influenza" post="types A and B across latitude gradient in Tropical"/>
   <result pre="Tropical AsiaInfluenza Respir. Viruses1032016176184 21mondiale de la SantéO.OrganizationW.H.Recommended composition of" exact="influenza" post="virus vaccines for use in the 2016–2017 northern hemisphere"/>
   <result pre="influenza virus vaccines for use in the 2016–2017 northern hemisphere" exact="influenza" post="seasonWkly. Epidemiol. Rec.= Relevé épidémiologique hebdomadaire9110201612113226971356 22El Guerche-SéblainC.CainiS.PagetJ.VanhemsP.SchellevisF.Epidemiology and"/>
   <result pre="Rec.= Relevé épidémiologique hebdomadaire9110201612113226971356 22El Guerche-SéblainC.CainiS.PagetJ.VanhemsP.SchellevisF.Epidemiology and timing of seasonal" exact="influenza" post="epidemics in the Asia-Pacific region, 2010–2017: implications for influenza"/>
   <result pre="seasonal influenza epidemics in the Asia-Pacific region, 2010–2017: implications for" exact="influenza" post="vaccination programsBMC Publ. Health1912019331 23SahaS.ChadhaM.Al MamunA.RahmanM.Sturm-RamirezK.ChittaganpitchM.Influenza seasonality and vaccination"/>
   <result pre="of southern and south-eastern AsiaBull. World Health Organ.92201431833024839321 24ChadhaM.S.BroorS.GunasekaranP.PotdarV.A.KrishnanA.Chawla-SarkarM.Multisite virological" exact="influenza" post="surveillance in India: 2004–2008. Influenza and other respiratory viruses632012196203"/>
   <result pre="Influenza and other respiratory viruses632012196203 25SunS.FuC.CongJ.LiY.XieS.WangP.Epidemiological features and trends of" exact="influenza" post="incidence in mainland China: a population-based surveillance study from"/>
   <result pre="from 2005 to 2015Int. J. Infect. Dis.2019 26SuzukiY.TairaK.SaitoR.NidairaM.OkanoS.ZaraketH.Epidemiologic study of" exact="influenza" post="infection in Okinawa, Japan, from 2001 to 2007: changing"/>
   <result pre="to 2007: changing patterns of seasonality and prevalence of amantadine-resistant" exact="influenza" post="A virusJ. Clin. Microbiol.473200962362919158265 27YangL.ChanK.H.SuenL.K.ChanK.P.WangX.CaoP.Impact of the 2009 H1N1"/>
   <result pre="Sci.162-31998283298 31YamayaM.NishimuraH.KalonjiN.L.DengX.MommaH.ShimotaiY.Effects of high temperature on pandemic and seasonal human" exact="influenza" post="viral replication and infection-induced damage in primary human tracheal"/>
   <result pre="cell culturesHeliyon522019e01149 32teamEeWHO recommendations on the composition of the 2016/17" exact="influenza" post="virus vaccines in the northern hemisphereEuro Surveill.218201630147 Acknowledgements We"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6995028\results\search\disease\results.xml">
   <result pre="engineered antiviral banana lectin inhibits fusion and is efficacious against" exact="influenza" post="virus infection in vivo http://orcid.org/0000-0002-9299-0878Covés-DatsonEvelyn M.ab1KingSteven R.cd1LegendreMaureenc1GuptaAuronic1ChanSusana M.de1GitlinEmilyc1KulkarniVikram V.fPantaleón"/>
   <result pre="engineered banana lectin (carbohydrate-binding protein) has broad-spectrum activity against all" exact="influenza" post="strains tested, including drug-resistant and currently circulating strains; is"/>
   <result pre="administration in mice; and, moreover, is efficacious at treating lethal" exact="influenza" post="infection via clinically pertinent routes of administration. We demonstrate"/>
   <result pre="H84T banana lectin (H84T), to retain broad-spectrum activity against multiple" exact="influenza" post="strains, including pandemic and avian, while largely eliminating the"/>
   <result pre="virus–endosome fusion. These studies reveal that H84T is efficacious against" exact="influenza" post="virus in vivo, and that the loss of mitogenicity"/>
   <result pre="the potential utility of H84T as a broad-spectrum antiinfluenza agent." exact="influenza" post="virus hemagglutinin membrane fusion lectin antiviral Funding DOD |"/>
   <result pre="to 2018 United States season to be only ∼25% against" exact="influenza" post="A subtype H3N2 viruses, which comprised ∼69% of infections"/>
   <result pre="(3), only three classes of drugs are approved to treat" exact="influenza" post="virus infection in the United States: Adamantanes, neuraminidase (NA)"/>
   <result pre="to overwhelmingly high levels of resistance to them among circulating" exact="influenza" post="A strains and due to their intrinsic inactivity against"/>
   <result pre="influenza A strains and due to their intrinsic inactivity against" exact="influenza" post="B strains. The current standard of care treatment is"/>
   <result pre="certain seasons (5, 7). With the twin threats of another" exact="influenza" post="pandemic and emergence of antiviral resistance ever present and"/>
   <result pre="high densities in glycoproteins on the surfaces of viruses. Indeed," exact="influenza" post="viruses are potential targets of lectins because they possess"/>
   <result pre="H84T) (12). H84T is highly efficacious against pandemic, epidemic, and" exact="avian influenza" post="in vitro and against lethal influenza virus infection in"/>
   <result pre="(12). H84T is highly efficacious against pandemic, epidemic, and avian" exact="influenza" post="in vitro and against lethal influenza virus infection in"/>
   <result pre="pandemic, epidemic, and avian influenza in vitro and against lethal" exact="influenza" post="virus infection in vivo when administered intranasally, yet its"/>
   <result pre="Taken together, these studies reveal that H84T is efficacious against" exact="influenza" post="virus in vivo, even when given up to 72"/>
   <result pre="previous work demonstrates that H84T has robust activity against diverse" exact="influenza" post="viruses in vitro, including A/California/04/2009 (H1N1)pdm09, A/California/07/2009 (H1N1)pdm09, A/New"/>
   <result pre="BanLec mutant lacking carbohydrate-binding activity has no antiinfluenza activity. Because" exact="influenza" post="strains resistant to the standard-of-care therapy, oseltamivir, do circulate"/>
   <result pre="H84T shows some, but not striking, synergy with oseltamivir. Since" exact="influenza" post="B infections cannot be distinguished clinically from influenza A"/>
   <result pre="oseltamivir. Since influenza B infections cannot be distinguished clinically from" exact="influenza" post="A infections (23), antiinfluenza agents that have activity against"/>
   <result pre="A infections (23), antiinfluenza agents that have activity against both" exact="influenza" post="A and B are particularly attractive for empiric treatment"/>
   <result pre="We therefore sought to evaluate whether H84T is efficacious against" exact="influenza" post="B virus infection. We found that H84T has EC50"/>
   <result pre="of 0.15 and 0.33 μg/mL (∼4.8 and 11 nM) against" exact="influenza" post="B viruses B/Brisbane/60/2008 (Victoria lineage) and B/Florida/4/2006 (Yamagata lineage),"/>
   <result pre="Appendix, Fig. S4), indicating that H84T is indeed active against" exact="influenza" post="B viruses and has promise as an antiinfluenza A"/>
   <result pre="intranasal administration of H84T protects mice against otherwise lethal H1N1" exact="influenza" post="virus infection (12). To assess whether H84T is also"/>
   <result pre="(12). To assess whether H84T is also efficacious against another" exact="influenza" post="virus strain in vivo, we inoculated C57BL/6J mice via"/>
   <result pre="via aerosol with a lethal dose of A/Hong Kong/8/1968 (H3N2)" exact="influenza" post="virus and treated them with 0.1 mg/kg of H84T"/>
   <result pre="S5). Greater than 80% of H84T-treated mice survived otherwise lethal" exact="influenza" post="virus infection, as compared to &amp;lt;10% of placebo-treated animals,"/>
   <result pre="has robust activity against the two major contemporary subtypes of" exact="influenza" post="A in vivo. H84T, but Not WT BanLec, Is"/>
   <result pre="Well-Tolerated In Vivo. Given that H84T is highly efficacious against" exact="influenza" post="infection in vitro and in vivo via intranasal administration,"/>
   <result pre="of H84T in the lung, a key target organ for" exact="influenza" post="treatment, exceed plasma levels significantly, but in a nonlinear"/>
   <result pre="we inoculated BALB/c mice intranasally with a lethal dose of" exact="influenza" post="and treated them with H84T delivered intraperitoneally once daily"/>
   <result pre="time of prior H84T administration are 100% protected from lethal" exact="influenza" post="infection by H84T treatment (Fig. 2C). These mice also"/>
   <result pre="Fig. 2. Systemic H84T treatment is highly efficacious against lethal" exact="influenza" post="virus infection in mice. (A–C) Therapeutic efficacy of H84T"/>
   <result pre="examined whether subcutaneous administration of H84T conferred protection against lethal" exact="influenza" post="virus infection in mice (Fig. 2D). BALB/c mice were"/>
   <result pre="BALB/c mice were inoculated intranasally with a lethal dose of" exact="influenza" post="virus and survival of the mice monitored after treatment"/>
   <result pre="Virus. A detailed mechanistic understanding of H84T’s ability to inhibit" exact="influenza" post="replication is key to developing it as a potential"/>
   <result pre="types of N-glycans such as can be found on the" exact="influenza" post="virus glycoproteins HA and NA. To ascertain whether H84T"/>
   <result pre="viral proteins. Note that the lower band seen in the" exact="influenza" post="B lanes does not appear to be HA2 as"/>
   <result pre="To understand whether H84T exerts its primary inhibitory effect against" exact="influenza" post="virus replication early or late in the influenza virus"/>
   <result pre="effect against influenza virus replication early or late in the" exact="influenza" post="virus life cycle, we assessed whether viral protein expression"/>
   <result pre="viruses that encompassed the majority of the ∼69% of clinical" exact="influenza" post="infections caused by H3N2 strains in the 2017 to"/>
   <result pre="protein expression (SI Appendix, Fig. S12). Fig. 4. H84T prevents" exact="influenza" post="virus protein expression in MDCK cells. MDCK cells were"/>
   <result pre="at 37 °C. (A and C) Representative immunofluorescent micrographs of" exact="influenza" post="A antigen staining (green) and nuclei (blue) 5 h"/>
   <result pre="(B and D) Quantitation of the number of cells with" exact="influenza" post="protein-positive nuclei per field, as assessed by a trained"/>
   <result pre="sought to further delineate the step at which H84T inhibits" exact="influenza" post="virus replication, hypothesizing that H84T would inhibit influenza virus"/>
   <result pre="H84T inhibits influenza virus replication, hypothesizing that H84T would inhibit" exact="influenza" post="virus at the attachment or fusion steps, since we"/>
   <result pre="may act by inhibiting viral fusion. Fig. 5. H84T inhibits" exact="influenza" post="virus fusion. MDCK cells were pretreated for 1 h"/>
   <result pre="&amp;lt; 0.01, comparing groups indicated by brackets. If fusion of" exact="influenza" post="virus is inhibited by H84T, we reasoned that the"/>
   <result pre="Fig. S14). These results suggest that H84T prevents exit of" exact="influenza" post="viruses from the endosome. Indeed, colocalization between M1 in"/>
   <result pre="of the virus to the endosome. Fig. 6. H84T reduces" exact="influenza" post="virus uncoating. MDCK cells were pretreated for 1 h"/>
   <result pre="group. Error bars represent the SEM. Fig. 7. H84T restricts" exact="influenza" post="virus to the late endosomal/lysosomal compartment. (A) Representative immunofluorescent"/>
   <result pre="internalized into the late endosomal/lysosomal compartment in the absence of" exact="influenza" post="virus infection, we next treated cells with His-tagged H84T"/>
   <result pre="lectin, H84T BanLec, is highly active against an array of" exact="influenza" post="virus strains. While it is somewhat difficult to compare"/>
   <result pre="it is somewhat difficult to compare the overall sensitivity of" exact="influenza" post="viruses to the different lectins without head-to-head comparisons, H84T"/>
   <result pre="(e.g., CV-N EC50 = 0.005 to &amp;gt;10 μg/mL against tested" exact="influenza" post="virus strains). It is notable that H84T is quite"/>
   <result pre="broad-spectrum, capable of inhibiting multiple oseltamivir-resistant as well all other" exact="influenza" post="virus strains tested in this and our previous study"/>
   <result pre="in this and our previous study (12); H84T inhibits both" exact="influenza" post="A and B type viruses and a representative of"/>
   <result pre="proved especially deadly in the 2017 to 2018 Northern Hemisphere" exact="influenza" post="season (2). The finding that there is some synergy"/>
   <result pre="be ideal for all clinical situations (e.g., treating outpatients with" exact="influenza" post="virus infections). Oral administration is not a feasible clinical"/>
   <result pre="to limit activity given that the efficacy of H84T against" exact="influenza" post="infection was not lessened in mice with anti-H84T antibodies."/>
   <result pre="most binding to the H3N2 strain, followed by binding to" exact="influenza" post="B, then the H1N1 strain. Of course, multiple other"/>
   <result pre="the lysosome, accounting for the ability of H84T to decrease" exact="influenza" post="virus replication overall. Our data demonstrate that H84T BanLec"/>
   <result pre="that H84T BanLec has potential as a new antiviral against" exact="influenza" post="viruses. It is very well tolerated and nonmitogenic in"/>
   <result pre="nonmitogenic in vivo and is highly efficacious against otherwise lethal" exact="influenza" post="virus infection via three distinct routes of administration, even"/>
   <result pre="inhibits replication of all oseltamivir-resistant and -sensitive strains and all" exact="influenza" post="A and B strains tested, highlighting its promise as"/>
   <result pre="strains tested, highlighting its promise as an empiric drug for" exact="influenza" post="illness, which will be critically needed in the event"/>
   <result pre="be critically needed in the event of a new pandemic" exact="influenza" post="virus or increasing resistance to neuraminidase inhibitors. H84T is"/>
   <result pre="but also in the sense that it inhibits HIV and" exact="hepatitis" post="C virus as reported previously (12), and Ebola (55),"/>
   <result pre="25 mM Hepes). Supernatant from 293T cells transfected with eight" exact="influenza" post="gene plasmids was used to propagate A/WSN/33 (H1N1) on"/>
   <result pre="to GAPDH expression, qRT-PCR was performed using primers specific to" exact="influenza" post="A M1 and to GAPDH. Primer sequences are provided"/>
   <result pre="and Infectious Diseases for support for testing of H84T against" exact="influenza" post="virus in vitro and in vivo; S. Bedi from"/>
   <result pre="Bedi from the University of Michigan for providing supernatants from" exact="influenza" post="plasmid-transfected cells for virus propagation; S. Hensley from the"/>
   <result pre="T., KelleyN. S., SommerA., BelongiaE. A., Efficacy and effectiveness of" exact="influenza" post="vaccines: A systematic review and meta-analysis. Lancet Infect. Dis.12,"/>
   <result pre="Dis.12, 36–44 (2012).22032844 2FlanneryB.et al., Interim estimates of 2017-18 seasonal" exact="influenza" post="vaccine effectiveness—United States, February 2018. MMWR Morb. Mortal. Wkly."/>
   <result pre="al.; collab: Baloxavir Marboxil Investigators Group, Baloxavir marboxil for uncomplicated" exact="influenza" post="in adults and adolescents. N. Engl. J. Med.379, 913–923"/>
   <result pre="JonesM., DoshiP., Del MarC., Neuraminidase inhibitors for preventing and treating" exact="influenza" post="in healthy adults: Systematic review and meta-analysis. BMJ339, b5106"/>
   <result pre="AvalosR. T., PonimaskinE., NayakD. P., Influenza virus assembly: Effect of" exact="influenza" post="virus glycoproteins on the membrane association of M1 protein."/>
   <result pre="8709–8719 (2000).10954572 10ChlandaP.et al., Structural analysis of the roles of" exact="influenza" post="A virus membrane-associated proteins in assembly and morphology. J."/>
   <result pre="D.et al., Playing hide and seek: How glycosylation of the" exact="influenza" post="virus hemagglutinin can modulate the immune response to infection."/>
   <result pre="1294–1316 (2014).24638204 14MeijerA.et al.; collab: European Influenza Surveillance Scheme, Oseltamivir-resistant" exact="influenza" post="virus A (H1N1), Europe, 2007-08 season. Emerg. Infect. Dis.15,"/>
   <result pre="15DharanN. J.et al.; collab: Oseltamivir-Resistance Working Group, Infections with oseltamivir-resistant" exact="influenza" post="A(H1N1) virus in the United States. JAMA301, 1034–1041 (2009).19255110"/>
   <result pre="F., JulanderJ. G., TarbetE. B., GrossM., NguyenJ., Treatment of oseltamivir-resistant" exact="influenza" post="A (H1N1) virus infections in mice with antiviral agents."/>
   <result pre="13–20 (2012).22809862 17LackenbyA.et al., Emergence of resistance to oseltamivir among" exact="influenza" post="A(H1N1) viruses in Europe. Euro Surveill.13, 8026 (2008).18445375 18SheuT."/>
   <result pre="18SheuT. G.et al., Surveillance for neuraminidase inhibitor resistance among human" exact="influenza" post="A and B viruses circulating worldwide from 2004 to"/>
   <result pre="(2008).18625765 19SimonsenL.et al., The genesis and spread of reassortment human" exact="influenza" post="A/H3N2 viruses conferring adamantane resistance. Mol. Biol. Evol.24, 1811–1820"/>
   <result pre="ShayD. K., ShuB., CoxN. J., KlimovA. I., Adamantane resistance among" exact="influenza" post="A viruses isolated early during the 2005-2006 influenza season"/>
   <result pre="resistance among influenza A viruses isolated early during the 2005-2006" exact="influenza" post="season in the United States. JAMA295, 891–894 (2006).16456087 21SchinaziR."/>
   <result pre="of combinations of acyclovir with vidarabine or its 5′-monophosphate on" exact="herpes simplex" post="viruses in cell culture and in mice. Antimicrob. Agents"/>
   <result pre="23SuS.et al., Comparing clinical characteristics between hospitalized adults with laboratory-confirmed" exact="influenza" post="A and B virus infection. Clin. Infect. Dis.59, 252–255"/>
   <result pre="RobertsN. A., KlenkH.-D., Neuraminidase is important for the initiation of" exact="influenza" post="virus infection in human airway epithelium. J. Virol.78, 12665–12667"/>
   <result pre="epithelium. J. Virol.78, 12665–12667 (2004).15507653 27SuB.et al., Enhancement of the" exact="influenza" post="A hemagglutinin (HA)-mediated cell-cell fusion and virus entry by"/>
   <result pre="Chem.4, 973–988 (2006).16525538 33KadamR. U., WilsonI. A., Structural basis of" exact="influenza" post="virus fusion inhibition by the antiviral drug Arbidol. Proc."/>
   <result pre="5675–5681 (1984).6098295 36GilbertJ. M., MasonD., WhiteJ. M., Fusion of Rous" exact="sarcoma" post="virus with host cells does not require exposure to"/>
   <result pre="Med. Res. Rev.32, 349–387 (2012).20577974 42SmeeD. F.et al., Treatment of" exact="influenza" post="A (H1N1) virus infections in mice and ferrets with"/>
   <result pre="plasma cells that binds to group 1 and group 2" exact="influenza" post="A hemagglutinins. Science333, 850–856 (2011).21798894 50WeiC.-J.et al., Elicitation of"/>
   <result pre="hemagglutinins. Science333, 850–856 (2011).21798894 50WeiC.-J.et al., Elicitation of broadly neutralizing" exact="influenza" post="antibodies in animals with previous influenza exposure. Sci. Transl."/>
   <result pre="Elicitation of broadly neutralizing influenza antibodies in animals with previous" exact="influenza" post="exposure. Sci. Transl. Med.4, 147ra114 (2012). 51KallewaardN. L.et al.,"/>
   <result pre="al., Structure and function analysis of an antibody recognizing all" exact="influenza" post="A subtypes. Cell166, 596–608 (2016).27453466 52LearJ. D., DeGradoW. F.,"/>
   <result pre="and conformational properties of peptides representing the NH2 terminus of" exact="influenza" post="HA-2. J. Biol. Chem.262, 6500–6505 (1987).3571268 53ShenC.et al., A"/>
   <result pre="multimechanistic antibody targeting the receptor binding site potently cross-protects against" exact="influenza" post="B viruses. Sci. Transl. Med.9, eaam5752 (2017).29046433 54StadlmannJ.et al.,"/>
   <result pre="HobomG., WebsterR. G., A DNA transfection system for generation of" exact="influenza" post="A virus from eight plasmids. Proc. Natl. Acad. Sci."/>
   <result pre="NovikovD., HaydenF. G., GubarevaL. V., Effect of hemagglutinin glycosylation on" exact="influenza" post="virus susceptibility to neuraminidase inhibitors. J. Virol.79, 12416–12424 (2005).16160169"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6995199\results\search\disease\results.xml">
   <result pre="we present the CPEs of poxviruses (vaccinia virus [VACV] and" exact="cowpox" post="virus [CPXV] and arboviruses (yellow fever virus [YFV], chikungunya"/>
   <result pre="and cowpox virus [CPXV] and arboviruses (yellow fever virus [YFV]," exact="chikungunya" post="virus [CHIKV], and mayaro virus [MAYV]) on materials that"/>
   <result pre="and characterization of Mimivirus, the largest known virus and putative" exact="pneumonia" post="agentClin Infect Dis2007459510210.1086/51860817554709 6.SharmaVColsonPPontarottiPRaoultDMimivirus inaugurated in the 21st century"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6995725\results\search\disease\results.xml">
   <result pre="and consolidations. We initially suspected these patients of having influenza-associated" exact="pneumonia" post="and cryptogenic organizing pneumonia, respectively, and performed bronchoalveolar lavage,"/>
   <result pre="by multiplex polymerase chain reaction testing. These findings suggest that" exact="pneumonia" post="due to human parainfluenza virus-1 should be included in"/>
   <result pre="in the differential diagnosis of such cases. human parainfluenza virus" exact="viral pneumonia" post="multiplex PCR corticosteroid Introduction Human parainfluenza viruses (HPIVs) are"/>
   <result pre="the differential diagnosis of such cases. human parainfluenza virus viral" exact="pneumonia" post="multiplex PCR corticosteroid Introduction Human parainfluenza viruses (HPIVs) are"/>
   <result pre="In previous studies, 0.2 to 11.5% of hospitalized patients with" exact="pneumonia" post="were found to have HPIV infection (1,2); however, the"/>
   <result pre="to have HPIV infection (1,2); however, the characteristics of primary" exact="viral pneumonia" post="due to HPIV are not well known. We recently"/>
   <result pre="have HPIV infection (1,2); however, the characteristics of primary viral" exact="pneumonia" post="due to HPIV are not well known. We recently"/>
   <result pre="are not well known. We recently experienced two cases of" exact="pneumonia" post="in which HPIV-1 was isolated from bronchoalveolar lavage (BAL)"/>
   <result pre="21 Kit, Silema, Malta), which detects the following respiratory pathogens:" exact="influenza" post="A and B viruses; coronaviruses NL63, 229E, OC43, and"/>
   <result pre="was also negative. Rapid nasopharyngeal or oropharyngeal diagnostic tests for" exact="influenza" post="virus and Mycoplasma pneumoniae and urinary antigen tests for"/>
   <result pre="both lung fields (Fig. 1b and c). Pleural effusion or" exact="lymphadenopathy" post="were not found. We performed bronchoscopy and the BAL"/>
   <result pre="Blood culture was negative. We suspected her of having influenza-associated" exact="pneumonia" post="and started ampicillin/sulbactam and peramivir. Her chest shadows gradually"/>
   <result pre="titers against M. pneumoniae, C. pneumoniae, C. psittaci, Legionella spp.," exact="influenza" post="virus, adenovirus, and respiratory syncytial virus in paired sera"/>
   <result pre="she was 61 years old and had undergone gastrectomy. Her" exact="cancer" post="had not recurred. She was an ex-smoker with Brinkman"/>
   <result pre="anti-HIV antibody test. Rapid nasopharyngeal or oropharyngeal diagnostic tests for" exact="influenza" post="virus and Mycoplasma pneumoniae and urinary antigen tests for"/>
   <result pre="lobes (Fig. 3b). No centrilobular pulmonary nodules, pleural effusion, or" exact="lymphadenopathy" post="was detected. We performed bronchoscopy and BAL from the"/>
   <result pre="lung biopsy. We initially suspected her of having cryptogenic organizing" exact="pneumonia" post="(COP) and administered prednisolone 20 mg daily. Her chest"/>
   <result pre="titers against M. pneumoniae, C. pneumoniae, C. psittaci, Legionella spp.," exact="influenza" post="virus, adenovirus, and respiratory syncytial virus in paired sera"/>
   <result pre="In other studies, 0.2 to 11.5% of hospitalized patients with" exact="pneumonia" post="were found to have HPIV infection (1,2). Furthermore, HPIV"/>
   <result pre="HPIV is a frequent pathogen of both non-severe and severe" exact="pneumonia" post="(6). However, previous reports that investigated virus infections in"/>
   <result pre="However, previous reports that investigated virus infections in patients with" exact="pneumonia" post="used nasopharyngeal or oropharyngeal swabs to detect viruses, which"/>
   <result pre="the clinical characteristics of the immunocompetent patients with primary HPIV" exact="pneumonia" post="are not fully known. In our two cases, HPIV"/>
   <result pre="pathogens, nor did specific antibody titers against other pathogens of" exact="pneumonia" post="in paired sera increase, which support the diagnosis of"/>
   <result pre="before identification of HPIV-1 via multiplex PCR testing were primary" exact="influenza" post="virus pneumonia and COP, respectively. A previous study reported"/>
   <result pre="of HPIV-1 via multiplex PCR testing were primary influenza virus" exact="pneumonia" post="and COP, respectively. A previous study reported that viral"/>
   <result pre="virus pneumonia and COP, respectively. A previous study reported that" exact="viral pneumonia" post="is frequently misdiagnosed as COP (11). In the differentiation"/>
   <result pre="pneumonia and COP, respectively. A previous study reported that viral" exact="pneumonia" post="is frequently misdiagnosed as COP (11). In the differentiation"/>
   <result pre="these diseases, sore throat is a more frequent symptom of" exact="viral pneumonia" post="than of acute interstitial lung diseases including COP (11),"/>
   <result pre="diseases, sore throat is a more frequent symptom of viral" exact="pneumonia" post="than of acute interstitial lung diseases including COP (11),"/>
   <result pre="Cunha et al. reported that the clinical presentation of HPIV" exact="pneumonia" post="closely mimics H1N1 pneumonia (12). Chest CT findings in"/>
   <result pre="that the clinical presentation of HPIV pneumonia closely mimics H1N1" exact="pneumonia" post="(12). Chest CT findings in our patients included bronchial"/>
   <result pre="pneumonia. Pokharel et al. reported multinucleated giant cells with organizing" exact="pneumonia" post="as findings suggestive of HPIV infection (14), but the"/>
   <result pre="budesonide, are associated with fewer clinic visits and admissions for" exact="croup" post="and the reduced use of nebulized epinephrine (15). We"/>
   <result pre="efficacy of corticosteroid administration in immunocompetent adult patients with HPIV" exact="pneumonia" post="is not known. Some data suggest favorable effects on"/>
   <result pre="(in combination with acyclovir) and hantavirus (16) and in influenza-associated" exact="pneumonia" post="in some clinical settings (17,18). Among 13 previously reported"/>
   <result pre="in 6 and were effective (11). Among the patients with" exact="viral pneumonia" post="due to non-influenza viruses, corticosteroids were administered to 21,"/>
   <result pre="6 and were effective (11). Among the patients with viral" exact="pneumonia" post="due to non-influenza viruses, corticosteroids were administered to 21,"/>
   <result pre="significance of corticosteroids as a treatment option for primary HPIV" exact="pneumonia" post="in immunocompetent patients. However, much of the available data"/>
   <result pre="The efficacy of antiviral drugs in immunocompetent adults with HPIV" exact="pneumonia" post="has not been fully evaluated, and thus further studies"/>
   <result pre="experienced two immunocompetent patients with primary HPIV-1 pneumonia. Primary HPIV" exact="pneumonia" post="can resemble influenza-associated pneumonia and COP, and HPIV pneumonia"/>
   <result pre="with primary HPIV-1 pneumonia. Primary HPIV pneumonia can resemble influenza-associated" exact="pneumonia" post="and COP, and HPIV pneumonia should be included in"/>
   <result pre="HPIV pneumonia can resemble influenza-associated pneumonia and COP, and HPIV" exact="pneumonia" post="should be included in the differential diagnosis of such"/>
   <result pre="6.ChoiSH, HongSB, KoGB, et al.Viral infections in patients with severe" exact="pneumonia" post="requiring intensive care unit admission. Am J Respir Crit"/>
   <result pre="Am J Respir Crit Care Med186: 325-332, 2012.22700859 7.FalseyAR, WalshEEViral" exact="pneumonia" post="in older adults. Clin Infect Dis42: 518-524, 2006.16421796 8.IsonMGParainfluenza"/>
   <result pre="(4 pt B): 627-638, 2007.17944270 10.TamakiK, KinjoT, ToyoseT, et al.Fatal" exact="pneumonia" post="and viremia due to human parainfluenza virus type 1"/>
   <result pre="J Infect Chemother21: 820-823, 2015.26231316 11.IshiguroT, KobayashiY, UozumiR, et al.Viral" exact="pneumonia" post="requiring differentiation from acute and progressive diffuse interstitial lung"/>
   <result pre="12.CunhaBA, CorbettM, MickailNHuman parainfluenza virus type 3 (HPIV3) viral community-acquired" exact="pneumonia" post="(CAP) mimicking swine influenza (H1N1) during the swine flu"/>
   <result pre="virus type 3 (HPIV3) viral community-acquired pneumonia (CAP) mimicking swine" exact="influenza" post="(H1N1) during the swine flu pandemic. Heart Lung40: 76-80,"/>
   <result pre="2011.20888645 13.KooHF, LimS, ChoiSH, SungH, DoKHRadiographic and CT features of" exact="viral pneumonia." post="Radiographics38: 719-739, 2018.29757717 14.PokharelS, MeirickelCR, AlatassiHParainfluenza virus-3-induced cytopathic effects"/>
   <result pre="Syst RevCD001955, 2011.21249651 16.ChengVC, TangBS, WuAK, ChuCM, YuenKYMedical treatment of" exact="viral pneumonia" post="including SARS in immunocompetent adult. J Infect49: 262-273, 2004.15474623"/>
   <result pre="RevCD001955, 2011.21249651 16.ChengVC, TangBS, WuAK, ChuCM, YuenKYMedical treatment of viral" exact="pneumonia" post="including SARS in immunocompetent adult. J Infect49: 262-273, 2004.15474623"/>
   <result pre="low-to-moderate-dose corticosteroids on mortality of hospitalized adolescents and adults with" exact="influenza" post="A(H1N1)pdm09 viral pneumonia. Influenza Other Respir Viruses11: 345-354, 2017.28464462"/>
   <result pre="on mortality of hospitalized adolescents and adults with influenza A(H1N1)pdm09" exact="viral pneumonia." post="Influenza Other Respir Viruses11: 345-354, 2017.28464462"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6996800\results\search\disease\results.xml">
   <result pre="Sciences: Epidemiology Interdependence between confirmed and discarded cases of dengue," exact="chikungunya" post="and Zika viruses in Brazil: A multivariate time-series analysis"/>
   <result pre="A multivariate time-series analysis Interdependence between reported cases of dengue," exact="chikungunya" post="and Zika viruses in Brazil http://orcid.org/0000-0002-7167-8754OliveiraJuliane F.ConceptualizationData curationFormal analysisInvestigationMethodologySoftwareValidationVisualizationWriting"/>
   <result pre="2016. The series of reported cases of both Zika and" exact="chikungunya" post="reached their peak in late 2015 and early 2016."/>
   <result pre="model also suggests that the series of confirmed and discarded" exact="chikungunya" post="cases are almost independent of the cases of Zika,"/>
   <result pre="dengue virus (DENV), together with the emergence and dissemination of" exact="chikungunya" post="virus (CHIKV) and Zika virus (ZIKV), transmitted by Aedes"/>
   <result pre="in cities of the states of Amapá and Bahia. Although" exact="chikungunya" post="causes arthralgia with pain at a higher level than"/>
   <result pre="with ZIKV typically presented low (or no) fever and skin" exact="rash" post="within the first 24 hours of the disease onset,"/>
   <result pre="notified cases were impacted by the introduction and spread of" exact="chikungunya" post="and Zika virus in Brazil. Materials and methods We"/>
   <result pre="to understand how the classification of notified cases of dengue," exact="chikungunya" post="and Zika affected each other in Brazil from 2015"/>
   <result pre="data of suspected cases of dengue (from 2010 to 2017)," exact="chikungunya" post="(from 2014 up to 2017), and Zika (from 2015"/>
   <result pre="epidemiological compatibility with other diseases. Inconclusive cases of dengue and" exact="chikungunya" post="(≲ 10% reported cases) were excluded from the analyses."/>
   <result pre="C2t, D1t, D2t), where Z, D, and C denotes Zika," exact="chikungunya" post="and dengue respectively, the indices 1 and 2 stand"/>
   <result pre="in 2016 (with 1,101,228 registered confirmed cases). Confirmed Zika and" exact="chikungunya" post="cases reached their peaks in late 2015 and middle"/>
   <result pre="time series plots of confirmed and discarded cases of dengue," exact="chikungunya" post="and Zika by epidemiological week. Brazil, January 2015 to"/>
   <result pre="per epidemiological week, during the whole corresponding periods, for dengue," exact="chikungunya" post="and Zika in the country, we see that the"/>
   <result pre="confirmed cases of dengue, about 4 cases are discarded. For" exact="chikungunya" post="and Zika, the slopes are 3.2 and 3.6 respectively."/>
   <result pre="Proportion of confirmed and discarded cases, per semester, of dengue," exact="chikungunya" post="and Zika in Brazil. Proportions of dengue (from 2010"/>
   <result pre="in Brazil. Proportions of dengue (from 2010 up to 2017);" exact="chikungunya" post="(from 2014 up to 2017); Zika (from 2015 up"/>
   <result pre="lowest incidence of dengue, namely 2012, 2014 and 2017. Although" exact="chikungunya" post="presents lower incidence compared with Zika and dengue, in"/>
   <result pre="proportion of discarded cases is higher for dengue and Zika," exact="chikungunya" post="shows a pattern with a higher proportion of confirmed"/>
   <result pre="of the series of confirmed and discarded cases of dengue," exact="chikungunya" post="and Zika, the results shows the series are stationary"/>
   <result pre="the stationary series of confirmed and discarded cases of dengue," exact="chikungunya" post="and Zika. We interpret the values of positive/negative correlation"/>
   <result pre="the stationary series of confirmed and discarded cases of dengue," exact="chikungunya" post="and Zika. Brazil, January 2015 to December 2017. Conf.Zika"/>
   <result pre="associations between series of confirmed and discarded cases of dengue," exact="chikungunya" post="and Zika. Brazil, January 2015 to December 2017. Null"/>
   <result pre="cases of dengue 3.417 &amp;lt; 0.001 Reject Confirmed cases of" exact="chikungunya" post="do not affect confirmed cases of dengue 2.121 0.012"/>
   <result pre="confirmed cases of dengue 2.121 0.012 Reject Confirmed cases of" exact="chikungunya" post="do not affect discarded cases of dengue 1.942 0.025"/>
   <result pre="discarded cases of dengue 1.942 0.025 Reject Discarded cases of" exact="chikungunya" post="do not affect confirmed cases of dengue 2.172 0.010"/>
   <result pre="Confirmed cases of dengue do not affect confirmed cases of" exact="chikungunya" post="0.4283 0.959 Do not reject Confirmed cases of dengue"/>
   <result pre="Confirmed cases of dengue do not affect discarded cases of" exact="chikungunya" post="0.6629 0.799 Do not reject Discarded cases of dengue"/>
   <result pre="Discarded cases of dengue do not affect confirmed cases of" exact="chikungunya" post="1.070 0.384 Do not reject Confirmed cases of chikungunya"/>
   <result pre="of chikungunya 1.070 0.384 Do not reject Confirmed cases of" exact="chikungunya" post="do not affect confirmed cases of Zika 1.128 0.333"/>
   <result pre="not reject Confirmed cases of Zika do not affect confirmed" exact="chikungunya" post="0.9064 0.547 Do not reject Discarded cases of chikungunya"/>
   <result pre="confirmed chikungunya 0.9064 0.547 Do not reject Discarded cases of" exact="chikungunya" post="do not affect confirmed cases of Zika 0.9579 0.493"/>
   <result pre="Confirmed cases of Zika do not affect discarded cases of" exact="chikungunya" post="0.9339 0.518 Do not reject Confirmed cases of chikungunya"/>
   <result pre="of chikungunya 0.9339 0.518 Do not reject Confirmed cases of" exact="chikungunya" post="do not affect discarded cases of Zika 1.010 0.440"/>
   <result pre="Discarded cases of Zika do not affect confirmed cases of" exact="chikungunya" post="0.8859 0.568 Do not reject There is a significant"/>
   <result pre="and 0.04, respectively). We also found that discarded cases of" exact="chikungunya" post="have a significant association with the series of confirmed"/>
   <result pre="by turn confirmed and discarded cases of either dengue or" exact="chikungunya" post="or Zika are not included. Additionally, we show the"/>
   <result pre="in S3 Table. The restricted model excluding the series of" exact="chikungunya" post="has a better performance (AIC = 48.50, lag order"/>
   <result pre="of the restricted models between the cases of Zika and" exact="chikungunya" post="and the cases of dengue and chikungunya. The analysis"/>
   <result pre="cases of dengue and chikungunya. The analysis between Zika and" exact="chikungunya" post="also presents a better AIC value 41.67 (lag order"/>
   <result pre="results: i) confirmed cases of Zika affect discarded cases of" exact="chikungunya" post="(Test statistic = 2.206, p-value = 0.011); ii) discarded"/>
   <result pre="0.011); ii) discarded cases of Zika affect confirmed cases of" exact="chikungunya" post="(Test statistic = 2.447, p-value = 0.004); and iii)"/>
   <result pre="result where confirmed cases of Zika affect confirmed cases of" exact="chikungunya" post="(Test statistic = 1.761, p-value = 0.053). To conclude,"/>
   <result pre="conclude, the Granger tests for the analysis between dengue and" exact="chikungunya" post="(AIC = 52.06, lag order = 12) presented less"/>
   <result pre="presented less relations among them, with only confirmed cases of" exact="chikungunya" post="affecting discarded cases of dengue. Despite this, in both"/>
   <result pre="dengue had overall weaker effects on the notification of suspected" exact="chikungunya" post="cases, as indicated by the smaller correlation values between"/>
   <result pre="in Brazil. As to the mutual influence of dengue and" exact="chikungunya" post="notifications, Granger scores show that possibly a small amount"/>
   <result pre="and discarded cases of dengue were either confirmed cases of" exact="chikungunya" post="or dengue notification were increased by the notification of"/>
   <result pre="to reject the null hypothesis, as in the result for" exact="chikungunya" post="and Zika cases, or a very small correlation value,"/>
   <result pre="very small correlation value, as for both confirmed dengue and" exact="chikungunya" post="cases. Thus, the remaining they also support the conclusion"/>
   <result pre="of reported confirmed and discarded cases of each viruses, although" exact="chikungunya" post="presents lower incidence compared with Zika and dengue, in"/>
   <result pre="proportion of discarded cases is larger for dengue and Zika," exact="chikungunya" post="shows a pattern with a higher proportion of confirmed"/>
   <result pre="of Salvador, Brazil. They argued that the increased pattern of" exact="chikungunya" post="cases in opposition to the decrease of dengue and"/>
   <result pre="series of notifications of confirmed and discarded cases of dengue," exact="chikungunya" post="and Zika presented, in most of the cases, linear"/>
   <result pre="more similar clinical manifestations to each other as compared to" exact="chikungunya" post="[7]. The expressive joint manifestations produced by CHIKV infections"/>
   <result pre="results would not support the use of discarded cases of" exact="chikungunya" post="as complementary cases of Zika infection, as suggested by"/>
   <result pre="Oliveira et al [18]. However, as the total number of" exact="chikungunya" post="discarded cases was small (3.8%) in comparison to the"/>
   <result pre="and confirmed chikungunya, and confirmed cases of Zika and confirmed" exact="chikungunya" post="might be due to spatial factors that are not"/>
   <result pre="to the series of confirmed and discarded cases of dengue," exact="chikungunya" post="and Zika before and after differentiation. Brazil, January 2015"/>
   <result pre="models for the series confirmed and discarded cases of dengue," exact="chikungunya" post="and Zika. Brazil, January 2015 to December 2017. (PDF)"/>
   <result pre="associations between series of confirmed and discarded cases of dengue," exact="chikungunya" post="and Zika. Brazil, January 2015 to December 2017. (PDF)"/>
   <result pre="S3 Fig Probability plot and histograms for confirmed and discarded" exact="chikungunya" post="model’s residuals. The probability plot shows the unscaled quantiles"/>
   <result pre="time series analysis of confirmed and discarded cases of dengue," exact="chikungunya" post="and Zika. (PDF) LINK Click here for additional data"/>
   <result pre="infectious diseases, 17(3), e101–e106. (2017). 10.1016/S1473-3099(16)30518-728011234 2PaixãoES, TeixeiraMG, RodriguesLC. Zika," exact="chikungunya" post="and dengue: the causes and threats of new and"/>
   <result pre="prevention and control 2012–2020. 5Teixeira MariaG., et al.East/Central/South African genotype" exact="chikungunya" post="virus, Brazil, 2014. Emerging infectious diseases, 2015, 215: 90610.3201/eid2105.14172725898939"/>
   <result pre="and clinical presentation in Nicaraguan patients infected with Zika virus," exact="chikungunya" post="virus, and dengue virus. Clinical Infectious Diseases. 2016830:ciw589. 9DonalisioMR,"/>
   <result pre="13Oliveira JF. Multivariate time series analiysis of Zika dengue and" exact="chikungunya" post="viruses in Brazil. GitHub repository. https://github.com/Julian-sun/Multivariate-time-series-analiysis-of-Zika-dengue-and-chikungunya-viruses-in-Brazil.git. 14Seabold, Skipper and"/>
   <result pre="Science Conference, 2010. https://www.statsmodels.org/stable/index.html. 15NimmannityaS, HalsteadSB, CohenSN, MargiottaMR. Dengue and" exact="chikungunya" post="virus infection in man in Thailand. 1962–1964. The American"/>
   <result pre="BreimanRF, PowersAM. Chikungunya fever: an epidemiological review of a re-emerging" exact="infectious disease." post="Clinical infectious diseases. 2009915;49(6):942–8. 10.1086/60549619663604 17RibeiroGS, KikutiM, TauroLB, NascimentoLC,"/>
   <result pre="OliveiraWK, de FrançaGV, CarmoEH, DuncanBB, de Souza KuchenbeckerR, SchmidtMI. Infection-related" exact="microcephaly" post="after the 2015 and 2016 Zika virus outbreaks in"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6996850\results\search\disease\results.xml">
   <result pre="and trimester-dependent: A whole transcriptome analysis Comparitive transcriptome profile in" exact="hepatitis" post="E RamdasiAshwini Y.Data curationFormal analysisMethodologySoftwareValidationVisualizationWriting – original drafthttp://orcid.org/0000-0002-9940-3437ArankalleVidya A.ConceptualizationData"/>
   <result pre="the developing countries. The basis for high mortality among pregnant" exact="hepatitis" post="E patients remains unclear. Importantly, a large proportion of"/>
   <result pre="order to understand the possible mechanisms influencing clinical presentation of" exact="hepatitis" post="E in pregnant women, we explored a system biology"/>
   <result pre="here could be correlated with several studies reported earlier in" exact="hepatitis" post="E patients suggesting utility of PBMCs as an alternate"/>
   <result pre="future studies that will help in understanding pathogenesis of fulminant" exact="hepatitis" post="E. Funding VAA Financial support for this study was"/>
   <result pre="waterborne epidemics and is the major contributor of sporadic acute" exact="viral hepatitis" post="in adults from developing countries [1–5]. India is hyperendemic"/>
   <result pre="epidemics and is the major contributor of sporadic acute viral" exact="hepatitis" post="in adults from developing countries [1–5]. India is hyperendemic"/>
   <result pre="women, especially in the later trimesters [9]. In India, fulminant" exact="hepatitis" post="E in nonpregnant women and men has been recorded"/>
   <result pre="has been recorded [10]. A recent report documented severity of" exact="hepatitis" post="E in pregnant women from developed countries [11]. So"/>
   <result pre="in pregnant women from developed countries [11]. So far, chronic" exact="hepatitis" post="E is restricted to immuno-compromised patients from the industrialized"/>
   <result pre="importance and relevance for the endemic countries. However, pathogenesis of" exact="hepatitis" post="E in general and during pregnancy in particular is"/>
   <result pre="differential outcomes of HEV infection. TLRs have been evaluated in" exact="hepatitis" post="E patients with pregnancy. Contrary to the temporal activation"/>
   <result pre="was shown in pregnant women with FHF-E than with acute" exact="hepatitis" post="E [28]. As against the classical activation of CD14+"/>
   <result pre="poor outcome of HEV during pregnancy [34]. Our observations of" exact="hepatitis" post="E in pregnancy are twofold. First, confirmation of high"/>
   <result pre="mortality during later pregnancy and extending the etiology of fulminant" exact="hepatitis" post="to non-pregnant women and men [10]; Second, the observation"/>
   <result pre="investigate epidemics of viral diseases, including hepatitis. During epidemics of" exact="hepatitis" post="E, a written informed consent is obtained from all"/>
   <result pre="1 provides details of the study population. The diagnosis of" exact="hepatitis" post="E was based on the presence of anti-HEV-IgM antibodies"/>
   <result pre="we did not identify any trimester-1 pregnant woman with clinical" exact="hepatitis" post="E. Groups B and I were included only for"/>
   <result pre="0.7 The study population was identified during 3 epidemics of" exact="hepatitis" post="E in the rural areas of the state of"/>
   <result pre="A detailed clinical examination was done for all the acute" exact="viral hepatitis" post="(AVH) cases. All AVH-E patients had typical symptoms of"/>
   <result pre="detailed clinical examination was done for all the acute viral" exact="hepatitis" post="(AVH) cases. All AVH-E patients had typical symptoms of"/>
   <result pre="(AVH) cases. All AVH-E patients had typical symptoms of acute" exact="viral hepatitis," post="such as sudden onset of fever, nausea, vomiting, weakness"/>
   <result pre="genes after correction for multiple testing (FDR 5%), including: ribosome," exact="systemic lupus erythematosus" post="and oxidative phosphorylation with higher gene count in the"/>
   <result pre="after correction for multiple testing (FDR 5%), including: ribosome, systemic" exact="lupus erythematosus" post="and oxidative phosphorylation with higher gene count in the"/>
   <result pre="gene count in the convalescent phase (Fig 2C).The identification of" exact="systemic lupus erythematosus" post="pathway is probably on account of the overlap with"/>
   <result pre="count in the convalescent phase (Fig 2C).The identification of systemic" exact="lupus erythematosus" post="pathway is probably on account of the overlap with"/>
   <result pre="with enteric infection with HEV. Comparison of pregnant and non-pregnant" exact="hepatitis" post="E patients Pregnancy is known to modulate immune response"/>
   <result pre="response genes. Of the pathways enriched (Fig 3C), ribosome and" exact="systemic lupus erythematosus" post="were common to all the patient categories. Unique group-specific"/>
   <result pre="genes. Of the pathways enriched (Fig 3C), ribosome and systemic" exact="lupus erythematosus" post="were common to all the patient categories. Unique group-specific"/>
   <result pre="like receptor signaling pathway (PR-2-acute) (Fig 4C). Comparisons of pregnant" exact="hepatitis" post="E patients presenting with acute or subclinical infections Our"/>
   <result pre="functions. When we considered the KEGG pathways (Fig 6B), Ribosome," exact="systemic lupus erythematosus," post="cytokine-cytokine receptor interaction and chemokine signaling pathway were common"/>
   <result pre="When we considered the KEGG pathways (Fig 6B), Ribosome, systemic" exact="lupus erythematosus," post="cytokine-cytokine receptor interaction and chemokine signaling pathway were common"/>
   <result pre="were associated with NOD-like receptor signaling pathway and pathways in" exact="cancer" post="(VHL, MMP9, PIAS4, PTGS2, DVL2, SMAD4, SPI1, CRKL genes)."/>
   <result pre="PTGS2, DVL2, SMAD4, SPI1, CRKL genes). In the third trimester," exact="systemic lupus erythematosus" post="and proteasome were enriched in the acute disease while"/>
   <result pre="DVL2, SMAD4, SPI1, CRKL genes). In the third trimester, systemic" exact="lupus erythematosus" post="and proteasome were enriched in the acute disease while"/>
   <result pre="a few were modulated, though differently, in different groups of" exact="hepatitis" post="E patients. CD1D and GZMM We report higher expression"/>
   <result pre="This study showed the involvement of alpha defensins (DEFA) in" exact="hepatitis" post="E. In both clinical and subclinical categories, DEFA1 gene"/>
   <result pre="in the NPR patients. Higher expression of S100A8 during acute" exact="hepatitis" post="in both trimesters and additionally S100A12 in the third"/>
   <result pre="first time provides comparative transcriptome analysis of PBMCs obtained from" exact="hepatitis" post="E patients and addresses impact of pregnancy. Next generation"/>
   <result pre="of TLR2 / TLR3 /TLR4 genes was increased in acute" exact="hepatitis" post="E patients while a significant reduction was evident in"/>
   <result pre="down regulated in pregnant women with FHF-E than with acute" exact="hepatitis" post="E. Taken together, TLR3/4/9 seem to play crucial role"/>
   <result pre="activation. In the light of increased expression of NOD1 in" exact="hepatitis" post="C patients [47] and the involvement of NOD1 through"/>
   <result pre="in pregnant women that otherwise constitute high-risk category for severe" exact="liver disease." post="We could identify several GO terms specific to subclinical"/>
   <result pre="difference was seen among PR-3-SC and PR-3-acute patients. In fulminant" exact="hepatitis" post="E, the number of antigen-specific, IgG-producing B cells increased"/>
   <result pre="other hand, reported (i) higher anti-HEV titres in the fulminant" exact="hepatitis" post="patients than the self-recovering non-pregnant patients [24] and (ii)"/>
   <result pre="severity has been reported for several viral infections such as" exact="influenza" post="[50], SARS [51], dengue [52] and measles [53]. Of"/>
   <result pre="infections such as influenza [50], SARS [51], dengue [52] and" exact="measles" post="[53]. Of note, RNA-seq data with respect to defensins,"/>
   <result pre="12B–12D) strengthening the association of modulation of these genes with" exact="hepatitis" post="E and clinical presentation. A single pregnant woman in"/>
   <result pre="A single pregnant woman in the third trimester with fulminant" exact="hepatitis" post="E showed downregulation of defensin and S100 genes. At"/>
   <result pre="system that seem to have a role in protection/pathogenesis of" exact="hepatitis" post="E. The observed upregulation of some of the S100"/>
   <result pre="of human breast cancers [57–58]. Overexpression of alpha defensins in" exact="hepatitis" post="E patients (irrespective of pregnancy and clinical presentation) suggests"/>
   <result pre="to be confirmed by functional assays and extended to fulminant" exact="hepatitis" post="E. Response to vitamin D was uniquely associated with"/>
   <result pre="in a transgenic HBV transfer mouse model, induction of acute" exact="hepatitis" post="was mediated by CD1D-restricted NKT cells [63]. Myocarditis in"/>
   <result pre="and robust inflammatory response in the pregnant women with self-recovering" exact="hepatitis" post="E. The study revealed that immune responses during the"/>
   <result pre="functional studies reported earlier in acute as well as fulminant" exact="hepatitis" post="patients with or without pregnancy, it may be summarized"/>
   <result pre="without pregnancy, it may be summarized that clinical presentation in" exact="hepatitis" post="E represent distinct transcriptional profiles with respect to immune"/>
   <result pre="future studies that will help in understanding pathogenesis of fulminant" exact="hepatitis" post="E during pregnancy. Supporting information S1 Fig Hierarchical clustering"/>
   <result pre="10.1002/jmv.18904002088360633 2ArankalleVA, ChadhaMS, TsarevSA, EmersonSU, RisbudAR, et al.Seroepidemiology of water-borne" exact="hepatitis" post="in India and evidence for a third enterically-transmitted hepatitis"/>
   <result pre="water-borne hepatitis in India and evidence for a third enterically-transmitted" exact="hepatitis" post="agent. Proc Natl Acad Sci1994; 91: 3428–3432. 10.1073/pnas.91.8.34288159764 3ArankalleVA,"/>
   <result pre="10.1073/pnas.91.8.34288159764 3ArankalleVA, ChadhaMS, ChitambarSD, WalimbeAM, ChobeLP, et al.Changing epidemiology of" exact="hepatitis" post="A and hepatitis E in urban and rural India"/>
   <result pre="ChitambarSD, WalimbeAM, ChobeLP, et al.Changing epidemiology of hepatitis A and" exact="hepatitis" post="E in urban and rural India (1982–98). J Viral"/>
   <result pre="10.1046/j.1365-2893.2001.00279.x11454182 4KhurooMS, DuermeyerW, ZargarSA, AhangerMA, ShahMA. Acute sporadic non-A, non-B" exact="hepatitis" post="in India. Am J Epidemiol1983;118: 360–4. 10.1093/oxfordjournals.aje.a1136436412542 5ChadhaMS, WalimbeAM,"/>
   <result pre="22:11–15. 12617445 6ArankalleVA, ChobeLP, JoshiMV, ChadhaMS, KunduBet al.Human and swine" exact="hepatitis" post="E viruses from Western India belong to different genotypes."/>
   <result pre="Viral Hepat. 20076;14(6):435–45. 10.1111/j.1365-2893.2006.00801.x17501765 8GuptaN, SarangiAN, DadhichS, DixitVK, ChetriKet al.Acute" exact="hepatitis" post="E in India appears to be caused exclusively by"/>
   <result pre="in India appears to be caused exclusively by genotype 1" exact="hepatitis" post="E virus. Indian J Gastroenterol. 20181;37(1):44–49. 10.1007/s12664-018-0819-z29399748 9KhurooM.S.; KhurooM.S.Hepatitis"/>
   <result pre="al.Contribution of HEV and HCV in causing fulminant non-A, non-B" exact="hepatitis" post="in Western India. J.Viral.Hepatitis1995; 2: 189–193. 11LachishT, ErezO, DaudiN,"/>
   <result pre="India. J.Viral.Hepatitis1995; 2: 189–193. 11LachishT, ErezO, DaudiN, ShouvalD, SchwartzE. Acute" exact="hepatitis" post="E virus in pregnant women in Israel and in"/>
   <result pre="MansuyJM, OuezzaniL, PéronJM, GuitardJ, et al.Hepatitis E virus and chronic" exact="hepatitis" post="in organ-transplant recipients. Engl J Med2008; 358(8):811–7. 13HaagsmaEB, van"/>
   <result pre="13HaagsmaEB, van den BergAP, PorteRJ, BenneCA, VennemaH, ReimerinkJH, et al.Chronic" exact="hepatitis" post="E virus infection in liver transplant recipients. Liver Transpl2008;"/>
   <result pre="NazS, IsmailH. Comparison of foeto-maternal outcome in pregnant women with" exact="hepatitis" post="E—A review of 12 years. J Pak Med Assoc."/>
   <result pre="28420911 18GouillyJ, ChenQ, SiewieraJ, CartronG, LevyCet al.Genotype specific pathogenicity of" exact="hepatitis" post="E virus at the human maternal-fetal interface. Nat Commun."/>
   <result pre="97: 4–8. 8486409 21TsarevSA, TsarevaTS, EmersonSU, RippyMK, ZackP, ShapiroMet al.Experimental" exact="hepatitis" post="E in pregnant rhesus monkeys: failure to transmit hepatitis"/>
   <result pre="al.Experimental hepatitis E in pregnant rhesus monkeys: failure to transmit" exact="hepatitis" post="E virus (HEV) to offspring and evidence of naturally"/>
   <result pre="172(1):31–7. 10.1093/infdis/172.1.317797939 22XiaJet al., Experimental infection of pregnant rabbits with" exact="hepatitis" post="E virus demonstrating high mortality and vertical transmission. J"/>
   <result pre="25BorkakotiJ, HazamRK, MohammadA, KumarA, KarP. Does high viral load of" exact="hepatitis" post="E virus influence the severity and prognosis of acute"/>
   <result pre="Virol. 20134;85(4):620–6. 10.1002/jmv.2350823280991 26AryaRP, ArankalleVA. Toll like receptors in self-recovering" exact="hepatitis" post="E patients with or without pregnancy. Hum Immunol. 201412;75(12):1147–54."/>
   <result pre="TLR gene expression and cytokine profiling in the immunopathogenesis of" exact="viral hepatitis" post="E.J Clin Virol2015; 73:8–13. 10.1016/j.jcv.2015.09.01126512422 28SehgalR, PatraS,DavidP,VyasA,KhanamA,HissarSet al.Impaired monocyte-macrophage"/>
   <result pre="gene expression and cytokine profiling in the immunopathogenesis of viral" exact="hepatitis" post="E.J Clin Virol2015; 73:8–13. 10.1016/j.jcv.2015.09.01126512422 28SehgalR, PatraS,DavidP,VyasA,KhanamA,HissarSet al.Impaired monocyte-macrophage"/>
   <result pre="PatraS,DavidP,VyasA,KhanamA,HissarSet al.Impaired monocyte-macrophage functions and defective Toll-like receptor signaling in" exact="hepatitis" post="E virus-infected pregnant women with acute liver failure. Hepatology2015;"/>
   <result pre="ArankalleVA. Phenotypic analysis of monocytes and CD4+ T cells in" exact="hepatitis" post="E patients with or without pregnancy. Hum Immunol. 201910;80(10):855–862."/>
   <result pre="KumarA, KarP, AggarwalS, HusainAet al.Serum tumor necrosis factor-alpha level in" exact="hepatitis" post="E virus-related acute viral hepatitis and fulminant hepatic failure"/>
   <result pre="al.Serum tumor necrosis factor-alpha level in hepatitis E virus-related acute" exact="viral hepatitis" post="and fulminant hepatic failure in pregnant women. Hepatol Res."/>
   <result pre="tumor necrosis factor-alpha level in hepatitis E virus-related acute viral" exact="hepatitis" post="and fulminant hepatic failure in pregnant women. Hepatol Res."/>
   <result pre="10.1111/hepr.1202823279190 31KumarA, DeviSG, KarP, AgarwalS, HusainSAet al.Association of cytokines in" exact="hepatitis" post="E with pregnancy outcome. Cytokine. 20141;65(1):95–104. 10.1016/j.cyto.2013.09.02224416783 32DeviSG, KumarA,"/>
   <result pre="VyasA, VasudevanMet al.miRNA signatures can predict acute liver failure in" exact="hepatitis" post="E infected pregnant females. Heliyon. 201746;3(4):e0028710.1016/j.heliyon.2017.e0028728413835 35ArankalleVA, ChadhaMS, DamaBM,"/>
   <result pre="immune serum globulins in pregnant women during an epidemic of" exact="hepatitis" post="E. J Viral Hepat1998; 5: 199–204. 10.1046/j.1365-2893.1998.00096.x9658374 36MorG, AbrahamsV:"/>
   <result pre="20178;17(8):469–482. 10.1038/nri.2017.6428627518 39ArankalleVA, ParanjapeS, EmersonSU, PurcellRH, WalimbeAM. Phylogenetic analysis of" exact="hepatitis" post="E virus isolates from India (1976–1993). J Gen Virol."/>
   <result pre="interferonsNature1986; 323, 819–822. 10.1038/323819a02430188 43YuC, BoonD, McDonaldSL, et al.Pathogenesis of" exact="hepatitis" post="E virus and hepatitis C virus in chimpanzees: similarities"/>
   <result pre="43YuC, BoonD, McDonaldSL, et al.Pathogenesis of hepatitis E virus and" exact="hepatitis" post="C virus in chimpanzees: similarities and differences. J Virol2010;"/>
   <result pre="al.NOD1 participates in the innate immune response triggered by the" exact="hepatitis" post="C viral polymerase. J. Virol.2016; 90(13):6022–3510.1128/JVI.03230-1527099311 49SrivastavaR, AggarwalR, SachdevaS,"/>
   <result pre="JameelS, NaikS. Adaptive immune responses during acute uncomplicated and fulminant" exact="hepatitis" post="E. J Gastroenterol Hepatol2011; 26(2): 306–311. 10.1111/j.1440-1746.2010.06356.x21143520 50ReumanPD, BernsteinDI,"/>
   <result pre="YoungEC, SchiffGM. Influenza-specific ELISA IgA and IgG predict severity of" exact="influenza" post="disease in subjects prescreened with hemagglutination inhibition. Antiviral Res1990;"/>
   <result pre="IpMet al.Anti-SARS-CoV IgG response in relation to disease severity of" exact="severe acute respiratory syndrome." post="J.Clin. Virol2006; 35: 179–84. 10.1016/j.jcv.2005.07.00516112612 52ChareonsirisuthigulT, KalayanaroojS, UbolS. Dengue"/>
   <result pre="PandeyM, HarveyM, GriesmannGE, FederspielMJ, RussellSJ. Immunoglobulin G antibody-mediated enhancement of" exact="measles" post="virus infection can bypass the protective antiviral immune response."/>
   <result pre="metastasis-inducing protein S100A4 (p9Ka) with other prognostic markers in human" exact="breast cancer." post="Int. J. Cancer2000; 89:198–208. 10754500 58RudlandPS, Platt-HigginsAM, RenshawCA, et"/>
   <result pre="al.Prognostic significance of the metastasis-inducing protein S100A4 (p9Ka) in human" exact="breast cancer." post="Cancer Res2000; 60:1595–1603. 10749128 59KlotmanME, ChangTL. Defensins in innate"/>
   <result pre="al.Temporal dynamics of host molecular responses differentiate symptomatic and asymptomatic" exact="influenza" post="a infection. PLoS Genet2011; 7:e100223410.1371/journal.pgen.100223421901105 62DasR, TripathyA. Increased expressions"/>
   <result pre="NK/NKT-like cells are associated with impaired cytolytic function in self-limiting" exact="hepatitis" post="E infection. Med Microbiol Immunol2014; 203 (5):303–14. 10.1007/s00430-014-0338-124824867 63BaronJL,"/>
   <result pre="nonclassical NKT cell subset in a transgenic mouse model of" exact="hepatitis" post="B virus infection. Immunity2002; 16:583–94. 10.1016/s1074-7613(02)00305-911970881"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6997034\results\search\disease\results.xml">
   <result pre="doi: 10.1002/cti2.1107CTI21107 : Original Article: Original Article Assessment of enhanced" exact="influenza" post="vaccination finds that FluAd conveys an advantage in mice"/>
   <result pre="FluAd conveys an advantage in mice and older adults Enhanced" exact="influenza" post="vaccines in mice and humans N Kavian et al."/>
   <result pre="modifications or adaptations are made.file:CTI2-9-e1107.pdf Abstract Abstract Objectives Enhanced inactivated" exact="influenza" post="vaccines (eIIV) aim to increase immunogenicity and protection compared"/>
   <result pre="cross�?reactive memory responses were sustained by FluAd following lethal heterosubtypic" exact="influenza" post="challenge, with reduced lung damage and viral loads, coinciding"/>
   <result pre="mismatch between the vaccine strain and the circulating strain of" exact="influenza" post="viruses. In this randomised clinical trial, we showed that"/>
   <result pre="viruses. In this randomised clinical trial, we showed that enhanced" exact="influenza" post="vaccines boost antibody quality in older adults, and showed"/>
   <result pre="for antibody production. adjuvant antibody B cell HA stem infection" exact="influenza" post="vaccine Funding NIH/NIAID CEIRS grantHHSN272201400006C Centers for Disease Control"/>
   <result pre="of Hong Kong17113718 fig-count: table-count: page-count: word-count: Introduction Vaccination against" exact="influenza" post="viruses aims to mitigate morbidity and mortality associated with"/>
   <result pre="of age are the most susceptible group to complications of" exact="influenza" post="infection, account for the majority of influenza�?associated mortality and"/>
   <result pre="mismatch,3, 4 pandemic emergence,5 egg adaptations6 and age.7 Standard�?dose inactivated" exact="influenza" post="vaccines (S�?IIV) contain 15 µg of haemagglutinin (HA) per"/>
   <result pre="widely used vaccine formulation to reduce the burden of seasonal" exact="influenza" post="epidemics.8 Prioritising the use of newly available enhanced inactivated"/>
   <result pre="influenza epidemics.8 Prioritising the use of newly available enhanced inactivated" exact="influenza" post="vaccines (eIIVs) may increase the longevity, breadth and quality"/>
   <result pre="increase the longevity, breadth and quality of vaccine�?mediated protection against" exact="influenza" post="virus infections and associated morbidity and mortality in older"/>
   <result pre="significantly higher antibody responses and provides better protection against laboratory�?confirmed" exact="influenza" post="than S�?IIV among the elderly.14 H�?eIIV has also shown"/>
   <result pre="have shown R�?eIIV elicits higher titre microneutralisation antibody titres against" exact="influenza" post="A (H3N2) and CD4+ T�?cell boosting, followed by H�?eIIV,"/>
   <result pre="trends for H1�?HA�?specific responses (Supplementary figures 1 and 5) and" exact="influenza" post="B responses with limited reagents (data not shown). A�?eIIV"/>
   <result pre="limited reagents (data not shown). A�?eIIV in mice induces superior" exact="influenza" post="antibody responses for vaccine antigens, cross�?reactive proteins and neutralisation"/>
   <result pre="and cross�?reactivity against H3N2�?1968, we assessed further cross�?reactivity against an" exact="avian influenza" post="virus, H7N7, another group 2 influenza virus. Firstly, A�?eIIV"/>
   <result pre="cross�?reactivity against H3N2�?1968, we assessed further cross�?reactivity against an avian" exact="influenza" post="virus, H7N7, another group 2 influenza virus. Firstly, A�?eIIV"/>
   <result pre="cross�?reactivity against an avian influenza virus, H7N7, another group 2" exact="influenza" post="virus. Firstly, A�?eIIV elicited significantly increased H7�?HA�?specific IgG response"/>
   <result pre="of H3�?specific T and B cells by A�?eIIV during heterologous" exact="influenza" post="challenge in mice Human and mouse data for A�?eIIV"/>
   <result pre="(Supplementary figure 5). Differences in inflammation and viral clearance after" exact="influenza" post="challenge at long term may indicate changes in cellular"/>
   <result pre="(Figure 6d) and B cells (Figure 6e and f). Following" exact="influenza" post="virus challenge, A�?eIIV mice showed increased H3N2�?1968�?specific polyfunctional CD8+"/>
   <result pre="consequence of AID activity, the properties of immune sera at" exact="influenza" post="challenge time points were further assessed. The H3N2�?1968 VNA"/>
   <result pre="protection, as broadly protecting vaccines are needed, but no universal" exact="influenza" post="vaccine is licensed yet.27, 28 We therefore compared the"/>
   <result pre="(A�?eIIV), FluZone�?HD (H�?eIIV) and FluBlok (R�?eIIV), with a standard seasonal" exact="influenza" post="vaccine, FluQuadri (S�?IIV), in humans and mice. We found"/>
   <result pre="A�?eIIV and H�?eIIV may provide longer�?lasting and broader cross�?protection against" exact="influenza" post="viruses than S�?eIIV and R�?eIIV. Results from our randomised"/>
   <result pre="conserved neutralising epitopes, which may enable broader protection against different" exact="influenza" post="strains,29 rendering the induction of anti�?HA stem antibodies by"/>
   <result pre="of particular interest for increasing the breadth of protection by" exact="influenza" post="vaccination strategies. Our randomised clinical trial was designed to"/>
   <result pre="parallel in mice followed by challenge with a lethal heterologous" exact="influenza" post="strain, enabling access to infected tissues and immune sites"/>
   <result pre="the CSR process plays a vital role for protection from" exact="influenza" post="infections, as AID−/− mice showed severe morbidity with delayed"/>
   <result pre="the high�?dose vaccines, H�?eIIV and R�?eIIV. Previous vaccine studies for" exact="hepatitis" post="B and pneumococcal vaccines have also reported that low"/>
   <result pre="long�?term memory is an advantage for extended seasonal protection against" exact="influenza" post="infection. Vaccine�?mediated protection was further assessed by lethal H3N2�?1968"/>
   <result pre="and A�?eIIV�?treated mice had greater recall of NP antibodies during" exact="influenza" post="challenge. The NP protein has an even higher level"/>
   <result pre="and H�?eIIV provide better cross�?protection against a broader array of" exact="influenza" post="viruses. Future studies could examine whether combination strategies, for"/>
   <result pre="65–82 years old, which was initiated before the 2017/2018 winter" exact="influenza" post="season in Hong Kong (http://ClinicalTrials.gov NCT03330132). Older adults (Supplementary"/>
   <result pre="lineage). S�?IIV and R�?eIIV were quadrivalent and contained a second" exact="influenza" post="B virus, B/Phuket/3073/2013 (Yamagata lineage). For assessment of vaccination"/>
   <result pre="1% Pen/Strep). An equal volume of 200TCID50 35 μL−1 of" exact="influenza" post="viruses, H1N1�?2009, H3N2�?2013, H3N2�?1968 and H7N7 (low pathogenic avian"/>
   <result pre="of influenza viruses, H1N1�?2009, H3N2�?2013, H3N2�?1968 and H7N7 (low pathogenic" exact="avian influenza" post="(LPAI); A/Northern Shoveller/MPF518/2008), was added to the sample dilutions"/>
   <result pre="influenza viruses, H1N1�?2009, H3N2�?2013, H3N2�?1968 and H7N7 (low pathogenic avian" exact="influenza" post="(LPAI); A/Northern Shoveller/MPF518/2008), was added to the sample dilutions"/>
   <result pre="�? United States, 2014–15 season and composition of the 2015–16" exact="influenza" post="vaccine. MMWR Morb Mortal Wkly Rep2015; 64: 583–590.26042650 3XieH,"/>
   <result pre="583–590.26042650 3XieH, WanXF, YeZet alH3N2 mismatch of 2014–15 Northern hemisphere" exact="influenza" post="vaccines and head�?to�?head comparison between human and ferret antisera"/>
   <result pre="Sci Rep2015; 5: 15279.26472175 4AmbroseCS, LevinMJ. The rationale for quadrivalent" exact="influenza" post="vaccines. Hum Vaccin Immunother2012; 8: 81–88.22252006 5VijaykrishnaD, PoonLL, ZhuHCet"/>
   <result pre="Immunother2012; 8: 81–88.22252006 5VijaykrishnaD, PoonLL, ZhuHCet alReassortment of pandemic H1N1/2009" exact="influenza" post="A virus in swine. Science2010; 328: 1529.20558710 6WuNC, ZostSJ,"/>
   <result pre="alA structural explanation for the low effectiveness of the seasonal" exact="influenza" post="H3N2 vaccine. PLoS Pathog2017; 13: e1006682.29059230 7RussellK, ChungJR, MontoASet"/>
   <result pre="over five seasons. Vaccine2018; 36: 1272–1278.29402578 8BarberisI, MartiniM, IavaroneFet alAvailable" exact="influenza" post="vaccines: immunization strategies, history and new tools for fighting"/>
   <result pre="Prev Med Hyg2016; 57: e41–e46.27346939 9WongSS, WebbyRJ. Traditional and new" exact="influenza" post="vaccines. Clin Microbiol Rev2013; 26: 476–492.23824369 10XuC, ThompsonMG, CowlingBJ."/>
   <result pre="enhances diversity and affinity of antibody�?mediated immune response to pandemic" exact="influenza" post="vaccines. Sci Transl Med2011; 3: 85ra48. 12CoxMM, IziksonR, PostPet"/>
   <result pre="efficacy, and immunogenicity of Flublok in the prevention of seasonal" exact="influenza" post="in adults. Ther Adv Vaccines2015; 3: 97–108.26478817 13NayakJL, RichardsKA,"/>
   <result pre="Ther Adv Vaccines2015; 3: 97–108.26478817 13NayakJL, RichardsKA, YangHet alEffect of" exact="influenza" post="A(H5N1) vaccine prepandemic priming on CD4+ T�?cell responses. J"/>
   <result pre="211: 1408–1417.25378637 14DiazGranadosCA, DunningAJ, KimmelMet alEfficacy of high�?dose versus standard�?dose" exact="influenza" post="vaccine in older adults. N Engl J Med2014; 371:"/>
   <result pre="alHigher antigen content improves the immune response to 2009 H1N1" exact="influenza" post="vaccine in HIV�?infected adults: a randomized clinical trial. J"/>
   <result pre="J Infect Dis2012; 205: 703–712.22275399 16ZostSJ, ParkhouseK, GuminaMEet alContemporary H3N2" exact="influenza" post="viruses have a glycosylation site that alters binding of"/>
   <result pre="114: 12578–12583.29109276 17FrancisME, KingML, KelvinAA. Back to the future for" exact="influenza" post="preimmunity�?looking back at influenza virus history to infer the"/>
   <result pre="KelvinAA. Back to the future for influenza preimmunity�?looking back at" exact="influenza" post="virus history to infer the outcome of future infections."/>
   <result pre="HaiR, KrammerFet alHemagglutinin stalk antibodies elicited by the 2009 pandemic" exact="influenza" post="virus as a mechanism for the extinction of seasonal"/>
   <result pre="109: 2573–2578.22308500 23ValkenburgSA, LiOT, MakPWet alIL�?15 adjuvanted multivalent vaccinia�?based universal" exact="influenza" post="vaccine requires CD4+ T cells for heterosubtypic protection. Proc"/>
   <result pre="Natl Acad Sci USA2014; 111: 5676–5681.24706798 24ValkenburgSA, MallajosyulaVV, LiOTet alStalking" exact="influenza" post="by vaccination with pre�?fusion headless HA mini�?stem. Sci Rep2016;"/>
   <result pre="6: 22666.26947245 25PalacheA, AbelinA, HollingsworthRet alSurvey of distribution of seasonal" exact="influenza" post="vaccine doses in 201 countries (2004–2015): the 2003 World"/>
   <result pre="countries (2004–2015): the 2003 World Health Assembly resolution on seasonal" exact="influenza" post="vaccination coverage and the 2009 influenza pandemic have had"/>
   <result pre="Assembly resolution on seasonal influenza vaccination coverage and the 2009" exact="influenza" post="pandemic have had very little impact on improving influenza"/>
   <result pre="2009 influenza pandemic have had very little impact on improving" exact="influenza" post="control and pandemic preparedness. Vaccine2017; 35: 4681–4686.28754488 26RondyM, GherasimA,"/>
   <result pre="26RondyM, GherasimA, CasadoIet alLow 2016/17 season vaccine effectiveness against hospitalised" exact="influenza" post="A(H3N2) among elderly: awareness warranted for 2017/18 season. Euro"/>
   <result pre="season. Euro Surveill2017; 22: pii=17-00645. 27ErbeldingEJ, PostDJ, StemmyEJet alA universal" exact="influenza" post="vaccine: the strategic plan for the National Institute of"/>
   <result pre="MeldgaardTS, BertholetS. Novel platforms for the development of a universal" exact="influenza" post="vaccine. Front Immunol2018; 9: 600.29628926 29KirkpatrickE, QiuX, WilsonPCet alThe"/>
   <result pre="influenza vaccine. Front Immunol2018; 9: 600.29628926 29KirkpatrickE, QiuX, WilsonPCet alThe" exact="influenza" post="virus hemagglutinin head evolves faster than the stalk domain."/>
   <result pre="ShibataTet alUnmutated immunoglobulin M can protect mice from death by" exact="influenza" post="virus infection. J Exp Med2003; 197: 1779–1785.12796467 32TamHH, MeloMB,"/>
   <result pre="response in infants and children to pneumococcal polysaccharides conjugated to" exact="tetanus" post="toxoid. Vaccine1999; 17: 2726–2732.10418924 35LambertPH, LiuM, SiegristCA. Can successful"/>
   <result pre="WatsonB, IoliVAet alA randomized trial of alternative two�? and three�?dose" exact="hepatitis" post="B vaccination regimens in adolescents: antibody responses, safety, and"/>
   <result pre="of Flt3�?Ligand�?dependent de novo generation of conventional dendritic cells during" exact="influenza" post="infection contributes to respiratory bacterial superinfection. PLoS Pathog2018; 14:"/>
   <result pre="38OshanskyCM, GartlandAJ, WongSSet alMucosal immune responses predict clinical outcomes during" exact="influenza" post="infection independently of age and viral load. Am J"/>
   <result pre="189: 449–462.24308446 39DreyfusC, LaursenNS, KwaksTet alHighly conserved protective epitopes on" exact="influenza" post="B viruses. Science2012; 337: 1343–1348.22878502 40PaulesCI, MarstonHD, EisingerRWet alThe"/>
   <result pre="337: 1343–1348.22878502 40PaulesCI, MarstonHD, EisingerRWet alThe pathway to a universal" exact="influenza" post="vaccine. Immunity2017; 47: 599–603.29045889 41LaMereMW, LamHT, MoquinAet alContributions of"/>
   <result pre="LamHT, MoquinAet alContributions of antinucleoprotein IgG to heterosubtypic immunity against" exact="influenza" post="virus. J Immunol2011; 186: 4331–4339.21357542 42YewdellJW, FrankE, GerhardW. Expression"/>
   <result pre="virus. J Immunol2011; 186: 4331–4339.21357542 42YewdellJW, FrankE, GerhardW. Expression of" exact="influenza" post="A virus internal antigens on the surface of infected"/>
   <result pre="Immunol1981; 126: 1814–1819.7217668 43collab: Therapeutic Goods Administration . 2019 seasonal" exact="influenza" post="vaccines; https://www.tga.gov.au/alert/2019-seasonal-influenza-vaccines. Therapeutic Goods Administration Department of Health Australian"/>
   <result pre="CitronM, FerraraFet alHemagglutinin sequence conservation guided stem immunogen design from" exact="influenza" post="A H3 subtype. Front Immunol2015; 6: 329.26167164 46Herrera�?OrtizA, Conde�?GlezCJ,"/>
   <result pre="Obstet Gynecol2013; 2013: 140142.23986628 47ValkenburgSA, LiOTW, LiAet alProtection by universal" exact="influenza" post="vaccine is mediated by memory CD4 T cells. Vaccine2018;"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC7000767\results\search\disease\results.xml">
   <result pre="UKLondon pmcid: 700076758407 doi: 10.1038/s41598-020-58407-7 : Article Association of past" exact="dengue fever" post="epidemics with the risk of Zika microcephaly at the"/>
   <result pre="of past dengue fever epidemics with the risk of Zika" exact="microcephaly" post="at the population level in Brazil http://orcid.org/0000-0002-9566-0284CarvalhoMarilia Sámarilia.carvalho@fiocruz.br1http://orcid.org/0000-0001-9012-9382FreitasLaís Picinini2CruzOswaldo"/>
   <result pre="possible due to the large number of babies born with" exact="microcephaly" post="in the Northeast region (NE) in a narrow time."/>
   <result pre="ZIKV. In this ecological study, we analysed the interaction between" exact="dengue fever" post="epidemics from 2001 to 2014 and the 2015/2016 microcephaly"/>
   <result pre="dengue fever epidemics from 2001 to 2014 and the 2015/2016" exact="microcephaly" post="epidemic in 400 microregions in Brazil using random-effects models"/>
   <result pre="the most recent large dengue epidemic (&amp;gt;400/100,000 inhabitants) and the" exact="microcephaly" post="epidemic ranged from protection (up to 6 years prior)"/>
   <result pre="reasons that made it possible for researchers to associate the" exact="microcephaly" post="epidemic in the Northeast (NE) region of Brazil with"/>
   <result pre="robust analysis using secondary databases estimated a peak of 49.9" exact="microcephaly" post="cases per 10,000 live births in the NE region,"/>
   <result pre="not surpass 10 cases per 10,000 live births6. So far," exact="microcephaly" post="ratios as high as in the Brazilian NE region"/>
   <result pre="epidemiological context29,30. In this article, we analyse the interaction between" exact="dengue fever" post="epidemics from 2001 to 2014 and the 2015/2016 microcephaly"/>
   <result pre="dengue fever epidemics from 2001 to 2014 and the 2015/2016" exact="microcephaly" post="epidemic in 400 microregions in Brazil. Methods Data This"/>
   <result pre="did not have a specific code, we considered as a" exact="microcephaly" post="case a live-born with the microcephaly code &quot;Q02�? (10th"/>
   <result pre="we considered as a microcephaly case a live-born with the" exact="microcephaly" post="code &quot;Q02�? (10th edition of the ICD) in any"/>
   <result pre="any of the five fields. We compared the number of" exact="microcephaly" post="cases between 2015–2016, considered the epidemic period, to the"/>
   <result pre="System for Notifiable Diseases (SINAN). We obtained the number of" exact="dengue fever" post="cases by municipality and epidemiological week from 2001 to"/>
   <result pre="incomplete birth records, and the South region, not endemic for" exact="dengue fever" post="or any arboviral disease. Maps were made using QGIS"/>
   <result pre="socioeconomically homogeneous microregions, as defined by the census bureau. As" exact="dengue fever" post="counts are organized by epidemiological week, the first approach"/>
   <result pre="time scale (Fig. 1a,b). Maps (Fig. 2a,b) present the overall" exact="microcephaly" post="rate per 10,000 live-born babies and dengue fever incidence"/>
   <result pre="present the overall microcephaly rate per 10,000 live-born babies and" exact="dengue fever" post="incidence per 100,000 inhabitants by microregion in the three"/>
   <result pre="NE, Central-West (CW) and Southeast (SE). Figure 1 Microcephaly and" exact="dengue fever" post="indicators per week per macroregion, Brazil. Frame (a) presents"/>
   <result pre="week per macroregion, Brazil. Frame (a) presents the rate of" exact="microcephaly" post="cases per 10,000 live-births by week in each region"/>
   <result pre="week in each region analysed, and frame (b) depicts the" exact="dengue fever" post="incidence rate per 100,000 inhabitants, in the same time"/>
   <result pre="inhabitants, in the same time scale. Figure 2 Rate of" exact="microcephaly" post="cases per 10,000 live-born infants per microregion, Brazil, 2014."/>
   <result pre="Data by OpenStreetMap, under CC BY SA. Models Using the" exact="microcephaly" post="counts as the dependent variable and the total number"/>
   <result pre="Laplace approximation (INLA)32. To evaluate the time lag between the" exact="microcephaly" post="epidemic and a previous dengue fever epidemic, we assessed"/>
   <result pre="the time lag between the microcephaly epidemic and a previous" exact="dengue fever" post="epidemic, we assessed several rate thresholds (100, 200, 300,"/>
   <result pre="dengue epidemic. In brief, the model evaluates the number of" exact="microcephaly" post="cases, considering the total number of live births as"/>
   <result pre="considering the total number of live births as offset, and" exact="dengue fever" post="epidemics with an incidence above 400/100,000 between one and"/>
   <result pre="available in the Supplemental Material. Results The total number of" exact="microcephaly" post="cases increased more than 23-fold between 2014 and 2015"/>
   <result pre="Brazilian Health authorities. In just one week, the number of" exact="microcephaly" post="cases in 2015 in the NE region reached 29,"/>
   <result pre="reached 29, more than half of the total number of" exact="microcephaly" post="cases from the previous year. The number of microregions"/>
   <result pre="from the previous year. The number of microregions with no" exact="microcephaly" post="cases decreased first in the NE, the dispersion centre"/>
   <result pre="by the SE and CW regions. Table 1 Number of" exact="microcephaly" post="cases in neonates, number of live births, the maximum"/>
   <result pre="in neonates, number of live births, the maximum number of" exact="microcephaly" post="cases in one week, and proportion of microregions with"/>
   <result pre="cases in one week, and proportion of microregions with zero" exact="microcephaly" post="cases, by year and macroregion, Brazil. Year Northeast Southeast"/>
   <result pre="844590 1193720 247069 2016 799760 1123013 233888 Maximum number of" exact="microcephaly" post="cases in one week 2014 2 2 1 2015"/>
   <result pre="5 2016 19 10 3 Percentage of microregions with zero" exact="microcephaly" post="cases 2014 79.3% 78.8% 82.7% 2015 22.3% 61.3% 69.2%"/>
   <result pre="22.3% 61.3% 69.2% 2016 19.7% 37.5% 37.7% The rate of" exact="microcephaly" post="in neonates per 10,000 live births per week by"/>
   <result pre="Brazilian macroregions is presented in Fig. 1a. The increase of" exact="microcephaly" post="rate beginning at the end of 2015 is observed"/>
   <result pre="at the end of 2016. Comparing the incidence rates of" exact="dengue fever" post="(Fig. 1b) in the SE and CW regions, three"/>
   <result pre="map presented in Fig. 2 shows the usual pattern of" exact="microcephaly" post="rate among live-born neonates in 2014, before the Zika"/>
   <result pre="babies born in an area with a small population. The" exact="microcephaly" post="epidemic data map (Fig. 3) depicted a different pattern:"/>
   <result pre="proportion was just 20% (Table 1). Figure 3 Rate of" exact="microcephaly" post="cases per 10,000 live-born infants per microregion, Brazil, 2015–2016."/>
   <result pre="OpenStreetMap, under CC BY SA. Figure 4 depicts the mean" exact="dengue fever" post="incidence rate over five years (2010–2014). The spatial pattern,"/>
   <result pre="compared with Fig. 3, is inverted: in areas with high" exact="microcephaly" post="rates, dengue fever incidence rates were smaller. Figure 4"/>
   <result pre="Fig. 3, is inverted: in areas with high microcephaly rates," exact="dengue fever" post="incidence rates were smaller. Figure 4 Average annual dengue"/>
   <result pre="dengue fever incidence rates were smaller. Figure 4 Average annual" exact="dengue fever" post="incidence rate per 100,000 over 2010–2014 by microregion, Brazil."/>
   <result pre="BY SA. To estimate the association between both indicators –" exact="microcephaly" post="rate and previous dengue fever incidence – we estimated"/>
   <result pre="the association between both indicators – microcephaly rate and previous" exact="dengue fever" post="incidence – we estimated the effect of the time"/>
   <result pre="lag between the most recent large dengue epidemic and the" exact="microcephaly" post="epidemic. Figure 5 presents the main results of this"/>
   <result pre="of this article: the credibility time interval since the last" exact="dengue fever" post="epidemic above 400 cases/100,000 inhabitants over the rate of"/>
   <result pre="increased risk from 7 to 12 years. Figure 5 Estimated" exact="microcephaly" post="risk (log) and credibility interval by number of years"/>
   <result pre="and credibility interval by number of years since the last" exact="dengue fever" post="epidemic (incidence &amp;gt;400/100,000). The random effect estimated for each"/>
   <result pre="each microregion, as presented in Fig. 6, suggests that the" exact="dengue fever" post="epidemic effect is not enough to explain the large"/>
   <result pre="effect is not enough to explain the large number of" exact="microcephaly" post="cases in some areas in the NE. The Supplemental"/>
   <result pre="distributions. Blue areas are those with a lower rate of" exact="microcephaly" post="cases than predicted by the time lag after the"/>
   <result pre="cases than predicted by the time lag after the last" exact="dengue fever" post="epidemic, while orange/red areas are the opposite. In some"/>
   <result pre="in which an association, at the ecological level, between previous" exact="dengue fever" post="epidemics and the Zika-related microcephaly epidemic was described. It"/>
   <result pre="ecological level, between previous dengue fever epidemics and the Zika-related" exact="microcephaly" post="epidemic was described. It should be noted that the"/>
   <result pre="in the models. It is possible that the differences in" exact="microcephaly" post="rates were a consequence of different ZIKV attack rates"/>
   <result pre="ZIKV was assumed to be the only cause of the" exact="microcephaly" post="epidemic, with no unmeasured confounders or effect modifiers. However,"/>
   <result pre="effect modifiers. However, if Zika incidence alone explains the excess" exact="microcephaly" post="rates, then microcephaly would simply be a proxy for"/>
   <result pre="if Zika incidence alone explains the excess microcephaly rates, then" exact="microcephaly" post="would simply be a proxy for Zika, and it"/>
   <result pre="considered in the analysis. Our findings indicate that a previous" exact="dengue fever" post="epidemic may be related to microcephaly incidence and reinforce"/>
   <result pre="that a previous dengue fever epidemic may be related to" exact="microcephaly" post="incidence and reinforce the idea of a window of"/>
   <result pre="the early discovery of the causal link between Zika and" exact="microcephaly" post="may have generated a hyper-awareness of the problem. The"/>
   <result pre="Study of Congenital Malformations – ECLAMC) did not detect the" exact="microcephaly" post="epidemic in the early stages14, possibly due to the"/>
   <result pre="that we considered high enough to either protect or increase" exact="microcephaly" post="risk (of 400/100,000 inhabitants) was data-driven, based on the"/>
   <result pre="Other possible factors in the pathway between Zika infection and" exact="microcephaly" post="have been suggested, the most important of which is"/>
   <result pre="Aedes aegypti in poor areas and increased awareness of the" exact="microcephaly" post="risk in the upper socioeconomic classes, inducing either postponing"/>
   <result pre="not controlling for Zika incidence, are well known: accuracy of" exact="microcephaly" post="classification and completeness of dengue fever notification. We recognize"/>
   <result pre="are well known: accuracy of microcephaly classification and completeness of" exact="dengue fever" post="notification. We recognize the potential inaccuracy on the measurement"/>
   <result pre="fourfold, instead of five. As for the under notification of" exact="dengue fever," post="we have no reason to believe there was a"/>
   <result pre="Presumed Congenital Zika SyndromeAm. J. Public. Health201610659860010.2105/AJPH.2016.30311526959258 6.de OliveiraWKet al.Infection-related" exact="microcephaly" post="after the 2015 and 2016 Zika virus outbreaks in"/>
   <result pre="project http://www.r-inla.org/home. 37.BradyOJet al.The association between Zika virus infection and" exact="microcephaly" post="in Brazil 2015–2017: An observational analysis of over 4"/>
   <result pre="over 4 million birthsPLOS Med.201916e100275510.1371/journal.pmed.100275530835728 38.HalsteadSBNimmannityaSCohenSNObservations related to pathogenesis of" exact="dengue hemorrhagic fever." post="IVRelat. Dis. severity Antib. response virus recovered. Yale J."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC7001263\results\search\disease\results.xml">
   <result pre="10.1186/s12889-020-8294-8 : Research Article High prevalence of human immunodeficiency virus," exact="hepatitis" post="B and C viral infections among people who inject"/>
   <result pre="a potential stumbling block in the control of HIV and" exact="viral hepatitis" post="in Tanzania KawambwaRahim H.Kawambwa7@gmail.com1http://orcid.org/0000-0003-3726-2816MajigoMtebe V.mmajigo@gmail.com1MohamedAhmed A.Ahmedabade@yahoo.com2MateeMecky I.mateemecky@yahoo.com1[1], 0000 0001"/>
   <result pre="potential stumbling block in the control of HIV and viral" exact="hepatitis" post="in Tanzania KawambwaRahim H.Kawambwa7@gmail.com1http://orcid.org/0000-0003-3726-2816MajigoMtebe V.mmajigo@gmail.com1MohamedAhmed A.Ahmedabade@yahoo.com2MateeMecky I.mateemecky@yahoo.com1[1], 0000 0001"/>
   <result pre="decrease in the prevalence of human immunodeficiency virus (HIV) and" exact="viral hepatitis" post="in the general population attributed to several interventional measures."/>
   <result pre="in the prevalence of human immunodeficiency virus (HIV) and viral" exact="hepatitis" post="in the general population attributed to several interventional measures."/>
   <result pre="IgG antibodies against HIV and Hepatitis C virus (HCV) and" exact="hepatitis" post="B surface antigen (HBsAg). Data were entered in the"/>
   <result pre="at least two infections. The high prevalence of HIV and" exact="viral hepatitis" post="infections among PWID may hamper initiatives of ending HIV"/>
   <result pre="least two infections. The high prevalence of HIV and viral" exact="hepatitis" post="infections among PWID may hamper initiatives of ending HIV"/>
   <result pre="infections among PWID may hamper initiatives of ending HIV and" exact="viral hepatitis" post="epidemics in Tanzania. Keywords PWID HIV Hepatitis B virus"/>
   <result pre="among PWID may hamper initiatives of ending HIV and viral" exact="hepatitis" post="epidemics in Tanzania. Keywords PWID HIV Hepatitis B virus"/>
   <result pre="2004 [1] to 5.0% in 2017 [2]. The prevalence of" exact="hepatitis" post="B and C viruses in the general and some"/>
   <result pre="(Standard Diagnostic, Seoul, Korea) was used for the detection of" exact="hepatitis" post="B surface antigen (HBsAg). The presence of HCV infection"/>
   <result pre="attention as a strategy to achieve control of HIV and" exact="viral hepatitis" post="infections. Alarmingly none of our study participants knew their"/>
   <result pre="as a strategy to achieve control of HIV and viral" exact="hepatitis" post="infections. Alarmingly none of our study participants knew their"/>
   <result pre="high-risk behaviour, as well as increased access to HIV and" exact="viral hepatitis" post="testing services and enrolment to antiretroviral and methadone schemes,"/>
   <result pre="behaviour, as well as increased access to HIV and viral" exact="hepatitis" post="testing services and enrolment to antiretroviral and methadone schemes,"/>
   <result pre="Tanzania: current status and challengesJ Trop Med20182018423964629666656 4.ShaoERMboyaIBGundaDWRuhangisaFGTemuEMNkwamaMLet al.Seroprevalence of" exact="hepatitis" post="B virus infection and associated factors among healthcare workers"/>
   <result pre="Temeke District, Dar-es-salaam, 2011Int J Drug Policy2012241788123036650 6.KhatibAMatikoEKhalidFWeltySAliAOthmanAet al.HIV and" exact="hepatitis" post="B and C co-infection among people who inject drugs"/>
   <result pre="review and data synthesisPLoS Med2014116e100166324937136 11.NelsonPKMathersBMCowieBHaganHDes JarlaisDHoryniakDet al.Global epidemiology of" exact="hepatitis" post="B and hepatitis C in people who inject drugs:"/>
   <result pre="synthesisPLoS Med2014116e100166324937136 11.NelsonPKMathersBMCowieBHaganHDes JarlaisDHoryniakDet al.Global epidemiology of hepatitis B and" exact="hepatitis" post="C in people who inject drugs: results of systematic"/>
   <result pre="people who inject drugs in Mwanza, TanzaniaPLoS One20151012e014557826701616 17.TerraultNASex and" exact="hepatitis" post="CAm J Gastroenterol2005100482582615784026 18.KsobiechKAssessing and improving needle exchange programs:"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC7002134\results\search\disease\results.xml">
   <result pre="as a viral suppressor of RNAi (VSR). When NS2A-mediated RNAi" exact="suppression" post="was disabled, the resulting mutant DENV2 induced Dicer-dependent production"/>
   <result pre="numerous important human pathogens such as dengue virus (DENV), Japanese" exact="encephalitis" post="virus (JEV), Zika virus (ZIKV), West Nile virus (WNV),"/>
   <result pre="encephalitis virus (JEV), Zika virus (ZIKV), West Nile virus (WNV)," exact="yellow fever" post="virus (YFV), etc. (1). These viruses are transmitted between"/>
   <result pre="handful of VSR-disabled mutant viruses, including human enterovirus A71 (EV-A71)," exact="influenza" post="A virus (IAV), and Nodamura virus (NoV), have been"/>
   <result pre="of variance (ANOVA) (GraphPad Prism). To further confirm the RNAi" exact="suppression" post="activity of DENV2 NS2A, we adopted another canonical assay"/>
   <result pre="identify the critical residue(s) responsible for the dsRNA-binding and/or RNAi" exact="suppression" post="activities of DENV2 NS2A, we performed multiple sequence alignments"/>
   <result pre="&amp;lt; 0.0001. Together, our findings show that when the NS2A-mediated" exact="suppression" post="of RNAi was genetically disabled in DENV2, viral infection"/>
   <result pre="any of the four NS2As showed similar in vitro RNAi" exact="suppression" post="activities in both S2 (fig. S6, A and B)"/>
   <result pre="NS2As encoded by these viruses had similar in vitro RNAi" exact="suppression" post="activities to restore EGFP mRNA and inhibit siRNA production"/>
   <result pre="in public health: Focus on dengue, West Nile, and Japanese" exact="encephalitis" post="virus. J. Neurovirol.20, 539–560 (2014).25287260 6PangX., ZhangR., ChengG., Progress"/>
   <result pre="(2014).25287260 6PangX., ZhangR., ChengG., Progress towards understanding the pathogenesis of" exact="dengue hemorrhagic fever." post="Virol. Sin.32, 16–22 (2017).27853992 7DingS. W., RNA-based antiviral immunity."/>
   <result pre="X., CheloufiS., KarginovF. V., DingS. W., JeffreyK. L., Induction and" exact="suppression" post="of antiviral RNA interference by influenza A virus in"/>
   <result pre="JeffreyK. L., Induction and suppression of antiviral RNA interference by" exact="influenza" post="A virus in mammalian cells. Nat. Microbiol.2, 16250 (2016).27918527"/>
   <result pre="Dis.4, e848 (2010).21049014 23LiH., LiW. X., DingS. W., Induction and" exact="suppression" post="of RNA silencing by an animal virus. Science296, 1319–1321"/>
   <result pre="LinY. L., Blocking double-stranded RNA-activated protein kinase PKR by Japanese" exact="encephalitis" post="virus nonstructural protein 2A. J. Virol.86, 10347–10358 (2012).22787234 28LiuW."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC7002310\results\search\disease\results.xml">
   <result pre="in the United States. Foreign copyrights may apply.mSphere.00822-19.pdf Swine are" exact="influenza" post="virus reservoirs that have caused outbreaks and pandemics. Genomic"/>
   <result pre="used Nanopore sequencing and on-site analytics to interpret 13 swine" exact="influenza" post="virus genomes and identified an influenza virus cluster that"/>
   <result pre="to interpret 13 swine influenza virus genomes and identified an" exact="influenza" post="virus cluster that was genetically highly varied to currently"/>
   <result pre="While working overnight at a swine exhibition, we identified an" exact="influenza" post="A virus (IAV) outbreak in swine, Nanopore sequenced 13"/>
   <result pre="the development of a synthetically derived CVV. IMPORTANCE Swine are" exact="influenza" post="virus reservoirs that have caused outbreaks and pandemics. Genomic"/>
   <result pre="used Nanopore sequencing and on-site analytics to interpret 13 swine" exact="influenza" post="virus genomes and identified an influenza virus cluster that"/>
   <result pre="to interpret 13 swine influenza virus genomes and identified an" exact="influenza" post="virus cluster that was genetically highly varied to currently"/>
   <result pre="and was the dominant U.S. variant virus in 2018. KEYWORDS" exact="influenza" post="mobile sequencing Nanopore sequencing pandemic preparedness swine influenza Funding"/>
   <result pre="2018. KEYWORDS influenza mobile sequencing Nanopore sequencing pandemic preparedness swine" exact="influenza" post="Funding HHS | National Institutes of Health (NIH)https://doi.org/10.13039/100000002 HHSN272201400006CBowmanAndrew"/>
   <result pre="leveraged to identify a suitable vaccine. On the other hand," exact="influenza" post="viruses have multiple enzootic reservoirs, cause annual epidemics in"/>
   <result pre="we have an opportunity to mitigate the risk of an" exact="influenza" post="outbreak at its source in real time by analyzing"/>
   <result pre="that pandemic, there have been 465 human cases of swine-origin" exact="influenza" post="viruses (termed variant influenza viruses) in the United States"/>
   <result pre="been 465 human cases of swine-origin influenza viruses (termed variant" exact="influenza" post="viruses) in the United States resulting from exposure to"/>
   <result pre="humans. Children in particular may be immunologically naive to swine" exact="influenza" post="viruses that are genetically and antigenically distinct from recent"/>
   <result pre="viruses that are genetically and antigenically distinct from recent seasonal" exact="influenza" post="viruses or vaccines to which they have been exposed"/>
   <result pre="purple, and the Eurasian swine lineage is blue. In 2009," exact="influenza" post="A/H1N1Pdm09 virus displaced the previous human seasonal A/H1N1 virus"/>
   <result pre="Regulatory Laboratories have developed prepandemic CVVs that target specific swine" exact="influenza" post="virus subtypes and HA gene lineages that have caused"/>
   <result pre="To date, 11 CVVs representing antigenically diverse groups of swine" exact="influenza" post="viruses have been proposed or already developed for prepandemic"/>
   <result pre="RESULTS Development of the Mia platform. We created a mobile" exact="influenza" post="virus genomics platform to estimate the risk to humans"/>
   <result pre="local IAV outbreak by performing in-field extraction and amplification of" exact="influenza" post="A viruses, complete genome sequencing, automated genome assembly, BLAST"/>
   <result pre="variant detection to candidate vaccine viruses. We used our high-throughput" exact="influenza" post="virus sequencing pipeline as a template for developing Mia"/>
   <result pre="kit due to its small footprint and demonstrated effectiveness on" exact="influenza" post="A viruses (8). We chose the mini8 by miniPCR"/>
   <result pre="in the exhibition barn of animals with clinical signs of" exact="respiratory disease." post="During the day, the barns were very crowded with"/>
   <result pre="we swabbed ILI-identified swine and their pen neighbors (n = 94) for" exact="influenza" post="A virus (IAV) with the Flu Detect swine kits."/>
   <result pre="and NA gene segments were closely related to 2017/2018 H1N2" exact="influenza" post="viruses circulating in the U.S. swine population and have"/>
   <result pre="belonged to the H1-δ2 or clade 1B.2.1, using the swine" exact="influenza" post="virus H1 HA global nomenclature system. This lineage is"/>
   <result pre="1998 human seasonal H3N2 lineage now found in U.S. swine" exact="influenza" post="viruses. This NA is a distinct gene lineage from"/>
   <result pre="triple-reassortant internal gene (TRIG) cassette origin commonly found in swine" exact="influenza" post="viruses in the United States. The NP and M"/>
   <result pre="map displayed in Mia’s R Shiny application using the swine" exact="influenza" post="virus H1 HA global nomenclature system. This automatically generated"/>
   <result pre="high-priority swine-human interface that resulted in our identification of an" exact="influenza" post="A virus outbreak. We created Mia by selecting and"/>
   <result pre="unpacking Mia. This proactive strategy of identifying the predominant swine" exact="influenza" post="viruses in exhibition pigs prior to the start of"/>
   <result pre="efforts due to the pandemic risk of avian and swine" exact="influenza" post="viruses that circulate in these settings (18, 19). Mia"/>
   <result pre="potential to greatly expand the reach of the current global" exact="influenza" post="virus surveillance network. MATERIALS AND METHODS Logistics. Our inventory"/>
   <result pre="we screened 94 swine displaying ILI using the Flu Detect" exact="influenza" post="A virus swine rapid tests (Bridgewater, NJ, USA) via"/>
   <result pre="Amplification, barcoding, library preparation, and sequencing. We amplified the full" exact="influenza" post="A virus genome using a fast multisegment reverse transcription"/>
   <result pre="processed them with the Influenza Genomics Team’s standard Illumina MiSeq" exact="influenza" post="surveillance pipeline (San Diego, CA, USA). We processed and"/>
   <result pre="agreement no. 5U38OT000143-05. Nasal wipes were collected as part of" exact="influenza" post="A virus surveillance supported by the Centers of Excellence"/>
   <result pre="DonisR, et al.2009Antigenic and genetic characteristics of swine-origin 2009 A(H1N1)" exact="influenza" post="viruses circulating in humans. Science325:197–201. doi:10.1126/science.1176225.19465683 5.BowmanAS, WaliaRR, NoltingJM,"/>
   <result pre="6.collab: World Health Organization. 2018Antigenic and genetic characteristics of zoonotic" exact="influenza" post="viruses and development of candidate vaccine viruses for pandemic"/>
   <result pre="CooneyCG, HolmbergR, ThakoreN, MokhiberB, BelgraderP, KnickerbockerC, SchiedJ, St. GeorgeK2012Rapid, simple" exact="influenza" post="RNA extraction from nasopharyngeal samples. J Virol Methods183:8–13. doi:10.1016/j.jviromet.2012.03.002.22425698"/>
   <result pre="NeuhausEB, DuganVG, WentworthDE, BarnesJR2018Direct RNA sequencing of the coding complete" exact="influenza" post="A virus genome. Sci Rep8:14408. doi:10.1038/s41598-018-32615-8.30258076 10.ShepardSS, MenoS, BahlJ,"/>
   <result pre="StrattonJ, LewisNS, VincentAL2018Antigenic and genetic evolution of contemporary swine H1" exact="influenza" post="viruses in the United States. Virology518:45–54. doi:10.1016/j.virol.2018.02.006.29453058 12.GaoS, AndersonTK,"/>
   <result pre="12.GaoS, AndersonTK, WaliaRR, DormanKS, Janas-MartindaleA, VincentAL2017The genomic evolution of H1" exact="influenza" post="A viruses from swine detected in the United States"/>
   <result pre="and automated annotation tool for H1 hemagglutinin genes from swine" exact="influenza" post="A viruses. mSphere1:e00275-16. doi:10.1128/mSphere.00275-16.27981236 15.collab: Centers for Disease Control"/>
   <result pre="15.collab: Centers for Disease Control and Prevention (CDC). 2009Update: novel" exact="influenza" post="A (H1N1) virus infections-worldwide, May 6, 2009. MMWR Morb"/>
   <result pre="KidaH, TakadaA2010Predicting the antigenic structure of the pandemic (H1N1) 2009" exact="influenza" post="virus hemagglutinin. PLoS One5:e8553. doi:10.1371/journal.pone.0008553.20049332 17.WaliaRR, AndersonTK, VincentAL2019Regional patterns"/>
   <result pre="doi:10.1371/journal.pone.0008553.20049332 17.WaliaRR, AndersonTK, VincentAL2019Regional patterns of genetic diversity in swine" exact="influenza" post="A viruses in the United States from 2010 to"/>
   <result pre="2016. Influenza Other Respir Viruses13:262–273. doi:10.1111/irv.12559.29624873 18.PeirisJSM, de JongMD, GuanY2007Avian" exact="influenza" post="virus (H5N1): a threat to human health. Clin Microbiol"/>
   <result pre="Clin Microbiol Rev20:243–267267. doi:10.1128/CMR.00037-06.17428885 19.CoxNJ, TrockSC, BurkeSA2014Pandemic preparedness and the" exact="influenza" post="risk assessment tool (IRAT), p 119–136. InCompansRW, OldstoneMBA (ed),"/>
   <result pre="WorkmanJD, SlemonsRD, SzablewskiCM, NoltingJM, BowmanAS2014Utility of snout wipe samples for" exact="influenza" post="A virus surveillance in exhibition swine populations. Influenza Other"/>
   <result pre="Respir Viruses8:574–579. doi:10.1111/irv.12270.25043408 21.NoltingJM, SzablewskiCM, EdwardsJL, NelsonSW, BowmanAS2015Nasal wipes for" exact="influenza" post="A virus detection and isolation from swine. J Vis"/>
   <result pre="ZmasekC, KlemEB, ScheuermannRH2017Influenza Research Database: an integrated bioinformatics resource for" exact="influenza" post="virus research. Nucleic Acids Res45:D466–D474. doi:10.1093/nar/gkw857.27679478 28.KatohK, StandleyDM2013MAFFT multiple"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC7002824\results\search\disease\results.xml">
   <result pre="been observed against a wide range of viruses such as" exact="influenza" post="viruses, HIV, Enterovirus 71 (EV71), coxsackievirus A16 (CVA16), dengue"/>
   <result pre="HIV, Enterovirus 71 (EV71), coxsackievirus A16 (CVA16), dengue virus and" exact="chikungunya" post="virus [15, 16, 17, 18]. This review will elucidate"/>
   <result pre="virus The available therapeutic treatment for infection caused by the" exact="hepatitis" post="C virus have many adverse effects (Headache, fatigue, nausea,"/>
   <result pre="with anti-HCV drugs [33]. Hepatocarcinoma (HCC) is associated with chronic" exact="hepatitis" post="C virus (HCV) infection which involves increase in plasma"/>
   <result pre="polymerase components of virus to inhibit its replication, NS5B, a" exact="hepatitis" post="C virus polymerase is a novel target for newly"/>
   <result pre="plant Clausena excavate [43]. These compounds were found to inhibit" exact="hepatitis" post="B virus surface antigen (HBsAg) in HepA2 cells. Their"/>
   <result pre="[44]. From the aforementioned studies, we can deduce that in" exact="hepatitis" post="virus infection, coumarin has shown to target a wide"/>
   <result pre="brasiliense demonstrated strong inhibitory activity on HIV-1 replication by the" exact="suppression" post="of NF-kB activation in both acutely and chronically virus-infected"/>
   <result pre="Anti-viral therapy which are currently used for the treatment of" exact="influenza" post="viruses, have the limitations on vaccine design, efficacy and"/>
   <result pre="expression of many chemokine genes and gene for Nucleoprotein, an" exact="influenza" post="structural protein that is a constituent of vRNPs viral"/>
   <result pre="and cytokine-cytokine receptor interactions. Recently, the mechanism of action against" exact="influenza" post="viral infection of eleutheroside B1 has been assessed showing"/>
   <result pre="show promising antiviral against the H3N2 and H1N1 strains of" exact="influenza" post="in MDCK cell-based assays. Molecular docking studies has shown"/>
   <result pre="binding affinity between the coumarin derivative and target protein of" exact="influenza" post="virus using molecular docking [64]. Another research study has"/>
   <result pre="of a compound containing both coumarin and monoterpenoid derivative in" exact="influenza" post="was viral hemagglutinin HA which is involved in viral"/>
   <result pre="viral reproduction [60]. Due to the high mutation tendency of" exact="influenza" post="viral proteins [66], redox-sensitive pathways which are useful for"/>
   <result pre="different catechol and pyrogallol derivatives have shown antiviral activity against" exact="influenza" post="A H1N1 by modulating proteins involved in redox pathways"/>
   <result pre="Coumarin has the potential to significantly suppress the Dengue and" exact="chikungunya" post="viral infections in vitro. However, the need is to"/>
   <result pre="retention in nucleus mediated by Sirt1 deacetylase) this leads to" exact="suppression" post="of dengue virus replication by increasing the production of"/>
   <result pre="conjugates have been used to see their inhibitory role against" exact="chikungunya" post="viruses. Jih Ru Hwu et al., used the triply"/>
   <result pre="the triply conjugated uracil-coumarin-arenes compound to see structure-activity relationship against" exact="chikungunya" post="virus. In this research, coumarin central moiety was found"/>
   <result pre="size of conjugated moiety (benzouracil &amp;gt; thymine &amp;gt; uracil) and" exact="chikungunya" post="inhibitory action [3]. Same research group have synthesized thioguanosine-coumarin"/>
   <result pre="3RuJ.KapoorM.TsayS.LinC.ChuK.Benzouracil – coumarin – arene conjugates as inhibiting agents for" exact="chikungunya" post="virusAntivir. Res.201516 4BandarageU.K.ClarkM.P.PerolaE.GaoH.JacobsM.D.TsaiA.Novel 2-substituted 7-azaindole and 7-azaindazole analogues as"/>
   <result pre="of curcuminJ. Funct. Foods.402018692699 14KannanS.KolandaivelP.Antiviral potential of natural compounds against" exact="influenza" post="virus hemagglutininComput. Biol. Chem.2017 15WangC.Y.HuangS.C.ZhangY.LaiZ.R.KungS.H.ChangY.S.LinC.W.Antiviral ability of Kalanchoe gracilis"/>
   <result pre="and chronically infected cellsBioorg. Med. Chem. Lett23201360660923290051 29SandmannL.SchulteB.MannsM.P.MaasoumyB.Treatment of chronic" exact="hepatitis" post="C: efficacy, side effects and complicationsVis. Med.352019161170 30MannsM.P.WedemeyerH.CornbergM.Treating viral"/>
   <result pre="chronic hepatitis C: efficacy, side effects and complicationsVis. Med.352019161170 30MannsM.P.WedemeyerH.CornbergM.Treating" exact="viral hepatitis" post="C: efficacy, side effects, and complicationsGut5520061350135916905701 31LyT.PermanenteK.CaliforniaN.DermatolA.A.TineaM.S.GesD.D.ManagementG.R.CosmetC.DermatolI.ScH.TineaB.J.JsM.InfectE.LmD.BgR.KhR.ControlI.EpidemiolH.PcS.RcS.JournalB.Cutaneous side-effects of"/>
   <result pre="hepatitis C: efficacy, side effects and complicationsVis. Med.352019161170 30MannsM.P.WedemeyerH.CornbergM.Treating viral" exact="hepatitis" post="C: efficacy, side effects, and complicationsGut5520061350135916905701 31LyT.PermanenteK.CaliforniaN.DermatolA.A.TineaM.S.GesD.D.ManagementG.R.CosmetC.DermatolI.ScH.TineaB.J.JsM.InfectE.LmD.BgR.KhR.ControlI.EpidemiolH.PcS.RcS.JournalB.Cutaneous side-effects of"/>
   <result pre="U. K. experienceBr. J. Dermatol.201420142015 32HenryB.Drug pricing &amp;amp; challenges to" exact="hepatitis" post="C treatment accessJ. Heal. Biomed. Law.142018265283http://www.ncbi.nlm.nih.gov/pubmed/30258323%0Ahttp://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=PMC6152913 33TsayS.LinS.HuangW.HsuM.HwangK.C.LinC.HorngJ.ChenI.HwuJ.R.ShiehF.LeyssenP.NeytsJ.Synthesis and Structure-activity"/>
   <result pre="Biomed. Law.142018265283http://www.ncbi.nlm.nih.gov/pubmed/30258323%0Ahttp://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=PMC6152913 33TsayS.LinS.HuangW.HsuM.HwangK.C.LinC.HorngJ.ChenI.HwuJ.R.ShiehF.LeyssenP.NeytsJ.Synthesis and Structure-activity relationships of imidazole-coumarin conjugates against" exact="hepatitis" post="C virusMolecules2016 34RinoY.OhkawaS.ShimizuA.TamaiS.MiyakawaK.AokiH.ImadaT.ShindoK.OkamotoN.TotsukaS.Association between high serum alanine aminotransferase levels"/>
   <result pre="and more rapid development and higher rate of incidence of" exact="hepatocellular carcinoma" post="in patients with hepatitis C virus-associated cirrhosisCancer199958959510440686 35O. PaperClose"/>
   <result pre="higher rate of incidence of hepatocellular carcinoma in patients with" exact="hepatitis" post="C virus-associated cirrhosisCancer199958959510440686 35O. PaperClose association between high serum"/>
   <result pre="association between high serum ALT and more rapid recurrence of" exact="hepatocellular carcinoma" post="in hepatectomized patients with HCV-associated liver cirrhosis and hepatocellular"/>
   <result pre="recurrence of hepatocellular carcinoma in hepatectomized patients with HCV-associated liver" exact="cirrhosis" post="and hepatocellular carcinomaIntervirology20002026081510773734 36OkamotoT.KajinoK.HinoO.Hepatoprotective drugs for the treatment of"/>
   <result pre="38HsuM.ShiehF.LinC.HwangK.C.Coumarins hinged directly on benzimidazoles and their ribofuranosides to inhibit" exact="hepatitis" post="C virusSCEur. J. Med. Chem.2013 39NeytsJ.De ClercqE.SinghaR.ChangY.H.DasA.R.ChakrabortyS.K.Structure - activity"/>
   <result pre="40HwuJ.R.LinS.TsayS.De ClercqE.LeyssenP.NeytsJ.Coumarin - purine ribofuranoside conjugates as new agents against" exact="hepatitis" post="C virusJ. Med. Chem.20112114212621375337 41NicholsD.B.LeR.A.C.BasuA.ChudayeuM.De FP.MoraesD.TaleleT.T.PauloR.R.Kaushik-basuN.Evaluation of coumarin and"/>
   <result pre="inhibitorsChem. Biol. Drug Des.815201360761423311976 42PengH.ChenW.LeeJ.YangS.TzengC.LinY.YangS.Novel anilinocoumarin derivatives as agents against" exact="hepatitis" post="C virus by the induction of IFN-mediated antiviral responsesOrg."/>
   <result pre="scoparoneCurr. HIV Res.201648449027697031 59SpanakisN.PitirigaV.A review of neuraminidase inhibitor susceptibility in" exact="influenza" post="strainsExpert Rev. Anti-infect. Ther.20141325133625301229 60KhomenkoT.M.V ZarubaevV.OrshanskayaI.R.KadyrovaR.A.SannikovaV.A.V KorchaginaD.VolchoK.P.SalakhutdinovN.F.Bioorganic &amp;amp; medicinal"/>
   <result pre="roots of Glycyrrhiza uralensisBioorg. Med. Chem. Lett20201097197420064716 66EscuretV.FrobertE.Bouscambert-duchampM.SabatierM.GrogI.ValetteM.LinaB.MorfinF.FerrarisO.Detection of human" exact="influenza" post="A ( H1N1 ) and B strains with reduced"/>
   <result pre="carp virus infection in zebrafish Authors: SCVirus Res.2019 79MorensD.M.TaubenbergerJ.K.HarveyH.A.MemoliM.J.The 1918" exact="influenza" post="pandemic: lessons for 2009 and the futureCrit. Care Med.382010e10e2020048675"/>
   <result pre="mortality associated with the first 12 months of 2009 pandemic" exact="influenza" post="A H1N1 virus circulation: a modelling studyLancet Infect. Dis.129201268769522738893"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC7003685\results\search\disease\results.xml">
   <result pre="be cited.https://peerj.com/articles/8518 Abstract Background The study of disease transmission of" exact="dengue fever" post="(DF) is perplexing in the Indian subcontinent as all"/>
   <result pre="medical encyclopaedia in 992 from the Jin Dynasty (265–420 AD)," exact="dengue fever" post="was referred as &quot;water poison�? associated with flying insects,"/>
   <result pre="as &quot;water poison�? associated with flying insects, but the term" exact="dengue fever" post="came into general use only after 1828 (Gupta et"/>
   <result pre="the South East Asian area, India has higher incidence of" exact="dengue fever" post="leading to threat in health care system (Kashinkunti &amp;amp;"/>
   <result pre="al., 1998; Hati, 2006). The study of disease transmission of" exact="dengue fever" post="is intricate and remains inadequately comprehended because of the"/>
   <result pre="the east. All the samples from patient suspected of having" exact="dengue fever" post="(as per WHO guidelines) referred to VRDL from the"/>
   <result pre="infection referred to the VRDL for confirmation of diagnosis of" exact="dengue fever" post="over a period of three years, from January 2016"/>
   <result pre="&amp;amp; Arima (2011)AnkerMArimaY2011Male–female differences in the number of reported incident" exact="dengue fever" post="cases in six Asian countriesWestern Pacific Surveillance Response Journal2172323908884"/>
   <result pre="Surveillance Response Journal2172323908884 Antony &amp;amp; Celine (2014)AntonyJCelineTM2014A descriptive study on" exact="dengue fever" post="reported in a Medical College HospitalSahel Medical Journal173838610.4103/1118-8561.140285 Arima,"/>
   <result pre="virus transmissionParasites &amp;amp; Vectors7Article 33810.1186/1756-3305-7-338 Chitkara et al. (2018)ChitkaraSChhinaDGuptaVMahajanRSharmaD2018Epidemiology of" exact="dengue fever" post="among clinically suspected febrile patients at a tertiary care"/>
   <result pre="et al. (2002)HaySICoxJRogersDJRandolphSESternDIShanksGDMyersMF2002Snow RW: climate change and the resurgence of" exact="malaria" post="in the East African highlandsNature41590590910.1038/415905a11859368 Kashinkunti &amp;amp; Shiddappa (2013)KashinkuntiMDShiddappaand"/>
   <result pre="&amp;amp; Shiddappa (2013)KashinkuntiMDShiddappaand Dhananjaya, M2013A study of clinical profile of" exact="dengue fever" post="in a tertiary care teaching hospitalScholars Journal of Applied"/>
   <result pre="et al. (2017)KumarARainy RongpharpiSDewan DuggalSGurRChoudharySKhareP2017Clinical, epidemiological and microbiological profile of" exact="dengue fever" post="at a tertiary care hospital in Delhi, IndiaJournal of"/>
   <result pre="of Tropical Medicine and Hygiene5975776210.4269/ajtmh.1998.59.7579840593 Murhekar et al. (2019)MurhekarMJoshuaVKanagasabaiKSheteVRaviMRamachandranRSabarinathanRKirubakaranBGuptaNMehendaleS2019Epidemiology of" exact="dengue fever" post="in India, based on laboratory surveillance data, 2014–2017International Journal"/>
   <result pre="of Infection and Microbiology15862 Sherchand et al. (2001)SherchandJBPandeyBDHarukiKJimbaM2001Serodiagnosis of Japanese" exact="encephalitis" post="and dengue virus infection from clinically suspected patients of"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC7004335\results\search\disease\results.xml">
   <result pre="A scoping review of entomological studies on Zika, dengue and" exact="chikungunya" post="virus vectors A scoping review of entomological studies on"/>
   <result pre="A scoping review of entomological studies on Zika, dengue and" exact="chikungunya" post="virus vectors JonesReillyConceptualizationData curationFormal analysisMethodologyWriting – original draft1http://orcid.org/0000-0002-5084-4960KulkarniManisha A.ConceptualizationFunding"/>
   <result pre="to their global spread and epidemiological impacts: Zika, dengue, and" exact="chikungunya" post="viruses. A large proportion of infections by these viruses"/>
   <result pre="entomological literature surrounding the mosquito vectors of Zika, dengue and" exact="chikungunya" post="viruses and factors affecting virus transmission. The rationale of"/>
   <result pre="have been conducted in the Americas since the introduction of" exact="chikungunya" post="virus in 2013, encompassing a period of arbovirus co-circulation,"/>
   <result pre="research available on natural infection and co-infection for dengue and" exact="chikungunya" post="viruses, although vertical transmission research was sparse for all"/>
   <result pre="spreading viruses causing human disease, such as Zika, dengue, and" exact="chikungunya" post="viruses. The term arbovirus does not encompass a taxonomically"/>
   <result pre="isolated in Tanzania in 1952 [7]. In the early 2000s," exact="chikungunya" post="virus cases and outbreaks were identified in countries in"/>
   <result pre="Caribbean region [8]. A large proportion of Zika, dengue, and" exact="chikungunya" post="viral infections are asymptomatic [9–11]. However, all three viruses"/>
   <result pre="Symptoms of Zika viral infection include rash, fever, arthralgia, and" exact="conjunctivitis" post="[11]. More importantly, since its initial emergence in the"/>
   <result pre="may include deadly hemorrhage and plasma leak [9]. Symptoms of" exact="chikungunya" post="viral infection include rash, fever, and arthralgia that may"/>
   <result pre="of the literature surrounding the vectors of Zika, dengue and" exact="chikungunya" post="viruses and factors affecting virus transmission in the Americas,"/>
   <result pre="virus transmission dynamics in the Americas since the introduction of" exact="chikungunya" post="in 2013. This timeframe includes the introduction of Zika"/>
   <result pre="co-circulation of three globally spreading arboviruses, namely Zika, dengue and" exact="chikungunya" post="viruses. Methods This study’s search strategy and data extraction"/>
   <result pre="start date for our search to reflect the timing of" exact="chikungunya" post="virus spread to the Americas, followed in 2014 by"/>
   <result pre="transmission dynamics, if they were related to Zika, dengue and/or" exact="chikungunya" post="arboviruses, and if they were related to the ongoing"/>
   <result pre="studies focusing exclusively on Zika virus, while studies focusing on" exact="chikungunya" post="virus or on a combination of arboviruses were the"/>
   <result pre="2017 and 2018 (Fig 2), closely reflecting the introductions of" exact="chikungunya" post="and Zika viruses in the Americas and subsequent epidemics,"/>
   <result pre="and Haemagogus leucocelaenus [70] are all experimentally competent to transmit" exact="chikungunya" post="virus. Chikungunya virus transmission in Ae. aegypti has also"/>
   <result pre="under silenced RNAi conditions, Ae. aegypti were more predisposed to" exact="chikungunya" post="infection at lower temperatures. Alto et al. [64] found"/>
   <result pre="fluctuations in diurnal temperature range led to higher rates of" exact="chikungunya" post="infection, and Xiao et al. [47] found that maximum"/>
   <result pre="Americas and found that mean temperature data accurately reflected Zika," exact="chikungunya" post="and dengue human case data. Transmission was found to"/>
   <result pre="pools for any or a combination of Zika, dengue and" exact="chikungunya" post="viruses, along with information on authors, year and country"/>
   <result pre="aegypti in Colombia. A study measured the naturally-occurring prevalence of" exact="chikungunya" post="virus in wild mosquito populations (Table 2). Díaz-González et"/>
   <result pre="557 tested. A study reported on the prevalence of both" exact="chikungunya" post="and Zika viruses among Ae. aegypti in Ecuador (Table"/>
   <result pre="aegypti in Ecuador (Table 2) [30]. Three studies tested both" exact="chikungunya" post="and dengue viruses in wild mosquito populations (Table 2)."/>
   <result pre="aegypti in Mexico by Cigarroa-Toledo et al. [71], although both" exact="chikungunya" post="and dengue viruses were isolated in Mexico in Ae."/>
   <result pre="albopictus together with corresponding risk of dengue. One study estimated" exact="chikungunya" post="transmission risk according to temperature threshold for breeding and"/>
   <result pre="January in southern Argentina. A study compared endemic and transient" exact="chikungunya" post="and dengue transmission dynamics, and the role of virus"/>
   <result pre="number. A study modelled transmission risk of Zika, dengue and" exact="chikungunya" post="and found temperature data to match well with human"/>
   <result pre="al. [46] artificially infected Ae. aegypti and Ae. albopictus with" exact="chikungunya" post="and DENV-2 simultaneously, separately, and in reverse order. Simultaneous"/>
   <result pre="[27] found that the co-infection of Ae. aegypti with Zika," exact="chikungunya" post="and dengue viruses minimally affected vector competence, and that"/>
   <result pre="Ae. albopictus to be susceptible to Indian Ocean and Asian" exact="chikungunya" post="virus genotypes. Human disease risk Five articles studied correlations"/>
   <result pre="species composition and arbovirus transmission dynamics of Zika, dengue and/or" exact="chikungunya" post="in the Americas. We observed a steady increase in"/>
   <result pre="research available on natural infection and co-infection for dengue and" exact="chikungunya" post="viruses, although vertical transmission research was sparse for all"/>
   <result pre="are needed that investigate a combination of Zika, dengue and" exact="chikungunya" post="viruses and use a variety of approaches to answer"/>
   <result pre="2016;214: S436–S440. 10.1093/infdis/jiw39127920169 8YactayoS, StaplesJE, MillotV, CibrelusL, Ramon-PardoP. Epidemiology of" exact="chikungunya" post="in the Americas. J Infect Dis. 2016;214: S441–S445. 10.1093/infdis/jiw39027920170"/>
   <result pre="https://www.cdc.gov/dengue/clinicallab/clinical.html 10NakkharaP, ChongsuvivatwongV, ThammapaloS. Risk factors for symptomatic and asymptomatic" exact="chikungunya" post="infection. Trans R Soc Trop Med Hyg. 2013;107: 789–796."/>
   <result pre="mosquito Aedes albopictus across Panama—implications for control of dengue and" exact="chikungunya" post="viruses. PLoS Negl Trop Dis. 2015;9: e000338310.1371/journal.pntd.000338325569303 17WaddellLA, GreigJD."/>
   <result pre="e000510110.1371/journal.pntd.000510127783679 30CevallosV, PonceP, WaggonerJJ, PinskyBA, ColomaJ, QuirogaC, et al.Zika and" exact="chikungunya" post="virus detection in naturally infected Aedes aegypti in Ecuador."/>
   <result pre="Lourenço-de-OliveiraR. Culex quinquefasciatus from areas with the highest incidence of" exact="microcephaly" post="associated with Zika virus infections in the Northeast Region"/>
   <result pre="HiggsS, MillerAL, PylesRB, SprattHM, et al.Evaluation of simultaneous transmission of" exact="chikungunya" post="virus and dengue virus type 2 in infected Aedes"/>
   <result pre="virus in Medellín suggests its possible role as vector of" exact="dengue fever" post="in Colombia. Biomed Rev Inst Nac Salud. 2017;37: 135–142."/>
   <result pre="Gutiérrez-CastroC, López-DamiánL, Ibarra-LópezJ, et al.Arbovirus surveillance and first report of" exact="chikungunya" post="virus in wild populations of Aedes aegypti from Guerrero,"/>
   <result pre="CricoS, ÉtienneM, MoussonL, HamelR, et al.First detection of dengue and" exact="chikungunya" post="viruses in natural populations of Aedes aegypti in Martinique"/>
   <result pre="64AltoBW, WigginsK, EastmondB, OrtizS, ZirbelK, LounibosLP. Diurnal temperature range and" exact="chikungunya" post="virus infection in invasive mosquito vectors. J Med Entomol."/>
   <result pre="Dis. 2017;11: e000597610.1371/journal.pntd.000597628961239 66LedermannJP, BorlandEM, PowersAM. Minimum infectious dose for" exact="chikungunya" post="virus in Aedes aegypti and Ae. albopictus mosquitoes. Rev"/>
   <result pre="American countries as a crucial factor in the spread of" exact="chikungunya" post="virus. J Virol. 2014;88: 6294–6306. 10.1128/JVI.00370-1424672026 69AltoBW, WigginsK, EastmondB,"/>
   <result pre="69AltoBW, WigginsK, EastmondB, VelezD, LounibosLP, LordCC. Transmission risk of two" exact="chikungunya" post="lineages by invasive mosquito vectors from Florida and the"/>
   <result pre="Negl Trop Dis. 2017;11: e000572410.1371/journal.pntd.000572428749964 70Lourenço-de-OliveiraR, FaillouxA-B. High risk for" exact="chikungunya" post="virus to initiate an enzootic sylvatic cycle in the"/>
   <result pre="Laguna-AguilarM, LangsjoenRM, et al.First report of Aedes aegypti transmission of" exact="chikungunya" post="virus in the Americas. Am J Trop Med Hyg."/>
   <result pre="the impact of temperature on transmission of Zika, dengue, and" exact="chikungunya" post="using mechanistic models. PLoS Negl Trop Dis. 2017;11: e000556810.1371/journal.pntd.000556828448507"/>
   <result pre="for dengue outbreaks and identification of high risk areas for" exact="dengue fever" post="in Colombia using climate and non-climate datasets. BMC Infect"/>
   <result pre="et al.Aedes aegypti (Diptera: Culicidae) longevity and differential emergence of" exact="dengue fever" post="in two cities in Sonora, Mexico. J Med Entomol."/>
   <result pre="Soc Vector Ecol. 2017;42: 3–12. 10.1111/jvec.1223428504449 99CarbajoAE, VezzaniD. Waiting for" exact="chikungunya" post="fever in Argentina: spatio-temporal risk maps. Mem Inst Oswaldo"/>
   <result pre="259–262. 10.1590/0074-0276015000525946252 100ManoreCA, HickmannKS, XuS, WearingHJ, HymanJM. Comparing dengue and" exact="chikungunya" post="emergence and endemic transmission in A. aegypti and A."/>
   <result pre="for infestation trends of Aedes aegypti, the vector of dengue," exact="chikungunya" post="and Zika. Parasit Vectors. 2017;10: 7810.1186/s13071-017-2025-828193291 113Stewart-IbarraAM, LoweR. Climate"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC7004624\results\search\disease\results.xml">
   <result pre="the proportion of HIV infections diagnosed, treated, and achieving viral" exact="suppression" post="reaches a certain level, the HIV epidemic may be"/>
   <result pre="regional, and national incidence and mortality for HIV, tuberculosis, and" exact="malaria" post="during 1990–2013: a systematic analysis for the Global Burden"/>
   <result pre="10.1186/1471-2334-13-192.23627258 14.collab: Humana People to People China. Progress reports in" exact="infectious disease" post="control in Yuexi, Sichuan Province. Available from: http://www.hppchina.org.cn/article/index/index/?lang=Cn&amp;amp;id=273. [Accessed"/>
   <result pre="doi: 10.1136/sextrans-2014-051877.25935929 35.WangAQiaoYDouLWangQWangXSuMet al.Challenges of eliminating mother-to-child transmission of HIV," exact="syphilis" post="and hepatitis B in China: a cross-sectional survey. Poster"/>
   <result pre="35.WangAQiaoYDouLWangQWangXSuMet al.Challenges of eliminating mother-to-child transmission of HIV, syphilis and" exact="hepatitis" post="B in China: a cross-sectional survey. Poster Abstract. Lancet,"/>
   <result pre="using suppressive antiretroviral therapy. JAMA2016; 316:171–181. doi: 10.1001/jama.2016.5148.27404185 39.BavintonBRPintoANPhanuphakNGrinsztejnBPrestageGPZablotska-ManosIBet al.Viral" exact="suppression" post="and HIV transmission in serodiscordant male couples: an international,"/>
   <result pre="67.AbubakarSIliyasuGDayyabFMInuwaSTudun WadaRASadiqNMet al.Post-exposure prophylaxis following occupational exposure to HIV and" exact="hepatitis" post="B: an analysis of a 12-year record in a"/>
  </snippets>
 </snippetsTree>
</projectSnippetsTree>
